<SEC-DOCUMENT>0001564590-20-012977.txt : 20200326
<SEC-HEADER>0001564590-20-012977.hdr.sgml : 20200326
<ACCEPTANCE-DATETIME>20200326070659
ACCESSION NUMBER:		0001564590-20-012977
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		126
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200326
DATE AS OF CHANGE:		20200326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Frequency Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001703647
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472324450
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39062
		FILM NUMBER:		20743962

	BUSINESS ADDRESS:	
		STREET 1:		19 PRESIDENTIAL WAY, SUITE 203
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		781-315-4600

	MAIL ADDRESS:	
		STREET 1:		19 PRESIDENTIAL WAY, SUITE 203
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>freq-10k_20191231.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
freq-10k_20191231.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:center;border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-K<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark&#160;One) </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:95.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended December 31, 2019</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4.76%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:95.24%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number&#160;001-39062</p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:21pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">FREQUENCY THERAPEUTICS, INC.</font><font style="color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Delaware</font></p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">47-2324450</font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:3pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">19 Presidential Way, 2nd Floor</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Woburn, MA</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">01801</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: <font style="Background-color:#FFFFFF;color:#000000;">(866)&#160;389-1970</font></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:41%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:41%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style="width:41%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Common Stock, $0.001 par value per share</font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">FREQ</font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:41%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Nasdaq Global Select Market</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: <font style="font-weight:bold;">None </font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:10.8pt;">
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font>NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Registrant was not a public company as of the last business day of its most recently completed second fiscal quarter and therefore, cannot calculate the aggregate market value of the voting and non-voting common equity held by non-affiliates as of such date.</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The number of shares of Registrant&#8217;s Common Stock outstanding as of March&#160;20, 2020 was 30,946,354. </p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-bottom:3pt;margin-top:3pt;text-indent:4.86%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the Proxy Statement for the registrant&#8217;s&#160;2020&#160;Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form 10-K.</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:83%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><font style="text-decoration:underline;">PART I</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><font style="text-decoration:underline;">Business</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><font style="text-decoration:underline;">Unresolved Staff Comments</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><font style="text-decoration:underline;">Properties</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><font style="text-decoration:underline;">Legal Proceedings</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><font style="text-decoration:underline;">Mine Safety Disclosures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><font style="text-decoration:underline;">PART&#160;II</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><font style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><font style="text-decoration:underline;">Selected Financial Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><font style="text-decoration:underline;">Financial Statements and Supplementary Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><font style="text-decoration:underline;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">Controls and Procedures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><font style="text-decoration:underline;">Other Information</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><font style="text-decoration:underline;">PART&#160;III</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><font style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><font style="text-decoration:underline;">Executive Compensation</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><font style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><font style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><font style="text-decoration:underline;">Principal Accounting Fees and Services</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><font style="text-decoration:underline;">PART&#160;IV</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><font style="text-decoration:underline;">Exhibits, Financial Statement Schedules</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><font style="text-decoration:underline;">Form 10-K Summary</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FORWARD-LOOKING STATEMENTS</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, product candidates, clinical development plans and expectations, prospective products, product approvals, research and development costs, timing and likelihood of success, and plans and objectives of management for future operations and results, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. The forward-looking statements in this Annual Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the risks, uncertainties and assumptions described under the sections in this Annual Report titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; These forward-looking statements are subject to numerous risks, including, without limitation, the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the impact of the novel coronavirus, COVID-19, on our ongoing and planned clinical trials, our research and development activities and our business and financial markets;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the initiation, timing, progress and results of our preclinical and clinical trials and research and development of programs, including our ongoing Phase 2a clinical trial and any planned additional Phase 2 clinical trials for FX-322 and our program to develop a product candidate for the treatment of multiple sclerosis, or MS;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to continue to develop our progenitor cell activation, or PCA, platform and identify additional product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to successfully complete clinical trials of any product candidate and obtain regulatory approval for it;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing or likelihood of regulatory filings and approvals, including our planned filing of an investigational new drug application for our MS product candidate;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the commercialization, marketing and manufacture of any product candidate, if approved;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the pricing and reimbursement of any product candidate, if approved;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the rate and degree of market acceptance and clinical utility of any products for which we receive regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the implementation of our strategic plans for our business, product candidates, and technology;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, PCA platform, and technology;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">estimates of our expenses, future revenues, capital requirements, and our needs for additional financing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to maintain and establish collaborations, including our License and Collaboration Agreement with Astellas Pharma Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our financial performance and the sufficiency of our financial resources; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">developments relating to our competitors and our industry, including the impact of government regulation.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report will prove to be accurate. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should read this </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Report and the documents that we reference in this </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> all of our forward-looking statements by these cautionary statements.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><a name="PART_I"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I"></a>PAR</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">T I</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_BUSINESS"></a><a name="ITEM_1_BUSINESS"></a>Item 1. Business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biotechnology company focused on harnessing the body&#8217;s innate biology to repair or reverse damage caused by a broad range of degenerative diseases and an industry leader in the science and development of medicines for inner-ear cellular regeneration and hearing restoration.&#160;Our initial focus is on advancing our lead product candidate, FX-322, through clinical studies with the goal of developing and commercializing a medicine to help millions of patients with the most common form of hearing loss and build upon the potential of regenerative therapeutics for hearing. We believe we are the only company to have shown clinical results demonstrating the potential of a therapeutic<font style="font-size:12pt;"> </font>candidate to help patients with the most common form of hearing loss and that FX-322 has the potential to meaningfully improve overall hearing function and enhance quality of life. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our proprietary approach, called Progenitor Cell Activation, or PCA, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue.&nbsp;&nbsp;These progenitor cells, which are closely related to stem cells, are already resident in the targeted location in the body and programmed to develop and differentiate into specific cell types within an organ, which we believe provide us the opportunity to pursue multiple proposed indications and develop potential<font style="font-size:12pt;"> </font>treatments for an array of degenerative diseases throughout the body. To that end, in addition to our lead program in hearing, we are working to rapidly advance discovery efforts focused on using our PCA approach to potentially remyelinate nerves in patients with multiple sclerosis, or MS, and are advancing this program in collaboration with The Scripps Research Institute, or Scripps, and Cambridge Enterprise Limited (the technology transfer arm of the University of Cambridge), or Cambridge. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our hearing program is for a condition called sensorineural hearing loss, or SNHL, which is the most prevalent type of hearing loss, typically caused by permanent loss of sensory hair cells in the cochlea within the ear. Cochlear sensory hair cells can be lost by noise exposure, as a result of aging, certain viral infections or exposure to ototoxic drugs.  FX-322 aims to treat the underlying cause of SNHL by regenerating hair cells through the activation of progenitor cells already present in the cochlea. In July 2019, we entered into a license and collaboration agreement, or the Astellas Agreement, with Astellas Pharma Inc., or Astellas, under which we granted them rights to develop and commercialize FX-322 outside of the United States.&nbsp;&nbsp;In September 2019, at the annual meeting of the American Academy of Otolaryngology, the principal investigator from our Phase 1/2 clinical trial evaluating FX-322 in 23 patients with stable SNHL shared preclinical and clinical data that showed that FX-322 was well-tolerated with no serious adverse effects and that we observed statistically significant and clinically meaningful improvement in key measures of hearing loss, including word recognition, or WR, and clarity of sound. The same results were shared at the 2nd Annual International Symposium on Inner Ear Therapeutics in November 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34906381"></a><a name="_Hlk34650132"></a>In October 2019, we commenced dosing in a Phase 2a clinical trial of FX-322 and the U.S. Food and Drug Administration, or FDA, granted FX-322 Fast Track designation.&nbsp;&nbsp; The goals of the trial are to further establish the hearing signal observed in the Phase 1/2 clinical trial, evaluate the impact of multiple doses and provide insights on endpoints and patient population for further studies. The key efficacy endpoints are WR, words-in-noise, or WIN, and standard pure tone audiometry in the range of 250 to 8000 Hz.<a name="_Hlk34650132"></a> The exploratory efficacy endpoints are extended high frequency pure tone audiometry, the Tinnitus Functional Index, or TFI, and the Hearing Handicap Inventory in Adults, or HHIA.<font style="font-size:11pt;font-family:Calibri;"> </font>Our Phase 2a clinical trial of FX-322 is a randomized, double blind, placebo-controlled single- and repeat dose clinical trial of up to&nbsp;&nbsp;96 patients with &#8220;stable&#8221; hearing loss, meaning that a patient&#8217;s hearing deficit has remained consistent over a defined period of time based on a patient&#8217;s audiograms. All subjects in the clinical trial have meaningful WR deficits including patients who are considered to have &#8220;mild&#8221; hearing loss.&nbsp;&nbsp;The Phase 2a clinical trial is also using validated measures of hearing function, including WR, WIN, and pure tone audiometry. Building upon the Phase 1/2 clinical trial, which only included one dose of FX-322, the Phase 2a study utilizes four dose cohorts, and all patients will be regularly tested over the course of seven months.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk32657877"></a><a name="_Hlk32657877"></a>As of March 26, 2020, the Phase 2a clinical trial was approximately at the halfway point of enrollment based on the original trial design and we are continuing to enroll and dose patients in the trial. However, we have observed an impact on the Phase 2a clinical trial from the COVID-19 pandemic as several clinical trial sites have informed us that they have temporarily halted enrollment in the trial.&nbsp;&nbsp;We expect that the effects of the pandemic may result in other clinical trial sites being similarly affected for an unknown period of time, slowing or temporarily halting patient enrollment and potentially impacting patient retention.&nbsp;&nbsp;As a result, we will provide updated guidance on the timing of completion and reporting of top-line data of the Phase 2a clinical trial once we better understand the extent of the impact of the COVID-19 pandemic on the trial. Nevertheless, we do believe that, if necessary,<font style="font-size:12pt;"> </font>we could achieve the key objectives of the Phase 2a clinical trial with fewer study subjects than originally designed.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, no drug therapies have been approved by the FDA or, to our knowledge, by other regulatory bodies, for the treat</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ment of SNHL. Existing devices such as hearing aids amplify sounds but do not replace hair cells, which have roles in clarifying sound and improving speech intelligibility, particularly in noisy environments. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hearing aids also cannot repair the underlying pathology of hearing loss.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While hearing loss is often thought to be caused by aging, the condition is strongly correlated with living in an industrialized society. According to the World Health Organization, or WHO, more than 800&#160;million adults suffer from hearing loss worldwide, and, according to the National Institutes of H</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ealth, or NIH, more than 90% of people with hearing loss have SNHL. Based on our estimates, we believe that 59 million people in the United States alone have SNHL. The WHO also estimates that 1.1&#160;billion children and adults ages 12 to 35 years old are at r</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">isk for hearing loss from recreational noise exposure. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk32674668"></a>Under our agreement with Astellas, Astellas is responsible for the development and commercialization of FX-322 outside of the United States. As consideration for the licensed rights under the Astellas A<a name="_Hlk32674668"></a>greement, Astellas paid us an upfront payment of $80.0 million in July 2019 and has agreed to pay potential development milestone payments of up to $230.0 million. Specifically, we would receive development milestone payments of $65.0 million and $25.0 million upon the first dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively, and $100.0 million and $40.0 million upon the first dosing of a patient in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively.&nbsp;&nbsp;If the Astellas licensed products are successfully commercialized, we would be eligible for up to $315.0 million in potential commercial milestone payments plus tiered royalties on any future product sales ranging from low- to mid-teen percentages. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our MS program focuses on activating oligodendrocyte progenitor cells in the central nervous system to repair the myelin sheath that protects nerves and may have the potential to reverse damage done by the disease. We intend to submit an investigational new drug application, or IND, to FDA, for an MS product candidate in the second half of 2021. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our PCA platform has the potential to produce a new class of medicines and provide transformative benefits for patients across a wide range of degenerative conditions, including diseases of the muscle, gastrointestinal tract, skin, and bone. Our PCA platform has the following key attributes: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Activates progenitor cells in the right location</font><font style="font-family:Times New Roman;">. We overcome the major challenge of delivering and integrating cells into the proper location within tissue. Our small molecule therapeutic candidates are designed to activate the body&#8217;s own progenitor cells at the desired location in targeted tissues. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Enables ease of manufacturing</font><font style="font-family:Times New Roman;">. We eliminate the need to remove and grow live cells </font><font style="font-style:italic;font-family:Times New Roman;">ex vivo</font><font style="font-family:Times New Roman;">, which can be costly and complex to manufacture, difficult to control quality, and may pose potential safety risks. In contrast, our small molecule therapeutic candidates will be produced using standard manufacturing methods. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Avoids permanent genetic changes</font><font style="font-family:Times New Roman;">. Instead of altering genes, our small molecules are designed to temporarily activate the innate genes that play a central role in the development of organs and tissues. This small molecule approach could create a disease-modifying or restorative effect without changing the body&#8217;s genetic code. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our product pipeline </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our PCA therapeutic candidate pipeline and discovery research programs: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g5lvsimk4gaq000001.jpg" title="" alt="" style="width:671px;height:303px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our team and history </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our company was founded in 2014 with the goal of creating medicines based on breakthrough research focused on activating the body&#8217;s regenerative potential. In their groundbreaking research, Professors Robert S. Langer at the Massachusetts Institute of Technology and Jeffrey Karp at Harvard Medical School, decoded the natural signals between cells that make the intestine one of the most regenerative organs in the body through the continuous activation of progenitor cells. Recognizing that similar progenitor cells were present but inactive in other organs, they discovered how to adapt these natural signals using small molecules to temporarily activate progenitor cells in other organs, including the cochlea, and create a localized healing response. Using these insights, we are developing FX-322 for the treatment of SNHL, and, in a Phase 1/2 trial of FX-322 in stable hearing loss patients, we have observed statistically significant improvement in WR, a key measure of hearing function. Further, we have identified several additional potential indications for our PCA platform and expanded our team to incorporate domain expertise to pursue our goal of becoming a fully integrated biotechnology company. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our leadership team includes experienced biotech executives David L. Lucchino, our Chief Executive Officer, Christopher R. Loose, our Chief Scientific Officer, Carl P. LeBel, our Chief Development Officer, Dana C. Hilt, our Chief Medical Officer,<font style="font-size:12pt;"> </font>Wendy S. Arnold, our Chief People Officer, and Will McLean, Vice President of Regenerative Medicine and a pioneer in inner ear stem cell biology. We have also assembled a world-class team of leaders in regenerative biology, otology, drug development, and drug delivery. Our Clinical Advisory Board is comprised of leaders in hearing science and technology who shape how the community thinks about hearing function and restoration. Our Regenerative Medicine Advisory Board members are at the forefront of scientific discovery on the activation of progenitor cells and their potential application to therapeutic interventions in diseases of multiple tissues and organs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our strategy </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to create and commercialize therapeutics to potentially transform the lives of patients by repairing or reversing damage done to cells, tissue, and organs. To do so, we are implementing the following strategies: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Advance development of FX-322 for the treatment of SNHL</font><font style="font-family:Times New Roman;">. We believe our lead product candidate has the potential to improve hearing function for the millions of patients affected by SNHL who currently have no therapeutic options. In our Phase 1/2 clinical trial evaluating FX-322 in 23 patients with stable SNHL, we observed a statistically significant improvement in WR, a key measure of hearing function. In addition, FX-322 was observed to be well-tolerated with no serious adverse effects. We commenced dosing in a Phase 2a clinical </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">trial of FX-322 in October</font><font style="font-family:Times New Roman;"> 2019</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;As of March 26, 2020, the Phase 2a clinical trial was approximately at the halfway point of enrollment based on the original trial design and we are continuing to enroll and dose patients in the trial. However, we have observed an impact on the Phase 2a clinical trial from the COVID-19 pandemic as several clinical trial sites have informed us that they have temporarily halted enrollment in the trial.&nbsp;&nbsp;As a result, we will provide updated guidance on the timing of completion and reporting of top-line data of the Phase 2a clinical trial once we better understand the extent of the impact of the COVID-19 pandemic on the trial. Nevertheless, we do believe that, if necessary, we could achieve the key objectives of the Phase 2a clinical trial with fewer study subjects than originally designed. </font><font style="font-family:Times New Roman;"> </font><font style="font-family:Times New Roman;">We received Fast</font><font style="font-family:Times New Roman;"> </font><font style="font-family:Times New Roman;">Track Designation </font><font style="font-family:Times New Roman;">from </font><font style="font-family:Times New Roman;">the FDA for FX-322 for the treatment of SNHL in adults</font><font style="font-family:Times New Roman;"> in October 2019</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Establish our position as a leader in the field of hearing function. </font><font style="font-family:Times New Roman;">We plan to continue to grow our discovery organization and add experts in the field of otology to drive the optimization of our PCA approach for the treatment of hearing loss. We also plan to expand our presence in the field of hearing restoration and to work closely with the broader community of advocates, physicians, and payors to bring new treatments to patients globally. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_Hlk34126144"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Expand the opportunities of our PCA platform beyond hearing.</font><font style="font-family:Times New Roman;"> We believe our PCA platform has the potential to address a wide range of clinical applications. We will continue to invest in research and development to enhance our PCA platform with the goal of delivering new therapeutics in additional indications, such as diseases of the muscle, gastrointestinal tract, skin, and bone. We identified MS as a disease where PCA has the potential to produce a restorative effect by stimulation of oligodendrocyte precursor cells (OPCs) to myelinate axons.<a name="_Hlk34126144"></a> We have obtained worldwide licenses for intellectual property from Scripps and Cambridge, on approaches to promote remyelination of nerve fibers. We are working to identify a product candidate for the treatment of MS and intend to submit an IND to the FDA for an MS product candidate in the second half of 2021. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Continue to build strategic collaborative relationships</font><font style="font-family:Times New Roman;">. Given the broad potential opportunity of our PCA platform, we believe entering into strategic research, development, and commercial collaborations in select therapeutic areas may provide an attractive avenue to facilitate the capital-efficient development of our PCA platform and product pipeline. We believe these strategic collaborations could potentially provide significant funding to advance our product candidates while allowing us to benefit from the development and therapeutic area expertise of our collaborators. We may collaborate with large pharmaceutical companies, biotechnology companies, and academic institutions to maximize the potential of our PCA platform to create new therapies for patients. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our approach: Progenitor cell activation within the body </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are pioneering a new class of small molecule therapeutics designed to activate progenitor cells already present within the body to create healthy functional tissues and organs. We developed our PCA platform to identify combinations of small molecules that selectively activate progenitor cells to regenerate tissues. Our initial therapeutic focus is SNHL. We believe that our preclinical and clinical studies in SNHL have validated the potential of our PCA platform to provide a new approach to regenerative medicine. Other potential applications of our PCA platform include, but are not limited to, diseases of the muscle, gastrointestinal tract, skin, and bone. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The graphic below illustrates the application of our PCA platform to activate progenitor cells and create healthy functioning target cells. Our small molecules are designed to activate key genes in a progenitor cell, which enable </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the cell</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to go through asymmetric division, leaving behind a copy of the progenitor cell as well as</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> creating</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a functional cell, such as a hair cell. This asymmetric division process is </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a common mechanism used</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> during the natural development and repair of tissues. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g5lvsimk4gaq000002.jpg" title="" alt="" style="width:556px;height:316px;"></p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Relationship between stem cells and progenitor cells </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All cells in the human body arise from a single unspecialized, or undifferentiated, cell type called a pluripotent stem cell. Two of the key characteristics of pluripotent stem cells are their ability to renew themselves through cell division and the ability to differentiate into any cell type. Progenitor cells have similar self-renewal properties as pluripotent stem cells. However, progenitor cells are programmed to develop and differentiate into specific cell types within an organ. This process can be visualized using Waddington&#8217;s epigenetic landscape, which depicts a pluripotent stem cell as a ball rolling down a hill as development progresses (see graphic below). As the ball commits to specific valleys, the cell becomes more specialized and increasingly commits to a tissue-specific fate, such as a progenitor cell. The progenitor cells are programmed to create specific cell types, and, in some cases, allow mature tissue and organs to repair and renew. However, researchers have discovered that many organs throughout the human body that do not spontaneously regenerate do contain inactive progenitor cells that, if stimulated, are potentially available to drive regeneration. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Over the course of several decades, multiple attempts have been made to harness the regenerative potential of stem cells. More recently, the 2012 Nobel Prize in Physiology or Medicine was awarded to Dr.&#160;Shinya Yamanaka for discovering how to create induced pluripotent stem cells by adding four genetic factors to a fully differentiated cell, as illustrated by the solid black arrow in the graphic below. However, the Yamanaka factors cannot be applied <font style="font-style:italic;">in vivo</font>, and<font style="font-style:italic;"> </font>it has proven challenging to manufacture pluripotent or other human stem cells outside of the body and to control their differentiation to produce a particular cell type. Further, delivering and properly integrating these cells back into the body adds substantial complexity. Using another approach, some investigators have tried to force progenitor cells within the body to directly convert into other cell types through a process called trans-differentiation, as illustrated by the dotted black arrow in the graphic below. However, trans-differentiation may deplete progenitor cells, which reduces the target cell population for future treatments. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our PCA approach bypasses the challenges presented by stem cell therapies by utilizing small</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">molecule therapeutics to temporarily reactivate progenitor cells that are already located at the tissue target site within the body and are pre-programmed to make specific cell types. Our combinations of small molecules are designed to induce a progenitor cell to temporarily enter an active state, where it then divides asymmetrically, replacing itself (blue arrows) and regenerating a desired cell type (orange arrow). Asymmetric division occurs when organs naturally regenerate, so progenitor cells are thought to be maintained for future use. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g5lvsimk4gaq000003.jpg" title="" alt="" style="width:612px;height:316px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">=</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Key attributes of our PCA platform </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our discoveries in regenerative medicine allow us to activate the innate and under-utilized capabilities of progenitor cells. We believe our PCA platform represents a transformative step in the evolution of regenerative medicine by providing the following key attributes: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Activates progenitor cells in the right location</font><font style="font-family:Times New Roman;">. We overcome the major challenge of delivering and integrating cells into the proper location within tissue. Our small molecule therapeutic candidates activate the body&#8217;s own progenitor cells at the desired location in targeted tissues. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Enables ease of manufacturing</font><font style="font-family:Times New Roman;">. We eliminate the need to remove and grow live cells </font><font style="font-style:italic;font-family:Times New Roman;">ex vivo</font><font style="font-family:Times New Roman;">, which can be costly and complex to manufacture, difficult to control quality, and may pose potential safety risks. In contrast, our small molecule therapeutic candidates will be produced using standard manufacturing methods. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Avoids permanent genetic changes</font><font style="font-family:Times New Roman;">.&#160;&#160;&#160;&#160;Instead of altering genes, our small molecules are designed to temporarily activate the innate genes that play a central role in the development of organs and tissues. This small molecule approach could create a disease-modifying or restorative effect without changing the body&#8217;s genetic code. In addition, we believe we avoid the risk of acquiring immune reactivity to our therapeutics, which is commonly associated with genetically modifying cells. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our therapeutic discovery process </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We utilize a proprietary process to identify small molecule combinations for activating progenitor cells. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Discovery in the right context</font><font style="font-family:Times New Roman;">. Traditional drug screening uses immortalized cell lines that are convenient for use in a laboratory but may not reflect the complex biology of tissue-specific cell types in the body. In our discovery process, we develop primary progenitor cell assays that are designed to maintain these cells in their </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">natural state in order to increase the likelihood of successful drug discovery and translation into an effective tissue-specific therapeutic. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.71%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Decoding and controlling activation pathways for progenitor cells</font><font style="font-family:Times New Roman;">. We use our accumulated insights into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; progenitor cell signaling and aging to identify biological pathways that may activate a specific progenitor cell. We then select and apply combinations of small molecules from our proprietary toolbox of compounds to modulate the chosen biological pathways and achieve PCA.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By assessing our small molecule combinations in a highly relevant context, we and our collaborators have applied this discovery process to identify compounds that activate progenitor cells in numerous tissues. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our hearing program </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We first applied our PCA platform to create FX-322, our lead product candidate designed to restore hearing function in patients with SNHL. We completed a Phase 1/2 clinical trial in 23 patients with stable SNHL in which we observed a statistically significant improvement in WR, a key measure of hearing function, and FX-322 was observed to be well-tolerated. We believe that FX-322 has the potential to meaningfully improve overall hearing function and significantly enhance quality of life for patients with hearing loss.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019 we commenced dosing in a Phase 2a clinical trial of FX-322 in which we may enroll up to 96 patients with stable SNHL. The goals of the trial are to further establish the hearing signal seen in the Phase 1/2 study, evaluate the impact of multiple doses and provide insights on endpoints and patient population for further studies.&nbsp;&nbsp;The key efficacy endpoints are WR, WIN, and standard pure tone audiometry in the range of 250 to 8000 Hz. The exploratory efficacy endpoints are extended high frequency pure tone audiometry, the Tinnitus Functional Index, or TFI, and the Hearing Handicap Inventory in Adults, or HHIA. Frequency&#8217;s Phase 2a clinical trial of FX-322 is a randomized, double blind, placebo-controlled single and repeat-dose clinical trial in which we may enroll up to 96 patients aged 18 to 65 with &#8220;stable&#8221; hearing loss, meaning that a patient&#8217;s hearing deficit has remained consistent over a defined period of time based on a patient&#8217;s audiograms. All subjects in the clinical trial have meaningful WR deficits including patients who are considered to have &#8220;mild&#8221; hearing loss. The Phase 2a clinical trial is also using validated measures of hearing function, including WIN, WR, and pure tone audiometry. Building upon the Phase 1/2 clinical trial, which only included one dose of FX-322, the Phase 2a study utilizes four dose cohorts, and all patients will be regularly tested over the course of seven months.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 26, 2020 the Phase 2a clinical trial was approximately at the halfway point of enrollment based on the original trial design and we are continuing to enroll and dose patients in the study. However, we have observed an impact on the Phase 2a clinical trial from the COVID-19 pandemic as several clinical trial sites have informed us that they have temporarily halted enrollment in the trial. We expect that the effects of the pandemic may result in other clinical trial sites being similarly affected for an unknown period of time, slowing or temporarily halting patient enrollment and potentially impacting patient retention. As a result, we will provide updated guidance on the timing of completion and reporting of top-line data of the Phase 2a clinical trial once we better understand the extent of the impact of the COVID-19 pandemic on the trial.&nbsp;&nbsp;Nevertheless, we believe that, if necessary, we could achieve the key objectives of the Phase 2a clinical trial with fewer study subjects than originally designed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impact and prevalence of hearing loss </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">According to the WHO, approximately 800&#160;million adults suffer from hearing loss worldwide, and, according to the NIH more than 90% of people with hearing loss have SNHL. Based on our estimates, we believe that 59&#160;million people in the United States alone have SNHL. The WHO also estimates that 1.1&#160;billion children and adults ages 12 to 35 years old are at risk for hearing loss from recreational noise exposure. In middle- and high-income countries, the WHO estimates that nearly 50% of people aged 12 to 35 listen to personal audio devices at unsafe sound levels. Moreover, damage from noise exposure in early childhood can render the ears more susceptible to the effects of aging. Noise exposure is difficult to avoid in modern society. Noise at restaurants, for example, routinely climbs into the high 70-decibel, or dB, range, equivalent to a canister vacuum cleaner, and sometimes to the mid-80 dB, as loud as a nearby diesel truck. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>U.S. prevalence of hearing loss, including prevalence of SNHL generally, moderate-to-profound SNHL, and diagnosis of SNHL, divided between hearing loss in one ear or both ears, is shown in the graph below, which is from a study commissioned by us from Health Advances LLC. According to the study, U.S. prevalence of hearing loss is estimated to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">grow to more than 78&#160;million patients by 2025. We estimate that the prevalence of patients with moderate to moderately severe SNHL is 30.3&#160;million. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">U.S. Hearing Loss Patient Population (2019) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g5lvsimk4gaq000004.jpg" title="" alt="" style="width:594px;height:228px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After a patient first complains of hearing loss, which is most often to their primary care physician, patients with SNHL are primarily managed by otolaryngologists, who are trained as ear, nose, and throat specialists, or ENTs. In the United States, there are about 13,000 audiologists and about 12,500 ENTs. Developing a therapeutic to potentially modify an underlying cause of SNHL may provide a critically important treatment option for this group of health-care providers and their patients. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are also further direct and indirect impacts on individuals suffering from SNHL. Hearing loss profoundly affects an individual&#8217;s ability to participate in the social interactions of daily life, which can lead to feelings of loneliness, isolation, and frustration. Untreated hearing loss is associated with a 50% increase in dementia and a 40% increase in depression. Adults with hearing loss also have higher unemployment rates than non-hearing-impaired adults, and a relationship between hearing loss and diminished employment and advancement opportunities has been reported. According to a 2017 study in the medical journal <font style="font-style:italic;">The Lancet</font>, hearing loss is the largest modifiable risk factor for developing dementia.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Biology and measurement of hearing </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As shown in the figure below, we hear sounds when sound waves enter the inner ear and generate movement of the fluid in the cochlea, a portion of the inner ear that looks like a snail shell. This fluid movement causes hair cells within the cochlea to bend and in turn generate electrical signals that are transmitted to the brain via the auditory nerve. The cochlea is arranged so that hair cells at the base detect high frequencies and hair cells at the apex detect low frequencies. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<img src="g5lvsimk4gaq000005.jpg" title="" alt="" style="width:594px;height:287px;"><font style="font-size:12pt;"></font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Humans are born with about 15,000 hair cells in the cochlea of each ear. Hair cells are commonly lost due to noise exposure in work settings, travel or leisure activities, or as a result of aging, certain viral infections or exposure to ototoxic drugs. Lost hair cells do not spontaneously regenerate. Over time, hearing loss can accumulate with greater prevalence at high frequencies. The left panel of the figure below shows a picture of the inside of a healthy cochlea, with one row of inner hair cells, or IHCs, and three rows of outer hair cells, or OHCs. OHCs amplify or dampen sound volume and tune the cochlea to detect specific frequencies. IHCs convert sound waves into nerve impulses that are sent to the auditory nerve. Functional hair cells allow the auditory system to focus on a sound and filter it appropriately throughout the cochlea. The right panel shows a cochlea after noise damage, with both IHCs and OHCs missing. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Healthy and Noise-Damaged Cochlea </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g5lvsimk4gaq000006.jpg" title="" alt="" style="width:611px;height:174px;"></p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The two primary components for hearing testing are intelligibility, or the ability to understand spoken words, and the audibility or loudness of sound. While amplifying devices such as hearing aids can make sounds louder, they have limited ability to improve intelligibility, particularly in noisy environments. Intelligibility is particularly important to understand speech in social settings such as in meetings or at restaurants, where filtering sound is critical for communication. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intelligibility is typically measured by playing a list of words that are repeated back by the person being tested and scoring based on the number of words that the person gets correct. The two validated testing methods of speech intelligibility that are most widely used by audiologists are: word recognition, or WR, where patients are asked to identify monosyllabic words delivered at a loud, but conversational volume level, and words-in-noise, or WIN, where patients are asked to identify monosyllabic words in the presence of background, multi-talker noise. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audibility is determined by measuring hearing function at different levels of loudness and pitch or frequency. Patients are most often tested using pure tone audiometry, in which a tone is played at a particular frequency and patients are asked to indicate whether they can hear the tone at varying levels of loudness. Loudness is recorded in dB. Frequency is recorded in Hertz, or Hz, and is generally measured in the range of 250 to 8000 Hz. According to the WHO, normal hearing is defined as the ability to hear sounds at a loudness value of less than 26 dB, which is the average of loudness values measured at a range of low, middle, and high frequencies, such as 500, 1000, 2000, and 4000 Hz. The larger the loudness value needed for a patient to hear sounds the greater the decline in hearing function, or more severe hearing loss. The graphic below depicts the severity of hearing loss across a range of frequencies based on the American Speech-Language-Hearing Association scale. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g5lvsimk4gaq000007.jpg" title="" alt="" style="width:439px;height:252px;"></p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Limitations of current treatment options </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current treatment options for hearing loss have significant limitations and none are disease modifying. The only available treatments for hearing loss are hearing aids, or in extreme cases, cochlear implants. No drug therapies have been approved by the FDA or, to our knowledge, by other regulatory bodies, for the treatment of SNHL. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Hearing aids </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hearing aids help many patients cope with mild-to-moderate hearing loss and are used or have been tried by more than 10&#160;million patients in the United States. Only one in four patients with hearing loss has ever used hearing aids, and approximately half of patients who seek medical assistance for their hearing loss do not get hearing aids.&nbsp;&nbsp;Limitations of hearing aids include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Poor sound quality</font><font style="font-family:Times New Roman;">. Hearing aids amplify sounds, allowing patients to perceive sounds that would otherwise be too soft for them to hear, but do not address the loss of hair cells, which determine sound quality and intelligibility, particularly in noisy environments. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Challenges in social settings</font><font style="font-family:Times New Roman;">. The wide range of frequencies and sharp tuning provided by hair cells enables the auditory system to accurately recognize and distinguish different sounds, allowing the brain to focus on a single sound source. Hearing aids on the other hand typically amplify all sounds and do not enable this important sound-processing capability. As a result, interactions in social settings, which require distinguishing one speaker among many sound sources, are significantly impaired. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Difficulties with background noise</font><font style="font-family:Times New Roman;">. Patients with hearing loss may become more sensitive to background noise, and many patients with hearing aids turn them off in noisy environments. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-style:italic;font-family:Times New Roman;">Stigma associated with wearing a visible device</font><font style="font-family:Times New Roman;">.</font><font style="font-weight:bold;font-family:Times New Roman;"> </font><font style="font-family:Times New Roman;">Some patients refuse to wear hearing aids, or do not wear them regularly, as they do not want to be stigmatized or identified as having a physical handicap. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Need for maintenance</font><font style="font-family:Times New Roman;">.</font><font style="font-weight:bold;font-family:Times New Roman;"> </font><font style="font-family:Times New Roman;">Hearing aids must be replaced, on average, every four to six years, need regular battery replacement, and can require repair due to damage during use. Medicare and most private insurance plans do not pay for hearing aids, and most patients must pay for these devices out of pocket. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Cochlear Implants </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients with severe or profound hearing loss who have not been helped by hearing aids may be candidates for a cochlear implant. Of the roughly one million people in the United States who qualify, only about 100,000 patients have cochlear implants. Cochlear implants comprise an external microphone, sound processor and transmitter system, which receive sounds from the environment, and an implanted receiver and electrode system that directly stimulates the auditory nerve. Cochlear implants do not mimic natural hearing, and patients with cochlear implants need to learn to interpret the low-resolution electric signal produced by the device as sound. Cochlear implants also require an invasive, costly surgical procedure. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our lead product candidate: FX-322 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Using our PCA platform, we are developing our lead product candidate, FX-322, for the treatment of SNHL. FX-322 is designed to treat the underlying cause of SNHL by regenerating hair cells through activation of progenitor cells already present in the cochlea. We believe that FX-322 has the potential to meaningfully improve overall hearing function and significantly enhance quality of life for patients with hearing loss. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Mechanism of Action </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By studying the most regenerative organ in the body, the intestine, we discovered that signaling for proliferation and differentiation among stem cells could be replicated with small molecules. Specifically, activating the Wnt pathway, which is fundamental for cell growth, using a glycogen synthase kinase 3, or GSK3, inhibitor and inhibiting histone deacetylase, or HDAC, caused intestinal stem cells expressing the protein Lgr5 to proliferate. The inner ear contains progenitor cells with the Lgr5 protein that do not regenerate on their own. On the hypothesis that these progenitor cells lacked the signals required for regeneration, we applied a GSK3 inhibitor and HDAC inhibitor to these cells and found that they proliferated and regenerated lost hair cells. Based on this discovery, we created FX-322, which is a proprietary combination of an FDA-approved HDAC inhibitor, sodium valproate, and a new chemical entity that inhibits GSK3. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Administration </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FX-322 is our proprietary thermoreversible polymer formulation that is administered through the eardrum, or intratympanically, into the middle ear in a procedure that takes approximately 10 to 15 minutes. The intratympanic administration procedure is generally well-tolerated and is routinely performed by ENTs as an office-based procedure. FX-322, which is liquid at room temperature, gels at body temperature inside the middle ear, allowing the active ingredients to diffuse into the inner ear and reach the cochlea. Similar thermoreversible polymer formulations have been used in FDA-approved products for other indications in the ear. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The image below shows delivery of FX-322 that turns to a gel in the middle ear. The drug diffuses into the cochlea and is expected to create the greatest concentration of drug in the high frequency region of the cochlea. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g5lvsimk4gaq000008.jpg" title="" alt="" style="width:593px;height:299px;"></p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical results </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Phase 1/2 clinical trial </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted a Phase 1/2 clinical trial of FX-322 in which we enrolled 23 adult patients aged 33 to 64 with an established diagnosis of mild to moderately severe stable SNHL, defined as the average pure tone value of 26 to 70 dB at the 500, 1000, 2000 and 4000 Hz frequencies, who had no change of 10&#160;db or more at any frequency for more than six months. Fourteen patients had mild SNHL and nine patients had moderate to moderately severe SNHL. Of the nine moderate to moderately severe patients, six were randomized to FX-322 and three to placebo. In this trial, 15 patients were treated with a single injection of FX-322 and eight patients received placebo. Each patient had a documented medical history consistent with either noise-induced hearing loss, or NIHL, typically from noise exposure at work, or sudden SNHL, or SSNHL, which is characterized as a loss of 30 dB at three adjacent frequencies occurring over a 72-hour period. All patients had stable SNHL, meaning their hearing function at study entry was not significantly different based on a documented audiogram from at least six months prior to the study. Hearing function, specifically speech intelligibility, was assessed using WR and WIN. Hearing loudness was also measured using pure tone audiometry. Patients were randomized to a single injection of FX-322 or placebo administered at one of two different dose volumes (0.05 mL and 0.2 mL) to assess the safety of FX-322 administration and systemic exposure to FX-322. Follow-up visits occurred at 15, 30, 60, and 90 days after injection. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The objectives of the trial were to assess: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the systemic safety of FX-322; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the plasma pharmacokinetic profile to determine the systemic exposure to FX-322; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the effect of FX-322 on measures of ear health and hearing function. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FX-322 was observed to be well-tolerated in this trial. No serious adverse events were observed, and all treatment-related adverse events were mild, procedure-related, and generally resolved within minutes after dosing. We also observed limited concentrations of the FX-322 components in systemic circulation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the prospective analysis, we conducted a prospective statistical analysis where we tested whether the Day 90 WR value for each patient fell outside of the 95% confidence interval compared to their baseline WR value. A confidence interval, or CI, is a range of values in which, statistically, there is a specified level of confidence where the result lies. In this patient-by-patient analysis, we observed statistically significant and clinically meaningful increases in WR in four of 15 patients treated with FX-322 at Day 90, who were among the six FX-322 patients that had moderate to moderately severe SNHL (as shown in the figure below).We also observed improvements for the two remaining FX-322 patients in the study that had moderate to moderately severe SNHL in the range of 30-50% from their baseline score, but these improvements were not statistically significant .</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There was no apparent association between WR improvements and whether the patients had stable NIHL, or stable SSNHL, and similar results were obtained with both dose volumes. This is consistent with published work showing drug delivery to the cochlea depends more on the concentration of the drug than the volume of injection. There were no clinically meaningful WR improvements observed in the placebo group. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g5lvsimk4gaq000009.jpg" title="" alt="" style="width:671px;height:293px;"></p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also performed a <font style="font-style:italic;">post hoc</font> analysis that showed a statistically significant improvement in WR by all FX-322-treated patients versus all placebo patients (p=0.010). A p value, as expressed in the data above, is the probability that the difference between two data sets was due to chance. The smaller the p value, the more likely the differences are not due to chance alone. In general, if the p value is less than or equal to 0.05, the outcome is statistically significant. The data are presented as adjusted mean relative percent change from baseline in the figure below. FX-322 treated patients saw improvements as early as 15 days after treatment that were sustained over 90 days. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Word Recognition </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g5lvsimk4gaq000010.jpg" title="" alt="" style="width:515px;height:348px;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We performed an additional </font><font style="font-style:italic;">post hoc</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> analysis on WIN data. As shown in the figure below, the adjusted mean relative percent change from baseline was assessed at 15, 30, 60, and 90 days after injection, and a trend in improvement was seen in FX-322-treated patients versus placebo. Also, there were non-statistically significant trends in improved WIN scores at Day 90 in the four FX-322, treated patients that had statistically significant and clinically meaningful improvements in WR in the prospective statistical analysis. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Words-In-Noise </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g5lvsimk4gaq000011.jpg" title="" alt="" style="width:515px;height:328px;"></p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We assessed audiometric changes from 250 Hz to 8000 Hz for all patients. Since drug enters closest to the high frequency region, the greatest drug exposure is expected to occur in the high frequency region. While no statistical differences were observed at any frequency when comparing pooled treatment groups, four of the moderate to moderately severe FX-322 patients showed a 10 dB threshold improvement at 8000 Hz at Day 90. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Phase 2a clinical trial </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our analysis of the data from our Phase 1/2 clinical trial, we initiated a randomized, double-blind, placebo-controlled, single- and repeat-dose Phase 2a clinical trial of FX-322 in the fourth quarter of 2019. We are in the process of enrolling up to 96 adults aged 18 to 65 with stable SNHL at up to approximately 20 sites in the United States. As in the Phase 1/2 clinical trial, patients must have a documented medical history consistent with either stable NIHL or stable SSNHL, meaning that a patient&#8217;s hearing deficit has remained consistent over a defined period of time based on a patient&#8217;s audiograms. &nbsp;&nbsp;All subjects in the clinical trial have meaningful word recognition deficits including patients who are considered to have &#8220;mild&#8221; hearing loss.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To explore how a single dose compares to multiple doses of FX-322, we are randomizing patients to one of four groups, each of which will receive four injections, once per week at weekly intervals starting at the initial visit. Group 1 will receive one injection of FX-322 and three injections of placebo. Group two will receive two injections of FX-322 and two injections of placebo. Group three will receive four injections of FX-322. Group four will receive four injections of placebo. Patients will have follow-up visits two weeks after dosing and then monthly for seven months. The efficacy endpoints of this trial are WR, WIN, and pure tone audiometry in the range of 250 to 8000 Hz. The exploratory efficacy endpoints are the Tinnitus Functional Index, the Hearing Handicap Inventory for Adults, and pure tone audiometry in the range of 9000 to 16000 Hz. The selection of the efficacy endpoints in this study builds on the learnings from the Phase 1/2 trial, and we believe will add to our knowledge on the potential ways in which FX-322 may improve hearing function. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 26, 2020, the Phase 2a clinical trial was </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approximately at</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the halfway point of enrollment based on the original trial design and we are continuing to enroll and dose patients in the study. However, we have observed an impact on the Phase 2a clinical trial from the COVID-19 pandemic as several clinical trial sites have informed us that they have temporarily halted enrollment in the trial. We expect that the effects of the pandemic may result in other clinical trial sites being similarly affected for an unknown period of time, slowing or temporarily halting patient enrollment and potentially impacting patient retention. As a result, we will provide updated guidance on the timing of completion and reporting of top-line data of the Phase 2a clinical trial once we better understand the extent of the impact of the COVID-19 pandemic on the trial.&nbsp;&nbsp;Nevertheless, we believe that, if necessary, we could achieve the key objectives of the Phase 2a clinical trial </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fewer study subjects than originally designed</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical studies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to commencing clinical trials, we tested FX-322 in multiple preclinical studies, including in human cells <font style="font-style:italic;">ex vivo</font> and functional hearing tests in mice <font style="font-style:italic;">in vivo</font>. In <font style="font-style:italic;">in vitro</font> testing of isolated human inner ear progenitor cells with the compounds comprising FX-322, we observed the formation of new progenitor cells and their subsequent conversion into hair cells. We also observed translation across species in our <font style="font-style:italic;">in vitro</font> studies of the inner ear progenitor cells from rhesus macaques in which a similar expansion of cell numbers were observed as in the <font style="font-style:italic;">in vitro</font> studies of human cells<font style="font-style:italic;">.</font> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also conducted <font style="font-style:italic;">ex vivo</font> testing in intact cochlea isolated from mice. To cause hair cell loss, we exposed the cochlea for 16 hours to an aminoglycoside antibiotic that is toxic to hair cells. We then treated the cochlea for 72 hours with the compounds comprising the active agents in FX-322. Aminoglycoside treatment (left panel in the figure below) killed more than 80% of the hair cells in the cochlea (shown in green). By contrast, cochlea treated with the compounds in FX-322 (shown in the middle panel) regenerated hair cells to a near native level, as shown graphically in the right panel. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restoration of Hair Cells in Mouse Cochlea </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g5lvsimk4gaq000012.jpg" title="" alt="" style="width:623px;height:167px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g5lvsimk4gaq000013.jpg" title="" alt="" style="width:190px;height:203px;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also tested FX-322 in a mouse model of severe noise-induced hearing loss. Following noise exposure, 47 mice were treated with FX-322 and 37 were treated with placebo. Hearing function was measured using auditory brainstem response, or ABR, in which the signal generated by the auditory nerve upon sensing sound is detected by electrodes on the scalp. We performed ABR testing after 24&#160;hours, and measured hearing recovery after 30 days. The figure below shows the percentage of mice treated with FX-322 (shown in orange) or with placebo (shown in blue) that achieved a hearing recovery of at least 10 dB at 20000 Hz, a mid-range frequency for mice. The improvement observed in the placebo-treated mice was due to recovery of temporary effects not related to hair cell death, which is typical following acute hearing loss. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hearing Recovery in Mice Treated with FX-322 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g5lvsimk4gaq000014.jpg" title="" alt="" style="width:286px;height:184px;"></p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also conducted pharmacokinetic tests in multiple species in which we observed that FX-322 administration achieved therapeutic levels of the active pharmaceutical ingredients in the cochlea. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our multiple sclerosis program </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have initiated a discovery program in MS after identifying MS as a degenerative disease that has the potential to be treated with small molecules that activate oligodendrocyte progenitor cells leading to remyelination. In 2017, we initiated a relationship with Scripps, where researchers had discovered that anti-muscarinic agents activate oligodendrocyte progenitor cells in the brain. We are pursuing this and other approaches to stimulating myelination of axons in MS.<font style="font-size:12pt;"> </font>Oligodendrocytes are responsible for making myelin, the protective sheath that covers nerve fibers. We believe that stimulating progenitor cells in the central nervous system to grow oligodendrocytes and remyelinate axons<font style="font-size:12pt;"> </font>could potentially reverse the damage caused by the immune system in MS. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The potential for anti-muscarinic drugs to treat the symptoms of MS was supported by an independently-run, double-blinded Phase 2 cross-over study entitled Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD), conducted at the University of California, San Francisco. In the ReBUILD study, 50 adult, relapsing-remitting MS patients with optic neuropathy were randomized to either clemastine, which has anti-muscarinic and anti-histaminic activity, or placebo, both in combination with standard of care. The primary endpoint of the study was visual evoked potential<font style="font-size:12pt;"> </font>latency, or VEP, a test commonly used for optic neuritis and other demyelinating events, such as MS. Patients treated with clemastine showed an improvement in VEPs indicating remyelination of optic nerve axons. The results of this study were published in the<font style="font-size:12pt;"> </font>medical journal <font style="font-style:italic;">The</font><font style="font-style:italic;font-size:12pt;"> </font><font style="font-style:italic;">Lancet</font> and showed a statistically significant improvement in VEP in patients treated using a single agent, clemastine. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been applying our expertise in finding synergistic combinations of small molecules for activating progenitor cells to the treatment of MS. We have licensed the worldwide rights to the related Scripps patent estate and are continuing to advance this discovery both on our own and through a sponsored research arrangement with Scripps. Through this work we have discovered combinations that enhance both <font style="font-style:italic;">in vitro</font> and <font style="font-style:italic;">in vivo</font> remyelination<font style="font-size:12pt;"> </font>over single agents, and have obtained a worldwide, exclusive license from Cambridge for one such combination. We are working to identify a product candidate for the treatment of MS, and we plan to submit an IND to the FDA for an MS product candidate in the second half of 2021. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview of multiple sclerosis </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">According to the National Multiple Sclerosis Society, nearly one million people in the United States are living with MS. The symptoms of MS include numbness or tingling, weakness, dizziness and vertigo, spasticity, vision problems, sexual problems, bladder or bowel problems, pain, cognitive changes, emotional changes, and depression. Most MS is initially<font style="font-size:12pt;"> </font>relapsing-remitting MS in which patients experience periods of new or relapsing symptoms followed by recovery and periods of remission. As the disease progresses the ability of the body to remyelinate&nbsp;&nbsp;axons decreases. This leads to a progressive neurological deficit.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has approved </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a number of</font><font style="font-size:12pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disease-modifying therapies for MS that reduce the immune system attack, which may reduce the number of relapses, delay progression of disability, and limit new disease activity. However, none of these products repair the central nervous system or lead to remyelination of the nerve</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> fibers, and there is no cure for MS. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our program aims to induce OPCs (Oligodendrocyte Precursor Cells) to become functional myelinating oligodendrocytes leading to myelin repair.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leveraging our PCA platform for future applications </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our hearing and MS programs, we believe our PCA platform has the potential to address a wide range of clinical applications. In directing our internal research, research collaborations, and in-licensing efforts, we intend to target areas of high unmet medical need for which the underlying disease process involves loss or degeneration of key cells that could be reversed using PCA. We believe the PCA platform could further be applied to diseases of the muscle, gastrointestinal tract, skin, and bone. We intend to continue to identify areas with high unmet need where our PCA platform and novel approach to regenerative medicine could lead to potentially disease-modifying therapeutics that create healthy functional tissues and improve patients&#8217; lives. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates consist of small chemical compounds to stimulate cell and tissue regeneration <font style="font-style:italic;">in vivo</font>. As a result, we can rely on the well-established and available manufacturing and drug-delivery technologies developed over decades by the pharmaceutical industry. We source our active pharmaceutical ingredients from contract manufacturers with a track record of FDA-compliant manufacturing. After rigorous internal and external quality control testing, we release these materials to additional contract manufacturers for formulation and packaging into final drug product for use in clinical testing. We expect to use a similar hybrid of internal and contract resources for commercialization of our products, at least until our operations reach a scale sufficient to justify investment in internal manufacturing capacity. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commercialization </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to directly market and commercialize our lead product candidate, FX-322 for the treatment of SNHL, if approved in the United States, by developing our own sales and marketing force, targeting ENTs and audiologists. Under the Astellas Agreement, Astellas has the right to market and commercialize FX-322 for the treatment of SNHL, if approved, outside of the United States. For any other product candidates that may be approved, we intend to establish marketing and commercialization strategies for each as we approach potential approval, and expect to be able to leverage our then-existing sales and marketing force. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual property </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to the development of our business, including by seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. We also rely on trade secrets, know-how, continuing technological innovation, and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in our field. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future commercial success depends, in part, on our ability to: obtain and maintain patent and other proprietary protection for commercially important technology, inventions, and know-how related to our business; defend and enforce our intellectual property rights, in particular our patent rights; preserve the confidentiality of our trade secrets; and operate without infringing, misappropriating, or violating the valid and enforceable patents and proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell, or importing products identical or similar to ours may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions of biotechnology and pharmaceutical companies like ours are generally uncertain and can involve complex legal, scientific, and factual issues. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. We also cannot ensure that patents will issue with respect to any patent applications that we or our licensors may file in the future, nor can we ensure that any of our owned or licensed patents or future patents will be commercially useful in protecting our product candidates and methods of manufacturing the same. In addition, the coverage claimed in a patent application may be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our products will be protected or remain protectable by enforceable patents. Moreover, any patents that we hold may be challenged, circumvented, or invalidated by third parties. See &#8220;Risk factors&#8212;Risks related to our intellectual property&#8221; for a more comprehensive description of risks related to our intellectual property. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU22"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In an effort to secure our intellectual property positions we generally file patent applications directed to our programs.&nbsp;&nbsp;As of February 29, 2020, we owned, licensed, or have an option to license 42 patent families.&nbsp;&nbsp;These patent families include 13 pending Patent Cooperation Treaty (PCT) applications, 20 U.S. patents, 25 ex-U.S. patents, 76 pending ex-U.S. patent applications, and three pending U.S. provisional applications.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The intellectual property portfolio for our lead programs as of February 29, 2020, are summarized below. Prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the U.S. Patent and Trademark Office may be significantly narrowed before issuance, if issued at all. We expect this may be the case with respect to some of our pending patent applications referred to below. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Hearing loss </p>
<p style="margin-bottom:0pt;margin-top:18pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.14%;">The patent portfolio for our Hearing Loss program is based upon our owned and in-licensed patent families that include patents and patent applications directed generally to compositions of matter, pharmaceutical compositions, and methods of using the same to treat hearing loss; and specifically directed to compositions of matter of our lead product FX-322, pharmaceutical compositions of FX-322 and methods of using the same to treat hearing loss. The in-licensed patents and patent applications are subject to license agreements with Massachusetts Institute of Technology and Massachusetts Eye and Ear Infirmary described herein. As of February 29, 2020, we have rights to, through ownership and in-licensing, 35 patent families, including 18 U.S. patents, 23 foreign patents, 22 pending U.S. nonprovisional patent applications, 69 pending foreign patent applications, 10 pending PCT applications, and 3 pending U.S. provisional patent applications for treating hearing loss, both generally and using FX-322. While we believe that the specific and generic claims contained in our issued U.S. patents provide protection for the composition of matter and the method of using FX-322 to treat hearing loss and/or diseases associated with the absence or lack of certain tissue cells, third parties may nevertheless challenge such claims in our patents. If any such claims are invalidated or rendered unenforceable for any reason, we will lose valuable intellectual property rights, and our ability to prevent others from competing with us would be impaired. Any U.S. or ex-U.S. patents that may issue from pending applications that we control, if any, for our hearing program, including our lead product FX-322, are projected to have a statutory expiration date in between 2035 and 2040, excluding any additional term for patent term adjustments or patent term extensions, if applicable.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Multiple sclerosis program </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to use a similar intellectual property strategy when building protection with respect to other programs. Within our MS program, we advise on a portfolio of intellectual property directed to the treatment of MS, through ownership and exclusive in-licensing from Scripps and Cambridge. As of February 29, 2020, no development candidate has been designated, but the intellectual property portfolio for our MS research program currently includes three patent families including two U.S. patents, two foreign patents, two pending U.S. nonprovisional patent applications, three foreign patent applications, and one pending PCT application. While we believe that the specific and generic claims, contained in our U.S. and ex-U.S. patents provide protection for the claimed pharmaceutical compositions and methods of use third parties may nevertheless challenge such claims. If any such claims are invalidated or rendered unenforceable for any reason, we will lose valuable intellectual property rights, and our ability to prevent others from competing with us would be impaired. Any U.S. or ex-U.S. patents that may issue from pending applications that we control, if any, for our MS are projected to have a statutory expiration date between 2032 and 2039, excluding any additional term for patent term adjustments or patent term extensions. The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the term of a patent covering an FDA-approved drug may, in certain cases, be eligible for a patent term extension under the Hatch-Waxman Act as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years, but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. It is possible that issued U.S. patents covering the use of products from our intellectual property may be entitled to patent term extensions. If our use of drug candidates or the drug candidate itself receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved use or drug candidate. We also intend to seek patent term extensions in any jurisdictions where available, however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and, even if granted, the length of such extensions. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU23"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to patent protection, we rely upon unpatented trade secrets and confidential know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and confidential know-how are difficult to protect. We seek to protect our proprietary information, in part, using confidentiality agreements with any collaborators, scientific advisors, employees and consultants and invention assignment agreements with our employees. We also have agreements requiring assignment of inventions with selected consultants, scientific advisors, and collaborators. These agreements may not provide meaningful protection. These agreements may also be breached, and we may not have an adequate remedy for any such breach. In addition, our trade secrets and/or confidential know-how may become known or be independently developed by a third party, or misused by any collaborator to whom we disclose such information. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, or our drugs or processes, obtain licenses, or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future drugs may have an adverse impact on us. If third parties have prepared and filed patent applications prior to March&#160;16, 2013, in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the United States Patent and Trademark Office, or USPTO, to determine priority of inventions. See &#8220;Risk factors&#8212;Risks related to our intellectual property&#8221; for a more comprehensive description of risks related to our intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Astellas Pharma Inc. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, we entered into the Astellas Agreement with Astellas, under which we granted Astellas an exclusive, royalty-bearing, sub-licensable, nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a GSK-3 inhibitor and an HDAC inhibitor, or the Astellas licensed products, including our product candidate FX-322, outside of the United States. We also granted Astellas a right of first negotiation and a right of last refusal if we enter into any negotiation or agreement of any kind (other than an acquisition of all of our stock or assets) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas licensed products in the United States. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and Astellas have agreed to jointly develop the Astellas licensed products, including carrying out joint studies. Each party has agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas licensed product in SNHL and in age-related hearing loss, in each case, in one major Asian country and one major European country. We have agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas licensed product in the United States. Astellas has the sole right to commercialize the Astellas licensed products outside of the United States, and we have the sole right to commercialize the Astellas licensed products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas licensed products in a major Asian country and a major European country following receipt of regulatory approval in such countries. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the licensed rights under the Astellas agreement, Astellas paid us an upfront payment of $80.0 million in July 2019 and has agreed to pay potential development milestone payments up to $230.0 million. Specifically, we would receive development milestone payments of $65.0 million and $25.0 million upon the first dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively, and $100.0 million and $40.0 million upon the first dosing of a patient in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively.&nbsp;&nbsp;If the Astellas licensed products are successfully commercialized, we would be eligible for up to $315.0 million in potential commercial milestone payments and also tiered royalties at rates ranging from low- to mid-teen percentages.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Astellas Agreement remains in effect until the expiration of all royalty obligations. Royalties are paid on a licensed product-by-licensed product and country-by-country basis until the latest of (i) the expiration of the last valid claim in the licensed patent rights with respect to such Astellas licensed product in such country or (ii) a set number of years from the first commercial sale of such Astellas licensed product in such country. Astellas may terminate the Astellas Agreement at will upon 60 days&#8217; written notice. Each party has the right to terminate the Astellas Agreement due to the other party&#8217;s material breach if such breach remains uncured for 90 days (or 45 days in the case of nonpayment) or if the other party becomes bankrupt. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Massachusetts Institute of Technology </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, we entered into an Exclusive Patent License Agreement, or the MIT License, with the Massachusetts Institute of Technology, or MIT, under which we received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease, and import products, or the MIT licensed products, and to develop and perform processes, or the MIT licensed processes, which incorporate the licensed technology for the treatment of disease, including, but not limited to, the prevention and remediation of hearing loss. We also have the right to grant sublicenses under the MIT License. MIT and Brigham and Women&#8217;s Hospital retain the right on behalf of themselves and all other nonprofit research institutions to practice the licensed patent rights for nonclinical research, teaching, and educational purposes. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are required to use diligent efforts to develop and commercialize the MIT licensed products or processes and to make such products or processes reasonably available to the public. We are also subject to certain development obligations with regards to a first MIT licensed product. We have satisfied certain obligations related to preclinical studies and the filing of an IND for a first MIT licensed product with our development activities related to FX-322. Our future development obligations are: (i)&#160;to commence a Phase&#160;II clinical trial for such product within two years of the IND filing for such product, (ii)&#160;to commence a Phase III clinical trial for such product within five years of the IND filing for such product, (iii)&#160;to file a New Drug Application, or NDA, or equivalent with the FDA or comparable European regulatory agency for such product within nine years of the IND filing for such product, and (iv)&#160;to make a first commercial sale of such product within 11&#160;years of the IND filing for such product. We also have certain development obligations with regards to a second MIT licensed product. If we fail to meet our development obligations, other than those relating to a second MIT licensed product, MIT may terminate the MIT License. In the event that we have failed to fulfill our development timeline obligation with respect to a second MIT licensed product and fail to cure such breach within 90&#160;days of written notice by MIT, MIT may restrict the licensed field to the prevention and remediation of hearing loss in humans and animals. We do not have the right to control prosecution of the in-licensed patent applications, and our rights to enforce the in-licensed patents are subject to certain limitations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering the MIT License, we paid a $50&#160;thousand license fee payment and issued to MIT shares of our common stock equal to 5% of our then-outstanding capital stock. We are required to pay certain annual license maintenance fees ranging from $30 thousand to $0.1 million per year prior to first commercial sale of a MIT licensed product and an annual license maintenance fee of $0.2 million every year afterwards, which may be credited to running royalties during the same calendar year, if any. We are also required to make potential milestone payments in an aggregate amount of up to $2.9&#160;million on each MIT licensed product or process. In addition, we agreed to pay a low single-digit royalty on the MIT licensed products and processes and a 20% royalty on sub-license revenues. In 2019, we paid MIT $16.0 million dollars representing the royalty on the upfront payment received from Astellas.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The MIT License will remain in effect until the expiration or abandonment of all licensed issued patents and filed patent applications, unless terminated earlier. We have the right to terminate for any reason upon three months&#8217; prior written notice. MIT has the right to terminate immediately if we cease to carry on any business related to the MIT License. MIT may also terminate the MIT License for our material breach if such breach remains uncured for 90 days (or 30 days in the case of nonpayment). MIT may also terminate the MIT License if we or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed, or if our sub-licensee commences such actions and we do not terminate such sub-license within 30 days after MIT&#8217;s demand. MIT has the right to increase all payments due by us, instead of terminating the MIT License in the case of a patent challenge. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, the MIT License was amended to update the diligence milestones for a second MIT licensed product. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Massachusetts Eye and Ear Infirmary </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, we entered into an Non-Exclusive Patent License Agreement, or the MEEI License, with the Massachusetts Eye and Ear Infirmary, or MEEI, under which we received a non-exclusive, non-sub-licensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products and to develop and perform processes that incorporate the licensed technology for the treatment or prevention of hearing loss, or the MEEI licensed products.<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>We are obligated to use diligent efforts to develop and commercialize the MEEI licensed products. We are also subject to milestone timeline obligations to dose a first patient in a Phase&#160;II trial by December&#160;31, 2020 and to dose a first patient in a Phase&#160;III trial by December&#160;31, 2024. We do not control the filing, prosecution, enforcement, and defense of any licensed patent rights. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering the MEEI License, we made a $20&#160;thousand license fee payment. We are obligated to pay certain annual license maintenance fees between $5 thousand and $7.5 thousand per each MEEI patent family case number included in the licensed MEEI patent rights prior to first commercial sale of an MEEI licensed product. We are also obligated to pay a minimum annual royalty payment of $15 thousand per each MEEI patent family case number included in the licensed MEEI patent rights after first commercial sale of an MEEI licensed product. We are also obligated to make milestone payments up to $350&#160;thousand on each product or process that incorporates the licensed patent rights. In addition, we have agreed to pay a low single-digit royalty on products and processes that incorporate the licensed patent rights. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The MEEI License remains in effect until all issued patents and filed patent applications within the licensed patent rights have expired or been abandoned, unless terminated earlier. We have the right to terminate the MEEI License at will by 30 business days&#8217; advance written notice to MEEI. MEEI has the right to terminate the MEEI License (i)&#160;if we fail to make any payment due within 30 business days after MEEI notifies us of such failure, (ii)&#160;if we fail to maintain required insurance, (iii)&#160;upon 45 business days&#8217; written notice if we become insolvent, or (iv)&#160;for any other default by us that is not cured within 60 business days of receipt of written notice. MEEI also has the right to terminate if we or our affiliates challenge the validity of the licensed patent rights. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Scripps Research Institute (California Institute for Biomedical Research) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, we entered into a license agreement, or the CALIBR License, with the California Institute for Biomedical Research, or CALIBR, a division of Scripps, under which we received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products, or the CALIBR licensed products, which incorporate licensed technology for the treatment of MS. We also have the right to grant sublicenses under the CALIBR License. CALIBR reserves the right to use for itself and the right to grant nonexclusive licenses to other nonprofit or academic institutions for any internal research and educational purposes. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have agreed to use commercially reasonable efforts to develop, manufacture, and sell at least one CALIBR licensed product. We are also subject to certain milestone timeline obligations to: (i) submit an IND (or equivalent) for a CALIBR licensed product by the 30th month after the effective date of the CALIBR License, (ii) initiate a Phase II clinical trial (or equivalent) for a CALIBR licensed product by the fourth anniversary of the effective date of the CALIBR License, and (iii) initiate a Phase III clinical trial (or equivalent) for a CALIBR licensed product by the sixth anniversary of the effective date of the CALIBR License. We do not have the right to control prosecution of the in-licensed patent applications, and our rights to enforce the in-licensed patents are subject to certain limitations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering the CALIBR license, we made a $1.0&#160;million license fee payment, and are required to make milestone payments in an aggregate amount of up to $26.0&#160;million for each category of CALIBR licensed products. Category&#160;1 is any CALIBR licensed products containing a compound that modulates any muscarinic receptor, and Category&#160;2 is any CALIBR licensed products not included in Category&#160;1 that could differentiate oligodendrocyte precursor cells from <font style="font-style:italic;">in vitro</font> studies and/or are active in animal models relevant to MS. We are also required to pay a mid-single-digit royalty on CALIBR licensed products and a royalty on sub-license revenues ranging from a low-teen percentage to 50%. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CALIBR License continues in effect until expiration of all our obligations to pay royalties. Royalties are payable by us on a country-by-country and licensed-product-by-licensed product basis upon the later of (i)&#160;the expiration or abandonment of all valid claims of the licensed patent rights in such country and (ii)&#160;10&#160;years from the first commercial sale of each CALIBR licensed product in such country. We may terminate the CALIBR License at will upon 30 days&#8217; prior written notice. We may also elect to terminate our license to one or more licensed patents in any or all jurisdictions by giving 90 days&#8217; prior written notice to CALIBR. CALIBR may terminate the CALIBR License for our material breach if such breach remains uncured for 30&#160;days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if we fail to use diligent efforts to develop and commercially exploit CALIBR licensed products. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Scripps Research Institute </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, we entered into a Research Funding and Option Agreement, or the Scripps option agreement, with Scripps, under which we were granted an exclusive option to acquire an exclusive, sublicensable, worldwide license under certain intellectual property related to the treatment of MS. If we exercise such option, the CALIBR License shall be amended to include such intellectual property. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU26"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the Scripps option agreement, we are required to make funding payments totaling $0.7 million to Scripps to support its research activities. Scripps has agreed to use reasonable efforts to perform the research program pursuant to the Scripps option agreement. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Scripps option agreement was renewed in 2019 for a second year by mutual written agreement. We have the right to terminate by giving 90&#160;days&#8217; advance written notice. Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10&#160;days. Each party has the right to terminate in the event of the other party&#8217;s material breach that remains uncured for 60&#160;days or if the other party becomes bankrupt. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cambridge Enterprise Limited </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, we entered into an Exclusive Patent License Agreement, or the Cambridge License, with Cambridge, under which we received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products, or the Cambridge licensed products, which incorporate licensed technology for the treatment of demyelinating diseases. We also have the right to grant sublicenses under the Cambridge License. Cambridge reserves the right to use for itself (as well as for the inventors and the funder) and the right to grant nonexclusive licenses to other academic institutions for any academic publication, research and teaching and clinical patient care. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have agreed to use diligent and good faith efforts to develop and commercially exploit at least one Cambridge licensed product. Upon entering into the Cambridge License, we made a $50.0 thousand license fee payment. We are obligated to pay an annual license fee of $50.0 thousand. We are also obligated to make milestone payments up to $10.5 million on each Cambridge licensed product. In addition, we have agreed to pay a low single-digit royalty on products that incorporate the licensed patent rights, subject to offset in certain circumstances.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Cambridge License continues in effect on a country-by-country basis until the expiration or revocation, without right of further appeal, of all licensed issued patents and filed patent applications, unless terminated earlier. We have the right to terminate for any reason upon 90 days&#8217; prior written notice. Each party has the right to terminate immediately if the other party ceases to carry on its business. Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days. Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge licensed product or we or our affiliates or sub-licensees commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a clinical-stage biotechnology company, we face competition from a wide array of companies in the pharmaceutical, biotechnology, and medical device industries. These include both small companies and large companies with much greater financial and technical resources and far longer operating histories than our own. We also compete with the intellectual property, technology, and product development efforts of academic, governmental, and private research institutions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitors may have significantly greater financial resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific, sales, marketing, and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The key competitive factors affecting the success of any product candidates that we develop, if approved, are likely to be their efficacy, safety, convenience, price, and the availability of reimbursement from government and other third-party payors. Our commercial opportunity for any of our product candidates could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours and may commercialize products more quickly than we are able to. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU27"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are aware of the following competitors in the areas that we are initially targeting: </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Hearing loss </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect FX-322 to compete with hearing aids and cochlear implants. There are dozens of hearing aid brands, although approximately 80% of these devices are manufactured by four leading companies. There are three manufacturers of cochlear implants that market in the United States. We are also aware of two companies with potential therapies to regenerate hair cells currently in clinical trials. Novartis conducted a Phase 1/2 trial with intracochlear delivery of an adenovirus-based gene therapy in subjects with severe to profound hearing loss, and Audion Therapeutics is conducting a Phase 2 study of its notch inhibitor, LY3056480. Neither Novartis nor Audion have disclosed the results from these trials that were started in 2014 and 2017, respectively. In 2019 Otonomy, Inc. disclosed it was conducting a Phase 1/2 study with a neurotrophic factor, brain-derived neurotrophic factor, in subjects with a condition described as speech-in-noise impairment. There are also multiple programs in early-stage or preclinical development by pharmaceutical and biotechnology companies. In addition, there are several companies with programs to regrow neurons in the cochlea to treat hearing loss, and companies developing otoprotective therapies, which are intended to reduce damage to hair cells. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Multiple sclerosis </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are multiple therapeutic options for treating the symptoms of MS, as well as the underlying disease. However, all approved therapies are directed at blocking demyelination, and, to our knowledge, there are no approved therapies which promote remyelination. We are aware of numerous efforts to identify drugs or biologics that can stimulate oligodendrocyte regeneration and myelin repair in the central nervous system. Acorda Therapeutics has conducted two Phase 1 trials of its monoclonal antibody rHIgM22 in MS patients, and Convelo Therapeutics is developing potential remyelinating compounds that inhibit enzymes in the brain involved in the production of cholesterol for which they planned to begin clinical trials in 2019. Biogen Inc. is in clinical development with an antibody that promotes remyelination in animal models of MS.  </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government regulation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing, and distribution of drugs, such as those we are developing. These agencies and other federal, state, and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling, and export and import of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. drug development process </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process, or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before a drug may be marketed in the United States generally involves the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">completion of preclinical laboratory tests, animal studies, and formulation studies in compliance with the FDA&#8217;s good laboratory practice, or GLP, regulations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and efficacy of the proposed drug product for each indication; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">submission to the FDA of an NDA; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU28"></a><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">satisfactory completion of an FDA advisory committee review, if applicable; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practice, or cGMP, requirements, and to assure that the facilities, methods, and controls are adequate to preserve the drug&#8217;s identity, strength, quality, and purity; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to commercial marketing or sale of the drug in the United States; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, or to conduct a post-approval study. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical studies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical studies include laboratory evaluation of product chemistry, toxicity, and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about on-going or proposed clinical trials or noncompliance with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical trials </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Information about certain clinical trials must be submitted within specific time frames to the National Institutes of Health, or NIH, for public dissemination on their www.clinicaltrials.gov website. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion, and, if possible, to gain an early indication of its effectiveness. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases, and to determine dosage tolerance and optimal dosage. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies usually complete additional animal studies, and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate, and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA, and more frequently if serious adverse events occur. Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. There are also requirements governing the reporting of ongoing clinical trials and completed trial results to public registries. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketing approval </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls, and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes 12&#160;months from the date the NDA is submitted to the FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision. Specifically, the FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged, or held meets standards designed to assure the product&#8217;s continued safety, quality, and purity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA also may require submission of a REMS plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings, or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU30"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or the FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a noncompliance letter to any sponsor that fails to submit the required assessment, keep a deferral current, or fails to submit a request for approval of a pediatric formulation. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">FDA-expedited development and review programs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has various programs, including fast track designation, accelerated approval priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and the FDA review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may give a priority review designation to drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of 10&#160;months under current PDUFA guidelines. Under the new PDUFA agreement, these six- and 10-month review periods are measured from the &#8220;filing&#8221; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission. Most products that are eligible for fast track designation are also likely to be considered appropriate to receive a priority review. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, under the provisions of the Food and Drug Administration Safety and Innovation Act, or FDASIA, passed in July 2012, a sponsor can request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy. The designation includes all the benefits of a fast track designation. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU31"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, fast track designation, priority review, and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process. We may explore some of these opportunities for our product candidates as appropriate. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Post-approval requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion, and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state and local agencies and are subject to periodic unannounced inspections by government agencies for compliance with cGMP and other requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing warning or other safety information about the product; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">fines, warning letters, or holds on post-approval clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product seizure or detention, or refusal to permit the import or export of products; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU32"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketing exclusivity </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section&#160;505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application. This three-year exclusivity covers only the modification for which the drug received approval based on the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other healthcare laws and compliance requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the state, local, and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, U.S. federal and state anti-kickback, fraud and abuse, false claims, consumer fraud, pricing reporting, data privacy and security, and transparency laws and regulations, as well as similar foreign laws in the jurisdictions outside the U.S. State laws may require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, as well as require the registration of pharmaceutical sales representatives and the reporting of pricing information and marketing expenditures. Violations of such laws, or any other governmental regulations that apply, may result in penalties, including, without limitation, civil and criminal penalties, damages, fines, additional reporting and oversight obligations, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs, and individual imprisonment. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Coverage and reimbursement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor&#8217;s decision to cover a product does not ensure that other payors will also provide coverage for the product. As a result, the coverage determination process can require manufactures to provide scientific and clinical support for the use of a product to each payor separately, and can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU33"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, third-party payors are increasingly reducing reimbursements for pharmaceutical products and services. The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement, and requirements for substitution of generic products. Third-party payors are more and more challenging the prices charged, examining the medical necessity, and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available, or that the third-party payors&#8217; reimbursement policies will not adversely affect the ability of manufacturers to sell products profitably. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Healthcare reform </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system that could affect the pharmaceutical industry. In March 2010, the ACA was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. The ACA contains a number of provisions of particular import to the pharmaceutical industry, including those governing enrollment in federal healthcare programs, reimbursement adjustments, and fraud and abuse changes. Additionally, the ACA increases the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; requires collection of rebates for drugs paid by Medicaid managed care organizations; imposes a nondeductible annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded prescription drugs&#8221; to specified federal government programs; implements a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expands of eligibility criteria for Medicaid programs; creates a new Patient-Centered Outcomes Research Institute to oversee; identify priorities in, and conducts comparative clinical effectiveness research, along with funding for such research; and establishes a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, in December 2018, a U.S. district court judge ruled that the ACA is unconstitutional in its entirety because the Tax Cuts and Jobs Act modified the individual mandate. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the district court&#8217;s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. It is unclear how these decisions, subsequent appeals, if any, or other efforts to challenge, repeal or replace the ACA will impact the law.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year and reduced payments to several types of Medicare providers. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries, and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference-pricing systems and publication of discounts and list prices. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU34"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Foreign regulation </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of foreign countries before we can commence clinical trials, and approval of foreign countries or economic areas, such as the EU, before we may market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Economic Area, or EEA, which is comprised of the Member States of the European Union plus Norway, Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA. There are two types of MAs: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Community MAs&#8212;These are issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, and are valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune, and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA; for products that constitute a significant therapeutic, scientific or technical innovation; or for products that are in the interest of public health in the EU. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">National MAs&#8212;These are issued by the competent authorities of the Member States of the EEA and only cover their respective territory and are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure, an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State. The competent authority of the Reference Member State prepares a draft assessment report, a draft summary of the product characteristics, or SmPC, and a draft of the labeling and package leaflet, which are sent to the other Member States (referred to as the Member States Concerned) for their approval. If the Member States Concerned raise no objections, based on a potential serious risk to public health, to the assessment, SmPC, labeling or packaging proposed by the Reference Member State, the product is subsequently granted a National MA in all the Member States, i.e., in the Reference Member State and the Member States Concerned. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA assess the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety, and efficacy. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As in the United States, it may be possible in foreign countries to obtain a period of market and/or data exclusivity that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s generic product. For example, if any of our products receive marketing approval in the EEA, we expect they will benefit from eight years of data exclusivity and 10&#160;years of marketing exclusivity. An additional noncumulative one-year period of marketing exclusivity is possible if during the data exclusivity period (the first eight years of the 10-year marketing exclusivity period) we obtain an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies. The data exclusivity period begins on the date of the product&#8217;s first marketing authorization in the EEA and prevents generics from relying on the marketing authorization holder&#8217;s pharmacological, toxicological, and clinical data for a period of eight years. After eight years, a generic product application may be submitted, and generic companies may rely on the marketing authorization holder&#8217;s data. However, a generic cannot launch until two years later (or a total of 10 years after the first marketing authorization in the EU of the innovator product), or three years later (or a total of 11 years after the first marketing authorization in the EU of the innovator product) if the marketing authorization holder obtains marketing authorization for a new indication with significant clinical benefit within the eight-year data exclusivity period. In Japan, our products may be eligible for eight years of data exclusivity. There can be no assurance that we will qualify for such regulatory exclusivity, or that such exclusivity will prevent competitors from seeking approval solely on the basis of their own studies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU35"></a>When conducting clinical trials in the EU, we must adhere to the provisions of the European Union Clinical Trials Directive (Directive 2001/20/EC) and the laws and regulations of the EU Member States implementing them. These </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provisions require, among other things, that the prior authorization of an Ethics Committee and the competent Member State authority is obtained before commencing the clinical trial. In April 2014, the EU passed the Clinical Trials Regulation (Regulation 536/2014), which will replace the current Clinical Trials Directive. To ensure that the rules for clinical trials are identical throughout the European Union, the EU Clinical Trials Regulation was passed as a regulation that is directly applicable in all EU member states. All clinical trials performed in the European Union are required to be conducted in accordance with the Clinical Trials Directive until the Clinical Trials Regulation becomes applicable. According to the current plans of the EMA, the Clinical Trials Regulation is expected to become applicable </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sometime </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in 2020. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Data privacy and security laws </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EU member states, the United Kingdom, Switzerland and other jurisdictions have also adopted data protection laws and regulations, which impose significant compliance obligations. In the EEA and the United Kingdom, the collection and use of personal data, including clinical trial data, is governed by the provisions of the General Data Protection Regulation, or GDPR. The GDPR became effective on May&#160;25, 2018, repealing its predecessor directive and increasing responsibility and liability of pharmaceutical companies in relation to the processing of personal data of EU data subjects. The GDPR, together with national legislation, regulations and guidelines of the EU member states and the United Kingdom governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze and transfer personal data, including health data from clinical trials and adverse event reporting. In particular, these obligations and restrictions concern the consent of the individuals to whom the personal data relates, the information provided to the individuals, the transfer of personal data out of the EEA or the United Kingdom, security breach notifications, security and confidentiality of the personal data and imposition of substantial potential fines for breaches of the data protection obligations. European data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which add to the complexity of processing personal data in or from the EEA or United Kingdom. Guidance on implementation and compliance practices are often updated, or otherwise revised. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_cp_text_1_146"></a><a name="_Hlk35341521"></a>Employees</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_147"></a>As of December 31, 2019, we had 47 employees, 43 of which were full-time employees.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_cp_text_1_148"></a>Our Corporate Information</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_149"></a>We were incorporated under the laws of the state of Delaware in November 2014. Our principal executive offices are located at 19 Presidential Way, Woburn, Massachusetts 01801 and our telephone number is (866) 389-1970. Our corporate website address is <font style="font-style:italic;">www.frequencytx.com</font>. The information contained in, or accessible through, our website is not incorporated by reference into this Annual Report and you should not consider information on our website to be a part of this Annual Report. We have included our website address in this Annual Report solely as an inactive textual reference.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_cp_text_1_150"></a>Where you can find more information</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_151"></a><a name="_cp_field_47_152"></a><a name="_cp_field_47_152"></a>We are subject to the information requirements of the Securities Exchange Act of 1934, as amended. The SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically, such as ourselves, with the SEC at <font style="font-size:12pt;"></font><font style="color:#000000;text-decoration:underline;">http://www.sec.gov</font><font style="font-size:12pt;"></font>.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a><a name="ITEM_1A_RISK_FACTORS"></a>Item 1A. Risk Factors.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU36"></a>Our future operating results could differ materially from the results described in this Annual Report on Form&#160;10-K due to the risks and uncertainties described below. You should consider carefully the following information about risks below in evaluating our business. If any of the following risks actually occur, our business, financial conditions, results of operations and future growth prospects would likely be materially and adversely affected. <font style="color:#000000;">Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations</font> in these circumstances, the market price of our common stock would likely decline. In addition, we cannot assure investors that our assumptions and expectations will prove to be correct. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements. See &#8220;Forward Looking Statements&#8221; for a discussion of some of the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">forward-looking statements that are qualified by these risk factors. Factors that could cause or contribute to such differences include those factors discussed below.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our financial position and need for additional capital </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability. If we are unable to achieve or sustain profitability, the market value of our common stock will likely decline. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biotechnology company with a limited operating history. As a result, we are not profitable and have incurred significant losses since our formation. We had net losses of $20.2&#160;million, $19.2&#160;million and $19.8 million for the years ended December&#160;31, 2017, 2018 and 2019, respectively. As of December 31, 2019, we had an accumulated deficit of $68.9 million. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to gain regulatory approval and become commercially viable. We have not commercialized any products and have never generated revenue from the commercialization of any product. To date, we have devoted most of our financial resources to licensing technologies and research and development, including our preclinical platform development activities and clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to incur significant additional operating losses for the next several years, at least, as we advance FX-322 and any other product candidate through clinical development, complete clinical trials, seek regulatory approval and commercialize FX-322 or any other product candidate, if approved. The costs of advancing product candidates into each clinical phase tend to increase substantially over the duration of the clinical development process. Therefore, the total costs to advance any product candidate to marketing approval in even a single jurisdiction are substantial. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of any product candidates or achieve or maintain profitability. Our expenses will also increase substantially if and as we: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue our Phase 2a trial of FX-322 in sensorineural hearing loss, or SNHL, and commence additional clinical studies relating to FX-322; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expand our development programs based on our progenitor cell activation, or PCA, platform, including our program for a treatment for multiple sclerosis, or MS, and develop other product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue to develop our PCA platform; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek regulatory approvals for FX-322 and any other product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expand the target indications and patient population for FX-322; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">secure a commercial manufacturing source and supply chain capacity sufficient to produce commercial quantities of any product candidate for which we obtain regulatory approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establish a sales, marketing and distribution infrastructure to commercialize FX-322 for the treatment of SNHL, if approved, and for any other product candidates for which we may obtain marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">maintain, expand, and protect our intellectual property portfolio; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">hire additional clinical, scientific, and commercial personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">add operational, financial, and management personnel, including personnel to support our product development and planned future commercialization efforts, as well as to support operations as a public company; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">acquire or in-license other product candidates or technologies. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU37"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our ability to successfully develop, commercialize and license any product candidates and generate product revenue is subject to substantial additional risks and uncertainties, as described under &#8220;&#8212;Risks related to development, clinical testing, manufacturing, and regulatory approval&#8221; and &#8220;&#8212;Risks related to commercialization.&#8221; As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. The amount of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If we are unable to develop and commercialize one or more product candidates, either alone or through collaborations, or if revenues from any product that receives marketing approval are insufficient, we will not achieve profitability. Even if we successfully commercialize FX-322, we may continue to incur substantial research and development and other expenses to identify and develop other product candidates. Even if we do achieve profitability, we may not be able to sustain profitability or meet outside expectations for our profitability. If we are unable to achieve or sustain profitability or to meet outside expectations for our profitability, the value of our common stock will be materially adversely affected. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of FX-322 and additional product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34125699"></a><a name="_Hlk34125699"></a>We expect to spend substantial amounts to complete the development of, seek regulatory approvals for and, if approved, commercialize FX-322. These expenditures will include costs related to the Phase 2a trial of FX-322 for the treatment of SNHL and other planned clinical trials of FX-322, and, if such trials are supportive, a planned Phase 2b trial of FX-322, and any additional trials we conduct to support the development of FX-322. In addition, we are obligated to make milestone and royalty payments in connection with the sale of resulting products and licensing revenues under our license agreements with Massachusetts Institute of Technology, or MIT, the Scripps Research Institute, or Scripps, and Cambridge Enterprise Limited (the technology transfer arm of the University of Cambridge), or Cambridge. We also expect to spend substantial amounts to identify and develop new product candidates based on our PCA platform. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will require additional capital to enable us to develop additional product candidates based on our PCA platform, which we may acquire through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative effect on our financial condition and our ability to pursue our business strategy. In addition, attempting to secure additional financing may divert the time and attention of our management from day-to-day activities and harm our development efforts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon our current operating plan, we believe that our existing cash, cash equivalents, and short-term investments of $217.4 million will enable us to fund our operating expenses and capital expenditure requirements into 2022. This estimate and our expectation regarding the sufficiency of our current financial resources to advance the clinical development of FX-322 and any other product candidates are based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect, or our clinical trials, including our Phase 2a trial of FX-322 for the treatment of SNHL and other planned clinical trials of FX-322, may be more expensive, time consuming or difficult to design or implement than we currently anticipate. Changing circumstances, including any unanticipated expenses, could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. Because the length of time and scope of activities associated with successful development of FX-322 or any product candidate we may develop is highly uncertain, we are unable to estimate the actual funds we will require for development and any marketing and commercialization activities. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the initiation, progress, timing, costs and results of our clinical trials through all phases of development, including the Phase 2a trial for FX-322, our other planned clinical trials of FX-322 and the development of any other product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the outcome, timing and cost of meeting regulatory requirements established by the U.S. Food and Drug Administration, or the FDA, and other comparable foreign regulatory authorities, including any additional clinical trials required by the FDA or other comparable foreign regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the willingness of the FDA and other comparable foreign regulatory authorities to accept our clinical trial designs, as well as data from our completed and planned clinical trials and preclinical studies, as the basis for review and approval of FX-322 and any other product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of filing, prosecuting, defending, and enforcing our patent claims and other intellectual property rights; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU38"></a><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the effect of competing technological and market developments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost and timing of completion of commercial-scale manufacturing activities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of operating as a public company; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of making royalty, milestone or other payments under current and any future in-license agreements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which we in-license or acquire other product candidates or technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of establishing sales, marketing and distribution capabilities for our product candidates, if approved; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to maintain our collaboration with Astellas Pharma Inc., or Astellas, including  achievement of the development milestones and to establish new collaborations; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the initiation, progress, and timing of our commercialization of FX-322, if approved, or any other product candidate. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of FX-322 or any other product candidate, or potentially discontinue operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial revenues, we may finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. We do not currently have any committed external source of funds. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, our existing stockholders&#8217; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. In addition, debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. Furthermore, any capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to advance research programs, product development activities or product candidates. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate product candidate development or future commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were established and began operations in 2014. Our operations to date have been limited to financing and staffing our company, licensing technologies, developing our PCA platform, developing and conducting preclinical and clinical studies of FX-322 for the treatment of SNHL, and developing a pipeline of preclinical and research programs, including our program for the treatment of MS. We have not yet demonstrated the ability to successfully complete a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a commercial-scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU39"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. We will eventually need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition and, as a result, our business may be adversely affected. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, the results of any quarterly or annual period are not necessarily indicative of future operating performance. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our ability to use our net operating loss carryforwards to offset future taxable income may be subject to certain limitations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, we had net operating loss carryforwards, or NOLs, of $50.2&#160;million for federal income tax purposes and $41.2&#160;million for state income tax purposes, which may be available to offset our future taxable income, if any. Our NOLs begin to expire in various amounts in 2036, provided that NOLs generated after December&#160;31, 2019 will not be subject to expiration. As of December&#160;31, 2019, we also had federal and state research and development and other tax credit carryforwards of approximately $0.7&#160;million and $0.5&#160;million, respectively, available to reduce future tax liabilities. Our tax credit carryforwards expire at various dates through 2039. These NOLs and tax credit carryforwards could expire unused, to the extent subject to expiration, and be unavailable to offset future income tax liabilities. In addition, in general, under Sections&#160;382 and 383 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to use its pre-change NOLs and tax credit carryforwards to offset future taxable income. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. We believe we have experienced an ownership change in the past and may experience ownership changes in the future as a result of future transactions in our stock, some of which may be outside our control. If we undergo another ownership change, our ability to use our NOLs and tax credit carryforwards could be further limited. For these reasons, we may not be able to use a material portion of our NOLs or tax credit carryforwards, even if we attain profitability. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future tax benefits of such assets. The reduction of the corporate tax rate under the Tax Cuts and Jobs Act of 2017, or TCJA, from 35% to 21% may cause a reduction in the economic benefit of our NOLs and other deferred tax assets available to us. Furthermore, under the TCJA, although the treatment of tax losses generated before December&#160;31, 2017 has generally not changed, tax losses generated in calendar year 2018 and beyond will only be able to offset 80% of taxable income. This change may require us to pay federal income taxes in future years despite generating a loss for federal income tax purposes in prior years. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to development, clinical testing, manufacturing, and regulatory approval </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are heavily dependent on the success of FX-322, our lead product candidate, which is still under clinical development, and if FX-322 does not receive regulatory approval or is not successfully commercialized, our business will be materially adversely harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have invested a significant portion of our efforts and financial resources in the development of FX-322 for the treatment of SNHL. Our future success is substantially dependent on our ability to successfully complete clinical development for, obtain regulatory approval for, and successfully commercialize FX-322, which may never occur. We currently have no products that are approved for commercial sale and may never be able to develop a marketable product. We expect that a substantial portion of our efforts and expenditures over the next few years will be devoted to FX-322, which will require additional clinical development, management of clinical and manufacturing activities, regulatory approval, establishing commercial scale manufacturing, and significant sales, marketing, and distribution efforts before we can generate any revenues from any commercial sales. We cannot be certain that we will be able to successfully complete any of these activities or that, even if it receives regulatory approval, FX-322 will be as effective as anticipated at treating SNHL. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The research, testing, manufacturing, labeling, approval, sale, packaging, marketing, and distribution of drug products are subject to extensive regulation by the FDA and comparable regulatory authorities in other countries. We are not permitted to market FX-322 in the United States until we receive approval of a New Drug Application, or NDA, from the FDA, or in any foreign countries until our collaborator, Astellas, receives the requisite approval from such countries. We have not submitted an NDA to the FDA and Astellas has not submitted comparable applications to other regulatory authorities for FX-322. We or Astellas may not be in a position to do so for several years, if ever. If we or Astellas are unable to obtain the necessary regulatory approval for FX-322 in a country, we or Astellas will not be able to commercialize FX-322 for the treatment of SNHL in that country. As a result, our financial position will be materially adversely affected, and we may not be able to generate sufficient revenue to continue our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU40"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We utilize our PCA platform to develop product candidates that are designed to activate progenitor cells, which is a new approach to therapeutic intervention and, as a result, successful development, approval, and commercialization of our product candidates, including FX-322, is uncertain. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We utilize our PCA platform to develop product candidates, including FX-322, for the treatment of SNHL. Our PCA platform is designed to identify pathways to activate progenitor cells already present in the body to treat conditions or diseases through cellular regeneration. We have not, nor to our knowledge has any other company, received regulatory approval utilizing this mechanism of cellular regeneration. Given the novelty of our approach, we could encounter a longer than expected regulatory review process, increased development costs, or unexpected delays in, or even prevention of, the regulatory approval and commercialization of our product candidates, and we cannot be certain that our approach will lead to the development of any approvable or marketable products. For example, the FDA-approved treatment options available for patients with SNHL are hearing aids and cochlear implants. Unlike FX-322, which is a therapeutic that targets the underlying biology of SNHL, these treatment options are medical devices that are designed to target the symptoms of SNHL. As a result, these treatment options are not directly comparable to FX-322, and FDA requirements for marketing authorization of these treatment options may not be relevant for FX-322. While we are developing what we believe are appropriate measurements of efficacy for FX-322, we cannot be certain that the FDA will agree with our measurements or that they will be sufficient for approval. If we were to encounter any of the foregoing, our business and financial prospects could be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical trials are expensive, time consuming, and difficult to design and implement, and involve an uncertain outcome. The results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and completed clinical trials are not necessarily predictive of future results, and any product candidates we develop may not be further developed or have favorable results in later studies or trials. Clinical trial failure may result from a multitude of factors, including, but not limited to, flaws in study design, dose selection, placebo effect, patient enrollment criteria, selection of patients based on patient misrepresentations, and failure to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing. Several companies in the pharmaceutical industry have suffered setbacks in the advancement of their drug candidates into later-stage clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding favorable results in earlier preclinical studies or clinical trials. Based upon negative or inconclusive results or a need for additional information, we may decide, or regulatory authorities may require us, to conduct additional clinical trials or preclinical studies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may experience delays in initiating and completing any clinical trials that we intend to conduct, and we do not know whether our clinical trials will begin on time, need to be redesigned, enroll patients on time, or be completed on schedule, or at all. Clinical trials can be delayed for a variety of reasons, including delays related to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtaining regulatory approval to commence a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">reaching an agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtaining Institutional Review Board, or IRB, approval at each site within the United States, or Independent Ethics Committee, or IEC, approval at sites outside the United States; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">recruiting suitable patients to participate in a trial in a timely manner and in sufficient numbers; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">having patients complete a trial or return for post-treatment follow-up; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">imposition of a clinical hold by regulatory authorities, including as a result of unforeseen safety issues or side effects or failure of trial sites or investigators to adhere to regulatory requirements or follow trial protocols; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">clinical sites deviating from the trial protocol or dropping out of a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">addressing patient safety concerns that arise during a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">adding a sufficient number of clinical trial sites; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">manufacturing sufficient quantities of a product candidate for use in clinical trials. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU41"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs or IECs of the institutions in which such trials are being conducted, the FDA or other regulatory authorities, or recommended for termination by a Data and Safety Monitoring Board, or DSMB, for such trial. Such authorities may impose a suspension or termination or recommend an alteration due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical trial. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance, as described in the section titled &#8220;&#8212;Risks related to our dependence on third parties.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidate, FX-322, is still in development and will require the successful completion of one, and possibly more, Phase 3 trials before we are prepared to submit an NDA for regulatory approval by the FDA. We cannot predict with any certainty if or when we might complete the development of FX-322 and submit an NDA for regulatory approval by the FDA of FX-322 or whether any such NDA will be approved by the FDA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we experience delays in the commencement or completion of any clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of any product candidate we develop could be harmed, and our ability to generate revenues may be delayed. In addition, any delays in our clinical trials could increase our costs, slow the development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may materially harm our business, financial condition, and results of operations. In addition, many of the factors that may cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of a clinical trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site, and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of a product candidate. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time- consuming, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for FX-322 or any other product candidates, our business will be substantially harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that we will never obtain regulatory approval for any product candidate. We are not permitted to market any of our product candidates in the United States until we receive approval of an NDA from the FDA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authority, that such product candidates are safe and effective for their intended uses. In addition, data obtained from preclinical trials and clinical trials are susceptible to varying interpretations, and regulatory authorities may not interpret our data as favorably as we do, which may further delay, limit, or prevent development efforts, clinical trials, or marketing approval. Furthermore, as more competing drug candidates within a class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other comparable regulatory authorities. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU42"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or any foreign regulatory authority can delay, limit, or deny approval of FX-322 or any other product candidates that we develop or require us to conduct additional preclinical or clinical testing or abandon a program for many reasons, including: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates, or other products containing an active ingredient in our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA&#8217;s or the applicable foreign regulatory authority&#8217;s disagreement regarding the formulation, the labeling, and/or the specifications of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may fail to approve or find deficiencies with the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the large number of drugs in development, only a small percentage successfully complete the regulatory approval processes and are commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the FDA or the applicable foreign regulatory authority also may approve a product candidate for a more limited indication or patient population than we originally requested, and the FDA or applicable foreign regulatory authority may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing circumstances could materially harm the commercial prospects for our product candidates and our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_Hlk36019407"></a><font style="font-family:Times New Roman;"><a name="_Hlk36019407"></a>Patient enrollment and retention in clinical trials depends on many factors, including: the extent of the ongoing COVID-19 pandemic, see --- </font><font style="font-style:italic;font-family:Times New Roman;">The COVID-19 pandemic could adversely impact our business, including our preclinical studies, clinical trials and operations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the patient eligibility criteria defined in the protocol, such as the requirement to establish stable hearing loss in our Phase 2a clinical trial;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU43"></a><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">the nature of the trial protocol; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the existing body of safety and efficacy data with respect to the product candidate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the proximity of patients to clinical sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to recruit clinical trial investigators with the appropriate competencies, motivation and experience; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs or medical devices that may be approved for the indications we are investigating; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">competing clinical trials being conducted by other companies or institutions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to obtain and maintain patient consents; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the risk that patients enrolled in clinical trials will drop out of the trials before completion. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our clinical trials will compete with other clinical trials for product candidates and medical devices that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Furthermore, any negative results we may report in clinical trials of any product candidate may make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result in increased costs or program delays, which could have a harmful effect on our ability to develop a product candidate or could render further development impossible. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Results of preclinical studies, clinical trials, or analyses may not be indicative of results that may be obtained in later trials. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of preclinical studies, clinical trials, or analyses of the results from such trials, including our prospective and <font style="font-style:italic;">post hoc</font> analyses of the data from the Phase 1/2 trial of FX-322 for the treatment of SNHL, may not be predictive of the results of later clinical trials. Product candidates in later clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and prior clinical trials or having shown promising results based on analyses of data from earlier trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding earlier promising results. In addition, conclusions based on promising data from analyses of clinical results, such as the prospective and <font style="font-style:italic;">post hoc</font> analysis of results from our Phase 1/2 clinical trial of FX-322 for the treatment of SNHL, may be shown to be incorrect in subsequent clinical trials that have pre-specified end points or may not be considered adequate by regulatory authorities. Even if we complete later clinical trials as planned, we cannot be certain that their results will support the safety and efficacy requirements sufficient to obtain regulatory approval, and, as a result, our clinical development plans may be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interim and preliminary &#8220;top-line&#8221; data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publicly disclose interim, top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the top-line or preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU44"></a>From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim data and final data </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Any product candidate that we develop or the administration thereof, may cause serious adverse events or undesirable side effects, which may halt their clinical development, delay or prevent marketing approval, or, if approved, require them to be taken off the market, include safety warnings, or otherwise limit their sales. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Serious adverse events or undesirable side effects caused by any product candidate we develop could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. Results of any clinical trial we conduct could reveal a high and unacceptable severity and prevalence of side effects. In our Phase 1/2 study, subjects treated with FX-322 experienced adverse events that include ear discomfort and ear pain that are considered to be associated with the intratympanic injection procedure. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If unacceptable side effects arise in the development of any product candidate, we, the FDA, or the IRBs or IECs at the institutions in which our studies are conducted, or the DSMB, if constituted for our clinical trials, could recommend a suspension or termination of our clinical trials, or the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of a product candidate for any or all targeted indications. In addition, drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We may have to train medical personnel regarding the proper administration protocol for our product candidates and to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition, and prospects significantly. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if FX-322 or any other product candidate we develop receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory authorities may suspend, withdraw, or limit approvals of such product, or seek an injunction against its manufacture or distribution; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory authorities may require us to recall a product or we may decide to initiate a voluntary recall of a product; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">additional restrictions may be imposed on the marketing of the product or the manufacturing processes for the product or any component thereof; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may be required to conduct post-market studies or agree to post marketing commitments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we could be sued and held liable for harm caused to patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the product may become less competitive; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our reputation may suffer. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU45"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, results of operations, and prospects. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital, we must prioritize development of certain product candidates, the choice of which may prove to be wrong and adversely affect our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we intend to explore additional product candidates based on our PCA platform, we may fail to identify viable new product candidates for clinical development for several reasons. If we fail to identify additional potential product candidates, our business could be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research programs to develop additional product candidates based on our PCA platform require substantial technical, financial, and human resources whether or not they are ultimately successful. Our research programs may initially show promise in identifying potential indications or product candidates, yet fail to yield results for clinical development for several reasons, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the research methodology used may not be successful in identifying potential indications or product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">potential product candidates may, after further study, be shown to have harmful or unexpected adverse effects or other characteristics that indicate they are unlikely to be effective drugs; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">it may take greater human and financial resources than we possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify, and expand our product portfolio. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and human resources, we intend to initially focus on research programs and product candidates for a limited set of indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that could have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects. For example, we may encounter delays in the process of selecting a product candidate for the treatment of MS and we may not achieve the time line we currently anticipate for submitting an IND. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The market opportunities for FX-322, if approved, may be smaller than we anticipate and, as a result, our commercial opportunity may be limited. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU46"></a>We expect to initially seek approval of FX-322 for the treatment of SNHL. Our projections of the number of eligible patients are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, patient foundations, and market research, and may prove to be incorrect. Further, new sources may reveal a change in the estimated number of eligible patients, and the number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our current programs or future product candidates may be limited. For example, even if we obtain FDA approval for FX-322, it may be approved for a target population that is more </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limited than what we currently anticipate. Even if we obtain significant market share for any product candidate, if approved, if the potential target populations are smaller, we may never achieve profitability without obtaining marketing approval for additional indications. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any product candidate. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review any NDAs that we submit for our product candidates or may conclude after review of our data that our applications are insufficient to obtain marketing approval of our product candidates. We believe our approach of activating progenitor cells to treat conditions or diseases through cellular regeneration is novel and, as a result, the process for, and the outcome of, FDA approval is especially uncertain. If the FDA does not accept or approve our NDAs for our product candidates, it may require that we conduct additional clinical, preclinical, or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA that we submit may be delayed or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our NDAs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates, generating revenues, and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we obtain FDA approval for a product candidate in the United States, we or our collaborators may never obtain approval for or commercialize the product candidate in any other jurisdiction, which would limit our ability to realize its full market potential. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market any product in a particular jurisdiction, we or our collaborators must establish and comply with numerous and varying regulatory requirements regarding safety and efficacy on a country-by-country basis. Approval by the FDA in the United States does not ensure approval by comparable regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our or our collaborators&#8217; ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time- consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we or our collaborators fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and we will be unable to realize the full market potential of any product we develop. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval for any product candidate, we will still face extensive and ongoing regulatory requirements and obligations, which may result in significant additional expense, and any product candidates, if approved, may face future development and regulatory difficulties. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, and advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with current Good Manufacturing Practice, or cGMP, requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and Good Clinical Practice, or GCP, and requirements for any clinical trials that we conduct post-approval. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU47"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product candidate may be marketed or to the conditions of approval, including a requirement to implement a REMS. If a product candidate receives marketing approval, the accompanying label may limit the approved indicated use of the product, which could limit sales of the product. The FDA may also require costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if we market our products for uses beyond their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug, and Cosmetic Act, or FDCA, relating to the promotion of prescription drugs, may lead to FDA enforcement actions and investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers, or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">restrictions on manufacturing such products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">restrictions on the labeling or marketing of products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">restrictions on product distribution or use; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">requirements to conduct post-marketing studies or clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">warning letters or untitled letters; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refusal to approve pending applications or supplements to approved applications that we submit; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">recalls or market withdrawals of products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">fines, restitution, or disgorgement of profits or revenues; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">suspension or withdrawal of marketing approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refusal to permit the import or export of our products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product seizure; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">injunctions, consent decrees, or the imposition of civil or criminal penalties. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, the FDA&#8217;s policies may change, and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of a product candidate. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects, and ability to achieve or sustain profitability. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. The policies of the FDA and of other comparable regulatory authorities may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of a product candidate. For example, certain policies of the current presidential administration may impact our business and industry. Namely, the current presidential administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. These executive actions and other policies of the current administration may impact the FDA&#8217;s ability to exercise its regulatory authority, though the extent to which they will impact the development of FX-322 or any other product candidates we develop is unknown. If these executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition, and results of operations. Furthermore, noncompliance by us or any collaborator with regulatory requirements, including safety monitoring or pharmacovigilance, may also result in significant financial penalties, which would adversely affect our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU48"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">received</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> Fast Track designation by the FDA for </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">FX-322 and may seek Fast Track designation by the FDA for any future product candidates</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">, but </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">we might not receive such a designation. However, </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">such designation may not lead to a faster development or regulatory review or approval process. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, FX-322 received Fast Track designation by the FDA. If a drug is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, a drug sponsor may qualify for FDA Fast Track designation. Fast Track designation provides increased opportunities for sponsor meetings with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed. The FDA has broad discretion whether to grant Fast Track designation, and we may not receive such a designation for all of the product candidates for which we may request it. Morever, even if we receive Fast Track designation, Fast Track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular time frame. We may not experience a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may seek a Breakthrough Therapy designation for our product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek a Breakthrough Therapy designation for FX-322 if future results support such designation or other product candidates we may develop. A Breakthrough Therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for priority review if supported by clinical data at the time the NDA is submitted to the FDA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe that a product candidate meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such a designation. Even if we receive Breakthrough Therapy designation, the receipt of such designation may not result in a faster development or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if a product candidate qualifies as a Breakthrough Therapy, the FDA may later decide that it no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of any product candidate we may develop in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by patients, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">impairment of our business reputation and significant negative media attention; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">withdrawal of participants from our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">significant costs to defend the litigation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">distraction of management&#8217;s attention from our primary business; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">substantial monetary awards to patients or other claimants; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">inability to commercialize a product candidate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">decreased market demand for any product; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">loss of revenue. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU49"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The product liability insurance we currently carry, and any additional product liability insurance coverage we acquire in the future, may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for any product candidate, we intend to acquire insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operation and business, including preventing or limiting the commercialization of any product candidates we develop. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The COVID-19 pandemic could adversely impact our business, including our preclinical studies, clinical trials and operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.57%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-1 has spread to multiple countries, including the United States and several European countries. If COVID-19 continues to spread in the United States and worldwide, we may experience disruptions that could severely impact our business, operations, preclinical studies and clinical trials, including: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delays, difficulties or postponement in enrolling and retaining patients in our clinical trials;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.14%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delays, difficulties or postponement in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.14%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of ENT practices and academic centers serving as our clinical trial sites and staff supporting the conduct of our clinical trials;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.14%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others; and</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.14%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">limitations in employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.14%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">inability to obtain additional financing or access the financial markets</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.14%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">if any of the CMOs involved in the manufacture and supply of FX-322 experience a delay or disruption due to COVID-19, we may not have sufficient quantities of FX-322 for our planned activities and may not be able to transition to a new CMO in a timely or cost-effective manner, or at all, which would negatively impact our ability to develop and potentially commercialize FX-322.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global outbreak of COVID-19 continues to rapidly evolve and has begun to have indeterminable adverse effects on general commercial activity and the world economy. We have observed an impact from COVID-19 as several clinical trial sites have informed us that they have temporarily halted enrollment.&nbsp;&nbsp;We believe that other clinical trial sites may be similarly affected and that the rate of patient enrollment, participation and retention in the trial may be reduced, and for a number of the clinical sites, halted for an unknown period of time. Any reduction in enrollment, participation and retention and any halts may delay our Phase 2a clinical trial and our development plans for FX-322, which could have an adverse impact on our business and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU50"></a>The extent to which COVID-19 may impact our business, preclinical studies, clinical trials (including the completion and timing of our Phase 2a clinical trial) and operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. In addition, if we or any of the third parties with whom we engage were to experience shutdowns or other business disruptions, our ability to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted, which could have a material adverse effect on our business and our financial results. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to commercialization </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We face significant competition from biotechnology, pharmaceutical, and medical device companies, and our operating results will suffer if we fail to compete effectively. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology, pharmaceutical, and medical device industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to acquire, develop, and obtain marketing approval for new products on a cost-effective basis and to market them successfully. If a product candidate we develop is approved, we will face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies, and early-stage companies, particularly if the early-stage company has a collaborative arrangement with a large and established company. We are aware of several companies developing products to treat SNHL through the regeneration of hair cells, and we also anticipate that new companies will enter the SNHL market in the future. If we successfully develop and, if approved, commercialize FX-322 for the treatment of SNHL, it may compete, or potentially be used in conjunction, with currently marketed devices, including the hearing aids and cochlear implants currently available and the next generation of improved hearing aids and cochlear implants, and any new therapies that may become available in the future. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competition could render any product candidate we develop obsolete, less competitive, or uneconomical. Our competitors may, among other things: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">have significantly greater name recognition and financial, manufacturing, marketing, product development, technical, and human resources than we do, with mergers and acquisitions in the biotechnology, pharmaceutical, and medical device industries resulting in even more resources being concentrated in our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">more effectively recruit and retain qualified scientific and management personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">more effectively establish clinical trial sites and patient registration; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">develop and commercialize products that are safer, more effective, less expensive, more convenient, or easier to administer, or have fewer or less severe side effects; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtain quicker regulatory approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">better protect their patents and intellectual property or acquire technologies that are complementary to, or necessary for, our programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">implement more effective approaches to sales, marketing, pricing, coverage, and reimbursement; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">form more advantageous strategic alliances or collaborations. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not able to effectively compete for any of the foregoing reasons, our business will be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The successful commercialization of any product candidate we develop will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our or our collaborators&#8217; ability to market those products and decrease our or our collaborators&#8217; ability to generate revenue. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU51"></a>The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers, and other third-party payors are essential for most patients to be able to afford prescription medications. Our ability to achieve acceptable levels of coverage and reimbursement for products or procedures using our products by governmental authorities, private health insurers and other organizations will influence our ability to successfully commercialize any product candidates we develop. Obtaining adequate coverage and reimbursement for any product candidate we develop that is administered under the supervision of a physician, which is what we anticipate for FX-322, may be particularly difficult because of the higher prices associated with such products. In addition, we believe that FX-322 is a novel approach to treating hearing loss and, as a result, availability of coverage and reimbursement by payors is highly uncertain. A decision by a third-party payor not to cover or separately reimburse for our products or procedures using our products could reduce physician utilization of our products once approved. Assuming we obtain coverage for our product candidates or procedures using our products by a third-party payor, the resulting reimbursement payment rates may not be </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States or elsewhere will be available for any product we commercialize, and any reimbursement that may become available may be decreased or eliminated in the future. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and the current presidential administration and Congress have introduced several proposals related to drug pricing. Many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar, or a less expensive therapy is available. Although there are currently no FDA approved drugs for the treatment of SNHL, it is possible that a third-party payor may consider FX-322 as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy, pricing of existing drugs may limit the amount we will be able to charge for any product we commercialize. Payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize a satisfactory return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our product candidates. Additionally, our ability to obtain a satisfactory financial return depends on what, if any, proposals related to drug pricing may be implemented and, if implemented, when they might take effect. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor, and one third-party payor&#8217;s decision to cover a product does not ensure that other payors will also provide similar coverage. Additionally, the process for determining whether a third-party payor will provide coverage for a product is typically separate from the process for setting the price of such product or establishing the reimbursement rate that the payor will pay for the product once coverage is approved. As a result, the determination of coverage and reimbursement is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, increasing efforts by governmental and third-party payors in the United States to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for any product we commercialize. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations, and additional legislative, administrative, or regulatory changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or our collaborators may also be subject to extensive governmental price controls and other market regulations outside of the United States, and we believe the increasing emphasis on cost-containment initiatives in other countries have and will continue to put pressure on the pricing and usage of medical products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we or our collaborators are able to charge for products we or our collaborators commercialize. Accordingly, in markets outside the United States, the reimbursement for products we or our collaborators commercialize may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if a product candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors, or others in the medical community necessary for commercial success. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a>If a product candidate we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community. If it does not achieve an </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adequate level of acceptance, we may not generate significant product revenues or become profitable. The degree of market acceptance of our product candidates, if approved, will depend on several factors, including, but not limited to: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the efficacy and potential advantages compared to alternative treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">effectiveness of sales and marketing efforts; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of treatment in relation to alternative treatments, including any similar generic treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to offer our products for sale at competitive prices; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the convenience and ease of administration compared to alternative treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the strength of marketing and distribution support; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the availability of third-party coverage and adequate reimbursement; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the prevalence and severity of any side effects; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any restrictions on the use of our product together with other medications. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we expect sales of our product candidates, if approved, to generate substantially all our revenues for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business and could require us to seek additional financing. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to establish sales and marketing capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing any product candidate we develop, if approved. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market and successfully commercialize any product candidate we develop, if approved, we must build our sales and marketing capabilities or enter into collaborations with third parties for these services. We currently have no sales, marketing or distribution capabilities and as a company have no experience in marketing products. We intend to directly market and commercialize FX-322 for the treatment of SNHL, if approved, in the United States by developing our own sales and marketing force, targeting ear, nose, and throat doctors and audiologists. There are significant expenses and risks involved with establishing our own sales and marketing capabilities, including our ability to hire, train, retain, and appropriately incentivize a sufficient number of qualified individuals, generate sufficient sales leads and provide our sales and marketing team with adequate access to physicians who may prescribe our product, effectively manage a geographically dispersed sales and marketing team, and other unforeseen costs and expenses. Any failure or delay in the development of a product candidate that affects the expected timing of commercialization of the product candidate or results in the failure of the product candidate to be commercialized could result in us having prematurely or unnecessarily incurred costly commercialization expenses. Our investment would be lost if we are unable to retain or reposition our sales and marketing personnel. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU53"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also enter into collaborations for the sales and marketing of our product candidates, if approved. To the extent that we depend on collaborators for sales and marketing activities, any revenues we receive will depend upon the success of those collaborators&#8217; sales and marketing teams and the collaborators&#8217; prioritization of our product and compliance with applicable regulatory requirements, and there can be no assurance that the collaborators&#8217; efforts will be successful. For example, under the License and Collaboration Agreement with Astellas, or the Astellas Agreement, we will depend on Astellas to sell and market FX-322 for the treatment of SNHL, if approved, outside of the United States, and we can have no assurance that it will be successful in its efforts or devote sufficient resources to the sale and marketing of FX-322. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to build our own sales and marketing team or enter into a collaboration for the commercialization of product candidates we develop, if approved, we may be forced to delay the commercialization of our product candidates or reduce the scope of our sales or marketing activities, which would have an adverse effect on our business, operating results and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">A variety of risks associated with operating internationally could materially adversely affect our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business strategy includes potentially expanding internationally if any of our product candidates receive regulatory approval. Doing business internationally involves several risks, including, but not limited to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">multiple, conflicting, and changing laws and regulations, such as privacy regulations, tax laws, export and import restrictions, economic sanctions laws and regulations, employment laws, regulatory requirements, and other governmental approvals, permits, and licenses; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">additional potentially relevant third-party patent rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">complexities and difficulties in obtaining protection and enforcing our intellectual property; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">difficulties in staffing and managing foreign operations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">complexities associated with managing multiple payor reimbursement regimes, government payors, or patient self-pay systems; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">limits in our ability to penetrate international markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products, and exposure to foreign currency exchange rate fluctuations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade, and other business restrictions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">certain expenses, including, among others, expenses for travel, translation, and insurance; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, its books and records provisions, or its anti-bribery provisions, as well as other applicable laws and regulations prohibiting bribery and corruption. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these factors could significantly harm any future international expansion and operations and, consequently, our results of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our dependence on third parties </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Astellas Agreement is important to our business. If we or Astellas fail to adequately perform under the Astellas Agreement, or if we or Astellas terminate the Astellas Agreement, the development and commercialization of FX-322 for SNHL outside the United States would be materially delayed and our business would be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Astellas Agreement, Astellas is responsible for the development and commercialization of FX-322 outside of the United States and we are responsible for development and commercialization in the United States. We and Astellas are jointly responsible for conducting global clinical studies and coordinating commercial launch activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU54"></a>We have received an upfront payment from Astellas of $80.0 million, and we may also receive development milestone payments up to $230.0 million. If the Astellas licensed products are successfully commercialized, we would be eligible for up </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to $315.0 million in potential commercial milestone payments </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">plus</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> tiered royalties at rates ranging from low- to mid-teen percentages. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination of the Astellas Agreement could cause significant delays in our development and commercialization efforts for FX-322 for the treatment of SNHL outside of the United States. If the Astellas Agreement is terminated, we would need to expand our internal capabilities or enter into another agreement to compensate for the loss in funding and clinical development support from Astellas. Any suitable alternative agreement would take considerable time to negotiate and could also be on less favorable terms to us. Whether or not we identify another suitable collaborator, we may need to seek additional financing to continue the development of FX-322, or we may be forced to discontinue development of FX-322, either of which could have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We intend to continue to collaborate with third parties for the development and commercialization of our product candidates. We may not succeed in establishing and maintaining collaborations, which may significantly limit our ability to successfully develop and commercialize our other product candidates, if at all. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into the Astellas Agreement for the development and commercialization of FX-322 for the treatment of SNHL outside the United States and may seek collaborations for the development and commercialization of other product candidates. The process of establishing and maintaining collaborative relationships is difficult, time-consuming, and involves significant uncertainty, such as: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a collaborator may shift its priorities and resources away from our product candidates due to a change in business strategies, or a merger, acquisition, sale, or downsizing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a collaborator may seek to renegotiate or terminate its relationships with us due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a collaborator may cease development in therapeutic areas which are the subject of our collaboration; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a collaborator may not devote sufficient capital or resources towards our product candidates, or may fail to comply with applicable regulatory requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a collaborator may change the success criteria for a product candidate, thereby delaying or ceasing development of such candidate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a significant delay in initiation of certain development activities by a collaborator will also delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a collaborator could develop a product that competes, either directly or indirectly, with our product candidate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a collaborator with commercialization obligations may not commit sufficient financial resources or personnel to the marketing, distribution, or sale of a product; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a collaborator with manufacturing responsibilities may encounter regulatory, resource, or quality issues and be unable to meet demand requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a collaborator may terminate a strategic alliance; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a dispute may arise between us and a collaborator concerning the research, development, or commercialization of a product candidate resulting in a delay in milestones or royalty payments or termination of the relationship and possibly resulting in costly litigation or arbitration, which may divert management&#8217;s attention and resources; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a collaborator may use our products or technology in such a way as to invite litigation from a third party. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, our research, clinical development, manufacturing, or commercialization efforts related to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility of our collaborator. If we are unable to establish and maintain collaborations on acceptable terms or to successfully transition away from terminated collaborations, we may have to delay or discontinue further development of one or more of our product candidates, undertake development and commercialization activities at our own expense, or find alternative sources of capital, which would have a material adverse impact on our clinical development plans and business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU55"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization of our product candidates, could engage in misconduct, including intentional, reckless, or negligent conduct or unauthorized activities that violate applicable laws, rules, and regulations including: the laws and regulations of the FDA or other similar regulatory requirements of other authorities, including those laws that require the reporting of true, complete, and accurate information to such authorities; manufacturing standards; data privacy, security, fraud and abuse, and other healthcare laws and regulations; or laws that require the reporting of true, complete, and accurate financial information and data. Specifically, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Activities subject to these or other laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government agency could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us or them and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal, and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We currently rely on third-party contract manufacturing organizations, or CMOs, for the production of clinical supply of FX-322 and intend to rely on CMOs for the production of commercial supply of FX-322, if approved, and for clinical and commercial supply of our future product candidates, as well as to supply raw materials necessary to produce our product candidates. Our dependence on CMOs may impair the development of our product candidates and may impair their commercialization, which would adversely impact our business and financial position. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own facilities for manufacturing FX-322 or any product candidate. Instead, we rely on and expect to continue to rely on CMOs for the supply of cGMP grade clinical trial materials of FX-322 and any product candidates we develop and, in future, for commercial quantities. Reliance on CMOs may expose us to more risk than if we were to manufacture our product candidates ourselves. If any CMO we engage is unable to provide sufficient supply of any product candidate we develop, we may be unable to arrange for an alternative supply or to do so on commercially reasonable terms or in a timely manner, which could delay any clinical trials, the commercial launch of our product candidates, if approved, or, regarding any commercial supply, result in a shortage in supply that could negatively impact our revenues. For example, we are substantially dependent on the CMO that supplies us with the proprietary glycogen synthase kinase 3, or GSK3, inhibitor that is a key component of FX-322 and the CMO that lyophilizes FX-322 into a powder. While there are other CMOs who are able to supply the GSK3 inhibitor or lyophilize FX-322, manufacture of the GSK3 inhibitor and the lyophilization process require proprietary knowledge or specialized capabilities that only a limited number of CMOs have. As a result, transitioning to a new CMO for either the supply of the GSK3 inhibitor or to conduct the lyophilization process would be particularly time consuming and costly. We have not engaged any other CMOs as back-up for the manufacture and supply of FX-322. As a result, if any of the CMOs involved in the manufacture and supply of FX-322 experience a delay or disruption, or if we fail to obtain the appropriate approvals to manufacture and supply FX-322 outside the US (e.g., Bayh-Dole), we may not have sufficient quantities of FX-322 for our planned activities and may not be able to transition to a new CMO in a timely or cost-effective manner, or at all, which would negatively impact our ability to develop and potentially commercialize FX-322. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The facilities used to manufacture our product candidates must be inspected by the FDA and comparable foreign regulatory authorities. While we provide oversight of manufacturing activities, we do not and will not control the execution of manufacturing activities by, and are or will be dependent on, our CMOs for compliance with cGMP requirements for the manufacture of our product candidates. As a result, we are subject to the risk that our product candidates may have manufacturing defects that we have limited ability to prevent. If a CMO cannot successfully manufacture material that conforms to our specifications and the regulatory requirements, we will not be able to secure or maintain regulatory approval for the use of our product candidates in clinical trials, or for commercial distribution of our product candidates, if approved. While we have engaged independent auditors to assess the compliance with the protocol that we co-developed with our CMOs regarding the manufacturing process for FX-322, in general, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance, and qualified personnel, and we were not involved in developing our CMOs&#8217; policies and procedures. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU56"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA or comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval or finds deficiencies in the future, we may need to find alternative manufacturing facilities, which would delay our development program and significantly impact our ability to develop, obtain regulatory approval for, or commercialize our product candidates, if approved. In addition, any failure to achieve and maintain compliance with laws, regulations, and standards related to manufacturing could subject us to risks, including the risk that we may have to suspend the manufacture of our product candidates, that obtained approvals could be revoked, and that the FDA or another governmental regulatory authority may take enforcement actions, including untitled letters, warning letters, seizures, injunctions, or product recalls. Furthermore, CMOs may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate CMO or another acceptable solution in time, our clinical trials could be delayed, or our commercial activities could be harmed. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We contract for the supply of the active pharmaceutical ingredient, or API, and other raw material necessary to produce FX-322 and we may contract in the future for the supply of API and other raw material for any other product candidate we develop. Supplies of API or other raw material could be interrupted from time to time and we cannot be certain that alternative supplies could be obtained within a reasonable time frame, at an acceptable cost, or at all. In addition, a disruption in the supply of API or other raw material could delay the commercial launch of our product candidates, if approved, or result in a shortage in supply, which would impair our ability to generate revenues. Growth in the costs and expenses of API or other raw material may also impair our ability to cost-effectively manufacture our product candidates. In addition, there may be a limited number of suppliers for API or other raw material that we may use to manufacture our product candidates, and we cannot be certain that we will be able to engage such suppliers in a timely manner or at all. If we are unable to do so, clinical development of our product candidates, commercialization for any approved product, or our business could be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finding new CMOs or third-party suppliers involves additional cost and requires our management&#8217;s time and focus. In addition, there is typically a transition period when a new CMO commences work. Although we have not, and do not intend to, begin a clinical trial unless we believe we have on hand, or will be able to obtain, a sufficient supply of our product candidates to complete the clinical trial, any significant delay in the supply of our product candidates or the raw materials needed to produce our product candidates, could considerably delay conducting our clinical trials and potential regulatory approval of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of their manufacture of our product candidates, our CMOs and third-party suppliers are expected to comply with and respect the proprietary rights of others. If a CMO or third-party supplier fails to acquire the proper licenses or otherwise infringes the proprietary rights of others in the course of providing services to us, we may have to find alternative CMOs or third-party suppliers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for, or commercialize our product candidates, if approved. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We intend to rely on third parties to conduct, supervise, and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely, and will continue to rely, on CROs, CRO-contracted vendors, and clinical trial sites to ensure the proper and timely conduct of our clinical trials, including our Phase 2a trial and other planned clinical trials of FX-322 for the treatment of SNHL. Our reliance on CROs for clinical development activities limits our control over these activities and we were not involved in developing our CRO&#8217;s policies and procedures, but we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory, and scientific standards. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our CROs will be required to comply with the Good Laboratory Practice requirements for our preclinical studies and GCP requirements for our clinical trials, which are regulations and guidelines enforced by the FDA and are also required by comparable foreign regulatory authorities. Regulatory authorities enforce GCP requirements through periodic inspections of trial sponsors, principal investigators, and clinical trial sites. If we or our CROs fail to comply with GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with product produced under cGMP requirements. Accordingly, if our CROs fail to comply with these requirements, we may be required to repeat clinical trials, which would delay the regulatory approval process. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU57"></a>Our CROs are not our employees, and we do not control whether they devote sufficient time and resources to our clinical trials. Our CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities, which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, or fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our relationship with any CROs terminates, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management&#8217;s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to healthcare laws and other legal compliance matters </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved, and may affect the prices we may set. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes, and additional proposed changes, to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of health care. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the biotechnology and pharmaceutical industries include the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs and biologics that are inhaled, infused, instilled, implanted, or injected; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establishment of a Center for Medicare Innovation at the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been judicial challenges to certain aspects of the ACA, and we expect there will be additional challenges to the ACA in the future. For example, in December 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was modified as part of the TCJA, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the district court&#8217;s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. It is unclear how these decisions, subsequent appeals, or other efforts to challenge, repeal or amend some or all aspects of the ACA will impact the law or our business or financial condition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU58"></a>Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the Budget Control Act of 2011 resulted in aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2029 unless additional action is taken by Congress. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws or any other similar laws </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">introduced in the future may result in additional reductions in Medicare and other healthcare funding, which could negatively affect our potential customers and accordingly, our financial operations. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been administration efforts, Congressional inquiries and proposed federal and state legislation designed to bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient assistance programs and reform government program reimbursement methodologies for drugs. For example, the current presidential administration&#8217;s fiscal year 2019 budget proposal contained further drug price control measures which could be implemented in future legislation or through rulemakings or administrative or executive actions. These measures include, for example, allowing some states to negotiate drug prices under Medicaid and eliminating cost sharing for generic drugs for low-income patients. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. We expect that additional U.S. federal healthcare reform measures will be implemented in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition, and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. These reforms could reduce the ultimate demand for our product candidates or put pressure on our product pricing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business operations and current and future relationships with contractors, investigators, healthcare professionals, consultants, third-party payors, patient organizations, customers, and others will be subject to applicable healthcare regulatory laws, which could expose us to penalties. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business operations and current and future arrangements with contractors, investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell, and distribute our product candidates, if approved. Such laws include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any good, facility, item or service for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The U.S. federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU59"></a><font style="font-family:Times New Roman;">the U.S. federal false claims and civil monetary penalties laws, including the civil False Claims Act, or FCA, which, among other things, impose criminal and civil penalties, including through civil whistleblower or </font><font style="font-style:italic;font-family:Times New Roman;">qui tam</font><font style="font-family:Times New Roman;"> actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. A claim </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">includes &#8220;any request or demand&#8221; for money or property presented to the federal government. In addition, pharmaceutical manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose, among other things, specified requirements relating to privacy, security and breaches of individually identifiable health information by covered entities subject to the rule, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information. HITECH created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA, as amended by HITECH, and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics, and medical devices; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on approved products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the U.S. federal legislation commonly referred to as the Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics, and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by certain physicians and their immediate family members; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state laws governing privacy, security, and breaches of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For example, the California Consumer Privacy Act, or the CCPA, which went into effect on January 1, 2020, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU60"></a><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">similar healthcare laws and regulations in the European Union, or EU, and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and laws governing the privacy and security of personal information, such as, where applicable, the General Data Protection Regulation, or GDPR, which imposes obligations and restrictions on the collection, use, and disclosure of personal data relating to individuals located in the EU and the European Economic Area, or EEA, (including health data); and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">laws and regulations prohibiting bribery and corruption such as the FCPA, which, among other things, prohibits U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations or foreign government-owned or affiliated entities, candidates for foreign public office, and foreign political parties or officials thereof. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our business activities, including our consulting agreements and other relationships with healthcare providers, some of whom receive stock or stock options as compensation for their services, could be subject to challenge under one or more of such laws. Ensuring that our current and future internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance, or case law involving applicable fraud and abuse or other healthcare laws and regulations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to actions including the imposition of civil, criminal, and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements, or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time consuming, and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Any clinical trial programs, marketing, or research collaborations in the European Economic Area will subject us to the GDPR. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU61"></a>The GDPR applies to companies established in the EEA, as well as to companies that are not established in the EEA and which collect and use personal data in relation to (i)&#160;offering goods or services to, or (ii)&#160;monitoring the behavior of, individuals located in the EEA. If we conduct clinical trial programs in the EEA (whether the trials are conducted directly by us or through a clinical vendor or collaborator), or enter into research collaborations involving the monitoring of individuals in the EEA, or market our products to individuals in the EEA, we will be subject to the GDPR. The GDPR puts in place stringent operational requirements for processors and controllers of personal data, including, for example, high standards for obtaining consent from individuals to process their personal data (or reliance on another appropriate legal basis), the provision of robust and detailed disclosures to individuals about how personal data is collected and processed (in a concise, intelligible and easily accessible form), a comprehensive individual data rights regime (including access, erasure, objection, restriction, rectification and portability), maintaining a record of data processing, data export restrictions governing transfers of data from the EEA, short timelines for data breach notifications to be given to data protection regulators or supervisory authorities (and in certain cases, affected individuals) of significant data breaches, and limitations on retention of information. The GDPR also puts in place increased requirements pertaining to health data and other special categories of personal data, as well as a definition of pseudonymized (i.e., key-coded) data. Further, the GDPR provides that EEA member states may establish their own laws and regulations limiting the processing of genetic, biometric, or health data, which could limit our ability to collect, use, and share such data and/or could cause our costs to increase. In addition, there are certain obligations if we contract third-party processors in connection with the processing of personal data. If our or our collaborators&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data, or fines of up to 20&#160;million Euros or up to 4% of our total worldwide annual revenue of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, including class-action type litigation, negative publicity, reputational harm and a potential loss of business and goodwill.  Additionally, following the United Kingdom&#8217;s withdrawal from the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">European Union, we will have to comply with the GDPR and the United Kingdom GDPR, each regime having the ability to fine up to the greater of &#8364;20 million/ &#163;17.5 million or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which exposes us to further compliance risk.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations, including our development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release, and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds, and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our intellectual property </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to obtain, maintain, enforce and protect patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends in large part on our ability to obtain and maintain protection of the intellectual property we may own solely and jointly with others, or may license from others, particularly patents, in the United States and other countries with respect to any proprietary technology and product candidates we develop. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our technologies and product candidates that are important to our business and by in-licensing intellectual property related to such technologies and product candidates. If we are unable to obtain or maintain patent protection with respect to any proprietary technology or product candidate, our business, financial condition, results of operations and prospects could be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, defend, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing, and prosecution of patent applications, or to maintain, enforce, and defend the patents, covering technology that we license from third parties. Therefore, these in-licensed patents, and applications may not be prepared, filed, prosecuted, maintained, defended, and enforced in a manner consistent with the best interests of our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU62"></a>The patent position of pharmaceutical and biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the scope of patent protection outside of the United States is uncertain and laws of foreign countries may not protect our rights to the same extent as the laws of the United States or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. With respect to both owned and in-licensed patent rights, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not published at all. Therefore, neither we nor our licensors can know with certainty whether either we or our licensors were the first to make the inventions claimed in the patents and patent applications we own or in-license now or in the future, or that either we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability, and commercial value of our owned and in-licensed patent rights are uncertain. Moreover, our owned and in-licensed pending and future patent applications may not result in patents being issued which protect our technology and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents and our ability to obtain, protect, maintain, defend, and enforce our patent rights, narrow the scope of our patent protection and, more generally, could affect the value or narrow the scope of our patent rights. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, we or our licensors may be subject to a third-party pre-issuance submission of prior art to the United States Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, <font style="font-style:italic;">inter partes</font> review, post-grant review, or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our owned and in-licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us, or otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost and require significant time from our management and employees, even if the eventual outcome is favorable to us. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our competitors may be able to circumvent our owned or in-licensed patents by developing similar or alternative technologies or products in a non-infringing manner. As a result, our owned and in-licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar or identical to any of our technology and product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural<font style="font-weight:bold;font-style:italic;"> </font>expiration of a patent is generally 20 years from its earliest United States non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales or an obligation on our part to pay royalties and/or other forms of compensation. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU63"></a>If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if we fail to comply with our obligations under license agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, or impede, or delay or prohibit the further development or commercialization of, one or more product candidates that rely on such agreements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for any product candidates we may develop, our business may be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the patent term of a patent that covers an FDA-approved drug may be eligible for limited patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. In addition, only one patent applicable to an approved drug may be extended, and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and certain other non-United States jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when our product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product candidates, there is no guarantee that the applicable authorities will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. We may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. If we are unable to obtain any patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following the expiration of our patent rights, and our business, financial condition, results of operations, and prospects could be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is possible that we will not obtain patent term extension under the Hatch-Waxman Act for a United States patent covering any of our product candidates that we may identify even where that patent is eligible for patent term extension, or if we obtain such an extension, it may be for a shorter period than we had sought. Further, for our licensed patents, we may not have the right to control prosecution, including filing with the USPTO, of a petition for patent term extension under the Hatch-Waxman Act. Thus, if one of our licensed patents is eligible for patent term extension under the Hatch-Waxman Act, we may not be able to control whether a petition to obtain a patent term extension is filed, or obtained, from the USPTO. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also, there are detailed rules and requirements regarding the patents that may be submitted to the FDA for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. We may be unable to obtain patents covering our product candidates that contain one or more claims that satisfy the requirements for listing in the Orange Book. Even if we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If one of our product candidates is approved and a patent covering that product candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any abbreviated new drug application filed with the FDA to obtain permission to sell a generic version of such product candidate. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU64"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs surrounding the prosecution of our owned and in-licensed patent applications and the maintenance, enforcement, or defense of our owned and in-licensed issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution, and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, <font style="font-style:italic;">inter partes</font> review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Although we or our licensors are not currently involved in any litigation, we may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors and other third parties may infringe, misappropriate or otherwise violate our or our licensors&#8217; issued patents or other intellectual property. As a result, we or our licensors may need to file infringement, misappropriation or other intellectual property related claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke such parties to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property. In addition, in a patent infringement proceeding, such parties could counterclaim that the patents we or our licensors have asserted are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, <font style="font-style:italic;">inter partes</font> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). The outcome following legal assertions of invalidity and unenforceability is unpredictable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An adverse result in any such proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated or interpreted narrowly and could put any of our owned or in-licensed patent applications at risk of not yielding an issued patent. A court may also refuse to stop the third party from using the technology at issue in a proceeding on the grounds that our owned or in-licensed patents do not cover such technology. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during this type of litigation. Any of the foregoing could allow such third parties to develop and commercialize competing technologies and products and have a material adverse impact on our business, financial condition, results of operations, and prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU65"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs, and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical and biotechnology industries. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our technology and product candidates, including interference proceedings, post grant review, <font style="font-style:italic;">inter partes</font> review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the European Patent Office. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our technologies or product candidates that we may identify may be subject to claims of infringement of the patent rights of third parties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive and time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. The risks of being involved in such litigation and proceedings may increase if and as our product candidates near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of merit. We may not be aware of all such intellectual property rights potentially relating to our technology and product candidates and their uses, or we may incorrectly conclude that third party intellectual property is invalid or that our activities and product candidates do not infringe such intellectual property. Thus, we do not know with certainty that our technology and product candidates, or our development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third party&#8217;s intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the discovery, use or manufacture of the product candidates that we may identify or related to our technologies. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that the product candidates that we may develop may be found to infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, as noted above, there may be existing patents that we are not aware of or that we have incorrectly concluded are invalid or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover, for example, the manufacturing process of the product candidates that we may develop, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU66"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize the product candidates that we may identify. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products, or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may choose to take a license or, if we are found to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, we could also be required to obtain a license from such third party to continue developing, manufacturing and marketing our technology and product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us and could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right and could be forced to indemnify our customers or collaborators. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. In addition, we may be forced to redesign our product candidates, seek new regulatory approvals, and indemnify third parties pursuant to contractual agreements. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could compromise our ability to compete in the marketplace. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the USPTO and foreign patent agencies in several stages or annually over the lifetime of our owned and in-licensed patents and patent applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our licensing partners to pay these fees to, or comply with the procedural and documentary rules of, the relevant patent agency. With respect to our patents, we rely on an annuity service, outside firms, and outside counsel to remind us of the due dates and to make payment after we instruct them to do so. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, it would have a material adverse effect on our business, financial condition, results of operations, and prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU67"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to comply with our obligations in our intellectual property licenses and funding arrangements with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are party to license and funding agreements that impose, and we may enter into additional licensing and funding arrangements with third parties that may impose, diligence, development, and commercialization timelines, milestone payment, royalty, insurance and other obligations on us. Under our existing licensing and funding agreements, we are obligated to pay royalties on net product sales of product candidates or related technologies to the extent they are covered by the agreements. If we fail to comply with such obligations under current or future license and funding agreements, our counterparties may have the right to terminate these agreements or require us to grant them certain rights. Such an occurrence could materially adversely affect the value of any product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, which would have a material adverse effect on our business, financial condition, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disputes may arise regarding intellectual property subject to a licensing agreement, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope of rights granted under the license agreement and other interpretation related issues; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the sublicensing of patent and other rights under our collaborative development relationships; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the priority of invention of patented technology. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology and product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents and patent applications we in-license. If other third parties have ownership rights to patents and/or patent applications we in-license, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize product candidates and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products and technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU68"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property and proprietary rights throughout the world. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, and even where such protection is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses, but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect, to the same extent or at all, inventions that constitute new methods of treatment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets, or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims by third parties asserting that our employees, consultants or contractors have wrongfully used or disclosed confidential information of third parties, or we have wrongfully used or disclosed alleged trade secrets of their current or former employers, or claims asserting we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our employees, consultants and contractors were previously employed at universities or other pharmaceutical or biotechnology companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU69"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, while it is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment agreements with them may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial conditions, results of operations, and prospects. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be non-exclusive. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our registered and unregistered trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trade names or trademarks that incorporate variations of our unregistered trade names or trademarks. Over the long term, if we are unable to successfully register our trade names and trademarks and establish name recognition based on our trade names and trademarks, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trade names and trademarks may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU70"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual property rights do not necessarily address all potential threats. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual property rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">it is possible that our owned and in-licensed pending patent applications or those we may own or in-license in the future will not lead to issued patents; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we cannot ensure that any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates or will provide us with any competitive advantages; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before the relevant patents that we own, or license expire; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may not develop additional proprietary technologies that are patentable; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the patents of others may harm our business; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our employees, managing our growth and our operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on the expertise of David L. Lucchino, our President and Chief Executive Officer, as well as the other principal members of our management, scientific, and clinical teams. Although we have employment agreements, offer letters or consulting agreements with our executive officers, these agreements do not prevent them from terminating their services at any time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize product candidates successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous biotechnology and pharmaceutical companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU71"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by other companies or organizations and may have commitments that limit their availability. If we are unable to continue to attract and retain highly qualified personnel, our ability to develop and commercialize our product candidates will be limited. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical development, regulatory affairs and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities or acquire new facilities, and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may engage in transactions that could disrupt our business, cause dilution to our shareholders or reduce our financial resources. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, we may enter into transactions to acquire or in-license rights to product candidates, products or technologies, or to acquire other businesses. If we do identify suitable candidates, we may not be able to enter into such transactions on favorable terms, or at all. Any such acquisitions or in-licenses may not strengthen our competitive position, and these transactions may be viewed negatively by analysts, investors, customers, or other third parties with whom we have relationships. We may decide to incur debt in connection with an acquisition, or in-license or issue our common stock or other equity securities as consideration for the acquisition, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the sellers of the acquired business. In addition, we may not be able to successfully integrate the acquired personnel, technologies, and operations into our existing business in an effective, timely, and nondisruptive manner. Such transactions may also divert management attention from day-to-day responsibilities, increase our expenses, and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or in-licenses or the effect that any such transactions might have on our operating results. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business and operations would suffer in the event of system failures. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the implementation of security measures, our computer systems, as well as those of our CROs and other contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural and manmade disasters (including hurricanes), terrorism, war, and telecommunication and electrical failures. While we do not believe that we have experienced any such system failure, accident, or security breach to date, if such an event were to occur and cause interruptions in our or their operations, it could result in delays and/or material disruptions of our research and development programs. For example, the loss of preclinical or clinical trial data from completed, ongoing, or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we currently rely on third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability, and the development of our product candidates could be delayed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our proprietary or confidential information may be lost, or we may suffer security breaches. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU72"></a>The U.S. federal and various state and foreign governments have enacted or proposed requirements regarding the collection, distribution, use, security and storage of personally identifiable information and other data relating to individuals. In the ordinary course of our business, we and third parties with which we have relationships will continue to collect and store sensitive data, including clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in data centers and on networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our and our collaborators&#8217; security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or internal bad actors, breaches due to employee error, technical vulnerabilities, malfeasance, or other disruptions. A number of proposed and enacted federal, state </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and international laws and regulations obligate companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by third parties, including collaborators, vendors, contractors, or other organizations with which we have formed strategic relationships. Although, to our knowledge, neither we nor any such third parties have experienced any material security breach, and even though we may have contractual protections with such third parties, any such breach could compromise our or their networks and the information stored therein could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure, notifications, follow-up actions related to such a security breach or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, and significant costs, including regulatory penalties, fines, and legal expenses, and such an event could disrupt our operations, cause us to incur remediation costs, damage our reputation, and cause a loss of confidence in us and our or such third parties&#8217; ability to conduct clinical trials, which could adversely affect our reputation and delay the clinical development of our product candidates. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our common stock </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for our stockholders. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The market price of our common stock is likely to be highly volatile and may be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this section titled &#8220;Risk factors&#8221; and elsewhere in this Annual Report on Form 10-K, these factors include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any delay in the enrollment or ultimate completion of our Phase 2a clinical trial and other planned clinical trials of FX-322 for the treatment of SNHL; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the results of the Phase 2a clinical trial or other planned clinical trials of FX-322 for the treatment of SNHL or clinical trials of our competitors for the same indication; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to develop additional product candidates based on our PCA platform, including MS; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any delay in submitting a regulatory filing and any adverse development or perceived adverse development with respect to the regulatory review of such filing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">failure to successfully develop and commercialize FX-322 for the treatment of SNHL or any future product candidate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">inability to obtain additional funding; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory or legal developments in the United States and other countries applicable to our PCA platform or any product candidate: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">adverse regulatory decisions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes in the structure of healthcare payment systems; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">adverse developments concerning our CMOs or CROs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">inability to obtain adequate product supply for our other product candidates, or the inability to do so at acceptable prices; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">introduction of new products, services or technologies by our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to effectively manage our growth; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">failure to meet or exceed financial projections we provide to the public; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">failure to meet or exceed the estimates and projections of the investment community; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes in the market valuations of companies similar to us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">market conditions in the biotechnology and pharmaceutical sectors, and the issuance of new or changed securities analysts&#8217; reports or recommendations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the termination of a collaboration agreement, licensing agreement or other strategic arrangement, or the inability to establish additional collaboration arrangements that we need on favorable terms, or at all; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU73"></a><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">significant lawsuits, including patent or shareholder litigation, and disputes or other developments relating to our proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our product candidates and PCA platform; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">additions or departures of key scientific or management personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">sales of our common stock by us or our shareholders in the future; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">trading volume of our common stock; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">general economic, industry and market conditions. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, as well as general economic, political, regulatory, and market conditions, may negatively affect the market price of our common stock, regardless of our actual operating performance. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We could be subject to securities class action litigation. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, securities class action litigation has often been brought against companies following a decline in the market price of their securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant share price volatility in recent years. As a result, we may be more susceptible to these types of lawsuits and legal proceedings than other companies with more stable security prices. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our directors, executive officers and shareholders affiliated with our directors and executive officers own a significant percentage of our common stock and, if they choose to act together, will be able to exert significant influence over matters subject to shareholder approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our directors, executive officers, and shareholders affiliated with our directors and executive officers exert significant influence on us. As of February 29, 2020, these holders beneficially own approximately&#160;17.1% of the voting power of our outstanding common stock. As a result, these holders, acting together, have significant influence over all matters that require approval of our stockholders, including the election of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transactions. The interests of these holders may not always coincide with our corporate interests or the interests of other shareholders, and they may act in a manner with which our shareholders may not agree or that may not be in the best interests of our other shareholders. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If securities or industry analysts issue an adverse or misleading opinion regarding our common stock, our stock price and trading volume could decline. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical studies and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for our stockholders. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our common stock will be the sole source of gain on an investment in our common stock for the foreseeable future. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU74"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock, or the perception that substantial sales might occur, could cause the price of our common stock to fall. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. The shares of common stock that were sold in the initial public offering of our common stock are freely transferable without restrictions or further registration under the Securities Act of 1933, as amended, or the Securities Act, except for any shares acquired by our affiliates, as defined in Rule 144 under the Securities Act. The remaining shares of our common stock that are outstanding are restricted as a result of securities laws, lock-up agreements or other contractual restrictions that restrict, subject to certain exceptions, transfers for 180 days after the date of our initial public offering. We or certain of the underwriters of our initial public offering may release certain stockholders from the lock-up agreements or other contractual restrictions prior to the end of the 180-day period. In addition, there are shares of common stock that are either subject to outstanding options or reserved for future issuance under our existing equity incentive plans and may become eligible for future sale subject to vesting, the lock-up agreements, and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the shares of capital stock outstanding as of March 20, 2020, certain holders of shares of our common stock acquired prior to our initial public offering are entitled to rights with respect to the registration of their shares under the Securities Act, subject to the 180-day lock-up agreements and other contractual restrictions described above Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, and particularly after we no longer qualify as an emerging growth company, we will incur significant legal, accounting and other expenses that we did not incur previously. The Sarbanes-Oxley Act of 2002, or SOX, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Stock Market LLC, and other applicable securities rules and regulations impose various requirements on U.S. reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time consuming and costly. For example, we expect that these rules and regulations may make it more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified senior management personnel or members for our board of directors. In addition, these rules and regulations are often subject to varying interpretations, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;404 of SOX, or Section&#160;404, as a public company, we will be required to furnish a report by our senior management on our internal control over financial reporting, and our independent registered public accounting firm will be required to provide an attestation report on our internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to provide the attestation report. To ensure compliance with Section&#160;404, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&#160;404. If we identify one or more material weaknesses, it could result in an adverse reaction on the price of our common stock in the market due to a loss of confidence in the reliability of our financial statements. Furthermore, if we are unable to conclude that our internal control over financial reporting is effective, our investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could decline. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU75"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and a &#8220;smaller reporting company&#8221; as defined under the rules promulgated under the Securities Act. As an emerging growth company and a smaller reporting company we may follow reduced disclosure requirements and do not have to make all the disclosures that public companies that are not emerging growth companies or smaller reporting companies do. We will remain an emerging growth company until the earlier of (a) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (b) the last day of the fiscal year following the fifth anniversary of the date of the completion of our initial public offering; (c) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (d) the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, or SEC, which means the market value of our voting and non-voting common stock that is held by non-affiliates exceeds $700 million as of the last business day of our second fiscal quarter. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">not being required to comply with the auditor attestation requirements of Section 404;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an exemption from compliance with the requirement of the Public Company Accounting Oversight Board regarding the communication of critical audit matters in the auditor&#8217;s report on the financial statements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">progressively adding to the number of years of audited financial statements required to be included in our periodic reports; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation, stockholder approval of any golden parachute payments not previously approved and having to disclose the ratio of the compensation of our chief executive officer to the median compensation of our employees. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for complying with new or revised accounting standards; and as a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also a smaller reporting company, and we will remain a smaller reporting company until the fiscal year following the determination that our voting and non-voting common stock held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is more than $700 million measured on the last business day of our second fiscal quarter. Similar to emerging growth companies, smaller reporting companies are able to provide simplified executive compensation disclosure, are exempt from the auditor attestation requirements of Section 404, and have certain other reduced disclosure obligations, including, among other things, being required to provide only two years of audited financial statements and not being required to provide selected financial data, supplemental financial information or risk factors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may choose to take advantage of some, but not all, of the available exemptions for emerging growth companies and smaller reporting companies. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our shares price may be more volatile. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Provisions in our restated certificate of incorporation and our amended and restated bylaws or Delaware law may discourage, delay or prevent a merger, acquisition or other change in control of our company that our shareholders may consider favorable, including transactions in which our shareholders might otherwise receive a premium for their shares. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation and our amended and restated bylaws include certain anti-takeover provisions, including those establishing: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU76"></a><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents shareholders from filling vacancies on our board of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability of our board of directors to alter our bylaws without obtaining stockholder approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the required approval of the holders of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our restated certificate of incorporation regarding the election and removal of directors: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, the president, or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors: and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a shareholders&#8217; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our restated certificate of incorporation designates specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (1)&#160;any derivative action or proceeding brought on our behalf, (2)&#160;any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers, or other employees to us or our stockholders, (3)&#160;any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware, our restated certificate of incorporation, or our amended and restated bylaws, (4)&#160;any action to interpret, apply, enforce, or determine the validity of our restated certificate of incorporation or our amended and restated bylaws, or (5)&#160;any action asserting a claim governed by the internal affairs doctrine. Under our restated certificate of incorporation, this exclusive forum provision will not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. For instance, the provision would not apply to actions arising under federal securities laws, including suits brought to enforce any liability or duty created by the Securities Exchange Act of 1934, as amended, or the rules and regulations thereunder. This exclusive forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. For example, stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the State of Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition, or results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU77"></a><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a>Item 1B. Unresolve</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">d Staff Comments. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_PROPERTIES"></a><a name="ITEM_2_PROPERTIES"></a>Item 2. Properties. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Our principal office is located at 19 Presidential Way, Woburn, Massachusetts 01801, where we lease approximately 17,000 square feet of office and laboratory space. We lease this space under a lease that terminates on February 24, 2025. We also lease approximately 2,133&#160;square feet of office and laboratory space at 400&#160;Farmington Avenue, Farmington, Connecticut 06030. This lease is set to terminate on July&#160;31, 2020. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">On January 7, 2020, we entered into an indenture of lease for the lease of approximately 61,307 square feet of office and laboratory space located at 75 Hayden Avenue, Lexington, Massachusetts 02421, which, once occupied, we expect will be our new principal office. We expect to move to this new location in early 2021.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_LEGAL_PROCEEDINGS"></a><a name="ITEM_3_LEGAL_PROCEEDINGS"></a>Item 3. Legal Proceedings. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not subject to any material legal proceedings. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a>Item 4. Mine Safety Disclosures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Executive officers and directors</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth information regarding our executive officers and directors as of the date of this Annual Report on Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:504pt;;">
<tr>
<td style="width:128.75pt;"></td>
<td style="width:9.95pt;"></td>
<td style="width:7.85pt;"></td>
<td style="width:15.45pt;"></td>
<td style="width:6pt;"></td>
<td style="width:12.05pt;"></td>
<td style="width:323.95pt;"></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:2.1pt;">
<td valign="middle"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Age</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Position</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Executive Officers</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David L. Lucchino</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer, and Director</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carl P. LeBel, Ph.D.</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Development Officer</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Christopher R. Loose, Ph.D.</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Scientific Officer</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dana Hilt, M.D.</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Medical Officer</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wendy S. Arnold</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief People Officer</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk35366256"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Mitrano</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President of Finance and Operations</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Non-Employee Directors</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marc A. Cohen</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Chairman and Director</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Timothy J. Barberich</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Huang</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert S. Langer, Sc.D.</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joel S. Marcus</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr style="height:2.6pt;">
<td colspan="7" valign="top" >
<p style="border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU78"></a><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Executive officers</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">David L. Lucchino<font style="font-style:normal;"> has served as our President and Chief Executive Officer and a member of our board of directors since November 2014 and was a co-founder of our company with Dr. Robert S. Langer and Dr.&#160;Christopher R. Loose. From December 2014 until June 2016, Mr.&#160;Lucchino served as the President and Chief Executive Officer of Entrega Bio, a PureTech Health-founded biotechnology company focused on oral drug delivery technology. Prior to that, Mr.&#160;Lucchino co-founded Semprus BioSciences, or Semprus, a biotechnology company, and served as its President and Chief Executive Officer from June 2007 to June 2012. Mr. Lucchino oversaw the development of the company&#8217;s lead medical product, which received FDA clearance in 2012. Semprus was acquired by Teleflex, Inc., or Teleflex, in June 2012. Prior to Semprus, Mr. Lucchino worked at the investment firm Polaris Partners. Mr.&#160;Lucchino is the chairman of the board of directors of MassBio, a non-profit organization that represents and provides services and support for the biotechnology industry in Massachusetts. He is a member of the College of Fellows of the American Institute for Medical and Biological Engineering and was appointed by Governor Charlie Baker as a member of the Commonwealth&#8217;s Economic Planning Council. Mr. Lucchino also serves as a trustee of Mt. Auburn Hospital, a Harvard Medical School facility, a trustee of the Multiple Myeloma Research Foundation, and a member of the Board of Advisors of Life Science Cares. Mr.&#160;Lucchino holds an MBA from the Massachusetts Institute of Technology&#8217;s, or MIT&#8217;s, Sloan School of Management, an M.S. from the Newhouse School of Journalism at Syracuse University, and a B.A. in Philosophy and Religious Studies from Denison University. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Carl P. LeBel, Ph.D.<font style="font-style:normal;"> has served as our Chief Development Officer since March 2018. In 2017, Dr.&#160;LeBel founded LeBel Consulting, LLC, a biopharmaceutical consulting company. Prior to joining our company, from February 2009 until November 2016, Dr. LeBel served as the Chief Scientific Officer of Otonomy, Inc., or Otonomy, a biopharmaceutical company where he was responsible for all research and development activities. From 2008 to 2009, he served as the President and Chief Executive Officer of Akesis Pharmaceuticals, Inc., or Akesis, a virtual metabolic disorders company. Prior to Akesis, Dr. LeBel served as an Executive Director in a variety of research and development management positions for Amgen, Inc., or Amgen, a biopharmaceutical company. Before joining Amgen, Dr. LeBel served as a Research Scientist at Alkermes, Inc. Dr. LeBel is a scientific fellow of the American Academy of Otolaryngology and a full member of the American Association for the Advancement of Science and the Society of Toxicology. Dr. LeBel is a co-inventor on numerous patents in the field of drug delivery for otology-related disorders. He was a National Institute of Environmental Health Sciences post-doctoral fellow in Molecular Neurotoxicology at the University of California Irvine. Dr. LeBel holds a Ph.D. in Biomedical Sciences and Toxicology from Northeastern University and a B.S. in Chemistry from the University of Detroit.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Christopher R. Loose, Ph.D.<font style="font-style:normal;"> co-founded our company and has served as our Chief Scientific Officer since January 2016. Prior to our Company, Dr. Loose co-founded Semprus with Mr. Lucchino and Dr. Langer and served as its Chief Technology Officer from June 2007 until its acquisition by Teleflex in June 2012. At Semprus, he led the technology team in the development through regulatory clearance of medical products designed to reduce infection and clotting. Prior to Semprus, Dr. Loose worked as a chemical engineer at Merck Research Labs. In 2011, Dr. Loose was awarded the inaugural Peter Strauss Entrepreneurial Award from the Hertz Foundation. Since 2014, Dr. Loose has served as an Associate Professor Adjunct of Urology at the Yale School of Medicine. Dr. Loose is also the Executive Director of Yale University&#8217;s Center for Biomedical and Interventional Technology. Dr. Loose holds a Ph.D. in Chemical Engineering from MIT and a BSE in Chemical Engineering summa cum laude from Princeton University.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Dana Hilt, M.D.<font style="font-style:normal;"> has served as our Chief Medical Officer since August 2019. From October 2016 to August 2019, Dr. Hilt served as Chief Medical Officer for Lysosomal Therapeutics, Inc., or Lysosomal, a life sciences drug development company in the field of neurodegeneration, where he was responsible for all clinical development activity for a product candidate for the treatment of Parkinson&#8217;s Disease. Prior to Lysosomal, beginning in 2006, Dr. Hilt served in the roles of Senior Vice President of Drug Development and Chief Medical Officer for FORUM Pharmaceuticals, Inc., or FORUM, where he oversaw the clinical, chemistry manufacture controls, regulatory and quality control activities for therapies focused on the treatment of cognitive impairment in schizophrenia and Alzheimer&#8217;s disease. Prior to FORUM, Dr. Hilt served as the Chief Medical Officer and Senior Vice President of Clinical Research, Medical Affairs, and Development for Ascend Therapeutics US, LLC, or Ascend, a specialty pharmaceutical company concentrating on women&#8217;s health and transdermal drug delivery. Before joining Ascend, Dr. Hilt served as the Vice President of Clinical Research at Guilford Pharmaceuticals Inc., or Guilford, a biopharmaceutical company engaged in the research, development, and commercialization of drugs that target the acute care market and neurological indications including Parkinson&#8217;s disease and brain cancer. Prior to Guilford, he served as a Director of Clinical Development at Amgen, where he established its clinical neuroscience group. Prior to that, Dr. Hilt served on the staff of the National Institute of Health. He holds an M.D. from Tufts University School of Medicine and a B.S. from the University of Maine.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU79"></a><font style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Wendy</font><font style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> S. Arnold</font><font style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> </font><font style="font-style:normal;">has served as our Chief People Officer since February 2020</font><font style="font-style:normal;">. Ms. Arnold previously served as Senior Vice President, Human Resources at Kaleido Biosciences where she </font><font style="font-style:normal;">oversaw</font><font style="font-style:normal;"> the HR infrastructure, compensation, performance and development programs. Prior to Kaleido</font><font style="font-style:normal;"> Biosciences</font><font style="font-style:normal;">, </font><font style="font-style:normal;">Ms. Arnold</font><font style="font-style:normal;"> was the head of the HR business partnership function at Moderna Therapeutics, where she </font><font style="font-style:normal;">oversaw the</font><font style="font-style:normal;"> HR organization. Prior to </font><font style="font-style:normal;">Moderna</font><font style="font-style:normal;">, </font><font style="font-style:normal;">Ms. Arnold</font><font style="font-style:normal;"> was at Celgene Avilomics Research (formerly Avila Therapeutics), where she was responsible for building and developing the HR infrastructure for the company&#8217;s early research and development division. </font><font style="font-style:normal;">Ms. Arnold has</font><font style="font-style:normal;"> also held senior HR positions at Inotek Pharmaceuticals and Amylin Pharmaceuticals. Ms. Arnold </font><font style="font-style:normal;">holds a</font><font style="font-style:normal;"> </font><font style="font-style:normal;">B.S.</font><font style="font-style:normal;"> from Colorado State University.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Richard Mitrano<font style="font-style:normal;"> has served as our Vice President of Finance and Operations since July 2016. From 2012 to 2015, Mr. Mitrano served as the Director of Finance and Operations of Semprus, where he oversaw all accounting and finance operations and provided strategic direction and oversight. Prior to Semprus, Mr. Mitrano was a contract Accounting Manager for Predictive Biosciences, Inc., or Predictive, a diagnostics company, from 2010 to 2012. Prior to Predictive, from 2008 to 2010, Mr. Mitrano served as Corporate Controller of Pioneer Behavioral Health, a company providing behavioral health services. Mr. Mitrano holds a B.A. in Accounting from Bentley University.</font></p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Non-Employee Directors</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Marc A. Cohen<font style="font-style:normal;"> has served as a member of our board of directors and as Executive Chairman since September 2016. Since 2012, Mr. Cohen has served as the Chief Executive Officer of Bublup, Inc., an online knowledge-sharing platform, as well as CoBro Ventures, Inc., an investment management company. Mr. Cohen is also Executive Chairman of C4 Therapeutics and Mana Therapeutics. Mr. Cohen holds an M.S. in Electrical Engineering from Stanford University and a Bachelor&#8217;s degree in Engineering Science from Harvard University. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Timothy J. Barberich<font style="font-style:normal;"> has served as a member of our board of directors since September 2016. Mr. Barberich also serves on the board of directors of GI Dynamics, Inc., Verastem, Inc., and TScan Therapeutics, Inc. Mr. Barberich previously served as a director for Tokai Pharmaceuticals, Inc. from 2009 to 2017, for HeartWare International, Inc. from 2008 to 2016, for Inotek Pharmaceuticals Corporation from 2016 to 2017, and for Neurovance, Inc. from 2010 to 2016. Mr. Barberich is co-founder, and served as the CEO and Chairman of Sepracor Inc. from 1984 to 2009. He holds a B.S. in Chemistry from Kings College. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Michael Huang<font style="font-style:normal;"> has served as a member of our board of directors since October 2018. Mr. Huang serves as Managing Partner at Taiwania Capital Management Corporation, a venture capital firm. From 2014 to 2017, Mr. Huang served as Chief Executive Officer of NeuroVive Pharmaceutical Asia, Inc., a biopharmaceutical company. Mr. Huang holds an MBA from Rice University, a M.A. in Chemistry from the University of Texas, Arlington, and a B.S. from University of Texas, Austin. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Robert S. Langer, Sc.D.<font style="font-style:normal;">, has served as a member of our board of directors since September 2016. Dr. Langer has served as a David H. Koch Institute Professor at the Massachusetts Institute of Technology since 2005. Dr. Langer currently serves on the board of directors of Rubius Therapeutics, Inc., Moderna, Inc., and Puretech Health plc, Abpro-Korea, and previously served on the board of directors of Momenta Pharmaceuticals, Inc., Kala Pharmaceuticals, Inc., and Rubius. Dr. Langer holds a Sc.D. in Chemical Engineering from MIT and a B.S. in Chemical Engineering from Cornell University. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Joel S. Marcus<font style="font-style:normal;"> has served as a member of our board of directors since December 2018. Mr. Marcus currently serves as Executive Chairman of Alexandria Real Estate Equities, Inc., or Alexandria, a real estate investment and development company, and served as the Chief Executive Officer of Alexandria from March 1997 to April 2018. Mr. Marcus also currently serves on the boards of directors of Intra-Cellular Therapies, Inc., MeiraGTx Holdings plc, and Applied Therapeutics, Inc. Mr. Marcus holds a B.A. and J.D. from the University of California, Los Angeles. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU80"></a><a name="PART_II"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a>PAR</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">T II</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a>Item 5. Market for <a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a>Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Information</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is traded under the symbol &#8220;FREQ&#8221; on the Nasdaq Global Select Market. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 20, 2020, there were approximately 228 registered holders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. The number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any dividends on our capital stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors. Investors should not purchase our common stock with the expectation of receiving cash dividends.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Equity Compensation Plan Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides information on our equity compensation plans as of December 31, 2019.</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:8.1pt;">
<td valign="bottom"  style="width:35.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:19.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:19.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.19%;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Securities</p></td>
</tr>
<tr style="height:8.1pt;">
<td valign="bottom"  style="width:35.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:19.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:19.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.39%;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available for Future</p></td>
</tr>
<tr style="height:8.1pt;">
<td valign="bottom"  style="width:35.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:19.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Securities to be</p></td>
<td valign="bottom"  style="width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:19.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.39%;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issuance Under Equity</p></td>
</tr>
<tr style="height:8.1pt;">
<td valign="bottom"  style="width:35.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:19.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issued Upon Exercise of</p></td>
<td valign="bottom"  style="width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:20.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:3.37%;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Exercise</p></td>
<td colspan="2" valign="bottom"  style="width:19.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.19%;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation Plans</p></td>
</tr>
<tr style="height:8.1pt;">
<td valign="bottom"  style="width:35.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:19.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding Options,</p></td>
<td valign="bottom"  style="width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:20.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:3.37%;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price of Outstanding Options,</p></td>
<td colspan="2" valign="bottom"  style="width:19.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.19%;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(excludes securities</p></td>
</tr>
<tr style="height:8.55pt;">
<td colspan="2" valign="bottom"  style="width:37.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Plan Category</p></td>
<td valign="bottom"  style="width:19.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants and Rights</p></td>
<td valign="bottom"  style="width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:20.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:3.37%;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants, and Rights</p></td>
<td colspan="2" valign="bottom"  style="width:19.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.19%;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reflected in first column) <font style="font-size:6pt;">(1)</font></p></td>
</tr>
<tr style="height:10.45pt;">
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:35.72%; border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation plans approved by</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.4%; border-top:solid 1pt #CFF0FC;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:19.12%; border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2.08%; border-top:solid 1pt #CFF0FC;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.4%; border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:18.92%; border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.58%; border-top:solid 1pt #CFF0FC;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:18.92%; border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:0.86%; border-top:solid 1pt #CFF0FC;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr style="height:11.5pt;">
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="width:37.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">security holders <font style="font-size:7.5pt;">(2)</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:19.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 5,968,672<font style="font-size:7.5pt;">(3)</font></p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="width:3.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:18.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 5.20<font style="font-size:7.5pt;">(4)</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:18.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2,167,633<font style="font-size:7.5pt;">(5)</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:10.75pt;">
<td colspan="2" valign="bottom"  style="width:37.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation plans not approved by</p></td>
<td valign="bottom"  style="width:19.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:18.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr style="height:11.5pt;">
<td colspan="2" valign="bottom"  style="width:37.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">security holders</p></td>
<td valign="bottom"  style="width:19.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:20.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.79%;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td colspan="2" valign="bottom"  style="width:19.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.19%;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr style="height:11.5pt;">
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="width:37.12%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:19.12%; border-bottom:solid 1pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,968,672 </p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="width:3.48%; border-bottom:solid 1pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:18.92%; border-bottom:solid 1pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.20</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.58%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:18.92%; border-bottom:solid 1pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,167,633</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:0.86%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.08%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top" style="width:3.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">Pursuant to the terms of the 2019 Incentive Award Plan, or the 2019 Plan, the number of shares of common stock available for issuance under the 2019 Plan automatically increases on each January 1 until and including January 1, 2029, by an amount equal to the lesser of: (a) 4% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as is determined by our board of directors. Pursuant to the terms of the 2019 Employee Stock Purchase Plan, or the 2019 ESPP, the number of shares of common stock available for issuance under the 2019 ESPP automatically increases on each January 1 until and including January 1, 2029, by an amount equal to the lesser of: (a) 1% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as is determined by our board of directors.</p></td>
<td valign="top" style="width:1.19%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td></tr></table></div>
<p style="line-height:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.08%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top" style="width:3.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">Consists of the 2014 Stock Incentive Plan, or the 2014 Plan, the 2019 Plan, and the 2019 ESPP.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.08%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top" style="width:3.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">Includes 4,721,334 outstanding options to purchase shares of common stock under the 2014 Plan and 1,247,337 outstanding options to purchase stock under the 2019 Plan.</p></td>
<td valign="top" style="width:1.19%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td></tr></table></div>
<p style="line-height:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.08%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top" style="width:3.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">As of December 31, 2019, the weighted-average exercise price of outstanding options under the 2014 Plan was $2.85 and the weighted-average exercise price per share of outstanding options under the 2019 Plan was $14.09.</p></td>
<td valign="top" style="width:0.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.08%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td>
<td valign="top" style="width:3.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">As of December 31, 2019, a total of 2,167,663 shares of common stock were available for issuance, consisting of (a) 315,000 shares of common stock available for future issuance under the 2019 ESPP, none of which shares were subject to outstanding purchase rights under the 2019 ESPP and (b) 1,852,663 shares of common stock available for future issuance under the 2019 Plan.</p></td>
<td valign="top" style="width:2.98%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:7pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unregistered Sales of Equity Securities and Use of Proceeds</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Equity Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_258"></a><a name="_cp_blt_2_258"></a>During the period covered by this Annual Report on Form 10-K, we have issued the following securities which were not registered under the Securities Act:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU81"></a><a name="_cp_text_1_257"></a>From January 2019 through October 2019, we issued stock options to purchase an aggregate of 3,015,381 shares of our common stock, with a weighted &#8211; average exercise price of $4.17, to our employees, directors and consultants pursuant to our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_257"></a>2014 Stock Incentive Plan.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> These securities were issued under Section 4(a)(2) and Rule 701 of the Securities Act in transactions not involving a public offering.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_261"></a><a name="_cp_text_1_260"></a><a name="_cp_text_1_260"></a>From January 2019 through October 2019, we issued an aggregate of 297,620 shares of common stock to employees, directors and consultants for cash consideration in the aggregate amount of approximately $0.33 million upon the exercise of stock options and stock awards pursuant to our 2014 Stock Incentive Plan. These securities were issued under Section 4(a)(2) and Rule 701 of the Securities Act in transactions not involving a public offering.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_265"></a><a name="_cp_text_1_263"></a><a name="_cp_text_1_264"></a><a name="_cp_text_1_263"></a>In January and February 2019, we issued 288,911 shares of Series B convertible preferred stock, or the Series B shares, at a price of <a name="_cp_text_1_264"></a>$0.920439 per share for aggregate proceeds of approximately $0.27 million to three accredited investors. On October 7, 2020, upon the closing of the initial public offering of our common stock, or the IPO, we issued 42,890 shares of our common stock upon conversion of the Series B shares. These securities were issued under Section 4(a)(2) of the Securities Act in transactions not involving a public offering.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_268"></a><a name="_cp_text_1_267"></a><a name="_cp_text_1_270"></a><a name="_cp_text_1_274"></a><a name="_cp_text_1_276"></a><a name="_cp_text_1_267"></a>In July 2019, we issued 39,392,960 shares of Series C convertible preferred stock, or the Series C shares, at a price of <a name="_cp_text_1_270"></a>$1.569884 per share for aggregate proceeds of approximately $62.0 million to seventy-five accredited investors. On October 7, 2020, upon the closing of the IPO, we issued 5,848,482 shares of our common stock upon conversion of the Series C shares. These <a name="_cp_text_1_274"></a>securities were issued <a name="_cp_text_1_276"></a>under Section 4(a)(2) of the Securities Act in transactions not involving a public offering.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Proceeds </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_282"></a><a name="_cp_text_1_285"></a><a name="_cp_text_1_286"></a><a name="_cp_text_1_289"></a><a name="_cp_text_1_291"></a><a name="_cp_text_1_293"></a><a name="_cp_text_1_294"></a><a name="_cp_text_1_296"></a><a name="_cp_text_1_297"></a><a name="_cp_text_1_299"></a><a name="_cp_text_1_301"></a>In <a name="_cp_text_1_285"></a>October 2019, we issued and sold 6,325,000 <a name="_cp_text_1_286"></a>shares of our common stock in our IPO at a public offering <a name="_cp_text_1_289"></a>price of $14.00 per share.&#160;&#160;The offer and sale of all <a name="_cp_text_1_291"></a>the shares in the <a name="_cp_text_1_293"></a>IPO were <a name="_cp_text_1_294"></a>registered under the Securities Act pursuant to a <a name="_cp_text_1_296"></a>registration statement <a name="_cp_text_1_297"></a>on Form S-1 (File No.&#160;333-233652), as amended, <a name="_cp_text_1_299"></a>which was declared effective by <a name="_cp_text_1_301"></a>the SEC on October 2, 2019. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_304"></a><a name="_cp_text_1_306"></a><a name="_cp_text_1_308"></a><a name="_cp_text_2_303"></a><a name="_cp_text_1_307"></a><a name="_cp_text_1_310"></a><a name="_cp_text_1_311"></a><a name="_cp_text_1_312"></a><a name="_cp_text_1_313"></a>The $79.7 <a name="_cp_text_1_306"></a>million in net proceeds <a name="_cp_text_1_308"></a>we received from the IPO have been invested in cash and cash equivalents<a name="_cp_text_2_303"></a><a name="_cp_text_1_307"></a>.<a name="_cp_text_1_310"></a> There has been no material change in the expected <a name="_cp_text_1_311"></a>use of the net <a name="_cp_text_1_312"></a>proceeds from our IPO as described in our final prospectus, dated October 2, 2019, <a name="_cp_text_1_313"></a>filed with the SEC pursuant to Rule 424(b) relating to our registration statement on Form S-1 on October 4, 2019.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU82"></a><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a>Item 6. S</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">elected Financial Data. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should read the following selected consolidated financial data together with our consolidated financial statements and the related notes included elsewhere in this Annual Report on Form 10-K and the section titled &#8220;Management&#8217;s discussion and analysis of financial condition and results of operations.&#8221; We have derived the consolidated statement of operations data for the years ended December&#160;31, 2019, 2018 and 2017 and the consolidated balance sheet data as of December&#160;31, 2019 and 2018 from our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K. Our historical results are not necessarily indicative of results that may be expected in any future period, and our results for any interim period are not necessarily indicative of results that may be expected for any full year. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statements of Operations Data:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,947</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,784</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,880</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,966</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,838</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,064</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,340</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,622</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,944</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,306</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,675</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,944</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,306</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income (expense)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,784</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(106</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(174</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of debt</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(269</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,749</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized gain on investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange gain (loss)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net Loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,237</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative Series C preferred stock dividends</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,054</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,237</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted(1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.29</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12.53</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28.79</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock outstanding,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted(1)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,649,245</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,530,218</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">702,918</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">See Note 2 within the notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for an explanation and details of the method used to calculate the basic and diluted net loss per share of common stock. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.38%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Balance Sheet Data:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and short-term</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; investments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,355</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,189</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Working capital(1)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,575</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,164</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,218</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,548</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,860</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,122</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock and non-controlling</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,708</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,888</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,088</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; (deficit) equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167,358</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48,282</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We define working capital as current assets less current liabilities. See our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for further details regarding our current assets and current liabilities. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU83"></a><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a>Item 7. Management&#8217;s Discussion and Analysis of </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Condition and Results of Operations. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis contains forward-looking statements that involve risks and uncertainties. You should review the section titled &#8220;Risk factors&#8221; in this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described below. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biotechnology company focused on harnessing the body&#8217;s innate biology to repair or reverse damage caused by a broad range of degenerative diseases and an industry leader in the science and development of medicines for inner-ear cellular regeneration and hearing restoration. Our initial focus is on advancing our lead product candidate, FX-322, through clinical studies with the goal of developing and commercializing a medicine to help millions of patients with the most common form of hearing loss and build upon the potential of regenerative therapeutics for hearing.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our initial therapeutic focus is sensorineural hearing loss, or SNHL, which is the most prevalent type of hearing loss. We are developing FX-322 to treat the underlying cause of SNHL, which is the loss of hair cells. FX-322 is designed to regenerate hair cells through the activation of progenitor cells already present in the ear. In our Phase 1/2 clinical trial evaluating FX-322 in 23 patients with stable SNHL, we observed a statistically significant and clinically meaningful  improvement in key measures of hearing loss, including word recognition, and clarity of sounds, and FX-322 was observed to be well-tolerated. We commenced dosing of a Phase 2a clinical trial of FX-322 in patients with SNHL in October 2019. As of March 26, 2020, the Phase 2a clinical trial was approximately at the halfway point of enrollment based on the original trial design and we are continuing to enroll and dose patients in the trial. However, we have observed an impact on the Phase 2a clinical trial from the COVID-19 pandemic as several clinical trial sites have informed us that they have temporarily halted enrollment in the trial. We expect that the effects of the pandemic may result in other clinical trial sites being similarly affected for an unknown period of time, slowing or temporarily halting patient enrollment and potentially impacting patient retention. As a result, we will provide updated guidance on the timing of completion and reporting of top-line data of the Phase 2a clinical trial once we better understand the extent of the impact of the COVID-19 pandemic on the trial.&nbsp;&nbsp;Nevertheless, we believe that, if necessary, we could achieve the key objectives of the Phase 2a clinical trial with fewer study subjects than originally designed. We are also working to identify a product candidate for the treatment of multiple sclerosis, or MS. This program focuses on activating progenitor cells in the central nervous system to repair the myelin sheath that protects nerves and may have the potential to reverse damage done by the disease. We intend to submit an investigational new drug application or, IND, to the U.S. Federal Drug Administration, or the FDA, for our MS product candidate in the second half of 2021. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, we completed the initial public offering of our common stock, or the IPO. In the IPO, we issued and sold 6,325,000 shares of our common stock at a price to the public of $14.00 per share, inclusive of the underwriters&#8217; exercise in part of their over-allotment option. We received approximately $79.7 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. <font style="color:#000000;">In July 2019, we closed our Series C convertible preferred stock financing in which we issued and sold 39,492,960 shares of our Series C convertible preferred stock for aggregate gross proceeds of approximately $61.7&#160;million. In July 2019, we also entered into a License and Collaboration Agreement, or the Astellas Agreement, with Astellas Pharma Inc., or Astellas, pursuant to which Astellas paid us an upfront payment of $80.0&#160;million. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our formation in 2014, we have devoted substantially all our resources to developing our PCA platform, conducting research and development activities, including product candidate development, recruiting skilled personnel, establishing our intellectual property portfolio, and providing general and administrative support for these operations. We have financed our operations primarily through proceeds from the sale of convertible notes and of our convertible preferred stock, the IPO and the Astellas Agreement. To date, we have raised approximately $316.5&#160;million through a combination of convertible notes, convertible preferred stock financings, the upfront payment under the Astellas Agreement, grants and the IPO. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our formation, we have incurred significant operating losses and have not generated any revenue from the sale of products. Our ability to generate any product revenue or product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our product candidates. Our net losses were $18.7&#160;million, $19.2&#160;million and $20.2 million for the years ended December&#160;31, 2019, 2018 and 2017, respectively. As of December 31, 2019, we had an accumulated deficit of $68.9 million. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU84"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our operating expenses to increase substantially in connection with the expansion of our product development programs and capabilities.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In addition, we expect to continue to incur significant additional costs associated with operating as a public company.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> We will not generate revenue from product sales unless and until we successfully complete clinical development, obtain regulatory approval for, and successfully commercialize our product candidates, or until our collaborators do so, which could result in milestone payments or royalties to us. If we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing and distribution. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of these anticipated expenditures, we will need additional financing to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our cash needs through a combination of public or private equity or debt financings and other sources, which may include current and new collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our inability to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We cannot be sure that we will ever generate sufficient revenue to achieve profitability. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with the development of therapeutics, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we can generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be required to raise additional capital on terms that are unfavorable to us or we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Astellas Pharma Inc. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, we entered into the Astellas Agreement with Astellas, under which we granted Astellas an exclusive, royalty-bearing, sub-licensable, nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek, and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a GSK-3 inhibitor and an HDAC inhibitor, or the Astellas licensed products, including our product candidate FX-322, outside of the United States. We and Astellas have agreed to jointly develop the Astellas licensed products, including carrying out joint studies. Each party has agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas licensed product in SNHL and in age-related hearing loss, in each case in one major Asian country and one major European country. We have agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas licensed product in the United States. Astellas has the sole right to commercialize the Astellas licensed products outside of the United States and we have the sole right to commercialize the Astellas licensed products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas licensed products in a major Asian country and a major European country following receipt of regulatory approval in such countries. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a consideration for the licensed rights under the Astellas Agreement, Astellas paid us an upfront payment of $80.0 million in July 2019 and has agreed to pay potential development milestones up to $230.0 million. Specifically, we would receive development milestone payments of $65.0 million and $25.0 million upon the first dosing of a patient in Phase 2b clinical trial for SNHL in Europe and Asia, respectively and $100.0 million and $40.0 million upon the first dosing of a patient in a Phase 3 clinical for SNHL in Europe and Asia, respectively. If the Astellas Licensed Products are successfully commercialized, we would be eligible for up to $315.0 million in potential commercial milestone payments and tiered royalties at rates ranging from low to mid-teen percentages. The parties shall share equally, on a 50/50 basis, all out-of-pocket costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan. Pursuant to our Exclusive Patent License Agreement, or the MIT License, with the Massachusetts Institute of Technology, or MIT, we are required to pay MIT a royalty on sublicense revenues. A royalty of $16.0 million related to the $80.0 million upfront payment received from Astellas was expensed in the quarter ended September 30, 2019 and paid in November 2019.The $80.0&#160;million upfront payment received from Astellas in July 2019 has been recorded as deferred revenue and is being recognized as revenue, using the input method, over the period in which we will be conducting Phase 2a clinical trials for FX-322. We have recognized $28.9 million of the $80.0 million as revenue as of December 31, 2019. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Massachusetts Institute of Technology </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU85"></a>In December 2016, we entered into the MIT License, with MIT under which we received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease, and import </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products, or the MIT licensed products, and to develop and perform processes, or the MIT licensed processes, which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. We are required to use diligent efforts to develop and commercialize the MIT licensed products or processes, and to make such products or processes reasonably available to the public. We are also subject to certain development obligations with regards to a first MIT licensed product. We have satisfied certain obligations related to preclinical studies and the filing of an IND for a first MIT licensed product with our development activities related to FX-322. Our future development obligations are: (i)&#160;to commence a Phase&#160;II clinical trial for such product within two years of the IND filing for such product, (ii)&#160;to commence a Phase&#160;III clinical trial for such product within five years of the IND filing for such product, (iii)&#160;to file a New Drug Application, or NDA, or equivalent with the FDA or comparable European regulatory</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> agency for such product within nine years of the IND filing for such product, and (iv)&#160;to make a first commercial sale of such product within 11&#160;years of the IND filing for such product. We also have certain development obligations with regards to a second MIT licensed product. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering into the MIT License, we paid a $50&#160;thousand license fee payment and issued shares of our common stock equal to 5% of our then-outstanding capital stock to MIT. We are required to pay certain annual license maintenance fees ranging from $30 thousand to $0.1 million per year prior to first commercial sale of a MIT licensed product and an annual license maintenance fee of $0.2 million every year afterwards, which may be credited to running royalties during the same calendar year, if any. We are also required to make potential milestone payments in an aggregate amount of up to $2.9&#160;million on each MIT licensed product or process. In addition, we agreed to pay a low single-digit royalty on the MIT licensed products and processes and a low-twenties royalty on sub-license revenues. In the year ended December 31, 2019, we paid MIT a $16.0 million royalty on the upfront license fee received from Astellas. See &#8220;Business&#8212;License and collaboration agreements&#8212;Massachusetts Institute of Technology.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Massachusetts Eye and Ear Infirmary </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, we entered into an Non-Exclusive Patent License Agreement, or the MEEI License, with the Massachusetts Eye and Ear Infirmary, or MEEI, under which we received a non-exclusive, non-sub-licensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease, and import products, and to develop and perform processes that incorporate the licensed technology for the treatment or prevention of hearing loss, or the MEEI licensed products. We are obligated to use diligent efforts to develop and commercialize the MEEI licensed products. We are also subject to milestone timeline obligations to dose a first patient in a Phase&#160;II trial by December&#160;31, 2020 and to dose a first patient in a Phase&#160;III trial by December&#160;31, 2024. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering into the MEEI License, we made a $20&#160;thousand license fee payment. We are obligated to pay certain annual license maintenance fees between $5&#160;thousand and $7.5&#160;thousand per each MEEI patent family case number included in the licensed MEEI patent rights prior to first commercial sale of an MEEI licensed product. We are also obligated to pay a minimum annual royalty payment of $15&#160;thousand per each MEEI patent family case number included in the licensed MEEI patent rights after first commercial sale of an MEEI licensed product. We are also obligated to make milestone payments up to $350&#160;thousand on each product or process that incorporates the licensed patent rights. In addition, we have agreed to pay a low single-digit royalty on products and processes that incorporate the licensed patent rights. See &#8220;Business&#8212;License and collaboration agreements&#8212;Massachusetts Eye and Ear Infirmary.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Scripps Research Institute (California Institute for Biomedical Research) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, we entered into a license agreement, or the CALIBR License, with the California Institute for Biomedical Research, or CALIBR, a division of Scripps, under which we received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products, or the CALIBR licensed products, which incorporate licensed technology for the treatment of MS. We have agreed to use commercially reasonable efforts to develop, manufacture, and sell at least one CALIBR licensed product. We are also subject to certain milestone timeline obligations to: (i)&#160;submit an IND (or equivalent) for a CALIBR licensed product by the 30th month after the effective date of the CALIBR License, (ii)&#160;initiate a Phase&#160;II clinical trial (or equivalent) for a CALIBR licensed product by the fourth anniversary of the effective date of the CALIBR License, and (iii)&#160;initiate a Phase&#160;III clinical trial (or equivalent) for a CALIBR licensed product by the sixth anniversary of the effective date of the CALIBR License. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU86"></a>Upon entering into the CALIBR License, we made a $1.0&#160;million license fee payment, and are required to make milestone payments in an aggregate amount of up to $26.0&#160;million for each category of CALIBR licensed products. Category 1 is any CALIBR licensed products containing a compound that modulates any muscarinic receptor, and Category 2 is any CALIBR licensed products not included in Category 1 that could differentiate oligodendrocyte precursor cells from <font style="font-style:italic;">in vitro</font> </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">studies and/or are active in animal models relevant to MS. We are also required to pay a mid-single-digit royalty on CALIBR licensed products and a royalty on sub-license revenues ranging from a low-teen percentage to 50%. See &#8220;Business&#8212;License and collaboration agreements&#8212;The Scripps Research Institute (California Institute for Biomedical Research).&#8221; </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Scripps Research Institute </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, we entered into a Research Funding and Option Agreement, or the Scripps option agreement, with Scripps, under which we were granted an exclusive option to acquire an exclusive, sublicensable, worldwide license under certain intellectual property related to the treatment of MS. As consideration for the Scripps option agreement, we are required to make funding payments totaling $0.7 million to Scripps to support its research activities. Scripps has agreed to use reasonable efforts to perform the research program pursuant to the Scripps option agreement.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Scripps option agreement had a one-year term and was renewed for a second year by mutual written agreement.&nbsp;&nbsp;We have the right to terminate by giving 90 days&#8217; advance notice.&nbsp;&nbsp;Scripps has the right to terminate in the event of nonpayment by us that remains uncured for 10 days.&nbsp;&nbsp;Each party has the right to terminate in the event of the other party&#8217;s material breach that remains uncured for 60 days or if the other party becomes bankrupt.  See &#8220;Business&#8212;License and collaboration agreements&#8212;The Scripps Research Institute (California Institute for Biomedical Research).&#8221; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cambridge Enterprise Limited </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, we entered into an Exclusive Patent License Agreement, or the Cambridge License, with Cambridge, under which we received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products, or the Cambridge licensed products, which incorporate licensed technology for the treatment of demyelinating diseases. We also have the right to grant sublicenses under the Cambridge License. Cambridge reserves the right to use for itself (as well as the investors and the funder) and the right to grant nonexclusive licenses to other academic institutions for any academic publication, research and teaching and clinical patient care. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have agreed to use diligent and good faith efforts to develop and commercially exploit at least one Cambridge licensed product. Upon entering into the Cambridge License, we made a $50 thousand license fee payment. We are obligated to pay an annual license fee of $50 thousand. We are also obligated to make milestone payments up to $10.5 million on each Cambridge licensed product. In addition, we have agreed to pay a low single-digit royalty on products that incorporate the licensed patent rights, subject to offset in certain circumstances.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Cambridge License continues in effect on a country-by-country basis until the expiration or revocation, without right of further appeal, of all licensed issued patents and filed patent applications, unless terminated earlier. We have the right to terminate for any reason upon 90 days&#8217; prior written notice. Each party has the right to terminate immediately if the other party ceases to carry on its business. Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days. Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge licensed product or we or our affiliates or sub-licensees commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU87"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comp</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">onents of our results of operations </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales in the foreseeable future. In July 2019, we entered into the Astellas Agreement and received an upfront license fee payment of $80.0 million. In accordance with ASC 606, we are recognizing the $80.0 million as revenue over the period that research and development services and the Phase 2a clinical study for FX-322 are being provided using the input method. For the purpose of revenue recognition, this is the period from execution of the Astellas Agreement to, based on management&#8217;s best estimate, the estimated completion date of the Phase 2a clinical study. In the year ended December 31, 2019, we recognized $28.9 million of the $80.0 million upfront fee as revenue. This reflects revenue of $16.0 million equal to the royalty expense under the MIT License as well as $12.9 million from applying the input method to the remaining $64.0 million of the upfront payment.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Royalty</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are required to pay royalties under the MIT License on the receipt of fees for the sublicense of the MIT intellectual property. We expensed the $16.0 million royalty due MIT on the $80.0 million license fee pursuant to the Astellas Agreement in the third quarter of 2019.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and for the development of our product candidate, FX-322. These include the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expenses incurred under agreements with third parties, including contract research organizations, or CROs, and other third parties that conduct preclinical research and development activities and clinical trials on our behalf; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">costs to manufacture our clinical trial material for use in our preclinical studies and clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">costs of outside consultants, including their fees and related travel expenses; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">option and license payments made to third parties, including MIT, Scripps, MEEI and Cambridge, for intellectual property used in research and development activities; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">facility-related expenses, which include direct depreciation costs and expenses for rent and maintenance of facilities and other operating costs if specifically, identifiable to research activities. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense research and development costs as incurred. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We track external research and development costs, including the cost of services, outsourced research and development, clinical trials, contract manufacturing, laboratory equipment and maintenance, and certain other development costs, by product candidate when the costs are specifically identifiable to a product candidate. Internal and external costs associated with infrastructure resources, other research and development costs, facility-related costs, and depreciation and amortization that are not identifiable to a specific product candidate are included in the platform development, early-stage research, and unallocated expenses category in the table below. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU88"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our research and development expenses by product candidate or development program for the years ended December&#160;31, 2019, 201</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 201</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">: </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct research and development expenses by</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; product candidate:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FX-322 external development costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,294</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,669</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,948</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Platform development, early-stage research and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; unallocated expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee-related costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,249</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,432</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,155</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">395</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">409</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outsourced research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,241</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,395</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">635</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facility-related costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,155</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">414</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">450</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other research and development costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">409</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">225</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,784</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,880</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,966</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we initiate and complete our Phase 2a clinical trial and additional clinical trials for FX-322 and continue to discover and develop additional product candidates. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to increased scale, duration and the higher costs associated with later stage clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot determine with certainty the duration and costs of future clinical trials of FX-322 or any other product candidate we may develop or if, when, or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. The duration, costs, and timing of clinical trials and development of FX-322 and any other product candidate we may develop will depend on a variety of factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope, rate of progress, expense and results of clinical trials of FX-322, as well as of any future clinical trials of other product candidates and other research and development activities that we may conduct; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the actual probability of success for our product candidates, including their safety and efficacy, early clinical data, competition, manufacturing capability, and commercial viability; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">significant and changing government regulation and regulatory guidance; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing and receipt of any marketing approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the progress of the development efforts of parties with whom we may enter into collaboration agreements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to secure manufacturing supply through relationships with third parties; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the commercialization of our product candidates, if and when approved; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and administrative expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, business development, and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and expenses for rent and maintenance of facilities, and other operating costs that are not specifically attributable to research and development activities. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU89"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support our continued research activities and development of product candidates. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, due to our IPO in October 2019, we </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expect to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory, and&#160;tax-related&#160;services associated with maintaining compliance with the requirements of The Nasdaq Stock Market LLC and the SEC; director and officer insurance costs; and investor and public relations costs. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest income </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income consists of interest earned on cash equivalents and short-term investments. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest expense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense consists of interest paid on convertible notes payable which were converted in our Series A convertible preferred stock financing in 2017 and our Series B convertible preferred stock financing in 2018. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Realized gain on investments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized gain on investments represents the gain realized on our marketable securities in the year ended December 31, 2019. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Loss on extinguishment of debt </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2015 and 2016, we issued notes payable, which were convertible at a 20% discount to the price of shares issued in a qualified financing. In March 2017, the notes payable converted into Series A convertible preferred stock at a 20% discount to the price of the Series A convertible preferred stock, which we recorded as a $3.7&#160;million loss on extinguishment of debt. In 2018, we issued notes payable, which were convertible at a 5% discount to the price of shares issued in a qualified financing. In October 2018, the notes payable converted into Series B convertible preferred stock at a 5% discount to the price of the Series B convertible preferred stock, which we recorded as a $0.3&#160;million loss on extinguishment of debt. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign exchange gain (loss) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange gain (loss) represents the gain or loss recorded as a result of remeasuring the financial statements of our foreign subsidiaries. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception in 2014, we have generated cumulative federal and state net operating loss and research and development credit carryforwards for which we have not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within their respective carryforward periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, we had federal net operating loss carryforwards, or NOLs, of approximately $50.2&#160;million and Massachusetts state NOLs of approximately $41.2&#160;million which may be available to offset future taxable income. Our federal NOLs include $22.4&#160;million available to reduce future taxable income through 2037 and approximately $27.8&#160;million of NOLs that do not expire and are available to reduce future taxable income indefinitely. The state NOLs are available to offset future taxable income through 2039. As of December&#160;31, 2019, we also had federal and Massachusetts research and development tax credit carryforwards of $0.7 million and $0.5&#160;million, respectively, which are available to offset federal and state tax liabilities through 2039 and 2034, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU90"></a>Realization of future tax benefits is dependent on many factors, including our ability to generate taxable income within the NOL period. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as provided under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, as well as under similar state provisions. These ownership changes may limit the amount of NOLs that can be utilized annually to offset future taxable income. In general, an ownership change, as defined under Section&#160;382 of the Code, or Section&#160;382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. We have completed several financings and have conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception and have determined that an ownership change did occur in March 2017. Accordingly, utilization of $12.4&#160;million of the federal NOLs that were incurred </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prior to March 2017 (pre-ownership change) is limited under Section&#160;382. After the Section&#160;382 limitations, we may utilize approximately $10.8&#160;million of our pre-ownership change NOLs based upon an annual usage of approximately $1.6&#160;million for each of the next five years after the ownership change and approximately $0.2&#160;million for each of the 15 years thereafter. The remaining pre-ownership change NOLs of approximately $1.6&#160;million were written off due to expiration under limitation. The limitation has been determined by first multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate. These NOLs may be subject to further annual limitations under Section&#160;382 in the event of future changes in ownership. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we determined that a second ownership change occurred in October of 2019 as a result of the IPO. Accordingly, utilization of approximately $46.1 million of the federal NOL carryforwards incurred prior to October 2019 is also limited under Section 382. We have determined that we will be able to utilize the entire $46.1 million of pre-ownership change NOL&#8217;s based upon the limitations calculated from the October 2019 ownership change. These NOL&#8217;s may be subject to further annual limitations under Section 382 in the event of future changes in ownership.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, the Tax Cuts and Jobs Act was signed into U.S. law. The Tax Cuts and Jobs Act included a number of changes to the tax law, including, among other things, a permanent reduction in the federal corporate income tax rate from a top marginal tax rate of 35% to a flat rate of 21%, which went into effect on January&#160;1, 2018, as well as a limitation of the deduction for NOLs to 80% of annual taxable income, and elimination of net operating loss carrybacks, in each case, for losses arising in taxable years beginning after December&#160;31, 2017 (though any such NOLs may be carried forward indefinitely). The federal tax rate change resulted in a reduction in the gross amount of our deferred tax assets and liabilities recorded as of December&#160;31, 2017, and a corresponding reduction in our valuation allowance. As a result, no income tax expense or benefit was recognized as of the enactment date of the Tax Cuts and Jobs Act. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comparison of years ended December 31, 2019 and 2018 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the years ended December 31, 2019 and 2018: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Decrease)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,947</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,947</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,784</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,880</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,904</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,838</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,064</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,774</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,622</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,944</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,678</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,675</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,944</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,731</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,784</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,784</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(106</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from extinguishment of debt</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(269</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">269</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized gain on investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange gain</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(144</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">422</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue was $28.9 million for the year ended December 31, 2019. We had no revenue for the year ended December 31, 2018. In July 2019, we entered into the Astellas Agreement and received an upfront license fee payment of $80.0 million. In accordance with ASC 606, we are recognizing the $80.0 million as revenue over the period that research and development services and the Phase 2a clinical study for FX-322 are being provided using the input method. In the year ended December 31, 2019, we recognized revenue of $16.0 million equal to the royalty payment under the MIT License as well as $12.9 million applying the input method to the remaining $64.0 million of the upfront payment.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:16pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU91"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development expenses </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Decrease)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct research and development expenses by product</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; candidate:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FX-322 external development costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,294</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,669</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,625</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Platform development, early-stage research and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; unallocated expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee-related costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,249</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,432</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,817</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">395</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outsourced research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,241</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,395</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">846</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facility-related costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,155</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">793</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">450</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other research and development costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">409</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(409</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,784</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,880</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,904</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses for the year ended December 31, 2019 were $18.8 million, compared to $11.9 million for the year ended December 31, 2018. The increase of $6.9 million was primarily due to an increase of $1.6&#160;million in FX-322 external research and development expenses and an increase of $5.3&#160;million in platform development, early-stage research and unallocated expenses. The $4.3&#160;million of FX-322 external development costs incurred for the year ended December 31, 2019 consisted primarily of $2.1&#160;million of clinical development costs including manufacturing costs for FX-322 to be used in clinical trials, $0.7 million of outside consulting costs, $1.1 million in clinical trial costs and $0.3 in milestone payments under the MIT License. The $2.7&#160;million of FX-322 external development costs incurred in the year ended December 31, 2018 consisted primarily of approximately $1.6&#160;million of preclinical costs for safety testing and consulting, and approximately $1.1&#160;million related to conducting the Phase 1 clinical trial. FX-322 external development costs for the year ended December 31, 2018 are presented net of approximately $0.7&#160;million in research and development tax credits received from the Australian government related to our Phase 1 clinical trial conducted in Australia. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Platform development, early-stage research and unallocated expenses were $14.5 million for the year ended December 31, 2019, compared to $9.2&#160;million for the year ended December 31, 2018. The increase of $5.3&#160;million was primarily due to a $0.8&#160;million increase in outsourced research and development spending on our development programs, excluding our FX-322 program, a $3.8&#160;million increase in employee-related costs associated with increased headcount to support preclinical and clinical development of FX-322 and research on our PCA platform development and a $0.7 million increase in facility-related and other costs associated with the increase in research and development headcount.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and administrative expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $14.8 million for the year ended December 31, 2019, compared to $7.1&#160;million for the year ended December 31, 2018. General and administrative expenses increased by $7.8 million due to an increase of $1.3 million in the infrastructure necessary to manage research and development and fundraising activities, increases of $0.7&#160;million in directors and officers insurance, $0.3 million in audit, tax and consulting fees, $1.5&#160;million in legal and patent filing fees incurred to file and defend intellectual property, $0.7&#160;million in corporate legal fees and $3.1&#160;million in employee-related costs as we increased our general and administrative headcount to manage our growth and the impact of becoming a public company. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest income </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income was $1.8&#160;million for the year ended December 31, 2019 compared to $0.0 million for the year ended December 31, 2018, due to an increase in cash equivalents and short-term investments in 2019. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest expense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense was $0.1 million for the year ended December 31, 2018. This represents interest on convertible notes payable issued in 2018 and converted into Series B convertible preferred stock in 2018. We did not incur interest expense in the year ended December 31, 2019. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU92"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Realized gain on investments </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized gain on investments was $138 thousand for the year ended December 31, 2019 due to our purchasing short-term marketable securities in 2019. We held no investments in the year ended December 31, 2018. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign exchange gain</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange gain was $7 thousand for the year ended December 31, 2019 as compared to $151 thousand for the year ended December 31, 2018. The decrease of $144 thousand was due to differences in foreign exchange remeasurement of the financial statements of our foreign subsidiaries. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comparison of years ended December&#160;31, 2018 and 2017 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the years ended December&#160;31, 2019 and 2018: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Decrease)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,880</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,966</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(86</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,064</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,340</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,724</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,944</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,306</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,638</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,944</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,306</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,638</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(106</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(174</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of debt</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(269</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,749</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,480</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange gain (loss)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,237</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,069</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We had no revenue for the years ended December&#160;31, 2018 and 2017.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development expenses </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Decrease)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct research and development expenses by product</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; candidate:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FX-322 external development costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,669</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,948</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,279</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Platform development, early-stage research and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; unallocated expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee-related costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,432</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,155</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,277</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">409</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outsourced research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,395</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">635</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,760</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facility-related costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">414</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other research and development costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">409</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">225</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,880</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,966</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(86</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU93"></a>Research and development expenses for the year ended December&#160;31, 2018 were $11.9&#160;million, compared to $12.0&#160;million for the year ended December&#160;31, 2017. The decrease of $0.1&#160;million in 2018 was primarily due to a decrease of $4.3&#160;million in FX-322 external research and development expenses and a comparable increase of $4.2&#160;million in platform development, early-stage research, and unallocated expenses.&nbsp;&nbsp;The $2.7&#160;million of FX-322 external development costs incurred in 2018 consisted primarily of approximately $1.6&#160;million of preclinical costs for safety testing and consulting and approximately $1.1&#160;million of costs of conducting the Phase 1 clinical trial and the Phase 1/2 clinical trial. FX-322 external development costs for the year ended December&#160;31, 2018 are presented net of approximately $0.7&#160;million in research and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development tax credits received from the Australian government related to our Phase 1 clinical trial conducted in Australia. The $6.9&#160;million of FX-322 external development costs incurred in 2017 consisted primarily of approximately $4.5&#160;million of preclinical costs, including $3.2&#160;million for toxicology and the manufacture of FX-322 for toxicity testing, and approximately $2.4&#160;million of clinical development costs for conducting the Phase 1 clinical trial and manufacturing FX-322 to be used in the Phase 1 clinical trial and in the Phase 1/2 clinical trial conducted in 2018. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Platform development, early-stage research, and unallocated expenses were $9.2&#160;million for the year ended December&#160;31, 2018, compared to $5.0&#160;million for the year ended December&#160;31, 2017. The increase of $4.2&#160;million in 2018 is primarily due to a $2.8&#160;million increase in outsourced research and development spending on our development programs, excluding our FX-322 program. This includes approximately $1.7&#160;million of outsourced research to Scripps for our MS program, including an upfront $1.0&#160;million license fee. We also incurred $1.3&#160;million of increased employee-related cost associated with increased headcount to support our preclinical and clinical development of FX-322 and research on our PCA platform development. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and administrative expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $7.1&#160;million for the year ended December&#160;31, 2018, compared to $4.3&#160;million for the year ended December&#160;31, 2017. General and administrative expenses increased by $2.7&#160;million in 2018 due to increased business development activities, increase in the infrastructure necessary to manage research and development, and fund-raising activities. Contributing to the increase were increases of $0.8&#160;million in audit, tax, and consulting fees, $0.5&#160;million in legal and patent filing fees incurred to file and defend intellectual property, $0.4&#160;million in corporate legal fees, and $0.5&#160;million in employee-related costs as we increased our general and administrative headcount to manage our growth. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Loss on extinguishment of debt </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of debt was $0.3&#160;million for the year ended December&#160;31, 2018, compared to $3.7&#160;million for the year ended December&#160;31, 2017. The decrease of $3.4&#160;million in loss on extinguishment of debt was due to the lower discount rate of 5% upon conversion of the notes payable that converted in 2018 compared to the discount rate of 20% for notes payable that converted in 2017 and the lower amount of notes that converted in 2018 compared to 2017.<font style="font-weight:bold;font-style:italic;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest expense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense was $0.1 million for the year ended December 31, 2018 compared to $0.2 million for the year ended December 31, 2017. The decrease of $0.1 million was due to lower amounts outstanding under convertible notes payable. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign exchange gain (loss) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange gain (loss) was a gain of $0.2 million for the year ended December 31, 2018, compared to a foreign exchange loss of $8 thousand for the year ended December 31, 2017. The increase of $0.2 million was due to differences in foreign exchange remeasurement of the financial statements of our foreign subsidiaries. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and capital resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have incurred significant operating losses. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and clinical development of our product candidates. We expect that our research and development and general and administrative costs will continue to increase, including in connection with conducting preclinical studies and clinical trials for our product candidates, contracting with contract manufacturing organizations, or CMOs, to support preclinical studies and clinical trials, expanding our intellectual property portfolio, and providing general and administrative support for our operations particularly as a public company. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements or other sources. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU94"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have any approved products and have never generated any revenue from product sales. We have financed our operations primarily through proceeds from the sale of our convertible notes, convertible preferred stock, our IPO and the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upfront payment under the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas Agreement. To date, we have raised approximately $316.5&#160;million through a combination of convertible notes, convertible preferred stock, the upfront payment under the Astellas Agreement, grants and our IPO. Our cash, cash equivalents and short-term investments totaled $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217.4</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> mil</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lion as of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dec</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ember 3</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2019. In October 2019, we completed an IPO of our common stock and issued and sold 6,325,000 shares of common stock at a public offering of $14.00 per share, inclusive of the exercise in part by the underwriters of their option to purchase additional shares, resulting in net proceeds of $79.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million after deducting underwriting discounts and commissions and offering expenses. We had no indebtedness as of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dec</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ember 3</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2019. In July 2019, we closed our Series&#160;C convertible preferred stock financing, in which we issued 39,492,960 shares of our Series&#160;C convertible preferred stock, for aggregate gross proceeds of approximately $62.0&#160;million.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash flows </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our sources and uses of cash for the periods presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="8" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,215</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,024</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,261</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(436</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,015</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,712</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,969</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,252</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash flows for the year ended December 31, 2019 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by operating activities for the year ended December 31, 2019 was $34.2&#160;million, primarily consisting of a net loss of $18.7&#160;million as we incurred expenses associated with our FX-322 program, platform development and early-stage research, and general and administrative expenses. In addition, we had non-cash charges of $4.3&#160;million primarily for depreciation, stock-based compensation expense and deferred lease incentives. Net cash used in operating activities was also impacted by a net $48.0 million change in operating assets and liabilities, including an increase of $51.5&#160;million in deferred revenues from the upfront payment under the Astellas Agreement and a $1.5 million increase accrued expenses,&#160;which were partially offset by an increase of $3.3&#160;million in prepaid expenses and other current assets and a $.6 million decrease in accounts payable.. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investing activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities for the year ended December 31, 2019 was $18.3&#160;million, which was attributable to $1.1 million of purchases of property and equipment and $17.2 million of net purchases of marketable securities. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Financing activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for the year ended December 31, 2019 was $142.0&#160;million, consisting of proceeds from our IPO of $79.7 million, the issuance of our Series C convertible preferred stock of $61.7 million, the issuance of additional shares of our Series B convertible preferred stock of $0.3 million, and $0.3 million of proceeds from the exercise of stock options. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash flows for the year ended December&#160;31, 2018 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the year ended December&#160;31, 2018 was $17.0&#160;million, primarily consisting of a net loss of $19.2&#160;million as we incurred expenses associated with our FX-322 program, platform development and early-stage research, and general and administrative expenses. In addition, we had non-cash charges of $1.3&#160;million for depreciation, stock-based compensation expense, non-cash interest expense, loss on extinguishment of debt, and deferred lease incentives. Net cash used in operating activities was also impacted by $0.8&#160;million in changes in operating assets and liabilities, including $0.8&#160;million in accounts payable, and $0.7&#160;million in accrued expenses,&#160;which were partially offset by an increase of $0.7&#160;million in grants receivable, prepaid expenses, and other current assets. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU95"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investing activities </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities for the year ended December&#160;31, 2018 was $0.4&#160;million, which was attributable to purchases of property and equipment. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Financing activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for the year ended December&#160;31, 2018 was $41.7&#160;million, consisting primarily of the net proceeds from the issuance of our Series B convertible preferred stock financing of $37.8&#160;million, including the issuance and subsequent conversion of $5.0&#160;million notes payable into Series B convertible preferred stock and net of offering costs. We also issued shares of preferred stock in Frequency Therapeutics Japan KK, our majority-owned subsidiary, in 2018 for proceeds of $3.8&#160;million, which has been recorded as a liability. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash flows for the year ended December&#160;31, 2017 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the year ended December&#160;31, 2017 was $14.6&#160;million, primarily consisting of our net loss of $20.2&#160;million as we incurred expenses associated with preclinical and clinical activities on our FX-322 program, research activities on other applications for our PCA platform, and incurred general and administrative expenses. In addition, we had non-cash charges of $5.3&#160;million for depreciation, stock-based compensation expense, non-cash interest expense, loss on extinguishment of debt, deferred lease incentives, and the issuance of common stock for a license agreement. Net cash used in operating activities was also impacted by $0.3&#160;million in changes in operating assets and liabilities, including $0.4&#160;million in accrued expenses,&#160;which was partially offset by a decrease in accounts payable of $0.2&#160;million and an increase of $0.1&#160;million in grants receivable, prepaid expenses, and other current assets. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investing activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities for the year ended December&#160;31, 2017 was $1.9&#160;million, which was attributable to purchases of property and equipment. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Financing activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for the year ended December&#160;31, 2017 was $28.0&#160;million, primarily consisting of the net proceeds from the issuance of our Series A convertible preferred stock, net of expenses. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Funding requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operating expenses increased substantially in the years ended December 31, 2019 and 2018 and are expected to increase substantially in the future in connection with our ongoing activities, particularly as we advance FX-322 through clinical trials and as we research and develop additional product candidates including preclinical activities, studies for INDs, and initiation of human clinical trials. In addition, we expect to incur additional general and administrative costs to build the infrastructure necessary to manage the growth of our research and development efforts and the increased costs associated with operating as a public company. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, our costs and expenses will increase as we: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">advance the clinical development of FX-322; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">pursue the preclinical and clinical development of other product candidates using our PCA platform, including our program for the treatment of MS; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">in-license or acquire the rights to other products, product candidates or technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">maintain, expand, and protect our intellectual property portfolio; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">hire additional personnel in research, manufacturing, and regulatory and clinical development, as well as management personnel; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expand our operational, financial, investor relations, and management systems and increase personnel, including personnel to support our operations as a public company. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU96"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our existing cash, cash equivalents, and short-term investments, will enable us to fund our operating expenses and capital expenditure requirements into 2022. We have based this estimate on assumptions that may prove to be incorrect, and we could utilize our available capital resources sooner than we expect. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with the research, development, and commercialization of therapeutics, it is difficult to estimate with certainty the amount of our working capital requirements. Our future funding requirements will depend on many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the progress, costs, and results of our clinical development and clinical trials for FX-322; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the progress, costs, and results of our additional research and preclinical development programs, including our program for the treatment of MS; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the outcome, timing and cost of meeting regulatory requirements established by the FDA and comparable foreign regulatory authorities, if applicable, for our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs and timing of internal process development, manufacturing activities, and clinical trial management associated with FX-322 and other product candidates we advance through preclinical and clinical development; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to establish and maintain strategic collaborations, licensing or other agreements and the financial terms of such agreements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope, progress, results, and costs of any product candidates that we may derive from our PCA platform or any other product candidates we may develop alone or with collaborators; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which we in-license or acquire rights to other products, product candidates, or technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">additions or departures of key scientific or management personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and protecting our intellectual property rights, and defending against any intellectual property-related claims; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales, and distribution for any product candidates for which we or our collaborators obtain marketing approval. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our cash needs through a combination of public or private equity or debt financings and other sources, which may include current and new collaborations with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through other sources, such as collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, product development, and research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual obligations and commitments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of our contractual obligations and commitments as of December&#160;31, 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments due by period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1 year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1 - 3 years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> 4 - 6 years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6 years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease obligations (1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,371</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">504</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,237</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,386</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,244</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Represents future minimum lease payments under our operating leases for office and laboratory space at our Woburn, Massachusetts,<font style="font-size:12pt;"> </font>Lexington, Massachusetts and Farmington, Connecticut facilities (see Note 16 of notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10K for additional information on these lease agreements). </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU97"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not included future milestone payments under our collaboration and license agreements in the table above since the payment obligations under these agreements are contingent upon future events, such as the achievement of specified product development milestones or generating product sales, and we are unable to estimate the timing or likelihood of achieving these milestones or generating future product sales. We are also required to spend certain minimum amounts on research and development of licensed products or processes under the MIT License, and may have certain funding obligations under the Scripps option agreement, which are not included in the table above. See &#8220;&#8212;License and collaboration agreements&#8221; for more information regarding our payment obligations under these agreements. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also enter into contracts in the normal course of business with CROs, CMOs, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by us upon prior written notice although, purchase orders for clinical materials are generally non-cancelable. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation or upon completion of a manufacturing run. These payments are not included in the table above as the amount and timing of such payments are not known or are not material</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical accounting policies and use of estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our audited consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While our significant accounting policies are described in more detail in the notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognition</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for contracts with customers in accordance with Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;), including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. Our disclosure in the accompanying consolidated financial statements reflects the Company&#8217;s accounting policies in compliance with this standard.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Topic 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies its performance obligations. We only apply the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of Topic 606, we assess the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a) a good or service (or bundle of goods and services) that is distinct, or (b) a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU98"></a>We assess whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&#160;the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, we consider factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the &#8220;customer&#8221; in this type of arrangement) and the availability of the associated expertise in the general marketplace. We also consider the intended benefit of the contract in </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> identif</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> all performance obligations, which may include, for example, a license to IP and know-how, research and development activities, and/or manufacturing services. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, we estimate the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. We determine the amount of variable consideration by using the expected value method or the most likely amount method. We include the estimated variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, we re-evaluate the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an arrangement includes development and regulatory milestone payments, we evaluate whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, we recognize royalty revenue and sales-based milestone payments at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, we adjust the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company&#8217;s customer with a significant benefit of financing the transfer of goods and services. We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. We assess each of its revenue generating arrangements in order to determine whether a significant financing component exists. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time.&nbsp;&nbsp;For performance obligations satisfied over time, we measure progress toward completion of its performance obligations using an input method based on our efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets.</p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued research and development expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf, and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Most of our service providers invoice us in arrears for services performed, on a&#160;pre-determined&#160;schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development expenses include fees paid to the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:540pt;;">
<tr>
<td style="width:31.1pt;"></td>
<td style="width:5.35pt;"></td>
<td style="width:503.55pt;"></td>
</tr>
<tr style="height:20.65pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CROs and other third parties in connection with performing research and development activities and conducting preclinical studies and clinical trials on our behalf;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:540pt;;">
<tr>
<td style="width:31.1pt;"></td>
<td style="width:5.35pt;"></td>
<td style="width:503.55pt;"></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vendors in connection with preclinical development activities; and</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU99"></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:540pt;;">
<tr>
<td style="width:31.1pt;"></td>
<td style="width:5.35pt;"></td>
<td style="width:503.55pt;"></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CMOs and other vendors in connection with product manufacturing and development and distribution of preclinical supplies.</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We base our expenses related to preclinical studies on our estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct and manage preclinical studies and clinical trials and CMOs that manufacture product for our research and development activities on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or amount of prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may cause us to report amounts that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of accrued research and development expenses.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-based compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure stock options and other stock-based awards granted to our employees, directors, consultants, advisors based on the fair value on the date of the grant, awards, net of actual forfeitures, over the requisite service period, which is generally the vesting period of the respective award. For stock-based awards granted to&#160;non-employees,&#160;compensation expense is recognized over the period during which services are rendered by such&#160;non-employees&#160;until completed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options, and our expected dividend yield.</p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Determination of fair value of common stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the IPO, there had been no public market for our common stock and as such, the estimated fair value of our common stock had been determined by our board of directors as of the date of each option grant, with input from management, taking into consideration our most recently available third-party valuations of common stock at the time of the grants, as well as our board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. Third-party valuations, or valuation reports, were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide,&#160;Valuation of Privately-Held-Company Equity Securities Issued as Compensation.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock valuation reports were prepared using a market approach, utilizing either the guideline M&amp;A or guideline public company methodologies. Under the guideline M&amp;A methodology, a set of mergers and acquisitions within the biotechnology and pharmaceutical industries for similar stage companies were reviewed and an applicable equity value was selected to apply to our company. Under the guideline public company methodology, the market capitalizations of similar public companies were analyzed, and an applicable capitalization for our company was selected based on qualitative and quantitative factors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each valuation report, an option pricing allocation method, or OPM, was selected to allocate the total equity value across the various securities outstanding at the time of the valuation. The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to considering the results of the valuation reports, our board of directors considered various objective and subjective factors to determine the fair value of our common stock as of each grant date, including:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:540pt;;">
<tr>
<td style="width:31.1pt;"></td>
<td style="width:5.35pt;"></td>
<td style="width:503.55pt;"></td>
</tr>
<tr style="height:20.65pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the prices at which we sold shares of convertible preferred stock and the superior rights and preferences of the convertible preferred stock relative to our common stock at the time of each grant;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:540pt;;">
<tr>
<td style="width:31.1pt;"></td>
<td style="width:5.35pt;"></td>
<td style="width:503.55pt;"></td>
</tr>
<tr style="height:20.65pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the progress of our research and development programs, including the status and results of preclinical studies and clinical trials for our product candidates;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:540pt;;">
<tr>
<td style="width:31.1pt;"></td>
<td style="width:5.35pt;"></td>
<td style="width:503.55pt;"></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our stage of development and commercialization and our business strategy;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:540pt;;"></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:540pt;;">
<tr>
<td style="width:31.1pt;"></td>
<td style="width:5.35pt;"></td>
<td style="width:503.55pt;"></td>
</tr>
<tr>
<td style="width:31.1pt;"></td>
<td style="width:5.35pt;"></td>
<td style="width:503.55pt;"></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU100"></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">external market conditions affecting the biotechnology industry and trends within that industry;</p></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our financial position, including cash on hand, and our historical and forecasted performance and operating results;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:540pt;;">
<tr>
<td style="width:31.1pt;"></td>
<td style="width:5.35pt;"></td>
<td style="width:503.55pt;"></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the lack of an active public market for our common stock and our convertible preferred stock;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:540pt;;">
<tr>
<td style="width:31.1pt;"></td>
<td style="width:5.35pt;"></td>
<td style="width:503.55pt;"></td>
</tr>
<tr style="height:20.6pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the likelihood of achieving a liquidity event, such as an initial public offering, or IPO, or sale of our company considering prevailing market conditions; and</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:540pt;;">
<tr>
<td style="width:31.1pt;"></td>
<td style="width:5.35pt;"></td>
<td style="width:503.55pt;"></td>
</tr>
<tr style="height:10.3pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the analysis of IPOs and the market performance of similar companies in the biotechnology industry.</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions underlying these valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result, if we had used different assumptions or estimates, the fair value of our common stock and our stock-based compensation expense could have been materially different.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent accounting pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A description of recent accounting pronouncements that may potentially impact our financial position, results of operations, or cash flows is disclosed below:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued <font style="font-style:italic;">ASU No. 2016-02, Leases</font>, which is intended to increase transparency and comparability among companies that enter into leasing arrangements. The new standard establishes a right-of-use model that requires a lessee to record a right-of-use asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either financing or operating, with classification affecting the pattern of expense recognition. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. In July 2018, the FASB <font style="font-style:italic;">issued ASU No. 2018-11,</font> with targeted improvements to the guidance including an additional transition method, which allows us to apply the provisions of the new leasing standard as of January 1, 2021, without adjusting the comparative periods presented by recognizing a cumulative-effect adjustment to the opening balance of retained earnings.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to elect early adoption of this standard effective January 1, 2020 and elect the new transition method approved by the FASB. We also plan to elect the package of practical expedients intended to ease transition whereby the Company need not assess (1) whether any expired or existing contracts are or contain leases, (2) the lease classification for any expired or existing leases and (3) initial direct costs for any existing leases. Furthermore, we will elect the practical expedient to combine non-lease components and lease components. As we finalize our adoption processes, we estimate the adoption of the ASU in the first quarter of 2020 will result in the recognition of a right-of-use asset and related lease liability related to the lease for our Woburn Massachusetts facility in the range of approximately $1 million to $2 million with an estimated immaterial effect to our retained earnings and our consolidated statement of operations. As disclosed in Note 16, we have entered into a lease for a facility in Lexington Massachusetts which has an estimated commencement date of December 1, 2020. In accordance with ASU No. 2016-02, we will recognize a right-of-use asset and related lease liability at such time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are no other recent accounting pronouncements that we believe will have a material impact on our consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Off-balance sheet arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:1pt;">&nbsp;</p>
<p style="margin-top:17pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a>Item 7A. Quantitative and Qualitative Disclosures About Market Risk. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. Our interest-earning assets consist of cash, cash equivalents and short-term investments, which are denominated in U.S. dollars. We had cash, cash equivalents and short-term investments of $217.4 million, or 97.3% of our total assets, at December 31, 2019. Interest income earned on these assets was $1.8 million for the year ended December 31, 2019. Our interest income is sensitive to changes in the general level of interest rates, primarily U.S. interest rates. Such interest-earning instruments carry a degree of interest rate risk; however, a change by 10% in interest rates would not have a material impact on our financial position or results of operations. We had no debt outstanding as of December 31, 2019.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a>Item 8. Financial Statements and Supplementary Data. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU101"></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our consolidated financial statements, together with the reports of our independent registered public accounting firms, appear at pages&#160;F-1 through F-21 of this Annual Report on Form&#160;10-K for the year ended&#160;December&#160;31, 2019. </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An index of those financial statements is found in Item 15 of Part IV of this Annual Report on Form 10-K.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a>Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9A_CONTROLS_PROCEDURES"></a><a name="ITEM_9A_CONTROLS_PROCEDURES"></a>Item 9A. Controls and Procedures. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms and (2) accumulated and communicated to our management, including our principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our Chief Executive Officer and Vice President of Finance and Operations (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2019. Based on the evaluation of our disclosure controls and procedures as of December 31, 2019, our Chief Executive Officer and Vice President of Finance and Operations concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control Over Financial </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This annual report does not include a report of management&#8217;s assessment regarding internal control over financial reporting or an attestation report of the Company&#8217;s registered public accounting firm due to a transition period established by the rules of the Securities and Exchange Commission for newly public companies. Additionally, our independent registered accounting firm will not be required to opine on the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 until we are no longer an &#8220;emerging growth company&#8221; as defined in the JOBS Act.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There was no change in our internal control over financial reporting that occurred during the period covered by this Annual Report on Form 10-K that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9B_OR_INFORMATION"></a><a name="ITEM_9B_OR_INFORMATION"></a>Item 9B. Other Information. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU102"></a><a name="PART_III"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_III"></a>PART </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">III </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a>Item 10. Directors, Executive Officers and Corporate Governance. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 10 will be included in our Definitive Proxy Statement to be filed with the Securities and Exchange Commission, or SEC, with respect to our 2020 Annual Meeting of Stockholders and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a>Item 11. Executive Compensation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 11 will be included in our Definitive Proxy Statement to be filed with the Securities and Exchange Commission, or SEC, with respect to our 2020 Annual Meeting of Stockholders and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 12 will be included in our Definitive Proxy Statement to be filed with the Securities and Exchange Commission, or SEC, with respect to our 2020 Annual Meeting of Stockholders and is incorporated herein by reference.<font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a>Item 13. Certain Relationships and Related Transactions, and Director Independence. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 13 will be included in our Definitive Proxy Statement to be filed with the Securities and Exchange Commission, or SEC, with respect to our 2020 Annual Meeting of Stockholders and is incorporated herein by reference</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a>Item 14. Principal Accounting Fees and Services. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 14 will be included in our Definitive Proxy Statement to be filed with the Securities and Exchange Commission, or SEC, with respect to our 2020 Annual Meeting of Stockholders and is incorporated herein by reference<font style="color:#000000;">. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU103"></a><a name="PART_IV"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IV"></a>PART</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> IV</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a>Item 15. Exhibits, Financial Statement Schedules. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1) Financial Statements</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following documents are included on pages F-1 through F-32 attached hereto and are filed as part of this Annual Report on Form 10-K.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:92.36%;"></td>
<td style="width:0.48%;"></td>
<td style="width:7.16%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:underline;">Report of an Independent Registered Public Accounting Firm</font></a></p></td>
<td colspan="2" valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated financial statements As of December 31, 2019 and 2018</p></td>
<td colspan="2" valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><font style="text-decoration:underline;">Consolidated balance sheets</font></a></p></td>
<td colspan="2" valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS"><font style="text-decoration:underline;">Consolidated statements of operations</font></a></p></td>
<td colspan="2" valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO"><font style="text-decoration:underline;">Consolidated statements of comprehensive income</font></a></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENT_CONVERTIBLE_PREFE"><font style="text-decoration:underline;">Consolidated statements of convertible preferred stock, non-controlling interest and stockholders&#8217; deficit</font></a></p></td>
<td colspan="2" valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Consolidated statements of cash flows</font></a></p></td>
<td colspan="2" valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><font style="text-decoration:underline;">Notes to consolidated financial statements</font></a></p></td>
<td colspan="2" valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(2) Financial Statement Schedules:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the Consolidated Financial Statements or the Notes thereto set forth below beginning on page F-1.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(3) Exhibits.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a list&#160;of&#160;exhibits filed as part of this Annual Report on Form 10-K.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.65%;"></td>
<td style="width:0.68%;"></td>
<td style="width:40.48%;"></td>
<td style="width:0.83%;"></td>
<td style="width:8.69%;"></td>
<td style="width:0.96%;"></td>
<td style="width:10.94%;"></td>
<td style="width:1.85%;"></td>
<td style="width:8.87%;"></td>
<td style="width:0.95%;"></td>
<td style="width:8.57%;"></td>
<td style="width:1.4%;"></td>
<td style="width:8.12%;"></td>
</tr>
<tr>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #FFFFFF;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #FFFFFF;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="9" valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated&#160;by&#160;Reference</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;Description</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #FFFFFF;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #FFFFFF;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File&#160;No.</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed/</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Furnished</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Herewith</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519263787/d796545dex31.htm"><font style="text-decoration:underline;">Restated Certificate of Incorporation of Frequency</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519263787/d796545dex31.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519263787/d796545dex31.htm"><font style="text-decoration:underline;"> Therapeutics, Inc.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-39062</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/7/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519263787/d796545dex32.htm"><font style="text-decoration:underline;">Amended and Restated Bylaws of Frequency</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519263787/d796545dex32.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519263787/d796545dex32.htm"><font style="text-decoration:underline;"> Therapeutics, Inc.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-39062</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex41.htm"><font style="text-decoration:underline;">Form of Specimen Common Stock Certificate</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/23/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519239976/d72917dex42.htm"><font style="text-decoration:underline;">Second Amended and Restated Investors&#8217;</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519239976/d72917dex42.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519239976/d72917dex42.htm"><font style="text-decoration:underline;"> Rights Agreement, dated as of July 17, 2019</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/6/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;4.3</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="freq-ex43_875.htm"><font style="text-decoration:underline;">Description of Frequency Therapeutics, Inc. Securities</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex102.htm"><font style="text-decoration:underline;">2014 Stock Incentive Plan, as amended and form of option</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex102.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex102.htm"><font style="text-decoration:underline;"> agreements thereunder</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/6/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex102.htm"><font style="text-decoration:underline;">2019 Incentive Award Plan and form of option</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex102.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex102.htm"><font style="text-decoration:underline;"> agreements thereunder</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/23/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex103.htm"><font style="text-decoration:underline;">Non-Employee Director Compensation Program</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/23/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex105.htm"><font style="text-decoration:underline;">Form of Indemnification Agreement for Directors</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex105.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex105.htm"><font style="text-decoration:underline;"> and Officers</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/23/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk32847514"></a>10.5.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="exhibit10_51.htm"><font style="text-decoration:underline;">Lease Agreement, dated as of August 24, 2016, as amended, between ARE-MA Region No. 20 and Frequency Therapeutics, Inc.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.65%;"></td>
<td style="width:0.68%;"></td>
<td style="width:40.48%;"></td>
<td style="width:0.83%;"></td>
<td style="width:8.69%;"></td>
<td style="width:0.96%;"></td>
<td style="width:10.94%;"></td>
<td style="width:1.85%;"></td>
<td style="width:8.87%;"></td>
<td style="width:0.95%;"></td>
<td style="width:8.57%;"></td>
<td style="width:1.4%;"></td>
<td style="width:8.12%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex1062.htm"><font style="text-decoration:underline;">Lease Agreement, effective as of August 1, 2019</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex1062.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex1062.htm"><font style="text-decoration:underline;"> between the University of Connecticut and</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex1062.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex1062.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex1062.htm"><font style="text-decoration:underline;"> Frequency Therapeutics, Inc.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6.2</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/23/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex107.htm"><font style="text-decoration:underline;">Second Amended and Restated Executive</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex107.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex107.htm"><font style="text-decoration:underline;"> Employment Agreement, dated as of September</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex107.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex107.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex107.htm"><font style="text-decoration:underline;"> 20, 2019, between David L. Lucchino and</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex107.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex107.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex107.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex107.htm"><font style="text-decoration:underline;"> Frequency Therapeutics, Inc.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/23/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex108.htm"><font style="text-decoration:underline;">Amended and Restated Employment Agreement,</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex108.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex108.htm"><font style="text-decoration:underline;"> dated as of September 20, 2019, between</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex108.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex108.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex108.htm"><font style="text-decoration:underline;"> Christopher R. Loose and Frequency Therapeutics,</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex108.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex108.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex108.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex108.htm"><font style="text-decoration:underline;"> Inc.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/23/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex109.htm"><font style="text-decoration:underline;">Employment Agreement, dated as of September</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex109.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex109.htm"><font style="text-decoration:underline;"> 19, 2019, between Carl P. LeBel and Frequency</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex109.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex109.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519251257/d72917dex109.htm"><font style="text-decoration:underline;"> Therapeutics, Inc.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/23/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312519239976/d72917dex1010.htm"><font style="text-decoration:underline;">Exclusive Patent License Agreement, dated as of December 13, 2016, as amended, between Massachusetts Institute of Technology and Frequency Therapeutics, Inc.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/6/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312519239976/d72917dex1011.htm"><font style="text-decoration:underline;">Non-Exclusive Patent License Agreement, dated as of February 7, 2019, between Massachusetts Eye and Ear Infirmary and Frequency Therapeutics, Inc.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/6/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk32847805"></a>10.11</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519239976/d72917dex1012.htm"><font style="text-decoration:underline;">License and Collaboration Agreement, dated as of</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519239976/d72917dex1012.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519239976/d72917dex1012.htm"><font style="text-decoration:underline;"> July 16, 2019, between Astellas Pharma, Inc. and</font></a><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519239976/d72917dex1012.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519239976/d72917dex1012.htm"><a href="http://www.sec.gov/Archives/edgar/data/0001703647/000119312519239976/d72917dex1012.htm"><font style="text-decoration:underline;"> Frequency Therapeutics, Inc.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/6/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1703647/000119312519251257/d72917dex1013.htm"><font style="text-decoration:underline;">2019 Employee Stock Purchase Plan</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-233652</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/23/19</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk32848501"></a>10.13</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="freq-ex1013_758.htm"><font style="text-decoration:underline;">Indenture of Lease, effective as of January 7, 2020 between HCP/KING 75 Hayden LLC and Frequency Therapeutics, Inc.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="freq-ex211_757.htm"><font style="text-decoration:underline;">Subsidiaries of Frequency Therapeutics, Inc.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="freq-ex231_1116.htm"><font style="text-decoration:underline;">Consent of RSM US, LLP, Independent Registered Public Accounting Firm</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="freq-ex311_9.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="freq-ex312_8.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="freq-ex321_7.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="freq-ex322_6.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.65%;"></td>
<td style="width:0.68%;"></td>
<td style="width:40.48%;"></td>
<td style="width:0.83%;"></td>
<td style="width:8.69%;"></td>
<td style="width:0.96%;"></td>
<td style="width:10.94%;"></td>
<td style="width:1.85%;"></td>
<td style="width:8.87%;"></td>
<td style="width:0.95%;"></td>
<td style="width:8.57%;"></td>
<td style="width:1.4%;"></td>
<td style="width:8.12%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU104"></a><font style="color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Extension Definition Linkbase Document</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:92.86%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**<font style="margin-left:36pt;">Furnished herewith</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***<font style="margin-left:36pt;">Submitted electronically herewith</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16_FORM_10K_SUMMARY"></a><a name="ITEM_16_FORM_10K_SUMMARY"></a>Item 16. Form 10-K Summary</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU105"></a><a name="SIGNATURES"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a>SIGNAT</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">URES</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized<font style="font-weight:bold;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FREQUENCY THERAPEUTICS, INC.</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 26, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;David L. Lucchino</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David L. Lucchino</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director (Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">POWER OF ATTORNEY </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each person whose individual signature appears below hereby authorizes and appoints David L. Lucchino and Richard Mitrano, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;David L. Lucchino</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director (Principal Executive Officer)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 26, 2020</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">David L. Lucchino</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Richard Mitrano</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Finance and Operations (Principal Financial and Accounting Officer)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 26, 2020</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Richard Mitrano</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Marc A. Cohen</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Chairman and Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 26, 2020</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marc A. Cohen</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Timothy J. Barberich</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 26, 2020</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Timothy J. Barberich</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Michael Huang</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 26,, 2020</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Michael Huang</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Robert S. Langer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 26, 2020</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Robert S. Langer, Sc.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Joel S. Marcus</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 26, 2020</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Joel S. Marcus</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU106"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:underline;">Report of an Independent Registered Public Accounting Firm</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated financial statements </p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><font style="text-decoration:underline;">Consolidated balance sheets</font></a></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS"><font style="text-decoration:underline;">Consolidated statements of operations</font></a></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO"><font style="text-decoration:underline;">Consolidated statements of comprehensive loss</font></a></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENT_CONVERTIBLE_PREFE"><font style="text-decoration:underline;">Consolidated statements of convertible preferred stock, non-controlling interest and stockholder&#8217;s equity (deficit</font></a><font style="text-decoration:underline;">)</font></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Consolidated statements of cash flows</font></a></p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><font style="text-decoration:underline;">Notes to consolidated financial statements</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p></td>
</tr>
<tr>
<td valign="top"  style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU107"></a><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a>Report of independent regist</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ered public accounting firm </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and the Board of Directors of Frequency Therapeutics, Inc. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Frequency Therapeutics, Inc. and its subsidiaries (the Company) as of December 31, 2019 and 2018, the related consolidated statements of operations, comprehensive loss, convertible preferred stock, non-controlling interest, and stockholders&#8217; equity (deficit) and cash flows for each of the three years in the period ended December 31, 2019, and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019, in conformity with accounting principles generally accepted in the United States of America. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2017. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ RSM US LLP </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 26, 2020 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU108"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_BALANCE_SHEETS"></a><a name="CONSOLIDATED_BALANCE_SHEETS"></a>Consolidated Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,158</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,189</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,197</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">748</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221,355</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,937</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,762</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,511</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,218</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,548</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, Convertible Preferred Stock, Non-Controlling Interest and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Stockholders&#8217; Equity (Deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,219</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,863</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,239</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,749</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,152</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,780</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,773</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,900</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">349</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,860</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,122</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B convertible preferred stock, $0.001 par value; no shares authorized,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issued or outstanding at December 31, 2019; 49,296,987 shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; authorized at December 31, 2018; 41,857,005 shares issued and outstanding</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; at December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,224</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B-1 convertible preferred stock, $0.001 par value; no shares authorized,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issued or outstanding at December 31, 2019; 10,000 shares authorized,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issued and outstanding at December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A convertible preferred stock, $0.001 par value; no shares authorized,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issued or outstanding at December 31, 2019; 64,891,735 shares authorized</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; at December 31, 2018; 62,528,507 shares issued and outstanding at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,694</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A-1 convertible preferred stock, $0.001 par value; no shares authorized,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issued or outstanding at December 31, 2019; 10,000 shares authorized,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issued and outstanding at December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,773</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity (deficit):</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.001 par value; 100,000,000 and 165,000,000 shares authorized</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; at December 31, 2019 and December 31, 2018, respectively; 30,844,507 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 2,084,710 shares issued and outstanding at December 31, 2019 and 2018, respectively</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236,161</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">804</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,888</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,088</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167,358</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48,282</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities, convertible preferred stock, non-controlling interest and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stockholders&#8217; equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,218</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,548</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU109"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_OPERATIONS"></a>Consolidated S<a name="CONSOLIDATED_STATEMENTS_OPERATIONS"></a>tatements of Operations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,947</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalty</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,784</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,880</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,966</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,838</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,064</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,340</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,622</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,944</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,306</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,675</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,944</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,306</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income (expense)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,784</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(106</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(174</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of debt</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(269</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,749</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized gain on investments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign exchange gain (loss)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,237</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative Series C preferred stock dividends</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,054</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common shareholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,237</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders-basic</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.29</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12.53</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28.79</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock outstanding-basic</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,649,245</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,530,218</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">702,918</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU110"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO"></a>Conso<a name="CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO"></a>lidated Statements of Comprehensive Loss</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,237</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive gain:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total comprehensive gain</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,692</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,237</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU111"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENT_CONVERTIBLE_PREFE"></a>Consolidated S<a name="CONSOLIDATED_STATEMENT_CONVERTIBLE_PREFE"></a>tatement of Convertible Preferred Stock, Non-controlling Interest and Stockholder&#8217;s Equity (Deficit)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:4pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series C</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">issued</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series C</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series B</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">issued</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series B</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series B-1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">issued</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series B-1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">issued</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A-1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">issued</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A-1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">controlling</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">issued</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">par</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additi-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">onal</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">paid-in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumu-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">lated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">holders&#8217;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31, 2016</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,658,459</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,683</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,663</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,974</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; exclusive patent license</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,802</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series A convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock, net of issuance</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; costs of $203</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,538,421</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,951</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series A convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock related to the</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; conversion of convertible notes</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,990,086</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,743</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,237</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,237</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31, 2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">62,528,507</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">46,694</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1,954,235</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">276</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(29,920</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(29,642</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">455</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">455</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,253</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of restricted stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,423</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase of restricted stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,201</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series A-1 convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series B convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock, net of issuance</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; costs of $302</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,017,542</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,849</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series B convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock related to the</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; conversion of convertible notes</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,839,463</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,375</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series B-1 convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling interest</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,773</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">41,857,005</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">38,224</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">62,528,507</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">46,694</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3,773</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2,084,710</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">804</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(49,088</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(48,282</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,609</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,609</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">357,170</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">365</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">366</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series B convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">288,991</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">266</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series C convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,492,960</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,687</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion of Series C preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; dividend</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,054</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,054</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,054</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial public offering of common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,325,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,690</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,696</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of preferred stock and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; non-controlling interest into</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; common stock in connection</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; with the IPO</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,492,960</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,741</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,145,996</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,490</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,528,507</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,694</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,773</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,077,627</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,693</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,715</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">30,844,507</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">236,161</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(68,888</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">167,358</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:4pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU112"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a>Consolidated S<a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a>tatements of Cash Flows</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,237</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,609</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">455</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">813</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">654</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">531</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of convertible notes payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">269</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,749</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for license agreement</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred lease incentives</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(160</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(159</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,253</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(727</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(644</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">869</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(231</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,052</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,490</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">677</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">365</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,215</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,024</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,614</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,064</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(436</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,863</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Redemption of available for sale securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(282,618</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of available for sale securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265,421</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,261</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(436</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,863</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sale of non-controlling interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,773</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of convertible notes payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of Series A convertible preferred stock, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,951</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of Series A-1 convertible preferred stock, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of Series B convertible preferred stock, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">266</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,849</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of Series B-1 convertible preferred stock, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of Series C convertible preferred stock, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,687</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,062</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,712</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,978</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,969</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,252</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,501</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash at beginning of year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,189</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,937</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,436</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash at end of year</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,158</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,189</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,937</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash paid during the year for:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-cash items</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible notes payable and accrued interest into</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,375</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,743</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative Series C convertible preferred stock dividends</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,054</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of preferred stock and non-controlling interest into common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,715</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU113"></a><font style="font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>Notes to C<a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>onsolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Amounts in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Organization and basis of presentation </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics, Inc., together with its wholly owned subsidiaries, Frequency Therapeutics, PTY, LTD, Frequency Therapeutics Securities Corporation and Frequency Therapeutics Japan KK (Frequency Japan) (the Company), headquartered in Woburn, Massachusetts, was incorporated in November 2014 as a Delaware corporation. The Company is a clinical-stage biotechnology company focused on harnessing the body&#8217;s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 20, 2019, the Company effected a 1-for-6.7355 reverse stock split of its common stock. The par value of the common stock was not adjusted as a result of the reverse stock split and the authorized capital was amended to 100,000,000 shares of common stock and 148,724,922 shares of $0.001 par value preferred stock (the Preferred Stock). The reverse stock split resulted in an adjustment to the Series A Convertible  Preferred Stock (Series A Preferred), Series B Convertible Preferred Stock (Series B Preferred) and Series C Convertible Preferred Stock (Series C Preferred) conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. Shares of common stock underlying outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, the Company completed the initial public offering of its common stock (the &#8220;IPO&#8221;). In the IPO, the Company issued and sold 6,325,000 shares of its common stock at a price to the public of $14.00 per share, inclusive of the underwriters&#8217; exercise in part of their over-allotment option. The Company received approximately $79.7 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. In connection with the IPO, on October 7, 2019 all Preferred Stock and the preferred stock of Frequency Japan converted into 22,077,627 shares of common stock and all outstanding shares of Series A-1 Preferred Stock and B-1 Preferred Stock were forfeited.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Uncertainties </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and capital resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has funded its operations primarily with proceeds from the sale of its capital stock, convertible notes and amounts received under a collaboration agreement. The Company has incurred recurring losses since its inception. In addition, as of December&#160;31, 2019, the Company had an accumulated deficit of ($68,888). The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. The Company believes that existing resources will be sufficient to fund planned operations for at least 12 months from the date the financial statements were available to be issued.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU114"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of significant accounting policies </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB <font style="font-style:italic;">Accounting Standards</font> Codification (ASC). </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of consolidation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics PTY, LTD and Frequency Japan (majority owned at December 31, 2018). All intercompany transactions and balances have been eliminated. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include but are not limited to management&#8217;s judgments of accrued expenses, revenue, fair value of common stock, valuation of share-based awards and income taxes. Actual results could differ from those estimates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes significant estimates and assumptions in determining the fair value of its common stock in periods prior to the IPO. The Company had utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation (the Practice Aid), to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive income (loss) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders which for the year ended December 31, 2019 consists of unrealized gain on marketable securities.&nbsp;&nbsp;There were no elements of comprehensive loss for the years ended December 31, 2018 and 2017.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s chief executive officer, views the Company&#8217;s operations and manages its business as a single operating segment, which is in the business of discovering and developing small molecule drugs that activate progenitor cells within the body to create healthy tissue. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign currency </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All periods presented are reported in US dollars. The functional currency for entities outside the United States is the US dollar. Realized and unrealized gains and losses from foreign currency transactions are reflected in the consolidated statements of operations as other expense. During the years ended December&#160;31, 2019, 2018 and 2017 the Company recorded $7, $151 and ($8) of foreign currency exchange gains (losses), respectively. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU115"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and cash equivalents </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with an original maturity of six months or less at acquisition to be cash equivalents which are stated at fair market value. Cash and cash equivalents at December&#160;31, 2019 and 2018 consists entirely of cash held in banks and money market funds. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;">Short-term marketable debt securities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company&#8217;s investment policy. Short-term marketable investment mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders&#8217; equity (deficit) until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, together with interest on securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investment are reflected as a component of other income (expense).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities at December 31, 2019 consist of investment in U.S. Treasury Securities.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;">Concentration of credit risk and off-balance sheet risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instrument that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of U.S. Treasury securities with maturities of less than twelve months. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Significant suppliers </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a single manufacturer of its product candidates for use in clinical trials. The Company would be adversely affected by a significant interruption in the supply of product for use in clinical programs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair value measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic&#160;820, <font style="font-style:italic;">Fair Value Measurement</font> (ASC&#160;820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quoted prices in active markets for identical assets or liabilities.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable,&nbsp;&nbsp;&nbsp;&nbsp; such as quoted market prices, interest rates and yield curves.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU116"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of lab equipment, computer equipment, furniture and office equipment and leasehold improvements recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</p></td>
</tr>
<tr>
<td valign="top"  style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top"  style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top"  style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top"  style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of the estimated useful</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">life or lease term</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statements of operations.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of long-lived assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development costs and accruals </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with research institutions, contract research organizations, contract manufacturers and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, pre-clinical and clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Collaborative arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU117"></a>The Company analyzes its collaborative arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements (&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship (e.g., a licensing arrangement) where the contracted party has obtained goods or services that are an output of the Company&#8217;s ordinary activities in exchange for a consideration and therefore within the scope of Topic 606. For those elements of the arrangement that are accounted for pursuant to Topic 606, including those to which Topic 606 is applied by analogy, the Company applies the five-step model described in the Company&#8217;s revenue recognition policy. For elements of collaborative arrangements that are accounted for pursuant to ASC 808, an appropriate and rational recognition method is determined and applied consistently. Reimbursements from the counterparty that are the result of a collaborative relationship with the counterparty, instead of a customer relationship, such as co-development or clinical activities, are recorded as a reduction to research and development </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expense as the services are performed. Similarly, amounts that are owed to a collaboration partner related to the co-development clinical activities are recognized as research and development expense. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into out-licensing agreements that are within the scope of Topic 606. The terms of such out-license agreements include licenses to functional intellectual property (IP), given the functionality of the intellectual property is not expected to change substantially as a result of the licensor&#8217;s ongoing activities. Such arrangements typically include payment of one or more of the following: non-refundable up-front license fees; reimbursement of certain costs; development and regulatory milestone payments and milestone payments based on the level of sales; and royalties on net sales of licensed products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers the economic and regulatory characteristics of the licensed IP, research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace to determine if it has standalone value at the inception of the licensing arrangement, which would make the license distinct. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of any additional good or services promised in the contract, whether the value of the license is dependent on the remaining goods and services, whether there are other vendors that could provide the remaining promise, and whether the license is separately identifiable from the remaining good and services. For licenses that are combined with other goods and services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue is allocated to the licensed IP on a relative standalone selling price basis and, for functional IP, is recognized at a point when the licensed IP is made available for the customer&#8217;s use and benefit, which generally occurs at the inception of the arrangement. However, in cases, where the functionality of the IP is expected to substantively change as a result of activities of the Company that do not transfer additional promised goods or services, or in cases, where there is an expectation that the Company will undertake activities to change the standalone functionality of the IP and the customer is contractually or practically required to use the latest version of the IP, revenue for the license to functional IP is recognized over time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into a collaboration arrangement with Astellas Pharma Inc. (&#8220;Astellas&#8221;), as further described in Note 15 of notes to unaudited consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for contracts with customers in accordance with Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;), including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. The Company&#8217;s disclosure within the below sections or elsewhere within these consolidated financial statements reflects the Company&#8217;s accounting policies in compliance with this new standard.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Topic 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies its performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a) a good or service (or bundle of goods and services) that is distinct, or (b) a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU118"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&#160;the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the &#8220;customer&#8221; in this type of arrangement) and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, the Company identifies all performance obligations, which may include, for example, a license to IP and know-how, research and development activities, and/or manufacturing services. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the estimated variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestone payments at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company&#8217;s customer with a significant benefit of financing the transfer of goods and services. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time.&nbsp;&nbsp;For performance obligations satisfied over time, the Company measures progress toward completion of its performance obligations using an input method based on the Company&#8217;s efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU119"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based compensation </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for its stock-based compensation in accordance with ASC Topic&#160;718, <font style="font-style:italic;">Compensation&#8212;Stock Compensation</font> (ASC&#160;718). ASC&#160;718 requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company adopted FASB Accounting Standards Update (ASU) 2016-09 which identifies areas for simplification of several areas of share-based payment transactions. The Company retroactively applied the mark to market approach on vesting to non-employee grants and the impact on the consolidated financial statements was not material and as such, the Company will treat non-employee grants the same as employee grants. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a)&#160;the expected stock price volatility, (b)&#160;the expected term of the award, (c)&#160;the risk-free interest rate and (d)&#160;expected dividends. Due to the lack of sufficient company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s common stock prior to the IPO. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses the fair value of its share-based compensation awards to employees and non-employees on a straight-line basis over the requisite service period, which is generally the vesting period. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Non-controlling interest </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2018, the Company accounted for shares of preferred stock issued in Frequency Japan as a non-controlling interest in the mezzanine section of the consolidated balance sheets. The value ascribed to the non-controlling interest was the liquidation preference of the preferred stock in Frequency Japan as the holders of such shares do not share in any profits or losses of the subsidiary. <font style="color:#000000;">In connection with the IPO, all preferred stock of Frequency Japan converted into shares of the Company&#8217;s common stock, see Note 1.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, <font style="font-style:italic;">Income Taxes</font> (ASC 740) which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December&#160;31, 2019 and 2018, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 13). </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU120"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net loss per share </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&#160;31, 2019, 2018 and 2017 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses are not allocated to such participating securities. In periods where the Company reported a net loss attributable to common stockholders, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,237</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> outstanding-basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,649,245</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,530,218</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">702,918</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributed to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> stockholders-basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.29</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12.53</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28.79</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,366</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345,608</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">637,746</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C Preferred (as converted to common stock)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,172,676</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred (as converted to common stock)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,759,079</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,214,387</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred (as converted to common stock)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,070,574</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,283,425</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,283,425</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Frequency Japan preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,047</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">673,605</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options (as converted to common stock)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,968,672</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,089,334</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">985,521</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,554,414</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,606,359</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,906,692</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently adopted accounting pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU 2014-09, <font style="font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font>. The standard will apply one comprehensive revenue recognition model across all contracts, entities, and sectors. The core principle of the new standard is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Once effective, ASU 2014-09 will replace most of the existing revenue recognition requirements in U.S. GAAP. The FASB also issued ASU 2015-14, <font style="font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font>, which deferred the effective date of the standard one year. As a result, the new standard is effective for annual reporting periods beginning after December&#160;15, 2018, including interim periods within the reporting period. Early adoption is permitted. The Company early adopted ASU 2014-09 effective January&#160;1, 2018, and its adoption had no impact on the Company&#8217;s consolidated financial statements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU121"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2016, the FASB issued ASU No.&#160;2016-15, </font><font style="font-style:italic;">Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (ASU No.&#160;2016-15). This guidance addresses the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. The standard is effective for annual periods beginning after December&#160;15, 2017 and for interim periods within those fiscal years. Early adoption is permitted. The Company adopted this standard effective January&#160;1, 2018. The adoption of ASU No.&#160;2016-15 did not have a material impact on the Company&#8217;s consolidated financial statements. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, the FASB issued ASU No.&#160;2017-09, <font style="font-style:italic;">Compensation-Stock Compensation (Topic&#160;718): Scope of Modification Accounting</font> (ASU No.&#160;2017-09). This update clarifies the changes to terms or conditions of a share-based payment award that require an entity to apply modification accounting. ASU No.&#160;2017-09 is effective for annual reporting periods, and interim periods therein, beginning after December&#160;15, 2017. Early application is permitted, and prospective application is required. The Company adopted this standard effective January&#160;1, 2018. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently issued accounting pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued <font style="font-style:italic;">ASU No. 2016-02, Leases</font>, which is intended to increase transparency and comparability among companies that enter into leasing arrangements. The new standard establishes a right-of-use model that requires a lessee to record a right-of-use asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either financing or operating, with classification affecting the pattern of expense recognition. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. In July 2018, the FASB <font style="font-style:italic;">issued ASU No. 2018-11,</font> with targeted improvements to the guidance including an additional transition method, which allows companies to apply the provisions of the new leasing standard as of January 1, 2020, without adjusting the comparative periods presented by recognizing a cumulative-effect adjustment to the opening balance of retained earnings.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company plans to elect early adoption of this standard effective January 1, 2020 and elect the new transition method approved by the FASB. The Company also plans to elect the package of practical expedients intended to ease transition whereby the Company need not assess (1) whether any expired or existing contracts are or contain leases, (2) the lease classification for any expired or existing leases and (3) initial direct costs for any existing leases. Furthermore, the Company will elect the practical expedient to combine non-lease components and lease components. As the Company finalizes its adoption processes, it estimates the adoption of the ASU in the first quarter of 2020 will result in the recognition of a right-of-use asset and related lease liability related to the lease for our Woburn Massachusetts facility in the range of approximately $1,000 to $2,000 with an estimated immaterial effect to the retained earnings and the consolidated statement of operations. As disclosed in Note 16, the Company has entered into a lease for a facility in Lexington Massachusetts which has an estimated commencement date of December 1, 2020. In accordance with ASU No. 2016-02, the Company will recognize a right-of-use asset and related lease liability at such time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU122"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Fair value measurements </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial assets measures at fair value on a recurring basis by level within the fair value hierarchy at December 31, 2019 are summarized as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Market</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,131</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,119</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Government treasury securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,131</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,197</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,262</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,316</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had no financial assets subject to fair value reporting requirements at December 31, 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts reflected in the consolidated balance sheet for prepaid expenses and other current assets, accounts payable and accrued expenses and other liabilities are shown at their historical values which approximate their fair values.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. Prepaid expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent and deposits</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">801</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">428</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant receivable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">805</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,132</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">748</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5. Property and equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment include the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,846</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,109</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,419</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,406</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">306</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,828</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,764</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,066</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,253</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,762</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,511</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized $813 and $654 of depreciation expense for the years ended December&#160;31, 2019 and 2018, respectively. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU123"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. Accrued expenses </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and employee related expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,686</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,034</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">435</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">322</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">393</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,239</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,749</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. Convertible notes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, the Company entered into $5,000 of convertible notes with existing shareholders and investors (Series B Notes) with a maturity date of May&#160;31, 2019. The Series B Notes bore interest at a rate of 5% per annum and were automatically convertible into the security issued in the next financing of at least $5,000, excluding the proceeds of the Series B Notes (Qualified Series B Financing) at a conversion price equal to 95% of the per share price paid by investors in such financing. In the event of a sale of the Company, prior to the conversion or repayment of the Series B Notes at maturity, the Series B Notes would have been repaid at an amount equal to one and one-half times the outstanding principal and interest. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;17, 2018, the Company closed a Qualified Series B Financing and the Series B Notes converted pursuant to their contractual terms. The $5,000 of principal plus $106 of accrued interest were converted into Series B Preferred shares at a 5% discount to the offering price of $0.92 per share resulting in the issuance of 5,839,463 Series B shares and the recognition of a loss on conversion of $269 (see Note 8). For the year ended December&#160;31, 2018, the Company recorded $106 in interest expense on the Series B Notes. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2015 and 2016, the Company entered into $14,285 of convertible notes with investors (Series A Notes) with a maturity date of January&#160;21, 2017, which was extended to April&#160;30, 2017. The Series A Notes bore interest at a rate of 5% per annum and were automatically convertible into the security issued in the next financing in excess of $4,000 (Qualified Series A Financing) at a conversion price equal to 80% of the per share price paid by investors in such financing. If, prior to the Company completing a Qualified Series A Financing, the Company received funds in excess of $15,000 pursuant to a non-equity financing, grant or other similar event, then the Company would have obtained an outside valuation and thereafter the Series A Notes would have automatically converted into shares of common stock of the Company, at a 20% discount to such valuation. In the event of a sale of the Company, prior to conversion or repayment of the Series A Notes at maturity, the Series A Notes would have been repaid at an amount equal to three times the outstanding principal and interest. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;30, 2017, the Company closed a Qualified Series A Financing and the Series A Notes converted pursuant to their contractual terms. The $14,285 of principal plus $709 of accrued interest were converted into Series A Preferred shares at a 20% discount to the offering price of $0.75 per share resulting in the issuance of 24,990,086 Series A Preferred shares and the recognition of a loss on conversion of $3,749 (see Note 8). For the year ended December&#160;31, 2017, the Company recorded $174 in interest expense on the Series A Notes. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Series A Notes and Series B Notes did not contain an optional conversion feature. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluated all the settlement features included within the Series A Notes and Series B Notes, noting that none of the features was considered to be predominant or met the definition of a derivative under FASB ASC Topic 815, <font style="font-style:italic;">Derivatives and Hedging</font> with the exception of the repayment premium in the event of a Company sale. In such event the noteholders were entitled to receive an amount equal to three times the outstanding principal, in the case of Series A Notes, and one and one half and three times the outstanding principal, in the case of the Series B Notes, plus all accrued and unpaid interest. Based on the qualitative and quantitative considerations, management determined that the fair value of the derivative was de minimis as of December&#160;31, 2017. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Convertible preferred stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2018, the Company had authorized 114,208,722 shares of Preferred Stock and had designated 64,891,735 shares as Series A Preferred, 10,000 shares as Series A-1 Preferred Stock, 49,296,987 shares as Series B Preferred and 10,000 shares as Series B-1 Preferred Stock. Since the Preferred Stock was redeemable upon a liquidation event, which is not considered to be within the Company&#8217;s control, it has been classified in temporary equity on the accompanying consolidated balance sheet as of December 31, 2018. The carrying value of the Preferred Stock was the proceeds received less issuance costs. In October 2019, in connection with the IPO, all shares of Preferred Stock were automatically converted into common stock.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU124"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Issuances of preferred stock </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;30, 2017, the Company converted $14,285 of Series A Notes plus accrued interest of $709 into 24,990,086 shares of Series A Preferred at a 20% discount to the offering price of $0.75 per share. The Company also issued 9,783,522 shares of Series A Preferred for proceeds of $7,338 on the same date. Additional issuances of Series A Preferred took place in April, May, August and December of 2017 for an additional aggregate issuance of 27,754,899 shares of Series A Preferred shares for proceeds of $20,816. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurred $203 of share issuance costs in connection with the issuance of the Series A Preferred described above which was recorded as a reduction in the proceeds received and the carrying value. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;17, 2018, the Company converted $5,000 of Series B Notes plus accrued interest of $106 into 5,839,463 shares of Series B Preferred at a 5% discount to the offering price of $0.92 per share. The Company also issued 7,544,029 shares of Series B Preferred for proceeds of $6,944 on the same date. Additional issuances of Series B Preferred took place in November and December of 2018 for an additional aggregate issuance of 28,473,513 shares of Series B Preferred shares for proceeds of $26,208. The Company also issued 288,991 shares of Series B Preferred in January and February 2019 for proceeds of $266. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurred $302 of share issuance costs in connection with Series B Preferred described above which was recorded as a reduction in the proceeds received and the carrying value. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;17, 2018, the Company issued 10,000 shares of Series A-1 Preferred Stock (Series A-1 Preferred) at a price of $0.75 per share for proceeds of $8. The Company also issued 10,000 shares of Series B-1 Preferred Stock (Series B-1 Preferred) at a price of $0.92 per share for proceeds of $9 on the same date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated the tranched nature of the issuance of Series A Preferred and Series B Preferred as well as the rights, preferences, and privileges of such shares and has concluded that there were no freestanding derivative instruments or any embedded derivatives requiring bifurcation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;17, 2019, the Company authorized and issued 39,492,960 shares of Series&#160;C Preferred for net proceeds of $61,687. The Company has evaluated the rights, preferences and privileges of the Series C Preferred and has concluded that there were no freestanding derivative investments or any embedded derivatives requiring bifurcation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Non-controlling Interest</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, the Company issued shares of preferred stock in its subsidiary, Frequency Japan, to a Japanese investor. The Company has consolidated Frequency Japan in the consolidated financial statements and has recorded the proceeds received for the sale of the preferred stock in Frequency Japan as a non-controlling interest in the temporary equity section of the consolidated balance sheets as of December 31, 2018. The liquidation preference of the shares of preferred stock equaled the purchase price of such shares. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Frequency Japan preferred stock held by such investor was convertible, at the option of the holder, into 673,605 shares of Company common stock, adjustable for certain dilutive events, upon an initial public offering of Company common stock, a Company liquidation or upon a 70% vote of the holders of the Preferred Stock. The preferred shares also had a liquidation preference equal to the amount paid for the shares. The Company had the option to acquire the preferred shares of Frequency Japan under certain circumstances and the holder of such preferred shares had the right to require the Company to purchase such shares under certain circumstances, primarily a merger or liquidation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with this sale of the preferred stock in Frequency Japan, FT-FJ Investment, LLC (FT-FJ), a Delaware limited liability company controlled by the Company, purchased 10,000 shares of the Company&#8217;s Series A-1 Preferred Stock and 10,000 shares of the Company&#8217;s Series B-1 Preferred Stock. FT-FJ also granted to the Japanese investor an irrevocable proxy to vote the shares of Series A-1 and Series B-1 Preferred Stock held by FT-FJ. Each share of Series A-1 Preferred had 236 times the voting power of one share of common stock and each share of Series B-1 Preferred Stock has 217 times the voting power of one share of common stock. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU125"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 20, 2019, the Company, Frequency Japan, the Japanese investor, and FT-FJ entered into an agreement pursuant to which, contingent upon the closing of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> initial public offering of the Company&#8217;s common stock: (i) the Japanese investor agreed to convert its shares of preferred stock held in Frequency Japan and to terminate its proxy over the shares of Series A-1 and B-1 Preferred Stock held by FT-FJ and (ii) FT-FJ agreed to forfeit its shares of Series A-1 and Series B-1 Preferred Stock. The shares were converted into common stock and the Series A-1 and B-1 preferred s</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hares</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> were forfeited in conjunction with the IPO.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Stockholders&#8217; deficit </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common stock </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has authorized 100,000,000 shares of $0.001 par value common stock of which 30,844,507 were issued and outstanding as of December 31, 2019. Common shares are voting, and dividends may be paid when, as and if declared by the Board of Directors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 20, 2019, the Company effected a 1-for-6.7355 reverse stock split of its common stock. The par value of the common stock was not adjusted as a result of the reverse stock split and the authorized capital was amended to 100,000,000 shares of common stock and 148,724,922 shares of $0.001 par value preferred stock. The reverse stock split resulted in an adjustment to the Series A Preferred, Series B Preferred and Series C Preferred conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reserved the following shares of common stock for future issuance as of December 31, 2019, 2018 and 2017:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred conversion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,283,425</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,283,425</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Frequency Japan preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">673,605</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred conversion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,214,387</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,968,672</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,089,334</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">985,521</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future grant under stock option plan</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,859,654</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,028,096</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">646,871</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,828,326</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,288,847</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,915,817</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. Stock-based compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November&#160;13, 2014, the Company adopted the 2014 Stock Incentive Plan (2014 Plan). All of the Company&#8217;s employees, officers, directors, and consultants are eligible to be granted options to purchase common shares and restricted stock under the terms of the 2014 Plan. The Company reserved an aggregate of 8,550,415 shares of common stock for issuance under the 2014 Plan. As of December&#160;31, 2019, there were no shares of common stock available for future grants under the 2014 Plan.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 17, 2019, the Company&#8217;s board of directors and on September 19, 2019, its stockholders approved and adopted the 2019 Incentive Award Plan (&#8220;the &#8220;2019 Plan&#8221;) which became effective on the day prior to the IPO.&nbsp;&nbsp;Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock and cash-based awards to individuals who are then employees, officers, directors or consultants of the Company, and employees and consultants of the Company&#8217;s subsidiaries.&nbsp;&nbsp;A total of 3,100,000 shares of common stock were approved to be initially reserved for issuance under the 2019 plan.&nbsp;&nbsp;The number of shares under the 2014 Plan subject to outstanding awards as of the effective date of the 2019 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2019 Plan.&nbsp;&nbsp;In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company&#8217;s common stock on December 31, of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU126"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All stock option grants are non-statutory stock options except option grants to employees (including officers and directors) intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Incentive stock options may not be granted at less than the fair market value of the Company&#8217;s common stock on the date of grant, as determined in good faith by the Board of Directors at its sole discretion. Nonqualified stock options may be granted at an exercise price established by the Board of Directors at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Vesting periods are generally four years and are determined by the Board of Directors. Stock options become exercisable as they vest. Options granted under the 2014 Plan and the 2019 Plan expire no more than ten years from the date of grant. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock options </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019 Plan</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014 Plan</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">985,520</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.54</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,436,734</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.67</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(126,253</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.54</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(206,667</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.54</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,089,334</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.61</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,247,338</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.09</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,015,381</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(357,170</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.02</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,211</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.09</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,247,338</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.09</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.76</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,287</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,721,334</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.85</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.89</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,051</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,433</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.01</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.75</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,866,700</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.07</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.71</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,034</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options unvested as of December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,197,905</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,113</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,854,634</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock option valuation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions that the Company used to determine the grant-date fair value of stock options granted to<font style="font-weight:bold;font-style:italic;"> </font>employees and directors were as follows, presented on a weighted average basis: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1%-2.2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% </p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0-7.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.14%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Risk-Fee Interest Rate<font style="font-style:normal;">: The Company based the risk-free interest rate over the expected term of the options based on the constant maturity of U.S. Treasury securities with similar maturities as of the date of the grant.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Term<font style="font-style:normal;">:&nbsp;&nbsp;The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU127"></a><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Volatility</font><font style="font-style:normal;">: The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock.&nbsp;&nbsp;The Company will continue to apply this process until a sufficient amount of historical information regarding volatility of its own stock price options becomes available.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Dividend Yield<font style="font-style:normal;">: The Company has not paid and does not anticipate paying any dividends in the near future.&nbsp;&nbsp;Therefore, the expected dividend yield was zero.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. During the years ended December&#160;31, 2019 and 2018, 357,170 and 126,253 shares were exercised, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2019 and 2018 was $5,896 and $149 respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value of options granted to employees during the years ended December&#160;31, 2019, 2018 and 2017 was $4.05, $0.47 and $.041, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total grant date fair value of options vested during the years ended December&#160;31, 2019 and 2018 was $2,990 and $244, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted common stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issued common stock to founders, employees and advisors which was subject to vesting over four years. If any of these individuals ceased to be employed or to provide services to the Company prior to vesting, the Company had the right to repurchase any unvested Common Stock at the price paid by the holder. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the status of restricted common stock as of December&#160;31, 2019 and 2018 is presented below: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,658,459</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.27</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,423</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.75</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,336</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.07</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchased</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,201</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.07</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,657,345</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.28</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchased</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,657,345</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.28</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested during period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">275,243</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.26</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested as of December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,366</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.36</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company repurchased 3,201 shares of restricted stock forfeited by a former employee in 2018. The total value of restricted stock awards that vested during the years ended December&#160;31, 2019 and 2018, based on estimated fair values of the stock underlying the restricted stock awards on the day of vesting was $73 and $81, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense of $3,609 and $455 for the years ended December&#160;31, 2019 and 2018 respectively, is included in research and development and general and administrative expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, total unrecognized stock-based compensation expense relating to unvested stock options was $13,820 and $717, respectively. This amount is expected to be recognized over a weighted-average period of 2.76 years and 2.76 years, respectively. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU128"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">. Employee stock purchase plan </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 20, 2019, the Company&#8217;s board of directors and stockholders approved and adopted the 2019 Employee stock Purchase Plan (the &#8220;ESPP&#8221;) which became effective on the date of the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. A total of 315,000 shares of common stock were approved to be initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first ten-years of the term of the ESPP, beginning with January 1, 2020 and ending with January 1, 2029, by an amount equal to 1% of the outstanding number of shares of the Company&#8217;s common stock on December 31 of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors. No shares were issued under the ESPP at December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13. Income taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception in 2014, the Company has generated cumulative federal and state net operating loss and research and development credit carryforwards for which we have not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within the respective carryforward periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, the Company had federal net operating loss carryforwards of approximately $50,199 and Massachusetts state operating loss carryforwards of approximately $41,242&#160;which may be available to offset future taxable income. The U.S. federal net operating loss carryforwards include $22,400 available to reduce future taxable income through 2037 and approximately $27,779 which do not expire and are available to reduce future taxable income indefinitely. The state net operating loss carryforwards are available to offset future taxable income through 2039. As of December&#160;31, 2019, the Company also had federal and Massachusetts research and development tax credit carryforwards of $701 and $533, respectively, which are available to offset federal and state tax liabilities through 2039 and 2034, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realization of future tax benefits is dependent on many factors, including the Company&#8217;s ability to generate taxable income within the net operating loss carryforward period. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as provided under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, respectively, as well as similar state provisions. These ownership changes may limit the number of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has completed several financings and has conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception and has determined that an ownership change did occur in March 2017. Accordingly, utilization of $12,400 of the U.S. net operating loss carryforwards which were incurred prior to March 2017 (pre-ownership change) is limited under Section 382. After the Section 382 limitations, the Company may utilize approximately $10,800 of its pre-ownership change net operating loss carryforwards based upon an annual usage of approximately $1,600 for each of the next five years after the ownership change and approximately $180 for each of the 15 years thereafter. The remaining pre-ownership change net operating losses of approximately $1,600 were written off due to expiration under limitation. The limitation has been determined by first multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate. These carryforwards may be subject to further annual limitations under Section&#160;382 in the event of future changes in ownership.&nbsp;&nbsp;Additionally, the Company has determined an ownership changed occurred in October of 2019 as a result of the IPO.&nbsp;&nbsp;Accordingly, utilization of approximately $46,123 of the U.S. net operating loss carryforwards incurred prior to October 2019 is also limited under Section 382.&nbsp;&nbsp;The Company has determined it will be able to utilize the entire $46,123 of its pre-ownership change net operating loss carryforwards based upon the limitations calculated from the October 2019 ownership change. These carryforwards may be subject to further annual limitations under Section 382 in the event of future changes in ownership.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December&#160;31, 2019 and 2018 because the Company&#8217;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its cumulative loss position and, as a result, a valuation allowance of approximately $16,204 and $12,229 as of December&#160;31, 2019 and 2018 has been established. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU129"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no unrecognized tax benefits. The Company has not, as yet, conducted a study of its research and development credit carryforwards. Such a study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment were required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheet or consolidated statements of operations if an adjustment were required. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which no interest or penalties were recorded for the years ended December&#160;31, 2019 and 2018. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the U.S. and Massachusetts. The statute of limitations for assessment by the Internal Revenue Service and Massachusetts tax authorities remains open for all years since 2014. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state authorities to the extent utilized in a future period. No federal or state tax audits are currently in process. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2019, 2018 and 2017 is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S federal statutory income tax rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of federal rate change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other items</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in deferred tax asset valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26.3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25.9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s deferred tax assets at December&#160;31, 2019 and 2018 consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,253</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,710</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,138</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangibles</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">358</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">496</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax asset</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,204</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,229</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,204</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,229</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December&#160;22, 2017, the Tax Cuts and Jobs Act was signed into United States law. The Tax Cuts and Jobs Act includes a number of changes to existing tax law, including, among other things, a permanent reduction in the federal corporate income tax rate from a top marginal tax rate of 35% to a flat rate of 21%, effective as of January&#160;1, 2018, as well as a limitation of the deduction for net operating losses to 80% of annual taxable income and elimination of net operating loss carrybacks, in each case, for losses arising in taxable years beginning after December&#160;31, 2017 (though any such net operating losses may be carried forward indefinitely). The federal tax rate change resulted in a reduction in the gross amount of our deferred tax assets and liabilities recorded as of December&#160;31, 2017, and a corresponding reduction in our valuation allowance. As a result, no income tax expense or benefit was recognized as of the enactment date of the Tax Cuts and Jobs Act. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU130"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">. Research and license agreements </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Massachusetts Institute of Technology </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, the Company entered into an exclusive patent license agreement (MIT License Agreement), with the Massachusetts Institute of Technology, (MIT), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products (Licensed Products) and to develop and perform processes (Licensed Processes) which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. The Company also has the right to grant sublicenses of its rights under the MIT License Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to use diligent efforts to develop and commercialize the Licensed Products or Processes, and to make such products or processes reasonably available to the public and to spend certain minimum amounts on research and development of Licensed Products and/or Processes each year until the first commercial sale of a Licensed Product and/or a first commercial performance of a Licensed Process. The Company is also subject to certain development obligations with regards to a first Licensed Product. The Company has satisfied certain obligations related to preclinical studies and the filing of an IND for a first Licensed Product with its development activities related to FX-322. The Company&#8217;s future development obligations are: (i) to commence a Phase II clinical trial for such Product, (ii) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product within two years of the IND filing for such product, (iii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such product, and (iv) to make a first commercial sale of such Product within 11 years of the IND filing for such product. The Company also has certain development obligations for as second Licensed Product. In the event that the Company has failed to fulfill the development timeline obligation with respect to a second Licensed Product and fail to cure such breach within ninety (90)&#160;days of written notice by MIT, MIT may restrict the licensed field to the prevention and remediation of hearing loss in humans and animals. The Company does not have the right to control prosecution of the in-licensed patent applications, and its rights to enforce the in-licensed patents are subject to certain limitations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering into the MIT License Agreement, the Company paid a $50 license fee payment and issued to MIT shares of our common stock equal to 5% of total then-outstanding capital stock. The Company is required to pay certain annual license maintenance fees which may be credited to running royalties during the same calendar year, if any, and to make potential milestone payments up to $2,900 on each Licensed Product or Licensed Process. In addition, The Company is required to pay a low single-digit royalty on Licensed Products and Licensed Processes and a low-twenties royalty on sublicense revenues. In the year ended December 31, 2019 the Company paid MIT a royalty of $16,000 related to the upfront payment received from Astellas, see Note 15.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The MIT License Agreement will remain effect until the expiration or abandonment of all issued patents and filed patent applications licensed thereunder remain in effect, unless terminated earlier. The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company&#8217;s material breach uncured within ninety (90)&#160;days (or thirty (30)&#160;days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30)&#160;days after MIT&#8217;s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, the Company entered into an amendment with MIT, updating the diligence milestones for a second Licensed Product. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">California Institute for Biomedical Research </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, the Company entered into a license agreement, (CALIBR License Agreement), with the California Institute for Biomedical Research, (CALIBR), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products (CALIBR Licensed Products) which incorporate the licensed technology for the treatment of multiple sclerosis. The Company also have the right to grant sublicenses of our rights under the CALIBR License Agreement. CALIBR reserves the right to use for itself and the right to grant non-exclusive licenses to other nonprofit or academic institutions, for any internal research and educational purposes. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU131"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to use commercially reasonable efforts to develop, manufacture, and sell at least one Licensed Product and does not have the right to control prosecution of the in-licensed patent applications, and to enforce the in-licensed patents are subject to certain limitations. The Company is also subject to certain milestone timeline obligations to: (i) submit an IND (or equivalent) for a CALIBR Licensed Product by the 30th month after the effective date of the CALIBR License Agreement, (ii) initiate a Phase II clinical trial (or equivalent) for a CALIBR Licensed Product by the fourth anniversary of the effective date of the CALIBR License Agreement, and (iii) initiate a Phase III clinical trial (or equivalent) for a CALIBR Licensed Product by the sixth anniversary of the effective date of the CALIBR License Agreement. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering into the CALIBR License Agreement, the Company made a $1,000 license fee payment and are required to make milestone payments up to $26,000 for each Category of CALIBR Licensed Products (Category 1 means any CALIBR Licensed Products containing a compound that modulates any muscarinic receptor and Category 2 means any CALIBR Licensed Products not included in Category 1 that could differentiate oligodendrocyte precursors) . The Company is also required to pay a middle single-digit royalty on CALIBR Licensed Products and a royalty on sublicense revenues ranging from low-teen percentage to 50%. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CALIBR License Agreement shall continue in effect until expiration of all Company obligations to pay royalties. Royalties shall be payable on a country-by-country and CALIBR Licensed Product-by-CALIBR Licensed Product basis upon the later of (1)&#160;the expiration or abandonment of all valid claims of the licensed patent rights in such country and (2)&#160;ten years from the first commercial sale of each CALIBR Licensed Product. The Company may terminate the CALIBR License Agreement at will upon a 30-day prior written notice. The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90)&#160;days&#8217; prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30)&#160;days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Massachusetts Eye and Ear Infirmary </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, the Company entered into an Non-Exclusive Patent License Agreement (MEEI License Agreement) with the Massachusetts Eye and Ear Infirmary (MEEI) under which it received a non-exclusive, non-sublicensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products and to develop and perform processes which incorporate the licensed technology for the treatment or prevention of hearing loss. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to use diligent efforts to develop and commercialize the licensed products and MEEI has control over the filing, prosecution, enforcement and defense of any licensed patent rights. The Company is also subject to milestone timeline obligations to dose a first patient in a Phase II trial by December&#160;31, 2020 and to dose a first patient in a Phase III trial by December&#160;31, 2024. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering into the MEEI License Agreement, the Company made a $20 license fee payment and is required to pay certain annual license maintenance fees until the first commercial sale and a minimum annual royalty payment after the first commercial sale. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also required to make milestone payments up to $350 on each product or process which incorporates the licensed patent rights and pay a low single-digit royalty on products and processes that incorporate the licensed patent rights. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The MEEI License Agreement shall remain in effect until all issued patents and filed patent applications within the licensed patent rights have expired or been abandoned, unless terminated earlier. The Company has the right to terminate the MEEI License Agreement at will by giving thirty (30)&#160;business days advance written notice to MEEI. MEEI has the right to terminate the MEEI License Agreement if the Company fails to make any payment due within thirty (30)&#160;business days after MEEI notifies the Company of such failure. MEEI shall have the right to terminate if the Company fails to maintain the required insurance. MEEI shall also have the right to terminate the MEEI License Agreement upon forty-five (45)&#160;business days written notice if the Company becomes insolvent. MEEI has the right to terminate for any other default not cured within sixty (60)&#160;business days written notice. MEEI also has the right to terminate if the Company or its affiliates challenge the validity of the licensed patent rights. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU132"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cambridge Enterprise Limited</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.14%;">In December 2019, we entered into an Exclusive Patent License Agreement ( the &#8220;Cambridge License&#8221;) with Cambridge Enterprise Limited (the technology transfer arm of the University of Cambridge)<font style="font-size:12pt;"> </font>(&#8220;Cambridge&#8221;) under which we received an executive worldwide royalty-bearing license to certain patent rights to make, have made, sell, offer to sell and import products, or the (the &#8220;Cambridge License Product&#8221;) which incorporate licensed technology for the treatment of demyelinating diseases.&nbsp;&nbsp;We also have the right to grant nonexclusive licenses to other academic institutions for any academic publication, research and teaching and clinical patient care.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.14%;">We have agreed to use diligent and good faith efforts to develop and commercially exploit at least one Cambridge Licensed Product.&nbsp;&nbsp;Upon entering into the Cambridge License, we made a $50 license fee payment.&nbsp;&nbsp;We are obligated to pay an annual license fee of $50. We are also obligated to make milestone payments up to $10.5 million on each Cambridge License Product.&nbsp;&nbsp;In addition, we have agreed to pay a low single-digit royalty on products that incorporate the licensed patent rights, subject to offset in certain circumstances. </p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.14%;">The Cambridge License continues in effect on a country-by-country basis until the expiration or revocation, without right of further appeal, of all licensed issued patents and filed patent applications, unless terminated earlier.&nbsp;&nbsp;We have the right to terminate for any reason upon 90 days&#8217; prior to written notice.&nbsp;&nbsp;Each party has the right to terminate immediately if the other party ceases to carry on its business.&nbsp;&nbsp;Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days.&nbsp;&nbsp;Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge Licensed Product or we or our affiliates or sub-licenses commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Department of Defense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the Company received a grant (the Grant) from the Department of Defense (DoD) under which the Company is receiving funding to further the Company&#8217;s research and development of a therapeutic drug to treat hearing loss. The Company is receiving funding of $1,596 over two years from the date of the Grant. The Company has determined that the DoD is not considered a customer under ASC Topic 606, therefore funding received from the DoD under the Grant is recorded as a reduction of research and development expenses. The Company has recorded $845 and $428 as a reduction in research and development expenses for the years ended December&#160;31, 2019 and 2018, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15. Collaboration agreement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, the Company entered into a License and Collaboration Agreement with Astellas (the Astellas Agreement), under which the Company granted Astellas an exclusive, royalty-bearing, sub-licensable, nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a GSK-3 inhibitor and an HDAC inhibitor, (the Astellas Licensed Products), including the product candidate FX-322, outside of the United States. The Company also granted Astellas a right of first negotiation and a right of last refusal if it entered into any negotiation or agreement of any kind (other than an acquisition of all of the stock or assets of the Company) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas Licensed Products in the United States. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has agreed to conduct Phase 2a clinical studies in the United States. Upon the completion thereof, the Company and Astellas have agreed to jointly develop the Astellas Licensed Products, including carrying out joint studies. Each party has agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in sensorineural hearing loss and in age-related hearing loss, in each case, in one major Asian country and one major European country. The Company has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in the United States. Astellas has the sole right to commercialize the Astellas Licensed Products outside of the United States, and the Company has the sole right to commercialize the Astellas Licensed Products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas Licensed Products in a major Asian country and a major European country following receipt of regulatory approval in such countries. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU133"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collaboration is governed by a joint steering committee (&#8220;JSC&#8221;) established under the Astellas Agreement and shall be comprised of three representatives each from the Company and Astellas. The JSC shall oversee and coordinate the overall conduct of the development, manufacture and commercialization of the Astellas Licensed Products. All decisions of JSC shall be taken through a unanimous vote with each party&#8217;s representatives collectively having one vote. Both the parties shall be responsible for carrying out the development and manufacturing activities in their defined territory in accordance with the plan as reviewed and approved in the JSC. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the licensed rights under the Astellas Agreement, Astellas paid the Company an upfront payment of $80.0&#160;million in July 2019 and has agreed to pay potential development milestone payments up to $230.0&#160;million and commercialization milestones of up to $315.0 million. Specifically, the Company would receive development milestone payments of $65.0. million and $25.0 million upon the first dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively and $100.0 million and $40.0 million upon the first dosing of a patient in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively.&nbsp;&nbsp;If the Astellas Licensed Products are successfully commercialized, the Company would be eligible for up to $315.0&#160;million in potential commercial milestone payments and also tiered royalties at rates ranging from low- to mid-teen percentages. The parties shall share equally, on a 50/50 basis, all out-of-pocket costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Astellas Agreement remains in effect until the expiration of all royalty obligations. Royalties are paid on a licensed product-by-licensed product and country-by-country basis until the latest of (i)&#160;the expiration of the last valid claim in the licensed patent rights with respect to such Astellas Licensed Product in such country or (ii) a set number of years from the first commercial sale of such Astellas Licensed Product in such country. Astellas may terminate the Astellas Agreement at will upon 60 days&#8217; written notice. Each party has the right to terminate the Astellas Agreement due to the other party&#8217;s material breach if such breach remains uncured for 90 days (or 45 days in the case of nonpayment) or if the other party becomes bankrupt. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Astellas Agreement is a collaborative agreement that is within the scope of ASC 808. The Company analyzed the joint research and development activities to assess whether they fall within the scope of ASC 808, and will reassess this throughout the life of the arrangement based on changes in the roles and responsibilities of the parties. Based on the terms of the arrangement as outlined above, both parties are deemed to be active participants in the collaboration. Both parties are performing research and development activities in their defined territory and will be performing joint clinical studies in accordance with the development plan and the study protocol approved by the JSC. Additionally, Astellas and the Company are exposed to significant risks and rewards dependent on the commercial success of any product candidates that may result from the collaboration. As such, the collaboration arrangement is deemed to be within the scope of ASC 808. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The arrangement consists of two components; the license of IP and the research and development activities, including committee participation, to support the co-development and research plan. Under the provisions of ASC 808, the Company has determined that it will apply the guidance in ASC 606 to recognize the revenue related to the license since that component of the arrangement is more reflective of a vendor-customer relationship. The Company determined that the license and the related research and development services associated with the Phase 2a clinical study were not distinct from one another, as the license has limited value to Astellas without the performance of the research and development activities and the Phase 2a study is essential to the use of the license. As such, the Company determined that these activities should be accounted for as a single combined performance obligation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue associated with this single performance obligation is being recognized as the research and development work is performed, using an input method on the basis of research and development costs incurred to date relative to total research and development costs expected to be incurred. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. The Company has determined that the period of performance of the research and development services began upon the signing of the Astellas Agreement and will continue until the completion of the Phase 2a clinical trial of FX-322. The transaction price of $80.0 million has been allocated to the single combined performance obligation and will be recognized over such period. Management has analyzed the progress of the Phase 2a clinical trial and has estimated the completion date of such trial and the total costs it expects to incur in performing the trial and is recognizing the $80.0 million upfront fee as revenue over the period from July 2019 until the estimated completion date using the input method. The Company regularly assesses its estimates and to the extent that facts and circumstances dictate, the Company revises its estimates of total cost or completion date and accounts for such change on a prospective basis. The estimated completion date of the Phase 2a clinical trial as of December 31, 2019 has changed from the date used for accounting purposes as of September 30, 2019.&nbsp;&nbsp;The Company was required to pay MIT a royalty of $16.0 million on the $80.0 million of sublicense revenues. The $16.0 million royalty was expensed in the third quarter of 2019.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU134"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $80.0&#160;million upfront payment received from Astellas in July 2019 was initially recorded as deferred revenue and is being recognized as revenue according to the policy described above. In the year ended December 31, 2019, the Company recorded $28.9 million of revenue under the Astellas Agreement which included $16.0 million related to the royalty payment to MI0T and $12.9 million based upon the application of the input method to the remaining $64.0 million to be recognized over the estimated period to completion of the Phase 2a clinical trial for FX-322. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The potential development and regulatory milestone payments are fully constrained until the Company can conclude that achievement of the milestone is probable and that it is probable that recognition of revenue related to the milestone will not result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is ultimately resolved and as such these have been excluded from the transaction price. As part of its evaluation of the constraint, the Company considers numerous factors, including the fact that achievement of the milestones is outside the control of the Company and contingent upon the future success of clinical trials, the licensee&#8217;s efforts, and the receipt of regulatory approval. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to Astellas and therefore are recognized at the later of when the performance obligation is satisfied, or the related sales of licensed products occur. The Company re-evaluates the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, at each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Astellas Agreement contains joint research and development activities that are not within the scope of ASC 606. The Company will recognize research and development expense related to the joint study costs for all the joint activities in future periods and reimbursements received from Astellas will be recognized as an offset to research and development expense on the consolidated statement of operations during the development period. In the year ended December 31, 2019, the Company received $186 from Astellas for joint costs.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16. Commitments and contingencies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating leases </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2016, the Company and a related third party (see Note 18) entered into a five-year operating lease for the Company&#8217;s primary office and laboratory space in Woburn, Massachusetts. In February 2020, the Company entered into a new lease for its office and laboratory space with the same landlord in Woburn, Massachusetts.&nbsp;&nbsp;The new lease includes additional office space and is for a five-year period.&nbsp;&nbsp;The Company intends to sublease this facility at the time it moves into its new facility discussed below. The Company also leases a laboratory facility in Connecticut under an operating lease which expires in 2019. Rent expense was $269 and $271 for the years ended December&#160;31, 2019 and 2018, respectively. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 7, 2020 the Company entered into an indenture of lease (the &#8220;Lexington Lease&#8221;) with HCP/KING 75Hayden LLC,(the &#8220;Landlord&#8221;), for the lease of approximately 61,307 square feet of rentable area in Lexington, Massachusetts or (the &#8220;Lexington Premises&#8221;).&nbsp;&nbsp;The commencement date of the Lexington Lease is expected to be on or about December 1, 2020, (the &#8220;Commencement Date&#8221;).&nbsp;&nbsp;The Company expects to use the Lexington Premises as its new principal executive offices and as a laboratory for research and development, and other related uses.&nbsp;&nbsp;The term of the Lexington Lease, (the &#8220; Initial Term&#8221;), is ten years from the rent commencement date (which is five months following the Commitment Date) and the Initial Term is expected to end on April 30, 2031 (assuming a December 1, 2020 Commencement Date).&nbsp;&nbsp;We also have the option to extend the Initial Term for two additional terms of five years each.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU135"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The minimum aggregate future operating lease commitments</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the leases noted above</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are as follows: </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum&#160;lease</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">commitments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">504</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,613</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,741</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,883</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,034</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thereafter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,596</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,371</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contract commitments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has contracted with a research institution to provide research for a therapeutic drug to treat multiple sclerosis. As of December&#160;31, 2019, the Company has committed to total payments of $705 over twelve months beginning in October 2019.&nbsp;&nbsp;We also enter into contracts in the normal course of business with CROs, CMOs, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by us upon prior written notice although, purchase orders for clinical materials are generally non-cancelable. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation or upon the completion of a manufacturing run. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Guarantees </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, <font style="font-style:italic;">Guarantees</font>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#8217;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#8217; and officers&#8217; insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office space under a five-year noncancelable operating lease. The Company has standard indemnification arrangements under this lease that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, 2018 and 2017, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17. Employee benefit plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employees of the Company are eligible to participate in the Company&#8217;s 401(k) retirement plan (the &#8220;401(k) Plan&#8221;). Participants may contribute up to 90% of their annual compensation to the 401(k) Plan, subject to statutory limitations. The 401(k) Plan has a Safe Harbor Match of 100% of the first 5% and vests 100% at time of match. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU136"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">. Related party transactions </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#8217;s lease for its Woburn, Massachusetts facility, see Note 16, is with an entity affiliated with one of the Company&#8217;s directors and shareholders. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">19. Subsequent events </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated subsequent events for recognition, remeasurement and disclosure purposes through March 26, 2020, the date which the consolidated financial statements were available to be issued. The identified subsequent event is as follows; </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 30, 2020, the World Health Organization declared the coronavirus outbreak a "Public Health Emergency of International Concern" and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The coronavirus and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in<font style="color:#000000;"><br /></font>which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will be to the Company, it is reasonably possible that estimates made in the consolidated financial statements, including the estimated time and costs necessary to complete our performance obligations under the Astellas Agreement, will be materially and adversely impacted in the near term as a result of these<font style="color:#000000;"><br /></font>conditions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">20. Selected Quarterly Data (Unaudited) </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table contains quarterly financial information for 2019 and 2018.&nbsp;&nbsp;The Company believes that the following information reflects all normal recurring adjustments necessary for the fair statement of the information for the periods presented.&nbsp;&nbsp;The operating results for any quarter are not necessarily indicative of results for any future period.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,238</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,709</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">28,947</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,826</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,852</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,813</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,202</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">47,693</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,826</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,852</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(575</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,493</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative series C convertible preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; dividends</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1,054</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,826</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,852</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,589</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,533</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders -</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.24</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.42</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.73</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.19</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2.29</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,149</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,436</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,136</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,447</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">19,168</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,149</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,436</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,136</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,447</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative series C convertible preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; dividends</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,149</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,436</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,136</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,447</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders -</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.03</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.01</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.26</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.23</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(12.53</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:7.14%;text-indent:3.57%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-31</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>freq-ex43_875.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
freq-ex43_875.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4.3</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a><font style="font-weight:bold;color:#000000;">Description of capital stock </font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">General </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following description summarizes some of the terms of the restated certificate of incorporation and amended and restated bylaws of Frequency Therapeutics, Inc. (&#8220;we&#8221; or &#8220;our&#8221;) and of the General Corporation Law of the State of Delaware. This description is summarized from, and qualified in its entirety by reference to, our amended and restated certificate of incorporation and amended and restated bylaws, each of which has been publicly filed with the Securities and Exchange Commission, as well as the relevant provisions of the General Corporation Law of the State of Delaware. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Capital stock</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized capital stock consists of 200,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Common stock </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matters. Our restated certificate of incorporation and amended and restated bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of our restated certificate of incorporation. See below under &#8220;&#8212;Anti-takeover effects of Delaware law and our certificate of incorporation and bylaws&#8212;Amendment of charter provisions.&#8221; Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately our net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>Under the terms of our restated certificate of incorporation, our board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. </font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Anti-takeover effects of Delaware law and our certificate of incorporation and bylaws </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some provisions of Delaware law, our restated certificate of incorporation and our amended and restated bylaws could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:12pt;font-family:Arial;text-transform:none;font-variant: normal;">Undesignated preferred stock </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of our board of directors, without action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:12pt;font-family:Arial;text-transform:none;font-variant: normal;">Stockholder meetings </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws provide that a special meeting of stockholders may be called only by our chairman of the board, chief executive officer or president (in the absence of a chief executive officer), or by a resolution adopted by a majority of our board of directors. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:12pt;font-family:Arial;text-transform:none;font-variant: normal;">Requirements for advance notification of stockholder nominations and proposals </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the board of directors or a committee of the board of directors. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:12pt;font-family:Arial;text-transform:none;font-variant: normal;">Elimination of stockholder action by written consent </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:12pt;font-family:Arial;text-transform:none;font-variant: normal;">Staggered board </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third-party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:12pt;font-family:Arial;text-transform:none;font-variant: normal;">Removal of directors </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote in the election of directors. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:12pt;font-family:Arial;text-transform:none;font-variant: normal;">Stockholders not entitled to cumulative voting </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:12pt;font-family:Arial;text-transform:none;font-variant: normal;">Delaware anti-takeover statute </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to Section 203 of the General Corporation Law of the State of Delaware, which prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:12pt;font-family:Arial;text-transform:none;font-variant: normal;">Choice of forum </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>Our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will, to the fullest extent permitted by applicable law, be the sole and exclusive forum for: (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3) any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws; (4) any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (5) any action asserting a claim governed by the internal affairs doctrine. Under our restated certificate of incorporation, this exclusive forum provision </font><font style="color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">does </font><font style="color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. For instance, the provision would not apply to actions arising under federal securities laws, including suits brought to enforce any liability or duty created by the Exchange Act or the rules and regulations thereunder. Our restated certificate of incorporation</font><font style="color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">also provide</font><font style="color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. Our restated certificate of incorporation further provide</font><font style="color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. It is possible that a court of law could rule that the choice of forum provision contained in our restated certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:12pt;font-family:Arial;text-transform:none;font-variant: normal;">Amendment of charter provisions </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock and the provision prohibiting cumulative voting, would require approval by holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote thereon. The provisions of Delaware law, our restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5.1
<SEQUENCE>3
<FILENAME>exhibit10_51.htm
<DESCRIPTION>EX-10.5.1
<TEXT>
<HTML><HEAD>
<TITLE>HTML</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEASE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS
LEASE AGREEMENT (this &#147;<B>Lease</B>&#148;) is made this 24<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of August, 2016, between <B><FONT STYLE="white-space:nowrap">ARE-MA</FONT> REGION NO. 20, LLC</B>, a Delaware limited
liability company (&#147;<B>Landlord</B>&#148;), and <B>FREQUENCY THERAPEUTICS, INC.</B>, a Delaware corporation (&#147;<B>Tenant</B>&#148;). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Building:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">19 Presidential Way, Woburn, Massachusetts</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Premises:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">That portion of the Building, consisting of (i)&nbsp;Suite 203, consisting of approximately 9,521 rentable square feet of laboratory/office space on the second floor of the Building, and (ii)&nbsp;Suite 100D, consisting of
approximately 424 rentable square feet of storage space on the first floor of the Building, all as determined by Landlord, as shown on <B>Exhibit A</B>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Project:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The real property on which the Building in which the Premises are located, together with all improvements thereon and appurtenances thereto as described on <B>Exhibit B</B>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Base Rent:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$30.00 per rentable square foot of the Premises per annum, as adjusted pursuant to <U>Section&nbsp;4</U> hereof.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rentable Area of Premises:</B> 9,945 sq. ft. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rentable Area of Project:</B> 144,892 sq. ft. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tenant&#146;s Share of Operating Expenses:</B> 6.86% </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Security Deposit:</B> $99,450.00
<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Target Commencement Date:</B> December&nbsp;23, 2016 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rent Adjustment Percentage:</B> 3% </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Base Term:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Beginning on the Commencement Date and ending 60 months from the first day of the first full month of the Term (as defined in <U>Section&nbsp;2</U>) hereof.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Permitted Use:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">With respect to the laboratory/office portion of the Premises, research and development laboratory, related office and other related uses consistent with the character of the Project and otherwise in compliance with the provisions
of <U>Section&nbsp;7</U> hereof.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">With respect to the storage area portion of the Premises, the storage of Hazardous Materials (as defined in <U>Section&nbsp;30(h)</U> below) of Tenant in compliance with the provision of
<U>Section&nbsp;7</U>.</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Address for Rent Payment:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Landlord&#146;s Notice Address:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">ARE-MA</FONT> Region No.&nbsp;20, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">385 E. Colorado Boulevard, Suite 299</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Capital One Bank</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pasadena, CA 91101</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">P.O. Box 37526</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Corporate Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Baltimore, MD 21297-3526</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tenant&#146;s Notice Address: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">19 Presidential Way, Suite 203 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Woburn, MA 01801 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: President </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
2<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following Exhibits and Addenda are attached hereto and incorporated herein by this reference: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746; <B>EXHIBIT A</B> - PREMISES DESCRIPTION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#9746; <B>EXHIBIT B</B> - DESCRIPTION OF PROJECT</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746; <B>EXHIBIT C</B> - WORK LETTER</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#9746; <B>EXHIBIT D</B> - COMMENCEMENT DATE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746; <B>EXHIBIT E</B> - RULES AND REGULATIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#9746; <B>EXHIBIT F</B> - TENANT&#146;S PERSONAL PROPERTY</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B>Lease of Premises</B>. Upon and subject to all of the terms and conditions hereof, Landlord hereby
leases the Premises to Tenant and Tenant hereby leases the Premises from Landlord. The portions of the Project which are for the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> use of tenants of the Project are collectively referred to herein
as the &#147;<B>Common Areas</B>.&#148; The Common Areas shall include, without limitation, all common lobbies, entrances, stairs, elevators, restrooms, walkways, sidewalks, loading areas and recreation areas located at the Project. Tenant shall
have the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right to use the Common Areas. Landlord reserves the right to modify Common Areas, provided that such modifications do not materially adversely affect Tenant&#146;s use of or access to
the Premises for the Permitted Use. From and after the Commencement Date through the expiration of the Term, Tenant shall have access to the Building and the Premises 24 hours a day, 7 days a week, except in the case of emergencies, as the result of
Legal Requirements, the performance by Landlord of any installation, maintenance or repairs, or any other temporary interruptions, and otherwise subject to the terms of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B>Delivery; Acceptance of Premises; Commencement Date</B>. Landlord shall use reasonable efforts to deliver the Premises to Tenant on the
Target Commencement Date, with Landlord&#146;s Work Substantially Completed (&#147;<B>Delivery</B>&#148; or &#147;<B>Deliver</B>&#148;). If Landlord fails to timely Deliver the Premises, Landlord shall not be liable to Tenant for any loss or damage
resulting therefrom, and this Lease shall not be void or voidable except as provided herein. Notwithstanding anything to the contrary contain herein, if Landlord fails to Deliver the Premises to Tenant on or before the date that is 60 days after the
Target Commencement Date (as such date may be extended for Force Majeure delays and Tenant Delays), then Base Rent shall be abated 1 day for each day thereafter until Landlord Delivers the Premises to Tenant with Landlord&#146;s Work Substantially
Completed. If Landlord does not Deliver the Premises within 90 days of the Target Commencement Date for any reason other than Force Majeure delays and Tenant Delays, this Lease may be terminated by Tenant by written notice to Landlord, and if so
terminated by Tenant: (a)&nbsp;the Security Deposit, or any balance thereof (i.e., after deducting therefrom all amounts to which Landlord is entitled under the provisions of this Lease), shall be returned to Tenant, and (b)&nbsp;neither Landlord
nor Tenant shall have any further rights, duties or obligations under this Lease, except with respect to provisions which expressly survive termination of this Lease. As used herein, the terms &#147;<B>Landlord&#146;s Work</B>,&#148;&#147;<B>Tenant
Delays</B>&#148; and &#147;<B>Substantially Completed</B>&#148; shall have the meanings set forth for such terms in the Work Letter. If Tenant does not elect to void this Lease within 5 business days of the lapse of such 90 day period (as extended
for Force Majeure delays and Tenant Delays), such right to void this Lease shall be waived and this Lease shall remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The &#147;<B>Commencement Date</B>&#148; shall be the earliest of: (i)&nbsp;the date Landlord Delivers the Premises to Tenant with
Landlord&#146;s Work Substantially Completed; (ii)&nbsp;the date Landlord could have Delivered the Premises with Landlord&#146;s Work Substantially Completed but for Tenant Delays; and (iii)&nbsp;the date Tenant conducts any business in the Premises
or any part thereof; provided, however, in no event shall the Commencement Date occur prior to November&nbsp;15, 2016. Upon request of Landlord, Tenant shall execute and deliver a written acknowledgment of the Commencement Date and the expiration
date of the Term when such are established in the form of the &#147;Acknowledgement of Commencement Date&#148; attached to this Lease as <B>Exhibit D</B>; <U>provided</U>, <U>however</U>, Tenant&#146;s failure to execute and deliver such
acknowledgment shall not affect Landlord&#146;s rights hereunder. The &#147;<B>Term</B>&#148; of this Lease shall be the Base Term, as defined above on the first page of this Lease and any Extension Term which Tenant may elect pursuant to
<U>Section</U><U></U><U>&nbsp;39</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the period of 30 consecutive days after the Commencement Date, Landlord shall, at its
sole cost and expense (which shall not constitute an Operating Expense), be responsible for any repairs that are required to be made to the Building Systems (as defined in <U>Section</U><U></U><U>&nbsp;13</U>) serving the Premises, unless Tenant or
any Tenant Party was responsible for the cause of such repair, in which case Tenant shall pay the cost. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
3<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of <U>Section</U><U></U><U>&nbsp;6</U> of the Work Letter, Landlord
shall permit Tenant access to the Premises for a period of 30 days prior to the Commencement Date for Tenant&#146;s installation and setup of furniture, fixtures, tele/data cabling and equipment (&#147;<B>FF&amp;E Installation</B>&#148;), provided
that such FF&amp;E Installation is coordinated with Landlord, and Tenant complies with the Lease and all other reasonable restrictions and conditions Landlord may impose. All such access shall be reasonably coordinated with Landlord. Any access to
the Premises by Tenant before the Commencement Date shall be subject to all of the terms and conditions of this Lease, excluding the obligation to pay Base Rent and Operating Expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise expressly set forth in this Lease or in the Work Letter: (i)&nbsp;Tenant shall accept the Premises in their condition as
of the Commencement Date, subject to all applicable Legal Requirements (as defined in <U>Section</U><U></U><U>&nbsp;7</U> hereof); (ii) Landlord shall have no obligation for any defects in the Premises; and (iii)&nbsp;Tenant&#146;s taking possession
of the Premises shall be conclusive evidence that Tenant accepts the Premises and that the Premises were in good condition at the time possession was taken. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant agrees and acknowledges that neither Landlord nor any agent of Landlord has made any representation or warranty with respect to the
condition of all or any portion of the Premises or the Project, and/or the suitability of the Premises or the Project for the conduct of Tenant&#146;s business, and Tenant waives any implied warranty that the Premises or the Project are suitable for
the Permitted Use. This Lease constitutes the complete agreement of Landlord and Tenant with respect to the subject matter hereof and supersedes any and all prior representations, inducements, promises, agreements, understandings and negotiations
which are not contained herein. Landlord in executing this Lease does so in reliance upon Tenant&#146;s representations, warranties, acknowledgments and agreements contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B>Rent</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Base
Rent</B>. The first month&#146;s Base Rent and the Security Deposit shall be due and payable on delivery of an executed copy of this Lease to Landlord. Tenant shall pay to Landlord in advance, without demand, abatement, deduction or <FONT
STYLE="white-space:nowrap">set-off,</FONT> equal monthly installments of Base Rent on or before the first day of each calendar month during the Term hereof, in lawful money of the United States of America, at the office of Landlord for payment of
Rent set forth above, or to such other person or at such other place as Landlord may from time to time designate in writing. Payments of Base Rent for any fractional calendar month shall be prorated. The obligation of Tenant to pay Base Rent and
other sums to Landlord and the obligations of Landlord under this Lease are independent obligations. Tenant shall have no right at any time to abate, reduce, or <FONT STYLE="white-space:nowrap">set-off</FONT> any Rent (as defined in
<U>Section</U><U></U><U>&nbsp;5</U>) due hereunder except for any abatement as may be expressly provided in this Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Additional
Rent</B>. In addition to Base Rent, Tenant agrees to pay to Landlord as additional rent (&#147;<B>Additional Rent</B>&#148;): (i) commencing on the Commencement Date, Tenant&#146;s Share of &#147;Operating Expenses&#148; (as defined in
<U>Section</U><U></U><U>&nbsp;5</U>), and (ii)&nbsp;any and all other amounts Tenant assumes or agrees to pay under the provisions of this Lease, including, without limitation, any and all other sums that may become due by reason of any default of
Tenant or failure to comply with the agreements, terms, covenants and conditions of this Lease to be performed by Tenant, after any applicable notice and cure period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B>Base Rent Adjustments</B>. Base Rent shall be increased on each annual anniversary of the first day of the first full month during the
Term of this Lease (each an &#147;<B>Adjustment Date</B>&#148;) by multiplying the Base Rent payable immediately before such Adjustment Date by the Rent Adjustment Percentage and adding the resulting amount to the Base Rent payable immediately
before such Adjustment Date. Base Rent, as so adjusted, shall thereafter be due as provided herein. Base Rent adjustments for any fractional calendar month shall be prorated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
4<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <B>Operating Expense Payments</B>. Landlord shall deliver to Tenant a written estimate of
Operating Expenses for each calendar year during the Term (the &#147;<B>Annual Estimate</B>&#148;), which may be revised by Landlord from time to time during such calendar year. Commencing on the Commencement Date and continuing thereafter on the
first day of each month during the Term, Tenant shall pay Landlord an amount equal to 1/12th of Tenant&#146;s Share of the Annual Estimate. Payments for any fractional calendar month shall be prorated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;<B>Operating Expenses</B>&#148; means all costs and expenses of any kind or description whatsoever incurred or accrued each
calendar year by Landlord with respect to the Project (including, without duplication, Taxes (as defined in <U>Section</U><U></U><U>&nbsp;9</U>), capital repairs and improvements amortized over the lesser of 10 years and the useful life of such
capital items, the cost of amenities available to tenants of the Project, and the costs of Landlord&#146;s third party property manager (not to exceed $1.00 per rentable square foot of the Premises per year) or, if there is no third party property
manager, administration rent in the amount of $1.00 per rentable square foot of the Premises per year), excluding only: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the original
construction costs of the Project and renovation prior to the date of the Lease and costs of correcting defects in such original construction or renovation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) capital expenditures for expansion of the Project; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) interest, principal payments of Mortgage (as defined in <U>Section</U><U></U><U>&nbsp;27</U>) debts of Landlord, financing costs and
amortization of funds borrowed by Landlord, whether secured or unsecured; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) depreciation of the Project (except for capital
improvements, the cost of which are includable in Operating Expenses); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) advertising, legal and space planning expenses and leasing
commissions and other costs and expenses incurred in procuring and leasing space to tenants for the Project, including any leasing office maintained in the Project, free rent and construction allowances for tenants; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) legal and other expenses incurred in the negotiation or enforcement of leases; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) completing, fixturing, improving, renovating, painting, redecorating or other work, which Landlord pays for or performs for other tenants
within their premises, and costs of correcting defects in such work; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) costs to be reimbursed by other tenants of the Project or Taxes
to be paid directly by Tenant or other tenants of the Project, whether or not actually paid; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) salaries, wages, benefits and other
compensation paid to (i)&nbsp;personnel of Landlord or its agents or contractors above the position of the person, regardless of title, who has <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management
responsibility for the Project or (ii)&nbsp;officers and employees of Landlord or its affiliates who are not assigned in whole or in part to the operation, management, maintenance or repair of the Project; provided, however, that with respect to any
such person who does not devote substantially all of his or her employed time to the Project, the salaries, wages, benefits and other compensation of such person shall be prorated to reflect time spent on matters related to operating, managing,
maintaining or repairing the Project in comparison to the time spent on matters unrelated to operating, managing, maintaining or repairing the Project; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) general organizational, administrative and overhead costs relating to maintaining Landlord&#146;s existence, either as a corporation,
partnership, or other entity, including general corporate, legal and accounting expenses; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) costs (including attorneys&#146; fees and
costs of settlement, judgments and payments in lieu thereof) incurred in connection with disputes with tenants, other occupants, or prospective tenants, and costs and expenses, including legal fees, incurred in connection with negotiations or
disputes with employees, consultants, management agents, leasing agents, purchasers or mortgagees of the Building; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
5<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) costs incurred by Landlord due to the violation by Landlord, its employees, agents or
contractors or any tenant of the terms and conditions of any lease of space in the Project or any Legal Requirement (as defined in <U>Section</U><U></U><U>&nbsp;7</U>); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) penalties, fines or interest incurred as a result of Landlord&#146;s inability or failure to make payment of Taxes and/or to file any tax
or informational returns when due, or from Landlord&#146;s failure to make any payment of Taxes required to be made by Landlord hereunder before delinquency; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) overhead and profit increment paid to Landlord or to subsidiaries or affiliates of Landlord for goods and/or services in or to the Project
to the extent the same exceeds the costs of such goods and/or services rendered by unaffiliated third parties on a competitive basis; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)
costs of Landlord&#146;s charitable or political contributions, or of fine art maintained at the Project; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) costs in connection with
services (including electricity), items or other benefits of a type which are not standard for the Project and which are not available to Tenant without specific charges therefor, but which are provided to another tenant or occupant of the Project,
whether or not such other tenant or occupant is specifically charged therefor by Landlord; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) costs incurred in the sale or refinancing
of the Project; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) net income taxes of Landlord or the owner of any interest in the Project, franchise, capital stock, gift, estate or
inheritance taxes or any federal, state or local documentary taxes imposed against the Project or any portion thereof or interest therein; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) any expenses otherwise includable within Operating Expenses to the extent actually reimbursed by persons other than tenants of the Project
under leases for space in the Project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within 90 days after the end of each calendar year (or such longer period as may be reasonably
required), Landlord shall furnish to Tenant a statement (an &#147;<B>Annual Statement</B>&#148;) showing in reasonable detail: (a)&nbsp;the total and Tenant&#146;s Share of actual Operating Expenses for the previous calendar year, and (b)&nbsp;the
total of Tenant&#146;s payments in respect of Operating Expenses for such year. If Tenant&#146;s Share of actual Operating Expenses for such year exceeds Tenant&#146;s payments of Operating Expenses for such year, the excess shall be due and payable
by Tenant as Rent within 30 days after delivery of such Annual Statement to Tenant. If Tenant&#146;s payments of Operating Expenses for such year exceed Tenant&#146;s Share of actual Operating Expenses for such year Landlord shall pay the excess to
Tenant within 30 days after delivery of such Annual Statement, except that after the expiration, or earlier termination of the Term or if Tenant is delinquent in its obligation to pay Rent, Landlord shall pay the excess to Tenant after deducting all
other amounts due Landlord. Landlord&#146;s and Tenant&#146;s obligations to pay any overpayments or deficiencies due pursuant to this paragraph shall survive the expiration or earlier termination of this Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Annual Statement shall be final and binding upon Tenant unless Tenant, within 90 days after Tenant&#146;s receipt thereof, shall contest
any item therein by giving written notice to Landlord, specifying each item contested and the reason therefor. If, during such 90 day period, Tenant reasonably and in good faith questions or contests the accuracy of Landlord&#146;s statement of
Tenant&#146;s Share of Operating Expenses, Landlord will provide Tenant with access to Landlord&#146;s books and records relating to the operation of the Project and such information as Landlord reasonably determines to be responsive to
Tenant&#146;s questions (the &#147;<B>Expense Information</B>&#148;).<I> </I>If after Tenant&#146;s review of such Expense Information, Landlord and Tenant cannot agree upon the amount of Tenant&#146;s Share of Operating Expenses, then Tenant shall
have the right to have an independent public accounting firm selected by Tenant from among the 4 largest in the United States, working pursuant to a fee arrangement other than a contingent fee (at Tenant&#146;s sole cost and expense) and approved by
Landlord (which approval shall not be unreasonably withheld or delayed), audit and/or review the Expense Information for the year in question </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
6<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(the &#147;<B>Independent Review</B>&#148;). The results of any such Independent Review shall be binding upon Landlord and Tenant. If the Independent Review shows that the payments actually made
by Tenant with respect to Operating Expenses for the calendar year in question exceeded Tenant&#146;s Share of Operating Expenses for such calendar year, Landlord shall at Landlord&#146;s option either (i)&nbsp;credit the excess amount to the next
succeeding installments of estimated Operating Expenses or (ii)&nbsp;pay the excess to Tenant within 30 days after delivery of such statement, except that after the expiration or earlier termination of this Lease or if Tenant is delinquent in its
obligation to pay Rent, Landlord shall pay the excess to Tenant after deducting all other amounts due Landlord. If the Independent Review shows that Tenant&#146;s payments with respect to Operating Expenses for such calendar year were less than
Tenant&#146;s Share of Operating Expenses for the calendar year, Tenant shall pay the deficiency to Landlord within 30 days after delivery of such statement. If the Independent Review shows that Tenant has overpaid with respect to Operating Expenses
by more than 5% then Landlord shall reimburse Tenant for all costs incurred by Tenant for the Independent Review.<I> </I>Operating Expenses for the calendar years in which Tenant&#146;s obligation to share therein begins and ends shall be prorated.
Notwithstanding anything set forth herein to the contrary, if the Project<B> </B>is not at least 95% occupied on average during any year of the Term, Tenant&#146;s Share of Operating Expenses for such year shall be computed as though the Project<B>
</B>had been 95% occupied on average during such year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tenant&#146;s Share</B>&#148; shall be the percentage set forth on the
first page of this Lease as Tenant&#146;s Share as reasonably adjusted by Landlord for changes in the physical size of the Premises or the Project occurring thereafter. Landlord may equitably increase Tenant&#146;s Share for any item of expense or
cost reimbursable by Tenant that relates to a repair, replacement, or service that benefits only the Premises or only a portion of the Project that includes the Premises or that varies with occupancy or use. Base Rent, Tenant&#146;s Share of
Operating Expenses and all other amounts payable by Tenant to Landlord hereunder are collectively referred to herein as &#147;<B>Rent</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B>Security Deposit</B>. Tenant shall deposit with Landlord, upon delivery of an executed copy of this Lease to Landlord, a security
deposit (the &#147;<B>Security Deposit</B>&#148;) for the performance of all of Tenant&#146;s obligations hereunder in the amount set forth on page 1 of this Lease, which Security Deposit shall be in the form of an unconditional and irrevocable
letter of credit (the &#147;<B>Letter of Credit</B>&#148;): (i) in form and substance reasonably satisfactory to Landlord, (ii)&nbsp;naming Landlord as beneficiary, (iii)&nbsp;expressly allowing Landlord to draw upon it at any time from time to time
by delivering to the issuer notice that Landlord is entitled to draw thereunder, (iv)&nbsp;issued by an FDIC-insured financial institution satisfactory to Landlord, and (v)&nbsp;redeemable by presentation of a sight draft in the Commonwealth of
Massachusetts. If Tenant does not provide Landlord with a substitute Letter of Credit complying with all of the requirements hereof at least 10 days before the stated expiration date of any then current Letter of Credit, Landlord shall have the
right to draw the full amount of the current Letter of Credit and hold the funds drawn in cash without obligation for interest thereon as the Security Deposit. The Security Deposit shall be held by Landlord as security for the performance of
Tenant&#146;s obligations under this Lease. The Security Deposit is not an advance rental deposit or a measure of Landlord&#146;s damages in case of Tenant&#146;s default. Upon each occurrence of a Default (as defined in
<U>Section</U><U></U><U>&nbsp;20</U>), Landlord may use all or any part of the Security Deposit to pay delinquent payments due under this Lease, future rent damages, and the cost of any damage, injury, expense or liability caused by such Default,
without prejudice to any other remedy provided herein or provided by law. Landlord&#146;s right to use the Security Deposit under this <U>Section</U><U></U><U>&nbsp;6</U> includes the right to use the Security Deposit to pay future rent damages
following the termination of this Lease pursuant to <U>Section</U><U></U><U>&nbsp;21(c)</U> below. Upon any use of all or any portion of the Security Deposit, Tenant shall pay Landlord on demand the amount that will restore the Security Deposit to
the amount set forth on Page 1 of this Lease. Tenant hereby waives the provisions of any law, now or hereafter in force which provide that Landlord may claim from a security deposit only those sums reasonably necessary to remedy defaults in the
payment of Rent, to repair damage caused by Tenant or to clean the Premises, it being agreed that Landlord may, in addition, claim those sums reasonably necessary to compensate Landlord for any other loss or damage, foreseeable or unforeseeable,
caused by the act or omission of Tenant or any officer, employee, agent or invitee of Tenant. Upon bankruptcy or other debtor-creditor proceedings against Tenant, the Security Deposit shall be deemed to be applied first to the payment of Rent and
other charges due Landlord for periods prior to the filing of such proceedings. If Tenant shall fully perform every provision of this Lease to be performed by Tenant, the Security Deposit, or any balance thereof (i.e., after deducting therefrom all
amounts to which Landlord is entitled under the provisions of this Lease), shall be returned to Tenant (or, at Landlord&#146;s option, to the last assignee of Tenant&#146;s interest hereunder) within 60 days after the expiration or earlier
termination of this Lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
7<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Landlord transfers its interest in the Project or this Lease, Landlord shall either
(a)&nbsp;transfer any Security Deposit then held by Landlord to a person or entity assuming Landlord&#146;s obligations under this <U>Section</U><U></U><U>&nbsp;6</U>, or (b)&nbsp;return to Tenant any Security Deposit then held by Landlord and
remaining after the deductions permitted herein. Upon such transfer to such transferee or the return of the Security Deposit to Tenant, Landlord shall have no further obligation with respect to the Security Deposit, and Tenant&#146;s right to the
return of the Security Deposit shall apply solely against Landlord&#146;s transferee. The Security Deposit is not an advance rental deposit or a measure of Landlord&#146;s damages in case of Tenant&#146;s default. Landlord&#146;s obligation
respecting the Security Deposit is that of a debtor, not a trustee, and no interest shall accrue thereon.<I> </I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <B>Use</B>. The
Premises shall be used solely for the Permitted Use set forth in the basic lease provisions on page 1 of this Lease, and in compliance with all laws, orders, judgments, ordinances, regulations, codes, directives, permits, licenses, covenants and
restrictions now or hereafter applicable to the Premises, and to the use and occupancy thereof, including, without limitation, the Americans With Disabilities Act, 42 U.S.C. &#167; 12101, et seq. (together with the regulations promulgated pursuant
thereto, &#147;<B>ADA</B>&#148;) (collectively, &#147;<B>Legal Requirements</B>&#148; and each, a &#147;<B>Legal Requirement</B>&#148;). Tenant shall, upon 5 days&#146; written notice from Landlord, discontinue any use of the Premises which is
declared by any Governmental Authority (as defined in <U>Section</U><U></U><U>&nbsp;9</U>) having jurisdiction to be a violation of a Legal Requirement. Tenant will not use or permit the Premises to be used for any purpose or in any manner that
would void Tenant&#146;s or Landlord&#146;s insurance, increase the insurance risk, or cause the disallowance of any sprinkler or other credits. The use that Tenant has disclosed to Landlord that Tenant will be making of the Premises as of the
Commencement Date will not result in the voidance of or an increased insurance risk or cause the disallowance of any sprinkler or other credits with respect to the insurance currently being maintained by Landlord. Tenant shall not permit any part of
the Premises to be used as a &#147;place of public accommodation&#148;, as defined in the ADA or any similar legal requirement. Tenant shall reimburse Landlord promptly upon demand for any additional premium charged for any such insurance policy by
reason of Tenant&#146;s failure to comply with the provisions of this Section or otherwise caused by Tenant&#146;s use and/or occupancy of the Premises. Tenant will use the Premises in a careful, safe and proper manner and will not commit or permit
waste, overload the floor or structure of the Premises, subject the Premises to use that would damage the Premises or obstruct or interfere with the rights of Landlord or other tenants or occupants of the Project, including conducting or giving
notice of any auction, liquidation, or going out of business sale on the Premises, or using or allowing the Premises to be used for any unlawful purpose. Tenant shall cause any equipment or machinery to be installed in the Premises so as to
reasonably prevent sounds or vibrations from the Premises from extending into Common Areas, or other space in the Project. Tenant shall not place any machinery or equipment weighing 500 pounds or more in or upon the Premises or transport or move
such items through the Common Areas of the Project or in the Project elevators without the prior written consent of Landlord. Except as may be provided under the Work Letter, Tenant shall not, without the prior written consent of Landlord, use the
Premises in any manner which will require ventilation, air exchange, heating, gas, steam, electricity or water beyond the existing capacity of the Project as proportionately allocated to the Premises based upon Tenant&#146;s Share as usually
furnished for the Permitted Use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Landlord shall be responsible for the compliance of the Premises and the Common Areas of the Project
with Legal Requirements as of the Commencement Date. Following the Commencement Date, Landlord shall, as an Operating Expense (to the extent such Legal Requirement is generally applicable to similar buildings in the area in which the Project is
located) and at Tenant&#146;s expense (to the extent such Legal Requirement is triggered by reason of Tenant&#146;s, as compared to other tenants of the Project, specific use of the Premises or Tenant&#146;s Alterations) make any alterations or
modifications to the Common Areas or the exterior of the Building that are required by Legal Requirements.<B> </B>Following the Commencement Date, except as provided in the 2 immediately preceding sentences, Tenant, at its sole expense, shall make
any alterations or modifications to the interior or the exterior of the Premises or the Project that are required by Legal Requirements (including, without limitation, compliance of the Premises </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
8<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the ADA) related to Tenant&#146;s specific use or occupancy of the Premises. Notwithstanding any other provision herein to the contrary, Tenant shall be responsible for any and all demands,
claims, liabilities, losses, costs, expenses, actions, causes of action, damages or judgments, and all reasonable expenses incurred in investigating or resisting the same (including, without limitation, reasonable attorneys&#146; fees, charges and
disbursements and costs of suit) (collectively, &#147;<B>Claims</B>&#148;) arising out of or in connection with Legal Requirements related to Tenant&#146;s specific use or occupancy of the Premises or Tenant&#146;s Alterations, and Tenant shall
indemnify, defend, hold and save Landlord harmless from and against any and all Claims arising out of or in connection with any failure of the Premises to comply with any Legal Requirement related to Tenant&#146;s specific use or occupancy of the
Premises or Tenant&#146;s Alterations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <B>Holding Over</B>. If, with Landlord&#146;s express written consent, Tenant retains
possession of the Premises after the termination of the Term, (i)&nbsp;unless otherwise agreed in such written consent, such possession shall be subject to immediate termination by Landlord at any time, (ii)&nbsp;all of the other terms and
provisions of this Lease (including, without limitation, the adjustment of Base Rent pursuant to <U>Section</U><U></U><U>&nbsp;4</U> hereof) shall remain in full force and effect (excluding any expansion or renewal option or other similar right or
option) during such holdover period, (iii)&nbsp;Tenant shall continue to pay Base Rent in the amount payable upon the date of the expiration or earlier termination of this Lease or such other amount as Landlord may indicate, in Landlord&#146;s sole
and absolute discretion, in such written consent, and (iv)&nbsp;all other payments shall continue under the terms of this Lease. If Tenant remains in possession of the Premises after the expiration or earlier termination of the Term without the
express written consent of Landlord, (A)&nbsp;Tenant shall become a tenant at sufferance upon the terms of this Lease except that the monthly rental shall be equal to 150% of Rent in effect during the last 30 days of the Term, and (B)&nbsp;Tenant
shall be responsible for all damages suffered by Landlord resulting from or occasioned by Tenant&#146;s holding over, including consequential damages; provided, however, that if Tenant delivers a written inquiry to Landlord within 30 days prior to
the expiration or earlier termination of the Term, Landlord will notify Tenant whether the potential exists for consequential damages. No holding over by Tenant, whether with or without consent of Landlord, shall operate to extend this Lease except
as otherwise expressly provided, and this <U>Section</U><U></U><U>&nbsp;8</U> shall not be construed as consent for Tenant to retain possession of the Premises. Acceptance by Landlord of Rent after the expiration of the Term or earlier termination
of this Lease shall not result in a renewal or reinstatement of this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <B>Taxes</B>. Landlord shall pay, as part of Operating
Expenses, all taxes, levies, fees, assessments and governmental charges of any kind, existing as of the Commencement Date or thereafter enacted with respect to the Project (collectively referred to as &#147;<B>Taxes</B>&#148;), imposed by any
federal, state, regional, municipal, local or other governmental authority or agency, including, without limitation, quasi-public agencies (collectively, &#147;<B>Governmental Authority</B>&#148;) during the Term, including, without limitation, all
Taxes: (i)&nbsp;imposed on or measured by or based, in whole or in part, on rent payable to (or gross receipts received by) Landlord under this Lease and/or from the rental by Landlord of the Project or any portion thereof, or (ii)&nbsp;based on the
square footage, assessed value or other measure or evaluation of any kind of the Premises or the Project, or (iii)&nbsp;assessed or imposed by or on the operation or maintenance of any portion of the Premises or the Project, including parking, or
(iv)&nbsp;assessed or imposed by, or at the direction of, or resulting from Legal Requirements, or interpretations thereof, promulgated by any Governmental Authority, or (v)&nbsp;imposed as a license or other fee, charge, tax, or assessment on
Landlord&#146;s business or occupation of leasing space in the Project. Landlord may contest by appropriate legal proceedings the amount, validity, or application of any Taxes or liens securing Taxes. Taxes shall not include any net income taxes
imposed on Landlord or any franchise, capital stock, gift, estate or inheritance taxes or any federal, state or local documentary taxes imposed against the Project or any portion thereof or interest therein. If any such Tax is levied or assessed
directly against Tenant, then Tenant shall be responsible for and shall pay the same at such times and in such manner as the taxing authority shall require. Tenant shall pay, prior to delinquency, any and all Taxes levied or assessed against any
personal property or trade fixtures placed by Tenant in the Premises, whether levied or assessed against Landlord or Tenant. If any Taxes on Tenant&#146;s personal property or trade fixtures are levied against Landlord or Landlord&#146;s property,
or if the assessed valuation of the Project is increased by a value attributed by the taxing authority to improvements in or alterations to the Premises, whether owned by Landlord or Tenant and whether or not affixed to the real property so as to
become a part thereof, higher than the base valuation on which Landlord from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> allocates Taxes to all tenants in the Project, Landlord shall have the right,
but not the obligation, to pay such Taxes. Landlord&#146;s determination of any excess assessed valuation shall be binding and conclusive, absent manifest error. The amount of any such payment by Landlord shall constitute Additional Rent due from
Tenant to Landlord immediately upon demand. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
9<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <B>Parking</B>. Subject to all matters of record, Force Majeure, a Taking (as defined in
<U>Section</U><U></U><U>&nbsp;19</U> below) and the exercise by Landlord of its rights hereunder, Tenant shall have the right, at no additional charge, in common with other tenants of the Project pro rata in accordance with the rentable area of the
Premises and the rentable areas of the Project occupied by such other tenants, to park in those areas designated for <FONT STYLE="white-space:nowrap">non-reserved</FONT> parking, subject in each case to Landlord&#146;s rules and regulations (which
rules and regulations shall not be enforced in a discriminatory manner). As of the Commencement Date, Tenant&#146;s pro rata share of parking is equal to 3.2 parking spaces per 1,000 rentable square feet of the Premises. Landlord may allocate
parking spaces among Tenant and other tenants in the Project pro rata as described above if Landlord determines that such parking facilities are becoming crowded. Landlord shall not be responsible for enforcing Tenant&#146;s parking rights against
any third parties, including other tenants of the Project. Landlord shall in no event grant rights to other tenants of the Project to use more parking spaces in the surface parking lot than, together with the spaces allocated to Tenant pursuant to
this <U>Section</U><U></U><U>&nbsp;10</U>, are available for use by tenants of the Project in the surface parking lot. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <B>Utilities,
Services</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>General</B>. Landlord shall provide, subject to the terms of this <U>Section</U><U></U><U>&nbsp;11</U>, water,
electricity, HVAC, light, power, sewer and other utilities (including gas and fire sprinklers to the extent the Project is plumbed for such services), refuse and trash collection and janitorial services (collectively, &#147;<B>Utilities</B>&#148;).
Landlord shall pay, as Operating Expenses or subject to Tenant&#146;s reimbursement obligation, for all Utilities used on the Premises, all maintenance charges for Utilities, and any storm sewer charges or other similar charges for Utilities imposed
by any Governmental Authority or Utility provider, and any taxes, penalties, surcharges or similar charges thereon. The Premises shall be separately metered to measure Tenant&#146;s usage of electricity for lights and plugs in the Premises. Landlord
may cause, at Landlord&#146;s expense, any Utilities to be separately metered or charged directly to Tenant by the provider. Tenant shall pay directly to the Utility provider, prior to delinquency, any separately metered Utilities and services which
may be furnished to Tenant or the Premises during the Term. Tenant shall pay, as part of Operating Expenses, its share of all charges for jointly metered Utilities based upon consumption, as reasonably determined by Landlord. No interruption or
failure of Utilities, from any cause whatsoever other than Landlord&#146;s willful misconduct, shall result in eviction or constructive eviction of Tenant, termination of this Lease or, except as expressly set forth in the immediately following
paragraph, the abatement of Rent. Tenant agrees to limit use of water and sewer with respect to Common Areas to normal restroom use.<I> </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary set forth herein, if (i)&nbsp;a stoppage of an Essential Service (as defined below) to the Premises
shall occur and such stoppage is due solely to the gross negligence or willful misconduct of Landlord and not due in any part to any act or omission on the part of Tenant or any Tenant Party or any matter beyond Landlord&#146;s reasonable control
(any such stoppage of an Essential Service being hereinafter referred to as a &#147;<B>Service Interruption</B>&#148;), and (ii)&nbsp;such Service Interruption continues for more than 5 consecutive business days after Landlord shall have received
written notice thereof from Tenant, and (iii)&nbsp;as a result of such Service Interruption, the conduct of Tenant&#146;s normal operations in the Premises are materially and adversely affected, then there shall be an abatement of one day&#146;s
Base Rent for each day during which such Service Interruption continues after such 5 business day period; provided, however, that if any part of the Premises is reasonably useable for Tenant&#146;s normal business operations or if Tenant conducts
all or any part of its operations in any portion of the Premises notwithstanding such Service Interruption, then the amount of each daily abatement of Base Rent shall only be proportionate to the nature and extent of the interruption of
Tenant&#146;s normal operations or ability to use the Premises. The rights granted to Tenant under this paragraph shall be Tenant&#146;s sole and exclusive remedy resulting from a failure of Landlord to provide services, and Landlord shall not
otherwise be liable for any loss or damage suffered or sustained by Tenant resulting from any failure or cessation of services. For purposes hereof, the term &#147;<B>Essential Services</B>&#148; shall mean the following services: HVAC service,
water, sewer and electricity, but in each case only to the extent that Landlord has an obligation to provide same to Tenant under this Lease. The provisions of this paragraph shall only apply as long as the original Tenant is the tenant occupying
the Premises under this Lease and shall not apply to any assignee or sublessee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
10<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Emergency Generator</B>. Landlord&#146;s sole obligation for either providing
emergency generators or providing emergency <FONT STYLE="white-space:nowrap">back-up</FONT> power to Tenant shall be: (i)&nbsp;to provide emergency generators with not less than the capacity to provide 4 watts of electricity per rentable square foot
of the Premises, and (ii)&nbsp;to contract with a third party deemed by Landlord to be reputable to maintain the emergency generators as per the manufacturer&#146;s standard maintenance guidelines. Notwithstanding anything to the contrary contained
herein, Landlord shall, at least once per month as part of the maintenance of the Building, run the emergency generator for a period reasonably determined by Landlord for the purpose of determining whether it operates when started. Landlord shall,
upon written request from Tenant, make available the maintenance contract and maintenance records for the emergency generators for the 12 month period immediately preceding Landlord&#146;s receipt of Tenant&#146;s written request. Landlord shall
have no obligation to supervise, oversee or confirm that the third party maintaining the emergency generators is maintaining the generators as per the manufacturer&#146;s standard guidelines or otherwise. During any period of replacement, repair or
maintenance of the emergency generators when the emergency generators are not operational, including any delays thereto due to the inability to obtain parts or replacement equipment, Landlord shall have no obligation to provide Tenant with an
alternative <FONT STYLE="white-space:nowrap">back-up</FONT> generator or generators or alternative sources of <FONT STYLE="white-space:nowrap">back-up</FONT> power. Tenant expressly acknowledges and agrees that Landlord does not guaranty that such
emergency generators will be operational at all times or that emergency power will be available to the Premises when needed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
<B>Compressed Air and Vacuum</B>. Landlord&#146;s sole obligation for either providing compressed air and vacuum systems to Tenant shall be to contract with a third party to maintain the compressed air and vacuum systems as per the
manufacturer&#146;s standard maintenance guidelines. Notwithstanding anything to the contrary contained herein, Landlord shall, at least once per month as part of the maintenance of the Building, run the compressed air and vacuum systems for a
period reasonably determined by Landlord for the purpose of determining whether it operates when started. Landlord shall have no obligation to supervise, oversee or confirm that the third party maintaining the compressed air and vacuum systems is
maintaining the compressed air and vacuum systems as per the manufacturer&#146;s standard guidelines or otherwise. During any period of replacement, repair or maintenance of the compressed air and vacuum systems when the compressed air and vacuum
systems are not operational, including any delays thereto due to the inability to obtain parts or replacement equipment, Landlord shall have no obligation to provide Tenant with an alternative compressed air and vacuum systems. Tenant expressly
acknowledges and agrees that Landlord does not guaranty that such compressed air and vacuum systems will be operational at all times or that compressed air and vacuum systems will be available to the Premises when needed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Freight Elevator/Loading Dock</B>. Tenant may use the freight elevator and loading dock in common with others entitled thereto at no
additional charge. The regular hours of operation of the freight elevator and loading dock are 24 hours per day, 7 days per week, subject to downtime for maintenance and repairs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>Acid Neutralization System</B>. During the Term, Landlord shall provide Tenant with access to and use of the acid neutralization system
existing as of the date of this Lease (&#147;<B>Acid Neutralization System</B>&#148;) pursuant to the terms and conditions of this Lease. Tenant acknowledges and agrees that the Acid Neutralization System shall be shared with other tenants of the
Project. Tenant&#146;s obligation to pay its share of ongoing operation costs shall be allocated among Tenant and other user tenants on a pro rata basis, with Tenant&#146;s share based on the ratio of the rentable square footage of the Premises to
the sum of the rentable square footages of the Premises and the premises of all other user tenants. Landlord&#146;s sole obligations for providing the Acid Neutralization System, or any acid neutralization system facilities, to Tenant shall be (the
&#147;<B>Acid Neutralization Obligations</B>&#148;) to (i)&nbsp;use commercially reasonable efforts to obtain and maintain the permit required from the Massachusetts Water Resources Authority for discharge through the Acid Neutralization System (the
&#147;<B>Discharge Permit</B>&#148;), </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
11<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provided that Tenant cooperates with Landlord and provides all information and documents necessary in connection with the Discharge Permit, and (ii)&nbsp;contract with a third party to maintain
the Acid Neutralization System as operating as per the manufacturer&#146;s standard maintenance guidelines. Notwithstanding anything herein to the contrary, if the Acid Neutralization System must be replaced and the cost thereof is not included in
such third party maintenance contract, then, Landlord shall replace the Acid Neutralization System, it being acknowledged, however, that Tenant shall be responsible for its share of all costs incurred in connection as an Operating Expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant shall be solely responsible for the use of the Acid Neutralization System by Tenant, its employees, any sublessees, invitees or any
party other than Landlord or Landlord&#146;s contractors, and Tenant shall be jointly and severally responsible for the use of the Acid Neutralization System with the other user tenants. Tenant shall use, and cause other parties under its control or
for which it is responsible to use, the Acid Neutralization System in accordance with this Lease and in accordance with all applicable Legal Requirements, the Discharge Permit and any permits and approvals from Governmental Authorities for or
applicable to Tenant&#146;s use of the Acid Neutralization System. Tenant shall not take any action or make any omission that would result in a violation of the Discharge Permit or any other permit or Legal Requirements applicable to the Acid
Neutralization System. The scope of the Surrender Plan (as defined in <U>Section</U><U></U><U>&nbsp;28</U> of this Lease) shall include all actions for the proper cleaning, decommissioning and cessation of Tenant&#146;s use of the Acid
Neutralization System, and all requirements under this Lease for the surrender of the Premises shall also apply to Tenant&#146;s cessation of use of the Acid Neutralization System, in each case whether at Lease expiration, termination or prior
thereto (but Tenant shall not be required to complete the decommissioning of the Acid Neutralization System if other tenants or occupants will continue to use the same after the expiration or earlier termination of the Lease, nor shall Tenant be
responsible for or bear any costs of decommissioning arising from the use of the Acid Neutralization System by any party other than Tenant; it being agreed that if multiple tenants use the Acid Neutralization System, then Landlord shall be
responsible for completing the decommissioning thereof, and Tenant shall pay to Landlord within thirty (30)&nbsp;days after invoice therefor Tenant&#146;s share of the reasonable, actual costs of decommissioning based on the ratio of the rentable
square footage of the Premises to the rentable square footage of the Premises and the premises of all other user tenants). The obligations of Tenant under this Lease with respect to the Acid Neutralization System shall be joint and several with such
other tenants as aforesaid, except in the event that Tenant can provide evidence to Landlord&#146;s reasonable satisfaction that neither Tenant nor any Tenant Party caused, contributed to or exacerbated the matter for which Tenant would otherwise be
responsible but for this exception. Without in any way limiting the Acid Neutralization Obligations, Landlord shall have no obligation to provide Tenant with operational emergency or <FONT STYLE="white-space:nowrap">back-up</FONT> acid
neutralization facilities or to supervise, oversee or confirm that the third party maintaining the Acid Neutralization System is maintaining such system as per the manufacturer&#146;s standard guidelines or otherwise. During any period of
replacement, repair or maintenance of the Acid Neutralization System when such system is not operational, including any delays thereto due to the inability to obtain parts or replacement equipment, Landlord shall have no obligation to provide Tenant
with an alternative <FONT STYLE="white-space:nowrap">back-up</FONT> system or facilities. Tenant expressly acknowledges and agrees that Landlord does not guaranty that such Acid Neutralization System will be operational at all times or that such
system will be available to the Premises when needed. Without in any way limiting the Acid Neutralization Obligations, in no event shall Landlord be liable to Tenant or any other party for any damages of any type, whether actual or consequential,
suffered by Tenant or any such other person in the event that the Acid Neutralization System or <FONT STYLE="white-space:nowrap">back-up</FONT> system, if any, or any replacement thereof fails or does not operate in a manner that meets Tenant&#146;s
requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <B>Alterations and Tenant&#146;s Property</B>. Any alterations, additions, or improvements made to the Premises by or
on behalf of Tenant, including additional locks or bolts of any kind or nature upon any doors or windows in the Premises, but excluding installation, removal or realignment of furniture systems (other than removal of furniture systems owned or paid
for by Landlord) not involving any modifications to the structure or connections (other than by ordinary plugs or jacks) to Building Systems (as defined in <U>Section</U><U></U><U>&nbsp;13</U>) (&#147;<B>Alterations</B>&#148;) shall be subject to
Landlord&#146;s prior written consent, which may be given or withheld in Landlord&#146;s sole discretion if any such Alteration affects the structure or Building Systems and shall not be otherwise unreasonably withheld, conditioned or delayed.
Tenant may construct nonstructural, cosmetic Alterations in the Premises without Landlord&#146;s prior approval if the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
12<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
aggregate cost of all such work in any 12 month period does not exceed $50,000 (a &#147;<B>Notice-Only Alteration</B>&#148;), provided Tenant notifies Landlord in writing of such intended
Notice-Only Alteration, and such notice shall be accompanied by plans, specifications, work contracts and such other information concerning the nature and cost of the Notice-Only Alteration as may be reasonably requested by Landlord, which notice
and accompanying materials shall be delivered to Landlord not less than 15 business days in advance of any proposed construction. <I></I>If Landlord approves any Alterations, Landlord may impose such conditions on Tenant in connection with the
commencement, performance and completion of such Alterations as Landlord may deem appropriate in Landlord&#146;s sole and absolute discretion. Any request for approval shall be in writing, delivered not less than 15 business days in advance of any
proposed construction, and accompanied by plans, specifications, bid proposals, work contracts and such other information concerning the nature and cost of the alterations as may be reasonably requested by Landlord, including the identities and
mailing addresses of all persons performing work or supplying materials. Landlord&#146;s right to review plans and specifications and to monitor construction shall be solely for its own benefit, and Landlord shall have no duty to ensure that such
plans and specifications or construction comply with applicable Legal Requirements. Tenant shall cause, at its sole cost and expense, all Alterations to comply with insurance requirements and with Legal Requirements and shall implement at its sole
cost and expense any alteration or modification required by Legal Requirements as a result of any Alterations. Tenant shall pay to Landlord, as Additional Rent, within 30 days of demand an amount equal to Landlord&#146;s reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses for plan review, coordination, scheduling and supervision. Before Tenant begins any Alteration, Landlord may post on and about the Premises notices of <FONT
STYLE="white-space:nowrap">non-responsibility</FONT> pursuant to applicable law. Tenant shall reimburse Landlord for, and indemnify and hold Landlord harmless from, any expense incurred by Landlord by reason of faulty work done by Tenant or its
contractors, delays caused by such work, or inadequate cleanup. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant shall complete all Alterations work free and clear of liens, and
shall provide (and cause each contractor or subcontractor to provide) certificates of insurance for workers&#146; compensation and other coverage in amounts and from an insurance company satisfactory to Landlord protecting Landlord against liability
for personal injury or property damage during construction. Upon completion of any Alterations, Tenant shall deliver to Landlord: (i)&nbsp;sworn statements setting forth the names of all contractors and subcontractors who did the work and final lien
waivers from all such contractors and subcontractors; and (ii) &#147;as built&#148; plans for any such Alteration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for Removable
Installations (as hereinafter defined), all Installations (as hereinafter defined) shall be and shall remain the property of Landlord during the Term and following the expiration or earlier termination of the Term, shall not be removed by Tenant at
any time during the Term, and shall remain upon and be surrendered with the Premises as a part thereof. Notwithstanding the foregoing, Landlord may, at the time its approval of any such Installation is requested, or at the time it receives notice of
a Notice Only Alteration, notify Tenant that Landlord requires that Tenant remove such Installation upon the expiration or earlier termination of the Term, in which event Tenant shall remove such Installation in accordance with the immediately
succeeding sentence. Upon the expiration or earlier termination of the Term, Tenant shall remove (i)&nbsp;all wires, cables or similar equipment which Tenant has installed in the Premises or in the risers or plenums of the Building, (ii)&nbsp;any
Installations for which Landlord has given Tenant notice of removal in accordance with the immediately preceding sentence, and (iii)&nbsp;all of Tenant&#146;s Property (as hereinafter defined), and Tenant shall restore and repair any damage caused
by or occasioned as a result of such removal, including, without limitation, capping off all such connections behind the walls of the Premises and repairing any holes. During any restoration period beyond the expiration or earlier termination of the
Term, Tenant shall pay Rent to Landlord as provided herein as if said space were otherwise occupied by Tenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this
Lease, (x) &#147;<B>Removable Installations</B>&#148; means any items listed on <B>Exhibit F</B> attached hereto and any items agreed by Landlord in writing to be included on <B>Exhibit F</B> in the future, (y)&nbsp;&#148;<B>Tenant&#146;s
Property</B>&#148; means Removable Installations and, other than Installations, any personal property or equipment of Tenant that may be removed without material damage to the Premises, and (z)&nbsp;&#148;<B>Installations</B>&#148; means all
property of any kind paid for with the TI Fund, all Alterations, all fixtures, and all partitions, hardware, <FONT STYLE="white-space:nowrap">built-in</FONT> machinery, <FONT STYLE="white-space:nowrap">built-in</FONT> casework and cabinets and other
similar additions, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
13<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
equipment, property and improvements built into the Premises so as to become an integral part of the Premises, including, without limitation, fume hoods which penetrate the roof or plenum area, <FONT
STYLE="white-space:nowrap">built-in</FONT> cold rooms, <FONT STYLE="white-space:nowrap">built-in</FONT> warm rooms, <FONT STYLE="white-space:nowrap">walk-in</FONT> cold rooms, <FONT STYLE="white-space:nowrap">walk-in</FONT> warm rooms, deionized
water systems, glass washing equipment, autoclaves, chillers, <FONT STYLE="white-space:nowrap">built-in</FONT> plumbing, electrical and mechanical equipment and systems, and any power generator and transfer switch. In no event shall Tenant be
required to remove any of Landlord&#146;s Work at the expiration or earlier termination of the Term, and Tenant shall have no right to remove any of Landlord&#146;s Work at any time during the Term or at the expiration or earlier termination of the
Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <B>Landlord&#146;s Repairs</B>. Landlord, as an Operating Expense, shall maintain and repair all of the structural, exterior,
parking and other Common Areas of the Project, including HVAC, plumbing, fire sprinklers, elevators and all other building systems serving the Premises and other portions of the Project (&#147;<B>Building Systems</B>&#148;), in good repair,
reasonable wear and tear and uninsured losses and damages caused by Tenant, or by any of Tenant&#146;s agents, servants, employees, invitees and contractors (collectively, &#147;<B>Tenant Parties</B>&#148;) excluded. Losses and damages caused by
Tenant or any Tenant Party shall be repaired by Landlord, to the extent not covered by insurance, at Tenant&#146;s sole cost and expense. Landlord reserves the right to stop Building Systems services when necessary (i)&nbsp;by reason of accident or
emergency, or (ii)&nbsp;for planned repairs, alterations or improvements, which are, in the judgment of Landlord, desirable or necessary to be made, until said repairs, alterations or improvements shall have been completed. Landlord shall have no
responsibility or liability for failure to supply Building Systems services during any such period of interruption; <U>provided</U>, <U>however</U>, that Landlord shall, except in case of emergency, make a commercially reasonable effort to give
Tenant 48 hours advance notice of any planned stoppage of Building Systems services for routine maintenance, repairs, alterations or improvements. Tenant shall promptly give Landlord written notice of any repair required by Landlord pursuant to this
Section, after which Landlord shall make a commercially reasonable effort to effect such repair within a reasonable timeframe. Landlord shall use reasonable efforts to minimize interference with Tenant&#146;s operations in the Premises during such
planned stoppages of Building Systems. Landlord shall not be liable for any failure to make any repairs or to perform any maintenance unless such failure shall persist for an unreasonable time after Tenant&#146;s written notice of the need for such
repairs or maintenance. Tenant waives its rights under any state or local law to terminate this Lease or to make such repairs at Landlord&#146;s expense and agrees that the parties&#146; respective rights with respect to such matters shall be solely
as set forth herein. Repairs required as the result of fire, earthquake, flood, vandalism, war, or similar cause of damage or destruction shall be controlled by <U>Section</U><U></U><U>&nbsp;18</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <B>Tenant&#146;s Repairs</B>. Subject to <U>Section</U><U></U><U>&nbsp;13</U> hereof, Tenant, at its expense, shall repair, replace and
maintain in good condition all portions of the Premises, including, without limitation, entries, doors, ceilings, interior windows, interior walls, and the interior side of demising walls, reasonable wear and tear and damage by casualty excluded.
Should Tenant fail to make any such repair or replacement or fail to maintain the Premises, Landlord shall give Tenant notice of such failure. If Tenant fails to commence cure of such failure within 30 days of Landlord&#146;s notice, and thereafter
diligently prosecute such cure to completion, Landlord may perform such work and shall be reimbursed by Tenant within 30 days after demand therefor; provided, however, that if such failure by Tenant creates or could create an emergency, Landlord may
immediately commence cure of such failure and shall thereafter be entitled to recover the costs of such cure from Tenant. Subject to <U>Sections 17</U> and <U>18</U>, Tenant shall bear the full uninsured cost of any repair or replacement to any part
of the Project that results from damage caused by Tenant or any Tenant Party and any repair that benefits only the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.
<B>Mechanic&#146;s Liens</B>. Tenant shall discharge, by bond or otherwise, any mechanic&#146;s lien filed against the Premises or against the Project for work claimed to have been done for, or materials claimed to have been furnished to, Tenant
within 15 days after Tenant receives written notice of the filing thereof, at Tenant&#146;s sole cost and shall otherwise keep the Premises and the Project free from any liens arising out of work performed, materials furnished or obligations
incurred by Tenant. Should Tenant fail to discharge any lien described herein, Landlord shall have the right, but not the obligation, to pay such claim or post a bond or otherwise provide security to eliminate the lien as a claim against title to
the Project and the cost thereof shall be immediately due from Tenant as Additional Rent. If Tenant shall lease or finance the acquisition of office equipment, furnishings, or other personal property of a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
14<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
removable nature utilized by Tenant in the operation of Tenant&#146;s business, Tenant warrants that any Uniform Commercial Code Financing Statement filed as a matter of public record by any
lessor or creditor of Tenant will upon its face or by exhibit thereto indicate that such Financing Statement is applicable only to removable personal property of Tenant located within the Premises. In no event shall the address of the Project be
furnished on the statement without qualifying language as to applicability of the lien only to removable personal property, located in an identified suite held by Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <B>Indemnification</B>. Tenant hereby indemnifies and agrees to defend, save and hold Landlord harmless from and against any and all
Claims for injury or death to persons or damage to property occurring within or about the Premises, arising directly or indirectly out of use or occupancy of the Premises or a breach or default by Tenant in the performance of any of its obligations
hereunder, unless caused solely by the willful misconduct or negligence of Landlord.&nbsp;Landlord shall not be liable to Tenant for, and Tenant assumes all risk of damage to, personal property (including, without limitation, loss of records kept
within the Premises).&nbsp;Tenant further waives any and all Claims for injury to Tenant&#146;s business or loss of income relating to any such damage or destruction of personal property (including, without limitation, any loss of
records).&nbsp;Landlord shall not be liable for any damages arising from any act, omission or neglect of any tenant in the Project or of any other third party.<I> </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <B>Insurance</B>. Landlord shall maintain all risk property and, if applicable, sprinkler damage insurance covering the full replacement
cost of the Project. Landlord shall further procure and maintain commercial general liability insurance with a single loss limit of not less than $2,000,000 for bodily injury and property damage with respect to the Project. Landlord may, but is not
obligated to, maintain such other insurance and additional coverages as it may deem necessary, including, but not limited to, flood, environmental hazard and earthquake, loss or failure of building equipment, errors and omissions, rental loss during
the period of repair or rebuilding, workers&#146; compensation insurance and fidelity bonds for employees employed to perform services and insurance for any improvements installed by Tenant or which are in addition to the standard improvements
customarily furnished by Landlord without regard to whether or not such are made a part of the Project. All such insurance shall be included as part of the Operating Expenses. The Project may be included in a blanket policy (in which case the cost
of such insurance allocable to the Project will be determined by Landlord based upon the insurer&#146;s cost calculations). Tenant shall also reimburse Landlord for any increased premiums or additional insurance which Landlord reasonably deems
necessary as a result of Tenant&#146;s specific use of the Premises.<I> </I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant, at its sole cost and expense, shall maintain during
the Term: all risk property insurance with business interruption and extra expense coverage, covering the full replacement cost of all property and improvements installed or placed in the Premises by Tenant at Tenant&#146;s expense; workers&#146;
compensation insurance with no less than the minimum limits required by law; employer&#146;s liability insurance with such limits as required by law; and commercial general liability insurance, with a minimum limit of not less than $2,000,000 per
occurrence for bodily injury and property damage with respect to the Premises. The commercial general liability insurance policy shall name Alexandria Real Estate Equities, Inc., and Landlord, its officers, directors, employees, managers, agents,
invitees and contractors (collectively, &#147;<B>Landlord Parties</B>&#148;), as additional insureds; insure on an occurrence and not a claims-made basis; be issued by insurance companies which have a rating of not less than policyholder rating of A
and financial category rating of at least Class&nbsp;X in &#147;Best&#146;s Insurance Guide&#148;; not contain a hostile fire exclusion; contain a contractual liability endorsement; and provide primary coverage to Landlord (any policy issued to
Landlord providing duplicate or similar coverage shall be deemed excess over Tenant&#146;s policies). Tenant shall (i)&nbsp;provide Landlord with 30 days advance written notice of cancellation of such commercial general liability policy, and
(ii)&nbsp;request Tenant&#146;s insurer to endeavor to provide 30 days advance written notice to Landlord of cancellation of such commercial general liability policy (or 10 days in the event of a cancellation due to
<FONT STYLE="white-space:nowrap">non-payment</FONT> of premium). Copies of such policies (if requested by Landlord), or certificates of insurance showing the limits of coverage required hereunder and showing Landlord as an additional insured, along
with reasonable evidence of the payment of premiums for the applicable period, shall be delivered to Landlord by Tenant prior to (i)&nbsp;the earlier to occur of (x)&nbsp;the Commencement Date, or (y)&nbsp;the date that Tenant accesses the Premises
under this Lease, and (ii)&nbsp;each renewal of said insurance. Tenant&#146;s policy may be a &#147;blanket policy&#148; with an aggregate per location endorsement which specifically provides that the amount of insurance shall not be prejudiced by
other losses covered by the policy. Tenant shall, at least 5 days prior to the expiration of such policies, furnish Landlord with renewal certificates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
15<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In each instance where insurance is to name Landlord as an additional insured, Tenant shall
upon written request of Landlord also designate and furnish certificates so evidencing Landlord as additional insured to: (i)&nbsp;any lender of Landlord holding a security interest in the Project or any portion thereof, (ii)&nbsp;the landlord under
any lease wherein Landlord is tenant of the real property on which the Project is located, if the interest of Landlord is or shall become that of a tenant under a ground or other underlying lease rather than that of a fee owner, and/or
(iii)&nbsp;any management company retained by Landlord to manage the Project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The property insurance obtained by Landlord and Tenant
shall include a waiver of subrogation by the insurers and all rights based upon an assignment from its insured, against Landlord or Tenant, and their respective officers, directors, employees, managers, agents, invitees and contractors
(&#147;<B>Related Parties</B>&#148;), in connection with any loss or damage thereby insured against. Neither party nor its respective Related Parties shall be liable to the other for loss or damage caused by any risk insured against under property
insurance required to be maintained hereunder, and each party waives any claims against the other party, and its respective Related Parties, for such loss or damage. The failure of a party to insure its property shall not void this waiver. Landlord
and its respective Related Parties shall not be liable for, and Tenant hereby waives all claims against such parties for, business interruption and losses occasioned thereby sustained by Tenant or any person claiming through Tenant resulting from
any accident or occurrence in or upon the Premises or the Project from any cause whatsoever. If the foregoing waivers shall contravene any law with respect to exculpatory agreements, the liability of Landlord or Tenant shall be deemed not released
but shall be secondary to the other&#146;s insurer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Landlord may require insurance policy limits to be raised to conform with
requirements of Landlord&#146;s lender and/or to bring coverage limits to levels then being generally required of new tenants within the Project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <B>Restoration</B>. If, at any time during the Term, the Project or the Premises are damaged or destroyed by a fire or other insured
casualty, Landlord shall notify Tenant within 60 days after discovery of such damage as to the amount of time Landlord reasonably estimates it will take to restore the Project or the Premises, as applicable (the &#147;<B>Restoration
Period</B>&#148;). If the Restoration Period is estimated to exceed 9 months (the &#147;<B>Maximum Restoration Period</B>&#148;), Landlord may, in such notice, elect to terminate this Lease as of the date that is 75 days after the date of discovery
of such damage or destruction; <U>provided</U>, <U>however</U>, that notwithstanding Landlord&#146;s election to restore, Tenant may elect to terminate this Lease by written notice to Landlord delivered within 5 business days of receipt of a notice
from Landlord estimating a Restoration Period for the Premises longer than the Maximum Restoration Period. Unless either Landlord or Tenant so elects to terminate this Lease, Landlord shall, subject to receipt of sufficient insurance proceeds (with
any deductible to be treated as a current Operating Expense), promptly restore the Premises (excluding the improvements installed by Tenant or by Landlord and paid for by Tenant), subject to delays arising from the collection of insurance proceeds,
from Force Majeure events or as needed to obtain any license, clearance or other authorization of any kind required to enter into and restore the Premises issued by any Governmental Authority having jurisdiction over the use, storage, handling,
treatment, generation, release, disposal, removal or remediation of Hazardous Materials (as defined in <U>Section</U><U></U><U>&nbsp;30</U>) in, on or about the Premises (collectively referred to herein as &#147;<B>Hazardous Materials
Clearances</B>&#148;); <U>provided</U>, <U>however</U>, that if repair or restoration of the Premises is not substantially complete as of the end of the Maximum Restoration Period or, if longer, the Restoration Period, Landlord may, in its sole and
absolute discretion, elect not to proceed with such repair and restoration, or Tenant may by written notice to Landlord delivered within 5 business days of the expiration of the Maximum Restoration Period or, if longer, the Restoration Period, elect
to terminate this Lease, in which event Landlord shall be relieved of its obligation to make such repairs or restoration and this Lease shall terminate as of the date that is 75 days after the later of: (i)&nbsp;discovery of such damage or
destruction, or (ii)&nbsp;the date all required Hazardous Materials Clearances are obtained, but Landlord shall retain any Rent paid and the right to any Rent payable by Tenant prior to such election by Landlord or Tenant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
16<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tenant, at its expense, shall promptly perform, subject to delays arising from the collection of insurance
proceeds, from Force Majeure (as defined in <U>Section</U><U></U><U>&nbsp;34</U>) events or to obtain Hazardous Material Clearances, all repairs or restoration not required to be done by Landlord and shall promptly
<FONT STYLE="white-space:nowrap">re-enter</FONT> the Premises and commence doing business in accordance with this Lease. Notwithstanding the foregoing, either Landlord or Tenant may terminate this Lease upon written notice to the other if the
Premises are damaged during the last year of the Term and Landlord reasonably estimates that it will take more than 2 months to repair such damage; provided, however, that such notice is delivered within 10 business days after the date that Landlord
provides Tenant with written notice of the estimated Restoration Period. Landlord shall also have the right to terminate this Lease if insurance proceeds are not available for such restoration. Rent shall be abated from the date all required
Hazardous Material Clearances are obtained until the Premises are repaired and restored, in the proportion which the area of the Premises, if any, which is not usable by Tenant bears to the total area of the Premises, unless Landlord provides Tenant
with other space during the period of repair that is suitable for the temporary conduct of Tenant&#146;s business. In the event that no Hazardous Material Clearances are required to be obtained by Tenant with respect to the Premises, rent abatement
shall commence on the date of discovery of the damage or destruction. Such abatement shall be the sole remedy of Tenant, and except as provided in this <U>Section</U><U></U><U>&nbsp;18</U>, Tenant waives any right to terminate the Lease by reason of
damage or casualty loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of this Lease, including this <U>Section</U><U></U><U>&nbsp;18</U>, constitute an express
agreement between Landlord and Tenant with respect to any and all damage to, or destruction of, all or any part of the Premises, or any other portion of the Project, and any statute or regulation which is now or may hereafter be in effect shall have
no application to this Lease or any damage or destruction to all or any part of the Premises or any other portion of the Project, the parties hereto expressly agreeing that this <U>Section</U><U></U><U>&nbsp;18</U> sets forth their entire
understanding and agreement with respect to such matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <B>Condemnation</B>. If the whole or any material part of the Premises or
the Project is taken for any public or quasi-public use under governmental law, ordinance, or regulation, or by right of eminent domain, or by private purchase in lieu thereof (a &#147;<B>Taking</B>&#148; or &#147;<B>Taken</B>&#148;), and the Taking
would in Landlord&#146;s reasonable judgment, either prevent or materially interfere with Tenant&#146;s use of the Premises or materially interfere with or impair Landlord&#146;s ownership or operation of the Project, then upon written notice by
Landlord this Lease shall terminate and Rent shall be apportioned as of said date. If part of the Premises shall be Taken, and this Lease is not terminated as provided above, Landlord shall promptly restore the Premises and the Project as nearly as
is commercially reasonable under the circumstances to their condition prior to such partial Taking and the rentable square footage of the Building, the rentable square footage of the Premises, Tenant&#146;s Share of Operating Expenses and the Rent
payable hereunder during the unexpired Term shall be reduced to such extent as may be fair and reasonable under the circumstances. Upon any such Taking, Landlord shall be entitled to receive the entire price or award from any such Taking without any
payment to Tenant, and Tenant hereby assigns to Landlord Tenant&#146;s interest, if any, in such award. Tenant shall have the right, to the extent that same shall not diminish Landlord&#146;s award, to make a separate claim against the condemning
authority (but not Landlord) for such compensation as may be separately awarded or recoverable by Tenant for moving expenses and damage to Tenant&#146;s trade fixtures, if a separate award for such items is made to Tenant. Tenant hereby waives any
and all rights it might otherwise have pursuant to any provision of state law to terminate this Lease upon a partial Taking of the Premises or the Project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <B>Events of Default</B>. Each of the following events shall be a default (&#147;<B>Default</B>&#148;) by Tenant under this Lease: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Payment Defaults</B>. Tenant shall fail to pay any installment of Rent or any other payment hereunder when due; provided, however, that
Landlord will give Tenant notice and an opportunity to cure any failure to pay Rent within 3 business days of any such notice not more than twice in any 12 month period and Tenant agrees that such notice shall be in lieu of and not in addition to,
or shall be deemed to be, any notice required by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
17<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Insurance</B>. Any insurance required to be maintained by Tenant pursuant to this
Lease shall be canceled or terminated or shall expire or shall be reduced or materially changed, or Landlord shall receive a notice of nonrenewal of any such insurance and Tenant shall fail to obtain replacement insurance at least 20 days before the
expiration of the current coverage. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Abandonment</B>. Tenant shall abandon the Premises. Tenant shall not be deemed to have
abandoned the Premises if (i)&nbsp;Tenant provides Landlord with reasonable advance notice prior to vacating and, at the time of vacating the Premises, Tenant completes Tenant&#146;s obligations with respect to the Surrender Plan in compliance with
<U>Section</U><U></U><U>&nbsp;28</U>, (ii) Tenant has made reasonable arrangements with Landlord for the security of the Premises for the balance of the Term, and (iii)&nbsp;Tenant continues during the balance of the Term to satisfy all of its
obligations under the Lease as they come due. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Improper Transfer</B>. Tenant shall assign, sublease or otherwise transfer or attempt
to transfer all or any portion of Tenant&#146;s interest in this Lease or the Premises except as expressly permitted herein, or Tenant&#146;s interest in this Lease shall be attached, executed upon, or otherwise judicially seized and such action is
not released within 90 days of the action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>Liens</B>. Tenant shall fail to discharge or otherwise obtain the release of any lien
placed upon the Premises in violation of this Lease within 15 days after Tenant receives written notice that any such lien is filed against the Premises. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>Insolvency Events</B>. Tenant or any guarantor or surety of Tenant&#146;s obligations hereunder shall: (A)&nbsp;make a general
assignment for the benefit of creditors; (B)&nbsp;commence any case, proceeding or other action seeking to have an order for relief entered on its behalf as a debtor or to adjudicate it a bankrupt or insolvent, or seeking reorganization,
arrangement, adjustment, liquidation, dissolution or composition of it or its debts or seeking appointment of a receiver, trustee, custodian or other similar official for it or for all or of any substantial part of its property (collectively a
&#147;<B>Proceeding for Relief</B>&#148;); (C) become the subject of any Proceeding for Relief which is not dismissed within 90 days of its filing or entry; or (D)&nbsp;die or suffer a legal disability (if Tenant, guarantor, or surety is an
individual) or be dissolved or otherwise fail to maintain its legal existence (if Tenant, guarantor or surety is a corporation, partnership or other entity). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <B>Estoppel Certificate or Subordination Agreement</B>. Tenant fails to execute any document required from Tenant under <U>Sections 23</U>
or <U>27</U> within 5 days after a second notice requesting such document. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <B>Other Defaults</B>. Tenant shall fail to comply with any
provision of this Lease other than those specifically referred to in this <U>Section</U><U></U><U>&nbsp;20</U>, and, except as otherwise expressly provided herein, such failure shall continue for a period of 30 days after written notice thereof from
Landlord to Tenant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any notice given under <U>Section</U><U></U><U>&nbsp;20(h)</U> hereof shall: (i)&nbsp;specify the alleged default, (ii)&nbsp;demand
that Tenant cure such default, (iii)&nbsp;be in lieu of, and not in addition to, or shall be deemed to be, any notice required under any provision of applicable law, and (iv)&nbsp;not be deemed a forfeiture or a termination of this Lease unless
Landlord elects otherwise in such notice; <U>provided</U> that if the nature of Tenant&#146;s default pursuant to <U>Section</U><U></U><U>&nbsp;20(h)</U> is such that it cannot be cured by the payment of money and reasonably requires more than 30
days to cure, then Tenant shall not be deemed to be in default if Tenant commences such cure within said 30 day period and thereafter diligently prosecutes the same to completion; <U>provided</U>, <U>however</U>, that such cure shall be completed no
later than 60 days from the date of Landlord&#146;s notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <B>Landlord&#146;s Remedies</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Payment By Landlord; Interest</B>. Upon a Default by Tenant hereunder, Landlord may, without waiving or releasing any obligation of
Tenant hereunder, make such payment or perform such act to the extent necessary to cure such Default. All sums so paid or incurred by Landlord, together with interest thereon, from the date such sums were paid or incurred, at the annual rate equal
to 12% per annum or the highest rate permitted by law (the &#147;<B>Default Rate</B>&#148;), whichever is less, shall be payable to Landlord on demand as Additional Rent. Nothing herein shall be construed to create or impose a duty on Landlord to
mitigate any damages resulting from Tenant&#146;s Default hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
18<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Late Payment Rent</B>. Late payment by Tenant to Landlord of Rent and other sums due
will cause Landlord to incur costs not contemplated by this Lease, the exact amount of which will be extremely difficult and impracticable to ascertain. Such costs include, but are not limited to, processing and accounting charges and late charges
which may be imposed on Landlord under any Mortgage covering the Premises. Therefore, if any installment of Rent due from Tenant is not received by Landlord within 5 days after the date such payment is due, Tenant shall pay to Landlord an additional
sum equal to 6% of the overdue Rent as a late charge. Notwithstanding the foregoing, before assessing a late charge the first time in any calendar year, Landlord shall provide Tenant written notice of the delinquency and will waive the right if
Tenant pays such delinquency within 5 days thereafter. The parties agree that this late charge represents a fair and reasonable estimate of the costs Landlord will incur by reason of late payment by Tenant. In addition to the late charge, Rent not
paid when due shall bear interest at the Default Rate from the 5th day after the date due until paid. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Other Remedies</B>. Upon and
during the continuance of a Default, Landlord, at its option, without further notice or demand to Tenant, shall have in addition to all other rights and remedies provided in this Lease, at law or in equity, the option to pursue any one or more of
the following remedies, each and all of which shall be cumulative and nonexclusive, without any notice or demand whatsoever. No cure in whole or in part of such Default by Tenant after Landlord has taken any action beyond giving Tenant notice of
such Default to pursue any remedy provided for herein (including retaining counsel to file an action or otherwise pursue any remedies) shall in any way affect Landlord&#146;s right to pursue such remedy or any other remedy provided Landlord herein
or under law or in equity, unless Landlord, in its sole discretion, elects to waive such Default. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) This Lease and the
Term and estate hereby granted are subject to the limitation that whenever a Default shall have happened and be continuing, Landlord shall have the right, at its election, then or thereafter while any such Default shall continue and notwithstanding
the fact that Landlord may have some other remedy hereunder or at law or in equity, to give Tenant written notice of Landlord&#146;s intention to terminate this Lease on a date specified in such notice, which date shall be not less than 5 days after
the giving of such notice, and upon the date so specified, this Lease and the estate hereby granted shall expire and terminate with the same force and effect as if the date specified in such notice were the date hereinbefore fixed for the expiration
of this Lease, and all right of Tenant hereunder shall expire and terminate, and Tenant shall be liable as hereinafter in this <U>Section</U><U></U><U>&nbsp;21(c)</U> provided. If any such notice is given, Landlord shall have, on such date so
specified, the right of <FONT STYLE="white-space:nowrap">re-entry</FONT> and possession of the Premises and the right to remove all persons and property therefrom and to store such property in a warehouse or elsewhere at the risk and expense, and
for the account, of Tenant. Should Landlord elect to <FONT STYLE="white-space:nowrap">re-enter</FONT> as herein provided or should Landlord take possession pursuant to legal proceedings or pursuant to any notice provided for by law, Landlord may
from time to time <FONT STYLE="white-space:nowrap">re-let</FONT> the Premises or any part thereof for such term or terms and at such rental or rentals and upon such terms and conditions as Landlord may deem advisable, with the right to make
commercially reasonable alterations in and repairs to the Premises. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the event of any termination of this Lease as
in this <U>Section</U><U></U><U>&nbsp;21</U> provided or as required or permitted by law or in equity, Tenant shall forthwith quit and surrender the Premises to Landlord, and Landlord may, without further notice, enter upon, <FONT
STYLE="white-space:nowrap">re-enter,</FONT> possess and repossess the same by summary proceedings, ejectment or otherwise, and again have, repossess and enjoy the same as if this Lease had not been made, and in any such event Tenant and no person
claiming through or under Tenant by virtue of any law or an order of any court shall be entitled to possession or to remain in possession of the Premises. Landlord, at its option, notwithstanding any other provision of this Lease, shall be entitled
to recover from Tenant, as and for liquidated damages, the sum of; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
19<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) all Base Rent, Additional Rent and other amounts payable by Tenant
hereunder then due or accrued and unpaid: and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) the amount equal to the aggregate of all unpaid Base Rent and Additional
Rent which would have been payable if this Lease had not been terminated prior to the end of the Term then in effect, discounted to its then present value in accordance with accepted financial practice using a rate of 5% per annum, for loss of the
bargain; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) all other damages and expenses (including reasonable attorneys&#146; fees and expenses), if any, which
Landlord shall have sustained by reason of the breach of any provision of this Lease; less </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) the net proceeds of any <FONT
STYLE="white-space:nowrap">re-letting</FONT> actually received by Landlord and (ii)&nbsp;the amount of damages which Tenant proves could have been avoided had Landlord taken reasonable steps to mitigate its damages. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Nothing herein contained shall limit or prejudice the right of Landlord, in any bankruptcy or insolvency proceeding, to
prove for and obtain as liquidated damages by reason of such termination an amount equal to the maximum allowed by any bankruptcy or insolvency proceedings, or to prove for and obtain as liquidated damages by reason of such termination, an amount
equal to the maximum allowed by any statute or rule of law whether such amount shall be greater or less than the excess referred to above. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Nothing in this <U>Section</U><U></U><U>&nbsp;21</U> shall be deemed to affect the right of either party to
indemnifications pursuant to this Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) If Landlord terminates this Lease upon the occurrence of a Default, Tenant
will quit and surrender the Premises to Landlord or its agents, and Landlord may, without further notice, enter upon, <FONT STYLE="white-space:nowrap">re-enter</FONT> and repossess the Premises by summary proceedings, ejectment or otherwise. The
words &#147;enter&#148;, <FONT STYLE="white-space:nowrap">&#147;re-enter&#148;,</FONT> and <FONT STYLE="white-space:nowrap">&#147;re-entry&#148;</FONT> are not restricted to their technical legal meanings. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) If either party shall be in default in the observance or performance of any provision of this Lease, and an action shall
be brought for the enforcement thereof in which it shall be determined that such party was in default, the party in default shall pay to the other all fees, costs and other expenses which may become payable as a result thereof or in connection
therewith, including attorneys&#146; fees and expenses. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) If Tenant shall default in the keeping, observance or
performance of any covenant, agreement, term, provision or condition herein contained, Landlord, without thereby waiving such default, may perform the same for the account and at the expense of Tenant (a)&nbsp;immediately or at any time thereafter
and without notice in the case of emergency or in case such default will result in a violation of any legal or insurance requirements, or in the imposition of any lien against all or any portion of the Premises, and (b)&nbsp;in any other case if
such default continues after any applicable cure period provided in <U>Section</U><U></U><U>&nbsp;20</U>. All reasonable costs and expenses incurred by Landlord in connection with any such performance by it for the account of Tenant and also all
reasonable costs and expenses, including reasonable attorneys&#146; fees and disbursements incurred by Landlord in any action or proceeding (including any summary dispossess proceeding) brought by Landlord to enforce any obligation of Tenant under
this Lease and/or right of Landlord in or to the Premises, shall be paid by Tenant to Landlord within 10 days after demand. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
20<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) In the event that Tenant is in breach or Default under this Lease,
whether or not Landlord exercises its right to terminate or any other remedy, Tenant shall reimburse Landlord upon demand for any costs and expenses that Landlord may incur in connection with any such breach or Default, as provided in this
<U>Section</U><U></U><U>&nbsp;21(c)</U>. Such costs shall include reasonable legal fees and costs incurred for the negotiation of a settlement, enforcement of rights or otherwise. Tenant shall also indemnify Landlord against and hold Landlord
harmless from all costs, expenses, demands and liability, including without limitation, reasonable legal fees and costs Landlord shall incur if Landlord shall become or be made a party to any claim or action instituted by Tenant against any third
party, or by any third party against Tenant, or by or against any person holding any interest under or using the Premises by license of or agreement with Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in this <U>Section</U><U></U><U>&nbsp;21</U>, no right or remedy herein conferred upon or reserved to Landlord is
intended to be exclusive of any other right or remedy, and every right and remedy shall be cumulative and in addition to any other legal or equitable right or remedy given hereunder, or now or hereafter existing. No waiver of any provision of this
Lease shall be deemed to have been made unless expressly so made in writing. Landlord shall be entitled, to the extent permitted by law, to seek injunctive relief in case of the violation, or attempted or threatened violation, of any provision of
this Lease, or to seek a decree compelling observance or performance of any provision of this Lease, or to seek any other legal or equitable remedy. Notwithstanding any contrary provision of this Lease, Tenant shall not be liable to Landlord for any
indirect, special or consequential damages, arising from a default by Tenant under this Lease; provided that this sentence shall not apply to Landlord&#146;s damages (x)&nbsp;as expressly provided for in <U>Section</U><U></U><U>&nbsp;8</U>, and/or
(y)&nbsp;in connection with Tenant&#146;s obligations as more fully set forth in <U>Section</U><U></U><U>&nbsp;30</U>. In no event shall the foregoing limit the damages to which Landlord is entitled under this <U>Section</U><U></U><U>&nbsp;21</U>
including, without limitation, the liquidated damages provided for in <U>Section</U><U></U><U>&nbsp;21(c)(ii)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <B>Assignment and
Subletting</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>General Prohibition</B>. Subject to the terms of <U>Section</U><U></U><U>&nbsp;22(b)</U> below, Tenant shall not,
without Landlord&#146;s prior written consent, directly or indirectly, voluntarily or by operation of law, assign this Lease or sublease the Premises or any part thereof or mortgage, pledge, or hypothecate its leasehold interest or grant any
concession or license within the Premises, and any attempt to do any of the foregoing shall be void and of no effect. If Tenant is a corporation, partnership or limited liability company, the shares or other ownership interests thereof which are not
actively traded upon a stock exchange or in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, a transfer or series of transfers whereby 50% or more of the issued and outstanding shares or
other ownership interests of such corporation are, or voting control is, transferred (but excepting transfers upon deaths of individual owners) from a person or persons or entity or entities which were owners thereof at time of execution of this
Lease to persons or entities who were not owners of shares or other ownership interests of the corporation, partnership or limited liability company at time of execution of this Lease, shall be deemed an assignment of this Lease requiring the
consent of Landlord as provided in this <U>Section</U><U></U><U>&nbsp;22</U>. Notwithstanding the foregoing, Tenant shall have the right to obtain financing from institutional investors (including venture capital funding and corporate partners) or
undergo a public offering which results in a change in control of Tenant without such change of control constituting an assignment under this <U>Section</U><U></U><U>&nbsp;22</U> requiring Landlord consent, provided that (i)&nbsp;Tenant notifies
Landlord in writing of the financing at least 5 business days prior to the closing of the financing, and (ii)&nbsp;provided that in no event shall such financing result in a change in use of the Premises from the use contemplated by Tenant at the
commencement of the Term. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Permitted Transfers</B>. If Tenant desires to assign, sublease, hypothecate or otherwise transfer this
Lease or sublet all or a portion of the Premises other than pursuant to a Permitted Assignment (as defined below), then at least 15 days, but not more than 45 days, before the date Tenant desires the assignment or sublease to be effective (the
&#147;<B>Assignment Date</B>&#148;), Tenant shall give Landlord a notice (the &#147;<B>Assignment Notice</B>&#148;) containing such information about the proposed assignee or sublessee, including the proposed use of the Premises and any Hazardous
Materials proposed to be used, stored handled, treated, generated in or released or disposed of from the Premises, the Assignment Date, any relationship between Tenant and the proposed assignee or sublessee, and all material terms and conditions of
the proposed assignment or sublease, including a copy of any proposed assignment or sublease in its final form, and such other information as Landlord may deem reasonably necessary or appropriate to its consideration whether to grant its consent.
Landlord may, by giving written notice to Tenant within 15 days after receipt of the Assignment Notice: (i)&nbsp;grant such consent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
21<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(provided that Landlord shall further have the right to review and approve or disapprove the proposed form of sublease prior to the effective date of any such subletting), (ii) refuse such
consent, in its reasonable discretion; or (iii)&nbsp;if the assignment or sublease is for all of the Premises for the remainder of the Term, terminate this Lease with respect to the space described in the Assignment Notice as of the Assignment Date
(an &#147;<B>Assignment Termination</B>&#148;). Among other reasons, it shall be reasonable for Landlord to withhold its consent in any of these instances:&nbsp;(1) the proposed assignee or subtenant is a governmental agency; (2)&nbsp;in
Landlord&#146;s reasonable judgment, the use of the Premises by the proposed assignee or subtenant would entail any alterations that would lessen the value of the leasehold improvements in the Premises, or would require increased services by
Landlord; (3)&nbsp;in Landlord&#146;s reasonable judgment, the proposed assignee or subtenant is engaged in areas of scientific research or other business concerns that are controversial such that they may (i)&nbsp;attract or cause negative
publicity for or about the Building or the Project, (ii)&nbsp;negatively affect the reputation of the Building, the Project or Landlord, (iii)&nbsp;attract protestors to the Building or the Project, or (iv)&nbsp;lessen the attractiveness of the
Building or the Project to any tenants or prospective tenants, purchasers or lenders; (4)&nbsp;in Landlord&#146;s reasonable judgment, the proposed assignee or subtenant lacks the creditworthiness to support the financial obligations it will incur
under the proposed assignment or sublease; (5)&nbsp;in Landlord&#146;s reasonable judgment, the character, reputation, or business of the proposed assignee or subtenant is inconsistent with the desired
<FONT STYLE="white-space:nowrap">tenant-mix</FONT> or the quality of other tenancies in the Project or is inconsistent with the type and quality of the nature of the Building; (6)&nbsp;Landlord has experienced previous defaults by or is in
litigation with the proposed assignee or subtenant; (7)&nbsp;the use of the Premises by the proposed assignee or subtenant will violate any applicable Legal Requirement; (8)&nbsp;the proposed assignee or subtenant, or any entity that, directly or
indirectly, controls, is controlled by, or is under common control with the proposed assignee or subtenant, is then an occupant of the Project; (9)&nbsp;the proposed assignee or subtenant is an entity with whom Landlord is then negotiating to lease
space in the Project; or (10)&nbsp;the assignment or sublease is prohibited by Landlord&#146;s lender. If Landlord delivers notice of its election to exercise an Assignment Termination, Tenant shall have the right to withdraw such Assignment Notice
by written notice to Landlord of such election within 5 business days after Landlord&#146;s notice electing to exercise the Assignment Termination. If Tenant withdraws such Assignment Notice, this Lease shall continue in full force and effect. If
Tenant does not withdraw such Assignment Notice, this Lease, and the term and estate herein granted, shall terminate as of the Assignment Date with respect to the space described in such Assignment Notice. No failure of Landlord to exercise any such
option to terminate this Lease, or to deliver a timely notice in response to the Assignment Notice, shall be deemed to be Landlord&#146;s consent to the proposed assignment, sublease or other transfer. Tenant shall pay to Landlord a fee equal to One
Thousand Five Hundred Dollars ($1,500) in connection with its consideration of any Assignment Notice and/or its preparation or review of any consent documents. Notwithstanding the foregoing, Landlord&#146;s consent to an assignment of this Lease or
a subletting of any portion of the Premises to any entity controlling, controlled by or under common control with Tenant (a &#147;<B>Control Permitted Assignment</B>&#148;) shall not be required, provided that Landlord shall have the right to
approve the form of any such sublease or assignment. In addition, Tenant shall have the right to assign this Lease, upon 10 days&#146; prior written notice to Landlord but without obtaining Landlord&#146;s prior written consent, to a corporation or
other entity which is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successor-in-interest</FONT></FONT> to Tenant, by way of merger, consolidation or corporate reorganization, or by the purchase of all or substantially all of
the assets or the ownership interests of Tenant provided that (i)&nbsp;such merger or consolidation, or such acquisition or assumption, as the case may be, is for a good business purpose and not principally for the purpose of transferring the Lease,
and (ii)&nbsp;the net worth (as determined in accordance with generally accepted accounting principles (&#147;<B>GAAP</B>&#148;)) of the assignee is not less than the greater of the net worth (as determined in accordance with GAAP) of Tenant as of
(A)&nbsp;the Commencement Date, or (B)&nbsp;as of the date of Tenant&#146;s most current quarterly or annual financial statements, and (iii)&nbsp;such assignee shall agree in writing to assume all of the terms, covenants and conditions of this Lease
(a &#147;<B>Corporate Permitted Assignment</B>&#148;). Control Permitted Assignments and Corporate Permitted Assignments are hereinafter referred to as &#147;<B>Permitted Assignments</B>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
22<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Additional Conditions</B>. As a condition to any such assignment or subletting,
whether or not Landlord&#146;s consent is required, Landlord may require: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) that any assignee or subtenant agree, in
writing at the time of such assignment or subletting, that if Landlord gives such party notice that Tenant is in default under this Lease, such party shall thereafter make all payments otherwise due Tenant directly to Landlord, which payments will
be received by Landlord without any liability except to credit such payment against those due under the Lease, and any such third party shall agree to attorn to Landlord or its successors and assigns should this Lease be terminated for any reason;
<U>provided</U>, <U>however</U>, in no event shall Landlord or its successors or assigns be obligated to accept such attornment; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) A list of Hazardous Materials, certified by the proposed assignee or sublessee to be true and correct, which the proposed
assignee or sublessee intends to use, store, handle, treat, generate in or release or dispose of from the Premises, together with copies of all documents relating to such use, storage, handling, treatment, generation, release or disposal of
Hazardous Materials by the proposed assignee or subtenant in the Premises or on the Project, prior to the proposed assignment or subletting, including, without limitation: permits; approvals; reports and correspondence; storage and management plans;
plans relating to the installation of any storage tanks to be installed in or under the Project (provided, said installation of tanks shall only be permitted after Landlord has given its written consent to do so, which consent may be withheld in
Landlord&#146;s sole and absolute discretion); and all closure plans or any other documents required by any and all federal, state and local Governmental Authorities for any storage tanks installed in, on or under the Project for the closure of any
such tanks. Neither Tenant nor any such proposed assignee or subtenant is required, however, to provide Landlord with any portion(s) of the such documents containing information of a proprietary nature which, in and of themselves, do not contain a
reference to any Hazardous Materials or hazardous activities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>No Release of Tenant, Sharing of Excess Rents</B>. Notwithstanding
any assignment or subletting, Tenant and any guarantor or surety of Tenant&#146;s obligations under this Lease shall at all times remain fully and primarily responsible and liable for the payment of Rent and for compliance with all of Tenant&#146;s
other obligations under this Lease. Except in connection with a Permitted Assignment, if the Rent due and payable by a sublessee or assignee (or a combination of the rental payable under such sublease or assignment plus any bonus or other
consideration therefor or incident thereto in any form) exceeds the sum of<B> </B>the rental payable under this Lease, (excluding however, any Rent payable under this Section) and actual and reasonable brokerage fees, legal costs, free rent, any
design or construction fees and any tenant improvement costs directly related to and required pursuant to the terms of any such sublease or assignment) (&#147;<B>Excess Rent</B>&#148;), then Tenant shall be bound and obligated to pay Landlord as
Additional Rent hereunder 50% of such Excess Rent within 10 days following receipt thereof by Tenant. If Tenant shall sublet the Premises or any part thereof, Tenant hereby immediately and irrevocably assigns to Landlord, as security for
Tenant&#146;s obligations under this Lease, all rent from any such subletting, and Landlord as assignee and as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for Tenant, or a receiver for Tenant
appointed on Landlord&#146;s application, may collect such rent and apply it toward Tenant&#146;s obligations under this Lease; except that, until the occurrence of a Default, Tenant shall have the right to collect such rent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>No Waiver</B>. The consent by Landlord to an assignment or subletting shall not relieve Tenant or any assignees of this Lease or any
sublessees of the Premises from obtaining the consent of Landlord to any further assignment or subletting nor shall it release Tenant or any assignee or sublessee of Tenant from full and primary liability under the Lease. The acceptance of Rent
hereunder, or the acceptance of performance of any other term, covenant, or condition thereof, from any other person or entity shall not be deemed to be a waiver of any of the provisions of this Lease or a consent to any subletting, assignment or
other transfer of the Premises. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>Prior Conduct of Proposed Transferee</B>. Notwithstanding any other provision of this
<U>Section</U><U></U><U>&nbsp;22</U>, if (i)&nbsp;the proposed assignee or sublessee of Tenant has been required by any prior landlord, lender or Governmental Authority to take remedial action in connection with Hazardous Materials contaminating a
property, where the contamination resulted from such party&#146;s action or use of the property in question, (ii)&nbsp;the proposed assignee or sublessee is subject to an enforcement order issued by any Governmental Authority in connection with the
use, storage, handling, treatment, generation, release or disposal of Hazardous Materials (including, without limitation, any order related to the failure to make a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
23<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required reporting to any Governmental Authority), or (iii)&nbsp;because of the existence of a <FONT STYLE="white-space:nowrap">pre-existing</FONT> environmental condition in the vicinity of or
underlying the Project, the risk that Landlord would be targeted as a responsible party in connection with the remediation of such <FONT STYLE="white-space:nowrap">pre-existing</FONT> environmental condition would be materially increased or
exacerbated by the proposed use of Hazardous Materials by such proposed assignee or sublessee, Landlord shall have the absolute right to refuse to consent to any assignment or subletting to any such party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. <B>Estoppel Certificate</B>. Tenant shall, within 10 business days of written notice from Landlord, execute, acknowledge and deliver a
statement in writing in any form reasonably requested by a proposed lender or purchaser, (i)&nbsp;certifying that this Lease is unmodified and in full force and effect (or, if modified, stating the nature of such modification and certifying that
this Lease as so modified is in full force and effect) and the dates to which the rental and other charges are paid in advance, if any, (ii)&nbsp;acknowledging that there are not any uncured defaults on the part of Landlord hereunder, or specifying
such defaults if any are claimed, and (iii)&nbsp;setting forth such further information with respect to the status of this Lease or the Premises as may be reasonably requested thereon. Any such statement may be relied upon by any prospective
purchaser or encumbrancer of all or any portion of the real property of which the Premises are a part. Tenant&#146;s failure to deliver such statement within such time shall, at the option of Landlord, constitute a Default under this Lease, and, in
any event, shall be conclusive upon Tenant that the Lease is in full force and effect and without modification except as may be represented by Landlord in any certificate prepared by Landlord and delivered to Tenant for execution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24. <B>Quiet Enjoyment</B>. So long as Tenant is not in Default under this Lease, Tenant shall, subject to the terms of this Lease, at all
times during the Term, have peaceful and quiet enjoyment of the Premises against any person claiming by, through or under Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25.
<B>Prorations</B>. All prorations required or permitted to be made hereunder shall be made on the basis of a 360 day year and 30 day months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26. <B>Rules and Regulations</B>. Tenant shall, at all times during the Term and any extension thereof, comply with all reasonable rules and
regulations at any time or from time to time established by Landlord covering use of the Premises and the Project. The current rules and regulations are attached hereto as <B>Exhibit E</B>. If there is any conflict between said rules and regulations
and other provisions of this Lease, the terms and provisions of this Lease shall control. Landlord shall not have any liability or obligation for the breach of any rules or regulations by other tenants in the Project and shall not enforce such rules
and regulations in a discriminatory manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27. <B>Subordination</B>. This Lease and Tenant&#146;s interest and rights hereunder are
hereby made and shall be subject and subordinate at all times to the lien of any Mortgage now existing or hereafter created on or against the Project or the Premises, and all amendments, restatements, renewals, modifications, consolidations,
refinancing, assignments and extensions thereof, without the necessity of any further instrument or act on the part of Tenant; <U>provided</U>, <U>however</U> that so long as there is no Default hereunder, Tenant&#146;s right to possession of the
Premises shall not be disturbed by the Holder of any such Mortgage. Tenant agrees, at the election of the Holder of any such Mortgage, to attorn to any such Holder. Tenant agrees upon demand to execute, acknowledge and deliver such instruments,
confirming such subordination, and such instruments of attornment as shall be requested by any such Holder, provided any such instruments contain appropriate <FONT STYLE="white-space:nowrap">non-disturbance</FONT> provisions assuring Tenant&#146;s
quiet enjoyment of the Premises as set forth in <U>Section</U><U></U><U>&nbsp;24</U> hereof. Notwithstanding the foregoing, any such Holder may at any time subordinate its Mortgage to this Lease, without Tenant&#146;s consent, by notice in writing
to Tenant, and thereupon this Lease shall be deemed prior to such Mortgage without regard to their respective dates of execution, delivery or recording and in that event such Holder shall have the same rights with respect to this Lease as though
this Lease had been executed prior to the execution, delivery and recording of such Mortgage and had been assigned to such Holder. The term &#147;<B>Mortgage</B>&#148; whenever used in this Lease shall be deemed to include deeds of trust, security
assignments and any other encumbrances, and any reference to the &#147;<B>Holder</B>&#148; of a Mortgage shall be deemed to include the beneficiary under a deed of trust. As of the date of this Lease, there is no existing Mortgage encumbering the
Project. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
24<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the written request of Tenant, Landlord agrees to use reasonable efforts to cause the
Holder of any future Mortgage to enter into a subordination, <FONT STYLE="white-space:nowrap">non-disturbance</FONT> and attornment agreement (&#147;<B>SNDA</B>&#148;) which provides that such Holder will recognize and not disturb Tenant&#146;s
right of possession pursuant to this Lease provided that Tenant is not in Default under this Lease. The SNDA shall be on the form proscribed by the Holder and Tenant shall pay the Holder&#146;s fees and costs in connection with obtaining such SNDA;
provided, however, that Landlord shall request that Holder make any changes to the SNDA requested by Tenant. Landlord&#146;s failure to cause the Holder to enter into the SNDA with Tenant (or make any of the changes requested by Tenant) shall not be
a default by Landlord under this Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28. <B>Surrender</B>. Upon the expiration of the Term or earlier termination of Tenant&#146;s
right of possession, Tenant shall surrender the Premises to Landlord in the same condition as received, subject to any Alterations or Installations permitted by Landlord to remain in the Premises, free of Hazardous Materials brought upon, kept,
used, stored, handled, treated, generated in, or released or disposed of from, the Premises by any person other than a Landlord Party (collectively, &#147;<B>Tenant HazMat Operations</B>&#148;) and released of all Hazardous Materials Clearances,
broom clean, ordinary wear and tear and casualty loss and condemnation covered by <U>Sections 18</U> and <U>19</U> excepted. At least 3 months prior to the surrender of the Premises, Tenant shall deliver to Landlord a narrative description of the
actions proposed (or required by any Governmental Authority) to be taken by Tenant in order to surrender the Premises (including any Installations permitted by Landlord to remain in the Premises) at the expiration or earlier termination of the Term,
free from any residual impact from the Tenant HazMat Operations and otherwise released for unrestricted use and occupancy (the &#147;<B>Surrender Plan</B>&#148;). Such Surrender Plan shall be accompanied by a current listing of (i)&nbsp;all
Hazardous Materials licenses and permits held by or on behalf of any Tenant Party with respect to the Premises, and (ii)&nbsp;all Hazardous Materials used, stored, handled, treated, generated, released or disposed of from the Premises, and shall be
subject to the review and approval of Landlord&#146;s environmental consultant. In connection with the review and approval of the Surrender Plan, upon the request of Landlord, Tenant shall deliver to Landlord or its consultant such additional <FONT
STYLE="white-space:nowrap">non-proprietary</FONT> information concerning Tenant HazMat Operations as Landlord shall request. On or before such surrender, Tenant shall deliver to Landlord evidence that the approved Surrender Plan shall have been
satisfactorily completed and Landlord shall have the right, subject to reimbursement at Tenant&#146;s expense as set forth below, to cause Landlord&#146;s environmental consultant to inspect the Premises and perform such additional procedures as may
be deemed reasonably necessary to confirm that the Premises are, as of the effective date of such surrender or early termination of the Lease, free from any residual impact from Tenant HazMat Operations. Tenant shall reimburse Landlord, as
Additional Rent, for the actual <FONT STYLE="white-space:nowrap">out-of</FONT> pocket expense incurred by Landlord for Landlord&#146;s environmental consultant to review and approve the Surrender Plan and to visit the Premises and verify
satisfactory completion of the same, which cost shall not exceed $5,000. Landlord shall have the unrestricted right to deliver such Surrender Plan and any report by Landlord&#146;s environmental consultant with respect to the surrender of the
Premises to third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Tenant shall fail to prepare or submit a Surrender Plan approved by Landlord, or if Tenant shall fail to
complete the approved Surrender Plan, or if such Surrender Plan, whether or not approved by Landlord, shall fail to adequately address any residual effect of Tenant HazMat Operations in, on or about the Premises, Landlord shall have the right to
take such actions as Landlord may deem reasonable or appropriate to assure that the Premises and the Project are surrendered free from any residual impact from Tenant HazMat Operations, the cost of which actions shall be reimbursed by Tenant as
Additional Rent, without regard to the limitation set forth in the first paragraph of this <U>Section</U><U></U><U>&nbsp;28</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant
shall immediately return to Landlord all keys and/or access cards to parking, the Project, restrooms or all or any portion of the Premises furnished to or otherwise procured by Tenant. If any such access card or key is lost, Tenant shall pay to
Landlord, at Landlord&#146;s election, either the cost of replacing such lost access card or key or the cost of reprogramming the access security system in which such access card was used or changing the lock or locks opened by such lost key. Any
Tenant&#146;s Property, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
25<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Alterations and property not so removed by Tenant as permitted or required herein shall be deemed abandoned and may be stored, removed, and disposed of by Landlord at Tenant&#146;s expense, and
Tenant waives all claims against Landlord for any damages resulting from Landlord&#146;s retention and/or disposition of such property. All obligations of Tenant hereunder not fully performed as of the termination of the Term, including the
obligations of Tenant under <U>Section</U><U></U><U>&nbsp;30</U> hereof, shall survive the expiration or earlier termination of the Term, including, without limitation, indemnity obligations, payment obligations with respect to Rent and obligations
concerning the condition and repair of the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29. <B>Waiver of Jury Trial</B>. TO THE EXTENT PERMITTED BY LAW, TENANT AND LANDLORD
WAIVE ANY RIGHT TO TRIAL BY JURY OR TO HAVE A JURY PARTICIPATE IN RESOLVING ANY DISPUTE, WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE, BETWEEN LANDLORD AND TENANT ARISING OUT OF THIS LEASE OR ANY OTHER INSTRUMENT, DOCUMENT, OR AGREEMENT EXECUTED
OR DELIVERED IN CONNECTION HEREWITH OR THE TRANSACTIONS RELATED HERETO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">30. <B>Environmental Requirements</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Prohibition/Compliance/Indemnity</B>. Tenant shall not cause or permit any Hazardous Materials (as hereinafter defined) to be brought
upon, kept, used, stored, handled, treated, generated in or about, or released or disposed of from, the Premises or the Project in violation of applicable Environmental Requirements (as hereinafter defined) by Tenant or any Tenant Party. If Tenant
breaches the obligation stated in the preceding sentence, or if the presence of Hazardous Materials in the Premises during the Term or any holding over results in contamination of the Premises, the Project or any adjacent property or if
contamination of the Premises, the Project or any adjacent property by Hazardous Materials brought into, kept, used, stored, handled, treated, generated in or about, or released or disposed of from, the Premises by anyone other than Landlord and
Landlord&#146;s employees, agents and contractors otherwise occurs during the Term or any holding over, Tenant hereby indemnifies and shall defend and hold Landlord, its officers, directors, employees, agents and contractors harmless from any and
all actions (including, without limitation, remedial or enforcement actions of any kind, administrative or judicial proceedings, and orders or judgments arising out of or resulting therefrom), costs, claims, damages (including, without limitation,
punitive damages and damages based upon diminution in value of the Premises or the Project, or the loss of, or restriction on, use of the Premises or any portion of the Project), expenses (including, without limitation, attorneys&#146;,
consultants&#146; and experts&#146; fees, court costs and amounts paid in settlement of any claims or actions), fines, forfeitures or other civil, administrative or criminal penalties, injunctive or other relief (whether or not based upon personal
injury, property damage, or contamination of, or adverse effects upon, the environment, water tables or natural resources), liabilities or losses (collectively, &#147;<B>Environmental Claims</B>&#148;) which arise during or after the Term as a
result of such contamination. This indemnification of Landlord by Tenant includes, without limitation, costs incurred in connection with any investigation of site conditions or any cleanup, treatment, remedial, removal, or restoration work required
by any federal, state or local Governmental Authority because of Hazardous Materials present in the air, soil or ground water above, on, or under the Premises. Without limiting the foregoing, if the presence of any Hazardous Materials on the
Premises, the Project or any adjacent property caused or permitted by Tenant or any Tenant Party results in any contamination of the Premises, the Project or any adjacent property, Tenant shall promptly take all actions at its sole expense and in
accordance with applicable Environmental Requirements as are necessary to return the Premises, the Project or any adjacent property to the condition existing prior to the time of such contamination, provided that Landlord&#146;s approval of such
action shall first be obtained, which approval shall not unreasonably be withheld so long as such actions would not potentially have any material adverse long-term or short-term effect on the Premises or the Project. Notwithstanding anything to the
contrary contained in <U>Section</U><U></U><U>&nbsp;28</U> or this <U>Section</U><U></U><U>&nbsp;30</U>, Tenant shall not be responsible for, and the indemnification and hold harmless obligation set forth in this paragraph shall not apply to
(i)&nbsp;contamination in the Premises which Tenant can prove existed in the Premises immediately prior to the Commencement Date, (ii)&nbsp;the presence of any Hazardous Materials in the Premises which Tenant can prove migrated from outside of the
Premises into the Premises, or (iii)&nbsp;contamination caused by Landlord or any Landlord&#146;s employees, agents and contractors, unless in any case, the presence of such Hazardous Materials (x)&nbsp;is the result of a breach by Tenant of any of
its obligations under this Lease, or (y)&nbsp;was caused, contributed to or exacerbated by Tenant or any Tenant Party. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
26<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Business</B>. Landlord acknowledges that it is not the intent of this
<U>Section</U><U></U><U>&nbsp;30</U> to prohibit Tenant from using the Premises for the Permitted Use. Tenant may operate its business according to prudent industry practices so long as the use or presence of Hazardous Materials is strictly and
properly monitored according to all then applicable Environmental Requirements. As a material inducement to Landlord to allow Tenant to use Hazardous Materials in connection with its business, Tenant agrees to deliver to Landlord prior to the
Commencement Date a list identifying each type of Hazardous Materials to be brought upon, kept, used, stored, handled, treated, generated on, or released or disposed of from, the Premises and setting forth any and all governmental approvals or
permits required in connection with the presence, use, storage, handling, treatment, generation, release or disposal of such Hazardous Materials on or from the Premises (&#147;<B>Hazardous Materials List</B>&#148;). Tenant shall deliver to Landlord
an updated list at any additional time that Tenant is required to deliver a Hazardous Materials List to any Governmental Authority (<U>e.g.</U>, the fire department) in connection with its use or occupancy of the Premises. Tenant shall deliver to
Landlord true and correct copies of the following documents (the &#147;<B>Haz Mat Documents</B>&#148;) relating to the use, storage, handling, treatment, generation, release or disposal of Hazardous Materials prior to the Commencement Date, or if
unavailable at that time, concurrent with the receipt from or submission to a Governmental Authority: permits; approvals; reports and correspondence; storage and management plans, notice of violations of any Legal Requirements; plans relating to the
installation of any storage tanks to be installed in or under the Project (provided, said installation of tanks shall only be permitted after Landlord has given Tenant its written consent to do so, which consent may be withheld in Landlord&#146;s
sole and absolute discretion); all closure plans or any other documents required by any and all federal, state and local Governmental Authorities for any storage tanks installed in, on or under the Project for the closure of any such tanks; and a
Surrender Plan (to the extent surrender in accordance with <U>Section</U><U></U><U>&nbsp;28</U> cannot be accomplished in 3 months). Tenant is not required, however, to provide Landlord with any portion(s) of the Haz Mat Documents containing
information of a proprietary nature which, in and of themselves, do not contain a reference to any Hazardous Materials or hazardous activities. It is not the intent of this Section to provide Landlord with information which could be detrimental to
Tenant&#146;s business should such information become possessed by Tenant&#146;s competitors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Tenant Representation and
Warranty</B>. Tenant hereby represents and warrants to Landlord that (i)&nbsp;neither Tenant nor any of its legal predecessors has been required by any prior landlord, lender or Governmental Authority at any time to take remedial action in
connection with Hazardous Materials contaminating a property which contamination was permitted by Tenant of such predecessor or resulted from Tenant&#146;s or such predecessor&#146;s action or use of the property in question, and (ii)&nbsp;Tenant is
not subject to any enforcement order issued by any Governmental Authority in connection with the use, storage, handling, treatment, generation, release or disposal of Hazardous Materials (including, without limitation, any order related to the
failure to make a required reporting to any Governmental Authority). If Landlord determines that this representation and warranty was not true as of the date of this lease, Landlord shall have the right to terminate this Lease in Landlord&#146;s
sole and absolute discretion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Testing</B>. Landlord shall have the right to conduct annual tests of the Premises to determine
whether any contamination of the Premises or the Project has occurred as a result of Tenant&#146;s use. Tenant shall be required to pay the cost of such annual test of the Premises if there is a violation of this <U>Section</U><U></U><U>&nbsp;30</U>
or if contamination for which Tenant is responsible under this <U>Section</U><U></U><U>&nbsp;30</U> is identified; provided, however, that if Tenant conducts its own tests of the Premises using third party contractors and test procedures acceptable
to Landlord which tests are certified to Landlord, Landlord shall accept such tests in lieu of the annual tests to be paid for by Tenant. In addition, at any time, and from time to time, prior to the expiration or earlier termination of the Term,
Landlord shall have the right to conduct appropriate tests of the Premises and the Project to determine if contamination has occurred as a result of Tenant&#146;s use of the Premises. In connection with such testing, upon the request of Landlord,
Tenant shall deliver to Landlord or its consultant such <FONT STYLE="white-space:nowrap">non-proprietary</FONT> information concerning the use of Hazardous Materials in or about the Premises by Tenant or any Tenant Party. If contamination has
occurred for which Tenant is liable under this <U>Section</U><U></U><U>&nbsp;30</U>, Tenant shall pay all reasonable costs to conduct such tests. If no such contamination is found, Landlord shall pay the costs of such tests (which shall not
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
27<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
constitute an Operating Expense). Landlord shall provide Tenant with a copy of all third party, <FONT STYLE="white-space:nowrap">non-confidential</FONT> reports and tests of the Premises made by
or on behalf of Landlord during the Term without representation or warranty and subject to a confidentiality agreement. Tenant shall, at its sole cost and expense, promptly and satisfactorily remediate any environmental conditions identified by such
testing in accordance with all Environmental Requirements. Landlord&#146;s receipt of or satisfaction with any environmental assessment in no way waives any rights which Landlord may have against Tenant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>Control Areas</B>. Tenant shall be allowed to utilize up to its pro rata share of the Hazardous Materials inventory within any control
area or zone (located within the Premises), as designated by the applicable building code, for chemical use or storage. As used in the preceding sentence, Tenant&#146;s pro rata share of any control areas or zones located within the Premises shall
be determined based on the rentable square footage that Tenant leases within the applicable control area or zone. For purposes of example only, if a control area or zone contains 10,000 rentable square feet and 2,000 rentable square feet of a
tenant&#146;s premises are located within such control area or zone (while such premises as a whole contains 5,000 rentable square feet), the applicable tenant&#146;s pro rata share of such control area would be 20%. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>Underground Tanks</B>. Tenant shall have no right to use or install any underground or other storage tanks at the Project. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <B>Tenant&#146;s Obligations</B>. Tenant&#146;s obligations under this <U>Section</U><U></U><U>&nbsp;30</U> shall survive the expiration or
earlier termination of the Lease. During any period of time after the expiration or earlier termination of this Lease required by Tenant or Landlord to complete the removal from the Premises of any Hazardous Materials (including, without limitation,
the release and termination of any licenses or permits restricting the use of the Premises and the completion of the approved Surrender Plan), Tenant shall continue to pay the full Rent in accordance with this Lease for any portion of the Premises
not relet by Landlord in Landlord&#146;s sole discretion, which Rent shall be prorated daily. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <B>Definitions</B>. As used herein, the
term &#147;<B>Environmental Requirements</B>&#148; means all applicable present and future statutes, regulations, ordinances, rules, codes, judgments, orders or other similar enactments of any Governmental Authority regulating or relating to health,
safety, or environmental conditions on, under, or about the Premises or the Project, or the environment, including without limitation, the following: the Comprehensive Environmental Response, Compensation and Liability Act; the Resource Conservation
and Recovery Act; and all state and local counterparts thereto, and any regulations or policies promulgated or issued thereunder. As used herein, the term &#147;<B>Hazardous Materials</B>&#148; means and includes any substance, material, waste,
pollutant, or contaminant listed or defined as hazardous or toxic, or regulated by reason of its impact or potential impact on humans, animals and/or the environment under any Environmental Requirements, asbestos and petroleum, including crude oil
or any fraction thereof, natural gas liquids, liquefied natural gas, or synthetic gas usable for fuel (or mixtures of natural gas and such synthetic gas). As defined in Environmental Requirements, Tenant is and shall be deemed to be the
&#147;<B>operator</B>&#148; of Tenant&#146;s &#147;<B>facility</B>&#148; and the &#147;<B>owner</B>&#148; of all Hazardous Materials brought on the Premises by Tenant or any Tenant Party, and the wastes,
<FONT STYLE="white-space:nowrap">by-products,</FONT> or residues generated, resulting, or produced therefrom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31. <B>Tenant&#146;s
Remedies/Limitation of Liability</B>. Landlord shall not be in default hereunder unless Landlord fails to perform any of its obligations hereunder within 30 days after written notice from Tenant specifying such failure (unless such performance will,
due to the nature of the obligation, require a period of time in excess of 30 days, then after such period of time as is reasonably necessary). Upon any default by Landlord, Tenant shall give notice by registered or certified mail to any Holder of a
Mortgage covering the Premises and to any landlord of any lease of property in or on which the Premises are located (to the extent Tenant has received notice of the same) and Tenant shall offer such Holder and/or landlord a reasonable opportunity to
cure the default, including time to obtain possession of the Project by power of sale or a judicial action if such should prove necessary to effect a cure; <U>provided</U> Landlord shall have furnished to Tenant in writing the names and addresses of
all such persons who are to receive such notices. All obligations of Landlord hereunder shall be construed as covenants, not conditions; and, except as may be otherwise expressly provided in this Lease, Tenant may not terminate this Lease for breach
of Landlord&#146;s obligations hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
28<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All obligations of Landlord under this Lease will be binding upon Landlord only during the
period of its ownership of the Premises and not thereafter. The term &#147;<B>Landlord</B>&#148; in this Lease shall mean only the owner for the time being of the Premises. Upon the transfer by such owner of its interest in the Premises, such owner
shall thereupon be released and discharged from all obligations of Landlord thereafter accruing, but such obligations shall be binding during the Term upon each new owner for the duration of such owner&#146;s ownership. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">32. <B>Inspection and Access</B>. Landlord and its agents, representatives, and contractors may enter the Premises at any reasonable time to
inspect the Premises and to make such repairs as may be required or permitted pursuant to this Lease and for any other reasonable business purpose. Landlord and Landlord&#146;s representatives may enter the Premises during business hours on not less
than 48 hours advance written notice (except in the case of emergencies in which case no such notice shall be required and such entry may be at any time) for the purpose of effecting any such repairs, inspecting the Premises, showing the Premises to
prospective purchasers and, during the last year of the Term, to prospective tenants or for any other business purpose. Landlord may erect a suitable sign on the Premises stating the Premises are available to let or that the Project is available for
sale. Landlord may grant easements, make public dedications, designate Common Areas and create restrictions on or about the Premises, <U>provided</U> that no such easement, dedication, designation or restriction materially, adversely affects
Tenant&#146;s use or occupancy of the Premises for the Permitted Use. At Landlord&#146;s request, Tenant shall execute such instruments as may be reasonably necessary for such easements, dedications or restrictions. Tenant shall at all times, except
in the case of emergencies, have the right to escort Landlord or its agents, representatives, contractors or guests while the same are in the Premises, provided such escort does not materially and adversely affect Landlord&#146;s access rights
hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">33. <B>Security</B>. Tenant acknowledges and agrees that security devices and services, if any, while intended to deter crime
may not in given instances prevent theft or other criminal acts and that Landlord is not providing any security services with respect to the Premises. Tenant agrees that Landlord shall not be liable to Tenant for, and Tenant waives any claim against
Landlord with respect to, any loss by theft or any other damage suffered or incurred by Tenant in connection with any unauthorized entry into the Premises or any other breach of security with respect to the Premises. Tenant shall be solely
responsible for the personal safety of Tenant&#146;s officers, employees, agents, contractors, guests and invitees while any such person is in, on or about the Premises and/or the Project. Tenant shall at Tenant&#146;s cost obtain insurance coverage
to the extent Tenant desires protection against such criminal acts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">34. <B>Force Majeure</B>. Except for the payment of Rent, neither
Landlord nor Tenant shall be held responsible<B> </B>or liable for delays in the performance of its obligations hereunder when caused by, related to, or arising out of acts of God, sinkholes or subsidence, strikes, lockouts, or other labor disputes,
embargoes, quarantines, weather, national, regional, or local disasters, calamities, or catastrophes, inability to obtain labor or materials (or reasonable substitutes therefor) at reasonable costs or failure of, or inability to obtain, utilities
necessary for performance, governmental restrictions, orders, limitations, regulations, or controls, national emergencies, delay in issuance or revocation of permits, enemy or hostile governmental action, terrorism, insurrection, riots, civil
disturbance or commotion, fire or other casualty, and other causes or events beyond their reasonable control (&#147;<B>Force Majeure</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">35. <B>Brokers</B>. Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person
(collectively, &#147;<B>Broker</B>&#148;) in connection with this transaction and that no Broker brought about this transaction, other than Transwestern RBJ and Colliers International. Landlord and Tenant each hereby agree to indemnify and hold the
other harmless from and against any claims by any Broker, other than the broker, if any named in this <U>Section</U><U></U><U>&nbsp;35</U>, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as
applicable, with regard to this leasing transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
29<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">36. <B>Limitation on Landlord&#146;s Liability</B>. NOTWITHSTANDING ANYTHING SET FORTH HEREIN
OR IN ANY OTHER AGREEMENT BETWEEN LANDLORD AND TENANT TO THE CONTRARY: (A)&nbsp;LANDLORD SHALL NOT BE LIABLE TO TENANT OR ANY OTHER PERSON FOR (AND TENANT AND EACH SUCH OTHER PERSON ASSUME ALL RISK OF) LOSS, DAMAGE OR INJURY, WHETHER ACTUAL OR
CONSEQUENTIAL TO: TENANT&#146;S PERSONAL PROPERTY OF EVERY KIND AND DESCRIPTION, INCLUDING, WITHOUT LIMITATION TRADE FIXTURES, EQUIPMENT, INVENTORY, SCIENTIFIC RESEARCH, SCIENTIFIC EXPERIMENTS, LABORATORY ANIMALS, PRODUCT, SPECIMENS, SAMPLES, AND/OR
SCIENTIFIC, BUSINESS, ACCOUNTING AND OTHER RECORDS OF EVERY KIND AND DESCRIPTION KEPT AT THE PREMISES AND ANY AND ALL INCOME DERIVED OR DERIVABLE THEREFROM; (B)&nbsp;THERE SHALL BE NO PERSONAL RECOURSE TO LANDLORD FOR ANY ACT OR OCCURRENCE IN, ON OR
ABOUT THE PREMISES OR ARISING IN ANY WAY UNDER THIS LEASE OR ANY OTHER AGREEMENT BETWEEN LANDLORD AND TENANT WITH RESPECT TO THE SUBJECT MATTER HEREOF AND ANY LIABILITY OF LANDLORD HEREUNDER SHALL BE STRICTLY LIMITED SOLELY TO LANDLORD&#146;S
INTEREST IN THE PROJECT OR ANY PROCEEDS FROM SALE OR CONDEMNATION THEREOF AND ANY INSURANCE PROCEEDS PAYABLE IN RESPECT OF LANDLORD&#146;S INTEREST IN THE PROJECT OR IN CONNECTION WITH ANY SUCH LOSS; AND (C)&nbsp;IN NO EVENT SHALL ANY PERSONAL
LIABILITY BE ASSERTED AGAINST LANDLORD IN CONNECTION WITH THIS LEASE NOR SHALL ANY RECOURSE BE HAD TO ANY OTHER PROPERTY OR ASSETS OF LANDLORD OR ANY OF LANDLORD&#146;S OFFICERS, DIRECTORS, EMPLOYEES, AGENTS OR CONTRACTORS. UNDER NO CIRCUMSTANCES
SHALL LANDLORD OR ANY OF LANDLORD&#146;S OFFICERS, DIRECTORS, EMPLOYEES, AGENTS OR CONTRACTORS BE LIABLE FOR INJURY TO TENANT&#146;S BUSINESS OR FOR ANY LOSS OF INCOME OR PROFIT THEREFROM. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">37. <B>Severability</B>. If any clause or provision of this Lease is illegal, invalid or unenforceable under present or future laws, then and
in that event, it is the intention of the parties hereto that the remainder of this Lease shall not be affected thereby. It is also the intention of the parties to this Lease that in lieu of each clause or provision of this Lease that is illegal,
invalid or unenforceable, there be added, as a part of this Lease, a clause or provision as similar in effect to such illegal, invalid or unenforceable clause or provision as shall be legal, valid and enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">38. <B>Signs; Exterior Appearance</B>. Tenant shall not, without the prior written consent of Landlord, which may be granted or withheld in
Landlord&#146;s sole discretion: (i)&nbsp;attach any awnings, exterior lights, decorations, balloons, flags, pennants, banners, painting or other projection to any outside wall of the Project, (ii)&nbsp;use any curtains, blinds, shades or screens
other than Landlord&#146;s standard window coverings, (iii)&nbsp;coat or otherwise sunscreen the interior or exterior of any windows with materials not approved by Landlord (which approval shall not be unreasonably withheld), (iv) place any bottles,
parcels, or other articles on the window sills, (v)&nbsp;place any equipment, furniture or other items of personal property on any exterior balcony, or (vi)&nbsp;paint, affix or exhibit on any part of the Premises or the Project any signs, notices,
window or door lettering, placards, decorations, or advertising media of any type which can be viewed from the exterior of the Premises. Signage at the front entrance of the Premises and the directory tablet shall be inscribed, painted or affixed
for Tenant by Landlord at the sole cost and expense of Landlord, and shall be of a size, color and type reasonably acceptable to Landlord. Nothing may be placed on the exterior of corridor walls or corridor doors other than Landlord&#146;s standard
lettering. The directory tablet shall be provided exclusively for the display of the name and location of tenants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">39. <B>Right to Extend
Term</B>. Tenant shall have the right to extend the Term of the Lease upon the following terms and conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Extension
Rights</B>. Tenant shall have 1 right ( &#147;<B>Extension Right</B>&#148;) to extend the term of this Lease for 5 years (the &#147;<B>Extension Term</B>&#148;) on the same terms and conditions as this Lease (other than with respect to Base Rent<B>
</B>and the Work Letter) by giving Landlord written notice of its election to exercise each Extension Right at least 9 months prior to the expiration of the Base Term of the Lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
30<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the commencement of the Extension Term, Base Rent shall be payable at the Market Rate
(as defined below). Base Rent shall thereafter be adjusted on each annual anniversary of the commencement of such Extension Term by a percentage as determined by Landlord and agreed to by Tenant at the time the Market Rate is determined. As used
herein, &#147;<B>Market Rate</B>&#148; shall mean the rate that comparable landlords of comparable buildings have accepted in current transactions from <FONT STYLE="white-space:nowrap">non-equity</FONT> (i.e., not being offered equity in the
buildings) and nonaffiliated tenants of similar financial strength for space of comparable size and quality (including all Tenant Improvements, Alterations and other improvements) in lab/office buildings of similar quality to the Building in the
Route 128 North marketplace for a comparable term, with the determination of the Market Rate to take into account all relevant factors, including tenant inducements, parking costs, leasing commissions, allowances or concessions, if any.
Notwithstanding the foregoing, the Market Rate shall in no event be less than $32.00 per rentable square foot of the Premises per annum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, on or before the date which is 180 days prior to the expiration of the Base Term of this Lease, Tenant has not agreed with Landlord&#146;s
determination of the Market Rate and the rent escalations during the Extension Term after negotiating in good faith, Tenant shall be deemed to have elected arbitration as described in <U>Section</U><U></U><U>&nbsp;39(b)</U>. Tenant acknowledges and
agrees that, if Tenant has elected to exercise the Extension Right by delivering notice to Landlord as required in this <U>Section</U><U></U><U>&nbsp;39(a)</U>, Tenant shall have no right thereafter to rescind or elect not to extend the term of the
Lease for the Extension Term. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Arbitration</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Within 10 business days of Tenant&#146;s notice to Landlord of its election (or deemed election) to arbitrate Market Rate
and escalations, each party shall deliver to the other a proposal containing the Market Rate and escalations that the submitting party believes to be correct (&#147;<B>Extension Proposal</B>&#148;). If either party fails to timely submit an
Extension Proposal, the other party&#146;s submitted proposal shall determine the Base Rent and escalations for the Extension Term. If both parties submit Extension Proposals, then Landlord and Tenant shall meet within 7 days after delivery of the
last Extension Proposal and make a good faith attempt to mutually appoint a single Arbitrator (and defined below) to determine the Market Rate and escalations. If Landlord and Tenant are unable to agree upon a single Arbitrator, then each shall, by
written notice delivered to the other within 10 days after the meeting, select an Arbitrator. If either party fails to timely give notice of its selection for an Arbitrator, the other party&#146;s submitted proposal shall determine the Base Rent for
the Extension Term. The 2 Arbitrators so appointed shall, within 5 business days after their appointment, appoint a third Arbitrator. If the 2 Arbitrators so selected cannot agree on the selection of the third Arbitrator within the time above
specified, then either party, on behalf of both parties, may request such appointment of such third Arbitrator by application to any state court of general jurisdiction in the jurisdiction in which the Premises are located, upon 10 days prior
written notice to the other party of such intent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The decision of the Arbitrator(s) shall be made within 30 days
after the appointment of a single Arbitrator or the third Arbitrator, as applicable. The decision of the single Arbitrator shall be final and binding upon the parties. The average of the two closest Arbitrators in a three Arbitrator panel shall be
final and binding upon the parties. Each party shall pay the fees and expenses of the Arbitrator appointed by or on behalf of such party and the fees and expenses of the third Arbitrator shall be borne equally by both parties. If the Market Rate and
escalations are not determined by the first day of the Extension Term, then Tenant shall pay Landlord Base Rent in an amount equal to the Base Rent in effect immediately prior to the Extension Term and increased by the Rent Adjustment Percentage
until such determination is made. After the determination of the Market Rate and escalations, the parties shall make any necessary adjustments to such payments made by Tenant. Landlord and Tenant shall then execute an amendment recognizing the
Market Rate and escalations for the Extension Term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
31<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) An &#147;<B>Arbitrator</B>&#148; shall be any person appointed by or on
behalf of either party or appointed pursuant to the provisions hereof and: (i)&nbsp;shall be (A)&nbsp;a member of the American Institute of Real Estate Appraisers with not less than 10 years of experience in the appraisal of improved life science
space in the greater Boston metropolitan area, or (B)&nbsp;a licensed commercial real estate broker with not less than 15 years experience representing landlords and/or tenants in the leasing of high tech or life sciences space in the greater Boston
metropolitan area, (ii)&nbsp;devoting substantially all of their time to professional appraisal or brokerage work, as applicable, at the time of appointment and (iii)&nbsp;be in all respects impartial and disinterested. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Rights Personal</B>. The Extension Right is personal to Tenant and is not assignable without Landlord&#146;s consent, which may be
granted or withheld in Landlord&#146;s sole discretion separate and apart from any consent by Landlord to an assignment of Tenant&#146;s interest in this Lease, except that they may be assigned in connection with any Permitted Assignment of this
Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Exceptions</B>. Notwithstanding anything set forth above to the contrary, the Extension Right shall, at Landlord&#146;s
option, not be in effect and Tenant may not exercise any of the Extension Right: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) during any period of time that Tenant
is in Default under any provision of this Lease; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) if Tenant has been in Default under any provision of this Lease 3
or more times, whether or not the Defaults are cured, during the 12 month period immediately prior to the date that Tenant intends to exercise the Extension Right, whether or not the Defaults are cured. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>No Extensions</B>. The period of time within which the Extension Rights may be exercised shall not be extended or enlarged by reason of
Tenant&#146;s inability to exercise the Extension Right. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>Termination</B>. The Extension Right shall, at Landlord&#146;s option,
terminate and be of no further force or effect even after Tenant&#146;s due and timely exercise of the Extension Right, if, after such exercise, but prior to the commencement date of the Extension Term, (i)&nbsp;Tenant fails to timely cure any
default by Tenant under this Lease; or (ii)&nbsp;Tenant has Defaulted 3 or more times during the period from the date of the exercise of the Extension Right to the date of the commencement of the Extension Term, whether or not such Defaults are
cured. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">40. <B>Intentionally Omitted</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">41. <B>Miscellaneous</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<B>Notices</B>. All notices or other communications between the parties shall be in writing and shall be deemed duly given upon delivery or refusal to accept delivery by the addressee thereof if delivered in person, or upon actual receipt if
delivered by reputable overnight guaranty courier, addressed and sent to the parties at their addresses set forth above. Landlord and Tenant may from time to time by written notice to the other designate another address for receipt of future
notices. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Joint and Several Liability</B>. If and when included within the term &#147;<B>Tenant</B>,&#148; as used in this
instrument, there is more than one person or entity, each shall be jointly and severally liable for the obligations of Tenant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
<B>Financial Information</B><I>. </I>Tenant shall furnish Landlord with true and complete copies of (i)&nbsp;Tenant&#146;s most recent audited annual financial statements within 90 days of the end of each of Tenant&#146;s fiscal years during the
Term, and (ii)&nbsp;Tenant&#146;s most recent unaudited quarterly financial statements within 45 days of the end of each of Tenant&#146;s first three fiscal quarters of each of Tenant&#146;s fiscal years during the Term. Notwithstanding the
foregoing, in no event shall Tenant be required to provide any financial information to Landlord which Tenant does not otherwise prepare (or cause to be prepared) for its own purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
32<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Recordation</B>. Neither this Lease nor a memorandum of lease shall be filed by or on
behalf of Tenant in any public record. Landlord may prepare and file, and upon request by Landlord Tenant will execute, a memorandum of lease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>Interpretation</B>. The normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of this Lease or any exhibits or amendments hereto. Words of any gender used in this Lease shall be held and construed to include any other gender, and words in the singular number shall be held to include
the plural, unless the context otherwise requires. The captions inserted in this Lease are for convenience only and in no way define, limit or otherwise describe the scope or intent of this Lease, or any provision hereof, or in any way affect the
interpretation of this Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>Not Binding Until Executed</B>. The submission by Landlord to Tenant of this Lease shall have no
binding force or effect, shall not constitute an option for the leasing of the Premises, nor confer any right or impose any obligations upon either party until execution of this Lease by both parties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <B>Limitations on Interest</B>. It is expressly the intent of Landlord and Tenant at all times to comply with applicable law governing the
maximum rate or amount of any interest payable on or in connection with this Lease. If applicable law is ever judicially interpreted so as to render usurious any interest called for under this Lease, or contracted for, charged, taken, reserved, or
received with respect to this Lease, then it is Landlord&#146;s and Tenant&#146;s express intent that all excess amounts theretofore collected by Landlord be credited on the applicable obligation (or, if the obligation has been or would thereby be
paid in full, refunded to Tenant), and the provisions of this Lease immediately shall be deemed reformed and the amounts thereafter collectible hereunder reduced, without the necessity of the execution of any new document, so as to comply with the
applicable law, but so as to permit the recovery of the fullest amount otherwise called for hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <B>Choice of Law</B>.
Construction and interpretation of this Lease shall be governed by the internal laws of the state in which the Premises are located, excluding any principles of conflicts of laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <B>Time</B>. Time is of the essence as to the performance of Tenant&#146;s obligations under this Lease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <B>OFAC</B>. Tenant and all beneficial owners of Tenant are currently (a)&nbsp;in compliance with and shall at all times during the Term of
this Lease remain in compliance with the regulations of the Office of Foreign Assets Control (&#147;<B>OFAC</B>&#148;) of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the
&#147;<B>OFAC Rules</B>&#148;), (b) not listed on, and shall not during the term of this Lease be listed on, the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List, or the Sectoral Sanctions Identification List,
which are all maintained by OFAC and/or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c)&nbsp;not a person or entity with whom a U.S. person is
prohibited from conducting business under the OFAC Rules. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <B>Incorporation by Reference</B>. All exhibits and addenda attached hereto
are hereby incorporated into this Lease and made a part hereof. If there is any conflict between such exhibits or addenda and the terms of this Lease, such exhibits or addenda shall control. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <B>Entire Agreement</B>. This Lease, including the exhibits attached hereto, constitutes the entire agreement between Landlord and Tenant
pertaining to the subject matter hereof and supersedes all prior and contemporaneous agreements, understandings, letters of intent, negotiations and discussions, whether oral or written, of the parties, and there are no warranties, representations
or other agreements, express or implied, made to either party by the other party in connection with the subject matter hereof except as specifically set forth herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
33<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <B>No Accord and Satisfaction</B>. No payment by Tenant or receipt by Landlord of a
lesser amount than the monthly installment of Base Rent or any Additional Rent will be other than on account of the earliest stipulated Base Rent and Additional Rent, nor will any endorsement or statement on any check or letter accompanying a check
for payment of any Base Rent or Additional Rent be an accord and satisfaction. Landlord may accept such check or payment without prejudice to Landlord&#146;s right to recover the balance of such Rent or to pursue any other remedy provided in this
Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <B>Hazardous Activities</B>. Notwithstanding any other provision of this Lease, Landlord, for itself and its employees, agents
and contractors, reserves the right to refuse to perform any repairs or services in any portion of the Premises which, pursuant to Tenant&#146;s routine safety guidelines, practices or custom or prudent industry practices, require any form of
protective clothing or equipment other than safety glasses. In any such case, Tenant shall contract with parties who are acceptable to Landlord, in Landlord&#146;s reasonable discretion, for all such repairs and services, and Landlord shall, to the
extent required, equitably adjust Tenant&#146;s Share of Operating Expenses in respect of such repairs or services to reflect that Landlord is not providing such repairs or services to Tenant.<I> </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[ Signatures on next page ] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Net Multi-Tenant Laboratory</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
34<B>
</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Landlord and Tenant have executed this Lease as of the day and year first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TENANT:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FREQUENCY THERAPEUTICS, INC.</B>,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">a Delaware corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David L. Lucchino</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chairman and CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LANDLORD:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><FONT STYLE="white-space:nowrap">ARE-MA</FONT> REGION NO. 20, LLC,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">a Delaware limited liability company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">ALEXANDRIA REAL ESTATE EQUITIES, L.P., a Delaware limited partnership, managing member</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">ARE-QRS</FONT> CORP., a Maryland corporation, general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eric S. Johnson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Senior Vice President RE Legal Affairs</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>1<B></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A TO LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DESCRIPTION OF PREMISES </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g833164page0035.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>2<B></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g833164page036.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>
37<B>
 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B TO LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DESCRIPTION OF PROJECT </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parcel 1:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A parcel of land near Presidential Way, Woburn, Middlesex County, Massachusetts, shown as Lot <FONT STYLE="white-space:nowrap">5B-1</FONT> on a plan
entitled &#147;Subdivision Plan of Land in Woburn, Massachusetts,&#148; prepared for Eastern Development dated January&nbsp;16, 2001 by Vanasse Hangen Brustlin, Inc. recorded in Middlesex South Registry of Deeds in Plan Book 32475, Page 319. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parecels 2 and 3: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Two contiguous parcels of Registered Land on
Presidential Way, Woburn, Middlesex County, Massachusetts shown as Lot 11 and Lot 12 on Land Court Plan <FONT STYLE="white-space:nowrap">36099-D,</FONT> a copy of which is filed with the Middlesex South Registry District with Certificate No. 212009.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Together with the right to use Presidential Way for all purposes for whcigh streets and ways are commonly used in the City of Woburn. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Together with the benefit of and subject to provisions of Easement and Agreement dated December&nbsp;7, 2000, by and between 500 MetroNorth Corporate Center
LLC and MetroNorth Corporate Center LLC recorded in Book 32138, Page 391 and filed as Document No.&nbsp;1158395. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>1<B></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT C TO LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>WORK LETTER </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS
WORK LETTER dated August <U>&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2016 (this &#147;<B>Work Letter</B>&#148;) is made and entered into by and between <B><FONT STYLE="white-space:nowrap">ARE-MA</FONT> REGION NO. 20, LLC</B>, a Delaware limited liability
company (&#147;<B>Landlord</B>&#148;), and <B>FREQUENCY THERAPEUTICS, INC.</B>, a Delaware corporation (&#147;<B>Tenant</B>&#148;), and is attached to and made a part of the Lease Agreement dated August <U>&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2016 (the
&#147;<B>Lease</B>&#148;), by and between Landlord and Tenant. Any initially capitalized terms used but not defined herein shall have the meanings given them in the Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B>General Requirements</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Tenant&#146;s Authorized Representative</B>. Tenant designates Richard Mitrano (&#147;<B>Tenant&#146;s Representative</B>&#148;) as the
only person authorized to act for Tenant pursuant to this Work Letter. Landlord shall not be obligated to respond to or act upon any request, approval, inquiry or other communication (&#147;<B>Communication</B>&#148;) from or on behalf of Tenant in
connection with this Work Letter unless such Communication is in writing from Tenant&#146;s Representative. Tenant may change Tenant&#146;s Representative at any time upon not less than 5 business days advance written notice to Landlord. Neither
Tenant nor Tenant&#146;s Representative shall be authorized to direct Landlord&#146;s contractors in the performance of Landlord&#146;s Work (as hereinafter defined). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Landlord&#146;s Authorized Representative</B>. Landlord designates Tim White and Mike Carli (either such individual acting alone,
&#147;<B>Landlord&#146;s Representative</B>&#148;) as the only persons authorized to act for Landlord pursuant to this Work Letter. Tenant shall not be obligated to respond to or act upon any request, approval, inquiry or other Communication from or
on behalf of Landlord in connection with this Work Letter unless such Communication is in writing from Landlord&#146;s Representative. Landlord may change either Landlord&#146;s Representative at any time upon not less than 5 business days advance
written notice to Tenant. Landlord&#146;s Representative shall be the sole persons authorized to direct Landlord&#146;s contractors in the performance of Landlord&#146;s Work. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Architects, Consultants and Contractors</B>. Landlord and Tenant hereby acknowledge and agree that: (i)&nbsp;TRG Builders, Inc. shall be
the general contractor for the Tenant Improvements, (ii)&nbsp;R.H. Dineen shall be the architect (the &#147;<B>TI Architect</B>&#148;) for the Tenant Improvements, and (iii)&nbsp;any subcontractors for the Tenant Improvements shall be selected by
Landlord, subject to Tenant&#146;s approval, which approval shall not be unreasonably withheld, conditioned or delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B>Tenant
Improvements</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Tenant Improvements Defined</B>. As used herein, &#147;<B>Tenant Improvements</B>&#148; shall mean all
improvements to the Project of a fixed and permanent nature as shown on the TI Construction Drawings, as defined in <U>Section</U><U></U><U>&nbsp;2(c)</U> below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tenant shall have the right to have a representative present for all design and construction meetings relating to Landlord&#146;s Work (as
defined in <U>Section</U><U></U><U>&nbsp;3(a)</U> below). Tenant shall be solely responsible for ensuring that the design and specifications for Landlord&#146;s Work are consistent with Tenant&#146;s requirements. Landlord shall be responsible for
obtaining all permits, approvals and entitlements necessary for Landlord&#146;s Work, but shall have no obligation to, and shall not, secure any permits, approvals or entitlements related to Tenant&#146;s specific use of the Premises or
Tenant&#146;s business operations therein. Other than Landlord&#146;s Work, Landlord shall not have any obligation whatsoever with respect to the finishing of the Premises for Tenant&#146;s use and occupancy. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Tenant&#146;s Space Plans</B>. The schematic drawings and outline specifications attached to this Work Letter as <B>Schedule 1</B> (the
&#147;<B>Space Plans</B>&#148;) have been approved by Landlord and Tenant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>2<B></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Working Drawings</B>. Landlord shall cause the TI Architect to prepare and deliver to
Tenant for review and comment construction plans, specifications and drawings for the Tenant Improvements (&#147;<B>TI Construction Drawings</B>&#148;), which TI Construction Drawings shall be prepared substantially in accordance with the Space
Plans. Tenant shall be solely responsible for ensuring that the TI Construction Drawings reflect Tenant&#146;s requirements for the Tenant Improvements. Tenant shall deliver its written comments on the TI Construction Drawings to Landlord not later
than 5 business days after Tenant&#146;s receipt of the same; provided, however, that Tenant may not disapprove any matter that is substantially in accordance with the Space Plans without submitting a Change Request. Landlord and the TI Architect
shall consider all such comments in good faith and shall, within 5 business days after receipt, notify Tenant how Landlord proposes to respond to such comments, but Tenant&#146;s review rights pursuant to the foregoing sentence shall not delay the
design or construction schedule for the Tenant Improvements. Any disputes in connection with such comments shall be resolved in accordance with <U>Section</U><U></U><U>&nbsp;2(d)</U> hereof. Provided that the design reflected in the TI Construction
Drawings is substantially in accordance with the Space Plans, Tenant shall approve the TI Construction Drawings submitted by Landlord, unless Tenant submits a Change Request. Once approved by Tenant, subject to the provisions of
<U>Section</U><U></U><U>&nbsp;4</U> below, Landlord shall not materially modify the TI Construction Drawings except as may be reasonably required in connection with the issuance of the TI Permit (as defined in <U>Section</U><U></U><U>&nbsp;3(b)</U>
below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Approval and Completion</B>. It is hereby acknowledged by Landlord and Tenant that the TI Construction Drawings must be
completed and approved not later than August&nbsp;31, 2016, in order for the Landlord&#146;s Work to be Substantially Complete by the Target Commencement Date (as defined in the Lease). Upon any dispute regarding the design of the Tenant
Improvements, which is not settled within 10 business days after notice of such dispute is delivered by one party to the other, Tenant may make the final decision regarding the design of the Tenant Improvements, provided (i)&nbsp;Tenant acts
reasonably and such final decision is either consistent with or a compromise between Landlord&#146;s and Tenant&#146;s positions with respect to such dispute, (ii)&nbsp;that all costs and expenses resulting from any such decision by Tenant shall be
payable out of the TI Fund (as defined in <U>Section</U><U></U><U>&nbsp;5(d)</U> below), and (iii)&nbsp;Tenant&#146;s decision will not affect the base Building, structural components of the Building or any Building systems. Any changes to the TI
Construction Drawings following Landlord&#146;s and Tenant&#146;s approval of same requested by Tenant shall be processed as provided in <U>Section</U><U></U><U>&nbsp;4</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B>Performance of Landlord&#146;s Work</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Definition of Landlord&#146;s Work</B>. As used herein, &#147;<B>Landlord&#146;s Work</B>&#148; shall mean (i)&nbsp;the work of
constructing the Tenant Improvements, and (ii)&nbsp;the work of demising the Premises from the adjacent premises, which demising work shall be performed by Landlord, at Landlord&#146;s cost and not out of the TI Allowance. The components and
specifications of Landlord&#146;s Work in addition to the specifications set forth on the Space Plan are attached hereto as <B>Schedule 2</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Commencement and Permitting</B>. Landlord shall commence construction of the Tenant Improvements upon obtaining a building permit (the
&#147;<B>TI Permit</B>&#148;) authorizing the construction of the Tenant Improvements consistent with the TI Construction Drawings approved by Tenant. The cost of obtaining the TI Permit shall be payable from the TI Fund. Tenant shall assist
Landlord in obtaining the TI Permit. If any Governmental Authority having jurisdiction over the construction of Landlord&#146;s Work or any portion thereof shall impose terms or conditions upon the construction thereof that: (i)&nbsp;are
inconsistent with Landlord&#146;s obligations hereunder, (ii)&nbsp;increase the cost of constructing Landlord&#146;s Work, or (iii)&nbsp;will materially delay the construction of Landlord&#146;s Work, Landlord and Tenant shall reasonably and in good
faith seek means by which to mitigate or eliminate any such adverse terms and conditions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Completion of Landlord&#146;s Work</B>.
Landlord shall substantially complete or cause to be substantially completed Landlord&#146;s Work in a good and workmanlike manner, in accordance with Legal Requirements and the TI Permit subject, in each case, to Minor Variations and normal
&#147;punch list&#148; items of a <FONT STYLE="white-space:nowrap">non-material</FONT> nature that do not interfere with the use of the Premises and, so long as Tenant has obtained all of the permits required by the applicable Governmental
Authorities in order for Tenant to operate in and use the Premises for the Permitted Use, shall obtain a temporary certificate of occupancy </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>3<B></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or permit card issued by the applicable Governmental Authorities permitting occupancy of the Premises (&#147;<B>Substantial Completion</B>&#148; or &#147;<B>Substantially Complete</B>&#148;).
Upon Substantial Completion of Landlord&#146;s Work, Landlord shall require the TI Architect and the general contractor to execute and deliver, for the benefit of Tenant and Landlord, a Certificate of Substantial Completion in the form of the
American Institute of Architects (&#147;<B>AIA</B>&#148;) document G704. For purposes of this Work Letter, &#147;<B>Minor Variations</B>&#148; shall mean any modifications reasonably required: (i)&nbsp;to comply with all applicable Legal
Requirements and/or to obtain or to comply with any required permit (including the TI Permit); (ii) to comply with any request by Tenant for modifications to Landlord&#146;s Work; (iii)&nbsp;to comport with good design, engineering, and construction
practices that are not material; or (iv)&nbsp;to make reasonable adjustments for field deviations or conditions encountered during the construction of Landlord&#146;s Work. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Selection of Materials</B>. Where more than one type of material or structure is indicated on the TI Construction Drawings approved by
Landlord and Tenant, the option will be selected at Landlord&#146;s sole and absolute subjective discretion. As to all building materials and equipment that Landlord is obligated to supply under this Work Letter, Landlord shall select the
manufacturer thereof in its sole and absolute subjective discretion unless a specific manufacturer has been identified during the design process. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>Delivery of the Premises</B>. When Landlord&#146;s Work is Substantially Complete, subject to the remaining terms and provisions of this
<U>Section</U><U></U><U>&nbsp;3(e)</U>, Tenant shall accept the Premises. Tenant&#146;s taking possession and acceptance of the Premises shall not constitute a waiver of: (i)&nbsp;any warranty with respect to workmanship (including installation of
equipment) or material (exclusive of equipment provided directly by manufacturers), (ii) any <FONT STYLE="white-space:nowrap">non-compliance</FONT> of Landlord&#146;s Work with applicable Legal Requirements, or (iii)&nbsp;any claim that
Landlord&#146;s Work was not completed substantially in accordance with the TI Construction Drawings (subject to Minor Variations and such other changes as are permitted hereunder) (collectively, a &#147;<B>Construction Defect</B>&#148;). Tenant
shall have one year after Substantial Completion within which to notify Landlord of any such Construction Defect discovered by Tenant, and Landlord shall use reasonable efforts to remedy or cause the responsible contractor to remedy any such
Construction Defect within 30 days thereafter. Notwithstanding the foregoing, Landlord shall not be in default under the Lease if the applicable contractor, despite Landlord&#146;s reasonable efforts, fails to remedy such Construction Defect within
such <FONT STYLE="white-space:nowrap">30-day</FONT> period. If the contractor fails to remedy such Construction Defect within a reasonable time, Landlord shall use reasonable efforts to remedy the Construction Defect within a reasonable period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tenant shall be entitled to receive the benefit of all construction warranties and manufacturer&#146;s equipment warranties relating to equipment installed in
the Premises. If requested by Tenant, Landlord shall attempt to obtain extended warranties from manufacturers and suppliers of such equipment, but the cost of any such extended warranties shall be borne solely out of the TI Fund. Landlord shall
promptly undertake and complete, or cause to be completed, all punch list items. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>Commencement Date Delay</B>. Except as otherwise
provided in the Lease, Delivery of the Premises shall occur when Landlord&#146;s Work has been Substantially Completed, except to the extent that completion of Landlord&#146;s Work shall have been actually delayed by any one or more of the following
causes (&#147;<B>Tenant Delay</B>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Tenant&#146;s Representative was not reasonably available to give or receive
any Communication or to take any other action required to be taken by Tenant hereunder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Tenant&#146;s request for
Change Requests (as defined in <U>Section</U><U></U><U>&nbsp;4(a)</U> below) whether or not any such Change Requests are actually performed; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Construction of any Change Requests; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>4<B></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Tenant&#146;s request for materials, finishes or installations requiring
unusually long lead times, provided that Landlord has advised Tenant of such long lead time items and Tenant continued to require such long lead time items; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Tenant&#146;s delay in reviewing, revising or approving plans and specifications beyond the periods set forth herein; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) Tenant&#146;s delay in providing information critical to the normal progression of the Project. Tenant shall provide such
information as soon as reasonably possible, but in no event longer than one week after receipt of any request for such information from Landlord; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) Tenant&#146;s delay in making payments to Landlord for Excess TI Costs (as defined in
<U>Section</U><U></U><U>&nbsp;5(d)</U> below); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) Any other act or omission by Tenant or any Tenant Party (as
defined in the Lease), or persons employed by any of such persons that continues for more than one (1)&nbsp;business day after Landlord&#146;s notice thereof to Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Delivery is delayed for any of the foregoing reasons, then Landlord shall cause the TI Architect to certify the date on which the Tenant Improvements would
have been completed but for such Tenant Delay and such certified date shall be the date of Delivery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B>Changes</B>. Any changes
requested by Tenant to the Tenant Improvements after the delivery and approval by Landlord of the Space Plan shall be requested and instituted in accordance with the provisions of this <U>Section</U><U></U><U>&nbsp;4</U> and shall be subject to the
written approval of Landlord and the TI Architect, such approval not to be unreasonably withheld, conditioned or delayed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<B>Tenant&#146;s Request For Changes</B>. If Tenant shall request changes to the Tenant Improvements (&#147;<B>Changes</B>&#148;), Tenant shall request such Changes by notifying Landlord in writing in substantially the same form as the AIA standard
change order form (a &#147;<B>Change Request</B>&#148;), which Change Request shall detail the nature and extent of any such Change. Such Change Request must be signed by Tenant&#146;s Representative. Landlord shall, before proceeding with any
Change, use commercially reasonable efforts to respond to Tenant as soon as is reasonably possible with an estimate of: (i)&nbsp;the time it will take, and (ii)&nbsp;the architectural and engineering fees and costs that will be incurred, to analyze
such Change Request (which costs shall be paid from the TI Fund to the extent actually incurred, whether or not such change is implemented). Landlord shall thereafter submit to Tenant in writing, within 5 business days of receipt of the Change
Request (or such longer period of time as is reasonably required depending on the extent of the Change Request), an analysis of the additional cost or savings involved, including, without limitation, architectural and engineering costs and the
period of time, if any, that the Change will extend the date on which Landlord&#146;s Work will be Substantially Complete. Any such delay in the completion of Landlord&#146;s Work caused by a Change, including any suspension of Landlord&#146;s Work
while any such Change is being evaluated and/or designed, shall be Tenant Delay. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Implementation of Changes</B>. If Tenant:
(i)&nbsp;approves in writing the cost or savings and the estimated extension in the time for completion of Landlord&#146;s Work, if any, and (ii)&nbsp;deposits with Landlord any Excess TI Costs required in connection with such Change, Landlord shall
cause the approved Change to be instituted. Notwithstanding any approval or disapproval by Tenant of any estimate of the delay caused by such proposed Change, the TI Architect&#146;s determination of the amount of Tenant Delay in connection with
such Change shall be final and binding on Landlord and Tenant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>5<B></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <B>Costs</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Budget For Tenant Improvements</B>. Landlord and Tenant have agreed upon that certain initial budget dated July&nbsp;27, 2016 attached
hereto as <B>Schedule 3</B>, for the costs incurred or that will be incurred in connection with the design and construction of the Tenant Improvements (the &#147;<B>Budget</B>&#148;). Landlord does not guaranty the initial Budget and Tenant
acknowledges and agrees that the amounts set forth in such initial Budget may increase including, without limitation, in connection with and Changes. The Budget may be amended from time to time but shall be submitted to Tenant each time for its
approval, which approval shall not be unreasonably withheld, conditioned or delayed. Notwithstanding anything to the contrary contained herein, if Tenant does not approve or disapprove the Budget or any amended Budget within 2 days after
Landlord&#146;s delivery to Tenant of such Budget or amended Budget, Tenant shall be deemed to have approved such Budget or amended Budget. If the Budget is greater than the TI Allowance, Tenant shall deposit with Landlord the difference, in cash,
prior to the commencement of construction of the Tenant Improvements or Changes, for disbursement by Landlord as described in <U>Section</U><U></U><U>&nbsp;5(d)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>TI Allowance</B>. Landlord shall provide to Tenant a tenant improvement allowance (the &#147;<B>TI Allowance</B>&#148;) in the maximum
amount of $80.00 per rentable square foot in the Premises, which is included in the Base Rent set forth in the Lease. The TI Allowance shall be disbursed in accordance with this Work Letter. Notwithstanding anything to the contrary contained in this
Work Letter, a portion of the TI Allowance, equal to $5.00 per rentable square foot of the Premises, shall be allocated toward the cost of updating and modifying the Building HVAC controls to the Premises. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tenant shall have no right to the use or benefit (including any reduction to or payment of Base Rent) of any portion of the TI Allowance not required for the
hard and soft costs of design and construction of (i)&nbsp;the Tenant Improvements described in the TI Construction Drawings approved pursuant to <U>Section</U><U></U><U>&nbsp;2(d)</U> or (ii)&nbsp;any Changes pursuant to
<U>Section</U><U></U><U>&nbsp;4</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Costs Includable in TI Fund</B>. The TI Fund shall be used solely for the payment of design,
engineering, permits and construction costs in connection with the construction of the Tenant Improvements, including, without limitation, the cost of preparing the Space Plan and the TI Construction Drawings, all costs set forth in the Budget,
including Landlord&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, costs resulting from Tenant Delays and the cost of Changes (collectively, &#147;<B>TI Costs</B>&#148;). Notwithstanding
anything to the contrary contained herein, the TI Fund shall not be used to purchase any furniture, personal property or other <FONT STYLE="white-space:nowrap">non-Building</FONT> system materials or equipment, including, but not limited to,
Tenant&#146;s voice or data cabling, <FONT STYLE="white-space:nowrap">non-ducted</FONT> biological safety cabinets and other scientific equipment not incorporated into the Tenant Improvements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>Excess TI Costs</B>. Landlord shall have no obligation to bear any portion of the cost of any of the Tenant Improvements except to the
extent of the TI Allowance. If at any time and from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time,</FONT></FONT> the remaining TI Costs under the Budget exceed the remaining unexpended TI Allowance (&#147;<B>Excess
TI Costs</B>&#148;), monthly disbursements of the TI Allowance shall be made in the proportion that the remaining TI Allowance bears to the outstanding TI Costs under the Budget, and Tenant shall fund the balance of each such monthly draw. For
purposes of any litigation instituted with regard to such amounts, those amounts required to be paid by Tenant will be deemed Rent under the Lease. The TI Allowance and Excess TI Costs are herein referred to as the &#147;<B>TI Fund</B>.&#148;
Notwithstanding anything to the contrary set forth in this <U>Section</U><U></U><U>&nbsp;5(d)</U>, Tenant shall be fully and solely liable for TI Costs and the cost of Minor Variations in excess of the TI Allowance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>Construction Contract</B>. The contract for construction of the Tenant Improvements shall be written substantially on Landlord&#146;s
standard form of construction agreement with modifications reasonably acceptable to Landlord where the contract sum is the costs of the work plus a fee not to exceed a &#147;Guaranteed Maximum Price&#148; in an amount equal to the construction costs
and contingencies set forth in the Budget (which Budget shall be based upon completed permit drawings and shall not include comments raised by Governmental Authorities as part of their permit review) subject to the terms of such contract and subject
to any increases resulting from Changes and any changes to the permit drawings required by Governmental Authorities implemented after approval of the Budget. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>6<B></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B>Tenant Access</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Tenant&#146;s Access Rights</B>. Landlord hereby agrees to permit Tenant access, at Tenant&#146;s sole risk and expense, to the Building
(i) 30 days prior to the Commencement Date to perform any work (&#147;<B>Tenant&#146;s Work</B>&#148;) required by Tenant other than Landlord&#146;s Work, provided that such Tenant&#146;s Work is coordinated with the TI Architect and the general
contractor, and complies with the Lease and all other reasonable restrictions and conditions Landlord may impose, and (ii)&nbsp;prior to the completion of Landlord&#146;s Work, to inspect and observe work in process; all such access shall be during
normal business hours or at such other times as are reasonably designated by Landlord. Notwithstanding the foregoing, Tenant shall have no right to enter onto the Premises or the Project unless and until Tenant shall deliver to Landlord evidence
reasonably satisfactory to Landlord demonstrating that any insurance reasonably required by Landlord in connection with such <FONT STYLE="white-space:nowrap">pre-commencement</FONT> access (including, but not limited to, any insurance that Landlord
may require pursuant to the Lease) is in full force and effect. Any entry by Tenant shall comply with all established safety practices of Landlord&#146;s contractor and Landlord until completion of Landlord&#146;s Work and acceptance thereof by
Tenant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>No Interference</B>. Neither Tenant nor any Tenant Party (as defined in the Lease) shall interfere with the performance of
Landlord&#146;s Work, nor with any inspections or issuance of final approvals by applicable Governmental Authorities, and upon any such interference, Landlord shall have the right to exclude Tenant and any Tenant Party from the Premises and the
Project until Substantial Completion of Landlord&#146;s Work. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>No Acceptance of Premises</B>. The fact that Tenant may, with
Landlord&#146;s consent, enter into the Project prior to the date Landlord&#146;s Work is Substantially Complete for the purpose of performing Tenant&#146;s Work shall not be deemed an acceptance by Tenant of possession of the Premises, but in such
event Tenant shall defend with counsel reasonably acceptable by Landlord, indemnify and hold Landlord harmless from and against any loss of or damage to Tenant&#146;s property, completed work, fixtures, equipment, materials or merchandise, and from
liability for death of, or injury to, any person, caused by the act or omission of Tenant or any Tenant Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <B>Miscellaneous</B>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>Consents</B>. Whenever consent or approval of either party is required under this Work Letter, that party shall not unreasonably
withhold, condition or delay such consent or approval, unless expressly set forth herein to the contrary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>Modification</B>. No
modification, waiver or amendment of this Work Letter or of any of its conditions or provisions shall be binding upon Landlord or Tenant unless in writing signed by Landlord and Tenant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>Default</B>. Notwithstanding anything set forth herein or in the Lease to the contrary, Landlord shall not have any obligation to
perform any work hereunder or to fund any portion of the TI Costs during any period that there is a Default by Tenant under the Lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>7<B></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Space Plans </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g833164bawa43.gif" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>8<B></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g833164page045.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>9<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Landlord&#146;s Work Components and Specifications </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BASIS OF DESIGN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FREQUENCY THERAPEUTICS </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>19 Presidential Way </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Woburn, MA </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The Richmond
Group </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">August 16, 2016 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g833164page46.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g833164page46a.jpg" ALT="LOGO">
</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page <B>1</B> of <B>15</B>
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>10<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Frequency Therapeutics </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Basis of Design </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">August&nbsp;16, 2016
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TABLE OF CONTENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1
</B>&#150; Plumbing Systems <I>(pages 3 </I><I>&#150; </I><I>8)</I> <B> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2 </B>&#150; HVAC Systems <I>(pages 9 &#150;
12)</I> <B> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3 </B>&#150; Electrical Systems <I>(pages 13</I> &#150;<I>15)</I> </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page <B>2</B> of <B>15</B>
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>11<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>PLUMBING </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All plumbing systems shall be designed in conformance with the Massachusetts Plumbing Code (248CMR) and related
ANSI Standards </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All utility generation and fuel distribution systems will conform to applicable NFPA guidelines and good
engineering practice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cross-connection control will be installed in conformance with Massachusetts Department of Environmental
Protection requirements (310CMR Section&nbsp;22.22) and the city/town water authority </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tepid/emergency water generation and distribution will be governed by ANZI standard Z358.1 guidelines and OSHA
Recommendations. (See Section below) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If applicable, all domestic water, natural gas, sanitary sewer and storm sewer will be coordinated with the
existing site utilities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Plumbing Fixtures&nbsp;&amp; Trim: unless otherwise specified, fixtures shall be as follows: (See Attached
Fixture Schedule_Tenant Specific) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Acceptable Manufacturers include: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Vitreous China: American Standard, Kohler or equal </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Faucets: American Standard, Sloan, Kohler or equal </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Carrier supports: Zurn, JR Smith or equal </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stainless Steel Sink: Elkay, Advance Tabco or equal </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shower Stalls: Clarion Bathware, Aquabath or equal </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shower valves: Symmons or equal </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mop Basin Sinks: Fiat, Mustee or equal </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Electric Water Coolers: Halsey Taylor, Oasis, Elkay or equal </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stops&nbsp;&amp; Supplies: Brasscraft or equal </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">P-Traps:</FONT> Maguire, Boston, Zurn or equal </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Color&nbsp;&amp; Finish: All trim exposed to view shall be polished chrome plated, and all fixtures and toilet
seats shall be white unless specified otherwise </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page <B>3</B> of <B>15</B>
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>12<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Piping guards: Provide handilav-guard insulation by Truebro on water supplies and waste piping below
handicapped use lavatories. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lead Content: All applicable wetted components shall comply with the Safe Water Drinking Act (SWDA) lead
reduction </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">g.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fixture quantities and utility (i.e.: Vacuum, Air, N2, etc.) use points will be based on:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Equipment utility matrix: <B>TBD &#150; Pending to be determined</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Plans: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">PL-5</FONT> TEST FIT dated 07/07/2016 </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Massachusetts Plumbing Code (248CMR) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Current Applicable OSHA&nbsp;&amp; ANZI standard Requirements </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Site Utilities Plan: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Base Building: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Domestic Cold water will be provided by existing house building service </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Natural gas loads will be based upon review of existing building conditions; as well as, review of New
Mechanical, Plumbing<I>&nbsp;&amp;</I> Process equipment load requirements. The Gas Company will need to be contacted to determine building availability and confirmation of incoming service load/psig. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Site sanitary waste and vent drainage will be coordinated with the current waste line inverts in the facility
to support the new fixtures, drainage specialties and equipment listed on the Architectural Plans&nbsp;&amp; Equipment Matrix which require sanitary waste drain connections. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Storm sewer drainage on the project; existing to remain as is. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>C.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Water Systems: (Domestic, Protected<I>&nbsp;&amp;</I> Tepid/Emergency) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Domestic water is currently metered for building service; no new tenant
<FONT STYLE="white-space:nowrap">sub-meters</FONT> are included. All new fixtures and equipment that require domestic water shall connect to existing house service mains and extend as necessary to support new domestic fixtures and equipment.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A new electric hot water heater will provide domestic hot water for new Tenant (i.e.: Kitchen/Pantry/Wellness)
sinks. All core toilet rooms shall remain in present condition/configuration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Currently, <FONT STYLE="white-space:nowrap">non-potable</FONT> cold and hot water service is house generated.
All new services needed for lab fixtures and equipment shall extend from existing rack services for new tenant <FONT STYLE="white-space:nowrap">build-out.</FONT> No tenant <FONT STYLE="white-space:nowrap">sub-metering.</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page <B>4</B> of
<B>149</B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>1<B>3 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Point-of-use</FONT></FONT> filters (AP200
model) on the domestic&nbsp;&amp; protected cold water will be provided for all coffee stations and ice makers, as applicable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The existing Tepid/Emergency water distribution originates in mechanical closets in corridor. NSMC has carried
costs to <FONT STYLE="white-space:nowrap">re-furbish</FONT> the existing central mixing valve station (Lawler type); as well as, provide a new time clock / solenoid valve (dump) on line to keep water from becoming stagnant. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All new emergency equipment shall connect to new tepid/emergency water distribution which shall comply with
applicable OSHA, ANZI&nbsp;&amp; Massachusetts Plumbing Code 248CMR Standards. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pipe&nbsp;&amp; Fitting Materials: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pipe or tubing: Hard drawn Type L seamless copper tubing; Fittings: Wrot copper and/or Viega Propress; Joints:
Solder 95/5 or Press Fit; Ball Valves: Viega Propress / Apollo (Lead-free, Full Port, 2piece) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>D.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sanitary Waste and Vent Drainage System: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sanitary waste will collect from all domestic fixtures, drainage specialties and equipment, per the equipment
matrix and Architectural Plans (referenced above), and terminate into existing building sanitary sewer system. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Inverts will be coordinated with the site conditions and other drainage systems. Gravity flow will be utilized
whenever possible. Pump discharged waste will be used only when current sanitary waste inverts are not able to be made by gravity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Maintenance of pumps (if applicable) shall be the tenant responsibility upon completion of project renovations.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pipe&nbsp;&amp; Fitting Materials: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pipe&nbsp;&amp; fittings: Service weight bell&nbsp;&amp; spigot cast iron soil pipe and fittings joined with
neoprene resilient gaskets for all under slab drainage. No hub cast iron pipe and fittings with approved stainless steel mechanical coupling with neoprene gasket for all above slab drainage. Type DWV hard drawn seamless copper tubing with wrot
copper drainage pattern fittings joined with 95/5 solder shall be used for all <FONT STYLE="white-space:nowrap">1-1/2&#148;</FONT> or smaller waste lines. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>E.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Laboratory Waste and Vent Drainage: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All lab waste shall be treated by an existing house chemically adjusted treatment system located in south wing
basement level. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NSMC requires a &#145;notarized&#146; letter furnished by client/tenants listing all potential chemicals which
could enter lab waste system for treatment per Massachusetts 248CMR code. (Typically this is chemical list submitted to local/state authority for wastewater permitting. This list is required prior to Stamped Engineered Permit Submission Plans from
NSMC. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page <B>5</B> of <B>15</B>
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>1<B></B>4<B></B><B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Landlord will hold wastewater permitting for this system </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Equipment Selection/List: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ETR House system </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All new laboratory waste&nbsp;&amp; vent (Sinks, Floor Drains, Lab Equipment, etc.) shall drain by gravity to
central chemically adjusted treatment system. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pump&nbsp;&amp; transfer equipment installed only when inverts for gravity drain are unattainable and NSMC has
been given local jurisdictional authority approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All lab fixtures, floor drains and equipment requiring laboratory waste shall be determined by the client
utility equipment matrix, Architectural&nbsp;&amp; Plumbing Plans referenced above. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Waste streams requiring treatment for separation of metals, solvents or RDNA waste streams are <U>not</U>
included in this Basis of Design narrative. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Inverts will be coordinated with site conditions and current designated tenant floor level waste and vent
risers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">g.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pipe&nbsp;&amp; Fitting Materials: (Manufacturer IPEX/Enfield or equal) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All &#145;gravity&#146; waste and vent shall be schedule 40 polypropylene pipe with socket drainage pattern
fittings and heat fusion joints. All Pumped waste shall be schedule 40 polypropylene pipe with pressure rated socket fittings and heat fusion joints. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>F.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Natural Gas: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New equipment loads shall include: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>i.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Not applicable for Frequency TI Project </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Coordination with Gas Supplier (National Grid) for new equipment loads, available pressure / capacity and
design load added to facility. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">System pipe sizing and design will conform to Massachusetts Plumbing Code 248CMR&nbsp;&amp; NFPA 54 Standards.
All pipe routing will be determined based upon service entry (Meter location) and current building configurations/layouts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pipe and fitting materials: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page <B>6</B> of <B>15</B>
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>15<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All new distribution <FONT STYLE="white-space:nowrap">2-1/2&#148;</FONT> <U>&lt;</U> shall be Schedule 40
carbon steel pipe and fittings with BUTT WELD joints. Flanged Plug Valves for <FONT STYLE="white-space:nowrap">Shut-off</FONT> / Service Isolation to equipment </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All new distribution <U>&lt;</U> 2&#148; size shall be Schedule 40 carbon steel pipe with black malleable
threaded fittings. Tee Handle ball valves for <FONT STYLE="white-space:nowrap">Shut-off</FONT> / Service Isolation to equipment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>G.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Compressed Air (CA) &#150; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Equipment: <B>ETR House system</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As applicable, all compressed air distribution piping shall be governed by provided equipment matrix and
Architectural Plan layouts (referenced above). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pipe&nbsp;&amp; Fitting Materials: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All distribution piping shall be type ACR/OXY hard drawn seamless copper tubing, with cleaned and bagged wrot
copper fittings. Joints shall be brazed with nitrogen purge. (NFPA99 requirements). All <FONT STYLE="white-space:nowrap">shut-off</FONT> valves shall be clean 3 piece ball valves by Apollo <FONT STYLE="white-space:nowrap">82-200</FONT> series oxygen
cleaned </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>H.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lab Vacuum System: - </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Equipment: <B>ETR House System</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As applicable, all new Vacuum distribution piping shall be governed by provided equipment matrix and
Architectural plan layouts (referenced above). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pipe&nbsp;&amp; Fitting Materials: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All distribution piping shall be type L hard drawn seamless copper tubing, with Viega Propress fittings. All <FONT
STYLE="white-space:nowrap">shut-off</FONT> valves shall be 2 piece, full port ball valves by Viega, Apollo or equal </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>I.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Specialty Gases: (C02.) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Equipment<B></B>:<B></B><B> OFCI </B>&#150;<B> NSMC shall receive and mount owner provided manifold</B>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New (Co2) distribution shall be to (2)&nbsp;stacked incubators in Tissue Culture lab. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pipe&nbsp;&amp; Fitting Materials: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All distribution piping shall be type ACR/OXY hard drawn seamless copper tubing, with cleaned and bagged wrot
copper fittings. Joints shall be brazed with nitrogen purge. (NFPA99 requirements). All <FONT STYLE="white-space:nowrap">shut-off</FONT> valves shall be clean 3 piece ball valves by Apollo <FONT STYLE="white-space:nowrap">82-200</FONT> series oxygen
cleaned </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page <B>7</B> of <B>15</B>
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>16<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>J.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Pure Water (RODI) &#150; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Equipment: Not applicable / No house system currently available </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New lab distribution loop: Not applicable </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">RO Reject Reclaim: Not applicable </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All usage points: Not applicable </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pipe&nbsp;&amp; Fitting Materials: Not applicable </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page <B>8</B> of <B>15</B>
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>17<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>HVAC </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Outdoor Temperature Design Criteria</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Summer </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">91 degrees Fahrenheit design dry bulb </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">74 degrees Fahrenheit design wet bulb </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Winter </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">0 degrees Fahrenheit design dry bulb </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Indoor Temperature Design Criteria</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Office&nbsp;&amp; Support areas non lab </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Summer </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">74 degrees Fahrenheit design dry bulb <FONT STYLE="white-space:nowrap">(+/-2</FONT> degrees) </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Winter </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">70 degrees Fahrenheit design dry bulb (+/- 2 degrees) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Laboratory Areas </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Summer </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">72 degrees Fahrenheit design dry bulb (+/-2 degrees) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Winter </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">72 degrees Fahrenheit design dry bulb (+/- 2 degrees) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Support Areas&nbsp;&amp; Corridors </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Summer </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">72 degrees Fahrenheit design dry bulb <FONT STYLE="white-space:nowrap">(+/-3</FONT> degrees) </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Winter </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">70 degrees Fahrenheit design dry bulb (+/- 3 degrees) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page <B>9</B> of <B>15</B>
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>18<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Indoor Humidity Design Criteria</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Office&nbsp;&amp; Support areas </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Summer 50% RH +/- 15% </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Winter No added humidity </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Laboratory areas </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Summer 50% RH +/- 15% </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Winter No added humidity </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Support Areas </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Summer 50% RH <I>+/-</I> 15% </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Winter No added humidity </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">D.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Ventilation Design Criteria</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Office&nbsp;&amp; Support areas </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on International mechanical code and ASHRAE ventilation 62.1 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Laboratory Areas </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lab area will be provided with a minimum of six to eight outside air changes/hour. The actual air change rate
may be higher where additional <FONT STYLE="white-space:nowrap">make-up</FONT> air is required for hood exhaust or to meet design cooling loads. Labs will be once through design </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Support Areas </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lab support areas will be provided with a minimum of <FONT STYLE="white-space:nowrap">4-6</FONT> outside air
changes per hour. The actual air change rate may be higher to meet cooling loads </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">F.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Space Pressurization or Air directionality</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The facility will be maintained at a slight positive pressure with Respect to atmosphere to minimize
uncontrolled infiltration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Office areas will be maintained at a higher positive pressure than surrounding labs and support areas
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page <B>10</B> of
<B>15</B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>19<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Laboratory areas will be maintained at a negative pressure relative to surrounding spaces including offices and
corridors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No specialized or validated pressure controls are currently in this program. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">G.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Space Filtration Criteria</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Office Areas, Support Areas </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">a. 85% efficient <FONT STYLE="white-space:nowrap">Pre-filters</FONT> in main air handler </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Laboratory Areas </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">a. 30% efficient <FONT STYLE="white-space:nowrap">Pre-filters</FONT> and 85% cartridge filters in Air handler </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">H.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>House Air Allocation Criteria</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The House Air allocation for this tenant space is based on the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lab Air Allocation (Once through Air) 8,025 CFM </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Office / Support Air Allocation (recirculated Air) 6,880 CFM </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Total air to the Frequency space 14,905 CFM </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(5)&nbsp;Bench hoods </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Laboratory Areas </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">30% efficient <FONT STYLE="white-space:nowrap">Pre-filters</FONT> and 85% cartridge filters in Air handler
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">I.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>General System description</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The office and lab Areas will be serviced utilizing the existing hot water chilled water AH&#146;S in
penthouse. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Three house AH&#146;S are connected with a common plenum which services the entire south wing of the
building. Supply and return air risers are connected to supply and return vav and constant volume boxes throughout. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Three exhaust fans in
penthouse are also set up with a common exhaust plenum. Exhaust risers provide lab exhaust at each floor on the south wing and are terminated with exhaust boxes or valves. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">All lab areas will be once through design New&nbsp;&amp; existing supply and exhaust vav boxes will be dedicated for the new lab areas. The
boxes are pressure independent. Supply vav boxes will have hot water modulating <FONT STYLE="white-space:nowrap">re-heat</FONT> for zone temperature control. Each lab area will have its own zone control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page <B>11</B> of
<B>15</B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>20<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The office will use fan powered vav boxes with hot water reheat coils piped to existing hot
water mains. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">J.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>BMS Controls</U> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Building Management System (BMS) shall be Johnson controls and replace the existing house control system.
The Building Management System (BMS) shall use an open architecture and fully support a multi-vendor environment. To accomplish this effectively, the BMS shall support open variety of third-party devices and applications. The system shall be
designed for use on the Internet, or intranets using off the shelf, industry standard technology compatible with other owner provided networks. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Building Management System shall consist of the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Standalone Network Automation Engine(s) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Field Equipment Controller(s) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Input/output Module(s) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Local Display Device(s) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Distributed User Interface(s) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Network processing, data storage and communications equipment </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The system shall be modular in nature, and shall permit expansion of both capacity and functionality through
the addition of sensors, actuators, controllers and operator devices, while <FONT STYLE="white-space:nowrap">re-using</FONT> existing controls equipment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">System architectural design shall eliminate dependence upon any single device for alarm reporting and control
execution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The failure of any single component or network connection shall not interrupt the execution of control
strategies at other operational devices. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The System shall maintain all settings and overrides through a system reboot </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page <B>12</B> of
<B>15</B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>21<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>ELECTRICAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Temporary Light and Power: </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Temporary service will be provided for electrical light and power meeting OSHA requirements while the tenant
space is under construction and until permanent lighting and power are in operation. All temporaries shall be removed upon completion of the project. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Conduit and Fittings: </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">EMT, RMC, IMC, PVC, and MC cable may be used throughout where applicable by Code. Armored cable shall be used
for lighting and devices shall be furnished and installed complete as part of thereof, as specifically called for herein. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Conductors shall be 600 volt insulation and shall conform to the following Underwriters&#146; Laboratories
approved type and specifications. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Branch circuits to be Type THWN, THW, THHN, feeders to be Type THWN, THHN, and signal wiring to be minimum
No.&nbsp;14 <FONT STYLE="white-space:nowrap">AWG-Type</FONT> TW, THHN. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">System and equipment grounding shall be provided in accordance with NEC art 250. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fire Alarm MC cable to be used. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lighting: </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All lighting systems (normal, emergency and exit) include all fixtures, lamps, plaster and/or tile frames,
standards, switches, outlets, wiring, dimmers, raceways and all the components and fittings as required for complete lighting systems. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Design performance will utilize existing recessed and surface mounted fixtures. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Typical foot-candle (F/C) illumination levels will be designed around the following criteria per respective
building application: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">a.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Office Space</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30F/C</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">b.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Conference Rooms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">30F/C - 50F/C</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">c.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stairways/Corridors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">10F/C</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">d.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Break Room</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15F/C</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">e.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Laboratory Space</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">50F/C <FONT STYLE="white-space:nowrap">-</FONT> 60F/C</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page <B>13</B> of
<B>15</B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>22<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lighting control based upon local occupancy sensors and power packs for lab space and open offices, vacancy
sensor wall switches for private offices for Energy Code requirement functionality. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Emergency and Egress Lighting: </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Emergency exit lighting shall be provided in all areas in accordance with the latest edition of the
Massachusetts Fire Safety Code. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This system shall consist of nickel cadmium battery packs powering double halogen heads and provide backup
power to exit signs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Emergency egress lighting provided with one (1)&nbsp;foot-candle egress lighting as required by Code.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Distribution Equipment/Metering: </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Existing panelboards to remain. New circuit breakers which match existing electrical characteristics shall be
added as required for new circuitry. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Power Receptacles: </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General building convenience outlets shall be specification grade 20 A, 125 volt duplex type.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New offices shall have three (3)&nbsp;outlets each, and utility/mechanical rooms to contain one (1)&nbsp;duplex
receptacle. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Power to ceiling panels for island benchtops with receptacles in wall for benches along walls. Equipment zones
to be supplied by receptacles mounted in Wiremold. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Power to lab Equipment per Owner Equipment Matrix and site visits. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Standby Power for Owner Equipment is included utilizing available 4 watts per square foot allotment.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Fire Alarm System: </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Existing building fire alarm control panel is manufactured by Notifier<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, and will be maintained and extended for SLC circuits and NAC loops, with an additional power booster for horn/strobe and strobe only appliances being added for the tenant space.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Existing local energy master box #2657 will be maintained in its current capacity and current interfacing with <FONT
STYLE="white-space:nowrap">24-hour</FONT> central monitoring station. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page <B>14</B> of
<B>59</B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>23<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fire alarm zoning to remain the same unless otherwise noted. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Class A&#148; addressable system with pull stations, horn/strobe units, strobe only units and smoke/heat
detectors in <FONT STYLE="white-space:nowrap">non-sprinkled</FONT> areas. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fire alarm to be connected to all existing to remain sprinkler flow and tamper switches. No new zones are
anticipated on this project. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any required third party monitoring company fees and coordination by owner. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Bi-Directional</FONT> Amplifier System (BDA) is not included in this proposal.
Should the AHJ determine this is a requirement, a separate price will be provided upon further investigation. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Mechanical/Plumbing
System: </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">480/277V and 208/120V, 60 Hz single point power connections to equipment and pumps as indicated per ESI and
SNM&#146;s equipment matrix and progress drawings. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Control/interlock low voltage wiring by others. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Starters, HOA switches, VFD&#146;s and control equipment (thermostats) furnished and installed by HVAC
contractor. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page <B>15</B> of
<B>15</B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>24<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g833164page46.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Budget </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Frequency</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>19 Presidential
Way</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Woburn, MA</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>7/27/2016&nbsp;RSF</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>9,521</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="12" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Conceptual Budget per
<FONT STYLE="white-space:nowrap">PL-5</FONT> dated 7/7/2016 &amp; FM Corp Notes dated 7/21/2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Previous</B><br><B>Budget</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Updated</B><br><B>Budget</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Difference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Comments</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Demolition/Temporary Protection</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>36,868</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>35,219</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>-$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,649</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Updated per new take off</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Concrete</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>1,450</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,450</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carpentry and Millwork</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 60,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49,233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>-$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,074</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Made the break room cabinetry 12LF shorter and now with <FONT STYLE="white-space:nowrap">p-lam</FONT> tops in lieu of solid surface</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roofing and Sealants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>1,450</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,450</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Doors and Hardware</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>20,224</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,512</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>-$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,712</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">A few doors changed to glass doors in the flex area offices this is a savings for the DFH scope</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Glass and Glazing</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>50,994</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,610</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,616</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">There was three glass doors added per FM notes</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GWB Drywall</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>87,262</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>84,542</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>-$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,720</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Revised the GWB take off</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acoustic Ceiling Tiles</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>29,195</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32,846</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,651</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Added Vinyl faced tiles at the <FONT STYLE="white-space:nowrap">BL-2</FONT> lab</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Flooring</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>41,072</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>41,467</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>395</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Updated the flooring scope per FM notes using 1&#146;x2&#146; vinyl plank flooring&nbsp;&amp; vinyl flooring at BL2 lab</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Painting</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 11,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,499</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Specialties</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,784</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>990</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Added more corner guard per FM notes</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 57,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>-$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>57,998</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Removed the cold room from scopre</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory Casework</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 113,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>29,370</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>-$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>84,409</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Removed the mobile bench casework from scope</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fire Protection</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 17,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17,100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plumbing</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 158,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>145,964</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>-$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,080</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Remove ESEW in GW, remove Co2 Manifold, remove sink in Cold Room&nbsp;&amp; removed N2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HVAC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 194,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>189,542</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>-$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Rebudgeted <FONT STYLE="white-space:nowrap">start-up/commisioning,</FONT> balancing&nbsp;&amp; controls</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Electrical</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>130,800</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>118,300</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>-$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Reuseing exisitng light fixtures in lieu of new fixtures</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Requirements</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>40,253</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>40,253</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Conditions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>24,760</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24,760</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supervision</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 142,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>141,312</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>-$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,616</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Engineering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>37,400</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>37,400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insurance and Permits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>31,652</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>27,015</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>-$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,637</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingency</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>63,305</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>54,031</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>-$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,274</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Overhead and Profit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>54,442</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46,466</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>-$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,976</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Budget</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>1,415,499</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,208,126</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>-$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>207,373</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">Cost/SF:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">148.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>126.89</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>-$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21.78</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>25<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g833164page46.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Frequency</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>19 Presidential
Way</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Woburn, MA</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B>7/27/2016<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Division/Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Qty</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>UM</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unit&nbsp;$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Line&nbsp;Sum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Div. Sum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Demolition/Temporary Protection</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interior demolition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Select Demo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">sf</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ceiling Demo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">sf</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Floor Demo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">sf</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wall Demo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">sf</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Casework demo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">If</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Temporary protection</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Floor protection</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">shts</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dust protection materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">sf</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>0.11<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restroom protection</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ea</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Protection of existing finishes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">sf</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>35,219</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Concrete</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Coring for mechanical systems</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 day</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,450</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Carpentry/Millwork</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Door and hardware installation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ea</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Carpentry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">days</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carpentry Material</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">days</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Install specialties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">days</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closet shelving&nbsp;&amp; rod</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">If</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Break Room cabinetry <FONT STYLE="white-space:nowrap">p-lam</FONT> cabinetry w/ <FONT
STYLE="white-space:nowrap">p-lam</FONT> top</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">If</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Coffee Area millwork <FONT STYLE="white-space:nowrap">p-lam</FONT> cabinetry w/ <FONT
STYLE="white-space:nowrap">p-lam</FONT> top</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">If</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mothers room millwork</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">If</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printer/Copier area</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">If</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Barricades/safety carpentry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">wks</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reception Desk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NIC</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Window sills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NIC</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49,233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Sealants/Roofing/Thermal protection</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interior sealants allowance (1 caulker for 1 day)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;days</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Misc. flashing and repairs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NIC</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,450</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Doors and Hardware</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3&#146;0&#148; x 7&#146;0&#148; Wood door in HM frame w/closer, lockset, butts, stop</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ea</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closet door at the Reception area</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ea</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4&#146;0&#148; x 7&#146;0&#148; Wood door in HM frame w/closer, lockset, butts, stop</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ea</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4&#146;0&#148; x 7&#146;0&#148; HM door in HM frame w/closer, lockset, butts, stop</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ea</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,512</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Glass and Glazing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Door glass - Full lites</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ea</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Door glass - Half lites</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ea</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Glass doors (7&#146;) at Entrance&nbsp;&amp; Conference Rooms</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ea</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Glass Partitions - Butt Glazing (7&#146; in Height)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">sf</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,610</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 of 6 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>26<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Division/Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Qty</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>UM</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unit $</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Line&nbsp;Sum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Div. Sum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Gypsum Drywall</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GWB partitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">If</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GWB header for glazing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">If</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GWB Columns</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ea</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Soffits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">If</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FRP at GW room</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">sf</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patching</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">days</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Level&nbsp;5 finish&nbsp;&amp; Whiteboard Walls</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NIC</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Acoustic Tile Ceilings</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>84,542</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Standard Office ACT - 2&#146;x2&#146;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">sf</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Standard Lab area ceiling - 2&#146;x4&#146;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">sf</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vinyl Faced Tile for GW room&nbsp;&amp; TC Lab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">sf</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32,846</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Flooring</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carpet</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">sy</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vinyl Plank - Break Room&nbsp;&amp; Lounge Areas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">sf</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VCT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">sf</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sheet Vinyl</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">sy</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vinyl base</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">If</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Floor prep</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">sf</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tiled back splashes at cabinetry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NIC</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>41,467</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Painting</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Latex wall paint</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">sf</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">0.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Door frames</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ea</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patch and repaint</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">days</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Specialties</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fire extinguishers and cabinets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ea</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Window treatments - Remove, clean&nbsp;&amp; reinstall per new layout</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">If</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corner guards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ea</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conference room whiteboards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NIC</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,784</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Equipment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cold rooms (10&#146; x 10&#146;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NIC</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biosafety cabinets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NIC</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Refrigerators/freezers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NIC</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Incubators</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NIC</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Laboratory Casework</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed casework</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">If</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ceiling utility panels</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ea</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Relocate&nbsp;&amp; refurbish existing Fumehoods from the 3rd floor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ea</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mobile Tables (5&#146;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NIC</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mobile Benches (5&#146;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NIC</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>29,370</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fire Protection</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rework existing system per new layout</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">17,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17,100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 of 6 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>27<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Division/Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Qty</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>UM</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unit&nbsp;$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Line&nbsp;Sum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Div. Sum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Plumbing</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixtures&nbsp;&amp; equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sanitary waste</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compressed Air</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Co2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vacuum distribution</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Domestic Water</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tepid Water</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Protected Water</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tags/markers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Demo/CTE services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Coring/sleeves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Seismic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hangers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab waste drainage</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insulation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Coordination/drawings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permits/Inspections</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Testing/cleaning</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Specialty Gas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NIC</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remove ESEW in GW lab, remove Co2 Manifold, remove sink in Cold Room&nbsp;&amp; removed
N2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-12,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>145,964</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>HVAC</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VAV boxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RGDS&nbsp;&amp; HEPAs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sheet Metal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piping</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reprogram Phoenix controls</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Start up and commissioning</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Control wiring and mounting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Johnson Controls</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insulation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balancing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rebudgeted <FONT STYLE="white-space:nowrap">start-up/commisioning,</FONT> balancing&nbsp;&amp;
controls</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-5,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>189,542</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Electrical</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Demolition&nbsp;&amp; temp power</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lighting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fire alarm</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Emergency Egress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory power</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Switching&nbsp;&amp; Sensors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Power</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mechanical power</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Breakers/shutdowns</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture Feeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Engineering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New light fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NIC</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reuse exisitng light fixtures in lieu of new fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-12,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>118,300</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 of 6 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>28<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Division/Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Qty</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>UM</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unit&nbsp;$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Line&nbsp;Sum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Div. Sum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>General Requirements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Project signage</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daily cleaning</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">days</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closeout documents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Misc. tools and supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">wks</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debris dumpsters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ea</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drinking water</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">mnths</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Work in occupied spaces allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">alw</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Final cleaning</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">days</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Temporary sanitary facilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NIC</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Power consumption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">NIC</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>40,253</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>General Conditions</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Safety/third party inspection</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">wks</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consumables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ea</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Field operation expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">wks</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Field Office</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24,760</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supervision</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Project Planner (1 day per week)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">wks</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Project Manager - half time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">wks</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Project Superintendent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">wks</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimator</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">wks</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Field Operations Manager</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">wks</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MEP Coordinator</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">wks</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Project Executive 1/2 day per week</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">days</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Project Administrative Assistant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">days</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Project Accountant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">days</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>141,312</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Engineering</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Design Part 1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CA Part 2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Is</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>37,400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insurance and Permits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Liability Insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Building Permits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>27,015</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Contingency</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>54,031<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>54,031</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Overhead and Profit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>46,466.38</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Budget</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,208,126</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 of 6 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>29<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Exclusions&nbsp;&amp; Assumptions:</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">* This work will entail coring for meachincal utilities that will affect any tenants on the 1st floor below </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">* Tel/Data&nbsp;&amp; AV (NIC) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">*
Card Readers (NIC) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">* Security (NIC) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">* Kitchen equipment (NIC) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">*
Kitchen stove (NIC) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">* Lab equipment (NIC) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">* Work associated with the elevator (NIC) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">* Common area egress stairways (NIC) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">* Loading dock work (NIC) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">*
Furniture (NIC) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">* Equipment Alarms (NIC) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">* Servers Racks&nbsp;&amp; UPS (NIC) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">* Monitoring alarms (NIC) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">*
Signage (NIC) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">* New Fume Hoods (NIC) We are reusing exisitng Fume Hoods from the 3rd floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">* New window treatments (NIC) We will clean&nbsp;&amp; modify existing per new layout </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 of 6 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>1<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT D TO LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ACKNOWLEDGMENT OF COMMENCEMENT DATE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>ACKNOWLEDGMENT OF COMMENCEMENT DATE</B> is made this 25<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of January, 2017,
between <B><FONT STYLE="white-space:nowrap">ARE-MA</FONT> REGION NO. 20, LLC</B>, a Delaware limited liability company (&#147;<B>Landlord</B>&#148;), and <B>FREQUENCY THERAPEUTICS, INC.</B>, a Delaware corporation (&#147;<B>Tenant</B>&#148;), and is
attached to and made a part of the Lease dated August 24<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>, 2016 (the &#147;<B>Lease</B>&#148;), by and between Landlord and Tenant. Any initially capitalized terms used but not defined herein
shall have the meanings given them in the Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Landlord and Tenant hereby acknowledge and agree, for all purposes of the Lease, that
the Commencement Date of the Base Term of the Lease is January 12<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>, 2017<I>, </I>and the termination date of the Base Term of the Lease shall be midnight on January 31<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP>, 2022. In case of a conflict between the terms of the Lease and the terms of this Acknowledgment of Commencement Date, this Acknowledgment of Commencement Date shall control for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Landlord and Tenant have executed this ACKNOWLEDGMENT OF COMMENCEMENT DATE to be effective on the date first above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TENANT:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FREQUENCY THERAPEUTICS, INC.,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Delaware corporation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David L. Lucchino</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>LANDLORD:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B><FONT STYLE="white-space:nowrap">ARE-MA</FONT> REGION NO. 20, LLC,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">a Delaware limited liability company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">ALEXANDRIA REAL ESTATE EQUITIES, L.P.,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">a Delaware limited partnership,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">managing member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">ARE-QRS</FONT> CORP.,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">a Maryland corporation,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">general partner</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Eric S. Johnson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Senior Vice President RE Legal Affairs</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Rules and Regulations</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>1<B></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT E TO LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Rules and Regulations </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The sidewalk, entries, and driveways of the Project shall not be obstructed by Tenant, or any Tenant Party, or used by them for any purpose
other than ingress and egress to and from the Premises. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Tenant shall not place any objects, including antennas, outdoor furniture,
etc., in the parking areas, landscaped areas or other areas outside of its Premises, or on the roof of the Project. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Except for animals
assisting the disabled, no animals shall be allowed in the offices, halls, or corridors in the Project. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. Tenant shall not disturb the
occupants of the Project or adjoining buildings by the use of any radio or musical instrument or by the making of loud or improper noises. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. If Tenant desires telegraphic, telephonic or other electric connections in the Premises, Landlord or its agent will direct the electrician
as to where and how the wires may be introduced; and, without such direction, no boring or cutting of wires will be permitted. Any such installation or connection shall be made at Tenant&#146;s expense. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. Tenant shall not install or operate any steam or gas engine or boiler, or other mechanical apparatus in the Premises, except as specifically
approved in the Lease. The use of oil, gas or inflammable liquids for heating, lighting or any other purpose is expressly prohibited. Explosives or other articles deemed extra hazardous shall not be brought into the Project. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. Parking any type of recreational vehicles is specifically prohibited on or about the Project. Except for the overnight parking of operative
vehicles, no vehicle of any type shall be stored in the parking areas at any time. In the event that a vehicle is disabled, it shall be removed within 48 hours. There shall be no &#147;For Sale&#148; or other advertising signs on or about any parked
vehicle. All vehicles shall be parked in the designated parking areas in conformity with all signs and other markings. All parking will be open parking, and no reserved parking, numbering or lettering of individual spaces will be permitted except as
specified by Landlord. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. Tenant shall maintain the Premises free from rodents, insects and other pests. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. Landlord reserves the right to exclude or expel from the Project any person who, in the judgment of Landlord, is intoxicated or under the
influence of liquor or drugs or who shall in any manner do any act in violation of the Rules and Regulations of the Project. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. Tenant
shall not cause any unnecessary labor by reason of Tenant&#146;s carelessness or indifference in the preservation of good order and cleanliness. Landlord shall not be responsible to Tenant for any loss of property on the Premises, however occurring,
or for any damage done to the effects of Tenant by the janitors or any other employee or person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. Tenant shall give Landlord prompt
notice of any defects in the water, lawn sprinkler, sewage, gas pipes, electrical lights and fixtures, heating apparatus, or any other service equipment affecting the Premises. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. Tenant shall not permit storage outside the Premises, including without limitation, outside storage of trucks and other vehicles, or
dumping of waste or refuse or permit any harmful materials to be placed in any drainage system or sanitary system in or about the Premises. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Rules and Regulations</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>2<B></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. All moveable trash receptacles provided by the trash disposal firm for the Premises must
be kept in the trash enclosure areas, if any, provided for that purpose. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. No auction, public or private, will be permitted on the
Premises or the Project. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. No awnings shall be placed over the windows in the Premises except with the prior written consent of
Landlord. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. The Premises shall not be used for lodging, sleeping or cooking or for any immoral or illegal purposes or for any purpose
other than that specified in the Lease. No gaming devices shall be operated in the Premises. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. Tenant shall ascertain from Landlord the
maximum amount of electrical current which can safely be used in the Premises, taking into account the capacity of the electrical wiring in the Project and the Premises and the needs of other tenants, and shall not use more than such safe capacity.
Landlord&#146;s consent to the installation of electric equipment shall not relieve Tenant from the obligation not to use more electricity than such safe capacity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. Tenant assumes full responsibility for protecting the Premises from theft, robbery and pilferage. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. Tenant shall not install or operate on the Premises any machinery or mechanical devices of a nature not directly related to Tenant&#146;s
ordinary use of the Premises and shall keep all such machinery free of vibration, noise and air waves which may be transmitted beyond the Premises. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>19 Presidential Way/Frequency - Page </B>1<B> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT F TO LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TENANT&#146;S PERSONAL PROPERTY </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g833164pagebb.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED FIRST AMENDMENT TO LEASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS AMENDED AND RESTATED FIRST AMENDMENT TO LEASE AGREEMENT (the <B>&#147;Restated First Amendment&#148;) </B>is made as of this 28th day of
January, 2020, between <B><FONT STYLE="white-space:nowrap">ARE-MA</FONT> REGION NO. 20, LLC, </B>a Delaware limited liability company <B>(&#147;Landlord&#148;), </B>and <B>FREQUENCY THERAPEUTICS, INC., </B>a Delaware corporation
<B>(&#147;Tenant&#148;). </B>&#145; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RECITALS: </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Tenant and Landlord are parties to that certain Lease Agreement dated as of August <B>24, </B>2016, as amended by that certain First
Amendment to Lease Agreement dated November&nbsp;8, 2019 (the <B>&#147;Lease&#148;). </B>Pursuant to the Lease: (1)&nbsp;Tenant leases from Landlord certain premises consisting of (a)&nbsp;Suite 203, consisting of approximately 9,521 rentable square
feet of laboratory/office space on the second floor of the Building and (b)&nbsp;Suite 100D, consisting of approximately 424 rentable square feet of storage space on the first floor of the Building (the <B>&#147;Original Premises&#148;) </B>in that
certain building located at 19 Presidential Way, Woburn, Massachusetts (the <B>&#147;Building&#148;), </B>as more particularly described in the Lease, and (n)&nbsp;Tenant is scheduled to increase the size of the Original Premises by adding to the
Original Premises Suite 205 of the Building, consisting of approximately 7,550 rentable square feet Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B The <B>&#147;Commencement Date&#148; </B>of the Lease occurred on January&nbsp;25, 2017 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. Landlord and Tenant desire, subject to the terms and conditions set forth below, to amend the size of Suite 205 which shall become subject
to the Lease, to 7,41 0 rentable square feet, as shown on <B>Exhibit A </B>attached to this Restated First Amendment (the <B>&#147;Expansion Premises&#148;) </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing Recitals, which are incorporated herein by this reference, the mutual promises and conditions
contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Tenant and Landlord hereby agree as follows. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Expansion Premises</U>. </B>In addition to the Original Premises, commencing on the Expansion Premises
Commencement Date (as defined below), Landlord leases to Tenant, and Tenant leases from Landlord, the Expansion Premises, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Delivery</U> </B>Landlord shall use reasonable efforts to deliver the Expansion Premises to Tenant
<B>(&#147;Delivery&#148; or &#147;Deliver&#148;) </B>on or before the Target Expansion Premises Commencement Date (subject to Force Majeure delays). If Landlord fails to timely Deliver the Expansion Premises, Landlord shall not be liable to Tenant
for any loss or damage resulting therefrom, and this Restated First Amendment shall not be void or voidable. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The
<B>&#147;Expansion Premises Commencement Date&#148; </B>shall be the date that Landlord Delivers the Expansion Premises to Tenant in broom clean condition. The <B>&#147;Target Expansion Premises Commencement Date&#148; </B>shall be February&nbsp;19,
2020. Upon the request of Landlord, Tenant shall execute and deliver a written acknowledgment of the Expansion Premises Commencement Date in substantially the form of the &#147;Acknowledgement of Commencement Date&#148; attached to the Lease as
<B>Exhibit D, </B><U>provided</U>, <U>however</U>, Tenant&#146;s failure to execute and deliver such acknowledgment shall not affect Landlord&#146;s rights hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise expressly set forth in the Lease or this Restated First Amendment: (1)&nbsp;Tenant shall accept the Expansion Premises in
their condition as of the Expansion Premises Commencement Date; (Ii) Landlord shall have no obligation for any defects in the Expansion Premises; and (iii)&nbsp;Tenant&#146;s taking possession of the Expansion Premises shall be conclusive evidence
that Tenant accepts the Expansion Premises and that the Expansion Premises were in good condition at the time possession was taken. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g833164dsp1.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Copyright &copy; 2005, Alexandria Real Estate, Equities, Inc. ALL RIGHTS RESERVED, Confidential and Proprietary - Do Not</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Copy or Distribute, Alexandria and the Alexandria Logo are registered trademarks of Alexendria Real Estate Equities, Inc.</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the period of 30 consecutive days after the Expansion Premises Commencement Date,
Landlord shall, at its sole cost and expense (which shall not constitute an Operating Expense), be responsible for any repairs that are required to be made to the Building Systems serving only the Expansion Premises, unless Tenant or any Tenant
Party was responsible for the cause of such repair, in which case Tenant shall pay the cost. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Tenant agrees and acknowledges that neither
Landlord nor any agent of Landlord has made any representation or warranty with respect to the condition of all or any portion of the Expansion Premises, and/or the suitability of the Expansion Premises for the conduct of Tenant&#146;s business, and
Tenant waives any implied warranty that the Expansion Premises are suitable for the Permitted Use. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Premises and Rentable Area of Premises</U>. </B>Commencing on the Expansion Premises Commencement Date,
the defined terms <B>&#147;Premises&#148; </B>and <B>&#147;Rentable Area of Premises&#148; </B>on page 1 of the Lease shall be deleted in their entirety and replaced with the following </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;Premises: </B>That portion of the Building, consisting of (1)(a) Suite 203, consisting of approximately 9,521 rentable square feet of
laboratory/office space on the second floor of the Building and (b)&nbsp;Suite 100D, consisting of approximately 424 rentable square feet of storage space on the first floor of the Building (collectively, the <B>&#147;Original Premises&#148;),
</B>and <B>(11)</B><B></B>&nbsp;Suite 205, consisting of approximately 7,410 rentable square feet of laboratory/office space on the second floor of the Building (the <B>&#147;Expansion Premises&#148;), </B>all as determined by Landlord, as shown on
<B>Exhibit A.&#148; </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;Rentable Area of Premises: </B>17,355 sq ft &#147; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of the Expansion Premises Commencement Date, <B>Exhibit A </B>to the Lease shall be amended to include the Expansion Premises as shown on
<B>Exhibit A </B>attached to this Restated First Amendment. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Base Rent</U>. </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>a. Original Premises. </B>Tenant shall continue to pay Base Rent with respect to the Original Premises as provided for under the Lease
through the Expiration Date (as defined below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>b. Expansion Premises </B>Commencing on the Expansion Premises Commencement Date,
Tenant shall pay Base Rent with respect to the Expansion Premises in the amount of $29.00 per rentable square foot of the Expansion Premises per year. Base Rent payable with respect to the Expansion Premises shall be increased on each annual
anniversary of the first day of the first full month during the Term of the Lease for the Expansion Premises (each, an <B>&#147;Expansion Premises Adjustment Date&#148;) </B>by multiplying the Base Rent payable immediately before such Expansion
Premises Adjustment Date by the Rent Adjustment Percentage and adding the resulting amount to the Base Rent payable immediately before such Expansion Premises Adjustment Date </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Base Term</U> </B>Commencing on the date of this Restated First Amendment, the defined term <B>&#147;Base
Term&#148; </B>on page 1 of the Lease shall be deleted in its entirety and replaced with the following&#148; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g833164dsp1.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Copyright &copy; 2005, Alexandria Real Estate, Equities, Inc. ALL RIGHTS RESERVED, Confidential and Proprietary - Do Not</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Copy or Distribute, Alexandria and the Alexandria Logo are registered trademarks of Alexendria Real Estate Equities, Inc.</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;Base Term: </B>Commencing (i)&nbsp;with respect to Original Premises, on the
Commencement Date, and (ii)&nbsp;with respect to the Expansion Premises, on the Expansion Premises Commencement Date, and ending with respect to the entire Premises on the date that is 60 months from the Expansion Premises Commencement Date (the
<B>&#147;Expiration Date&#148;) </B>&#147; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Tenant&#146;s Share</U> </B>Commencing on the Expansion Premises Commencement Date, the defined term
<B>&#147;Tenant&#146;s Share of Operating Expenses&#148; </B>on page 1 of the Lease shall be deleted in its entirety and replaced with the following: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;Tenant&#146;s Share of Operating Expenses: </B>11.98%&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Amendment and Restatement of Second Amendment to Lease</U>. </B>This Restated First Amendment amends,
restates and supersedes in its entirety that certain First Amendment to Lease Agreement entered into by Landlord and Tenant and dated November&nbsp;8, 2019 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>OFAC</U>. </B>Tenant and all beneficial owners of Tenant are currently (a)&nbsp;in compliance with and
shall at all times during the Term of the Lease remain in compliance with the regulations of the Office of Foreign Assets Control <B>(&#147;OFAC&#148;) </B>of the U.S. Department of Treasury and any statute, executive order, or regulation relating
thereto (collectively, the <B>&#147;OFAC Rules&#148;), </B>(b) not listed on, and shall not during the Term of the Lease be listed on, the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List, or the Sectoral
Sanctions Identification List, which are all maintained by OFAC and/or on any other similar list maintained by OFAC or other governmental authority pursuant to <I>any </I>authorizing statute, executive order, or regulation, and (c)&nbsp;not a person
or entity with whom a U.S person is prohibited from conducting business under the OFAC Rules. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Brokers</U>. </B>Landlord and Tenant each represents and warrants that it has not dealt with any broker,
agent or other person (collectively, <B>&#147;Broker&#148;) </B>in connection with the transaction reflected in this Restated First Amendment and that no Broker brought about this transaction Landlord and Tenant each hereby agree to indemnify and
hold the other harmless from and against any claims by any Broker claiming a commission or other form of compensation by virtue of having dealt with Landlord or Tenant, as applicable, with regard to this Restated First Amendment.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Miscellaneous </U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>a. </B>This Restated First Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes
all prior and contemporaneous oral and written agreements and discussions. This Restated First Amendment may be amended only by an agreement in writing, signed by the parties hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>b.</B> This Restated First Amendment is binding upon and shall inure to the benefit of the parties hereto, and their respective successors
and assigns. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>c.</B> This Restated First Amendment may be executed in 2 or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. Counterparts may be delivered <I>via </I>facsimile, electronic mail (including pdf or any electronic signature process complying with the US. federal ESIGN Act of 2000) or other
transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. Electronic signatures shall be deemed original signatures for purposes of this Restated First
Amendment and all matters related thereto, with such electronic signatures having the same legal effect as original signatures </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g833164dsp1.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Copyright &copy; 2005, Alexandria Real Estate, Equities, Inc. ALL RIGHTS RESERVED, Confidential and Proprietary - Do Not</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Copy or Distribute, Alexandria and the Alexandria Logo are registered trademarks of Alexendria Real Estate Equities, Inc.</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>d. </B>Except as amended and/or modified by this Restated First Amendment, the Lease is
hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this Restated First Amendment. In the event of any conflict between the provisions of this Restated First Amendment and
the provisions of the Lease, the provisions of this Restated First Amendment shall prevail. Whether or not specifically amended by this Restated First Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary
to give effect to the purpose and intent of this Restated First Amendment </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Signatures are on the next page} </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g833164dsp1.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Copyright &copy; 2005, Alexandria Real Estate, Equities, Inc. ALL RIGHTS RESERVED, Confidential and Proprietary - Do Not</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Copy or Distribute, Alexandria and the Alexandria Logo are registered trademarks of Alexendria Real Estate Equities, Inc.</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have caused their duly authorized representatives to execute
this Restated First Amendment as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TENANT:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FREQUENCY THERAPEUTICS, INC.,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">a Delaware corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David L. Lucchino</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print&nbsp;Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David L. Lucchino</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>LANDLORD:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"><B><FONT STYLE="white-space:nowrap">ARE-MA</FONT> REGION NO. 20, LLC,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7">a Delaware limited liability company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">ALEXANDRIA REAL ESTATE EQUITIES, L.P.,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">a Delaware limited partnership,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">managing member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">ARE-QRS</FONT> CORP.,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">a Maryland corporation,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jackie Clem</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Print&nbsp;Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jackie Clem</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Senior Vice President</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">RE Legal Affairs</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g833164dsp1.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Copyright &copy; 2005, Alexandria Real Estate, Equities, Inc. ALL RIGHTS RESERVED, Confidential and Proprietary - Do Not</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Copy or Distribute, Alexandria and the Alexandria Logo are registered trademarks of Alexendria Real Estate Equities, Inc.</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXPANSION PREMISES </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g833164page06.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:61%">&nbsp;</P></center>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g833164dsp1.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Copyright &copy; 2005, Alexandria Real Estate, Equities, Inc. ALL RIGHTS RESERVED, Confidential and Proprietary - Do Not</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Copy or Distribute, Alexandria and the Alexandria Logo are registered trademarks of Alexendria Real Estate Equities, Inc.</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>4
<FILENAME>freq-ex1013_758.htm
<DESCRIPTION>EX-10.13
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
freq-ex1013_758.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.13</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662596"></a>75 HAYDEN AVENUE<br />LEXINGTON, MASSACHUSETTS 02421</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662597"></a>LEASE SUMMARY SHEET</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Execution Date:</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 7, 2020</p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Tenant:</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">FREQUENCY THERAPEUTICS, INC.,</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware corporation</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Tenant&#8217;s Mailing Address Prior to Occupancy:</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19 Presidential Way</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Woburn, Massachusetts 01801</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Richard Mitrano</p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Landlord:</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">HCP/KING 75 HAYDEN LLC<font style="font-weight:normal;">,<br />a Delaware limited liability company</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Building:</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75 Hayden Avenue, Lexington, Massachusetts 02421.&nbsp;&nbsp;The Building is currently under construction and shall consist of four (4) stories and contain approximately 214,440 rentable square feet.&nbsp;&nbsp;The land (the &#8220;<font style="font-weight:bold;">Land</font>&#8221;) on which the Building is located is described as &#8220;<font style="font-weight:bold;">Building 75</font>&#8221; on <font style="text-decoration:underline;">Exhibit 2A</font> attached hereto and made a part hereof.</p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Campus:</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of the land described on <font style="text-decoration:underline;">Exhibit 2B</font> (including the Land described above, which Land is a portion of the land described on <font style="text-decoration:underline;">Exhibit 2B</font>) together with the Building described above, the buildings now known as and numbered 45 Hayden Avenue, 55 Hayden Avenue and 65 Hayden Avenue (&#8220;<font style="font-weight:bold;">Building 65</font>&#8221;), and any other building and/or improvements constructed on the Land.&nbsp;&nbsp;The Campus includes an existing nine-story garage with 1,091 spaces (the &#8220;<font style="font-weight:bold;">Garage</font>&#8221;) which is used in common by the tenants of the Campus.</p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Premises:</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Areas on the first (1<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup>) floor, the third (3<sup style="font-size:85%;line-height:120%;vertical-align:top">rd</sup>) floor, the Penthouse and the roof of the Building, containing approximately 61,307 rentable square feet in the aggregate.&nbsp;&nbsp;The Premises consist of:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Prime Premises<font style="font-weight:normal;">, which will be located on the entire third (3<sup style="font-size:85%;line-height:120%;vertical-align:top">rd</sup>) floor;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">PH System Premises<font style="font-weight:normal;">, which will be located on the first (1<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup>) floor. The PH System Premises are located in a common room (the &#8220;</font>PH System Room<font style="font-weight:normal;">&#8221;) which contains the PH systems of other tenants;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Storage Premises<font style="font-weight:normal;">, which will be located on the first (1<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup>) floor.&nbsp;&nbsp;The Storage Premises will be a caged area located in a common room (the &#8220;</font>Storage Room<font style="font-weight:normal;">&#8221;) which contains storage areas of other tenants; and</font></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Penthouse Equipment Premises<font style="font-weight:normal;">, which will be located on the Penthouse floor.&nbsp;&nbsp;The Penthouse Equipment Premises are located in a common room (the &#8220;</font>Penthouse Equipment Room<font style="font-weight:normal;">&#8221;) which contains equipment of other tenants.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Generator Area<font style="font-weight:normal;">, as defined in Section 1.3(c), which will be located on the roof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term &#8220;<font style="font-weight:bold;">Premises</font>&#8221; shall mean the Prime Premises, PH System Premises, Storage Premises, Penthouse Equipment Premises and Generator Area, as applicable.&nbsp;&nbsp;The Premises are shown on the Lease Plans attached hereto as <font style="text-decoration:underline;">Exhibit 1A</font>, <font style="text-decoration:underline;">Exhibit 1B</font>, <font style="text-decoration:underline;">Exhibit 1C</font>, and <font style="text-decoration:underline;">Exhibit 1D</font> and made a part hereof (the &#8220;<font style="font-weight:bold;">Lease Plans</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord and Tenant stipulate and agree that the Rentable Square Footage of the Building and the Rentable Square Footage of the Premises are correct and shall not be remeasured.</p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Property:</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Building, the Garage, the Land, and other improvements located on, and to be constructed on, the Land.</p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Parking Areas:</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parking structures (surface lots and parking decks, including the Garage adjacent to the Building) located on the Campus that Landlord provides for parking by all tenants of space on the Property.&nbsp;&nbsp;The parties acknowledge that the parking garage serving 65 Hayden Avenue is not included in the Parking Areas.</p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Term Commencement Date:</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />The earlier of (i) the date that Tenant first commences to use the Premises, or any portion thereof, for any Permitted Use or (ii) the Substantial Completion, as hereinafter defined, of Landlord&#8217;s Work, as hereinafter defined.&nbsp;&nbsp;The parties estimate that that the Term Commencement Date will occur on or about December 1, 2020 (&#8220;<font style="font-weight:bold;">Estimated Term Commencement Date</font>&#8221;).&nbsp;&nbsp;The installation of Tenant&#8217;s furniture and fixtures in the Premises shall not be deemed to be &#8220;use of the Premises for any Permitted Use&#8221; for the purposes of the definition of Term Commencement Date.</p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Rent Commencement Date:</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The date that is five (5) months after the Term Commencement Date.</p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Expiration Date:</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ten (10) years after the Rent Commencement Date, except that if the Rent Commencement Date does not occur on the first day of a calendar month, then the Expiration Date shall be the last day of the calendar month in which the date ten (10) years after the Rent Commencement Date occurs.</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Extension Term(s):</font></p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to Section 1.2 below, two (2) extension term(s) of five (5) years each.</p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Contribution:</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Up to $11,954,865.00 (comprised of the TI Allowance of up to $11,035,260.00 and the Additional TI Allowance, if so elected by Tenant, of up to $919,605.00), all subject to Article 4 below and <font style="text-decoration:underline;">Exhibit 4</font> attached hereto. </p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Permitted Uses:</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to Legal Requirements, Tenant shall have the right to use the following portions of the Premises only for the following uses:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Prime Premises<font style="font-weight:normal;">:</font> <font style="font-weight:normal;">General office, research, development, warehouse and laboratory use, and other ancillary uses (including, but not limited to, the Approved Vivarium Uses) related to the foregoing.&nbsp;&nbsp;&#8220;</font>Approved Vivarium Uses<font style="font-weight:normal;">&#8221; shall mean small rodents and guinea pigs, subject to Section 4.6 of this Lease;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">PH System Premises<font style="font-weight:normal;">: Operation and maintenance of Tenant&#8217;s Acid Neutralization Tank;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Storage Premises<font style="font-weight:normal;">: Subject to Section 17.1 hereof, storage of Tenant&#8217;s Hazardous Materials, waste and other materials used or generated by Tenant in the Premises;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Penthouse Equipment Premises<font style="font-weight:normal;">: Installation, operation and maintenance of Tenant&#8217;s Penthouse Equipment; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Generator Area<font style="font-weight:normal;">: Installation and operation of Tenant&#8217;s Generator.</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Base Rent:</p></td>
<td valign="top"  style="width:17.3%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">RENT YEAR</font></p></td>
<td valign="top"  style="width:28.22%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ANNUAL BASE RENT</font></p></td>
<td valign="top"  style="width:29.48%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">MONTHLY PAYMENT</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:17.3%;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Rent Year 1</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Rent Year 2</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Rent Year 3</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Rent Year 4</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Rent Year 5</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Rent Year 6</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Rent Year 7</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Rent Year 8</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Rent Year 9</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Rent Year 10</p></td>
<td valign="top"  style="width:28.22%;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="color:#000000;">4,076,915.50</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="color:#000000;">4,199,529.50</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="color:#000000;">4,325,821.92</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="color:#000000;">4,455,792.76</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="color:#000000;">4,589,442.02</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="color:#000000;">4,727,382.77</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="color:#000000;">4,869,001.94</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="color:#000000;">5,014,912.60</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="color:#000000;">5,165,114.75</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="color:#000000;">5,320,221.46</font></p></td>
<td valign="top"  style="width:29.48%;">
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="color:#000000;">339,742.96</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="color:#000000;">349,960.79</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="color:#000000;">360,485.16</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="color:#000000;">371,316.06</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="color:#000000;">382,453.50</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="color:#000000;">393,948.56</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="color:#000000;">405,750.16</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="color:#000000;">417,909.38</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="color:#000000;">430,426.23</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;margin-left:-24.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="color:#000000;">443,</font>351<font style="color:#000000;">.79</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Rent Year:</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent Year 1 shall be the twelve-(12)-month period commencing as of the Rent Commencement Date, except that if the Rent</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commencement Date occurs on other than the first day of a calendar month, then Rent Year 1 shall commence as of the Rent Commencement Date and shall end on the last day of the calendar year in which the first anniversary of the Rent Commencement Date occurs.&nbsp;&nbsp;Each Rent Year after Rent Year 1 shall be the twelve-(12)-month period immediately following the preceding Rent Year.</p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Costs and Taxes:</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />See Sections 5.2 and 5.3.</p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Tenant&#8217;s Share:</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A fraction, the numerator of which is the number of rentable square feet in the Premises and the denominator of which is the number of rentable square feet in the Building.&nbsp;&nbsp;As of the Execution Date, Tenant&#8217;s Share with respect to the Premises is 28.59%.</p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Security Deposit/ Letter of Credit:</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />$1,698,714.80.</p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Guarantor:</p></td>
<td colspan="3" valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:1.23%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:20.5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 1A</p></td>
<td valign="top"  style="width:79.48%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LEASE PLAN - PRIME PREMISES</p></td>
</tr>
<tr>
<td valign="top"  style="width:20.5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 1B</p></td>
<td valign="top"  style="width:79.48%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LEASE PLAN - PH SYSTEM PREMISES</p></td>
</tr>
<tr>
<td valign="top"  style="width:20.5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 1C</p></td>
<td valign="top"  style="width:79.48%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LEASE PLAN - STORAGE PREMISES</p></td>
</tr>
<tr>
<td valign="top"  style="width:20.5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 1D</p></td>
<td valign="top"  style="width:79.48%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LEASE PLAN &#8211; PENTHOUSE EQUIPMENT PREMISES AND GENERATOR AREA</p></td>
</tr>
<tr>
<td valign="top"  style="width:20.5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 1E</p></td>
<td valign="top"  style="width:79.48%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LEASE PLAN &#8211; NITROGEN TANK AREA</p></td>
</tr>
<tr>
<td valign="top"  style="width:20.5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 2A</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 2B</p></td>
<td valign="top"  style="width:79.48%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LEGAL DESCRIPTION &#8211; LAND</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LEGAL DESCRIPTION</p></td>
</tr>
<tr>
<td valign="top"  style="width:20.5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 3</p></td>
<td valign="top"  style="width:79.48%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PARKING AREAS</p></td>
</tr>
<tr>
<td valign="top"  style="width:20.5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 4</p></td>
<td valign="top"  style="width:79.48%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WORK LETTER</p></td>
</tr>
<tr>
<td valign="top"  style="width:20.5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 4-1</p></td>
<td valign="top"  style="width:79.48%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BASE BUILDING PLANS</p></td>
</tr>
<tr>
<td valign="top"  style="width:20.5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 4-2</p></td>
<td valign="top"  style="width:79.48%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TENANT/LANDLORD RESPONSIBILITY MATRIX</p></td>
</tr>
<tr>
<td valign="top"  style="width:20.5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 5</p></td>
<td valign="top"  style="width:79.48%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BASE BUILDING CAPACITIES</p></td>
</tr>
<tr>
<td valign="top"  style="width:20.5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 5-1</p></td>
<td valign="top"  style="width:79.48%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FLOOR LOAD CAPACITIES</p></td>
</tr>
<tr>
<td valign="top"  style="width:20.5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 6</p></td>
<td valign="top"  style="width:79.48%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FORM OF LETTER OF CREDIT</p></td>
</tr>
<tr>
<td valign="top"  style="width:20.5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 7</p></td>
<td valign="top"  style="width:79.48%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD&#8217;S SERVICES </p></td>
</tr>
<tr>
<td valign="top"  style="width:20.5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 8</p></td>
<td valign="top"  style="width:79.48%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[INTENTIONALLY OMITTED]</p></td>
</tr>
<tr>
<td valign="top"  style="width:20.5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 9</p></td>
<td valign="top"  style="width:79.48%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RULES AND REGULATIONS</p></td>
</tr>
<tr>
<td valign="top"  style="width:20.5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 9-1</p></td>
<td valign="top"  style="width:79.48%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BUILDING RULES AND REGULATIONS</p></td>
</tr>
<tr>
<td valign="top"  style="width:20.5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 9-2</p></td>
<td valign="top"  style="width:79.48%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONSTRUCTION RULES AND REGULATIONS</p></td>
</tr>
<tr>
<td valign="top"  style="width:20.5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 10</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 11</p></td>
<td valign="top"  style="width:79.48%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TENANT WORK INSURANCE SCHEDULE</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[INTENTIONALLY OMITTED]</p></td>
</tr>
<tr>
<td valign="top"  style="width:20.5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 12</p></td>
<td valign="top"  style="width:79.48%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PLAN&#8212;LOADING DOCKS, RECEPTION AREA, AND FREIGHT ELEVATORS</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="text-decoration:underline;">TABLE OF CONTENTS</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LEASE GRANT; TERM; APPURTENANT RIGHTS; EXCLUSIONS</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease Grant</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extension Terms</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appurtenant Rights</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant&#8217;s Access</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No recording // Notice of Lease</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exclusions</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acid Neutralization Tank</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nitrogen Tank</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RIGHTS RESERVED TO LANDLORD</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions and Alterations</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions to the Property</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name and Address of Building</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Access</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pipes, Ducts and Conduits</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimize Interference</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONDITION OF PREMISES; CONSTRUCTION.</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Condition of Premises</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Work</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant&#8217;s Remedies in the Event of Delays in Term Commencement Date.</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF PREMISES</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permitted Uses</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prohibited Uses</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transportation of Animals</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MWRA Permit</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parking and Traffic Demand Management Plan</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vivarium</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RENT; ADDITIONAL RENT</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base Rent; Additional Rent.</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating Costs</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taxes</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Late Payments</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Offset; Independent Covenants; Waiver</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.6</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Survival</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INTENTIONALLY OMITTED.</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LETTER OF CREDIT</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.1</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Application of Proceeds of Letter of Credit</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transfer of Letter of Credit</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash Proceeds of Letter of Credit</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.5</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Return of Security Deposit or Letter of Credit</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INTENTIONALLY OMITTED.</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UTILITIES, LANDLORD&#8217;S SERVICES</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Electricity</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Water</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gas</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.4</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other Utilities</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interruption or Curtailment of Utilities</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.6</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Services</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAINTENANCE AND REPAIRS</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maintenance and Repairs by Tenant</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maintenance and Repairs by Landlord</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accidents to Sanitary and Other Systems</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Floor Load--Heavy Equipment</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Premises Cleaning</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pest Control</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Service Interruptions</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALTERATIONS AND IMPROVEMENTS BY TENANT</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Consent Required</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After-Hours</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Harmonious Relations</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liens</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General Requirements</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SIGNAGE</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.1</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restrictions</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exterior Signage</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building Directory</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASSIGNMENT, MORTGAGING AND SUBLETTING</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Consent Required</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.2</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Recapture Right</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.3</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Standard of Consent to Transfer</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.4</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Listing Confers no Rights</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.5</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Profits In Connection with Transfers</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.6</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prohibited Transfers</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.7</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exceptions to Requirement for Consent</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INSURANCE; INDEMNIFICATION; EXCULPATION</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant&#8217;s Insurance</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indemnification</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.3</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property of Tenant</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.4</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Limitation of Landlord&#8217;s Liability for Damage or Injury</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.5</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Waiver of Subrogation; Mutual Release</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.6</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant&#8217;s Acts--Effect on Insurance</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.7</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Insurance</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASUALTY; TAKING</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.1</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Damage</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.2</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination Rights</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.3</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent Abatement</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.4</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taking for Temporary Use</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.5</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disposition of Awards</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESTOPPEL CERTIFICATE.</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HAZARDOUS MATERIALS</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.1</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prohibition</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.2</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Environmental Laws</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.3</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hazardous Material Defined</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.4</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chemical Safety Program</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.5</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Testing</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.6</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indemnity; Remediation</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.7</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disclosures</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.8</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Removal</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RULES AND REGULATIONS.</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.1</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rules and Regulations</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.2</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Energy Conservation</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.3</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recycling</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LAWS AND PERMITS.</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.1</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal Requirements</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEFAULT</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.1</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Events of Default</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.2</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remedies</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.3</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Damages - Termination</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.4</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Self-Help; Fees and Expenses</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.5</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Waiver of Redemption, Statutory Notice and Grace Periods</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.6</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Remedies Not Exclusive</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.7</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Waiver</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.8</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restrictions on Tenant&#8217;s Rights</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.9</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord Default</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SURRENDER; ABANDONED PROPERTY; HOLD-OVER</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Surrender</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.2</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Abandoned Property</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.3</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holdover</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.4</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warranties</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.</font></p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MORTGAGEE RIGHTS</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.1</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subordination</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.2</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notices</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.3</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mortgagee Consent</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.4</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mortgagee Liability</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">QUIET ENJOYMENT.</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOTICES.</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.</p></td>
<td colspan="2" valign="top"  style="width:85%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MISCELLANEOUS</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.1</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separability</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.2</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Captions</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.3</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Broker</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.4</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entire Agreement</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.5</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Governing Law</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.6</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Representation of Authority</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.7</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expenses Incurred by Landlord Upon Tenant Requests</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.8</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Survival</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.9</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Limitation of Liability</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.10</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Binding Effect</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.11</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord Obligations upon Transfer</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.12</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Grant of Interest</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.13</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial Information</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.14</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OFAC Certificate and Indemnity</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.15</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidentiality</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.16</p></td>
<td valign="top"  style="width:75%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Force Majeure</p></td>
<td valign="top"  style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS INDENTURE OF LEASE (this </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">Lease</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) is hereby made and entered into on the Execution Date by and between Landlord and Tenant. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each reference in this Lease to any of the terms and titles contained in any Exhibit attached to this Lease shall be deemed and construed to incorporate the data stated under that term or title in such Exhibit. All capitalized terms not otherwise defined herein shall have the meanings ascribed to them as set forth in the Lease Summary Sheet which is attached hereto and incorporated herein by reference.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662598"></a><a name="_Toc28868614"></a>LEASE GRANT; TERM; APPURTENANT RIGHTS; EXCLUSIONS</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868615"></a><a name="_Toc504662599"></a>1.1<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Lease Grant</font><font style="font-weight:normal;">.&nbsp;&nbsp;Landlord hereby leases to Tenant, and Tenant hereby leases from Landlord, the Premises upon and subject to terms and conditions of this Lease, for a term of years commencing on the Term Commencement Date and, unless earlier terminated or extended pursuant to the terms hereof, ending on the Expiration Date (the &#8220;</font>Initial Term<font style="font-weight:normal;">&#8221;; the Initial Term and any duly exercised Extension Terms are hereinafter collectively referred to as the &#8220;</font>Term<font style="font-weight:normal;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868616"></a><a name="_Toc504662600"></a>1.2<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Extension Terms</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>Provided that the following conditions, which may be waived by Landlord in its sole discretion, are satisfied (i) Tenant has not assigned its interest in this Lease nor sublet more than fifty percent (50%) of the Premises to anyone other than an Affiliated Entity (hereinafter defined) and/or a Successor (hereinafter defined); and (ii) no uncured Event of Default exists (1) as of the date of the Extension Notice (hereinafter defined), and (2) at the commencement of the applicable Extension Term (hereinafter defined), Tenant shall have the option to extend the Term for two (2) additional term(s) of five (5) year(s) each (each, an &#8220;<font style="font-weight:bold;">Extension Term</font>&#8221;), commencing as of the expiration of the Initial Term, or the prior Extension Term, as the case may be.&nbsp;&nbsp;Tenant must exercise such option to extend, if at all, by giving Landlord written notice (the &#8220;<font style="font-weight:bold;">Extension Notice</font>&#8221;) on or before the date that is twelve (12) months prior to the expiration of the then-current Term of this Lease, <font style="font-style:italic;">time being of the essence</font>.&nbsp;&nbsp;Upon the timely giving of such notice, the Term shall be deemed extended upon all of the terms and conditions of this Lease, except that Base Rent during each Extension Term shall be calculated in accordance with this Section 1.2, Landlord shall have no obligation to construct or renovate the Premises and Tenant shall have one (1) fewer option to extend the Term.&nbsp;&nbsp;If Tenant fails to give timely notice, as aforesaid, Tenant shall have no further right to extend the Term.&nbsp;&nbsp;Notwithstanding the fact that Tenant&#8217;s proper and timely exercise of such option to extend the Term shall be self-executing, the parties shall promptly execute a lease amendment reflecting such Extension Term after Tenant exercises such option.&nbsp;&nbsp;The execution of such lease amendment shall not be deemed to waive any of the conditions to Tenant&#8217;s exercise of its rights under this Section 1.2.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>(b)<font style="margin-left:108pt;"></font>The Base Rent during each Extension Term (the &#8220;<font style="font-weight:bold;">Extension Term Base Rent</font>&#8221;) shall be determined in accordance with the process described hereafter.&nbsp;&nbsp;Extension Term Base Rent shall be the fair market rental value of the Premises then demised to Tenant as of the commencement of the applicable Extension Term as determined in accordance with the process described below, for renewals of first class office/research/laboratory building/campus in the Lexington/Route 128/Route 2 corridor real estate market (the &#8220;<font style="font-weight:bold;">Market Area</font>&#8221;) of equivalent quality, size, utility and location, with the length of the Extension Term, the credit standing of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant, any economic concessions (including, without limitation, tenant improvement allowances and free rent) then being provided by landlords to tenants, </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and all other relevant factors to be taken into account.&nbsp;&nbsp;Within thirty (30) days after receipt of the Extension Notice, Landlord shall deliver to Tenant written notice of its determination of the Extension Term Base Rent for the applicable Extension</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Term.&nbsp;&nbsp;Tenant shall, within thirty (30) days after receipt of such notice, notify Landlord in writing whether Tenant accepts or rejects Landlord</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s determination of the Extension Term Base Rent (</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">Tenant</font><font style="font-weight:bold;">&#8217;</font><font style="font-weight:bold;">s Response Notice</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">).&nbsp;&nbsp;If Tenant fails timely to deliver Tenant</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s Response Notice, Landlord</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s determination of the Extension Term Base Rent shall be binding on Tenant.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:108pt;"></font>If and only if Tenant&#8217;s Response Notice is timely delivered to Landlord and indicates both that Tenant rejects Landlord&#8217;s determination of the Extension Term Base Rent and desires to submit the matter to arbitration, then the Extension Term Base Rent shall be determined in accordance with the procedure set forth in this Section 1.2(c).&nbsp;&nbsp;In such event, within ten (10) days after receipt by Landlord of Tenant&#8217;s Response Notice indicating Tenant&#8217;s desire to submit the determination of the Extension Term Base Rent to arbitration, Tenant and Landlord shall each notify the other, in writing, of their respective selections of an appraiser (respectively, &#8220;<font style="font-weight:bold;">Landlord&#8217;s Appraiser</font>&#8221; and &#8220;<font style="font-weight:bold;">Tenant&#8217;s Appraiser</font>&#8221;).&nbsp;&nbsp;Landlord&#8217;s Appraiser and Tenant&#8217;s Appraiser shall then jointly select a third appraiser (the &#8220;<font style="font-weight:bold;">Third Appraiser</font>&#8221;) within ten (10) days of their appointment.&nbsp;&nbsp;All of the appraisers selected shall be individuals with at least five (5) consecutive years&#8217; commercial appraisal experience for office and laboratory space in the area in which the Premises are located, shall be members of the Appraisal Institute (M.A.I.), and, in the case of the Third Appraiser, shall not have acted in any capacity for either Landlord or Tenant within five (5) years of his or her selection.&nbsp;&nbsp;The three appraisers shall determine the Extension Term Base Rent in accordance with the requirements and criteria set forth in Section 1.2(b) above, employing the method commonly known as Baseball Arbitration, whereby Landlord&#8217;s Appraiser and Tenant&#8217;s Appraiser each sets forth its determination of the Extension Term Base Rent as defined above, and the Third Appraiser must select one or the other (it being understood that the Third Appraiser shall be expressly prohibited from selecting a compromise figure). Landlord&#8217;s Appraiser and Tenant&#8217;s Appraiser shall deliver their determinations of the Extension Term Base Rent to the Third Appraiser within five (5) days of the appointment of the Third Appraiser and the Third Appraiser shall render his or her decision within ten (10) days after receipt of both of the other two determinations of the Extension Term Base Rent.&nbsp;&nbsp;The Third Appraiser&#8217;s decision shall be binding on both Landlord and Tenant.&nbsp;&nbsp;Each party shall bear the cost of its own appraiser and the cost of the Third Appraiser shall be paid by the party whose determination is not selected.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868617"></a><a name="_Toc504662601"></a>1.3<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Appurtenant Rights</font><font style="font-weight:normal;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>(a)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Common Areas</font>.&nbsp;&nbsp;Subject to the terms of this Lease and the Rules and Regulations (hereinafter defined), Tenant shall have, as appurtenant to the Premises, rights to use in common with others entitled thereto, the following areas (such areas are hereinafter referred to as the &#8220;<font style="font-weight:bold;">Common Areas</font>&#8221;): (i) the common loading docks, hallways, lobby, and elevator of the Building serving the Premises, (ii) the common lavatories located on the floor(s) on which the Premises are located, (iii) common walkways and driveways necessary for access to the Building, (iv) the Parking Areas, and (v) other areas and facilities located in the Building, on the Land, or elsewhere on the Campus designated by Landlord from time to time for the common use of tenants of the Building and other entitled thereto; and no other appurtenant rights or easements.&nbsp;&nbsp;<font style="font-weight:bold;">&#8220;Rules and Regulations&#8221; </font>shall be defined as the rules and regulations promulgated by Landlord pursuant </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to, and subject to, the provisions of Section 18.1 of the Lease.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">two (2</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) loading docks, receiving area, and freight elevators shown on </font><font style="text-decoration:underline;">Exhibit 1</font><font style="text-decoration:underline;">2</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, attached hereto and incorporated herein, are available for the use of the tenants in the Building and are part of the Common Areas.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Parking</font>.&nbsp;&nbsp;During the Term, Landlord shall, subject to the terms hereof, make available up to one hundred fifty-three (153) parking spaces for Tenant&#8217;s use free of charge (except that the costs of maintenance and repair of the parking areas shall, subject to the provisions of Section 5.2, be included in Operating Costs) in the Parking Areas serving the Building as shown on <font style="text-decoration:underline;">Exhibit 3</font>.  The number of parking spaces in the parking areas reserved for Tenant, as modified pursuant to this Lease or as otherwise permitted by Landlord, are hereinafter referred to as the &#8220;<font style="font-weight:bold;">Parking Spaces</font>.&#8221;&nbsp;&nbsp;Tenant shall have no right to hypothecate or encumber the Parking Spaces, and shall not sublet, assign, or otherwise transfer the Parking Spaces other than to employees of Tenant occupying the Premises or to a Successor (hereinafter defined), an Affiliated Entity (hereinafter defined), or a transferee pursuant to an approved Transfer under Section 13 of this Lease.&nbsp;&nbsp;Subject to Landlord&#8217;s right to reserve parking for other tenants of the Building, said Parking Spaces will be on an unassigned, non-reserved basis, and shall be subject to such Rules and Regulations, as may be in effect for the use of the parking areas from time to time.&nbsp;&nbsp;Reserved and handicap parking spaces must be honored.&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, Landlord shall have the right, upon at least three (3) months&#8217; prior written notice to Tenant, to temporarily (i.e., for a period of time not to exceed twelve (12) months and not more than one time every three year period, other than for reasons of Force Majeure) relocate all or any portion of the Parking Spaces in to other portions of the Property and/or parking areas owned, controlled or leased by Landlord and located on the Campus or on Hayden Avenue in Lexington.&nbsp;&nbsp;In the event that Landlord relocates Parking Spaces on Hayden Avenue but outside the Campus, Landlord shall provide reasonable shuttle service between the Building and such relocated parking area during the period of any such relocation.&nbsp;&nbsp;To the extent possible given any existing rights of other tenants under their respective leases, any such relocation of the Parking Spaces shall be done on an equitable basis as between Tenant and those other tenants with rights to park in the Parking Areas.&nbsp;&nbsp;In addition, Landlord may, at its election, implement valet parking in order to accommodate the parking needs of the Property from time to time.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Generator Area</font>.&nbsp;&nbsp;Landlord shall demise and lease the Generator Area, as hereinafter defined, to Tenant, and Tenant shall hire and take the Generator Area from Landlord for the Lease Term. The &#8220;<font style="font-weight:bold;">Generator Area</font>&#8221; shall be defined as the area on the roof of the Building shown on <font style="text-decoration:underline;">Exhibit 1D</font> attached hereto.&nbsp;&nbsp;Tenant shall have the right to use the Generator Area solely for the purpose of using Tenant&#8217;s own emergency generator (&#8220;<font style="font-weight:bold;">Tenant&#8217;s Generator</font>&#8221;) in accordance with the provisions of this Section 1.3(c).  Landlord shall install Tenant&#8217;s Generator as a part of Landlord&#8217;s Work.  Tenant&#8217;s Generator and the Generator Area are deemed to be the &#8220;<font style="font-weight:bold;">Generator Premises</font>&#8221;.&nbsp;&nbsp;Said demise of Tenant&#8217;s Generator Area shall be upon all of the same terms and conditions of the Lease, except as set forth herein.&nbsp;&nbsp;Tenant shall not operate Tenant&#8217;s Generator until Landlord has obtained copies of all required governmental permits, licenses, and authorizations necessary for the installation and operation of Tenant&#8217;s Generator.&nbsp;&nbsp;In addition, Tenant shall comply with all reasonable construction rules and regulations promulgated by Landlord in the maintenance and operation of Tenant&#8217;s Generator.&nbsp;&nbsp;Tenant shall be permitted to use Tenant&#8217;s Generator Area solely for the maintenance and operation of Tenant&#8217;s Generator, and Tenant&#8217;s Generator and Generator Area are solely for the benefit of Tenant.&nbsp;&nbsp;All electricity generated by Tenant&#8217;s Generator may only be consumed by Tenant in the Premises.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"></font><font style="margin-left:36pt;">(i)</font><font style="margin-left:36pt;">Tenant shall have no obligation to pay B</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ase Rent </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in respect of Tenant&#8217;s Generator Area.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">(ii)</font>Landlord shall have no obligation to provide any services to Tenant&#8217;s Generator Area other than electricity which will be measured by a submeter in accordance with Section 9.1.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;">Tenant shall have no right to make any changes, alterations, additions, decorations or other improvements (collectively &#8220;</font><font style="font-weight:bold;">Installations</font>&#8221;) to Tenant&#8217;s Generator Area without Landlord&#8217;s prior written consent, which consent Landlord may withhold in its sole but bona fide business judgment.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:36pt;">Tenant shall have no right to sublet Tenant&#8217;s Generator Area or to assign its interest hereunder, other than to an Affiliated Entity or Successor as defined in Section 13.7 of this Lease.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="margin-left:36pt;"></font>In addition to and without limiting Tenant&#8217;s obligations under the Lease, Tenant shall comply with all applicable environmental and fire prevention laws, ordinances and regulations in Tenant&#8217;s use of Tenant&#8217;s Generator Area.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">(</font>vi)<font style="margin-left:36pt;"></font>In addition to and without limiting Tenant&#8217;s obligations under the Lease, Tenant covenants and agrees that Tenant&#8217;s use of Tenant&#8217;s Generator and Installations shall not adversely affect the insurance coverage for the Building.&nbsp;&nbsp;If for any reason, the use of Tenant&#8217;s Generator and/or the installation or use of the Installations shall result in an increase in the amount of the premiums for such coverage, then Tenant shall be liable for the full amount of any such increase.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vii)<font style="margin-left:36pt;"></font>Tenant shall, at Tenant&#8217;s sole cost and expense, repair and maintain Tenant&#8217;s Generator and Installations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">(</font>viii)<font style="margin-left:36pt;">In addition to and without limiting the insurance provisions of the Lease, Tenant shall procure, keep in force and pay for Commercial General Liability Insurance in respect of Tenant&#8217;s Generator Area satisfying the requirements of Section 14.1 of the Lease.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">(</font>ix)<font style="margin-left:36pt;">To the maximum extent permitted by </font>Legal Requirements, Tenant&#8217;s Generator and all installations in Tenant&#8217;s Generator Area shall be at the sole risk of Tenant.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(x)<font style="margin-left:36pt;">In addition to and without limiting the indemnification provisions set forth in the Lease, Tenant shall, to the maximum extent permitted </font>by law and subject to Section 14.5, indemnify, defend, and hold Landlord harmless from any and all claims, losses, demands, actions, or causes of actions suffered by any person, firm, corporation, or other entity arising from Tenant&#8217;s use of Tenant&#8217;s Generator Area, except to the extent caused by the negligent acts, negligent omissions or willful misconduct of Landlord or any Landlord Parties.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>(d)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Penthouse Equipment Premises</font>.&nbsp;&nbsp;Landlord shall, as part of Landlord&#8217;s Work, install certain equipment within a portion of the Penthouse of the Building designated by </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord (the &#8220;</font><font style="font-weight:bold;">Penthouse Equipment Premises</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, as shown on </font><font style="text-decoration:underline;">Exhibit 1D</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any equipment installed within the </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penthouse Equipment</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Premises, as the same may be modified, altered or replaced during the Term, is collectively referred to herein as &#8220;</font><font style="font-weight:bold;">Tenant&#8217;s Penthouse Equipment</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">), </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for Tenant&#8217;s exclusive use</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> during the Term</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> accordance with the provisions of this Lease, including, without limitation, Section 11 hereof.</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall have the right, throughout the Term of the Lease, as the same may be extended, to use </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant&#8217;s Penthouse Equipment</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in accordance with Legal Requirements. </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall not operate Tenant</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penthouse Equipment</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> until </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord has obtained </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">copies of all required governmental permits, licenses, and authorizations necessary for the installation and operation thereof.&nbsp;&nbsp;In addition,</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> following the delivery of Tenant&#8217;s Penthouse Equipment by Landlord in good working order and repair, </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall comply with all reasonable construction rules and regulations promulgated</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> by Landlord pursuant to Section 18.1</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Tenant shall be responsible for the cost of repairing and maintaining Tenant</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penthouse Equipment</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and the cost of repairing any damage to the Building, or the cost of any necessary improvements to the Building, caused by or as a result of the installation, replacement and/or removal of Tenant</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penthouse Equipment</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except for Landlord&#8217;s Warranty, as </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">set forth in Section 1</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of </font><font style="text-decoration:underline;">Exhibit 4</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Landlord</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> makes no warranties or representations to Tenant </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as to the suitability of the </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penthouse Equipment</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Premises for the installation and operation of Tenant&#8217;s </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penthouse Equipment.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that at any time during the Term, Landlord determines, in its </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reasonable</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> business judgment, that the operation and/or periodic testing of Tenant</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penthouse Equipment</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> materially</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> interferes with the operation of the Building or the business operations of any of the occupants of the Building, then Tenant shall, upon </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">written </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">notice from Landlord, cause all further testing of Tenant</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penthouse Equipment</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to occur after normal business hours (hereinafter defined).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Cafeteria</font>.&nbsp;&nbsp;During the Term, Tenant, its employees, contractors, and visitors shall have the right to use the Cafeterias, as hereinafter defined, in common with others entitled thereto.  Notwithstanding anything to the contrary contained herein, during the Term, as the same may be extended hereby, Landlord shall be obligated to operate one Cafeteria (as hereinafter defined), and Tenant shall be entitled to use the same in accordance with this Section 1.3(e).&nbsp;&nbsp;The &#8220;<font style="font-weight:bold;">Cafeterias</font>&#8221;, as the same may be relocated as hereinafter set forth, shall be defined as food services facilities which provide food to tenants and occupants of the Campus.&nbsp;&nbsp;As of the Execution Date: (i) one (1) Cafeteria is located in Building 55 (the &#8220;<font style="font-weight:bold;">Building</font> <font style="font-weight:bold;">55</font> <font style="font-weight:bold;">Cafeteria</font>&#8221;), and (ii) the normal operating hours of the Building 55 Cafeteria are from 7:30 a.m. to 1:30 p.m., Monday through Friday, excepting holidays.  As of the Term Commencement Date, one (1) additional Cafeteria will be located in the Building.&nbsp;&nbsp;Tenant hereby acknowledges that the Cafeterias may be relocated, from time to time, to other buildings located on the Campus.&nbsp;&nbsp;A third party provider is currently contemplated to operate the Cafeterias.&nbsp;&nbsp;Any amounts paid by Landlord on account of the operation of the Cafeterias in excess of the net revenues derived from the operation of the Cafeterias shall be included in Operating Costs, as shall all of Landlord&#8217;s costs of cleaning, maintaining, and repairing the Cafeterias.&nbsp;&nbsp;Card readers shall, at no cost to Tenant, be installed and maintained at appropriate access points to the Cafeterias and identification cards shall be issued to authorized users.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>(f)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Fitness Center</font>.&nbsp;&nbsp;During the Term, Tenant, its employees and visitors shall have the right to use the Fitness Center, as hereinafter defined, in common with others entitled thereto.&nbsp;&nbsp;The &#8220;<font style="font-weight:bold;">Fitness Center</font>&#8221;, as the same may be relocated as hereinafter set forth, shall be a work-out facility for the use of tenants and occupants of the Campus.&nbsp;&nbsp;As of the Execution Date, the Fitness Center is located in Building 65.&nbsp;&nbsp;Tenant acknowledges that the Fitness Center may be </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relocated, from time to time, to other buildings located on the Campus.&nbsp;&nbsp;Card readers shall, at no cost to Tenant, be installed and maintained at appropriate access points to the Fitness Center and identification cards shall be </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issued to </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorized users.&nbsp;&nbsp;Users of the fitness center shall be required to execute such liability waivers as Landlord shall reasonably require.&nbsp;&nbsp;Any amounts paid by Landlord on account of the operation of the Fitness Center in excess of any net revenues derived from the operation of the Fitness Center shall be included in Operating Costs, as shall all of Landlord</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s costs of cleaning, maintaining, and</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> repairing the Fitness Center</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868618"></a><a name="_Toc504662602"></a>1.4<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Tenant&#8217;s Access</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>From and after the Term Commencement Date and until the end of the Term, Tenant shall, except in an emergency, and subject to Landlord&#8217;s reasonable Building security requirements, causes beyond Landlord&#8217;s reasonable control, Legal Requirements, the Rules and Regulations, the terms of this Lease, Force Majeure (hereinafter defined) and matters of record, have access to the Premises twenty-four (24) hours a day, seven (7) days a week.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk28422835"></a>(b)<font style="margin-left:108pt;"></font>Tenant and its employees shall have access to the Building after normal business hours by means of a card reader access system.&nbsp;&nbsp;In addition to the foregoing, Tenant shall have the right, subject to Tenant&#8217;s obtaining Landlord&#8217;s prior written approval of Tenant&#8217;s plans and specifications therefor (which approval shall not be unreasonably withheld, delayed or conditioned), to install a security system within the Premises (&#8220;Tenant&#8217;s Security System Work&#8221;).&nbsp;&nbsp;Tenant&#8217;s Security System Work shall be performed in accordance with this Lease, including, without limitation, Section 11 hereof.&nbsp;&nbsp;Tenant shall provide Landlord and the cleaning personnel with access cards permitting normal entry to Tenant&#8217;s Premises.&nbsp;&nbsp;In addition to the foregoing, such security system shall be designed with a master key override using the Building master key, so that Landlord shall have access to the Premises in an emergency, but Landlord shall only use such master key access in an emergency.&nbsp;&nbsp;Additionally, Tenant shall ensure that such system shall comply with all applicable laws, rules and regulations, including all fire safety laws, and in no event shall Landlord be liable for, and Tenant shall defend, indemnify, and hold harmless Landlord and its representatives and agents from and against, any claims, demands, liabilities, causes of action, suits, judgments, damages and expenses arising from such system or the malfunctioning thereof in accordance with Tenant&#8217;s indemnity obligations set forth in Section 14.2.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk28422774"></a>(c)<font style="margin-left:108pt;"></font>Subject to Section 11, Tenant shall have the right to access the Premises, at Tenant&#8217;s sole risk, prior to the Estimated Term Commencement Date for purposes reasonably related to the installation of Tenant&#8217;s cabling and wiring, provided such access does not materially interfere with the preparation for or performance of the Landlord Work or the Tenant Improvement Work (as said terms are defined in <font style="text-decoration:underline;">Exhibit 4</font>).&nbsp;&nbsp;Tenant shall, prior to the first entry to the Premises pursuant to this Section 1.4(c), provide Landlord with certificates of insurance evidencing that the insurance required in Section 14 hereof is in full force and effect and covering any person or entity entering the Building.&nbsp;&nbsp;Tenant shall defend, indemnify and hold the Landlord Parties (hereinafter defined) harmless from and against any and all Claims (hereinafter defined) for injury to persons or property resulting from or relating to Tenant&#8217;s access to and use of the Premises prior to the Term Commencement Date as provided under this Section 1.4(c).&nbsp;&nbsp;Tenant shall coordinate any access to the Premises prior to the Term Commencement Date with Landlord&#8217;s property manager.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868619"></a><a name="_Toc504662603"></a><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">1.5</font><font style="margin-left:72pt;"></font><font style="text-decoration:none;">No recording // Notice of Lease</font><font style="font-weight:normal;">.&nbsp;&nbsp;Neither party shall record this Lease.&nbsp;&nbsp;Tenant shall not record a memorandum of this Lease and/or a notice of this Lease.&nbsp;&nbsp;Notwithstanding the foregoing, if the Initial Term plus any Extension Term(s) exceed in the aggregate seven (7) years, Landlord agrees to join in the execution, in recordable form, of a statutory notice of lease and/or written declaration in which shall be stated the Term Commencement Date, the Rent Commencement Date, the number and length of the Extension Term(s) and the Expiration Date, which notice of lease may be recorded by Tenant with the Middlesex South Registry of Deeds and/or filed with the Middlesex South Registry District of the Land Court, as appropriate (alternatively and collectively, the </font><font style="font-weight:normal;">&#8220;</font><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Registry</font><font style="font-weight:normal;">&#8221;</font><font style="font-weight:normal;">) at Tenant</font><font style="font-weight:normal;">&#8217;</font><font style="font-weight:normal;">s sole cost and expense.&nbsp;&nbsp;If a notice of lease was previously recorded with the Registry, upon the expiration or earlier termination of this Lease, Landlord shall deliver to Tenant a notice of termination of </font><font style="font-weight:normal;">Lease</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">and Tenant shall promptly execute, acknowledge, and deliver the same (together with any other instrument(s) that may be necessary in order to record and/or file same with the Registry) to Landlord for Landlord</font><font style="font-weight:normal;">&#8217;</font><font style="font-weight:normal;">s execution and recordation with the Registry, which obligation shall survive the expiration or earlier termination of the Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868620"></a><a name="_Toc504662604"></a>1.6<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Exclusions</font><font style="font-weight:normal;">.&nbsp;&nbsp;The following are expressly excluded from the Premises and reserved to Landlord:&nbsp;&nbsp;all the perimeter walls of the Premises (except the inner surfaces thereof), the Common Areas, and any space in or adjacent to the Premises used for shafts, stacks, pipes, conduits, wires and appurtenant fixtures, fan rooms, ducts, electric or other utilities, sinks or other Building facilities, and the use of all of the foregoing, except as expressly permitted pursuant to Section 1.3(a) above.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868621"></a><a name="_Toc504662605"></a>1.7<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Acid Neutralization Tank</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>Landlord shall, as part of Landlord&#8217;s Work, install a separate acid neutralization tank (&#8220;<font style="font-weight:bold;">Tenant&#8217;s Acid Neutralization Tank</font>&#8221;) within the PH System Room for Tenant&#8217;s exclusive use in accordance with the provisions of this Lease, including, without limitation, Section 11 hereof.&nbsp;&nbsp;Tenant shall have the right, throughout the Term of the Lease, as the same may be extended, to use Tenant&#8217;s Acid Neutralization Tank in accordance with Legal Requirements.&nbsp;&nbsp;Tenant shall obtain, and maintain, all governmental permits and approvals necessary for the operation and maintenance of Tenant&#8217;s Acid Neutralization Tank.&nbsp;&nbsp;Following the installation and commissioning of Tenant&#8217;s Acid Neutralization Tank by Landlord as part of Landlord&#8217;s Work, and except for Landlord&#8217;s Warranty, as set forth in Section 14 of <font style="text-decoration:underline;">Exhibit 4</font>, Tenant shall be responsible for all costs, charges and expenses incurred from time to time in connection with or arising out of the operation, use, maintenance and repair of Tenant&#8217;s Acid Neutralization Tank, including all clean-up costs relating to Tenant&#8217;s Acid Neutralization Tank (collectively, &#8220;<font style="font-weight:bold;">Tank Costs</font>&#8221;), except, subject to Section 14.5, to the extent such costs are caused by the negligence or willful misconduct of any of the Landlord Parties.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>(b)<font style="margin-left:108pt;"></font>Following the delivery of Tenant&#8217;s Acid Neutralization Tank by Landlord in good working order and repair, Tenant shall be responsible for assuring that the maintenance and operation of Tenant&#8217;s Acid Neutralization Tank shall in no way damage any portion of the Building or Property.&nbsp;&nbsp;To the maximum extent permitted by Legal Requirements, Tenant&#8217;s Acid Neutralization Tank and all appurtenances thereto shall be at the sole risk of Tenant, and Landlord shall have no liability to Tenant if Tenant&#8217;s Acid Neutralization Tank or any appurtenant installations are damaged for any reason following the delivery of Tenant&#8217;s Acid Neutralization </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tank by Landlord in good working order and repair</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except for Landlord&#8217;s</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or any Landlord Parties&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> negligence or willful misconduct, Tenant agrees to be responsible for any damage caused to the Building or Property in connection with the maintenance</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> operation of Tenant&#8217;s Acid Neutralization Tank.&nbsp;&nbsp;Tenant</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;s responsibility with respect to Tenant&#8217;s </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acid Neutralization Tank </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">includes costs actually incurred by Landlord: (</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) in connection with any investigation required by any Governmental Authority of site conditions</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to the extent resulting from the breach by Tenant of its obligations with respect to the Acid Neutralization Tank</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, (</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) in connection with any investigation required by Landlord pursuant to which it is determined that Tenant has breach its obligations with respect to Tenant&#8217;s Acid Neutralization Tank, and (</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) any clean-up, remediation, and/or removal of any Hazardous Materials and/or restoration of the Property required by any Governmental Authority caused by Tenant&#8217;s improper use of Tenant&#8217;s Acid Neutralization Tank</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:108pt;"></font>Tenant shall be responsible for the operation, cleanliness and maintenance of Tenant&#8217;s Acid Neutralization Tank and the appurtenances.&nbsp;&nbsp;Such maintenance and operation shall be performed in a manner to avoid any unreasonable interference with any other tenants or Landlord.&nbsp;&nbsp;Except for Landlord&#8217;s Warranty, as set forth in Section 14 of <font style="text-decoration:underline;">Exhibit 4</font>, Landlord makes no warranties or representations to Tenant as to the suitability of Tenant&#8217;s Acid Neutralization Tank Premises for the installation and operation of Tenant&#8217;s Acid Neutralization Tank.&nbsp;&nbsp;Tenant shall have no right to make any changes, alterations, additions, decorations or other improvements to Tenant&#8217;s Acid Neutralization Tank Premises without Landlord&#8217;s prior written consent which shall not be unreasonably withheld, conditioned or delayed.&nbsp;&nbsp;Tenant agrees to maintain Tenant&#8217;s Acid Neutralization Tank in good condition and repair, reasonable wear and tear excepted.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:108pt;"></font>Landlord shall have no obligation to provide any services, including, without limitation, electric current, to Tenant&#8217;s Acid Neutralization Tank.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:108pt;"></font>Tenant shall have no right to remove Tenant&#8217;s Acid Neutralization Tank unless Tenant replaces it with an equivalent Acid Neutralization Tank approved by Landlord. Tenant shall, upon the expiration or earlier termination of the Lease, deliver Tenant&#8217;s Acid Neutralization Tank in good working condition, subject to reasonable wear and tear, provided, however, that the Acid Neutralization Tank shall be decommissioned.&nbsp;&nbsp;Tenant&#8217;s Surrender Plan, as required pursuant to Section 21.2, shall include the decommissioning of Tenant&#8217;s Acid Neutralization Tank.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc19795764"></a><a name="_Toc28868622"></a><a name="_Toc504662606"></a>1.8<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Nitrogen Tank</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a>(a)<font style="margin-left:108pt;"></font>Subject to Landlord&#8217;s review and approval of Tenant&#8217;s plans therefor, Tenant shall have the right, as appurtenant to the Premises, to install a nitrogen tank (the &#8220;<font style="font-weight:bold;">Nitrogen Tank</font>&#8221;) on a portion of the common pad area at the exterior of the Building (the &#8220;<font style="font-weight:bold;">Nitrogen Tank Area</font>&#8221;) as shown on <font style="text-decoration:underline;">Exhibit 1(E)</font> attached hereto.&nbsp;&nbsp;The Nitrogen Tank, together with any associated piping and infrastructure, shall be installed by Tenant in accordance with plans and specifications therefor that have been approved in advance, in writing, by Landlord and otherwise in accordance with the provisions of this Lease, including, without limitation, Section 11 hereof.  All required tank clearances for the Nitrogen Tank shall be provided for by Tenant within the Nitrogen Tank Area.&nbsp;&nbsp;Tenant shall be solely responsible for obtaining all necessary governmental and regulatory approvals and for the cost of installing, operating, maintaining and removing the Nitrogen Tank.&nbsp;&nbsp;Landlord shall reasonably cooperate with Tenant with respect to obtaining such approvals.&nbsp;&nbsp;Tenant </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shall not install or operate the Nitrogen Tank until Tenant has obtained and submitted to Landlord copies of all required governmental permits, licenses and authorizations necessary for the installation and operation of the Nitrogen Tank.&nbsp;&nbsp;In addition to, and without limiting Tenant&#8217;s obligations under the Lease, Tenant shall comply with all applicable environmental and fire prevention laws pertaining to the Nitrogen Tank.&nbsp;&nbsp;Tenant shall also be responsible for the cost of all utilities consumed in the operation of the Nitrogen Tank.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font>Tenant shall be responsible for assuring that the installation, maintenance, operation and removal of the Nitrogen Tank shall in no way damage any portion of the Building or Property.&nbsp;&nbsp;To the maximum extent permitted by Legal Requirements, the Nitrogen Tank and all appurtenances thereto shall be at the sole risk of Tenant, and Landlord shall have no liability to Tenant if the Nitrogen Tank or any appurtenant installations are damaged for any reason.&nbsp;&nbsp;Except for Landlord&#8217;s or any Landlord Parties&#8217; negligence or willful misconduct, Tenant agrees to be responsible for any damage caused to the Building or Property in connection with the installation, maintenance, operation or removal of the Nitrogen Tank.&nbsp;&nbsp;Tenant&#8217;s Responsibility with respect to Tenant&#8217;s Nitrogen Tank includes costs actually incurred by Landlord: (1) in connection with any investigation required by any Governmental Authority of site conditions to the extent resulting from the breach by Tenant of its obligations with respect to the Nitrogen Tank, (2) in connection with any investigation required by Landlord pursuant to which it is determined that Tenant has breach its obligations with respect to Tenant&#8217;s Nitrogen Tank, and (3) any clean-up, remediation, and/or removal of any Hazardous Materials and/or restoration of the Property required by any Governmental Authority caused by Tenant&#8217;s improper use of Tenant&#8217;s Nitrogen.&nbsp;&nbsp;In addition to, and without limiting Tenant&#8217;s obligations under the Lease, Tenant covenants and agrees that the installation and use of the Nitrogen Tank and appurtenances shall not adversely affect the insurance coverage for the Building.&nbsp;&nbsp;If for any reason, the installation or use of the Nitrogen Tank and/or the appurtenances shall result in an increase in the amount of the premiums for such coverage, then Tenant shall be liable for the full amount of any such increase.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:108pt;"></font>Tenant shall be responsible for the installation, operation, cleanliness, maintenance and removal of the Nitrogen Tank and the appurtenances, all of which shall remain the personal property of Tenant, and shall be removed by Tenant at its own expense at the expiration or earlier termination of the Lease.&nbsp;&nbsp;Tenant shall repair any damage caused by such removal, including the patching of any holes to match, as closely as possible, the color surrounding the area where the Nitrogen Tank and appurtenances were attached.&nbsp;&nbsp;Such maintenance and operation shall be performed in a manner to avoid any unreasonable interference with any other tenants or Landlord.&nbsp;&nbsp;Tenant shall take the Nitrogen Tank Area &#8220;as is&#8221; in the condition in which the Nitrogen Tank Area is in as of the Term Commencement Date, without any obligation on the part of Landlord to prepare or construct the Nitrogen Tank Area for Tenant&#8217;s use or occupancy.&nbsp;&nbsp;Without limiting the foregoing, Landlord makes no warranties or representations to Tenant as to the suitability of the Nitrogen Tank Area for the installation and operation of the Nitrogen Tank.&nbsp;&nbsp;Tenant shall have no right to make any changes, alterations, additions, decorations or other improvements to the Nitrogen Tank Area without Landlord&#8217;s prior written consent which shall not be unreasonably withheld, conditioned or delayed.&nbsp;&nbsp;Tenant agrees to maintain the Nitrogen Tank in good condition and repair.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a>(d)<font style="margin-left:108pt;"></font>Tenant shall have access to the Nitrogen Tank and the Nitrogen Tank Premises, and the surrounding area for the purpose of installing, repairing, maintaining and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">removing said Nitrogen Tank.</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord shall have no obligation to provide any services, including, without limitation, electric current, to the Nitrogen Tank.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662607"></a><a name="_Toc28868623"></a>RIGHTS RESERVED TO LANDLORD </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868624"></a><a name="_Toc504662608"></a>2.1<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Additions and Alterations</font><font style="font-weight:normal;">.&nbsp;&nbsp;Landlord reserves the right, at any time and from time to time, to make such changes, alterations, additions, improvements, repairs or replacements in or to the Property (including the Premises but, with respect to the Premises, only for purposes of repairs, maintenance, replacements and the exercise of any other rights expressly reserved to Landlord herein) and the fixtures and equipment therein, as well as in or to the street entrances and/or the Common Areas, as it may deem necessary or desirable, provided, however, that there be no material obstruction of permanent access to, or material interference with the use and enjoyment of, the Premises by Tenant. Subject to the foregoing, Landlord expressly reserves the right to temporarily close all, or any portion, of the Common Areas for the purpose of making repairs or changes thereto, provided that Landlord shall use commercially reasonable efforts to complete the work in a timely manner, subject to causes beyond Landlord&#8217;s reasonable control.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868625"></a><a name="_Toc504662609"></a>2.2<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Additions to the Property</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>Landlord may at any time or from time to time (i) construct additional building(s) and improvements and related site improvements (collectively, &#8220;<font style="font-weight:bold;">Future Development</font>&#8221;) in all or any part of the Property and/or (ii) change the location or arrangement of any improvement outside the Building in or on the Property or all or any part of the Common Areas, or add or deduct any land to or from the Property; provided that there shall be no material increase in Tenant&#8217;s obligations or material interference with Tenant&#8217;s rights under this Lease in connection with the exercise of the foregoing reserved rights.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font>In case any excavation shall be made for building or improvements or for any other purpose upon the land adjacent to or near the Premises, Tenant will afford without charge to Landlord, or the person or persons, firms or corporations causing or making such excavation, license to enter upon the Premises for the purpose of doing such work as Landlord or such person or persons, firms or corporation shall deem to be necessary to preserve the walls or structures of the Building from injury, and to protect the Building by proper securing of foundations.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a>(c)<font style="margin-left:108pt;"></font>Tenant acknowledges and agrees that this Lease is subject and subordinate to (i) The Hayden Science Center Condominium (the &#8220;<font style="font-weight:bold;">Condominium</font>&#8221;), which was established by Master Deed dated December 1, 2017, recorded in Book 70325, Page 108, in the Middlesex South District Registry of Deeds and filed as Document No. 195793 in the Middlesex South Registry District of the Land Court, (ii) the Condominium Floor Plans and Site Plans dated December 1, 2017, and filed with the Middlesex Registry of Deeds, Southern District, as Plan No. 1090, Pages 1 through 13, and (iii) the Declaration of Trust of The Hayden Science Center Condominium Trust dated December 1, 2017, recorded in Book 70325, Page 148, in the Middlesex South District Registry of Deeds and filed as Document No. 195794 in the Middlesex South Registry District of the Land Court (the Master Deed, Declaration of Trust, and the Plans are being referred to herein as the &#8220;<font style="font-weight:bold;">Condominium Documents</font>&#8221;).&nbsp;&nbsp;Tenant acknowledges and confirms that, as of the date hereof, the Building is not yet a Unit of the Condominium, provided, however, Landlord may amend the Master Deed to submit the Building to the provisions of Chapter 183A </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the Massachusetts General Laws and to include the Building as a Unit of the Condominium.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> further</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> agrees that the Condominium Documents</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, as so amended,</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may be </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">further </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amended and that this Lease shall remain subject to and subordinate to the Condomin</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ium Documents, as so amended, so long as such amendments do not: not: (x) materially adversely affect Tenant&#8217;s rights under this Lease, or (y) materially increase Tenant&#8217;s obligations under this Lease.&nbsp;&nbsp;Landlord agrees to provide Tenant with copies of any such amendments at least ten (10) business days prior to recording same</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:108pt;"></font>Landlord and Tenant each hereby acknowledges and agrees that, in connection with any Future Development, (i) Landlord shall have the right to enter into, and subject the Property to the terms and conditions of, a commercially reasonable reciprocal easement agreement with any one or more of the neighboring property owners in order to create a commercial campus-like setting (&#8220;<font style="font-weight:bold;">REA</font>&#8221;); (ii) upon Landlord&#8217;s request in connection with the recording of the REA, Tenant shall execute a commercially reasonable instrument in recordable form making this Lease subject and subordinate to the REA; (iii) Landlord shall have the right to subdivide the Property so long as Tenant continues to have all of the rights and obligations contained in this Lease (e.g., the appurtenant right to use all Common Areas); and (iv) Tenant shall execute such reasonable documents (which may be in recordable form) evidencing the foregoing promptly upon Landlord&#8217;s request, so long as such agreements do not (x) materially adversely affect Tenant&#8217;s rights under this Lease or (y) materially increase Tenant&#8217;s obligations under this Lease.&nbsp;&nbsp;Landlord agrees to provide Tenant with copies of any such agreements at least ten (10) business days prior to recording same.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868626"></a><a name="_Toc504662610"></a>2.3<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Name and Address of Building</font><font style="font-weight:normal;">.&nbsp;&nbsp;Landlord reserves the right at any time and from time to time to change the name or address of the Building and/or the Property, provided Landlord gives Tenant at least three (3) months&#8217; prior written notice thereof. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868627"></a><a name="_Toc504662611"></a>2.4<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Landlord&#8217;s Access</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a>(a)<font style="margin-left:108pt;"></font>Subject to the terms hereof, Tenant shall (a) upon reasonable advance notice (not less than forty-eight (48) hours), which may be by email at rmitrano@frequencytx.com or some other email address as may be provided in writing by Tenant to Landlord (except that no notice shall be required in emergency situations), permit Landlord and any holder of a Mortgage (hereinafter defined) (each such holder, a &#8220;<font style="font-weight:bold;">Mortgagee</font>&#8221;), and the agents, representatives, employees and contractors of each of them, to have reasonable access to the Premises at all reasonable hours for the purposes of inspection, making repairs, replacements or improvements in or to the Premises or the Building or equipment therein (including, without limitation, sanitary, electrical, heating, air conditioning or other systems), complying with all applicable laws, ordinances, rules, regulations, statutes, by-laws, court decisions and orders and requirements of all public authorities (collectively, &#8220;<font style="font-weight:bold;">Legal Requirements</font>&#8221;), or exercising any right reserved to Landlord under this Lease (including without limitation the right to take upon or through, or to keep and store within the Premises all necessary materials, tools and equipment); (b) permit Landlord and its agents and employees, at reasonable times, upon reasonable advance notice, to show the Premises during normal business hours (i.e. Monday &#8211; Friday 7 A.M. - 6 P.M., Saturday 7 A.M. &#8211; 12 P.M., excluding holidays) to any prospective Mortgagee or purchaser of the Building and/or the Property or of the interest of Landlord therein, and, during the last twelve (12) months of the Term or at any time after the occurrence of an Event of Default, prospective tenants; and (c) </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upon reasonable prior written notice from Landlord, permit Landlord and its agents, at Landlord</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s sole cost and expense, to perform environmental audits, environmental site investigations and environmental site assessments (</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">Site Assessments</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) in, on, under and at the Premises and the Land, it being understood that Landlord shall repair any damage arising as a result of the Site Assessments, and such Site Assessments may include both above and below the ground testing and such other tests as may be necessary or appropriate to conduct the Site Assessments.&nbsp;&nbsp;In addition, to the extent that it is necessary to enter the Premises in order to access any area that serves any portion of the Building outside the Premises, then Tenant shall, upon as much advance notice as is practical under the circumstances, and in any event at least twenty-four (24) hours</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> prior written notice (except that no notice shall be required in emergency situations), permit contractors engaged by other occupants of the Building to pass through the Premises in order to access such areas but only if accompanied by a representative of Landlord.</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, Tenant shall be entitled to have a representative present for any access by Landlord or any Landlord Parties in exercising its rights under this Section 2.4.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Secure Area within the Premises</font>.&nbsp;&nbsp;Notwithstanding the foregoing, Tenant, at its own expense may, as hereinafter set forth, designate one or more areas of the Premises to be &#8220;<font style="font-weight:bold;">Secure Areas</font>&#8221; (i.e., portions of the Premises to which Landlord shall not have a right of entry or access for any reason whatsoever (except as otherwise provided below).&nbsp;&nbsp;Tenant may, from time to time, exercise its right to create Secure Areas by delivering to Landlord, for Landlord&#8217;s written approval, a plan showing the location of any such Secure Areas.&nbsp;&nbsp;Landlord agrees that it will not unreasonably withhold, condition or delay such consent.&nbsp;&nbsp;If Landlord must gain access to a Secure Areas in a non-emergency situation, Landlord shall contact Tenant, and Landlord and Tenant shall arrange a mutually agreed upon time for Landlord to have such access.&nbsp;&nbsp;Landlord shall be accompanied by an employee of Tenant or a party designated by Tenant (the &#8220;<font style="font-weight:bold;">Escort</font>&#8221;).&nbsp;&nbsp;Tenant shall make an Escort available to Landlord during business hours.&nbsp;&nbsp;At all times, Landlord shall comply with all reasonable security measures of the Tenant pertaining to the Secure Areas.&nbsp;&nbsp;If an emergency representing an imminent risk of injury to persons or material property damage in the Building or the Premises, including, without limitation, a suspected fire or flood, requires Landlord to gain access to the Secure Areas, Landlord may enter the Secure Areas without an Escort.&nbsp;&nbsp;If practicable under the circumstances, Landlord shall immediately notify (which may be oral notification) and request that Tenant make an Escort available to Landlord if time permits, and if Tenant shall not make an Escort available to accompany Landlord, then Tenant hereby authorizes Landlord to enter the Secure Areas forcibly or with a master key, and to enter without an Escort.&nbsp;&nbsp;In any such event, except (subject to Section 14.5 of this Lease) to the extent resulting from Landlord&#8217;s negligence or willful misconduct, Landlord shall have no liability whatsoever to Tenant, and Tenant shall pay all reasonable expenses incurred by Landlord in repairing or reconstructing any entrance, corridor, door or other portions of the Premises damaged as a result of a forcible entry by Landlord.&nbsp;&nbsp;Landlord shall have no obligation to provide either janitorial service or cleaning in the Secure Areas unless Tenant shall make arrangements to have an Escort in the Secure Areas at the time such service or cleaning is provided to the remainder of the Premises.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868628"></a><a name="_Toc504662612"></a><a name="_AEIOULastRenderedPageBreakAEIOU17"></a>2.5<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Pipes, Ducts and Conduits</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant shall permit Landlord to erect, use, maintain and relocate pipes, ducts and conduits in and through the Premises, provided the same do not reduce the rentable square footage of the Premises, other than in a de minimis amount, or adversely affect the appearance of the Premises.&nbsp;&nbsp;In exercising its rights under this Section 2.5, Landlord </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">shall make commercially reasonable efforts to locate any pipes, ducts, and conduits behind walls and above ceilings so as to minimize interference with the Premises</font><font style="font-weight:normal;">.</font><font style="font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868629"></a><a name="_Toc504662613"></a>2.6<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Minimize Interference</font><font style="font-weight:normal;">.&nbsp;&nbsp;Except in the event of an emergency, Landlord shall use commercially reasonable efforts to minimize any interference with Tenant&#8217;s business operations and use and occupancy of the Premises in connection with the exercise any of the foregoing rights under this Section 2.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662614"></a><a name="_Toc28868630"></a>CONDITION OF PREMISES; CONSTRUCTION.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868631"></a><a name="_Toc504662615"></a>3.1<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Condition of Premises</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant acknowledges and agrees that, except as expressly provided in this Lease, Tenant is leasing the Premises in their &#8220;</font>AS IS<font style="font-weight:normal;">,&#8221; &#8220;</font>WHERE IS<font style="font-weight:normal;">&#8221; condition and with all faults on the Execution Date, without representations or warranties, express or implied, in fact or by law, of any kind, and without recourse to Landlord, except that:&nbsp;&nbsp;(i) Landlord represents to Tenant that, as of the Term Commencement Date, the Building shall have the systems and capacities set forth on </font><font style="text-decoration:underline;font-weight:normal;">Exhibit 5</font><font style="font-weight:normal;"> and (ii) Landlord shall perform Landlord&#8217;s Work in accordance with the provisions of this Section 3 and </font><font style="text-decoration:underline;font-weight:normal;">Exhibit 4</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant shall not exceed its allotted base building capacities defined on </font><font style="text-decoration:underline;font-weight:normal;">Exhibit 5</font><font style="font-weight:normal;"> attached hereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868632"></a><a name="_Toc504662616"></a>3.2<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Landlord&#8217;s Work</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>Subject to Force Majeure, as defined in Section 25.16 and any Tenant Delay, as hereinafter defined, Landlord shall perform Landlord&#8217;s Work in order to prepare the Premises for Tenant&#8217;s use and occupancy in accordance with <font style="text-decoration:underline;">Exhibit 4</font> attached hereto.&nbsp;&nbsp;Landlord shall use diligent efforts to achieve Substantial Completion of Landlord&#8217;s Work by the Estimated Term Commencement Date.&nbsp;&nbsp;Landlord shall advise Tenant periodically of the progress of Landlord&#8217;s Work.&nbsp;&nbsp;However, except to the extent that such failure constitutes a delay in the occurrence of the Term Commencement Date (as provided in the definition of the Term Commencement Date), and, except for Tenant&#8217;s remedies set forth in Section 3.3 hereof: (i) Tenant&#8217;s sole remedies shall be a delay in the Term Commencement Date, (ii) Tenant shall have no claim or rights against Landlord, and Landlord shall have no liability or obligation to Tenant in the event of delay in Landlord&#8217;s Work, and (iii) no delay in Landlord&#8217;s Work shall have any effect on the parties rights or obligations under this Lease.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Definitions</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a>(i)<font style="margin-left:144pt;"></font>&#8220;<font style="font-weight:bold;">Tenant Delay</font>&#8221; shall mean any delay in the performance of Landlord&#8217;s Work arising from: (i) long lead time items selected by Tenant, (ii) the default, negligence or willful misconduct of Tenant or any other Tenant Party, or (iii) any Changes (as defined in <font style="text-decoration:underline;">Exhibit 4</font> attached hereto).&nbsp;&nbsp;Notwithstanding the foregoing, except where a Tenant Delay arises from Tenant&#8217;s failure timely to act within on or before a date or time period expressly set forth in the Lease (in which event no Tenant Delay Notice shall be required): (x) in no event shall any act or omission be deemed to be a Tenant Delay until and unless Landlord has given Tenant written notice (the &#8220;<font style="font-weight:bold;">Tenant Delay Notice</font>&#8221;) advising Tenant (a) that a Tenant Delay is occurring, and (b) of the basis on which Landlord has determined that a Tenant Delay is occurring, and (y) no period of time prior to the time that Tenant receives a Tenant Delay Notice shall be included in the period of time charged to Tenant pursuant to such Tenant Delay Notice.  Tenant shall pay for </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any increase in the cost to Landlord in the performance of</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Landlord&#8217;s Work arising from any Tenant Delay</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> within thirty (30) days of billing by Landlord</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:144pt;"></font>&#8220;<font style="font-weight:bold;">Substantially Complete</font>&#8221; or &#8220;<font style="font-weight:bold;">Substantial Completion</font>,&#8221; when referring to Landlord&#8217;s Work shall mean that:&nbsp;&nbsp;(1) Landlord&#8217;s Work is completed, other than minor work which does not materially affect Tenant&#8217;s use of, or access to, the Premises, (2) the Premises and those portions of the Common Areas of the Building which affect Tenant&#8217;s occupancy are in conformance with all applicable building codes, permits, laws and regulations, including without limitation, ADA, (3) all structural elements and subsystems of the Building, including but not limited to HVAC, mechanical, electrical, lighting, plumbing, and life safety systems, will be in good working condition and repair, (4) Landlord has delivered to Tenant a certificate of substantial completion from Landlord&#8217;s architect stating that Landlord&#8217;s Work is substantially complete, and (5) such evidence (the &#8220;<font style="font-weight:bold;">Town Approval</font>&#8221;) as is customarily provided by the Town of Lexington to evidence its acceptance of Landlord&#8217;s Work and Tenant&#8217;s right to lawfully occupy the Premises (e.g., sign-offs on the Building permit by all applicable Town of Lexington departments or a certificate of occupancy, which may be a temporary certificate of occupancy) has been provided by the Town of Lexington.&nbsp;&nbsp;No costs incurred by Landlord in completing the Landlord&#8217;s Work or satisfying the definition of Substantial Completion shall be included in Operating Costs.&nbsp;&nbsp;Notwithstanding anything to the contrary herein contained, in the event that Landlord&#8217;s Work is delayed by reason of any Tenant Delay, then Landlord shall be deemed to have achieved Substantial Completion of Landlord&#8217;s Work on the date that Landlord would have achieved Substantial Completion of Landlord&#8217;s Work, but for such Tenant Delay.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Punchlist</font>.&nbsp;&nbsp;Promptly following Substantial Completion of Landlord&#8217;s Work, Landlord shall provide Tenant with a punchlist prepared by Landlord&#8217;s architect (the &#8220;<font style="font-weight:bold;">Punchlist</font>&#8221;) incorporating those items jointly identified by Landlord and Tenant during their joint inspection of Landlord&#8217;s Work, of outstanding items (the &#8220;<font style="font-weight:bold;">Punchlist Items</font>&#8221;).&nbsp;&nbsp;Promptly after Substantial Completion of Landlord&#8217;s Work, Landlord and Tenant shall jointly inspect the Premises.&nbsp;&nbsp;Subject to Force Majeure (as defined in Section 25.16) and Tenant Delays, Landlord shall complete all Punchlist Items within thirty (30) days of the date of the Punchlist (other than seasonal items, such as landscaping, requiring a longer period), provided that Tenant reasonably cooperates in connection with the completion of such Punchlist Items.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868633"></a><a name="_Hlk32338658"></a><a name="_Toc504662617"></a>3.3<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Tenant&#8217;s Remedies in the Event of Delays in Term Commencement Date.</font><font style="font-weight:normal;">&nbsp;&nbsp; This Section 3.3 sets forth Tenant&#8217;s sole remedies, both at law and in equity, in the event of any delay in Landlord&#8217;s Work or the Term Commencement Date:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc513624751"></a><a name="_Toc513737885"></a>(a)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Rent Credit</font><a name="_Toc513624751"></a><a name="_Toc513737885"></a>.&nbsp;&nbsp;If the Term Commencement Date has not occurred on or before the Outside Rent Credit Date (defined below), then, as Tenant&#8217;s sole remedy, based upon any delay in the Term Commencement Date, Tenant shall be entitled to a rent credit against Tenant&#8217;s obligation to pay Base Rent equal to one (1) day for each day between the Outside Rent Credit Date and the Commencement Date.&nbsp;&nbsp;The &#8220;<font style="font-weight:bold;">Outside Rent Credit Date</font>&#8221; shall mean the date that is thirty (30) days after the Estimated Term Commencement Date, provided, however, that the Outside Rent Credit Date shall be extended by the lesser of: (x) ninety (90) days, or (y) the length of any delays in Landlord&#8217;s Work arising from delay by Force Majeure (as defined in Section 25.16) occurring prior to the Outside Rent Credit Date.<font style="font-weight:bold;">&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Termination Right</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term Commencement Date</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has not </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">occurred</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> on or before the Outside Termination Date, as hereinafter defined, then Tenant shall have the right</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to terminate the Lease, </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which shall be </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exercisable by a written thirty (30) day termination notice given on or after the Outside Termination Date but before the date that </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term Commencement Date</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> occurs</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160; If </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term Commencement Date occurs on or before the&#160;thirtieth (30th) day after Landlord receives such termination notice, Tenant's termination notice shall be deemed to be void and of no force or effect.&#160; If the Term Commencement Date does not occur on or before such thirtieth (30th) day, this Lease shall terminate and shall be of no further force or effect</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and, except for provisions of the lease which are intended to survive termination of the Lease (e.g.</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> indemnification provisions), neither party shall have any further obligation to the other party</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&nbsp;&nbsp;For the purposes hereof, the &#8220;</font><font style="font-weight:bold;">Outside Termination Date</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; shall be defined as </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">four (4) months after the Estimated Term Commencement Date</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, provided however, that the Outside Termination Date shall be extended by the lesser of: (x) </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ninety (90)</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> days, or (y) the length of any delays in Landlord&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Work arising from delay by Force</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Majeure (as defined in Section 25.16</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">).</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662618"></a><a name="_Toc28868634"></a>USE OF PREMISES</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868635"></a><a name="_Toc504662619"></a>4.1<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Permitted Uses</font><font style="font-weight:normal;">.&nbsp;&nbsp;During the Term, Tenant shall use the Premises only for the Permitted Uses and for no other purposes.&nbsp;&nbsp;Service and utility areas (whether or not a part of the Premises) shall be used only for the particular purpose for which they are designed.&nbsp;&nbsp;Tenant shall keep the Premises equipped with appropriate safety appliances to the extent required by applicable laws or insurance requirements.&nbsp;&nbsp;Landlord shall cooperate with Tenant, in such manner as Tenant may reasonably request, in assisting Tenant to obtain any governmental permits or approvals necessary to enable Tenant to use the Premises for any of the Permitted Uses, provided that Landlord shall not be obligated to incur any out-of-pocket costs or expenses or incur any liability in connection with any such request.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868636"></a><a name="_Toc504662620"></a>4.2<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Prohibited Uses</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a>(a)<font style="margin-left:108pt;"></font>Notwithstanding any other provision of this Lease, Tenant shall not use the Premises or the Building, or any part thereof, or suffer or permit the use or occupancy of the Premises or the Building or any part thereof by any of the Tenant Parties (i) in a manner which would violate any of the covenants, agreements, terms, provisions and conditions of this Lease or otherwise applicable to or binding upon the Premises; (ii) for any unlawful purposes or in any unlawful manner; (iii) which, in the reasonable judgment of Landlord (taking into account the use of the Building as a combination laboratory, research and development and office building and the Permitted Uses) shall (a) impair, interfere with or otherwise diminish the quality of any of the Building services or the proper and economic heating, cleaning, ventilating, air conditioning or other servicing of the Building or Premises, or the use or occupancy of any of the Common Areas; (b) occasion impairment, interference or injury in any material respect (and Tenant shall not install or use any electrical or other equipment of any kind, which, in the reasonable judgment of Landlord, will cause any such impairment, interference, or injury), or cause any injury or damage to any occupants of the Premises or other tenants or occupants of the Building or their property; or (c) cause harmful air emissions, laboratory odors or noises or any unusual or other objectionable odors, noises or emissions to emanate from the Premises; (iv) in a manner which is inconsistent with the operation and/or maintenance of the Building as a first-class combination office, research, development and laboratory facility; or (v) in a manner which shall increase such insurance rates </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the Building or on property located therein over that applicable when Tenant first took occ</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upancy of the Premises hereunder, unless Tenant otherwise agrees in writing to be responsible for the increased cost of such insurance rates</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Notwithstanding the foregoing, Landlord agrees that Tenant&#8217;s use of the Premises for the Permitted Use (as opposed to the particular manner of Tenant&#8217;s use of the Premises) shall not, in and of itself, be deemed to breach the provisions of this Section 4.2</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font>With respect to the use and occupancy of the Premises and the Common Areas, Tenant will not:&nbsp;&nbsp;(i) place or maintain any signage (except as set forth in Section 12.2 below), trash, refuse or other articles in any vestibule or entry of the Premises, on the footwalks or corridors adjacent thereto or elsewhere on the exterior of the Premises, nor obstruct any driveway, corridor, footwalk, parking area, mall or any other Common Areas; (ii) permit undue accumulations of or burn garbage, trash, rubbish or other refuse within or without the Premises; (iii) permit the parking of vehicles so as to interfere with (x) the ability of others, entitled thereto, to park in the common parking areas, or (y) the use of any driveway, corridor, footwalk, parking area, or other Common Areas; (iv) receive or ship articles of any kind outside of those areas reasonably designated by Landlord; (v) conduct or permit to be conducted any auction, going out of business sale, bankruptcy sale (unless directed by court order), or other similar type sale in or connected with the Premises; (vi) use the name of Landlord, or any of Landlord&#8217;s affiliates in any publicity, promotion, trailer, press release, advertising, printed, or display materials without Landlord&#8217;s prior written consent; or (vii) except in connection with Alterations (hereinafter defined) approved by Landlord, cause or permit any hole to be drilled or made in any part of the Building.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868637"></a><a name="_Toc504662621"></a>4.3<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Transportation of Animals</font><font style="font-weight:normal;">.&nbsp;&nbsp;No animals, animal waste, food or supplies relating to the animals maintained from time to time in the animal storage areas of the Premises shall be transported within the Building except as provided in this Section 4.3.&nbsp;&nbsp; All deliveries of animals or animal food or supplies to Tenant at the Building shall be made prior to 11:00 a.m.&nbsp;&nbsp;No transportation of animals, animal waste, food or supplies within the Building shall occur between the hours of 11:00 a.m. and 1:00 p.m.&nbsp;&nbsp;At all times that animals are transported within the Common Areas, they shall be transported in an appropriate cage or other container.&nbsp;&nbsp;At no time shall any animals, animal waste, food or supplies relating to the animals be brought into, transported through, or delivered to the lobby of the Building or be transported within the Building in elevators other than the freight elevator.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868638"></a><a name="_Toc504662622"></a><a name="_AEIOULastRenderedPageBreakAEIOU21"></a>4.4<font style="margin-left:72pt;"></font><font style="text-decoration:none;">MWRA Permit</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant shall establish and maintain with respect to its use of wastewater facilities exclusively serving the Leased Premises, an MWRA waste water discharge program administered by a licensed, qualified individual (which individual may be (i) a third party contractor/consultant approved by Landlord, which approval shall not be unreasonably withheld, or (ii) an employee of Tenant or Tenant&#8217;s affiliate) in accordance with the requirements of the Massachusetts Water Resources Authority (&#8220;</font>MWRA<font style="font-weight:normal;">&#8221;) and any other applicable governmental authority.&nbsp;&nbsp;Tenant shall be solely responsible for all costs incurred in connection with such MWRA waste water discharge, and Tenant shall provide Landlord with such documentation as Landlord may reasonably require evidencing Tenant&#8217;s compliance with the requirements of (a) the MWRA and any other applicable governmental authority with respect to such chemical safety program and (b) this Section.&nbsp;&nbsp;Tenant shall obtain and maintain during the Term (i) any permit required by the MWRA (&#8220;</font>MWRA Permit<font style="font-weight:normal;">&#8221;) and (ii) a wastewater treatment operator license from the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">Commonwealth of Massachusetts with respect to Tenant</font><font style="font-weight:normal;">&#8217;</font><font style="font-weight:normal;">s use of any acid neutralization tank exclusively serving the Leased Premises in the Building.&nbsp;&nbsp;Tenant shall not introduce anything into the acid neutralization tank serving the Premises, if any (x) in violation of the terms of the MWRA Permit, (y) in violation of Legal Requirements or (z) that would interfere with the proper functioning of any such acid neutralization tank.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868639"></a><a name="_Toc504662623"></a>4.5<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Parking and Traffic Demand Management Plan</font><font style="font-weight:normal;">.&nbsp;&nbsp;The Property is subject to a Parking and Traffic Demand Management Plan with the Town of Lexington, for Expanded Multi-Tenant Life Science Center, for 45, 55, 65, and 75 Hayden Avenue, Lexington, Massachusetts, updated December 6, 2017 (the &#8220;</font>Initial PTDM<font style="font-weight:normal;">&#8221;).&nbsp;&nbsp;Tenant agrees, at its sole expense, to comply with the requirements of the Initial PTDM, only insofar as they apply to the Premises and/or Tenant&#8217;s use and occupancy thereof.&nbsp;&nbsp;In the event that the Initial PTDM is ever modified, supplemented, amended or replaced (&#8220;</font>PTDM Modifications<font style="font-weight:normal;">&#8221;), Tenant agrees, at its sole expense, to comply with the requirements of the PTDM Modifications, only insofar as they apply to the Premises and/or Tenant&#8217;s use and occupancy thereof.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868640"></a><a name="_Toc504662624"></a>4.6<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Vivarium</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant shall be responsible, at its sole expense, for the operations of its vivarium in accordance with all Legal Requirements and with best industry practices.&nbsp;&nbsp;Without limiting the general application of the foregoing, Tenant shall separately dispose of all waste products from the operation of Tenant&#8217;s vivarium, including, without limitation, dead animals, strictly in accordance with Legal Requirements.&nbsp;&nbsp;Landlord shall have the right, from time to time by written notice to Tenant, to promulgate reasonable rules and regulations with respect to the operation of Tenant&#8217;s vivarium so as to minimize any adverse effects that such operation may have on other occupants of the Building, including without limitation, regulations as to noise mitigation.&nbsp;&nbsp;Notwithstanding any other provision of this Lease, provided that (a) there is no Event of Default of Tenant and (b) the Lease is in full force and effect, in the event Tenant desires to expand the Approved Vivarium Uses to include cats (the &#8220;</font>Additional Vivarium Use<font style="font-weight:normal;">&#8221;), Tenant shall make such request in writing to Landlord for Landlord&#8217;s approval therefor, which approval shall not be unreasonably withheld, conditioned or delayed, subject to (x) this Section 4.6, (y) Tenant&#8217;s obtaining Landlord&#8217;s prior written approval of Tenant&#8217;s plans and specifications for the Additional Vivarium Use in accordance with Section 11 below, and (z) such additional rules and regulations as Landlord may reasonably determine in connection with the operation of the Additional Vivarium Use in the Building.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662625"></a><a name="_Toc28868641"></a>RENT; ADDITIONAL RENT</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868642"></a><a name="_Toc504662626"></a>5.1<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Base Rent; Additional Rent.  </font><font style="font-weight:normal;">Commencing as of the Rent Commencement Date and continuing thereafter throughout the remainder of the Term, Tenant shall pay Base Rent to Landlord in equal monthly installments, in advance and without demand on the first day of each month for and with respect to such month. Unless otherwise expressly provided herein, the payment of Base Rent, Additional Rent and other charges reserved and covenanted to be paid under this Lease with respect to the Premises (collectively, &#8220;</font>Rent<font style="font-weight:normal;">&#8221;) shall commence on the Rent Commencement Date, and shall be prorated for any partial months.&nbsp;&nbsp;Rent shall be payable to Landlord or, if Landlord shall so direct in writing, to Landlord&#8217;s agent or nominee, in lawful money of the United States which shall be legal tender for payment of all debts and dues, public and private, at the time of payment.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868643"></a><a name="_Toc504662627"></a><a name="_AEIOULastRenderedPageBreakAEIOU22"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.2</font><font style="margin-left:72pt;"></font><font style="text-decoration:none;">Operating Costs</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>&#8220;<font style="font-weight:bold;">Operating Costs</font>&#8221; shall mean all costs incurred and expenditures of whatever nature made by Landlord in the operation, management, repair, replacement, maintenance and insurance (including, without limitation, environmental liability insurance and property insurance on Landlord-supplied leasehold improvements for tenants, but not property insurance on tenants&#8217; equipment) of the Property or allocated to the Property, including without limitation all costs of labor (wages, salaries, fringe benefits, etc.) up to and including the Director of Property Management, however denominated, any costs for utilities supplied to exterior areas and the Common Areas, and any costs for repair and replacements, cleaning and maintenance of exterior areas and the Common Areas, related equipment, facilities and appurtenances and HVAC equipment, security services, a management fee in the amount of four percent (4%) of gross Building revenues (increased, if applicable, in accordance with Section 5.2(g)), the costs (&#8220;<font style="font-weight:bold;">Management Office Costs</font>&#8221;), including, without limitation, a commercially reasonable rental factor, of Landlord&#8217;s management office for the Property, which management office may be located outside the Property and which may serve other properties in addition to the Property (in which event such costs shall be equitably allocated among the properties served by such office), the cost of operating any amenities in the Property available to all tenants of the Property and any subsidy provided by Landlord for or with respect to any such amenity, and the Annual Charge-Off (as hereinafter defined) with respect to a Permitted Capital Expenditure (as hereinafter defined).&nbsp;&nbsp;For costs and expenditures made by Landlord in connection with the operation, management, repair, replacement, maintenance and insurance of the Building as a whole, Landlord shall make a reasonable allocation thereof between the retail and non-retail portions of the Building, if applicable.&nbsp;&nbsp;The allocation of Operating Costs relating to the Common Areas of the Campus shall be made in accordance with the Condominium Documents.&nbsp;&nbsp;Operating Costs shall not include Excluded Costs (hereinafter defined). </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font><font style="font-weight:bold;">Capital Expenditures</font>. Permitted Capital Expenditures (as hereinafter defined) shall only be included in Operating Costs for each fiscal year during the Term to the extent of the Annual Charge-Off, as hereinafter defined, for such fiscal year with respect to such capital expenditure.&nbsp;&nbsp;Operating Costs shall not include any Annual Charge-Off with respect to Excluded Costs, as hereinafter defined.&nbsp;&nbsp;For the purposes hereof:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:144pt;"></font>&#8220;<font style="font-weight:bold;">Annual Charge-Off</font>&#8221; means the annual amount of principal and interest payments which would be required to repay a loan in equal monthly installments over the Useful Life, as defined below, of the capital item in question on a direct reduction basis at an annual interest rate equal to the Capital Interest Rate, as defined below, where the initial principal balance is the cost of the capital item in question.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:144pt;"></font>&#8220;<font style="font-weight:bold;">Useful Life</font>&#8221; shall be reasonably determined by Landlord in accordance with generally accepted accounting principles in effect at the time of acquisition of the capital item.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU23"></a>(iii)<font style="margin-left:144pt;"></font>&#8220;<font style="font-weight:bold;">Capital Interest Rate</font>&#8221; shall be defined as an annual rate of either one percentage point over the AA bond rate (Standard &amp; Poor&#8217;s corporate composite or, if unavailable, its equivalent) as reported in the financial press at the time the capital expenditure is </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">made or, if the capital item is acquired through third-party financing, then the actual (including fluctuating) rate paid by Landlord in financing the acquisition of such capital item.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk32339486"></a><a name="_Hlk32339605"></a><a name="_AEIOULastRenderedPageBreakAEIOU24"></a>(c)<font style="margin-left:108pt;"></font>&#8220;<font style="font-weight:bold;">Excluded Costs</font>&#8221; shall be defined as (i) any fixed or percentage ground rent payable to any ground lessor, or any mortgage charges (including interest, principal, points and fees) and any debt service costs (provided however, that the provisions of this clause (i) shall not be deemed to exclude mortgage charges and debt service costs incurred with respect to Permitted Capital Expenditures, as hereinafter defined, from Operating Costs); (ii) brokerage commissions, marketing costs, concessions and leasehold improvement costs incurred in connection with the leasing of any rentable space at the Building or Campus including, without limitation, finders&#8217; fees, attorneys&#8217; fees and expenses, entertainment costs and travel expenses; (iii) salaries and bonuses and benefits of officers, executives of Landlord and administrative employees above the grade of Director of Property Management; (iv) the cost of work done by Landlord for a particular tenant or any special work or service performed for any tenant (including Tenant) billable to such tenant or any costs in connection with services or benefits that are provided to or for the particular benefit of other tenants but not offered to Tenant; (v) the cost of items which, by generally accepted accounting principles, would be capitalized on the books of Landlord or are otherwise not properly chargeable against income, except to the extent such capital item is (A) required by any Legal Requirements following the Execution Date of this Lease, or (B) reasonably projected to reduce Operating Costs (collectively, &#8220;<font style="font-weight:bold;">Permitted Capital Expenditures</font>&#8221;); (vi) the costs of Landlord&#8217;s Work and any contributions made by Landlord to any tenant of the Property in connection with the build-out of its premises; (vii) franchise or income taxes imposed on Landlord; (viii) costs paid directly by individual tenants to suppliers, including tenant electricity, telephone and other utility costs; (ix) increases in premiums for insurance when such increase is caused by the use of the Building by Landlord or any other tenant of the Building; (x) depreciation of the Building or Campus or any part thereof; (xi) costs relating to maintaining Landlord&#8217;s existence as a corporation, partnership or other entity; <a name="_Hlk32339605"></a>(xii) advertising and other fees and costs incurred in procuring tenants; (xiii) the cost of any items for which Landlord is reimbursed by insurance, condemnation awards, refund, rebate or otherwise, and expenses for repairs or maintenance covered by warranties, guaranties and service contracts; (xiv) attorneys&#8217; fees incurred in connection with lease negotiations, disputes with individual tenants and/or for the existence, maintenance or non-Building or Campus related operations of the legal entity or entities of which Landlord is comprised or the development of additional space at the Building or Campus; (xv) the cost of any items for which Landlord may be reimbursed by condemnation awards, refund, rebate or otherwise; (xvi) costs incurred in connection with any disputes between Landlord and its employees, between Landlord and Building management, or between Landlord and other tenants or occupants, (xvii) Taxes; (xviii) the cost of any repairs or restoration required because of fire, other casualty or taking, provided, however, that Operating Costs may include costs of repairs which are not covered because the cost of such repairs is within a commercially reasonable deductible carried under Landlord&#8217;s casualty insurance policy (Tenant hereby agreeing that, as of the Execution Date, $25,000.00 is a commercially reasonable deductible, (xix) management and administrative fees, other than as provided in Section 5.2(a) above; (xx) the cost of remediating Hazardous Materials from the Building or the Campus other than Included Hazardous Materials, as hereinafter defined; &#8220;<font style="font-weight:bold;">Included Hazardous Materials</font>&#8221; shall be defined as all Hazardous Materials, other than:&nbsp;&nbsp;(A) any material or substance located in the Building or the Property on the Execution Date which, as of the Execution Date, is not considered under then existing Legal Requirements, to be Hazardous Material, but which is subsequently determined to be a Hazardous </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Material by reason of a Legal Requirement which first becomes effective after the Execution Date of this Lease, and (B) any material or substance that is introduced to the Building or the Property after the Execution Date which, when introduced to the Building or the Property, is not then (i.e., at the time of introduction to the Building or the Property) considered, as a matter of any Legal Requirement, to be a Hazardous Material, but which is subsequently determined to be a Hazardous Material by reason of Legal Requirements which first becomes effective after the date of introduction of such material or substance </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Building or Property; (x</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">x</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) any cost covered by a warranty</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, guaranty and service contract</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that Landlord is required to obtain in connection with the Building or the Land; (</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">xxii) any amounts paid to a person, firm, corporation or other entity under common ownership and control with Landlord that is in excess of a commercially reasonable amount paid on a market rate basis (other than management fees); (xxiii) the cost of acquiring sculptures, paintings, and other objects of art; (xxiv) depreciation of the Building or Campus or any part thereof (provided however, that the provisions of this clause (xxv) shall not be deemed to exclude depreciation incurred with respect to Permitted Capital Expenditures from Operating Costs; (xxvi) any compensation paid to personnel in retail concessions operated by Landlord and any subsidies or concessions to third parties operating retail concessions at the Building or the Campus, provided that the provisions of this clause (xxvii) shall not be deemed to exclude from Operating Costs such compensation, subsidies or concessions incurred by Landlord with respect the Cafeteria and the Fitness Center; (xxviii) replacement or contingency reserves; (xxix) Landlord&#8217;s general overhead, provided however, that the provisions of this clause (xxx) shall not be deemed to exclude an equitable allocation of Management Office Costs, as set forth in Section 5.2(a) above; and (xxxi) any costs incurred with respect to the retail portions of the Building, provided that the provisions of this clause (xxxii)</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall not be deemed to exclude from Operating Costs incurred by Landlord with respect the Cafeteria and the Fitness Center.&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, the properly passed through cost of any Permitted Capital Expenditures shall be amortized over the useful life of such capital item</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:108pt;"></font><font style="font-weight:bold;">Payment of Operating Costs</font>.&nbsp;&nbsp;Commencing as of the Term Commencement Date and continuing thereafter throughout the remainder of the Term of the Lease, Tenant shall pay to Landlord, as Additional Rent, Tenant&#8217;s Share of Operating Costs.&nbsp;&nbsp;Landlord may make a good faith estimate of Tenant&#8217;s Share of Operating Costs for any fiscal year or part thereof during the Term, and Tenant shall pay to Landlord, on the Term Commencement Date and on the first (1st) day of each calendar month thereafter, an amount equal to Tenant&#8217;s Share of Operating Costs for such fiscal year and/or part thereof divided by the number of months therein.&nbsp;&nbsp;Landlord may estimate and re-estimate Tenant&#8217;s Share of Operating Costs and deliver a copy of the estimate or re-estimate to Tenant.&nbsp;&nbsp;Thereafter, the monthly installments of Tenant&#8217;s Share of Operating Costs shall be appropriately adjusted in accordance with the estimations so that, by the end of the fiscal year in question, Tenant shall have paid all of Tenant&#8217;s Share of Operating Costs as estimated by Landlord.&nbsp;&nbsp;Any amounts paid based on such an estimate shall be subject to adjustment as herein provided when actual Operating Costs are available for each fiscal year.&nbsp;&nbsp;As of the Execution Date, the Property&#8217;s fiscal year is January 1 &#8211; December 31. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a>(e)<font style="margin-left:108pt;"></font><font style="font-weight:bold;">Annual Reconciliation</font>.&nbsp;&nbsp;Landlord <font style="font-size:11pt;">shall</font>, within one hundred twenty (120) days after the end of each fiscal year, deliver to Tenant a reasonably detailed statement of the actual amount of Operating Costs for such fiscal year (&#8220;<font style="font-weight:bold;">Year End Statement</font>&#8221;).&nbsp;&nbsp;Failure of Landlord to provide the Year End Statement within the time prescribed shall not relieve Tenant from its obligations hereunder; provided, however, Landlord shall be obligated to bill any </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating Costs on or before the date (&#8220;</font><font style="font-weight:bold;">Outside Billing Date</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) which is two (2) years after the end of the fiscal year in which the expenditure is made.&nbsp;&nbsp;If the total of such monthly remittances on account of any fiscal year is greater than Tenant&#8217;s Share of Operating Costs actually incurred for such fiscal year, then, provided no Event of Default has occurred, Tenant may credit the difference against the next installment of Additional Rent on account of Operating Costs due hereunder, except that if such difference is determined after the end of the Term, Landlord shall refund such difference to Tenant within thirty (30) days after such determination to the extent that such difference exceeds any amounts then due from Tenant to Landlord.&nbsp;&nbsp;If the total of such remittances is less than Tenant&#8217;s Share of Operating Costs actually incurred for such fiscal year, Tenant shall pay the difference to Landlord, as Additional Rent hereunder, within thirty (30) days of Tenant&#8217;s receipt of an invoice therefor.&nbsp;&nbsp;Landlord&#8217;s estimate of Operating Costs for the next fiscal year shall be based upon the Operating Costs actually incurred for the prior fiscal year as reflected in the Year-End Statement plus a reasonable adjustment based upon estimated increases in Operating Costs.&nbsp;&nbsp;The provisions of this Section 5.2(</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) shall survive the expiration or earlier termination of this Lease</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:108pt;"></font><font style="font-weight:bold;">Part Years</font>.&nbsp;&nbsp;If the Term Commencement Date or the Expiration Date occurs in the middle of a calendar year, Tenant shall be liable for only that portion of the Operating Costs with respect to such calendar year within the Term from and after the Term Commencement Date on pro-rated basis.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:108pt;"></font><font style="font-weight:bold;">Gross-Up</font>.&nbsp;&nbsp;If, during any calendar year, less than 95% of the Building is occupied by tenants or if Landlord was not supplying all tenants with the services being supplied to Tenant hereunder, actual Operating Costs incurred shall be reasonably extrapolated by Landlord on an item-by-item basis to the reasonable Operating Costs that would have been incurred if the Building was 95% occupied and such services were being supplied to all tenants, and such extrapolated Operating Costs shall, for all purposes hereof, be deemed to be the Operating Costs for such fiscal year.&nbsp;&nbsp;This &#8220;gross up&#8221; treatment shall be applied only with respect to variable Operating Costs arising from services provided to Common Areas or to space in the Building being occupied by tenants (which services are not provided to vacant space or may be provided only to some tenants) in order to allocate equitably such variable Operating Costs to the tenants receiving the benefits thereof.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk32317637"></a><a name="_AEIOULastRenderedPageBreakAEIOU26"></a>(h)<font style="margin-left:108pt;"></font><font style="font-weight:bold;">Audit Right</font>.&nbsp;&nbsp;Provided there is no Event of Default nor any event which, with the passage of time and/or the giving of notice would constitute an Event of Default, Tenant may, upon at least sixty (60) days&#8217; prior written notice, inspect or audit Landlord&#8217;s records relating to Operating Costs for any periods of time within the previous fiscal year before the audit or inspection.&nbsp;&nbsp;However, no audit or inspection shall extend to periods of time before the Rent Commencement Date.&nbsp;&nbsp;If Tenant fails to object to the calculation of Tenant&#8217;s Share of Operating Costs on the Year-End Statement within ninety (90) days after such statement has been delivered to Tenant and/or fails to complete any such audit or inspection within one-hundred twenty (120) days after receipt of the Year End Statement, then Tenant shall be deemed to have waived its right to object to the calculation of Tenant&#8217;s Share of Operating Costs for the year in question and the calculation thereof as set forth on such statement shall be final.&nbsp;&nbsp;Tenant&#8217;s audit or inspection shall be conducted only at Landlord&#8217;s offices or the offices of Landlord&#8217;s property manager during business hours reasonably designated by Landlord.&nbsp;&nbsp;Tenant shall pay the cost of such audit or inspection.&nbsp;&nbsp;Tenant may not conduct an inspection or have an audit performed more than once </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">during any fiscal year.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If, after such inspection or audit has been performed, it is finally determined or mutually agreed that there has been an underpayment by Tenant, then Tenant shall pay to Landlord, as Additional Rent hereunder,</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> any underpayment of any such costs, as the case may be, within thirty (30) days after receipt of an invoice therefor.&nbsp;&nbsp;In the event the Landlord disagrees in good faith with the results of the audit, Landlord shall notify Tenant within fifteen (15) days of the audit, and Landlord and Tenant shall mutually select a neutral third party to evaluate the charges for Tenant&#8217;s Share of Operating Costs, and the results of such third party&#8217;s evaluation shall bind Landlord and Tenant and shall be final. Costs charged by any such third party shall be shared equally by Landlord and Tenant. </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> If, after such inspection or audit has been performed, it is finally determined or mutually agreed that that there has been overpayment by Tenant, then Landlord shall credit such overpayment against the next installment(s) of Base Rent thereafter payable by Tenant, except that if such overpayment is determined after the termination or expiration of the Term, Landlord shall promptly refund to Tenant the amount of such overpayment less any amounts then due from Tenant to Landlord.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall maintain the results of any such audit or inspection confidential and shall not be permitted to use any third party to perform such audit or inspection, other than an independent firm of certified public accountants (A) reasonably acceptable to Landlord, (B) which is not compensated on a contingency fee basis or in any other manner which is dependent upon the results of such audit or inspection, and (C) which executes Landlord&#8217;s standard confidentiality agreement whereby it shall agree to maintain the results of such audit or inspection confidential.&nbsp;&nbsp;The provisions of this Section 5.2(</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) shall survive the expiration or earlier termination of this Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868644"></a><a name="_Toc504662628"></a>5.3<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Taxes</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>&#8220;<font style="font-weight:bold;">Taxes</font>&#8221; shall mean the real estate taxes and other taxes, levies and assessments imposed upon the Unit of the Condominium in which the Building and the Land are located (the &#8220;<font style="font-weight:bold;">Unit</font>&#8221;) and upon any personal property of Landlord used in the operation thereof, or on Landlord&#8217;s interest therein or such personal property; charges, fees and assessments for transit, housing, police, fire or other services or purported benefits to the Building and the Land (including without limitation any community preservation assessments); service or user payments in lieu of taxes; and any and all other taxes, levies, betterments, assessments and charges arising from the ownership, leasing, operation, use or occupancy of the Building and the Land or based upon rentals derived therefrom, which are or shall be imposed by federal, state, county, municipal or other governmental authorities.&nbsp;&nbsp;Taxes shall not include any inheritance, estate, succession, gift, franchise, rental, income or profit tax, capital stock tax, capital levy or excise, or any income taxes arising out of or related to the ownership and operation of the Unit, provided, however, that any of the same and any other tax, excise, fee, levy, charge or assessment, however described, that may in the future be levied or assessed as a substitute for or an addition to, in whole or in part, any tax, levy or assessment which would otherwise constitute Taxes, whether or not now customary or in the contemplation of the parties on the Execution Date of this Lease, shall constitute Taxes, but only to the extent calculated as if the Unit were the only real estate owned by Landlord.  &#8220;Taxes&#8221; shall also include reasonable expenses (including without limitation legal and consultant fees) of tax abatement or other proceedings contesting assessments or levies.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU27"></a>Prior to the fiscal year in which the Unit has been created and assessed (the &#8220;<font style="font-weight:bold;">Applicable Fiscal Year</font>&#8221;), Landlord shall allocate Taxes which are incurred with respect to the Common Areas of the Campus on a reasonable basis.&nbsp;&nbsp;From and after substantial completion of any occupiable </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">improvements constructed as part of a Future Development, if such improvements are not separately assessed, Landlord shall reasonably allocate Taxes between the Building and such improvements and the land area associated with the sam</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e.&nbsp;&nbsp;From and after</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Applicable Fiscal Year</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, such allocation shall be effected based upon the Taxes payable by Landlord with respect to the unit in the Condominium in which the Property is located.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font>&#8220;<font style="font-weight:bold;">Tax Period</font>&#8221; shall be any fiscal/tax period in respect of which Taxes are due and payable to the appropriate governmental taxing authority (i.e., as mandated by the governmental taxing authority), any portion of which period occurs during the Term of this Lease.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:108pt;"></font><font style="font-weight:bold;">Payment of Taxes</font>.&nbsp;&nbsp;Commencing as of the Term Commencement Date and continuing thereafter throughout the remainder of the Term of the Lease, Tenant shall pay to Landlord, as Additional Rent, Tenant&#8217;s Share of Taxes.&nbsp;&nbsp;Landlord may make a good faith estimate of the Taxes to be due by Tenant for any Tax Period or part thereof during the Term, and Tenant shall pay to Landlord, on the Term Commencement Date and on the first (1st) day of each calendar month thereafter, an amount equal to Tenant&#8217;s Share of Taxes for such Tax Period or part thereof divided by the number of months therein. Landlord may estimate and re-estimate Tenant&#8217;s Share of Taxes and deliver a copy of the estimate or re-estimate to Tenant.&nbsp;&nbsp;Thereafter, the monthly installments of Tenant&#8217;s Share of Taxes shall be appropriately adjusted in accordance with the estimations so that, by the end of the Tax Period in question, Tenant shall have paid all of Tenant&#8217;s Share of Taxes as estimated by Landlord.&nbsp;&nbsp;Any amounts paid based on such an estimate shall be subject to adjustment as herein provided when actual Taxes are available for each Tax Period.&nbsp;&nbsp;If the total of such monthly remittances is greater than Tenant&#8217;s Share of Taxes actually due for such Tax Period, then, provided no Event of Default has occurred, Tenant may credit the difference against the next installment of Additional Rent on account of Taxes due hereunder, except that if such difference is determined after the end of the Term, Landlord shall refund such difference to Tenant within thirty (30) days after such determination to the extent that such difference exceeds any amounts then due from Tenant to Landlord.&nbsp;&nbsp;If the total of such remittances is less than Tenant&#8217;s Share of Taxes actually due for such Tax Period, Tenant shall pay the difference to Landlord, as Additional Rent hereunder, within thirty (30) days of Tenant&#8217;s receipt of an invoice therefor.&nbsp;&nbsp;Landlord&#8217;s estimate for the next Tax Period shall be based upon actual Taxes for the prior Tax Period plus a reasonable adjustment based upon estimated increases in Taxes.&nbsp;&nbsp;The provisions of this Section 5.3(c) shall survive the expiration or earlier termination of this Lease.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:108pt;"></font><font style="font-weight:bold;">Effect of Abatements</font>.&nbsp;&nbsp;Appropriate credit against Taxes shall be given for any refund obtained by reason of a reduction in any Taxes by the assessors or the administrative, judicial or other governmental agency responsible therefor after deduction of Landlord&#8217;s expenditures for reasonable legal fees and for other reasonable expenses incurred in obtaining the Tax refund. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:108pt;"></font><font style="font-weight:bold;">Part Years</font>.  If the Term Commencement Date or the Expiration Date occurs in the middle of a Tax Period, Tenant shall be liable for only that portion of the Taxes, as the case may be, with respect to such Tax Period within the Term from and after the Term Commencement Date.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868645"></a><a name="_Toc504662629"></a>5.4<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Late Payments</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU28"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font><font style="margin-left:108pt;"></font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any payment of Rent due hereunder not paid when due shall bear interest for each month or fraction thereof from the due date until paid in full at the annual rate of eighteen percent (18%), or at any applicable lesser maximum legally permissible rate for debts of this nature (the </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">Default Rate</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font>Additionally, if Tenant fails to make any payment within five (5) business days after the due date therefor, Landlord may charge Tenant a fee, which shall constitute liquidated damages, equal to three percent (3%) of any such late payment; provided, however, Landlord shall waive the late fee once in any twelve-(12)-month period in the event Tenant shall pay such late payment within five (5) business days following Landlord&#8217;s written notice to Tenant of the occurrence of such late payment.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:108pt;"></font>For each Tenant payment check to Landlord that is returned by a bank for any reason, Tenant shall pay a returned check charge equal to the amount as shall be customarily charged by Landlord&#8217;s bank at the time.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:108pt;"></font>Money paid by Tenant to Landlord shall be applied to Tenant&#8217;s account in the following order: first, to any unpaid Additional Rent, including without limitation late charges, returned check charges, legal fees and/or court costs chargeable to Tenant hereunder; and then to unpaid Base Rent.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:108pt;"></font>The parties agree that the late charge referenced in Section 5.4(b) represents a fair and reasonable estimate of the costs that Landlord will incur by reason of any late payment by Tenant, and the payment of late charges and interest are distinct and separate in that the payment of interest is to compensate Landlord for the use of Landlord&#8217;s money by Tenant, while the payment of late charges is to compensate Landlord for Landlord&#8217;s processing, administrative and other costs incurred by Landlord as a result of Tenant&#8217;s delinquent payments.&nbsp;&nbsp;Acceptance of a late charge or interest shall not constitute a waiver of Tenant&#8217;s default with respect to the overdue amount or prevent Landlord from exercising any of the other rights and remedies available to Landlord under this Lease or at law or in equity now or hereafter in effect.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:108pt;"></font>If Tenant during any six (6) month period shall be more than five (5) days delinquent in the payment of any installment of Rent on three (3) or more occasions, then, notwithstanding anything herein to the contrary, Landlord may, by written notice to Tenant, elect to require Tenant to pay all Base Rent and Additional Rent on account of Operating Costs and Taxes quarterly in advance.&nbsp;&nbsp;Such right shall be in addition to and not in lieu of any other right or remedy available to Landlord hereunder or at law on account of Tenant&#8217;s default hereunder.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868646"></a><a name="_Toc504662630"></a><a name="_AEIOULastRenderedPageBreakAEIOU29"></a>5.5<font style="margin-left:72pt;"></font><font style="text-decoration:none;">No Offset; Independent Covenants; Waiver</font><font style="font-weight:normal;">.&nbsp;&nbsp;Rent shall be paid without notice or demand, and without setoff, counterclaim, defense, abatement, suspension, deferment, reduction or deduction, except as expressly provided herein.&nbsp;&nbsp;</font>TENANT WAIVES ALL RIGHTS (I) TO ANY ABATEMENT, SUSPENSION, DEFERMENT, REDUCTION OR DEDUCTION OF OR FROM RENT, AND (II) TO QUIT, TERMINATE OR SURRENDER THIS LEASE OR THE PREMISES OR ANY PART THEREOF, EXCEPT AS EXPRESSLY PROVIDED HEREIN.&nbsp;&nbsp;TENANT HEREBY ACKNOWLEDGES AND AGREES THAT THE OBLIGATIONS OF TENANT HEREUNDER SHALL BE SEPARATE AND INDEPENDENT COVENANTS AND AGREEMENTS, THAT RENT </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">SHALL CONTINUE TO BE PAYABLE IN ALL EVENTS AND THAT THE OBLIGATIONS OF TENANT HEREUNDER SHALL CONTINUE UNAFFECTED, UNLESS THE REQUIREMENT TO PAY OR PERFORM THE SAME SHALL HAVE BEEN TERMINATED PURSUANT TO AN EXPRESS PROVISION OF THIS LEASE.&nbsp;&nbsp;LANDLORD AND TENANT EACH ACKNOWLEDGES AND AGREES THAT THE INDEPENDENT NATURE OF THE OBLIGATIONS OF TENANT HEREUNDER REPRESENTS FAIR, REASONABLE, AND ACCEPTED COMMERCIAL PRACTICE WITH RESPECT TO THE TYPE OF PROPERTY SUBJECT TO THIS LEASE, AND THAT THIS AGREEMENT IS THE PRODUCT OF FREE AND INFORMED NEGOTIATION DURING WHICH BOTH LANDLORD AND TENANT WERE REPRESENTED BY COUNSEL SKILLED IN NEGOTIATING AND DRAFTING COMMERCIAL LEASES IN MASSACHUSETTS, AND THAT THE ACKNOWLEDGEMENTS AND AGREEMENTS CONTAINED HEREIN ARE MADE WITH FULL KNOWLEDGE OF THE HOLDING IN </font><font style="text-decoration:underline;">WESSON V. LEONE ENTERPRISES, INC.</font><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">, 437 MASS. 708 (2002).&nbsp;&nbsp;SUCH ACKNOWLEDGEMENTS, AGREEMENTS AND WAIVERS BY TENANT ARE A MATERIAL INDUCEMENT TO LANDLORD ENTERING INTO THIS LEASE.</font><font style="font-weight:normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868647"></a><a name="_Toc504662631"></a>5.6<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Survival</font><font style="font-weight:normal;">.&nbsp;&nbsp;Any obligations under this Section 5 which shall not have been paid at the expiration or earlier termination of the Term shall survive such expiration or earlier termination and shall be paid when and as the amount of same shall be determined and be due.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662632"></a><a name="_Toc28868648"></a>INTENTIONALLY OMITTED.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662633"></a><a name="_Toc28868649"></a>LETTER OF CREDIT</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868650"></a><a name="_Toc504662634"></a><a name="_AEIOULastRenderedPageBreakAEIOU30"></a>7.1<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Amount</font><font style="font-weight:normal;">.&nbsp;&nbsp;Contemporaneously with the execution of this Lease, Tenant shall deliver to Landlord either (i) cash in the amount of $1,698,714.80 (the &#8220;</font>Cash Security Deposit<font style="font-weight:normal;">&#8221;), which shall be held by Landlord in accordance with Section 7.5 below, or (ii) an irrevocable letter of credit (the &#8220;</font>Letter of Credit<font style="font-weight:normal;">&#8221;) that shall (a) be in the initial amount of $1,698,714.80; (b) be issued on the form attached hereto as </font><font style="text-decoration:underline;font-weight:normal;">Exhibit 6</font><font style="font-weight:normal;"> or other form reasonably approved by Landlord; (c) name Landlord as its beneficiary; (d) be drawn on an FDIC insured financial institution reasonably satisfactory to Landlord (&#8220;</font>Approved Issuer<font style="font-weight:normal;">&#8221;) that both (x) has an office in the greater Boston metropolitan area that will accept presentation of, and pay against, or allow for facsimile presentment for the payment of the Letter of Credit and (y) satisfies both the Minimum Rating Agency Threshold and the Minimum Capital Threshold (as those terms are defined below).&nbsp;&nbsp;The &#8220;</font>Minimum Rating Agency Threshold<font style="font-weight:normal;">&#8221; shall mean that the issuing bank has outstanding unsecured, uninsured and unguaranteed senior long-term indebtedness that is then rated (without regard to qualification of such rating by symbols such as &#8220;+&#8221; or &#8220;-&#8221; or numerical notation) &#8220;Baa&#8221; or better by Moody&#8217;s Investors Service, Inc. and/or &#8220;BBB&#8221; or better by Standard &amp; Poor&#8217;s Rating Services, or a comparable rating by a comparable national rating agency designated by Landlord in its discretion.&nbsp;&nbsp;The &#8220;</font>Minimum Capital Threshold<font style="font-weight:normal;">&#8221; shall mean that the issuing bank has combined capital, surplus and undivided profits of not less than $10,000,000,000.&nbsp;&nbsp;Notwithstanding the foregoing, Landlord hereby agrees that, as of the Execution Date, First Republic Bank is an Approved Issuer.&nbsp;&nbsp;The Letter of Credit (and any renewals or replacements thereof) shall be for a term of not less than one (1) year.&nbsp;&nbsp;If the issuer of the Letter of Credit gives notice of its election not to renew such Letter of Credit for any additional period, Tenant shall be </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">required to deliver a substitute Letter of Credit satisfying the conditions hereof at least thirty (30) days prior to the expiration of the term of such Letter of Credit.&nbsp;&nbsp;If the issuer of the Letter of Credit fails to satisfy either or both of the Minimum Rating Agency Threshold or the Minimum Capital Threshold, Tenant shall be required to deliver a substitute letter of credit from another issuer reasonably satisfactory to the Landlord and that satisfies both the Minimum Rating Agency Threshold and the Minimum Capital Threshold not later than ten (10) business days after Landlord notifies Tenant of such failure.&nbsp;&nbsp;Tenant agrees that it shall from time to time, as necessary, whether as a result of a draw on the Letter of Credit by Landlord pursuant to the terms hereof or as a result of the expiration of the Letter of Credit then in effect, renew or replace the original and any subsequent Letter of Credit so that a Letter of Credit, in the amount required hereunder, is in effect until a date which is at least </font><font style="font-weight:normal;">sixty (6</font><font style="font-weight:normal;">0) days after the Expiration Date.&nbsp;&nbsp;If Tenant fails to furnish such renewal or replacement at least sixty (60) days prior to the stated expiration date of the Letter of Credit then held by Landlord, Landlord may draw upon such Letter of Credit and hold the proceeds thereof (and such proceeds need not be segregated) as a Security Deposit pursuant to the terms of this Article 7.&nbsp;&nbsp;Any renewal or replacement of the original or any subsequent Letter of Credit shall meet the requirements for the original Letter of Credit as set forth above, except that such replacement or renewal shall be issued by an Approved Issuer</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868651"></a><a name="_Toc504662635"></a>7.2<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Application of Proceeds of Letter of Credit</font><font style="font-weight:normal;">.&nbsp;&nbsp;Upon an Event of Default, or if any proceeding shall be instituted by or against Tenant pursuant to any of the provisions of any Act of Congress or State law relating to bankruptcy, reorganizations, arrangements, compositions or other relief from creditors (and, in the case of any proceeding instituted against it, if Tenant shall fail to have such proceedings dismissed within thirty (30) days) or if Tenant is adjudged bankrupt or insolvent as a result of any such proceeding, Landlord at its sole option may draw down all or a part of the Letter of Credit.&nbsp;&nbsp;The balance of any Letter of Credit cash proceeds shall be held in accordance with Section 7.5 below.&nbsp;&nbsp;Should the entire Letter of Credit, or any portion thereof, be drawn down by Landlord, Tenant shall, upon the written demand of Landlord, deliver a replacement Letter of Credit in the amount drawn, and Tenant&#8217;s failure to do so within ten (10) business days after receipt of such written demand shall constitute an additional Event of Default hereunder.&nbsp;&nbsp;The application of all or any part of the cash proceeds of the Letter of Credit to any obligation or default of Tenant under this Lease shall not deprive Landlord of any other rights or remedies Landlord may have nor shall such application by Landlord constitute a waiver by Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868652"></a><a name="_Toc504662636"></a>7.3<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Transfer of Letter of Credit</font><font style="font-weight:normal;">.&nbsp;&nbsp;In the event that Landlord transfers its interest in the Premises, Tenant shall upon notice from and at no cost to Landlord, deliver to Landlord an amendment to the Letter of Credit or a replacement Letter of Credit naming Landlord&#8217;s successor as the beneficiary thereof. If Tenant fails to deliver such amendment or replacement within ten (10) days after written notice from Landlord, Landlord shall have the right to draw down the entire amount of the Letter of Credit and hold the proceeds thereof in accordance with Section 7.5 below.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868653"></a><a name="_Toc504662637"></a><a name="_AEIOULastRenderedPageBreakAEIOU31"></a>7.4<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Cash Proceeds of Letter of Credit</font><font style="font-weight:normal;">.&nbsp;&nbsp;Landlord shall hold the Cash Security Deposit and/or the balance of proceeds remaining after a draw on the Letter of Credit (each hereinafter referred to as the &#8220;</font>Security Deposit<font style="font-weight:normal;">&#8221;) as security for Tenant&#8217;s performance of all its Lease obligations.&nbsp;&nbsp;After an Event of Default, Landlord may apply the Security Deposit, or any part thereof, to Landlord&#8217;s damages without prejudice to any other Landlord remedy.&nbsp;&nbsp;Landlord has no obligation to pay interest on the Security Deposit and may co-mingle the Security Deposit with </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">Landlord</font><font style="font-weight:normal;">&#8217;</font><font style="font-weight:normal;">s funds.&nbsp;&nbsp;If Landlord conveys its interest under this Lease, the Security Deposit, or any part not applied previously, may be turned over to the grantee in which case Tenant shall look solely to the grantee for the proper application and return of the Security Deposit.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868654"></a><a name="_Toc504662638"></a>7.5<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Return of Security Deposit or Letter of Credit</font><font style="font-weight:normal;">.&nbsp;&nbsp;Should Tenant comply with all of such terms, covenants and conditions and promptly pay all sums payable by Tenant to Landlord hereunder, the Security Deposit and/or Letter of Credit or the remaining proceeds therefrom, as applicable, shall (less any portion thereof which may have been utilized by Landlord to cure any default or applied to any actual damage suffered by Landlord) be returned to Tenant within forty-five (45) days after the latest to occur of:&nbsp;&nbsp;(i) the end of the Term, (ii) the delivery by Tenant to Landlord of the Premises free and clear of all parties claiming under Tenant and in compliance with Section 21 of the Lease, and (iii) the delivery to Landlord of an acceptable Surrender Report, as defined in Section 21 of the Lease, unless an Event of Default (or a default that with notice and the passage of time would constitute an Event of Default) exists at the end of the Term, in which event, the forty-five-(45)-day period shall commence on the date that Tenant cures such Event of Default or default.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">8.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662639"></a><a name="_Toc28868655"></a>INTENTIONALLY OMITTED.&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">9.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662640"></a><a name="_Toc28868656"></a>UTILITIES, LANDLORD&#8217;S SERVICES</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868657"></a><a name="_Toc504662641"></a>9.1<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Electricity</font><font style="font-weight:normal;">.&nbsp;&nbsp;Landlord shall contract with the utility provider for electric service to the Property, including the Premises.&nbsp;&nbsp;Commencing on the Term Commencement Date, Tenant shall pay all charges for electricity furnished to the Premises and any equipment exclusively serving the Premises, as Additional Rent, as measured by a submeter, with such metering equipment to be installed as part of Landlord&#8217;s Work.&nbsp;&nbsp;At Tenant&#8217;s request, Landlord shall provide Tenant with reasonable back-up documentation regarding the total charges and the method of allocating the charges to Tenant.&nbsp;&nbsp;Tenant shall, at Tenant&#8217;s sole cost and expense, maintain and keep in good order, condition and repair the metering equipment used to measure electricity furnished to the Premises and any equipment exclusively serving the same.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868658"></a><a name="_Toc504662642"></a>9.2<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Water</font><font style="font-weight:normal;">.&nbsp;&nbsp;Landlord shall contract with the utility provider for water service to the Property, including the Premises.&nbsp;&nbsp;Except as otherwise provided below, the cost of providing water service to the Premises and all other portions of the Building (including, without limitation, the premises of other tenants or occupants of the Building) shall be included in Operating Costs.&nbsp;&nbsp;Notwithstanding the foregoing, if Landlord determines that Tenant is using water in excess of its proportionate share (by floor area) of the total water usage in the Building, Landlord may elect, at Tenant&#8217;s expense, to furnish and install in a location in or near the Premises metering equipment to measure water furnished to the Premises and any equipment exclusively serving the same.&nbsp;&nbsp;In such event, Tenant shall, within thirty (30) days after Landlord&#8217;s written demand therefor from time to time, pay to Landlord, as Additional Rent, the full amount of any water service charges attributable to such meter.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868659"></a><a name="_Toc504662643"></a><a name="_AEIOULastRenderedPageBreakAEIOU32"></a>9.3<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Gas</font><font style="font-weight:normal;">.&nbsp;&nbsp;Landlord shall contract with the utility provider for gas service to the Property, including the Premises.&nbsp;&nbsp;The cost of gas used to serve base building plumbing, mechanical and electrical systems shall be included in the costs reimbursed by Tenant pursuant to Section 9.6 below.&nbsp;&nbsp;If Tenant requires gas service for the operation of Tenant&#8217;s laboratory </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">equipment in the Premises, Tenant shall pay all charges for gas furnished to the Premises and/or any equipment exclusively serving the Premises as Additional Rent, based, at Landlord</font><font style="font-weight:normal;">&#8217;</font><font style="font-weight:normal;">s election, (i) on Landlord</font><font style="font-weight:normal;">&#8217;</font><font style="font-weight:normal;">s reasonable estimate of such gas usage or (ii) on metering or submetering equipment installed by Landlord at Tenant</font><font style="font-weight:normal;">&#8217;</font><font style="font-weight:normal;">s expense.</font><font style="font-weight:normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868660"></a><a name="_Toc504662644"></a>9.4<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Other Utilities</font><font style="font-weight:normal;">.&nbsp;&nbsp;Subject to Landlord&#8217;s reasonable rules and regulations governing the same, Tenant shall obtain and pay, as and when due, for all other utilities and services consumed in and/or furnished to the Premises, together with all taxes, penalties, surcharges and maintenance charges pertaining thereto.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868661"></a><a name="_Toc504662645"></a>9.5<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Interruption or Curtailment of Utilities</font><font style="font-weight:normal;">.&nbsp;&nbsp;When necessary by reason of accident or emergency, or for repairs, alterations, replacements or improvements which in the reasonable judgment of Landlord are desirable or necessary to be made, Landlord reserves the right, upon as much prior notice to Tenant as is practicable under the circumstances and no less than forty-eight (48) hours&#8217; notice except in the event of an emergency, to interrupt, curtail, or stop (i) the furnishing of hot and/or cold water, and (ii) the operation of the plumbing and electric systems.&nbsp;&nbsp;Landlord shall exercise reasonable diligence to eliminate the cause of any such interruption, curtailment, stoppage or suspension, but, except as set forth in Section 10.7, there shall be no diminution or abatement of Rent or other compensation due from Landlord to Tenant hereunder, nor shall this Lease be affected or any of Tenant&#8217;s obligations hereunder reduced, and Landlord shall have no responsibility or liability for any such interruption, curtailment, stoppage, or suspension of services or systems.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868662"></a><a name="_Toc504662646"></a>9.6<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Landlord&#8217;s Services</font><font style="font-weight:normal;">.&nbsp;&nbsp;Subject to reimbursement pursuant to Section 5.2 above, Landlord shall provide the services described in </font><font style="text-decoration:underline;font-weight:normal;">Exhibit 7</font><font style="font-weight:normal;"> attached hereto and made a part hereof (&#8220;</font>Landlord&#8217;s Services<font style="font-weight:normal;">&#8221;).&nbsp;&nbsp;Except for the cost of providing and maintaining supplemental HVAC equipment exclusively serving the Premises (which shall be Tenant&#8217;s responsibility), all costs incurred in connection with the provision of Landlord&#8217;s Services shall be included in Operating Costs to the extent allowable pursuant to Section 5.2. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk32340176"></a>9.7<font style="margin-left:72pt;"></font>HVAC Services<font style="font-weight:normal;">.<a name="_Hlk32340176"></a>&nbsp;&nbsp;The cost of utilities serving the Building common penthouse HVAC equipment, which provides heated, chilled, and fresh air to the Premises as defined in </font><font style="text-decoration:underline;font-weight:normal;">Exhibit 4-1</font><font style="font-weight:normal;"> (&#8220;</font>HVAC Services<font style="font-weight:normal;">&#8221;) shall be included in Operating Costs pursuant to Section 5.2 hereof. Tenant shall pay such costs monthly, together with monthly installments of Base Rent, on an estimated basis in amounts from time to time reasonably determined by Landlord. After the close of each fiscal year, Landlord shall determine the actual amount of such costs for such year and deliver to Tenant a reasonably detailed statement thereof, together with a statement of the amounts paid by Tenant on an estimated basis toward such costs as aforesaid. If such statement indicates that the estimated amounts paid by Tenant are less than Tenant&#8217;s allocable share of the actual amount of such costs for such fiscal year, then Tenant shall pay the amount of such shortfall to Landlord within thirty (30) days after delivery of such statement. If such statement indicates that Tenant&#8217;s estimated payments for such year exceed the actual amount of such costs for such year, then Landlord shall credit the excess against the next due installment(s) of Additional Rent payable under this Section 9.7.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">10.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662647"></a><a name="_Toc28868663"></a><a name="_AEIOULastRenderedPageBreakAEIOU33"></a><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"></font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"></font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">MAINTENANCE AND REPAIRS</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868664"></a><a name="_Toc504662648"></a>10.1<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Maintenance and Repairs by Tenant</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant shall keep neat and clean and free of insects, rodents, vermin and other pests (except as otherwise allowable pursuant to Section 4.6) and in good repair, order and condition (reasonable wear and tear and damage by Casualty excepted):&nbsp;&nbsp;the Premises, including without limitation the entire interior of the Premises, all electronic, phone and data cabling and related equipment (other than building service equipment) that is installed by or for the exclusive benefit of the Tenant (whether located in the Premises or other portions of the Building), all fixtures, equipment and specialty lighting therein, any supplemental HVAC and humidification equipment exclusively serving the Premises, electrical equipment wiring, doors, non-structural walls, interior windows (for the avoidance of doubt, exterior windows and related assemblies shall be the responsibility of Landlord in accordance with Section 10.2 hereof) and floor coverings, and all laboratory specific systems and equipment that exclusively serve the Premises, including, without limitation, equipment critical to laboratory operations.&nbsp;&nbsp;Without limiting the foregoing, Tenant agrees that it shall maintain in the same repair, order, and condition as on the Term Commencement Date (reasonable wear and tear and damage by Casualty excepted) any equipment installed in the Premises or Building by or on behalf of Tenant (including as part of the Tenant Improvement Work) .&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868665"></a><a name="_Toc504662649"></a>10.2<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Maintenance and Repairs by Landlord</font><font style="font-weight:normal;">.&nbsp;&nbsp;Except as otherwise provided in Section 15, and subject to Tenant&#8217;s obligations in Section 10.1 above, Landlord shall maintain and keep in good working order the Building foundation, the roof, Building structure, exterior windows and related assemblies, the common mechanical systems serving the Building, the common Building HVAC system, the structural floor slabs and columns, and the common plumbing system serving the Building in good repair, order and condition.&nbsp;&nbsp;In addition, Landlord shall operate and maintain the Common Areas in substantially the same manner as comparable combination office and laboratory facilities in the vicinity of the Premises.&nbsp;&nbsp;All costs incurred by Landlord under this Section 10.2 shall be included in Operating Costs, subject to, and in accordance with Section 5.2.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868666"></a><a name="_Toc504662650"></a>10.3<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Accidents to Sanitary and Other Systems</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant shall give to Landlord prompt notice of any fire or accident in the Premises or in the Building and of any damage to, or defective condition in, any part or appurtenance of the Building including, without limitation, sanitary, electrical, ventilation, heating and air conditioning or other systems located in, or passing through, the Premises.&nbsp;&nbsp;Except as otherwise provided in Section 15, and subject to Tenant&#8217;s obligations in Section 10.1 above, such damage or defective condition shall be remedied by Landlord with reasonable diligence, but, subject to Section 14.5 below, if such damage or defective condition was caused by any of the Tenant Parties, the cost to remedy the same shall be paid by Tenant.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868667"></a><a name="_Toc504662651"></a><a name="_AEIOULastRenderedPageBreakAEIOU34"></a>10.4<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Floor Load--Heavy Equipment</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant shall not place a load upon any floor of the Premises exceeding the floor load per square foot of area which such floor was designed to carry and which is allowed by Legal Requirements.&nbsp;&nbsp;The floor load capacity of the Premises is (i) 50 lbs. per square foot live load in the areas shown on </font><font style="text-decoration:underline;font-weight:normal;">Exhibit 5-1</font><font style="font-weight:normal;"> attached hereto and (ii) 100 lbs. per square foot live load in the remainder of the Premises.&nbsp;&nbsp;Landlord reserves the right to prescribe the weight and position of all safes, heavy machinery, heavy equipment, freight, bulky matter or fixtures (collectively, &#8220;</font>Heavy Equipment<font style="font-weight:normal;">&#8221;), in a commercially reasonable manner, which shall be placed so as to distribute the weight.&nbsp;&nbsp;Heavy Equipment shall be placed and maintained by Tenant at Tenant&#8217;s expense in settings sufficient in Landlord&#8217;s reasonable judgment to absorb and </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">prevent vibration, noise and annoyance. Tenant shall not move any Heavy Equipment into or out of the Building without giving Landlord prior written notice thereof and observing all of Landlord&#8217;s Rules and Regulations with respect to the same.&nbsp;&nbsp;If such Heavy Equipment requires special handling, Tenant agrees to employ only persons holding a Master Rigger&#8217;s License to do said work, and that all work in connection therewith shall comply with Legal Requirements.&nbsp;&nbsp;Any such moving shall be at the sole risk and hazard of Tenant and Tenant will defend, indemnify and save Landlord and Landlord&#8217;s agents (including without limitation its property manager), contractors and employees (collectively with Landlord, the &#8220;</font><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Landlord Parties</font><font style="font-weight:normal;">&#8221;) harmless from and against any and all claims, damages, losses, penalties, costs, expenses and fees (including without limitation reasonable legal fees) (collectively, &#8220;</font><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Claims</font><font style="font-weight:normal;">&#8221;) resulting directly or indirectly from such moving, except, </font><font style="font-weight:normal;">subject to Section 14.5 hereof, to the extent caused by the negligence or willful misconduct of any</font><font style="font-weight:normal;"> Landlord Parties.&nbsp;&nbsp;Proper placement of all Heavy Equipment in the Premises shall be Tenant&#8217;s responsibility</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868668"></a><a name="_Toc504662652"></a>10.5<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Premises Cleaning</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant shall be responsible, at its sole cost and expense, for janitorial and trash removal services and other biohazard disposal services for the Premises, including the laboratory areas thereof.&nbsp;&nbsp;Such services shall be performed by licensed (where required by law or governmental regulation), insured and qualified contractors approved in advance, in writing, by Landlord (which approval shall not be unreasonably withheld, delayed or conditioned) and on a sufficient basis to ensure that the Premises are at all times kept neat and clean.&nbsp;&nbsp;Landlord shall provide a dumpster and/or compactor at the Building loading dock for Tenant&#8217;s disposal of non-hazardous and non-controlled substances. All costs incurred by Landlord in connection with such dumpster and/or compactor shall be included in Operating Costs as provided in Section 5.2.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868669"></a><a name="_Toc504662653"></a>10.6<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Pest Control</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant, at Tenant&#8217;s sole cost and expense, shall cause the Premises to be exterminated on a monthly basis to Landlord&#8217;s reasonable satisfaction and shall cause all portions of the Premises used for the storage, preparation, service or consumption of food or beverages to be cleaned daily in a manner reasonably satisfactory to Landlord, and to be treated against infestation by insects, rodents and other vermin and pests whenever there is evidence of any infestation.&nbsp;&nbsp;Tenant shall not permit any person to enter the Premises for the purpose of providing such extermination services, unless such persons have been approved by Landlord.&nbsp;&nbsp;If requested by Landlord, Tenant shall, at Tenant&#8217;s sole cost and expense, store any refuse generated in the Premises by the consumption of food or beverages in a cold box or similar facility.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868670"></a><a name="_Toc504662654"></a>10.7<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Service Interruptions</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU35"></a>(a)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Abatement of Rent</font>.&nbsp;&nbsp;In the event that: (i) there shall be an interruption, curtailment or suspension of any service or failure to perform any obligation required to be provided or performed by Landlord pursuant to Sections 9 and/or 10 (and no reasonably equivalent alternative service or supply is provided by Landlord) that shall materially interfere with Tenant&#8217;s use and enjoyment of the Premises, or any portion thereof (any such event, a &#8220;<font style="font-weight:bold;">Service Interruption</font>&#8221;), <font style="text-decoration:underline;">and</font> (ii) such Service Interruption shall continue for five (5) consecutive business days following receipt by Landlord of written notice (the &#8220;<font style="font-weight:bold;">Service Interruption Notice</font>&#8221;) from Tenant describing such Service Interruption (&#8220;<font style="font-weight:bold;">Abatement Service Interruption Cure Period</font>&#8221;), <font style="text-decoration:underline;">and</font> (iii) such Service Interruption shall not have been caused by an act or omission of Tenant or Tenant&#8217;s agents, employees, contractors or invitees (an event that satisfies the foregoing conditions </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)-(iii) being referred to hereinafter as a &#8220;</font><font style="font-weight:bold;">Material Service Interruption</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) then, Tenant, subject to the next following sentence, shall be entitled to an equitable abatement of Base Rent, Operating Costs and Taxes based on the nature and duration of the Material Service Interruption and the area of the Premises affected, for any and all days following the Material Service Interruption Cure Period that </font><font style="text-decoration:underline;">both</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (x) the Material Service Interruption is continuing and (y) Tenant does not use such affected areas of the Premises for </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any of the Permitted Uses</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Any efforts by Tenant to respond or react to any Material Service Interruption, including, without limitation, any activities by Tenant to remove its personal property from the affected areas of the Premises, shall not constitute a use that precludes abatement pursuant to this Section 10.7(a).&nbsp;&nbsp;The Abatement Service Interruption Cure Period shall be extended by reason of any delays in Landlord&#8217;s ability to cure the Service Interruption in question caused by Force Majeure, provided however, that in no event shall the Abatement Service Interruption Cure Period with respect to any Service Interruption be longer than </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ten (10</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) consecutive business days after Landlord receives the applicable Service </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interruption Notice</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk32318907"></a>(b)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Tenant&#8217;s Termination Right</font>.&nbsp;&nbsp;In the event that: (i) a Service Interruption occurs, <font style="text-decoration:underline;">and</font> (ii) such Service Interruption continues for a period of ninety (90) consecutive days after Landlord receives a Service Interruption Notice with respect to such Service Interruption (&#8220;<font style="font-weight:bold;">Termination Service Interruption Cure Period</font>&#8221;), <font style="text-decoration:underline;">and</font> (iii) such Service Interruption shall not have been caused by an act or omission of Tenant or Tenant&#8217;s agents, employees, contractors or invitees, <font style="text-decoration:underline;">and</font> (iv) for so long as Tenant ceases to use the affected portion of the Premises during such Service Interruption, then Tenant shall have the right to terminate this Lease by giving a written termination notice to Landlord after the expiration of the Termination Service Interruption Cure Period.&nbsp;&nbsp;If such Service Interruption is cured within ten (10) days (&#8220;<font style="font-weight:bold;">Post-Termination Notice Cure Period</font>&#8221;) after Landlord receives such termination notice, then Tenant shall have no right to terminate this Lease based upon such Service Interruption and Tenant&#8217;s termination notice shall be of no force or effect.&nbsp;&nbsp;The Termination Service Interruption Cure Period and the Post-Termination Notice Cure Period shall each be extended by reason of any delays in Landlord&#8217;s ability to cure the Service Interruption in question caused by Force Majeure, provided however, that in no event shall the aggregate extension of the Termination Service Interruption Cure Period and the Post-Termination Notice Cure Period by reason of Force Majeure exceed sixty (60) days.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:108pt;"></font>The provisions of this Section 10.7 shall not apply in the event of a Service Interruption caused by Casualty or Taking (see Section 15 hereof).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:108pt;"></font>The provisions of this Section 10.7 set forth Tenant&#8217;s sole rights and remedies, both in law and in equity, in the event of any Service Interruption.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">11.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662655"></a><a name="_Toc28868671"></a>ALTERATIONS AND IMPROVEMENTS BY TENANT</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868672"></a><a name="_Toc504662656"></a><a name="_AEIOULastRenderedPageBreakAEIOU36"></a>(a)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:none;">Landlord&#8217;s Consent Required</font>.&nbsp;&nbsp;Tenant shall not make any alterations, decorations, installations, removals, additions or improvements (collectively, &#8220;<font style="font-weight:bold;">Alterations</font>&#8221;) in or to the Premises without Landlord&#8217;s prior written approval of the contractor(s), written plans and specifications and a time schedule therefor.&nbsp;&nbsp;Landlord reserves the right to require that Tenant use Landlord&#8217;s preferred vendor(s) for any Alterations that involve roof penetrations, alarm tie-ins, sprinklers, fire alarm and other life safety equipment.&nbsp;&nbsp;Tenant shall not make any amendments or additions to plans and specifications approved by Landlord without Landlord&#8217;s prior written </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consent.&nbsp;&nbsp;Landlord</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s approval of non-structural Alterations shall not be unreasonably withheld, conditioned or delayed.&nbsp;&nbsp;Notwithstanding the foregoing, Landlord may withhold its consent in its sole discretion (a) to any Alteration to or affecting the fixed lab benches, fume hoods, roof and/or building systems, (b) with respect to matters of aesthetics relating to Alterations to or affecting the exterior of the Building, and (c) to any Alteration affecting the Building structure.&nbsp;&nbsp;Tenant shall be responsible for all elements of the design of Tenant</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s plans (including, without limitation, compliance with Legal Requirements, functionality of design, the structural integrity of the design, the configuration of the Premises and the placement of Tenant</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s furniture, appliances and equipment), and Landlord</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s approval of Tenant</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s plans shall in no event relieve Tenant of the responsibility for such design.&nbsp;&nbsp;In seeking Landlord</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s approval, Tenant shall provide Landlord, at least fourteen (14) days in advance of any proposed construction, with plans, specifications, bid proposals, certified stamped engineering drawings and calculations by Tenant</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s engineer o</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f record or architect of record</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (including connections to the Building</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s structural system,</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the Building&#8217;s mechanical, electrical and plumbing systems,</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> modifications to the Building</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s envelope, non-structural penetrations in slabs or walls, and modifications or tie-ins to life safety systems), work contracts, requests for laydown areas and such other information concerning the nature and cost of the Alterations as Landlord may reasonably request.&nbsp;&nbsp;Landlord shall have no liability or responsibility for any claim, injury or damage alleged to have been caused by the particular materials (whether building standard or non-building standard), appliances or equipment selected by Tenant in connection with any work performed by or on behalf of Tenant.&nbsp;&nbsp;Except as otherwise expressly set forth herein, all Alterations shall be done at Tenant</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s sole cost and expense and at such times </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and in such manner as Landlord may from time to time reasonably designate.&nbsp;&nbsp;If Tenant shall make any Alterations, then</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, if Landlord, in Landlord&#8217;s reasonable judgment,</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> determines that the A</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lterations (i) adversely affect the general utility of the Building for use by prospective </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tenants thereof, </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or (ii) require unusual expense to restore and/or redapt the Premises to </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">usual</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> use as a biotechnology office and research and development facility, </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord may elect to require</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Tenant at the expiration or sooner termination of the Term to restore the Premises to substantially the same condition as existed immediately prior to the Alterations.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord agrees that it will make such election with respect to any Alteration at the time that Landlord approves Tenant&#8217;s plans and specifications for an Alteration, if Tenant gives written notice to Landlord requesting Landlord to make such election at the time of such approval. </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall provide Landlord with reproducible record drawings (in CAD format) of all Alterations within sixty (60) days after completion thereof</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font><font style="font-weight:bold;">Alterations Permitted without Landlord&#8217;s Consent</font>.&nbsp;&nbsp;Notwithstanding anything to the contrary herein contained, Tenant shall have the right without obtaining the prior consent of Landlord, but upon prior notice to Landlord as provided below, to make Alterations to the Premises where:&nbsp;&nbsp;(i) the same are within the interior of the Premises, and do not affect the exterior of the Building and do not affect any of the Building&#8217;s systems or the ceiling of the Premises; (ii) the same do not affect the roof or any structural element of the Building, or the fire protection systems of the Building; (iii) the cost of any individual Alteration shall not exceed $150,000.00 in cost; (iv) Tenant shall comply with the provisions of this Lease, and if such work increases the cost of insurance or taxes, Tenant shall pay for any such increase in cost; and (v) Tenant gives Landlord at least five (5) business days&#8217; prior notice describing such work in reasonable detail, accompanied by copies of plans and specifications therefor (to the extent plans and specifications are typically prepared in accordance with such work (the &#8220;<font style="font-weight:bold;">Permitted Alterations</font>&#8221;). </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868673"></a><a name="_Toc504662657"></a><a name="_AEIOULastRenderedPageBreakAEIOU37"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:none;">After-Hours</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Landlord and Tenant recognize that to the extent Tenant elects to perform some or all of the Alterations during times other than normal construction hours (i.e., Monday-Friday, 7:00 a.m. to 3:00 p.m., excluding holidays), Landlord may need to make arrangements to have supervisory personnel on site.&nbsp;&nbsp;Accordingly, Landlord and Tenant agree as follows:&nbsp;&nbsp;Tenant shall give Landlord at least two (2) business days</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> prior written notice of any time outside of normal construction hours when Tenant intends to perform any Alterations (the </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">After-Hours Work</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">).&nbsp;&nbsp;Tenant shall reimburse Landlord, within </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thirty (3</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0) days after </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">written </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">demand therefor, for the </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reasonable third party out of pocket c</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ost of Landlord</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s supervisory personnel overseeing the After-Hours Work.&nbsp;&nbsp;In addition, if construction during normal construction hours unreasonably disturbs other tenants of the Building, in Landlord</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reasonable</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> discretion, Landlord may require Tenant to stop the performance of Alterations during normal construction hours and to perform the same after hours, subject to the foregoing requirement to pay for the cost of Landlord</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s supervisory personnel.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868674"></a><a name="_Toc504662658"></a>(d)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:none;">Harmonious Relations</font>.&nbsp;&nbsp;Tenant agrees that it will not, either directly or indirectly, use any contractors and/or materials if their use will create any difficulty, whether in the nature of a labor dispute or otherwise, with other contractors and/or labor engaged by Tenant or Landlord or others in the construction, maintenance and/or operation of the Building, the Property or any part thereof.&nbsp;&nbsp;In the event of any such difficulty, upon Landlord&#8217;s request, Tenant shall cause all contractors, mechanics or laborers causing such difficulty to leave the Property immediately.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868675"></a><a name="_Toc504662659"></a><a name="_Hlk32320222"></a>(e)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:none;">Liens</font><a name="_Hlk32320222"></a>.&nbsp;&nbsp;No Alterations shall be undertaken by Tenant until: (i) Tenant has made provision for written waiver of liens from all contractors for such Alteration; and (ii) with respect to any Alteration, the cost of which exceeds $500,000.00: (x) Tenant has provided Landlord with reasonable evidence that there is sufficient funding to pay for such Alteration, and (y) Tenant has required its general contractor to obtain appropriate surety payment and performance bonds which shall name Landlord as an additional obligee and has filed lien bond(s) (in jurisdictions where available) on behalf of such contractors.&nbsp;&nbsp;Any mechanic&#8217;s lien filed against the Premises or the Building for work claimed to have been done for, or materials claimed to have been furnished to, Tenant shall be discharged by Tenant within ten (10) business days thereafter, at Tenant&#8217;s expense by filing the bond required by law or otherwise.&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868676"></a><a name="_Toc504662660"></a>(f)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:none;">General Requirements</font>.&nbsp;&nbsp;Unless Landlord and Tenant otherwise agree in writing, Tenant shall (a) procure or cause others to procure on its behalf all necessary permits before undertaking any Alterations in the Premises (and provide copies thereof to Landlord); (b) perform all of such Alterations in a good and workmanlike manner, employing materials of good quality and in compliance with Landlord&#8217;s construction rules and regulations, all insurance requirements of this Lease, and Legal Requirements; and (c) defend, indemnify and hold the Landlord Parties harmless from and against any and all Claims occasioned by or growing out of such Alterations, except to the extent caused by the negligence or willful misconduct of any Landlord Parties.&nbsp;&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">12.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662661"></a><a name="_Toc28868677"></a>SIGNAGE</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868678"></a><a name="_Toc504662662"></a><a name="_AEIOULastRenderedPageBreakAEIOU38"></a>12.1<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Restrictions</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant shall have the right, at Tenant&#8217;s expense, to install Building standard signage identifying Tenant&#8217;s business at the entrance to the Premises, which signage shall </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">be subject to Landlord</font><font style="font-weight:normal;">&#8217;</font><font style="font-weight:normal;">s prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed).&nbsp;&nbsp;Subject to the foregoing, and subject to Section 12.2 below, Tenant shall not</font><font style="font-weight:normal;">, without first obtaining Landlord&#8217;s written approval (which</font><font style="font-weight:normal;"> approval Landlord may withhold, </font><font style="font-weight:normal;">in Landlord&#8217;s sole discretion)</font><font style="font-weight:normal;"> place or suffer to be placed or maintained on the exterior of the Premises, or any part of the interior visible from the exterior thereof, any sign, banner, advertising matter or any other thing of any kind (including, without limitation, any hand-lettered advertising), and shall not place or maintain any decoration, letter or advertising matter on the glass of any window or door of the Premises without first obtaining Landlord</font><font style="font-weight:normal;">&#8217;</font><font style="font-weight:normal;">s written approval. No signs may be put on or in any window or elsewhere if visible from the exterior of the Building.</font><font style="font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868679"></a><a name="_Toc504662663"></a>12.2<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Exterior Signage</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Monument Signage</font>.&nbsp;&nbsp;Subject to the provisions of this Section 12.2(a), for so long as:&nbsp;&nbsp;(x) there is no Event of Default of Tenant and (y) the Lease is in full force and effect (the &#8220;<font style="font-weight:bold;">Monument Signage Condition</font>&#8221;), then Tenant shall have the right to require Landlord to list, at Landlord&#8217;s initial cost and expense, Tenant&#8217;s name (&#8220;<font style="font-weight:bold;">Tenant&#8217;s Monument Signage</font>&#8221;) on each of the two (2) exterior monument signs to be constructed by Landlord (as a part of Landlord&#8217;s Work) on the Property.&nbsp;&nbsp;Such monument signs shall each be a common monument (i.e. other tenant(s) in the Building may have identification signage installed on such monuments).<font style="font-weight:bold;">&nbsp;&nbsp;</font>The right to the Tenant&#8217;s Monument Signage granted pursuant to this Section 12.2(a) is personal to Tenant, and may not be exercised by any occupant, subtenant, or other assignee of Tenant, other than an Affiliated Entity or Successor (the parties hereby agreeing that Tenant shall be responsible for the cost of any change in Tenant&#8217;s Monument Signage).  The parties hereby agree that the maintenance and removal of such Tenant&#8217;s Monument Signage (including, without limitation, the repair and cleaning of the existing monument fa&#231;ade upon removal of Tenant&#8217;s Monument Signage) shall be performed at Landlord&#8217;s sole cost and expense, except that Tenant shall be responsible for the cost of any change in Tenant&#8217;s Monument Signage during the initial Term of the lease.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Exterior Signage</font>.&nbsp;&nbsp;Subject to the provisions of this Section 12.2(b), for so long as:&nbsp;&nbsp;(x) there is no Event of Default of Tenant, (y) the Lease is in full force and effect, and (z) Landlord has permitted another existing tenant of the Building to install one or more signs on the exterior fa&#231;ade of the Building (the &#8220;<font style="font-weight:bold;">Exterior Signage Condition</font>&#8221;), Tenant shall be entitled to install signage representing its proportionate share based on the rentable area of the Premises on the exterior fa&#231;ade of the Building, at Tenant&#8217;s sole cost and expense (&#8220;<font style="font-weight:bold;">Tenant&#8217;s Exterior Signage</font>&#8221;).  Tenant&#8217;s Exterior Signage and the installation thereof shall be (i) subject to the approval by Landlord of the plans and specifications therefor, and (ii) subject to and in accordance with all applicable Legal Requirements, including applicable zoning approvals.&nbsp;&nbsp;The right to the Tenant&#8217;s Exterior Signage granted pursuant to this Section 12.2(b) is personal to Tenant, and may not be exercised by any occupant, subtenant, or other assignee of Tenant, other than an Affiliated Entity or Successor (the parties hereby agreeing that Tenant shall be responsible for the cost of any change in Tenant&#8217;s Exterior Signage).  The parties hereby agree that the maintenance and removal of such Tenant&#8217;s Exterior Signage (including, without limitation, the repair and cleaning of the existing Building fa&#231;ade upon removal of Tenant&#8217;s Exterior Signage) shall be performed by Landlord on behalf of Tenant, at Tenant&#8217;s sole cost and expense,<font style="Background-color:#FFFFFF;color:#000000;"> and will be paid for by Tenant to Landlord based on the cost incurred by Landlord for such maintenance and removal, all due and payable within thirty (30)&#160;days after receipt of billing by Landlord.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868680"></a><a name="_Toc504662664"></a><a name="_AEIOULastRenderedPageBreakAEIOU39"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">12.3</font><font style="margin-left:72pt;"></font><font style="text-decoration:none;">Building Directory</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord shall list Tenant within the directory in the Building lobby.&nbsp;&nbsp;The initial listing shall be at Landlord&#8217;s cost and expense, and any changes to such directory listing shall be at Tenant&#8217;s cost and expense.&nbsp;&nbsp;Tenant shall have the right, at Landlord&#8217;s cost for such initial signage, to install a Building standard Tenant identification sign at the entrance to the Premises.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">13.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662665"></a><a name="_Toc28868681"></a>ASSIGNMENT, MORTGAGING AND SUBLETTING </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868682"></a><a name="_Toc504662666"></a><a name="_Hlk32321275"></a><a name="_Hlk32321314"></a>13.1<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Landlord&#8217;s Consent Required</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant shall not mortgage or encumber this Lease or in whole or in part whether at one time or at intervals, operation of law or otherwise.&nbsp;&nbsp;Except as expressly otherwise set forth herein, Tenant shall not, without Landlord&#8217;s prior written consent, assign, sublet, license or transfer this Lease or the Premises in whole or in part whether by changes in the ownership or control of Tenant, or any direct or indirect owner of Tenant, whether at one time or at intervals, by sale or transfer of stock, partnership or beneficial interests, operation of law or otherwise, or permit the occupancy of all or any portion of the Premises by any person or entity other than Tenant&#8217;s employees (each of the foregoing, a &#8220;</font>Transfer<font style="font-weight:normal;">&#8221;)<a name="_Hlk32321275"></a>; provided, however, the provisions of this Article 13 shall not apply to (i) the transfer of ownership interests in Tenant if and so long as Tenant is a publicly traded on a nationally recognized stock exchange, (ii) the transfer of ownership interests among the members of Tenant existing as of the Effective Date provided that such transfer of ownership interests does not result in a change in Control of Tenant, (iii) the transfer of ownership interests to institutional or individual investors (including venture capital funding and corporate partners) which regularly invest in private biotechnology companies provided that such transfer of ownership interests does not result in a change in Control of Tenant, or (iv) a public offering of the stock of Tenant on a national securities exchange.&nbsp;&nbsp;Any purported Transfer made without Landlord&#8217;s consent, if required hereunder, shall be void and confer no rights upon any third person, provided that if there is a Transfer, Landlord may collect rent from the transferee without waiving the prohibition against Transfers, accepting the transferee, or releasing Tenant from full performance under this Lease.&nbsp;&nbsp;In the event of any Transfer in violation of this Section 13, Landlord shall have the right to terminate this Lease upon thirty (30) days&#8217; written notice to Tenant given within sixty (60) days after receipt of written notice from Tenant to Landlord of any Transfer, or within one (1) year after Landlord first learns of the Transfer if no notice is given. No Transfer shall relieve Tenant of its primary obligation as party-Tenant hereunder, nor shall it reduce or increase Landlord&#8217;s obligations under this Lease.<a name="_Hlk32321314"></a>&nbsp;&nbsp;For purposes of this Section, &#8220;</font>Control<font style="font-weight:normal;">&#8221; shall mean the ownership, directly or indirectly, of 50% (or more than 50%) of the voting stock, partnership interests, membership interests, or beneficial ownership interest in such entity, and the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such corporation, partnership, limited liability company, or entity.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868683"></a><a name="_Toc504662667"></a><a name="_AEIOULastRenderedPageBreakAEIOU40"></a>13.2<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Landlord&#8217;s Recapture Right</font><font style="font-weight:normal;">. Subject to the provisions of this Section 13.2, Tenant shall, prior to offering or advertising the Premises or any portion thereof for a Transfer (other than to a Permitted Transferee, as defined in Section 13.7), give a written notice (the &#8220;</font>Recapture Notice<font style="font-weight:normal;">&#8221;) to Landlord which: (i) states that Tenant desires to make a Transfer, (ii) identifies the affected portion of the Premises (the &#8220;</font>Recapture Premises<font style="font-weight:normal;">&#8221;),&nbsp;&nbsp;(iii) identifies the period of time (the &#8220;</font>Recapture Period<font style="font-weight:normal;">&#8221;) during which Tenant proposes to sublet the Recapture Premises, or indicates that Tenant proposes to assign its interest in this Lease, and (iv) offers to </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">Landlord to terminate this Lease with respect to the Recapture Premises (in the case of a proposed assignment of Tenant's interest in this Lease or a subletting for the remainder of the term of this Lease) or to suspend the Term for the Recapture Period (i.e. the Term with respect to the Recapture Premises shall be terminated during the Recapture Period and Tenant's rental obligations shall be proportionately reduced).&nbsp;&nbsp;Landlord shall have fifteen (15) business days within which to respond to the Recapture Notice</font><font style="font-weight:normal;"> by either accepting or rejecting the Recapture Offer</font><font style="font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;</font><font style="font-weight:normal;">Tenant shall not be required to give Landlord a Recapture Notice (and Landlord shall not have a right to recapture) with respect to Early Minor Subleases, as hereinafter defined.&nbsp;&nbsp;An &#8220;</font><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Early Minor Sublease</font><font style="font-weight:normal;">&#8221; shall be defined as any proposed sublease: (i) the term of which would commence as of a date (&#8220;</font><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Sublease Commencement </font><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Date</font><font style="font-weight:normal;">&#8221;) which is </font><font style="font-weight:normal;">prior</font><font style="font-weight:normal;"> to the third anniversary of the Term Commencement Date, and (ii) the rentable area which would be subleased under such sublease when added to the rentable area of all other subleases in effect as of the Sublease Commencement Date will not exceed fifty percent (50%) of the rentable area of the Premises then demised to Tenant</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868684"></a><a name="_Toc504662668"></a><a name="_Hlk32321634"></a>13.3<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Standard of Consent to Transfer</font><font style="font-weight:normal;"><a name="_Hlk32321634"></a>.&nbsp;&nbsp;If Landlord does not timely give written notice to Tenant accepting a Recapture Offer or declines to accept the same, then Landlord agrees that, subject to the provisions of this Section 13, Landlord shall not unreasonably withhold, condition or delay its consent to a Transfer on the terms contained in the Recapture Notice to an entity which will use the Premises for any of the Permitted Uses.&nbsp;&nbsp;In any event, Landlord shall respond to Tenant&#8217;s request for its consent to a Transfer within fifteen (15) business days after Tenant gives Landlord a written request for such consent and provides to Landlord all information and documentation relating to such proposed Transfer as Landlord may reasonably request.&nbsp;&nbsp;Without limiting the reasonable reasons why Landlord may withhold its consent to a proposed Transfer, it shall be reasonable for Landlord to withhold its consent to a proposed Transfer if, in Landlord's reasonable opinion: (a) the Proposed Transferee does not have a tangible net worth and other financial indicators sufficient to meet the Transferee&#8217;s obligations under the Transfer instrument in question; (b) the Proposed Transferee has a business reputation that is not compatible with the operation of a first-class combination laboratory, research, development and office building; or (c) the intended use of such entity violates any restrictive use provisions then in effect with respect to space in the Building.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868685"></a><a name="_Toc504662669"></a>13.4<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Listing Confers no Rights</font><font style="font-weight:normal;">.&nbsp;&nbsp;The listing of any name other than that of Tenant, whether on the doors of the Premises or on the Building directory, or otherwise, shall not operate to vest in any such other person, firm or corporation any right or interest in this Lease or in the Premises or be deemed to effect or evidence any consent of Landlord, it being expressly understood that any such listing is a privilege extended by Landlord revocable at will by written notice to Tenant.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868686"></a><a name="_Toc504662670"></a>13.5<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Profits In Connection with Transfers</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant shall, within thirty (30) days of receipt thereof, pay to Landlord fifty percent (50%) of any rent, sum or other consideration to be paid or given in connection with any Transfer (other than a Permitted Transfer), either initially or over time, after deducting reasonable actual out-of-pocket legal, and brokerage expenses incurred by Tenant and unamortized improvements paid for by Tenant in connection therewith and any rental concessions, in excess of Rent hereunder as if such amount were originally called for by the terms of this Lease as Additional Rent.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868687"></a><a name="_Toc504662671"></a><a name="_AEIOULastRenderedPageBreakAEIOU41"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">13.6</font><font style="margin-left:72pt;"></font><font style="text-decoration:none;">Prohibited Transfers</font><font style="font-weight:normal;">.&nbsp;&nbsp;Notwithstanding </font><font style="font-weight:normal;">any contrary provision of this Lease, Tenant shall have no right to make a Transfer unless on both (i) the date on which Tenant notifies Landlord of its intention to enter into a Transfer and (ii) the date on which such Transfer is to take effect, there is no Event of Default under this Lease.&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, Tenant agrees that in no event shall Tenant make a Transfer to (a) any government agency; (b) any tenant, subtenant or occupant of other space in the Building if vacant space of a size </font><font style="font-weight:normal;">and term </font><font style="font-weight:normal;">comparable to the portion of the Premises subject to the Transfer then exists in the Building; or (c) any entity with whom Landlord </font><font style="font-weight:normal;">is currently negotiating</font><font style="font-weight:normal;">,</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">or </font><font style="font-weight:normal;">shall have negotiated </font><font style="font-weight:normal;">in the three (3</font><font style="font-weight:normal;">) months immediately preceding such proposed Transfer</font><font style="font-weight:normal;">, for space in the Property</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868688"></a><a name="_Toc504662672"></a>13.7<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Exceptions to Requirement for Consent</font><font style="font-weight:normal;">.&nbsp;&nbsp;Notwithstanding anything to the contrary herein contained, Tenant shall have the right, without obtaining Landlord's consent and without giving Landlord a Recapture Notice, to (a) make a Transfer to an Affiliated Entity (hereinafter defined) so long as the transfer to such Affiliated Entity is for legitimate business purposes (and not for the purpose of avoiding the provisions of this Section 13), and (b) assign all of Tenant&#8217;s interest in and to the Lease to a Successor, provided that prior to or simultaneously with any assignment pursuant to this Section 13.7, such Affiliated Entity or Successor, as the case may be, and Tenant execute and deliver to Landlord an assignment and assumption agreement in form and substance reasonably acceptable to Landlord whereby such Affiliated Entity or Successor, as the case may be, shall agree to be independently bound by and upon all the covenants, agreements, terms, provisions and conditions set forth in the Lease on the part of Tenant to be performed, and whereby such Affiliated Entity or Successor, as the case may be, shall expressly agree that the provisions of this Section 13 shall, notwithstanding such Transfer, continue to be binding upon it with respect to all future Transfers.&nbsp;&nbsp;For the purposes hereof, an &#8220;</font>Affiliated Entity<font style="font-weight:normal;">&#8221; shall be defined as any entity which is controlled by, is under common control with, or which controls Tenant. For the purposes hereof, a &#8220;</font>Successor<font style="font-weight:normal;">&#8221; shall be defined as any entity into or with which Tenant is merged or with which Tenant is consolidated or which acquires all or substantially all of Tenant&#8217;s stock or assets, provided that the surviving entity shall have a net worth immediately following the Transfer to such entity which is not less than Tenant&#8217;s net worth immediately preceding such Transfer.&nbsp;&nbsp;Affiliated Entities and Successors are referred to collectively herein as &#8220;Permitted Transferees&#8221; and a Transfer to a Permitted Transferee which is permitted pursuant to this Section 13.7 is referred to herein as a &#8220;</font>Permitted Transfer<font style="font-weight:normal;">&#8221;.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU42"></a>13.8<font style="margin-left:72pt;"></font><font style="color:#000000;font-family:TimesNewRomanPSMT;">Approved Users</font><font style="color:#000000;font-family:TimesNewRomanPSMT;font-weight:normal;">.&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, Tenant shall have the right, upon ten (10) Business Day&#8217;s prior notice to Landlord, but without having to obtain Landlord&#8217;s consent, to permit Tenant&#8217;s strategic business partners (each, an &#8220;</font><font style="color:#000000;font-family:TimesNewRomanPSMT;">Approved User</font><font style="color:#000000;font-family:TimesNewRomanPSMT;font-weight:normal;">&#8221;) to temporarily occupy space within the Premises, provided that (a) Tenant does not separately demise such space and the Approved Users utilize, in common with Tenant, common entryways to the Premises as well as shared central services, such as reception, photocopying and the like; (b) the Approved Users occupy space in the Premises for the Permitted Use and for no other purpose; and (c) if requested by Landlord, Tenant notifies Landlord, in writing, of the identity of any such Approved Users prior to occupancy of the Premises by such Approved Users, (d) no such &#8220;desk sharing&#8221; arrangement is effected solely for the purpose of qualifying as a transaction which does not require Landlord&#8217;s consent (i.e. and thereby avoiding the operation of the provisions of this Article XIII, and (e) the Approved Users shall not occupy, in the aggregate, more than 5,000 rentable square feet at any one time.&nbsp;&nbsp;If any Approved Users </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:TimesNewRomanPSMT;font-weight:normal;">occupy any portion of the Premises as described herein, (i) the Approved Users shall comply with all provisions of this Lease, and a default by any Approved User shall be deemed a default by Tenant under this Lease; (ii) all notices required to be provided by Landlord under this Lease shall be forwarded only to Tenant in accordance with the terms of this Lease and in no event shall Landlord be required to send any notices to any Approved Users; (iii) in no event shall any use or occupancy of any portion of the Premises by any Approved User release or relieve Tenant from any of its obligations under this Lease; (iv) the Approved Users shall be deemed to be contractors of Tenant for purposes of Tenant&#8217;s indemnification obligations set forth in this Lease; and (v) in no event shall the occupancy of any portion of the Premises by Approved Users be deemed to create a landlord/tenant relationship between Landlord and such Approved Users, and, in all instances, Tenant shall be considered the sole tenant under this Lease notwithstanding the occupancy of any portion of the Premises by the Approved Users.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">14.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662673"></a><a name="_Toc28868689"></a>INSURANCE; INDEMNIFICATION; EXCULPATION</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868690"></a><a name="_Toc504662674"></a>14.1<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Tenant&#8217;s Insurance</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>Tenant shall procure, pay for and keep in force throughout the Term (and for so long thereafter as Tenant remains in occupancy of the Premises) commercial general liability insurance insuring Tenant on an occurrence basis against all claims and demands for personal injury liability (including, without limitation, bodily injury, sickness, disease, and death) or damage to property which may be claimed to have occurred from and after the time any of the Tenant Parties shall first enter the Premises, of not less than One Million Dollars ($1,000,000) per occurrence and Two Million Dollars ($2,000,000) in the aggregate annually, and from time to time thereafter shall be not less than such higher amounts, if procurable, as may be reasonably required by Landlord. Tenant shall also carry umbrella liability coverage in an amount of no less than Ten Million Dollars ($10,000,000). Such policy shall also include contractual liability coverage covering Tenant&#8217;s liability assumed under this Lease, including without limitation Tenant&#8217;s indemnification obligations.&nbsp;&nbsp;Such insurance policy(ies) shall name Landlord, Landlord&#8217;s managing agent and persons claiming by, through or under them, if any, as additional insureds.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font>Tenant shall take out and maintain throughout the Term a policy of fire, vandalism, malicious mischief, extended coverage and so-called &#8220;all risk&#8221; coverage insurance in an amount equal to one hundred percent (100%) of the replacement cost insuring (i) all items or components of Alterations (collectively, the &#8220;<font style="font-weight:bold;">Tenant-Insured Improvements</font>&#8221;), and (ii) all of Tenant&#8217;s furniture, equipment, fixtures and property of every kind, nature and description related or arising out of Tenant&#8217;s leasehold estate hereunder, which may be in or upon the Premises or the Building, including without limitation Tenant&#8217;s Penthouse Equipment and all of Tenant&#8217;s animals (collectively, &#8220;<font style="font-weight:bold;">Tenant&#8217;s Property</font>&#8221;).&nbsp;&nbsp;The insurance required to be maintained by Tenant pursuant to this Section 14.1(b) (referred to herein as &#8220;<font style="font-weight:bold;">Tenant Property Insurance</font>&#8221;) shall insure the interests of both Landlord and Tenant as their respective interests may appear from time to time.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:108pt;"></font>Tenant shall take out and maintain a policy of business interruption insurance throughout the Term sufficient to cover at least twelve (12) months of Rent due hereunder and Tenant&#8217;s business losses during such 12-month period.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU43"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font><font style="margin-left:108pt;"></font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During periods when any </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;s </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work or </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alterations are being performed, Tenant shall maintain, or cause to be maintained, so-called all risk or special cause of loss property insurance or its equivalent and/or builders risk insurance on 100% replacement cost coverage basis, including hard and soft costs coverages. Such insurance shall protect and insure Landlord, Landlord</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s agents, Tenant and Tenant</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s contractors, as their interests may appear, against loss or damage by fire, water damage, vandalism and malicious mischief, and such other risks as are customarily covered by so-called all risk or special cause of loss property / builders risk coverage or its equivalent.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:108pt;"></font>Tenant shall procure and maintain at its sole expense such additional insurance as may be necessary to comply with any Legal Requirements.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:108pt;"></font>Tenant shall cause all contractors and subcontractors to maintain during the performance of any Alterations the insurance described in <font style="text-decoration:underline;">Exhibit 10</font> attached hereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:108pt;"></font>The insurance required pursuant to Sections 14.1(a), (b), (c), (d) and (e) (collectively, &#8220;<font style="font-weight:bold;">Tenant&#8217;s Insurance Policies</font>&#8221;) shall be effected with insurers approved by Landlord, with a rating of not less than &#8220;A-XI&#8221; in the current <font style="font-style:italic;">Best&#8217;s Insurance Reports</font>, and authorized to do business in the Commonwealth of Massachusetts under valid and enforceable policies.&nbsp;&nbsp;Tenant&#8217;s Insurance Policies shall each provide that it shall not be canceled or modified without at least ten (10) days&#8217; prior written notice to each insured named therein; provided, however, in the event Tenant&#8217;s insurer will not provide such notice, Tenant shall be obligated to provide Landlord with ten (10) days&#8217; prior written notice of any cancellation or modification.&nbsp;&nbsp;Tenant&#8217;s Insurance Policies may include deductibles in an amount no greater than the greater of $25,000 or commercially reasonable amounts.&nbsp;&nbsp;On or before the date on which any of the Tenant Parties shall first enter the Premises and thereafter not less than five (5) days prior to the expiration date of each expiring policy, Tenant shall deliver to Landlord binders of Tenant&#8217;s Insurance Policies issued by the respective insurers setting forth in full the provisions thereof together with evidence satisfactory to Landlord of the payment of all premiums for such policies.&nbsp;&nbsp;In the event of any claim, and upon Landlord&#8217;s request, Tenant shall deliver to Landlord complete copies of Tenant&#8217;s Insurance Policies.&nbsp;&nbsp;Upon request of Landlord, Tenant shall deliver to any Mortgagee copies of the foregoing documents. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868691"></a><a name="_Toc504662675"></a>14.2<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Indemnification</font><font style="font-weight:normal;">.&nbsp;&nbsp;Except to the extent caused by the negligence or willful misconduct of any of the Landlord Parties, Tenant shall defend, indemnify and save the Landlord Parties harmless from and against any and all Claims asserted by or on behalf of any person, firm, corporation or public authority arising from:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>Tenant&#8217;s breach of any covenant or obligation under this Lease;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font>Any injury to or death of any person, or loss of or damage to property, sustained or occurring in, at or upon the Premises; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:108pt;"></font>Any injury to or death of any person, or loss of or damage to property arising out of the use or occupancy of the Premises by or the negligence or willful misconduct of any of the Tenant Parties; and</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU44"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font><font style="margin-left:108pt;"></font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On account of or based upon any work or thing whatsoever done (other than by Landlord or any of the Landlord Parties) at the Premises during the Term and during the period of time, if any, prior to the Term Commencement Date that any of the Tenant Parties may have been given access to the Premises. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868692"></a><a name="_Toc504662676"></a>14.3<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Property of Tenant</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant covenants and agrees that, to the maximum extent permitted by Legal Requirements, all of Tenant&#8217;s Property at the Premises shall be at the sole risk and hazard of Tenant, and that if the whole or any part thereof shall be damaged, destroyed, stolen or removed from any cause or reason whatsoever, no part of said damage or loss shall be charged to, or borne by, Landlord, except, subject to Section 14.5 hereof, to the extent such damage or loss is due to the negligence or willful misconduct of any of the Landlord Parties.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868693"></a><a name="_Toc504662677"></a>14.4<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Limitation of Landlord&#8217;s Liability for Damage or Injury</font><font style="font-weight:normal;">.&nbsp;&nbsp;Landlord shall not be liable for any injury or damage to persons, animals or property resulting from fire, explosion, falling plaster, steam, gas, air contaminants or emissions, electricity, electrical or electronic emanations or disturbance, water, rain or snow or leaks from any part of the Building or from the pipes, appliances, equipment or plumbing works or from the roof, street or sub-surface or from any other place or caused by dampness, vandalism, malicious mischief or by any other cause of whatever nature, except, subject to Section 14.5, to the extent caused by or due to the negligence or willful misconduct of any of the Landlord Parties, and then, where notice and an opportunity to cure are appropriate (i.e., where Tenant has an opportunity to know of such condition sufficiently in advance of the occurrence of any such injury or damage resulting therefrom as would have enabled Landlord to prevent such damage or loss had Tenant notified Landlord of such condition) only after (i) notice to Landlord of the condition claimed to constitute negligence or willful misconduct, and (ii) the expiration of a reasonable time after such notice has been received by Landlord without Landlord having commenced to take all reasonable and practicable means to cure or correct such condition.&nbsp;&nbsp;Notwithstanding the foregoing, in no event shall any of the Landlord Parties be liable for any loss which is covered by insurance policies actually carried or required to be so carried by this Lease; nor shall any of the Landlord Parties be liable for any such damage caused by other tenants or persons in the Building or caused by operations in construction of any private, public, or quasi-public work; nor shall any of the Landlord Parties be liable for any latent defect in the Premises or in the Building.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868694"></a><a name="_Toc504662678"></a><a name="_AEIOULastRenderedPageBreakAEIOU45"></a>14.5<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Waiver of Subrogation; Mutual Release</font><font style="font-weight:normal;">.&nbsp;&nbsp;Landlord and Tenant each hereby waives on behalf of itself and its property insurers (none of which shall ever be assigned any such claim or be entitled thereto due to subrogation or otherwise) any and all rights of recovery, claim, action, or cause of action against the other and its agents, officers, servants, partners, shareholders, or employees (collectively, the &#8220;</font>Related Parties<font style="font-weight:normal;">&#8221;) for any loss or damage that may occur to or within the Premises or the Building or any improvements thereto, or any personal property of such party therein which is insured against under any Property Insurance (as defined in Section 14.7) policy actually being maintained by the waiving party from time to time, even if not required hereunder, or which would be insured against under the terms of any Property Insurance policy required to be carried or maintained by the waiving party hereunder, whether or not such insurance coverage is actually being maintained, including, in every instance, such loss or damage that may be caused by the negligence of the other party hereto and/or its Related Parties.&nbsp;&nbsp;Landlord and Tenant each agrees to cause appropriate clauses to be included in its Property Insurance policies necessary to implement the foregoing provisions.&nbsp;&nbsp;For avoidance of doubt, each party (&#8220;</font>Waiving </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Party</font><font style="font-weight:normal;">&#8221;) expressly waives any claim which it might have against the other party (&#8220;</font><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Released Party</font><font style="font-weight:normal;">&#8221;) for damage to property which is not covered by reason of any deductible or self-insured retention under the Waiving Party&#8217;s Property Insurance, or by reason of the fact that the Waiving Party is self-insuring damage to its property</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868695"></a><a name="_Toc504662679"></a>14.6<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Tenant&#8217;s Acts--Effect on Insurance</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant shall not do or permit any Tenant Party to do any act or thing upon the Premises or elsewhere in the Building which will invalidate or be in conflict with any insurance policies covering the Building and the fixtures and property therein; and shall not do, or permit to be done, any act or thing upon the Premises which shall subject Landlord to any liability or responsibility for injury to any person or persons or to property by reason of any business or operation being carried on upon said Premises or for any other reason.&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, Tenant shall not be liable for any increases in the rate of insurance unless such increases arise from Tenant&#8217;s manner of use of the Premises (as opposed to Tenant&#8217;s use of the Premises for the Permitted Uses).&nbsp;&nbsp;If by reason of the failure of Tenant to comply with the provisions hereof the insurance rate applicable to any policy of insurance shall at any time thereafter be higher than it otherwise would be, Tenant shall reimburse Landlord within thirty (30) days of Landlord&#8217;s written demand for that part of any insurance premiums which shall have been charged because of such failure by Tenant, together with interest at the Default Rate until paid in full, within thirty (30) days after receipt of an invoice therefor.&nbsp;&nbsp;In addition, Tenant shall reimburse Landlord for any increase in insurance premium arising as a result of Tenant&#8217;s use and/or storage of any Hazardous Materials in the Premises.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868696"></a><a name="_Toc504662680"></a>14.7<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Landlord&#8217;s Insurance</font><font style="font-weight:normal;">.&nbsp;&nbsp;Landlord shall carry at all times during the Term of this Lease: (i) commercial general liability insurance with respect to the Building, the Land and the Common Areas thereof in an amount not less than Five Million Dollars ($5,000,000) combined single limit per occurrence, (ii) with respect to the Building, excluding Tenant-Insured Improvements and improvements made by other tenants or occupants, insurance against loss or damage caused by any peril covered under fire, extended coverage and all risk insurance with coverage against vandalism, malicious mischief and such other insurable hazards and contingencies as are from time to time normally insured against by owners of similar first class offices/research/laboratory buildings/campuses in the Market Area or which are required by Landlord&#8217;s mortgagee, in an amount equal to one hundred percent (100%) of the full replacement cost thereof above foundation walls (&#8220;</font>Landlord Property Insurance<font style="font-weight:normal;">&#8221;), and (iii) rent interruption insurance covering at least eighteen (18) months.&nbsp;&nbsp;Any and all such insurance: (x) may be maintained under a blanket policy affecting other properties of Landlord and/or its affiliated business organizations, and (y) may be written with commercially reasonable deductibles as determined by Landlord.&nbsp;&nbsp;The costs incurred by Landlord related to such insurance shall be included in Operating Costs.&nbsp;&nbsp;Tenant Property Insurance and Landlord Property Insurance are referred to collectively herein as &#8220;</font>Property Insurance<font style="font-weight:normal;">&#8221;.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">15.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662681"></a><a name="_Toc28868697"></a>CASUALTY; TAKING</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868698"></a><a name="_Toc504662682"></a><a name="_AEIOULastRenderedPageBreakAEIOU46"></a>15.1<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Damage</font><font style="font-weight:normal;">.&nbsp;&nbsp;If the Premises are damaged in whole or part because of fire or other insured casualty (&#8220;</font>Casualty<font style="font-weight:normal;">&#8221;), or if the Premises are subject to a taking in connection with the exercise of any power of eminent domain, condemnation, or purchase under threat or in lieu thereof (any of the foregoing, a &#8220;</font>Taking<font style="font-weight:normal;">&#8221;), then unless this Lease is terminated in accordance with Section 15.2 below, Landlord shall restore the Building and/or the Premises to substantially the same </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">condition as existed immediately following completion of Landlord&#8217;s Work, or in the event of a partial Taking which affects the Building and the Premises, restore the remainder of the Building and the Premises not so Taken to substantially the same condition as is reasonably feasible.&nbsp;&nbsp;</font><font style="font-weight:normal;">Landlord shall, within sixty (60) days after any Casualty, deliver to Tenant an engineering estimate (&#8220;</font><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Restoration Estimate</font><font style="font-weight:normal;">&#8221;) from a reputable contractor or engineer, setting forth an estimate of the period of time (&#8220;</font><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Restoration Period</font><font style="font-weight:normal;">&#8221;) that it will take for Landlord to restore the Building and/or Premises, as aforesaid.&nbsp;&nbsp;</font><font style="font-weight:normal;">If, in Landlord&#8217;s reasonable judgment, any element of the Tenant-Insured Improvements can more effectively be restored as an integral part of Landlord&#8217;s restoration of the Building or the Premises, such restoration shall also be made by Landlord, but at Tenant&#8217;s sole cost and expense.&nbsp;&nbsp;Subject to rights of Mortgagees, Tenant Delays, Legal Requirements then in existence and to delays for adjustment of insurance proceeds or Taking awards, as the case may be, and instances of Force Majeure, Landlord shall substantially complete such restoration within one (1) year after Landlord&#8217;s receipt of all required permits therefor with respect to substantial reconstruction of at least 50% of the Building, or, within one hundred eighty (180) days after Landlord&#8217;s receipt of all required permits therefor in the case of restoration of less than 50% of the Building.&nbsp;&nbsp;Upon substantial completion of such restoration by Landlord, Tenant shall use diligent efforts to complete restoration of the Premises to substantially the same condition as existed immediately prior to such Casualty or Taking, as the case may be, as soon as reasonably possible.&nbsp;&nbsp;Tenant agrees to cooperate with Landlord in such manner as Landlord may reasonably request to assist Landlord in collecting insurance proceeds due in connection with any Casualty which affects the Premises or the Building.&nbsp;&nbsp;In no event shall Landlord be required to expend more than the Net (hereinafter defined) insurance proceeds Landlord receives for damage to the Premises and/or the Building or the Net Taking award attributable to the Premises and/or the Building.&nbsp;&nbsp;&#8220;</font><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Net</font><font style="font-weight:normal;">&#8221; means the insurance proceeds or Taking award actually paid to Landlord (and not paid over to a Mortgagee) less all costs and expenses, including adjusters and attorney&#8217;s fees, of obtaining the same.&nbsp;&nbsp;In the Operating Year in which a Casualty occurs, there shall be included in Operating Costs Landlord&#8217;s deductible under its property insurance policy.&nbsp;&nbsp;Except as Landlord may elect pursuant to this Section 15.1, under no circumstances shall Landlord be required to repair any damage to, or make any repairs to or replacements of, any Tenant-Insured Improvements</font><font style="font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868699"></a><a name="_Toc504662683"></a>15.2<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Termination Rights</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Landlord&#8217;s Termination Rights</font>.&nbsp;&nbsp;Landlord may terminate this Lease upon thirty (30) days&#8217; prior written notice to Tenant if:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:11.54%;text-indent:11.54%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:144pt;"></font>any material portion of the Building or any material means of access thereto is taken;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:11.54%;text-indent:11.54%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:144pt;"></font>more than thirty-five percent (35%) of the Building is damaged by Casualty; or</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:11.54%;text-indent:11.54%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:144pt;"></font>if the estimated time to complete restoration exceeds one (1) year from the date on which Landlord receives all required permits for such restoration</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Tenant&#8217;s Termination Rights</font>. Tenant may terminate this Lease upon thirty (30) days&#8217; prior written notice to Landlord if:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:11.54%;text-indent:11.54%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU47"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font><font style="margin-left:144pt;"></font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any material portion of the </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Premises</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or any material means of access thereto is taken, so that, in Tenant&#8217;s reasonable judgment, the continued operation of Tenant&#8217;s business in the Premises is materially adversely affected;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:11.54%;text-indent:11.54%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:144pt;"></font>if, 50% or more of the Building is damaged by a Casualty and the estimated Restoration Period, as set forth in the Restoration Estimate, exceeds one (1) year from the date on which Landlord receives all required permits for such restoration; or </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:11.54%;text-indent:11.54%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:144pt;"></font>if less than 50% of the Building is damaged by a Casualty, Tenant&#8217;s use of and/or access to the Premises is materially adversely affected by such Casualty, estimated Restoration Period, as set forth in the Restoration Estimate, exceeds six (6) months from the date on which Landlord receives all required permits for such restoration; and the </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:11.54%;text-indent:11.54%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:144pt;"></font>if Landlord is so required but fails to complete restoration of the Premises within the time frames and subject to the conditions set forth in Section 15.1 above, then Tenant may terminate this Lease upon thirty (30) days written notice to Landlord; provided, however, that if Landlord completes such restoration within thirty (30) days after receipt of any such termination notice on account of Landlord&#8217;s failure to so complete within the time period required, such termination notice shall be null and void and this Lease shall continue in full force and effect.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:11.54%;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The remedies set forth in this Section 15.2(b) and in Section 15.2(c) below are Tenant&#8217;s sole and exclusive rights and remedies based upon Landlord&#8217;s failure to complete the restoration of the Premises as set forth herein.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Either Party May Terminate</font>.&nbsp;&nbsp;In the case of any Casualty or Taking affecting the Premises and occurring during the last twelve (12) months of the Term, then (i) if such Casualty or Taking results in more than twenty-five percent (25%) of the floor area of the Premises being unsuitable for the Permitted Uses, or (ii) the damage to the Premises costs more than $250,000 to restore, then either Landlord or Tenant shall have the option to terminate this Lease upon thirty (30) days&#8217; written notice to the other.&nbsp;&nbsp;In addition, if Landlord&#8217;s Mortgagee does not release sufficient insurance proceeds to cover the cost of Landlord&#8217;s restoration obligations, then Landlord shall (i) notify Tenant thereof, and (ii) have the right to terminate this Lease.&nbsp;&nbsp;If Landlord does not terminate this Lease pursuant to the previous sentence and such notice by Landlord does not include an agreement by Landlord to pay for the difference between the cost of such restoration and such released insurance proceeds, then Tenant may terminate this Lease by written notice to Landlord on or before the date that is thirty (30) days after such notice.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Automatic Termination</font>.&nbsp;&nbsp;In the case of a Taking of the entire Premises, then this Lease shall automatically terminate as of the date of possession by the Taking authority.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868700"></a><a name="_Toc504662684"></a><a name="_AEIOULastRenderedPageBreakAEIOU48"></a>15.3<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Rent Abatement</font><font style="font-weight:normal;">.&nbsp;&nbsp;In the event of a Casualty affecting the Premises, there shall be an equitable adjustment of Base Rent, Operating Costs and Taxes based upon the degree to which Tenant&#8217;s ability to conduct its business in the Premises is impaired by reason of such Casualty from and after the date of a Casualty, and continuing until the following portions of the repair and </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">restoration work to be performed by Landlord, as set forth above, are substantially completed: (i) any repair and restoration work to be performed by Landlord within the Premises, and (ii) repair and restoration work with respect to the Common Areas to the extent that damage to the Common Areas caused by such Casualty materially adversely affects Tenant</font><font style="font-weight:normal;">&#8217;</font><font style="font-weight:normal;">s use of, or access to, the Premises.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868701"></a><a name="_Toc504662685"></a>15.4<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Taking for Temporary Use</font><font style="font-weight:normal;">.&nbsp;&nbsp;If the Premises are Taken for temporary use, this Lease and Tenant&#8217;s obligations, including without limitation the payment of Rent, shall continue.&nbsp;&nbsp;For purposes hereof, a &#8220;</font>Taking for temporary use<font style="font-weight:normal;">&#8221; shall mean a Taking of ninety (90) days or less.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868702"></a><a name="_Toc504662686"></a>15.5<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Disposition of Awards</font><font style="font-weight:normal;">.&nbsp;&nbsp;Except for any separate award for Tenant&#8217;s movable trade fixtures, relocation expenses, and unamortized leasehold improvements paid for by Tenant (provided that the same may not reduce Landlord&#8217;s award), all Taking awards to Landlord or Tenant shall be Landlord&#8217;s property without Tenant&#8217;s participation, and Tenant hereby assigns to Landlord Tenant&#8217;s interest, if any, in such award.&nbsp;&nbsp;Tenant may pursue its own claim against the Taking authority.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">16.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662687"></a><a name="_Toc28868703"></a>ESTOPPEL CERTIFICATE.&nbsp;&nbsp;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall at any time and from time to time upon not less than ten (10) business days&#8217; prior notice from Landlord, execute, acknowledge and deliver to Landlord a statement in writing certifying that this Lease is unmodified and in full force and effect (or if there have been modifications, that the same is in full force and effect as modified and stating the modifications), and the dates to which Rent has been paid in advance, if any, stating to Tenant&#8217;s knowledge whether or not Landlord is in default in performance of any covenant, agreement, term, provision or condition contained in this Lease and, if so, specifying each such default, and such other facts as Landlord may reasonably request, it being intended that any such statement delivered pursuant hereto may be relied upon by Landlord, any prospective purchaser of the Building or of any interest of Landlord therein, any Mortgagee or prospective Mortgagee thereof, any lessor or prospective lessor thereof, any lessee or prospective lessee thereof, or any prospective assignee of any mortgage thereof.&nbsp;&nbsp;<font style="font-style:italic;">Time is of the essence with respect to any such requested certificate</font>, Tenant hereby acknowledging the importance of such certificates in mortgage financing arrangements, prospective sales and the like.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">17.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662688"></a><a name="_Toc28868704"></a><a name="_Toc504662689"></a><a name="_Toc504662689"></a>HAZARDOUS MATERIALS</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868705"></a>17.1<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Prohibition</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>Tenant shall not, without the prior written consent of Landlord, bring or permit to be brought or kept in or on the Premises or elsewhere in the Building or the Property (i) any inflammable, combustible or explosive fluid, material, chemical or substance (except for standard office supplies stored in proper containers); and (ii) any Hazardous Material (hereinafter defined), other than the types and quantities of Hazardous Materials which are listed on an initial&nbsp;&nbsp;hazardous materials list to be provided by Tenant prior to the Term Commencement Date and which shall be subject to Landlord&#8217;s approval, not to be unreasonably withheld, conditioned or delayed (&#8220;<font style="font-weight:bold;">Tenant&#8217;s Hazardous Materials</font>&#8221;), provided that the same shall at all times be:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU49"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font><font style="margin-left:144pt;"></font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">brought upon, kept or used in</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Tenant&#8217;s Control Areas (as hereinafter defined)</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:144pt;"></font>in compliance with the Control Area Limitations, as hereinafter defined;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:144pt;"></font>in accordance with all applicable Legal Requirements, including, without limitation, all applicable Environmental Laws (hereinafter defined); and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:144pt;"></font>in accordance with prudent environmental practice and (with respect to medical waste and so-called &#8220;biohazard&#8221; materials) good scientific and medical practice.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font>&#8220;<font style="font-weight:bold;">Tenant&#8217;s Control Areas</font>&#8221; consist of the entirety of the Prime Premises and the Storage Area.&nbsp;&nbsp;The &#8220;<font style="font-weight:bold;">Control Areas Limitations</font>&#8221; are determined in accordance with the International Building Code (2018) (&#8220;<font style="font-weight:bold;">IBC</font>&#8221;), and are as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Prime Premises</font>.&nbsp;&nbsp;The parties acknowledge that the Prime Premises shall be deemed to consist of two (2) Control Areas, as defined by the IBC, and Tenant shall not, in the Prime Premises, exceed the limitations which are imposed by the IBC on use and storage of Hazardous Materials for premises consisting of two Control Areas, and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Storage Area</font>.&nbsp;&nbsp;Tenant shall not, at any time, exceed in the Storage Area, fifty percent (50%) of the solvent storage capacity permitted for a Control Area under the IBC.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:108pt;"></font>Tenant shall be responsible for assuring that all laboratory uses are adequately and properly vented.&nbsp;&nbsp;On or before each anniversary of the Term Commencement Date, and on any earlier date during the 12-month period on which Tenant intends to add a new Hazardous Material or materially increase the quantity of any Hazardous Material to the list of Tenant&#8217;s Hazardous Materials, Tenant shall submit to Landlord an updated list of Tenant&#8217;s Hazardous Materials for Landlord&#8217;s review and approval, which approval shall not be unreasonably withheld, conditioned or delayed. Landlord shall have the right, from time to time, to inspect the Premises for compliance with the terms of this Section 17.1.&nbsp;&nbsp;Notwithstanding the foregoing, with respect to any of Tenant&#8217;s Hazardous Materials which Tenant does not properly handle, store or dispose of in compliance with all applicable Environmental Laws (hereinafter defined), prudent environmental practice and (with respect to medical waste and so-called &#8220;biohazard materials&#8221;) good scientific and medical practice, Tenant shall, upon written notice from Landlord, no longer have the right to bring such material into the Building or the Property until Tenant has demonstrated, to Landlord&#8217;s reasonable satisfaction, that Tenant has implemented programs to thereafter properly handle, store or dispose of such material.&nbsp;&nbsp;In order to induce Landlord to waive its otherwise applicable requirement that Tenant maintain insurance in favor of Landlord against liability arising from the presence of radioactive materials in the Premises, and without limiting the foregoing, Tenant hereby represents and warrants to Landlord that at no time during the Term will Tenant bring upon, or permit to be brought upon, the Premises any radioactive materials whatsoever. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868706"></a><a name="_Toc504662690"></a><a name="_AEIOULastRenderedPageBreakAEIOU50"></a>17.2<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Environmental Laws</font><font style="font-weight:normal;">.&nbsp;&nbsp;For purposes hereof, &#8220;</font>Environmental Laws<font style="font-weight:normal;">&#8221; shall mean all laws, statutes, ordinances, rules and regulations of any local, state or federal governmental </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">authority having jurisdiction concerning environmental, health and safety matters, including but not limited to any discharge by any of the Tenant Parties into the air, surface water, sewers, soil or groundwater of any Hazardous Material (hereinafter defined) whether within or outside the Premises, including, without limitation (a) the Federal Water Pollution Control Act, 33 U.S.C. Section 1251 et seq., (b) the Federal Resource Conservation and Recovery Act, 42 U.S.C. Section 6901 et seq., (c) the Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C. Section 9601 et seq., (d) the Toxic Substances Control Act of 1976, 15 U.S.C. Section 2601 et seq., and (e) Chapter 21E of the General Laws of Massachusetts.&nbsp;&nbsp;Tenant, at its sole cost and expense, shall comply with (i) Environmental Laws, and (ii) any rules, requirements and safety procedures of the Massachusetts Department of Environmental Protection, the Town of Lexington and any insurer of the Building or the Premises with respect to Tenant</font><font style="font-weight:normal;">&#8217;</font><font style="font-weight:normal;">s use, storage and disposal of any Hazardous Materials.</font><font style="font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868707"></a><a name="_Toc504662691"></a>17.3<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Hazardous Material Defined</font><font style="font-weight:normal;">.&nbsp;&nbsp;As used herein, the term &#8220;</font>Hazardous Material<font style="font-weight:normal;">&#8221; means asbestos, oil or any hazardous, radioactive or toxic substance, material or waste or petroleum derivative which is or becomes regulated by any Environmental Law, including without limitation live organisms, viruses and fungi, medical waste and any so-called &#8220;biohazard&#8221; materials.&nbsp;&nbsp;The term &#8220;</font>Hazardous Material<font style="font-weight:normal;">&#8221; includes, without limitation, oil and/or any material or substance which is (i) designated as a &#8220;hazardous substance,&#8221; &#8220;hazardous material,&#8221; &#8220;oil,&#8221; &#8220;hazardous waste&#8221; or toxic substance under any Environmental Law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868708"></a><a name="_Toc504662692"></a>17.4<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Chemical Safety Program</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant shall establish and maintain a chemical safety program administered by a licensed, qualified individual in accordance with the requirements of any applicable governmental authority.&nbsp;&nbsp;Tenant shall be solely responsible for all costs incurred in connection with such chemical safety program, and Tenant shall provide Landlord with such documentation as Landlord may reasonably require evidencing Tenant&#8217;s compliance with the requirements of (a) any applicable governmental authority with respect to such chemical safety program and (b) this Section.&nbsp;&nbsp;Tenant shall obtain and maintain during the Term any permit required by any such applicable governmental authority.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868709"></a><a name="_Toc504662693"></a><a name="_AEIOULastRenderedPageBreakAEIOU51"></a>17.5<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Testing</font><font style="font-weight:normal;">.&nbsp;&nbsp;If any Mortgagee or governmental authority requires testing to determine whether there has been any release of Hazardous Materials and such testing is required as a result of the acts or omissions of any of the Tenant Parties in violation of this Lease, then Tenant shall reimburse Landlord within thirty (30) days of Landlord&#8217;s written demand, as Additional Rent, for the reasonable costs thereof, together with interest at the Default Rate until paid in full.&nbsp;&nbsp;Tenant shall execute affidavits, certifications and the like, as may be reasonably requested by Landlord from time to time concerning Tenant's best knowledge and belief concerning the presence of Hazardous Materials in or on the Premises, the Building or the Property.&nbsp;&nbsp;In addition to the foregoing, if Landlord reasonably believes that any Hazardous Materials have been released on the Premises in violation of this Lease or any Legal Requirement, Landlord shall have the right to conduct appropriate tests of the Premises or any portion thereof to demonstrate that Hazardous Materials are present or that contamination has occurred due to the acts or omissions of any of the Tenant Parties in violation of this Lease.&nbsp;&nbsp;Tenant shall pay all reasonable costs of such tests if such tests reveal that Hazardous Materials exist at the Premises in violation of this Lease or any Legal Requirement.&nbsp;&nbsp;Further, Landlord shall have the right to cause a third party consultant retained by Landlord, at Landlord&#8217;s expense (provided, however, that such costs shall be included in Operating Costs, if allowable pursuant to Section 5.2), to review, but not more than once in any calendar </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">year, Tenant&#8217;s lab operations, procedures and permits to ascertain whether or not Tenant is complying with law and adhering to best industry practices.&nbsp;&nbsp;Tenant agrees to cooperate in good faith with any such review and to provide to such consultant any information requested by such consultant and reasonably required in order for such consultant to perform such review, but nothing contained herein shall require Tenant to provide proprietary or confidential information to such consultant</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868710"></a><a name="_Toc504662694"></a>17.6<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Indemnity; Remediation</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>Tenant hereby covenants and agrees to indemnify, defend and hold the Landlord Parties harmless from and against any and all Claims against any of the Landlord Parties arising out of contamination of any part of the Property or other adjacent property, which contamination arises as a result of: (i) the presence of Hazardous Material in the Premises, the presence of which is caused by any act or omission of any of the Tenant Parties, or (ii) from a breach by Tenant of its obligations under this Section 17.&nbsp;&nbsp;This indemnification of the Landlord Parties by Tenant includes, without limitation, reasonable costs incurred in connection with any investigation of site conditions or any cleanup, remedial, removal or restoration work or any other response actions required by any federal, state or local governmental agency or political subdivision because of Hazardous Material present in the soil, soil vapor or ground water on or under or any indoor air in the Building based upon the circumstances identified in the first sentence of this Section 17.6.&nbsp;&nbsp;The indemnification and hold harmless obligations of Tenant under this Section 17.6 shall survive the expiration or any earlier termination of this Lease.&nbsp;&nbsp;Without limiting the foregoing, if the presence of any Hazardous Material in the Building or otherwise in the Property is caused or permitted by any of the Tenant Parties and results in any contamination of any part of the Property or any adjacent property, Tenant shall promptly take all actions at Tenant&#8217;s sole cost and expense as are necessary to return the Property and/or the Building or any adjacent property to their condition as of the date of this Lease, provided that Tenant shall first obtain Landlord&#8217;s written approval of such actions, which approval shall not be unreasonably withheld, conditioned or delayed so long as such actions, in Landlord&#8217;s reasonable discretion, would not potentially have any adverse effect on the Property, and, in any event, Landlord shall not withhold its approval of any proposed actions which are required by applicable Environmental Laws.&nbsp;&nbsp;The provisions of this Section 17.6 shall survive the expiration or earlier termination of the Lease.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font>Without limiting the obligations set forth in Section 17.6(a) above, if any Hazardous Material is in, on, under, at or about the Building or the Property as a result of the acts or omissions of any of the Tenant Parties and results in any contamination of any part of the Property or any adjacent property that is in violation of any applicable Environmental Law or that requires the performance of any response action pursuant to any Environmental Law, Tenant shall promptly take all actions at Tenant&#8217;s sole cost and expense as are necessary to reduce such Hazardous Material to amounts below any applicable Reportable Quantity, any applicable Reportable Concentration and any other applicable standard set forth in any Environmental Law such that no further response actions are required; provided that Tenant shall first obtain Landlord&#8217;s written approval of such actions, which approval shall not be unreasonably withheld, conditioned or delayed so long as such actions would not be reasonably expected to have an adverse effect on the market value or utility of the Property for the Permitted Uses, and in any event, Landlord shall not withhold its approval of any proposed actions which are required by applicable Environmental Laws (such approved actions, &#8220;<font style="font-weight:bold;">Tenant&#8217;s Remediation</font>&#8221;).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:108pt;"></font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that Tenant fails to complete Tenant</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s Remediation prior to the end of the Term, then:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:144pt;"></font>until the completion of Tenant&#8217;s Remediation (as evidenced by the certification of Tenant&#8217;s Licensed Site Professional (as such term is defined by applicable Environmental Laws), who shall be reasonably acceptable to Landlord) (the &#8220;<font style="font-weight:bold;">Remediation Completion Date</font>&#8221;), Tenant shall pay to Landlord, with respect to the portion of the Premises which reasonably cannot be occupied by a new tenant until completion of Tenant&#8217;s Remediation, (A) Additional Rent on account of Operating Costs and Taxes and (B) Base Rent in an amount equal to the greater of (1) the fair market rental value of such portion of the Premises (determined in substantial accordance with the process described in Section 1.2 above), and (2) Base Rent attributable to such portion of the Premises in effect immediately prior to the end of the Term; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:144pt;"></font>Tenant shall maintain responsibility for Tenant&#8217;s Remediation and Tenant shall complete Tenant&#8217;s Remediation as soon as reasonably practicable in accordance with Environmental Laws.&nbsp;&nbsp;If Tenant does not diligently pursue completion of Tenant&#8217;s Remediation, Landlord shall have the right to either (A) assume control for overseeing Tenant&#8217;s Remediation, in which event Tenant shall pay all reasonable costs and expenses of Tenant&#8217;s Remediation (it being understood and agreed that all costs and expenses of Tenant&#8217;s Remediation incurred pursuant to contracts entered into by Tenant shall be deemed reasonable) within thirty (30) days of demand therefor (which demand shall be made no more often than monthly), and Landlord shall be substituted as the party identified on any governmental filings as the party responsible for the performance of such Tenant&#8217;s Remediation or (B) require Tenant to maintain responsibility for Tenant&#8217;s Remediation, in which event Tenant shall complete Tenant&#8217;s Remediation as soon as reasonably practicable in accordance with Environmental Laws, it being understood that Tenant&#8217;s Remediation shall not contain any requirement that Tenant remediate any contamination to levels or standards more stringent than those associated with the Property&#8217;s current office, research and development, laboratory, and vivarium uses.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:108pt;"></font>The provisions of this Section 17.6 shall survive the expiration or earlier termination of this Lease.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868711"></a><a name="_Toc504662695"></a>17.7<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Disclosures</font><font style="font-weight:normal;">.&nbsp;&nbsp;Prior to bringing any Hazardous Material into any part of the Property, Tenant shall deliver to Landlord the following information with respect thereto: (a) a description of handling, storage, use and disposal procedures; (b) all plans or disclosures and/or emergency response plans which Tenant has prepared, including without limitation Tenant&#8217;s Spill Response Plan, and all plans which Tenant is required to supply to any governmental agency or authority pursuant to any Environmental Laws; (c) copies of all Required Permits relating thereto; and (d) other information reasonably requested by Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868712"></a><a name="_Toc504662696"></a>17.8<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Removal</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant shall be responsible, at its sole cost and expense, for Hazardous Material and other biohazard disposal services for the Premises.&nbsp;&nbsp;Such services shall be performed by contractors reasonably acceptable to Landlord and on a sufficient basis to ensure that the Premises are at all times kept neat, clean and free of Hazardous Materials and biohazards except in appropriate, specially marked containers reasonably approved by Landlord.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU53"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">17.9</font><font style="margin-left:72pt;"></font><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Landlord Representations, Covenants and Indemnity</font><font style="font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;Landlord hereby represents and warrants to Tenant that, to the Best of Landlord&#8217;s Knowledge (as that term is defined in clause (c) below), except to the extent (if any) as may be disclosed in the following described environmental assessment reports which have been made available by Landlord to Tenant (the &#8220;</font><font style="text-decoration:underline;">Disclosed Materials</font><font style="font-weight:normal;">&#8221;), there exist, as of the Execution Date of this Lease, no Hazardous Materials on the Property which are in violation of applicable Environmental Laws or that require reporting, investigation, remediation or other response under Chapter 21E or other Environmental Laws: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;">Phase I Environmental Site Assessment<br /></font>45, 55, 65 Hayden Avenue<br />Lexington, MA 02421<br /><br />Prepared for<br />King Street Properties<br />200 Cambridge Park Drive<br />Cambridge, MA 02141<br /><br />Prepared by<br />Boston Environmental Corporation<br />338 Howard Street<br />Brockton, Massachusetts 02302<br /><br />July 7, 2016<br />Project No. BEC 16-142</p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:-7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord covenants that neither Landlord nor any of the Landlord Parties shall bring any Hazardous Materials in or on to the Property or discharge any Hazardous Materials in or on to the Property which are, in either case, in violation of applicable Environmental Laws.&nbsp;&nbsp;<font style="color:#000000;">Landlord hereby indemnifies and shall defend and hold Tenant, its officers, directors, employees, and agents harmless from any Claims arising as result of any breach by Landlord of its representations, warranties, or covenants under this Section 17.9(a).</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Landlord Remediation</font>.&nbsp;&nbsp;If Hazardous Materials are discovered in, on or under the Property which are not in compliance with applicable Environmental Laws or that require reporting, investigation, remediation or other response under Chapter 21E or other Environmental Laws, and which are not the responsibility of Tenant pursuant to this Article 17, then Landlord shall remove or remediate the same, when, if, and in the manner required by applicable Environmental Laws.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">To the Best of Landlord&#8217;s Knowledge</font>.&nbsp;&nbsp;The phrase &#8220;to the Best of Landlord&#8217;s Knowledge&#8221; under shall mean the best of the knowledge of Michael DiMinico, Landlord&#8217;s asset manager with respect to the Property</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">18.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662697"></a><a name="_Toc28868713"></a><a name="_AEIOULastRenderedPageBreakAEIOU54"></a><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"></font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"></font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">RULES AND REGULATIONS.</font><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868714"></a><a name="_Toc504662698"></a>18.1<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Rules and Regulations</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant will faithfully observe and comply with the Rules and Regulations attached hereto as </font><font style="text-decoration:underline;font-weight:normal;">Exhibit 9</font><font style="font-weight:normal;"> (&#8220;</font>Current Rules and Regulations<font style="font-weight:normal;">&#8221;)&nbsp;&nbsp;and reasonable rules and regulations as may be promulgated, from time to time, with respect to the Building, the Property and construction within the Property (collectively, the &#8220;</font>Rules and Regulations<font style="font-weight:normal;">&#8221;).&nbsp;&nbsp;The Current Rules and Regulations consist of the Building Rules and Regulations attached hereto as </font><font style="text-decoration:underline;font-weight:normal;">Exhibit 9-1</font><font style="font-weight:normal;"> and the Construction Rules and Regulations attached hereto as </font><font style="text-decoration:underline;font-weight:normal;">Exhibit 9-2</font><font style="font-weight:normal;">.&nbsp;&nbsp;In the case of any conflict between the provisions of this Lease and the Rules and Regulations or any future rules and regulations, the provisions of this Lease shall control.&nbsp;&nbsp;Nothing contained in this Lease shall be construed to impose upon Landlord any duty or obligation to enforce the Rules and Regulations or the terms, covenants or conditions in any other lease as against any other tenant and Landlord shall not be liable to Tenant for violation of the same by any other tenant, its servants, employees, agents, contractors, visitors, invitees or licensees.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868715"></a><a name="_Toc504662699"></a>18.2<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Energy Conservation</font><font style="font-weight:normal;">.&nbsp;&nbsp;Landlord may institute upon written notice to Tenant such policies, programs and measures as may be necessary, required, or expedient for the conservation and/or preservation of energy or energy services (collectively, the &#8220;</font>Conservation Program<font style="font-weight:normal;">&#8221;), provided however:&nbsp;&nbsp;(i) that the Conservation Program does not, by reason of such policies, programs and measures, reduce the level of energy or energy services being provided to the Premises below the level of energy or energy services then being provided in comparable combination laboratory, research and development and office buildings in the vicinity of the Premises, provided the same shall not come at a material cost to Tenant, or materially adversely affect Tenant&#8217;s use of the Premises for any of the Permitted Uses, or (ii) as may be necessary or required to comply with Legal Requirements or standards or the other provisions of this Lease.&nbsp;&nbsp;Upon receipt of such notice, Tenant shall comply with the Conservation Program.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868716"></a><a name="_Toc504662700"></a>18.3<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Recycling</font><font style="font-weight:normal;">.&nbsp;&nbsp;Upon written notice, Landlord may establish policies, programs and measures for the recycling of paper, products, plastic, tin and other materials (a &#8220;</font>Recycling Program<font style="font-weight:normal;">&#8221;).&nbsp;&nbsp;Upon receipt of such notice, Tenant will comply with the Recycling Program at Tenant&#8217;s sole cost and expense.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">19.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662701"></a><a name="_Toc28868717"></a>LAWS AND PERMITS.&nbsp;&nbsp;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868718"></a><a name="_Toc504662702"></a><a name="_AEIOULastRenderedPageBreakAEIOU55"></a>19.1<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Legal Requirements</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant shall not cause or permit the Premises, or cause the Property or the Building to be used in any way that violates any Legal Requirement, order, permit, approval, variance, covenant or restrictions of record or any provisions of this Lease, interferes with the rights of tenants of the Building, or constitutes a nuisance or waste.&nbsp;&nbsp;Tenant shall obtain, maintain and pay for all permits and approvals needed for the operation of Tenant&#8217;s business and/or Tenant&#8217;s Penthouse Equipment, as soon as reasonably possible, and in any event shall not undertake any operations or use of Tenant&#8217;s Penthouse Equipment unless all applicable permits and approvals are in place and shall, promptly take all actions necessary to comply with all Legal Requirements, including, without limitation, the Occupational Safety and Health Act, applicable to Tenant&#8217;s use of the Premises, the Property or the Building.&nbsp;&nbsp;Tenant shall maintain in full force and effect all certifications or permissions required by any authority having jurisdiction to authorize, franchise or regulate Tenant&#8217;s use of the Premises.&nbsp;&nbsp;Tenant shall be solely responsible for procuring and complying at all times with any and all necessary permits and approvals directly </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">or indirectly relating or incident to: the conduct of its activities on the Premises; its scientific experimentation, transportation, storage, handling, use and disposal of any chemical or radioactive or bacteriological or pathological substances or organisms or other hazardous wastes or environmentally dangerous substances or materials or medical waste or animals or laboratory specimens.&nbsp;&nbsp;Within ten (10) days of a request by Landlord, which request shall be made not more than once during each period of twelve (12) consecutive months during the Term hereof, unless otherwise requested by any mortgagee of Landlord or unless Landlord reasonably suspects that Tenant has violated the provisions of this Section 19.1, Tenant shall furnish Landlord with copies of all such permits and approvals that Tenant possesses or has obtained together with a certificate certifying that such permits are all of the permits that Tenant possesses or has obtained with respect to the Premises.&nbsp;&nbsp;Tenant shall promptly give written notice to Landlord of any warnings or violations relative to the above received from any federal, state or municipal agency or by any court of law and shall promptly cure the conditions causing any such violations.&nbsp;&nbsp;Tenant shall not be deemed to be in default of its obligations under the preceding sentence to promptly cure any condition causing any such violation in the event that, in lieu of such cure, Tenant shall contest the validity of such violation by appellate or other proceedings permitted under applicable law, provided that: (i) any such contest is made reasonably and in good faith, (ii) Tenant makes provisions, including, without limitation, posting bond(s) or giving other security, reasonably acceptable to Landlord to protect Landlord, the Building and the Property from any liability, costs, damages or expenses arising in connection with such alleged violation and failure to cure, (iii) Tenant shall agree to indemnify, defend (with counsel reasonably acceptable to Landlord) and hold Landlord harmless from and against any and all liability, costs, damages, or expenses arising in connection with such condition and/or violation, (iv) Tenant shall promptly cure any violation in the event that its appeal of such violation is overruled or rejected, and (v) Tenant</font><font style="font-weight:normal;">&#8217;</font><font style="font-weight:normal;">s decision to delay such cure shall not, in Landlord</font><font style="font-weight:normal;">&#8217;</font><font style="font-weight:normal;">s good faith determination, be likely to result in any actual or threatened bodily injury, property damage, or any civil or criminal liability to Landlord, any tenant or occupant of the Building or the Property, or any other person or entity.&nbsp;&nbsp;Nothing contained in this Section 19.1 shall be construed to expand the uses permitted hereunder beyond the Permitted Uses.&nbsp;&nbsp;Landlord shall comply with any Legal Requirements and with any direction of any public office or officer relating to the maintenance or operation of the structural elements of the Building and the Common Areas, and the costs so incurred by Landlord shall be included in Operating Costs in accordance with the provisions of Section 5.2.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">20.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662703"></a><a name="_Toc28868719"></a>DEFAULT</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868720"></a><a name="_Toc504662704"></a>20.1<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Events of Default</font><font style="font-weight:normal;">.&nbsp;&nbsp;The occurrence of any one or more of the following events shall constitute an &#8220;</font>Event of Default<font style="font-weight:normal;">&#8221; hereunder by Tenant:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>If Tenant fails to make any payment of Rent or any other payment required hereunder, as and when due, and such failure shall continue for a period of five (5) business days after notice thereof from Landlord to Tenant; provided, however, an Event of Default shall occur hereunder without any obligation of Landlord to give any notice if (i) Tenant fails to make any payment within five (5) days after the due date therefor, and (ii) Landlord has given Tenant written notice under this Section 20.1(a) on more than two (2) occasions during the twelve (12) month interval preceding such failure by Tenant;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font>Intentionally omitted; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU56"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:108pt;"></font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Tenant shall fail to execute and deliver to Landlord an estoppel certificate pursuant to Section 16 above or a subordination and attornment agreement pursuant to Section 22 below, within the timeframes set forth therein; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:108pt;"></font>If Tenant shall fail to maintain any insurance required hereunder;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:108pt;"></font>If Tenant shall fail to restore the Security Deposit to its original amount or deliver a replacement Letter of Credit as required under Section 7 above;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:108pt;"></font>If Tenant causes or suffers any release of Hazardous Materials in or near the Property; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:108pt;"></font>If Tenant shall make a Transfer in violation of the provisions of Section 13 above, or if any event shall occur or any contingency shall arise whereby this Lease, or the term and estate thereby created, would (by operation of law or otherwise) devolve upon or pass to any person, firm or corporation other than Tenant, except as expressly permitted under Section 13 hereof;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:108pt;"></font>Intentionally omitted;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:108pt;"></font>The failure by Tenant to observe or perform any of the covenants or provisions of this Lease to be observed or performed by Tenant, other than as specified above, and such failure continues for more than thirty (30) days after notice thereof from Landlord; provided, further, that if the nature of Tenant's default is such that more than thirty (30) days are reasonably required for its cure, then Tenant shall not be deemed to be in default if Tenant shall commence such cure within said thirty (30) day period and thereafter diligently prosecute such cure to completion, which completion shall occur not later than ninety (90) days from the date of such notice from Landlord;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(j)<font style="margin-left:108pt;"></font>Tenant shall be involved in financial difficulties as evidenced by an admission in writing by Tenant of Tenant&#8217;s inability to pay its debts generally as they become due, or by the making or offering to make a composition of its debts with its creditors; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(k)<font style="margin-left:108pt;"></font>Tenant shall make an assignment or trust mortgage, or other conveyance or transfer of like nature, of all or a substantial part of its property for the benefit of its creditors, </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(l)<font style="margin-left:108pt;"></font>an attachment on mesne process, on execution or otherwise, or other legal process shall issue against Tenant or its property and a sale of any of its assets shall be held thereunder; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(m)<font style="margin-left:108pt;"></font>the leasehold hereby created shall be taken on execution or by other process of law and shall not be revested in Tenant within thirty (30) days thereafter; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(n)<font style="margin-left:108pt;"></font>a receiver, sequesterer, trustee or similar officer shall be appointed by a court of competent jurisdiction to take charge of all or any part of Tenant&#8217;s Property and such appointment shall not be vacated within thirty (30) days; or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU57"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(o)</font><font style="margin-left:108pt;"></font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any proceeding shall be instituted by or against Tenant pursuant to any of the provisions of any Act of Congress or State law relating to bankruptcy, reorganizations, arrangements, compositions or other relief from creditors, and, in the case of any proceeding instituted against it, if Tenant shall fail to have such proceedings dismissed within thirty (30) days or if Tenant is adjudged bankrupt or insolvent as a result of any such proceeding.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk32325310"></a>With respect to the defaults set forth in subsections (c), (d), (e), (f) and (g) above, if Tenant shall fail to cure the default within the respective required timeframes set forth in this Lease, and such failure shall continue for three (3) business days after Tenant&#8217;s receipt of a Reminder Notice (as defined below), then such events shall be deemed to be an Event of Default.&nbsp;&nbsp;For purposes hereof, a &#8220;<font style="font-weight:bold;">Reminder Notice</font>&#8221; shall be a notice from Landlord to Tenant that states in bold faced capital letters at the top of the first page thereof the following:&nbsp;&nbsp;&#8220;<font style="font-weight:bold;">TENANT&#8217;S FAILURE TO CURE DEFAULT WITHIN THREE (3) BUSINESS DAYS AFTER RECEIPT OF THIS NOTICE SHALL CONSTITUTE AN EVENT OF DEFAULT</font>.&#8221;&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868721"></a><a name="_Toc504662705"></a>20.2<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Remedies</font><font style="font-weight:normal;">.&nbsp;&nbsp;Upon an Event of Default, Landlord may, by notice to Tenant, elect to terminate this Lease; and thereupon (and without prejudice to any remedies which might otherwise be available for arrears of Rent or preceding breach of covenant or agreement and without prejudice to Tenant&#8217;s liability for damages as hereinafter stated), upon the giving of such notice, this Lease shall terminate as of the date specified therein as though that were the Expiration Date.&nbsp;&nbsp;Upon such termination, Landlord shall have the right to utilize the Security Deposit or draw down the entire Letter of Credit, as applicable, and apply the proceeds thereof to its damages hereunder.&nbsp;&nbsp;Without being taken or deemed to be guilty of any manner of trespass or conversion, and without being liable to indictment, prosecution or damages therefor, Landlord may, by lawful process, enter into and upon the Premises (or any part thereof in the name of the whole); repossess the same, as of its former estate; and expel Tenant and those claiming under Tenant.&nbsp;&nbsp;The words &#8220;re-entry&#8221; and &#8220;re-enter&#8221; as used in this Lease are not restricted to their technical legal meanings.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868722"></a><a name="_Toc504662706"></a>20.3<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Damages - Termination</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>Upon the termination of this Lease under the provisions of this Section 20, Tenant shall pay to Landlord Rent up to the time of such termination, shall continue to be liable for any preceding breach of covenant, and in addition, shall pay to Landlord as damages, at the election of Landlord, either: </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:144pt;"></font>the amount (discounted to present value at the rate of five percent (5%) per annum) by which, at the time of the termination of this Lease (or at any time thereafter if Landlord shall have initially elected damages under Section 20.3(a)(ii) below), (x) the aggregate of Rent projected over the period commencing with such termination and ending on the Expiration Date, exceeds (y) the aggregate projected rental value of the Premises for such period, taking into account a reasonable time period during which the Premises shall be unoccupied, plus all Reletting Costs (hereinafter defined); or </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU58"></a>(ii)<font style="margin-left:144pt;"></font>amounts equal to Rent which would have been payable by Tenant had this Lease not been so terminated, payable upon the due dates therefor specified herein following such termination and until the Expiration Date, <font style="font-style:italic;">provided</font>, <font style="font-style:italic;">however</font>, if Landlord shall re-let the Premises during such period, that Landlord shall credit Tenant with the net rents received </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by Landlord from such re-letting, such net rents to be determined by first deducting from the gross rents as and when received by Landlord from such re-letting the expenses incurred or paid by Landlord in terminating this Lease, as well as the expenses of re-letting, including altering and preparing the Premises for new tenants, brokers</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> commissions, and all other similar and dissimilar expenses properly chargeable against the Premises and the rental therefrom (collectively, </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">Reletting Costs</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">), it being understood that any such re-letting may be for a period equal to or shorter or longer than the remaining Term; and </font><font style="font-style:italic;">provided</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-style:italic;">further</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, that (x) in no event shall Tenant be entitled to receive any excess of such net rents over the sums payable by Tenant to Landlord hereunder and (y) in no event shall Tenant be entitled in any suit for the collection of damages pursuant to this Section 20.3(a)(ii) to a credit in respect of any net rents from a re-letting except to the extent that such net rents are actually received by Landlord prior to the commencement of such suit.&nbsp;&nbsp;If the Premises or any part thereof should be re-let in combination with other space, then proper apportionment on a square foot area basis shall be made of the rent received from such re-letting and of the expenses of re-letting. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font>In calculating the amount due under Section 20.3(a)(i), above, there shall be included, in addition to the Base Rent, all other considerations agreed to be paid or performed by Tenant, including without limitation Tenant&#8217;s Share of Operating Costs and Taxes, on the assumption that all such amounts and considerations would have increased at the rate of three percent (3%) per annum for the balance of the full term hereby granted. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:108pt;"></font>Suit or suits for the recovery of such damages, or any installments thereof, may be brought by Landlord from time to time at its election, and nothing contained herein shall be deemed to require Landlord to postpone suit until the date when the Term would have expired if it had not been terminated hereunder. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:108pt;"></font>Nothing herein contained shall be construed as limiting or precluding the recovery by Landlord against Tenant of any sums or damages to which, in addition to the damages particularly provided above, Landlord may lawfully be entitled by reason of any Event of Default hereunder.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868723"></a><a name="_Toc504662707"></a>20.4<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Landlord&#8217;s Self-Help; Fees and Expenses</font><font style="font-weight:normal;">.&nbsp;&nbsp;If Tenant shall default in the performance of any covenant on Tenant&#8217;s part to be performed in this Lease contained, including without limitation the obligation to maintain the Premises in the required condition pursuant to Section 10.1 above, Landlord may, upon reasonable advance notice, except that no notice shall be required in an emergency, immediately, or at any time thereafter, perform the same for the account of Tenant.&nbsp;&nbsp;Tenant shall pay to Landlord within thirty (30) days of Landlord&#8217;s demand therefor any costs incurred by Landlord in connection therewith, together with interest at the Default Rate until paid in full.&nbsp;&nbsp;In addition, Tenant shall pay all of Landlord&#8217;s costs and expenses, including without limitation reasonable attorneys&#8217; fees, incurred (i) in enforcing any obligation of Tenant under this Lease or (ii) as a result of Landlord or any of the Landlord Parties, without its fault, being made party to any litigation pending by or against any of the Tenant Parties.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868724"></a><a name="_Toc504662708"></a><a name="_AEIOULastRenderedPageBreakAEIOU59"></a>20.5<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Waiver of Redemption, Statutory Notice and Grace Periods</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant does hereby waive and surrender all rights and privileges which it might have under or by reason of any present or future Legal Requirements to redeem the Premises or to have a continuance of this Lease for the Term hereby demised after being dispossessed or ejected therefrom by process of law or </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">under the terms of this Lease or after the termination of this Lease as herein provided.&nbsp;&nbsp;Except to the extent prohibited by Legal Requirements, any statutory notice and grace periods provided to Tenant by law are hereby expressly waived by Tenant.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868725"></a><a name="_Toc504662709"></a>20.6<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Landlord&#8217;s Remedies Not Exclusive</font><font style="font-weight:normal;">.&nbsp;&nbsp;The specified remedies to which Landlord may resort hereunder are cumulative and are not intended to be exclusive of any remedies or means of redress to which Landlord may at any time be lawfully entitled, and Landlord may invoke any remedy (including the remedy of specific performance) allowed at law or in equity as if specific remedies were not herein provided for. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868726"></a><a name="_Toc504662710"></a>20.7<font style="margin-left:72pt;"></font><font style="text-decoration:none;">No Waiver</font><font style="font-weight:normal;">.&nbsp;&nbsp;Landlord&#8217;s failure to seek redress for violation, or to insist upon the strict performance, of any covenant or condition of this Lease, or any of the Rules and Regulations promulgated hereunder, shall not prevent a subsequent act, which would have originally constituted a violation, from having all the force and effect of an original violation.&nbsp;&nbsp;The receipt by Landlord of Rent with knowledge of the breach of any covenant of this Lease shall not be deemed a waiver of such breach.&nbsp;&nbsp;The failure of Landlord to enforce any of such Rules and Regulations against Tenant and/or any other tenant in the Building shall not be deemed a waiver of any such Rules and Regulations.&nbsp;&nbsp;No provisions of this Lease shall be deemed to have been waived by either party unless such waiver be in writing signed by such party.&nbsp;&nbsp;No payment by Tenant or receipt by Landlord of a lesser amount than the Rent herein stipulated shall be deemed to be other than on account of the stipulated Rent, nor shall any endorsement or statement on any check or any letter accompanying any check or payment as Rent be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to Landlord&#8217;s right to recover the balance of such Rent or pursue any other remedy in this Lease provided.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868727"></a><a name="_Toc504662711"></a>20.8<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Restrictions on Tenant&#8217;s Rights</font><font style="font-weight:normal;">.&nbsp;&nbsp;During the continuation of any Event of Default, (a) Landlord shall not be obligated to provide Tenant with any notice pursuant to Sections 2.3 and 2.4 above; and (b) Tenant shall not have the right to make, nor to request Landlord&#8217;s consent or approval with respect to, any Alterations or Transfers. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868728"></a><a name="_Toc504662712"></a>20.9<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Landlord Default</font><font style="font-weight:normal;">.&nbsp;&nbsp;Notwithstanding anything to the contrary contained in the Lease, Landlord shall in no event be in default in the performance of any of Landlord&#8217;s obligations under this Lease unless Landlord shall have failed to perform such obligations within thirty (30) days (or such additional time as is reasonably required to correct any such default, provided Landlord commences cure within 30 days) after notice by Tenant to Landlord properly specifying wherein Landlord has failed to perform any such obligation.&nbsp;&nbsp;Except as expressly set forth in this Lease, Tenant shall not have the right to terminate or cancel this Lease or to withhold rent or to set-off or deduct any claim or damages against rent as a result of any default by Landlord or breach by Landlord of its covenants or any warranties or promises hereunder, except in the case of a wrongful eviction of Tenant from the Premises (constructive or actual) by Landlord, and then only if the same continues after notice to Landlord thereof and a opportunity for Landlord to cure the same as set forth above.&nbsp;&nbsp;In addition, Tenant shall not assert any right to deduct the cost of repairs or any monetary claim against Landlord from rent thereafter due and payable under this Lease.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">21.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662713"></a><a name="_Toc28868729"></a>SURRENDER; ABANDONED PROPERTY; HOLD-OVER</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662714"></a><a name="_Toc28868730"></a>21.1<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Surrender</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU60"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font><font style="margin-left:108pt;"></font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the expiration or earlier termination of the Term, Tenant shall (i) peaceably quit and surrender to L</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">andlord the Premises (including, </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">without limitation</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> all fixed lab benches, fume hoods, electric, plumbing, heating and sprinkling systems, fixtures and outlets, vaults, paneling, molding, shelving, radiator enclosures, cork, rubber, linoleum and composition floors, ventilating, silencing, air conditioning and cooling equipment therein</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Tenant&#8217;s Generator, Landlord&#8217;s Work</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and all other furniture, fixtures, and equipment that was either provided by Landlord or paid for in whole or in part by any allowance provided to Tenant by Landlord under this Lease) broom clean, in good order, repair and condition excepting only ordinary wear and tear and damage by fire or other insured Casualty; (ii) remove all of Tenant&#8217;s Property, all autoclaves and cage washers and, at Landlord&#8217;s election, any Alterations made by Tenant (in accordance with Section 11(a)); and (iii) repair any damages to the Premises or the Building caused by the installation or removal of Tenant&#8217;s Property and/or such Alterations.&nbsp;&nbsp;Tenant&#8217;s obligations under this Section 21.1(a) shall survive the expiration or earlier termination of this Lease</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU61"></a>(b)<font style="margin-left:108pt;"></font>Prior to the expiration of this Lease (or within thirty (30) days after any earlier termination), Tenant shall clean and otherwise decommission all interior surfaces (including floors, walls, ceilings, and counters), piping, supply lines, waste lines, acid neutralization systems and plumbing in and/or exclusively serving the Premises, and all exhaust or other ductwork in and/or exclusively serving the Premises, in each case which has carried or released or been contacted by any Hazardous Materials or other chemical or biological materials used in the operation of the Premises, and shall otherwise clean the Premises so as to permit the Surrender Plan (defined below) to be issued.&nbsp;&nbsp;At least thirty (30) days prior to the expiration of the Term (or, if applicable, within five (5) business days after any earlier termination of this Lease), Tenant shall deliver to Landlord a reasonably detailed narrative description of the actions proposed (or required by any Legal Requirements) to be taken by Tenant in order to render the Premises (including any Alterations permitted or required by Landlord to remain therein) free of Hazardous Materials and otherwise released for unrestricted use and occupancy including without limitation causing the Premises to be decommissioned in accordance with the regulations of the U.S. Nuclear Regulatory Commission and/or the Massachusetts Department of Public health (the &#8220;<font style="font-weight:bold;">MDPH</font>&#8221;) for the control of radiation, and cause the Premises to be released for unrestricted use by the Radiation Control Program of the MDPH (the &#8220;<font style="font-weight:bold;">Surrender Plan</font>&#8221;).&nbsp;&nbsp;The Surrender Plan (i) shall be accompanied by a current list of (A) all Required Permits held by or on behalf of any Tenant Party with respect to Hazardous Materials in, on, under, at or about the Premises, and (B) Tenant&#8217;s Hazardous Materials, and (ii) shall be subject to the review and approval of Landlord&#8217;s environmental consultant.&nbsp;&nbsp;In connection with review and approval of the Surrender Plan, upon request of Landlord, Tenant shall deliver to Landlord or its consultant such additional non-proprietary information concerning the use of and operations within the Premises as Landlord shall request.&nbsp;&nbsp;On or before the expiration of the Term (or within thirty (30) days after any earlier termination of this Lease, during which period Tenant&#8217;s use and occupancy of the Premises shall be governed by Section 21.3 below), Tenant shall (i) perform or cause to be performed all actions described in the approved Surrender Plan, and (ii) deliver to Landlord a certification from a third party certified industrial hygienist reasonably acceptable to Landlord certifying that the Premises do not contain any Hazardous Materials and evidence that the approved Surrender Plan shall have been satisfactorily completed by a contractor acceptable to Landlord, and Landlord shall have the right, subject to reimbursement at Tenant&#8217;s expense as set forth below, to cause Landlord&#8217;s environmental consultant to inspect the Premises and perform such additional procedures as may be deemed reasonably necessary to confirm that the Premises are, as of the expiration of the Term </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(or, if applicable, the date which is thirty (30) days after any earlier termination of this Lease), free of Hazardous Materials and otherwise available for unrestricted use and occupancy as aforesaid.&nbsp;&nbsp;Landlord shall have the unrestricted right to deliver the Surrender Plan and any report by Landlord</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s environmental consultant with respect to the surrender of the Premises to third parties.&nbsp;&nbsp; Such third parties and the Landlord Parties shall be entitled to rely on the Surrender Report.&nbsp;&nbsp;If Tenant shall fail to prepare or submit a Surrender Plan approved by Landlord, or if Tenant shall fail to complete the approved Surrender Plan, or if such Surrender Plan, whether or not approved by Landlord, shall fail to adequately address the use of Hazardous Materials by any of the Tenant Parties in, on, at, under or about the Premises, Landlord shall have the right to take any such actions as Landlord may deem reasonable or appropriate to assure that the Premises and the Property are surrendered in the condition required hereunder, the cost of which actions shall be reimbursed by Tenant as </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional Rent within thirty (30) days of Landlord&#8217;s written demand</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Tenant</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s obligations under this Section 21.1(b) shall survive the expiration or earlier termination of the Term.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:108pt;"></font>No act or thing done by Landlord during the Term shall be deemed an acceptance of a surrender of the Premises, and no agreement to accept such surrender shall be valid, unless in writing signed by Landlord.&nbsp;&nbsp;Unless otherwise agreed by the parties in writing, no employee of Landlord or of Landlord&#8217;s agents shall have any power to accept the keys of the Premises prior to the expiration or earlier termination of this Lease.&nbsp;&nbsp;The delivery of keys to any employee of Landlord or of Landlord&#8217;s agents shall not operate as a termination of this Lease or a surrender of the Premises.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:108pt;"></font>Notwithstanding anything to the contrary contained herein, Tenant shall, at its sole cost and expense, remove from the Premises, prior to the end of the Term, any item installed by or for Tenant and which, pursuant to Legal Requirements, must be removed therefrom before the Premises may be used by a subsequent tenant.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868731"></a><a name="_Toc504662715"></a>21.2<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Abandoned Property</font><font style="font-weight:normal;">.&nbsp;&nbsp;After the expiration or earlier termination hereof, if Tenant fails to remove any property from the Building or the Premises which Tenant is obligated by the terms of this Lease to remove within five (5) business days after written notice from Landlord, such property (the &#8220;</font>Abandoned Property<font style="font-weight:normal;">&#8221;) shall be conclusively deemed to have been abandoned, and may either be retained by Landlord as its property or sold or otherwise disposed of in such manner as Landlord may see fit.&nbsp;&nbsp;If any item of Abandoned Property shall be sold, Tenant hereby agrees that Landlord may receive and retain the proceeds of such sale and apply the same, at its option, to the expenses of the sale, the cost of moving and storage, any damages to which Landlord may be entitled under Section 20 hereof or pursuant to law, and to any arrears of Rent. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868732"></a><a name="_Toc504662716"></a>21.3<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Holdover</font><font style="font-weight:normal;">.&nbsp;&nbsp;If any of the Tenant Parties holds over (which term shall include, without limitation, the failure of Tenant or any Tenant Party to perform all of its obligations under Section 21.1 above) after the end of the Term, Tenant shall be deemed a tenant-at-sufferance subject to the provisions of this Lease.&nbsp;&nbsp;Whether or not Landlord has previously accepted payments of Rent from Tenant: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>Tenant shall pay Base Rent at the Hold Over Percentage, as hereinafter defined, of the highest rate of Base Rent payable during the Term, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU62"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:108pt;"></font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall continue to pay to Landlord all Additional Rent, and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:108pt;"></font>in the event such hold over extends beyond sixty (60) days after the end of the Term, Tenant shall be liable for all damages, including without limitation lost business and consequential damages, incurred by Landlord as a result of such holding over, Tenant hereby acknowledging that Landlord may need the Premises after the end of the Term for other tenants and that the damages which Landlord may suffer as the result of Tenant&#8217;s holding over cannot be determined as of the Execution Date.&nbsp;&nbsp;Nothing contained herein shall grant Tenant the right to holdover after the expiration or earlier termination of the Term.&nbsp;&nbsp;The &#8220;<font style="font-weight:bold;">Hold Over Percentage</font>&#8221; shall be 150% for the first sixty (60) days of such holdover, and 200% for any period of hold over after the first sixty (60) days.&nbsp;&nbsp;Nothing contained herein shall grant Tenant the right to holdover after the expiration or earlier termination of the Term.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868733"></a><a name="_Toc504662717"></a>21.4<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Warranties</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant hereby assigns to Landlord any warranties in effect on the last day of the Term with respect to any fixtures and Alterations installed in the Premises.&nbsp;&nbsp;Tenant shall provide Landlord with copies of any such warranties prior to the expiration of the Term (or, if the Lease is earlier terminated, within five (5) days thereafter).</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">22.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662718"></a><a name="_Toc28868734"></a>MORTGAGEE RIGHTS</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868735"></a><a name="_Toc504662719"></a><a name="_Hlk32327185"></a>22.1<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Subordination</font><font style="font-weight:normal;">. Tenant&#8217;s rights and interests under this Lease shall be (i) subject and subordinate to any ground lease, overleases, mortgage, deed of trust, or similar instrument covering the Premises, the Building and/or the Land and to all advances, modifications, renewals, replacements, and extensions thereof (each of the foregoing, a &#8220;</font>Mortgage<font style="font-weight:normal;">&#8221;), or (ii) if any Mortgagee elects, prior to the lien of any present or future Mortgage.&nbsp;&nbsp;Tenant further shall attorn to and recognize any successor landlord, whether through foreclosure or otherwise, as if the successor landlord were the originally named landlord.&nbsp;&nbsp;The provisions of this Section 22.1 shall be self-operative and no further instrument shall be required to effect such subordination or attornment; however, Tenant agrees to execute, acknowledge and deliver such instruments, confirming such subordination and attornment in such form as shall be requested by any such holder within fifteen (15) days of request therefor.<a name="_Hlk32327185"></a>&nbsp;&nbsp;Notwithstanding the foregoing, it shall be a condition to Tenant&#8217;s obligation to subordinate the Lease to any future Mortgage that the holder of such future Mortgage enters into an SNDA with Tenant.&nbsp;&nbsp;An &#8220;</font>SNDA<font style="font-weight:normal;">&#8221; shall be defined as a subordination, non-disturbance and attornment agreement on the standard form of SNDA then being used by the holder of the Mortgage in question, with such commercially reasonable modifications as may be requested by Tenant.&nbsp;&nbsp;Tenant shall pay any reasonable charges (including legal fees) required by such holder as a condition to entering into such SNDA.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868736"></a><a name="_Toc504662720"></a>22.2<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Notices</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant shall give each Mortgagee the same notices given to Landlord concurrently with the notice to Landlord, and each Mortgagee shall have a reasonable opportunity thereafter to cure a Landlord default, and Mortgagee&#8217;s curing of any of Landlord&#8217;s default shall be treated as performance by Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868737"></a><a name="_Toc504662721"></a><a name="_AEIOULastRenderedPageBreakAEIOU63"></a>22.3<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Mortgagee Consent</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant acknowledges that, where applicable, any consent or approval hereafter given by Landlord may be subject to the further consent or approval of a Mortgagee; and the failure or refusal of such Mortgagee to give such consent or approval shall, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">notwithstanding anything to the contrary in this Lease contained, constitute reasonable justification for Landlord</font><font style="font-weight:normal;">&#8217;</font><font style="font-weight:normal;">s withholding its consent or approval.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868738"></a><a name="_Toc504662722"></a><a name="_Hlk32327285"></a>22.4<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Mortgagee Liability</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant <a name="_Hlk32327285"></a>acknowledges and agrees that if any Mortgage shall be foreclosed, (a) the liability of the Mortgagee and its successors and assigns shall exist only so long as such Mortgagee or purchaser is the owner of the Premises, and such liability shall not continue or survive after further transfer of ownership; and (b) subject to the last sentence of this Section 22.4, such Mortgagee and its successors or assigns shall not be (i) liable for any act or omission of any prior lessor under this Lease; (ii) liable for the performance of Landlord&#8217;s covenants pursuant to the provisions of this Lease which arise and accrue prior to such entity succeeding to the interest of Landlord under this Lease or acquiring such right to possession; (iii) subject to any offsets or defense which Tenant may have at any time against Landlord; (iv) bound by any base rent or other sum which Tenant may have paid previously for more than one (1) month; or (v) liable for the performance of any covenant of Landlord under this Lease which is capable of performance only by the original Landlord.&nbsp;&nbsp;Notwithstanding the foregoing: (x) nothing shall relieve any Mortgagee, purchaser at foreclosure, or grantee of a deed in lieu of foreclosure from: (i) any liability which it has party-Landlord from and after the date which it succeeds to Landlord&#8217;s interest under the Lease, and (y) any obligation which Landlord has to perform repairs or maintenance under the Lease based upon the fact that the need for such repairs or maintenance first arose after the Succession Date.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">23.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662723"></a><a name="_Toc28868739"></a>QUIET ENJOYMENT.&nbsp;&nbsp;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord covenants that so long as Tenant keeps and performs each and every covenant, agreement, term, provision and condition herein contained on the part and on behalf of Tenant to be kept and performed, Tenant shall peaceably and quietly hold, occupy and enjoy the Premises during the Term from and against the claims of all persons lawfully claiming by, through or under Landlord subject, nevertheless, to the covenants, agreements, terms, provisions and conditions of this Lease, any matters of record or of which Tenant has knowledge and to any Mortgage to which this Lease is subject and subordinate, as hereinabove set forth. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">24.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662724"></a><a name="_Toc28868740"></a>NOTICES.&nbsp;&nbsp;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any notice, consent, request, bill, demand or statement hereunder (each, a &#8220;<font style="font-weight:bold;">Notice</font>&#8221;) by either party to the other party shall be in writing and shall be deemed to have been duly given when either delivered by hand or by nationally recognized overnight courier (in either case with evidence of delivery or refusal thereof) addressed as follows:&nbsp;&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:15.65%;width:399.9pt;;">
<tr>
<td style="width:130.5pt;"></td>
<td style="width:269.4pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Landlord:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HCP/King 75 Hayden LLC</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c/o King Street Properties</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800 Boylston Street, Suite 1570</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, MA 02199</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention:&nbsp;&nbsp;Stephen D. Lynch</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:15.65%;width:399.9pt;;">
<tr>
<td style="width:130.5pt;"></td>
<td style="width:269.4pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With a copy to:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goulston &amp; Storrs PC</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400 Atlantic Avenue&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, MA 02110 </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU64"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention:&nbsp;&nbsp;King Street</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU65"></a>if to Tenant:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Term Commencement Date: </p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant&#8217;s Mailing Address Prior to Occupancy</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the Term Commencement Date:</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics, Inc.</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75 Hayden Avenue</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lexington, MA 02421</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Richard Mitrano</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing, any notice from Landlord to Tenant regarding ordinary business operations (e.g., exercise of a right of access to the Premises, maintenance activities, invoices, etc.) may also be given by written notice delivered by email to those parties listed in Section 2.4.&nbsp;&nbsp;Either party may at any time change the address or specify an additional address for such Notices by delivering or mailing, as aforesaid, to the other party a notice stating the change and setting forth the changed or additional address, provided such changed or additional address is within the United States.&nbsp;&nbsp;Notices shall be effective upon the date of receipt or refusal thereof.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">25.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc504662725"></a><a name="_Toc28868741"></a>MISCELLANEOUS </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868742"></a><a name="_Toc504662726"></a>25.1<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Separability</font><font style="font-weight:normal;">.&nbsp;&nbsp;If any provision of this Lease or portion of such provision or the application thereof to any person or circumstance is for any reason held invalid or unenforceable, the remainder of this Lease (or the remainder of such provision) and the application thereof to other persons or circumstances shall not be affected thereby. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868743"></a><a name="_Toc504662727"></a>25.2<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Captions</font><font style="font-weight:normal;">.&nbsp;&nbsp;The captions are inserted only as a matter of convenience and for reference, and in no way define, limit or describe the scope of this Lease nor the intent of any provisions thereof. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868744"></a><a name="_Toc504662728"></a>25.3<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Broker</font><font style="font-weight:normal;">. Tenant and Landlord each warrants and represents that it has dealt with no broker in connection with the consummation of this Lease other than Colliers International and JLL New England (collectively, &#8220;</font>Broker<font style="font-weight:normal;">&#8221;). Tenant and Landlord each agrees to defend, indemnify and save the other harmless from and against any Claims arising in breach of the representation and warranty set forth in the immediately preceding sentence.&nbsp;&nbsp;Landlord shall be solely responsible for the payment of any brokerage commissions to the Broker pursuant to separate agreements between Landlord and each of the Broker. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868745"></a><a name="_Toc504662729"></a>25.4<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Entire Agreement</font><font style="font-weight:normal;">. This Lease, Lease Summary Sheet and </font><font style="text-decoration:underline;font-weight:normal;">Exhibits 1-12</font><font style="font-weight:normal;"> attached hereto and incorporated herein contain the entire and only agreement between the parties and any and all statements and representations, written and oral, including previous correspondence and agreements between the parties hereto, are merged herein.&nbsp;&nbsp;Tenant acknowledges that all representations and statements upon which it relied in executing this Lease are contained herein and that Tenant in no way relied upon any other statements or representations, written or oral. This Lease may not be modified orally or in any manner other than by written agreement signed by the parties hereto.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868746"></a><a name="_Toc504662730"></a><a name="_AEIOULastRenderedPageBreakAEIOU66"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">25.5</font><font style="margin-left:72pt;"></font><font style="text-decoration:none;">Governing Law</font><font style="font-weight:normal;">.&nbsp;&nbsp;This Lease is made pursuant to, and shall be governed by, and construed in accordance with, the laws of the Commonwealth of Massachusetts and any applicable local municipal rules, regulations, by-laws, ordinances and the like.</font><font style="font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868747"></a><a name="_Toc504662731"></a>25.6<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Representation of Authority</font><font style="font-weight:normal;">.&nbsp;&nbsp;By his or her execution hereof, each of the signatories on behalf of the respective parties hereby warrants and represents to the other that he or she is duly authorized to execute this Lease on behalf of such party. Upon Landlord&#8217;s request, Tenant shall provide Landlord with evidence that any requisite resolution, corporate authority and any other necessary consents have been duly adopted and obtained.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868748"></a><a name="_Toc504662732"></a>25.7<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Expenses Incurred by Landlord Upon Tenant Requests</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>Tenant shall, upon demand, reimburse Landlord for all reasonable expenses, including, without limitation, legal fees, incurred by Landlord in connection with all requests by Tenant for consents, approvals or execution of collateral documentation related to this Lease, including, without limitation, costs incurred by Landlord in the review and approval of Tenant&#8217;s plans and specifications in connection with proposed Alterations to be made by Tenant to the Premises or in connection with requests by Tenant for Landlord&#8217;s consent to make a Transfer.&nbsp;&nbsp;Such costs shall be deemed to be Additional Rent under this Lease.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font>Notwithstanding the foregoing: (i) the amount of legal fees which Tenant is required to reimburse Landlord with respect to any Transfer shall not exceed the Transfer Legal Fee Cap, as hereinafter defined, with respect to such Transfer, and (ii) with respect any request by Tenant to review and approve Tenant&#8217;s plans and specifications with respect to any Alteration, Tenant shall only be required to reimburse Landlord for third party consultants engaged by Landlord to review such plans and specifications as Landlord, in good faith determines is necessary (e.g., reviews by structure engineers, MEP engineers, etc.).&nbsp;&nbsp;The &#8220;Transfer Legal Fees Cap&#8221; shall be defined as $2,500.00, except that (a) the Transfer Legal Fees Cap shall increase by $500 every fifth (5th) anniversary of the Term Commencement Date, and (b) the Transfer Legal Fees Cap shall not apply to Tenant&#8217;s request for Landlord&#8217;s approval of any sub-sublease of any tier.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:108pt;"></font>In the case of litigation or other legal proceeding between Landlord and Tenant relating to the provisions of this Lease or Tenant&#8217;s occupancy of the Premises, the losing party shall, upon demand, reimburse the prevailing party for its reasonable costs of prosecuting and/or defending such proceeding (including, without limitation, reasonable attorneys&#8217; fees.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868749"></a><a name="_Toc504662733"></a>25.8<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Survival</font><font style="font-weight:normal;">.&nbsp;&nbsp;Without limiting any other obligation of Tenant which may survive the expiration or prior termination of the Term, all obligations on the part of Tenant to indemnify, defend, or hold Landlord harmless, as set forth in this Lease shall survive the expiration or prior termination of the Term.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868750"></a><a name="_Toc504662734"></a>25.9<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Limitation of Liability</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU67"></a>(a)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Limitation on Landlord&#8217;s Liability</font>.&nbsp;&nbsp;Tenant shall neither assert nor seek to enforce any claim against Landlord or any of the Landlord Parties, or the assets of any of the Landlord Parties, for breach of this Lease or otherwise, other than against Landlord&#8217;s interest in the Building and in the uncollected rents, issues and profits thereof, and Tenant agrees to look solely to such interest for the satisfaction of any liability of Landlord under this Lease.&nbsp;&nbsp;This </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 25.9</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall not limit any right that Tenant might otherwise have to obtain injunctive relief against Landlord.&nbsp;&nbsp;</font><font style="font-weight:bold;">Landlord and Tenant specifically agree that in no event shall any officer, director, trustee, employee or representative of Landlord or any of the other Landlord Parties ever be personally liable for any obligation under this Lease, nor shall Landlord or any of the other Landlord Parties be liable for consequential or incidental damages or for lost profits whatsoever in connection with this Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk32327773"></a>(b)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Limitation on Tenant&#8217;s Liability</font>.&nbsp;&nbsp;Landlord shall neither assert nor seek to enforce any claim against Tenant or any of the Tenant Parties for breach of this Lease or otherwise, other than against the assets and property of Tenant, and Landlord agrees to look solely to such assets and property for the satisfaction of any liability of Tenant or any Tenant Parties under this Lease.&nbsp;&nbsp;This Section 25.9(b) shall not limit any right that Landlord might otherwise have to obtain injunctive relief against Tenant.&nbsp;&nbsp;Landlord and Tenant specifically agree that in no event: (i) any officer, director, trustee, employee or representative of Tenant or any of the other Tenant Parties ever be personally liable for any obligation under this Lease, and (ii) Tenant or any of the other Tenant Parties be liable for consequential or incidental damages or for lost profits whatsoever in connection with this Lease, except that nothing in this Section 25.9(b) shall limit or affect any liability or obligation which Tenant may have in the event of any breach by Tenant of its obligations under either Section 17 (Hazardous Materials) or Section 21.3 (Holdover).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868751"></a><a name="_Toc504662735"></a>25.10<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Binding Effect</font><font style="font-weight:normal;">.&nbsp;&nbsp;The covenants, agreements, terms, provisions and conditions of this Lease shall bind and benefit the successors and assigns of the parties hereto with the same effect as if mentioned in each instance where a party hereto is named or referred to, except that no violation of the provisions of Section 13 hereof shall operate to vest any rights in any successor or assignee of Tenant. A facsimile signature on this Lease shall be equivalent to, and have the same force and effect as, an original signature.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868752"></a><a name="_Toc504662736"></a>25.11<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Landlord Obligations upon Transfer</font><font style="font-weight:normal;">.&nbsp;&nbsp;Upon any sale, transfer or other disposition of the Building, Landlord shall be entirely freed and relieved from the performance and observance thereafter of all covenants and obligations hereunder on the part of Landlord to be performed and observed, it being understood and agreed in such event (and it shall be deemed and construed as a covenant running with the land) that the person succeeding to Landlord&#8217;s ownership of said reversionary interest shall thereupon and thereafter assume, and perform and observe, any and all of such covenants and obligations of Landlord, except as otherwise agreed in writing. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868753"></a><a name="_Toc504662737"></a>25.12<font style="margin-left:72pt;"></font><font style="text-decoration:none;">No Grant of Interest</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant shall not grant any interest whatsoever in any fixtures within the Premises or any item paid in whole or in part by Landlord&#8217;s Contribution or by Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868754"></a><a name="_Toc504662738"></a><a name="_AEIOULastRenderedPageBreakAEIOU68"></a>25.13<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Financial Information</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant shall deliver to Landlord, within thirty (30) days after Landlord&#8217;s reasonable request (which request may be made no more often than one time every twelve (12) month period provided that such limitation shall not apply in the event of a sale or financing of any of Landlord&#8217;s interest in the Lease or the Premises), Tenant&#8217;s most recently completed balance sheet and related statements of income, shareholder&#8217;s equity and cash flows statements (audited if available) reviewed by an independent certified public accountant and certified by an officer of Tenant as being true and correct in all material respects.&nbsp;&nbsp;Any such </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">financial information may be relied upon by any actual or potential lessor, purchaser, or mortgagee of the Property or any portion thereof</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868755"></a><a name="_Toc504662739"></a>25.14<font style="margin-left:72pt;"></font><font style="text-decoration:none;">OFAC Certificate and Indemnity</font><font style="font-weight:normal;">.&nbsp;&nbsp;Executive Order No. 13224 on Terrorist Financing, effective September 24, 2001 (the &#8220;</font>Executive Order<font style="font-weight:normal;">&#8221;), and the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (Public Law 10756, the &#8220;</font>Patriot Act<font style="font-weight:normal;">&#8221;) prohibit certain property transfers.&nbsp;&nbsp;Tenant hereby represents and warrants to Landlord (which representations and warranties shall be deemed to be continuing and re-made at all times during the Term) that neither Tenant nor to Tenant&#8217;s knowledge any stockholder, manager, beneficiary, partner, or principal of Tenant is subject to the Executive Order, that none of them is listed on the United States Department of the Treasury Office of Foreign Assets Control (&#8220;OFAC&#8221;) list of &#8220;Specially Designated Nationals and Blocked Persons&#8221; as modified from time to time, and that none of them is otherwise subject to the provisions of the Executive Order or the Patriot Act.&nbsp;&nbsp;The most current list of &#8220;</font>Specially Designated Nationals and Blocked Persons<font style="font-weight:normal;">&#8221; can be found at http://www.treas.gov/offices/eotffc/ofac/sdn/index.html.  Tenant shall from time to time, within ten days after request by Landlord, deliver to Landlord any certification or other evidence requested from time to time by Landlord in its reasonable discretion, confirming Tenant&#8217;s compliance with these provisions.&nbsp;&nbsp;No assignment or subletting shall be effective unless and until the assignee or subtenant thereunder delivers to Landlord written confirmation of such party&#8217;s compliance with the provisions of this subsection, in form and content satisfactory to Landlord.&nbsp;&nbsp;If for any reason the representations and warranties set forth in this subsection, or any certificate or other evidence of compliance delivered to Landlord hereunder, is untrue in any respect when made or delivered, or thereafter becomes untrue in any respect, then an Event of Default hereunder shall be deemed to occur immediately, and there shall be no opportunity to cure.&nbsp;&nbsp;Tenant shall indemnify, defend with counsel reasonably acceptable to Landlord, and hold Landlord harmless from and against, any and all liabilities, losses claims, damages, penalties, fines, and costs (including attorneys&#8217; fees and costs) arising from or related to the breach of any of the foregoing representations, warranties, and duties of Tenant.&nbsp;&nbsp;The provisions of this subsection shall survive the expiration or earlier termination of this Lease for the longest period permitted by law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868756"></a><a name="_Toc504662740"></a>25.15<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Confidentiality</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant acknowledges and agrees that the terms of this Lease are confidential.&nbsp;&nbsp;Disclosure of the terms hereof could adversely affect the ability of Landlord to negotiate other leases with respect to the Building and may impair Landlord&#8217;s relationship with other tenants of the Building.&nbsp;&nbsp;Tenant shall not disclose the terms and conditions of this Lease to any other person or entity without the prior written consent of Landlord, which may be given or withheld by Landlord, in Landlord&#8217;s sole discretion, except as required for financial disclosures or securities filings, as required by the order of any court or public body with authority over Tenant, or in connection with any litigation between Landlord and Tenant with respect to this Lease or to Tenant&#8217;s partners, officers, directors, employees, brokers, attorneys, or as may be required as part of any financing or Tenant&#8217;s normal course of business.&nbsp;&nbsp;It is understood and agreed that damages alone would be an inadequate remedy for the breach of this provision by Tenant, and Landlord shall also have the right to seek specific performance of this provision and to seek injunctive relief to prevent its breach or continued breach.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc28868757"></a><a name="_Toc504662741"></a><a name="_AEIOULastRenderedPageBreakAEIOU69"></a>25.16<font style="margin-left:72pt;"></font><font style="text-decoration:none;">Force Majeure</font><font style="font-weight:normal;">.&nbsp;&nbsp;Other than for Tenant&#8217;s obligations under this Lease that can be performed by the payment of money (e.g., payment of Rent and maintenance of insurance), </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">whenever a period of time is herein prescribed for action to be taken by either party hereto, such party shall not be liable or responsible for, and there shall be excluded from the computation of any such period of time, any delays due to strikes, riots, acts of God, shortages of labor or materials, war, acts of terrorism, governmental laws, regulations, or restrictions, or any other causes of any kind whatsoever which are beyond the control of such party (collectively </font><font style="font-weight:normal;">&#8220;</font><font style="font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Force Majeure</font><font style="font-weight:normal;">&#8221;</font><font style="font-weight:normal;">).&nbsp;&nbsp;In no event shall financial inability of a party be deemed to be Force Majeure.</font><font style="font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">[SIGNATURES ON FOLLOWING PAGE]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU70"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF the parties hereto have executed this Lease as a sealed instrument as of the Execution Date. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">HCP/KING 75 HAYDEN LLC<font style="font-weight:normal;">,</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware limited liability company</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="3" valign="top"  style="width:69.62%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">King Mattingly LLC, a Massachusetts limited</p></td>
<td valign="top"  style="width:24.36%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:69.62%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">liability company, its Manager</p></td>
<td valign="top"  style="width:24.36%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:57.58%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:24.36%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="2" valign="top"  style="width:63.6%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">King Street Properties Investments LLC, a</p></td>
<td valign="top"  style="width:24.36%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:63.6%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Massachusetts limited liability company, its Manager</p></td>
<td valign="top"  style="width:24.36%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:57.58%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:24.36%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:57.58%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:24.36%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:57.58%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:24.36%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:57.58%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Thomas Ragno</p></td>
<td valign="top"  style="width:24.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:57.58%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Thomas Ragno</p></td>
<td valign="top"  style="width:24.36%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:57.58%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Its Manager</p></td>
<td valign="top"  style="width:24.36%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">TENANT</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">FREQUENCY THERAPEUTICS, INC.,</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware corporation</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:6.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:69.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David L. Lucchino</p></td>
<td valign="top"  style="width:24.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:69.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: David L. Lucchino</p></td>
<td valign="top"  style="width:24.36%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.02%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:69.62%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: President and Chief Executive Officer</p></td>
<td valign="top"  style="width:24.36%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662742"></a><a name="_AEIOULastRenderedPageBreakAEIOU71"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 1A</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662743"></a>LEASE PLAN &#8211; PRIME PREMISES</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqr1p20dfppl000001.jpg" title="" alt="" style="width:791px;height:525px;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.56%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 1A, Page 1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662744"></a><a name="_AEIOULastRenderedPageBreakAEIOU72"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 1B</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662745"></a>LEASE PLAN &#8211; PH SYSTEM PREMISES</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqr1p20dfppl000002.jpg" title="" alt="" style="width:765px;height:497px;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.56%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.56%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 1B, Page 1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662746"></a><a name="_AEIOULastRenderedPageBreakAEIOU73"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 1C</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662747"></a>LEASE PLAN &#8211;STORAGE PREMISES</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqr1p20dfppl000003.jpg" title="" alt="" style="width:818px;height:533px;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.56%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 1C, Page 1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU74"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 1D</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LEASE PLAN &#8211; PENTHOUSE EQUIPMENT PREMISES AND GENERATOR AREA</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU75"></a><img src="gqr1p20dfppl000004.jpg" title="" alt="" style="width:864px;height:559px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 1D, Page 1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU76"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 1E</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LEASE PLAN &#8211; NITROGEN TANK AREA</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqr1p20dfppl000005.jpg" title="" alt="" style="width:702px;height:542px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 1E, Page 1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU77"></a><img src="gqr1p20dfppl000006.jpg" title="" alt="" style="width:583px;height:623px;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2A, Page 1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662750"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 2</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662751"></a>LEGAL DESCRIPTION - LAND</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Building 75</font>:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A certain portion of land in the Town of Lexington, Middlesex County, and Commonwealth of Massachusetts, being shown as &#8220;Expansion Unit Development Area = 286,017 Square Feet 6.566+/- Acres on a plan entitled, &#8220;The Hayden Science Center Condominium, Condominium Site Plan,&#8221; dated April 4, 2017, by Feldman Land Surveyors, (the &#8220;Plan&#8221;), and being more particularly described as follows:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commencing at the northwesterly corner of Parcel One, also being the northeasterly corner of Parcel Three, (being shown on the Plan as &#8220;POC-E&#8221;); </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thence running S 02&#176;20&#8217;56&#8221; W, a distance of 76.99 feet to a point;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thence turning and running N 87&#176;03&#8217;28&#8221; W, a distance of 12.00 feet to the point of beginning (being shown on the Plan as &#8220;POB-E&#8221;);</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk481388805"></a>thence turning and running S 87&#176;03&#8217;28&#8221; E, a distance of 693.77 feet to a point of curvature;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thence running along a curve to the right having a radius of 310.00 feet, an arc length of 466.24 feet, a chord bearing of S 43&#176;58&#8217;17&#8221; E, and a chord distance of 423.52 feet to a point;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thence turning and running N 87&#176;39&#8217;04&#8221; W, a distance of 661.94 feet to a point;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thence turning and running S 28&#176;10&#8217;16&#8221; W, a distance of 38.74 feet to a point;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thence turning and running N 87&#176;39&#8217;04&#8221; W, a distance of 321.21 feet to a point;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thence turning and running N 02&#176;20&#8217;56&#8221; E, a distance of 334.55 feet to the point of beginning.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Said portion of land contains an area of 286,017 square feet, or 6.566 acres, more or less.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 1E, Page 1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU78"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 2B</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LEGAL DESCRIPTION</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Real property in the Town of Lexington, County of Middlesex, Commonwealth of Massachusetts, described as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Parcel One (45 &amp; 55 Hayden Avenue)</font><font style="font-weight:normal;">:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A certain parcel of land in the Commonwealth of Massachusetts, County of Middlesex, Town of Lexington, and shown as Lot 2 on a plan entitled &#8220;Plan of Land in Lexington, Mass. (Middlesex County),&#8221; dated March 27, 1998, recorded October 6, 1998, with Middlesex South Registry of Deeds as Plan No. 1088 of 1998 in Book 29190, Page 447, prepared by Beals and Thomas, Inc., more particularly bounded and described as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning at the most southwesterly corner of the premises, at the southeasterly corner of Lot 1 as shown on said plan, then running:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N 02&#176; 20&#8217; 56&#8221; E 180.68 feet to a point, thence turning and running; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N 87&#176; 39&#8221; 04&#8221; W 40.00 feet to a point, thence turning and running; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N 02&#176; 20&#8217; 56&#8221; E 122.19 feet to a point, thence turning and running;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N 87&#176; 39&#8217; 04&#8221; E 40.00 feet to a point, thence turning and running;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N 02&#176; 20&#8217; 56&#8221; E 547.13 feet to a point, thence turning and running, said last five courses being bounded by Lot 1, as shown on said plan, thence turning and running;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S 87&#176; 36&#8217; 20&#8221; E 1,330.04 feet to a point of curvature, thence running;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Northeasterly to a curve to the left having a radius of 135.00 feet and a length of 58.90 feet to a point of tangency, thence running;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N 67&#176; 23&#8217; 52&#8221; E 146.89 feet to a point, thence turning and running;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S 03&#176; 52&#8217; 06&#8221; E 111.25 feet to a point, said last four courses being bounded by land now or formerly of the Town of Lexington, thence turning and running;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S 44&#176; 07&#8217; 54 W 561.19 feet to a point, thence turning and running;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S 22&#176; 29&#8217; 38&#8221; E 435.76 feet to a point, said last two courses are bounded in part by land now or formerly the Town of Lexington and, in part now or formerly of Hayden Office Trust, thence running;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Southwesterly by a curve to the right, having a radius of 985.00 feet and a length of 12.11 feet to a point of tangency, thence turning and running;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2B, Page 1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU79"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N 87&#176; 36</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 20</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> W 1,329.27 feet to the point of beginning, said last two courses being bounded by the northerly sideline of Hayden Avenue. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Containing 1,123,722 square feet more or less, or 25.797 acres, more or less.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A portion of said Lot 2 is registered land, described as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lot 293 on Land Court Plan 19485 N as approved by the Land Court and filed in the Land Registration Office; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lots 10 and 11 on Land Court Plan 16660 O as approved by the Land Court and filed with the Land Registration Office.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Parcel Two (Appurtenant Easements - 45 &amp; 55 Hayden Avenue)</font><font style="font-weight:normal;">:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">There is appurtenant to the above described Lot 11 the right and easement to use the drainage ditch running from west to east across the northerly portion of Lot 10, shown on said plan, as set forth in Registered Document No. 517903.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">There is appurtenant to the above described Lot 11 rights and easements for sewer purposes as set forth in Registered Document No. 479201.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">There is appurtenant to said Lot 293 the benefits of the agreement and reservation as to trunk sewer more particularly set forth in deed filed as Document No. 479738.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Lot 10 has the benefit of a reservation in the strip of land marked sewer easement as shown on said plan, set forth in Document 517903 and the rights and easements for sewer purposes as set forth in Registered Document No. 479201, insofar as applicable.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Together with the benefit of the appurtenant easements over Lot B shown on plan entitled &#8220;A Compiled Plan of Land in Lexington, Mass.&#8221; Dated August 27, 1970, by John J. McSweeney, recorded with Middlesex South District Deeds in Book 11928, Page 614, as shown on said plan, as reserved in a taking by the Town of Lexington dated November 30, 1970, recorded with said Deeds in Book 11928, Page 611, and in a deed from George H. Crawford to the Town of Lexington of the said Lot B dated December 7, 1970, recorded with said Deeds in Book 11928, Page 614.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Together with the benefit of the appurtenant easements set forth in Declaration of Covenants and Easements dated September 18, 1998 filed as Document No. 1084070 and recorded in Book 29287, Page 189; as affected by Amended and Restated Declaration of Covenants and Easements dated November 8, 1999, filed as Document No. 1123738, and recorded in Book 30855, Page 323; as affected by First Amendment to Amended and Restated Declaration of Covenants and Easements dated March 26, 2002, filed as Document No. 1261521, recorded in Book 37256, Page 364.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2B, Page 2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU80"></a><font style="text-decoration:underline;">Parcel Three (65 Hayden Avenue)</font><font style="font-weight:normal;">:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">That certain parcel of land situate in Lexington in the County of Middlesex and Commonwealth of Massachusetts shown as Lot 292 on Land Court Plan No. 19485-N.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of said boundaries are determined by the Court to be located as shown on a subdivision plan, as approved by the Court, filed in the Land Registration Office, a copy of which is filed in the Registry of Deeds for the South Registry District of Middlesex County in Registration Book 1178 Page 11.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Parcel Four (Appurtenant Easements - 65 Hayden Avenue)</font><font style="font-weight:normal;">:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is appurtenant to said Lot 292 the right to use the whole of Grassland Street and Valleyfield Street as shown on the plan Registered in the Registration Book 383 Page 149 in common with others entitled thereto; the right to use all streets or roads as shown on the plan Registered in Registration Book 506 Page 153, in common with all others legally entitled thereto; the benefit of the agreement and reservation as to trunk sewer more particularly set forth in the deed Registered as Document No. 479738; and the benefit of the appurtenant easements set forth in Declaration of Covenants and Easements dated September 18, 1998 filed as Document No. 1084070 and recorded in Book 29287, Page 189; as affected by Amended and Restated Declaration of Covenants and Easements dated November 8, 1999, filed as Document No. 1123738, and recorded in Book 30855, Page 323; as affected by First Amendment to Amended and Restated Declaration of Covenants and Easements dated March 26, 2002, filed as Document No. 1261521, recorded in Book 37256, Page 364.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2B, Page 3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662752"></a><a name="_AEIOULastRenderedPageBreakAEIOU81"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 3</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PARKING AREAS </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqr1p20dfppl000007.jpg" title="" alt="" style="width:824px;height:535px;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.56%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 3, Page 1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662754"></a><a name="_Hlk27229622"></a><a name="_AEIOULastRenderedPageBreakAEIOU82"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 4</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662755"></a>WORK LETTER</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Exhibit is attached to and made a part of the Lease (the &#8220;<font style="font-weight:bold;">Lease</font>&#8221;) by and between<font style="font-weight:bold;"> HCP/KING 75 HAYDEN LLC</font>, a Delaware limited liability company (&#8220;<font style="font-weight:bold;">Landlord</font>&#8221;), and <font style="font-weight:bold;">FREQUENCY THERAPEUTICS, INC.</font>, a Delaware corporation (&#8220;<font style="font-weight:bold;">Tenant</font>&#8221;), for space located at 75 Hayden Avenue, Lexington, Massachusetts.&nbsp;&nbsp;Capitalized terms used but not defined herein shall have the meanings given in the Lease.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Work Letter shall set forth the obligations of Landlord and Tenant with respect to the improvements to be performed in preparing the Premises for Tenant&#8217;s use.&nbsp;&nbsp;This Exhibit shall not be deemed applicable to any additional space added to the Premises at any time or from time to time, whether by any options under the Lease or otherwise, or to any portion of the original Premises or any additions to the Premises in the event of a renewal or extension of the original Term of the Lease, whether by any options under the Lease or otherwise, unless expressly so provided in the Lease or any amendment or supplement to the Lease.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Hlk28435447"></a><a name="_AEIOULastRenderedPageBreakAEIOU83"></a><font style="text-decoration:underline;">Definitions</font><a name="_Hlk28435447"></a>.&nbsp;&nbsp;This Work Letter shall set forth the obligations of Landlord and Tenant with respect to the improvements to be performed in the Premises for Tenant&#8217;s use.&nbsp;&nbsp;For the purposes of this Lease, &#8220;<font style="font-weight:bold;">Landlord&#8217;s Work</font>&#8221; consists of: (a) the Base Building Work described on <font style="text-decoration:underline;">Exhibit 4-1</font>, and (b) the Tenant Improvement Work, as hereinafter defined.  &#8220;<font style="font-weight:bold;">Tenant&#8217;s Work</font>&#8221; consists of the construction and/or installation, at Tenant&#8217;s sole cost and expense (subject to Section 11 below), all of Tenant&#8217;s furniture, fixtures and equipment, the card access system for Tenant&#8217;s entrances and interior doors, all telephone and data wiring throughout the Premises, and other equipment Tenant intends to install in connection with the initial preparation of the Premises for Tenant&#8217;s occupancy (including, without limitation, any equipment, alarms, audio visual equipment and wiring, white noise equipment and wiring, and UPS).&nbsp;&nbsp;The &#8220;<font style="font-weight:bold;">Tenant Improvement Work</font>&#8221; consists of the items listed on <font style="text-decoration:underline;">Exhibit 4-2</font> (Tenant/Landlord Responsibility Matrix) as &#8220;Landlord&#8221; (except to the extent included in the Base Building Work).&nbsp;&nbsp;The parties intend that the Tenant Improvement Work will be in accordance with construction documents (the &#8220;<font style="font-weight:bold;">Construction Documents</font>&#8221;) prepared by Landlord and approved by Tenant in accordance with this <font style="text-decoration:underline;">Exhibit 4</font>, and the Construction Documents will be based upon design development level plans (which plans shall include sufficient detail with respect to finishes selected by Tenant and engineering of the mechanical, electrical, and plumbing systems to be completed by the Contractor so as to be submitted for a building permit and enable Landlord to prepare the Construction Documents) (&#8220;<font style="font-weight:bold;">Initial Plans</font>&#8221;) to be prepared by Tenant and delivered to Landlord on or before February 15, 2020 (the &#8220;<font style="font-weight:bold;">Plan Delivery Deadline</font>&#8221;) for Landlord&#8217;s review and approval, which approval shall not be unreasonably withheld, conditioned or delayed.&nbsp;&nbsp;Tenant shall also deliver to Landlord by not later than the Plan Delivery Deadline a list of Tenant&#8217;s equipment that will be installed in the Premises.  Landlord and Tenant acknowledge that the Construction Documents have not yet been prepared and, therefore, it is impossible to determine the exact cost of the Tenant Improvement Work at this time.&nbsp;&nbsp;Accordingly, Landlord and Tenant agree that Landlord&#8217;s obligation to pay for the Cost of Tenant Improvement Work, as hereinafter defined, shall be limited to an amount (&#8220;<font style="font-weight:bold;">Landlord&#8217;s Contribution</font>&#8221;) which shall not exceed $11,035,260.00 (i.e., the TI Allowance, as hereinafter defined) or, $11,954,865.00 if Tenant timely elects to receive the Additional TI Allowance (as hereinafter defined) (the &#8220;<font style="font-weight:bold;">Maximum Amount</font>&#8221;) and that Tenant shall be </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4, Page 1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">responsible for the Cost of Tenant Improvement Work to the extent that it exceeds the Maximum Amount.&nbsp;&nbsp;The &#8220;</font><font style="font-weight:bold;">TI&#160;Allowance</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; shall mean $11,035,260.00 (i.e., </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00 </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">per rentable square foot of the Premises).&nbsp;&nbsp;The &#8220;</font><font style="font-weight:bold;">Additional TI Allowance</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; shall mean $919,605.00 (i.e., </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">per rentable square foot of the Premises).&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall give Landlord written notice on or bef</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ore </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 15, 2020</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> advising Landlord whether and how much of the Additional TI Allowance Tenant desires to use</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (failing which Tenant shall be deemed to have elected not to use the Additional TI Allowance).</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;The &#8220;</font><font style="font-weight:bold;">Cost of Tenant Improvement Work</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; shall be defined as all hard costs (&#8220;</font><font style="font-weight:bold;">Hard Costs</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) incurred by Landlord relating to the performance of the Tenant Improvement Work (including, without limitation, the cost of obtaining permits and any applicable state sales and use taxes) and soft costs (&#8220;</font><font style="font-weight:bold;">Soft Costs</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) incurred by Landlord in connection with the Tenant Improvement Work (including, without limitation, the cost of preparing the Initial Plan</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and the Construction Documents). For avoidance of doubt, and without limiting the generality of the foregoing, the Cost of Tenant Improvement Work shall not include the costs of the Tenant&#8217;s Work or other costs and fees incurred by Tenant in connection with the preparation of the Premises for Tenant&#8217;s initial occupancy (including, without limitation, consulting fees).</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Contractor; GMP</font>.&nbsp;&nbsp;Landlord shall enter into a contract (&#8220;<font style="font-weight:bold;">Contract</font>&#8221;) for the Tenant Improvement Work with B.W. Kennedy &amp; Company, LLC (&#8220;<font style="font-weight:bold;">Contractor</font>&#8221;).&nbsp;&nbsp;The Contract may be on the basis of a guaranteed maximum price (&#8220;<font style="font-weight:bold;">GMP</font>&#8221;).&nbsp;&nbsp;The GMP shall be determined based upon the sum of the following:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="text-decoration:underline;font-family:Times New Roman;">Contractor&#8217;s Fee</font><font style="font-family:Times New Roman;">:&nbsp;&nbsp;3% of the sum (&#8220;</font><font style="font-weight:bold;font-family:Times New Roman;">Cost of the Work</font><font style="font-family:Times New Roman;">&#8221;) of: (i) Direct Cost of the Work, and (ii) General Conditions Costs.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="text-decoration:underline;font-family:Times New Roman;">General Conditions Costs</font><font style="font-family:Times New Roman;">:&nbsp;&nbsp;9% of the Direct Cost of the Work.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="text-decoration:underline;font-family:Times New Roman;">Direct Cost of the Work</font><font style="font-family:Times New Roman;">:&nbsp;&nbsp;Determined by bids obtained from subcontractors in accordance with Section 5 below. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="text-decoration:underline;font-family:Times New Roman;">Contingency</font><font style="font-family:Times New Roman;">:&nbsp;&nbsp;3% of the Cost of the Work. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:12pt;margin-left:11.54%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that the Cost of the Work plus the Contractor&#8217;s Fee is less than the GMP set forth in the Contract for the Tenant Improvement Work, the Contractor shall each be entitled to fifty percent (50%) of such savings and the other fifty (50%) of such savings shall be applied by Landlord to the Cost of Tenant Improvement Work to reduce Excess Costs, as hereinafter defined.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Hlk28435685"></a><font style="text-decoration:underline;">Preparation of Construction Documents</font><a name="_Hlk28435685"></a>.&nbsp;&nbsp;Landlord shall engage R.E. Dinneen Architects &amp; Planners, Inc. and B.W. Kennedy &amp; Company, LLC as subconsultants to prepare the Construction Documents for Tenant&#8217;s approval.&nbsp;&nbsp;Tenant shall be required to approve the Construction Documents if the same are consistent with the Initial Plans.&nbsp;&nbsp;Otherwise, Tenant shall not unreasonably withhold or condition its approval of the Construction Documents.&nbsp;&nbsp; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Hlk28436185"></a><a name="_AEIOULastRenderedPageBreakAEIOU84"></a><font style="text-decoration:underline;">Tenant Responses</font><a name="_Hlk28436185"></a>.&nbsp;&nbsp;Tenant shall respond, in writing, to any requests from Landlord or the Contractor for approvals, information, consents, or authorizations to proceed, within five (5) business days of Tenant&#8217;s receipt of such request.&nbsp;&nbsp;Any failure by Tenant to respond in writing to Landlord within such time period shall be deemed to be a Tenant Delay. Tenant shall have the right to hire a mutually approved Tenant Construction Representative to oversee all required construction relative to the Tenant Premises.&nbsp;&nbsp;Tenant agrees to cooperate, and to cause any Tenant Party to cooperate, with Landlord in such manner as Landlord may reasonably request in </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4, Page 2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">connection with Landlord&#8217;s Work in order to perform Landlord&#8217;s Work in a timely and cost-effective manner.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Bid Process</font>.&nbsp;&nbsp;Tenant hereby acknowledges that: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">the Contractor will receive a single bid for each of the following portions of Landlord&#8217;s Work from the designated subcontractors (&#8220;<font style="font-weight:bold;">Designated Subcontractors</font>&#8221;) listed below who will perform both the design and construction such portions of Landlord&#8217;s Work: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">Mechanical/HVAC:&nbsp;&nbsp;Environmental Systems, Inc.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">Plumbing: North Shore Mechanical Contractors, Inc.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">Fire Protection:&nbsp;&nbsp;Legacy Fire Protection, Inc.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:12pt;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-family:Times New Roman;">Electrical:&nbsp;&nbsp;Nappa Electrical Contractors </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Landlord will cause the Contractor to use reasonable efforts to obtain at least three (3) bidders for other portions of Landlord&#8217;s Work; however, given the current market, it may not be possible to obtain more than one or two bidders with respect to portions of Landlord&#8217;s Work. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Tenant reasonably determines that the GMP is higher than is acceptable to Tenant, then Tenant shall have a one-time right to give request changes to Tenant Improvement Work.&nbsp;&nbsp;In order to exercise such one-time right to request changes to Tenant Improvement Work in order to reduce the GMP, Tenant shall, on or before the date five (5) business days after Tenant receives Landlord&#8217;s notice to Tenant of the GMP, give written notice to Landlord specifying the changes in Tenant Improvement Work requested by Tenant.&nbsp;&nbsp;Such changes shall be subject to Landlord&#8217;s prior written approval (which approval shall not be unreasonably withheld, conditioned, or delayed).&nbsp;&nbsp; Based upon the revised Construction Documents for Tenant Improvement Work, which are based upon the changes requested by Tenant, as approved by Landlord, as aforesaid, the Contractor shall revise the GMP for the construction of Tenant Improvement Work in accordance with this Section 5.&nbsp;&nbsp;Tenant shall pay for the design cost associated with the preparation of the revised Construction Documents. Tenant shall have the right to review the revised GMP within three (3) business days after receipt thereof. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Hlk28436290"></a><a name="_Hlk28436290"></a><font style="text-decoration:underline;">Tenant&#8217;s Share</font>.&nbsp;&nbsp;For the purposes of this <font style="text-decoration:underline;">Exhibit 4</font>: (i) if the Cost of Tenant Improvement Work is equal to, or less than, the Maximum Amount, then &#8220;<font style="font-weight:bold;">Tenant&#8217;s Share</font>&#8221; shall be 0%, or (ii) if the Cost of Tenant Improvement Work is greater than the Maximum Amount, then Tenant&#8217;s Share shall be a fraction, the numerator of which is the amount by which the total Cost of Tenant Improvement Work exceeds the sum of (x) the Maximum Amount plus (y) if Tenant has elected to use any portion of the Additional Landlord Contribution pursuant to Section 12 of this Exhibit 4, the Elected Amount of Additional Landlord Contribution, and the denominator of which is the total Cost of Tenant Improvement Work.&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Hlk28456482"></a><a name="_Hlk28456645"></a><a name="_AEIOULastRenderedPageBreakAEIOU85"></a><font style="text-decoration:underline;">Tenant&#8217;s Obligation to Pay</font><a name="_Hlk28456482"></a><a name="_Hlk28456645"></a>.&nbsp;&nbsp;If the Cost of Tenant Improvement Work exceeds the Maximum Amount (the &#8220;<font style="font-weight:bold;">Excess Costs</font>&#8221;), Tenant shall pay to Landlord such Excess Costs as follows:&nbsp;&nbsp;(i) Tenant shall pay Tenant&#8217;s Share of the Cost of Tenant Improvement Work within thirty (30) days of Billing, as hereinafter defined, (ii) with respect to any Changes to Tenant </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4, Page 3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Improvement Work, Tenant shall pay for the cost of such changes in accordance with Section 8 below, and (iii) with respect to any increases in the Cost of Tenant Improvement Work arising from Claims by the Contractor, Tenant shall pay for the cost of such Claims as set forth in Section 9 below.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">Billing</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; shall be defined as any invoice from Landlord setting forth, reasonable detail, the amount due from Tenant, and shall include invoices from vendors and service providers, and applications for payment from the Contractor for work completed through the date of Billing, as certified by the Contractor.&nbsp;&nbsp;Billing may not be submitted to Tenant more than one time per calendar month.&nbsp;&nbsp;The amounts payable by Tenant hereunder constitute Rent payable pursuant to the Lease, and the failure to timely pay same constitutes an event of default under the Lease.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Changes</font>.&nbsp;&nbsp;If Tenant shall request any change, addition or alteration in any of the Plans after approval by Landlord (&#8220;<font style="font-weight:bold;">Changes</font>&#8221;), Landlord shall have such revisions to the drawings prepared.&nbsp;&nbsp;Promptly upon completion of the revisions, Landlord shall notify Tenant in writing of the increased cost, if any, which will be chargeable to Tenant by reason of such change, addition or deletion.&nbsp;&nbsp;Tenant, within three (3) business days, shall notify Landlord in writing whether it desires to proceed with such Change.&nbsp;&nbsp;In the absence of such written authorization, Landlord shall have the option to continue work on the Premises disregarding the requested Change.&nbsp;&nbsp;To the extent that the cost of performing such revisions cause the cost of Tenant Improvement Work to exceed the Maximum Amount, Tenant shall reimburse Landlord for the Cost of Tenant Improvement Work associated with such Changes within thirty (30) days of approving the Changes.&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Claims</font>.&nbsp;&nbsp;To the extent that any claims (&#8220;<font style="font-weight:bold;">Claims</font>&#8221;) by the Contractor cause the Cost of Tenant Improvement Work to exceed the Maximum Amount, Tenant shall pay for such excess within thirty (30) days of Billing. Claims shall include any amounts properly due to the Contractor under the Contract based upon the claims of the Contractor under the Contract, provided however, that the Claims shall not include any amounts arising from the default or negligence of Landlord, or Landlord&#8217;s agents or employees, under the Contract.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Performance of Landlord&#8217;s Work</font>.&nbsp;&nbsp;Following approval of the Construction Documents and Tenant&#8217;s written authorization to proceed with Tenant Improvement Work, Landlord shall cause the Tenant Improvement Work to be constructed in all material respects in accordance with the approved Construction Documents.&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Landlord&#8217;s Contribution</font>:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Except as set forth in this Section 11, any portion of Landlord&#8217;s Contribution which exceeds the Cost of the Landlord&#8217;s Work shall accrue to the sole benefit of Landlord, it being agreed that Tenant shall not be entitled to any credit, offset, abatement or payment with respect thereto.&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Requisitions</font>.&nbsp;&nbsp;If there is any remaining portion of Landlord&#8217;s Contribution after full completion of Landlord&#8217;s Work and the final determination of the costs thereof, Tenant may submit Requisitions, as hereinafter defined, to Landlord to pay for costs incurred by Tenant in connection with Tenant&#8217;s Work (&#8220;<font style="font-weight:bold;">Other Permitted Costs</font>&#8221;), as follows: </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU86"></a>(1)<font style="margin-left:36pt;">A &#8220;</font><font style="font-weight:bold;">Requisition</font>&#8221; shall mean (1) an application for payment (accompanied by, without limitation, invoices from Tenant&#8217;s contractors, vendors, service providers and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4, Page 4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consultants (collectively, &#8220;</font><font style="font-weight:bold;">Contractors</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) listing in reasonable detail Other Permitted Costs, (2) a certification executed by an authorized representative of Tenant that the amount of the Requisition in question does not exceed the cost of the items, services and work covered by such Requisition, and (3) only with respect to those items and services covered by such Requisition for which mechanic&#8217;s lien rights arise under Massachusetts Law, partial lien waivers and subordinations of lien, as specified in M.G.L. Chapter 254, Section 32 (&#8220;</font><font style="font-weight:bold;">Lien Waivers</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;).&nbsp;&nbsp;Landlord shall have the right, upon reasonable advance notice to Tenant, to inspect Tenant&#8217;s books and records relating to each Requisition in order to verify the amount thereof.&nbsp;&nbsp;Tenant shall submit Requisition(s) no more often than monthly. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk28456807"></a>(2)<font style="margin-left:36pt;"><a name="_Hlk28456807"></a>On the condition that Tenant is not in default of its obligations under the Lease at the time </font>that Landlord receives a Requisition, Landlord shall pay the amount properly due under such Requisition within forty-five (45) days of receipt of such Requisition.&nbsp;&nbsp;Notwithstanding the foregoing, if Landlord declines to pay Tenant on account of any Requisition based upon Tenant then being in default of its obligations under the Lease, and if Tenant subsequently cures such default, then Tenant shall have the right to resubmit such Requisition, and Landlord shall pay the amount due on account of such Requisition, provided that the Lease is then in full force and effect and all of the conditions to payment on account of such Requisition are then satisfied.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)<font style="margin-left:36pt;">Notwithstanding anything to the contrary herein contained:&nbsp;&nbsp;(i) Landlord shall have no obligation to advance funds on account of Landlord&#8217;s Contribution more than once per month; (ii) if any contractor, subcontractor of any tier, or materialman records a Notice of Contract which is not discharged or bonded over by, on or behalf of, Tenant, Landlord shall thereafter have the right to have the relevant portion of Landlord&#8217;s Contribution paid directly to such lienor upon receipt of requisite documentation from such lienor evidencing payment to be due and owing, only upon Landlord notifying Tenant in writing of its intent to pay such portion of Landlord&#8217;s Contribution directly to such contractors and Tenant failing within five (5) business days of receipt of such notice to (x) bond over or discharge such lien, as a matter of record or (y) pay such lienor (and provide evidence of such payment to Landlord) the amounts claimed owing to such lienor; (iii) Landlord shall have no obligation to pay any portion of Landlord&#8217;s Contribution with respect to any Requisition submitted after the Outside Requisition Date, as hereinafter defined.&nbsp;&nbsp;The &#8220;</font><font style="font-weight:bold;">Outside Requisition Date</font>&#8221; shall be May 15, 2021.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Additional Landlord Contribution</font>. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU87"></a>At Tenant&#8217;s written election (&#8220;<font style="font-weight:bold;">Additional TI Allowance Election</font>&#8221;) Tenant shall have the right to require Landlord to provide the Additional TI Allowance towards Hard Costs only.&nbsp;&nbsp;Tenant must give the Additional TI Allowance Election on or before the commencement of the Tenant Improvement Work.&nbsp;&nbsp;The Additional TI Allowance Election shall set forth the amount (&#8220;<font style="font-weight:bold;">Elected Amount</font>&#8221;) of Additional TI Allowance which Tenant elects to apply towards Hard Costs. Landlord shall provide the Additional TI Allowance to Tenant on the same terms and conditions as Landlord provides the Landlord Contribution to Tenant, except as set forth in this Section 12.&nbsp;&nbsp;The Additional TI Allowance may only be used to pay for Hard Costs, and shall not </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4, Page 5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be used to pay for Other Permitted Costs (i.e. Subsections b and c of Section 11 above shall not apply to the Additional TI Allowance).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Construction Rent.&nbsp;&nbsp;If Tenant elects that Landlord provide the Additional TI Allowance to Tenant, then, commencing as of Construction Rent Commencement Date, as hereinafter defined, and continuing on the first day of each month thereafter throughout the Initial Term of the Lease, Tenant shall pay to Landlord, as Additional Rent, Construction Rent, as hereinafter defined.&nbsp;&nbsp;The &#8220;<font style="font-weight:bold;">Construction Rent Commencement Date</font>&#8221; shall be the Term Commencement Date, if the Term Commencement Date is the first day of a calendar month; otherwise, the Construction Rent Commencement Date shall be the first day of the calendar month next following the Term Commencement Date, </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&#8220;<font style="font-weight:bold;">Construction Rent</font>&#8221; shall be the monthly payments, based upon the Elected Amount of Additional TI Allowance, equal to the monthly payment of principal and interest which would be necessary to repay a loan in the amount of the Elected Amount, together with interest at the rate of eight (8%) percent per annum, on a level direct reduction basis over the period commencing as of the Construction Rent Commencement Date and ending as of the expiration of the initial Term of the Lease.&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Monthly payments of Construction Rent shall be payable at the same time and in the same manner as Base Rent is payable under the Lease.&nbsp;&nbsp;Construction Rent shall not be abated or reduced for any reason whatsoever (including, without limitation, untenantability of the Premises or termination of the Lease).&nbsp;&nbsp;Without limiting the foregoing, the rent abatement provisions of Sections 10.7 and 15.3 of the Lease shall not apply to Construction Rent.&nbsp;&nbsp;Since the payment of Construction Rent represents a reimbursement to Landlord of costs which Landlord will incur in connection with the construction of the Premises, if there is any default (beyond the expiration of any applicable grace periods) of any of Tenant&#8217;s obligations under the Lease (including, without limitation, its obligation to pay Construction Rent) of if the Term of this Lease is terminated for any reason whatsoever prior to the termination of the Term of the Lease, Tenant shall pay to Landlord, immediately upon demand, the unamortized balance of the Elected Amount.&nbsp;&nbsp;Tenant&#8217;s obligation to pay the unamortized balance of the Construction Contribution shall be in addition to all other rights and remedies which Landlord has based upon any default of Tenant under the Lease, and Tenant shall not be entitled to any credit or reduction in such payment based upon amounts collected by Landlord from reletting the Premises after the default of Tenant.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Punchlist</font>.&nbsp;&nbsp;Promptly following Substantial Completion of Landlord&#8217;s Work, Landlord shall provide Tenant with a punchlist prepared by Landlord&#8217;s architect (the &#8220;<font style="font-weight:bold;">Punchlist</font>&#8221;) incorporating those items jointly identified by Landlord and Tenant during their joint inspection of Landlord&#8217;s Work, of outstanding items (the &#8220;<font style="font-weight:bold;">Punchlist Items</font>&#8221;).&nbsp;&nbsp;Promptly after Substantial Completion of Landlord&#8217;s Work, Landlord and Tenant shall jointly inspect the Premises.&nbsp;&nbsp;Subject to Force Majeure and Tenant Delays, Landlord shall complete all Punchlist Items within thirty (30) days of the date of the Punchlist (other than seasonal items, such as landscaping, requiring a longer period), provided that Tenant reasonably cooperates in connection with the completion of such Punchlist Items.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Landlord&#8217;s Warranty</font>.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4, Page 6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU88"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="text-decoration:underline;">Landlord&#8217;s Warranty</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord hereby warrants and represents to Tenant that Landlord&#8217;s Work shall be performed: (i) in a good and workmanlike manner; (ii) in all material respects, in accordance with the </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction Documents</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and (iii) in accordance with all applicable Legal Requirements</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (&#8220;</font><font style="font-weight:bold;">Landlord&#8217;s Warranty</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;).&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Tenant&#8217;s Remedies in the Event of Breach of Landlord&#8217;s Warranty</font>.&nbsp;&nbsp;If, on or before the Warranty Expiration Date (as hereinafter defined), Tenant gives Landlord written notice of any breach of Landlord&#8217;s Warranty promptly after Tenant becomes aware of such breach, Landlord shall, at no cost to Tenant, correct or repair such breach as soon as conditions reasonably permit and as to which, in either case, Tenant shall have given notice to Landlord, as aforesaid.&nbsp;&nbsp; The &#8220;<font style="font-weight:bold;">Warranty Expiration Date</font>&#8221; shall be defined as the date eleven (11) months and two (2) weeks after the Term Commencement Date.&nbsp;&nbsp;Except to the extent to which Tenant shall have given Landlord notice of respects in which Landlord has breached Landlord&#8217;s Warranty or Landlord has otherwise failed&nbsp;&nbsp;to perform Landlord&#8217;s construction obligations under this <font style="text-decoration:underline;">Exhibit 4</font>, Tenant shall be deemed conclusively to have: (i) approved the Landlord&#8217;s Work, (ii) waived any claim that Landlord has breached Landlord&#8217;s Warranty, and (iii) have agreed that Tenant has no claim that Landlord has failed to perform any of Landlord&#8217;s obligations under this Work Letter.&nbsp;&nbsp;The provisions of this Section 14(b) set forth the Tenant&#8217;s sole remedies for any breach of the Landlord&#8217;s Warranty; however nothing in this Section 14(b) shall be deemed to relieve the Landlord of its responsibilities to perform maintenance and repairs as required pursuant to Section 10.2 of the Lease or affect or limit the provisions of Section 10.7 of the Lease.&nbsp;&nbsp;With respect to any latent defects in Landlord&#8217;s Work discovered by Tenant after the Warranty Expiration Date, Landlord shall, upon request of Tenant, assign to Tenant its rights against any contractor, subcontractor, and/or designer engaged by Landlord in connection with Landlord&#8217;s Work to the extent necessary to enable Tenant to assert claims against such contractor, subcontractor and/or designer in connection with such latent defect.&nbsp;&nbsp;Upon the Warranty Expiration Date, any then existing manufacturer warranties related to any portion of Landlord&#8217;s Work which Tenant is required to maintain shall be deemed assigned to Tenant.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;">Tenant shall have the right, during the performance of the Landlord&#8217;s Work, to have Tenant&#8217;s Representative participate in weekly construction meetings with Landlord and Landlord&#8217;s contractor as to the status of the performance of the Landlord&#8217;s Work.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Miscellaneous</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Tenant&#8217;s Authorized Representative</font>.&nbsp;&nbsp;Tenant designates Richard Mitrano (email: rmitrano@frequencytx.com; telephone 781-315-4604) &#8220;<font style="font-weight:bold;">Tenant&#8217;s Representative</font>&#8221;) as the only person(s) authorized to act for Tenant pursuant to this Work Letter.&nbsp;&nbsp;Landlord shall not be obligated to respond to or act upon any request, approval, inquiry or other communication (&#8220;<font style="font-weight:bold;">Communication</font>&#8221;) from or on behalf of Tenant in connection with this Work Letter unless such Communication is in writing from Tenant&#8217;s Representative.&nbsp;&nbsp;Tenant may change either Tenant&#8217;s Representative at any time upon not less than five (5) business days advance written notice to Landlord.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4, Page 7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU89"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Landlord</font><font style="font-weight:bold;text-decoration:underline;">&#8217;</font><font style="font-weight:bold;text-decoration:underline;">s Authorized Representative</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Landlord designates </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael DiMinico </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(email: </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mdiminico@ks-prop.com </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">telephone </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">617-910-5503</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">Landlord</font><font style="font-weight:bold;">&#8217;</font><font style="font-weight:bold;">s Representative</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) as the only person authorized to act for Landlord pursuant to this Work Letter.&nbsp;&nbsp;Tenant shall not be obligated to respond to or act upon any request, approval, inquiry or other Communication from or on behalf of Landlord in connection with this Work Letter unless such Communication is in writing from Landlord</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s Representative.&nbsp;&nbsp;Landlord may change either Landlord</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s Representative at any time upon not less than five (5) business days advance written notice to Tenant. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;">Tenant shall have the right, during the performance of Landlord</font>&#8217;s Work, to have Tenant&#8217;s Representative participate in weekly construction meetings with Landlord and Contractor as to the status of the performance of Tenant Improvement Work.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Disputes</font>. Any disputes relating to provisions or obligations in this Lease in connection with Landlord&#8217;s Work or the Tenant Improvement Work or this <font style="text-decoration:underline;">Exhibit 4</font> shall be submitted to arbitration in accordance with the provisions of applicable state law, as from time to time amended.&nbsp;&nbsp;Arbitration proceedings, including the selection of an arbitrator, shall be conducted pursuant to the rules, regulations and procedures from time to time in effect as promulgated by the American Arbitration Association.&nbsp;&nbsp;Notwithstanding the foregoing, the parties hereby agree that the arbitrator for any disputes relating to Landlord&#8217;s Work or the Tenant Improvement Work shall be a construction consultant, experienced in the construction of offices/research/laboratory buildings/campuses in the Market Area, as mutually agreed upon by the parties, or, if not then designated by the parties, within ten (10) days after either party makes a request for arbitration hereunder, or (if the parties do not mutually agree upon such arbitrator) as designated by the Boston office of the American Arbitration Association upon request by either party.&nbsp;&nbsp;Prior written notice of application by either party for arbitration shall be given to the other at least ten (10) days before submission of the application to the said Association&#8217;s office in Boston, Massachusetts.&nbsp;&nbsp;The arbitrator shall hear the parties and their evidence.&nbsp;&nbsp;The decision of the arbitrator shall be binding and conclusive, and judgment upon the award or decision of the arbitrator may be entered in the appropriate court of law; and the parties consent to the jurisdiction of such court and further agree that any process or notice of motion or other application to the Court or a Judge thereof may be served outside the Commonwealth of Massachusetts by registered mail or by personal service, provided a reasonable time for appearance is allowed.&nbsp;&nbsp;The costs and expenses of each arbitration hereunder and their apportionment between the parties shall be determined by the arbitrator in his award or decision.&nbsp;&nbsp;Except where a specified period is referenced in this Lease, no arbitrable dispute shall be deemed to have arisen under this Lease prior to the expiration of the period of twenty (20) days after the date of the giving of written notice by the party asserting the existence of the dispute together with a description thereof sufficient for an understanding thereof.&nbsp;&nbsp;In connection with the foregoing, it is expressly understood and agreed that the parties shall continue to perform their respective obligations under the Lease during the pendency of any such arbitration proceeding hereunder (with any adjustments or reallocations to be made on account of such continued performance as determined by the arbitrator in his or her award). </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4, Page 8</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662756"></a><a name="_AEIOULastRenderedPageBreakAEIOU90"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 4-1</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BASE BUILDING PLANS</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4-1, Page 1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU91"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 4-2</font></p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TENANT/LANDLORD RESPONSIBILITY MATRIX</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqr1p20dfppl000008.jpg" title="" alt="" style="width:617px;height:799px;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4-2, Page 1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU92"></a><a name="_AEIOULastRenderedPageBreakAEIOU93"></a><a name="_AEIOULastRenderedPageBreakAEIOU94"></a><img src="gqr1p20dfppl000009.jpg" title="" alt="" style="width:623px;height:807px;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU93"></a></font><img src="gqr1p20dfppl000010.jpg" title="" alt="" style="width:623px;height:807px;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU94"></a></font><img src="gqr1p20dfppl000011.jpg" title="" alt="" style="width:623px;height:807px;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4-2, Page 2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662758"></a><a name="_AEIOULastRenderedPageBreakAEIOU95"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 5</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BASE BUILDING CAPACITIES</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Air flow to Premises: 53,000 CFM</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Electric Capacity for Tenant Premises and Equipment: 471,560 watts</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 5, Page 1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU96"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 5</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-1</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FLOOR LOAD CAPACITIES</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqr1p20dfppl000012.jpg" title="" alt="" style="width:623px;height:481px;"></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 5-1, Page 1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662760"></a><a name="_AEIOULastRenderedPageBreakAEIOU97"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 6</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662761"></a>FORM OF LETTER OF CREDIT</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 6, Page 1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662763"></a><a name="_AEIOULastRenderedPageBreakAEIOU98"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 7</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662764"></a>LANDLORD&#8217;S SERVICES</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Hot and cold water to the common area lavatories</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Electricity for building common areas</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">HVAC services to the Building common areas and the Premises (but excepting those areas served by HVAC solely dedicated to any tenant)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Elevator service</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Trash removal</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Snow removal</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Exterior grounds and parking maintenance</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Management services</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Building security systems and services</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Maintenance of life safety systems (fire alarm and sprinkler)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M706"></a><a name="_DV_M706"></a>Such other services as Landlord reasonably determines are necessary or appropriate for the Property</p></td></tr></table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:-7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 7, Page 1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662765"></a><a name="_AEIOULastRenderedPageBreakAEIOU99"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 8</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[INTENTIONALLY OMITTED]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 8, Page 1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662767"></a><a name="_AEIOULastRenderedPageBreakAEIOU100"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 9-1</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662768"></a>BUILDING RULES AND REGULATIONS</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">75 HAYDEN AVENUE, LEXINGTON, MA</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">General</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">1.<font style="margin-left:36pt;"></font>Tenant and its employees shall not in any way obstruct the sidewalks, halls, stairways, or exterior vestibules of the Building, and shall use the same only as a means of passage to and from their respective offices. At no time shall Tenants permit its employees, contractors, or other representatives to loiter in Common Areas or elsewhere in and about the Property.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">2.<font style="margin-left:36pt;"></font>Corridor doors, when not in use, shall be kept closed.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">3.<font style="margin-left:36pt;"></font>Areas used in common by tenants shall be subject to such regulations as are posted therein.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">4. <font style="margin-left:36pt;"></font>Any Tenant or vendor sponsored activity or event in the Common Area must be approved and scheduled through Landlord&#8217;s representative, which approval shall not be unreasonably withheld.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">5<font style="margin-left:36pt;"></font>No animals, except Seeing Eye dogs, shall be brought into or kept in, on or about the Premises or Common Areas, except as approved by Landlord.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">6.<font style="margin-left:36pt;"></font>Alcoholic beverages (without Landlord&#8217;s prior written consent), illegal drugs or other illegal controlled substances are not permitted in the Common Areas, nor will any person under the influence of the same be permitted in the Common Areas. Landlord reserves the right to exclude or expel from the Building any persons who, in the judgment of the Landlord, is under the influence of alcohol or drugs, or shall do any act in violation of the rules and regulations of the Building.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">7.<font style="margin-left:36pt;"></font>No firearms or other weapons are permitted in the Common Areas.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">8.<font style="margin-left:36pt;"></font>No fighting or &#8220;horseplay&#8221; will be tolerated at any time in the Common Areas.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">9.<font style="margin-left:36pt;"></font>Tenant shall not cause any unnecessary janitorial labor or services in the Common Areas by reason of Tenant&#8217;s carelessness or indifference in the preservation of good order and cleanliness.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">10.<font style="margin-left:36pt;"></font>Smoking and discarding of smoking materials by Tenant and/or any Tenant Party is permitted only in exterior locations designated by Landlord. Tenant will instruct and notify its employees and visitors of such policy.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">11.<font style="margin-left:36pt;"></font>Bicycles and other vehicles are not permitted inside or on the walkways outside the Building, except in those areas specifically designated by Landlord for such purposes</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 9-1, Page 1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_AEIOULastRenderedPageBreakAEIOU101"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">12.</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall not operate or permit to be operated on the Premises any coin or token operated vending machine or similar device (including, without limitation, telephones, lockers, toilets, scales, amusement devices and machines for sale of beverages food, candy, cigarettes or other goods), except for those vending machines or similar devices which are for the sole and exclusive use of tenant</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s employees and located within the Tenant Premises.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">13.<font style="margin-left:36pt;"></font>Canvassing, soliciting, and peddling in or about the Building is prohibited. Tenant, its employees, agents and contractors shall cooperate with said policy, and Tenant shall cooperate and use best efforts to prevent the same by Tenant&#8217;s invitees.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">14.<font style="margin-left:36pt;"></font>Fire protection and prevention practices implemented by the Landlord from time to time in the Common Areas, including participation in fire drills, must be observed by Tenant at all times.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">15.<font style="margin-left:36pt;"></font>Except as provided for in the Lease, no signs, advertisements or notices shall be painted or affixed on or to any windows, doors or other parts of the Building that are visible from the exterior of the Building unless approved in writing by the Landlord.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">16.<font style="margin-left:36pt;"></font>The restroom fixtures shall be used only for the purpose for which they were constructed and no rubbish, ashes, or other substances of any kind shall be thrown into them. Tenant will bear the expense of any damage resulting from misuse.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">17.<font style="margin-left:36pt;"></font>Tenant will not interfere with or obstruct any building central HVAC, electrical, or plumbing systems.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">18.<font style="margin-left:36pt;"></font>Tenant shall utilize the pest control service designated by Landlord to control pests in the Premises. Except as included in Landlord&#8217;s Services, tenants shall bear the cost and expense of such pest control services.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">19.<font style="margin-left:36pt;"></font>Tenant shall not install, operate or maintain in the Premises or in any other area of the Building, any electrical equipment which does not bear the U/L (Underwriters Laboratories) seal of approval, or which would overload the electrical system or any part thereof beyond its capacity for proper, efficient and safe operation as determined by Landlord, taking into consideration the overall electrical system and the present and future requirements of the Building.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">20.<font style="margin-left:36pt;"></font>Tenants shall not use more than its proportionate share of telephone lines available to service the Building.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">21.<font style="margin-left:36pt;"></font>Tenants shall not perform improvements or alterations within the Building or their Premises, if the work has the potential of disturbing the fireproofing which has been applied on the surfaces of structural steel members, without the prior written consent of Landlord, subject to the provisions of the Lease.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">22.<font style="margin-left:36pt;"></font>Tenant shall manage its waste removal and janitorial program, at its sole cost and expense, keeping any recyclables, garbage, trash, rubbish and refuse in vermin proof containers for Tenants sole use within the Landlord designated area until removed with all work to be performed during non-business hours.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 9-1, Page 2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_AEIOULastRenderedPageBreakAEIOU102"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">23.</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab operators who travel outside lab space must abide by the one glove rule and remove lab coats where predetermined.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">24.<font style="margin-left:36pt;"></font>To the extent required by the Chemical Safety Program, chemical lists and MSDS sheets must be readily available at the entrance to each lab area. In the event of an emergency, first responders will require this information in order to properly evaluate the situation.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">25.<font style="margin-left:36pt;"></font>Tenant shall provide Landlord, in writing, the names and contact information of two (2) representatives authorized by Tenant to request Landlord services, either billable or non-billable and to act as a liaison for matters related to the Premises.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">26.<font style="margin-left:36pt;"></font>Parking of any trailers, trucks, motor homes, or unregistered vehicles in the parking lots is prohibited.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">27.<font style="margin-left:36pt;"></font>Tenants shall not use more than its proportionate share of Base Building Central HVAC or electrical capacity, subject to the provisions of the lease.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B. <font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Access &amp; Security</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">1.<font style="margin-left:36pt;"></font>Landlord reserves the right to close and keep locked all entrance and exit doors of the Building during the hours Landlord may deem advisable for the adequate protection of the Property. Use of the Building and the leased Premises before 8 AM or after 6 PM, or any time during Saturdays, Sundays or legal holidays shall be allowed only to persons with a key/card key to the Building or guests accompanied by such persons. Any persons found in the Building after hours without such keys/card keys are subject to the surveillance of building staff.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">2. <font style="margin-left:36pt;"></font>Tenant shall not place any additional lock or locks on any exterior door in the Premises or Building or on any door in the Building core within the Premises, including doors providing access to the telephone and electric closets and the slop sink, without Landlord&#8217;s prior written consent. A reasonable number of keys to the locks on the doors in the Premises shall be furnished by Landlord to Tenant at the cost of Tenant, and Tenant shall not have any duplicate keys made. All keys shall be returned to Landlord at the expiration or earlier termination of this Lease.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">3. <font style="margin-left:36pt;"></font>Landlord may from time to time adopt appropriate systems and procedures for the security or safety of the Building, its occupants, entry and use, or its contents, provided that Tenant shall have access to the Building 24 hours per day, 7 days a week. Tenant, Tenant&#8217;s agents, employees, contractors, guests and invitees shall comply with Landlord&#8217;s reasonable requirements relative thereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">4. <font style="margin-left:36pt;"></font>Tenant acknowledges that Property security problems may occur which may require the employment of extreme security measures in the day-to-day operation of the Common Areas. Accordingly, Tenant agrees to cooperate and cause its employees, contractors, and other representatives to cooperate fully with Landlord in the implementation of any reasonable security procedures concerning the Common Areas.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_AEIOULastRenderedPageBreakAEIOU103"></a>5. <font style="margin-left:36pt;"></font>Tenant and its employees, agents, contractors, invitees and licensees are limited to the Premises and the Common Areas. Tenants and its employees, agents, contractors, invitees and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 9-1, Page 3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licensees may not enter other areas of the Project (other than the Common Areas) except when accompanied by an escort from the Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C. <font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Shipping/Receiving</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">1. <font style="margin-left:36pt;"></font>Dock areas for the Building shall not be used for storage or staging by Tenant except in the Loading Dock Premises as permitted in the Lease.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">2.<font style="margin-left:36pt;"></font>In no case shall any truck or trailer be permitted to remain in a loading dock area for more than 60 minutes, except with prior written notice to Landlord, which notice may be given via email, provided that, in any event Landlord shall have the right, in good faith, to require Tenant to adjust its schedule for the use of the dock areas based upon the needs of the other tenants of the Building and Building operations.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">3.<font style="margin-left:36pt;"></font>There shall not be used in any Common Area, either by Tenant or by delivery personnel or others, in the delivery or receipt of merchandise, any hand trucks, except those equipped with rubber tires and sole guards.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">4.<font style="margin-left:36pt;"></font>Lab operators carrying any lab related materials may only travel within the Premises. At no time should any lab materials travel in the Common Areas, except at the Loading Dock and Freight Elevator.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">5.<font style="margin-left:36pt;"></font>Any dry ice brought into the building must be delivered through the loading dock.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">6. <font style="margin-left:36pt;"></font>All nitrogen tanks must travel through the loading dock and should never be left unattended outside of the Premises.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 9-1, Page 4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662769"></a><a name="_AEIOULastRenderedPageBreakAEIOU104"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 9-2</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662770"></a>TENANT CONSTRUCTION</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662771"></a>BUILDING RULES AND REGULATIONS</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">LINCOLN PROPERTY COMPANY<br />TENANT CONSTRUCTION<br /><font style="text-decoration:underline;">BUILDING RULES AND REGULATIONS</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">THE RULES MUST BE POSTED AT THE JOB SITE AT ALL TIMES!</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Parking</font>.&nbsp;&nbsp;Parking areas are designated by the Management Office and are subject to change at any time.&nbsp;&nbsp;Construction personnel are required to park in the parking areas designated by the Management Office.&nbsp;&nbsp;Failure to adhere to this regulation will result in the towing of the vehicle in violation at the owner&#8217;s expense.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Access</font>.&nbsp;&nbsp;Building entrances; lobbies, passages, corridors, public elevators, stairways, and other common areas may not be encumbered, or obstructed by the contractor, or contractor&#8217;s agents during construction of the tenant&#8217;s lease premises.&nbsp;&nbsp;Material deliveries must be scheduled in advance through the Management Office and coordinated with the Lincoln Property Company representative.&nbsp;&nbsp;Contractors are not to use Tenant phones, or Restrooms under any circumstances.&nbsp;&nbsp;Construction personnel found using phones, or restrooms located in the tenant&#8217;s suite will be asked to immediately leave the premises and will not be allowed to return.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Each contractor is responsible for their subcontractor(s), and for the actions of their personnel including clean-up of work and construction traffic.&nbsp;&nbsp;No alcoholic beverages, glass containers, or &#8220;controlled substances&#8221; are allowed on the premises.&nbsp;&nbsp;All work must be scheduled through the Management Office and include a list of contractors performing work prior to the start of the work.&nbsp;&nbsp;After-hours work must be scheduled through the Management Office 24 hours before the activity will occur.&nbsp;&nbsp;<font style="text-decoration:underline;">Weekend activity must be scheduled by Friday at 9 a.m.</font>&nbsp;&nbsp;Contractors will not be allowed to work in the Building after hours, or on weekends unless the procedures outlined above have been followed.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All after-hours work must be supervised by the general contractor.  There will be no exceptions to this rule.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the commencement and upon completion of each job, a walk-through of public areas will be made, i.e. restrooms, etc., and any subsequent damages will be the responsibility of the contractor.&nbsp;&nbsp;The contractor shall be responsible for cleaning the assigned restrooms each day at his own expense.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU105"></a><font style="text-decoration:underline;">Noise and Vapor Restrictions</font>.&nbsp;&nbsp;Any work that would cause inconvenience to other tenants in the Building, or that must be done in an occupied space must be done after hours or on the weekend.&nbsp;&nbsp;Structural modifications, floor penetrations created with the use of core drilling machines, pneumatic hammers, etc., shall be performed before 7:30 a.m. or after </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 9-2, Page 1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7:00 p.m.&nbsp;&nbsp;Likewise, any construction operations causing excessive noise, dust, vapors must be conducted during these hours.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When construction is on an occupied multi-tenant floor, noise, i.e., radios, loud talking, noise from equipment, etc., must be kept to a minimum.&nbsp;&nbsp;On these multi-tenant floors, public restrooms are not to be used by contractors.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Lincoln Property Company superintendent, or the Property Manager will have the sole authority to determine if an operation is causing excessive noise, dust, or vapors.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Lincoln Property Company has the right to inspect work at any time and may reject work that does not conform to code, tenant&#8217;s plans, or work that may affect the exterior appearance, structural components, or service system of the building.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Mechanical and electrical shop drawings must be reviewed and approved by Landlord&#8217;s approved engineer.&nbsp;&nbsp;Prior to starting work, the general, mechanical, and electrical contractors must review the work with the Facilities Manager and Facilities Supervisor.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All panels and transformers are to match the building standard systems and all materials and methods used to connect panels and transformers must be approved by Landlord.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unscheduled outages of any utility, or building service is strictly prohibited.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Dust and air contamination are to be controlled with temporary partitions which are sealed adequately to prevent dust from entering leased areas or mechanical equipment.&nbsp;&nbsp;Floor sweep or a comparable material will be used when sweeping concrete or tile floors.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Clean-up of Common and Lease Areas</font>.&nbsp;&nbsp;Premises must be kept in a clean, orderly fashion at all times and free of potential safety and fire hazards.&nbsp;&nbsp;A general clean-up of the space under construction is to be performed on a daily basis.&nbsp;&nbsp;Final clean-up will be the responsibility of the contractor, which is to include all vacuuming and dusting as required.&nbsp;&nbsp;Failure to adequately keep the work area clean and accessible will result in Lincoln Property Company using its own forces to achieve this through whatever means determined necessary, and the total cost will be deducted from the contract.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Trash Removal</font>.&nbsp;&nbsp;Contractor is responsible for removing all construction debris and trash from the construction site. <font style="text-decoration:underline;">UNDER NO</font> circumstances shall trash, or construction debris be allowed to accumulate.&nbsp;&nbsp;Trash removal must be coordinated through the Lincoln Property Company Management Office.  No vehicles, or dumpsters will be allowed to remain stationary on the site.&nbsp;&nbsp;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under no circumstances is the Landlord&#8217;s dumpster to be used.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU106"></a>If any fire sprinkler work, or modification to the fire sprinkler system is required, the system must be back in operation at the end of the work day.&nbsp;&nbsp;Under no circumstances shall the fire sprinkler system be left inoperative overnight.&nbsp;&nbsp;The facilities manager must be notified each morning of the location of and type of sprinkler work to be performed.&nbsp;&nbsp; The </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 9-2, Page 2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">engineer hourly rate of $75.00 will be charged for routine work and/or extended regular hour work.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Existing pull stations and horns and strobes located throughout the Building will remain live during construction.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">It shall be the responsibility of the general contractor to complete all punch list items before the tenant move-in date or the stipulated completion date.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">All construction staging, storage, and temporary contractor facilities will be located in specific areas assigned by the Lincoln Property Company.&nbsp;&nbsp;Contractors will be responsible for the maintenance, housekeeping, and demolition of all temporary facilities.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Any removal, replacement, or repair work to a base building system to accommodate work directed by the tenant, or unforeseen interference (i.e., sprinkler head conflicts) which is not part of the Work, will be performed by the tenant&#8217;s contractor at tenant&#8217;s sole expense.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">No fire arms or weapons are permitted on the property.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Insurance.&nbsp;&nbsp;Contractors will be required to carry standard requirements incorporating both the owner and LPC Commercial Services, Inc. as additionally insured parties.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">At no time is any welding, or cutting with a torch to be used in the building without prior approval and coordination from the Management Office.&nbsp;&nbsp;Hot work permits may be required depending on the status of the project for all hot work including welding, soldering, and torch cutting.&nbsp;&nbsp;All hot work requires a fire extinguisher supplied by the contractor and must be in the immediate vicinity and easily accessible.&nbsp;&nbsp;Fire extinguishers must be inspected at least monthly.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">A copy of these regulations shall be posted on the job site for all parties to observe.&nbsp;&nbsp;Contractor is responsible for instructing all of his personnel, subcontractors and supplies to comply with these regulations.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">ALL PASSENGER ELEVATORS AND PUBLIC AREAS SHALL BE RESTRICTED AND OFF LIMITS TO ALL CONSTRUCTION PERSONNEL</font>.&nbsp;&nbsp;Under no circumstances shall the exit stairwells be used for access to/from the first floor.&nbsp;&nbsp;All construction personnel for this project shall only use the freight elevator from the first floor back lobby.&nbsp;&nbsp;Under no circumstances shall the main entrance to the Building or the garage passenger elevators be used for access.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU107"></a><font style="text-decoration:underline;">All deliveries of materials and equipment must be scheduled at least twenty-four (24) hours prior to their delivery through the Lincoln Property Company Management Office</font>.&nbsp;&nbsp;The contractor will be provided access to the freight elevator to be used in the &#8220;independent mode&#8221; for after-hours deliveries.&nbsp;&nbsp;The Contractor shall provide an operator during work hours to ensure correct and safe usage.&nbsp;&nbsp;Contractor shall keep the elevator cab and door tracks clean and free of all debris.&nbsp;&nbsp;Contractor shall be responsible for repair costs incurred due to misuse or damage caused by his forces.&nbsp;&nbsp;All major deliveries must be made between the hours of 11:00 p.m. to 7:00 a.m. Monday through Friday and all day long on Saturday </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 9-2, Page 3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Sunday.&nbsp;&nbsp;Contractor will be charged for having an engineer on duty to assist with deliveries when the loading dock is closed.&nbsp;&nbsp;Additional charges incurred due to non-standard elevator use (i.e.</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> moving freight on top of elevator cab) shall be paid by the General Contractor.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Your signature below signifies that you have read the rules above and agree to abide by all of them.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.15%;width:467.5pt;;">
<tr>
<td style="width:180.35pt;"></td>
<td style="width:143.55pt;"></td>
<td style="width:143.6pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Firm Name</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:____________</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 9-2, Page 4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662772"></a><a name="_AEIOULastRenderedPageBreakAEIOU108"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 10</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc504662773"></a>TENANT WORK INSURANCE SCHEDULE</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall, at its own expense, maintain and keep in force, or cause to be maintained and kept in force by any general contractors, sub-contractors or other third party entities where required by contract, throughout any period of alterations to the Premises or the Building by Tenant, the following insurance coverages:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Property Insurance</font>.&nbsp;&nbsp;&#8220;All-Risk&#8221; or &#8220;Special&#8221; Form property insurance, and/or Builders Risk coverage for major renovation projects, including, without limitation, coverage for fire, earthquake and flood; boiler and machinery (if applicable); sprinkler damage; vandalism; malicious mischief coverage on all equipment, furniture, fixtures, fittings, tenants work, improvements and betterments, business income, extra expense, merchandise, inventory/stock, contents, and personal property located on or in the Premises.&nbsp;&nbsp;Such insurance shall be in an amount equal to the full replacement cost of the aggregate of the foregoing and shall provide coverage comparable to the coverage in the standard ISO &#8220;All-Risk&#8221; or &#8220;Special&#8221; form, when such coverage is supplemented with the coverages required above.&nbsp;&nbsp;Property policy shall also include coverage for Plate Glass, where required by written contract.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Builders Risk insurance coverage may be provided by the general contractor on a blanket builders risk policy with limits adequate for the project, and evidencing the additional insureds as required in the Lease.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Liability Insurance</font>.&nbsp;&nbsp;General Liability, Umbrella/Excess Liability, Workers Compensation and Auto Liability coverage as follows:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:15.65%;width:399.65pt;;">
<tr>
<td style="width:166.5pt;"></td>
<td style="width:233.15pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)General Liability</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1,000,000 per occurrence</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1,000,000 personal &amp; advertising injury</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2,000,000 products/completed operations aggregate</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The General Contractor is required to maintain, during the construction period and up to 3 years after project completion, a General Liability insurance policy, covering bodily injury, personal injury, property damage, completed operations, with limits to include a $1,000,000 limit for blanket contractual liability coverage and adding Landlord as additional insured as respects the project during construction and for completed operations up to 3 years after the end of the project.&nbsp;&nbsp;Landlord requires a copy of the ISO 20 10 11 85 Additional Insured endorsement, showing Landlord as an additional insured to the GC&#8217;s policy.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:15.65%;width:399.65pt;;">
<tr>
<td style="width:166.5pt;"></td>
<td style="width:233.15pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)Auto Liability</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1,000,000 combined single limit (Any Auto) for bodily injury and property damage, hired and non-owned cover.</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10, Page 1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:15.65%;width:399.65pt;;">
<tr>
<td style="width:166.5pt;"></td>
<td style="width:233.15pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:34.75pt;;text-indent:-34.75pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)Workers Compensation Employers Liability</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory Limits</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1,000,000 each accident*</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1,000,000 each employee*</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1,000,000 policy limit*</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU109"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* or such amounts as are customarily obtained by operators of comparable businesses</font></p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU110"></a>General Contractor shall ensure that any and all sub-contractors shall maintain equal limits of coverage for Workers Compensation/EL and collect insurance certificates verifying same.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:15.65%;width:399.65pt;;">
<tr>
<td style="width:166.5pt;"></td>
<td style="width:233.15pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:34.75pt;;text-indent:-34.75pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)Umbrella/Excess Liability</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$10,000,000 per occurrence</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:34.75pt;;text-indent:-34.75pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)Environmental Insurance</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent required by Landlord Contractors&#8217; commercial general liability/umbrella insurance policy(ies) shall include Landlord and Landlord&#8217;s designees as additional insureds&#8217;, and shall include a primary non-contributory provision.&nbsp;&nbsp;Liability policy shall contain a clause that the insurer may not cancel or materially change coverage without first giving Landlord thirty (30) days prior written notice, except cancellation for non-payment of premium, in which ten (10) days prior written notice shall be required.</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:underline;">Deductibles</font>.&nbsp;&nbsp;If any of the above insurances have deductibles or self-insured retentions, the Tenant and/or contractor (policy Named Insured) shall be responsible for the deductible amount.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of the insurance policies required in this <font style="text-decoration:underline;">Exhibit 10</font> shall be written by insurance companies which are licensed to do business in the State where the property is located, or obtained through a duly authorized surplus lines insurance agent or otherwise in conformity with the laws of such state, with an A.M. Best rating of at least A and a financial size category of not less than VII.&nbsp;&nbsp;Tenant shall provide Landlord with certificates of insurance upon request, prior to commencement of the Tenant/contractor work, or within thirty (30) days of coverage inception and subsequent renewals or rewrites/replacements of any cancelled/non-renewed policies.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10, Page 2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:9pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU111"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 11</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[INTENTIONALLY OMITTED]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 11, Page 1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU112"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 12</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PLAN&#8212;LOADING DOCKS, RECEPTION AREA, AND FREIGHT ELEVATORS</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqr1p20dfppl000013.jpg" title="" alt="" style="width:508px;height:786px;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 12, Page 1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>freq-ex211_757.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
freq-ex211_757.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 21.1</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subsidiaries of Frequency Therapeutics, Inc.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;white-space:nowrap;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Legal Name of Subsidiary</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jurisdiction of Organization</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics Pty Ltd</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Australia</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics Japan K.K.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Japan</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics Securities Corporation</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Massachusetts</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>freq-ex231_1116.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
freq-ex231_1116.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="Background-color:#FFFFFF;text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="Background-color:#FFFFFF;text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="Background-color:#FFFFFF;text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consent of Independent Registered Public Accounting Firm</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the Registration Statement (No. 333-234128) on Form S-8 of Frequency Therapeutics, Inc. of our report dated March&nbsp;&nbsp;26, 2020, relating to the consolidated financial statements of Frequency Therapeutics, Inc. and subsidiaries appearing in this Annual Report on Form 10-K of Frequency Therapeutics, Inc. for the year ended December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ RSM US LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 26, 2020 </p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>freq-ex311_9.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
freq-ex311_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATIONS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, David L. Lucchino, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Frequency Therapeutics, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">[OMITTED];</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 26, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;David L. Lucchino</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">David L. Lucchino</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief <font style="color:#000000;">Executive</font> Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>freq-ex312_8.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
freq-ex312_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATIONS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Richard Mitrano, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Frequency Therapeutics, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">[OMITTED];</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 26, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Richard Mitrano</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Richard Mitrano</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Vice President of Finance and Operations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>freq-ex321_7.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
freq-ex321_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.03%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of Frequency Therapeutics, Inc.&nbsp;&nbsp;(the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, David L. Lucchino, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.03%;text-indent:-5.03%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 26, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;David L. Lucchino</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">David L. Lucchino</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>freq-ex322_6.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
freq-ex322_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.03%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of Frequency Therapeutics, Inc.&nbsp;&nbsp;(the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Richard Mitrano, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.03%;text-indent:-5.03%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 26, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Richard Mitrano</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Richard Mitrano</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Vice President of Finance and Operations</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g833164bawa43.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g833164bawa43.gif
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M4M:4>^^4>\ZM:YQS6M:]G-;GWN>4:\ZE8^^]<ZV<A"D8&/_O[V-28RDI*0
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MAQ C2IQ(L>+$ !8S:K2(D: 4"1(B,(D@@ "",0'&C"'YIB0! 0Q2CF$@H*8
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MPA>,2B@B-O&X\$,M-3;SPP_QI#@B+WZ\P(FG(A[SCPLI-#,I-K(<0\\+_BX
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MB?_B!Y!@*'X@5RAD6X'P+XL2"\? "7]2AW)(AVHR!4S5 B^ AS_0 K/8 C>
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MZ4?*4 Y%DS*@)F) >0-3$ 13X (WT(_<%01-_F((07!28Q9& YF4E7EO-T
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M$"+K\ '?<TO!9  ]79 @RJHE&TSF, &GB@NHO78S;&\I.@%"K0TC\9E^'6.
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MBR.XA!3X@13X@JXTSNTTSD!( 2I8-NPL0OO"R]'1 3_0!)U8,7?X!EGHA@?
MA;ZH#Y_\ 0R8@N(YF\,X@,WDS_X\@"G@N/Y\@ -@'IT$'L>H+,Q2T*\)@A_8
M@1=X4%;B!FP(!@*A'J)<34IT 15PS:_2 =F\DZ0(E%,8A;(Z)U-(KQ"-"AG
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M]+,N6QG >[W'NG$'=VU)>F44?+XG?$<R_!+.PPF9"\LAAF9XAG;XP/ET&/>
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MW/-0+U4 E:KL(=X>< ,"2$$*L#0 !$1SRY&2%"*Y-!DO.P>*;FG"-RB1#4K
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M.'B#B-G+=]0B=AX)>83'@W8GC^X8WBR,A5YH &CHABHE#+R >CKDA_P&?W4
M#<!G2\BG5=!GA9CH5D;CH*2HF$4>BRJGBY8D^4$!*SA #_0 #Y3")?WH@M*D
M=KK*&Z:7A+(@WO !#!R -=R"+HQG>2XI0KH #KS&>@)@)O0!LO1FEI:H39QH
M4E!E%'KI!([I?U:=;&D!">0 5%& FU[ D#U4G.[+:9H@:L+% 40!#RTHWKS
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MLQ(L$HC#41N#";" #E1U53=U+R!#G,^Y55_U5>L "[B "[! "Z#OT%X)T?[
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MG0:XXAA99@D*EU+H*.4'#CG$A42Q1-SS*4BP>DI%/UMD\<4*T')&G'%J-$"
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M87 L!5Q )XN,)VGL C$C*)UQ*$5*&H\2!$F&#(/%X@8 _"32!6  "':@#:B
M#TJFTWZ@!<:MN;PR.4HR4$ZR%J%+L<[@+ .0 6"2+=O2,/PQO9;Q&0$D$SK
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M\DL^P!2^S-0N5W0\"R)-NW!-8R %4F +:-3)\#/!]C-=6"!N$ Q8QJ3:"&
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M3J-G C# !5 Q%KA!&N0/10R@*^$QJ( V)<OB!Z+  !9  MIB ,H 1Y26^%S
M$5*@!";H@S;H<?TGEZC6:F7 %#H $K;V:WVI&0_J+O'CHV*SR$Y5;$]V-UW@
M=%M@[% W;D1Q[*ZLG'3" N[A&(X!'?*D-^@O;ZO%0C43L1R'E-0B%^ZQ<&/R
M<.>MNSY@$3 A#[;(QISW>:$W>FV,BZC7B[P($_3 "+3U&"O7#[1V$KEV<]^S
M(&YIU]*+M4(WO4;7_F3;*M*\Y $&X >4!^LX"2K9Q *Z#,%V0 \XP0^,E/T.
M=2MUUT5XUV?1Q^V@P)Y DWB-]^[88Q&B]7S!%A/ U-XP(0:2\<<8\;7DB[Z@
M1 ;N($GJP\?(E6&F:CXBDP*:;#0V,=NJL9R<Q^(>0 6V$:925PB 8&,V1/Y2
M8X!=9&_)TNTB]6?*0 !>KH'KS-;@<F%*]#SQ$M\H<#(0,GT9+Q6H*@8(AH(C
M4#Q394MK,\E2>%98^"&?K4=[%.)Z-%998&<PSHSIU<K(00?\1MSHQ(?U%F!]
M]U@#<'*,&(EC3HF5#VPSH8(GHB"EV',7T>FJ.!.:X HN05LU5@YHR:'$_C-,
MO?B$-95D4X "Q#@,HT?:@,O:ZC<J@<M&6)!VD6$'<*B.[;A:@!A#I;1GQ*!]
M"M&/CY<T3P53GY R0"%[J_;F[%(R--<@&"^C%.&11V4@Y. *KJ\+3W63.[F%
M W,B?_,$?R P W-(RT65KZ.5?QB/!4LED34"E/5*;9G%0%27.Z6,>MD(?CGZ
M5, $D* )P* )[/F>\3F?]5F?;\D$7F!J"08)/.,.8F">]_F@$3JAD6"A&;JA
M%_H*PM@CQO@O+8]DJ-D"*O(BL=DFZ(%(-X0/6-F;C^)?>S><];@7@"\ EO6<
M9PU$$6X3VKEJ7;,$(&$4[N .U$AT^NBFX4AT_FY:#W8 $BZ!F<  $D'J"_1M
MC?QHJ9DZCO@(=.Y !U;@!53U3<DX!$$93 @@_)Z2E$MY #HZ $DMY&0P)?L5
M*UXY2L\@@4_I]UCIB%E:LEP:V6#:EQ<C#U[ !*)VKTO'$93$5(!-A/EZL =[
M!ZA:7:\:1]\61R\@HW&4MTP1"+2Y%T[& @)5I*T3G(%*Y0Y %]XA%V@$1^ Z
MKIEJKA&MKMWYKJ,@$*2IM8LI\:B$D5U[MEU;$40(L2G:A:TQACD)RE[J!Q#3
M;B8[IS+$@($JK1_U ?Y6"J2 &E#,.TD[B?T@$TI3^RC8B5TS"D;!HSPUDYN0
M/'U)@BTY?<<[=,4K_A!2%;>+!RE3<"D'H"E-!BH-0"KEA@ ,(*Q[H4Z*VQ;9
MS%]30[.9J\W.H SD(@!JI'"3-KJWJS"HNR:1[;I/U$BB@$PON<(W8TTM/,/U
M:SXZX+"M.K<?;IPP(!0K[N)^  -8( /D0!9DP1=*H:4N>S.+@ASKJL9MO#?H
MP,U*>J>$Z@P@H"*DX5P@P' 5')V5,/FLVZXIXA3\6IAI<Y@+PGFW[U0]W#YM
MBQJ[J67GYF7C&V/FIAL/K!-4H1H@H;)9T18G !<6E5'9_%!SSZQY#PK(Q1>$
MO(^+?,&/#\E?&GNIEKM]25,TP:\7*DJ:,&3),W3)^[0U-A!<0%6QQ).!_JL%
M0IDP47#"9&+;!@ &^  #*JU94@X7># LAFK'>7Q#UOK]"@!=[/S.)RL!]1SA
M3D$/^CP+-<43<, @"=V]#)V+G6[7+RN!4N"P'[V%,V[\1!S+F-9=U6^<8. *
MY'A#0'+=2,V_M0+ F6M#J$#.]Y@7C7BT6?V)8.#(!>JENTH58F<*:4R7*IE<
M-QP^#<*K5F /6J$?^J%&;?3[)DW+O22F>F7+008J*N >?J$9J@':0]IW<8'4
MI^( M*Z'C9M/3OJQW,?;O]V)PGT):9,*NTK/B.2S<IUKU=G=F6\#H( 51*,?
MQO;*I^X,H@=^)7V%@.M+]&8GX"$6#M3@62WA_H<(*AI^X:.T]Y)JI2O>G^IM
M V&% PL]? \=RN_MEC2@ 5B!WE->-_$=*@:@!8+C)>I*YJ='#SQ:W,K:%D&=
M0J,+K6_ 4(/@!P8UC\T"<GP!^%;)G(>>LG"9Z7<9 [G4[O<+?3O%Z5EA5MJJ
MZJ,'Z_,0AMC$$[X>IW(^U$=Z*D8=]K*%[#?;[3SS[9F  .5^[IW(M%_Z'Q]1
MZ<<[JGZ2^6)  _[^9#_"V7)K @8?T[\:N%0P)1#_0$\&QW->@'L(*; B.LS!
M 'X .)(;"&UA0UE)\XF^[NT^($DXD=G=N[\;\HS>[Z.^=)WM0Z+G$Q4[^Q>D
M-29 %6P>&>3PQ3^=_DS\>ZCZ]@6JTUAAA+&T(1H8P"T,UOCYR2V3/Y$3W>9$
M%=%']G-I4_HG^B$!@@6+ 1,J3+" ,*%"A04G3.@6"QLR.@]*T;F(,:/&C1P[
MTBG8(HC(D21+BKR! 1(N/@XG>'P),^.$'3L>W"   $   00(1 B0,ZC0H42+
M&CV*-*G2I4R;.GT*5>D+/TA*8-JT*9/6K5R[>OT*MBO6L6&W9BV+-JU:K5C5
MMEV;=I.,&!I8M>I'Q &1O7S[^MW+*H- @@\>M#R,N*7!A[&.(2M5\0#&Q XG
M'_X8<S(N# \@3?D,.O1G2#L.H(14.;-JCS-K4C'@()HY @-\ HV*.[?N_MV\
M>_L&\.+2D3Y7SW(=^Q;N6N1QLR)G+I8LV^?4JX\%E2F/]*V8,&5*GMPK=.MM
M0<F-H:55J[UZ_[KG&U@@A D#ZMN_C[\^_0'D9M4R5DI-#TB666JK?30!+COP
MX0)-&#P(X8,7["#2!%1@8()+!VYH&4T/P'# +K\X0T%M/_V&8HHJKLCB4,$-
M!P98SRD'%W3+42>>C<Z9I6-XWQGGEG@\1C>==.=IH!Y[[[WG0'PN6'!!E(9,
M26655N[01ANDK?!#!3N08AAE8HH)DT,*[M"".6.VA-J%J'$(IT,T54!%*;;$
MHDN)MK7(9Y]^_EG4BR5<D4HJ9A%Y') U;E=6_G*%/@III*E@4BBEDE[Z: PQ
M5-I==Z><H@FE0G97*"C><84=**#DT6FKF$:*B1%8))G7DGPYH!>NK*Q@082^
M_NIK$ \&4<$%+XS&@DG*+@N)864F2-,/&G8TP0%M8M@29G ^*^<.%=SPP9VZ
M1&#B;8">BVZZNL'PA1(J?'')'Z'\B.B0-/[HHXSE?<%OO_[^>\*_ OO;0<%?
M=" 'OQV<X$?##O?1QQ\QR&#<)DCH<0F_<G@B@U<Q_.%'"GTXW+# !O>;< HO
M;,&*DK;VU0 K4F1@; HVWXQSSCJGH$<YR!@31+(8T$1TT48;S4<%4^Q@($=F
MTM3"M$Y;:V%*%56[_JUJI;1F6KC8>,- 3PR8JV[99I\]% Q]_ "#$CJ4H C%
M;BEZ8[Y?D86)#GKOS7??)2BAR!]]#Z[W**/HK8C>D)3 >.,P/!Z%$C+DP=41
M#7^@Q D=:/)=YS*X6X(*CS>N0@HTZ+W/#H.GH,,.*K#L\LM$L)(#!QS\@$$&
M#B3 >^\)]+-'\ D([WL"#H 2BRS*_-#"#Y L"WT0SU?0 BY2.]T:FFM^1/6%
M& 3Q@[99L];9 3]0"(.=L823A@ 12$ VVO+/_R<,+[S0MB(OQ$WWW?TW%QU&
M38=27[B"I@Z(0$U=(1 J !P)-I"*!$IP4U=X 20B.,$K&% '$\L#Y3(1_@,Y
M=  25^A "?]@*++$@(,3/*#;_* ##*9"$3?0@2)>US(BK$=V_0@,%$*P@@QD
M@!4M(Z(16;&% ^1@B2PK8BN(N(F(((-H%4#0FA"S@_.YP'I-VPBTS/>]Z 5A
M!Q"X01 F8( I(&A\U$K0#_CP@AWT@0I0N-,I L"$,01 "O3KHQ]9Q"Y(P$!O
M@*"!W !X+Q_-*#J4N@0FD( OLC2A"4C0 2 4H8=.@($\63D5$OJ@"+3,96)8
MD0$F+A$(3"@B!AU PBDX\848M<44IN@86$RI S],+!.8D($IHM Z$L!.A[(C
M0@\S4(# ")$5>'% /Y[9I P$P@0=",00\?+,_MD10XI$PX5%+/.2UCQ@B]EJ
M(RY4<K1TTH0/*#& .2"Q1C9Z<0(/../Y^ "#<.%)"A+08_S^"-" 0B4X.R"!
M(N[ P<[=:Z$UXN4=OD!*L60'A#KXQ"?NH%#_E;(3H41+#.[0A$X>+!5(& 4K
MKX*)@J6B8S*X0PR:X+_LY#(&"DW%X3J0@F'N\&7'+,#,<L?,O.BE%0EH10:*
MVHH]K""H#E@/*Z(HD3,]0";E=-I'=A %+EY/(RY1IU<Q<(,?B"1\791G1@X@
MSAN4XA:R"(<$(A !/0ITKG1E"@R$LX@C9*()IZ(70_^JKTR X0Y_, (D/_@=
M#YZE.QD-K P$9TO$_FI%.[SL0 R0$(-+=, [,EAE!T)J2HR1U!-ZB)&,9*K+
MSE$."5=@GDZ+2<0,: $**AOB7G;8@"T4 )D%.( #EMJRILX.JH_!16$X)*>L
M5I4U5T2,:5I0@:N)SZQ>]- -('"-:T0C NZ#7UV_"]ZTG6 XQ:G8_P#+4.1@
MPA3WN((MV>)!?/DU+.:Q&$<C::2LA&(55_C#%[PC%QHLT+2\I,$EKO %5;!E
M.AGUQ$Q5BY48_. 'KUV27HBX!9ME  M\6,(.<]6*)6PA P?0@A8.L-1<Z8JX
M%/GFAI*[F*W.4\8=V<$+SEA6ZLK$NF70B00,4)NQA7?(WWU!"JIRE2+9_@B]
M3.X<)N[@R(X),*8!K$HHK8.J46CV5')11 F+DXG07D(/?:7O@Y,CX194V#VX
MNHL'.) #$3<U9GC)BP^@@(40D-AV*&:%BI^X36QTXP!5W-9,HA!C'5]$3G',
ML:*OZAH"+$ ":0#RGHB,Z8 :&<EGJ4Z3/YV=)H#!P#$ \'GME2B+P0V_VP&%
M#$X1"DR$]#N=_;)Q3!GKQGX%%&<V3IK7[![@F4 +"8B9GYN$322>.,XDGFV?
M<P5-) 2C&<8X@(N1B]5$/YK1.*8Q=5M3"K7VPAK.0,  RA#73*O;CYNV2J=/
M#>I[8:<ME;Q$"O\Z%BLKU&X2[;*M%\S+SIV:_M>I!=*O<[C3OT!S!2E()GMT
M5<0,<X#$%S@ !PI@@ PHH#W&[(<#=*"$-UFQN8G)]G)US&U'?]M#=9)%++Q!
M+@BD>]TT1UN[DSS?>'\Z*S)(A1[T0#FZ\;O*JW[W:8]3Z\T*?<JH.C-7#GY;
M6_5PQ"8H-C29&?$40 $*NX4"![  A0S<Y9D]Z,<6C)J!.'IU[=T,0A&T_6@$
M[< %&%"Y/,5Y!GUZHT3H_F?-__ZGJ7 ZDCK_=*%6R$$NYVANJKXR@ZG,EJ3C
M/(!E(3A-#>Y:A%O8F3K<00<2P$QD/]/L'<@!%+:P BCD0 -0^$$!0C""?HQ@
M"2$ @3P^\8-DB5&,_FC2JJ*E)B<7!&&ZOZ=)*?)Y)[!!0 !"!KSS 757\DXT
MD<;1#KR58YQ4=" 4H2@U>JFC[^N+1_+BW[73.Y=F"N2PSB\C(@=2L 0B.C,$
M]!]!"/H1@BW\0/4?R '\\[\%2^ #.0 &\V ,?> 9NK=[RS(%SK(:V\-5+M$2
M+- "<=<A.Q!N^G0*[?,^?O=\'X@B+T(<F8 ='F2")XB")D@>H)9].M $J\)D
MX%=TB41^#&5Y^P9"S*-^>\%^[9< . 5Z#K %(< #^?=,6Z!_#[!$!_!_2+@$
M4* %.? #*Z!VQD4@JG$ !()6WL9&AW$ %,(T%BAWKE%'L7 *;S4V'@B"_FNX
M&\'! R4 20LE W-(AW2X<]EW!Q1C?4V6;T57?F91@PMU@YV6@VJV?L64%ZR0
M +=C +RS!#RP!"/0 Y/8 SK0 3\71!0@B2,P G@  GA@ FEG7*5 ("27&I=1
M)HMV(*40$N S1L2W;31Q ,AGA@$ /VK(AKD8%2\@."6@-P4#C,$HC,"X-ZNP
M"HJ C,D8='^8(YOP0:FP"@+'C&'1AU<V=(E":UZF=#9X?EDA8136 #R(B'G1
M  J0 CC0 3NP B:P J%P#L, C],P"[. #CJ0 4KP#. P#-/ C]Q0CQ5(BF(X
M3^9@ #UA  >)D GI3A, ":WH G9G5EQ#B]WP_E:WJ(L7N1M<X B0\ (VI .&
M Y(A*9(BF3A^<#_WLP@I-(VI]HQZ((U\B!7A=XU#XF_;*(C="$(F0&$YQ''%
M]$0FP EZH ,K$$3HX'*Q@)1(^0VJH 4Q\ U)F93"X _2LFBFB!A<528',$8+
M*!(8, 4XID8".1DT$014< "Z\ Z8D 9PY5T8Z990 0,E$ B#I ,_IS<_AY=Y
M*92#8P*!@#-^(%F Y8Q:X7.'M)(:)9/,6).3MRB#N&"IH#(.ARL]*75[P JK
M( NV4 X-^0/ED)FV8 N?^0NCD &*\ N@B9JV< O^P#02*):+A@M!$" >\@"X
M8)NW>9L/L ,W< 'N_@1/7!B1-&$!5( 34M ^Z'8B;ZF<=N4'1V 5@=D5*6B"
M6\$JO(0$8!:#+:F'NI9>,>F'BAF(V+<)CODCF& ",* %?C:./$A4\X"4R; #
M0W,%[9 -SI +FA .X9 +62@-N> ,FJ )_AF@6P.<O[<95ND0-Q 2642@8LDU
M-S%I[6,B8["<%9H4T6<5W+DH;S&3RZ&=SMBAC)>8V!>>C=F-%M-:)'  =M&#
M[Y%-K%  *[ *=Y(,I$ 3WC1RV4(9\?2:EG&@(T<^-V "7N* #LIR$R .XB -
MM&$ R6FA3YHVPC&"8=$J5<I8CQ=O@YD)J: #>ABBS=%X\E4C);H<)'BB_C)P
M!5"8 CEP%\:40W[!3,^$1"FP DA H[-Y;:I8E3U:(#]:( =P(:AHI*Y1"BX'
M<P,@<[@(I6\) WX@#<2!(V@!'DN6G839I2!ZF,TXHF.JC8Q9IN192D90%UA
M NDII[72%W&:6QU@ 0F !W=JFU-U5GMZ$5EHJVC%IS+AIS%1+2BAHZ\);NF3
M?.32=XMJK,!!%>Y6>*A&(UI:F(.9J4KFG=8(GIZU2=R8 C256*44 QZ@0U!
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M'D2T PD@!3HP"\P #X\S!3?@ A?@/"8 7<JMW 9 $TY^H%6UHPDJW7,,;BK
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MLX[K: )33_7L.(55C_597_52_P-80)16K_5A7_49(/7L6/48\ (4(%0@#Z>
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MO%-R @-*[B##(C&[9<W@+:-.?@&*1 %'W0 &_B9EMTS@%5CC'=T G=WF(/:
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MP(7AQ8$)-W\"#6ISPHL'YG"]B#!AJ4^A0B<<B(*AJ=.J5H?&?'##   I# A
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M$"JZB;_\^ANA#"_<0!F_CAX&J:0[DECBI:%I2DK#'.20 149</!?:ZF^N*I
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M+4/0>]1E,-$'%1ALAW*CV\*VI[U=,20'*5"!^":%@AIL0 GG2Y] 2.0B$'A
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M=(!R,F4"!!BK <IJUK,:P!S7.9T^H;,>4KSC'1.0@ !$:#P+",$ ;6C#*P
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M%&2 !T01!ZB I52,0)B !Z0 ;Z#/BZQ(^FS$Y&A/B63 "R2@]S#>Z"W$!M1
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MG^9D+,GD$?C!'UR(B!(19P0.0O12C&1*!]2 %K1&:Z A0FQ &I&($DG:!NQ
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M "9TP"5@@@R87RX=_JH7%MJ'9(I"H$]KR.MJ.2H7B<:.5&6)Y$;A=&W'F(;
MNEM6=@ D'.P/J, +J !O).Q = ##)HEWX@1X6@L=L [!N(!8X0(,+(4/[(#J
M3  /^( /(!+/_$"PNM?#M<,OW (F4!P$L&S4:(4*J$ 4>&1]5,!<6 $4+$!<
MR$44/*C0(@_1,N/KPJ[3:L*@(@K@#1%D^ &'R,8PP<".B$@OH6&0>,:E+I'P
MJDAIJ :@J4C@D&J,;( *X(MP. *^@,#D'$#=/J!)+.SF,)T_*A"3&M(%J $4
M^  IN  7^(3AEE?3[4Q>.IS(XDS)0N32.-\ :"Z:*@@$_  "B$$!\)=?_BQ
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MAJ-QOGPXB#.&]%#/<%N&PF1 ( 3:K?R4&BE/_YQW<:1;!A1V_0A$%.4XN.7
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M!<(.M$DDC;Y;I\!@F/[I,\8/K3YQ6WMU>X:HRO[=NG3=#WK.U:.DJE3"_G[
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M)>C=W<MNZ 8N8"AAAP<0/2"TB3IT(8@=I@A1"(T8NBB( QXHQ?>RW?7S# @
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M =P0*B3  "[@ B;@ KPG ":@Y-(2<5Y@$92 !%QN[DSF#O,@$S A+I-+[U:
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M3N2BG91@CQ52+LJA%KKA"8-YH+%/H(VW FZ %#9!'+QO,IGW!$* A4)@"3[
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M@\[V\#I)AH1XLAK>X3\"XBE.XDN"SGZCR:6$)29 #;C [*= .6P+"M8>"OC
M[=T>"BZ@@U4>*KR6Z.U3Z!VM932A$,W7U#TZW X(-C/!%/S@"\CZQ7I^\,/W
MK$,WN5(]!9C^+IS^6A)J$&7M&VJM4J[^SQU[J"]RZT.+*DNBV:B]VE]  5?
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M16K'A1VE7@:U"5,FS:&P8\<^< /#:MFX)Q1%#6.?KEX4(@@/$+9MV@A<PKR
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M,$(.W8,V14;LFGOIW]O8YA"V/1)8*,#(2""Q&Y184G"8S"1K8+*#E*U,95'
MHCI?@A(Z*"X6QV"*4[BWEC@*H P$D&49RA !,;CRG^ :  0,T,HV!C2A"A7
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M6+G"J$8$J=WTI9"5 QOPEBEP!V::"U&4/'G'/&VJ&WVG&^908%NDFW.:H[)
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M*> '+Z "*Z #N=L'?M##/=P'0 S$/OS#05S$_D9\Q$<\Q&1+MV#@K#)  R?
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MHE%(%*/95SV1+PN>DMH$>C 2>G P\O/"7*/>]94$@1!LX&!!N2"OR.,\+_
M;UU4F56_5"#7J6@44ONJ 56$U(%^XFS'TV'@_K&0"62 SO0&%6,P!XB@#G/P
M%!CLX%&AF=L-GIEP"C/L"8_*->]AX8M*4SIV%QSNX5929'J SQ"YVIZA1,['
M,1:4#:'JXC">WV.&(3!0"O<YUV<BM<>@?D">;?"&F$>90HS9X%5A%D*>"?!'
M%<0A %0 !Y3)!?SPY% NY97J._A  S]$95BZY==JU5W^K8L%YAW.4TD&&(IP
M!ZOCH1<#=VR9 1IW NAP#$$+1=('YS'^9EX6!'0R)R;@ BY@ ,O6C@^@YVF
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MF/:V=Q4GF" %D)#&8;I5NO.YKTUH.LM?@L Z$[)E+!5H6[C2,#\2$3!&$+C
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MO6I^S&A&KGH59&_"10QE05:SRC4CD7E%&]0ZF;.ZMFXN4$$@7J #WO96!S0
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M?9@'ROR!*3A%#)#,:\=V5!3/]S"!%[C3I30 7X.!CO*\QMP!:M^!C@K1YZZ
M3G 9.A%:C1TP B@"0C"[+""!$%  "8""%V"#4-=/Z[W>R/F#+[#@16::1GYR
M5T?7QS*<6-<>S"*!%,AUJZ@!#@!MK/B 0,@ /^B$>[B$>[B'3CB!$_@#?,@'
M>+ '>X %:+ '.4BQ9CB&78#O\1K8,_[P+V29&W6!K6J!^J66%ACW;%;(LS@
M7"A,X74=-'5W/\LO>=\O 8"_6F: _!0 (8 #O=[KCK!>++4@3/B"#O"$_H/_
MNZCX*:<M7\MN@JEU"L(5& WZ  ZX]0^HOA-(C^1<@118@0-/@1K0 "VHP VP
MBBLP D4P@@Y( 26@ 6:(!6'X*,N47Z2DKT]Y'QBR>1: @9]7GQ1J:S8%>C)N
M"Q1U=#3M Y=9!ZB\6-J3^B'H@!#(3]IXA=U @*WWB*Y/>R21T"]@->XB9+/7
M1K1W9%A;>_*%>&WR@"30@!200A3@@ [(> !'_ [( 0_8  [P^P[@  ^HON3'
MRP#/ \:WA1VX5?D=F;78U1->ECW?YEQ5%L00V/'RR>4VH[3^?)$1?[$VZ0HH
M_5A8AY6NX_T"" )##BP 8#!  (,LPJ108/ A_L2($B=2K&CQ(L:,%U_XR50"
MS*:0(3.1'$GR),J4*E-Z.I$"Y"90)4^:7#F39)Y->3+%<(2IILV@0H?:W-1$
MCXD.,G1N(@JTY*88*5YXJ&KUPQ42'7*<L.K5*HH.8L%^^,"AZPH5)J!H< +&
M:HQCL6SM:($K2) '!WX\H%/J :[ @G'II0,X\([$A/4"WH%KQXT6/UZ\N/%B
MP@0ZFC=SWHRYQ8T@F3-W+MUYPH,7.S";-CTA<84^<M.ED2 !H<;<NG='C/!
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MS9+'$(I>'\)O>7B'[M+OZ2EB",G E>C!'622)P0GO4%'LI*+#O@!9:A VG4
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M%ILY;0F\S0\8R-5V98@E@>-F@)YU  T,X"Z!& I<\M1^' J,6 :\@ X< (6
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M (^=&C,5(G\! (5SQ/AU N8T-PX0!5LOL9E%4CQA@L02%$#! ;A*&5D "UP
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M S=0*.L0_\!@,S(X=ESC'_Y,:4!FBCF6RI0._O !TKLYP$M/U)=(6H6_&54
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M@T>:L+2F/2T%VEE!_@::DCL-U@D%']  O'#W A*XJVM900$)8 4V"S1O A<
MF/,>=+RT\:M!TON%:'*!O0?,C6X.N]OW5!0JSSQ &;NPACG0)X!4\2\UIYG
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MJ=KL FRN GX 02C)_S!ODE8K0:!J+)6!GN@ JT"I(S%CZ4*D%.R0!>S0UI2
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MH.JR4KD,F6$2!,F]$H6O8ND+9;*@10&!B$(6LF %'-AJ+!B@G59$0B)<!6
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MGOF9HD0 0% &,!4&HA4!+C"(6O$ <' &:*"?:$ (17!F!J85!9 %)"!::O<
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MVN $B!JR[0,-4C"A@PY^\.B'#AI*0H,3=GOAA[GP?#(A%-R:M+4.0$!+@PY
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M3PE+2), &$):A>""(,34@BI006G9.AZW$%*KL$&H(B'!FD4Z(*"*F.!K)-!
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M9O3NE;Z$4ID'"%@@"3YJ1@+P+X#]K"461.%DY"54"A8LE"A\P <\X($?_G0
M AY .A [* !-=@"#U$'!"C<X;0V!9)H/U( $6/B $EZP(]3PAF(U;J ';H-$
M;W+ ;38&03(%EI@@,[<"HP5CB_[6&- $P05!,*-T[>5%#%P  AA@C 4?@($'
MU(W5'E"FJU$S$!U 00DEZ,.)#1(2(^4H0#HP[YOA?&XXR[FO>!P.%#1@I+F0
M@(+2M0 &_WQOU?V #P!80+_[#5H%W" "9V*!!#Z;F,^Z) (O&("97"*% %Q
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M60D6U$ 9)U@S]:K#-KO#/-Q#X=LK" " "\C$0MQ&0E2 )7B0)5" FGC$2!R
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MK G&4M+NDPD(" 05,,[\! ]S[$\L@8#/(#UL/)'2#)8"/8C(,:I_22:6*\/
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M\C'".9$+11U3%# B5Q/9VI(5'Y&<>^F4 YB"K]2F*3L1ZK*@5>S0+UR5-6W
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MF&-^^828/7!@ $;CY=>FFV_"^1$$;/JG5$@'N-#?1^O]()($4)P0Q1 E<*
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MV!>K"C?N@08I.)P"WP<<B0$$%KQ 6F@_[&QI3;/,;1Z  <VY  .IP4#_/';
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MM+D:1J2G:@!=ZH(XQ&V*Z0 :M2<#'.  "$B  A2P@ 6T.,8RGC&-:VSC%B<
MQ0Q80 -N[&,:I_@ !4@ D8E<@",?V<A(+H #B@Q' T#@  ;0EY2E3(![96$Y
MRUK.,@0D  $"2*#$$9C3F.\U)^P*8  2($"7R4SF 9CYNF2^UP0$D&4""( "
M#M@SG_OLYS\#.M""'C2A"^T  Q0  16HEX@;[>A'=X31D*ZAI!]=Z4EC.M.:
+WC2G.^WIZ@0$ #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g833164dsp1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g833164dsp1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( ", 30,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /?Z "@ H RM:\0V&A+ MRTDES</L@MH$,DLI_V5'8=R< =S
M0!C1^*M5DD+CP_=>6 LI@S$;A8B2 Q3S<\D'''8T ;6A>(=.\167VBPE;<AV
MRP2KLF@;^[(AY4\=^HY&1S0!J4 % !0 4 % !0 4 <$VF6-YXH\07=Q%>&_:
M9;43P7DD"V\*0Q.H9T=2H+.6XY.2.<4 <UI%S-:_&S4- 6Y,T\6@);-.SLB[
MUPZL5!ST<?Q9'//)H Z*RM8;#QQHUQ;V]U;W5Y'<07 EO'N!/$HWK(&9B2JG
M;@D#'FX[8H ] H * "@ H * "@ H XOQMX"/B:VNFTZ_.G7=V(DNSMW)<QQM
MN16'52">&7!Y(Y[ '*R?"[6&U>;5T*IJDZ"*2Y_MN8EEQM(/[C)& .,]L9[T
M =AX,\$#PS:6CWU\VH7]O;BVBD*[8[>/C*1KVS@98\M@9[  '74 % !0 4 <
MGXIL/$]WK>C7.BSQQ6=C,);B(O@W&3M*]<8"%CSWQ3IZ5+RVV^_K\M/Q">L+
M+??[ME\S1MFU.+Q9?K+9W#Z?-''Y-P'C\N,J&W*1OW9)(YVX_*E'X6GW_"R_
MX(I?$FMK?C=_\ QM)\+ZA8>#]8T]7,=]>W-Q)&_G;"@9SL.]1GA=O7/3'2E*
M[IPC%V:2^_KZ_J7=*I*;5U_7W?H/31]?'P_&B)*(]38&"6[:=B2"3NF!!R"<
MY SP3CH*JH^9IQ5EV[66B\]4EZ$T_<;;UU^_7_(SM9\.>*-<MK.598[*\ATU
MH77SV:-Y20&1@#RK+GYNJG%/W74<NCY=/+5O[M/7;84;QC%=KZ_=9_/6Z-?Q
M#HEQ<?V7%;6 N+6WAEBDBCF\K9E0%*G(((QP1R*B=Y3D[[K?SNAP]R,5V:^Z
MS_6QGZ_X4UO5?#>CV;7$,]Y9VY$SR.3OE" !AGOD'#'D$Y]JN3_?^TBM/^"G
M\M$_R$HWI\G?\K27SM=?<=!#8WY\51ZC*JK;?V>(642;L2;\\<#(QWXJ5HY^
M=K?*_P#F*S:AY7O\^7_)F1IUGXNT_5+VY:*TN%O9TD9&G94@3<P(7@Y;9L).
M%!/KUIPTBHOY_=T\K_GT*GK)R7:R^75^OX6ZG94@"@ H * "@ H * "@ H *
% "@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g833164page06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g833164page06.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MU>?XOGV#D<Y/>@#N=*\*Z7I$B2V\<SS1IL22>=Y2B^@W$X'TQ0!M]* "@ H
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M.Z0_WV \M_R"1_\ ?0H VZ "@ H * "@ H * "@#F/'Q(\++C@_;['_TJBH
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M1QD'F@"6WN4N$RN0PZJPP5^HH FH * ."<X/Q)&"#D<_]N4= '>*, 4=0%H
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MNT$&7_[^2EVSGNNVF8G2VWA+1;:196M/M4Z]);MS.XYSP7SC\* -I55%"JH
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M.@]6Z<]N#0!SO@R\_L#QW::0 @M1<WMG'(KY!1MD\2]..,XYZL:2&CVJ@ H
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M8.\;$XD3YE.. " 9<_[I]Q0!QVCPOK?B>[DU.T_M2R2UBF-L]PP\K<H5MBY
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M(M)T_2O VO+I]E!:K_9\_$,:IG]VQ["F9W#X=$GX<^'R>]E'_*@1T] !0 4
M% !0 4 >;_$+Q5J%GKEEX<T^RENA=Q&29+5RL[K\V44C[N0O)ZXSC'6@!MIX
MWU^RM(K6U^&]_#!$H2.-9" H'0#Y* )_^$_\4X'_ !;V_P#^_P"?_B* '_\
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ME1@,$!;IC[QY[>M,QNWN; &* "@ H Q/&7_(DZ]CM83_ /HMJ *?PZ!'PZT
M'K]D3^5 '3T % !0 4 % !0!Y3?Z8++]H32KP2E_MT#RE<8V;863'O\ =S2O
MT#I<]6I@% !0 4 97B;CPIK'_7E-_P"@&@#CO#=PB^*TB-Q9!VDF C:/]\?W
MDOW6QTX_0UGISGHQB_JC=GZWTWZH]&K0\X* "@ H * "@ H * *FJ_\ ('O?
M^N#_ /H)H \W\(/);V\"W@3<UA:*LB9.Q=KE>OMC/I],X:$SH+FS_>NT*JMP
M I5E7(<=AZ= !^&/>@"F[R0Q^9"L@*-^]C;D9X![_4\>G3(PP!9\JWO(W5<_
M.P&<8:(X QP.V??[QZ@T 5KF/9/'YF\.%_=2#@ 8)SU].O3^1H&12VT&H7$2
MW(ECN+=&CVPRM&)5)7.2O+#*>W^((=!I=IITXN;2VV?=1B1\P Q@;B-QZ$=3
M^>: +Z%PTDD;' ;J ">G(]QSG_.: *'B;1M,U:&QU&YAOGN-/<O"++[Y;J"%
MQC.5&.@_2@-BGHTK&UNYS<S7-QYI+1SD>9$#C8KC Q@ GIUSC/(IH1J1%;F
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ME %22.6)!%.2I9&*2@XX [C/H1GZ?3 !-%<^9N#*GFC<"N3AN",CCID?7\J
M&3N;(>:(Y&M\Y<'.1WQ@G!Z'IZYQ@'(!%?Z[INA2V[SW11KLXA9(VD8E0"WR
MJ"?0T 8VM^*- >6RU&*\ECU%Y4A.ZUEA$Z.0"C,RJ/ESN!R#\O7O0!MRO&(D
MNM/DCEAD+%7C<,& R./QS[>WH 3EX;BV9=K>7N/(ZJ<8/&/;% $$K2(ZP3!0
MV56.3GD]^O?@^_/KU )[*ZWR!)4R_*$<<\?3'0_X<4 #V[&Y@"^:L<TXWO%*
M59"3SSUQDCVX^F0:+7@\"74M1N;,O<:83LBOKCYIIW#,6"M_%$N<+GONQD<E
M =?0 4 <OXLFCCFL1)-ID0+G_C^CWD]/N>AK.=E:YV86_O:/Y.WWGE?@?QEX
M@TBRM] TG18+V6ZFGF@9Y=N\;SN/T!!_*K6QRRW9ZM'X5C-C>SZ@PU#5KJ%X
MWN2NPJ".$C_N*#C@'.1DDGFF2<[:^)OB+':1++X(1W"@,QO$!)QR: (M1\>>
M-=*2%[WP=%"LT@BC'VQ69V/0 #)[=: (/$5]X_U_P_>Z3)X+CBCNHS'O6]C)
M'OC- ''V/@SQ9:SM(_@R!PUO+ %\V,!=X&#]XYV\D9YYZT =CH>I^/\ 0=!L
M=*B\%+,EI"L0<WB O@=<9H S/%\?CSQA96EM/X0%L+:?S@R72,2=I&,$CUH
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MZ:C>6XCNW(CB$.TG Y^9&8$_ES]:%L4SHUT&6UU&341J-Z+Z1!')*([?+(O
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MM0'D.T2R\,ZS9&>WT.QCDB<Q30M:H'AD'WD;CJ/UX(X- &E_PC>A?] :P_\
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MD\()?-:0F\%U./.:,>8!N(QNZ]*T6B.66YZ33)"@#@?BV=OA?3_^PK;?^A4
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MN(I5+I;78D ;8Z6\ASUX. /;J1T'.0" 1YY\3W.HVVDI#:SO(OG+(# RX8A
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M@T#)UR''KL?_  H Y#XA^-/#NO:-I]EIFIQW-S_:5N_EJK X#<GD>] 'K8H
M* "@ H * "@ H * "@#S_7-0N8_C-X7L4<"W>UG9EQR<JW_Q HV#H>@9'K0
M4 &1ZT &10!E^)?^16U?'7['+_Z : ./\,6C-XH2X^R*P1[C]\9<%,RS<!<\
M_P#UZR^V=ZG;"<M_P\^YZ)6IP!0 4 % !0 4 % !0!GZ]_R+NI_]>LO3_=-
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MA_$",8N9AC.<?.:VZ'')WDST*@04 <!\721X:TO'_06MO_0C0!WPZ4 +0 4
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M?RJGN!U%( H * /.M=GF7XW^%H1*XB-I,2@8[3\DG4?@/RH#I<]$R* #(]:
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M_#;>#SU]^1CKZ?[)H FAEBNHFBG8]N,]<=".1SD=?_U4 //R/'#/*V[ATF)
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MEHMNIZ#;_P"I3[WW1][K^-:'';5DU !0!YQKO_)<_"W_ %Z3?^@24NH'H],
MH * "@#.\0?\BWJG_7K+_P"@&@#D/"88^*[UFM+9&\V4;_.S+@$A3M]QC\,5
MDM)L[YK_ &6.K_0[\BM3@.:U:";1]1&N6:%XL;;V)?XD_P">@'=E_45F_<]Y
M;';0E[>/U>;_ ,+_ $]'^9T%M<1W4"31,'C< JP[BM-'JCC<91;C):HD?[M!
M+.6TXE?'6M,1A?L\&#_WU6,?BGZ_H>C45\'27FQ/#MQ'J&K7EY\Y^2,J9(U5
MOF!.?E..5VX[\<T1ES79%>'LZ<4MG<E\ _\ (K)S_P O$W;I^\:G1_AHUS/_
M 'CY1_)'3UJ>:9^NX_X1[4L]/LLG_H)H XGPN0890XPGV.US]?*ZTT!I2VSK
M^YRQ7^]G.>1QZC[O7KQZXH$.BED\TQ.63:0 P_/V]?Z^H  LL,$:NW+ _>4L
M./EQZ^X__5T (X_W4A(?>AQD')/&?\!]?KU!EQS'*H$@#1Y#%0>21C#*<\$=
MC0(C ^<(PSQ\CIC#KQR/SY'X_0 F5O,B9 P4X^7=DJ<^O3*F@"E/;>1Y@0GR
M<_-%C+)DDCCTZ\__ %\@#8/]'W1HFY<Y4@=!GV'I_G'0 EGA!VE!ND&T$,=I
M8<9Y/7_]5/8+%,.8'6YBB8@#:RGN/0#\^G^.$!DZ=X9M=&TAK/1KN0H)6<Q7
M(1U+'C!. 5X&,@X]0>X%S2MK@7EL)8F:.7<RD,/NNI*D-ZG</\G!(!I1S>?$
M;:0 #[R\ XQZ<X_#\\9H SO$-NT'A36HI/WD:Z?/Y38W%,QD8SZ8QU_&@#3^
M&/\ R3G1_P#<?I_UT:D,ZV@ H \T^%.J6.E?#.UEO[J*V4W%QM\Q@-W[P\ =
M_H* .H?Q%J-Y((]%T&XG4\&XNS]FB'7GY@7/3LN.>M ")HNK7XSK&MN$/6WL
M%\E#ST+\N?J"OTH UM.TK3M)A\JPM(K=3UV)@M[D]2?<T 6WDCBC9W8(B@DD
MG  '4T 9/_"7>', _P!NV&#T_P!(7G]: &R^)_#,L31RZSIS(X(*O.A!'H1F
M@#"9?!P??I7B2#2Y/^G&]1%/7JARAY)/2@!B>+KK3I&#ZMHVM09 'DW*6\X'
M')#,48]>ZT <UXY\2Z9XB'A];-F^T17Z,\3*5E7(_P"69Z%\XP02,XJ)IZ6.
MS!6YY7MMU/6K?_5*/FQM'WNOXU9QWNV34 % 'G&N?\ES\+<_\N<_'_ 9*74#
MT>F 4 % !0!F^(3CPUJG_7I+_P"@&@#DO#")_P )C>N(K/(>0;R_[_\ +T_I
MBL(_Q&>G4?\ L<=7^AW];GF$4YC6%BY55QR6. * WT.9M=OAG4O)$H&DW[[H
M"#E89#SM]E/4>]9)\CY>C.^3>+I\WVX[^:Z/Y=3J'(\OK6IY[V.8T[)\<ZTI
MZ"W@[?[W^%90WE_70]"KI@Z7JQOAB$PZCJ B+M;;4P[[LE@6SG=STVTJ;O<C
M$6]G&^__  Q)\/ACPG'_ -=YO_1C44/X:-\T_P!XT[1_)'45L>89VOG'AS4R
M/^?67_T$T >9Z#9ZD=4LI6U5H;..UM0]ND8Q*/*.WD\K]Y?8D8[BF@.M>ZD:
M41A5S@XR3@G!/]1_G- $-PKPH[,[/'N/..4'IGCI@\_3T)H%L,BN3&Z(JL1*
MV$8G [DCCIPIX]OPH&3"U<JH4#8X_>( 6## SUSTS],&@1#]I:-1)"X9%Y9'
MXQWR3]!^/'3DT 7+<"16#+@[B<C.Y2,C(XX.%Q@_2@8%3#(JMDJ>(BHPIXY4
M#/!XZ=^W3  )Y#'N3#C#)GD9!7T([CD<=LT <OXM\+W6N:=!%'>M D%P9Y%!
M/S+M; !QR/FY)']30(DT%)-%\-VME)=&]>"-PTR\$DL3Z]!TY.1CV. +FNL/
MG2(VY@#_ ',X/UR#Z?K3 \VM;KXG*[H(U$BG8=D5MVX'3_/2DM0T-KPY)XMN
M--OGG33GF^V,[M<NZL&*)T$:E<8(/N2<T;#-1E\3H\ \C1DD9693YLPXX[;>
MO/7'?WP06A!K%YXDF\/:M')%HPM_LLI;RYYMY&QLD#&,XSC/<>W!J&AT_P ,
M,#X<Z.!TV/C_ +[:D,ZZ@ H \-^'?AVUNYDFO+:*2X>V62UAEF:+Y0[9DC9!
MSR0".HP#GD4 >C-X2MVZZ5$><_\ (3G_ ,* ,OQ#IEEX=T*ZU:ZT42V]L [K
M'JL^XC(!(R ,\T 5HX;&:-98_ >OLD@#!OM<8R#SWN* '_9+)U*/X"UXJ05(
M:[C8$>A'G]* ,32='O+/2K>UN/!%S))&!N8VUJW1V/5I,OE2JX)&-O% &E/:
ML]X6C\ 7*0F17 %E9D!!MRA7S.<_-\V1C(X..0!L5FRZ@LS^ +HPAV+*;2SP
MRG.!MWC:1D?,"<@'(YX ,G6-%U*^\/WEE8^#+N"[DCV1R^1:1_-O4[LHV4P
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MCIKTXU:;KTOFNWGZ?D5]/)_X3W73Z6MN.G^]4Q^*1K5_W.EZL;X1NKF0W8N
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M;NP&QD#HJ.T\/SC#9XX(P><=LTP+NJ27WV+3AJ<EK>['N(V>-2F]@&53C/'
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M7&<_YZ>O#0&[("KR-&F]FY:/H' XSZ9P..GH?4 &<[?V5>R:I"LLT$T2K-&
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M5DU2107D892T0YQ(_KR.%ZGZ F@"KX TV'1O#\^F6[,T5K>3QAFZMASDG\:
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M+H/@KP]X9N9+C2--2VFE0([AV8D9SCDFM#QS?H \]^-@_P"+8:@Q&0LL)_\
M(BT#6C.]M\?9HL<#8/Y4"): ///B3QK_ ('_ .PQ'_,4NHUL>ATQ!0!C>)]-
ML;_0KMKRSAN##!(T?FQAMAVGD9Z4 <OX-V+K[Q+]D0(FU(RF)@H4 8/]W@?@
M164;\[/3K)_5(.SMZZ'H-:GF%2^TVUU%(UN48F-MZ,CLC(<8R&4@C@D<'O0
MZRL+?3H##;(50L6)9BS,3U))))/UH LT % !0 4 % &9XB /AC5@>GV27_T
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M8Y8BI#X#<K_=(QR./Q[_ )4 59/W4<,+.Q7.$<<YXXR/H?IQ^0!R/B3PC?\
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M[=:QC%*;=CTJ\K8:$>;\/U.\K8\T* "@ H * "@ H * *.L_\@/4!_T[R?\
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M@Q<&3#9VKQL_K[5C!OG9Z5:7^RP7-\K'=5L>:)D#O0 H.>E !0 4 % !0 4
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M_,-@QOP"1\IZ@5G!6DV=M2<7AH)/\/U/0ATK0X@H * "@ H * "@ H * "@
MH * "@"AK?\ R -1_P"O:3_T$T <EX. 'B"[W"U#[<@M_KR"J?\ CO\ ]:LX
MOWF>A6_W6&_Z'>5H>>% !0 4 % !0 4 % %'6>-#O_\ KWD_]!- '"^%;.&*
MP"1KMB&GVC<C?C='G'S<XZ^G''I30%V)YEDB6VWA?XT.>#D#/MUZ>Q[Y!!%H
ME;B$*73+@[)N#MR&]<^OTY],T#*B)Y,[(L>V>/++MX,@Q^O;J?[O/0T 6;:=
M)971U D5AN4MG.#M! )_V?T['(H JR@6X5E0FU9#N Y*'&<?JW3/\P01+;W
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M.Z>[G3#QV:N[H<C[RL0 ..U9Q6K.ZHVL-'7\/U.K'Q@TWD#PYX@X_P"G-?\
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M0 <AKMK;V'QF\#6=K&L,$5O.J1H, #8] 'J6!Z4 &!Z4 % 'F/C+CXR>!O\
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MS6) E$JYY]N>] "2V<]_XHLVN;42W$(N5D)LM_VC"VYW/%O 4_/]X'G SZ4
M.\5Z;Y7A>_<:1;P ("9$TH1%>1_%YIQ^1H [KP-_R*D'_7>X_P#1ST =%0 4
M >8^"(%E\,QK%\DR,@#XZ_N8_P /QI@;<<X\THS*)4&&4C!Q@9ZGITXR>H]C
M0(MVDD>]MXQ%(3N48(SSUXSCCK[4 9M_ ]G=2!V9H9%^0MPIP#D<GK@'/3(Y
MZ?=:#8PO"61\9=;3SF(6R_U>/E'^JP0>YK&&[/0K3;P\$VSU<=*T. * /,?%
M0;_A=_@O:,XBFR?3Y'H ].H * "@#S'QF<?&7P,/:;^5 ^AZ=0(* "@ H *
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MHGZ__7K*#]Z2/2KN^%I[?J=Y6IYH4 % !0 4 % !0 4 4-;.- U$@9Q;2?\
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M\-:?;*K.+MFE>/=@,(W&#GN<YXJ8-\]FSIQG*\/SPC:[/=:W/%"@ H * "@
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MZ#J#C/(XSG^H(<;;9*3& RG&Y0W*GCWSGB@&"3"W=2P"Q?PX& HQ].GU_D>
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M_4?C2 ROAHY>*]^1HUV0X1L9'##.1QSC- '>T % !0 4 % !0 4 % %+6?\
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MCKUX4_A^0,L/*397"3@!O*;DGAOEQ[T@*OPXR#?(>JPV_;V:@#O* "@ H *
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M$78-[8B=L.OW69<@9#=_3GMTH&37-I]OADRVUHWW*PZKC/'7]?\ ) *WGO\
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M/:CX4\)Z59B>728".D<<:',A[+MSU.",XZFF!:\/6,VE:#;Z?/$$N$W.T>,
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M]/T]> -BQ\-)8KB&]N(G+;EB0Y!&"H92,$9&&##\*0SOJ "@ H * "@ H *
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MZQM&_B.Y-K.""PM8AGKG/<=/UI +:?#V*SLDLX]=NA:XV@_9T)'.3Z]S_GN
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M^@Q^0[\ @$6(YG1C'GA.05'('O\ B:0R.YC5$EF@7?$ 2R@<]"3@#D]??\:
M&Q2F)S)&K."022,8Y/<\=AW_ $YIW DD07=OC<P?=\K;B#D@#U!'_P!8=".
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M(X.,< C''4G\.PZ &?\ #)0D%T H7]S;DXXR2K$G\3F@#OZ "@ H * "@ H
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M 8]AC'_U^*!%-7D63RIG,<J+@#)!;J3U[X'Y?C@ X[XAHRP^%W.TRG7("&
MR ,<\\X.?2D-';WEO<1O]I10\_ EC&!O.,;AZ'\_3IR&20023-$&6(O!*H4J
M"5*9'.,G.<GV/T(^8&9OB(QPVUH[RNL5W,())<\&(*SX.,]<;?7YCCJ:!E-?
M$6CVP!M=2M88B!&(0^T<]AT&<%./PZ8- CH/+CO8U)3<BX);=G:589'Z'/T[
M&A#*,L<J0F.:3$BE1%,O\6<8^IR1_P#KX((NQW4HEACE++/_  @\!ASGO_+^
M5 $,MJT,C-:(,X&^#&<@D#\.OX9].@,+>X\A3<666M. \98_N\=<^O&.?H.F
M#0(U52/4D2:)E!B8B-AU7H"IYZ9!!!QZ<&@9G2)+'('V%90N)HB2 1GL>_0X
M/N??" F$B30!2&$++M*R#GMP0?KCG]10!GS0?9P[-N>%V^1P?NL>@8]^3P??
M^]C< 7(Y3&[ LP!;(8GIUXS]!_D=&(9>0>7,9K9<-_RTCQG*CCC\%'\CQ@A
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MS=6<GD0M$S;SM=0W&0.3@$XZ=>F$,N_"\8\0>)@1@B+3P1_VZB@#TR@ H *
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M* &KIOBX.Y$6IA6/03VF2,=SCUQ0 LFD>)WD5FAU1MARN;BTR.A')0]Q^@H
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M * "@ H * "@ H * ,C1^-2UW_K]7_TGAH UZ "@ H * "@ H * "@#'U/\
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M5U_;-M_I272ZHY>8(BJH(0@21[6)V 1H"&_OKR#E: .]H * "@ H * "@ H
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M0 4 % !0 4 0RVEM-*DDL$<DD9RC,H)4^WI0!-TH BEMX)]OFPI)M.1N4'%
M$O2@ H * "@ H * (Y8(ITV31)(G]UUR* 'JH4 *  .PH 6@ H * "@ H *
$"@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g833164page0035.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g833164page0035.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M!A_;.F?]!&T_[_K_ (T"N']LZ9_T$;3_ +_K_C0,/[9TS_H(VO\ W_7_ !H
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M[L*J?-YCQCQ*PC2_A_B;NGR-+ &;K7J'S:+M!0E !0 4 % !0 4 % "T )0
M4 *.HI,# L+33[W5;B#5+LVMFVG3;Y1_#_I0Q6-:*E"TG9&V!JUJ6*C.C&\E
M>R/0] G@MHK.RLY?/M(XE6*4_P 2]C54TE!);'+BYSG7G*HK.^IV JSF"@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H 2@#
MS;PM>:S:>'6&DV*W0:^OC)N.-I$QV_UXH R>3=ZAGK]NN,_]_6KQL3_$/H\%
M_ B/Q6!UA0%@H 3% "T % %6^_U$?_7>'_T8M7#<BIHEZF1%_P C9:_[EW_Z
M,%;R5J;^7Y''#^/'Y_F= *Y3OZ"T##% !0(* ,OQ!_R#/^!'_P! :M:/Q'/B
M?@7J:K_ZQOJ:R.E"4 !Z4 8VN?\ 'QIG_7=?_1L5=%+9_P!=SDQ&\?7_ "-F
MN<ZPH$% /8QI?^1L@_ZXK_*:MX_PCEG_ +RC9K ZEL% Q&.U"Q[#--:B;LKF
M-#KL]PA>'1[F102N5D7&1UK9T4NIR1Q,I*\8-C_[6O/^@'=_]]K1[*/\Q7MI
M_P C%_M:]'_,"N_^^TH]E'^8/;3_ )&0-XAD5Y$;2IPT2[G!D4;!TR:KV&UF
M0\2T[<NPR/Q.LLBQQV#N['"JMQ&23[<T_J]MV"Q=W;E,Z6YN'\2/<'39P1&
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M0!C:Y_Q\:9_UW7_T;%6]+9_UW.7$;P]?\C9K ZPH$!Z4 ]C&E_Y&N#_KBO\
M*:MX_P (Y9_[PC9K ZEL% RAJ5P\ C1)8HA(KY:4<< 8 Y'K6M."D]3"M)Q5
MD5O#;!M)+*05,\F"#GO3K?$1A7>&G<UZQ.H.?6@1S-TZ)JNJHRLY>$ *J%L_
M,,C ]J[(J\(GGR:4YDYN--$ZFWM+A7:Y23<;1E" ,N><<# I>_U8[T[^['KV
M*\^IX\0W"(Q\F6) ?W;9^4''&,_Q&GAJDE/D/0Q>#I2P+Q>O-<V=.O[=+<!W
M<'_KD_\ A7JV/G+]R[_:5K_ST?\ []/_ /$TPN@_M*U_YZ/_ -^7_P#B: NC
MEY+S7A-JGV%9UMUFFDB?RN<'Y@%!&>N?SJ3)\QKZ6\W_  B>G"TFB6X\B/[Y
M&!ZBC8T2NBY8R7@E8WLT)7:,!6'![T[@E;<Q_$%A967AK5I+=LO,B!@9-W23
M/ _X$:"9*R.G[T(T6P4P"@ H * %'44F!S]CJSZ'JESJ"01S-%ITN$D^Z<W0
M%8UI^SAS&^!PRQ6+A1;M>^IWGA^^EU$V=XT8C$\2OL7[JY["G3ES03.;&450
MQ$Z:=[';CI6AR"T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!X%#J2B>VA@@DGFMKG45D7! ^:=2"#CG&/UKEQ%G&USO
MP7-"=TNAM6\KS0+(\+0L<_(QR1SC]>M>5*/*SW82<E=DPZ4BPH$% !0 4 %
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M-WTT8<.B+C+DC[PHL$HI(Z&WM8[4OY9?#'.UG) Y)X!Z=:$4MB:F,* "@ H
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MM.4I; '@UZY\RBW0 HX84 8FDW4UEH]G:S:;>^9#"J-A%QD#_>H)V+@U)O\
MH&WW_?M?_BJ3'=]B"+46@EG,FGWJ^?."G[M>?W:C^]_LFBY-VNAG^)[YIO#5
M]&;&[CRB_,Z*%'S#K@T/8)/0Z7O0BUL%, H * "@!1U%)@<W::S<:)J=W?63
M1_:8-.E&&&0,W0ZCZ5A7FX4W)'3@,/#%8J%&>S._\.W5SJ(LKZXY>XA5V*C
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M?0](\/[-.M[/3!(LWD1*@E7HWN*NG%1@D<V,J^VQ$ZC5KLZT=*LY0H * "@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *  T
M% 'SE9Z9;W>LW'F%U\RYOBVT_P!V50/T/Z"N*O4<6SU<+1C-*_F=7:VZ6EI#
M;19\N) BYZX Q7FR;D[L]>,5"/*B6D4% !0 8H#<JW-C%=2Q2L2LD9RK#O\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?/\ I'_(9?\
MZ^=0_P#1R5YN)ZGM8+:/S_0Z.N$]4* "@04 '2@!!]X4UN!FZ("+'_OW_P"B
M8ZTJZ,Y\-\#]33K(Z0H$% "8YH&9VE?>N?\ >_\ 9GK:KT.7#]32Z5B=(4#
MCMCB@0 =!0!F:/\ <O/^OAJVJ]/0YJ'VO4T@.^*Q.D6@ H&% @H QI?^1L@Q
M_P \%_E-6\/X3.6?^\KT_P S9%<YU+8*8$<W^ID_W3_*JCN)[,R_#G_(*/\
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MA45UJ>F^&/M%U%87<[%WEMT=G/<D#)JZ;O!,\_&PC3Q,X1V39VPK0Y!: "@
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M0244D<6*G*=>4IJS;.K%6<XM !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_:$/1_D>O^$;-!I&E3;_ )C:Q\?\!%:TOX:/+S#7%U'_ 'F=C6IQ"T % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % "4 ?/\
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M3T/0+V2^EM;KRQ$LT*OL7HN0#@5<)<T;G'BJ?LJTH7O9G9BK.86@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ - "4 ?.MA:2
M2ZW<%+N6+?=7V IQMQ,O3GOG]*X<1)1OH>IA*;E:S[FW_9EQ_P!!.?\ [Z/^
M-<7M(]CT?82_F8?V9<?]!.?_ +Z/^-'M(]@]A+^9A_9EQ_T$Y_\ OH_XT>TC
MV#V$OYF']F7'_03G_P"^C_C1[2/8/82_F8?V9<?]!.?_ +Z/^-'M(]@]A+^9
MB_V9<$_\A.?_ +Z/^--5%V#V,K?$QN@QQQ6!6*-8T+*VU1@ F)"?U-%9WD/#
M647;^M#4K$Z2"6[MX)%BEE59'!*IU)'?BJ46]3-RBG9E33XY(KF1(59-.(RB
MR#!5L\[1UV_6KFTTK[F=)6;ML:59&]@H&'2@#&D_Y&V#_KBW\JW7\+YG(_\
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MB31W.CR1PDR^0#YA3E8SN3&3TSU'XU35H,]/)W_MU-(YCPQ9/%IT#R#:69G
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M6)Y)VBM:3;@KGF8])8J:2V;.U%:'&+0 4 % !0 4 % !0 4 % !0 4 % !0
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MVE[3XKZ^IU]6<P4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % "4 > :0#_;+X'_ "\ZA_Z.2O-Q&[/:P6T?F=%R#C%<)Z@M
M !0 4 % "K]X?6@'L<[X,_Y )_Z^)/Z5TXK^)\D<6!_AOU9T-<QW&/<?\C?I
MW_7I-_-:WC_!EZG+/_>(^C-BL6=2V#.*0!0 F>* L8[_ /(VP?\ 7%OY5O\
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M&!@^:Y+#J.JW!10;G:"LB@0KU!##^'VKK6NQXK4D[-:FC]MUK_IZ_P"_"_\
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MQ?U/%QK6O:^B/4=!=;..TT\E7:W@2,NO1L*!D5I#2-CS\1/GJRGW?YG4"K,
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_?2?_%4>Q?=![?\ NL/[?B_Y])_^^D_^*H]B^Z#ZQ_=8G_"00CK;2\]MR?\
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MSU<A_P"1C!>3_(]>\*6;"PTRXSPUI%_Z *WI_ CQ\;_O53U9V0JSE"@ H *
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M;^T7 LKN8EWFMXW9O4E02:UAK%,\S%14*\XQV3?X'9BK.<6@ H * "@ H *
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M?WS\GIGKZ ?E0"5C)\4V4$7AB_= ^Y47&96(^\.Q-)DR5D=#WH1:V"F 4 %
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M.IO<ZH51D% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M*R/6R)J.80;[,]C\,VL265A(#AS;1Y'I\HKHAI!'C8O6O-^;.JJSE"@ H *
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M-/8],\/SS75Q#<R#'FQ)(0.@) /%;0=XW/-Q$%3JR@NC_([ 4S$* "@ H *
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M?MI7NM#HH3F%2?2NT\L?0 4 % !0 4 % !0 4 5381%W823IO8N0DS*,DY/
M- K!_9\?_/:Z_P# A_\ &@7*97B*U@MO#M]*YGF58_N/<.5)) !//8G/X4A2
M22-_I0BUL%, H * "@!1U% ',P:++XAU233K>:**1K*1MTAXXN<US8BFZD.5
M'5EN+C@\7&M)-I)[>9ZKH;K;"WL& :2"%(V8="0 ,UK%6C8\[$5%4JRFNK;^
M\Z451B% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 ?/NCHJZY,P #-<ZAN/KB9,5YN)ZGM8%?"_4Z7O7">J% !0 4 %
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MC/\ XZ*Z(? CQ\9;ZS-+NSKA5G*+0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % 'S[I+*NLOE@/\ 2=0ZG_ILE>=B$[L]
MK!-+E^9T89#T8'Z&N"S/3YEW%R!U(Q]:+,.9=PQB@H-P!P2,^F::3);6UPSC
MBD5L+0(* "@8AQ0(SM5M9)(TNK8'[5 <KCJP[C_/O6M.5M&85H-^]'=%>/Q
M98UD2PD96&05?(/TXJG12>YFL2VK\HC^(?* +Z?* S!1\V.3]135'FV8I8I1
M5VBQ_:5V0"-&NR#R"%;_ .)H]AYF?UZ/9E6_GOKJ.W5-(NE,5S',=RMR%.2/
MNUI"DHMW?0RJXM32TZEK^TKP?\P6[_[Y;_XFL_866YL\?'LQ?[2O/^@+=_\
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M_/\ 0Z2N$]43\:!$,-G;6\TTT4*I),<R,.K53;:29,8*+NBG)_R,<'_7 ?\
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M0 4 % !0!\^Z4P767)( ^TZAU/\ TV2O.Q*;;L>S@I)*-WW.DXK@/5T8M%P
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M^>1@,X2WD) _*CV4D/GN2_\ "8Z+_P ]KC_P%E_^)I>SD','_"8Z+_SVN/\
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M"@# U*7;XPT:#;]]6?=GIM60?^S?I2ZD/XDC?IEA0 HZB@#@=?Z\_P#/N_\
MZ4FN+&?PSVN'_P#??DSVOP]9>7%;3;A\T"''_ 171#X4>!B?XT_4Z>K.<* "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M3EAGD?W2*DSMJ7_[.OO^@@?SD_\ BZ!V8?V=??\ 00/YR?\ Q= 68?V=??\
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M'F58N%246[V.KJC(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M2DDM3G_!9!T E3D?:'Z?A71B=9_(Y,#_  OFSHJYCM"@ H SM=_Y T_UC_\
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ME[P72UL>F:>(QIUJ(F+1B)=K'J1@8-,"S0 4 % &+XKTRYUCPU>V%G(J3RH
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MM;(FL[)+-&^8R3/\TLK?><_X>U*4N8:C8M"H&8\(%EJ1CU$)()Y/]'N'Y_X
M<]#Z8ZUL_>C[IG\+LS+T:%YIM0&2=DX R>G+5U8%M\USZ3/XJ,:*2Z?Y'8PK
MMB4&O2/FA] &+9?\C5J'_7$?S%22OB-JJ*"@"M?ZA::7:&ZO9A# I +D$@9^
ME&^PI-11F-XPT)98X_MI^<$@B)\<?A5<I/.KE37-0B@U*]6XUK[#);6ZR6T6
MY5WN0Q)((^;) &*2C)["E**>H_PYJ$.I3"ZEU>&>^FBWM:6[ )$.,_+U)' R
M:'&2U:"$HO2]V:EO96UQY\DL6]S<2C)8]!(P'?TJ46M5J2_V78_\^X_[Z/\
MC3"R,CQ386L/AB_DCA"NJ+@Y/'SBD3)61T5"+"F 4 % !0 HZB@#E1K<WA_5
M/MUO!%,_V.5-LRY7!N:YL14]G"Z.W+,&L9B?9R;6CV/4=!FEGNTE<8\R-6P.
M@R :V@[JYY-:')4E'LSK*9F+0 4 % "4 >1_$"6QNO$US:S:##=7-M"DPDEE
MDBC:,*2[2%3@@<*!ZMCI0E'NQKFZ;'JMDZR6-O(L?EJT:D)_=&.E&PBQ0 4
M% &+XJU:?0_#5YJ%M$LD\858U=L+N9@HR?3+ T;"9X_XF\2^.? %O]CU+6[3
M5M1U;Y;41QC=;MD G!'0YP/<4TTU><=A6L[1D=3X0C\;^&-5T^'Q5JL>I0:L
MQA2/=E[>4(7ZXY&%8<=\4N?FZ6*Y8QV9Z@* %H * "@ H * "@ H * "@ H
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MG25RFQ#>V[7>GW5LAPTL3(">@)!%--1DFQ/8Q&N==M;RRTXFP+2QML;:V $
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M8EQY=G<]$'2F HH * "@ H * "@ H * "@ H * "@ H 2@#Y_P!(_P"0R_\
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MKBQ<6XI(]C(:U.CBW*H[*S/<-&@AC="IQ)Y:[AZ' KKCLCY^M_$D_,WZ9D%
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M /B*/9+N'MY_R_G_ )!_;%S_ - M_P#OIO\ XBCV2[A[>?\ +^?^0?VS=?\
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M % !0 4 ?/FEQI)K+AT5A]IU#J,_\MD_QKSL0VKGLX.*:C==SI54(H51A0,
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MGN9SAZ5*A1<(VNOT.WMP5A4&O0/GB2@#%L?^1IU#_KD/YBE<E?$;5,H* "@
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M "@ H * "@#Y]TAU.MRJ&!9;G4,CT_?)7FXGJ>S@7\*]?T.E%<)ZH4 % !0
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MJ2%N;=46% !0 4 % !0 4 % &+XM_P"14U'_ '%_]#6D]B9;&UW-,I;!0 4
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M)_X]_P#%4O:1[!]17\PTZ-=$G&K3CV&[_P"*I^UC_*'U%?S"?V+=?]!:X_\
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MSG4C&\4?\@=?^OF'_P!&"MZ'Q_)G+C/X:]4;;??;ZUSH['N-Q^5,FXO2@84
M% !0 4 '2@ H * ,2+_D<KG_ *]O_B*Z'_!/&Q/^\,VZYR!!0 V0XB?_ '3_
M "IK1HE['+^'8?L=I--)M*R.$'KE>#7J82FXMR9ZF98ZGB:=.$5;E1V$)!B4
MCI7:>./H Q;+_D:M0_ZY#^8J2%N;546% !0 4 % !0!4LY(Q'.#(@(N9N"P_
MYZ-0):(L^;%_SU3_ +[% [HQ?%DD;>%=0"R(3L7@,"?OK4O8B3T-SO5%K8*
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M,US!,E[)E43[R<]ZYJ5+EJ-WW/9QN-5?"TJ2BURZ>IV]FZR6J,HP#72>,3T
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M]S.5HF=:ZG<ZI<70:7S(8B/*PN,+VKLPDY-N+Z'M9G@Z-##TJE-6<M_N.IM
M1;J#7>>&M":@#%L>/%.H?]<A_,5)"W-JJ+"@ H J7&G17-TMP[.'4*  2!\K
M$_UH%8MT#"@ H * ,7Q;_P BIJ/^XO\ Z&M(F6QM=Z92V"@ H * "@"*>W2X
M$:N6 20/\IP<CW_&DQ-7.3MX?#UEJ\ UV*62T^QR*NPDDN)2%[^@-<U=P4??
M._+(8MUG]4>MM?2Y['HMV\MZ\?.Q1\H]NU="/&E>[N=%02+0 AZ4 ]#SR/5-
M*?7=6BTRP:VO89<7,I_Y:'-84IP=222U/8QE#%0PM*=6=XO;R.YTYV>RC9NI
M%;GCEN@!* .3\>MH"Z7;'Q LK0>=^[\K.0^/:L*_)R^^>ME7UKVLOJKUMKZ%
MO1;MI;MHQG8 -OT[5OL>7*ZD[]V=#F@D#0!Y_P"/-<\3P:S9Z'X1L(7U"Z@:
M:6YEZ11JVW^;>_THYHQU:N+E<M+V(O"NN^,]-U2STKQG8PNMZQCMKRV/_+0*
M6VN/<*3D>E)3C/51L/V?)]JYZ**$ M, H * "@ H * "@ H * "@ H * "@
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MM8],CTH$8OBJ6X@T"3[2T,MN\D:2(D15BNX$X.X^E(F5['1]Z98E !0 4 %
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M\IZ#]\G2O.Q/5'L8&-N5^OZ'35P'K!0 4 ![4 (: %7[P'O0E?0'L<[X,_Y
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MQTU'_P =/^-5S4^P.G4_F%T7!LB0,#*8'I^ZCJ:OQ?UW'AOA?]=$:59'2%
M.*-@WT,K22VGQ1:3<#$D0(AD'29>O'H1W%;U%S>]$YJ+</W<MT:F:P.G8,T
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M4?>'<BE<F6QH:<B?:[B6WM&M[8HJ*Q(_>,&?<0 >.PYH0XFC3*#I0 4 &:
M=12'8Y0:AI.FZW#-K.GF^MFM9E6,8X;SR<\^P/YUS5Y1BDYH[<MH8BO6<<//
ME=KOT/6]$N9);^123L'0>@K=;'C25FTSI:9(4 % !0 4 % !0 4 % !0!RWQ
M%N+ZT\":G<:87%\BH8=G4MYBX'X]*+VU"U]#S&#X8^/?&LBW'C+Q$]K;YW"U
MC;<0/3:,*/UI>UD_A5AJ$([ZGI/ACX;^&/"3I-IVG)]K48^T2$M)^!/3\*23
M6[&Y)]#KA5$A0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?/FC[QKDVXC9]IO]
MH'4?ODSG\:\[$]3V<#?W?G^ATHK@/6%H *!!0 =* (I;B"T57N)DB7/5CBJ4
M6V3*48Z,P_!?_(!)Y_X^'ZC'I6^*^,Y,"K4OFSH:YCM"@ '#"FMPW3,OPYQX
M<T__ *Y?U-:5?XC,,-_!B:8ZUD= M !0(* "@ H !R0/6A=@V,FQO+K58I'1
MH[9$?80HWD@JK=^GWJVE%4V<T)2K)]#0@MXK2W2"%=L:# &<UG)N6IT1CRJQ
M-@5)16FM=[F6"0PSXQN R&'N.]6I65F9RA=W3L4;>YF/B22VF5"4MA\Z9&?F
M!Z?\"_2M)17LKGEXB3]K9FO6!F% #)#^ZD_W3_*B.Y+T1R^AM!;P32129F9L
M.GHH^Z?QKU<-&$6^5ZGIX^MB)T*<:L+)+0ZZW;? K5VGD$M &+8_\C3J'_7(
M?S%20MS:JBPH * "@#!\3/'$^CRRKNB2]#.#C& C9Z\4F1/H9.EWMM;^(6N+
MBZA2-_,(8 (/N1#H"0.5/?M20H^9TO\ ;NE?]!&#_OJJ+N@_MW2A_P Q&#_O
MJ@+HR?$VKZ?<>&[Z&&]BDD95PJMR?F%(F321M6!EB#VDT6QXLL&W9#!F8CZ4
M(I;%NF,Q-6>X;5;*U@N7A\["Y#-@<2,3@$9/R 4$2OL/_LG4/^@Q)^3_ /Q=
M)#Y1/[(U#_H,2?D__P 73%R^8Z/3-0CD4G46G3NC221_J&-(=F<M<Z)J^JZH
MEM:Q_:G6"218T.2BB4@Y)Z\G]:X\5"4XI1/8R3$TL+B)2K.R:M^)[UI(@6<A
M!B0* WUKJ6B/GI.\FS;IDA0 4 % !0 4 % !0 4 % #64,,$9'O2:OH O2F!
MS6O^//#WAG4[?3M3O"EW.N]8TC9R%]3@' X/Y52A?4EMKH=%#-'/"DL3AXW
M96!R"#T(J=AK5$E PH * "@ H * "@ H * "@ H * "@ H ^?M(_Y#3_ /7S
MJ'_HY*\W$]3VL%M'YG29KALSU R*+, R*+,89%%F 4[,1CJW]E7[&[_>Q7,G
M[NY8<QD]$;T'H:VTG'W>AR_PI/GU3-CGO6+.O3H%(04  ^\*%N'0RO#G_(NZ
M?_UR_J:UJ_&S##?P8FK61T!0 4 % F% !0,5?OK]:%N2]C#\-\65Q_UV'_HJ
M.MZ_Q(YL)\,O4VA6!UBT % C$B_Y'*Y_Z]O_ (BNA_P4>/B?]X9MUSD#>AH
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M6(E"JKI1O^*/:-#AE6]D=P<, <^M=2/G9Z2=CI:"1: "@ H * "@ H * "@
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M[+<37PU64Z,.9VL>QZ->>;<M"!P@P#]*W6QXTM9,WZ9(4 % !0 4 % !0 4
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MM:3/X<U2\DU32I;*YN678\T)5GQGH2.:/9*+O8%5YE:YMBJ 6@ H * "@ H
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MA%=G76T_^T9MHMA/OWOG.[;C[U:77)S6ZF2C-U>2_0N_V;<_]!2X_P"^F_\
MBJS]I%=#7V,OYF']FW _YBMQ_P!]-_\ %4>TCV#V,OYF1PZ*\ 98+^6)202$
MW*"0 ,_>] *;JI[H2P[CLV2?V;<?]!2X_P"^F_\ BJ7M%V'[&7\S+5K;R6T;
MK)<R3DMD%R3@8 P,D^F?QK.<E)Z&U.+BK-W)CR,'TJ%HRWJK&!IT3VOB%+-I
M?,2ULA$C;<$CY.M=,]:7-W9X^(357D;O8Z"N8@6@!#0!F:Y \]@0LZ1@'[CG
M"RG'"GN>>W>M:32>I$UH0Z+>VWD^2(;A+AFS*S(7#-_O#Z>V*NK%[MDP?0V>
ME<YJ'2E80&@88Q3 .E A03T!I6"QES3RZC,UI9R;;9?EN+A>O^XGOZGM71%*
M%I2);N[(JR3FVU0:':6\4-K'%N4*.1QG^=>A&O)U>3I8]3^SZ:R_ZTM[_J;E
M@C1VX#=:ZSQT6Z!B4 % $-U:07L!AN$#H?P*GU![&@35RI;74UM=+8WTFZ1^
M;>;&/. '(/HP[^O6D@6FAHT#"BP"CJ*&!QT^A7WB'6K:TT]$>6.WEE(9MORB
M<C^HKDQ-.51)(]3*<=2P52<JO56/:]*EA:=D10'4 ,?>NI:'@2=VVC:H)"@
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MH,?:96+/TP<=A^%)*6[93:>R.P[51(M !0 4 % !0 4 % !0 4 % !0 4 %
M!0!\_:1_R&G_ .OG4/\ T<E>;B>OR_(]K [1^?Z'2=*X3U H&% @H .E "?Q
M"A;@9VAG_0?^^/\ T3'6M7<YL-\+]?\ (TNE9'2'2@ '44(?0R_#G'AS3_\
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M>&;1+N*V,:7DNZ7H<3*,?7FN7$4O:)*]CMRO'+ U9RY7*ZMH>CZ3=))</$%
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MXK<CVK(M$:[.LS"\FD>4*XPQ(&/D(^7H#S4UDE'0*;;EJ='G%<9N&<4##M0
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M(]?(9J%6I)KH>Q^'K5US.RE=P!KK6Q\[/XF=#3)"@ H * "@ H * "@ H *
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MCWA3TH .E  :!"4  ZB@#&\/DXOADD>>S8)Z')']!6]?2QX;TDS9K 8M "4
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MK*/9(ZBTTVRL$*V=I#;J>HBC"Y_*MTDMCRIU)S^)MEH#%,C8* %H * "@ H
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M7)"(6SM&"GXD _C0!;EU)UW@0K$5"DM/(!C<< X&2?TH A:XPXBN-2:64_\
M+.SCP/S&?YT .,2H#*+%$])KR7I_/\LB@#)GU[38%<27GVN]:0.%M%* ,!MX
M//;ZUG4GR1<CJPE%5JT:;=K]2C]EU74Y/.BLD@0\AY3N;\VYKS7BZCVT/JWA
M<KPJ:J2<Y>1?'AE[@AM0OFD..5B78H^@K*K4=1W.#!9B\'3<*<4W??R&:KI%
MA8V=JUO;J'^VVZ[FY.#(,CFKPBM4./,,=7Q4?WKT0ZQ&-3\'_P#8;;_T5;UZ
MZ5MCQFV]SW[%,0N,4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!'++'#&7E=
M41>K,< ?C0&QPWCC1Y]>C6XT'Q/;Z9?")H)"9%*3Q'^%AGC!S@^YJDIQV5R;
MP>[.?\%^"[Z#QE:ZMXH\3Q:MJ5O"XLH;=R5B485F/3LV,8[^U*\GNK%+D7PL
M]<I <?\ $O4[C2?!\EU;:NNDN)HU:Y,>\A2W( [G%-7OH)VZF2OQD\&66B)*
M^NB\N8H065(65Y6 YP,8!)]^*KD;U)4ELDST.)_,B20# 8 @?6H+/'?%5Q\0
M8OB'K:^"H8W@,=N;@NJ'YMAQ][VI<\8[JX<G,M[&+90_&S3Y[R:VL+9'O)O/
MF.R'YFVA<_DHI>UI_P K'[)_S'J_P\?49/!-FVKC&I&6?[2..)/.?=TXZU5[
MZBM;0ZF@ H * "@".6:*!"\LBQH.K.< ?C0!R^I_$;PQI<CQR7_G2H=K) A?
M!^O3]:3:0[,YJY^+4\S2+INAN IP)+J0(#^ _H:S=6,2E!LYV7Q)XJUJ5$EU
MA[6&4[5\B/8.>Q(P<^AS6,L0DM$6J1AZ#:K-=QV]RS3JINP=[$Y.] 3CL3S6
M6(J-Q.W!0BZEFC?OHM]TT,+7'VBYC)58WVK\H W$^V17/!MK4].I%1>FYDZC
M-;#2K=X#"+Y2DNQ09'9AQU_/K5PNI.^QS5IP5--/467^T[^%$O+%8[=6;$EQ
M,$8@@C&!^';M5>Y&]F8O$2ENB6?4YS&IEU,1*  1;P\D_5^?TJ5!+6WWBEBY
MO1,B<B:V>X33Y9U12QEN7+X'? ; _0T;.US!SE+<O)IFH21!)+M($](AGCZ#
M _2H<X)]Q*+-"RLX[& Q1L6!8NS'N< ?TK*<^=W+C'E+.*@H.E  : ,._D_<
M22F_9)([APJ>:HV[5;'%=,+:*VEC&1K0DG6ICZVD)_5J]2'PJQR2W)Y[7S76
M6.1H9UZ,O0CT([BK)%%W']J-LV4EQE0W\8]0: )O2@ .* #I0 9XH BN)X[6
M$RRD[1@  9))Z >] "10>7++*S%I)#U/\*]E'M0!/0 AS@_2C8#@+2*YG_T.
MVM",Q,K%L+W#'K[D5P5%%7;9TQ3>B.V4815/4 "O/>YU;#J0!0 F<4 **-@.
M6MU:TU2=Y9&>:TO%^9B26CD''Y$8_$U[5*7-!,\^:M*QI16EV+J]O+:ZM[>W
MGD/ES.-S!?XL \<L":U(())M,(*7=[=:F^=I09"Y]-HP*& EKILYODEM['[-
M8[65ED*@[6&",]??G/3K18":XUF.VV6\VK1B1 %9+2(R,QQW/.,^U2VENQV9
M#-&;H-+%H<UQ(0/GO9PI.#D8&3_2LI8FFBU3DQ6MO$=V"'OH-/B/\%NF3^=9
M2Q<5\*-(T>K'1>%[(G?>RSWTG]Z9R?TKEEBIO;0U5&*W-6"RMK1=MO;11#_9
M0"L)3G+=FJ45L3<YYJ4 M S&\1>9]BM=A0#[;!G<#G/F#'X>M=.%_B&-;X2C
MIHG&L>$?,:,I_;1VA5((/EP9[^F/UKUSB/H04 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 87B_0F\3>%K[1EE$7VI54N>P# G] :5VM@/&M;^%O@;0?$-
MKI^J:[>V,,T#3++/* LA#8VAL8!'7WS37M9;2!NG%7<2?PMH_@_0?BAH47AC
M6+K5))TE\XQSADB 4X+$#!!Z8]<&J<:B^)BO&6R/>ATJ1G,>/1HB^%Y9_$%L
MUU86\BR_9T&3*X.%4#ODGI2M?0:\CR&UU_P%JMW_ &?J/P\FTBUN#Y0OC'@1
M9X#$X&WKUYQ2Y*?V9#O4CJT?04*JD**ARH4 'VQ5$G,BZU&Y\:7EI8S6\%E:
M1QM=L\&9'=AE0&STV]21Q1HN@M]V>=VGB_Q=\0_'=[9^%K^+3-)TS.97C+B;
MG W#OD@\#&!5.:@K6N)1YM6['K/AR[EO=#@FN(4AN0SQSI']WS%<JY'L6!/X
MU"26Q6QJTP"@"CK-\VEZ'J%^B!VM;>28*3@,54G'Z4 >0ZWX]\2W%H;JT<6E
MI*6".J['62)<R+@DG'/?%)Z($8[Z/>ZA?R)?:G+=RP8+&60D?-R, YXXKSGB
MFUH=4:5C0BT*TM@KR.$51CY0$'YGG]:YW6FS7V:1*DNGQ/MMH#._K$F_GW8\
M?K2?,]V/1;$SB[N=B^6D*AU?+ON;@YZ#I^=2G%=0>IRUC<V]J[S/J"VK"XN8
M_P#5;SAI!@^@^[WKLFI-62(I5/9NZ+%Q>6OG[?)NM4E5B$9]S@\X)"J ,'%0
MH2MJ[%2JRD[[EJ&+6KA1Y%M#81?W2=OYJO/ZBDY4X[NY'O,>/#3ROOO-1E;/
M581L!]LG)/XU'MDOA17LWU-*TTJPL7WV]JBR8QO/+?F:RE4E+J6HI%QE$B,C
M#*L"I^AJ5N,K:?(9+"+<<O&/+?\ WEX/\L_C535G<2>A:%04% !0 9]* ,F^
MG8 3BQB=(;@Y8R ,VT'/&WV]:Z(+HWT,Y.QHQG.N3GUM(3^K5ZE/2*.*6Y>J
M[DC616V[E#;3D9'0TP*\1N(&*3L)(0"1.3@@>C#^HH LY#*"""#R".AH 6@!
MI*J"2P4#DDG % %:W(NU2Y>$*%8F')YV_P!XCL3_ "H M"@!: $]* ,5?^1E
MG_W&_P#08J\FKL_5G;#=&D.E<JT-A: $H 3% "]!B@1S.MB"VUR.:YD\FVO+
M=H9'ZX*G(./R_6O1P<].5G+674KI=:7#$SVVFWVH)&OWY1LC51VR>P]ZZG4B
MG:YERLUHTUJ:%5A%CID1 QY*[W ^O2N>6,C'1&D:3)(]#A8@WT\]])W,[G;G
MV4<"N2>(G(V5**-"&"&W4+#"D2CLB@5@Y2>[-4DB6IL,9(Q2)V"[BJDA?4XZ
M4XI7L+8P9;O6)-*%Z9+:&*500L:DL@/0[NG6NE*"E9&3<K$UO:PZ7?6[G4Y9
MS-F-EFE!SD9#8[=/UI3;FGI8=K/<UWGACD$;S1H[' 5G )/I6"3>QHY)#Z0S
M)\0?\>5K_P!?UO\ ^C!73A?XAE57NE2Q_P"0IX/_ .PVW_HJWKUCA/?Q3 *
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M9AN)).3R:T=23T(4$BYG P. .U9W+"BP@S1<=@XH #0!3MD$%_>0KTD(G'_
MN#^JU;UBF1'1LN 8J"Q: $S0 =!0!A:A#IQDR]Q=*IG_ 'P1Y=@X.[IQ^5=,
M.;\#)VN:\?\ R&YP.GV2''TRU>G3^!7..6Y>_&M"1: $([=1Z4 51#]AAE:V
MC:12=PA#  >NWT^G2@":"=+B(.A..A!&"I]".QH 1A*UPJ@*(-I+9Y+'L/84
M 2XH ,8- "T (>U &*O_ ",D_P#N-_Z#%7E5MGZO\SLANC2'2N0W%H * $H
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M;P@JLI(UIB0#T_=6_P#@:]<X3Z!% !0 4 % !0 4 % !0 4 % !0 4 % !0
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M&(3'/<-M9MV1N#?XUO!K?L9.]K%^(;=;G'I:0C]6KU:?PHXY;E_%:$A[4 %
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M'2[.VM]9\)2PV\<<CZR59D4 D". @'VRS'\37JV.,^A13$+0 4 % !0 4 %
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M/!__ &&V_P#15O7KG$>_B@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 E
M'G/Q"LK'6M=TW18Y]3L]8N87\N[LD)5(B0&$N/X,X^E%W'5.P63TDKH3P9\+
M(_#VM_VWK&K3:QJJ+L@FER!"N,< D\X)'X]*7-.7Q#?(M(H]'IB///"EQJUA
MX/CURX:\UB23S9C"LJH(T#'"JIP#@#UI7L[,/0Z/2_$2ZIX=.LWVGO8::]N9
M\W+*3Y>,Y*C.!CFC1Z"5T]3>C97C5D^Z1D8]*8Q>*6@!3N!';W$5S$9('#H&
M9"1V*D@C\""* )J "@#&\7''@S73_P!.$_\ Z+:@#P6_TV*#P]#,L]R6-U?)
MAIV(^11@X]3W/?O4O1#6YV<<8BC6(,S! %!=LL?J>]>#>[N>BE9&#X@OH+BS
MDM+9V>ZBE0DI&6$1#=ST%=-*#3YF93DK:$[:=/JKQSW\P\GRV 2,X)#8XR .
M.!Q2]HJ=U$KE;5V/ET"U,,O#2W!0['D.2&QP:B-6?,/DT+EG+;?V;%=1K'#"
MZAB<!5![\_7-1)-NR!62&KJUJY_T=GN3V\A"PS]>GZTU3:W8<URG927WESVU
MM;1Q>5,<&=\[5;Y@-J^Q]:UFH*S;$F]BV+*XD4?:K^5CW6'$2_IS^M9N27PH
M=F936L46KW<+W4ME Z!@4FV;SCAF8\DYW=_X:U3O!65S-Z2M<O>'KR2^TA)9
M7WLK%-_]X#O65:*C(TAL:GL1Q6>Q12THNMEY$G#V[M%^ ^[_ ..E:TJ?%<F.
MQ>K,L*!"'UH&8U]/J.TS1O;"*&X;8K(Q8[0W4[L=O2NB*BK+R,I-K4TXCG6Y
MSZVD)_5J]6GI%(XY.[N7AZ51($4P&2RI!$TDC;47J: (X[=?M#73C,I&U,C'
MEK_= ^O6@"?H: %H * *R6H@F+V[%$;)>(?=)]1Z&@!UO=1W 8+E)$^_&XPR
M_44 3$TF!BH?^*DG_P!QO_08J\NML_5_F=D-T:1.*Y#<,T  H 6@ H 2@".X
M@6YMI('9E612I*G!&:$^65Q._0HI-=:;'LNH_/MD&%FA7YE7T9!_,?E6K2GJ
MMR+RCN:,;K)&LB-N1@&!'<&LFN5V9H.H * *&L0I/I-SO0N40NN#@AAR"#VK
M2D[27F1/8RL;--L=8DNC+*6C?)/&TG#!<_YXK9ZMP(Z7-676=.BD\O[9&\AY
M"1G<2/PK!4YOH6Y114N[EM0@BC2UFAC,R;;B3 "G=P0O)/I^-:0BH/5BD[[%
M];(&XBN9II)IH@0A8@ 9Z\#Z"L^;2RV&EKJ9_B69H[.T @DDS=PME ,##@XZ
M]3T%;X5+VA%9M1*&E7+RZWX3C:UFA":R6#N!ALQP# P>HVY^C"O6.(^AJ %H
M * "@ H * "@ H * "@ H * "@ H * "@!#Q0!YMXWT'Q+XH\0VC^%_$<&GQ
MV41$I63+>86Z8'., 9SQ0W*&J0ERRW90T3P5X^L_%VC:AK?B9=6T^UE=I(@2
MNW,;*&Q@9Y(_.CGD]&A\L(_"SUB@#Y_L/A;X]O[ 3P>+)=/MIF<I:&64>6I8
M\8''_P"NE[2:T2#ECN1:G\)/'MEH%TH\7R7-O#;D"T267#J%^X!TZ#&*/:36
MZ'R09[_:@K:0@C!"*,?A3$>:_$3P[XLU'Q1I(\.:Y<Z?!>*\<Y$C>6C(NY3@
M=,@$?6FIRCL+DC+<Q!\-?B:.OQ ;_OIZ3K5']E?A_D'LJ2V9Z+\/K*]TWP9:
M66HS&>]@EG2:4DGS&$SY;)Y.>M%V]6.R6QT] !0!B^+_ /D2]=_Z\)__ $6U
M 'A^I3PMX9@19HRWVS43@.,X*C'YTFKH:W1UF0W((([$'(->!L>BC#>QU&"Z
MU%;6UAEAO/F+R2;0I.<Y[]_T%=49QDHWZ&6J;L3:==7;Z9 L-KYC!,>9+(%3
M/L!DD?E6<XQYM65&3MH6$M[^3_CYO@G/W;:,+^IR:CFBMD.S>Y6T_2[.*2Y@
M>'S6@E^1I3N^5@&'7W)JYU)-)H48K9FG(\5I"7D(BC7KQ@?I6*YF[%Z(Q)=:
MM;?6BT<C2+/$J>6H.2X/!_(]?:NA4Y.&IESI2T%U#7;NSB??9&'<N^-BV<*&
M ;(]?F'840I1;W&YM$<MJK:WI\>HW$%X9=X"!0P! R/PZU;;4&HJUB=+HZ!%
M5%"HH51T & *Y+WW-K);#Z!E1"(]5FC)QY\:R*/4C@_IMJ[-POV(7Q%NH184
M"$- S%OS8[LLER4%P?.V^9MZ'=T./RKIASV^1DTC5BQ_;<^.GV2''YM7IT_A
M1QRT9>K0D0]: *T,D.H(DRJ3"DFZ)B>'QQNQZ9SCZ9H L]Z %H *  &@ Z4
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MT2&"QUR6T2S:6V@AX)D&6D'(/TSFGS4D^9!:=CH*YMC4R?$'_'E:C_I^M_\
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MR[$-NMSCTM(1^K5ZU/6".*6Y?JR2J\C2W7V=$!B09F+=\CA1_,__ %Z +(4
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MSOH(M=CM?)NK9Q\TT+892ON-H]1C-/D=KBYE>PSQ?K7@B_D;P[KVI6JW$H9
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MR22[D+6NIS)9P-Y?E?*6.TX[C*CC\:WFTMUJ0E=Z,VJPN7L% Q* ,'4+8,)
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % %>]O;?3K*6\NYEAMX5+.[G  %
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ML]!_X^M<_P"P@W_HN.OH#PS:Z4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MZ4G5HQT8O9U.Z+VC^./&.N>-/#MCK7AN31[-[ER9,./,(A?"G/'O^%"J4Y?
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M /1BUT8;^-$QQ'\)G::#_P ?6M_]A!O_ $7'7T!X1M4 % !0 4 % !0 4 %
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M_MTD<I3HS(JH3^.W/XU[$7=)GE-<K:.QJA"T % !0 4 % !0 4 % !0 4 %
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M*O+:\,9>:^FN%\MB1M=LC/'6O3A'EBD>=)WDV=+5DA0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
74 % !0 4 % !0 4 % !0 4 % !0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g833164page036.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g833164page036.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_[0 L4&AO=&]S:&]P(#,N,  X0DE-!"4      !
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M)/\ ?CL/XFXI^\:>)M/@'G*>'O\ XSZ/K2_F9R61O_+%8;?[S<4_N?3Q%I\
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MAO)0_P#3%8?Q-Q3]XU3Q-G\ \Y5QCO",#ZOK2?F=R3_?CL/XFXI^\:KXFT^
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M_'8?Q-Q3]XT\3:? /.4\/?\ QGT?6C\SN2?[\=A_$W%/WC3Q-I\ \Y3P]_\
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M1^9W)/\ ?CL/XFXI^\:>)M/@'G*>'O\ XSZ/K1^9W)/]^.P_B;BG[QIXFT^
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MB:]ZJ[B!MT\=ON>W]/530;:!8H:OJ'$X)=C[M4V[ %4M P)=4]J3<;[=/U=
MYKA4 4*KRR,"37O1JN' )D[7>=(?#510FE JAG:[SI?;MK'([**@"M53)VN\
MZ/ =?'J/N[;ZNV;0%;&"[:3M0!U^ETZ^[8_HVUC!D,QP')H*8;]ZN>&-.7,:
M]ZN;)W/TMON@:N#CS"*#+1.6"-I\Z"@;$[J\-_'IJ^O8%:8FCVJN\ZM$@>)
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M\M_DOM,G"EUC55++Z8#EF.ZL7*<4A+I!!UI;1SX.GM1CRGFRRU WFIV@;3Y
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MR'&4,K#A402==/!=Q0:UJ,Y(,<]KD;B*5R[C^6*T%S97$^BVMJTD2PWH>>)
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M#7SV\DD6UL9/F%5K[V9UG.R%PKG<&^<T4:_L@O7'ZU?5UZ_/M*X_+. <:U>
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MQ4=\?H5:R_ ?R\J3XV./&1'_ *^R/^OUE#'TK4GR*E9?@*7XQD^#[']=:/\
MU^A%,"37N5:R_ 4GQ;/0?$L#<[#=UKJ?=^/XZ5ILJ>Q*R' M+>U'QC&X'Q4;
M<[$#SV=R#X;#OZ[[:K]H?=C<F5_'T(^,9'C(8'_96OW>J8<?0F:7X"JD26UD
M!#S*R=R$I6VHD#8'8)42=M^NJ-?F<6!I--^Y7@FGM"A62E1.^_LVU<BJT1&B
M(T18SP*DNA)[5%M82KKT5Y9V/3KT.K7FC2>Q6O:7L+6FCB" N=RLFR4NNK_.
M&\[G''BH_6TW;J^[X)\W9.W0#;V:T_,N?B"\NNM2O&F1I=7EORGM[E0[DV3I
M:>6B\R20IIA]\1XEC,=EO^0RMXLQ6B^GS9+@1LVC<=RR!OUTYES\06K-_?F3
M+GI4IK>)_4!-Y@JKR\QMOF&CK*+)+G$Y;V?UD[&'Y&0XS<3L>R>%":5/?$A=
M)>UST9X)_9HZ;C3F7)VN"V$S]0M&L<Z5KN8*X5PIAO3J')LH(^CD=V"=CO\
M6LW;Q!\?-UDB=*7_ &IJP FG<*K!^(7AP<[!0H]9.?<DXP[PUD%1GV8U-=89
M/D6%WPK,FMXH==LZ--SC.\=IWR)#SEQ2J9#B]O+0X0#NK7EGS1O-6@Z;?K>G
M29(XS3)CF/<1@O8/D_J=M?:S^':LTO9N.%/2N6'"',_-E/G7/_&=US5R_96&
M*9]&R?'?KK/;NPE-X-G-<Q8U+<8F0VF/$C.CRPWNHI4%>S7BFJ=27UQI,6IV
M]S.62_HYL6]^[S+W[3=$TSQ$L4D6,7=CCN_.I)IY7Y?4G?\ E5Y*'CU_/*W2
M/G[3,WUQ/\P=05.2ZN VO$K>G1],?[44+0PC8:*O^5;EWIMRSR07%'8;9G<'
MO.W1"=Y( 6H]$C]D>FJLZBZCKRFW5QS),![162'1=)#)'SQ,HUM0,,351XRW
MU(<[9_EK_#O%7-O)=?*KED\O<EP\JN)L7CNK4V4N8I0/N21%>Y-MEN]C2TA;
M=:VE;J]SL-=CIFI:OH5J^ZU2YG\3E)8,V)-,!BN=99V-_<&""W#(R:$D-/YU
M:;Y)YZP^ZI.!Z3G'F6129/7?6U?E][R!?VV:4^#U+<EO/XIR5U\+E77QCL)J
M&^6^^*+$E /8-7P=:Z[-:2ZJ+F81Q5.4N]HTX;E230K!DG*<QI*M0^=^:.";
MZLQ#,.9^8+?B"^<B5V$<EY-GEW:6&&95-E*2./\ .K=,A)E5,SO3]4V3J$ $
MEEU?0'5]QU5K&MZ;'=VMU/'(Z,.R.=5QJ.Q8OPZST^<":$.8XX$ ;/*I('E?
MF $C^5?D4;>UG+[KRSN 00L2UI7T/B#KD)M;ZB:X-?=SL<!L+BNGDTC2Y&,?
M%&P@MX#! Y9Y;[D%7+/(;H0M*_*5F%RL+[=_HJ29'0'P/R:P'J37[0MN3?39
M8W!QQ.(!Q'>=R@7FBZ?R#FA%*C911ABYODM'#Y1>R[/^9+F?A.=60(@<@YC8
M75G0YD["R#$WFV4W#*)2P;EV.D)[4-,1T)/XNNSO>K^H+W4+)UK=2AD[12I.
M!PV^?<M0=(T,"CVAIIOHO=<R[-SV=M+ZH^[8J2/SIR1"=RV=D+VS-!ZI6#L>
MGM\=2F]3]:1ZG(Z:_A:R%U"*/Q[OSK%%H>BLAR.8"_C@I->FSU5<*\>X3E.$
M\^\#^I[.<KQ?(KS)J[+?.R.QDS>,[J4]+QTVL]>;LEQVDFLRX([]UK0PD]1M
MKWOI_P"86F.TVWCU68&^<TYG#W3B:=NR@7 :MTO=.OY'V8'AB1EP/ ?352#J
MO6KZ+LBK8MQ2>E#U2V-9,5(1%F,BZ0VZY$>5&EM[*Y"!2Y'D-E"P1T4-;"?Y
MF])6\Y@EN6@BF/%:UO2NK/KE9L[UE/\ JV])7D2$L^D;U4,RW(TE,13QMUL)
MDK8<3'4Z1R&0EM+Q22HCZ(Z[';6(_-'I1P+;6[9XD@Y:\:*X](ZH[V9&')OP
MW+CQG.?>K1CB7#48%5^HJ?R90Y1AUK:5]O9QT0IF/P;Z0]E%996AR)A5@TWC
MKR0([CP3+6RD$]-]>?P?,Z]GULPRWD0L\W;1=+<]&6/X8!';R"ZI[V%/K6H3
M>9OM$I]C25U1C/(&,5]A:.P<CRO)ZRLLU8]3I;*UV=3047(,A=[=JV+;3+GE
ML(<4E1/T3KH?]6+N&TE%M/:%S<P&!W;%@CZ+BR-S YLHKMX*0N&Y9R9AV.0,
M=:L?6-DR((?4NZS.:G(LCF/27W)#YFVKUFA3K2'7"EEH#MCLA+220@$^7L^;
M'55Y(][+BT920C%KMF'#O6TMNA[8VYD=&Y]"=GYTT>>\N^M"GY ?D<?XWSI>
M8-;8W6N/O7#E4BSJ<HB/NL.UT&LFYC6-,UTNL+<AQ202'3\IUUUK\S]5=:B+
M4[NV:W U:UPQX=VU09.G+)CL@M)B>PA>%_+QZ]3^+Q_S8H>PAK%0#]_D7?63
M_4J/_GXO,Y6?R[:?\E/YPJD\Z^O=6_\ YON;!M_\%BI__N-I_J5'_P _#YG)
M_+MI_P G/YPJSSGZ]QU/'_-G]9Q;_P"N+J\?,4D5;>1$>5/Y=M/^3F\X^M6S
MSOZ]AX<?\V'_ +%BP_3Y%U:?F0&^_>Q#R$^I/Y<M/^2G\X^M5?RZ^O?;<\?\
MU@>_R\6/C\G\HN@^9#3@V^B)[BG\NVG_ "4_G"!SKZ]CX<?\W'Y4L8N1_P 8
MWCJ[_45__-Q>E/Y=M?\ DY_.%XV(\\>M:3R;554[ ?4?DK37)V.O9YB%!;8U
M#MIV!,<;R)<O#<2,[*I,#&LDL&!*NA+=<7$<3# *0HIWW>C=?MFB$'CHL[ZX
MT=0=^"Y_J#1'Z58>/M8G!O [?J74+%9DO+,7QO+:C%/7#]4Y70U.25HWJWRB
M%=06)[+9?:MFH[ZV0\4*6VD-J*24C;7*W/S#U^*YDBT^\M'VS7D5<UU2=_DX
M+RR37[UKJ2@!_#LW+VW*RY2$@8MZX2%J"5;MU1 'CX"U/NU&=\R.JV8^)LS_
M .%RL_F&[WT7CP:'.XUCDDBZA>L2WIIUI">PZLKL=KJB;C-*W6QVK"MOK!5^
M\C)K2=<M+D-R0AH,LJ0UL>TDVCYE]5D_Q%G_ &7)_,-WV+W/JRZ !&)^N#K[
MFZSV>_MMT>_Y=9?]1NJ_^9LO[+E3^8;KL6!;4N62*JS9HZ;UI55Z_7S&J6SL
MJNNNJZKN'8[B*VQL*9N\C.VL*#-*'78WFH\Y""@JV)U+9\SNIVL ,]I4#X2J
M_P PW?8EJZ;+8];7QKNC]:]I<L08;5O9U]975-?96B(K*+&PKZKZ]<-9!G34
MN.M1^]?DH4$[]-89_F7U7(06W%F,/A<JMZ@N2,2T*]\!=.$MC$O7$#U^DI%<
M1T^076_746?YD]71L#FW-F3F ]UV]7C7KDX MJHY\U9ARWA6:\956&Q_4Q2T
MT^':9'G%=FM-]97>34D7D+BOCYFFQ)^+?(8H'4+Y&<D+GJ#JOBFXS'9VN*4.
MHT3K_J*[LYKF:2V)B&(RG' [%)9JE[(*AS1YU)9RJN6W9#:<5]<G8E]Q ;<1
M6E0\I13W*"KA:=]<Y_J-U9_S-G_9<H7\PW5-RI^K+?;=>*^N% '512W4)6D#
MQ4E1M" H#J.FL\7S+ZI803<69_\ "Y/YANNQ:Q2T?(#"[YS(XGK&O8LR^D2L
M4C56-5E'(QW&51HZ6*2]?7?REY#<)G)>>5.'EI4VXE 0-M9+GYG=4S-:UMQ:
M C]5R?S!=;Z+9!5W/ECMQ7UO)5V]/R57T/W+8*_#K!%\QNJ.8.9=6>2N/LN5
M'=1736UPH$Q7/.:9YQWB\%K$,=]8,#,LIF2H=7DF4Q:RRQG!:*A89OLVS[(,
M:%TBPR^MQ3%H\B5]61G$.R74('4;ZG:!\Q>H9KYT_B+-T;3L#756>WUJ\N/=
M("]GAK,<HY$Q^6;[ /6_39=BR\>K,L:9EX],K+*QN\6KLCA914,UEZX*.GRN
MLG-S(L"0M<F,TX$.'N3J'J7S*ZG@N7EMS9Y7/<0,KJ@$G X;E9<Z_=VKLKZ'
MN3P?5=R/_DQZWC_B4UZA]\76H)^9O5FUL]H1^RY6#J&Y(K0+R9=-F,BQJ7(E
M7ZT(=+&<LOKVMF5%?8S[B.Y7.-5*:NU%\V:%V!:*2^Z>U:GTCMZ#5/\ 4[J[
M]]:_V2JCJ"Z)H2 LT0KD'M&)>N18Z#N**[J=@%'K='Q5N?;H?F=U<!]]:X?J
ME5/4$X%<S2LENLNO.8 Q+UR *>;0LLIJDNA#B@VKRB+5)\XA7T-B#W:JWYF]
M7/+0)K3V]GLE61]174FRB8?B3(^6,GS;F.AS-OU27U/C=G466#1,-IF:JVQ_
M'K:]SFB329D9&0R6KF>R<.\P34A*G'G7FRGL;2=;Z?K[JBQA:Z::T>ZFYI'K
M4B76;R*,2$M(*?85UN?#%?7 G_L5:-_Z&W1OK62_,SJF4 PR6K>-6E8OQZ[R
MAQIBM>RN@Y L,=M8F#L^L3%LO?CLHI,AR+%:[+J>KD)GQG92YV.)R"$;1,FK
M0]'1N\DM.NI=Z]FQQL^9?5L3A(Z:U+1NRE4_F"[[*+8UU=TE3JTXIZXO+4XI
M38<17EWL)^B73]<#Z>W3Q/0#KK+_ *L=4_O+;^R53^8+K?14BLNO'\TO7 /^
MQU?_ %MND_AU7_5CJG]Y;?V2LGX]/\06OS*3D)>24\N)%]9D;#H];:L7V+JQ
MBNDY#<7$A<8TMI695^<:345E6VVZ)43RE?$E:3N-M4_U7ZI_>6W]DJGX]<;G
M-7NMU5\"2O%_6]MM^T@^.X]]WJYOS2ZIFJ.;:MH*XM/F5IU^X&\%:MG=Y.P+
M$[/*[#"?7/:1Z]VO9CT\.SQVCGW5A8V4.K@UT*QM[14%EZ3*FI2"X2D'QVW&
MJVGS*ZKN;EL9?;F$O =1IKE)QIY%G9J]Y(-K0%'O@G/.<LERW+<+YBQ3U1BZ
M74RLNQ7\RH,.N=QMO'<D8P_D3BK)(TG(9RLCON-\BMJ]@WK'E1K$27-D#RQK
M<:QU?K4,1EM[J)@[0?H6.35I8]M5++ZJM^XI3BGK@(!*0H-50WVW!(_U4^37
M*M^9O5;6!K9[9S0,"6FI[5B_F&Y&#:46O9-0\ASJ:7$PICUEXGD2W8)B7V08
MO69=4Q([=E"=M6)%"C((/QCUC4-R(\=9<VC2'$.[*[2-28?FEU7$"'2VQJ?A
M*K_,-UV+U_@+;S3V8IZXPGN4$I4U![P.NP43=#Z0'CJZ?YK]5F,ALEM7]DJO
M\PW78LKZJN/V6*^M_<CVMUA.W_3VRSJ#_JGU=^\MO[)5/Y@N]U%XPI,[3D)E
MIA>LM6)''4PSC***O5=?G,;-;_YP')!?H2*551VQQ7AK^V IXKZ]NME_JOU3
M^\MO[)3^8;KL7K(J[DGM_-/UP;@#<^56?@WME*W^[J-+\T>K)'YA+:@?LE7#
M7[DBI<T*MNKMRXV7<7]<H:2M*W&VE5[3K[:5 N,-*^N%D.NHW 5N.W??5T/S
M2ZLC)+I;4BGPE'=07 V$%:]CE+R)"JDP\SC>L?*+OZTN9!ML=Q>NQ:L13OVT
MV1CE2[3+R*;O8U%(['B297F'XMYDO;#NVUG=\UNJ2"!);##X2K?YANNQ>ZJO
MN$[?[4?6_P!=_P#(JGV?/::C_P"J/57[RU_LGZD'4-UV+7,HJ<^G4<R+AL/U
MDXQD:UPS N,@Q>KRRIC(:G1W9[,BG1?07)!FUZ'6&R'!Y+CB7.H1L9K/FEU5
ME'VMML^$I_,-UV+9366^RW4XCZWP%*)*0FK7\Q*C;+*E*'B2=_O:A77S3ZL#
MP!+;;/A*?S#=]BL?5]P^4L-XIZXT+>4&TE"*E!W5_AS9[H^<==]8&?,OJRY>
M(3-;BIVAI5S=<NICD.SL4-\.YGYGO^6)7?Q]ZM;#AJTB/_5E)5/XU#S[$Z)O
M,*K :'F'(LK>O_J_)<9RO,&[2 NBBM"QKS"86DGS%C7=0]9=06EIS9[VVJ6F
M@RNVT60ZG<4J 5,?ZNNF5K2O%_7 K92T?08KAU0K8GZ-L@['7(?ZC=6?\S9?
MV7+".H+KL4NO1#'LXO/];(D4?J:@1G<-RMI4CEA,48@E0-40WNQ825HM7>[\
M@"D[_2.X&NRZ%ZMUK6-7-K?SV[PX5HT$;%N=-U07I$;@1+O.Y=JQX#Y@?O\
MZVO7VR"0D@$ &G>MPX463J]6HT1&B*PY_DG^(5_C#JR3W'=Q51M7-(_CJ_Q3
MO^;N:U"\=O/:==9<?MSZU;>0767F0XXT7F7&O-96IMYKS4*;+C3B"%MN("MT
MJ&Q21N-"6C::+7W69M#'4O&T=JT7CWC;%>-:^PK,5C6S-=96UOD,N):W%E<K
M<R'(+27<W]NV;"5*6S*N+F8[*?6D@N.N$G5H>QWND$*2ZX?(UC)<'@8 K??
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MVQ.R..--V*O;;O<*BGG2@@GH0=M5@<V:=C6'&M<<-Q5WAI:BE-O%0NYW4O\
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M[ME=JPH;CH-4?J%WJ%I(Z[<'9*9:=M:^I9F6L=K<,Y9)S?11/ZD !(   2
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M_B&VWL_S[K6LZ?=3%]37>1]:QG2GM- 58/JIQ4__ "(R)/\ B,@PY)^7JN<
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M@LHY1S998_GCRYB@\9:.!:Z$TH29 :;CO6[K[C:(Y=,1*EO("U+\HN*[0GN
MUTL/_3Y[EM+G^'"DSKBUSZ9[FS^T.'__ +(OB?\ S/+=;?1_?E_9"V=K]T/+
MZTT_KO04>F>^6=MD\K^F_?;QZ>H7CT].@]VM[TK_ )P/[F?_ .TY;?3?XQI7
M@_9^?\FEW_[([UE?@]4/)6LOS/\ ^I)?_P"O_P"VQ1-4_P S/D3Y\/?VUZ@O
M_LJ^6_\ Z7.-=:WJG^(M?_;A5N?X3R)XM:1GN#N"Y\;$NKU5 ('4D #W^T^
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M$1HB-$1HB-$1HBPE-J+A)22-O=TWWU7!5PKBM,Y%HU6V$Y!'C#ML(L,7U6H
ME:;7')+%U!*=NH'FPMCMUV4=3=.&6]#G81%A!.Y1+YL>1LC2.8U1XYF<L)$W
M!^2<39QEQ&>5M"^S:6ML[27V.Y?C:).0TEUB245=DF6W.QNUL($]@ALOM%"=
M_H=.PZ:NFQ0S65[[-MGJVNP[:K3SO@!%P:&=VWC@FJP5BXQ>7A&3VEI*R+-,
M/M'8QF2KZ*BLF8/)^MH$V@;2]7JL4N)K+5;K#2E>6)B$GP UM=7FTZ[M_ 0M
M!C<*9MPWU]"US'N-Y'=N/N.K3R?G4F6^>JTVE-$G8RF,S;6L*L5)3?07G834
MR:S <M7*]49IR7!K7+".7PA7<GS$G7(3].OB;GC:2SCN6\_&-]$_GEK:>+?;
MVA'<EQ*22E*AN-MU?2(W'0GKKG7#*2T[C1;9KLS0[<0#YU?U:JI&W&&I#+JU
M)26WF5GZ!<)"74DCM'7PZ[^PC5CB\21EHJ!(VO8*XGR*IKRWC>6$!,3@:,XP
M7!Z##Y?&-I</8^J\C+MH&<8=&@6")F47EO'E1H\U*)3+:XMD@%*]B% ZZ;5[
M72;_ %*6Z\1'EY+:8G$MIAL4"U8Z*V(D!:0:^11SSJRE2N4^6[2\II&,.1,/
MXZFRJZ58U]Z]'@5^2\.2%3ES*,.1E,JC-N.*2D%24I).NKBLK>ZT2,6[P\@8
MTW+G)W-?J(E::QUVJ6C_ #3Q/YCX&?8]Y9<=/>%S">U2U$[$1/EUP=UIMX+V
M0QQO=%FP(&!V+>.NV$U:X%JU.+F.)9CS!QS^:5]"OT56'<R.6JH"9*FX")S.
M!(A&2X[':;1\4J*L(&^ZO+/NULH+:>.QFYC'#W=OE6!US&;F,O<*8_0GX21]
M%._T@D;CVCIM^GKE6O;S"VOM<%NB>86O;BWBJ]9E<MUXL)5R-B@V[BBR\P]-
M^U*(CX[@0#L.U0\#UWU6W?.^9T=H"\,]ZGZ/>N-^8@)Z4NR/TFX=JG.@[@[?
MMEC<>T!1 \/D&MSG90&HV+XDD(J!P 58UBD.<4;B5B2ZQL8_,,#M1)J6[V?>
MP54:LSLXA$:N!!V(@:O;[U-Y5\?O*('K&0DXQA7<-Q]6^H4J!/3=/ &4=2-]
MCLG?[FNLZ=VR<6M->S:MY:?: AF)HIF?6-@/+ F/A 8C! \PA.R8S.P \.B=
MM<SS(>,OG6J\;*.*3ZQG]W>)DGO"2D*#RP0D[[@;$;;[^S5SI8C'D#23Q+L4
M\=+VI%6ED-MIDQ74?YX=Z#V_L]1H97VF>1G,]H#W379Q5#>7!:>6"7)D.1;Q
M6$\E8;R-=6+K>&WE),XOR^RG3U-U&(R7YSN0X1D=F\^L1X<&5:&7 D.K(0UY
MC2E$)[SJ;:00ZW&ZU<^1MU(*-S'>I5DZ2\!CNO9<=E5'AJ'9^MU^:Y9RY%3Z
M,:^S1%QZOJG)M7DGJ9O*&>8UO97UB\RZY7\$19\93<=AM*95XXRI2EB.I.^^
MBBL^FH1D -X/TE+<ZWL,'.!6SY4Q'A^JO!H42/'B1*Y[A*L@0XC#4:+ K8&$
M>H"- @1([(#4>'#CH"&FT_1;2 !JZ(OU+2)I9G8ESCYS526S>(A,A]W=]"F&
M"DCZ.VVZ@-OVH.R?^I UQD41A!8>*YR61TDAS;L$H\?T>[4F$@2"JQT)/<H=
M<JI*?6/Z6G$N%I?YOY1]))V4GMN5]JD^.RD]QV/CUUU.@C+HEX7B@+G>I='9
M&EL91[F4X^13239V*!V-S)"4)('<'5)6X0-N]121N"-<HW)"*Q@U_:*TWC9.
MU4O3YTIB1"D3)'PTR-*A2'/-=[Q'F1W(SZ@4GN[DMNDC;VC66&Y@;=QR,=/S
M_P!( ^R/R"K:WET)W%S2(CL.Y0?D<^V7&6!XOQ!2X_'S?U01;-?$.#\7>;Y#
M%_:XS7MJA\E9+,0M#U?Q34X?Y%K;32>Y:4K9:/G* '41:9#=W+M4N7AMM"!4
M']*M?513(H9+B8NRDL&T\%9RWA-7'/ WJBY$R_))'(7.O)'I_P"0(W)N>=JH
M=-\)!PZV6SA& 4BP1CO'51(_M:*I:WY'8AYQ2E:,U2UN]?M[:S(CLCG#N!I&
M^GIHI+9N7=LMH#4NK@.XK<*3B7$^7N,,KQK*1;5RZGU&\S9+B.78K,;JLVP/
M*86>OJA9)B5PIEXQ+",1NXA8+,EH%IP$*Z4N-:GMM09:RL)A\.:5W[52[DD;
M7,"%C4/J&F<93LGXZ]1$R.KE/"ZF1D>+7M/5.5=)ZAL61*:&/SL&@+=D*:S^
M1)>8K[FLWV38%;K21&VVL=HKYK@2V\P=:T!)&P5%2/)L4B*"WD@,C2"\!2.X
MWKK/$,"Q:@<;E4TYFO?MKNJ3)6I-=DN4V<_+,HA((5VJ;BY#>26T%/T5(2".
MAUH]2>\7) /-:UH&8$TPW>1:4W,]2 #0%;F;.>L%*I<K8CJ"\YL0>A&Q4=]]
M]08)Y!,W(<F.)J3A18WSSNH'5:*J(63N/#UD80XE3@4G%.(^Q3827$@4?K26
ML-E6P[NF_L!.NQBFEM^FW2LJZ,SXD<*A;ZTB;R3*7 N:TD#B1BFLY ]*7(^7
M6DX_F[Z>K6''Y6Y-Y(J<EL;_ #.MS&^K^0,@N+>'29G%1C<^O2NCA6X9;;CN
M%I!83L.FJ:=KUG;?><P]ZOAU8Q?>#+WKR>,O2#R+Q98U]E!P7TV9:JN,Y0B9
MAG&=2F9OQ2K13?UB]&PQ,B4U7L611';'EAI+:0._Q&V?U;#*QT32&LV"NVBH
M[48I7EP<*DKUX>/W6#^L/T"8C=/UQN,5]%GK&I+-=$[,>I$2F+_AAPHI9$]M
MF<[3MN2.R.7DI6&TCN&M8VX:_IG4;AV=P$[,6[O8<KWW-;=U#O71#ZRL$J*3
M+D!P %0+BMQO[Q[-]]<!;.YC&W#72\P5H"M/#=AA+7D!RLNRI#Z>QY]QQ'<%
M=JEJ*2H$*!(WV5L4@]?=J6^6>Z;RYG$-[5@N+G,:MQ7EVEC!IZNUNK22(E72
M55K>6LLI*Q&K*:NE6EC)*4@J4(\*(M>P!)[=M7P02W$S;>!I=,[W6C:>Y7#V
MG96XN3;\9\YX-R7/?@83<6[UA$QJMRY;,^DM:)Y_';KMCU=O#3:PF6WXK\GH
MKL((WZ>_4B[TC5;6(7+LT30X@UW$&AJLLT4MLP2.:0XE0!]1?*&%P>?>6.-L
MGXXS7-<TR%_@!_!LIAY'"CXSA4)@U,ZR<EU,JQC29 ^+8\]PMMK*U%(.^O1=
M%LI;C3HK@R9VD[0M_9QNY+;@@T)VKR_37RE@5UG_  IA>&8K<4N;XIR/RU5<
MEY0G+V)-#?(DSN5)+5>K&&%>='$JRCH=;"AV)4UNKKXXNJ;"XM-/DN0""(R6
M]I[%356R1RM-#G KY.*Z*<C\UX#QE.J8&=V]BS:9!4WUW4PZRAL[U]=)BOP+
M=Q/=%:P\8D*N=LXZ%$@;ET;#QUPMAI%WJUL9V-<]XVT6K;$^Y:7T)8-I6_TM
MQ6Y%24U_3R$S*?(*FONJB6&UMB95VD9J9!E);<"76TOQG4J"5 *&^Q&HUXT0
M/9;/PE: *;ZA1)6QM%8S4KVVI4EA/8S(=:25=Q2A1 [M]]^A]^LKW,(:*OJ!
M^B?7VK#%+* <P(Q5]-A8*(2)<@[]-@M7A[=SOL !JP.C:YKL[V .&+C@LO.<
M".]<[\RQ.]Y%]5GK.PFCE5T6]SGT&\#8W73[I<MJM1+LLVY48CJMGH <G)K>
M](#Y;3WAK<C77P.=:=/17%P?\/SB<QV4.P^5;*ZF<V)I. J%Y?*'I$Y"Y4LE
M6$K /31AG?C[N/\ D8;F.=06F4.3V9[5I',O$'UL6;#D<)W'<E3?T?;JMKK^
MGVAJ'2.\JF_B<7$*</V<7 ^8<1<_N65IA_"\"MM\&R:*Y;8;>Y-8Y/"D_&US
M["6HMI0UU<EFQ2#\6L.A?T$ )Z:]"^7W5 U#JAMO$T\O(1CM\JVNBW$<MRYP
M(J5WT0-]]P"-^AV]FP_5U] P4RDC>XKI#Q5S6941HB-$6/(5^1?3M_D+O7_L
M:CK%-]R_]D^I5;[P[U\C86&W)8V)_P!4[3P_UPDG]77YXZECJ\__ +J3UKZG
MMQ_A!_[5OJ60D]P!V(WZ['Q'SZ@1^X$2ZO1&B(T1&B(T1&B(T1&B(T1&B(T1
M&B(T16UN-H4V%@*'<H*21N"AQ/EK01[4J2>OSZOBGR/R\%;) 'LS<4S;_$##
MU9 I3F^2&GJ)\B?3U[L&G?15.O+FJ0(DA443$".W-6A'Y3HCIMK:_BS[-H+&
MYLWT+5&Q$CCLP6$.#XG3;,<@".FP$2N3T Z=0C<'5S.I)B\#E;^"N_#!169G
M!,"5&DQG,TR-@RX,RO,EJ#4N3(\><EI,E4*0^PZJ(^KR4$+1LH*2DCJ-26]9
MSO=X;E[%0Z:.Q/PVDH0E)6MTAIILN.;>8X6T!/F+V '>YMN>GB=<_([.]SME
M7$^<K:M%&!O  *O5BJK"V M7=W$?)MHE4CK'F ;%/<-MMT[[D#I^R2?'Y=5'
M8*E6O&9A;Q!3+9?P539?F5EF[N7Y?06UK$K(<J/1R8#$5+%971ZQ+://A/NE
MB6S"94\A2BE:VP?'73VG4\]C;^&$5%J_PP4V+Q_YNU<$E(Y+Y'WV.VT^I 'N
M 'U9X#PU9_.=U'[ MZ@;Z;5;^"Q..8R4)W56=2\&1J&ZIKE/(G(<T5%I#M!
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MAUGA)-02:*H)&Q&L[?9]W#N0DD4.(1JI<X[25:&M&P!1 RS_ )66+>_ZRX9
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MTCD)26)$!V7&+ABGS5]Z4GIXZ],U#38I+8W,4;2P?#B<>(P7-Q74[YB V@'
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MB0\8>E4??7\;#(2V@%=H6S?S0>.=R?K%6Y\?_-1Z>?\ ZT&L/\R:O\<G]O\
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M\N W\1)F4FS:F6$N+$A1._4F]D44X=%,2&.;3 T*L?)(T!D=*DU\R=#TBYO
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MX?7DN1CB26XYCO/UKY;FIS#@K_>D_P"1(^^Y^[U1V6+%K14]I^M8<.".Y/\
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M*>7ZU#EIG*3O0?\ (D_?<_=ZM#2#7*/3]:L1WH_J2?ON?N]2&RO]TM;E/?\
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M%JE81^,C^E#L"CLHDF#%>3N@;#X:7*:U/+=ACOP5S9I96DS4J-B>?TO/M1^
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MMWZ[GK\FN08(PP&/W:+;N]XK,U56HT14+3W #?;;0*H-%CK3L>PE([T+0%*
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M*JWKLDO+W*>?IA_X5X7^]V[_ .XSKT/Y0QUZK:^OZ!6YZ>;ENG-[/H73=O\
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M*7CTBPP6KLTUYH'BY!:F>1.:7)_'4.XD;[[[ ZZ.VU^PCU=\VH,+W%H#:;J
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M4$:[?2I(M0TY]M,P>+$9=FIC1HQ"R6[?$UE/PE=-.OUD>Y1.]BH@D)! ,K<
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M66,)E/!*4H/Q 4?$:Z7YLVIEO[340!E<WZ%9TA="&S_#C[X*Z()<"-FU)4%
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M:"0.PE>@=-3TN@R4_9"G8IWLO7^/H+==0<6\-1SYS@D7,JLN[M]M9;#3GU=
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M$]O3?7HO2EM/!H-^R^!82'T)PK[)77Z9"+6VN' >TVH'=L741S^FO?Y:]O\
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MGX9UB511Q8,OX2+B%K"OIAR6OEXYR/:)O5QKRD@5ST"!+BLI+:U.*\U2%!)
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MQ0/<GX]8) .PWEJ]_P IUI+>+GS&V! (>#4[-JUULUTEP=PJF(X"'_F^D_\
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M4.)KL*]L'3=A:73+H$.@D%6O'N\-NQ>SCW"=E4,0X*9.-5#5?$9KTWL-J[Y
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M%OK56_@\8_2'H2_SP<#3_P#$CQV]OY_<;_I_7>KOY=D?[+#E>=AW!4_!6/\
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M&A"B3N%45.2.O3N/P1ZCY]<D-2U!TCFQ$B([3V+5NN;K*1V*GZGIO_ 6/?[
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M-6JBJT1&B(T1&B(T1&B*PXWT44D]WB/G)U6JK7<J&FU$'O)\>FE:)4C:LD=
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MXMR?A^0YLY#F6+&-TUD9\V37P&#*F3(;[;8@3V(T;\HX6'7"A()(U/ETR[=
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M-JI5&VJQN,>Q*I/^CJ6)3**D4I@JHU<B-4.Q4. 1J/SG< D)YAH<%(GTP_\
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M]NOSC56REDF4;P5)MY#"PR#:' I)33$A3C4AEF0R^V>]AYI#K#S3@[7&G67
MIMUM2SL4J!!'0@Z\&ZLL3IVJ/DBP?(25]9]"ZB[6]!9,35T0 \^'J4;_ %-M
MXU.X]K<$L<"QCD"XS[(*W%, P[(:F%-I$9&L..(R!<)+23$A817AVQ<<;[0G
MRTI)V.K>F[FZ;-7,0%M=1=9VDPM)6U#NQ;?QGP9@'&'%^+\5U]-7W%'B\6@/
MG3X)=;M;O'ICEM OG&):Y"V7ZZXD+D0AW$,=VR>@U@O=<O=1U)\]JXM8!CNV
M8+8,TKD8RT+5O@Q['OB8T_ZCJQ-@6E_=PY8B-^=%M\H:+.263)((^,OF5+3+
M60?/2M05N/#16][J)EDD:XCF&GFP61PMFF@&"KH\5QBB,9RFQZGJG(E%$QF"
M:^&B,8F,P)<B? HF5((6*^'-ENNMH)/:IQ774ES[H6S89W5:'EP[RC>5_P ,
M4*V+RT@[CW[_ ":CU*NJ57HBQ9#H [!ON>A/R@@G]+1%;9<4$GY_;\VJC%5&
M*SAJBHC1$:(C1$:(C1$:I4*BPI#A&R01L?O[CW'556H0R\$)V4#N5=/'KN!M
M[-/6J@$XA9+R5):4^OM:BH!*Y3KC;;#?:"HEQQUQIM" D$DE0U>V.X><ML"9
M/H5,D,F$QHT8ID,K]0O#6'N/1+CD*ADV,<$&EH)";^X+O87D#X2O\U*"XC;M
M2I7TB1L=;NRZ0U[4'-</9C+A4\!7'T+47.M:38G)4F3=W[DPF0>LB2XW8_F3
MQ7;SO@F7)#4S*[9%!!?CEA3S$A,5N#)FN-K( V/9LM03OUUT[OEQ \TN[VG<
M1]:B?S$S:0?,I8<69Q'Y,XWPGD&%%:A1\LQV%;N0FW?,^K):EF+/KW%>UZ+,
M9<0L>*%%(UQ&I:?'I5]+I\3B^*)V4./Z6 -?2MW:SMNK=EPW8\56_:@K.K2V
MB0HH!*@03XD#<[]?=N-]5%3@$KNJE90X$$J'M)W .P&P\3X>S3:*C$*A(WD+
M%F)2F.^^V.UUIA]YM2.U7:XPRM]I:D*W\Q+;C844^W;4BPIXYD-?9)'<L-U;
MR/MY8+D!K',/J46.(?6!ZK>5["ZH:;,BBRQ6OIGK6=:P<5K8<Q<ZO@/EZ"VG
M$IJQ$#THM@J<4L*1VGKUUZ'K%E;:1;QW$P!9( O!]/\ E[I&HS2!QK]J\^E>
MRKF7D^-S9B-QS+RMD5&]BV24];;6^$8K19Y)B*MN->4)..N0ZN%C\.2)B#8R
M&YB0@I#3J5JW*1K;:8R2YM3#8BD>6M/0G470L&G:<YFFT,AP([*?7128/J;P
MUPA;GJ?YW2LA)4D>G%E: 0D#9'^H7:IOITZ>&K(NG=1<V2:C<S6D^9>;Q]+W
MXMVYFBF;'NJFA]0/J6F2>#.7(/%7J$YJR?D2UP&_I,2QR=Z=XE;#NK*^CII7
M84BP^I&3"2NNGO[.]P[#UU)TG1KJVF%S.UI<K+;IR3Q:FMA/J!X*PS!<#P^L
M<N*:OQ/!\/Q>)3Q<:6U&K(^/8] K6ZYAMN0KL9BN,*  )'36FU31I+_6'S'
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ML3;=B9+T-WCL/"^0^);-2F)W&7(5FJNCK0MAQ..YFA601V4,J6MYV-'LFY2
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M7T*M_BCYAKTTK5;E<U141HB-$5F3_:[_ /E+O^,5I2N"H[W3W+Y)G^DN</\
M\9V7WOC7]M> 7Q(N+F,>[SSZUQ-Y_%>56P=MR/$^.J$ &@V*/)[Y[U2>AW]I
MZG6"4G+D_1*QEC7.S':$)0'$K;)2E)2I:BKN/XGY38;=0HE.PV\-<=UQ#)==
M/2\O[YI90\/;%?15>@?+6^-CU/!"32U>) X<?8=3';MIO4=8KK>*\\S*CX/M
M8S^&Y=P98W"8SMG6L"?7]^^Q6_D^+%](WV"Y+BSU7U\]$$-[I+'R@NO(1[)J
M</)L/E"^DK:62SU-LL6%N[R^DJ0"W'"A/:>XD?2V )^Z-NAUS2W7;O5QA *
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MGP-NAF,S7.X8#NHK'$ACW#:&DJ?H((2I*N]"D]R%]A1WH4.Y*^U1) (/R?*
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MM\?QAJXR>7*O933#K0;0TVHMA [2-;"*W,> $>7L:H#WN>,I+LO>MB;MN?\
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M79/9MS^A7,B9XJ5FWJ"9RZOL;'*'S3LU!@IY 3W1W>+(C,1KMQ=UJO4X[,6
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M=_7UO>FR'7Q(_+!1[AW-A;3#_:OH5;'T1\HUZ<5JU7JB(T1&B*P[X.?XA?\
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MN2A;S<ID%P'Z)&PUN8[N".&-KZ5+33MR^]YMZD![6M%2!@O3A8GQJJ:U27F
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M3F8Z^;<U'AN26YMU:'!>OC7)>/<WY!7T5]CBL9R? 'E\F8]6<H8IF.$28KE
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M "+<_<]8[S3?<A\[\]Q>(K/*^+<\R^V@NO<G>FQAY^;/X]PO&HZ(=569O29
MP&+IMM*US&UMN]X21J9</;?:(UNC?=B9I=3B*J/<VM[%<L?+]QD/G.Q-SBW\
MCO$".&>3?1;ZG;B#1\A<C<;54KTB7^<5_(=5DU1GN21H&2X?28]8RI^7\?W^
M-)G/K4$)$>&N(LDA(!UD>^6XL3#<[6L/H"J-HIMJO>X8X.R_D/E[UG9#BWJ=
MYGXEK:KU<Y#7O8AQXQC3F.VKE=CN,ONS)[]Q#D3OBYR"672A03Y8.W4ZB"ZM
M[;1M.,Q$@R#:M6&77XI(#MQ7TC_9QG?U.0O'IQOF@^D$A1*7L<25*"/H!2R.
MX[;#<^ U,TJ:.XU)\T(RQNI0=PHI3@X0 /\ >_.OH4;_ !$_-^OKO-ZURKU5
M$:(C1%8<\'/\0O\ QAU0["B^-7A[_<"Q_OVYA_XY^0]>"ZQ_G$RXC5OXH]Z<
MXZBQ?=A1$:R(D]^J.=E%5>S:>X^I-KRR#"Q1G*V$N.2\$OZ/+&TMH6X1"C34
M5]X@!#B5?E::>]N0/ '?7$]56\MQ'G83FIMKBO1OE/>FUO'VLCCF<=A*QLR\
MNIR[C/+&E[07[J;A-B\E8<:-)GE>RNL><"21O%R.IAJW2" ETCVG7DUO"/PX
MV<8 N,<1@?/M7TC<@>(!IBG3 [>GM!.X]HZ] K?KW;:UD,3X&<N0DN!.U;$D
MFE>"76541HB-$1HBI2M*]^T[['8]".OW0-$2J( ^EX?H(_2U<Q[&$YP""",<
M=JJ*"I--GI4-_5U3EF!QWGL1!+V.9.UC<M2/H"/4Y851G)!< !:7'F(0M'[$
MJ\=>M_)K4?PO6#:$Y0X[-@QPV+SSKVS=<Z4)CB\';OIWJ2'%%XF=D5K8--E4
M'DS#<2Y76AM!2T,GB,-8#G4-UXN%0?FNTE>OR0D%L=RAN5D#["7C*@_AW-=%
MZ6)/,G 5O:R:FX8YTL;'!'&,?G7TFFX^SNICY'9Y!$K:EI]VP<BVSCD6O:<V
M\^2\DJ 0V3HB=RHYWY,L:-JB]._IPS"THH8<>:SKG"TC\>5\U=G+<DVES,9L
MP;:?*D3!YKN[K9/T>T;;'1%838^H+*BJ!R'S[BV&,*3'<5C/IRXZFY;D 4E"
MFI=>,KE*L8[#KBUCL?#H4@@J(&B+2++T]<90[-F_R&CM<PF*=2J9D'J)Y7EW
MKWG)2J(XJ%QKC'Q$I2I$-7>$$I;+F^_:3OHB?2#C$6UHZJDQ3$K"V@4MI0Y#
M J<+PZMX6PF;<8U81;2E58WF0*L;R5&CR(C12L*4"A';T"M:;J'I+0NH96W<
MS)#.UH!..-!2E>'9P6WCUK488Q'$"(P-V 6_T_$]R[96^26M/QQB,ZZN)EHZ
MBFHU9Q9"2^\7I$I%Q?J:Q^"\MQ2G'1&A=A)*NXDG:NG:)I.G6WA;2!C8PXDU
M:*DX5.Q1KG4;ZY?FF>\&E*5-*=RL9'3-ILZBG.=VF45&;KMN,,QBSKN%.K*J
M=E5-)L<.FHI:SX:IQ\P[NO2E!2T%.=Z03X:V]K;01R'DM;&YS2"6@-J#N--H
M/#L6LG!>6.=B1(#ZTRO#_,V)8[C$_!\@NLCN;G!;)^*)[])(E&RK+J2]9TK$
M&6PQ\*Z[6M2%L/=ZMFO+ )&VOC[YE])SVG5SKICBV&5U *D-JXTV;-Z]RZ8U
M]QM&0AN9C0*X5P"=;CSE['N2[O-J.JK[FKL,$ET\>:U;1T-,6L2YKFYC%Q1R
M6W7F;"N5**V%%"CV/(*3[M<)J_3%YI<1G>X%HX'ZEV&EZK97D\K9*AH2<V9Q
M983B*8^,QC.Y SBQ9P?CJO[RTMS*[MMU#5BX\E!,>#00D+FO+V/8VUOK!TO;
M1ZG,;BX:!!#CB!0]IXE0=0NRV-T%O4AQ]D[Z=Z3B+BD<3T=A5O97,R^YMG*>
M5?74V((IFV554M5"Y+;96^YY\MQEQY]Q;BBXXX2 !XX]:ZA.N7SH S+':^P"
M!2H=CZ*+/I43XX"V04?7$[SWIV&7-@4J4K?8A())VV]F_4=-M:C>MGV;U2CN
M\[=1)/L).YVZ^'N&KDWJB65?"3@#_P#%]C^-L4[F%(&Y"OHGM)WZ^[633?:E
MB)Q.?Z5#N:FW=5<">-N;<Y1S[8\8\<6&(1["FFXC56]7</3(.96T"9QU+N^2
M9>)VJGD8U$D5^%*:$2!(0[*GSW63' 6T=_HG4M'L;_1[>6[J9.0XBN(P<P B
MN_M"\\%^ZWO'0M]VE?.G0](/,UQSA*LLYFHQ&KJK'E6E5BN&TS601;W%,4@<
M>\CTV/,7C.0-MJ>=EU5>V\7F.]AR0X[U!&VJRZ5:V$[A%B<C!0X@>P":;MO#
M:M3J-X;I^4BE,5TB0ZDI!4H[[$'N'7?PV/:-O9K5S !V"YN?WTBOI;=H)V\=
M@>F_W-8EB6AXO]'D3D_O!2%/\8$ I.QVQ>X\P^&P^BH;^\:KJ,3WZ9%**U9+
M0'> =H!W [U*LG"W>Z8X,WIF?2?6S:RJYY39U\N J7ZK>9[6$F=$=C*EUTJ?
M6F+.AI?;09$5Y*24.(W20.AUVFK2036MN8P"^.W#:4_5KZ"HNE B:ZG^)U6G
MAANX>1;3355E.YJ]0R(LNTH'+?C[@F)3Y)#B(==B2V<=SF.Y+K'9;+L*5+JY
M+J%*1LL)5L%#KKE+5S1HEK/*T9_&8@C:,VP\1WK:ZL266K_TRQU3O/?Q37VO
MI7Y!EY%QYE]-ZDYS^2X'D]OF*K3DWC7',BI,FR"55(I:*RN,?QZ;BM0V_B<;
MSU1Y!_+!R2I?=W#736FO-M;VZB9 SEO: VC1[/$MPP\BU=7<2M'])&8Y_"XO
MK<&O[>!-RAS-N0G49%;82<+Q"IKDYE<&Q&...393V>S["P4J3';\QGRD.I3L
MM()-VL6^DR1AL;RZ9N\DD^?:K0*;,%->HQ"NI+&5>"1/M+Z0DAZ[O'6WK4M*
M^DN%":;;;CT\0GZ1990-ATWVZZYJ2[#798JE@ICZT-3BMK2#W*4HGS"2%IWW
M*%;[D'W%1._RZCRSNF #A2B!5^/3<@'ITW\#T/X-8JY<1@0KVM:YV5P!!XID
M<CD/L<NXBAF2^@*L.,2XE#KB 2)_(!3W=J@%;'?;6WA<^/1ILA(J#6F%5:YH
M&GRX"H3Q,.09')_,TFWXYN\VEHR7$5(OH=/36ZV([7'5&E%?\5:64:0WLM1(
M2 0-SKC;J*ZDL[.MRW*YLI()X9J ]VZNQ<54[=Z]CC7X6/G7,!K,5EX3&<;X
MH6BI?@0:MU9=QC)G')1CU<F4P0^" 5%04HIV(Z#6HOWW3-#M723&22A]H$X#
M.X4KY$;A4C"HH>T<"GA2.@4D;!)V!'3;?PV]NM-,UE&"@IE]=%C#&MI0 4Q&
M&SN5_P#*R#W*>=6K9(/<XH]$#9 W)\$CP]VK"YQ;E).4##'9W*I8T@N(%3M[
M>]74KDMN_$"2_P";U)=#SGFCM'CYG=W[@#WZS\Z6'E")SF D Y217OHHA (
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MB1QCF&:2&+2Y@4]?\0M"7D<B75YR-DB8R4]BE+J*]=;B$!UI204-I2\T!L2
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MI'+=5QPQ>3Z G&KLM>9DMX_F42%0Y(ZAMV+)CO.+QF^!)V<H[*64EB0I6_\
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MXALH28R'U\?<MJ"' ^T\-TIP\^QG;Y-]>@?ZZ:7<?:W-H' G#*YHIQKBK?\
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MW45*944B<4I304D"K4A+9C(EA:$/.RD'S9[[[*OB)+BY"U^4YL0>@'W-<[,
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MR+CGU#0'1">K;?%!DT1CL;-Y!ASWN/[ZSF^0@S9;]3B&>L>6.Y++;43O4%*
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M9-09OQ1E+Q4\G=+\-K-L5=6VD^0MUFWH7V$*6.Y*92PG\<C1$Z7)6)G.N/\
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M]7\RE6?6?4%B\AMW<B",@Q@3S4#:X-IFW<%C5&$?5<>8RJ8ZI,A)Z=I40"?
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MSK6#)A8]3S'@BRR61 :=+MPBJ9^D(:/Z8H@GH-2;6UN ![ 0&VVYBF"95#3
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M=RHW3L3N  >TDD#Z77IUVW([3X:KD:W$/S=BJT3D^R'$TJCIU\#MTZ'?V=?
M^(U571LDN#1KBTA)UZGW [_-MU^YMI@I!<2W(?=3@>FS'N LF]8G"5;S7E^7
MXK<HD4<KA]K%X")K%]R<G+(Z,8IL@[H<HQZ*;+64/. ME"=CW#;?7R_\](M
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MN::SRQ%3DV'Y) ):M\2R^BG4#5C2Y'42@IMYI]M)4 %I*VU(6K7_ .CO0?\
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M1RM((<R*W9&[9\+P6D;<-BF6?U.GR ?J:^B'P2F)TE/9(7Y,.E/+K'4[ >S
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MP&X-7#0\$,;A]<EZ3UFS)SKG>Y+E6#BE*>4YN5A12?H]-1;W4]0==B[CJVR
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M_"JV "BGOW]VOESY[7=C'USTY;3 >)>QX:>!SE?KU_V^OE7U?UM_2E\T^N]
MUI]GHNESQ>.M6FG-'*&44VXMHOLK]-.&LX9A*Z^-+8F(<G275NL'=O=:^_\
MHB3K. YC>7)C*":^A<+$&LM8HX!ELPRK1OJ2<Q/>I'ZHJHT1&B(T1&B(T1&B
M(T18<MAN0AUEUMIUJ0PN.^T\GN;=8<^@ZTXG8]R'6E*21X==$47O2G,54XEE
M_$,R6)%MP1R%DW'SH(8;=&.R7V\LP!Y;,?9##3^$9%#\I&VZ6T#?QT12J2H
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MN)<\Y7ZA/56_Q%S+ XOJF\RX[3>5-IAD#*GI]E(X]I9,5SXF4TM<#R8BBTI
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M5UG3VRKR"?Y3<S>KF[1R6N>^^Y4N6I@/-2)CJG'6RCL<)ZC4.WT2PMI.;")
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MQEGCVN;Q(DTZ7WO*[M]_,\Y??^-]+[^IS;IU]))>92UCI"T [?9I4\*&J\K
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MQ,R8^W&BLH[DMA3TAXAMM)4M(W)\2-<F_3[J[D$L3'GV@< <5MG/:UI<X@,
MQ)W#>L"IR?'+I2X]'D-';R&&R^^Q5VT.Q>98\Q+/G.MQR5M,^<H([C]'N.WC
MK/+:7,/WT;V]X(6*.YMI?NY&.[B"MC2=TC?Q]OS@['[Q&L.1QQ -%GRDX@&B
MJTY;^!3*[@4A.P)W U<QD@=4--5<QE74=L6OV]13Y#%17Y#2UU]!:G0[)J':
M1#*CLV-<X7:^P92GRU-383A):=2L+05';;<[Y8G3V;^9$UV8\ 5%GM<QP!HF
M5YPK\.PCB'D+,H?'>$V,C'L<DV+57<5DR95SU-.,CX>PB*G]LB,YW?22KH3K
M'+>7(#XG.:)#& !A4FNRG%>X?TY]"Z3UO\YM%Z;FN;JS9<W3LLL)(D!#2:&@
M)H=^&Q<J.%?JZ]L+G)FHL&KD6UN;=%+5L+CU%6W.B1WA6US"UN*8A5X4&VD=
MQ"0-M]?I1_3G(Z3Y;Z<9",[>8UW8>8<#P.S!?F-_W-NDHOE]_5IU)TO!<S7=
MA8",NN)34^W$''.X[*%V7'L"D\?T>_7T2"&3F)YI+08';YE^<QB:R%CV[VU\
MA-0?*#AQ2;']35YEC!(+A5HJ<=@[>"PN>QLG)<0):5IOIQIMHC8^&Q\-_N:N
M8YLK^7&0Z2E:#$T[D:]CV"1A!830$;*]Z364QR-&9P("N!!V&N)]&WS;T;'6
M.,B5V6,YG<!B5:Q['C,P@M[$H2I1V )/N'7V@?IG60QR-89'-(8W::8#O61S
M7,9S7@B/B=GG7E-WE*Y)$1NXJW)?F>3\*B?&5(\[O#?E>4EPK\SS#V]NV^_3
M4'QUD7B,31YSL&85/<%,_#-2Y9E$$V0&E<AI6E:;. KW+UR%#J4[>(W.X\1L
M1X^T:EO86,$CP1&=A.SSK4^)<79:^U2M.Q/[Z((7']SZX^,Z#)(5N[G%KQQR
M!&XMG5LEQJ!7Y&JKLQ+5<MI[?,CN5!D)3N>U*U)5N=MM?,'S:DT-OS/T N:'
M:J87TXN%30@;Z##!?L/_ $4V_P \;;^B;KWJ'I^XT[_1&;7(?'->YO,=(QL$
M9 ]JN;-EH*;*+[)O35B<W#N,JRHLEA<IMUY6^Y)[%.*4D%7@L[GQ&J\R-P='
M%3(V5WG-,%PC9C+&&M:1;U+F5P-'4^K#BI!ZHJHT1&B(T1&B(T1&B(T1&B(T
M1&B*A8W /M3](=/:.H^4#1%&#B<KQ#FCGGCI:1'B7=M0<RXTR$*;0_5YA6_4
M>4*CJ6I7G*B99CZE/=@"4&6D>)W)%)YOV_<_5T17-$1HBI2KN.VVWW=$56B*
MA?A]W]0Z(HN^I-DT"N'^76AVGBOE>DD73Z7G62C#,YBRL!R5+ZF1N]$C_7T>
M8IE0*%N1&U';M!!%)ON25$)Z@>WV$^X'V@>_1%D;[)!\>@T1<VO7Y$_,RR]/
MO/T>Z72GC'DR'&N84>0S6_GG4V.UH,6N+!?<^[0HBU$YY41M*E2'%A/3VD7S
M)3>!.2N$?4#ZGL3PN%/PN$>6YV08O58OGE E,#C3.HS68X5"AG(:&>%T9C6C
MKK7EH1V*)22>W7FO5OS$T3HVX$5VR2KCC]*Z30NCKO5V&5LF&U;3]7<_))"\
MKY!*@=MT\@<<I'W/]J2-Q\NVM _YY]+1!HBBD<US0:]I\BW+N@+MQ^\V8)?J
MOG\?_*KD _\ T?\ '+?X?S/1O\V^L7^O/37_ "\BM'R^O/WA2&NY\\#E/(6_
MN_E#XY/C\OYJ:K_KUTT/:$$F'Y<$/R_NQCS"L.7C'+]HJ.C)I.6917QF[)+-
M5<\A8*NO<<LZF;2N&2FOQ1N2MGRK E200%=O76-_SNZ>NK":+PX^U!"ROZ"N
MX9(;KF;""O9K5V&(W.#Y#R _"KC)XGKL!N; ///4]=EM=>1+-"'YR6E):9MH
MS"TMK4$),A "CVZ^=-5OK.]GDDM&AC7N)#>%=R]5M7NM[=D#C5S&@$]R<Z_S
M#'\6@IF3IT*6]+045%1%D1IL^_ENL.&)5P(S#KA<=L%$-CNV 2HD^&QYVWL;
MP73;G'(WZ5?<2\V$G@F@X\B+XJD_"YJD4L'*<<Q,PK^>X#70<G@_634[!K&6
M XJ#+99M&7X9<[&WBMX#8@#70WKX[^'E-QN,*>3$^A1[)V1A<G3S?):RJI9<
M-N;73;R[KYM9CN.A]E^;D-I.C.Q8\"+%0IWS0LODJ4K9 :[E;[C;6FY5W:X8
MJ9XE-QDO&\BPB<:Q'>/L0SR5B-/4P;2WO,BLJM31@4LZ$Y5PD1"$38[4^2W(
M3W;%2HP23UW&]L;FU\0ZNW*HUS;71F!Q3ZGN0\A79T02-@?!(44I3O\ X1
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MM@-8S:VQ<'F-F<"@-!4#AW+##J%_;QR0P32LBF=FD#7$![C@2ZAQ/:5J%/\
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M,B :P; -BUU[//J-[^(Z@]TVH9<O,>2Y^7X<QQIV+I-3TU?1PV8-7&1&BM
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M00''8=_F#8BC'\YIGDN)9IK=J.AV/9)"0F:T6UD>8G<D3_M^W[GZNB*L*!Z
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M<4QSEVU@3XD"R@N(XZM&%3:JTOE8]#L(B'7?[(:3,25O)2>]EG9:PD* T12
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M=@F56=E(>E9ORA2OA+MAQ_;Y$XM=';.@O,,.)5,"$.!P_3UJU[6,8T-;&P4
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M0]6L7D"O47C(<WC4<12DDJD*VT1:#GF 93<\D5LW';:%:>M1[X&]5GE>Y/\
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MU5D^C?9DB(A/GK?B/!"E'91Z[D3T?R<\[X69$O!>8$Y]#[U_#8MRO51W2S'
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M&B*A*3OU'3;Y#HBN;;>&B)-Q[Q]\:(C<>\??T1+HB-$1HB-$1HB-$1HB-P?
M[Z(C1$:(C1$:(C1$:(C1$:(C1%91^,/N_I'1%>T1&B(T1&B(T1&B(T1&B(T1
M&B(T1&B(T1&B(T1(3MX#?1%2%']J?T?<T1"0 >B@>GZ/;HBKT1&B(T1&B*@
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g833164page045.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g833164page045.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_[0 L4&AO=&]S:&]P(#,N,  X0DE-!"4      !
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M)]]&YSY?NJ4FFC[LB[.5(.H_44N>[<;*Q;>2[#$']&SIQIP6.,F2^DM!ZK'
M#B:\=W8HUX__ (S/#FT3HCN<SCLFVUA6A]J=R\KVP9;L=3.\"EX[#,YC'R:"
MOT5"LWPY-E+9!FFY7662:)H![L9,IC'$ &7;P>]3V5O :NO(/$&&S#T5X[ED
MG=!;1WLTA=X=GM.&T"IKU#@OJ/CY%O*,VCUNH59N^:-WC94"F(59NZ0(X;J
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MV;NXV+O7;.7265[+=Y3MJ/SO/<-RI.=R>:>P"J0N82-Q063&.:63;HJE+<
MPCMM&U*/3IO%?7^$?%LKB]A;3S[535;:+4;>2!AQ<]KAN]5U?(O0#NR[0NWG
M[Q#[TCLU[CNWK?<%(Y!J9QMO57>%":UESN5\AUSJY:/.^P;*GB"*?N7O69S"
M6/2""X![XQ>'(3J!$_3H=',FFWUQF -E-$0-YS$\.'S*E[+<2::(&T]Z;@#7
M=7'%3A[AM_=\6K?O.>T34.N5-%Y'VD;K:/\ '<PU8S;3INX''20V-RTKDNW'
MZR)!@H37>(J,631,YC@FNL[*@4IU3>S?8#+<7$EZ?LW#[.F./3P62\&>PCB@
M_B0>]NPKN*]>)_'8G+,=G,7R*/;R4%D43)P$U&.2];9_#RK)>-DF#@@6ZD'3
M-P<A@N%RF\*@7-G[S"^.3UBZK5F@>(96SC[QH':%\YW93]PA!=LG9/\ >/=H
M^4Y-&Y5']XV;;:;Z\61%VK'8+J]\Q61TXU69N4400R"$D3IO)$$2F1,X;)B0
MYK!4C5S<W^E06L=#=0%I%33$$$X]05+.3W;69-5IWI&.:1T'-\ZFQVE_==XY
MH[[IF*^[;S.:%^MDFC,OU_M+,(?SW1GN;;#92:F0Y%$@_,"YV<1+2119('$$
M_(;$)8I1X2.8V1\PQF"<D1N:QKCOHT#'I.85ZL%@T7Q-.D;=R "[$CG$#$ $
M[!Y/.O+3!/N/^Y7(M9_=?=HFYIG7$9HW[L;=65[B>[=Q.=E);)>X-)UF4KE>
M%0&.X8YBTAP9=L,@F274D'2G2*9@:=91*-;&SOA:Z['KP'^ICLC;TW4+6M%>
MCNC9OJKKF-DMA+9M)^UE:X[/5%:^7%=UJC[KWOL[=-]_>S[1PN+TELF%^]!D
M,Z@X-FZSV<QQ]H^-?FS*.QS+\J,XQ]V7*6SR*V$Z67CX^SE-=B5,# 4_4'.6
MEHX<NC1;D4=[X^7 U[I>7#$;Z4P4S4)FW&M,U"(DPQVD<0K@?LV-:,/]W:MG
MOK[CC8N/]@OW;W;7VLYAAV0;(^[SWQ@>\Q'8ZLMCF*;AG&,JI/[ (J_B&<H^
MQP)J?=*K- \I4$T/9,/F %;5\CCS+9:RW[BTA,0K2N5P /EPQIU;%J#9Q_E=
MW9_\VXE\0<*CY%=[2_NT>_72WW@'WG/>1MN(T-D"?>_HR;Q_#X+6F:Y WC\>
MSDS:&)#P4J3)X1!^6*4*S,BN_L<PJ)"H"12J  5N!"[E2XT*(_;/NC*P4H#F
MK6IW;:J=.XW&K6M\_P"[@M_#/'ZN[?BW;T[,*J27W,O9#W5?=_\ W?.?=J>[
ML7P28SR+RC:^58'(X+F2DCCV9!LM!S)M8R4=R,4P5QYS%2ZONZRAR*$,F?K
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M?PB>RN[A6OFXK7ZL3^::C^]^4J7/WG<'B6H?O_/N0XK'(I&'PW L!VN\9Q;
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M=*HKIMW!TR+)H.#)&*@JHD80\TB:H@(EN'4 6N%[U7(7M-/6&(5I!+A[.]>
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M5V+L)F1G1W7L239OETI:&R^9%473GSE7[F1=&54N8U2=$R-TV_![@=*T@8[
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M4466*4Q!P'UA1,#W ?=B=B/=3+8=-]Q/;AA&W)#7^(L\#PD^6JSSAOC.*,0
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M.A^Z@>!-F:NZO7E>W^7C_P!PI_U*L!_S;AW0'"OH3^G-2_ MO\KOVD?8+W4
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M(W ! 95AS;)>:QD9?WO=_P 3/V%DM-2N9S1\A'4F)[8L?V(H]3U^]PKMQSR
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MYQU8G&_N?\S?V4_-;KVS1;L-5Y6/$=0=J@#Z/K9L#P_]C_13^L-6_P#/W/\
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M1IO"$6XF(6IL?.&K-8&^_P!S4?XF_LJGYK=>V5MPU5E?6!0T]VJ^T(CQRW8
MVN/A_L-"P5;)S7JDI!=J%UAP<W]E/S>5OWDCDIM49,8>A73O:L<G4 &*3*L^
M.>P& ?9 <-$ ,%N=N%6LYIU1CLXU"[\KF_LJOYQ(<&R.S=86@C]$Y%&2^43;
M?6/;X_5RYW#.GD3,[+V9)XQ ?0<02#1:X/"N,*3;8LU?MD@6>HMPZ%W@BL/M
M#4C^L=6I3W^YPZ6_LJGYI=?B%;T^K,L*%PT]VJ<P#_;;L$1_O/K#_5>J?_R%
MU_F;^RGYK<^V5@O-394]:.V2NG^V%)-ZU<-%',;F^Q8^01(Y1.@99D]0Q %F
MKQ$J@F24"XIJ !@XA4F+FO5<O\PN?\S?V4_-;GVRL;'-+9+!0,3CZ.L.W*73
M@HQG%H2>4[ V5.9(_29I B5W.SCS"RN)>5<@4#+.##U*&"XAP"L-WS5JI8,N
MH76WVF_LJOYI<^V5L#ZORZQ@^QGM5.%A_P#2S8%A"W'EA]^ 5#;S-JSR&NU"
MZ+2<>\/V5<S4KE[PS.<2H$;&Q7<,KW PS3&F7:YA2N*9PZPG#</6R[8#?6\V
MZ@,"<[+SI[M_&4F#)YG$7ET&]1BX@4Q9'C7:8*)B8QC#7H.FZH+>R]YEN[QS
M^AS:?\*G^+=;*A3IBM;Y7(1,1+%TSVM$^DX>'E/*'*L^1 AI2-;O3I^2&'G\
MHI#+B %ZC"4.%QYUR%US3*ZYD<-1O6@O.&9N&.SU-RU[]2NF/+2\X%.UI?7&
M3,=Q:JDE]5=M\05AGL X/)8YDN:N<A9()N!,LYA47V*-6;B02+Q33453*(\;
M\!K<<K\R&77K=DE]=2%SPWO.:</(T+9Z7JT[Y? <0X..T[5] A!$2@8>%[\_
M3>W'B/'T\:^I1(72F,8L &.^OZ="[!P:-BR0Y!\ ?BK(K$M$11$41%$11%;4
M\/C_ "410)V=_&%EG^FI/];([\U:B3UW?K'Y5YKKSP[7)0-HA'H7#7&_P?F]
M/PU;0TJ 2N:=&XVX8!WO-MXK2,\?@HZ05E6L-#,9%4ZJJ\FU9-4)!ZHOTG4]
M[=E2245NI?F8;A5M230M</(JL,T,(;+B"=V*W@=1S7  .8P@:Q.(#UF'@'P6
MX^%6F0##&JRO#F-#J$UX+'<M6K]LZC'Z9#LI%%:,?(J@82G:NR U=I*)!P$!
M0<\0/PL-^-98K8/MY8YB&^(",33M5+:=POHC;AQ>UPQHOF*[K<+DH35B;595
MVC)=O&XP9S1R-&CYVUA&DH]Q-T^1;NDU&0K)0<PT=$ZR&3L0HB%?+<C#RUSK
MJMA/&UT$[R8BWO U8TX[-_6OL+3&Q:KRI87,9E;>M8,]108.(P-378N^:Z#Q
MV4;-I)EG^6G;2#1H_;K$AL 4(J@\0*Y3%-4F.'(<A!4$H!S"U<*.8+B NAG8
MSQ&O=LX5P7:VVEQN;[P'N\-X%..%:^E98=O4( 6#.\M!0 &Q@A,!N)BA^NMC
M11Z3"%C<>0C62/F7OCQ8P6=2F#38VG,'.)3E8'A./X!B$1A>*-18Q,$@+8AE
M"(^]2+DZAUW,J_623)Y[YXLL8QS6L'(M@ *T&IZA=7KS1U8?9.Q;"!L=MWHQ
MWUUHMDS)E!=-)04E4UT15("H).$Q'RURE&UE$[C8>87K76YF@!RT#BL%Y&ZY
M>',IY4&5N<1\L.H!NF/&Q1YA8/"QN-8!'<-%&D8.S#'ZQQQ4N-X;:BVDV5/G
M34Y7I7'\LR)[E*DU+P4G*-6#>6)#Q>+.6\FO')'00DG2LS#/W8OC(GZ#"!ND
MQ0#Q"NHL=>G;%6^ =.,,,11:EVGQN>34AG0M#_@[P'/Z\9> ^J$UY8!]5\4$
M_P"&IS>8HPX.\,8'@K7Z7"6$%[MA_3:M+*ZG2UV^QC/X7)<GG7>+91$G=1;V
M/Q5DR<0LTH,%,>\KP\*Q?E31:R'F6*H!1$G&D6M&_MIH&L:T DCK48Z:VWC\
M1O>;TK02FFC9'D.X\+9/L8QQHE-OLD:O&< 5[EL@VV%&NY1-8CQ\H:,9MF^2
M(ND@,DD=7I*!;7&X2F:HV!MK>2@NI (W?KC;Y.E8H[6*XJYHH5GZPP;!X)WK
M3-44C'E\\QF3QR:3G%_I%5?-H)-K-HN46[CS&\:Z;!CD@B4$.CI3./,> 8M=
MOK^ZM6P6I;$YM:TV&N-51ENP24:2 -JD;$8W!P2[]Q%1C1@YE%O>)%=L02J/
M5^)C*.#"(@8154.;AXC7'R.?)E;/(XS-'##MJNDC9;L@JQSO%ZOI6Z,8I1L(
M#>WA5/#'M'L^E4&8_6*#E$P6#Q&XW\:P^$QO=8T9%%FM\TN:-Y\-8:ABE$Q3
M$ QA#B;F(W#A?TV"LK(X816$=]30YK!E9BWI2J<#IB(7Z2  \+CS_+6=DQ:"
M7-;F*.=FIB6CH5P# )P-:P7 >7'E;T^BHLCKF1^7NMB.TUQ Z,%3PXJ9@YV?
M=A]*O>:3T#\G\FGN_P#]Q_9]*I1WM%6BB'F7Y!<P\?6 ^%J>[_\ W'=GTJE'
M>T5>%4H<N/P!3P&?6)<>E5H[VB@3D#Q*/P!QIX#-Q+3Q"I1WM%6Q3(H/6'YN
M54]W VR.[!\ZH0=[BE6$P %NGGZ/5\ U7P(^"J,VYQ41N]3%<>F>WW/,FD8I
MHYR3$&44?&II4AA>PP2V5X^VED69P.0ID9!I<IRCP :[CD>^F@UJ.UP\#PS0
M>4KE.:(G#2+E^8U(^1>V.#X3B&O,7B\7P?'(S%<=011DT8:*(I[J1_,,F;V4
M>F.L8ZIW+YT;J/<PAP"U1-;;<ZAJDTEP1E#SEHOB.[ED][D!<31QV]975W#T
M!\@!6L;IH!J3@L'B/XHO67\OBXE/$>JK>HOR5KS!""15RIXKD<O OR5>VTC<
M*@E/$<4!\5O4%5]R9Q*9@_"38EX6JUUFP D$UHL[+9I[[=V/8H\=RH?[%]8"
M%K!OO#!$/_83:OYJ[/D@L?J4S035MLZOF6RMGOH"G&U%8=.:;&P#?4FKQY?^
MH4%SKF;VWCEO)9 30R./G6NNGN]X?T.*[_AZ"_)43W)G$K!XK^*/B+\E/<F<
M2J>(Y'#T%^2GN3.)5?%?Q3:[?QK'\KU+M''\KAV4_ /M=YHN\BWY3F06<16.
M24Q&+@=(Z:R*[&58(KIG*-P.F'@(ULM+CFMM:;X+6UD%1CPXX+):2.@ER/\
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MEJJ/S5'N 2W!$> ?#6"WP(KABB3Q_5ZJVCW-\,8A-R6PUAJ%1%QZBAX#S^(
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MX!\8</R5SOU#UK01[TE6+*BB)0J)+ZY5$#5\&_R(%0;YH_!6<[NL>E#L4/\
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MXK]<A_ZAXB(^FXPC2N NY1)?!C7%S/#W@;:GH706 #8<-YJ>P+7[4_T-P4/
M=TZ1O;A_P@Q'H] A4C1@)/$<_$AKAY%6_P#N!^N/E3F 4#E#K#J]L_$1$1^<
M/,>8UII8V>\NPWJ0_"%OD5PI0*%BA8*O5ZC-WE?]&/:_K98Y?_K<O@!#Y!KJ
M.1O_ ),W]V5S?,_\EN/U?D7MJA_6S#_2F%_UI9U=JO\ ,Y_UROAF[_C)?USZ
M2KM05@11$7&K/#9P5*(JX -%!L54  CR"]N(^H/7ZJJ'1@_:&@/I5*.<0&[:
MI+@(B4! 3 !A$ 'B  8"B-O4(U61L4+"7/Q(PZU*GA,>4MP-0H\]RU_JOJZW
M/[?,,M_DOJ)M;I^.N@Y$[VJW6;_RSOD6QMMH3DZB 1TYIL "XCJ;6%@#G<<"
MQO\ !<H_)6JEC9XCJ#ZQ4"YC<9WG=F*[X.(!80&_*UAO<+^OPJ/-"UPJ HSF
M%IQ1?UUKV->V;'U<58BIBJN/V)?[.MD>@-;;#$?4'U+GJRV$C_SNVQ^J?0LP
MI[SY5SNG/XN<?_\ %XBWP?4'7UJR<P$F0$[?$=Z5M[OOM#78MH/0G2Y?J]=8
M)FAQ%>"TCO9^J$<:QB%KCE Q*QD8&FU5  C<0O8O$1\ "PC<?DJA?!&[PBS,
M_P JSV\+G^MBK9^)#6X@ V$0#D-[6^6H\O\ #G"G?V>5# 6O):,:E1I=% _=
M?CI1"X_06PBV\;#K/3]P$.?A75M<6Z0T X4^1;6 .]PDS^W\@4F%! JJMQL
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M^@W$.D;@-O#GZ/AJ]T#V N+92!T?0GNUR<'1Y1QQ50HJAU7(;V1Z1X<AN)1
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M.D.@0'B-ZT$_-EW!I4&I>[VI,Q(R^'LITUQ[%07<AB,F&"<(_95IHPW^L>U
M&UK?6X?[%K5/YLU"<&9K(6-V4:W##R[UKOSJ7V1^GD5/^!-J'_=+M+^%X_V-
M4(\W:B#3+'V*[\ZE]@?IY%<#LLT\4O0.2[4OQ#AEHCS]%VP@/.J'G'4&C,YD
M;FC:*4KT55!K<V;!H_3R)B<YT%@V)[*@=<1;_+%X3-76C6\A)R4XZ7R*)2R/
M96:P\RGCL@F=%*-*_C8=!)2Z2ER@-='9:S+>:>Z_\.-N4>K2OG^A;'\RN_!\
M6K.K+]*>&)[:\'U)M[4.Q<7F=AN7JDGDFNI/ZPY2YD,>3C,O@#O&2[V,*5)J
MJZ^EX%-%%P<HG(=<"A<3<=)+K<U]:/ADHQKL0 *TZ%K9[ML[<V0-D.T@[3QH
MI?Q>T\9U[M[M_P ;E1=O\FV?MC',:Q3'(=NH_FW"1CKK2V2O&"1!6C\6QQF@
M91Z^6 B"9NE(#"H8"CL.0+634->AF;4-@E Q'K';AP\ZR:/ YUV'N=4@\%[D
MI<  +WYA<.7#A?XZ^R@2V7*?6([%Z0T96@<%?K*KD41%$5 @;J\;7#Q^7A1%
M71$416S@ 6L !S_)1%\K7>3J7$9/N][A)Z6)(3!Y7,6"CJ(5>GCXA(1P[%4O
M-.2("/?/3]+<!LNNH3U6X5\9?%;6IK3G:\A:^@RL%,>A>U<KVT<O+T#@<?$Q
MZ,4V4/!1$"S]RQR'C(9(3<4XUBBU66.<"W.=5 OGK&$ #J,)S#RN->=7-U>N
MF+<Q =0^9=K$YD.9C.\,WR!<OD.Q,'Q%<&.59IC$*_%=!$[=_+,DW#=5V0I6
MXOR@J8S)-8H@ &6Z"B-@O6(:5J-T08"^1Q.(H1AO-30*EQ<L;'62C6UVIG-K
M9#JK/,7<LG4BYDRQ+XQV4W%C)LH=C*#Y:3MJKDJ2D?&H(R$<=9$Q3.!*J"E@
MORKJ]!L-1M+@QW$1%L1M);\ZA^^6QP#A4]!3AZ:E$)+6N+$:)$0;1#5YC2*2
M*:Z;84<=?N(Q%5J+D 66:K(I%,53VB*7$2F&N9YF!MK_ "1_=J1;)S2"3S4P
M  #G?A^N$>'ASJ$TYF@C913SM6=1411$41%$11$41 C8+CX<:(L+J4Z_G&Z/
MA_)>]5HKJ>A<ELO#VFP]=YS@S@"F3RW%)N#] @N^CUDVI^KA8R;D$S /A:ME
MR_<QV&O6TLQRQ/<YI/6*#951]7B#[(2Q"N5O>Z"H:Z@S;>.:XEI/-9DV&XGC
M\<"FG,GGXKSI?,&IUG37%%'3Z/D0%JV<$RO&VBJMC@FD0U[<:]"OHK.QM)[
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M&,K2<R_R&X_4*](VNQ.X<8]D)-61)R_1L45,PXK,J"<I8UJ4B@&3S),# =,
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MP=N] QQ,N41!+IM8;C6&?2.77GNW#2.IWS*SW+3_ ,0>?YEVT[E?<3.X]D4
M?6L>V)D..3^/*N4\1EU3MDI^&?1"SE(@Y@)#+-TWHG(!@$IC% !X#6O%KI,5
MU;R1RMRLVX'#S+!FMO:"N1$SNC$&;:!Q;72[V"8MHHK=QE&(/BS"KEKB^.P3
MXRI8S,2,R(*.X,540 +@10.KC>I>I#1;@,^W:9 \DX.V5P.S@J"*SDDK(\ >
M7YEHLWVCWA14 9YKW06,9KD(R44U-$3*4GBK)O%.GJ:4I+C**90\$RT8T$RA
M4"I&%;B 6&U28K/ER]?E=<,HUHW.^9;!EII%*LE;FWX'YEQ(;>^\/ _Z/MJT
MZ8O7<O\ LCRT"] FO;BXOP+PK,_1N6(F&7WEF9HKL=N\BO;:Z<'=V5M>H_,N
M_P"W]_W+95MK8N8]P>J,9UJRC=8X#A^NW&)S"TLQG7#C*LWR'-7 (/W"D@R7
M;(OHY$PJE)U](6OTA;6:N-"_IUMOI\[7WPDKE <#2O$@#SJ#>MBC]3O>9.EO
M#2,1NR$@4#S;[ ]@X%+?6G4NU\:Z0R;766A<K@R J@"<CB^1$*1*6C5 ,D]2
MZ0X&( UK]!U>:SF$5\[-:$;\:="UT5PW-ED-!VJ(CM[WL+,8C;I='8Z;N1BI
M;(<2=8<<WD:L>XWD!,(P#[1$LH'(@=I+LX+&QR(S#R?;.H+0@  #73"^Y>NI
MG1S2MBMZYA@[$^0+;Q75@(3$Z04)KL/S*9&EM.16EL>F&?TJ?+M@9M+*9-MK
M9;QJ1"4V'ERRG6=V8OMF8X[&  )1D> @FT0"UA,(C7&\PZM<ZA-[I:-I9,V.
M& --G X]2@7'N\K? MW BH._<F?W[(=R^+;5P#*NWO4F,;'CGVM<LQK.9')Y
MYY%-8)5MD\5+P""3*,6*]=JO2"KTJ=/2F!!#QK8:,W2[O3O==8E$4H.%037'
MH!4^SM+ -_U$@:ZG3\R;XNWOO$#&*!NVG3!@ZR<5,DS'RR )@ QC>6L)@L01
MMX7KH/R/EG_S+.QWS*1[KIF^5O8?F7;8+M+O"FH,9#/M XQ@^0DG)QF,)#HR
MN4L3PL>\42A)U.72RIH059UL7SE&WE@+81*7C[05K[O3.6F5:R[87#=E=Z<J
MBR6VFYS]J.P_,NU^T7N- I@^S".,(AP_V+3'"U^7^S'QK3-LM&:XY96X_K8^
M98_=+%_W3P>.WY5BFV+W(V'JU='=/CU8O,"7GX@&9 -OCK([3M)>SORM$>%3
M0X"HZ%1]I!$PR!P)"C'W;[&R]EJ=I);R90FK\,99@DE$SKC')1BWE\]E\,S6
M$P_$5I)WDLDVC@R5S)JD25$@]2R92 %S!?>:-IF34))M/^UB<R@(WX=-%+M
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ME-%,I$OUEJUUYS)K,A)A80SY%F_+@T%W!."*06*7D5,IB$*4  "D$1.!
M *4QAM\-:QTSKEGO-R:A9K7%*5,H6'Q#QJUCV2-#X_4.Q3RKE7*B*(BB(HB*
M(BB)!"X"'I 0^6B*WY0>D?P56JKF5H#^0H"@!U"DH4X!Q]H2" @7AQ]H0MPJ
MDG=DCD_# <L@:)F&T.QXJH@X-AK^*ENZG2X-'+2-F,E)MW6C\X=+-='.6*4B
M\3;+6 O7!YS"'%8H&#H%T3TUVM_-'?V=GJLKBUSR(^L$K001#3W2P#V_D66U
MV=F.8RVI]GXC@GND;EB4AK!\YSC(4(MB>7GC?2":YHR#3E7J)6F18JNF"BH)
MF$5BE"W54]NE:=#+=,N9/L8HC(>MHS#SJ))/G?D*=O3#UP&%&QR428ISV"9)
MDV%SS>*577C4'T9*K/FX,5')$G'NBT7)(&3ZP W.]<CJOAVIM18-#VR@R?IY
M%L;;8G7*?H&_2)N%K%"X^F_X*U96V.Q9!3W)U](AP$>D>?"_X[5:K5CF5ZQ*
M'08O'F8+?)0(#17%$2G*%[\  ;>FUA#\(5BG/V3NI7 ]Y186C\<-G^TO?,)C
M<MR#)]V0F*Q9'TFM$I((L= X#/*+++IE62(F@@R/Q!+J$3<1Y5Z UURW0K'P
M;B.+[%WK4^5<]-C=^51PG"QA.[.":1^--\3<X_KMUBLY#M9)669K2T+LM\X&
M2;/UC"*Q%8Z10 I>DEO:N'"NMM;<NY%>YQ#G&]MZD;"<C:D=!VA::X_F[%/S
M5104UEKA0">S]1<1,6P7N'T&RXWL/C7DVHQB/5W-_P !_P"(KK+'U'#_ !?(
M%K=IE-]'X((B:WVTZ5'EP_C'BOSU(T.E)1T.2_'V(_7'RIT"C< '^6,'R&&M
M3+_$.ZU(>*0M\B4Q0,%AX6J@-%D!HHP]Y*10[8]L#>]V>-7 0 0]C+X W$!
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M81XC;A>W*_IM0-#<0 $I16CH@8_7>W$/P5?F-*5*K7!7ZLH*9?JJT #8$4
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M.T!6OB\,524RM&X*Q%7(<=J3J+XC5%G; X@$;*(N7TT5?=WJKAZ_P?GIBJ>
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M&"[]E*X_%BY@915X@C_5IF4-B>;BY<"C82I$$>05Z7R,=.#+S3M4!?:QM)8
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M?AJ6YI8T5X*J+5@\9O2J(M5S9 \T%4162M,5<WUAUIG]^!?5C_U9_HL?_O\
M>LB_C-70Z(P_F+8OK$56WLWA\HC'K)=" !],Z\-X$C)L!O\ W99&GPY^(5#U
M29OYE/\ 9L/VAV[5$NW217+XZXM<0G>L'[$/U?%4-MRYK2UC6M!X!1O&EXH$
M!$H@6U[6"_+Y+#48!WB>*T-+Z':*#S551),\Y0<4V>VL?FIK'(J8Q-LBZSO7
M\]'9MB+58I0)*/(L%&\SCA3CQ,ME6.NG+)(HV#SCD&X!<:S:?=-\<MNHF.;7
M=]("RV9GBEK<$%G1CZ5&E!A,]XV2NGF21>88AVI83)JQ8Z[R!FXQN2[D<R1&
M\FIFC(Y4I)/46$21!;)-.I,TS((G.<1;@2_5"'3^7[<LL:/)W[UM[EUO9#,P
M%;3NS:-(UEKF/8-6K%@QQ#8[1@Q8-46+%BS:!@:2#-DR;%(W9M&Z1 *FDF $
M(4  *Q:).;Z2>2<D@BF/0EC=&[!D-<FRG4IKNS@9V[ /!<X#\)3' ?'UUR\T
M#(9WEFPDK37;G&X</JK'JRM,2HX!<<HVE0K[YRE'6NOA, C_ +[T=:WKUIM*
MNKY8!&I3R_5\);S2/M XCZFVOR*<,G[,@^(G["?O;DPE#AU'%8_48WPCQKG;
MB0>,\MI7,=PXK6SSO\=]#AG/I6#=0+=!Q+Q\/$:B/N!A&^*-\U:AQPH.&P[\
M5@9[RZ<3-<!&!0BIKZ%$K8N<9UH>3S"+PW7DWLZ2W#D9)G3,0S9N#8\TVCD0
M-V.6P^?2+8GEPN#Q*[4N0O7!BFZF?G)D'S! *["TMK347--]1L$;"[#BW9P6
MTBC?=SAH(P%<>A.?H31:&M9)#*<VR%3:V]\LD(\FP]PSB0*/7B1WR"H8=A;<
M1%+&M90*X>3',&X%!1$A%51,<1K6ZSK@OS%;0-+;9DK!44J:."NO9FPEL<50
M^H'1M3']FZ!5H'*DETT%T7.N-2LWC9PBFX:O&SB;W>FLU<H+$.DNV7 UCE,
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M'63I$3&$0$.D4^HPB4JG+H.(#RKSN%CI'2&>(#O&G;U+3&X,$I+JFIW*GAZ
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M\>":R<GIS1"T7*Y3D9\FTK)2[" 3G\D?-_KAK%],.4F,*R</KD5S/$WSY<J
M*FO(,[AU"J3YNQCE;JAD9!&<K&%Q(!I@*[541"2,O?@0"G^(:X<3 (ASL%P
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M1%$11$416U/#X_R41?-)W?W-W2;Q H](_6J-X_!BF.7^6]?#7Q2%/B#JA_\
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MK7W=S744"I;)>W?M[VM$P^?=R[AA*X9DV:[0B=73&*QRR<,ONUWD^1*#)Y#
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M(HB*(BB(HB*(BB(HB*(BB*PZ<MV39P\=KI-FC5%5PZ<KJ%31;MT2]:JZQS"
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M (VX_P U/7+3??/_ %CZ5IYOO7?K'TK"K&L:*PSDB(T19\3_ *+15O&2C_\
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M4=+ZP:H-VC7%3-&K5))NU9L\BRMNU:MT2E(DW:MV\TDV0013*!2$*4I"E
M+5&EU;4I699)Y"VG%1G7ET&DA[J@;5'+((*-Q7O'T5#XZG(,89_B>22KN-6F
M9B38K29,<VFU3?@WE)!\FDZ*T*4G60"CT@ > 5UUE=7$W+\CI'ESFC"NY;"&
M:62VSR.)=Q*FV40 "EX7  "UO57G^4.&=V).*U+VL<\D@5)7?:NX[(P(H<1^
MM<2(AZA7+^U'Y*Z'E( <RVE/Q1Z5L-*8T7C:!>P"'S ^#\HU]NP_>NZ@O2Z
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MZA-)X@N;84/M'YE .BW'$*@.]K7!@%NCJ/O#Z+F-Y0=KVR! #''J$W];#U%
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M>81:H(0L<R>[ G#?4_'2"F[45;/7I7!Q*!2%3(!03L(\*(H3;+($_C#7((S
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MQ:,2&<Y'CL!I\CB/<9]LC.<N>PN<AC&83:ZT,NZG2&BGD>R39*'!,;@8Q!$
M&IMQS!<WD\0?%;Q.<X>J.\#_ (2!MX*WW^XD[C<''!-7JWMXVOE+B3VIB7<N
MRPGWG:N0YTVQV2PV R!XVRS)]3X-A.3NWKZ55.^??34401 I[ 0RHJ  F #5
ML;CF2..'W0VSY)O:_P!I6Q.I3P6^1X+WTWA3OCM':(;1\6Q-K_6KI6.CV+%9
MVHP@^IZX:,TFR[M4#+W%1TJF*@@-QN:N%DFU.6=YCS!I<<.&.Q:[\QG..0@<
M*;$ZNG]0Z<BMM:SE(; ]>1\JQS:$7CWD<PATWS9T18XIJM#HJ@<K@H_-$!,(
M>BM]R?+?,YHMV7&8YC08;Z[%FLIYI[]A(I0=6]>Z:'S0X<1YC;C?AU7$ MSK
M[4 (8T.]8 +T49LHJK]%5%$11$41%$11%;4\/C_)1%\M?>E*RC'NTWDV:Y/J
M/7'GYDQ60DWA&$[F\YY>(8R91P:-41\]!<+>65,3#;I ;<:(HKO(F&RXKV&F
M8S<NX7DHV=L5'+AN]PW"Q0>-U&@I]1EH=BX2;F6 R9[* )2W P\@(O-SN&"=
M@P[?,V>)X-@4M#L\EU'D$7!O8^1G_?<?D' -IR:8'12.DL^FH,P-U"&.)P7
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MQ?5<WVFD=JR1X.S<!5/OVE9^.;Z6@S/9 7<GC+]YC4B]40%J+L3E"?BG(HF
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M.&)X]?%>>'<B[<ETMD'2<O4.;9( _H6XW <"TWT7ND(>)K5Z#RBXF6V_=/\
M^-RXO60/R:XIMRE?3"U45!NR$1"PQ4+^M)S")9W_ %OKKA=3).J7%?Q#N'S+
MY$U _P"H=^L[TK)\U3TA_,D_:U >2UI(H#U#YE!JE\P_I#^9+^:H_C2^T?-\
MR5*7S5/2'\P3]K5N9W'T*E2J15/Z0_F2?M:DPN=DV[^A5!*/-/Z0_F2?M:RY
MG<?0E2CS3^D/Y@G[6JASB:'T!7-)S#K3/[V<H_9H\]Z4=%;AG&F!,9BBS4<>
M<&\=;>Y% KM,R(I'>= *7"X)B80XA6_T61_OH=7O#"N^BW-J2*42=OJRAM)Z
M\,8P7&-FA-[! X_7+(P$+ 6U@5O:H7,KW,U7*PT:78@4Q6LNB?>'_K)XO-/Z
M0_F"?M:T4KG"0@;,-P^91JE JGMS#^9)^UI$YV?;Z$J4GFG](?S)/VM2LSN/
MH5:E5>:?TA_,$_:U3.[CZ%.RMX#L2>8?TA_,D_:U@DED#J X>119<'T&Q(*I
M_P!E_P!B7]K5T4DCJU->Q6![AL-$GFG\3</'V2?M:RN<[+] 61DCRX DTJH6
M=\C@Y=;:_,F8H&-MZ- P^6D(C_O:[2$ 'J(-==RR3[Y/7\+@%M]%^T$N?&FR
MNY3CDE#_ $B^XA_7;C]:7^BG_E:Y>>20O?&3W,QPPIM4:0G.[K*P154#Q#^9
M)^UJ*]KW4H< . 4*<]X=23SE/5_,D_:U9X<G'S!84>:?U?S)?VM7CWAN <0/
M(E2CS3^D/YDG[6LN9W'T)4H\T_I#^9+^UJQQG)P<<J5*/-4](?S)/VM&>(VN
M8[>@)4H\U3TA_,$_:U?F=ACO'#BJ.)HH<=\RZI-0XL(&*!1V<4JGZ-(3"G]E
MNT!.!.HA@ U@YUUW+[C^9RBO_+^9=#IAV+!B9!XKG+256E)HV[/M4D<9?PBR
MDF>%3T2&.OE6C8D49$D0WQ!+#RMWP. .*QIHY;&&PE"KKAH>:TVG<%*>XN<0
M=E4^_;X=0FAM.!U]7^]_"B4XIIE$Y#&=&3-8A"D_G8AQ  ^6]<SJ\SC=U::#
M(.'2M=<T$F' ?*G=%0Y@L82B'H$A!Y?];P&M7XLFVIKY%#E:7@4V@U2/5"R4
M<^AI1LSEHF22*@_BY5BQD(EZ@0R9P2>LG:"J#HA3I%$I5"F* E"I#=1OXZ%L
MT@RXBAX<%4W%]'&2)7T V5X+CD=<ZX(<I_LRU<4H6$YW.O,-(W3* @<RJQSP
MXD*D1,IA$1L%KUM[;F#7'>M/.?\ >*K:7-_=_P#-D;_O%1HU%E<KD^SMU97H
MO \ C,/A7L#KAI/K-X_#\?R!.#9'FY.1CFV.PQ7TN67>22*J2JJ8)"V1+TW
MPUT%P9S9Q7K[R82R-J1F.U2WLN&N+2]SG5VUVKN"Y=E\WW'ZVB,OPQUB[R/U
M-N-VU=E?L)2"GFIWF(I'4B'S9))T"B+@H"9)5,O20P %^-1)[M\FDW!=*^1O
MAD=XUQ(P6(NE:<CG&A&/2%ARF:Y!CO<YDV/X_E& XLID&@M6*%D,W%45 70V
M3M9$R$$V;@V:N7KH%^I4'"Y! "%L @ U9I-Q-;\I0EA/B-<ZO$UK3L4R/[*W
MRQ#*T;A@N=[BI>4PZ=TIG&R97!=NX_$[ -C\MC$GK> <Y$UQ[.XE2(F<AQV/
M;#)MG<5B*R2+UZX41(8K8AK&.;A4S1;J[DTR1MQ*_P <G DXCRJSQ9?:/:I)
M_9UK< (*6K=5KIK(IJHF2UUAHI+M5B%42<-U4XDQ5454Q 2F*(@(#7*.U[F2
M$]Z[N33_ !DJ)[Q/[;NU=7&^[P;!*(@&4= Q#=0RJ$1#1L?%QK9<QC&4408L
MFR#=%0QSB(B4H"(B(\Z-U74KD>-/-*93A5Q-:#K4>6YN:Y<[LO"JJ\U2U@,%
MO0!2>'+];X7K"Z1[G9G&KN."AN\0FK31RX[8:B@Z\V1<W_!OL(36(F/ ,/F!
M)<IB6,6_@/.I5@]PO82=GB#AQ6ULHW^*PN-:."AKC\TH1EB<DVE\J+OEA,]N
MD'KF!.:1+#JZ[?XYKL)ANA$&3&'6Q9[B"LLXD5U! Z;Q!,0&X  ]6R>,7N8T
M&.T 54\'_5>5=OV<+F^JD_TG 4_JMHSR1Z$;BF; GXIC=-,A1N #R  ]%0->
M)=1V%3CL"LU4-J, O0'5ZAQV+@87#CED5?V2!?\ 3I^@M7\GDCF.S _$&X<5
M9I^%Y%3A\J]>T!);V;7XWL%OU<:^U&>N[J"](9ZC>-%D5D61%$11$41%$11%
M;4\/C_)1%\.O?7'JZW^^&VK(N,>QZ94V7D[%FUF<Y!13&6[;(-98L:%!7].;
MW?Z#G,=7)Y@)B404!,+"-Z(G@5SDB!/HV9V@JZD!6,E]7-(8PW!PW."%_=49
M1;WMTB=,Q+)J "%O"B)NLRUT\?XAD.6XWJEPTF(I)'+VF7;FR=RYR$7N/+IR
MQ%6;!15X!U7B38R2B9@)<IQMQJC@2*!8Y#ERO]EP*A--3?V?=Y\5DK/*X.?:
M;41P+/EF&'1;A+'DIN635P_(8L$2 X%))I$3#DW20P!Y@E,8+ %<7S_8?G>@
M'3"*96.(<,36AXX+H.7M0DT_5VWL;02]S6D&M "0">."]9"^4FJZ:D62558N
M#-7:9%"F406"YBIJD +IF%.QA UA"X<*^'7VES!',;IN1\1H!QZU]",N/$/<
M R*[45IS-!XA9P:BH15RJBB(HB*(BB(HB*(BB(HB*(L=9$I^(B/AXV#@8#7$
M0]%JLD#G-HW=CY JC:#P3<08FBMGY?#',FFURV$BLZ;%$ $#/6BRF-9(4Q37
M XE%!N<Y \% OSK8OB;<:=[RUQ$(P)WJ+=SDSB:@%!LW)KW<YGTYGD).XPPQ
MO&&>5AEVKU'^2NW,F]4FL.>R4I&BZ@XH4C-A5]S<"S**X%434]K@%=!IL;+J
MS&GWKRUWAY*C;YUH99'QR>*&@D)Q].YT[V)K'#LSETFC.=D62\?DK)F3RVT?
MEN/R+R R-B1N55<[=-*5CS=!3&,( ;B-ZT.L6+-(G]TA)<UK6T)IO:#N6_L[
MAUU;MF> '&HH.@T3H^</[$/EJ T5C#SM*E4"O%&X /I"J*TI:(J3#TE$?1;\
M=J! L90XB43\K<+>'#C^6JE[6,<2T%P%5<P9I2P[,M:I@9K(]C*1FY<DB,CQ
MZ,9Z\F\MCH2(>8>$BJY98K#-91,\I*%FFBRYW)US%#H3 .5;Z&R@8^!\P'AS
M,J:[ <-B@W4CGV;Y("X3,=NX;UL<"?;3RV.=2+G.\68K-,IEX)(B6N43D,A&
M+M2-W1CJ9(!P54*XN>P6 0X5FOQI5E<"!OADD>6JUUBV]O;<RR2N;C2F"LZ4
MEYV0QG/(J>>,)!;%,ZS"$:/(V,")0<LUSO97S%F?O3LP.P>/5P$0-;IZ?$:D
MZM9,@U*QHXDRQ5-:88;E(M)1[C<1[HC0=.[%0M[DQZ=+Y";G;-<A-;_(X)IL
MH!\AJ[7E-H;>10[FV+I/*9I&TZN[5<=K0 T>X V95],[0W4U8A;E%0P_S42R
M&O/]5D+=2N#_ /><.P_2OD'4<+EWZSO2LFU:YTI<*8*"EK$J(HBI&I4/J>55
M"*RJJ3GP]-4)ICP56^L.M,QO\@)ZM?& 1'_9[HOG_P OFL:Z/1&C\S;%N+:K
M<VF)JK_;\'^\GKX/_-LW_?SDM:S6W>\ZF][L"QY&&^BUMUA<OZRGBO6K?$'N
M+J[5&HB]&Q!IK5*)*RJJ6]4HLWCNX!)?B-4= '-\2N*Q/)<<Q1Z/CK%$*.(5
MJI-P*;X*S$ X'8KV>L.M0H[XOXM< _Y8(W_FTVE74:!(^.[G,8K]BMUH7JR^
M53HDO]$'W+^NW'C_ /73US+R7/<20"25!DD:)'=9]*P!O_U*N8[*/JE8'Y7F
MJ+#Z1_#5_B'@U6Y&<46'U_AH7G@U,C.*/U?JX5ARGB%3(WBEM\-96O+13NJA
MC?7NBK46^&K7DN]D*GA2^RBWJ&K0VI[Q%%:Z.;+ZJAIWT 8^H\4(4/:-LZQ?
M68^K-HD('QFKJ.5!<W5S+<@- I3:NATMIH,^"<9EMF=<NF\LGCL*&L1RMSII
M*8*[7^NQ\@9QZV._6 S<R)6*V)ADS;Z/40.IYH',4X!TWJLEB\2.J3FS'TJ0
M[UC3BN2T_NS6N*:HU=B$S+2Y\CA-?8D27816.3,LC'&E&*LDQ*HZ:-5$NITS
M7(N!0'V2&]%JU=UI%U+/&2#W\/(/]JAS6US,_-"&EM*8IQ![B-5@ "#S+C7"
M_47!<CZ; F=03"(M0]D2)F$/4%8&:#<N,@->X:#I5([2X829PT,INXK;DV>7
M,=?YAE6DHY+8N3XVX6B8_$99PKAHO\H:JQJR^/23R70*,4J2)?"Y!4Y!(8I;
M!QJ/;6+!<M9>DLC#A6E-E<=O0K'%HD#"!D) /4HE3<IWZY\$O![)[8\$^SUT
M8E\4P3=<9%O<E8^8F<8O*<G?- ?)Q#D LZ19 D"Z?4F)^DU=K'!RO'LGE/\
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ML&R1FQS*9B\NCL1QJ-R.&VD5\E!C)Y)C\I )-"9,Z8.'RXPK0'K!)P8Y13.
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M3RKI]RZ^8*85W%:HCV3>(A\YTRGL? D"E\E%+,-=MRPLB5NJH;RA<LUHJ$=
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MZT5@B;$T>YQ<[5S)-<-V-J3:*,(D8Y4UL162=XYD$VY01,V<.'2\6 =:I_,
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MX>E6=9?Q;:O_ .3#6O\ >+C]6:AW+LY>*ONI'^][5RN"_P ;G<6 <BSNI3?
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MXC8G R&C@:\=G4ISA5I:-X*A%O\ Q5YC.FUWKV&U_A1M$[K9'39-W0RF5/\
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M(#1%YY;I@/I)U/Q"P.%F>9:KDSL$T"BH<V3ZMD398@FT+^L=R&//WJ/"QC@
M!Q HA6"_MFW&F35QE8*L&\NX!2[-SV3!^.2NW<H4]GJPEP/+\.1Q77>/*:DV
M%/1AY[/%B.9N.Q[*R?6_$3$8K*>[G.VAI Y1."A"&)TC;QKY,Y]TQS=1BGR/
M(=&2_+]5U10.\E5Z_HU] 8AG>T-IQWJ3RLY'.E"IGV%GVU')'0)&@-7L%6,
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MN(632Z"F.;V;A6^T:WOO>1+G^S&_<KK!KHW=\44<]-YSO:.U?@:6N<:V4_P
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MD4S'*F"BXAP$P@/I_-<?YOR#;W1Q\/Y'$+F]'=^2ZK):# /=3S!>K0&,F =
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M>SW*QN(6M?2>W^%J[GD3^;S?NOE6YT#^+'6I_P '_H!C7]RF)_WMQ-</J/\
M,)_WS_\ B*RZC]_)^N[TE;:H*T)VE(/*I5I]]Y"@VH\0JEQM5=RJJ,K441)1
M8Y-H2</$+A<>'QU<W;Y/D6PA]106[Q[?:GV*V#I_WX.XW_\ 5"VE7;\K?P5U
M^M;?\3%M+#_Q?[OY$X#2QL+[#C#R^T'4P&+P$#!_@];0,(#<!X#YGX*R6W\Q
MO^IWI*US?5HI2I]0$*!36"P<   #D'(  O  KBX1W3^L5'E];R*L;^ V]=K_
M /4K,/7;UK%O'6H6]ZH=4-HWYPF^VG&PO[(F,)IG%P !,)1&U=ARR.[>_P#I
M9?\ @<NCMOX5_P"H?0IM.B*E<KB**O!54MP*(AP5/Q$?"O/P10=2YSH3,;_D
M9".T?LYY$OW\1)A!QK=G+1#M1E)QPO\ *<?C'*\>\1LJW=&9/5"E.40$O5<*
MW.B,]YF<P_4*VFEPY'.F&]1HV[VN:YQ.0R2.Q;4N?98A(X3EV9OUY+:.;O7\
MEE>-SL0XC(<SOW5ZN4%FKY=9N!%2$ZTBE O(*ZN*\D@8^*.9T5'# "M?]BVE
MO/XTY_PK7*Z@A\)UAW#99B<MM6$?XUG1Y?'W[+-,UQ^'>/Y"4Q22ECN8J202
M:2H-Y21=-G"A" #AP"ACA[8#6:_DGN;F&.9SWPEKJDMH,&DC'K6*Y_C6]1]!
M4MMXX?F^<ZTRW&-=95]2<QD6S16*G3(F.1T2.=)/UX1ZLCT*1S?)FJ1F2CM,
M2G0\\#US6DS6UCJKCJ'W%=ZAV_\ $E<IH/:.#9S&R&-16'L=2[2P1!@ALW2J
MS5BRRO"7*Q3&:2A'8MD'64XO.BF*S24;*+MUP&PF*>Y0D:QH5S8'QK64BWV]
MJR;T_=NNQS"8_4'4!C@'M%$1$.!1 !+Q]%<YGFE[T+LS-E>D;5%FG\-Y:JPM
MX</58H!\5B@(!ZKU5HF!^TV+&)O$PX+C=BC;76S1X\-9; Y"(#_M/F^0AQ :
MV&G_ ,=#^\'I6>W_ (AGZX5G60_[VVKPX\-8:WXB-QXX)CP\_56.Y_B9^LJZ
MZ_B_*N4P,>C;7<6//KR#4Q;<K?[W;CC^"I-__ 0?NF^A8]3]5O4I/ZN"VQ\#
M]>6Q0_\ \00/R5M.2O\ Y%9_O0LVE_Q<?5\J]@4N7QC7VVSUSU!>FL]1O4KU
M9%D11$41%$11$416U/#X_P E$7SI]V/'N9W,(<@R9C?^"V-A1%&Z7@TLBBY6
M#<V,RFXJ1A7B8B  =&5:+,A$+\ .050,4WZT2@/.L]N]D;ZO (Z<4H"15>-?
M=-&+8Q*:.WS)XN24>XU+X>YS%)\Y.K&&>8I).=1[ 0D(Q83D?IO56\>Z$2)\
M4$KFN%J\VYNM))_&?$YS&N80*$C;U+I](=X=PPC!@->A3>#,5Y%1&*^U."C6
M!P04;8AJ+&GLN^9-5%%%DVZ3M%)9@W!5!4I ."0 42W&UJ^29G/TN^?;7 \1
MQ?7O=[?TU7M-I.QT0F'W9;2FZM%:R+7K*>QJ:CE-83&2*/HA\U3RO;^5H'3C
MG)V+DK9Z#!Z[<)-EVQSEZ2@W)UF$.-@K/F%_> N#:C86"A'52BAW!<W%I(/0
MH [ARAVWV)H+;S?)L74D)7'B8%+P. L% +'9%@T@US'&(N462(9L[<R,[#K$
M$Z E,4 MQ+7J_*C&3Z'J'+\E7XUC#^\6B@.%:TQX+G[PB#4K:\DQQ%:[\=_%
M>P\7*LYR/83,><%(^7CV,LP.6X%%G)-B/$"@4P%,02 L(" @ @->$ZG$+>^D
MMZ .8:%>B&=ER?'CH&. 6:90A.!C6^(1_$ U HBJ 0$+ARHB6B(HBH.!A#V;
MWOX#;A8?@H$'2E)<"AU<^-[C?Q'QH4*JHBH%0A;W&UN? ?R!2B4*H\]+]G_V
M)OVM$5T!N "'(>(?'1$M$2<.%[<!N'J$.5O75*"N;>J$ [15-O--EH_8^'S+
M4_DH3T'.X;)GMTHE68=&4P1Q'@05"^[.B%]/6 !QX5M8F"\L7V^8YQT]BU]!
M[XYGU:##R<$VNP,NR]QFL2,!'Q\4A@&4P\7,9!//E7HN(K:4,JR0?-X9JD11
M6,9R:+<JAE5+BIPJ;HEC!+&?S.:0N#793F).S9MV#<H4PK([HV='4NKU-E&8
M2I=C8SGRT:MEVN=DRV+.Y"-9&BV$U!/6++(\/FF+)91PX(G)0$PD)BG-<3HF
MMX@%.8=,M[5MI+9FF:,EU,,V/UN/E4[37O>PYW$]9JG>*8YR&L;J, A80N6W
M/Q&U:#K6PZT>6<2E 2W->YKB WX#S&_'C5 J@I% ,"0@/K\;\.'*KMK7@8'+
MMX>558&NE-0#W%#C-=MX=A$/W*8A/O)%&:D9O8\@V;L&2CUG[K-XDQ*T\Y5H
M*A45C)@-RB4#A<.JU=_:Z2^8V1BD)<YE2*X'9B1Q"T#IHH[>:2XQ8*TZ#N6_
MT'NG Y7!EYEBME2C*:S;)G[$Y\$R\5U$5'C) BBZ;:+Z$%1%OQ P 8  !$*U
M/.FAWD=_$\.I0@[>!6'2M3M'6AQ<75HMUV_R3:7A]O/V?O'DJ[/RH"^]M'+%
MQ[+-40ZVKQ)%R0  W#J*%.8S_P"^Z9_BBQZ<-_%-+>\VUX234.H,=F.Y11[C
MRC]AV4#;GF>1F#B'(,%TT%_BKN.5<+JWI^&[S/<1V;1P7.ZX*:1<?JGT!?2V
MSX-V8!_\Z80?C&):7'XZX/4OYI<#<'_.OD'4/XAWZSO2LNHB@HHB6H1<ZNTJ
MU(-2(B2W'BJA%AM</24/3Q,(%+\HC5TE<I(W*]C"\T"01#CQ + !A$1Y!?IL
M/[$W5PMSO6.>&2WM1=/)R/P'E640/!J=@30;\_BK?_W?:)_Y_-95U?+>.LQA
MV/V:V=LC07\3&OA]#"<'_P#K/)"_Y:M/K$<AU2XH3E\5U,5K;G^(?^L4\''T
M5J_=WJ,CCZ*N9"YCLQV(BLRJBB+A\OV+CV#.H2.FV\V\>Y&CD3R,;P<6,DJD
MPQ6/;2$[(OU3+-6K!@T;NB=2BRI2@(\+B-JV>GZ?=ZF'16[1E9C7>IT$&>,.
MHFZ+W*:J-E& X6L]FV,]L_*2X7A:+B/251E,D&+DIH(\[J/D7Q8[^UL0X5%5
M<I4@!.PF 3%O+/*]]-:RSM=3(*G'I4AMJ,CS0;."?H#%M^D'ATW$1L("%KAQ
M]DH]06\0YUSEQ[O! P2..<.QI7'K6HBMY'ES,25Y<?>49]CF2ZOVMIN%5<N<
M]U?@#G;F?L"(>3'P&!97J3;D%CTB616<)%DWCZ5<D*+9JFLX2#VSE*0.JO3>
M3-'N[#4'W\V-G)%AZ5VFG6HMKTU %(N'G7IO!V&!QOD-L4Q+D%@_VMQ7(+C:
MN U'PWZA.Y@[IF>1U9BM'>$N+G':25M/BJ Z$NQ:,%J#M2?%5!!(TU:2"J)?
MBHZ&2E2242U'5$41)61D;I*TW)0':CXJRMA<UU3L^A79G 8$J"G>/_&CV*>O
M<'<8 ?"/9]M8 _[(0KO.5FM]RN\!3-;?\3%T&G?RRZ?]>MN*[Z%S <>FN/'>
MG!;>SA?8>'+JV%JD2^L [=]G>CT6K60.=^::@*GZ_I*M@8PB2H&T[NM2G 2!
M<+@ W'V0$+V H#\T.(7\/2-<C:&W,9\9S@_,=YV+27#'NE.4T"JX6 0\;V^(
M0 ?@$!&I33;YV^$XEU=_!8,CVXN*\]OO(32X:>Q0N/2RV/9$?*)%/'<B;I L
MKCV0+%QQM"3B2)BB5=>(DG*;@A! ;B2UN-=]R0&NOY6O +2PU!%010U%-X.Q
M==R_1\;O$&84.W'<H6]PV0[NUG@.XDL8[N^Y%[NS0XQLALN(F9K W6 F:(9C
MCV.O5,;?Q\"FMDZ4RC+^8JW0.+B)!00= 02WKI-,BTRYO_=O=+<DA^'AL\FY
M;;P[*GW4?^4?,O7+N9S;%L PMXWRW%D<HQ7*Y\V'2<6XFC8^T18^[.Y@SIU+
M$0<.P$%X8/+!N0' .#$Z/"O/=!L72ZM)".YE:ZM,,:[^E:0%HNY@P49F- -@
M\BBH]V1AD0S?2,UJ7;4='M""N[=N]R;K02:HDZ5C**F/'@H0O6(6N 7$ MX5
MN(&Q0T@CDC,KW&I=0G TVFJP6]!(\MPQ"YQ?;^FY-*3;2&M<WG(^(G3X[+LY
MK=.WY>-;SD0D,W]"2#-^U49&5;HL17\A4HD$J0B)1 HA6S?9WER1:SW+1&X'
M&NRF.'!3&1">3*?6._?LXIZX_O(0R%4BD1JV2E#.F:TD@,=)9 Y(I&MI$T.J
M[24+AP$,V2DT3-^ C8Y!#P&N9NN5X+>8RW-VQS>DU]*C3Z=D=5KB#T%,EO38
M3S+WN.[?PS7+_6N\-: F?%]DRCK(R1+S%Q734F,#V89GA:;J?U_(I&.H"*J@
M^X.!!9,0$O'J=$TZ"-SX+N4SMRX!YSCL-56W:"<153UU)G$ELW5>"Y_+P3/&
MY7*H1.3D82.>&D(Z.>^].&CIO&/SD24>1P+MQ%!0Q2F.F("(5PFJPQVE_)!;
M@,B!J W 8X[!@H.H05NB6"@H/0G#$0*)0$;"<0*'PB(!Q'D 7$*UI<3@350A
M#(-F"XW8MQUQLVWCK/8(>@;_ %/F^ WY"'X*EZ?_ !T/[QOI6>".43L))]8*
MWK,HEUOJ^X6_WK];>C_<)CWHJRX_B9^LJRZ>[WHXE<G@_P#&SW$?W0ZE_P";
MIQ4B^_@(/W3?0LVH_=LZ@I0ZO_C%P/\ NLBO_*"5-Y/)',EE0G[QOI6?2_XR
M/J"]@$>5?;L1)E?U!>G,]1JO5)5Z*(BB(HB*(BB*VIX?'^2B+YIN\+/\$A>Z
M/=;"8S?$8AXEE+!-9K*S\?'N45QQ7'3^[F2<K$$5C$,0Q0X"(#Z:5 V[%>&.
M(JH[FV9KA(HK#L/#"%(EUG.?(8\I$R_KSGZ5C6Z2V$O&K7MSGN. AIB=]?F6
M9D(R>(\TQHH*]S,#CV\=>;@QZ-=X_F!<5RLDGCDA"220LF,/N+%09*(K2C?J
M0*Y@LSB#OE@$3]15$RA8QA$>9YEL;B;3 ^S+7L\9NS;L=YE/M)Y()PV9O<<*
M8;5DZ,VB;)-)ZP7C,_U_AA'&'Q<<]QS&X5:;S,D_"=6/2_G1Z1#H-Y)P^C3F
M2$Z-RF4]H35\G\R6SF:\YMY!(#NILKTX;./0O:]*9%)IK69B ,<=N&*[*2D,
M7(JP^N<)FF3D;')[G(;?RAK!1A7'F@8%4\6:K=-Q, ] $9CUAP$HU M[":&7
MQ8LD;O-YRKI ;C[G%1H[@,$S[--(9TXPUA%MH?4VTH?;FMXC%<9DTGDR5804
MG&N.N'2#%9=*.1E7)4TQ;$_3$$;B7GUW+>M,TG76RW,C'22-RNKLZ\#U+2ZY
MI]W+8-<!WX^'RJ7_ &P9($YIO&T 77='Q@[K%#+/"E!V=&-%-RP]X$@$(*Y8
MU\B50  +'*/"U@#@.;K,0:]/<,-89G9F_+Z5T?+YN'::SWD .'!2#,D54"F,
M(@-@Y6M^$!KF:T6Z/!72E H6#P]-41+1$41%$11%;4.);6MQOS]5O750*JH%
M5Q61[!PC#W;9CEF31D(_?M#R+-HY]]576CTW/NBCOH;,UDR(@Y,!+F.'M7J5
M;Z;J-T?L&@L.S;L4"]U.ULZ-<'5WKFS[GU$<0$-@0Q; -_ZFDS?Y1F8 ^.MT
MWE;4G-SD -&U8QJUE)%XD9->E.#CV1P&4QA);&Y=G-1AEUFA7C(ROE@X:F,D
MNBH1PFBN50IR#S( ?#6@O;6YL;H02Y<IKUJ=;W%O<0E[#]IPW+>5A618:BAC
M 4.7M!RN \A]8U=2F*NI1<'L]PZBL//D#1,%SXG,X]E+@M^M4\5$2B:D^BF6
MX%34/!N'/M#P H\> 5?I+"=7+'.(CE;CT4&Y0;AHB=[P,7GCL7*[.UW.YF2=
M=XGDL1#K9#@[>%567CD)A1XM"R'UEQ.2ACBX(S]X:O4B<5"F]@Q> V&MOI]P
M;:^,):U\+GN95U:@<10@54:2%I:)<<S\"MOJ:.CE8$N>-Y29FI?9;'&YO)).
M97:JJK24/$GQ\&"9&*#9HFE" BJT*!2B-D^(C:J\PW?CSQ6S !'"V@IOKQ4R
MTA;"PY:FO%.R4H%Y<+UHE)55$5"B9U0Z$R'4./(A+=0_  _!6*2<1=QX)8_
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M7"2 8E"YG"MX9S*8Q(NV)DI]N5W#&B<@*14ZLBS.42.5&$Q&HG; >Z?6L;J
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MKJJ&TL3ZQ1]M&_+V-J61MX_[TNP;\/5]8JR?D^EM[S'MS=:I[E8\4?;1OLO
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M > >BKL%=@K*[9I(MEV4FR:2#%42><U?-DG+97RU 42\Q%<ITE 35*!BW 0
M>-4BO)6298J@@J!,PS.+-U5IU<4PD@"<,0Q4QN/SL>AS=/5Q-8/<_9$WI#C6
MQ=J>IM&02&AZ5@BTR!ISO )6R804'&F,M%PD1%'6*4%#1L<T8"H4/F@I[JDE
MY@%OPZKVJ'(^[D[TSZM4^-T3?LV"A6U  #@ 6K"LJ6B(HB0Q0,%AY41!2@4
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M'J,(@!0N81-?I-U (@81"]_P50&%OJ1%QZ2F6?VE0  4"E"UB@!0 /04+!^
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MIO2%.!KV"UK?AH115(HJ0(('ZKA:XC\M_P ]5K@E<**[5%14=9/V042A50"
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MOZA :42BQ06#D8/TGI$!#V@XEOT@-@ ;>%7R>HU&"KVN.ULV'8$XV:YO.8/
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M!%([8%6A2B( %Q$  /6%1_%CXJUY#/6P6,L<QR_HNHP"41'H*8;EN)1$+!Q
M!JK98R:5%?.K!-$1M]*1!%R41Z$%37Z0L!!$;B(V"W.X^ 5D?6,!SP:..&!/
MHJLT#3<%PAHXM%3B,%JYW)<<QEJ+O)LB@\;;%)UG/.2+>/*H7K\L?+\Y4ACV
M/P]FX@-3+?3+^](CMHI"YV H#M6&6>VMS_JG ,&W] HV9-W>ZEAG:T?CI,KV
M _2,L $Q>#65B@50,5-1)S,NE44$T[J (#Y?M!Q U=)9_#R_NL;Q_AG_ !$#
MY5J;K7X(?X&+Q!T?31-O]N7<5L!P='7>N8V#BU$5A3=N&#S*Y-F"2@@FHY*@
M#:-3\\ANKVUQ%,P6$! ..^?RUR7I[&LU";-(*-.W%PP/G6O;JFISM,L<3LN_
M9AT;=R=;M2VKDNS<8SB-S:70D\QU]L&1QV1<IL$8[SH:0:_24 NJS1*"2*RO
M0ND8I1,5,$BV$>JN<YIT2RTIT=SI43F:6^($N-*%V8^791;'2-49?1N$CAXS
M7TIOV!2A*<AO9*:X@'(;]0VX>( (C^&N2J,H?]0F@*W+@6>M@L=\[91S55])
M.FC!DCY95GKY=%JU1,LJFW1*JX7,1),ZRZQ2$*(@)C#8 &KF R2^!'4R\!^E
M/.L,MQ#!3Q7!M59=.V4.DHZE7[./;)BW(=P_=H-4"G=+D;M2BJNH1/K<KG B
M87N<1"UZS0V\]S/):P-+KB+UVC:VG'=V*DES!%]X\!9JO2 *%4)82&.F8%4S
M6(H0W08IR^P:P*" #Q"H;96%^9AP8[O;13M^2JS,8'L;=L>'6[A]"\ZC9-GD
MUW+S6LFN6RD/CDMDF7&0>A+S3A9DYCSJ+$B631.=8LVS%NQ9@8A4TPZ1Z@$1
M UZ];DM[>#E@:Q'0M:-J\HET'2]1Y@FS1!SI"-VVE:KI=L8Z[Q=\SBYC*YO8
M-L==9@E%/).6Q]PD$1FV MB1[>4#(G*209"F8[=3S+$(4I3\1*%8^7KC\Q@9
M(#DB?6KMVSH4K6>5='M[22"!C8Y\FW@I1N]K869RX,?M>S,H&76,4@=S;H!2
M*90QA1$0FC%.5(QA #6+<.85NH]"M7W.>:X:&UZ?F7C+>4V-?*PRC,3AM5G[
M5L.$#>3VQYR14$UA1.'<^]#REO)4*@J A,A_.E1*;D-[<JQVFBP03&5\[30F
MFWBL+N6XO%;38-ZW_:KO*9T9V[ZUU1EN&FR#*,5;9$K.S"66J2 OY+(LPG\I
M<++OEFQSO'8#, 1143&ZS%O>K-;TUNIW3'N.9C6@5ZJJ5=<HP7<@E9,&C*!3
M'<L;NPW=D6\M!Y9KC",,3@\JD,@UYD$4_=9::.$!P[/,>R=T@V?E;)BS=N64
M6HFFKU!T":X#>LO+VD6MIS#X]RX,LA;N&8[,QI085*I;\H0VKS(9 ^HI3%:I
M7;6%J*G,;M<S90YS 83G[FW8&,<P!U":\R-Q$]QOXU"_(;4GU@/MG'R$FA6.
M;E=KSW1Y50.V,++S[6<T#_\ V;<_OM4P<OV9_P#$-\_S+#_24GMI/M;PK_\
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MX>G@%>V18Q G;180.[CM5ZKD11$41%$11$414F+U6XVM1%\UG=__ -*#=?\
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MD/\ #GK75LW]:CGW"?UIBWJC]A?]G#Q_XNBMUIHK;N\OH*NZ4Y:O#=KDW_\
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MQTE!4C:O)U>'C]?9I+ZT')\E<1\ XFH4[]%ZLQ^G589H\#'Y"=3*<P.IB3R
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MXROMBU!G^<92]*2%Q7'#.MD9K'_5S$HU<_EP^(X]&Q:8E,L<5!4 YC#TB !
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ME%7$O(+'-U7ZC#<;WJ:,\4; :5<P'M4*-TEQF=.,0\@4]D4HG,$QDR 0!LH
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ML;"&NJ5P2>3N<I<N&N%-6JS(@*HK9I(M2+0:3DO #P;,"%&<=(GN!3G,5 #
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M/E6WV].3+K-LAQ1S]4)?'<7Q"6,TG6&(-L<EU\P;YS@3.<021;N72/T?#).
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M?.[NWG/,"@=>,5),<?PG%L7:8A!8Q%N\XE&+)O-S+Z8GGSY4[=($DDQ3(/$
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M>6*"ACE C@G&P?.#TA?D.<Z^YLKP^5=3R\**0X]PK;QQM O 0_VTL N VO\
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M9\VDXA!84%DP @KAT!7B$_+NERV(NK>=KIL@);782*D>1>F6NK77YDV.YB-
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M1%$11%;4\/C_ "41?+!W%_\ 3@[VO^474_\ S+8W7C_.O\W8N7U_:U-^'SP
M?FV^*]Q\:YB.N/ZRTC=B! >L0+Q+;PX\?AK,JI!X<!X#Z^%6N(H1T)TJLAC$
M43,7I]@Y3V/R$Q! Y+^KJ+4>5C3:XC<I,;_ O(+@8 .";+&")16=;+Q00228
MNWL/G<.W$>DAF&5,S-98I2C<H)H9%&..LA>%CA?G7C7,=LUFI,EC%'D[1Y%]
M=<N7L>IZ#&ZN:5L8Q[5;U@FO&8](8RO[)\.R?(,:0]GI,:+;O/I"%,8HA</[
M62*8!Z@"M%J)D,P\0DX85706;BZ !VT)S ,'L@(AU" </$>%:U9U7>B*D#E$
M!$#!8.=*)1'67]D%*%*% %* B8 XCP$:(K*QC )0+<>(=10\;^ _"%,K7#*\
M58=HZ%<P5< =E585;(O$EFCE,Y6[INLS7 H@4QD'9?(7*41N #Y)S56PF,>H
ML>\_8Q^J-PZE9<QM\-T5!X;MHXKSU[?B.(')=HZDDIE?%U(B1D?<7ZR*;DL6
MXQ&:^TK%9)NP(<JSY B,;-LPO;S46YBASZA^\N2-6AU3E"VD:<URUK6YM^&[
ML7SIS59&UUM[81D@,A-!L4F&F291G4C$_1#3;&8IY' N<A@L@R>1C-3:UD6C
M5RT\T[&/QPZ^2OR+$>)JE3\P?-2"Y@N%=8<'EO"GH6C)[[F\"N_:ZO?E:&>9
M)D.-X.2P>5]0XED5\8#B98%9#-,W)*RIEDS&$!\HI4Q#C[(A:B++#['FB9DR
MN5-AO4%DC&2<*36P9!1=3V%3*-TB.(LAQ./6(E3 H>@ HBVJ4]G+@J;7"=7H
M0#<>)9+-WC;'HHI/F'4)"08K2ZPW # 02E$;\1HBSOJ1FDV('R[9TBB*EA5A
MM=,4<9A2'3&YD!EG@OLA=(*]5K@)!&P\JL=&Q_KBJ+2Y!"X!@<0>04Q0,KG5
MS'C\:B9=1UD,SD>1+ 4[*.;J2QW())*& 3N5NDA46Y3")BC:]XP&4; BY^7Q
M <(Q2"S6<<L9G*XS-HC),_D$6B:4=]#3RB>,Y'BL.W2 A&."8Y!R/E)H@( H
M1 RIKG,-V4.[IV%6O&9A'0FF2Q7)(//M9-VF,3DP[Q DSA.3R1(=51@TQ;&Y
MV=C<.FW$F\3!FH9[A,NDH;RCF4%4H<;% *\U^*UI/>\IF*R)$['5<1MHNQY.
MO/<M7A8PY6$BHXJ1&30;/+(->%DW"B9!42=,9! _6XAY=F?SF$PQ$PW%>/>%
M!0"%$/- !+^N&OBW28Q:7#VXT+S7$XFN.]>[7TCWGQ8323<<$R,/BNR<OVA"
MSVS6L<PQO4$/YF(,X=T+J-S[9$V@Y:O,]=M#@!FS?&X,A2,T5.*#MVKT@82@
M(=9<W%I;:>YMD!'.\U)&TX>5:6&*]F)$[G.CS5H>/%/R0Y@-[748# 4MC"/,
MH"!1MP ! !'P"]ZY2)SA;.:\U<75Z5T[GN-L&N.PA7Q;F'CU -^/P>KXJLPW
MJ-AO2^2<.(CU>@ \!]-5J%7!*(7'VN=PO^0/@JE 'MI]8X]*M>!X;CT+QXWM
MKC7VPMI9T&48MDTGDD?G,PHWG,;RQ7$$!PM.40>YK@^4/4DE?>8/+8Y$R":5
M@$5   'VAKWG0M0OK33HH+0-=$YM2'; X8-(Z<2O/9&LDOG/F&9C?E_V*RPU
MQK]AGVP<V90V2$RB;8Y1D+0[_-%LHP&%BI+86+Q$(WQF,53ZXO(AQR/0!<WG
MJ)E;J%(0I2C4R2^U9ENRUN6,;2HJ-H:<:#K-%"O8F>!+(YHV#+T8C9Y%Z#J%
M 5EK@;@L8/:'AS]KI#P"_@-07/>[UC5<7<XJ/N\\,R.88$R]CW)9_P!O>*X/
M 3\MECK"8#$95&1CVB9'[B1DULH:.5&RC!LU430\JQ3>9[5;:RNK6.X%E/:,
MDE(&)K\A1D!,)<?6HH-RI]QAB':$AM+?.<PT!M*1VM-;>W6<\'C&78+IV;5Q
M2;U["/IA%FUB\:<R@M8]!VN5N<4E7)R@(A8:ZRRL;23WQT4308[7,8L2W:!F
M.-:K5MFFAC.=QHZ0-QX<%VF+Y_L7,-8=N^I)/8N3*!N?N VO@33=..2#-CG&
M4:2U:PF\FC,DC)] CEJG*Y,R8LFBCPJ%U$1.(%#JN$*73(+3Q+Z1@]WBLF2-
MBQHUW=J[C7$C'L6=];33KAT/=G;=, .\--:CJ*>W0.Q)F%'<NG<ME\AV9EFD
MMK+X1C+]\FWD<WRW#I>#B,HQM?)';=-LR4>QB,J+15X?R0.5(!$HC<:CZI;1
M3Z.W5CW;26(N<W=F P=Y"*^1;$O>^]?9O-;7PFOR[LV!S<:J&V*1>(;2RON0
M?=P7>3LC4<] ;TS/'H'7<5O"+QS&\0QC'V+!>&=M<8DDW!Y9%-1<QCD.'D*"
M02>U<*V1N!:Q6+;*T:^)T0)?0XFFW:K)HV-U:>  >"R . X$C:MRWW'F64:^
M[6XS=VYLPT5JK,\5V>;*][X>D3")+/,HQ/)P@=<Q3S)'#%RQQ!KF6,">5,X!
MN@5P;YHVK,RVTFXOIKYX:_5&M+A$=YIT%0H.]9R%_P!\9J-.\-X#H6\V#CF>
M8;VV[ ?--]RYX4NX-8PNM>X#&LZC&,S/ZKS'-,7C)57/I: .,0$I!I2#E$\D
M!$UCH% ZMQ"L4#X+G4-.%W:L89Q*'LQHXM:XMKCNH**CZA\S/8C!'0<$^';G
M$ZTA<YE7,7W,;/V=D[2.7B7N+Y=NF$V7@Y@<O+IS$4O%) 07"H)61\\Y5B<0
M$!&M=K,89IX#;=D;@3F< :^N0-_#!7?7Z/#:?*=I4XU#@0U@*8;%ZC7"PEX
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MP&!WIX\!P#C7J60@IT"!;7OPO>WY*K)$^+ZKSY/I5]6<3V)P>U>R6Y]DF.8
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M8&F54RMZ:]2>GMJ5*?N)T:0@@)OM2Q@.GB(C9=7CU%ZB!\8WK/IK9_S6-F7
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M?2QC<\J9NJ8M/$MJ[]PM-54K.0R:"V;"-53',9%GF,6HUER)E./25%";BCE
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M?C510##8K@>M9E@] ?)5-FQ6[=J6B(HB*(J3G*0+FY?+1%:45+T\!'F'@-5
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M*:PF4HC'W".VG32&F7B<,D7&(I%-)641<24HS,NF[ %F\^+Q4#"81(/6)
M"MG[C?\ ^#L13JB7*$A'PTFQ,8S"1B8Y^S%3I!3W5VR17; H!!,F54$#EZ@
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M;9SS01Y#X0P)8*GYD_G2R$;@@Y#VN0.DO ?_ !/QM7'M="!E8QP:#3UJ[/\
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M!SF.K^M97W\DEW[V<K<X[S0QM!393"F*PX_!X>-7%=J@8 $@I@4#@4 (4H@
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MT'R$\\P%1PH*3#*@1*'TQ J*&>-5BG5( MS%,%O].:#OL[?_ "-^95_,K_\
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M>ZU**+2[22.VR-VCU01AFPP*V[S<68:'SG2NR\$&-+DD)M.*39'EFA7S&SM
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M./370:WR][A;-U$MRF05HM59ZW[]>/MJ^H?D4F"$,05 ,'2(&Z>D2F(<HAS
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MX@6YK#PXA8.'&JA5"K2$  1'D-K>NU_ST*%7.LM[7X_ /YJI0JE"D\TG[+\
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M.CCVB(UZICNCNWJ(8I0TUW!9(J[,C'2TU G01^C]>,U$E'OD.43$<)E,^<F
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M4PR?@(Z.F%7Z652N-[/G-BH1T>Q3B4U6.1QTI&3&/13599<HJMPFG#AN0R@
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MDJ E Y2FYA4W3IW6,GO+05#N8&]"T&U%5E(?%%%!,40VCK4R?2'EE 0R1F0
M(! +TE G#I+8MO"IFCM?'<2RRFH=4]N*A2@>[-'!R<M<A_/4Z;"'F#<1XF$;
MW&_KK3,E9,Z1\>#?$<%OYL0RFSPVJ_5RCHHB/0'B/  ](^@*HB;6>R&<D)5[
MBV!F1;RK S(^19:^)YL7BB+JY_=VB1>,CE2B >8W;@ )I!8YS7"U;33(XX@^
M6XH0<0HK_6/6NG@H*)QF'9X]!-Q:1\>)E! ;>\NGR_4H]DGZI;E<24@J<RBR
MH"(F,:U[!6G-W(^Z?$23&3@LT-*$+<!UD,4Y!,4Q $>'6<+= D,!B#U!T')[
M)P  *8HB @-Z32R1N$$6_'LQ61T8E;D.Q-*HU3U6JZDHUL^5UJY65?RD"T3!
M=7 Y*37(K(3,0V 1$^(F5$QUVR?MMS&$Q Z1$ W4V34;001X3 *#*\VQ[NQ=
MRI@K#<&.FD9W-3ZO[<8Z514R_N 3C%YAF]R/'SQV106 8&1N11D[G9UV1))1
MVYLR* F1(;SA"WL'PK^'$][.W5]8S-E8:T((]-%P_.7-L#VFVMJ8C<O5'LI[
M,9[,,7U_/[9<G+H'7\Y/Y1V]:<7@DL555^G\A?3Y,MV-C[=1TT6?"X>&,R2!
M50WNOE]7,U_JAF7*&L:&M:*4'1@O'WO=(XO=M*]II"(9R,>\BGC1N]CW[%=@
MYCG*93LG#1RB9JY9K(F Q#-%VJ@IF3^:)!$+5<K5"*%)D?9LM]#3#M3(>U,'
MC%GC$ZJY4<9-H5Q+.Q;%@\D%?I-)ZA0763(Q>$,=U%BH"2I3H@0Y2*=3==-9
M)-=!8CA%=,BJ2I%"JI*I'*!TU45"")%$52& Q3 (@8!"B+*#B #ZJ(EHB00
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M2OB1NH3LQ6Q#VRM\2+U%QT]BL@M(#F&).$X_-&T>9LHW? 8T+F#% G4A!Y"
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MV.8$BK7;* :Q.H0+QY5EETK4H(W2RPO;&SUB:8>=#?V8?X?B-S\.M=><A"@
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MAW*=L4])J0^.3LD+AW(Z)F)!?JAL9FY3]*9?5;]0PMF+M</-BEC$264\D2&
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MR9#&220?$1$ 4!,W4X,41$AN!1'FKB>)*YE;''#=^[<(9!*INGV1S#99<A2
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MN4CH2$*!;D4X"E H6 .8B(CSN(A81'X0X4195$11$41%$2=(7O;C1$M$2#P
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M7#K&GW$-W+%('>Z$YZ="ZS4N2>:]'U73-%U6PN(-2U@0NLVN;03-FRY'!U:
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MY][)BTD>&9F?8VFZN)G*4&Y,9J50?:."5QXC5SVD7+W_ %2!\JU]N28A7:G
MJJS(HB*(BB(HB*(BB(HB*(BB(HB*(BB(HB*(BB(HB*(BB(HB*(BB*T/S_C#\
ME$5VB(HB*(BB(HB*(BB(HB*(BB(HB*(BB(HB*(BB(HB*(BB(HB*(BB(HB*(B
MB(HB*(BB*CH#U_@_-1%IYAH9VQD6J1P(JZCGK5(YN)2*.&JJ)#& /UI3' 1J
MR1ADC=&-K@1VBBDV5PRSO(;N0$QQ2L>0-I#7!Q Z2 OFPPKMJ[R^Q[50X%IZ
M,U]MK<4ENO+MB,F#N6=PN&+0&93(.C@]?ODFZB4DP:)^V%A Q^ <*\LT[2N:
M.2N6[V+16&:7WUTK:XU<XBO^[T+[V^(7QP^ O]QGQ:T?5N?3J.D\MP<LV]@]
MT48>\26[ P'%S02:<,5)71'>-]X27<^/XYW0ZCT'@VKSLY1'))3$<W":R1E*
M)L%5(E%!CU6-[U)BFDH-A A#"/A6RT+5^>KB9GYQ91,M9!4$$Y^H[MNSH7#_
M !8Y'_L\T;DY]]\*>9]:ON:G7+&QPW,+(XFQFGB$@.<2X8TH:;-B;W.>[7[X
M?&7LM)-.WKMQ'&%):6+BLB]V44CI_!@_43AE'20 <$%5V8I&6#]:)N%6ZG>_
M$V"[>;.RM38-+:5J74-=N(Q\BZW1OA__ &(SV$3-7YPU^#6O=V&9GN[2QLI;
M5P8<PJTNK3A2F*D/M_NG[['.+:JDNUW5>F,_F%,-0>;O;99F2D0UQ3-3IH@K
M&X\X643(_B$U15#S@ ?FE#QX;'5]0YTBL89=*L8I+IP&=KG;_P#"O*OAWRU_
M:_=:CKD?Q4Y@U33=*MYR--EMK=LCKB/,1649QD.3O5J?D46LDB=R?>*:7RW1
M??8&):,DX;9F(9=KIYI61C\W6G A&KT7S292>.4V[-(KI8"@-Q,)1OX5I]0T
M76>==-&F<V0>[6P>'_9>MF'2:\>"]=T'XO?"?^UGXG6'Q!_MIN9N9[>\T:>V
MF;?TB=644<&Y :&GJG%>I_:G@<]B$MD2LDFJ$>LBS:QRR@EZG*#5)NU05,4H
M6()DF][!P"_HKTF&)L$#(&>HQC6CJ: !Y@OA#5[Q^KZQ<ZQ,W)/<7$LI:#4-
M,CW/+:[\N:E=]*J<UK?'QK(H(%%0?D'P_D&E:*JP%F35P<%%D$E5"E$I#JI)
MJF3 UNL$Q4*?H _2'4 <#=(7Y45" =O%6OHQAY7D>Z-A0 W65 6Z H$/Y@J@
M<J(I^4!_,$37M<1$1&A%=N)"O)!&4  = 5\6J!NCJ3(84Q,)#'*4QB"8.D1*
M)@$2\. 6Y!5"*FIVUJK1W8S$W!AW(%J@)#)&3*9(X"!DCE*=,0'F'EF*)>DP
M\PM8:2-;*S(\ A4C C:&MV!)[HWN!@23*8 Z0,5-,I@+;YH' H& !$;\!YU4
M%S6A@)R"F'4A%9!*?6"I!DV >H$B%-<3"<I"%,)C 4#&$P% >HW3Q&JUPITU
M\JI(P2O$CO6#2T=3MJK!J@4@D(F1,HF,803(0@"8WSC" %Z>H1&XC:XCSO5I
M#7.#B!4!7= P"3W-M_0$N(& WZ)*QNKYPF#HL83>/I\:N)JTMW$*Q\8>0349
M3445239%'J\I,J?7Q/T%*0#&L =9BE "BH(  "-KB !Z K&&-\'P/^6JY&^)
MXOUZ*@S%H83B+=$3*" G,*20F,)>("81(/4(>N]796UJ  <M/(KHOLFY6[*U
MQ5TZ"2H@*A"J=-[=9"&M<+#:Y1L-O'GQJZO<R;O.J4I6F&;:J2-D"!TE3(!.
MD"@3H)T 4!Z@*!>FW2!N-N5ZQM8&O\3$N  %=U.'3Q2@\-L7_+::T^=+[DV4
M*8#I$-U !!$Y"*")2\2%'S"G 0(/$ Y!8/0%"QI?XGUSM/'KXH!1Q=Q-5:]P
M;"%BH(@(% H?H40L4 *6P?H[ %BAP^;ZJ9!G#\:C9T<:=:KQX$(!BW( %,BD
M/LG+84DA 2*7ZR#['M$/?V@'YU@O>K&P,;&(A7('%WE*I3U>+=BK*U0(42%3
M*4HEZ+ 4H6)^Q"Q;@7\G#E65[0_;[-,-PZ.", 9LQXUQKUH,U0.8IC$*82F
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g833164page46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g833164page46.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MIK<?\1;%'\-?;XR4NK%Q-%(.JG_/\J36A.#DU-Q>S.CMIS=>'8[EOO2VP?\
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M+]VI^N.3^=.Z1'(V:5O:P6D0BMXDBC'\*# J7J4E8GH&% !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 8H ;L&[..: '8H * "@ H * "@ H
;* "@ H * "@ H * "@ H * "@ H * "@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g833164page46a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g833164page46a.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MS(M]]QXV,^TQB+3@LBGJ"TAV_P#H#?G5=">IT0J44%, H * "@ H * "@ H
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MYY].: *]N^H$*'5C*%4,<8"G!R<?E0!8G^U?:S)&)"@4#;C Z\GKSP>G^R*
M%,EV'PD;\G&Y@...N/S_ "H !->;L&%P"W7 .!S_ /6H :D5Y=HKSR/;D'[B
M<8_Q[4 :$:E(T4DG  R>] #Z "@ H * "@ H * #% !B@!,4   % "XH ,4
@&* #% !B@ Q0 F!0 N* #% !B@ Q0 4 % !0 4 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g833164pagebb.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g833164pagebb.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M=:%H,HGEMYHVNX'E<L&;Y P+;@3V,G3&>30 V'4]!TN.^EBADA2!GBE?T(8
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M%=@_.[;\P!*]<'@<8H LW/A_7GNGN(M07.Z0QAIG!569#MR!CHK*#C@-WQ0
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M;9G4G$<:C< .>4/KUH U]'M=1LXPEZ\<KL3YD@F9MQ  #!2/ESW X'O0!JT
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
5 4 % !0 4 % !0 4 % !0 4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g5lvsimk4gaq000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5lvsimk4gaq000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %= @0# 2(  A$! Q$!_\0
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M,C .1STJ*2Z@BFABDE19)B5C4GEB!D@?@,T 344=\44 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!!)_Q^0_1JGJ"3_C\A^C5/0 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***SM3CU=WC_ +,GMHU ._SD))/M3BKNUR9RY5>US1HKEK^W\2FS<3SP2P<>
M;':J5D9>X4GOBFZ?;^(A:_Z'-%#:EB88[M2TBKVR:V]BK7YD<_UE\W+R,ZNB
MLBSM=6E\V+5IK6:W=-NV)2I_.N<TJTU&QTW38K1+B)GCN)9@227D7'EAB<X!
M].]92C9VO<Z(2YE>UCNJ*\\;5-=31PYFG:X>0,A0']VX4%T?CG)S@?K4LDFL
M WB6US?!GNYY#QG:HB#1A<CA2U24=]17!37?B..<6XGD2(3.(YYE/+[8RJG
MY7+2<>V.U-NY-<DMI6FN+Y%:978QC'EJMR%^7';R^3],T =_12#[HP<\4M !
M1110 57?_D(0_P#7-OYBK%5W_P"0A#_US;^8H L4444 %%%% !1110 4444
M(0",$ CWI B*S,J*&;J0.33J* ()/^/R'Z-4]02?\?D/T:IZ "BBB@ HHHH
M**** "JEX'+6X6:2/,FT[".1@^WM5NJUU]^V_P"NP_D: +/:BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /3B
MJ]F\LD3-*RGYBHVC'0D58JO9?\>Y_P"NC_\ H1H L4444 %%%% !130ZEBH8
M%AR1GFE) !)( '4F@!:*J6>IV6H)(]I<QRK&?F(/3W^GO4,>O:5+$TJWT.P2
M"/);'S'H/Q[>M &C152'5+&>]DLXKF-KB/.Y >1CK^7>K= !1110 4444 %%
M%% !5=_^0A#_ -<V_F*L57?_ )"$/_7-OYB@"Q1110 4444 %%%% !1110 4
M444 02?\?D/T:IZ@D_X_(?HU3T %%%% !1110 4444 %5KK[]M_UV'\C5FJU
MU]^V_P"NP_D: +-%%% !1110 4444 %%%% %>^:1+.1XI"C*,@@ _P ZG4%5
M +%B.Y[U!?\ _'A/_N&K% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %5[+_CW/_71_P#T(U8JO9?\>Y_ZZ/\ ^A&@"Q1110 4444 <II.CW:^
M);F_DMT@C2YF(EW?/,K*H QC[H(SU[5HQZ 8H-2C-_/)]M1E&_&(\@]/S_2M
MJB@#D[?1-4*S^;';1&XM4L7$<I.V-5?,@X'S98<>G>H)/#^K2VSL8+59@EO
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M+K)?C_D7[>72#_#_ #.AHKGO^$?U%_\ 7>(+M_\ =0+_ "H'A2-_]=JFI/\
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M1112&%%%% !1110 4444 02?\?D/T:IZ@D_X_(?HU3T %%%% !1110 4444
M%5KK[]M_UV'\C5FLG6M6M=->T%PS9:7.%&<#!&3[<TU%R=D3*48J\G9&M12*
MP=0RG((R"*6D4%%%,:6-/O2(OU84!<?15=K^S3[UW OUD'^-02:WI<?WK^W_
M  <&J4)/9$.I!;LOT5COXJT./[VHQ#\S_2HCXOT7^"Y:3_<C)JE1J/[+^XAX
MFBOMK[S5O_\ CPG_ -PU8KF'U,^)+HZ=9S26MN%W2R,-LCCT4'MZFB#7=0MY
M);#[ ^HSVYVM-"P"L.V<]#ZU?L)?/L1]:A?R[^?YG3T5SW]H^(YO]5H\,/\
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M_P!"- %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K/_R$H?\
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M_P!R\>9'^^^[/S'W-:%5[+_CW/\ UT?_ -"- %BBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *I/-%_:T,?F+YGEM\N>>HJ[59_^0A#_ -<V_F*
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M2>(MB6>KVKP1NJW-I$)%E0E<#D8Z_CQ74:0TCZ5;M,UP\A!RUR@20\GJ!TH
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M81KH*?+\DQL""Q)8$GDEOR H Z6BBB@ HHHH @D_X_(?HU3U!)_Q^0_1JGH
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MB\-7NHW'AB;[;!,4BL8Y@6E3. V>U=310!BRZ[/%KFFZ:=)O&6\A:5[A5S'
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MO&<^]:(UFY_X2?\ LG^R;K[/]G\[[=QY>[/W/K6O10!RP\1Z[)X:N=1B\+W
MOXK@Q1V+S -(@;&_/ICG%:#ZAK UW3K9-(!T^>!GN;DRC,#@<+CO6S10!S8O
M_%+Z9K3_ -DVL=Y!(RZ<AFRLZCHS>GZ5YM''X9D\#W.JZA?,OB\%V=S,1=)=
M G:BIG.,X& ,8KVVLJ72--?7H;UM/MFNQ&Q\\Q#?U'>@"SI3W4FD6;WR[;MH
M4,P]'P,_K5RBB@ HHHH Y#QBDDL\/E:?%-Y$#3//,\BJB[@"!Y?)/.<>@K6\
M*2&3PW:,51?O@;-VT@.<$;OFP?>L;68=4U;79(884FM;1<&)+TQ'<V"&..^
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M(/\ GDM'V2#_ )Y+4U% $/V2#_GDM5KNTA+VN$ _?#^1J_5:Z^_;?]=A_(T
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MD@_YY+1]D@_YY+4U% $/V2#_ )Y+5:QM(!;ME ?WC]?]XU?JO9?\>Y_ZZ/\
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M%U);V5Y>"X>":..0HA^0<C!Q@\5W=E.EU86]Q&6*2Q*ZE_O8(!Y]Z )Z***
M"BBB@ HS17%>,&L1K^G+J<S1VIMIL8D9 7P,8VD<^E ':T5YQ::UJ4=WH]K+
M=W45SB*&XCF9<,'!VL%QG/3)SUK?\,W][J%O?2ZE(1%:C[(X88W/'GS)..S9
M'Y4 =/N!7.1CUS2UY>DL'VZ9!,IT4ZA$;E[>5S J&)\ L3G.X+N[<BNR\(-*
MVA$L7:'[1,+8N228=Y\OD\D;<4 ;U%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
? "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g5lvsimk4gaq000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5lvsimk4gaq000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $F J # 2(  A$! Q$!_\0
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M'8HQ3?-'_/.7_O@T>:/^><O_ 'P: L.Q1BF^:/\ GG+_ -\&CS1_SSE_[X-
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M25F;SK=?FR%.6.3N^;. >@X^O4?#&1IAK$K8#/)&QVC R=W:JKTH*DY*-O\
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M><5Z/\*/];JW^[%_-JUQ?\&7]=3#+?\ >H_/\F>E4445X9]89VNW$MKH=W/
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MWLD%>C_"C_6ZM_NQ?S:O.*]$^%:R-+JNR79\L6?E!SRU=>+_ (,OZZG!EO\
MO4?G^3/3:*A\J?\ Y^O_ "$*/*G_ .?K_P A"O#/K"AXE_Y%R^_ZYC_T(5YE
M7I'B*.8>'KTM<;AL&1Y8&>17F]?.YQ_&CZ?JSZS(/]WEZ_H@K2B_Y$WQ'_UR
MB_\ 0ZS:T(PQ\(>(2'P!%%D8Z_/664?[]3]33/\ _D6UO3]3@****_2S\4/2
M/A1UU;Z1?^S5Z3WKS/X5K(QU79+LXBS\H.?O5Z-Y4^?^/K_R$*\3%_QG_70^
MLRS_ '6/S_-CXB6B4EBQ(ZE=I/X=JS/$W_(MWO\ NC_T(5=BBN/*7-S(#C_E
MI&N[\<5F^)(YAX>O"UQN&T9'E@9^85P8G^#/T?Y'KX3_ 'BG_B7YGG%%%%?&
M'Z 6U_Y%;Q!_UPB_]&"N%KN<,?#&OD-@""+(QU_>"N&K] X<_P!Q7JS\GXQ_
MY&3]$%>A_"C_ (_M4_ZXI_Z$:\\KT#X6*[7NI[)-G[I,_*#GYC7JXO\ @R/"
MRW_>H_UT/4:*A\J?_GZ_\A"CRI_^?K_R$*\,^M)J*A\J?_GZ_P#(0H\J?_GZ
M_P#(0H FHJ'RI_\ GZ_\A"CRI_\ GZ_\A"@":BH?*G_Y^O\ R$*/*G_Y^O\
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M6!7).#C..#M.['I3U\,Z8DZSI!*LRY.\2MG)# L?<[FS]:C;0=%T^V9FA\F
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M1?R:O,Z],^%'^HU;_>B_DU:8S^"_ZZF.5_[U'Y_DST6BBBO$/JPHHHH *0D
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MV6.X65T\ER"-ZXY;KT/!K?HH QM+TB>RO5EFEC=(HYHXV7.Y_,E\PEAT!'3
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M;U*].H:A)<88*<*@8Y(4# !/KBI6_P"1$U__ 'H/_0JSZT&_Y$37_P#>@_\
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M!41I'@\>D:GZU)9:/9Z?>3W-LKHTR*C(9"5&&9L@$\$EC5^B@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>_0 [(NJNBLRAG.%!/+=^/7BD5T?=L96VMM;!S@^A]#7*3^'=9GM&MGOMZO
M5<O<.<R%)%)!Z@9,?3TZ>MHZ5K'GR-'<".-WW1+]H;]P<H<GC]YPK+@^OO0!
MT=%96BV-]8B07ERTRM%']Z5G/F#=O//0'Y?RK5H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
***** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g5lvsimk4gaq000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5lvsimk4gaq000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %) @0# 2(  A$! Q$!_\0
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M@^_>K44K.[HR;67'?.<U+T&!4$?_ !]S_1?ZT 3T444 %%%% !1110 4444
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M6/BZSU">W$$,QMYW6)9R, 2M'Y@0CK]WOZ\4 =#1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %01_P#'W/\ 1?ZU/4$?_'W/]%_K0!/1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 )@>@XKG-:\#:)KU\;VZBGCG
M90DK6\S1^<H[.!]X5T/G1 X,B?\ ?0K-U'Q#IVF3113S9:0_P#=M'J?05482
MD[)$2J0@KR=B_;6L%G:Q6MM"D4$2A4C48"@=!4=_I]OJ5N(+I-\8=7QGN#D5
M*MQ RAEFC*D9!##FJVI:K;:99&[E\R1-X0+"N]F8G  %*S*33V(;_0+#4I?-
MF1Q((Q&K(VW: VX8]\U7M_"FG6K1F%KE0JLKCS3B5222K^HR3^9J0^)+*.1(
M9X[B"XD562&6+#MN;: !W.:GU/6(-),;7,-P86.&F2/<D?('S'MUI#*J^%K%
M+2"W6:["V[[H&$Q#1?*4PI]-I(IUKX8TRRNH9K>.1%A*LD(<^6'"; ^W^]MX
MS0?$<"W%S;?8K\W$"[_)$'S2+NV[DYY&:T-/OX-3L(;RV8F&497<,$>H(]0:
M +-%%% !1110 444PS1"3RS(@<_PEAG\J 'T444 %%%% !1110 4444 %%%%
M !4$?_'W/]%_K4]01_\ 'W/]%_K0!/1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***HF"+^UUDVG=Y9/WCUR.W2@"]1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %5I/^0E!_P!<W_FM6:K2?\A*
M#_KF_P#-: +-%%% !1110 4444 %%%% !1110 5!'_Q]S_1?ZU/4$?\ Q]S_
M $7^M $]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5 MPS730>2
M0% )?<,8.<?RJ>J44V=5G3RY!\B?,5X_B[T 7:*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ JL?^0DO_ %R/\Q5FJQ_Y"2_]<C_,4 6:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ JM)_R$H/\ KF_\UJS7.W/B6QBU
MR.,[VAB!BDN%&41VQ@$_A51A*?PHSJ584_C=CHJ*0,& *D$'H12U)H%%%% '
M.^*O$DGAZ&)XXH3N!8M.Y52!C*@@'YCV'M6EI.J)JT$T\*_N4F:..0'B0#'S
M#VY(_"L3Q<UQ*UK'%+.;4,PFCM98E?=CC)?(Q[5J^&]W]CQAFNCAB!]ID1W
M^J<8H UJ*** "JDFI6L4DD;R;709*D')[<>O-6ZRI=+EFN))WF4N)%>)B/N[
M3D+]* -&&:.XB66)@R-T(ID?_'W/]%_K265K]DM5B+;SDLQQC))S20(L=S.%
M&!A3USZT 6:*** "BBB@ HHHH **** &B1"VT.I;T!YIU5(HXQJ4S"-0VT<A
M1FK= !1110 4444 %%%% !5:/_D(S_\ 7-/YM5FJT?\ R$9_^N:?S:@"S111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %5C_R$E_ZY'^8JS5$^=_;
M"\IY?E'USU% %ZBBB@ HHHH **** "BBD)"C)( ]30 M%4;G6=,L_P#CXOH(
M_8N*SF\6V#-MM8KJZ?L(H3@_B>*TC2G+9&4J]*.CDC?HKG_[7URY_P"/30S&
M/6ZE"_H*/LGB6Z_UVH6MJI[0Q[F'XFG[)KXFE\_\B/K"?PQ;^5OSL=!TZU4N
M-3L;1=UQ=PQC_:<5E?\ "+";F^U2^N3_ -=-@_(5:M_#6CVS;DL(B_\ ><;B
M?SHY:2W=_D'-6>T4O5_Y?YD$GB[2@=L#RW+=O(B+ _C3/[<U6Y_X\]"F&>C7
M#A :W8X8H1B*-$'HJ@4^CGIK:/WO_A@]G5?Q3MZ+_.YS<UKXFU&!XI;BSLXY
M%VLL8+-@^]9B/=V%@_ALZ6DMS)D1R!?W<BGJ[>XKMZJR?\A2W_ZY2?S6KC7M
MHTK$2PJ;NI.^W?0BT;3WTO2H;1YC*R Y8_7M[5?HHK"3<G=G3&*C%16R"BBB
MD4<+XKM?LUTTLLUJ\<K&40C2%N&0# 9V;<..G-='X<BCMM/EM$E@D:WG:.0P
MVP@4-P<;03ZCFLKQM;&[@BA;2'OU=&6-D9EV2'&-Q!&$ZYSQQ6CX6MI++2Y+
M26.)3!,R"2+.)> =_))R<XY/:@#;HHHH **** "H(_\ C[G^B_UJ>H(_^/N?
MZ+_6@">BBB@ HHHH **** "BBB@"M'_R$)O]Q:LU6C_Y"$W^XM6: "BBB@ H
MHHH **** "JT?_(1G_ZYI_-JLU6C_P"0C/\ ]<T_FU %FBBB@ HHHH ****
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M44 4H5F&J3EI%*;1@!>?SJ[5:/\ Y"$W^XM6: "BBB@ HHHH **** "JT?\
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MA<-DYI( XN9][!CA>0,>M %FBBB@ HHHH **** "BBN<\77JC3&L+>X<7TY
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MY/MBLUL%<?O0.I7UQ3H=7TVX2!X;ZW=;ARD)60'S&'4+ZD5*MA9HT+):0*8
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MZ7_&CSIO^?5_^^E_QH @MM'L+1X9([9#-#;BV29QN?RQ_"6/)%70     !T
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M,K(K2_OCG/ 4;1M]<J?>NJT:Q.GV'D-$B2;B7*R-)O/]XEN<GWK0HH ****
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M%% !1110 4444 %5C_R$E_ZY'^8JS58_\A)?^N1_F* +-%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 56D_Y"4'_ %S?^:U9JM)_R$H/^N;_ ,UH
M LT444 %%%% !1110 4444 %%-=UC0N[!5'4D\"J$FK(DLD2P2/(K[0H(^8;
M=Q(YZ8H T:@C_P"/N?Z+_6GP3+<6\<R9VNH89J*!TDNIRC!AA1D'ZT 6:***
M "BBB@ HHHH **** *T?_(0F_P!Q:LU6C_Y"$W^XM6: "BBB@ HHHH ****
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M% !1110 4444 %%%% !1110 4444 %5I/^0E!_US?^:U9JM)_P A*#_KF_\
M-: +-%%% !1110 4444 %%%% !1110 5!'_Q]S_1?ZU/4$?_ !]S_1?ZT 3T
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !5.1F_M*$B*0JJ,I<#C)VX_E5RB@ HHHH **** "BBB
M@ HHHH ***KM?6B-(K7$8:+[X+?=H L5!'_Q]S_1?ZU+'(DL:R1L'1N0RG(-
M11_\?<_T7^M $]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVG#4?[0^QP_:^2)=O()X)'OCO2V.D:=ILDCV5G# TG#&-<9'I]/:@"[1110
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MUK0K&*]GM8KF682M"P5CMC)'/UK!'C#4;70HIQ<17$T#2&57MR3-$LNP/N!
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; "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gqr1p20dfppl000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqr1p20dfppl000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,3 ?T# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC. *O:K/):Z/>W$1VR16\CH<9P0I(KS3X/>(O$/C/1I=6UC7Y7:"\:#[,EO
MB2*$4\X3=G+=B.E 'JU%9.FQZVE[(=0FMWMR#@)ZYXQP,#&<Y)/2M:@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR"KS_K@__H)JROW1]*K:E_R"KS_K@_\ Z":LK]T?2@"*[DAALIY;D P)&S2
MKD%0.>._%>!:1!8^(_C7HOB#P?I++X=ME$4T]O9^3%'*$?.1@8.&7GW%>YZ[
M_P B]J7_ %ZR_P#H!KR[]G'_ )$+4/\ L)/_ .BXZ /8:*QM-\0PZGJDUE%&
MH$2;B_G*23G'"CMC!S6S1< HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSZ9J2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KD?%E_K*^(O#VCZ/J,>GG4#<&69[838$:!@ "1ZUUU<9X
MO>_N/%7AG2K+4YM.6\-T9)H(XVD^2,$ %U;'OB@"8:%XS# GQK"0#R/['3G_
M ,?KK:\9OKSQ/9^'?%VJ)XOU-Y-$OS;0(T-OMD4",_/^[SGYSTQVKV:@"EIW
M_+W_ -?+_P!*NU2T[_E[_P"OE_Z5=H **** "BBB@"KJ7_(*O/\ K@__ *":
MLK]T?2JVI?\ (*O/^N#_ /H)JROW1]* *&N_\B]J7_7K+_Z :\N_9Q_Y$+4/
M^PD__HN.O4==_P"1>U+_ *]9?_0#7EW[./\ R(6H?]A)_P#T7'0![#1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5@>)])N[V.#4-/U(6%[8"1XW:V296!7D$,,@''\)!K?KA/B% NK:A
MH6@QV<5U=7KS.BW4\BVR)&H+M(D9!D/( 4G')H Y[2OB3+=:=8Q:IH^EZRVI
MQQRS6NBN9IDW '][ P.,<9)?M7KE>:S>*I?#Z:Q)H.@Z9'X>T"58;XQGRGE?
M"F3RE4;?D##[W4\5Z2"" 1T- %/3O^7O_KY?^E7:I:=_R]_]?+_TJ[0 4444
M %%%% %74O\ D%7G_7!__035E?NCZ56U+_D%7G_7!_\ T$U97[H^E %#7?\
MD7M2_P"O67_T UY=^SC_ ,B%J'_82?\ ]%QUZCKO_(O:E_UZR_\ H!KR[]G'
M_D0M0_["3_\ HN.@#V&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB@#D?#2ZK%X@OH]2:_"G>81-(K)(@8 -C<=K?0 8/;I77444 %%%% !1110
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M !1110 4444 %%%% !6OX8_X^Y_^!?\ LE9%:_AC_C[G_P"!?^R4 =11110
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MXC$A\V/"$XS\PK#7[J_2MOQV0/"\Q:7R@)8\R9'R_,/7BL1?NCC'% "T444
M%%%% !1110 4444 %%%% !6OX8_X^Y_^!?\ LE9%:_AC_C[G_P"!?^R4 =11
M110 4444 %%%% !7)>/7\+C2X8_$<44LDA86*>4TDQDQ_P L]@+ ].176UPG
MCYRNM^&4NM5O-+TF::>*ZNK:Y, #F/,:LXZ D'KWH YOPM:>/QIFE_V:=5M6
M6*/[:?$4R21,P W^6F#,.<XRRCVKU^O)_&6GVVB^'I)M*\9:[-JTKI'8V_\
M:[2&:1G  "#[W!/X5ZQ1IT#7J4M._P"7O_KY?^E7:I:=_P O?_7R_P#2KM !
M1110!S.K3W&BZTVI)8I/'<!+<,)B&SV&,8_&K">*K9+F.VO;6YM)W8*%=0PR
M3CJ#5/7K47&IGS['5;N%54A89 (@?IUS5&PU/1(-0CMK?0)!<%PN2%D93GKG
M)Z4P.NU+_D%7G_7!_P#T$U97[H^E5M2_Y!5Y_P!<'_\ 035E?NCZ4@%HHHH
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M@\X[$CFNJ\)EC+*77:WSY7T^Y656OX8_X^Y_^!?^R4 =11110 4444 %%%%
M!7+>+M,O6N=+U_39+3[5H[RN8;R3RXI8W3:X+X.P]"#@CCFNIKAOB!'"-0T&
M[U>W>X\-V\TC:A&(S(BOM'E/(@SN0'=G@@$@F@#(NM9U'XD64OAR&'1K.VG*
M_:YHM8BNY!&&!8(D8ZG&,L0!FO4*\I\4ZEX0UO3$M/"?V&[\2%T.G/ID8\R"
M0,/G9U'R(!G=D@$9'->JC.!GKWQ0!3T[_E[_ .OE_P"E7:I:=_R]_P#7R_\
M2KM !1110!R?BB/9=Q3W6DVMY;LRQ1MYA23<>W':JUG/H&GZE"D^C26=WO"H
M6/F $G'7)_E4NNB"ZUY[9['4+YHXU<Q13[8U'KCUIL%S9Z9+"6\+R6PDE6-9
M9-I(8GCDY-,#J-2_Y!5Y_P!<'_\ 035E?NCZ56U+_D%7G_7!_P#T$U97[H^E
M(!:*** "BBB@ HHHH **** "BBB@#FO']L+KP-JB$,=L8D^7K\K _P!*Y^TE
M$]E;RCH\2M^8%=MK<!N="U" #)DMY%''?:<5Y[X>E:7P]8LY!?R@&(Z9'% &
ME1110 4444 %%%% !1110 4444 07J>;8S)_>7 J709B(],E/) C!Y^@/]:2
M;_4OCLI-0:8=MN%!QY<[KGKC#DC^E &OK$3QZQ<%MO[S:ZX],8_]EJE5[5KV
M*^O$EA#A1'M.X8[_ /UZHT %%%4Y[R=;I[>VM!.Z1K(Y:81@!BP'8_W30!<H
MK/%UJ9S_ ,2N$$=C>C_XBG?:-3SC^S;;@9_X_P 8_P#0.OM0!>HJ@;K5 !_Q
M*X3GL+X<?^.59ADE8*L\'DRLGF;0X<8W%>O'=30!7O8[XSK+;K9NB(<+<,PP
MWJ, ]L5;AD,L$4A&"Z!L#MD9I9/]4Y_V3_*HK)@UA;,IR#$O\A0!/1110 44
M44 %%%% !1110 4444 %:_AC_C[G_P"!?^R5D5K^&/\ C[G_ .!?^R4 =111
M10 4444 %%%% !7)>+]0OO[9T'0K74&TR+5))1->QJID 101&A8$!FR>2#PI
MQS76US?C32KS6-)6UAAT2:UR7N5U:-W0 #AEVD;2.>: .=\1:;<^!=%FU_3O
M$FJS2V[*6L]0G6:.[RP'EX*Y#G/!4]>QKT4'(!QC/8UX_H_B76?%FM0VKCPB
MUU8SN;"26WG>.<+@-);R%L-CH<<C'XU[#0!2T[_E[_Z^7_I5VJ6G?\O?_7R_
M]*NT %%%% ')^(#8KJPD(U6&[6, S6<>0RGL35*UDL7O[9[E]=NRD@,:W$1V
M*V>":O\ B+4([*]).N7-N^T8M8(E8_7GIGWK.TV[U.ZNXGDU^*& NN(Y94,C
MC/3 Z9IC.QU+_D%7G_7!_P#T$U97[H^E5M2_Y!5Y_P!<'_\ 035E?NCZ4A"T
M444 %%%% !1110 4444 %%%% ",H=&4C((P:\G\,!8M*DM0"#;7,L1!]FKUF
MO+;%6@U_Q#:L5^6^,B*!C"L,T :=%%% !1110 4444 %%%% !1110 $9!'KQ
M5+3SS<IZ2!NOJBG^>:EO+IK2%'6$REI%C"A@O+' Y/OBH[..99YI)8O+61$P
M-X;!!;(X]BM %RBBB@ JA;Y.NZD=@($%L-V>5YFXJ_6?;KG7M2;8#M@M<-GD
M<S4 :%%%% !5.5Y?[7MMJHL7D-&_=F.XL#[=<5<JK+_R$K;_ '6_E0!/+_J)
M?]QOY5%8_P#'C#_N_P!:EE_U$G^X?Y5'9C%E$/08_4T 3T444 %%%% !1110
M 4444 %%%% !6IX95CJ$K"0A ) 4P,$GR\'/7C!_.LNM?PQ_Q]S_ / O_9*
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M*** "M?PQ_Q]S_\  O\ V2LBM?PQ_P ?<_\ P+_V2@#J**** "BBB@ HHHH
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M_(*O/^N#_P#H)JROW1]*K:E_R"KS_K@__H)JROW1]*0"T444 %%%% !1110
M4444 %%%% !7">/E6+7/#5T4)/GR0[@/N[E'^%=W7&_$B,_V)8W*L%-O?1,2
M1V.0?YT 4J*4]3BDH **** "BBB@ HHHH **** %'49Z9JCI!SI-NI^]&IC.
M<_PDCO\ 2KM4M.^3[5%_<N&[>H!H NT44UG1 "[JH) !8XY/04 .J)9&-W)%
MQM6-6''.26_PJ;:?0\=>*I&>*'5)1+/%'F",A78*3\S\\GI0!<HJ,7$!&1<0
MD>HD%'GP?\]XO^^Q0!)5290=3M6(&X*^#CIQ4_VB#_GO%_WV*KO(CZE;['1L
M*V=K XXH LR_ZB7_ '&_E45C_P >,/\ N_UJ67_42_[C?RJ*Q_X\8?\ =_K0
M!8HHHH **** "BBB@ HHHH **** "M?PQ_Q]S_\  O\ V2LBM?PQ_P ?<_\
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M '&_E45AG^SX,C!V\@?6A9EN+%I5QAD;H<X(R#SWYHL?^/&'_=_K0!8HHHH
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M* "BBB@ HHHH **** "D(# @@$'@@TM% 'F&BQ"VT]K58O*%O<30A,  !9&
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M ^1A N-R-_= '\ ZU-6=/;I:M:M'O \] V78Y'0?SK1H 69=^E7*GH9H,_\
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MLXK6ZR@CNE#))CDC!!!H X+QGIT>A>'9;C3/&>O2ZK(Z1V-NVJ>89I&< *$
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MHDRXVEY86R<?>3(^O*_SKKZY;QT NEV-P20(+^$D@XX;*8]Q\PXH R:*.]%
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MLHR<#Y6#?TK?JAKEO]JT#4;?_GK;2)UQU4CK0!Q_49]>:*JZ9,+C2K.89Q)
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M&\7Q!]HCB).!Y@4Y5<X&<$<\UZ]0!2T[_E[_ .OE_P"E7:I:=_R]_P#7R_\
M2KM !1110!QGB"'3[O7I(I;'4;JX2)21;L-H7Z=JKH;:TGMC+::] AE1$,LV
M$R3P.OZ5TFHZ$+R^%[;WL]G<[-C/$1\R^A%01>&W:ZAFOM4NKQ87#I')@+N'
M0G%,#4U+_D%7G_7!_P#T$U97[H^E5M2_Y!5Y_P!<'_\ 035E?NCZ4@%HHHH
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M.:MNPCC=VSM12QP,G JM_:5L1U?_ +YH 7[3<_\ /DW_ 'V*/M-S_P ^3?\
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MM(XW,?N=[+U]J /-Y-8M=5\'C0-2\:^'0U_=3&_E&H>>R0/(66.$G&3@A<G
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MPVJZ??P:W=W,DL$2W920)&"^"%"GDX]!T%8^IVVHFW7[%J$B2[L,-B]#D9_
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M.2W*@X7=U..V!^M7=?N8[?4=IUN]MW9 1;V\6_ ]?QJE97L<M]!&?$6I*S.
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M2WAWNJY4 ;CC)Q0!+563_D*P?]<F_K5DLJL%9E#-T!/)^E5I/^0K!_UR;^M
M%JJD4]U-"DJV\05U##,QS@_\!JW5>P_Y!]M_UR7^5 !ON_\ GA#_ -_C_P#$
MTZVC>.(B3:&9V<A3D#+$]?QJ:B@ HHHH *Z#PQ_Q[M_US_\ :LM<_70>&/\
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MW+6$?\ !H H76HVES9QNLZ^8L@?RMI+#!P?8<'-:$5Y;SBV9'XN4WQ @@L,
MGZ<'I4ZX3[@"_08JG#IT<42H\CR;.$8G!09SQCO[^U #-,D:;[3-Y4D<;RG8
M'(R<94G Z#CO5FZ=H[61T.&4<''2EMX$MH?*0L5W%LL<G)))_4TV\&;.4#N
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M,\?DK&BOUW'!SU '7CH,U7TV=))953[2ZE0_G7$+(Q]LL #[8H TJ*,BC(H
M**,BC(H *Z#PQ_Q[M_US_P#:LM<_D5T'A?\ X]V_ZY_^U9: -^BBB@ HHHH
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M&ZNM@MVB7H0>N>W7J*L/.;2:2%A-(F-T;[=W'/!/?&/UH W=/:"ZOUA;3M/
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MFNRP>6&4H))!&O[E -QZ5J^#62]L/[22!T616B1G !8+-+G@$X&30!T]%%%
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M5Y_UP?\ ]!-65^Z/I5;4O^05>?\ 7!__ $$U97[H^E(!:*** "BBB@ HHHH
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M:#6M1BF #):1*XSTPTN>:T]R%R(0@@55\LKGYAR2>??(_"@"I>W,"VY,TKH
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M!U&02/2I[NQ:TNWD\XR"YC211C 7C&!^0J)E#HRGHP(HS*S*TUQ)*538NX\
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M=:[JLI'9)%C!_ "K$?P\\.@,)K>>Y#<L)[EV!_#.*ZFB@#'@\)^'[8@Q:-9
MCH3"&/ZUIQ6MO!CR8(H\=-B ?RJ6B@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *6G?\O?_7R_]*NU
M2T[_ )>_^OE_Z5=H **** "BBB@"KJ7_ ""KS_K@_P#Z":LK]T?2JVI?\@J\
M_P"N#_\ H)JROW1]* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH I:=_R]_]?+_T
MJ[5+3O\ E[_Z^7_I5V@ HHHH **** *NI?\ (*O/^N#_ /H)JROW1]*K:E_R
M"KS_ *X/_P"@FK*_='TH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***80YD4A@$&=RXZ^E #Z*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *6G?\O?_7R_]*NU2T[_ )>_^OE_Z5=H **** "N-U?XD:?HNIRV%WH^
MN&6-9'5DL\K(D?WW4[N5&1S[UV5>;>,M7^'.LWPM==UAH;RP:6!O(DFC8*0!
M+&2@^92 -PH [B6[BU#PV][!DPW%H94R,':R9'Z&M!?NCZ5FM]E'A@BQV_8_
ML?[C;T\O9\N/;&*TE^Z/I0 M%%% !37=8T9W8*BC+,QP /6G5G:]SH%\/^F+
M?RH ?_;6E?\ 03L_^_Z_XU/;WEK=AC;7,,P7[WER!L?7%<8T,>X_NQU]8_\
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M'2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4
MM._Y>_\ KY?^E7:I:=_R]_\ 7R_]*NT %%%% !7 7/A[P>MU<_:M>@2Z$]ZY
MWWD:F)KI=L@*^P'&:[^O+/$OPNU77=8NM3CU#1HWE::*.!]+4JL4@P79A\SR
MC ()X!Z=30!WRVL-CX3%G;R&6&"Q\J.0D'<JI@'CCD"M1?NCZ5F?8AIOA7[
MKF1;:R\D.1@MM3&?TK37[H^E "T444 %5-3MGO-+NK:(J))8RJENF2.]6Z*
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M8 #"D$YZ<&J7A0Q?V2XM[R"YMA*1"85951,+A<,21^9X(H'T-VBBB@04444
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MJT=W*1MA;D!N00>N,'&<XR,U;T2 VVCV\321R, 2TD; JY+$ELX'4G/X]^M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9MA_SY6W_?I?\*/[-L/^?*V_[]+_ (4 6=R_WA^=&Y?[P_.JW]FV'_/E;?\
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M\K;_ +]+_A0!9W+_ 'A^=&Y?[P_.JW]FV'_/E;?]^E_PH_LVP_Y\K;_OTO\
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F1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g5lvsimk4gaq000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5lvsimk4gaq000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $] F4# 2(  A$! Q$!_\0
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MU%U'?/$(V&V*3#A]W!8Y]*DDT^\74IKJ%9U;SH=N'X9,8;([T<B[A[:72/\
M5CI****S.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "FJBH6*J!N.3@=33J* &JB)G8H7<<G ZGUIU%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% $,W^MM_P#?_H:FJ&;_ %MO_O\ ]#4U !1U&#110 @
M4    = *6BB@ I"H;&0#@Y&1TI:* "BBB@!"H)!(!(Z''2C:-V[ STSBEHH
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M("-P&4\GWP*H:=X<^R(@NI [%B5 _EZ5MQ JRHJF,(HQM/ !H 8-2M H/F@
M#IM;\P,4S^T+9P6:;<"> RG [C''7ZU<9&/S>9N&<\<#(_QI8SM*C#.2,E4'
M'0<^] %-;Z#>WF7*;APAVMG'Y?RJ0WEI$6(FVCD<JPSG/8"K8=VWNH4+C@CK
MGIS2+DKG<PCQM*DY '3K0!"EY9%?E;<N[G*D#AL],5.NHV6_=YY)(Z!6V_7I
M3BA!1=[$@YPO?GK_ #J:,L5VIMC&,D=2I/Z4 1_VE9@8$O\ XZ?\*/[2M/\
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MIS5E=0L\IB8Y7@*BM@]L'CFD:-5CV%VVMT5>K#':K,9;<JKM5CDN&//U'XT
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MB^9\A8D'D(,#VR?3M2@!""=@QPH4;B*5'5N 9)"#U P*:VX1A59(%/4#E@:
M'MA%W-\@'1F.6SS4B.I&\?=(^9CQTJNQ/F9C3+MD[IC]WZ#KBIHI$E W$Y(Q
MAAC=^% $X.1D44=!@44 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 444=!F@!DF3$P!PQ''&:J3@()#G8!M3( P /ITZU8=U/EN"-IZG';'KVJ
ME,'7<(WD=D )12/,0'T['IT- %8RJI8;=DB<C'R@9_SU'%5+B8[1*JLICX/
M#+GMCN/T.>U33[65'&T%^A'RI(WH>Z/63<^>J[DWC:VW)&"K?W6[ _\ CK4
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M#UR>GM7T]$5 CPF#D!BO'0>IZUY=;_!72[>6*<:O=%XW#C<@49!! ]>:]/!
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M!S=S(8IG28,!NRP89Y]1]:DAD93M&UEP0%).-OUZX_G4MY<HX/F6HPQR J\
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M\4?:?^F$_P#WQ0 LW^MM_P#?_H:FJE-<YE@_<3_?/\'L:F^T_P#3"?\ [XH
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MKJ99=F^*2&2 QGGY,K$S?SC;]*JRAMPB%O-',C!%4]CU"$_JK?A6WUGR./\
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M<X3\<G]: -&BJT%P)6&8Y4)'\2X'X59H **** "BBB@ HHHH **** "BBB@
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M B$,XVMVQC']36-;EDL3+#O$CGD98!OQ88JW;W?VCR]ZXD'WD$H;!^B]3^%
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MPOJ..0.:O_\ 'GK> VV*\4L22 0X'7VR/Y4VKJQ$6XN[]'^C-@;0[*6;\#G
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MLC2L[81QB.1<]AGG'X=>IK691#;[0&.>,#^E5[:,\= 5SRHY!SR/I3[N7:K
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M_P!4PZ./IQ]5-/GAD*[U^5T;*\?[3 #Z'<*JKMD@WID*5RN>R],?\!)_[Y-
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MX!!)[$^G3M^/UK&\/7AOK%>2T@&"VW"@>F0 %'L*VB5VX*A0!_$H Q[^WM0
MJDY&=R]QV9L'J?TYJVA+("1@D<@53*YW1_>#<G=_,_X5+NP.9-@4\DGK[']*
M 'S?ZVW_ -_^AJ/4&1;4[V95)VD+_%GC'MUH+>8\$@<.C/E<#MM-6) 2AVL%
M/J1G% '$7X)O)6 XQO\ I\J-_0UG/;(T%T3@A),J3QC((S_X[6[JT7E7CEBV
M61!ER"6R'7/\JQW^:WFCSG<H)_[[_P#LJ *D?FJ^)%+F3.<'_68]?1QV/>GP
MLL$SN!YD<J[9(QP)%/\ (_R(J6<--;! =I8$Y'X$'\*K(WF[B,@[F&U>NX=?
M^^AS]10!H1NJN\,\NZWE"DR#^#_GG,/?LU:4D<ETDDTL&Z\A7RKZV7_ENG9U
M]^X-85CEV:# :0Y:(-_RUS]Y#[,.?J*U;6:-3;B2YEA.-MG>A<X'_/*0>H]Z
M 'W$EO'%;W$G^D3,"(KA&*.4'0/ZG/\ *MJQM<0( Q;>-Q;.#SSGZY'ZU"UL
ML^H/+/MEDB4*H4?*".IQZY.<5H*C,_0L"&X/ Y/KZ=ZYZ<:CJ2G/;I_7F;3<
M%!1COU+1&^/?\Z97D 8;_P#76/>EKB-@IY+9Y)/%3:GJ]I8&.&24%_XHU)9L
M8]!_6LDZU93[5WF,,^?F!7MS]X8_"N@Q(I[YO)(W#:/O$<<^_4#\:JO'#=!M
MD0^7EC&N3CW3HP]UI\@+2&2,J!$G++D%<_WEZ@?3(JN%C680LPMW7YE?HA/J
M<?=_WAQ0 R6,K"9&+;-I",!YD9X['[R'V-/U6ZN(=&L8[=QY<C ,J1D*S8!'
M7J:?</*CRQ3I_I4D>-^[:SC\/ED'ZUN06/VB.U>XCN&%K(& E8$D[<# '0#W
MK6G)1LV<M>$IWC'LOS-&#SOLD(EQYP7YR@_B/4 5+$!@2(VYM^TA>0HSSC_&
MF*QN9NN4(X8=6^G^SZU9 3RV(4G@*VT'G'I^=9'2E96)53:S'<QW'.">GTK#
MUGQ&ME(UI9(+B\XRN?ECR0!D_B.*K:UK;Q,^GZ?(3("!+,/^6(.!@>IK&L[9
M(EC)7YV<%F/)8YB))/YT#(Y#<WSH]_=22AF \O.U1G!X ^M1C3K1FD?R@=I;
M;QTX<C^GY5;4 I$"/FRI'Y1?XTBGY&_O-(.?;8/_ (J@"%4GME5%EWQY(,$I
MW+U(&#U'3M51@MP28O,CE(WF-CEA[@_Q#]:N7; (9!R-P;'_  +/]:CA@4K)
M&PSD[L]P>?\ "@"F4:16BD &>=W4-[TRV,BMY3,1*O3U([5)+YBS%)",J,YQ
M@..Y']?SIC(6Z$#;RC'KCN#0!MVJRI*)/G5L#+19.0>^!S^7%=/8-Y\)VNZY
M7A6X/X^]<;IDR[1'=/&(@<H9D)4'ZCE3^AKLK$_)&-T:[ !Q\O'T_+\Z ,[6
M+.>6*4[8T7.<$'##'<^M<QILDNE7JNX$<)&203MZ^W)^E=OK%NDL09SM YR'
MVD\'_P"M7G=RDXGD4;VVL=N&YQZ@]30!Z)'<));(Z'".#]X8_/'0>WO4@5@<
MXQQC&,G_ .OCTKG/"U])<1>3(S/*APNU>%]^!@?6NE4;,+CC/!']/\>] "8X
MR2PSP&'4\=!5R)BT8+#!^N:J;0&!'(88(&>?IZ#WJ3[JL@?;QG([#_"@"U14
M,,JSDO'*KH/E(4=&[\U-0 4444 %%%% !145Q<PVL7F3R*B9QD^M9B^)M->[
MBM@[[I(S(&V_*%'<F@#8HJE_:U@>EU&>G?IGU]*:^LV";<7"N6<(-G.30 _^
MT[7[=)9E]LL8!;/ Y&0/RIJ:E874DT0FC8PD;MWOT(K/NCHUQ<2,;H+--(,N
MAZ%01^6,U$+?1+>YM)DF&7E!13DEFQM7Z?C0!7UJVC2\E=9"S$@,I'3*,!SW
MS66BEH@K8PS#)]BV?_9ZUM<MK='DF\C@O'G*C'#8X_.N=:*)@,1(,X!R/9/\
M#0!:C,<0 48CPCE<YQ_JR?ZU2VQB54#[3(0BEONJP4 9]CR#2S6Z9 $:X$>#
MQW <?^RBHKBUBQ*%C7 +<8]Y/\!0!/:0/%J4)@<PR%\;F'"8ZCWQTQW&#6I>
MW#:8GD65UYB,Q>2-E5E!SVXXK!_=)<'=A<;@A;HZYP,_[7'XTV0V^=NU <XZ
M5Y6,JUXU.6"?D>AA:=*4>:3]3T"SNUEM(YV(.],C)Y''/TK!U#59;^"XBM;@
MQVRC,DR#[XR1A/H>I[UD7]P9=,AM;: 1VT:[6<KAI>A_!>:2UAC*X\I-O3 7
MU85ZD;V5]S@=KZ$\D,4$3)  %(# ?51G]:CD426YC< Y(P#_ ,"I'AC/'EH
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M'<28BFVX8-VS@<UROB/2+G^T&GB@+B0!B$'?U ]ZA\,Z5<_VW!=S6KB.W;>
MPP"PZ ^@H ]RNM0@TRV\V:4G/15.6<]Q[^Y[5EVTEUK%[MN1MC4?)#V0@CKZ
MG!'-8<-LMTSR72JTK';D# 7.Y<#TYQ6QH-I'<(LY2/KC#(2&^[_\2: .H.__
M $7S H?=R%Z#Y35A@&4JP!!&"#WJG+9VRR6X$" ;_3V-3?8[;_G@GY4 8?B"
M",2HXD(<!?E([;QW]LUSH<E2.#M4_P E/]*Z+6["VRTJVV-D3[B% !X!'\JY
MTV\!,S"% ![=1AZ ".W"2?(,8!!YX)Y&?TJM(JQ322,66+ 5MOH2,'\#S4\T
M,<<: 1IRS=!]"/YTV6V@6$[8TW$>G>@"%K5ENUP0LI<#<#QGKN'H#]X?B*V[
MV5].+2VU]ON93F4%5*$@=<=C7/-#%;/&2H")PCGG!YRI]N.#VIK&W8?=3GGF
MO,QU6M"7+!/7L=^$ITY*\F=YIET9["*XD<,2,\^O3IZYZ8K-U'6)6EFM=/E"
MRA&WRCD(0,X]V('7M6*]V!HZ6=C"H*_ZRXV]<]E_,<U#;6\05%$*+\K9 'M)
MW[]J]&'-RKFW.*=N9\NQ?M[6*#9L)+-G<Q/+D.PY_ U&GSQN&QM90,'_ 'HR
M?YTOE1&[V^4@"R?-QV+(?_9JJ0QPM%@PJ=O)P.V$JB1;;SH51E#X7[NP_,G
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M_C_2@"JK;H\L,AU.5([D'_&I5MX'N\K$H!DSC'^TO^-$<1B52_\ " ?PR/\
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M -E;_CVC'&V$M^&ZIR/.W@'J2,_]]"FF,O*_ ^6!47ZDDT[S!;NS9R <@?\
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MP$MRC-AG+;0BYYW<&@#J**:F3&I)R<#/&/TIU !1110 4444 %%%% !1110
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M@PXBG;<?^>9X 8G^1KHM"OD9(HS&Q8X_V<8VK_2NHP/2C ]!0!%-_K;?_?\
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MJ:@ HHHH **** "BBB@ HHHH **** "BH;BY2V16?.&8+Q42:A$P/RN,>HH
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M:C$$!LXS[#-,^WQ<_*XQU.WI0!;HJHM_&SE"C!L\#UH.H0JVW#Y)XX^O^!H
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M'E1[0OEK@'(&.E/HH :8T*[2B[?3%((HP<B-0?7%/HH 9Y49P3&O'3BE"(H
M"J .@ IU% ###$<YC4YX/% BC!R(T!]=M/HH B^SP^=YNP;_ %IXC1?NHH^@
MIU% ##%&>J*<G/3OZU&UI;M%Y9B7;Z 5/10 P11KT11^%'E1@8V+^5/HH 9Y
M,6T#RUP.0,=*!%&JX$:@'L!3Z* (_(BQCRTQ_NTAMH&<.8D+#H<5+10 BJJY
+VJ!GDX%%+10!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g5lvsimk4gaq000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5lvsimk4gaq000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $] BT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT=C8J_\ $QQ\P]\X_*@#NBRJ0"0,G R>M+7(->>2[1W&R:WT6U5I)'/+7&.
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M@O[N.W,F=N\]<5>K/U+1--U<QF_M4G,>=FXGC/TH J?\)AX>_P"@M;_F:/\
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M** "BBB@ HHHH **** "BBB@ HHHH 9+*D,3RR,%C12S,>P'6LG_ (2W0/\
MH*V_YUK31)/"\,J[HW4JRGN#UK%/@_P\JDG38@ .22?\:TA[/[=_D85O;W7L
MK?._Z$G_  EN@?\ 04M_SJ&;Q'X:N,>=J%J^.F35'^R?")M(KE+%)$E8K&$5
MRS$=<#K33I7A-9Y(6TPJ\:;WS&X 7US6JC3\SD=7$]7#\2Y_;?A3_G[LZ%US
MPJK!A>68(Z5"FA^%),;;&,DRB(#YL[B,C]#4;Z3X12VGN/L"-'!(8Y2BN=I'
M7/M[T[0_O"YJZU]S\34_X2S0/^@I;_G1_P );H'_ $%+?\ZRX]'\*R3K"NEL
M9&4.1Y;_ "@YP3Z=#3['1/">H-MM[!"VW< P9=R^HSU%3R4EW_ I5<4W9.'X
MFY8:QI^J,ZV-W'.4&6"'I5ZJ&G:+IVDM(UC:I"9  VTGG%7ZQERW]W8[J?/R
M_O+7\@HHHJ2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *JWNG66HQ^7
M>6L4Z^CKFK5% &9I>AVVD2RM:RSB*0#]R\A95/J,]*X7QS/)K'BFST2 G"$
M@?WFZG\!7IM>8>%A_:OQ"O;YQN6,R./8YP/ZT >D6=K'8V<-K"NV.) J@>U8
M_B2[E80:5:L1/=G#,/X(QU-;]<=-.9-0U:\S\RNMM$?0=3B@#+U2XBCVVT/R
M6EL-JCU/<_4US=[?/,NT96,=%_QJ[K<@,JQ#(P-S>_I6/*?D&.YH @_B.>:L
MVT$\^6BB!']X\"JWR[T5CA68 GVKH[::&2>&UC^4LP7:>,#UH RWL[N-=QC1
M\=D;FF6]ZUO,LL9XZ,#79ZA8HULQAM]B1'#2Q')+>AK@YD=+N0.<[@&(],T
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M(QAI=MM&/=CS^E=U!&(8(XE&%10H'TH 68;H) >ZD?I7G'PV^76M40?="_\
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MAU= TH"0 W<WS3,.WHOX4 = JA5"J % P .U+110 4444 %%%% !1110 4C
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M'#L.@'L*](K:LU"*I+YG#A(RKU7BIK3:/IW^84445S'I"8'I0%4= !^%+10
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M110 4444 %%&<T4 %%%% !12%E4X+ <9Y/:EZC(H ***0D*,D@ =S0 M%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5QER?[&\7"8\12G)^C=?UKLZPO$^FF]L/.C7,L'.!W7O7#CZ<I4N>&
M\7='5A)J,^66TM#<!R,CH:R9QC59E/\ RTAR/?!J'PUJHO;(02-^_A&#G^)>
MQJ[J<+XCNH1F2$Y(]5[UK&I&O14X]25!TJCA(P[^(G;*/X>#5+&3FMR94>/S
M4^:)QD?X5DR6[AOD&5]NHKR*U-J1WTIW5F0GIBF@\  TKJP/S#%(J.Q^52?H
M*PUN;Z6'8J[8J1DX^]P*;!9$C,W ]*T$5+6/SF7V1>['M711I2<KG/4J*UD6
MK-=^IR$=(8PGXGFM2JFGVS6\&9/];(=[GW-6)ID@A>65@J(,DFO;@N6.IYM1
M\TK(YWQ?>>79QVBGYY6W$>P_^O6MHMI]BTF"(CYMNYOJ:YFQ1_$/B%KJ13]G
MC.<'T'05VM<.#_?5IXGILO0Z<1^[IQH]=V%%%%>D<04444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4=:** .,U?3Y]$U!=1L<B$MD@?PGN#[&NCTO58-5M]T9"R ?/&>H_^
MM5Z1$E1DD4,K#!!'!KD=1T"ZTV?[9I;.5'.Q?O+_ (BO+G3J82;J4E>#W7;S
M1W1G#$14*CM);/\ S-V:SDMF9[9 \3G+PG^8JLJP2-^Z<(_=)."*JZ=XLBD
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MWHM=%15PRZA%\TO>?GJ3+&56K+1>0R.-(4"1HJ*.@48%/HHKN2MHCE"BBB@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g5lvsimk4gaq000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5lvsimk4gaq000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #, +\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH YKQYJ=YH_A*ZO+"1H[A&0*R*&;!8 X!XSBN5MOB->Z;H&FO>P&]N[YYFA
M8_(1$AQ\X4'#]L 5Z/>V-KJ-N;>\@2:$L&*.,C(.1^M9]QX6T*Z@,,^F6[QF
M5IL;<?.WWCQZ]Z .:N?B-*;.2YL-&:1;>Q6\N5N)A"R YPH!')XILGQ.B374
ML$TR:2-6BCF=,EE:0 \*!R!GU%7O$?P[TWQ'=02S3RPQ10B#R44$;!V&>5^M
M:-MI?AN[UEWAM89-1TWRXW?!W1G;\N?4XH P8/B/(I,]]I#0V3"Y\J5)@[,8
M,Y^7'&0.*KVGQ1DN[.21-%D\[="(E\PA&$C!0"Q48(R*[2/0-)B\G9I\ \DR
M&,;?NF3._P#/)S5"?0_#&@Z7<3RV-O;V:,LTIP2 5.5/X&@#(N?'EY#=2"/2
M$>VBODT^20W(#"4D X7'*@GK6%I/CK4K)6GU<23%5N-D<;KM<B;8N3CC'3/3
M%=Y/X7T"^U!=4FTNWENBRR"8KSD=&^OO4-QI?AJRN;>TGLK9);T20Q(4SY@;
MYW'X]: ,G_A-]0\]]/&C(VJQS"-X1= QX*%PP?'HIXQ4]UXG:\\%66M0+-;-
M<3PH44@LN90A&3QCK6U9>'-'TV*..STZ"%8W,B[5Z,1@G/T.*E&BZ:NFQZ<+
M*(6<;!TAQ\JD-N!_/F@#G="\;7.JZE9P3Z3]FM[PSK;S"8,28C@Y7' -+J?C
MAK#4KR--.\VQL9HX+J8S!7#/C&U.K 9%;$]EH>A6D=]+;PVT-CO9) I_=;R-
MQ'U.*@U&Q\-?VQI]_?VML;^XD5+65D)9F R/Q ]: .7T?QGK(\ZTFLH[N^EO
M[E8 UP$18H\9!..HSQ]:B7XA7?\ ;,E^MJS:6^G1/%;F0!O-:4IR>F,\9Z8&
M:[2Y\*Z%>6YM[C2[>2(S-.5*_P#+1OO-]34S>'](=75M.MRKVXMF&S@Q#D+C
MT% '+WWQ"ETK3+^ZO]*"R:;,D=Y%%.'X==RE#_$>1D=:K7'C>^L]28_8VGEF
MAM/+M!,OEJTS$##8_.NKA\*Z#;P0P1:5;+%#(943;D!R,9YZG''-+'X6T*$H
M8],MU,>S;\O38<K^1/% %'1O&%O?V\0O+>2UNWNWLS$JF1?,4X/S 8 YZG%=
M+5:SL+6P25+2!(5ED:5P@^\[=3]35F@ HHHH **** "BJDNH0PW;V\@<,D)F
M+;<C:.OXU2?Q'9QP>8\4ZOYJQ"%E"N2PR.IQ@CWH V**BDF6* S2 JH&2".1
M4M !7FT_@JZF\=3ZB;/_ $2;4$F=A+C>@B[C/(W]J])HH \HTGP=XM@UN^FF
MOI(I72?%V) 5E+YV9&,\<?3%5G\$ZK<V5[ =$:W#Z9Y#!KSS1/<!U._VS@G-
M>P44 >6CP=XCC\:17*3.EFDL;0S1R+^YA50#'@\X[8[]:?I?A76(/%.EW5UI
MI,EM=3276H&ZWB<,#M(4].P]J]/HH XK4M$U";QI]NFL'U"U;ROLLBW9B%GM
M/SY7OG@^_2LRU\,^(DU_S0##="YFEEU4W)831,&V1^7VQE>.VVO2** /+D\*
M:H_AG4K!]&>/49;812WAOMXNGW@DA3TXYSVZ5(?!VK6VHK'81M%:17\<\#-+
MN$0\@JS#/^WVKTP,I) ()'49Z4!E;.U@<'!P>AH \CT;P7XNM]/U.-[J2"XD
MMO*),PVW+[LELCD$C(W=>:=)X1\036FLKIE@^E13BV\NU:[\S>J%O,7/09R/
MK7K=% '+^!-)U'1]">'47DW/,SQPNP/DK_=&.,=\=JZBBB@ HHHH **** "B
MBB@"E-92/?F[BD57$!B4,N1G.03[>U8\>@ZH;%XKB]LIII7)ED:V)W@C&<%N
M".V./:NEHH S[J$6VB- &+".((&;J<8%: Z54U/_ )!L_P#NU;'2@ HHHH *
M*** "BBB@ HHHH Q;#P^+'6;W4/MDTGVDY\IONI]/2DT'P\-#EO'^V2W'VF4
MR 2#[@)S@5IWM[#I]JUS/O\ +7KL4L?R%31N)(U=<X89&1@T .HHHH ****
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M,H[>_P"==?10!G7)D.A$RH(Y#$N]%Z*>,BM$=*J:G_R#9_\ =JV.E !1110
M4444 %%%%  >E>8WG_'[/_UT;^=>G'I7F-Y_Q^S_ /71OYUY.:_#'YGHY?O(
MAHHHKQCTS=\)_P#(7/\ US-=O7$>$_\ D+G_ *YFNWKZ#+?X'S/'QW\4****
M[SC"BBB@ HHHH QM:M"]Q#=QZC#9211NK&6,.&4]>XQBK>D6\EIID$#W,=PJ
M(!'(B;05QQW-<YXF2X_M*"6=[<()-MMO49R?^!#(^HKI],54TNU5"A01*%*=
M,8[4 6J*BN9/*M99,D;4)R!G''I7#0W;1V_E37\QME+E;N*1B)I=N5'/3'IT
MS0!V>I_\@V?_ ':MCI69(TS^'5>X!$S0*7R,'=@9K3'2@ HHHH **** "BBB
M@ /2O,;S_C]G_P"NC?SKTX]*\QO/^/V?_KHW\Z\G-?AC\ST<OWD0T445XQZ9
MN^$_^0N?^N9KMZXCPG_R%S_US-=O7T&6_P #YGCX[^*%%%%=YQA1110 4444
M <YXCMK>ZO;.-I)()T5I5F5@!A<':<]<G%:^DF)M'LS C)$85V*QY QWK+U[
M5]/M988KZT%S;L6!(3>8W'M^-;=M*D]K%+$"(W0,H(Q@?2@"6BBB@"IJ?_(-
MG_W:MCI534_^0;/_ +M6QTH **** "BBB@ HHHH #TKS&\_X_9_^NC?SKTX]
M*\QO/^/V?_KHW\Z\G-?AC\ST<OWD0T445XQZ9N^$_P#D+G_KF:[>N(\)_P#(
M7/\ US-=O7T&6_P/F>/COXH4445WG&%%%% !1110!S'B7RFN[?>Q>-5<-#%*
M$?<1PQ]16YI:21:5:1RN'D6)0S Y!./7O5'4=+N;N_AN(S:!826 DBW$Y!')
M_&M:)62%%;;N  .T8'X4 $QD$+F(*9 IVACQGMGVKF7U'6/L,WE3Q2M'-_Q\
MI$!E ,OM4GYL'C.:Z>2-98VC<91P58>H-9J>'=)2W6!;)!$K;E7<QQ].>GM0
M!)<RB?0S,K;EDB5@V,9S@].U: Z53U%0NES*H 4+@ #@5<'2@ HHI"0HR2 !
MW- "T4@(89!!![BEH ****  ]*\QO/\ C]G_ .NC?SKTX]*\QO/^/V?_ *Z-
M_.O)S7X8_,]'+]Y$-%%%>,>F;OA/_D+G_KF:[>N(\)_\A<_]<S7;U]!EO\#Y
MGCX[^*%%%%=YQA1110 4444 %%%% !116;J6I26<D<4%MY\C(TC#?M"JO7\:
M )]3_P"0;/\ [M6ATJA=3K=:&UP@(66(. >V<&KX9<=1^= ' Z[XMU6PUJYM
M8'A$4;84-'DUDW7C+6;FUE@<V[+(A4CRL9S^-0^*2/\ A);WG^/^E8]=T:<7
M%:'A5*]13=I/<WK;QEK-M:Q0*UNJQH% \K/0?6MKPYXIU34];AM;EX3$P).V
M/!X%</6]X-(_X2:WY'W6_D:)TXJ+T'2KU'4BG+J>JT4FY?4?G1N'J/SKA/<%
M/2O,;S_C]G_ZZ-_.O32RXZC\Z\RN_P#C]G_ZZ-_.O)S7X8_,]'+]Y$-%%%>,
M>F;OA/\ Y"Y_ZYFNWKB/"A']K'G_ )9FNVW#U'YU[^6_P/F>/COXHM%)N'J/
MSHR#T(KT#C%HHHH **** "BBB@ JAJ.E0ZEY9DDFB9,@-"^TD'J#[&K]% $2
MVT*VJVP0>2J! G; [5#_ &99?\^Z_K5NB@#/;1-+=BS6,+,>I*YI/[!TK_H'
MV_\ WQ5"[$G]L2_:DU!E+)]F-L3M P,YP>N<YSVJNMYX@FF:)5:-V<*Y: ;8
M!G^$Y^?CUIW8N5=C7_L'2O\ H'V__?%.71-,1MR6,*L.X7!K'4:^U\C>>X4H
M$8&)=N0QRWU(Q26ESK5QJ-F)DF\D3;IRT0C"'8^5'/S+G'/THNPY5V-W^S++
M_GW7]:/[,LO^?=?UJW5'6$GETFY2U)$[+A"/7-(8_P#LRR_Y]U_6F?V/IO\
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M6LC0M)DTR-_,,*EPH\N!2JC ZG)//O6O0 4444 %%%% !1110 4444 %%%%
G!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g5lvsimk4gaq000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5lvsimk4gaq000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #E E,# 2(  A$! Q$!_\0
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MVMB>Z^X/J%#L=I_PF-E_SPG_ "'^-6].\16VI78MHHI58@G+ 8XK@*VO"O\
MR'(_]QOY5OALSQ%2M&$GHWV,JV"HQIRDELCO:***^D/&"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHJ"\G:VM))E7<RC@?Y[4 3U0UO_D#77^Y_6J@U69G0*5R
MN 5Q_K#N*G'MWJ;Q!*T>D3 0N^\8)7'R\]3[4 :,/^HC_P!T?RI],A_U$?\
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M$7*C*,5=M,TI24:D92=DF>>T5)M@_P"?ZT_[^BC;!_S_ %I_W]%?)_V?B_\
MGW+[F>W_ &AA/^?L?O1'14FV#_G^M/\ OZ*-L'_/]:?]_11_9^+_ .?<ON8?
MVAA/^?L?O1'14FV#_G^M/^_HHVP?\_UI_P!_11_9^+_Y]R^YA_:&$_Y^Q^]$
M=%2;8/\ G^M/^_HHVP?\_P!:?]_11_9^+_Y]R^YA_:&$_P"?L?O1'6UX5_Y#
MD?\ N-_*LG;!_P _UI_W]%;/A<1#6TV75O(=C?*D@)Z5T87 XF%>$I4VDFNC
M,JV.PTZ<HQJ)MKNCNJ***^J/%"BBB@ HHHH *XCQ?_R%D_ZY#^9KMZXCQ?\
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M%.\_X#_Z$*TI?Q(^ISXO^!/T?Y'C]%%%>V?$!1110 4444 %%%% !73^ ?\
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MH **** "BBB@ HHHH **** ,2X5_[4(B#,OF(642$XZ<X'0?X5LODHP4 G'
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M=/\ KJ_]*\GKUCX?_P#(KI_UU?\ I7)C/X?S/5R;_>?DSJ:***\L^J"BBB@
MHHHH 9+_ *E_]TUY6?O'ZUZI+_J7_P!TUY8?O'ZUX&=[P^?Z'K99]KY"4445
MX)ZH4JHSL%52S'H *2I[298+@2-G !' SU&.E.*3:3$VTM" J58JPP1P01TH
MJ:ZD6:YDD0$*QR :AHDDG9 FVM0HHHI#)K3_ (_8/^NB_P Z]1KRZT_X_8/^
MNB_SKU&OH,D^&?R/(S/XHA1117NGEA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 444R5MD3N6"[5)W$<"@!]4-;_ .0-=?[G]:KK
MJ5T"OF)&,!21M(+AFV@CGCCGO4GB"7R]'G&QVWC;\JYQSU/M0!H0_P"HC_W1
M_*GTR'_4Q_[HI] !7/>-O^13O/\ @/\ Z$*Z&N>\;?\ (IWG_ ?_ $(5I2_B
M1]3GQ?\  GZ/\CQ^BBBO;/B HHHH 4 GH">W I""#@C!K5AO[==+%H$>*02*
MYDW9!(SD\<^W6JNIW$=UJ,T\9)5R.H]JE-WM8TE"*C=.Y4HHHJC,*Z?P#_R-
M47_7-_Y5S%=/X!_Y&J+_ *YO_*LJW\.7H=."_P!XAZH]:HHHKQ3[8**** "B
MBB@ KRWXB_\ (PQ?]<!_,UZE7EOQ%_Y&&+_K@/YFNK!_Q3R\X_W;YHY"BBBO
M5/E HHHH **** "BBB@ KUCX?_\ (KI_UU?^E>3UZQ\/_P#D5T_ZZO\ TKDQ
MG\/YGJY-_O/R9U-%%%>6?5!1110 4444 ,EQY,F3@;37E376F;C_ ,3%.O\
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M '1_*GT %<]XV_Y%.\_X#_Z$*Z&N>\;?\BG>?\!_]"%:4OXD?4Y\7_ GZ/\
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M_P!<!_,UZE7EOQ%_Y&&+_K@/YFNK!_Q3R\X_W;YHY"BBBO5/E HHHH ****
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M10!G?VS#_P ^U]_X"O\ X4?VS#_S[7W_ ("O_A6C10!G?VS#_P ^U]_X"O\
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M=1@X/^?P-.^W6VXKYRE@VW ]?\@_E6OUVIY''_8V'[O[_P#@'C/_  CNL_\
M0,NO^_1H_P"$=UG_ *!EU_WZ->QS:G:0PR2&4-Y><JO).,]/R/Y4]KR)9_).
M<A/,8]E7GD_D:/KM3R#^QL/W?W_\ \9_X1W6?^@9=?\ ?HT?\([K/_0,NO\
MOT:]E_M"TX_?ISZG_/H:7[=;?+F91N&1GCC_ "*/KE3R#^QL/W?W_P# /&?^
M$=UG_H&77_?HT?\ ".ZS_P! RZ_[]&O8_P"T;;)S( HQ@GOD9IXO;8L5$Z9'
MO1]<J>0?V-A^[^__ (!Y!9Z#J\-[!*^FW05)%9CY1Z UZM_;,/\ S[7O_@*_
M^%6?MUM@GSEV@@$]@33X)UN(1(@(!)'/L2/Z5C5K2JVYCLPN#IX9-0OKW*?]
MLP_\^U]_X"O_ (4?VS#_ ,^U]_X"O_A6C161UF=_;,/_ #[7W_@*_P#A1_;,
M/_/M??\ @*_^%:-0W5S':6[3S$B-,9('J<4 5/[9A_Y]K[_P%?\ PH_MF'_G
MVOO_  %?_"IEU*U9Y%\T H_EG/KQ_B*0:G:F1T\P?+CYNQSZ4 <IXT,VLZ;!
M#965X[I+N(-NPXQ]*XC_ (1W6?\ H&77_?HU[-]NMNTRD;MN>V?K217]M-L"
M2C+YV@\'@XKHIXF=./*CS\1EM&O4]I-NYXU_PCNL_P#0,NO^_1H_X1W6?^@9
M=?\ ?HU[*M_;,VWS0#O*<C'(IKZE;QW#12,4VD@L1\N0,GGZ5?UVIY&']C8?
MN_O_ . >.?\ ".ZS_P! RZ_[]&C_ (1W6?\ H&77_?HU[%-J=M#&S;R[+CY%
M'/./\14@OK8Y_?*"#@C/U_P/Y4?7:GD']C8?N_O_ . >,_\ ".ZS_P! RZ_[
M]&C_ (1W6?\ H&77_?HU[*;^U!8><N5ZTU-0BD%OM5R9UW*,<@>IH^NU/(/[
M&P_=_?\ \ \<_P"$=UG_ *!EU_WZ-'_".ZS_ - RZ_[]&O9?[0M, ^>G+;1S
MWI?MUMA3YRX8X!]:/KE3R#^QL/W?W_\  .#\$P7>BW-V]]8W:+(@"X@8YY]A
M79_VS#_S[7W_ ("O_A4YU&V#?ZP;<9W=NN,?G3A?6I8*)T).,<^M<]2;G+F9
MZ.'H1H4U3ALBM_;,/_/M??\ @*_^%']LP_\ /M??^ K_ .%63?6P#'S0=HR<
M<XI\-PDYDV9PC;2>QX!X_.H-BG_;,/\ S[7W_@*_^%%:-% !1110 4444 %%
M%% !45S;I=6TD$F=D@P<444 5Y-,MI%=0NQ751A0,#!R#CZTTZ3!G*LZ-L"9
M7 '7/3&.>]%% #%T2V7R_F<[.FX \8 QC'L*D72X4:-E>0&,@CD=L^WN:**
M&S:/:SN[N&W.221C/./\*:=&@)4F1^!C "@>_;BBB@"232X)69F9P6&."/3%
M4[&S$T5] \C;'8J<  CDG@_C110!;?2XY9"\DTCDC#!@N"<$ D8]Z?;:?':S
M"19'8[-G..><\^M%% %RBBB@ HHHH **** "J9TRW+3,5.^5]Y?C(Z< ^G%%
M% $;Z/;/YV=W[UMQP ".<\'&>U(^CP22O([R'=U&1^72BB@!4TB!%4;FXQR
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M2<DDKQ@@D''3U%/DTVWD-PS+\\XPS<9'&.*** &R:7#).TK/)RV_:", \?\
MQ(J-]&A?/[V4<\8(^4?-QT_VC110 _\ LF'<K*\@9&+*<C@DY]*632X9+:"W
M9W\N'&.F3CWQQ^%%% #%T:W1 H9N,\@ 'G'7CGI1_8\.6/F2 ,?F48 QUQC'
M'-%% #_[*@S&=TG[L<<C^]N]/6HUT6W3=M9P20P; R".^<>U%% #_P"R8?):
D(22 ,02<CG&?;WJQ:VJ6D;(C,VX@DM[ #^E%% $]%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>gqr1p20dfppl000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqr1p20dfppl000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,@ FH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M10 4444 %%%% !1110 4444 %%%% !61/K\%MK5UITL4@%M9+>O*HW94LRX
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M<0ENB<NOEE) <<$@R #I\N.]+E0^9GIO_"[/"7]W4_\ P":C_A=GA+^[J?\
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M99$@B2XV.$^1P&8Y53A2<D*[!2W3-4]/UW4]*A$5C<F&,7"7( 4'$B_=//\
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MK7/_ !]6?_71O_035FEU!A1113 **** "BBB@ J"[_U2?]=4_P#0A4]07?\
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M7_A$/%7_ $+6H_\ ?*?_ !5'_"(>*O\ H6M1_P"^4_\ BJ]Z_M33?^@E9?\
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M4_\ BJ]Z_M33?^@E9?\ @2G^-']J:;_T$K+_ ,"4_P :/:,.5'@O_"(>*O\
MH6M1_P"^4_\ BJ/^$0\5?]"UJ/\ WRG_ ,57O7]J:;_T$K+_ ,"4_P :/[4T
MW_H)67_@2G^-'M&'*CP7_A$/%7_0M:C_ -\I_P#%4?\ "(>*O^A:U'_OE/\
MXJO>O[4TW_H)67_@2G^-']J:;_T$K+_P)3_&CVC#E1X+_P (AXJ_Z%K4?^^4
M_P#BJ/\ A$/%7_0M:E_WRG_Q5>]?VIIO_02LO_ E/\:/[4TW_H)67_@2G^-'
MM&'*CP7_ (1#Q5_T+6I?]\I_\51_PB'BK_H6M2_[Y3_XJO7O%U^)M V:7J$+
M7 N8&*P72AS&) 7Z.I/RYX!&:Q;O5M:EN)H[?4!!81M;M;M&\'FD!H_-5MSD
M\#?C)R<,"3@9/:,.5'G?_"(>*O\ H6M1_P"^4_\ BJ/^$0\5?]"UJ7_?*?\
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MC#E1X+_PB'BK_H6M1_[Y3_XJHI_!GBN1%"^&]1R'5N53H#G^]7O_ /:FF_\
M02LO_ E/\:7^U-._Z"5E_P"!*?XT>T8<J/!/^$0\5?\ 0M:C_P!\I_\ %4?\
M(AXJ_P"A:U'_ +Y3_P"*KWK^U--_Z"5E_P"!*?XT?VIIO_02LO\ P)3_ !H]
MHPY4>"_\(AXJ_P"A:U'_ +Y3_P"*H_X1#Q5_T+6I?]\I_P#%5[U_:FF_]!*R
M_P# E/\ &C^U--_Z"5E_X$I_C1[1ARH\%_X1#Q5_T+6H_P#?*?\ Q5'_  B'
MBK_H6M2_[Y3_ .*KWK^U--_Z"5E_X$I_C1_:FF_]!*R_\"4_QH]HPY4>"_\
M"(>*O^A:U'_OE/\ XJC_ (1#Q5_T+6H_]\I_\57O7]J:;_T$K+_P)3_&C^U-
M-_Z"5E_X$I_C1[1ARH\ N?!GBN:VEC7PWJ.YE(&53_XJI?\ A$/%6/\ D6M2
M_P"^4_\ BJ][_M33CTU&R_\  E/\:3^U--_Z"5E_X$I_C1SL.5'@O_"(>*O^
MA:U'_OE/_BJ/^$0\5?\ 0M:C_P!\I_\ %5[U_:FF_P#02LO_  )3_&C^U--_
MZ"5E_P"!*?XT>T8<J/!?^$0\5?\ 0M:E_P!\I_\ %4?\(AXJ_P"A:U'_ +Y3
M_P"*KWK^U--_Z"5E_P"!*?XT?VIIO_02LO\ P)3_ !H]HPY4>"_\(AXJ_P"A
M:U'_ +Y3_P"*H_X1#Q5_T+6H_P#?*?\ Q5>]?VIIO_02LO\ P)3_ !H_M33?
M^@E9?^!*?XT>T8<J/!?^$0\5?]"UJ/\ WRG_ ,53)?!WBIX9%'AO4<LI ^5/
M3_>KWW^U--_Z"5E_X$I_C1_:FFX_Y"5E_P"!*?XT>T8<J-OPM;367A'1;6YC
M,<\%A!'(C=581J"#]"*UJ9$RO#&RL&4J""IR"*?4%!1110 4444 %%%% !11
M10 4444 %%%% !7%>$O#.@WOAR*YN]$TVXGDGN"\LMI&[,?.?J2,FNUKGO!'
M_(IVW_7:X_\ 1ST </)JWARWO6BG\&:,L*75]"TAM(E5A <+M8C&YC@'-3+K
M7A"6TAGB\"VC"2.$G=:VZA9)97B6,D]]T;Y/0 >^*]&?3M+GWQ265G)RS.C1
M*>7^\2,?Q=_6JSV^@"WN;1K?3C#$BB>#RT(5<EE#+CIDDCZG% 'FFD^(_"TV
MC6<M]X-TDWUQ%&T:16D*).\DFP!"W&T$C+$X!^HS?FUGP=%?7-DG@K3IIXGB
MCC\N"VV2,[;2-_0;6X/-=W#IOA^>T+QZ?IY@F@4L#;H T7WEW#'3O@^E-NO#
M>@7X"S:;9L#(DQ"QJ/,*_=W8^\/8Y% '#:?KO@;4&D:/P;:I!%9FYDF;3HML
M9$8DV' ZX. 1P3TIMI<:'9:;JAUGPIH+7U@]O&8(K6%&D>6)'V@$=07V\9SM
MKOKG1M#O5!EL[0DQJ Z*JL8T8$#<.=@(''3M275GX?N+MI+FRT^>YE"*[- D
MCLI.$SP3C(X)XX]J //SXD\#B,SGP5:BV:/,,ILK?]Y)LC?9CJ.)5^8X'6J]
MEK_A>.Q:35O!FDQ3;KG;Y5K!M;RYWC6-2>&;Y1N.<#.>G3T\Z;I'E",V5CY;
M;D"F),'*A2,8[J "/08IJZ/HL994TW3U*Q&,@0(,1MG*]/NGGCH>: . N=9\
M&V=\]E/X+TXSI )"(H+9P'R@,98< CS%.2<8I]GJO@^]U&&PC\$6AG:%I)L6
M4!6%E,HVEA\I!,+#=G'*^^.TN/#_ (=N+=XGTZP6,A$;9&J':""JY';@<="*
MM?V1HZ/ /[.L5:-#%"/(0%4P<JO' P3P/4T <3KH\/:/-:L?".B?99;&2YE=
M[:+,+?*$!P""I9MI(/&0>E)->^#[>WEGE\%6WDJ[1I(NG18E<;QL7(&6+(5
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M_ &+_P")JCK7A+PU'H6H.GA[259;:0JPLHP0=I]JZBJ&N_\ (OZE_P!>LO\
MZ : */@G_D0O#O\ V#+;_P!%+6[6%X)_Y$+P[_V#+;_T4M;M !1110 4444
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MI(N%*J!G"XD0-P.[#OFJ^L>#;O[(9=.D22\:1?.)49E3,60=QP<",\'CGZY
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MTPC.73R&BV_>Z9(;'M^-6!X5F&@R:>D]K'(]V;E6C@(CB).0%3.#CT.0?3T
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M]G\:_P#01T'_ , 9O_CM4M8@\9#0]0\S4-#,?V:3<%LI0<;3G'[VNQJAKO\
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M)TZ(?NE0.7&<9&".!DYXI8+;P;<6ZRQ^";4[MH -G  2TAC0 YY#,#@],<T
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MS[!X,CBNI+KPAIT*V\CI_P >L+%PK(I/'O(.* .W^W6G_/U!_P!_!1]NM/\
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MYN@.[ 'ODUC0/X N(WG3PI:?98U1GN#IT81-P0_,<8&!(I/T/I0!Z!]NM/\
MGZ@_[^"C[=:?\_4'_?P5PL,/@*XT6?5(O"MCY$)C1@]A&A#N0 IST(R,YZ9J
M''@;=L;P=:+(;;[2(S8P[@HV9# <J0)$//;)H ] ^W6G_/U!_P!_!1]NM/\
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M@#6N=+T,3LUQ8VGG7SB-F:(9E8?, 3C_ &<_45)+HFD3X,NG6DGSB0;HE/S
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M^A6UG_OJV_\ CU'_  D%]_T*VL_]]6W_ ,>H W:*PO\ A(+[_H5M9_[ZMO\
MX]1_PD%]_P!"MK/_ 'U;?_'J -VBL+_A(+[_ *%;6?\ OJV_^/4?\)!??]"M
MK/\ WU;?_'J -VBL+_A(+[_H5M9_[ZMO_CU'_"07W_0K:S_WU;?_ !Z@#=HK
M"_X2"^_Z%;6?^^K;_P"/4?\ "07W_0K:S_WU;?\ QZ@#=HK"_P"$@OO^A6UG
M_OJV_P#CU'_"07W_ $*VL_\ ?5M_\>H W:*PO^$@OO\ H5M9_P"^K;_X]1_P
MD%]_T*VL_P#?5M_\>H W:*PO^$@OO^A6UG_OJV_^/4?\)!??]"MK/_?5M_\
M'J -VBL+_A(+[_H5M9_[ZMO_ (]1_P )!??]"MK/_?5M_P#'J */B7_D<O!G
M_7[<?^DLM=77GGB#6KR3Q9X2D/AW54:.[G*HQ@S)FWD&%Q+CCKR1P*Z;_A(+
M[_H5M9_[ZMO_ (]0!NT5A?\ "07W_0K:S_WU;?\ QZC_ (2"^_Z%;6?^^K;_
M ./4 ;M%87_"07W_ $*VL_\ ?5M_\>H_X2"^_P"A6UG_ +ZMO_CU &[16%_P
MD%]_T*VL_P#?5M_\>H_X2"^_Z%;6?^^K;_X]0!NUSWC#_D&V'_85LO\ TH2I
M/^$@OO\ H5M9_P"^K;_X]6%XJUR\ET^R#>&]6CQJ5FP+F#DB=#CB4\GH.W/:
M@#NJ*PO^$@OO^A6UG_OJV_\ CU'_  D%]_T*VL_]]6W_ ,>H W:*PO\ A(+[
M_H5M9_[ZMO\ X]1_PD%]_P!"MK/_ 'U;?_'J -VBL+_A(+[_ *%;6?\ OJV_
M^/4?\)!??]"MK/\ WU;?_'J -VBL+_A(+[_H5M9_[ZMO_CU'_"07W_0K:S_W
MU;?_ !Z@"+Q[_P B#KO_ %YR?RKH$_U:_05PWC77+R;P3K4;^&]6A5K20&20
MP;5XZG$I./H*W%\07P11_P (MK/3^];?_': -^BL+_A(+[_H5M9_[ZMO_CU'
M_"07W_0K:S_WU;?_ !Z@#=HK"_X2"^_Z%;6?^^K;_P"/4?\ "07W_0K:S_WU
M;?\ QZ@#=HK"_P"$@OO^A6UG_OJV_P#CU'_"07W_ $*VL_\ ?5M_\>H W:H:
M[_R+^I?]>LO_ * :H_\ "07W_0K:S_WU;?\ QZJ.LZ]>OH>H*?#&KH#;2 LQ
MM\#Y3R<2T 7O!/\ R(7AW_L&6W_HI:W:PO!/_(A>'>__ !++;_T4M;M !111
M0 4444 %%%% !1110 4444 %%%% !7/>"/\ D4[;_KM<?^CGKH:Y[P1_R*=M
M_P!=KC_T<] '*WUAKVG:SJVH6MG<2V@F-X);AM[@JDF%15<AD!V$?*&&['/:
M#P]J?C75["TOH;N>:-)HQ*CP1(K@R@2+NQ\P6,YW+CYN.V*["3QA8P7?V:>W
MNXY#</ F(]VX(5#.,'[H+K[\].M)<>-=*M8IY9UN8T@*[RT6/D)8!QD\KF-^
MG/'2@#B+OQ#XUTPZ=#J9N;7[3>$@I!'.XCQ%\AVKAOF:0   X&>@KJ_"Q\5X
M5O$,C^8T_P T<<<>U!L;(W#DINVXQSV.1FM&7Q5:QW#01VEY(ZS+$,18#9D,
M9923R P.?PJOKWBQ-'6ZBCMS<74?*1H#C:!'N9SC@ R*.,]?K@ Y^+2_%UA<
M!X!++&!=S O.&:-I)U^0 G!^0%E]"2/2M,MXT2>"*)DE@94WSR1(C M\IRN>
MJ8WGUW8[8K1D\9Z7&ER^R[=;=V5BD!.X*&+,/8;&SWXZ<C-6X\9$VUV]E82O
M)#,T$8D'$C!XT##'\/[P$]#_ $ +>JP:]+>R-8WLL,(X1$CC(.(R<Y8$\OM'
MTS]:K1CQ++?7"/+-%$TA!;9%M1?-7:8^I/[O=G=GGI5Y/$<*QS>;!(S01[Y6
MB'R+\Q 7<V.3C/\ 6J,7CO3IA-.L<J64,<<S7+J=K(T32?*!DY 7&#B@!BS^
M*C;Q6YA<3^0Q>XVQ[=_E  8S][S,GIC\*2[B\4V\+""\FN S%2QBBWHHD(!4
M  $E,$Y].,5HIXKL&FBA>&[BE>40R*\)_<NS!5#GH,EEQC/6D/B6%-0N;5DX
M2X-M$PZ,XC5VW>GW@ !DG!XH Q=2M_&$MM*L5W,=\9_U*QQLI4PD%>X+?OL@
MDCH.*T]3;5CJ8"0RRZ>L*2'<JC8ZNK$\<N2 >!C&.^:<GC&Q,DD'D74EQ&$!
M6&(L&=L?*IX_O#KCOZ&K$WBO2;:ULKF:9TAO8UD@<QGY@S*OX$;USZ#)[&@#
MG-)U'Q)JV@FZM;N9[I#O*/#& 6(B(3. ".9#QR.A.16QJ+>(_P"V)Q9%Q;[#
MY65C,>WRFYY^;S/,V\=-M2KXF6>6$VT:O!+(JJS$@X)B&<8]),CZ#UJ:[\1V
M\&H2Z?&C&ZB,9(;&TJSHA((.<C>.H% &9>V/B2ZLK6%+IEN8-6W+<LJG-N V
M&95*ANH&..U4(O\ A+-,LH4+,L=M92//+)L96D 9@<?>!R .IX/M6W%XPT\"
M);E9HB0@>3RR8@[*K%=WL'!)Z8^AJQ;>);'4=/>[L'\Q$,>XR*R ;R!@\9S@
M],>F>M '-2#Q9J%W87;0R;5'VJ&,>6(HRT$ORR?Q%E=D7CC S[UIVJ^*/*LY
M'N)6VRIYL<D,:ED,@#ANOW4R05QGBG-XYL89G\^WNDA8)]G_ ')WS AV+ ?W
M=JY]?;/%6F\6V?FF**UO)6\Y(E(BVAPSF,LN>H##G\* ,^_M?$@\07>I648"
M-&UK"C39&U5WJY3[O,@9<]<,/2DA?QA)>N\Q\B-K8O%&L:.%=D8[&.?O*VT
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M_FR,"(HR(WD"[AD[L*#TZ&I+CQIIEKY_F17?[HD#]SCS,%@Q7)Y *-^F,Y%
M%;S_ !,NIA3%++;B[3+!4C5HR,-ZE0O7N6SCC%37!\12ZW>1PF6"Q(18Y/W;
M8^=-S+D?W#)P<]!5B^\56FGZ@UM-;7.T6B7/F*@Q\[[%3&>&)Q[<T#Q;I[,@
M$5WM:/>':$JH.POL).,-M!.#Z=: ,/3[?Q3<Z_H\VKQR^7;2LSE#&(]I@==S
M8^8N7(X'&#TKNJYR3QIIJ6T4ZQ73K+$9%Q%QD!SL)SC<?*?VXZ\BA?%L,T$4
MD5O(C;[;S8YQM95F95&,9S@L/;KS0!7\2_\ (Y>#/^OVX_\ 266NKKE/$O\
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M[P,[?[6.<>O^IH Z.BN>_M'Q7_T+NG_^#4__ !FC^T?%?_0NZ?\ ^#4__&:
M.AHKGO[1\5_]"[I__@U/_P 9IJ:IXHE0/'H&FNC#(9=6)!_\@T ='17/?VCX
MK_Z%W3__  :G_P",TQM6\3(VUM!TQ6VEL'5B#@=3_J>G(H Z2BN<75/%#LRK
MH&FL4.& U8\'&>?W/H13O[1\5_\ 0NZ?_P"#4_\ QF@"KXE_Y'+P9_U^W'_I
M++75UYUX@O?$;>*_";2Z'8I*MW.8D&HDAS]GDR"?*&WC)Z'IBND_M'Q7_P!"
M[I__ (-3_P#&: .AHKGO[1\5_P#0NZ?_ .#4_P#QFC^T?%?_ $+NG_\ @U/_
M ,9H Z&BN>_M'Q4/^9>T[_P:G_XS34U7Q/)]S0=,;@-\NK$\'H?]30!T=%<]
M_:/BO_H7=/\ _!J?_C-']H^*_P#H7=/_ /!J?_C- '0USWC#_D&V'_85LO\
MTH2C^T?%?_0NZ?\ ^#4__&:P_%-]XE?3[(3:%8QJ-2LRI74BV6\],#_5#@G
MSV]Z .]HKGO[1\5_]"[I_P#X-3_\9H_M'Q7_ -"[I_\ X-3_ /&: .AHKGO[
M1\5_]"[I_P#X-3_\9H_M'Q7_ -"[I_\ X-3_ /&: .AHKGO[1\5_]"[I_P#X
M-3_\9H_M'Q7_ -"[I_\ X-3_ /&: .AHKGO[1\5_]"[I_P#X-3_\9H_M'Q7_
M -"[I_\ X-3_ /&: $\>_P#(@Z[_ -><G\JZ!/\ 5K]!7!^-+[Q*_@K65N-"
ML8H3:2!W74BQ48Z@>4,_G6XNH>*MB_\ %/:?T_Z"I_\ C- '145SW]H^*_\
MH7=/_P#!J?\ XS1_:/BO_H7=/_\ !J?_ (S0!T-%<]_:/BO_ *%W3_\ P:G_
M .,T?VCXK_Z%W3__  :G_P",T =#17/?VCXK_P"A=T__ ,&I_P#C-']H^*_^
MA=T__P &I_\ C- '0U0UW_D7]2_Z]9?_ $ UF_VCXK_Z%W3_ /P:G_XS5+6+
M_P 4-H>H"3P_8*AMI S#5"2!M/./*YH T?!/_(A>'?\ L&6W_HI:W:PO!/\
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MNRN.S?+GKT(H JWWAO43J&K7VFSPVUQ=20-"ZDJ<*I60-@>C$CKR!44>@>)
M+7SM5:21&&Z07#J%VN@#%<8?=&IR#QN8^N:LW'C);5U66QW816D,5PCX+;]H
M']X?(<GMGZU+'XGNB[QRZ/)',#MC7[0AWMNC7&1T'[U3GZ^V0"CJ>A7M^^IV
MILX9X[F^29I96\MA#Y:#$;!3\V4()X(!^E+=Z#?:EX=>V53&[:G+<A&8*WEF
M1R ,JP!(.>0>M3/XS:.T6632W1Y/FC1[A &3:[$[N@/[MACOQ[XO6_B)KJYF
MBCL751!)-"[2#]YLVY! Y7EQ^M &9;:'XAC%A;2W-N;:V";RDK8?"QC:$(Z
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M%%% '.^/?^1!UW_KSD_E70)_JU^@KG_'O_(@Z[_UYR?RKH$_U:_04 .HHHH
M**** "BBB@ JAKO_ "+^I?\ 7K+_ .@&K]4-=_Y%_4O^O67_ - - %'P3_R(
M7AW_ +!EM_Z*6MVL+P3_ ,B%X=_[!EM_Z*6MV@ HHHH **** "BBB@ HHHH
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M -?_ (2^7_H6M:_*#_X[1_PE\O\ T+6M?E!_\=K(_P"$K\-_]##I/_@;'_\
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M&, )#0N@V_O>3EA^%;?_  E\O_0M:U^4'_QVLC_A*O#A!(\0:3QU_P!-C_\
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M+B'PC:20E-S-MA&"$+D=.1M4\CKQZY'275_H"37GVEK5IH2D5P#'O?YONJ0
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MBZ,C6CK$/(MQ^^'S?OER/]6^/E[\-S7?=1@U'';PPG,4,:84(-J@?*.@^@H
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MMK56N2Y%O;81H]T3@*N[Y#F+'?J36MI.HZI<2A[Y84MPBJ/*A<F1V=@#D_=
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M%!=SM*ZW:$(#;R $G/') _&NE_X3;PI_T,ND?^!L?^- $/\ PD&O?]";?_\
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M7O\ H3;_ /\  RV_^.5-_P )MX5_Z&32/_ V/_&C_A-O"O\ T,FD?^!L?^-
M$/\ PD&O?]";?_\ @9;?_'*/^$@U[_H3;_\ \#+;_P".5-_PFWA7_H9-(_\
M V/_ !H_X3;PK_T,FD?^!L?^- '.>--;UJ;P5K,<WA2]@C:T<-*UU;D(,=2
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M_P".5-_PFWA7_H9-(_\  V/_ !H_X3;PK_T,FD?^!L?^- $/_"0:]_T)M_\
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MP6MI&QT.&Y9G2%'_ ':>8YB\T\8PHQQUY/MS52#P_P"'(<M#XIU- RFZW"^
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MT,?B+_P/_P#K4?\ "'#_ *&/Q%_X'_\ UJ -W^SK'_GSM_\ OTO^%']G6/\
MSYV__?I?\*PO^$.'_0Q^(O\ P/\ _K4?\(</^AC\1?\ @?\ _6H RO#NL'5/
M&.JZ/<VFG"VLM_D3);X-V-^"5SQ^[/R-CJQ'2NR_LZQ_Y\[?_OTO^%<-IEEI
MNIZU=Z5;:YXG6]L=PN%>YV^3\PQDX_C^\N.H&:W/^$.'_0Q^(O\ P/\ _K4
M;O\ 9UC_ ,^=O_WZ7_"C^SK'_GSM_P#OTO\ A6%_PAP_Z&/Q%_X'_P#UJ/\
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M? 7AT_\ 4,MNG_7):W: "BBB@ HHHH **** "BBB@ HHHH **** "N>\$?\
M(IVW_7:X_P#1SUT-<]X(_P"13MO^NUQ_Z.>@!3X-TDZA)?8G\^0N6/F<9:02
M$XZ9!! /8,P[TLGA*R>?SQ<W<<@"^64=1L*MN!^[R<Y^]G@D=ZJ7EIXE_M"W
M>VO9/L[SRO,"J-Y:AU\L 97Y=F_/).2*RXIO&*R:A 4N);I+=64;H@AD<3C,
M9X&T$0\'D>GJ =$GA:P62=R\S&9_,;.W(8]3NVYY/."<4EMX5T^UU2341)</
M.Y7_ %DF0H4Y ''3-9T^G^(DM9VM)C'-M+*B%,2.SC<3[[,XY S6;?:;XBD=
M)=2:>YM;:*4Y78H*FWD7YD!+&3>V.#C% &\G@S3(RYB>="PC^8%2RO&%"N&*
MY! 1>^#CD4C^#-/=X6^T7:^7)YS .N)9,N=[ K@G,KG'3GIQ6UIZRKIMJMQG
MSA"@DR>=V!G]:LT 9,?AZSCTN'3R\[PPQR1J7?+8<$'MZ$XQP.*9-X9L)M0^
MVMYGF$,'4[2&!);N"1@DX((-;-% '/1^#M/2[AN6GO))(H! F^4$!0 /3KA1
M_/J:DD\*V4NE7&GO<77E7$QF<AP#DC!  &W'MCKSUYK=HH PIO">GS&)M]PC
MPY\ITD&4)\OD<=08DQ^/K4<7A*V2">*2ZN9"\D;Q2EAYD91S(#G&"=[,W(QS
MC'%=#10!E0>'K&WTVZL%\QH;I"DQ9_F;<#N.?4Y)^IJ!O"]M+<)-<7=Y.P"[
M_,=<2%=VUCA1R-YZ8'3.:W** ,-O"UD;N2Y2:YCDE0QR['&'0JB[3D=,(O3!
MZ^N*23PGITD]U+F5?M4/DR@;?[GE[@2,J=H X./:MVB@#(L_#UM8R7<D,DC/
M<ARYD53\S<L<@ \GG&<>@%9\7@BQ\JV^T75Y/+"T;,S2##E FW(QT&P8[\GG
MDUT]% '.0^#+"%45;J]*QO$R R*=HB&$4';D  XX.3SD\FK5_P"&;#49$EEW
MB5)VG5@%;#,FPC# @@J.XK9HH YE?!T,>IO<07UU#"R-LB1AF)VE\TE"1P"V
M>"#U[8%6H_"FG1::U@#,T#6QM6W/R4*(AY]<1K^.:W** ,!/"5C'=P7*SW D
MC9'<(419F0L5+A5 XWMTQGOG%27GA:QO9)GDEN%\]I/.".,2+(J*Z'(^Z1&O
M3GCK6W10!G3:+:3:,VEMO%LW]UL$?-NZ_6J\?AJPBO[B[3>'GF$[#"\.&5L@
MXW8)09&<5LT4 <U;>"-*M;F.=)+IC&C(BO+E5#$$XX[D5HPZ#:07-U,K2G[5
M&T<R%_E8%W?Z@@R/^!K4HH Y.[\"6DEG#':W<T,T6Q1(53#HLD;[6"J,_P"K
M'/7U)Z5:F\(V[07*QWEUYLL9BC:1PPB4A@ HP.!O;&>>E=%10!D6WARSMB6$
MD\DC2+*\DC@EV#E\GCU/; P!4%MX1TVTN&EB\P;C&S [3\R! &SC<.(U! ./
M:MZB@#)C\/VL2W*I+/LN86AD0L,$,SMGID',C?G2V&B1VDEO<RRO)=1Q[&<'
M"L2B*3CZ1K^M:M% '*>)?^1R\&?]?MQ_Z2RUU=<IXE_Y'+P9_P!?MQ_Z2RUU
M= !1110 4444 %%%% !7/>,/^0;8?]A6R_\ 2A*Z&N>\8?\ (-L/^PK9?^E"
M4 =#1110 4444 8FF^%]/TK6;G5;9I_M=UN^TLTF1-EMP+#_ &?NKZ+Q6W11
M0 4444 <[X]_Y$'7?^O.3^5= G^K7Z"N?\>_\B#KO_7G)_*N@3_5K]!0 ZBB
MB@ HHHH **** "J&N_\ (OZE_P!>LO\ Z :OU0UW_D7]2_Z]9?\ T T 4?!/
M_(A>'?\ L&6W_HI:W:PO!/\ R(7AW_L&6W_HI:W: "BBB@ HHHH **** "BB
MB@ HHHH **** "N!\+^))+'0([<:%JMP$GN )81#L;]\_(W2 _F!7?5YAH'B
M'0[/1TM[K6M.@GCGN \4MTBLI\Y^""<B@#J?^$OD_P"A:UO_ +Y@_P#CM'_"
M7R?]"UK?_?,'_P =K(_X2KPY_P!#!I/_ (&Q_P#Q5'_"5>'/^A@TG_P-C_\
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M#7_X2^3_ *%K6_\ OF#_ ..T?\)?)_T+6M_]\P?_ !VLC_A*O#G_ $,&D_\
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MIRH5'BS3"&C$)VW5M'G=#)F3.<A@_EC@XY)QZ 'IW_"7R?\ 0M:W_P!\P?\
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M#!I/_@;'_P#%4?\ "5>'/^A@TG_P-C_^*H U_P#A+Y/^A:UO_OF#_P".T?\
M"7R?]"UK?_?,'_QVLC_A*O#G_0P:3_X&Q_\ Q5'_  E7AS_H8-)_\#8__BJ
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M]/T+S&LV\5ZHSW,_V61(YDRSL'X;;'WVN,^H(K93PAY2!(_$&M(@Z*DT8 _
M)0!CPZIH5R\HA\)V[+%$K$^1$,.55@A.,?Q@9SU!JWI TO4]8N+)_#6FP)#
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M+_T,NO?^!"?_ !% %_\ X1[1/^@/I_\ X"I_A2_\(_HN,?V188_Z]D_PK/\
M^$5E_P"AEU[_ ,"$_P#B*/\ A%9?^AEU[_P(3_XB@"__ ,(]HG_0'T__ ,!4
M_P */^$>T3_H#Z?_ . J?X50_P"$5E_Z&77O_ A/_B*/^$5E_P"AEU[_ ,"$
M_P#B* +_ /PCVB?] ?3_ /P%3_"C_A'M$_Z ^G_^ J?X50_X167_ *&77O\
MP(3_ .(H_P"$5E_Z&77O_ A/_B* ,?Q%HFDQ^+O"$::58JDEY<!U%NF& MI"
M,\<\UT__  CVB?\ 0'T__P !D_PKC/$'AZ2+Q5X3B.O:RYENYP':=-R8MY#E
M?DX/;Z$UTG_"*R_]#+KW_@0G_P 10!?_ .$>T3_H#Z?_ . R?X4?\(]HG_0'
MT_\ \!D_PJA_PBLO_0RZ]_X$)_\ $4?\(K+_ -#+KW_@0G_Q% %X^'M$P?\
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M0!U?_"/:)_T!]/\ _ 9/\*/^$>T3_H#Z?_X#)_A5#_A%9?\ H9=>_P# A/\
MXBC_ (167_H9=>_\"$_^(H O_P#"/:)_T!]/_P# 9/\ "C_A'M$_Z ^G_P#@
M,G^%4/\ A%9?^AEU[_P(3_XBC_A%9?\ H9=>_P# A/\ XB@"_P#\(]HG_0'T
M_P#\!D_PH_X1[1/^@/I__@,G^%<KIJVNJZS>:3;^(?$PO+(M]I221 (N<+D[
M,?./F7U'/%;?_"*R_P#0RZ]_X$)_\10!?_X1[1/^@/I__@,G^%'_  CVB?\
M0'T__P !D_PJA_PBLO\ T,NO?^!"?_$4?\(K+_T,NO?^!"?_ !% &=XXT+2(
M? NMR1:58HZV<A5EMD!!QVXK?3P]HA13_8^G]/\ GU3_  KE/&GAR2V\%:S,
M=?UJ4):2'RY)T*MQT/R=*W%\+2E0?^$DU[D?\_"?_$4 :'_"/:)_T!]/_P#
M9/\ "C_A'M$_Z ^G_P#@,G^%4/\ A%9?^AEU[_P(3_XBC_A%9?\ H9=>_P#
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M*^3^-7FTCQ89DF71]'21&5E9=5EX*NS_ //#U=@?8U9L/#.LQ1W32W 2XFV
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MV1O,&S&#ND;<'/(Q[<@%P7_C=BP71_#Y*G# :G+P>O/[GT-+]L\=?] 70?\
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MIXS[5R'@;PO>^&3J"W?V5ENV65/(+?N/O9@7/_+-,_+_ +QX% $_VSQU_P!
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M#0HK/_MW1_\ H*V/_@0G^-']NZ/_ -!6Q_\  A/\: -"BL_^W='_ .@K8_\
M@0G^-']NZ/\ ]!6Q_P# A/\ &@#0HK/_ +=T?_H*V/\ X$)_C1_;NC_]!6Q_
M\"$_QH T**S_ .W='_Z"MC_X$)_C1_;NC_\ 05L?_ A/\: -"BL_^W='_P"@
MK8_^!"?XT?V[H_\ T%;'_P "$_QH T**S_[=T?\ Z"MC_P"!"?XT?V[H_P#T
M%;'_ ,"$_P : -"BL_\ MW1_^@K8_P#@0G^-']NZ/_T%;'_P(3_&@#0HK/\
M[=T?_H*V/_@0G^-']NZ/_P!!6Q_\"$_QH T**S_[=T?_ *"MC_X$)_C1_;NC
M_P#05L?_  (3_&@#0HK/_MW1_P#H*V/_ ($)_C1_;NC_ /05L?\ P(3_ !H
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M_&C^W='_ .@K8_\ @0G^- &A16?_ &[H_P#T%;'_ ,"$_P :/[=T?_H*V/\
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MG^%:=% &9_PCFA?] 73O_ 5/\*/^$<T+_H"Z=_X"I_A6G10!F?\ ".:%_P!
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M ./4 =S17#>=XT_Z#>C_ /@L?_X]1YWC3_H-Z/\ ^"Q__CU '<T5PWG>-/\
MH-Z/_P""Q_\ X]1YWC3_ *#>C_\ @L?_ ./4 =S17#>=XT_Z#>C_ /@L?_X]
M1YWC3_H-Z/\ ^"Q__CU '<T5PWG>-/\ H-Z/_P""Q_\ X]1YWC3_ *#>C_\
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ME:6(G3F5<NAC^;,OHQQ[XJ:;6_$EOJ,.G3>*-!CO9AF.!M.<,XYQ@>;['\J
M/1**X?SO&A.!K>CY]/[,?_X]4<M[XOA56DU[1E#NJ+_Q+)#EF. .)>] '>45
MPPG\9G&-<T8YZ8TQ^?\ R-0)_&9&1KFC$>HTQ_\ X]0!W-%<-YWC3_H-Z/\
M^"Q__CU'G>-/^@WH_P#X+'_^/4 =S7/>,/\ D&V'_85LO_2A*Q_.\:?]!O1_
M_!8__P >JIJ-IXMU.&**?7-*"Q3Q7"[=-?[T;AU_Y:],@9H ]$HKAO.\:?\
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M_(A>'?\ L&6W_HI:W:H:'I_]D>']-TT2>;]DM8H/,QC=L4+G';.*OT %%%%
M!1110 4444 %%%% !1110 4444 %>7Z!JEU#HZQ1^']8N52>X F@BC*/^^?D
M$N#C\*]0KGO!'_(IVW_7:X_]'/0!A_VS>_\ 0K:]_P!^(_\ XY1_;-]_T*VO
M?]^(_P#XY5=E\2V<VK/':ZJ^H->L1=+()(1:,Z[?)C9MN]4QP5ZACSGF%Y/B
M-<P*DA:%I+=H76**,;6-O(PDW9X;S!&N!P-Q^M %[^V;W_H5M>_[\1?_ !RC
M^V;W_H5M>_[\1?\ QRJUY<>.X]/$ULUVRLZ1A!:P^>JBW#;B"<'=,=K<\ <>
MM6I+3Q,_A*\LTAFBU*_U)@[QS[/)B9@SLK\E1M#!3C()'% "?VS>_P#0K:]_
MWXC_ /CE']LWO_0K:]_WXB_^.5GFY^(JZ6S1QO');I;V[1F-)&D(W"696.2Q
M^52 0.&)QG@/NM1^( ENO*MY@BV<>TK;1D/,/*),8ZKNS(/FW;2.E %W^V;W
M_H5M>_[\1?\ QRC^V;W_ *%;7O\ OQ%_\<KJM%EOI8)C?K,D@D&U941=HV+D
M J2&&=W/'.>, 5IT <%_;-[_ -"MKW_?B+_XY1_;-[_T*VO?]^(O_CE=[10!
MP7]LWO\ T*VO?]^(O_CE']LWO_0K:]_WXB_^.5WM% '!?VS>_P#0K:]_WXB_
M^.4?VS>_]"MKW_?B+_XY7>T4 <%_;-[_ -"MKW_?B+_XY1_;-[_T*VO?]^(O
M_CE=[10!P7]LWO\ T*VO?]^(O_CE']LWO_0K:]_WXB_^.5WM% '!?VS>_P#0
MK:]_WXB_^.4?VS>_]"MKW_?B+_XY7>T4 <%_;-[_ -"MKW_?B+_XY4=QJE]/
M:S0_\(QKP\R-DSY$?&01_P ]*]!HH \'D\(7<EIY3:+K?F&W-NTGV.,Y3[.L
M07'F] R;\?UYJ:/PU>MJ4UU=:%K4L<\L3R0K;*J[%9&,0'F_<^3 ST!QZY]R
MHH \,F\-ZK+>&<:9KJY#;6^QIYD66E.U&\WA3YH##OL'X:TUGJ,$6BMI'A[5
M[6?20PC$UFDD3ATVOD>:#D]<YSR?4UZ[10!X7'X6OC<[[O1=:GB,_F2I]C0&
MY4R,^)?WN&(W!1V"BDM_#.JP"(OI&KSM%]E;][8HXD>$CYF)ER 5&, X[XSU
M]UHH \,/AG4H[6S@M=*UR'8BBZ?[(A:9EG6;>#YW#':%.<\4U/#&I1B$IH>I
MI-' 8&G2P022#>C[V/G??.T@GH0QKW6B@#PN/PM>F63[3HNM30O(S.ALT'GY
M,I#2_O?F<>:!GIA!^'3Z=-J-E:Z=%)H?B:1K.W6!L11!)B% W,"^<\>M>FT4
M >(WGA_4+NSBMSH^OA4U"YO&46Z*'$S;L9$F0R]F'OTJG/X2U-[>YAATO6T6
MZ0"?=91MO</*V_)E^\!(H!Z_)[\>]44 >":IHK/>+%<:5K*7FHM*D?F6:-YS
M#RY%4_O>BB%CV^\<>^[J6FW&J:G+>W'AS7P39);Q1)"BHDJERLA E^8 OD ]
M,5V?B7_D<O!G_7[<?^DLM=70!X3=^$[R:4F#1_$$,7V-+=$$"CRR$VL1B7E6
MR6(/<YJ<>&[J"5FLM UNVC=]S1I:HH8"<R*IQ*. IV#';I7M]% '@]MX5U.&
M>UDETK79D@A,21"V6-4&7QM*R@GA\$DY.,GFNJT&;4='T2VT^7P]KD[0@@.M
MK$@QDD#'F=@<9ZG&37IU% '!?VS>_P#0K:]_WXB_^.4?VS>_]"MKW_?B+_XY
M7>T4 <%_;-[_ -"MKW_?B+_XY4-SXDFLXT>X\-Z[&KR)$I,$?+LP51_K.Y(%
M>AUSWC#_ )!MA_V%;+_TH2@##_MF]_Z%;7O^_$7_ ,<H_MF]_P"A6U[_ +\1
M?_'*[VB@#@O[9O?^A6U[_OQ%_P#'*/[9O?\ H5M>_P"_$7_QRN]HH X+^V;W
M_H5M>_[\1?\ QRC^V;W_ *%;7O\ OQ%_\<JSX<M-=M_&.IRWXO3I,WF'3UDF
MW"'YQO#C_:.&3KM7(XKM* ."_MF]_P"A6U[_ +\1?_'*/[9O?^A6U[_OQ%_\
M<KO:* //+OQ)-86<UW=^&]=BMX4+R2-!'A5'4_ZRIO[9O?\ H5M>_P"_$?\
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M!!'X5)0!RGB7_D<O!G_7[<?^DLM=77*>)?\ D<O!G_7[<?\ I++75T %%%%
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M6>2QC2';#*S;<)N. I],D]#4DMUI2PRI-/9B*,A9%=UVJ>H!ST/I55O#UO\
MV3-81-Y8DF$V\(#A@X89'<# '/:J47@JPCDN79O,,\DCY9 2-_F$CGC ,A(X
M&,4 :[S:5&;@/)9*40+/EE&U>P;T'IFDM;K2I+BX6UEM#- B^=Y97**1N7..
MV#D=JR8/!UM'J!NY;J6?"1HL<B@J%1D8#\XQ^9J2W\)6UMIU]8K<2&&\MT@?
MY5W+M39D''H!P>* +BZQI,U_#I\4L,\DT#3CR\,GEJ=I)/3&>/P--MM1T/4"
M(+>6SF5H0R ;2'C//R^HXY],5#I?ABWTS5)M1$S27$R,DGR!5.Y@<@#IT Q^
M/4U5/@JT>UAADN9"8D$8=$56*".2,#IZ2D_44 :=WJNE6ME%.[QRV\S^3'Y"
M>:'8@_* H.>%/Y4_[5IAM(+A1"\>%>$(@)YP05'7HP/XUDS^"K.XT2'3'=-D
M=R+IB80RR.!CYE).?_K4D?@R*.:V8ZC<R1V\7EHCJI).V-2Q;&2<1#\S[4 :
M,VNZ5&869U:6;)1%7,AP&YV]<?*W-6C?Z;$DKM=VB+"=LK&10$/HWIT[^E8T
MG@V"2Y\S[9($SO*^6F2VPI][&<8/3UJAKG@>2Y'F:;.BRR'$J2_*K+F9CT')
M)FP?8=C0!U_D6\JJWE1.N0ZG:",CH1_C3Q%& 0(T&6W'Y>I]?K5;3(;N"R6.
M]EADE!./)3:BKV4=^!W-7* &^7'_ '%_*D\F++'RT^9=I^4<CT^G)I]% $1M
MH"FPPQE-NW:4&,>GTX%!MX&1$,,91.44J,+]/2I:* (/L=KMV_9H< E@-@X)
MZGZFJEAH&E::FVTLHT&5/S98Y5=J\MD\ 8%:5% $9@B:3S&B0N5V%BHSM],^
ME.**3DJ"?<4ZB@"$6ELNS%O$-A)3"#Y2>N/2E6V@2/RUAC6,@KM"C&#U&*EH
MH B%K;JRLL$09 54A!E0>H'M2):6T90QV\2E 0A5 -N>N/2IJ* &^6G]Q?RI
M@M;=555@B"KG "# SU_.I:* (T@AB0)'$B*.BJH %-^QVWE"+[-#Y8.0NP8_
M*IJ* &-#$\BR-&ID485\<CZ'M4,.GVEO91645O&MM$H5(MN0H'3K5FB@"O=6
M-K>VTEO<0J\4@*NO3(/4<>N*L444 <IXE_Y'+P9_U^W'_I++75URGB7_ )'+
MP9_U^W'_ *2RUU= !1110 4444 %%%% !7/>,/\ D&V'_85LO_2A*Z&N>\8?
M\@VP_P"PK9?^E"4 =#1110 4444 %%%% !1110!SOCW_ )$'7?\ KSD_E70)
M_JU^@KG_ ![_ ,B#KO\ UYR?RKH$_P!6OT% #J*** "BBB@ HHHH *H:[_R+
M^I?]>LO_ * :OU0UW_D7]2_Z]9?_ $ T 4?!/_(A>'?^P9;?^BEK=K"\$_\
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MEAA=V8*<,Q &5"D@$G@9JE_PL+PV(]YO)N)7B<"VD)C*%=Q?"_*HWH<GCYJ
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M \-0O=(^H$&WZDPN!(=^SY"1A_FXXS6_8WMMJ5A;WUG*);:XC$D4B]&4C(-
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M*6+JZ2CHRN)LJ0.!@].*=%;75SX3DL+_ %>&6\DFA=FEFC<*%:,OC.01\K$
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M.#R*BNO E[>Z=:6$^J6+6UHABA5;!U(C*[60D39*D<$'@]ZZW^TK#_G]MO\
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M5_QH_M*P_P"?VV_[^K_C0!:HJK_:5A_S^VW_ ']7_&C^TK#_ )_;;_OZO^-
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M/[OTJE-X;TB>6SE:RB$EHVZ)E4 @88;3ZK\S<>] ',-8^#S=31P>%-,F\IS
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MEKJZ ,+_ (0KPK_T+6D?^ 4?^%'_  A7A7_H6M(_\ H_\*W:* ,+_A"O"O\
MT+6D?^ 4?^%'_"%>%?\ H6M(_P# */\ PK=HH PO^$*\*_\ 0M:1_P" 4?\
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M!_PG'A3_ *&/2_\ P*3_ !H_X3CPI_T,>E_^!2?XT 4_$O\ R.7@S_K]N/\
MTEEKJZ\[\0>+O#D_BOPG-%KNG/%!=SM*ZW"D(#;R $G/') _&NE_X3CPI_T,
M>E_^!2?XT ;]%8'_  G'A3_H8]+_ / I/\:/^$X\*?\ 0QZ7_P"!2?XT ;]%
M8'_"<>%/^ACTO_P*3_&C_A./"G_0QZ7_ .!2?XT ;]%8'_"<>%/^ACTO_P "
MD_QH_P"$X\*?]#'I?_@4G^- &_7/>,/^0;8?]A6R_P#2A*=_PG'A3_H8]+_\
M"D_QK#\5>,?#5QI]DL.OZ;(RZE9NP6Y4X59T)/7H ": .[HK _X3CPI_T,>E
M_P#@4G^-'_"<>%/^ACTO_P "D_QH WZ*P/\ A./"G_0QZ7_X%)_C1_PG'A3_
M *&/2_\ P*3_ !H WZ*P/^$X\*?]#'I?_@4G^-'_  G'A3_H8]+_ / I/\:
M-^BL#_A./"G_ $,>E_\ @4G^-'_"<>%/^ACTO_P*3_&@!GCW_D0==_Z\Y/Y5
MT"?ZM?H*X3QKXP\-77@G68+?7M.EFDM)%1$N5)8XZ 9K<3QQX4"*/^$CTOI_
MS])_C0!T-%8'_"<>%/\ H8]+_P# I/\ &C_A./"G_0QZ7_X%)_C0!OT5@?\
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M6=U!:V\*6PAVF95<.[Y/"@[>G/'2I'^(IB$DDVB0P0^2[1N]QN_>((<JVU"
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M\FD2]TUGC*7-J7N"=FV1<R$<''KCI0!S<OB>2"VDNKC3XHC#'O:'SE*LI$3
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MS3_OD4>5'_SS3_OD4^B@#FO'D<8\!:Z0B@_8Y.WM70)%'L7]VG3^Z*PO'O\
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M99Q<1/M!.]555W=FP%[_ -!B/_A8N@?W=6_\$]U_\;H_X6+H']W5O_!/=?\
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M_P +%T#^[JW_ ()[K_XW0!U=%<I_PL70/[NK?^">Z_\ C='_  L70/[NK?\
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M?^">Z_\ C='_  L70/[NK?\ @GNO_C= '5T5RG_"Q= _NZM_X)[K_P"-T?\
M"Q= _NZM_P"">Z_^-T =75#7?^1?U+_KUE_] -8?_"Q= _NZM_X)[K_XW5+6
M/B#H4VB7\2+JNY[:11G2;H#)4]S'@4 ;?@G_ )$+P[_V#+;_ -%+6[6%X*&/
M ?AT'MIEM_Z*6MV@ HHHH **** "BBB@ HHHH **** "BBB@ KGO!'_(IVW_
M %VN/_1SUT->?^%_!/AO4]!CO;W289KF6>=I)&+98^<_O0!+8Z[K-MXAU,7B
M3RV27#JO[LE8D$RJ"<(,?(Q(P6R%).,<RQZYK4ME;ZG]DFB:6,,\+QN8X\A/
MF*XW87+,1UX/2J'_  C_ (619;F7PS +);@VL!29VEEE#^7@)T +9 RW;)QF
MF2:?\/X[?[1_8$K1Y501$^2Y4ML&3]X $D>V.O% &C;ZMX@@T=KF.$W,^V20
MB:*0*RKYC (O!!;"@9SU'7O<T[Q/>WTFKY2U3[+&Y@B;<')5W7+=<K\HY ')
M([5E7?AWP997\,<N@*;:6%)!.H<A2SA5#<\9)'^16=_9_@-RXL?"XDDC@N)&
M(!PABV$J<-SGS5/&>OK0!JOXJUZ%+RX-J74Q0/:PM9N"2R,7R0W W+@<G!(Z
MYK1O-?UJVNID-E$(&R8Y?)D;R@)50EP/O<$MQCIZ5C'2/ PCW+X=F8AMC*(W
MRK^9Y80_-C<7&!^? YJ-M/\ A[&%9M$94/RLQCDPCX8^6><[OD;@>WJ* +^E
M>(->-O%:FT,LXLP[23P.N)2R=>Y7#GC /RGWJ[8:EK5WXFN89 BQPVLZI&(9
M%3S%D4(S$\'< 6&#P#WZUBG2_ 8BF>7P[-$(FVL)8G7G>$/);'!9<D\<]:LZ
MCX=\":9=PVUUHL8,J,Z%=S [59B,!LYPC'ICCWH N6/B/6=4D0/I$]I&KQN6
M*LI92RJ!R/42Y'H%/>L[5O$?B4V;VOV/[-*P4BY@@E;<2(F\M1V;]X_S'CY#
MQZ5;G3/!:QJL'AEVN#,D;QRHZ^4&=%R_S<9#@CK^%/DT/PI;ZQJ$$OAR%;.R
M*QLX,C/(Q0/\H!YX91CB@#5F\4:_&UQY.D+<;9#$B+'(I1RSHBL3U&0A+#@*
MV?>KY\0ZA_8UGJ!L&3[1=!# T3&41$D [?[W?&>ASSTK 71/!!:-GT%$CD=8
M0K;PZ2%W4JV3@ &,CKS^6:L5IX#6S62[\/M%<D+NA".6(968,O/*X5O?CITH
M U9/$/B#2[+9-9"XFPCQ,('.\$R91CD8;"#G_:''K&_B37AJ%[.MH0L86%86
MADV0YF==['^([0I^7& P^I='X;\#RV5W=1:&I2VD,3J25;<"!T+#'XXJ/3]#
M\!:FADM=&#(MLMT#M?)1AD8&<D_0=>.M &W9Z_?R1:H;JSV26D*2H((VD4Y4
MDKGC<P(/  X(ZYJ+2-:UB[F,EU BH;)I$@6%E,DBR2+PQ) ! 0X.?O#%<X]C
MX"A=);G0TCLW@69+CYF R)"5;#'!Q&>F:D;3_AY$P2[T8VLA=4,<Z.""2H&<
M$CHZDGH <GO0!IQ>)]=EM[,_V=$6NI&1GCCD/V<;5P7'^\2F,]<'@ X98^)O
M$4L>Q[""21+(2%FC>,R2>7DD+Z!_E(Z\$^U0V.@>!=2NXK>#0CF5-Z2.CA&^
M56QG/7:ZG_\ 526/A[P5>W%O:G0E$LR;@X63RBVP/M#$CG:0>E %^77-;LM2
M6U-IYP>4DL8G(E^=5*1XX3 );+9_F19O]9UZRT*SNX].ANKRY^7R8U<"-F7,
M8/4@9X8G&,US5GI?@M[=I[SP]%;QO>-90A?-8O('90.0!\Q7C!(YQG-,?2O"
M*V4LJ^&XA<0J6DB?S 67Y]I3&=P/EMZ=/I0!T(UO79[9KRUL/+::+SHXKE'P
MJ 2E05&"'8*F1GC=[<YMSXFUY=?+):-';HKPM$UO*5A!EB59G(X;Y2Q 7& 3
MGUJL^D^"UGME3PUO$]P+4H-PDCDR^=P+8P-G8GK1-IG@6V\1RZ9/I%G#;PP-
M(]W)<%5$BL@*8SZ2+S[XH UAXIU[S;>$Z&Q:94/F!'"+O^5"<]/F5R0>0NW/
M6M_0M1GU*TFDN(PCQSO&-J%58#&"I/+#!Z\<YX&*YK2O!_A?4)]2AE\-06[6
M5UY&/-9MX*(X;@\9#CBM(_#SPD>NB0'_ ($W^- '3T5S'_"NO"7_ $!+?_OI
MO\:/^%=>$O\ H"6__?3?XT =/17,?\*Z\)?] 2W_ .^F_P :/^%=>$O^@);_
M /?3?XT =/17,?\ "NO"7_0$M_\ OIO\:/\ A77A+_H"6_\ WTW^- '3T5S'
M_"NO"7_0$M_^^F_QH_X5UX2_Z EO_P!]-_C0!T]%<Q_PKKPE_P! 2W_[Z;_&
MC_A77A+_ * EO_WTW^- #/$N?^$Q\&X_Y_;C_P!)9:ZJO--?\#^&;?Q3X4MX
MM(@6*XNYUE4,WS 6\C#OZ@'\*Z3_ (5UX2_Z EO_ -]-_C0!T]%<Q_PKKPE_
MT!+?_OIO\:/^%=>$O^@);_\ ?3?XT =/17+GX=^$L<:';Y_WF_QKG/"6C>$O
M%*WY'A:"V^PS?9I<SE\S#.\+@\J/EPW?/3B@#TNBN8_X5UX2_P"@);_]]-_C
M1_PKKPE_T!+?_OIO\: .GKG_ !?G^S;#'_05LO\ TH2H/^%=>$O^@);_ /?3
M?XUB>*/ GABUT^S>'1X$9]1M(V(9N5:9 1U[@D4 >A45S'_"NO"7_0$M_P#O
MIO\ &C_A77A+_H"6_P#WTW^- '3T5S'_  KKPE_T!+?_ +Z;_&C_ (5UX2_Z
M EO_ -]-_C0!3\.:AK=QXPU2UOVNCI<?F'3Y)+?9YP\S#[CC^ _*G]Y3NYZU
MV=<Q_P *\\)?] 2#_OIO\:/^%=>$O^@);_\ ?3?XT =/17,?\*Z\)?\ 0$M_
M^^F_QH_X5UX2_P"@);_]]-_C0!+X\S_P@6NX_P"?*3^5="GW%SZ5YYXR\">&
M++P7K%S;Z/!'-%:.R.&;@@=>M;:_#OPD54_V);\C^\W^- '4T5S'_"NO"7_0
M$M_^^F_QH_X5UX2_Z EO_P!]-_C0!T]%<Q_PKKPE_P! 2W_[Z;_&C_A77A+_
M * EO_WTW^- '3T5S'_"NO"7_0$M_P#OIO\ &C_A77A+_H"6_P#WTW^- '3U
M0US_ )%_4O\ KUE_] -8_P#PKKPE_P! 2W_[Z;_&J6L?#_PI#HE_+'HL"NEM
M(RG<W!"GWH U_!/_ "(7AW_L&6W_ **6MVL+P22? 7ATGJ=,MO\ T4M;M !1
M110 4444 %%%% !1110 4444 %%%% !7 ^%M.\13:!')9^(;>VMVGGV0MIPD
M*#SGXW;QG\J[ZN>\$?\ (IVW_7:X_P#1ST <O;:)_:VHZE!;^)M.FNDE_P!+
M":40!(".<^8 'RHY7G(K2?PIJ:VRPGQ%IT<4;*ZA=,";2!M!!$H(XXJ5_ GE
MP79L]1,-Y<:D]^97C+H-V\;-FX#@2'D8R0":H+\*[$Z6MG-=),^7+RR6X)?-
MMY"9R?X?O#W_ #H EET2^U340D_B;39KRW# )+I(W!01GY3)\R@D<X(S[TL7
M@V^LXU$6O:9$B*Y_Y!8Z$ /DF7D850<_W1Z4I^'CAVFCU5?M+(R^=);[FSYD
M<BG.[. 8\$=PQZ57/PNB?3[N*74R]W.L86X$&"FV=YF7&[[K%P",]%'- %F\
M\.ZE!I]U)<^(]/6U;][,W]DCD[M^[(DSG<<@CG/2F0>#[^98KB+6[# CV)NT
M?;\N".5,G7!;DC/)K6LO"*6>@3Z2)HA'+#'"'CB(8!1CDEB6]N>!2:IX2?4;
MG"WWEV9.YH6C+L3Y3Q8W%NF'SC'4=: ,Z]\-:I-;2"Z\16+QR??"Z5RV\@'.
MV3)!.,]O6F2^&K^ZU1!+X@TV2\CAPG_$I'"?,N!^\QP"X]0"?6MB?PG ^IK>
MV\J6[ GY8X@,KMC 7@]!Y><?[55[;P4D7E/+<QO-#*CPLL&/*591(54DD\XV
MDDYP>] %*?P?J5S=^=-KVFO/&XE)_LH AAC!($G^PI&?[M+<:)JJ7B1S>)-/
M-Q?29'_$H!,C!.I_>?W4Z^U:D_A476O7&HW%RLD4RJI@,(P5#1MAC_%_J^X_
MB-5=,\%?V;JUI>K>1R+;L6 :W&__ %;1A0V?E0!L[<=<T 4SX7U.]0;O$%@R
MF5GVMI.W<P<DDCS!D;BQYXYII\,WTEP?^*FTSSXECR4TX*R+A@G(ER!@L!ZY
M/6M6\\(17<[7#3(9]^5=XLE5S*2N00<'S<'!'2J$O@)Y+6:+^T8]\]O%!)(;
M52<)OQCG@8<>^5'/)H KP^'+^Z-[9Q^(;)S(X>X4Z2<LRM@')DSP5XP>,<5)
M#X4U.QC::W\06$2K 8LQZ7]V(=5'[W@<#IZ5O#P]_HU_#]K<?:X7BWJN"F[/
M(YZ\U3;PM<R2P$WMM%$NPR106NQ25#@;?F^4'?SUZ>] &/'X5NS!% NN::82
MIG4/HX*D9;)),F"<R-G/)W&D3PA<WD'V;^V],ECC>6/;)I )W%=LG)DR<KP3
MZ8]*TH/!3P6CQB\@+,R-Y0ML0?+Y8QY>[H1'SSR3[5,WA -JD=Z]Q')M);8T
M; (V205VL,=<$<Y&* (8_#VO^8D\7B2PW*3L==)7C("G'[ST4#\*:GAS7+;R
MY$\1Z?%Y1^1O[*4;20%_YZ>@ J_I^@7,.B7.BW=Q%)9M#Y<+1IM9<EB>_094
M#DGY22>:RD\ ,D0\S4Q=2B3S/]*@WQL2CB3*;N=SRO(.>#@=!0! _A2^2=;1
M]?L"\K/,L;:7N .<LP!EPIRV<C'7BI;KPSJ.&2Z\1:6!,JP$/I2C>#N 7_6?
M[;_F:NGP1"IM'CNR)K:?S][1Y\XC: ).?F "_@<$=*FOO"IO=6FO3<0A'EAF
M$+0;P7C/5LG^[D<8'?!- &0_AV]M8HXV\2Z:H5C+&O\ 989RR$L2/WFXD$DG
MJ>?>K8\/ZV;W[?\ \))IWVJ.,KYW]D*'56P2"?,[[0>?2FVO@0P2>;)J"S3>
M9*VXVX &^(1DJ ?E/RAN/>K,7@J'[?Y]S-%-$'9C&8<>:&??^].?G(. O' H
M AM/#.O65Q=2VOB6T2:Y<2SD:;DNV, G,OH,?@/2K)T[Q0IP?%MF"3C!TM>O
MI_K*=I?AV\T>^CDM;N%H&CBAF1HB"RHN-V<GYN ,# QS@FFWG@Z"ZNTN!)'G
M[3)/*KQG$F\J1RK [EV@ ^YXH 3^S_$^<?\ "76?WMO_ ""U^]Z?ZSK[4R2S
M\20[?,\862EB54'2UR2!G 'F<G )Q4:>"<3V4DEU#(MJ[';Y+)YFYE;>Q5AF
M0;!\WN>*2S\&2)/'=SSVZS+)N$:6_P N/WHW'GF3][][_9'% $\=CXFE0.OB
MZTP5#\Z4 0#T)!DR/QIEU:^([*SDN[CQ?:)!&I=F.E#H!G_GIS20^!XTOO/G
MNEFC#!BIA^:3F,E9#GYE'E\#'&>^*=?^"Q=Z+8Z<MW&!:QRQ RVXD0AQC(7(
MPR]CVYH ?_9WB?G_ (JVS&" ?^)6O!/0?ZSWIMO8^)[J!)H?%EJT;C<I_LD#
M(_[^5$/!+1I/Y-Z@G>Y$ZW+QLSC#LW(+;21N(!QC';IC1T;0[G1+EHX+E);.
M9VFE,BGS=Y  4'/W1@XST&!0!6&G>)R"1XNLR =I(TM>OI_K*A6V\1O?/9+X
MNM3<)&)&0:4.%)P/^6GM38? R^1>)=7J7#7+.X)MP C%"@8*#C(SGBI['P?]
MCDU,_;01>P/!OCAV2#<[MN9L_,PWX!XZ"@""XCU^UC+R^,[$ (TF!I:DE5(!
M( DR0"1^=6/[-\494?\ "6V>6&5']EKS]/WE58O <:EV>XM]TL,D#HEMMC56
M6-?D7/RG]V,^NXTL/@2.#4I+I;L%&,GEQE"OD;FD8>7A@ !YF"""" .E &+K
MNG^(O^$I\*!_$EM+(]W.(I%TX 1D6\F21O\ FXR,<=<]JZ7^R?%G_0U6O_@J
M'_QRJ.K6<6G^(_ MI B)'#=3H B[1Q:R=J[.@#FO[)\6?]#5:_\ @J'_ ,<H
M_LGQ9_T-5K_X*A_\<KI:* .:_LCQ61_R-5K_ ."H?_'*I6/A#6M,8M8:[I]L
M3$D)\K2 ,HF=H/[SG&X^_-=E10!S7]D^+/\ H:K7_P %0_\ CE']D^+/^AJM
M?_!4/_CE=+10!S7]D^+/^AJM?_!4/_CE8GBC3/$T=A9F;Q+;RJ=2M H&F!<,
M9TP?O]C@X[XQ7H%<]XP_Y!MA_P!A6R_]*$H C_LGQ9_T-5K_ ."H?_'*/[)\
M6?\ 0U6O_@J'_P <KI:* .:_LGQ9_P!#5:_^"H?_ !RC^R?%G_0U6O\ X*A_
M\<KI:* .:_LGQ9_T-5K_ ."H?_'*/[)\6?\ 0U6O_@J'_P <KI:* .:_LGQ9
M_P!#5:_^"H?_ !RC^R?%G_0U6O\ X*A_\<KI:* //O&>F>)8_!>LO<>)+>:%
M;20O&--"EACIG><5MKI/BLJ,>*K7I_T"A_\ '*D\>_\ (@Z[_P!><G\JZ!/]
M6OT% '.?V3XL_P"AJM?_  5#_P".4?V3XL_Z&JU_\%0_^.5TM% '-?V3XL_Z
M&JU_\%0_^.5GK-K#:D=.'C>P-Z)/*,']EC?NV;^GF?W><]*[6N;7PHR>-V\4
M"^/VAX_LS0F(;?L^!A >H8/EMWOC&* $_LGQ9_T-5K_X*A_\<H_LGQ9_T-5K
M_P""H?\ QRNEHH YK^R?%G_0U6O_ (*A_P#'*I:QI7BE=$U!I/$]LZ"VD+*-
M+ R-IXSYE=E5#7?^1?U+_KUE_P#0#0!1\$_\B%X=P,?\2RV_]%+6[6%X)_Y$
M+P[_ -@RV_\ 12UNT %%%% !1110 4444 %%%% !1110 4444 %<]X(_Y%.V
M_P"NUQ_Z.>NAKS_0?%!T/2AIMUX=\1M-#--N:'2Y'1LRL00PZC!% %Z\O_$%
M]<RV4:/!$;@*TD<#JT*"=5'S9&[?'N;*XV@>]5M'O?$-I9:>+L7+RW04W,\T
M$DGDD^:V/+!XR0J\<#(XZ5>_X3Z#_H6_%'_@HEH_X3Z#_H6_%'_@HEH A;4O
M$6H>&=89H/LEX$Q;+%&_F(22",'J0 ,$'O\ 2KO]J:LUTNGVMNRM&WER3SV\
MA4 2;0<DC<2GS=>IYJ#_ (3Z#_H6_%'_ (*):/\ A/H/^A;\4?\ @HEH CN-
M1\1R).OD%)%C,T$D4#8!*3@(P)^8@I&>W+CCI4SZ[K!E%K;6QDD\LL9Y+214
MZP[3^.^0XSGY.V#3?^$^@_Z%OQ1_X*):/^$^@_Z%OQ1_X*): +^BZAJ]UJM]
M!?01QV\+,L9",K'#$ \\$,,-P>,XK>KDO^$^@_Z%OQ1_X*):/^$^@_Z%OQ1_
MX*): .MHKDO^$^@_Z%OQ1_X*):/^$^@_Z%OQ1_X*): .MHKDO^$^@_Z%OQ1_
MX*):/^$^@_Z%OQ1_X*): .MHKDO^$^@_Z%OQ1_X*):/^$^@_Z%OQ1_X*): .
MMHKDO^$^@_Z%OQ1_X*):/^$^@_Z%OQ1_X*): .MHKDO^$^@_Z%OQ1_X*):/^
M$^@_Z%OQ1_X*): .MHKDO^$^@_Z%OQ1_X*):/^$^@_Z%OQ1_X*): .MHKDO^
M$^@_Z%OQ1_X*):/^$^@_Z%OQ1_X*): .MHKDO^$^@_Z%OQ1_X*):/^$^@_Z%
MOQ1_X*): .MHKDO^$^@_Z%OQ1_X*):/^$^@_Z%OQ1_X*): .MHKDO^$^@_Z%
MOQ1_X*):/^$^@_Z%OQ1_X*): .MHKDO^$^@_Z%OQ1_X*):/^$^@_Z%OQ1_X*
M): .MHKDO^$^@_Z%OQ1_X*):/^$^@_Z%OQ1_X*): .MHKDO^$^@_Z%OQ1_X*
M):/^$^@_Z%OQ1_X*): '>)?^1R\&?]?MQ_Z2RUU=>:ZSXH:^\0^';Z'PUXF\
MG3[F:2?.E2 A6A=!@=_F85N_\)]!_P!"WXH_\%$M '6T5R7_  GT'_0M^*/_
M  42T?\ "?0?]"WXH_\ !1+0!UM%<E_PGT'_ $+?BC_P42T?\)]!_P!"WXH_
M\%$M '6T5R7_  GT'_0M^*/_  42T?\ "?0?]"WXH_\ !1+0!UM<]XP_Y!MA
M_P!A6R_]*$JG_P )]!_T+?BC_P %$M9/B#Q=_:5G:Q6_AKQ/NBOK:=MVDR#Y
M4E5F_0&@#T.BN2_X3Z#_ *%OQ1_X*):/^$^@_P"A;\4?^"B6@#K:*Y+_ (3Z
M#_H6_%'_ (*):/\ A/H/^A;\4?\ @HEH ZVBN2_X3Z#_ *%OQ1_X*):/^$^@
M_P"A;\4?^"B6@#K:*Y+_ (3Z#_H6_%'_ (*):/\ A/H/^A;\4?\ @HEH M^/
M?^1!UW_KSD_E70)_JU^@KSWQ3XM.K^%=4TZU\->)S<7-L\<8;29 -Q'&3VK5
M7Q[ % _X1OQ3P/\ H$2T =?17)?\)]!_T+?BC_P42T?\)]!_T+?BC_P42T =
M;17)?\)]!_T+?BC_ ,%$M'_"?0?]"WXH_P#!1+0!UM%<E_PGT'_0M^*/_!1+
M1_PGT'_0M^*/_!1+0!UM4-=_Y%_4O^O67_T U@_\)]!_T+?BC_P42U4U/QM'
M=Z3>6T7AOQ1YDT#QKG290,E2!0!M^"?^1"\._P#8,MO_ $4M;M8WA&WFM/!>
MA6UQ$T4\.GV\<D;C!1A&H((]0:V: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHILDB1+ND=47U8X%
M #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *YOQ?HL^N1Z7;0QPNB7A>8SQ^8B)Y,B[BN1DAF7'/7![5T
ME% 'GVIGQ)H\=X();LV=M:K"DTLBL96#0J&R?NDCS<D].I/3$^@OX@NKO3Y6
MO+I[#:/WCQJP<AG\P-R/]D*PR" ".IKNJ* .<TRWG@\9ZW,+&YCM[F&#;.Y!
M1W3?NQ\Q(X9>PZ&L>'2M<U-+>+5!=M%'<6TLJS-'S*I<RE=O!B^Y@>HKNZ*
M.6ETK56\?V>J2+%)9I#/$&60@Q(1'@%>A)8,<^F/3GJ:** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g5lvsimk4gaq000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5lvsimk4gaq000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "Y 1\# 2(  A$! Q$!_\0
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MU7\J?10 S$GJOY48D]5_*GT4 ,Q)ZK^5&)/5?RI]% #,2>J_E1B3U7\J?10
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MJ5*B@TM3*OE].G3<TWH=_P"6?^>C?I1Y9_YZ-^E/HKUCR!GEG_GHWZ4>6?\
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M/)?;N'?- &KBDP/04C-M_A8_04GF?[#_ )4 .P/048'H*;YG^P_Y4>9_L/\
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MG^P_Y4>9_L/^5 #L#T%&!Z4WS/\ 8?\ *@/DXVL/J* %*(2244YZ\=:7"@Y
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M<^+_ ($O0]#HIGE+[_\ ?1H\I??_ +Z-?2'S ^BF>4OO_P!]&CRE]_\ OHT
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=44 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>gqr1p20dfppl000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqr1p20dfppl000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (. Q@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[$U#_H9M4_[]VW_QJ@#:HK%_L34/^AFU3_OW;?\ QJC^Q-0_Z&;5/^_=M_\
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M ,:I_AJYN;K1$DNYVGF6>>(RLJJ6"3.@)"@#.%'04 :]%%% !1110!A>%O\
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M_83NO_1AK=K"\+?\>VI?]A.Z_P#1AK=H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "L3PI_R C_ -?EW_Z425MU
MB>%/^0$?^OR[_P#2B2@#;HHHH **** ,+PM_Q[:E_P!A.Z_]&&MVL+PM_P >
MVI?]A.Z_]&&MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *Q/"G_("/_7Y=_\ I1)6W6)X4_Y 1_Z_+O\ ]*)*
M -NBBB@ HHHH PO"W_'MJ7_83NO_ $8:W:PO"W_'MJ7_ &$[K_T8:W: "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K$\*?\@(_]?EW_ .E$E;=8GA3_ ) 1_P"OR[_]*)* -NBBB@ HHHH PO"W
M_'MJ7_83NO\ T8:W:PO"W_'MJ7_83NO_ $8:W: "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K$\*?\ ("/_ %^7
M?_I1)6W6)X4_Y 1_Z_+O_P!*)* -NBBB@ HHHH PO"W_ ![:E_V$[K_T8:W:
MPO"W_'MJ7_83NO\ T8:W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MC/BS(\7PMUYXW9'6!2&4X(^=>]>86'PZT>ZTB"[GOM:@9[2)[D&[RUJS+D2X
M ^>(YY(^[CZX]-^+G_)*O$'_ %P7_P!#6L;0B#X=TM@\EM+:VD.'D^9[3<@^
M]_?@?]/;' !RTGPRT4"4R7NLP>7&!.%O3(;<G.V=>/WD)[D<C'UPX_#+0U+F
M:]UF-8XA]H6.]+F'/W9TX_>1'OW&/K78X^S'(!LS:'<57YS8EOXE_P">EL_<
M=O;'"_ZCYAFT^RGS"(_G-EN_Y:1_\]+9^Z]O;' !R,GPMT.(EY+[61&D7[\1
M7I<Q@_=N$X_>1^HZBDD^%NB1_.]]K)18<S>3>ERJG[MQ'Q^\C]5ZC^?9QR?9
MMW'V9;<^:R0_.;/=_P MHO[]NW=>W/X2'_1,LN8H8OWS+;_,;7=_RWA_O0M_
M$G;F@#@Q\,=%1@)KW63LAW2^1>EMR'I<Q<?.G]Y>H]^X/AEHJ,HEO=9?;#ND
M\B]+>9'VN(N/G4?Q)U'OW[B2,1#(S'''_I!%M\QMB?\ EXM_[T1_B3MD\>L1
M&SY7&P)_I/\ HG/E9_Y>;;UC.?GCYQD\<\@'(0_##1,HDE[K,DBQ;V\B^R)X
M^,3P\?-CNG49^F2'X7Z)NCCDO=9ED6,N?)O21<1<?OHN.2/XDZC/TSUQ&W*.
M-JC_ $G_ $0YV?\ 3U;>JG/SQ^_?/,W^N'ER >9_Q\@VI^]_T\VQ]>?F3W[Y
MY .)7X7Z.IB4WNL3NJ%R(;T_Z5%Q^]AX^\O\49YYX[92+X8Z*1!B^UBY8(9,
M0WI_TR'_ )Z19'WU_BC/^%=Q_KLQ2C=(W^D VO'F8_Y>;?T8?Q)_//,;*SLP
M(\QY/](*VO'GX_Y>;;^[(/XD[^^>0#@;WX96G]DR'1[[4KK4Q!))9AKPB.]
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MOS?(+T+_  GIY=RF/;./^^94<7"B.0BZ6Y'EH\GR"\"_\LY/^>=PF.#QG'Y
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MDBB 9OWMH=X/DR?WX^Z-]*]HTK_D#V7_ %[Q_P#H(H MT444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5B>%/^0$?^OR[_\ 2B2MNL3PI_R
MC_U^7?\ Z424 ;=%%% !1110!A>%O^/;4O\ L)W7_HPUNUA>%O\ CVU+_L)W
M7_HPUNT %%%% !1110 4444 %%%% !1110 4444 %%%% '&?%G:?A;KP<D+Y
M*Y(&2!O7M6+H1!\.Z6RR/;R6MI" \PW-:[D'#_WX']>WMCC8^+G_ "2KQ!_U
MP7_T-:PM"D\OP]I;^:\)M[2%5EG&YK0L@^27^_;OV/\ #[8X -3IZV4UH?\
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M/,];:X'9A_"_\\\@$(.SYE. O^C?Z7SLS_RZW/JIS\DGN.N?F4'R\,I*!/\
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M[/CDVZP?N4>?Y_LF[_EA/_?@;^%NW%1_ZG@YM?LQ\H&;YS9[O^6,O_/2W?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B>%/^0$?^OR[_\
M2B2MNL3PI_R C_U^7?\ Z424 ;=%%% !1110!A>%O^/;4O\ L)W7_HPUNUA>
M%O\ CVU+_L)W7_HPUNT %%%% !1110 4444 %%%% !1110 4444 %%%% '%?
M%S_DE7B#_K@O_H:UA:$^WP[I;&5XO(M(8Q+<#<UJ60?NIA_' _9NWX5N_%S_
M ))5X@_ZX+_Z&M8NBY7P[I+F8J([.&))[E<F#<@_<W _BA?^%NV: +@S;G!S
M:&U/EAI/G-D6_P"6<G_/2V?LW;VQQ+]WULYK3Y?F^<V9;^%O[]N_8]O;'RQ?
MZGY6S:_9CY(,_P YLRW_ "QE_OV[_P +=OPX!FW(!)M#:GRPTGSFR+?\LY/^
M>EL_9NWMC@ E^[ZV4UH?]\V9;_T9;O\ I[8XA_X]R2 ;,VAW,J_.;$M_$O\
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MG_'O\R_Z)]E^<A/G-B6_C3_GI;/W';VQP ._U7(!M3;'SB(/G-F6_P"6T/\
M?MV_B3MS2\(IR# (3]H9;8[C:D_\O%O_ 'X6_B3MDTS_ %'S*#:_9CYA$7SF
MR+?\M8_^>EL_=>WMCAW^JY ^S&W/G$0?.;,M_P MH?[]NW\2=N: $(\O*/\
MNA'_ *3_ *+\WD9_Y>;?^]$<_.G;)_%O^KRCC:%_TDBTY\O/_+U;>J'/SQ]L
MGKGF0X12,>0(3]H9;8[C:D_\O%O_ 'X6_B3MDTTCR\HX,0C_ -(_T7GR,_\
M+S;_ -Z,Y^=.V3^( W[ORL./^/G_ $3M_P!/5M[<_/'[GKGYE_V6&Y6_TG_1
M._\ T]6WOS\\?N>N?F0_N\HX*A?])(M.?+S_ ,O5MZH<_/'[GKGE?NY5@<?\
M?.+3M_T]6WMS\\?N>N?F %*F0GCS&D_TDBT./.Q_R]6WI(/XD[^^>3_7]A,T
MO^D$6IV_:,?\O-O_ '9E_B3O_-.F58;E/^D_Z)W_ .GJV]^?GC]SUS\RE3(3
MP)&?_22+0X\['_+U;>D@_B3O[YY '?\ 'QGI.T_[\BV^7[5M_P"7B#^Y.O\
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MG['^'VQ\LO3N;*:T/^^;,M_Z,MW_ $]L< $7^H^9<VOV7]X1%\YLBW_+2/\
MYZ6S]U[>V.%_U/(S:FV_>D0_/]C+?\MHO^>EN_\ $O;VQPT_Z.20&LS:'<RK
M\YL2W\2_\]+9^X[>V.%_U'S+FU^R_O"(OG-D6_Y:1_\ /2V?NO;VQP 2(_V?
M/R^0L)\]TMSO^R[O^6\']^!OXE[<T21B)<@>7'&?M!%K\QMR?^7BW_O1'/S)
MVR?Q9_J>5'V7[-^](A^<V>[_ );1?\]+=_XE[>V.'H_V?/R^0L/[]TMSO-KN
M_P"7B#^_ W\2]N: (R/+RK#8$_TG_1.?*S_R\VWJAS\\?.,GUY:?ERC\*/\
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MWG[V+%RMS^]98?E%WM_Y;1?W)U_B7OBFNBW"F1 +I;D>8RQ?)]KV_P#+6/\
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M7 \E6G^07H7_ )8S?W)U_A?OBD_X^._GM-_HX-S\GVK;_P N\_\ <G7^%^]
M'&?$]XCX$NI)S=M'YL,+2CB1E60$P3CLZ]5?N/KS[7IVPZ9:&(,(_)3:&.2!
MM&,^]>)?%5PWP^OI3)<%F>*$3%?F?:X_<W [2)U#=Q7M>E?\@>R_Z]X__010
M!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K$\*?\@(_]
M?EW_ .E$E;=8GA3_ ) 1_P"OR[_]*)* -NBBB@ HHHH PO"W_'MJ7_83NO\
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M!NADP$_\NUQ_>C.?E?W'X@!)'Y&.?(6']PCW'S_9=W_+O/\ WX&_A?MQ4?\
MJ?E8_9?LW[H&;YS9EO\ EC+_ '[=_P"%NWMCB<'[-\K?NXD_T<-<_-]GS_R[
MS_WHF_A?MD?BQT\C'S>0L)\A'N/G^R[O^7>?^_ W\+]N* (_]1\K?Z)]E_=@
MR_.;(M_RSD_YZ6S]F[>V. ?Z.0"39FT.T,WSFQ+?PM_STMG['^'VQ\I_J?E8
M_9?LW[H&;YS9EO\ EC+_ ,]+=_X6[>V.#_4?*Q^R?9?W8,OSFR+?\LY/^>EL
M_9NWMC@ E^[ZV4UH?]\V9;_T9;O^GMCB$YMR2 UF;0[F5/G-B6_B7_GI;/W'
M;VQP#_1R 2;,VAV@O\YL2W\+?\]+9^Q_A]L?+-T];*:T/^^;,M_Z,MW_ $]L
M< $7^H^9<VGV7]X1%\YLBW_+2/\ YZ6S]U[>V.%_U/*C[+]F_>D0_.;,M_RV
MB_YZ6[_Q+V]L<*D?E%@-UE):G=M7Y_L1;^)?[]L_<=O;'#2#;Y(!M#:GS"L?
MSFR+?\M(_P#GI;/W7M[8X )$?[/GY?(2']^Z6_S_ &4M_P O$']^!OXE[<T2
M1B)<C,<<9^T$6OS&W)_Y>+?^]$<_,G;)X]6?ZG)7_1?LW[TB'YS9[O\ EM%_
MSTMW_B7M^'#T?[/N^7R%A_?.EO\ /]EW?\O$']^!OXE[<T 1$;/E8; G^D_Z
M)SY6?^7FV]4.?GCYQD^O*$;<HP(4?Z3_ *)SL_Z>K;U4Y^>/GJ>N>9I(Q$N1
MF../_2"+7YC;D_\ +Q;_ -Z(_P 2=LGCUB(V?*PV!/\ 2?\ 1.?*S_R\VWJA
MS\\?.,GUY )?]</+D&9#_I(-H?O^ES;'UY^9/?OGEC*S,P*[W?\ TEEM>/-Q
M_P O5MZ./XT[^^>6$;<HXPH_TG%H<[?^GJV]5.?GCYZ]\\S?ZX>7(/WG_'R#
M:G[_ /T\VQ]>?F3W[YY (_\ 7= )6E_TDBU^7S\?\O-O_=E'\:=^?Q<K-+NV
MXF:<>>RVWRBZ _Y>(/[LR_Q)WI&5F9@5WNW^DLMKQYN/^7JV]''\:=_?/*?Z
M[.,2M*/M)%K\OGX_Y>;?^[*/XT[_ ,P!Z.96RNVY:X'G,L'R"]"_\MH?[DZ_
MQ)WQ3G1;A2Z 72W/[QEB^3[7M_Y:Q_\ /.X3'*\9Q^4?^OZ8G:8?:"+;Y?M6
M/^7BW_N3+_$G>G(YE;*XN6N!YS+!\@O0O_+:'^Y.O\2=\4 1_P"MX_X^UNAN
M^3Y!>A?XEZ>7<ICD<9Q^2?ZSM]L6['^X+X+W[>7<ICVSC\IW1;A2Z 72W/[Q
MEB^3[7M_Y:1_\\[A,<KQG'Y0_P"MXXNUNAN^3Y!>A?XEZ>7<ICD<9Q^0!*CB
MY41R$7:W0VH[?(+P+_"W3R[E,<'C./R=_K?W,V+H7/R*TGR"\V_P/_SSN$QP
M>,X_*O\ ZSTO%NQG^X+X+W[>7<ICVSC\ID87*B-R+M;H;4=OD%X%_A;_ )YW
M*8X/&<?D .'[W]U+BZ%S^Z5I?D%V%_Y92?W+A<<-QG'Y,=3(VUBMPUP/)5KC
MY1> ?\L)_P"Y.O\ "_>G_P"M_<RXNA<C8K2?)]LV_P #_P#/.X3'!XSC\@'S
M?W4N+E;D>4K2_(+L+_RRD_N7"XX;C./R (U8R,&#>:\O^C@W/R_:<?\ +M<?
MW9E_A?O_ #D_U_[V([Y'_P!'(NN/.Q_R[7'I(/X7[\=<\L=3(P5B+AK@>2K7
M'RB\"_\ +"?^Y.O\+]\4BL9&!5O->7_1P;H;?M&/^7:X_NS+_"_?^8 \@3CS
M(_F<C[,1=#'F>MM<#LW/RO[CKGF <8=#\O\ Q[?Z7V_Z=;GVY^23W'7/S6/]
M?^]B^>1_]'(NN/.Q_P NUQZ2#^%^_'7/*$"<>9'AG(^S$77'F>MM<#LW]U_I
MUSR 0@[,,IVA?]&_TOG9G_EUN?53GY).>HZY^:6.01K@G9&A^S W7S& G_EV
MN/[T9S\K^X_&$?+AU/R_\>W^E]O^G6Y]N?DD]QUS\RCY,,IVA?\ 1O\ 2^=F
M?^76Y]5.?DD]QUS\P!8!^RX5CY<4?[A6N/F^S9_Y=Y_[T3?POVXIDB?9\?,8
M%@_<H\XW_9-W_+";^_ W\+=J(Y!&H!.R-#]G!NADP$_\NUQ_>C.?E?W'XO!^
MRX5CY<49\A6N/F^S9_Y=Y_[T3?POVR* (/\ 4\-FU-M^Z!F^<V9;_EE+_P ]
M+=_X6[>V.$_U'RMFT^RG8#)\YLBW_+.3_GI;/V;M[8XED3[/CYC L'[E'G&_
M[)N_Y83?WX&_A;MQ4?\ J>&S:FV_= S?.;,M_P LI?\ GI;O_"W;VQP -!-L
M0#FS-H< M\YL"W\+?\]+9^Q[>V/E4_Z-DC-G]D.2!\YL2W<?\]+9^X_A]L?*
M?ZCY6S:?93L!D^<V1;_EF_\ STMG[-V]L< )MB <V9M#@,QWFP+?PG_GI;/V
M/\/MCY0 _P"/?YE_T3[*=Y"?.;$M_&G_ #TMG[CM[8X7_499<VOV4^:1%\YL
MBW_+6/\ YZ6S]U[>V.$Q]FY -F;0Y('SFQ+=Q_STMG[C^'VQ\I_Q[_,N;3[*
M=Y"?.;'=_&G_ #TMG[CM[8X '?ZKD9MC;?OB(/G-F6_Y;0_W[=OXD[4I 0$8
M, @_TAEMOF-J3_R\6_\ ?A;^).V3Q3?]1\RYM?LQ\TB'YS9%O^6L?_/2V?NO
M;VQPO^JR1FV-M^^(@^<VA;_EO#_?MV_B3M0 A'EY1QY0C_TG_13N\G/_ "\V
MW]Z,Y^=.V?S:1Y>4<;0O^DD6ASY>?^7JV]4.?GCYZGUYD(" \& 0?Z0RVWS&
MU)_Y>+?^_"W\2=LGBF$>7E''E"/_ $G_ $7GR<_\O-M_>C.?G3MD_B 'W<JP
MX_X^?]$/3_IZMO;GYX_<]<_,>JL-P;_2?]$[_P#3U;>_/SQ^YZY^9,;,HZ[5
M7_22+0Y\O/\ R]6WJIS\\?/4^O)]W*L/E_X^?]$/3_IZMO;GYX^>IZY^8 <P
M,A/ D:3_ $DBTX\['_+U;>D@_B3O[YY,^?\ ]-FE_P!((M?E^TX_Y>;?^[,O
M\2=^?Q3U5AN#?Z3_ *)W_P"GJV]^?GC]^^?F5@9">/,:3_22+0X\['_+U;>D
M@_B3O[YY '?\?'0>>T_[\BV^3[5M_P"7B#^Y.O\ $G>DQ]HY %PUQ^^(@^07
MFW_EO#_<N%_B3OBDSY_;SFE_T@BU^7[3C_EYM_[LR_Q)W_F[_CX[>>T_[\BV
M^3[7M_Y>(/[DZ_Q)WH ;_P ?&?E6Z-R/,98OD%\%_P"6L?\ SSN$QRO&<?DG
M^M]+M;L9^7Y!>A>XZ>7<ICIQG'_?+B/M'( N&N!YQ$'R"\"_\MH?[EPO\2=\
M4G_'QGA;HW(\QEB^07P7_EK'_P \[A,<KQG'Y "?ZWTNUNA_N"]"_EY=RF/;
M..W\)_K?2[6Z&WYOD%Z%_A;IY=RF.O&<?]\I_K?2[6Z&?E^07P7N.GEW*8Z<
M9Q[?*O\ K?2[6Z'^X+X+^7EW*8]LX[?P@$J.+A1'(PNEN1Y:/)\@O O_ "SD
M_P">=PF.#QG'Y(RF5MK8N6N!Y(:?Y!>!?^6,W]R=?X7[XJ/_ %O_ $^+=#;\
MWR"]"_PMT\NY3'!XSC\I4<7"B.0BZ6Y'EH\OR"\"_P#+.3^Y<)C@\9Q^0!Q/
MQ6D#?#V^E,MP2\D40G*X:7:X_=7"]I4[-_$*]JTK_D#V7_7O'_Z"*\7^+#$?
M#^^=IIF,CQ1BXV_\? 5Q^[G'\,J=F[@&O:-*_P"0/9?]>\?_ *"* +=%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8GA3_ ) 1_P"OR[_]
M*)*VZQ/"G_("/_7Y=_\ I1)0!MT444 %%%% &%X6_P"/;4O^PG=?^C#6[6%X
M6_X]M2_["=U_Z,-;M !1110 4444 %%%% !1110 4444 %%%% !1110!ROQ'
MM%U#P#J=F[,JS^5$2O4!I4'&:YS1 )O#VFO$Z2LUG%;$SKM6;Y!_H\XQPW]Q
M\=QZ\]9XXY\)70QG]Y!Q_P!MDKE=$_?Z!ILT+I,[VL5N3,-JSX0?Z/./X7'\
M#_3\0";IAE.5/^C9N^__ $ZW/Y_))[CKGYC[F'0X4?Z,#=\[?^G6Y]5.?DD]
MQUSS.0)QYD?S.W^C$78QYG_3M<>C#^%_YYY8D>]=T;;C_P >P6['4?\ /K<^
M_/R/[CDY^8 =%($4 DI&G^C W7)@)_Y=KC^]&<_*_N/Q>#]FPK'RXD_<!KGY
MOL^?^7>?^]$W\+]LC\:WW,.APH_T8&[YV_\ 3K<^J\_))[CKGF:*01J 3LC3
M_1@;KYC 3_R[7']Z,Y^5_<?B *Z" KEC D)\A'G^8VN[_EWG_OP-_"_;BDDC
M^S8^8VZ0'RD>8;S9EO\ EC-_?MV[-VX_!X/V;"L?+C3]P&N?F^SY_P"7>?\
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MC./R:8UN(]R 7BW(W.J_)]M"_P :=/+N4QR.,X_( 576Y41N1=K=#:KM\@O
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M +"=U_Z,-;M87A;_ (]M2_["=U_Z,-;M !1110 4444 %%%% !1110 4444
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M?/(!UZM]FPK9BBC/D*UR-WV;/_+O/_>A;^%^V13'3[/CDVZP'R4><;OLA/\
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MTN;8^O\ >3W/7/+O]=^ZE&Z1O](!M>/-Q_R\V_HX_B3Z]<\US\N4?A1_I/\
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MZQOD_).N./7'UQ6T7095AM;6\M;62VMY)XK..1LB\&]ML<I_Y93HIPIZY^E
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MZ_\ ZZ]DMI?/M89@01(@;(Z<C- $M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5B>%/^0$?^OR[_P#2B2MNL3PI_P @(_\ 7Y=_^E$E &W1110
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M\QM"?^7B#^]"W\2=LF@",DJ-LA*A1]I_T4Y\O/\ R]6WJAS\\?;)ZYY=)(7
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MP^28P<X_X _YFI-+:[U#5Y[I='N(K"\M54P3LBFX:-CCRMIRDJ D@''0CCJ
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M<VGV4^81'\YLBW_+1/\ GI;/W';VQPO^H^9<VOV8^:1#\YLBW_+6+_GI;O\
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M<ICAN,X_)SH96PV+EK@>2K3_ ""]"_\ +&;^Y<+_  MWQ^0 BL796!\UY/\
M1P;KY?M&/^7:X_NRC^%^_P#.3_78EB.Z1O\ 1R+KCS<?\NUQZ./X7[^^>8O^
M/CKB=IA]G!N?E^U;?^7>?^Y.O\+]Z56+L&!\UY/]'!NOE^T8_P"7:X_NRC^%
M^_X\@#N)QYD9!<_Z,1=#[_\ T[7(]?[K^_?/,(.W#H<+_P >W^EC.W_IUN?;
MGY)/?OGYK'^NQ+$=\C?Z.1=<>;C_ )=KCT<?POW]\\M.)QYD9RY_T8BZ'W_^
MG:Y'KS\K^_?/(!%G9\RG:%_T;_2^?+S_ ,NMSZH<_))VR.3GE0?*PR$QB/\
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M9;O^64G_ #TMG[-V]L< #03;':Q-F;0X!/SFP+=C_P ]+9^Q_A]L?*IS;$D
MV9M#N(7YS8EOXE_YZ6S]Q_#[8^4_U'RL3:?93L!D^<V);^!_^>EL_8]O;'"
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MC^%^_OW '?ZX>9&<N?\ 1B+H??\ ^G:Y'KS\K^_?/,(.W#J?E_X]O]+YV_\
M3K<^HY^23GKWS\UC_78EB.Z1O]'(NN/-Q_R[7'HX_A?OQUSRF//'F1\R'_1B
M+H??];:Y'KS\K^XZYY (0=F&4[ O^C?Z7SY>?^76Y]4.?DDYQD>O*Y\OYT/E
MB/\ T;_2N?)S_P NUS_>C.?DDYQD?BT?+AU/R_\ 'M_I?.W_ *=;GU'/R2<]
M1US\RCY,,IVA?]&_TOGR\_\ +K<^J'/R2<XR/7D FBD$(P288HC]G!N?F-J3
M_P N\_\ >A;^%^V1221_9L?-]G6#]RKS_/\ 9-W_ "QF_OV[?PMVXJ,'R\,I
M\L1_Z-_I7/DY_P"7:Y_O1G/R2<XR/QECE$*X),,41^S@W(W&T)_Y=Y_[T+?P
MOVR* (O]3\K$VGV8^6#+\YLBW_+*3_GI;/V;M[8X3_4?*V;3[*=@,GSFQ+?P
M/_STMG['M[8XED3[-CYOLZP?N4><;_LF[_EC-_?MV_A;MQ4?^IX;-K]F_=@R
M_.;(M_RRD_YZ6S]F[>V. !H)MCM;=9FT. 3\YL"W8_\ /2V?U_A]L?*I!MB2
M ;,VAW%5^<V);^)?^>EL_<?P^V/E/]1\K9M/LIV R?.;$M_ _P#STMG['M[8
MX0$VQVG=9_9#@$_.; MV/_/2V?U_A]L?* +_ *CYE_T3[+\Y$?SFR+?\M$_Y
MZ6S]QV]L<+_J?F7_ $7[-^](A^<V1;_EK%_STMW_ (E[>V.$(-MD@&S-H=Q5
M?G-B6_B7_GI;/W'\/MCY3_499?\ 1/LIWD1_.;(M_P M$_YZ6S]U[>V. !W^
MJY ^S&W/GL+?YS:%O^6\/]^!OXD[<T]'\C.!Y*Q?OW2V^;[/G_EXM_[\+?Q)
MVR?QC_U&67_1?LQ\TB'YS9%O^6L7_/2W?^)>WMCA?]5DC_1C;_OB+?YS:%O^
M6\']^!OXD[4 # *&&TQ+&?M++:G<8,]+FV/\49_B3MD_CA^$3]@^..I0F&*)
M=0TA)PT!S%.P<?O$] 1DX['-;G^KY'[@P?Z01;?/]FW?\O%O_?A;^).W-<UO
M33_C7X7F*"'[7:SQ,D;9@8D%@\1_N-UQV.: /9Z*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K$\*?\ ("/_ %^7?_I1)6W6)X4_Y 1_Z_+O_P!*
M)* -NBBB@ HHHH PO"W_ ![:E_V$[K_T8:W:PO"W_'MJ7_83NO\ T8:W: "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /,_CM_R3H?>_X_X/N]>IZ5?/[X^3-BZ%R-JLWR"\"_PG_GG<)CKQG'Y4/C
MM_R3H?>_X_X/N]>IZ5>#"Y'ER$72W0^5ON"\"_EY=RF/;./^^0!0?-_<S'[4
M+D;%:3Y!>!?X'_N7"8X/&<?DQE,C;6Q<M<#R@9OD%Z%_Y8R_W+A?X6[X_)W^
MN_<S?Z4+D;59OD%X%_A;_GG<)CKQG'Y+_K?W,V+H7(V*TGR"\"_\LW_N7"8X
M/&<?D ,5C*P93Y[S?N ;CY/M>W_EWG_N3K_"_>G_ .O_ 'T.)'D_T<BY^7[1
MC_EWG_NRK_"_?^;&4R-M;%RUP/*!F^07H7_EC+_<N%_A?OC\A6,K!E/GO-^X
M!N/D^U[?^7>?^Y.O\+]Z '_Z[][$0[M_HY%UQYN/^7:X]''\+_SSRA F'F1X
M9R/LQ%U_'_T[7'HW/R/[CKGYG?Z_]]"1(\G^CD7(V_:,?\N\_P#=E7^%^_\
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MH<<_.;/=V/\ STMG]>WMCY8O]1\K$VOV;]T#-\YLBW_+*7_GI;O_  MV]L<
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M;=N\3Y^[V- 'N=%,B<2PQR Y#J&!^M/H **** "BBB@ HHHH **** "BBB@
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M%T+D;%:3Y!>!?^6;_P!RX3'!XSC\F,K2-M;%RUP/*#3?(+T+_P L9?[EPO\
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M^7>X_NRC^%^_\S_7?O8CO=_]'(NACS<?\NUQZ./X7_GGD K_ '<,IX_X]O\
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M(NQ=#Y6^X+T+^7EW*8]LX_[Y7_7?N9L70N?E5F^07@7^%NGEW"8Z\9Q^4/\
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M;_\ T+-;]KHNE6!S9Z996_\ UQ@5/Y"KU% !C'2BBB@ HHHH **** "BBB@
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M>'S8Y\Y&^2Z8EDW A>5X/'.<CV[UT_A_2+_3]5NYYXXX[>6-0JB8N<C& .
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %8GA3_D!'_K\N__ $HDK;K$\*?\@(_]?EW_ .E$
ME &W1110 4444 87A;_CVU+_ +"=U_Z,-;M87A;_ (]M2_["=U_Z,-;M !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5B>%/^0$?^OR[_ /2B2MNL3PI_R C_ -?EW_Z424 ;=%%% !1110!A
M>%O^/;4O^PG=?^C#6X0&!!&0>"#6'X6_X]M2_P"PG=?^C#6[0!S^BSKH[+H%
MX^QHR192.>)XL\ '^\N<$>P/>G:9G_A,->_ZY6O_ *"]:]Y96NH6S6]Y;QSP
MMU21<BL=?!>B+/)*(;H^:%#H;V8JP'0$;\$#T/% #=0FCU^^CTFU(EM895DO
MI5Y0;3D19[L2!D=@#GJ*Z&HK>V@M(%@MH8X84&%2-0H'X"I: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q/"G_("/_7Y=_\
MI1)6W6)X4_Y 1_Z_+O\ ]*)* -NBBB@ HHHH Q9/"FD27$TWE7*/-(9)/*O)
MHU+'DG:K@<_2F_\ "):1Z7W_ (,;C_XNMRB@##_X1+2/2^_\&-Q_\71_PB6D
M>E]_X,;C_P"+K<HH P_^$2TCTOO_  8W'_Q='_"):1Z7W_@QN/\ XNMRB@##
M_P"$2TCTOO\ P8W'_P 71_PB6D>E]_X,;C_XNMRB@##_ .$2TCTOO_!C<?\
MQ='_  B6D>E]_P"#&X_^+K<HH P_^$2TCTOO_!C<?_%T?\(EI'I??^#&X_\
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M^#&X_P#BZA\0W-RFI:?;1:@;*.;?ODXP,#C.:R6UG4+C3=/!O_(+WCP/<J
MRCHW/%-*X[&Y_P (EI'I??\ @QN/_BZ/^$2TCTOO_!C<?_%UD#6;\Z8G^EF1
MH]16W%PJ@>:E3QZU=6_B;48IYF:U1'\M3C"LJAOY4A&A_P (EI'I??\ @QN/
M_BZ/^$2TCTOO_!C<?_%UST6L:F?#TTTM\Z3?:T3S"!\BL,^GO75:&'-B7;4_
M[05G)67:!CVXIV K?\(EI'I??^#&X_\ BZ/^$2TCTOO_  8W'_Q=8FH:K?P7
M^J3)JOE_9)5$5JP4B0'J!WIVJ:I?IJ-\Z:G]E%O!'*D# $.Q ROK2#K8V?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
A10 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g5lvsimk4gaq000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5lvsimk4gaq000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $P J # 2(  A$! Q$!_\0
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M*4"F3<N:3H]_KM\+'38?.N2C.$+!?E49)R:HG(/Z&NZ^$O'CV/\ Z\KG_P!
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M;2JD_P JKC&8_P"Z??ZTY_$Y,,\2VC#A%MG:3+1  *Q)[EE'YU7_ .$7U?\
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MC3_H%+_X$)_C67LZ)NJN([&';:K!!=ZC,T5RZW<+Q!1(JD;NYXP<8K(KM/\
MA57C/_H%+_X$)_C1_P *I\9_] E?_ A/\:UBZ<=F8SC5GNCBZ*[/_A5/C/\
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MM*U:721=- BF:9 J.W(0@YSBNC_X5-XS_P"@7'_X$I_C2_\ "IO&7_0+C_\
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MO;O3DCMX$,DC"=3@#VKE,4U)/8B490^(913\48JB+BT4_ ]*,#TJK$7&44_
M]*,#THL%QE%/P/2C ]*+!<913\#THP/2BP7&44_ ]*,#THL%QE%/P/2C ]*+
M!<913\#THP/2BP7&44_ ]*,#THL%QE%/P/2C ]*+!<913\#THP/2BP7&44_
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M*+!<9S1S3\48HL%QG-'-/Q1BBP7&<TN33L48HL@N,YHI^*,46"XS%&*?BC%
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M@=UVZRER_.<#T%=#KGBVSTS6+>XL=.M+J]CL(XX[P2D^7E>00."17GF3G-(
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>gqr1p20dfppl000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqr1p20dfppl000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,H G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7EVL(E6(0Q*"C,80Q5AG( .X[L>@SBJ [JBBB@84444 %%%% !1110 4444
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M85_[[9E)WGGCIR:U[+PO=P^&;KP]-J"FP^PQV-HR1C>BB/8SMZL3SCH,#UH
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M*C_YYI_WR*/9ASGU-_PG7A+_ *&?1_\ P-C_ ,:/^$Z\)?\ 0SZ/_P"!L?\
MC7RSY4?_ #S3_OD4>5'_ ,\T_P"^11[,.<^IO^$Z\)?]#/H__@;'_C1_PG7A
M+_H9]'_\#8_\:^6?*C_YYI_WR*/*C_YYI_WR*/9ASGU-_P )UX2_Z&?1_P#P
M-C_QH_X3KPE_T,^C_P#@;'_C7RSY4?\ SS3_ +Y%'E1_\\T_[Y%'LPYSZF_X
M3KPE_P!#/H__ (&Q_P"-'_"=>$O^AGT?_P #8_\ &OEGRH_^>:?]\BCRH_\
MGFG_ 'R*/9ASGU-_PG7A+_H9]'_\#8_\:/\ A.O"7_0SZ/\ ^!T?^-?+/E1_
M\\T_[Y%'E1_\\T_[Y%'LPYSZF_X3KPE_T,^C_P#@;'_C1_PG7A+_ *&?1_\
MP-C_ ,:^6?*C_P">:?\ ?(H\J/\ YYI_WR*/9ASGU-_PG7A+_H9]'_\  V/_
M !H_X3KPE_T,^C_^!L?^-?+/E1_\\T_[Y%'E1_\ /-/^^11[,.<^IO\ A.O"
M7_0SZ/\ ^!L?^-'_  G7A+_H9]'_ / Z/_&OEGRH_P#GFG_?(H\J/_GFG_?(
MH]F'.?4W_"=>$O\ H9]'_P# V/\ QH_X3KPE_P!#/H__ (&Q_P"-?+/E1_\
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MOX%_=CDCD\4<J[A<]K_X3KPE_P!#/H__ (&Q_P"-'_"=>$O^AGT?_P #8_\
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MFOJZOE'Q3_R.OB+_ +"=Q_Z&:TI[DRV,JBBBMC,**** "BBB@ HHHH ****
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M^?B'_OX*/M=M_P _$/\ W\%?2G]AZ/\ ] C3_P#P%C_PH_L/1_\ H$:?_P"
ML?\ A1[0.0^:_M5M_P _$/\ W\%'VJV_Y^(?^_@KZ4_L/1_^@1I__@+'_A1_
M8>C_ /0(T_\ \!8_\*/:!R'S7]KMO^?B'_OX*/M5M_S\0_\ ?P5]*?V'H_\
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M+Y,FY3Y@X^]\N.>,%ACF@"M_PA[?]#)K?_?R'_XW1_PA[?\ 0R:W_P!_(?\
MXW73#I10!S/_  A[?]#)K?\ W\A_^-T?\(>W_0R:W_W\A_\ C==-10!P6CZ%
M=7^I:Y;S>(]8"6-Z((MKP@[3#&_/[ODY<_I6O_PA[?\ 0R:W_P!_(?\ XW3O
M#/\ R&_%7_837_TFAKI* .9_X0]O^ADUO_OY#_\ &Z/^$/;_ *&36_\ OY#_
M /&ZZ:B@#F?^$/;_ *&36_\ OY#_ /&Z/^$/;_H9-;_[^0__ !NNFHH YG_A
M#V_Z&36_^_D/_P ;H_X0]O\ H9-;_P"_D/\ \;KIJ* .9_X0]O\ H9-;_P"_
MD/\ \;K&.AW0\9II'_"1ZQ]F;3VN2=\.[>) O7R^F#7?US+?\E/B_P"P,_\
MZ.6@ _X0]O\ H9-;_P"_D/\ \;H_X0]O^ADUO_OY#_\ &ZZ:B@#F?^$/;_H9
M-;_[^0__ !NC_A#V_P"ADUO_ +^0_P#QNNFHH YG_A#V_P"ADUO_ +^0_P#Q
MNC_A#V_Z&36_^_D/_P ;KIJ* .9_X0]O^ADUO_OY#_\ &Z/^$/;_ *&36_\
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MK_L)K_Z30UTE !1110 4444 %%%% !7,M_R4^+_L#/\ ^CEKIJYEO^2GQ?\
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MAJT="UK7]0N9AJ&D-9PI 95RARQ. J<G[P*R$^Q3UH L_P#"6V__ $"=<_\
M!9+_ (4?\);;_P#0)US_ ,%DO^%9EEXCUTV6ZZTN?S7F*1?Z(^2,Q8+ ?=P'
MDYZ?)^<%EJWBF&&SBGA:>< ;P]HP\UO-97!8'";$"L#T;/% &U_PEMO_ - G
M7/\ P62_X4?\);;_ /0)US_P62_X52;4?$EM#++<(LRA#M6WLVW [$;/+'."
MS+C_ &?7BJFG:AXFN7,]];S*3!!)';+$R#>&D#_-GOA"5/\ >% &Q_PEMO\
M] G7/_!9+_A1_P );;_] G7/_!9+_A5>;5=<3PW;7=G;&[O7D$<D<EJT6"P(
M!VDY"JY7<?[H8U3_ +9\3W4ENHLEM!-$[!7@<G.2H7."%88##=@'<!0!J?\
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M[6^YHV_=.TC[VE&X-GY0H5"!@_>],53_ +3\3QVD,YM&AN61(9]T3ND&#)R
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MG_@LE_PKH** .?\ ^$MM_P#H$ZY_X+)?\*/^$MM_^@3KG_@LE_PKH** .?\
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M9!>> 8)_.'B73GD\M8\OJ2'A2A'?_IFGY>YH Z)/%.AN$(U&(!R FX%=V0[
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MW\)_]#-H_P#X&Q_XT?\ ";^$_P#H9M'_ / V/_&@#>HK!_X3?PG_ -#-H_\
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M$_\ H9M'_P# V/\ QH_X3?PG_P!#-H__ (&Q_P"- &]16#_PF_A/_H9M'_\
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M]');U*+0!K#PGX=2R_LY=/@2$.)UC1RI5@NT,"#D?+\O';BFMX0\-W:7$O\
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MOK&GQW5O)&VY<NJ,3L/(P<@'J#U Z5R'VGQAA1]F\*_*I4?)/P#U'3I3TO\
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MC_"C^U/'/IX:_P#)C_"@#N**X?\ M3QSZ>&O_)C_  H_M3QSZ>&O_)C_  H
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M6?\ P4W'_P 17H%% 'G_ /PE%C_SYZS_ ."FX_\ B*/^$HL?^?/6?_!3<?\
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M<$I^\=\X(()S(XY!X-:-[X1TR^\@R><C6]NEO"T3[#&$=)$88& P9%([<=*
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M_P#Z.6@#IJ*** "BBB@ HHHH **** .7\7_\A'PK_P!AE/\ T1-745R_B_\
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M[J3QN?(1Q&SK80L Q8*!P.N2!5!=1NW1F3QQ<-A@JJ-(3+Y?8-@VY8;N,C-
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MA(54,0EE Q /0_0U@_#[2=>G^'^ARVWB:2WA:T0I"+&)M@],GDT >DT5S?\
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ME%<W_8GB3_H;Y/\ P7P_X4?V)XD_Z&^3_P %\/\ A0!TE%<W_8GB3_H;Y/\
MP7P_X4?V)XD_Z&^3_P %\/\ A0!TE%<W_8GB3_H;Y/\ P7P_X4?V)XD_Z&^3
M_P %\/\ A0!TE%<W_8GB3_H;Y/\ P7P_X4?V)XD_Z&^3_P %\/\ A0!'XO\
M^0CX5_[#*?\ HB:NHK@=;T[5[36O"TE_KKW\1U=0(C:QQX/DR\Y7G\/>N^H
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MK45D_P#"4>'_ /H.Z9_X%Q_XT?\ "4>'_P#H.Z9_X%Q_XT :U%9/_"4>'_\
MH.Z9_P"!<?\ C1_PE'A__H.Z9_X%Q_XT 4?#/_(;\5?]A-?_ $FAKI*XGP[X
MAT2+6?$[R:SIRK)J2LA:Z0!A]GA&1SR,@C\*Z#_A*/#_ /T'=,_\"X_\: -:
MBLG_ (2CP_\ ]!W3/_ N/_&C_A*/#_\ T'=,_P# N/\ QH UJ*R?^$H\/_\
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MM<#,[1+_ *9'@,BY89\O P,_K0!:CUVQ:?R7\/Q!HYEBN&4QLD>YD"D'^/\
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M_$O_ (&)_P#$4?\ "%R?]#9XE_\  Q/_ (B@!GANPLGUKQ0&L[<A=24*#$O
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M?_ Q/_B* -_^S+#_ )\;;_OTO^%']F6'_/C;?]^E_P *P/\ A"Y/^AK\2_\
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M+0+.1H $A\S5\^7& X"#$ R!O;D\^]82>.H0EOYOB-7D2Z7<RK.H\E&4 D;
M"74.6!S@D >H;#XSL(!:11>(I56+C>6F8 ^:2Q8%,N&3  _A.>G6@#NO[1\8
M?]"YIG_@U;_XS2_VCXP_Z%S3/_!JW_QFN5TGQ]HMGJ<9N=?EGM1:*DC3+,Y\
M[C) V=_FSD<8&.#@=!_PL_P=_P!!?_R5F_\ B* +7]H^,/\ H7-,_P#!JW_Q
MFC^T?&'_ $+FF?\ @U;_ .,U5_X6?X._Z"__ )*S?_$4?\+/\'?]!?\ \E9O
M_B* +7]H^,/^A<TS_P &K?\ QFC^T?&'_0N:9_X-6_\ C-5?^%G^#O\ H+_^
M2LW_ ,11_P +/\'?]!?_ ,E9O_B* +7]H^,/^A<TS_P:M_\ &:/[1\8?]"YI
MG_@U;_XS57_A9_@[_H+_ /DK-_\ $4?\+/\ !W_07_\ )6;_ .(H M?VCXP_
MZ%S3/_!JW_QFC^T?&'_0N:9_X-6_^,U5_P"%G^#O^@O_ .2LW_Q%'_"S_!W_
M $%__)6;_P"(H M?VCXP_P"A<TS_ ,&K?_&:/[1\8?\ 0N:9_P"#5O\ XS57
M_A9_@[_H+_\ DK-_\11_PL_P=_T%_P#R5F_^(H M?VCXP_Z%S3/_  :M_P#&
M:/[1\8?]"YIG_@U;_P",U5_X6?X._P"@O_Y*S?\ Q%'_  L_P=_T%_\ R5F_
M^(H M?VCXP_Z%S3/_!JW_P 9H_M'QA_T+FF?^#5O_C-5?^%G^#O^@O\ ^2LW
M_P 11_PL_P '?]!?_P E9O\ XB@"U_:/C#_H7-,_\&K?_&:/[1\8?]"YIG_@
MU;_XS57_ (6?X._Z"_\ Y*S?_$4?\+/\'?\ 07_\E9O_ (B@"U_:/C#_ *%S
M3/\ P:M_\9H_M'QA_P!"YIG_ (-6_P#C-5?^%G^#O^@O_P"2LW_Q%'_"S_!W
M_07_ /)6;_XB@"RVH^+]I_XIS3.G_05;_P",US?P^OO$\?P_T-+30M/FMQ:*
M(Y)-2*,P]2OE''YFMIOB=X/*D?VOU'_/K-_\17.^ ?B#X7TWP%HEE=ZIY=Q#
M:JDB?9Y3@_4+B@#K?[1\8?\ 0N:9_P"#5O\ XS1_:/C#_H7-,_\ !JW_ ,9J
MK_PL_P '?]!?_P E9O\ XBC_ (6?X._Z"_\ Y*S?_$4 6O[1\8?]"YIG_@U;
M_P",UA:[I7B'7KJVN+S1+2.6S&ZV,6LE?)?<I\P?N?O?+CGC!8=S6G_PL_P=
M_P!!?_R5F_\ B*XWQGXH\/Z[J6F75CJ<!6RRTRR13I]J7>A\@X3A3M+9.1E5
M&,$T =W_ &CXP_Z%S3/_  :M_P#&:7^T?&'_ $+FF?\ @U;_ .,U5_X6?X/_
M .@O_P"2LW_Q%'_"S_!W_07_ /)6;_XB@"U_:/C#_H7-,_\ !JW_ ,9H_M'Q
MA_T+FF?^#5O_ (S57_A9_@[_ *"__DK-_P#$4?\ "S_!W_07_P#)6;_XB@#*
M\/WWBE=7\2&'0=/=VU!3*&U,@(WD1< ^4<C&#GCJ1VK?_M'QA_T+FF?^#5O_
M (S7,:#\0_"MMJWB*675=J7&H+)$?L\IW+Y$2Y^[QR"/PK=_X6?X._Z"_P#Y
M*S?_ !% %K^T?&'_ $+FF?\ @U;_ .,T?VCXP_Z%S3/_  :M_P#&:J_\+/\
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MD$JP[@Y!^H(!I;:V@L[=+>VB2*%!A408 H EHHHH 1ON-]*Y7X9_\DT\/?\
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M\$MS_P#$4 3;?'/_ #T\._\ ?$_^-&WQS_ST\._]\3_XU#_PL'3/^@7XA_\
M!+<__$4?\+!TS_H%^(?_  2W/_Q% $VWQS_ST\._]\3_ .-&WQS_ ,]/#O\
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M #T\._\ ?$_^-0_\+!TS_H%^(?\ P2W/_P 11_PL'3/^@7XA_P#!+<__ !%
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M$_[HHD"+9/)O#;<R%P0, E@1U&W-9T6C>#)[2QN(O#<3F])\J,6PWX'4D9P
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MTT. P2A?+F^R?(S,@<)G^]M.<4 >@=J*X.XL? 5M+*DFAVH,0<L?LX )5]A
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M!T-%<]_P@OA;_H V/_?H4?\ ""^%O^@#8_\ ?H4 =#17/?\ ""^%O^@#8_\
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M0KG?$6G^%_#^HZ;:'PG8SG4G\FW8%5_?97"MD<#:6.[_ &<8R10!Z'17/?\
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M"D?_ !VC^R?%G_0TV?\ X*1_\=KI:* .:_LGQ9_T--G_ ."D?_':/[)\6?\
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M_P#CM']D^+/^AIL__!2/_CM=+10!S7]D^+/^AIL__!2/_CM']D^+/^AIL_\
MP4C_ ..UTM% '*MX:UJ\U'3;C5/$$-S#87(N5ABT\1%F",HRV\\8<]JZJBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@!OF(9#&'7>!DKGD"G5QEQX;OW\1:QK,9
M7>&WV4:;4>5OLXC^:3J%SGY>.0#6-+-XBM-1T>ROKJ^3=(S$1MEF'G_(#@D-
M\F P).U<GK0!Z92!@PR""/4&N3T>P\2_V)?17=\Z7\R($,^&6)\?.RLK$D'M
MTQ@<=:@LM'UG3?!UKIT,)B:*]D,D5G.%<VYE=@$=N_*GJ#C(SF@#L/M$/V@6
M_FIYQ7>(]PW;>F<=<9[T\,#G!!P<'%<KHNC:M!J%YJ%W(?MLVFP0))+('42*
M92<@>FY,D=3G%6?"6D7NCP:E#>K%F6\,R/&Y;S,QH&8Y[E@QH Z*BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
%** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>gqr1p20dfppl000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqr1p20dfppl000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (6 S,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJG>/9=V3["N@T[69[SQ;JVFYC:TMK>WEA91R?,WYY[CY1BF]!<R#_A"O#?\
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MG:*$28'.5*@G!&!R."#72TP,'_A"O#?_ $![;\C1_P (5X;_ .@/;?D:WJ*
M,'_A"O#?_0'MOR-'_"%>&_\ H#VWY&MZB@#!_P"$*\-_] >V_(T?\(5X;_Z
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M'MOR-'_"%>&_^@/;?D:WJ* ,'_A"O#?_ $![;\C1_P (5X;_ .@/;?D:WJ*
M,'_A"O#?_0'MOR-'_"%>&_\ H#VWY&MZB@#!_P"$*\-_] >V_(T?\(5X;_Z
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M'MOR-'_"%>&_^@/;?D:WJ* ,'_A"O#?_ $![;\C1_P (5X;_ .@/;?D:WJ*
M,'_A"O#?_0'MOR-'_"%>&_\ H#VWY&MZB@#!_P"$*\-_] >V_(T?\(5X;_Z
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M'D[1MP/?\*]#HHH%8****!A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% & G_)0+C_L%Q_^
MC7K?K 3_ )*!<?\ 8+C_ /1KUOT %%%% !1110!@^"O^1,TK_K@/ZUO5@^"O
M^1,TK_K@/ZUO4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 8"?\E N/\ L%Q_^C7K?K 3_DH%Q_V"
MX_\ T:];] !1110 4444 8/@K_D3-*_ZX#^M;U8/@K_D3-*_ZX#^M;U !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%'09H **:CK)&LB,&1@"K#H0:=0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% & G_)0+C_ +!<?_HUZWZP$_Y*!<?]
M@N/_ -&O6_0 4444 %%%% &#X*_Y$S2O^N _K6]6#X*_Y$S2O^N _K6]0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6:*\DBT&^@A2*'7;F.-%"JB^: H'0#]]3_[&U+_H8+O\YO\ X]0!ZQ17D_\
M8VI?]#!=_G-_\>H_L;4O^A@N_P YO_CU 'K%%>3_ -C:E_T,%W^<W_QZC^QM
M2_Z&"[_.;_X]0!ZQ17C47A?58[Y[D^,=9D5L_P"CO*YB7/H!)GCZU=_L;4O^
MA@N_SF_^/4 >L45Y/_8VI?\ 0P7?YS?_ !ZC^QM2_P"A@N_SF_\ CU 'K%%>
M3_V-J7_0P7?YS?\ QZC^QM2_Z&"[_.;_ ./4 >L45Y/_ &-J7_0P7?YS?_'J
M/[&U+_H8+O\ .;_X]0!ZQ17CM[X:U2\1%7Q=JUIM.<VTDBEO8YD/%6O[&U+_
M *&"[_.;_P"/4 >L51N-8TZTU"&PN+N**ZF7<D;'!(SCZ=>/>O(]0@\4Z7J&
MGW&FW.HZE #)]IC@O/(<?+A<&5W4C))/R_PCI5[0;C4]4DU+4-164PW5K]BB
MM[R9)WC97;<VY%52,XQUZ=: /7*R[KQ!I]IJ4-A(\C3RR+%^[C+*C,"5#$<+
MG!QFO,H=?\5V/B"'2M2OSJ$MS9L]NUI(MJB!.'+!D<EN5P<X]JN0PZO_ ,(U
M#:W3O)J*:@;UIH[E5<G<<?/Y>.%('W>U 'JM%>7_ &OQ#_?U'_P;1?\ R/1]
MK\0_W]1_\&T7_P CT >H5F7.OV%GJ@T^=Y$EV(Y<QGRUWEE0%N@)*MC/I7G)
MUS5A?"P,NK_;"00O]IP[-NTMG=Y'7CIBKMA]O>35QJ:22PW]I';'SKL3. /,
MS@K&@ _><<'F@#N+77["]U/[!;M(\FQW63RSY;A&56VMT)!9>GK4NJZQ9Z/;
M>==N_(8K'&A=V"C)PHY.!S7 :S=7-K)I5Q:K-;V=A ;1OLMPL<@5WB5?O(P8
M#;TX^M-TF[O;U+F]N/M,D5Y8F"'[5=)*RALY(VQKM)XSUZ"@#TNUN8KRTANH
M&W0S1K(AQC*D9'Z&I:\6\,ZMKT^EM:)+J+2:9*;"5AJ42*SQ@ E1Y!^7D8R:
MV?M?B'^_J/\ X-HO_D>@#U"BO+_M?B'^_J/_ (-HO_D>C[7XA_OZC_X-HO\
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M^M;U8/@K_D3-*_ZX#^M;U !1110 4444 %%%% !1110 4444 %%%% !1110
M5YMXE_Y*3;_]>Z_^@35Z37FWB7_DI-O_ ->Z_P#H$U %NBBB@ HHHH ****
M"BBB@ HHHH *<G^L7ZBFTY/]8OU% '*^%+02^&RT;X\QYE(!(PWFMG_]=4+8
M>)K.V2WC\+^:-H!;^U8XN>.B@$"LW2-6O[/3WMGU.2VVSR[(UBMSM7>Q'WW#
M9.><BKQU^[)S_;DXXQQ#:?G_ *SK0!L>#)7FT_47DA:"3^T90\3-N*,%0$9[
M\@\]^M='7->"'N9=*OY;IM\LFHS-OP!O7"X/RDCIC.#C.:Z6@ HHHH ****
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M6D_F0^=;F/4,BY4=1'^[Y8=U.#5O3;P:CI=I?",QBXA6783DKD9Q0!:HHHH
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MH **** "BBB@ HHHH =O?^\WYT;W_O-^=-HH 4DDY))^M)110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 HZBN6\#_\ 'KKO_8<N_P#T
M(5U(ZBN6\#_\>NN_]AR[_P#0A0 ^^_Y*3HG_ &#KK_T)*Z6N:OO^2DZ)_P!@
MZZ_]"2NEH **** .>;_D>4_ZYC_T4]=#7/-_R/*?]<Q_Z*>NAH SM=_Y TW_
M %TA_P#1J4N@_P#(OZ?_ -<%_E2:[_R!IO\ KI#_ .C4I=!_Y%_3_P#K@O\
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MVAQ+>/;"XDFBO8VDF&XKEM^PGD$D\XR/6MC^T;X.V_1Y0@Z,+F$[N<#'S=Z
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M@7'_ &"X_P#T:];]8"?\E N/^P7'_P"C7K?H **** "BBB@#!\%?\B9I7_7
M?UK>K!\%?\B9I7_7 ?UK>H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^1?T_P#ZX+_*@#D- \*Z%K=YXBNM3TN"ZG76;B,2.6R%&T@<'W-;:_#WPB6
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M;KQW<RZAIYT^X\J0&W,RRX 2#!W+QS0!ZI1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!@)_R4"X_[!<?_ *->M^L!/^2@7'_8+C_]
M&O6_0 4444 %%%% &#X*_P"1,TK_ *X#^M;U8/@K_D3-*_ZX#^M;U !1110
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MC\ZV*RKO5KF&X>*VTM[I4;8SBZBCPWIACG\: (?^$-\+_P#0O:;_ . ZTO\
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M@73;C="\\.QXSN\JUM@V#QP1%P.>M2QZ;:^&=6M'&J:K=LTRYBN;IYB$,<W
M3ODJ.W:@"S\0O^1(O?\ KI!_Z.2JOA?4[71O MQJ-Z[);07MT9&52Q ,[#H/
M<BJGB^^O3X.U*'4[9HGGN8I+8A,A8S,A",1P&'<&LBRM/$6I>%+K2+<:7!8W
M-Y,4FEED$X'GEL@8V]1QS0!TPU:UTSXQ65W=7MM8QC1742W3#9DR].#U_&L?
M6?'+VNO76DZ;K'AW[';Q1M'>7328E)Y.W9D<$<YKU8W7A]A\WAU&^MM"?ZUD
MZK%:74L;:=9QV**I#)]@A;<?7K0!Y[X:\2W.I>.M8U&]EAU2>6QA5I-&@=XQ
MAC@$-@@UTMUJ6G7<HDFT[5BZC;Q;$?UKHY?LC7,3VEBML%AV2$1(F]LCG"U@
M_P!A[B6>1U9B20(58<^^\4 4;N;2;V6.2XL]<9XCF,^41M.Y6R.?5%_*K3ZO
M9.'#6NLD23>>P\@\R?WNO6MJRABL_#]YIFV5WN'W"4PKA1QQC?[5FIHR*6)9
MCF-D_P"/=>,C&?O]1VH =%XI\E2L0UQ5)R0(.]5/[4T_[:;QK'5VN"Q8NUN>
M3ZGFK4VCI-)*P^02$D*+9<+GT^>I]0T];^Z:8EE!"@?Z.N0%  &=_M0!GWFN
M03F KI^H,(Y-Y5[4X88(QUJ;X?.TOCB\F-M+ KB;8LJ;21MM^0/2MC1-FDWY
MN&B\Q&0JR1VRJ3G'?>?2KFGZA!J'Q!0PQO'Y5K,KHX ()$!'3CI0!VM%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% & G_)0+C_ +!<
M?_HUZWZP$_Y*!<?]@N/_ -&O6_0 4444 %%%% &#X*_Y$S2O^N _K6]6#X*_
MY$S2O^N _K6]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %<!\6?^0)H7_8>L__ $(UW]<!\62/[&T%<C<=
M>L\#_@1H <>II*<4;)^4_E2;&_NG\J $HI2K 9((_"DH *PM%4KK.M9*MNNF
M(,?0#CAO]JMVN=CU6WTF[O[>3[2S/>/+E;.9QAL="JD'&* .BHK"_P"$HL^?
MENOO8'_$ON.1Z_<_2C_A*+/GBZX8 ?\ $ON.1Z_<^OY4 ;M%81\468W8%T<$
M ?\ $ON.1Z_<_P XK2T_4(]1CD>$2;$;;F2%XL\9Z. : +=<G\3',?P^U-QU
M0PL,^HE0U:N/&=E;7,L#:7KCM&Y0M'IKLI(.,@]Q[US_ (O\3VFK^&;BQ32M
M97S)(2YGTYT0(LJLVX]AM!H :=?N[Z[\*ZFLMLE]>V3+*PCWK'O89PN>.G<U
MU27.H6\ERD][%/Y2[ABU\O'('J?7]*\I\-V+6_B&VGMM/:&TEU2;;/Y3C]T.
M4(!&-O!'7O7J6_[0UP/M#"XPYV!%VE0W3/7/&: *?B.[::SM$+ @S*V I'9J
MM>$[NVB\,QK/<Q+&LD_F*T@^[O;.1]*S];836UJ%E\PB16PJCL&R3^%8<7AB
MRU:)+\>&#?(^Y;B>2\C61RB[,HN.N5[X_.@#J_!4EE)X8M?L0080>9M7') *
MY_X 5_#%=#7)?#SS6T"622R^R1O*ODQ#./+$2*IY[\<^^:ZV@#@ICCXOY\[R
M/FM/WN/N?N9^:[BW_P!6W[PR_O'^<@@M\QYYKSG7I-2B^)4SZ1!:SWP-GY<5
MW_JF_=3YW<CM7565WXE^T6XOM)L;6!Y6,[17(8*#DC8.O7'7MF@#0U281JBF
M8*&!_='&'^OM3-(D$/AWQ#(,)A(=J+TSN.#Z\].O:K,BR72MB.$QG*@OG)'J
M..*CM;&6#1/$$"+&X:&W"ECG^-LC)QT'(]Z *]C?R221PS2Q1G. B@'(';K6
MP.HK,M[":T8F+R6R<GS"6)^AQQ4=_>ZJLMM_9=G!<J0QG224(RGC&,\>N?PH
M XWXDF,Z-9;+N29A;2;D8'$?[R+@9_IZ5Z2?O&O(/&UQXF;34C\066FV\$%K
M+]G-FQ+-^\BSOY/./I78Z;\2-"UJY>#3(=3NI57>R16N2!Z]: -GQ+J=QHWA
MG4M3M0AN+6 R1[QE<Y'4?C4]C;2 B\N;E[BYEC4%F&U47KM5>PR?J:YWQ1J,
MVK^%M3TZTT76#<7,!CC#VH49R.IW<5J1:\4@B1M$US<J*#_H?H/]Z@#;HK(&
MO$]-#UT_]N7_ -E5>_\ %MMI=E)>7VE:S;VT>-\LEGA5R<#^+UH V[;_ )&W
MP_\ ]=YO_1#UFZ)(MKX0L;F;*Q16:NS8Z +69X7\>:#XE\<:);:=-/YD3S2-
MYT6P8\EQUSZFLSPYX,TPZ3%<WL=U?K=0;_+FE9XQG!"A59<#K_\ 7H V;>WN
M=0\4Z?K,CVL:1VDT*V\<F^0!RI!8C@'CH*U;ZQ\^5Y-VQDB)(*!LXR>_2L^U
M\+^'M,D:;3]%2"9E="T<<BDC^$9\SOW]*NQ:;;1JL4-ILA4E5+R2#Y>W'F$_
MG0!GCY+B+RI$.-K>88]IY(XZ<]<5+(7:_P!-=Y/,;[6HW8Z#R9N.GO63XC\.
M*JR:E_:NMQC<B"VL9U5%R0 1O!QSU)--\/\ AG4K378[N[N]6^QPIO2&]O(Y
M2TN&7)"KP K'\: +OQ"_Y$B^_P"ND'_HY*AT/[7_ ,(_99\O[+]J;'][/FM6
M[K>D0:]H\^FW,DL<4VTEXB P*L&&,@]P*YZ+X?I BI%XG\0HJG<JBY3 .<Y^
M[ZT =D:2L.T\.2VMU!.?$&LS^2=S1RRH5E]GPH+?G6Y0 4444 %%%% !1110
M 5SWA5C_ ,+\U%<G;_8BG&>,[XZZ&N*BUI/"WQBOM7O+#49K232$@C:UMFDW
M/N4XR./X30![G17F4WQ@2*2QW^%]5MX+RYCMUN+DHB#<<9X)/Z5Z;0 4444
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M@C^M 'IM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8"?\
M)0+C_L%Q_P#HUZWZP$_Y*!<?]@N/_P!&O6_0 4444 %%%% &#X*_Y$S2O^N
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MOSS70T4 48M&TN *(M-M%V]#Y*DC\<5= "@!0 !T %+10 N3ZTE%% !1110
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MS2O^N _K6]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDYM==^'>I*=ICOQ;R.>P)V_U- 'L5%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 8"?\E N/^P7'_P"C7K?K 3_DH%Q_V"X__1KUOT %%%%
M!1110!@^"O\ D3-*_P"N _K6]6#X*_Y$S2O^N _K6]0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<%\5_^
M0/H'_8?LO_0S7>UP/Q7XT;03_P!1^R_]#- "GJ:2E/4TE !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% ' -%$E]<Q:EJ^JQ02:L;>WM;8_NE9\;2<#(SSSFM;5_ FF:G9NCFXE
MFR&4S3L5R#DCV!Z5CW_B6?PYX\U"S.G?:8;Y89ED#-F,[=O0*Q(R.PKOLLT&
M5/S%>"!WH YGPU;:+HVJW.D6&CMIMX;=)Y<N'$B9(&&R<X)/IUKH9;ZSMVVS
MW=O&?1Y5!_4UX1XDNM2U#QBT5UJ$\Q7= DBB.)60-GRU/(R">^3GM7I>J^'=
M&E\'321Z>F6AW@[SN..0,]>?PH W9?%>@P2>6VK6WF=D5LD_E5"^\>Z'8('G
MDF 8%DW1[=X'7&:\M\#);VWC!2=,=)8WVY?YQ$67\23_ $-=O\5+6.72H)'M
MFF'*X3@J.N<Y'Y9[4 ;FA>,[371<-'8WEK'%$TRR7 4+(JG!(P>W'7UJIX@\
M87=EH=KJ&DVUM(TL,LTJ7+$>7Y:@LF%_BY/Y55\$P6VNZ6MW=V[@PE?+4L55
MT=(S\P'WAE/I73:MH]C=VEY*UG"URUO*HDV#=RA'7]* -""0RVT,I&#)&KD>
MF0#4E8WA*9KCP=HTLC[Y#9Q[VSW P:V: "BBB@ HI%)<X17<_P"RA-2K;W+3
MK +6;S64LJLNW(&,GGZB@".BI;JUNK2WEEEBC7RQDJTRY/T )J"6YTNVS]K\
M0:5 P_A,NX_EQ0 ZN0^)=LL?@BWU)3)OM=5C=R7)"C(/ [=:TF\;^#K?SA<^
M)8G=)"JI;1[BRX'//?K6#XP\1VOB3PQ=Z!X>LM;O)+P!UCDT]P=ZX((.,8(%
M 'N\<BRQ)(ARKJ&!]C3JR_#<DDOAC2WFC>*7[+&'20$,K!0""#WS6I0 4444
M %%1)<PR7$L"2JTT0!D0'E<],_6I: "BBB@ HHHH **** "BBB@ HHHH ***
M* ,!/^2@7'_8+C_]&O6_6 G_ "4"X_[!<?\ Z->M^@ HHHH **** ,'P5_R)
MFE?]<!_6MZL'P5_R)FE?]<!_6MZ@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X#XL_\@30O^P]9_\ H1KO
MZX#XL_\ ($T+_L/6?_H1H <>II*4]324 %%%% !1110 4444 %%%% !1110
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MBB@ HHHH P$_Y*!<?]@N/_T:];]8"?\ )0+C_L%Q_P#HUZWZ "BBB@ HHHH
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MHHH **** "BBB@ HHHH P$_Y*!<?]@N/_P!&O6_6 G_)0+C_ +!<?_HUZWZ
M"BBB@ HHHH P?!7_ ")FE?\ 7 ?UK>K!\%?\B9I7_7 ?UK>H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M ^+/_($T+_L/6?\ Z$:[^N ^+/\ R!-"_P"P]9_^A&@!QZFDI3U-)0 4444
M%%%% !1110 44NTXS@X^E0RW5O;QEYKB&-!U9Y  * ):*Q;GQ?X<M%+3:Y8
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MR% 'BJ?$<W8;^S?"FO7>.C+;?*?QJ4:U\0;Z)6L? ,L6X\-=3@#\1\I%>X@
M# &** /&!HWQ:O74"WT/3E(Y)?S,?AS5I/AS\0+N7=?>-X;9?2RM_P"AQ7KM
M% 'D\?P3>>4R:GXUURY+#!$3B(?S-6[;X#^"HAFYBOKR0G)>:Z;)_P"^<5Z;
M10!R%K\+O!%F%\KPW8DKT:1"Y_7-;UMH&CV>/LVE6,..GEVZ#^E:-% !THHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \O\.$_
M\(UIO)_X]T_E5V"5HO%>DR#DI!=L,^R)4UEX.\06%C!:1:EI3QPH$5GM9,D#
MUQ)UK0TOPQJL&O6FH7][8R1VR2JL=O ZEBX4<EG/ QZ4 9]GX[OKS:C6UK:S
MIY8DBE+$R.PC.V/D9^_NSSQ^8L3>)M=AL;1X[:VN;B47+NL<+A=L3A>27^7J
M3DY],5V9C0D$HI(.0<=*7:/0?E3Z#NKGG!\?ZNK7*-;6BS06[3+#)&4>4XX7
M!DR,^OS9]JDF^(EV#<2);6L=O'(=K2$EG0*#P,C))/;)'H:]!,498,8U+#H2
M.:#%&<9C4X.1D4B>AQ>D^,KN]N-)29[%EO?OB(?,I(R  ';IZ\^^WOV],$,2
MD%8D!'0A1Q3Z!]0HHHH **** ,!/^2@7'_8+C_\ 1KUOU@)_R4"X_P"P7'_Z
M->M^@ HHHH **** ,'P5_P B9I7_ %P']:WJP?!7_(F:5_UP']:WJ "BBB@
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MZX#^M;U8/@K_ )$S2O\ K@/ZUO4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8"?\E N/^P7'_P"C
M7K?K 3_DH%Q_V"X__1KUOT %%%% !1110!@^"O\ D3-*_P"N _K6]6#X*_Y$
MS2O^N _K6]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M & G_)0+C_L%Q_\ HUZWZP$_Y*!<?]@N/_T:];] !1110 4444 <_P""I$'@
MS2OG7_4#O]:WO,3^^OYUDMX3\.,Q9M!TPL3DDVD?)_*D_P"$1\-_] #2_P#P
M$C_PH UF:)U*LR,I&""1@UF+X?\ #Z3^<FDZ:LN=V\6Z Y]>G6F?\(CX;_Z
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M?^%'_"(^&_\ H :7_P" D?\ A0!K^8G]]?SH\Q/[Z_G61_PB/AO_ * &E_\
M@)'_ (4?\(CX;_Z &E_^ D?^% &OYB?WU_.CS$_OK^=9'_"(^&_^@!I?_@)'
M_A1_PB/AO_H :7_X"1_X4 :_F)_?7\Z/,3^^OYUD?\(CX;_Z &E_^ D?^%'_
M  B/AO\ Z &E_P#@)'_A0!K^8G]]?SH\Q/[Z_G61_P (CX;_ .@!I?\ X"1_
MX4?\(CX;_P"@!I?_ ("1_P"% &OYB?WU_.CS$_OK^=9'_"(^&_\ H :7_P"
MD?\ A1_PB/AO_H :7_X"1_X4 :_F)_?7\Z/,3^^OYUD?\(CX;_Z &E_^ D?^
M%'_"(^&_^@!I?_@)'_A0!K^8G]]?SH\Q/[Z_G61_PB/AO_H :7_X"1_X4?\
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M(CX;_P"@!I?_ ("1_P"% &OYB?WU_.CS$_OK^=9'_"(^&_\ H :7_P" D?\
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MO_H :7_X"1_X4 :_F)_?7\Z/,3^^OYUD?\(CX;_Z &E_^ D?^%'_  B/AO\
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MPBP:8RELF)\= :Z+Q':SWN@W,%M&9)G VJ"!GD>M$VFI%H-Q;VMLB2R0%=J
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M!?E!,L6!GUX-<+)IFKVWQ FO+>VD?3[[Q)&MT#&3L\M%,<B_[)W,"?I7L]%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ J"Y@,Z+M?:Z.'4D9&1ZU/10!E-HY+2/YD?F3?ZUC'GO_#SQ5@V
M+B.U1)E_<R>8Q9,ESSGOQU-7:* ,TZ0GGATGEVX(*,Q(.6#'^53/9N\]P[/$
MR2QA C1DXQGKSSU]JN44 5;&S%G&XR"SMN8J,#^M6J** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>gqr1p20dfppl000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqr1p20dfppl000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )P D@# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** "BF&6-95B,BB1@2J$\D#K@4^@ HHHH ****
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M_A70T4 <]_PG7AG_ *"\/_?+?X4?\)UX9_Z"\/\ WRW^%=#10!SW_"=>&?\
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M@ HHHH **** "BBB@ HHHH *RYY[9?%-C UMNNGLYWCN,_<0/$&7'N2I_P"
MUJ5ESS6H\4V,+6Q:Z:SG:.?/W$#Q!EQ[DJ?^ T :E%%% !1110 V3_5/_NFL
M7P;_ ,B1H7_7A!_Z *VI/]4_^Z:Q?!O_ ")&A?\ 7A!_Z * -RBBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGZW_ ->$_P#Z+:KVG?\ (+M/^N*?^@B@"S1110 4444 %%%% !1110 4444
M%%%% !67/-;#Q38P-:[KI[.=H[C/W$#Q!EQ[DJ?^ UJ5ESW\\?BFQT]=OV>:
MSGF?Y>=R/$!SZ8=OTH U**** "BBB@!LG^J?_=-8O@W_ )$C0O\ KP@_] %;
M4G^J?_=-8O@W_D2-"_Z\(/\ T 4 ;E%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZI_]TUB^#?\ D2-"_P"O"#_T 4 ;E%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D>*O^1/UO_KPG
M_P#1;5>T[_D%VG_7%/\ T$51\5?\B?K?_7A/_P"BVJ]IW_(+M/\ KBG_ *"*
M +-%%% !1110 4444 %%%% !1110 4444 %94\=D?%-C(\KB^6SG6*,#Y6C+
MQ;R3CJ"$[]S6K67/'9GQ38R/,XO5LYUBB ^5HR\6\DXZ@A._<T :E%%% !11
M10 V3_5/_NFL7P;_ ,B1H7_7A!_Z *VI/]4_^Z:Q?!O_ ")&A?\ 7A!_Z *
M-RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ=:[#3M.L](T^"PL+=+>U@79'&@P /\ />@ T[3K/2-/@L+"W2WM8%"1QH,
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M_GGW5>_4T %M;7/Q%O([^_BD@\+0N'M+-QM:_8=)9!_SS[JO?J:[T *H
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M_7A!_P"@"@#<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7'>#OBAIOBGPQJ.O7-N=+L["7RY3-*&_A!SP!ZXQ3M-TV\\:ZC!KVO6[P:3
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M#-<>8\L;(0C;0-ORD]AFMKQ/XGCT&&&WMX&O=7O#LLK&,_-*WJ?[J#J6/2@
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M:FP/0=Q"#U/\7TKO(88[>%(88UCBC4*B(,!0.@ HAACMX4AAC6.*-0J(@P%
MZ "L_7]?L?#FEO?W[D("%CC0;GE<]$1>[$]J #7]?L?#FEO?W[D*"$CC0;GE
M<]$1>['TK!T#0;_4M43Q/XG0"_ /V&PSN2P0_P Y#W;MT%&@:#?:GJB>)_$\
M8%^ ?L-AG<E@A_G*>[=N@KL: "N7\2^);BUNX]"T*)+K7[I<HC?ZNU3O+*>R
MCL.I/%'B;Q+<6MW'H6A1)=Z_<KN1&_U=LG>64]E'8=2>*N>&?#-OX=M)/WKW
M>H73>9>7LO\ K)W]3Z = .@% !X9\,V_AVTD_>O=ZA<MYEY>R_ZR>3U/H!T
MZ 5N=!DT=!DUP=Y>W7C^^FTG29Y(/#L#F._U&,X:Z8=883Z=F<?04 %[>W7C
M^^FTG29Y(/#L#F._U&,X:Z8=883Z=F<?05VME96VG64-G9P)!;0H$CBC&%4#
ML*+*RMM.LH;.R@2"VA0)'%&,*H'85#J^KV.A:9-J.HSK!;0C+,>_H .Y/84
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MA[6T<%6U!ATDD':/^ZO?J: "WM[CXC7D=]?1R0>%87#VMHX*MJ##I)(.T?\
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M_I4,<UY& .H#^6!CZ9H#I<]5HJGI>JV6M:=%?Z?<+/;2CY77]01U!!Z@U<H
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M9PURPZPPGT[,X^@KM+&RM=-L8;*R@2"V@0)'%&,*H'846-E:Z;8PV5E D%M
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M3_[IK%\&_P#(D:%_UX0?^@"MJ3_5/_NFL7P;_P B1H7_ %X0?^@"@#<HHHH
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M** "LN<67_"4V+.9?MXLYQ$!]SR]\6_/OG9C\:U*RYQ9?\)38L[RB^%G.(E
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M]WJ5TWF7M]+]^=_Z*.@4< 4 'AGPS!X>M96:9[O4KIO,O;Z7[\[_ -%'0*.
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M ")&A?\ 7A!_Z * -RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]A_#]:[B@ KGO$WB<:*(+&RM_MVMWF5L[)3C=ZNY_A0=S1XF\3C11!8V5O\
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MFN"0!&I&"V3QQ[T <5X-\8^!++PAJ&J^'["73M/CN1&\)BP\\Q485%#'<Q&
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M>I)HTC2+'0M+AT[3H%AMH1A5'4GN2>Y/4DU/>7EMIUE->7DZ06T*%Y)9#A5
M[F@ O+VVTZRFO+R=(+:%"\DLAPJ@=S7%6=G=?$"]AU7589(/#<#B2QT^08:[
M8=)IA_=[JA^II+2SNOB!?0ZKJL,D'AN!Q)8Z?(,-=L.DTP_N]U0_4UWH  P!
M@"@   & , 5B>)?$MOX=LXR8GNK^Y;RK.RB_UEQ)Z#T [GH!1XE\2V_AVSC)
MB>ZO[EO*L[*+F2XD]!Z =ST JCX:\-7-M=R:]KTJ76OW*[69>8[6/_GE%Z =
MSU)H /#/AJXMKN37M>E2ZU^Y7:S+_J[6/_GE%Z =SU)KJ:*X_7]?OM1U1_#'
MAAU_M# ^VWQ&Z.P0_P Y#V7\30 :_K]]J.J/X8\,.O\ :&!]MOB-T=@A_G(>
MR_B:W- T"Q\-Z6EC8HVW)>25SNDF<_>=V[L?6C0- L?#>EK8V*-MR7EE<[I)
MG/5W;NQK1EEC@A>65UCC12SNQP% ZDGTH )98X(7EF=8XT4L[L<!0.I)]*X,
M+/\ $JZ#N)(?!\+Y53E6U1@>I[B$'_OKZ4 3_$FZ#N)(/!\+Y53E6U1@>I[B
M$'_OKZ5WJ(D4:QQHJ(@"JJC  '0 4 >=?&#Q%IOACP?'%=:-%>I=A[6 $*!;
ML8R P!!Z>V*Z_P )WD6H>$-'O(8!;Q3V44B1#&$!0''%<?\ &>'PO+X1#>))
MYHVC,C6*Q$Y>?8<#@'CZXKL/"B64?A#1TTUR]BMG$(&.<E-HP>?:@#8HHHH
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M!@?\)GHO]Z__ /!;<_\ QNC_ (3/1?[U_P#^"VY_^-UOT4 8'_"9Z+_>O_\
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M_P""VY_^-UOT4 8'_"9Z+_>O_P#P6W/_ ,;H_P"$ST7^]?\ _@MN?_C=;]%
M&!_PF>B_WK__ ,%MS_\ &Z/^$ST7^]?_ /@MN?\ XW6_10!@?\)GHO\ >O\
M_P %MS_\;K)\3ZYI&O\ A;5-(CN+V)[RV>!9&TNY(4L,9(\NNUHH ^<H[37?
M /P^FT_PI?W]YJMQJ:S,UKI,ZD0^65(/F)CJ%KH+3QCXL_X4_=B=M8_X2_S?
MW(.F2;]OF+_TSV_=W5[;10!X'\(=8UW3-3U^Z\60:M%)>*DB2S:=*S22<YY5
M"< 8XZ#M2?#?QAX['BLGQB=:&E?9WQYNF/CS,C;]R//K7OM% 'SQXM\1^-M2
M\?7%G9G7?^$2N+B*-S#I\B#R"%$F#LWC^+WJ3Q[XB\7Z=K5K9?#^'5H="@LT
M18[;2W"*X+9'SQYSC;7T'10!XCXM\8^+3\/_  \-!.L'Q %C_M$)IDF[/E_-
MG='M^]Z5FV]UXAU3P4VI>(KO5+GQ#:0R-IMA_94H\N?>=LC_ +O8SXQM[ >]
M?0%% 'B7PY\8^+!INO?\)@VL"Y,2?V?YNF29W8?.-D?KLZU@^!_&'Q)'BF ^
M(CJXTWRY=QN-,?R]^QMF[9'NQNQTKZ+HH ^:-+U+QSIWQ6.H3'5;C3[B\C6\
MO4TN0));AAD*"A94 SP/YUTOQ1\8^,6UFR/@@ZP;/[/^_P#)TR3'F;C_ 'X\
M],5[E10!X?\ $'Q9XJG\*:#%X9.LG4&@VZGY.G2AMQ1<Y)CX.[=]VJWAO7-?
MT7X)WFGQ0:K;^)(Y3]EC&F2;]I=3G/E[22-W)YKWFB@#R#X6^,?$"Z?J/_"<
M-JPN/-7[-YVF2_=P<XV1^N.M<?X3U7Q9K?BJ"'Q_#K4V@PEIA'-IT@C:5?N;
M@B?,.^#Q7T?10!\X7OB_XE#Q[-]E.M_V!_:1\LC3&V_9O,X_Y9YQM_&M;XF^
M,/&Y\30GP6=9.F_95W^5ICX\W<V?OQYSC;7O-% 'S_XJN_$-II5OK6C7>J:A
MXMGF5+B:'2I@L%OL/[N-73"C=M)/4FM+_A,?%O\ PIW&=8_X3#S>G]F2;]OF
M_P#7/;]RO;J* / O!OBKQ_/I&NPZ]=ZC:7CI$+*:ZTF5MGW]Y4(GWON]>*J_
M![6?%&AZ[<6_B.WU>WTAX))/WNFR'?.SJ<EE0L21NZFOH>B@#P"_\8>//^%I
M*;4ZU_PBWV^+)&F/L\C*[^L>[&-WO5+XMZWXPUO79;+P_%K4^@/#&6CCT^0(
MSCD@Y0$CIP>*^C** /$/&GB[Q4G@SPW'X6&K+JB0HNH+%I<@((C7((:/ ^;/
M2M*/QCKW_"GBKMJW_"8>2>/[,EW[_-./^6>W[E>NT4 ?+T>D:SXYT34)_&]Q
MK\6J68SIR-ITI$HVL2FU4P,MMYZU[SX/OM.M?#=CI5M)>/\ V=9(CM-92Q$A
M% _B49/L,FNHHH RI/$6G1:=%?LUU]GE8HA%G,6R,]4"[AT/)%">(M.DTV34
M%:Z^SQN$8FSF#YXZ(5W$<CD#%:M% &5?>(M.TYXEN6N@94$B^79S2<'UVJ<'
MV/->-WWPOTZY^+>G:P(Y?^$>U!OM7E_9I.9@1^[8;?D!)#?-@8S7O-%    ,
M 8 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MES<I)!X1A?=! P*MJ3 \.X[19Z#^+J>*[Y55$5$4*JC  & !0JJB*B*%51@
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MX[UZW10!Y+KGPU\3ZK\*]*\-KK:#4+9B;G=,QBG!9C\S;2QP",#I^0JSX"\
M^)O#?A/Q#IFJ:G#/<WT)CM'CN)&$7[ME') *\D=/2O4:* /+/A9X \5>$-8O
MKK7]6BO89K<1QHES))M;<#G# #H*S8?A;XI'Q:7Q1/J=K)ID>HR7,<+7$A=(
MV)^4*5P.".,XKV6B@#Q7Q_\ "_QKXD\9WNJZ/KD%K8S",1Q/=RH5VHJGA5('
M(-:VJ_"J[N/B)H'BNUO8VDMWA-_',YZ1JBCR\+R3AL[CZ5ZI10 4444 %%%%
M !1110!GZQHUIKEI':WJN8TFCG&QMIW(P9?PR*T*** N%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>gqr1p20dfppl000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqr1p20dfppl000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (8 SD# 2(  A$! Q$!_\0
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M:^&?^@W9?]_11_PFOAG_ *#=E_W]% &]16#_ ,)KX9_Z#=E_W]%'_":^&?\
MH-V7_?T4 ;U%8/\ PFOAG_H-V7_?T4?\)KX9_P"@W9?]_10!O45@_P#":^&?
M^@W9?]_11_PFOAG_ *#=E_W]% &]16#_ ,)KX9_Z#=E_W]%'_":^&?\ H-V7
M_?T4 ;U%8/\ PFOAG_H-V7_?T4?\)KX9_P"@W9?]_10!O45@_P#":^&?^@W9
M?]_11_PFOAG_ *#=E_W]% &]16#_ ,)KX9_Z#=E_W]%'_":^&?\ H-V7_?T4
M ;U%8/\ PFOAG_H-V7_?T4?\)KX9_P"@W9?]_10!O45@_P#":^&?^@W9?]_1
M1_PFOAG_ *#=E_W]% &]16#_ ,)KX9_Z#=E_W]%'_":^&?\ H-V7_?T4 ;U%
M8/\ PFOAG_H-V7_?T4?\)KX9_P"@W9?]_10!O45@_P#":^&?^@W9?]_11_PF
MOAG_ *#=E_W]% &]16#_ ,)KX9_Z#=E_W]%'_":^&?\ H-V7_?T4 ;U%8/\
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MO'J>/+GGL]CE6.!D\C@XY !KJ_#NK:)I^B:UJUAXDU+6(;2$R2_;)&;R\*2
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MNB6BHWGCC@,SMB,#.<'I57^V+'_GN?\ OAO\*:A)[(&TMR]15'^V+'_GN?\
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MIZI/%%JSNHTB2)BPL5C.Y"#@?,S<M['%;&@:1JL'B&^UC5!;+)>65M$Z0.6
MD3=OQD#CYABNGHHML#U//['P7JEM)IC.]MBVUZYU&3#G_52!]H''WOF&1^M8
M]MX+\8R>%H?"=U;Z)%IHGWO>I,[S!?.\W*J4 W=NM>L455]+#;=V^_\ P?\
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M9SVEXZS.7&X QNF2>58=,C@T1:%XLUK6-#D\06NDV\>D3BX-[:RL\MRRJ5
M*C:ISDC)Z8KT&BA:.X!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57OK./4+">TE
MSLF0J2.H]"/<=1]*L44 9VB7DEYIJ_:,?:X&,%P!_P ]%X)^AX8>Q%:-8]]I
MMU!>/J6DNJW+@>=;R'$=P!T_W6QT8?0Y[6M-U2#4HWV!HYXCMFMY!AXF]"/Y
M$<'M0!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P/!/_(FZ9_UR/\
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MUU!>VT=S;2I+#(,HZ'((J6L6YTNXLKF2_P!&VK(YW3V;'$<Y]1_<?WZ'OZT
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M3_T"[+_P'3_"C^Q-)_Z!=E_X#I_A0 W^W]&_Z"]A_P"!*?XT?V_HW_07L/\
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M_P"DQ]?^@O>__%?YQ65X<6;5?%EUI]W>ZG&+6WD62.+4[@H9%F*;@2V>0.E
M'IM%8O\ PC%I_P _VK_^#2X_^+H_X1BT_P"?[5__  :7'_Q= &U16+_PC%I_
MS_:O_P"#2X_^+H_X1BT_Y_M7_P#!I<?_ != &U16+_PC%I_S_:O_ .#2X_\
MBZ/^$8M/^?[5_P#P:7'_ ,70!M45B_\ ",6G_/\ :O\ ^#2X_P#BZ/\ A&+3
M_G^U?_P:7'_Q= &U16+_ ,(Q:?\ /]J__@TN/_BZ/^$8M/\ G^U?_P &EQ_\
M70!LD ]136AC;K&I_"L.;PG"^#%K&N0,.Z:C(WZ.6'Z4Q])\1VCL]AXA%RO&
M(=1ME8>_SQ[2/R- %S4?#FFZHH%U;1R$'*LZY*GU#?>!]P160UMKWAO,MC++
MJM@,EK.XDW2H/^F<IY/^Z^?]X5/_ ,)1<Z7\OB/2Y+&/I]MMR9[?ZL0-R?\
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M#&/XF]C[D+)*%5_WODQQ8MY9K4?ZOTM;8=W/1F'_ .R 9,FAQ*'+ZSK@CBF
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MJQ0?PAN"1ZC/>NGD<11/(02$4L0!D\5SW3XD\]](X]\3<_S%='0!YM:I%?\
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M\Z'*^'+UOLT*C]T&ESN8]W;J?3 ^I[%_^2A:']-1_E!7&Z<#'I=U&WV6,?\
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M*D$.%&"L)]3VIW]D_$+/'B"T_)/_ (Q5_5=2MM(\8-?WC,L$6DG=M4L23,H
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M_P"_)_Z$:[&N(^%MY:R>#+2W2YA:=6D+1K("P^8]1UH [>BBB@ HHHH 8/\
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MZ.?2NEH **** ,KPY_R ;9>Z[E/U#$&M6LKP]QI.T]4N)T/U$K"M6@ HHHH
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M0KJW>"XMIY89!AXWO)BK#W&^L_\ X5;X+_Z 47_?Z3_XJNOHH Y#_A5O@O\
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M?_0C0!OT444 %8/C90W@G6 R@C[*YP1GM6]6%XT_Y$K6/^O5_P"5 &[1110
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MZH"68*!U)- "T5GR:]I$1*OJ=H&'51,I;\@<U7_X2?3'X@:XG;^[%;2$G]*
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M7J*ZE\2=+DTZ*\-O!:W$-S*UI)'$P;:R_,P /*UZ50 R*&*",1PQI&@Z*B@
M?@*?110 4444 %%%% &3XGT2+Q'X:O\ 293@7,15&_N..48>X8 _A7GMKK4J
M3>&_&,RF.96.B:VI'*,6VAF]ED&<G'#YKUBO(_%7A[38/&.HV-[I]W?6WB&
MS6EO!)A4NU 60XR%W%=C[F)^Z>* /7**YKP)K-QK/A:#[?E=3LV-I?(3DB:/
M@D_7AL^]=+0 4C E>*6B@"+8WI1L;TJ6B@"+8WI1L;TJ6B@"+8WI1L;TJ6B@
M"+8WI1L;TJ6B@"+8WI2$$=14U% $%3*<C--V#=GMZ4^@ HHHH **** "BBB@
M#G/$>;;6/#VI*K'RKTVTF&QA)E*\^OSB,_A71USWC>$R^#]0=8R[VZBY0 \Y
MC8/Q_P!\UO02K/!',GW9%##Z$9H P?!I\K1Y]/+AC87DUMP,84.2N?\ @)%=
M#6!HSA?$WB2WV;?W\$V?4-"J_P T-;] &3HW_'WK/_7\?_14=:U96E\:KK"G
MKYZ''MY:UJT %%%% !1110 5@>"?^1-TS_KD?_0C6_6!X)_Y$W3/^N1_]"-
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M81XFM%F5ML\2S2A/E )E;(^Z 5Y;N.*]EUKCQQX7/?%V/P\L?X5DZB"^L:A
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M\=& Z/T;V/7K:BGB,T>P2,@)^8KU(]* ,VU\4Z!>S1PVVL6,LLIPB).I+'T
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MC795Q]X"?%<V!$?])M_]=]W_ %$W6E+8TI?%]_Y%^PCFMG5!XBM95>4NR")
M7+-D@8;OFNAK L[U9]3DM5@LE,)&YMN,_P"[6_32L1*3D[LPY->NI[J:WTG2
MI;SR7*23R2"&$,.JACDL1[ CWH\WQ/)RMKI4(_NO,[G\PHIDEE:QWL[6NM36
M:R.7E@B9,;^Y&X'!/?%/T.>5]2U6V-Y)=0P/'Y;R$$C*9/( [T" /XI')ATA
ML=A)(,_CBHWUO5+"6'^U-(CCMI)5A^T6]T)-K,< E2H.,D=,UT%8,V-<UQ(
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M3_D2M8_Z]7_E6[6%XT_Y$K6/^O5_Y4 ;M%%% !1110 4444 %%%,F?RX7?\
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M_,5UM8"_\E!D_P"P4G_HUJ #^U]?_P"A7D_\#HO\:/[7U_\ Z%>3_P #HO\
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MO%]NNK[7GB1/M+>3;A.@B4_>'^\V3^53+L;4M&YOI^?3_/Y'21HD4:QQJ%1
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M1^^3HNT9_.NZKC[?X=Z=!>6MS]ID)MYTG4+:V\>64Y'*Q@XR.QKL* "BBB@
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M3_L%)_Z-:M^L!?\ DH,G_8*3_P!&M0!OT444 %%%% !5#7?^1>U+'_/K+_Z
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MK0N(A!<07-J56:.>$QGG.",]C@U9>%]0TTQL_+2')/H'_P !5#2U2/Q?K<:
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MNAU0%?#UZIZBT<'_ +X- $VF?\@JS_ZX)_Z"*M55TS_D%6?_ %P3_P!!%6J
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MV/RUM51D8AF7<?EUCKV0U@SE+G4A9#SMUUJL!<3#$FR.(2<^V5'YUNEUR?\
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M]<5=MXQ#;11*,*B!0/3 K,\1_/I:P _--<0H/?\ >*3^@-:] !1110 4444
M%%%% !6!X)_Y$W3/^N1_]"-;]8'@G_D3=,_ZY'_T(T ;]%%% !6%XT_Y$K6/
M^O5_Y5NUA>-/^1*UC_KU?^5 &[1110 444V218D+N<** "218D+N<*.IKE-6
MOKG4]0.CV,AAF88NKH=+.,_P@_\ /5OT%2:KJ]W<WZZ5I2HVI,-YWGY+1/[[
M^K>BU?TC2X--L?(M=TJLQ-R)OONY^\Y/J?R]*T2Y%S/?I_F9M\SLMB:RT^&T
MMH[.UC%H8$"*$&59?7W_ )UHQ1B*)8UZ*,?6EC01H$!8@=-QR:BN)51<,65&
MX,B_PGWK-N^K--CGKBVNM'UN[UK35DOH;DJM]9@YD4J,!X\^W5>_:L+Q+XHA
MU^./3=*W7-I*RI,JY4W4IY6V!Z@8^:0_PH,=35[QEK\EA&NFVLT<>IS1F1KP
M'BVMQ]^5Q[= .Y(Q4W@CPXME;QZE/!)$YC,=G;S#YX(B<EG_ .FLA^9S]%[5
MK/6*;W_0SBK2:6QM>'M$&BV+"5UFOKAO-N[A5V^8^,8 [*HPJCL *UZ*CDGA
MB($DL:$] S 9K(T)*P/!?_(JVO\ UTF_]&O6Q]LM?^?F'_OX*Q_!>/\ A%;4
MJ<@R3$$?]=7H WZ*** "BBB@ HHHH **** "BBB@ KE=1N(F^(%E;AQYL>G,
M[+Z*T\0!_$J?RKJJ\]UW^TX_BG')INGI>L='7>C3B+:%N,YR>OI0!W-C_P >
MH_WW_P#0C7(Z_9V6J>*9H$\.O?WD%M&TLZWOV?Y6+;5X/.,'\ZT8M0\4(FV/
MPS;(N2<2:D,\G)Z(:=H=GJS>(=1U75+."T$\$,,<44_FD["Q))P/[U '-G04
M!P? M^<?]18$?^C*S]4TJVL-)N[J\\$WJP1_.SMJ0<(N1_#OYQZ5ZQ6%XSM;
MB]\&ZM;6L+S3R6[!(T&68^@H VXR#$A P"HQ3NU<XOBJ.&W7?HNN *HS_P 2
M]SV]JC_X3G3@,FPUD#U_LV7_ .)H O6D317UJLEN4D"ON<MG=TK9KB'^(FAR
M:U;6J1:HURH<>4-/EW?=SZ>G-:G_  F=E_T#=:_\%TO^% %S3X29()%MM@7>
M6DX^;-6-8(&GL6Q@,,YZ5S^G>.--DL(6BL=8D0CAUTZ4@\_2JNN>*6U6T72]
M)T_41>7,R1;[G3Y1%&K'#,3P.%R>M $EN?AY]FBR_ATG8,G=%UI9(_AQ*8R_
M_".GRY%D3YHN&!R#73Z1IRZ5HUEIX?S!:P)#O*XW;0!G'X5<VCT'Y4 <;)J/
M@>*:3RM4@AWG<RVEPRIGUPAQFHO#6HV=UX\U&'2[^6YL5TZ%]K2NZK(9'!(W
M=\ 5V^!Z"L%?^2@R?]@I/_1K4 ;]%%% !1110 51UK_D!:AD9_T:3_T$U>HH
M X#PO!X=M;#3+^]U.6^U!+:,I)>RES!E!D(N J_4#/O75_\ "1Z/_P _\7ZU
MJ44 <A?IX?N;]M1LM9?3=0< /<6K8\W XWHP*OCW&?>J_G3S?N[GQV?)((;[
M-9QQ.?\ @1#8_ 5V]% '.:5=>&=%MVALKJ)?,;?+([,\DK?WG8\L?K4FJ:_I
M4ND7L<=[&SO;R*JC.22IP*WZ* *VG KIEHK @B% 0>WRBK-%% !1110!YW+\
M)[4M>B'5[CR[NZ6Y9;B)9FC..=C'!5CGANW3FM#6?AY;:MK,^L)>>1J#R1/%
M<>2&:()&4V@Y[YS^%=I10"T=SAM/^&=EIUG'91ZA/-:Q7]O?QQW"B0K)$ #@
M^C #Z8JO?_##^T1<+<:R7C,LLMM&UJ"L1DE$CAOF^<':!VXKT&BC^OZ^X=W:
MQP:_#*U_MC3]4>^"7-E)"R"WMQ&A2//R;=Q^4D@]>"M2S?#B"XUV_P!6EU6Y
M>:_$\<\94;#$Z!50#/!7:ISWQ7;T4/41P=C\-8M.U'2+R&_BEDT^V2!C<6@D
M:1@[.T@;<-K,6//-=Y113;; ****0!7&2-M\/^&F\T18OT^<]!\LE=G7&.2-
M \-%61"+],,XX'RR=:F6QK1^+Y/\F=#'<AI54:K Y)^Z%7)]NM:548YI3(H:
M\LF!/(5#D_3YJO51D9C7"!B/[5QSTV+Q^E<Y;L'\>V["7S<O-\^ ,_N8ZZ.[
MO_L38NM3TZWSR!,-IQ^+US=C<1WGCR.6.Y@N%'G$20'*$^7$/4_SH [25@D3
M,75,#[S=!6-?3.^GW$AET^<+$S;C]#]:VI YC81E0^."PR/RKFO$+A_#^I[F
MTZ1EMY 2#A@=I^O-#V*BKR2-/PW!]F\,:7#_ ';6/K_NBM2JNF_\@NS_ .N"
M?^@BK5*.PZKO-OS"BBBF0%%%% !1110 4444 %%%% !7/>"@[>&UN9'W/=7$
M]P3_ +TK$?IBM36+E;/1;ZZ=MJPV\CD^F%)JKX6M5L_"FDVZ@C9:19!ZYV@G
M]: (=3#S>+M!A# )$ES<L/4A5C'_ *--;M<^@6?X@S-NR;73$4#T,DC$_HBU
MT% &1K($M_H]O_$;OS1_P!&-:]9%T!-XJT^,_P#+&WFF'U)5?_9C6O0 4444
M %%%% !1110 5@>"?^1-TS_KD?\ T(UOU@>"?^1-TS_KD?\ T(T ;]%%% !6
M%XT_Y$K6/^O5_P"5;M87C3_D2M8_Z]7_ )4 ;M%%5[F[2W1LLNY5W,6;"H/5
MCV% $DLR0KELY/ 4=2?:N6OM5O-4O9-/T<AIXC_I%R!NCM!W"]GEZX'05";J
M[\2LQLYI;;2<[)M0 VR3#NL0/W4_VNOI7066GQ6%O'9VD20"W'[HJ/E9??W]
M??FM+*&^_P#6_P#E]YG=SVV(-+TBVTVS6UM@[Q2'S/M).9"_=F/<^_X5KHF/
MF8 R$ ,P&,TJ1JF[:,;CD_6N<U77+N[U"30O#VQ[]0/M5VPW162GU_O2$=$_
M$X'6&VW=EI)*R.AED"D(&"N_W"1QFN<\0>($T.%?+A,NJ73>5!8+SY[G^+V4
M=2WH#FLK4KF_\$F(3SWFNZ?>L(HX99 UTEP>FP\;E;T_A/3BLK2-'O\ Q9J\
M]UJ;[XV'E7D\;?($!_X](3W&1^\<=?NCO5Q22YI$MMOE1-X1\.G6+IM5O9!<
M6S2B628#Y;Z93\NW_IWC/W!_$1N/:O2Z;'&D,211(J1HH5548"@= !3JAMMW
M9222L@J&:UM[A@TT$4A P"Z XJ:BD,J_V;8_\^=O_P!^Q65X* 'A2U 4* \P
M '8>:];]83^#/#<DCR-H]KN=BS$+C))R3^= &[17)67@_P .R7NH(VDVY6.5
M0H(/ VCWJ]_PA/AK_H#VW_?)H WZ*P/^$)\-?] >V_[Y-'_"$^&O^@/;?]\F
M@#?HKEK[PCX=C18HM'M?.F.U.#QZGKVJ9_ _AT6K*FD6YD"$ X.2<?6@#HZ*
MY*/PIHJQJ&\+QE@ "=PY/YT__A$]$_Z%B'_OH?XT =517*_\(GHG_0L0_P#?
M0_QJ2U\%: RR--HENA9\JIYP,#WH Z:N7_YJI_W!?_:]6?\ A"?#7_0'MO\
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M4>$]![Z7;GW8$_SK9HH Q?\ A$M![:=&/8,P'\Z!X2T$?\PR$_[V3_,UM44
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MP4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=G) LDCHTT3;\,Y;G#8_BH Z"BLK9KW_ #WT[_OR_P#\51LU[_GOIW_?E_\
MXJ@#5HK*V:]_SWT[_OR__P 51LU[_GOIW_?E_P#XJ@#5K*U[_467_7[#_P"A
M4;->_P">^G?]^7_^*J*:PU>\>W6YN;(0Q3I*WEQ-N.TYP,M0!M4444 %%%%
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M%_Z]5KH:Y[P)_P B+HO_ %ZK70T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %0W7_'G/_P!<V_E4U0W7_'G/
M_P!<V_E0!BZ/_P C1J__ %[6G\I*D\7?\B[)_P!?%M_Z/CJ/1_\ D:-7_P"O
M:T_E)2^,'*Z$B ?ZR\MDSZ?OD_PH V+/_4'_ *Z/_P"A&L^WQ-XKOG[P6L48
M_P"!%F_H*OV?_'O_ -M'_P#0C5'1_P!Y?:Q.>]WY:GU"HH_F6H UJ*** "BB
MB@ HHHH **** "L#P3_R)NF?]<C_ .A&M^L#P3_R)NF?]<C_ .A&@#?HHHH
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MVZ;=$=H7/Z&@#&\"?\B+HO\ UZI70U@>"%"^!]$ _P"?*/\ ]!%;] !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !4-U_QYS_]<V_E4U0W7_'G/_US;^5 &)H__(TZQ_U[6G\I*/&7_(&M_P#K
M_M?_ $<M-T217\5:V%ZQP6B-]=KG^3"G>,O^0)"W9;ZU)_[_ "4 ;-G_ ,>_
M_;1__0C5'PY\^D"?M<3S3#Z-(Q'Z$5,UQ]DT:ZN<9\E9I/R+&ET.$6^@V$*G
M(6W09_ 4 7Z*** "BBB@ HHHH **** "L#P3_P B;IG_ %R/_H1K?K \$_\
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M,XSUZ4RXNX;4*9GVAC@?*3_*C[2G]R;_ +]-_A1]I3^Y-_WZ;_"DK=0U*_\
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M]M_A4UO?6]TY6&0LRC)^4C^8I?M(_P"><O\ WQ1]I7'^KE_[XH;A;1?C_P
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M&?[I_B;TX'7BKP[/[_\ @"U-/P;-'=6>J>("NV*_NB\38/S0QJ(T;'OM+?\
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M4K+\$_\ (FZ9_P!<C_Z$:F;@_A5OG?\ 1#5^IOT445 PK"\:?\B5K'_7J_\
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MAQ\)/!^038W3 '.&OIB#]1OIEY\(?"=W=/.EO<VH;&8K:<H@(XR%[?A7=T4
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M-% '+?\ "#6__0=U_P#\#V_PH_X0>W_Z#FO_ /@P:NIHH Y?_A![?_H-Z_\
M^#!J3_A!K?\ Z#NO_P#@>W^%=310!RW_  @UO_T'=?\ _ ]O\*/^$&M_^@[K
M_P#X'M_A74T4 <J? MLW77-?/_<0;_"@>!+9>FN:^/\ N(-_A7544 <M_P (
M/ /^8[K_ /X'M_A3O^$)@_Z#FO?^![?X5T]% ',?\(3;_P#0;UW_ ,#V_P *
M3_A![<=-<UX?2_/^%=110!S">";=7R^M:](/[K:@P'_CN#4G_"%Z=G/VS5]W
MK_:<_P#\571T4 <[_P (9I__ #^ZQ_X-)_\ XJE_X0W3\?\ ']K _P"XI/\
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M $$-9_\ !G-_\51_PAMC_P!!#6?_  9S?_%5T5% '.#P7IRG*WNL*?;4Y_\
MXJG#P=8CK?:P?KJ<W_Q5=#10!S7_  @?A^2Y6XN[6:^D7[IO;F2<#Z!F(KHH
MH8H(Q'#&L:#HJC %/HH **** $(#*58 @C!![USI\#:"MW)<VMO/8R2<N+*Y
MD@5CZE4('Z5T=% & /"5D/\ E]U?_P &,W_Q55=3\,VUMI-Y/%?ZLLD4#NI_
MM"7@A21_%74U1UK_ ) .H_\ 7K)_Z": .9\,:=%JMM)=W$UPTA2!&82D%B(E
M8D_B];O_  CMG_STN?\ O\:SO /S^%XY_P#GLV<_[JJG_LE=10!D?\([9_\
M/2Y_[_&E_P"$=L_^>ES_ -_C6M10!D_\([9_\]+G_O\ &D/ARS(P9+K_ +_&
MM>B@#+CT&TBE219+G<C!AF8]JJ>"?^1-TS_KD?\ T(UOU@>"?^1-TS_KD?\
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M^ZS_ .#6X_\ BZF7PE8HH47NK8'KJ,Q_]FK>HH PO^$4LO\ G\U7_P &$O\
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MF_QH_P"$$\-_] Q/^^F_QKHZ* .<_P"$$\-_] Q/^^F_QH_X03PW_P! Q/\
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MO_O]'_\ $4?\(S-_T,>M_P#?Z/\ ^(H WZ*P/^$9F_Z&/6_^_P!'_P#$4?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>gqr1p20dfppl000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqr1p20dfppl000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'B G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW^;K5W^R;/\ NR_]_P!_\:?8^;BX\W=_KWV[O[O;'M5J@"E_95I_=E_[_O\
MXT?V5:'JLO\ W_?_ !J[10!2_LFS_NR_]_W_ ,:I:CHMG(+7(?Y;E&^:X<9Q
M_P "Y-;55;[S<6_E;O\ 7INV_P!WOGVH 9_9-G_=E_[_ +_XT?V39_W9?^_[
M_P"-7:* *7]E6GI-_P!_W_QH_LFS_NR_]_W_ ,:NT4 4O[)L_P"[+_W_ '_Q
MJE8:+9H]X<.=]PS';<.>R]?FZ\5KO+'&</(BGT+ 53M+E5^UM-,H59692S#
M3 Y^G6@!W]DV?]V7_O\ O_C1_95I_=E_[_O_ (TYM5T]02U[  !G)D&*5M3L
M46-FNX )/N9<?-SCC\: &?V5:'JLW_?]_P#&C^R;/^[+_P!_W_QJ;[=: H/M
M,.7&5&\?,/44UM1LD:56NH0T) D!<?)GIGTH SM2T6REA@4J^!<1-\UPX'#
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MW'F1,\,FR0 QL,J?6@#.O=:U&[O;.72);1-*2XV3W,I+&Y(R"D0 .!D<N?3
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M4?&-B;:2]BL4#WKPHL4@.Y,'8Q)7C(R3Z8KNZQ-<9)+S1T!5L7X5AZ?NGX-
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MAHYW:8C8QEY#C_@;5;N/^/:7_</\J ,G1;G4Y]%MW>*W>;E6+2D<#CLO7_\
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MY^Z?IR.F: .FHKE;35II9Q"==MI7",2%MR,\'!QCZ<9[4ZSUIEN85N=<MY0
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M<=QS6U;7BS@_*XVJ"SE=JY]LUD)>B_)FDBB1X=3^S(Z]653QS0!T-<YI^/\
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MV["+=7;*6CC8E8U4850>,GJ2<#DU=M_^/:+_ '!_*I* "BBB@ HHHH ****
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M:3:Z7=7L.EV<4&9I2DJ'A_,)R1TZ<=:Q+SP[;ZM=S2)<&RB@4[T@MPX9 5P
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M?,89'R@YSW.1TK4T/3I;3S[BX18I9Q&@A4Y\M$7:H)[GJ3CCG'.,D UZ***
M"BBB@ HHHH **** "BBB@ HHHH **** $*J6#%06'0XZ4M%% !1110 4444
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MS,P '[SWH RH[!;6YU&^$C%KH(2N/N[%P,?6M;PS%/<&V1K=)&DEG$R>>T9
M\M.N.^>GM5*]*+9SD[L*C<(>>E7_  G=2PZ9&/-:,O+*2(AN<D1J>?7';U%
M&Y<ZA/9^'[BVET]9/,GEA2**\!D;+L 067K@$\^G>N4FLO&TOB:.[T<QQ0 ^
M;)9370)<84%78+\IRN0".OM6S<0_;+V.WE(WR7D>Y]N"QW2X)_'/&>W3G-0Z
MO-:V-S;V)GE.N79\NWBM[=R79.6!8$JP 89ST'/RT 9_VKQMK6B1K#_9T%P)
M98IW_M)MRJ#\\94K]Y??\\5U_AN:XA6ZMHM,>&2-D+I/=AB05PK#"\ X/H<@
MGO69X>\(KX;U+^U+T WUY<//=SQR$0J2,*H#= ,XSG)/)XX&A,P'CE@=OS-!
M@L^ 3LDX [G&3^!H Q=4<B9[DVY;RY2/(BE_>2,7&[&X8P "<^QK3O\ Q3;:
MK8R6T4*2[)HS((;I&^0./F&.<<=<=Q61XG0P/=V]V)&EF\Z4*2"7CZ#!'W1C
M(P1GBI;:'^T=]I$2V;B1;0[<;8-R')QSUP<]<;?0T= )S<XU.SATO4/-N602
M*I^<HA#_ "\#D <9KOQTKD_$8BM=.TZ*5XO.0K$2K!1G;CN?NY[$UTCWMO'@
M&3).<!06Z<'I0!FZ2+E=3N1=%S)Y:X+L#QN;'3I6AJ(9M.N KB,E#\Y?:%]\
M]JY_P_=(-0U%H8)F'F$;57D'<W7/?_&M+7;B9?#U](MGDK;LP65AC/H=N?KQ
MGTH8%6VTZ>^L&6.^-LC3/YRQJL@F'3!9@3C ZC!]Z;?Z?<Z=ISLMPDEC$NZ2
MU6 *7.1SO!X]3P35S0A=#2TRL2_O'_B+=S[#O4NHV%Y?:=/;FX@WR*-N8B%!
M!!Y^;)''M0P'Z+C^RHL# W/@'M\YJIXF=8[.W=BX G!)7H  2<COP#@=SCBI
M=(M3]A4M<S$!Y1M! 'WV]!4][IEI/$9)HO-:,;T\QBVU@." 3P?>@#SKP[J6
MF^(]%L]=DA1KGS'6Q^TJC+:KO(PH)QO8C)/7D#H*[73=<L7NY+>%Y/*$8<!O
MF"G.,#!/7T[?C7+R:6EEHLMYH$FBPZD-T\UI?1JT4G)^;J#&Q ZC@XY'>MC0
M-2TZ^EDELM4M5=HP\HAB4;!QM!;[O1QP!WH Z@W2E-R13/QD 1D9YQWQ0L\K
MKD6KKU^^RCM[$_2H[=IH[J6WEE,H"JZ,5 ."2"#CCM^M6Z *Z-=M]Z*%.F/W
MA;OSV% CNRQ+7$87!P$BY]N235@D#J<5#)>6T./,N(ESTRXYH P-6L+B=KNW
M:^O)?/\ ),2!5*1L"2"0 #MRHS6:VDW]\\=N;&:WD%G)92.0@A5'/S."')9L
M9QP,GKCFMN^NK5]42(FY9S"77R(WY*D$<@8Z,>*QK%EU2\LS<S7!NKNW6X$T
M5VZ&$LK-A8Q\NU=NW)SD]<T =HH"J%'0#%+6?H=Y+J&BVMU/CS'7YF P&P2-
MP]CC/XUH4 %%%% !1110 4444 %%%% !1110 4444 %%%% !102 ,DX HH *
M*** "BBB@ HHHH **** "JMRRB[L@<Y,C 8 _N-U_P#K5:JK<[?M=EN )\QM
MN2>#L;I_]>@"U1110 4444 8H_Y%)O\ K@W]:YW0+B&R\;^*Y[B14B41L6(Z
M?,XQ[G/YUT. WA"16&0;=@1^=<]H%G#+\1=::5-WD(C1 GY0=[C..Y'8]N:R
MJWO&W?\ 1G?@>7EK<VW+_P"W1.FMK:;4+F._OXS&B'=:VK?\L_\ ;?U?V_A^
MN339YI=8G>SM)&CLT.VXN4."Q[QH?7U;MT'/0GFEUB=[.SD:.SC;;<7*'!8]
MXT/KZMVZ#GI-<W*:=%#I^GVZ/<LN((%X5%'\3>BC]>@YHTMY?F+WN9:>]T72
M*[O\]?5A<W*:=%#8:? C7++M@MUX5%'&YO11^O0<T006^C6DUW=W&^5\-<7+
MC!<]@!V'8*/U)Y(8+?1K2:[N[C?*WS7%RXY<]@!V'8*/U)YCMK:;4+E+^_C,
M:(=UM:M_RS_VW]7]OX?KDT];^?Y$^[RO7W>KZR?9?UYO6R"VMIM0N8[^_C,:
M(=UM:M_RS_VW]7]OX?KDUY(?#U[J<TVHPZC?QQ6.I3F2&.%'AV>8"Q9#S+QS
MCT& ,UZS-/+J]P]I9R-'9QMMN+E#@L1UC0^OJW;H.>GF^CQSE]3TVVM(O*DU
M"XMD8A5"$L,#<>0<#CZU"_B*WF=+O]5J<VFL=.RU_K\66O$_B.PU?P_+86DE
MK'<VN!-%$VY!NV,CJ!P8V5MP/'IUR*9I.G(GBK4=&N#'.6BCNI6\MB6GV;2J
M 2=-JYSUSQQ@8I7UMJ*>&[JQ?0[-GMK==UZB*N^-2IPY.,$;1@C.>W4@;FFS
M:<DKZVZZ0TJ,7CAM9PGR;@7=5)RQ)'4XZ 8Y.=SRC3\,PW":G?1+>;;H32^8
M&AWJ0" /FR"3T_4]ZU9=/N[^[OK>2]MG@FM$7"VW0[I.?O<C/:JOAE7N-8O[
MY"[VCRS"-\@+DLIZ8W$GKGIQ6II-M]EU&\C,<,;,BN5A8D<O)SSW- &-IB^3
MXK\GRY?]=+F3: C$1H!CT[\#OFMS7S*+",0^9YAGC "/MS\W.3Z8IFB ?:M8
M.TY^W-R?]Q.E:=S;0747EW,221A@^UQD9!R#^!YH KZ9'&VDV9**<PIU'^R*
MQ?$-O!;2V_V:(1/,SM+Y2A0X '+8ZGIUK4LKZTM=-MHKBZ@CECA0.K2KD' ]
MZJZE=Z7J$(4.)9ESY+K"[A2>I! /;/X4 ;M<WK^G8NX[]0LADEMXO*(P21("
M#N]!Z=ZOQ:]%<RM%:6EU.ZJ&8*JKC/3.XC&:I:Q)J=V;.%=+3R_M4;L9;D+@
M*P(/R@\Y[>U %O0M]EIEG97:I%=,KMY:@X(#<D?]]#\ZIW\4.G^(K6XAC_>2
MK+(PR?G?:%']!5+5KCQ!!XAM)BE@]NA*PQ0J[3$LC9SDJI'RTYK35M6U"!+L
MM"UJRR&6':C ,"/ESD^O!]/QH Z>VMQ#:+"Y#G!WD_Q$\D_B2:\\\3(P\1P6
M[KN^SVFW<PR-I<[#]<#'U!KIK/P[<,Q&I75S<* <$WDG)[948 _#K3-*\,Z:
M9I9;BTMY7BD>/!CW \Y!.XG/'Y4 >?SWGDW\$+>0]K-%)YC&0;E<8*C'<$;O
MRK2\/7VGZ7<R7SW<OV>V1G6WM+21R#G:00%)Z%>G&!7HEU8VUO:F6WM88VB8
M2?)&%SCKT]1D5@V4_P!IEO98[JV+1&6WA1GQO#QQ%>F2!N4^M %2]N?M&E>1
MJOG6Q:XDN('M@T+\EL'+D$$;@3UZ<U1BMK])RUG+-(UH&9<WIP%XW*"JMD'C
M('IZBEUBXEGL+/<\L][ DFU#:O( _ELW)8C."HP?;FNN35;DV5M-:Z5/*)25
M.<(5 '#$>A[8H P;.VU0)-<375P7=C&D/G2R*Q(W#;NV\8SU]*L:;IVHV^J3
M0QY0;8Y&G=06P=XP Q8@#;T&/O?6K>K7]\8["1([6'$T9F2:8%HR6Q@8.#P:
MJ2:T%UJ/?K=C$SV\+,D2&0. S[L'L/Y9H D\0Z7B.*0W<TMT985C:9]H/[U1
MM(11\IW\U9A\+JMSYLTD+#>6*+$<$$\KUQC\*QM=CEOK2*[BU/4)8S.N$2#8
M%7>,\\<X'Y]JZ<:F_P!G+VME+<11Y7SO,C"MMX)!W9/3TH H+H-I::G:[E29
M9'?*/&NT84XXQVQ6]=7"6EI-<RY\N)"[8&3@#)KFY?$#W3Q26UFKSH#)"NYV
MW C&[A<8Y]>XJ6\DUJ\26Q:%5BGB*F5(,@!E[[FZCTQ0!JQ*BZU,$50#;H?E
M'7YFYJ_U&*Y33O[4OH$*W4NX00.')C3<&7)Z+GKD=>#6Q::3MC5KN6>64'O<
MR,HQTXR![]/:@ T9S'H\37 6)MTA()P!\[5.^K:=&<-?6^[^Z) 3^0K/T;2-
M*BMYHHM.MT\JXE7E0Y^]G.3SR"*LMH-F9I95:XC,F<B.9E"Y&/EQT_#N2: *
M]KJUG9V2J9))?G<@Q0N1RQ;KC'0TZ?7(_LZDVDZK,,*9&2/((Y/+9_2FZ1::
M;-IMO"(XI'B56D1CN*.5Y)]"<5<U.WC_ +(F5$4"*,L@Q]W;R,?E0!S^F6@D
MDE:PL8HY77YY7D5789.-S+'D]#W[5@ZU G]E:)87-[#&+BY>T6)DEE5V7D#G
M(&&3/.!@5W$D&F^)M-:&[M#+;+*08I05Y4]P#T[^X-9VIZ2=.TQ8-.CMHK.*
M56CBP5\O/RX ';G/;J: -?RI$O(UDN'9Y$;#*BC&"#CIGO4K6\,6Z66>7;SD
MO,0HS^.*K^3>S-!>">%F1<K$$*JP;&<G).?0_H:S-0U62"^9+RT6-A#F',P.
M#SEAQUZ?Y- &U%;V,V)8TAEQ@!^'Z>]6E15^ZH'T%<]8Z@9-1MX$13.OR32"
M4$NNW.2,<\XY[9]ZZ*@"K<<7EF_JS(?Q4G_V6J<OAVSDE<B6ZBAD):2WBG98
MW)ZY Z9[@8![U<OAA(7_ +DZ'\SC^M6J &HBQHJ(H5%&%51@ >@IU%% !111
M0 4444 >?>(;GQ!>_$.#1-*U9[&!K-9G(16"_,03@CDXQQ5F^T37["W\V7QM
M=L20J1I9(6D8]%49Y)_SQ5?4+R*Q^+\<L@9C_96U(T&6D8N<*H[DUUMG92>>
M=2U$J;HJ0B Y2W3NH]3ZMW^E<D8J;EO>_=GT%:O+#TZ5E%1Y4_ABVWKU:?W_
M *G.P>&O%1M4DNO&<\4A7+JMJC!?;.>:P=3E\3:98?VI%XGN;BR^T111E[=$
M\[<V"PZ_+Z'O],$]SSXA;NNDJ?H;O_[7_P"A?3K@?$B\A_L6*QB4O(EU TFP
M?+$-W&[TSV%*I!*#DF_O9>"Q-2IB8TJD8N[U7)'1?=O^7KMW-%%%=A\X<+#>
M7R^(?[?:VD%A<SFT\[?D>3]V,[.H_> G/H]0SZWKUM9V327P#3V/VH22(D8:
M4X_=XVG(']T?,=W6NOCUW2I)9HEOX"\(9I,M@*%.&YZ<=_2GVNL:=>^7]GNX
MY"[E%&<'<!N(P><XY^E<ZAVD>Q]9:=YT-%IMT5[;K\=G;8Y9O$.HG7!#'<$*
M998GA>,$1[8F8'8!OQN Y)&X'@5H>'-7O;S3[\R2&[G@4,C#:4=BN<*R@9Y'
M0@$9 -:IU_21+#%]O@WSA3&-WW@QPI_$C ]ZA?Q-I::C]D%Q&VQ)'FD#?+'L
M(!SZ\MCCN,4)6=W(F<G4AR1H6=E^#NWMUV.5N;R[UC3TM'U![J&5;62X*P*/
M*D:90T1&.F"3M.2-O/!K4\71VXGM6FGMXQ!;2M#!<6QDCE;Y< 8(&[C  YY.
M*Z*+5+&6PDODN8_LT>XR2$X";>N<],>]0C7M*:T:Y%[$8E<1DCKN(R!CKDCG
MZ<T."Y;-[_UW!8FI[12A3:46]%W:2_EM^'^9RUJ6?6+=WB,6L-J(+1_Q);&+
M[O\ N <>F[WKNZHQZQITUW#;17D4D\T?FQHIR63GGZ<'\JO5I3BDG9G+C*LJ
MCCS1Y;+^K>78****T.,***JM?IN81Q32A3@M&N1GO]?PS0!:HID4J31K)&VY
M3T-/H IZI ;C3I8@)SG'^HDV/U'0]JYE]/ M[5WM-8;#R;4,PW#Y, GZ]O3D
MXZUT^IQF6Q91')(=RD+&VTD@YZUA0:;MU*R#6UU$(IW*R23;]P\LCKCO[T 1
M74$EQ;P VNM1;DE'[J7[GS C([DXX]B15B)Y+*U4QZ=J[R2'<<NK, F."<_Q
M>G4Y-:,.A6T+[A-=-A=H#3$C&W;T^GZ\TQ/#MHD,\?GW1$X <F8YX.>#VH I
MVA98TE>QU)?*D*!'?<3O.2_'4#]*MZ7']HMYXI8M0A59L@SR;6;CJ"N.*=-X
M>M)IWE,MTN\*"J3E1@  #\A6G%&(84B4DJBA06.3Q0!SHL8T\)O(L]RC"!CD
MSLP[]F)'Z5A:5;7=UXZUBW^TJL4D"F66,%79/,?A?3/<^G3U'3@9\(N..8&'
M/XUS&E7LT?C?41!:E[N>T7RXB"%7]Z^2Q[*/S/05C5M[M^_Z,]#+^;][R[\O
M_MT3L+FY33HX=/T^!&N67$$"\*BCC<WHH_7H.:(8;?1K2:[N[C?*V&N+EQRY
M[ #L.<!1^I/)#!;Z-:3W=W/OE;#7%RXY<]@!V'8*/U)Y9;6TVH7,=_?QF-4.
MZVM6_P"6?^V_J_\ Z#]<FJUOY_D9^[RO7W>KZR?9?UYO6R"VMIM0N$O[^,QH
MAW6UJW_+/_;?_;]OX?KDTR:>76)WM+.1H[.-MMQ<H<%B.L:'^;=N@YZ$T\FL
M326EI(T=G&VVXN4."Q[QH?7U;MT'/2:YN4TZ.#3["!'N67$$"\*BCC<WHH_7
MH.:6EO+\RO>YEI[W1=(KN_SU]6%S<QZ='!I]A C7++B"!>%11QN;T4?KT'-<
M+X6M"UQJ$\NI:D9K;59M]M;QL;>7$BL6*A3R<<?-QQ7=006^C6DUW=S[Y7PU
MQ<N.7/8 =AV"C]2>>4\&V4]_'K<RWU[9YU>8B%<#:<@\C'7G!!XXJ7_$C?S-
MHV^J5>776.O=W?\ 7XOL;VIZW;>7]DFMKN-I/F7(120I'.&;..G:N;OK>VU'
M7HI+?3@519VFA60!920N>B$DYP>#@\UT;:3(=3DB-_<;Y(Q()?XN"1CZ?-6G
M!IQBFAEDN[B=HE*J)-N.1@G@ _F:W/+.=M3<W)GDN[>S6)9BAN)K1G8$ ?>!
M(P,8Y QZ@5J6WAZ**X^UK/&DS(%\RVMHHR5&>^"<<GO5RVECBO-01W10) _)
M[%%S_(U )X+656L[A&MVD5'A7YE4L< KCISVZ?2@#.TFUM[?2YQ?ZC=NB7+(
M9)KAHR3@#!QCKCOZUFWD6F RW%O?O,#)NV+%O*)D!AEL_-C.#UJ>UG#:9XA@
MEM;MPEY*ZB)"6(PI7;NZ'T':KAU07.@)Y=E.JS6X99)%\O+%=W0\YSVH A>T
M@BT=9['2M0NI8LO&D3) \A.!@DE?KS6MI5LMUI=JUY;D31!HRDC[BN&(P2.#
MTK(FU/6;J\F^P30R0HV-L:;MO'()'7G//'TXJA+<WN%M1<SI(KR.2%/SC)8L
M>@(4\$CU^M '5PQ16NK7(AA12]NC84 ;MI8?U%9>K7D[VFCW#0"*1[^*.1#\
MVP;^>>G;K6?<:E>SA)UF*2;-OFJ1AX]P)( Y!X(Y]N*AN;1=+TZ6SFNIKB,7
MFZ(32$O\\F2#ZK\PH Z+5%N6UBR\B%"BAF>1Y  ""-HQ@G/)/YU5TZXF@UIT
MFO(+B)K7<65R[DJY]!@ !@,5>T/9+8>84B9Q(RETB" D$]AZ=.M5O$A>)+>6
M-WCV[AE&(SRK8/L=O/MF@#7-TOG>6(IB<XSY1"C\3Q6?#>O%J-U MOAY761%
M>15)R@R,9R<;3TK6!R ?:L#4U5/$=E)C!)3Y@.1][/\ 0'VH V)#=GB-(!R<
M[V)X[=JYO2)FM=6O[#<L#S7),9BA&W 7G)]^V>>,<UUE<LBR/XJ=@@,:3DMD
MXX"C!!)YY;MZT 2ZCH=Q<7%LLVLWY66=QB-E3:#&^.@[?UK-T[3M-N%WZG).
MIB>-8C)=OA\KQP3C).[CV%=3?Z9'J$UK(\UQ']GD+@12LFXE2O.#[UAZ5I%F
M;JZA>ZGD;S"WDF5_EVL0&SG'84 2SZ%H,=K=S65C;"X@3)95Y!7YL?F*-'FA
MC6>6\DC,<4:1B5U"C'F2 <8&.>.GI6D^BVY@EC26Z7S 0<7#C.1CUK&T'2K.
MY6:7?>YVHCJ]RQ!89?(&?5OTH O^('AN-/VI(A:&X0-QG#'@#V/S5+X<:-M+
M(3(Q*^0<<<]O;%5-=TF(:8%CDN]S31X NG7G</>K7A[[3]C<W#LRDJ8LI@!-
MHQVYH =K-X=->&]V;U1)%*[@N0<'J?\ =K41@Z*XZ,,BLKQ'%YNFJ-ZIB0#>
MP)"Y!7)QVYK0LG\RRA;S5E)09D5=H8]R!VH R;^>:QUJU2W"K'-Y:.@3JH+#
MCTQN!_"MVL#Q((4>TGG64QH6)\I]AR"I'/IP:WE.Y0?49H YV-_)\9/'Y@17
MW':6P&RB=!T)R#SUP*Z.L"^9H/$L#1P(YE6/<Q3<R %@2/3@@?E6L=0MQ??8
MMS&? )4(< $$]>G:@#(T2-HM9U!=KE#P&VX48=N,]S@C\!6[-&)89(ST=2OY
MUD6L-ROB&Y9'/V96.Y=W\3*ISC\ZVJ ,3PS&8;&128OG?S0%?+?, 26]#G/'
MM5/Q4NVZL9<,01(N5X P-W)]/EJ[H5K%;S7128&1F(:+'W0'8 _CBG>(C$MC
M&TD>]C*(T.<%6;*Y'YT +X:EGET2/[1(9)$=X]QQD[6([?2K6I6TUQ &M2J7
M*GY7)(P,\C/O67X3E1[2Y11-O67+F0Y&6&[ ]!@CCWJ]K^M1:#I4EX\$US+]
MV"U@4M)/(>B*!W/Z#)/ H =IEI>0;GOY(YIB,"1<],].>G;IUK1K&T#Q NLV
MRBXL;G3;\+NELKM=KK[J>CK[C\<'BMF@"KJ(SI\Q_NKO_+G^E1:3A89H]\S%
M)F!,RD'U'7J,=#5N=/-MY(_[ZE?S%,LW,EE YZM&I/Y4 3T444 %%%% !111
M0!P6OZ?XBMO'L>N:/I45[&MD(/WDRH =Q)ZD'T_.HKZ]\>:@J13>&+;[.#F2
M(7:XE] 3N^[ZCOWXR#Z%16#H:NTFK^G^1ZD,T:45*E%N*LF^:_X21PDFL?$$
MP,D7A>SC8KA6^TH=OH<;JR+ZP\8ZEI<6F/X;@AB-PD\LXNU9W8')9B6Y)_\
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MIBV-Q;V\-RL\LURJJ3M<.%4!VR20.>!CIZ5U5 !1110 4444 %%%% !1110
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M)'7T&*9K.Z.YMI_*RB.NYPO3YP>N>!U[5H75A;WDMM),I+6\GFQX.,-C'XT
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MMJ8$,4R2++</<+&RGJ,*H.2.G&*E%C=Q2VZ7=_"DY4A79F8N,]#]T$_-Q]:
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M@"M?QZ7I^H6MM+!'()E9@DDQ+#!4%@&/(P>>*325TE]=N6@TNWM[B6(.76W
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M;'7&>O0TSQ5',BVMY'<-&(-^4";@3C<#C&2?EX]ZTM$3R=-6'?"WEL5'DMD
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MENA&]MSN[%W=O5F)))^M %FBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMT'/26ZN4TZ.'3]/MT>Y9<00+PJ*.-S8Z*/UZ#FEI;R_,KWN9:>]T72*[O\
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M0!-K0!TJ9B,["LG_ 'RP/]*?I<HEL$P3\A*'+9(P?7 I^HP_:--NH!C,D+J
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M[QH?YMVZ#GHMS-)JUT]A:2,EK&=MU<(<'/\ SS0^OJ1TZ=3Q+=W2:9;PV5C
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M YR" ?3\JOQ:)ID%NL$=E"(E)(4KD G'K]!^57Z*T.,AAM+:WQY,$4>!M&U
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MVC'U9_Z"@"U5:Q3R[41[@=C,O'^\:K7LL]E:27-Q>81!]V& ;F).  "3DDD
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M.9Y5$A<*< 8#'D],DX')/ K:HHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>gqr1p20dfppl000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqr1p20dfppl000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'R OX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVD;$,[!4A 4DNV>H&.@ZG%3S+EYAI7=B;_A$-%_YX7'_ (&S?_%T?\(AHO\
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M$8 )&!@#KVH>B;#K8?\ \(AHO_/"X_\  V;_ .+H_P"$0T7_ )X7'_@;-_\
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MB&B_\\+C_P #9O\ XNC_ (1#1?\ GA<?^!LW_P 76[10!A?\(AHO_/"X_P#
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M(4D[CN)QCBO0J**8K!1110,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *PC_R/J?]@MO_ $:*W:PC_P CZG_8
M+;_T:* -VBBB@ K*\4?\BEK/_7C/_P"BVK5K*\4?\BEK/_7C/_Z+:@#0M_\
MCUA_W!_*I:BM_P#CUA_W!_*I: "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %81_Y'U/\
ML%M_Z-%;M81_Y'U/^P6W_HT4 ;M%%% !65XH_P"12UG_ *\9_P#T6U:M97BC
M_D4M9_Z\9_\ T6U &A;_ /'K#_N#^52U%;_\>L/^X/Y5+0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%,D
MFBA4-+(D:DA068 $GH*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%'?% !1110 4444 %%%% !1110
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M/_OE?_C]'_"6>,/^@79_]\K_ /'ZGHH @_X2SQA_T"[/_OE?_C]'_"6>,/\
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MVO4+22.^ENI)%6.5_*=4RJ,< JR*,"H=1)_X2W2^?X1_[4J'QN3_ &/8\_\
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MGOC-6ZR/"W_(H:+_ ->$'_HM:UZ "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %81_P"1]3_L%M_Z-%;M81_Y'U/^P6W_ *-% &[1110
M5E>*/^12UG_KQG_]%M6K65XH_P"12UG_ *\9_P#T6U &A;_\>L/^X/Y5+45O
M_P >L/\ N#^52T %%%% !1110 4444 %%%% !1110 4444 %%%% 'DGA+_D#
MR?\ 78?^BHZW:PO"7_('D_Z[#_T5'6[0 4444 %%%% !1110 4444 %97B:"
MXNO"^J06D1EN9+9Q%&.K-C@5JT4 >?KJ'BC8=UOXH#-@D+86N%(ZA?FZ?6J6
MMKXEUG3S:&Q\02;Y86V7%G;I&-KAB25;(XS^0KTVB@!7.78CN:2BB@ HHHH
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M'A;_ )%#1?\ KP@_]%K6O61X6_Y%#1?^O"#_ -%K6O0 4444 %%%% !1110
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M"^WAO30Q&R?K_P _#_XTG_"-Z;_<G_\  A_\:UV^\?K24 9/_"-Z;_<G_P#
MA_\ &JU[I>A:=&DEV\\2NVQ3YTK9;KC R>U;]9/B*ZAM=-3S)5ADDF5896;:
M(WZA\^P!/OTH S_!@*G7643?9SJ;?9FE5@6B$:!2-W)'!YICP7FG>)M T6PU
M2\6*_%PJI*L;JI10PS\H..6[YSBMO2+Q+VQ!74X=1>-BDD\("C=UP0"<'!'%
M96I!6^)/@P-(8U+7F75MI'[H=^U &L-,O1&MR/$D.V3;MB/E?(6('/';//\
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M]82*2%R-Z85V0GC@':I^AKF]-N+#Q'XAL+JT34OMDEO(KWNH60\I@G("!L@
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M>XDLVNV:XVB0W%PTN=O3&?K0!LZ/I8?6EU*5U;$_D+'M[&,DY]>*)0%O+I5
M"BXD  ' ^8TT":)LI-/%\^\!6P-V,9_*D"MDY+,S,6);DDDY)H RKJ>%M<\.
M1Q*5FABO$F.S;EL(>O?BMA7;>OSGKZUA:UI;RZAI>HVMFDUU9W!<YD\L[2C*
M>>G4K^59-YX2\.(AN-1TNUO=5N9<L/-93)*[$X W<*,]<=!0!H>%)1+IOR[B
ML<URC-CC=YS'&?6M>Z_X^])_["4'\S6=X;6SL]/DT^WM[6S^SW4L7V>"4D9!
MY(W<\UI27$":CID;^7)(;Z%0A<;E))PV.O'6@#K_  M_R*&B_P#7A!_Z+6M>
MLCPM_P BAHO_ %X0?^BUK7H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K"/\ R/J?]@MO_1HK=K"/_(^I_P!@MO\ T:* -VBBB@ K*\4?\BEK
M/_7C/_Z+:M6LKQ1_R*6L_P#7C/\ ^BVH T+?_CUA_P!P?RJ6HK?_ (]8?]P?
MRJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \9LK#QG8:?Y>C>'A=Y
M96D6\/V8HWEJ& +/\P!7J!BI,?$__H3-._\ !BO_ ,57L5% 'CN/B?\ ]"9I
MW_@Q7_XJC'Q/_P"A,T[_ ,&*_P#Q5>Q44 >.X^)__0F:=_X,5_\ BJ,?$_\
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MA$WV/R1/@1_/M/\ L^O/2N;_ .%J>&O[NI_^ 9_QH TOL?C/_H-:+_X+W_\
MBZ/L?C/_ *#6B_\ @O?_ .+K-'Q3\-EE4)J99B%4"S.23T YZUH?\)M9YYT7
MQ%_X*I* '?8_&?\ T&M%_P#!>_\ \71]C\9_]!K1?_!>_P#\74=SJE[;Q6.L
MRQ:HUM-.P:Q@MBSI$4?:60#.[(4GGCI37\>Z=')%')I>OI),VV)&TQP9#C.%
M'<XYXH F^Q^,_P#H-:+_ ."]_P#XNC['XS_Z#6B_^"]__BZCG\=6%K;R7%SI
M/B"&&,;GDDTMU51ZDG@5TP(90PZ$9% '._8_&?\ T&M%_P#!>_\ \75.W\0Z
MQ:ZAJ^DWHM;[4;5('MA:Q-&)?,!)!!)P% SG/>NEU+4+?2M,N=0NBPM[=#)(
M57)Q["LF'Q9:SVD5[#I&M/#,_EI(MB3N8$@CKG@@YSTQ0!2U(ZCXIDO]/TV^
MT]=,\B-9H[FW=W8ON)!*L"N-HXZUA?\ "LM1_P"@G8_^37_QZMB_^)GA[2;M
MK;4(=2M+CJ4EL]I(]>O(]ZZRSNH[ZRM[N'=Y4\:RIO7!VL,C(['F@#S\_#G5
M3;+;G5;'R4<R*FVZX8@ G_79R0 /P%;GA#PE/X:NM1GGO(9S=K$H6)9,+LW=
MW9B<[O6I?$'CS0O#&H+8ZF]RLS1B4>7#N&TDCKGVJ@/BEX;:6*%1J+32D!(E
MM<NV<$?+G/.1CUH U/$=IJ3:AH^I:;8)?-822M)"9EB;#IM!5FX&#U]C6AHN
MHSZKIB7=Q9&S=F91$95DX!QD,O!!YKD_$/CO1Q8&"^\/Z]-"^2PDM6@V@#.<
MDC/&?RJUI/C4+IL27FA>(4E7*C&FLV4_A.5XSC% '945S#>.]-BVF?3=<MXV
M=4\R?3G1 6( R3P.2*Z@C!(/:@#F?%EQXMMOL\GAFWL9H@K?:/M) *XZ$$D#
M&,U5TH^.-1TJWO)M1T>UDF3=Y+63-MYXY#]Q@_C4_B[4K.!K>QN],GO/,0RJ
MT=RD(3!QU=@"?;GZ4EAXRM_[/A^VQ2K=!<2!98""1WR),<\'\: ,?2G\9S>,
M;%?$-A8K& Q$MM(/E10W.W)."6 YQ73^*=*N]8TE(+*>&&:&XCN5:5"X)C.X
M  $=2!63HNHN^KQ75KH5U:V=]*T%Q<-=13(90A=>5=B#@'CIR*ZJ[G^RV5Q<
M!&?R8VDV*,EL#. .YH X;1[[XD:I$UQ<)HUI 8C)&_E>89&[* K\'Z]*NWB7
M^O>)--O-(U"SMY=/LF=A/ 9/GE)1U(!!!&SH:SO#_C+2K:[B.HZ7J.E2:@I=
M]0OQY<,KXW<<[0/3'MZUTR^*/"JRM,NN:0LC@!G%S&"P'3)SSUH @>YUW2[^
MRDU35--;3YIO*D MC&Z_(S9W;L=5]*;<:WJ%]]CM=,EMK*^GN)%9;N$OB((S
M*VW(/S +SVY%;5M=Z;K$"SVL]K?0QR?+)&RR*K@>O8X/ZU9DBB9UF>-&DB!*
M.5!9>.<'MQ0!D>'-'N](347OKN&YN;Z\:Z=H8C&H)51@ D_W:R?%.FRZOXV\
M(Z?#?7%D\S70\^W?:X 120#VSC%6=+\>Z3K-U';V-KJLA=E!?[$VQ-WW2S=@
M?4U)J6?^%E>"\2^4=]W\_'R_NQZ\4 7+;1EM+%HFO;V:8,5-P\Y,AYV_>_SB
MN?>SU'2OBMKFGZ;+>75K%I\2?Z5=%Q&[X*LVXY./FZ5V,F/L\NY]PWMENF?G
M//%8L'D_\+4\4?9W#Q?9+/:P8MGANYH PK32+KP_JNK6]GIFHWMG(D(@D2ZW
M;7"?.3O?/).<56US7Y;W2YK!/"VN1OE \T:C&T$%OF5NXS^==^\*>:SB9XV;
M&X*^*KM9P".:%;K:DN R[E)X'Y]J .,\->)7M/#VGZ=?Z3K@GMHMLLBQ_?.[
M/# DGCU%3_8C<>-'UK^SG,8MH3;S7&))%VLQ9AW& 0.W2NC&CQ0MNM[PH^"/
MGP0:LK96P2,-<,62/R\B7MW'TH YZW\.Q3>*M3UR"WB2Z?[//;32Q;<, P<=
M2<,,9/O[5D^'M.:S\>R7&I:4HOKK78Y;>Z#I)Y49SE=V<\\<8_*O0(((X0?+
M9FR OS-G '05S:_\CCIO_84C_F: /4?"W_(H:+_UX0?^BUK7K(\+?\BAHO\
MUX0?^BUK7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"/_(^
MI_V"V_\ 1HK=K"/_ "/J?]@MO_1HH W:*** "LKQ1_R*6L_]>,__ *+:M6LK
MQ1_R*6L_]>,__HMJ -"W_P"/6'_<'\JEJ*W_ ./6'_<'\JEH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\Z\8?\
ME+\/_P#8-O/_ $**O1:\Z\8?\E+\/_\ 8-O/_0HJ )Z*** "BBB@#/U-2TMD
M6"M;K*QF4C.5V,!^38-6H;2WMW#PQ*C $97WJ.]_U:_.RXR05&>U6J %W-ZG
M\Z-S>I_.DHH ,G.>]+N;U/YTE% '.>.F)\.1\G_D(6G_ *.6NE<G>W)ZURWC
M]I%\+!H4$DHOK4HA;:&/FK@9[?6HG\1>*_[3DL1X4M&G2-96 U08"L2!SL]5
M- '69KB_B$Z(V@R2PB=4NYG\MG*AB('(!(Y R.U6_P"VO&.,_P#"(6W7I_:B
M_P#Q-8>O2:WKM_866I:7!IA@9Y$9+H3E]Z-&.,   G/)Z4 -\6>&=5739([6
MSTB1[N9+:,1F5?*W<9.YB&R<#D<9]J]%C!6*-3U"@'\J\KU;7/&>I*(9?['L
M/LDPGDDM9Q*ZLJEE!4L>O! ]A7J<+%H(F/5D4G\J ,+QU_R(6N?]>C?S%7_#
M6?\ A"=-QG_C^N__ $.2J'CK_D0M<_Z]&_F*P="\,VU]#!=-K>M*[W5PS627
M3+;IAVY '(S_ (T =+K=BBI/JR0VLD]O;.72YA#K(J@L!ZJ?<>M6=+U1+[1]
M.O)O+@DO+:.?R]W W*#@9[#-4[S2)&T5--;5[B"W5/+:?(,LJE2"&8Y]?T%0
M:!IMG#J]GI9$=S:><L:LPR H0X50#QT^G% #KUVU7Q'<Z(T%JL<-G'.;B2$2
M28=F4JN>%^[UJCXBL(-&DTO4-/CBB<ZE:0LGE*<@GR\@]0=I]<' J2/PQ)/J
M%S?6NN7EA.Q,+_953E Q*J=^X\<UI:UX>37-!BTNXO[I6C:.072$"4NG1NF
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M@!W].M:NE^'M#T"XF?0;&:T6>)1/YCLQ9@3@#<3P,T 9=S?:3/J!N1J<84@
MH89.1C!&=M5H;FQAUB.^&K6A1%QY7V60 MY;IN^[U&_]*N>1K?\ >NO^_O\
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MQ8.7WF2&0NP/.1\V1WZXH R/$T]P_A:>*00RJQ575R"<!^O?)&.E==,JB.5
MJA K +CC&.F*\Y7PWJNI8CBU#67MUNA',;J6 +M5_G^4#=G&<?45Z._S[L_Q
M9_6@#S?P&)#X2N"D43J((MS.>5_=#I7HT?\ JD_W1_*N.L_A\=/MC;VGBC5X
M82 I11'@@# _A]*U8/#^HQ21%O%.IRA&#$-'%\X'\)(7I^M &]1110 4444
M%%%% !6!XWDDM_!FI7<$LD-Q:QB>"6-BK(ZL,$$5OU@^-H9;CP/K,,$3RRO;
M$*B*2S'(Z 4 >B>$F9_!NAN[%F;3[<DDY)/EK6Q7EN@?$E+3PYIEA!X8UZYF
MM;***0BW6,!E0 _>8'&1UQ79>#/%4/C+PY'K$-L]L'DDC:%V#,I5B.2/S_&@
M#H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"/_(^I_P!@MO\
MT:*W:PC_ ,CZG_8+;_T:* -VBBB@ K*\4?\ (I:S_P!>,_\ Z+:M6LKQ1_R*
M6L_]>,__ *+:@#0M_P#CUA_W!_*I:BM_^/6'_<'\JEH **** "BBB@ HHHH
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M** "BBB@ K"/_(^I_P!@MO\ T:*W:PC_ ,CZG_8+;_T:* -VBBB@ K*\4?\
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MS@9H UZ*R;+6"TM_%J0MK-[611@S#&UE# DG'/4<<<4RZ\6:!:*IEU:V;?\
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M<D5.D<<2A8XT11P J@ 4ZB@!<GUI*** "BBB@ HHHH **** "C)HHH ****
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M1SSU]ZZ+O7%K\.K5M5;4)];U:6?>9%*S;"A]CSTH N:K),/%4E@X!M;[1YR
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MX<QHAX7[??HKCZJ2: +Y= <%U!^M*C>8^R,,[C^%5)-5;?3/B5]G2.&/PQ8
MN26.^5T!.?[N#C/K5@>#?&EU=O->^.!#N0*386"QL<=,DL1CD]J )C;W(>-#
M:7 :5MJ9C*Y.,]\=@:G6&2P875XB);JK++^]4L%8$9QGG%5/^%7BY!;5?%OB
M&\DSD,ER(<?@JU-%\(O!RJ/M%A<7DG\4ES>RLS_7# '\J ,[X*3#_A%M4LU/
MR6FK7$:<_P )(8?SKTJLW1_#^D>'X9(=(T^WLHY"&=($VAB!C)'KCO6E0 44
M44 %%,6(+*\FYR7 !!8D#'H.U/H **** "BBB@ HHHH **** "BBB@ K"/\
MR/J?]@MO_1HK=K"/_(^I_P!@MO\ T:* -VBBB@ K*\4?\BEK/_7C/_Z+:M6L
MKQ1_R*6L_P#7C/\ ^BVH T+?_CUA_P!P?RJ6HK?_ (]8?]P?RJ6@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSK
MQA_R4OP__P!@V\_]"BKT6O.O&'_)2_#_ /V#;S_T**@">BBB@ HHHH ****
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M]IW-N)N9Y)#G\37<T4 85IX*\+6,:);^'=+0)]T_9$)'XD9K:2&*, )&B@#
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M/6'_ '!_*I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-/LUVVMC;0+Z11*H_05:HH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMAMEWE2JL2Q((&"Q'8?(>10M0.SHKS][[Q=:742J+ZZVB!V#VR[74C,@RJ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K"/\ R/J?]@MO_1HK=K"/_(^I_P!@MO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "L(_\CZG_8+;_P!&BMVL(_\
M(^I_V"V_]&B@#=HHHH *RO%'_(I:S_UXS_\ HMJU:RO%'_(I:S_UXS_^BVH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A
M'_D?4_[!;?\ HT5NUA'_ )'U/^P6W_HT4 ;M%%% !63XH_Y%+6O^O&?_ -%M
M6M39(TEB:.1%>-P596&0P/4$>E $%O<0_9HOWT?W!_$/2I?M$'_/:/\ [Z%9
MO_"+^'O^@%IG_@)'_A1_PB_A_P#Z 6F?^ D?^% $FH:?H^K($U"WM+D 8'FA
M20/K4>GZ1H6E-OL+2S@?&-Z ;L>F>M'_  B_A_\ Z 6F?^ D?^%'_"+^'_\
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M4?\ "+^'_P#H!:9_X"1_X4 :7VB#_GM'_P!]"C[1!_SVC_[Z%9O_  B_A_\
MZ 6F?^ D?^%'_"+^'_\ H!:9_P" D?\ A0!I?:(/^>T?_?0H^T0?\]H_^^A6
M;_PB_A__ * 6F?\ @)'_ (4?\(OX?_Z 6F?^ D?^% &E]H@_Y[1_]]"C[1!_
MSVC_ .^A6;_PB_A__H!:9_X"1_X4?\(OX?\ ^@%IG_@)'_A0!I?:(/\ GM'_
M -]"C[1!_P ]H_\ OH5F_P#"+^'_ /H!:9_X"1_X4?\ "+^'_P#H!:9_X"1_
MX4 :7VB#_GM'_P!]"C[1!_SVC_[Z%9O_  B_A_\ Z 6F?^ D?^%'_"+^'_\
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M4?\ "+^'_P#H!:9_X"1_X4 :7VB#_GM'_P!]"C[1!_SVC_[Z%9O_  B_A_\
MZ 6F?^ D?^%'_"+^'_\ H!:9_P" D?\ A0!I?:(/^>T?_?0H^T0?\]H_^^A6
M;_PB_A__ * 6F?\ @)'_ (4?\(OX?_Z 6F?^ D?^% &E]H@_Y[1_]]"C[1!_
MSVC_ .^A6;_PB_A__H!:9_X"1_X4?\(OX?\ ^@%IG_@)'_A0!I?:(/\ GM'_
M -]"C[1!_P ]H_\ OH5F_P#"+^'_ /H!:9_X"1_X4?\ "+^'_P#H!:9_X"1_
MX4 :7VB#_GM'_P!]"C[1!_SVC_[Z%9O_  B_A_\ Z 6F?^ D?^%'_"+^'_\
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M4?\ "+^'_P#H!:9_X"1_X4 :7VB#_GM'_P!]"C[1!_SVC_[Z%9O_  B_A_\
MZ 6F?^ D?^%'_"+^'_\ H!:9_P" D?\ A0!I?:(/^>T?_?0H^T0?\]H_^^A6
M;_PB_A__ * 6F?\ @)'_ (4?\(OX?_Z 6F?^ D?^% &E]H@_Y[1_]]"C[1!_
MSVC_ .^A6;_PB_A__H!:9_X"1_X4?\(OX?\ ^@%IG_@)'_A0!I?:(/\ GM'_
M -]"C[1!_P ]H_\ OH5F_P#"+^'_ /H!:9_X"1_X4?\ "+^'_P#H!:9_X"1_
MX4 :7VB#_GM'_P!]"C[1!_SVC_[Z%9O_  B_A_\ Z 6F?^ D?^%'_"+^'_\
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MYB\8ZS>/$5MY[>V2)\_>*^9N'X;A^=6Y+^3[/*\6QFBB+L64CD'ICMT-/FU
M1WL, ,>TG$I+<K\I(Q^5268/@2.^L=&?3+W3KBVD@FG<2/C:X:5V&"/8BG>!
M3?6F@VNDWVF7-K+:QD-)(!M8[CT(]N:V3?3@;O*4[H#*J '.01@?D:FLKO[2
M9E+(_ED#>@(!R,]Z +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %5?[/MN?D89Z8<_+SGY?3GTJU10!6%A;B"6$(VR7[_
M ,YRWX]:62QMI0OF1*Q7HQZ],=>O2K%% $)M8C,)OG#A"@PY  ^E.A@2!6";
MOF.6+,22?J:DHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g5lvsimk4gaq000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5lvsimk4gaq000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "O F0# 2(  A$! Q$!_\0
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MB@ HHHH **@BNH9YI8D<&2(X=>XJ>DI)JZ&TUN%%%%,04444 %%%% !1110
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M5@PPS+_3WI#H!^WBY^T A;CSU4Q@D<8VY]/2GQ:$L0@Q<,3")<$J.6?^+\*
M&2>(-FEPWXM&,;J68&105P<'KU_"EN?$$<#OLMI)8XU0RN"!L+?=&.YJ";PP
M)(%A6ZP@@6'YHPV,'.1Z9[U%<:5<RZF4CC=+>2:.29F*[6V#MWY]* +PUZ)M
M0%L(B5,OD&3>/OXSC;UQ[UKUE6>C_8[Z2998VB>1I-K0C<"?]KKBM6@ HHHH
M **** "BBB@ HHHH **** ,"3Q7:I")1;SLIZX XJ*/QE9RE@+>?*C)R!7'6
M<5U?W$=K"Y4Y^\3V]36I-I>+*YFAU!)5B&UU5>M=+IP6C/,6(K25T;P\8V9(
M_P!'FYZ=*8_C2T0D"UG;!QQC_&N.6 ;6)?&*CAME\W.XAM^=V>U5[*!/UJJ=
MN?&5FL:NUM.-W08'^-/C\6VLOW;:?ZX%<1<R"1\*QQV%6;$,LBL3D9&12=*-
MAK%5&[7.E3QWI[7!A>VN$(.,MC_&K+>+[)8U<12LI.!C%<-<Z?\ :+R2:*=%
MW-T85+Y5RD B9,LG.X<C%-TH=!+%5M;G8-XSLU90;:?GZ?XU-#XLLYEW+#,.
M<8.*\^G:56!=!CL0U6(X3/\ Z1&"CD<C. 30Z,1+&5;G:W/C*QMAEX9<]@,<
MU#'XXLI,?Z+<+GIG'/ZUP<L%\T;"X@)([XS4^FQ2QR+N@.T'[Q'/X4_8PL+Z
MY6<O^ =S)XTLHFVM;S_I_C1)XUL(T#>3,<]ABN"FF+S,QXR>1BF.'V_PD8S1
M[&(/&U3T!?&MBR[O(F&>G2I5\6V;J2L,QP,]J\^7FVC)(4<U;@D1)%$;E@>N
M:3HQ''&5.IUJ>.M/8<PSJ<XP<?XU*?&5EE@()C@9XQ_C7!7EC'([%7"R$\<\
M"J4:S0R@JZD@XR*?L8/8EXVLG9GHI\=6 _Y=K@_@/\:?'XULY%#?9;@ ]"0/
M\:XI8T7J@.X@L">_M22[?,V%BJ@]J7L8#^MU>K.Y7QC9.N5@F)].*/\ A+[;
MJUI.H]RO^-<3!@R2;?NA>.:K3,'.X%B V"<\4>QB-XRI:YWS^,K%& ,,W(]J
M<?&%D(C)Y$V!]*X&5"9?F8X[5/:X*M&Y!4BCV, 6,JMV.VA\8V4QP(95^I'^
M-$_C&RMX]S0S'G  Q7 /' ).&=2#R0,TG^O(!D/'M3]C$7URK:QZ##XNM9H]
MXMIP/0X_QIK^,[&,X:&;].*X:>_%O*L,:_*N,FI)O+G59D!)8\BE[&(_KE39
M,[63QC:Q@$VLY4]",<_K2)XSLG4M]GG&/7'^-<<CD1,C#*>F>GTJ$_+E000W
M0FCV,0>+J]SM6\;V"N%-O/SWX_QJ1?&-HX^6VG/?M_C7 73 *H'7M0"R2)(2
M &&=H-/V,1?7*MSMQX]TXDJT$ZL#C! K7TS78-4D"PQR#Y223C KRZ:,22%3
MP.I;VKM/!TD3R%(P $3 ]ZBI2C&-T:T,34G/EDSL:**X/4=;U*'4KB..[=46
M0A0 .!^5>9B\7##14IIN_8]FAAY5FU%['>45YU_PD&J_\_K_ )+_ (4?\)!J
MO_/Z_P"2_P"%</\ ;5'^5_A_F=7]FU.Z/1:*\Z_X2#5?^?U_R7_"C_A(-5_Y
M_7_)?\*/[:H_RO\ #_,/[-J]T>BT5YU_PD&J_P#/Z_Y+_A1_PD&J_P#/Z_Y+
M_A1_;5'^5_A_F']FU>Z)]4O)K'Q-<3P-M=6_ C'0UU^E:K!JEMYD?RR+]^,]
M5/\ A7G<T\MS,TTSEY&.68]Z?9WDUC<K/ VUU_(CT->;ALQ=&M*7V6]CLK8-
M5*:7VDCU"BJ&E:K#JMMYD?RR+]^,]5/^%7Z^GIU(U(J47=,\247!\LMQ"<#/
MI7/+XQLFFDC$,V8SM)(&,UT+?=/TKDK6WMI]25716W$Y&.M;P2=[G-6E--*+
M)SXWL ^WR)^N,X%3'Q=9KC=!.,^PK&.DII[M.\.=Q^4DYQ5*X/F29W]>QK7D
M@]CE=>M'XF="_C:P0X\B<C&<@"E7QK8NP403\]\"N1ELXHYC)NR7 ^3' -1_
M993E@-F/NY[U7LH&?UJM<Z]O&]BK$?9K@XZX _QI4\;64GW;:X([G X_6N,,
M(\LN6.[."<4KH(L*F<=*/90%]:K=SMO^$RLL?ZB?\A35\:6;MM%K<?D/\:XN
M*>1=T+$!3WJ-@T:#!(9L,1ZBCV,0^MU>YW$OC6QAQOMYQGIP/\:27QM8PG#P
M3@_05Q:)')<<CY00>:2XCD?<[ L2<@T>R@'UNK8[8>-+$IN$$V.W3_&G1^,;
M.121;SX'7@5P1#HX4IT&:GMV9[-I> "V#BAT8@L75;.T_P"$SL<[?(FSV''^
M--3QO9,2#:W"XZYQ_C7# ,95*@#'4^M.V2,LX7C:V:?L8"^N53NV\8VBJ&-M
M/@]#@5"WCJQ'_+K<'\!_C7&H9KN-D8D*HX%-C@V1C+9R3C-+V4!O%U7L=NOC
M:Q=-PMY_I@4O_":67_/M/^G^-<;;V+>9AF!(&[KCCTIGD32N?)0X5OF!/&/K
M1[* ?6JUCM'\:V" 'R9CGTQ_C3SXQLQY?^C3Y<9' XKCQIZ-(5C+,%'-739J
MRQL7",%P.:3IP+6(K,Z/_A,;3RFD%M.54X.,?XTY?%UH\9D%O-M!P>G'ZUS
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M2[XI%*S1A&/\:\4[BY5?<H2!5'/S9I\<N^U./E*=^^*?]F1NDW7U%30VT7S
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M;)*6R&8=*.5]Q>TAVU-ZZTNXA8&TB22$= W6FKI$^Q))I$@RV",U1L]<N;2
MR-&)6;())P1Z5#+J5S=PJ\OS/&P*9Z#\*5I%N=/<O3VT]M-N^S-)M(VNG<^X
MJQ#ITMW-YIWQ1D;BC]"W<5#:^)9A%))<P*Q48 7IFH+O79+V*-D4QM&<[5/!
M;UI6D'-3WO\ (D>PN$W$6&3N^5@U61H]UF,@J"PRP+8VU GB:Y48\I6$>-Q/
M!:J\^N7$I>Y3*OD(HSP%Z\T[3#FI(E-I<B<VXLR<'!?/!]ZNS:;=%=P,3LJ@
M!%SU]ZJ)XJN&A.+=!(J?,3W;VJO;ZY=^5<71P+C*Y'9A]*+2!2I;7+D=G>SR
MJGV.*%21ENIJ>727BB\VRD\Y]Q!,@R :HW'BF^>SS'%'&Y8KN';Z50@UBZM#
M#/%D+N)>/)PY]:.68.I26FYM?V8$LY;G59]B'_GF.E/N=.N8T1M/6)H-HP&Y
MS[YK$O\ 6[V[L@&* ;CNXZCTJ6TUG5K"Q#X+Q,0$,B_*/I1RRM<7M*=[6?J:
M,>B3S%&NI$B<'G:.OI2+H^I.Y0-&D6[&]5Y-9UKKM[<><EW*2!^\7:O0CL*2
M+7M3GMID:?IT('.*?+,%.EYF[,MGIMQ;6LJ(T<X83%N>0.#1'IFBOFZ5E,:Y
MRF_^E<K'/,R3AV+[EP"W4?2H[=3&7!)Y0\4<C[B]NF_AT.I_MNTM8F^QP1BU
MC!9FST?L<42>(K6YMY8[-C'(4W2.5QGUQ[URL,8,$RX/(Y]ZELG>"1I(<*P4
MXXS1[.(EB)[&OIWB:2WA:$1!XXUPA)Y%,D\4W%S.(S"L-N0=Z(>6R/6LD [I
M&P.>20*2)-SX'H:?)'>Q/MJEDKE@W]P--6*VE>%$;#*&/(KJ? VHW5S=R03S
M-*JID%SDC_ZU<:@VJ_S8S74^ VC_ +8F"L"?)_K4U4N1EX:4O:QU/1****X3
MW0HHHH **** "BBB@ HHHH **** &R?ZI_\ =->+?:#Y;1]"SDEJ]ID_U;?0
MUXH9HA,Z$9C8GZBNK#]3S,Q=N7YCKF.-T1(N,*"<=S5FROM4L$,<<V^/[NU^
M=N?2JUQ \6V>-MR*1D>WK4:W+[]I.3G=GUKIM='G7Y97V9T&D>(DM#]BN+9I
M'[/&,Y^HJQ/9V<EX8%NAYY7?B7 7-8"7"++)-&YCD*\,.H-5I(1Y41\PF1V.
M23D]:CDUNM#7VSY;/4Z*71[N/YY3&L*IDN&X'M5%)(R&52KX[;N:SQO2!XQ.
MY7<,Y;BG+#^]C$9 QR3[4*/<3FKZ(VAITD&G&\,3F(C*[#D_C["HHYU4K*C*
M^.Q':H;;4KRPDS:3[ARK0R<J1ZBHGNI+P/=O$%W'&U!C!I6?4IRC;0UH8!?)
M(;>V8B,[R6&.W2ITT2&2/-O(S2H")$SP>.@-9%QXDOP!9Q;;=2 "R)\Q'2BR
MUFZTN269)#<*N%DCDXY-+EE;0M5*5[,M1V-Z8Y&C"$1G:1GGZ5)#IJ7,,WF'
M$L*LQ4>O&*D@\0VT4.Q+=XSDN3G< 35=];M5L;F.%C)?3@@OMP /_P!5+WA_
MNUU*@(M1N*X8\9/.*FDN (8I8VWJ_!(ZJP[4^UUK34L8[:]M))7*X>3 R/I4
MG]L:8D$<%K:.?W@+"3^+_P"O3U[$KEM\0J.RQAGCPS]CQ21 23,CA<#GGJ/I
M4\_B33KEVAFLC$P4H)&YV&IDCT=;2%)K]!/Y>?,4GKZU.JW1I9-^Z[F?'ITE
MS/M50PSR0.WTK8FLG33XXUW,X8N54<D#BJ>F:@R:@EC8W231NV6F=<8^E96H
M:EJ[:H9DE.^,E8V3A1^%.TF["YH0C?>YK2Z/+!:_:9G8Q  D8Y -7K32[!X@
M8)8F&?F^89"^M8#WNIW"2"YNI&3 $JCA>?:H'L9HMK[_ )9.%8'@BCE?5@IQ
M3NHFM<ZG+:38TNYW*%^8D9#'Z5"=:OKZ)#=K&=AW848S]:@0&*\\A0I7&!QW
M IB,C6[ENH;(HY42YR[FTGB(P!(8M-0#[S*#U^E4K;6U\ZXU*96-RJA(XE&$
M /K6<]^(RC+C*G'U J/[4#*Q11Y<G2FH+L#K2ON6[W7-0O[<+(D:0RC!5!C(
M%079N[BYACGGE9,# W<$>]1^:0I7C .1[9J*XNRSJS'&  <>M4EV,Y3;^)FE
M"(19NDB@21'@X[4XWD*A43 5AT]#64UPTF['4\5'GRTW$8VBCE[A[2VQN1R$
M)\N"#15-+AP@ (_*BIL:*9GXD65=ZD9Z$BDE9"P5\;3ZUNRVUSJFEVCP&-IX
M28Y2S 8'K55-/L3JD=H9_.++AG ^4/V'TJE)&;IOIU,E(HE)5?NGMFJS(#*/
MG( /(S6Q!IC.EU-,##';Y#,PQN8=A3+FPMUTJ"_C+9=RK@]%/:J4E<S=-V*;
M(C(0V?0$4Q8_*!0.6!Z9JY%IMR\EN'/EK<'",W^%12021WDD !=D)!V^U%Q.
M+WL0M<3)A2 P/>M/2+Z.SO=TZ+M? ,G]RJ$T<I7S"IVYY.*)&PF/44-)JPXM
MQ=RYK%[;76I/);L64<%L\'Z52:2)PJAN?2HHU"_-C&>U$R)O25#\XZ^AH22T
M%*3D[LGX*B,D#%*8P(_O#&>QJ*0HR#<!@TZ+")@J",4 2/L\M5W@G/0&IHE0
MQ$9 QV)YJ@R1MDKPPQR*D;:\+$]=O6@:9:* 0,H[FF11[0Y]152V<A#&[;N>
MO>D\R6.;;YA*$T6%S+<NB(!9">XIFS]R1GOFHYO,9,PRC>>S=ZCA821XD+*P
MZBBP75[$X4*K8[TL:8AD/7(YJBR.)?EG; /W?6K)WF-PDA#8S38DQZ1@0,#_
M 'LTLD?[A0,C!JM:.TR%3*<FHI%E9SB5CL.2,]:+:AS:7L7O)#0D$CJ*FGN+
MB6S2"67,<9^5?2JJ*DD>">2OKS4"!DDV,2ZGIGK2L/FL65106*D<#FD@1=S9
M(VD<U2VQBY8;V0L,C!XI\@5E5F9E&>JFJL3S%M#&BON/!Z8J,W4 <*&)/2HX
M@(KAD?YE!X-0R(&D)\DD XR!_6BPG)V+:7"Q Y0D'N*9!<+,K>6-O..::QDV
MDQQLP&!TZ4@M9K6Y:&6,HY(^4]>>E*R'=W S7$>0JJ1ZYYJ9P5&Y9"K8ZD4X
MZ1?/-,D:,6B7=(G=11%9275C<3&0!+=06)[^WUHNA\LMK%) \<I6<JX(R&!K
MK/A^(QK]QL&#Y//YUA7VD&UCL[B.0S17"@(R@\-_=/O76>$K!-.\336Y.Z46
MP+'^Z2>E15DG!FV&IR5:-^YWE%%%>>>^%%%% !1110 4444 %%%% !1110 C
M8V-GICFO%M0T[R;N9[6:.YCR7S#R$!/>O9Y?]4_^Z:\0TW4'TG4IKA(TE5@R
M,C]"#75AKZV/,S%Q]U2\P6YE3(*DK]TY%*B9E4J,Y!-0?;#=7LURZ[ Q+%%Z
M"I_M*^4)]H5E.SCH1758\I-/J1P*&#@G!W\4Z:,I,I5MR+UHVPI&)3*5=P&5
M".O-5I5G1@SG&6YI]1/1#I;DB *!C+<TZWNV5RQ)]J;+$#MST)X-036T]N$=
MT95?.TD<&GH2W).Y<341]I8X_6K OLP,AX(;(K"4?*Q/)[4[SF5L=<BAP0E5
M:W-B/44-PCMC"L ,U/*\4WG.S !SD+Z^E<V&S,<58$I*E??CFAP'&L]F;]GY
M00B<G$S;1@]/>HXU2.5U?:=H.T>]9ID<Q(K'[HX%-FE/FEG/Y5/*7[16-<QQ
M3K;M(09!D/CZ\4^0P+<, P"],8KGKF5XQ%(DA!.<XJW%<>;%O8[G/6CE!54W
M:Q:\])=2DDD*GS#@@<5;>*WCB3 WDDYYZ5SK3+'=QN.QYK4N+H*=R  $CI0X
MA"HK.YH&..WWHHPA0$8[&EANU%F$4_,KY!/H:SC>,6\L\_+D4L?*9 X/6ER]
MS13UT-G[5N\UQ@!DYQ[4R*[F,!MQC:/F JFDNV)4"_>7GFF0/\RGN5P:FQ?.
MRQ,\D<XE+XW#\<TPR*A(+[@>!4%R'**A)SV-5B)#-M4<@=^*I(SE*S+,X$B.
M4/(PV#VJSHS64]I=/>3-')#@H%_BIG]D7L:/<2PND(BWLYZ;34*P&TC)\F3Y
MD#8*]0>A^E+1JPTI1E=HN7WEN[- VX?>!%9^)'B? )!Y_&K2RA;82Q*.NU@>
M<&E>:2&!)85 !&'('>A: [/4BACD"JQ5L@9SBK\]C=0;S/"X01"1L#^$]#6A
M?:XFIZ!)%#8B*<HJ22 \8'H*HG5]0N=!CTZ4CRVPJ-CYL#MFIO)]#7EA'1.^
MAL6/A<7EC#<6E\DD;J"2>Q[BBN9MHYXXV3=(FUL%=Q7'X45+C*^Y<9T[:P_$
MT(C$KK;$D,5.<'J>PJO;QN]WUPW4GIC%68I;:7Q% T4'E6Z%0P8Y/XU:GL);
M>XNKF\D2"W!8JRD%GST %.]B5'FU[%74+RYN[4&27S$!QZ?C]:73[R>"VVQQ
M))&QPR2#(S44$:-X;:5U+,T^%QUID\%Q;?8U=?+$C_(A/S?7%.RV"\K\P2W4
M\VJI.[%F0_+@<#'8"K\VH6Z)--:V?E7$P(>1SSSUQ5>51;:Q+;Q!I),XVXR2
M2*@5)I[.8N,&WDVMGU/:EHPO)774LV""YTJXM6G2*1V#JSGCCK39/LULUK;P
M$7#"4-)*PX/L/:H6:.&!25Y=N WI27"[+I0WR'CK3MJ*^A<N-*=M4G:9/)LD
M.X2G@8]!4 MX;K1I!;Q9F@<N0/O,AIMQ<-) ZF9Y-AP QZ4RSE:V1IXY1'LX
M##^5&MAMQN++:6]L+%+@GS)6#2)_=4]/QJ>319SJ$T0B,=H#D3L?E"U2O-\]
MWYA<NYYR>]6)I)3;R1FX>0(.$)X%&HO=UT&Q6EM-I5X]NADG@?(('+)ZTU[)
M+:SMY[QF0SN (A][;ZTVPDGM4>X@E\O;QN]?:H+]Y);A)9':60C<&/>GK<EM
M<M[:E^71F_M<VEO$_E. PE/0+ZYJJ=,2&WGO//$L<,VQL?SJ\+F]>Q\EIB(@
MF[9WQZ57TJY>U29#"DJL/G1QP123E8IJ%]B%=-DD2UF9UC2=]J;CC/\ ]:HD
MTV?^U#8 $W&<$'L/7Z5+J,TUU<QRS<;1PJC 4>@K3?5YY(6"P1K.(]KSX^8K
M3O)"48-F4VF*MC)>K/O\B78X Z#UIT&F3M]E=I%6.Z8A"33](O);-I@(Q*C?
M?1AD,*74;F6>YCDFPNT?*J\!5[ 47=["2AR\Q7M-*E.JM8!@'W'.1TQWJQ;Z
M5'<VE[-%,[31#_5JOWAGDUH?VDSQLX@1;HQ;'NN[+VK,TJ>>VNV,9*R')4_S
MS2O)ZCY81:6Y+:VYL+2+4YF"/O BBD7[XZ$XJ2^TR5M7B$"/,ESAT<#Y>>N?
M3%0:I/->NDDTFYF&0>WTJU!>WB68MQ<-&C';M]?QHUW&N7X>A%_9-O-/>):R
M>=<6Q!5/[_KCZ5$UHD&FI=W,>QI90$A;@LO<GTJ.T26.]+1MY<@.0X[&G:G<
M/>*LT\ID))!)[8[4];D^[RMVU-&;1!>7L-U9*HLI.923_J<=0:+:ZM9+[4+(
M,L=G, B.!PI'0UGV]T!:QF29PDC8*J>/QJ%(3'JOES*4W9+9';%*SZE<Z33B
MMR_?>5I>DM8QS+/<.X:69.BX/ %6H[O3;F2UO[P2&^A7&Q1\LI'0FLE56YAG
M6.$MY/S8!QQZTT3-#;;HHSD-N;C.!_A1RZ!SV=^G^0^#4+J/69+Q'(D9\X[-
M[5I:G>PR:;+%:VBVZSMNE_VF]O2LZ:(6OV:>0J8)QYBG/3GI4]E;RWEY<6EP
MQC::+S;=3QGTH:6X1<M8]_U_S)='U&ZLK5EC52G=9.0K>HK8\'^8WB:ZDD?<
MQBY)ZGFN;M()9;*^9&*QPKF1W& ".WN:ZSP7#'-)%?Q$%O(,<R]PV>#45+)-
MFN&<I3BNQVU%%%<1[04444 %%%% !1110 4444 %%%% #7QY;9Z8.:\9O--&
MHI=7FDVL@MXG$0C/S,S=S7LLO^J?_=->)6]Y>Z3)*UK<O"TG8'KS75AKZV/,
MS%Q]U2VU,V17M]T)&V0,5=>X(I]P6C@ACQC S^-;EE=Z(-)<W@D-]*S&1PN6
MSV(["GPV&D+;S6EY=M#/E94N&3<'0C.%]ZZN?NCRU1NO=:U,2=U$EJ"?E51_
M.KEI>0P:Y))=PBYM7SO3_9/<>XJ]!X=BU+35NK"]C<I*X;SF"X4'Y3^-89@D
M6<N^ N-I8<Y-"<9:"<9P:D79;BU35+A;$E[) 2BMSQ5G1TC\0236EY=>2L:%
MXMS<;C6,L+0>8<C)&!CO45M%O=MR9Q3<="54:EJM.Q;:SB@O+JU\WS8X1DRI
MT.*T;'PN^I6*ZB)HH[<'#AFY '4UD6Y6*UO-X^9@ ,]>M1/YPLR%:0(W)4,<
M'\*;3>S$I06LHW)9=*N4M5OX86>T=RJN.<8]:J%'5U;!&X<9'6KD6J:A::1+
M91S,EO-R5_GCTJU/XADE\.Q:9):0ML&(YS]Y1FG[Q-J;6]M/Q*2DN5R#G%+-
M$RQD]B.!UK1UJ[L)]/L7MW87GDK'*BC"@#U]35*"Z2VU*VFFB$L.!YB$]01@
MTDVU<<DD^6X6>D7&KM%!:X,HSPQP,>M.;3Y;*06]P,2<@ ?Q?2K5_-:Z3K4$
MNAW3L FXLW.">WN,55U'5[K4;Z.YN&4LN,*HP%'H*2<F_(;5.*L_B7W"VND)
MJ\S)9O\ O4 S&Q )Y[?2M2+PW+<^9$ES:KY+;7W2<@#^+Z5STGRWCL@*\Y7!
MZ5'L;SN"V7'KUIM2Z,49P6\;FY#HEU,BRVK&YC+NH:,<87KGTID;QXFV,3Y?
M)&.HJOIM]>:?&Z0W;PQS';(%/44D ,,]PK9W!"/K2L^I:E&RY476FA2&-I P
M+#A0.GO5W4M/M]/TN&[344FEF(VQH.@[YK(FR]O;&0$?+C\,\5(L(\J./;DL
MVT8/KTJ;%J6ZL/EN9/L4;*>03GVJ_=ZW;W>F$C3(UN#$(VG+=AQD#UJF=+N;
M>\6PN4,;2R",,WW0?K5^\T&;28 +V2..+S-JG.2X/<"D^6Z*BJMG;;J03:W?
MZAH<=@\@,*# '\1QT!-6H]8EO/#MMIC?ZT.8\@<LH'RC/UI;O0%TK3Q<"Y24
MR2CRMA^\N,YK/,KVLMM<Q\&)]_ [YI+E>Q;=2#]]]+?(?:G,/V9UVEWV8/4'
MM^M:DVCWMC:3^;'B"$CS'?C.?[OK46KZV^KQ""VLHK7<^^1E'+-[FHI[Z_OH
MDL;JZ:15C#JI/'TI>\QKD5UOV-F_TO3-/TEKFUO6E+@%8@1SGKFL+:X6(P\J
M'W9;JOI1 JQO!'(Z([$J6)X ]ZT+F.".Z6.!=T"QA3*.CGUI*ZT>I4K3U2L;
M">)-.DC5K[3-]R0-[ ?>]Z*P[QL2HI\PLJ -@<9HJ?9Q-77FO^&(+: >9-,V
M[:@YSWJ"Z<S6OR\DG R<\>U7KRRDT_2IGO9"L[L%CB5\_B:22U-M;V?DJTWV
MA=R_+R#GI5I]3%Q=K#]+EO+:.."&4)YHS\PX'O66S376J;V=I&Z!F/IWK3\J
M[?6([-E42>7G9NZ+Z?6HK)$-S,%C=W56^11R/QH3W8--I1+4NKW#0NZ1P).$
MVM.H^8U4T9X6LKJVNY"B3\^9U(8=ZA@W36-PZI\@(4MV%+$(8[,*6 D9N,46
M5K!S-M28S4I;5#!:6B,V&RTTG5OH.PK5N;5[X6MVEQ''"(PLS,>5(]JR+V$R
M3QXP, <U,P3?(HVD(N>O4T6T0D]7<L:?%'=MJD5HN&*CR=YY;!Y/XU%?V@L-
M&'VC!NYR L7_ #S'<_6JUBC@32)(4*#<"IP145X&D:%I&9MQW,2<DT[:B<ER
M;:FQ)9W-W%I\UK&FWRL22$@!2#WJA9P)<Z]>6\4QD4QD*6Z,P':E8M&)(E<[
M<9"[N#^%4M/C*S2-YA$H^8%>U"6C"4ES+0N264L&BW$UV&MF)VQ1D<LW^%33
M6C3:3I\]M 9"04<+DD-FL_4;B6\MQ(\KR,#CYST%7M/GN;:"-8[AHA+][%#O
M:X)Q<K=+$IA,>NQV9D!:1 CXZ D=*KQB7?=6T"F2=01C^Z!UR:I0RR#6/,4L
M'#?*>N"#6IJ6J2-9S^5!%;M)Q*\760T-.]@4HM-[$+*'T&&\=SN$NPX_.G;9
M&U2S^T_NX[D8 /!QTSBDT>^$&FF)[:.:(N#B3H'%5+V_GN=319F#LIX8#!4_
MX46=V@<H\J?H6UCEANKJRCC:6X!*JH'7%)<)MT>UN9,@[FCE!&=I':K5WJUR
M]M-MCB@EV[994'S/^-4=(U%K>R=/)BGB+ M'(,@-ZTM;7&W%/EN2S!K>XL/-
M?8DZ8\L]0N>I^M3QZ=)!K-S;@NL42%FE/0+C@_6L6_N9[O5TEF^:3&" , #L
M!6U<:C=W$7V&25 $4;@!@GTR:;3T%&46WY%?2@M]IVH(D/G21(&C&/FZ\XJ"
MZMWM-+MYY_W,C2?NX3]XCN346F^?:^;+#+LD1B21Z?X5'JK/=HEU),7D9B22
M>1BG;WB&_P!W?J=!/IT]S=V]S9QH+6:%3),3PAQR?K5'1?)N9-2TX.'WY^SN
M_!+ \?G4$$LCP0P&9Q')]Z,'C-4;:%HKQE8XRW7TI*.C1;FN922-*_T\V.D%
MK_$=TS#R85(^49Y)Q6EY5MJ4=E?SWB1+#&%N(S]YROI]:P+_ '31!M[,V<$L
M<D^E36:,]O'(R X.&)/-#6E[A&24K):$ECJBKXBN[AD_T:<E'0==IXJQ?/9V
M&D75MI\LD\DY >5UQM7LHK.M;7;J/S*,$D[B>*4NT@FA(# '=SQ^%#2N2IOE
M:?F:VE:M;PZ0EM=69N=I+197(!]ZRWO+N;7_ +2Y)F!'E[>BXZ"AC%;Z:CAS
MY@;+*.U27=N]LUK=^60MR \15LY/I0DD_4<I2<4NUBUJM_>:C:20R*D2QOS&
MB[03ZGUK5^'I;^TIU#?*(N>>O-98LYY=:73[AU%Q/&9"%.=O&0#[UJ^ 0J:Q
M<(JD%8R&].M1.WLVD;T>9UXR9Z+1117">V%%%% !1110 4444 %%%% !1110
M CXV-GICFO&;SP_>S32WFF6\EQ9R,61AR1ST(KV63_5/_NFO#5O[VRFEBM[F
M6&-F.45N#75AKZV/,S%Q]WF\RM<65Y; FXMV0MQ@CD4V2=I)&60MB./:N[TZ
M 5?T[5Y='U 7 'F[N)5<YW"M/7=:TW5H"%L#%<,,H^1G].HKJN[['E*$'%M2
ML^QRZ+C,:MZ X/6K8E7)3?E 0 I''X572-@F<$EAUZ8K8\,MIS7[6NJK'Y$P
MRLC\;&^OO52=E<BG&\E':YDR,IB!##<')QFMO5-<LM2T^".*Q6VGC8"1U YX
M]JZ>[\-^%FA<BZBB<C(=91Q[XK M?"EC?^=!8ZLLLJG=]W@J?ZUE[2#U?0ZG
MAZT+Q5G<YXRQ22R>;&PS@@^M()P9"P'RXZ'T]*Z/1DTG3UNK;5O+::.38"XR
M"/:N:N$1;BX2/_4ERR#_ &<UHG=V.:<7&*=RW8Z?+JL=X(@#+!&'$?\ $W/0
M50N;5XKIK>1-KQ_>7/2E0R1MOC=DD'&5;!-*JY61W)WENIJM;D.S25M2YI>C
M_P!K1WPC9C/#'OB0#)?VJ)[1(UDBN"ZW4+;=F,C ZU' \MO=))!,\3<?,AP:
M60,)&=V+;CG)ZGUI:W'[O*M-2[I^B"]L5NTF1?+EVS[N/+7&=WO2VVAK>Z;<
MW%M<)+)#-L+'A0F,[OZ50:)T8*'*JW7GK]:J>8T*D1NZHY(8 XW#WHLWLQ\T
M%O$V=-ET=[#_ (F)E6XB9MH0?ZX$<#/;!K/A95WDH<#(0YY7-1O$#"L@&%R
M#ZT_!<<>HR *+$N3=E;86YXM\( &Z,/:F6K2W#%)&SO3"N1R,5T&HZI#JL)M
MK2Q2 JH:9\?,Y Q6;#(JZ1&NQ0X)&<<Y[TDW;5%R@E+1Z%VSTJ[O(P\,!>-0
M 6)P"<=/>EELKF$,XB:-K<@N<?<.>*OQ.FHZ-;P?:HH)+7(D60X!SC# ^M:,
MFJVC)>XV3+]GCC7S <2D'DUDY2N=4:<+;F)J$VL:R;9;E/O?/$L:XW=MU5]1
ML[Q'C@NVF#=5\QLXKH?[1M?,A57CMWDLS$K+G$39)Y]/_KU!IMO!'?.E[);R
M!H\K(90RH<]>O-"E;H.5)2>]VSF(;@FY:%@YC48'.<'VK3=""F].O8]"*ABC
MBCN9Y$E#;-V,#[WIBGK,WV</<85F.$^E6]=C&*LM26.,329VX+G^$]*?]C4S
M_:D).T$;:60RI!NLXPQ9>2.HI+.*X%J\;L1Y@!Q4FEE>UA]BBC5;:[FBWQJV
M'B(SD =*T[G48;V>WM;.V>.S@^Y&1R3GDU!%:/'&XC8MN((R,?6I(+>Z,N5V
MQA3P2.:AM-W-8J25EU-$3LJA6B#E>,E<T5:6W7D@E<G)&:*SNCIY6<C=Q&6Z
MCB RHY))ZUI17MW9VY2*XQ",X4+ROTJ+RP"&?()X)(ID[^7&P..!P16N^AR*
M\6V9^G7,J:J;L9:0'<,GK]:T-0U:.&SF6UMTMC-D2,#EFS_2J=L(DW;"=S<D
MD\FGS1+-+%G!5>2#5-)LB+DHV3%T:6!--DM[M7,$Y!W1GYE(IE[=V[WMG:V\
M BMXG#.6^\W/4FI6V11[%&% Z552(^6TC  LW'KBC2]P;:BHFO<:-)'?R2M*
ML6G$[O,WYX]/K6;HGDW.L3Q*"T+(ZQ;C@DXXJ"XW+8/A\X[9J.SM'M8]Q8;F
M.X%3R/QH2TU8G)<ZLO,MW,4UAHLTUX6AED;;%#CEL=2?:B:VEBM+&=4\])8\
MJ44G!]#5+4S+>RQ1O([LPY9CGI6K9:C<6-@]M"=H8Y#==OKBAW2!.+DUT*ZV
MIA\26MG<RKF4 NJ_\LR>@IWV.[CDO7,8C6W#!I)%QD=L>I-9%LTESJDLY+';
MU8GG-:6HWMS<6HCGN9''8$\4VG<F,HM-B6L$;^'9+U5)DCE"NI'&#TI9[6\C
M6QFD7;'.VU$)YSVHTVXN=.B7[.=H<?,K#(-0ZKJ5SJFK1%OD6#E5!Z'UHUN-
MN*@N^A*B"#5 LD;^8K8:,<FD1&N-/GN#E81-MSCH:Z&YN;>RM%U0P(-0FCZD
MY'3K6+IFIE[.>WU"(SP2MNVQ_*5.:E-M7+E&,9<K>_\ 2N5-RVVFQHH9QYG+
M8P ?2K$]L;>_A\\%9&4,H!SG/2H-;U!)8;>R@A,%LC;BF<DGU-:4&L,EK&9+
M6&2:!,0SOU456MKDKE;Y;[6*ELEQ->7EJT/S1J6=2><"J^4AL97AB=MA!9@.
M%'O2:5J4D.KSWA4S-*"'#'[P/7Z5/K5Z&T_[):P"WMB<E <ESZDT6=[$WBX.
M5^XZ^ADA>"YEAV?:$#+BF>3<?\)'%:S+Y<TRC:&/8CC-:&C7-L-+C%]&)Q;G
MS( 3SN]/I5#[/J6M:[)>PQ.70YRHZ>E)/>Y<HII..M[:?F%I;37%S=6L<:QR
MJK>8S9PN/6H;*TDN-%FNHOWK1RA7B"Y.#W%:E_>:M<B6Q>VV.5S*4CVLP'<U
MG:,+VRBDN+9F15;:77H<]C1=VN)QCS):]274K.;3;6QFE>-))6'[GNGN:LG1
MKH:Q'"T:^7(-XF .P+CDUFZS9ZBV+V>"8Q\9D<=2:O0WUZ+$6WVAQ$5^YG],
MT:VT&N7G::?09I=LE[<:E:"3S)%5C RG;O(/%1ZK:'3]*A^V.5OF<%80<[5]
MZJVMO)"TDIRN>1@\@U'J237+Q#EF8_>)SDU5O>,V_P!WMJ=%'IEK>-::C%/#
M!;;0UQ&S\J1UP/>JD&JV[^)=0>91]BG7RB57H.QJD!Y;*F <<,<56L8"+J9V
MR0>^.,U*CO<T=1W7*C4U&>RL='FM+&1[EIR!),4QA?[H!_G4VEZO):6T5N+6
M*98SOB\WDH3Z50="$4XR W/%6O+W("?EXXQVH:5K,:E+FNM#,CO;G_A(_MX8
MM,LFX,>A/I7H?A;4[>XO98+:Q%MN!DD^;.6S7#VR@)F2$=<JYZBNG\%E#K,F
MP_\ +(Y_.HK).)KA'*-1:[L[ZBBBN$]L**** "BBB@ HHHH **** "BBB@!L
MG^K;Z&O&)$W.W3J1R,U[._\ JV^AKQR8LTC#[O)X Q73A^IYN8?9^93FL_-;
M)&>_!J'[$&.=Q&!QSTJ\$V#*\,<XQ4/V8AMPR6SW[UUW/+<5V*X0M,KYW(H
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MY;ECTIPBXP/F]2>U(JPQ5 APA^9AS]/2D5"SH/3M4PCX50O(/!S2R9)9%&T
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&Y5]R/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g5lvsimk4gaq000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5lvsimk4gaq000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #] ;@# 2(  A$! Q$!_\0
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M ***JOJ%M&\B,_S(0& '^?0T 6J*J?VC;;L!\GM@=?<44 6ZCGF6",LV3P2
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MJ_W1^5&U?[H_*@"K-<64\9CE=60]00:I^5ID;(%D<'HI!/RX Y]ONBM;:O\
M='Y4;5_NC\J ,^W&GVS Q28VC"@DD+GKCZU9^W6W_/4?D:GVK_='Y4;5_NC\
MJ (/MUM_SU'Y&FOJ%JB%C+D#T!-6=J_W1^5&U?[H_*@"#[=;?\]1^1H^W6W_
M #U'Y&I]J_W1^5&U?[H_*@"#[=;?\]1^1JD\.FR2O(96#.<DAC[_ .)K4VK_
M '1^5&U?[H_*@"A#86DB+-'YB@CY?F(P.X^AHK0HH **** (#=QBZ$!#;B<9
MQQG!./R%,MV5KRZVD'!4'!Z<5*;>(SB8H/,'>HX !>76 !DJ3@>U %FBBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "D9@B%FZ 9/%+374NC*#C(Q
MG% $4=W!,X2.0,Q&<57W,+ZXP2/N_P J?;Z=';.&5F..<'UQC/Y"H0BI?W6T
M8W%2?<XIH3)][_WC1O?^\:;13$.WO_>-&]_[QIM% #M[_P!XT;W_ +QIM% #
MM[_WC1O?^\:;10 [>_\ >-&]_P"\:;10 [>_]XT;W_O&FT4 .WO_ 'C1O?\
MO&FT4 .WO_>-&]_[QIM07=VEE )I 2NX*<=LGK0!9WO_ 'C1O?\ O&LI-;@<
M(PC?:_3UZL!Q_P !IXU>$",R(Z*\8<'KCKP?R- &EO?^\:-[_P!XU075+9F5
M0)-S 8&WDYI@UBVVJ6#AB,X S[X^N* -+>_]XT;W_O&J#ZI!'(R2!Q@*V<=B
M,\CM4EO?0W,FR,.#MW?,,<4 6][_ -XT;W_O&FT4 .WO_>-&]_[QIM% #M[_
M -XT;W_O&FT4 .WO_>-&]_[QIM% #M[_ -XT;W_O&FT4 .WO_>-&]_[QIM%
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M.2 /RXJG.NW4;CECG:>3G'%-"EL)1115$!1110 4444 %%%% !1110 4444
M%%%% !4%W=+9P>:ZDKN"G';/>IZ:R*Z[74,/0B@"A'K-N\:-LD!?@ #/.2 /
MTIT.K0R^6-DF]L<!> 2,]?85:^SP?\\4Z8Z4H@B4Y$:@_2@"G_;$'S'9+A1V
M7G.2,8_"G2ZI%!*Z2))P 5*KG=D9Q]:L?9;<# A3'TI[0Q/G=&ISUR* *O\
M:<+,45)"P[;?;-,&KVYVC9+N;  "]>,U<$$*L66)03U.*9+96\H4-&/E.1MX
MH @?4XHY9(W1\HQ'RC/;-3V]W'<EA&&&T _,,=:>T$3-N:-2>><4J11QYV(J
MYX.!0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M <C'/2@!^:Y_4?\ D)S?[J_RK0M-.:UN0X<%0.O<\#CZ9!/XUBZO<O;:M*I
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I#T-+2'H: /:-+_P"05:?]<E_E11I?_(*M/^N2_P J*Y6=RV+=%%4;
MUKL2_N%<KY9^Z!][(QU]LT#+U>:>._\ D8%_ZXK7?V7VGS)?/#!>V['7)SCV
MQBO/O'.[_A(?F '[H8P>U73^(SJ_"<U1116YR!1110 4444 %%%% !1110 4
M444 %%%% !5O3VMEN6:[ ,8C; (SEL<54HH UT&CN[,<HOW@K,3Z\?\ H(_$
MU(T>BS2%S,L6YLX7( &X9XQQQTK$HI6*YC:B31E^;>&8*1M<G!.#S]<XID*Z
M3);Q><X258L, 2-S;>_OFLBBBPN8V3'I$3Q%95DR<-][ XZX-+]DTR2PFEA<
M&2-/NM(1D[<Y'XY_*L6BBP[^1M"/1I"K/*JY"@@$@ [1V],Y]ZH7R6J-%]ED
M#@H-^,\-^-5**+";"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ I#T-+2'H: /:-+_ .05:?\ 7)?Y44:7_P @JT_Z
MY+_*BN5G<MBW115&\EN(Y<1;]IC/W4SALC'Z9H&7J\T\=_\ (P+_ -<5KO;)
M[MI7%QD@#^[@ YXQ]1S7/^(?"UYK6IFZ26*)0H0!B23CO50=F9U$W&R/.Z*Z
M_P#X5_?_ //W!^1H_P"%?W__ #]P?D:VYD<_LY=CD**Z_P#X5_?_ //W!^1H
M_P"%?W__ #]P?D:.9![.78Y"BNO_ .%?W_\ S]P?D:/^%?W_ /S]P?D:.9![
M.78Y"BNO_P"%?W__ #]P?D:/^%?W_P#S]P?D:.9![.78Y"BNO_X5_?\ _/W!
M^1H_X5_?_P#/W!^1HYD'LY=CD**Z_P#X5_?_ //W!^1H_P"%?W__ #]P?D:.
M9![.78Y"BNO_ .%?W_\ S]P?D:/^%?W_ /S]P?D:.9![.78Y"BNO_P"%?W__
M #]P?D:/^%?W_P#S]P?D:.9![.78Y"BNO_X5_?\ _/W!^1H_X5_?_P#/W!^1
MHYD'LY=CD**Z_P#X5_?_ //W!^1H_P"%?W__ #]P?D:.9![.78Y"BNO_ .%?
MW_\ S]P?D:/^%?W_ /S]P?D:.9![.78Y"BNO_P"%?W__ #]P?D:/^%?W_P#S
M]P?D:.9![.78Y"BNO_X5_?\ _/W!^1H_X5_?_P#/W!^1HYD'LY=CD**Z_P#X
M5_?_ //W!^1H_P"%?W__ #]P?D:.9![.78Y"BNO_ .%?W_\ S]P?D:/^%?W_
M /S]P?D:.9![.78Y"BNO_P"%?W__ #]P?D:/^%?W_P#S]P?D:.9![.78Y"BN
MO_X5_?\ _/W!^1H_X5_?_P#/W!^1HYD'LY=CD**Z_P#X5_?_ //W!^1H_P"%
M?W__ #]P?D:.9![.78Y"BNO_ .%?W_\ S]P?D:/^%?W_ /S]P?D:.9![.78Y
M"BNO_P"%?W__ #]P?D:/^%?W_P#S]P?D:.9![.78Y"BNO_X5_?\ _/W!^1H_
MX5_?_P#/W!^1HYD'LY=CD**Z_P#X5_?_ //W!^1H_P"%?W__ #]P?D:.9![.
M78Y"BNO_ .%?W_\ S]P?D:/^%?W_ /S]P?D:.9![.78Y"BNO_P"%?W__ #]P
M?D:/^%?W_P#S]P?D:.9![.78Y"D/0UV'_"O[_P#Y^X/R-(?A]?X_X^X/R-'-
M$/9R['<Z7_R"K3_KDO\ *BI+.$V]G#"Q!:- I(]A17.SK6Q/1110,**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g5lvsimk4gaq000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5lvsimk4gaq000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $L E(# 2(  A$! Q$!_\0
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MZU0B2BF"2,@$.I!Y!!ZT^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\3W>^Z,%E&\44X@1RQ^8D\-T^[6SI6H'4+*.61%CF9<M&&SCG&?I0!>HHHH
M**** "BBB@ HHHH **** "BBB@"('_2F'^P/YFB Y5_]]A^M,SMU  _QQ\?@
M?_KTZWX\U>XD)/X\T 34444 ,F.('/\ LFGU%='%K*?]@U*.E $5R<6[GZ?S
MJ0=!4=R,VLH_V#_*GQG,2'_9% #J*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BLK5X[^26#[$).^]E<  >F#U)]>U4Y8=8:-%B$J
M,H^0M(OR\Y^;UXX^M '0T5@VMOJRSN6,BH4.S?(&P-O /^UNYS3[)-:BNV%R
MXECPQ#8 4G:N!U)'.Z@#;HJ*WG6XB#J"#T93U4]P:AD>6>=H(G\M$QYCCKD]
MA2;L-(M%@K*#WK+N_FNV^@'ZTR>18+M! [N$YERV0#V_&G79S<%A]UEX/ZUE
M.5XLN*LRN_,GXG(^I_PJ//[LO[\_C_DU(QSR._\ 0T(%96C)ZXP3ZC_]9_2L
M5NC1D<:QL!YDI3(^7 .*@:[AMY9(WF7Y.&.>!]322V<T5[;,0RH6*L['Y0,'
MKS^53RB+SY-B 1XZ8ZGU_2BUK7"]]B$7D# ["THSQY:EJLK/*Z';;/\ >4AF
M('L>.M12NL,;2N3M0*#Q3Q=[1\\$RC"\[<]\]J2V^\;W+=F;YK20 1#KMV$E
MB?QP*STL]: 7S/.903N"S*"R?PCKPV>2?PK:TLJUIO5@RDG!%7:[(_"CGEN8
M5Q!K@5FAG#$%<( .?DP3D]MW:MJ'?Y*>8<OM&[ZT^BF(**** "BBB@ K$OKZ
M8ZG-:I9PR)' 69WW \CD9 P./4UMUEW=QI<<MQ'>/%$9-J.7DQOXR!UH @TW
M58+K2TDLH88GF4M;PNV"ZCC)Q_\ 7J"'6;J9+6X73HBTA,00/B3<"0< C@#&
M3G'%6!=Z$UO<PF:&.+SC'(-^WY\#ISQQCI4%Y#H&G747G!DF,+%")GY3//?G
MDT 6H-2"VT]U>01B2&7R0T.6$A.  I(!/)Q]167?^(FMX+J.'2U9XVP()!MR
M=NXD\8[&M&$:#!IT=FD\(M9SB-6G)W$'^$DYX..G>G26.AVLH@F$2RSGA9)2
M6<D8[G)ZXH BBUBTAM%O[BW9+EAY+K&I."O.T>W--;Q/I370@92\B\X";L/C
M./K[U*\>@O)<3F:'=&-LK+.1L[=CP>.O6H8F\/)*8X6166,%%25@'!!.5 /)
MZ\]: );_ %U+2SL[M;4O!/N,GJB!2QX[GBFKJVG6,,N;.2&$!M[>7D,P!8K[
MG&?Y5)'_ &%-:I9[X-D41?R6DY16&3GG/0TY8-$OO-ND:&97.UV$I*Y88Z9P
M"1QZT .M-4M[B;[)]CEAZQD21@+D#.W\CFJL.O(9Y()-/=(HV9"5 ( #E,GV
MXJY)=:7;W#O+)#&4<.9&<8WD%?7KA<5#=3Z-9Q++(8]MV&92K9\S&7./QYH
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M+C) /]X\GTJRVC)*LIEG9I)BA=PH'*@CC\ZRVT'4I&CWRQM*LF_[5YK;@-I
M7;C'&>OX]:>NA:@T15;D6@=@K)%*SX3&"03C#$\T 2#PG:*7'G/L(..!D,5"
MYR?IZ5?BTI/)O4N9C,;O_6D*% XQQCI4']DW,NFPP7-QYDIG$MPP8J'QV'M@
M#BJ$WAR]^RI%#=,.AE42G]YC/4D'L1V[4 7UT".WEAFMKAXYHHA&'8!MPR2Q
M([DDYS3_ .R+:33X=/\ /+"VC,1Z9Y7'(^AJC;^')P8S=7#S8D4G=,Q/EA,%
M>,9^;\\5 _A[4BDRI+&LTL:@70F?>I$>W&,=SWH O7?AFVNI_.\YE<J$QC(V
M[=O3Z5M1(D,"1)]U%"C\.*YN;0+[*I R#;MVS&=PR@(05QWYYJ.Y\-7[1)'!
M=LL2A"T:RD;F"$$DD'O@T =715:RCFAMDAF.XQJJARVXO@#D\#G-6: "BBB@
M HHHH *S[ZZF,Z6-F0+AQN9R,B)?7Z^E6KJYCM+62XE/R(,GW]JJZ5;21Q/<
MW _TJX.^3_9'9?P% #[;2K2W^8QB68_>EE^9F/U-7 H484 ?04M% !6=>#[%
M=+?J/W9&RX _N]F_#^1K1I" P((R#P0: $(62,CAE8?F#5&T!FTCRNLB!H^?
M[R\5!!)/;3M!8Q_:;49QEMHC/]T-W'\JO6,#V]N1*5\QW:1\= 2<F@"2WD\V
MWC?U7GZU+5:P_P"/*/T.<?3-6: &3#,+CU4U A+6,!'<)G]*L/\ ZMOH:@L2
M3IMN<9)B7@_2@!82RPX R0Q7&??K381LO[A3U<*X^F,58"@-PH'%5I_W-[!-
MT#YB8_J/UH MT444 %%'444 %%%% !1110 4444 %%%% !1110 452NM6L+&
M817=U% Q3?F5@HQG'4\4AUG2U\W.HV@\H R?OE^3/3//% %ZBJIU.P$,LIO;
M?RX3B1_-&$/N>U1MK.EI)Y;ZC:*^T-M,RYP>AZ]* +U%(#D9'>EH *J2Z;:3
MN'DA!8,7R"1R:MT4 <SYVD"XM8I;0"6X61\>82%5 >#GJ#Z5%_:EJEL8CIJ%
M$P"#/D_O!\O./3KZ5NW^(XX=L$3J9 K!ES@'O6*VH@62RQVEI*^7PJQGYP>P
M'8MSU]* +":C:644,(LW(<DXW%PIW[3R>V>>U23B.\BCEL( EU( PW*!A<]3
M]>U0V.IRW-XEK):P&' 7*QD C:6R,]@0%/O3K'5YA)# -,6$R)N"[@A^[G@=
M^3BDU=687L0NZ)<?Z9*OGIRD0''X#^(TI9X\W#J!,WR0PD\+GT/KZYK1N+5(
M[1WF >[F. PZ[CT ]A_2J<ME/8^4[;KV5L( 2 1]/;U/6L)4FMM3533W(EC"
M7%O;G@Q*SOD=2>/ZFK@C"_=)7Z&H(8WM][2@K)(<MQ\OL #V%2_*>@!_[9?_
M %JR::9HFF4'B"375R&?>DHW?.0"NT9_Q_"KLL2S6[(H"JPRKG@9Z@CU_"J<
MTB117H)PSG:H$>"25  Z5HQ03R!=L9!P,L_6G9R\Q72(()O,@!93OSAE[EAZ
MUJV=N8E+O_K&Z^U4)83I32W85) R;F+MM56'<GMD?K59O$[I)L:T53C< 9AD
MJ.IX'7GH>:Z(4^75F4I7T.BHK&G\0QV]S)"]M*=DACW#'S' QC/?GI6SVK0@
M**** "BBB@ HHHH **** "BBJDVH11N8T#2N.H7H/J:3DHJ[&DWL6Z*S?[1N
M/^?>/Z>9_P#6JS;WL=PQ3!20<[&[_3UJ8U(R=DQN$EJRS1115DA1110 4444
M %%%% !1110 4444 %%%17,Z6MM+/(<+&I8_A0!GW'_$PU>.UZP6N)91_>?^
M$?AU_*M6J&D0/%9>;,/W]PQFD]B>WX# J_0 QI54_-D#UQQ3E977<K!@>X-9
M!GN=6NI8;28P6<+;'F49:1NX7T ]:>F@V\;%TN+Q9#U<3MDT :M5+MFED2TC
M8J9!F1A_"G?\3TJ*&2XM+I+:YD\Z.3/E2D8.1_"?\:EM@6N[N1NH<1CZ  _U
M- "M*("MM;1!G"\*#A5'N:#!/.-L\JB,]5C&-WL326'SQR3$?-)(QS[ X'Z
M5;H 0 *H & . !2T44 07LABLY77[P4X^M20QB*%(UZ(H44VYA^T6TD6<%A@
M'T-):S&>W5R-K=&'H1P1^= #E&2KR*%<9 YHGA6>%HFR PZCJ/>AGPPR&P3@
M#'ZTJAPS%SQGC'I0!56Z>W CNT8$<"55)5ORZ&K,4\,X/E2H^.NU@<4AGB&
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M3B@ HJ*:XB@0M(X ';O67--)=$F4[(NT>?\ T*LYU% N,'(O/J,"G$>Z4_[
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M !17")?>,;#2 YL_M<Y0.0RG<"S-D?@ ./>I9O$7B2#48X'TO[RLQC2,GY5
M.5;."3GI0!VU4Y-+LY0 \"LH)('8$YS^>3FN8.M>+6NWB31T2/R@4=@2,D\=
M^OJ*E_MKQ#%'</<62QF"%G \HE9=N>=V?E)QTQWH Z&'2;&WE66*W177H1^7
MZ"G#3+-9H)5@57@&V,CC ]*Y_5M2\0KHEK):6;"XN(W9Q''O:(D HN,^YR?4
M5FMJ7C +'%%8R?NFC8LR9W@JVX$Y]=O3VH [VBN'@U#Q9!J4RM9R3(S':KQ_
M)WY#9X[<5'-J?BZ6\CNH=.E\@)\MN5VY.1][_P >X]J .\I,\X-<M8ZIXDFN
M[;SK!1:EU61FC*LRG^+&?EQZ5U) (P: %HJ(N8?OY*?WAV^M,FF61?*B8,S\
M<'.!WS0 JR*L;W$A 7KD]@*S99Y;OYF9HX>R X)'J3_2I]3/_'O;#[C'+#V4
M=*H7 \XM&Q.W@8]2?\ #7+6F[\J-Z<5:[&PPQO+YP0!1Q&/ZTA/VUV57Q#&<
M$J?O,/Z5,ZLYCMXOE:0[01_".Y_*M-M-M3&J"(+M&%9>"/QK*%)S6AI*:CN5
MH;^6$!9T#H/XT&"/J/\ "G:C.DUG&D3AEE<*<>G4U#/;R6GS,WF0Y^_CE?K_
M (U495^WQ$#&%8G'>KE4G%.,B5"+?,BY;IYMY&I'"_.?Z?K6E/ EPFUQSV8=
M15'374W,ZDC< N![5IUM1BN3U,JC?,8I5D8HW#H>H_0TZ:;>?,?C"\U9OH\.
MLH[C:?Z5393(5C'5V"_AW_3-<TTXR<4;1::YF:=BACLH588;:,U8I ,# [4M
M=R5E8YF[L****8@HHHH **** "BBB@ HHHH 1CM4L>@&:S= 7_B5K*?O3R/*
M?Q8X_3%7+UMEC<-Z1L?TJ'2%V:-9+_TQ3^5 %VL9AYNN7S'_ )8VH0?CD_X5
MLUEVB[]0U9B.2ZK^2"@#2C_U2?[HIU1P'-O&3_=J2@"%EDW,(S@,<ECV^E1S
MV^+7$0R\9WKSR2.?U_K5JB@"C=.#%;WT?/ED$GU1N#_0_A5[J,BJ<2*K2V<@
M_=ODIGNIZC\/Y8IMO.;;%K<MAEXCD/1QVY]: +U%%% !5:[A9@L\/^OBY7_:
M'=3]:LT4 1(Z75L&4Y21?T-1Q0NCH#]U <G/WJ;!_H]U);'[CDR1?U'X'^=6
M>=_ /(ZYZ4 1[3P\6".P-$4;B1Y),;GP,#L!3HO,^;S ,=J>201@9SU]J .(
MU4^+5UFX%A&_V SHR8QD1J ' _WBQ/\ P U#'>>,5DA+V\X$<)61?+# <IAL
MY^=L;CCC'-=VTBH?F8#ZT/($V\9#''% '"V5WXR@:V5[=Y5DD3S&F3.!M&X$
M#[HZG/K6EJ.H>*(]7O8[6R0V:1YB?9N)]QSRW7Y:WKJWF67[5:M^] PT9Z2#
MT]C[U/;7*74>Y,AE.'1NJGT- &1X>GUFZ69M6B\M JB-3&%+<G)(SQQCCWK:
M$:*A5%50>P&*RM5U.>VG\B$*ORY+D9JOIVL;#*+R9F'!3C)]ZQ=:"ERLT5.3
MCS$21?- C\20$H1]!_\ J-:NDJ/)FE_B>5L_AP/Y51O+FSFO(Y8)/WFX*_'#
M#!Q^5/T^Z:V>:%OF19"<=P#SQZBL(.,*F^AK.\H&I=R1QV[^9R&& OK[5S^T
MB.Z0CD!>/PJ]),)YV<-G'"CT%5]H^UR#_GI&/TXI5I\[T'3CRHO6MT(/D<YB
M/W3_ '?_ *U1WDXE9Y(SD!<*?6JL8WVY0X#*-AS[4V6=?*VJ0),C"9J74;CR
ML?(D[HWX(Q#!'&O15 %25D>==31!X9V2/N\B@8HCG#L0X=CG[P8XQZGTKL]H
MD<_*RS>L(KNSF8X7>8R?]X<56-_=3L3:6S&/M([X#?0>E0ZM&ATV1RMQM3#C
M&>QJY%!;3(&5VE3'&6Z5,I2>PTDMRM]MU:!MTUFLL7<Q-R/PJ]9:E;WP/E/A
MQ]Y&X(I/L4.<IOC;^\C'-9U_8L7$I<1W _U=RHP"?[K_ .-).<==QVBS>HK.
MTO4#=QM%,NRYB.V1#ZUHUM&2DKHS::=F%%%%,04444 %&!G..E%% !00",$9
MHHH **** "BBB@!*,<YI:* "FJBIG:H7/7 H9DC!9V"CN2:@BO[6>7RXIU9_
M0&E=+0=F5=44K-;2?PY*$_4<51VG[:6S\I3./0]/Y&MNZMUNK=XF_B'!]#V-
M8B%A=&.48F1,,/QZCV-<E>+4KG12E=6+FG)OOII3TC0(OU/)_D*U:R])D3S;
MJ,L-_F[L>V!6H3@9-;T;<B,:GQ#9 AC828V8.[/3%<['G[3%G_GD?YU?N;@W
M)VCB$=O[W_UJJ2#%W"?4,*YZ\U)Z=#:E%I:@F1<RLIVLNTJWX5LVUR)TYXD'
MWEK'^[=?[R?J*<Q907'!7D$=:FG4<&.<%(T+]ON)^-5[--][D_\ +-<_G_\
MJ-19=CF1R[=S4]C-%&TWF.%;<!SZ8JXR4ZMR6N6%C3HJ%KNW49:9 /<TGVI2
M,A)#G_9KKYD869/14'VH?\\Y/^^:BGO0D+%89&;'R@H<$TN9!RL2[OX;4#S+
MC:3T55R358ZPH&569QZF BHX0BMOP\TQ^\X7^7H*L9N.UL3_ -M *Q=23V->
M6*W(X->M99!$[;)#T5N"?SZUJ)(L@RISCK[5F3+%*FV\M"5]2NX#\1TJN;:X
MM%$]A*UQ .L9;+#_ '3W^AIQG);ZDN*>QNT53L;^.\C!5AD_K_@?:KE;)IJZ
M(::W"BBBF(KWR[]/N%]8F_E46D-NT:R/_3%/Y5;==\;+Z@BL[P^V=&A0]8BT
M9_!B* -.J%DNW4-1'K(I_P#'!5^J<8*:M..SQ*WXY(_PH FM?^/6/Z5-4< Q
M @]JDH *@E=WD\F$X;&6?^Z/\:F=@B,QZ 9J.W0K%N;[[G<WU/\ G% $1T^!
M@"P<N.0Y<Y!]:;)OB0K<*)[?NQ7D?4=_K5RB@"@#]A*NKE[-NN3GR_?/I5_J
M,BLZ7?I\A;9YEE(?G4#)C)[X]*=$K1J#9SHT1Z1R'I]#U_"@"_1587$X^_:.
M,=U8'_Z]'VZ('YUDC]W0@?G0 ^X@$\8 .UU.Y''\)J(7;1C;<0NC#JRKE3[Y
MJ9+B&0925"/K4M %;[=%UVR;1U;8<"K"LKJ&4@J>A%+59[?R]TEN_EMU*G[I
M_#M0 QV$;,DIP"=R,1D-Z@U/$I2# '/) /;VJ!M2ACP)0Z-Z;<_J*!J,+?=C
MG/N(FH LKO*C=@'/.*J36DWF?:H65;D<$?PR+Z-_CVJ47T1ZK*/K&:<+R)NF
M\_\  #0!S^K2BXFCE"E"%*2(W56[ U12*5T#)&2I;:".Y^E;&O/ 8,ID73+A
M..H_VO:LS0KCS+QXF!#JA+(?X3D<CV-<%:"]IZG73D^0@ +$;0V>V!5J0-<H
MMS 2+B(;7"]2*UDW-:,82H<@[3Z'MFL".1XGW@D2 X;/KWS64H\I:?,7K6Z%
MQ'NE49!VEEXQ]?2I2'9UDC^?RR<9.-P(_I4,4L$LWF!C!.1AL=&_QJ:*Z0S-
M \JLXZ$=Z$#'H&:9I"FP%<8)ZTW='&_"Y8]21@8JQ48B .X\GWIB(%<M(T9R
M$;YQ_7 _*M:"%+2U$EPW0YP><>WN:S[5@-4BW*&+'Y2>W!_PJQ<2F>X9OX$.
MU![]S6\)*,.9F4HMRL%S<37<<D2XBC=2O(R3G^54+ ;[2&59)0VW9NW<\<?T
MJSEF.%. .IJK:*BO<0Y(*2DCGH#T_K6;G*6K+44MC02YGB/7S5[AOO?G5A;Z
M">(XAF=#D$>42/I5')1@&.0>AI\;"*X5CD(Y"O@_D?Z5=.HT[,F<%:Z*MRUK
M8WT%[;%HR6$<R,#D@]#SZ5TG:J-W8FXM)8?/EPZD8)!%.TN5I]+MY&^\4 /U
M'%=$%RR:,9.ZN7****U("BBB@ HHHH **** "BBB@ HHI.<T +13 S,2,8QZ
MBGT <A>2R37,OFL6PY&">!@TRUG%O>12L"RHV2!4FH)Y>HW"_P"WG\^:JY"\
M$UY4FU.YWQ2<3H5U^ A\Q."/NC^]_A51[^.[N8)-FR4@HP]NWZUE9]#2?Q9'
M4=*N5><E9DJE%.Z-4D1WV2VWS%&PYQAA_P#K_2KTEZYMVCD7)/&]?3W%9TB+
MJ-EC@.#D?[+"JMO>RPGRY06 .T@_>4_UHC4<=%U!P4C5!##Y2#]*BN>$23^X
MX8_2G#RY1N7KWQP13)%9D:(G.Y?E)_D:0QTX(4.HRT9SCU'>GY5X\Y^5AUID
M<Z,N&(5U'S*W&#26^-CE<[-YV?3_ /7F@ \X1C$F3Z,.<TZWN&CE8E T<C<*
MX^Z>@/MFC8"=TF/8=J5\,A7^%AUJHMIW1,DFK,MR6B_ZRY90.RJ*B61A)F,,
M0?NH3Q3$D-R% <LXR#N[ =ZM6<+2!VW-Y1/![M[_ $KJ6NQAMN.C:5A@H#)W
M"GA?QI93-"F\HK#(&%;G]:L.\-K%EB$4=/>J,U[+,I6- BG^)QD_E3ERQ6KU
M%&\GH31SK(VWD./X6ZU-62Z-)C=-)P<C! Q4@DN%^[.3_O@&L5574T=-]#4%
M0O;%6,UL0DG4K_"_U]_>H8K\ [9UV9Z.#E?_ *U7P1CK6\6I+0RDG%F'=1X=
MK^S1EE3_ (^;?H3[CW'KWK6L[I+NW616!R,Y'?WI9K6*<AF!#CHZG!'XUEV\
M7]E:G]F4DP3 O%GLW\2_U'XT6<)7Z,>DEYFW1116IF%96D_N+[4K3LLWFK]'
M'^(-:M9-Q_HOB*UFZ+<QF%C[CE?ZT :U5I_EN[>3L24/X\C^56:@NU)MG(X*
M?./PYH DB&(E'M3Z9$P:,,.AYI] $4XS%M/1B ?SJ6F2C*CV8']:?0 5%<$K
M%O'52#4M177%I,?1&/Z4 2$ C!Y!JJUHL;;EB21?0@;E^AJ> [K>,^J@_I4E
M %18H2?W<DL;=QN.?R-2>7.OW9@P]&7K^-3,JL,,H(]Q2! .A(_&@"O)"TAW
M2VT$A'0]3^HJ/R/2VE!_V9O_ *]7J* *(@<]4F_X%+_A3Q:^L:'V:1F_0U;H
MH @2 H" 50'M&@6@Q>K.WU;_  IUS<1VMM+<3-MCB4NYQG '6JW]JV#,%^U1
M L0J[F W$@$8]>"*3&A[+CHS#_@1II9P"=[''O44FJZ>L3R_;("BD@D.#R.<
M?6HX=1L[DQK%<(7==RQDX8CUQ64KEJQ!?0N\,=[&=TD?S<\UG7BQ7FG/<VP%
MO<QL-S(.1SR/<5N0?=D@/\!X^AZ?UK!NT^Q37$(Y6=0%Q_GMS^E<]31<QK#L
M5K2^F65B25G!RZGHWO[BKET%N=EW .78)*G<-V-5:CEDCMT,\C[ G);.*YT[
MZ&S26I<>U6!E%Y((T;^%>6/Y5 ;NWL]PCE@DR,!4. !]3W_.LB.Y;4I3+<W#
MVUJ3P <R2#Z]OH*O2IH26^RVTZ5I".97/)_,UW0P<GOH<-3'06QM:<[RVPD+
M91N5YSCUJW7':-JATN\-K< I:RM\I)X0_P"%=C6%2FZ<N5G11JQJQYHC1A+F
M!\<AR?\ QTTB?+",=AQ2NN]<9P>H/H:9;EO)"O\ ?3AJB^EC2VMQX&$4#I3!
M"BS.X',@ /X=*<,+\K=.QI20.ISZ"D A&Y&7/MFFR-FU9^^S</K3B2D;,>OI
M391MM63N5VCZGB@#4%P^U2(';('1A_C4.AMNTM#C'S-QZ<FFSRF*VVIGS&7:
M@'KBI]*@^S:;#'Z#)KM@VY'-))1+E%%%;&84444 %%%% !1110 444E "T4P
MLW9<_C33,P_Y8N?IB@"6BH?//_/&3\J/.;_GA(/RH SM9TX2QO=Q\2(,N.S
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M\&_[^+1]JO/^?!O^_BU=HH I?:KS_GP;_OXM'VJ\_P"?!O\ OXM6V<+P>IZ
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M=5I](!-R_P!X?G2<L?11^M.P/2D)"@DG % #9#B,^IX%.4;5 ]!BF*"[;V&
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M$:!8U+2$#M@<?K3[9/DM?;<WYY_QH NT444 %%%% !5:V^6XNH^^\/\ F/\
MZU6:@ VWIQ_&F3^!_P#KT 3TU.,CT-.I,<YH 6BBB@ HHHH **** .?U;PNF
MJ:L=0^UM"_V?R0 F<88,"#GU'2J/_""0,Y,FH3-N"[L* 2P8G=G\<?2NNHH
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M*** "F,N9$;TS3Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g5lvsimk4gaq000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5lvsimk4gaq000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "H G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW_T'=/\ _ A?\:F7Q+H;Q>8NK61C_O"9<?SH$VEN9]KJ=[%!',TGVHR^80I
M7:B$\\=<TG_"5.+;S#:JK$@J"_WEQV]QD?G5E?$_AA2H75],!4%0!,G&>U))
MK7A6(K')?:4I4[@I=.,]Z!W()/$MQ%.Z?94D!D8($;G"X!_')JSIVL3:EJ:H
MJI' (F<@-EC\P SZ'K41\2>$MVXZII.X-NSYJ9W>OUIT?BCPG"[/%J^E(S?>
M*S("?K0!OT5B?\)CX:_Z#VG?^!"_XT?\)AX:_P"@[IW_ ($+_C0!MT5B_P#"
M7^&_^@[I_P#X$+_C1_PE_AO_ *#NG_\ @0O^- &U16+_ ,)?X<'_ #'=/_\
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M@!#UI*4]:2@84AI:2@#ZX^$?_),=&_ZYG_T(U!\9O^28ZE]4_P#0A5CX1_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!\L?&O_ )*=>_\ 7"+_ -!KSVO0OC7_ ,E.O?\
MKA%_Z#7GM(!0:2BB@ HHHH *3-%'>@!XY%)BI;=(W?$K%5]14WV9?(>8." <
M =S1<5RG24XXZTV@8E%%% !24M)0 AZTE*>M)0,**44&@#ZW^$?_ "3'1O\
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MF? C_DI<?_7G+_2O,Z],^!'_ "4N/_KSE_I3$?4=%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/^2EQ_\ 7G+_ $KS2O2_@1_R4N/_ *\Y?Z4 ?4=%%%,04444 %%%% !1110
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M/^2EQ_\ 7G+_ $KS2O2_@1_R4N/_ *\Y?Z4 ?4=%%%,04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'RM\;/^2GWW_7"+_T&O/*]"^-G_)4+W_KA#_Z#7GM(!:*2
MEH *0TM(>E #:4=:2E7[PH&6+>,R2*H[GDXZ5>-E$EK/(]VHE1@%C ^^/6G:
M+#>S7+)9(I=U*$MT -%WI_V6R66>91,7*^4.H [_ $J6];&,I^_RW,IB0?O&
MFT451J%%%% !1110 444UCB@!U(:;N-&Z@#ZY^$?_),=&_ZY'_T(U6^,_P#R
M3#4_JG_H0JS\(_\ DF.C?]<C_P"A&JWQG_Y)AJ?U3_T*F!\I4H8@TE%("0.*
M6H<4[<10!+130XI:!"&DIV,TF*!B4444 20-MF5B,@$&NY\5,L\$3HQY@1MI
M/%<-!_K5XSR.!7>>*/+DL+9A\DGD#<IZCZUA4^.)QXC^+ QVTQ+E(E2W*RLH
M8R1YP/K6!>)Y,LL.Y7"M]\=ZWXOMEO90R6SL%EA+,"VT<5S[SG;*I1?GZ\=/
MI5PN70YKO6Z*AIM.--K0Z@HHHX]: "O2_@1_R4N/_KSE_I7F>:],^!!_XN7'
M_P!><O\ 2@#ZCHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \/^)'PG\1^*
MO&MSJVG-9BVDCC5?-E*MD#!XQ7)?\*%\8_W]._[_ )_PHHH /^%"^,?[^G?]
M_P _X4O_  H7QC_?T[_O^?\ "BB@ _X4+XQ_OZ=_W_/^%'_"A?&'][3_ /O^
M?\*** $_X4)XP_OZ=_W_ #_A0/@)XQ!SOT[_ +_G_"BB@"S#\$O'%NA6*>P0
M$Y.V<@_RJ*3X%>-)#EI; _6<_P"%%%*PK*]QG_"A?&']_3O^_P"?\*/^%"^,
M/[^G?]_S_A113&'_  H7QA_?T[_O^?\ "C_A0OC#^_IW_?\ /^%%% !_PH7Q
MA_?T[_O^?\*/^%"^,/[^G?\ ?\_X444 '_"A?&']_3O^_P"?\*0_ /Q@?X].
M_P"_Y_PHHH 3_A07C#^_I_\ W_/^%'_"@_&']_3_ /O^?\*** />O 6AW?AO
MP7IVDWQC-S;H5?RVRO4]#4/Q$\/WOBCP7>:3IYC%S,5V^8V%X.>M%% 'AO\
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M+#_A0GC'^_IW_?\ /^%-_P"%!>,?[^G?]_S_ (444 '_  H+QC_?T[_O^?\
M"NR^%_PJ\1>$/&2:KJ36AMQ;R1GRI2S9.,<8]J** /;:*** "BBB@ HHHH *
:*** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>gqr1p20dfppl000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqr1p20dfppl000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,H G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7EVL(E6(0Q*"C,80Q5AG( .X[L>@SBJ [JBBB@84444 %%%% !1110 4444
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M85_[[9E)WGGCIR:U[+PO=P^&;KP]-J"FP^PQV-HR1C>BB/8SMZL3SCH,#UH
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M*C_YYI_WR*/9ASGU-_PG7A+_ *&?1_\ P-C_ ,:/^$Z\)?\ 0SZ/_P"!L?\
MC7RSY4?_ #S3_OD4>5'_ ,\T_P"^11[,.<^IO^$Z\)?]#/H__@;'_C1_PG7A
M+_H9]'_\#8_\:^6?*C_YYI_WR*/*C_YYI_WR*/9ASGU-_P )UX2_Z&?1_P#P
M-C_QH_X3KPE_T,^C_P#@;'_C7RSY4?\ SS3_ +Y%'E1_\\T_[Y%'LPYSZF_X
M3KPE_P!#/H__ (&Q_P"-'_"=>$O^AGT?_P #8_\ &OEGRH_^>:?]\BCRH_\
MGFG_ 'R*/9ASGU-_PG7A+_H9]'_\#8_\:/\ A.O"7_0SZ/\ ^!T?^-?+/E1_
M\\T_[Y%'E1_\\T_[Y%'LPYSZF_X3KPE_T,^C_P#@;'_C1_PG7A+_ *&?1_\
MP-C_ ,:^6?*C_P">:?\ ?(H\J/\ YYI_WR*/9ASGU-_PG7A+_H9]'_\  V/_
M !H_X3KPE_T,^C_^!L?^-?+/E1_\\T_[Y%'E1_\ /-/^^11[,.<^IO\ A.O"
M7_0SZ/\ ^!L?^-'_  G7A+_H9]'_ / Z/_&OEGRH_P#GFG_?(H\J/_GFG_?(
MH]F'.?4W_"=>$O\ H9]'_P# V/\ QH_X3KPE_P!#/H__ (&Q_P"-?+/E1_\
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MOX%_=CDCD\4<J[A<]K_X3KPE_P!#/H__ (&Q_P"-'_"=>$O^AGT?_P #8_\
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MFOJZOE'Q3_R.OB+_ +"=Q_Z&:TI[DRV,JBBBMC,**** "BBB@ HHHH ****
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MTV.?+MIIXH$5G^S^><@] JXZ]3P/6CV@<AX5]KMO^?F'_OX*/M=M_P _,/\
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M#D/DK[7;?\_,/_?P4?:[;_GYA_[^"OK7_A&]"_Z NG?^ J?X4?\ "-Z%_P!
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MW_/S#_W\%'VNV_Y^8?\ OX*^M?\ A&]"_P"@+IW_ ("I_A1_PC>A?] 73O\
MP%3_  I^T%R'R5]KMO\ GYA_[^"C[7;?\_,/_?P5]:_\(WH7_0%T[_P%3_"C
M_A&]"_Z NG?^ J?X4>T#D/DK[7;?\_,/_?P4?:[;_GYA_P"_@KZU_P"$;T+_
M * NG?\ @*G^%'_"-Z%_T!=._P# 5/\ "CV@<A\E?:[;_GYA_P"_@H^UVW_/
MS#_W\%?6O_"-Z%_T!=._\!4_PH_X1O0O^@+IW_@*G^%+V@<A\AP7-N)KDFXB
M ,F1EQS\HJ?[7;?\_,/_ '\%?2OAW0=&EUGQ.LFD6#+'J2J@-LAVC[/"<#C@
M9)/XUT'_  C>A?\ 0%T[_P !4_PH]H/D/DK[7;?\_,/_ '\%'VNV_P"?F'_O
MX*^M?^$;T+_H"Z=_X"I_A1_PC>A?] 73O_ 5/\*?M!<A\E?:[;_GYA_[^"C[
M7;?\_,/_ '\%?2_B^WTKPYH?]I6WAW2[IDFC5K;[*GF3*S8*QX'+\Y ]C5_1
M-(T34M#L;Z32=&D:X@24O;VR&,[AGY21G%'M Y#Y9^UVW_/S#_W\%'VNV_Y^
M8?\ OX*^M?\ A&]"_P"@+IW_ ("I_A1_PC>A?] 73O\ P%3_  H]H'(?)7VN
MV_Y^8?\ OX*@^TV_]H!O/BV^21G>,9W5]>?\(WH7_0%T[_P%3_"N=;0=&_X6
M1%!_9-AY7]D.^S[,FW=YRC.,=<4O:!R'S9]KMO\ GYA_[^"C[7;?\_,/_?P5
M]:_\(WH7_0%T[_P%3_"C_A&]"_Z NG?^ J?X4_:!R'R5]KMO^?F'_OX*/M=M
M_P _,/\ W\%?6O\ PC>A?] 73O\ P%3_  H_X1O0O^@+IW_@*G^%'M Y#Y*^
MUVW_ #\P_P#?P4?:[;_GYA_[^"OK7_A&]"_Z NG?^ J?X4?\(WH7_0%T[_P%
M3_"CV@<A\E?:[;_GYA_[^"C[7;?\_,/_ '\%?6O_  C>A?\ 0%T[_P !4_PH
M_P"$;T+_ * NG?\ @*G^%'M Y#YL\ 3PR_$CPX(Y8W(NV.%8'_EF]?4]<7XD
MTG3;#5O"LMGIUI;R'6%4O# J''DS<9 Z5VE9R=W<I*P4444AA1110 4444 %
M%%% !1110 4444 %<WX,_P"/+5O^PQ>_^CFKI*YOP9_QY:M_V&+W_P!'-0!I
MWMCHT27%_?6ED %W33RQ+T'=B1VQ4-H^AZD6B@@MI"%Y1X-IPPVGA@.RX/L!
M3M0T07MC?6ZW<Z/=%6#NWF+$RD%2JMP!D#([UGWGA:34K@W=W=QB\.Q?.@AV
M%%42#"DL2,^8>_:@#5_L[2&MA#]CL3;MP$\I-IP2>F,<')_.E>'2[K?;2V]M
M(JLK%9(05+$?*1D8)P.U8-KX%LXH8([CR)Q%MX:(D$AHV)^9C@D1@''K^<H\
M("*6U>&YBV6[';#+!OCVD8X7/!'&#V]* -AH]+:\M5,%LTX5E@;RP2@7J <<
M8STJC9Z=X;U&2&\M+*U86V]8RL&Q 25R0" "?D7##IC@TS1_#+Z7=_:)+P3,
M9'D($00'<B)Z_P"QG\:JW7@POHL>G6M_Y/[MXII'C+[PY4D@;OE/RCVY/% &
MQ9:-I%BLD-O:VX+RM(^5#,SL68DD\D_,WT!HGM=%BB:2:VLA',4MV8Q*0Y+!
M50\<\[0!]*S'\%V1F>=?+2X=RYG2(!P3([D@^OSXS[?A26_@Z&+P^-)>8%#<
M032.@8;_ "RA[L2"=G4'O0!JI;:->V\<"VUE+#%(ZQQF)2JNA(;:".""#G%1
M75IH%I923SV=@MO&Q=CY*$;AU.,=>/K60G@>*.2,)=*(5D9QF+,D?[YY0$<G
M*_?VD\Y"BJW_  KX^2R"^MPSQB(@V@** JKO52W$AV\M[].* .LDL;"ZN5N)
M;6VFGB&P2-&K,GMGJ.OZUSUE_P (;:Q3M;1V91KKS2GD[BLKJ!E%QD9$?\(Q
M\I/K6AI.D7NE7UP%N('L9Y))C$(R#&[$<*<DD$[B<GN ,"J%EX.;2Y8I[&]5
M9HV1R9HBZLP1T/\ %D AA@ X!&>YH ?;S^$?[7-S"UFUY=11@/MR-A5MH!QA
M<@OP,$\UM)#I=W;1RK#:R0W* H2BD2*P'YY 7\AZ5SR>"I5>1&U(-;3^2\Z^
M1AW>,E@0V[Y06.<8)P,9J6Z\)R7"Z3;&>'R;&U6!I6BRY*M&04Y^0GRSSSC-
M &^ME81! MK;($(V8C48Z@8_,C\3ZT^VM[2W3%I%!&O"_NE '' ''I7/1>$'
M-VDUY?).L(VPJL&TH )0#G)RP\WKC^$4MOX/%OX:GTJ*[$<[E'2Z1"2DB!=K
M[68\Y4$@8% '3&1%*@NH+'"Y/6HX+RVN8T>"XBE1\[61PP;'7&/2N/7X?^5:
M0VT.IL(HIUD3?%N98T9"B!LYXV$9[[CZ"IK;P+%;3PLMRA2)'1 (RI7+2,&&
MU@,_O,'(P<#I0!UWF)@'>N"< YZFFRW$,",\LT<:JI8EV   &2?P%85YX6AN
M;;2[:)XH(K'Y3MB^\A #J!G W $'()&<C!%95IX)NFT^$7E[']JDMYHKN3RM
M[2AU*@$DXPHV=!GY.N": .S$T3 XD0X4,<,.AZ'Z4>;'C/F+C(&<]STKF(/!
M<*W5Q-</%,)W5V7RVP &C8IMW;=F8Q@8X!_-G_"%);Q0"PFBMY(7CD5E@&05
M+\@9QDJ^WD'  ]!@ ZMG1,;F5=QP,G&345O>V]U LT4JM&R"0'./E/0D=JY;
M7]"U?5;C1)WCM9Y+4$W"!BJ%R\;<=\#8>1SP.Q-++X)>4N&OD=3;?9U#08QS
M&<DJPS@QY'U[CB@#K1(ASAUXQGGIGI0TB)C>ZKDX&3CFN<@\*NMOJ<-Q?"47
M\*(S+"%(D48\WKU^Z<# &.!S6>/ #+IUS:_VJSF=LEY(0VT$,7QSP3)([^V0
M.@H ZZ2\MXIXX7E422$JHSW SCVXJ5G1!EV503C)..:Y6?P4+J*]BFNX_+G:
M5X4$&1 \B,I<$DDMEMW7J.,5>U;1;S7="^PW-Q%!(S/N98]XVD,J]<?, 0<C
MN/2@#9FN(+=0TTT<:E@@+L "Q. .>Y-.\V/YOWB?*=K?-T/H:YFY\)2W5WYL
MM]$\4<@DAB:WS@B5)3N.[GE<=!P:K6_@3[-<Q3B]BD:%CM26WW)*I,AS*-WS
MN/,X;C&.G- '5V][;W4:R0RJRMDCL>#CI]14N]-X3<NXC(&>:Y"X\"_:KM))
M-0_=)#)&JK" V7##.[/."P8>X%2P^$9K&[6_M[E+B]CA^5IU909\/ESM;&&:
M0DC!]O8 ZHR(K!6=0Q&0">2*198V"[74[AE<'J/:N1U?P[JFH>*TO%-O]F^S
MB(2, 3$VR52P4]3\XXY!&<]!5G2/"<NEWUI<_;D?R3,7 AP7$C,VWDD  MQ@
M9XZX.* .G?[C?2N5^&7_ "33P]_UYI75/]QOI7*_#+_DFGA[_KS2@#JZ***
M"BBB@ HHHH **** .;\,_P#(;\5?]A-?_2:&NDKF_#/_ "&_%7_837_TFAKI
M* "BBB@!DD,<I0R1JY1MR;E!VGU'H:(88K>)8H8TCC485$4 #Z 4^B@ HHHH
M *YEO^2GQ?\ 8&?_ -'+735S+?\ )3XO^P,__HY: .FHHHH **** "BBB@ H
MHHH Y?Q?_P A'PK_ -AE/_1$U=17+^+_ /D(^%?^PRG_ *(FKJ* "BBB@ HH
MHH **** "BBB@ HHHH **** "N:\&?\ 'EJW_88O?_1S5TM<WX,_X\M6_P"P
MQ>_^CFH 2]U;7([^Y6VM;5K:%FV^8)-[A0A/3C)WD#_=[]!3/B?5YEU'[)8Q
MM]FE81M)$XW*$D8C .=V8P.WWAQTSV-% '"W>L:S!J:W*>8+54;,<J,40O+&
MNYL 95%8G'L>?2MJWB;78]'N)8HGAEN8&V2"&1A&PC)78H&<N>1GIWS7H=%
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M7_0X:W_WS;?_ !JC_A&=2_Z'#6_^^;;_ .-5TE% '-_\(SJ7_0X:W_WS;?\
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MX4?\(8G_ $,/B+_P8M_A0!TU%<S_ ,(8G_0P^(O_  8M_A1_PAB?]##XB_\
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M=#SQ3UT'2(Y5F&GVZNF=K;>F<_\ Q3?3)QUI9-#TZ2YBN/LX6:(KM93@@+C
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MHHH *YEO^2GQ?]@9_P#T<M=-7,M_R4^+_L#/_P"CEH Z:BBB@ HHHH ****
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M &MF97?[)(9'^5!S$&]3N^]ZBF'PSK+76XZ@HC:S,+LLT@=G;!)_!MV",8!
MKL:* .;.CZM!<1):7$0M//5F#2ON2-9 V!QR2H*\G\Z32O#=QI][!<O=RR.A
M7?NN9'#?NR'X8XY?:WX5TM% '&S^'-<DMO*6[@$@NS,;EIY"[C<2IQC"D A<
M#(..HK*L_#FOWLLC3RWD %P99%>[*B3)?;M.&PR94YQ@Y'3;7H]% ',?V-K
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MA+$;23<2Y(]/O=*1/AYX5C ":4% S@+/(,9.3_%ZUCY\<_\ 0R:1_P""EO\
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M*K$+>. "3XET< =?^)4W'_D:J&H:[XFTJ817_C#1;=BF_P"?2'Z%MHZ2]2>
M.^#Z4 =5_P (%X:_Z![_ /@5+_\ %4?\(%X:_P"@>_\ X%2__%5ST=]XOFLU
MNXO%NA/;,AD$RZ82I4=6SYW2I1)XW89'B?1B,;LC2FZ>O^NZ4 ;G_"!>&O\
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M_':,^.?^ADTC_P %+?\ QV@#;_X0+PU_T#W_ / J7_XJC_A O#7_ $#W_P#
MJ7_XJL3/CG_H9-(_\%+?_':,^.?^ADTC_P %+?\ QV@#;_X0+PU_T#W_ / J
M7_XJC_A O#7_ $#W_P# J7_XJL3/CG_H9-(_\%+?_':,^.?^ADTC_P %+?\
MQV@#;_X0+PU_T#W_ / J7_XJC_A O#7_ $#W_P# J7_XJL3/CG_H9-(_\%+?
M_':,^.?^ADTC_P %+?\ QV@#;_X0+PU_T#W_ / J7_XJC_A O#7_ $#W_P#
MJ7_XJL3/CG_H9-(_\%+?_':,^.?^ADTC_P %+?\ QV@#H+7P5X>L[V"\@T_%
MQ;OOB=YI'V-@C(#,1G!/YUOUR6A'Q3_:L?\ :FM:?=6FUMT4.GM$Q../F,AQ
MS[5UM !1110 4444 %%%% !1110 4444 %%%% !7F.DZG<VTNL11Z%JUVHU>
M\(FMHD9#F4]"7!_2O3JYOP9_QY:M_P!AB]_]'-0!C?VU>_\ 0K:__P!^(_\
MXY1_;5[_ -"MK_\ WXC_ /CE&JV/B.SU[Q!?Z5]ME'V:V-DDERSQ!V=A.5C)
MV[@FT@$8STZU1MK?7;N^_L[5O.+ZI<6\DC[2BM#"FZ3C/R[B$0CC.\T 7O[:
MO?\ H5M?_P"_$?\ \<H_MJ]_Z%;7_P#OQ'_\<K!2?X@Q?VA?):WYOYXX%&88
MO+1U$Q9%7)RF2B[N"<@DUL&?QK:WD<,(O+A6U21I&EAB\O[.73"@]<;&<@\8
M*X]!0!-_;5[_ -"MK_\ WXC_ /CE']M7O_0K:_\ ]^(__CE;NHVMW?65@5-V
M9%O%\TJQA;RMYW9"D<8Q^%9<5]X@A@FO-5@.VUG9T@B0] )0H!_B!_=^IR?R
M *W]M7O_ $*VO_\ ?B/_ ..4?VU>_P#0K:__ -^(_P#XY4?V/Q%8ZE8Q+'=2
MPV8DD_<JNR5FMV+.6)SN,S, O3&#BK7VGQ2L1F<7AD:WVHB11X#"9P'(*\'9
ML.,<^@[ $/\ ;5[_ -"MK_\ WXC_ /CE']M7O_0K:_\ ]^(__CE;<MSK8&F%
MH95WVN^X$$:MF?"_(<GY5^]R/S]<:*X\6,]M.T-QYWF/&%:)-KH7B(\SIMX,
MG( /'Y@#?[:O?^A6U_\ [\1__'*/[:O?^A6U_P#[\1__ !RK7E>(K.P8V22"
M5%9]K@.92JKM4Y/&3GD>E5])U75]?T/Q!&]P3=")UMXX4"E"=X&&]\#@\C&3
MU% #?[:O?^A6U_\ [\1__'*/[:O?^A6U_P#[\1__ !RKER/$EC;+%9-*P4RI
M BVZ$#:5$*MZ*PW%FZ].G>[&/$8U3>]QFT\T'RO(7&PR,I&[.>$VMGKG\J ,
M;^VKW_H5M?\ ^_$?_P <H_MJ]_Z%;7_^_$?_ ,<J\\^OV>NW9AM[B:Q,Q=E\
MI<!/W7,9SEB?WF0<8QQVS#.?$;VPOX;.5;WRF8(V.#\X *[L9"[3CN: *_\
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M?^A6U_\ [\1__'*@_P"$FD%^+'_A'-=^U&(S"+[/'G8#C/W_ %(%>B5S+?\
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MZ9I\!AMK8*A5T8,Q;(;&[.3WP/RH K2^*;!(;=\3JUTCM;B6%D$A52V,D<9
M)%0)XRT\Q)+()(D\O<X>-E=7.S:NTC)R'!!J:+POH;312K"TLELOE*SW#N5
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M8\>I/)I] "/]QOI7*_#+_DFGA[_KS2NJ?[C?2N5^&7_)-/#W_7FE '5T444
M%%%% !1110 4444 <WX9_P"0WXJ_[":_^DT-=)7-^&?^0WXJ_P"PFO\ Z30U
MTE !1110 4444 %%%% !7,M_R4^+_L#/_P"CEKIJYEO^2GQ?]@9__1RT =-1
M110 4444 %%%% !1110!R_B__D(^%?\ L,I_Z(FKJ*Y?Q?\ \A'PK_V&4_\
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MHH **** $?[C?2N5^&7_ "33P]_UYI75/]QOI7*_#+_DFGA[_KS2@#JZ***
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MU]+&P734L?#&E27%[)-&L1LTE)*(S #;P,E1DGIGFE-QH3:BME#X7TMG%U'
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MKEZ;J.E7]Y=./#.EF$"(V]NEO"782(A7<W0'YQQV_F =O_PE/A[_ *#VE_\
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M)L?NW=-Q"\ B,_X&DDO="M8U>?PSICL\1G,:0Q 1QK'&SX8CYS^\&!@9Y]*
M.L_X2GP]_P!![2__  ,C_P :/^$I\/?]![2__ R/_&L.T/AZY:_#>&+&+[+
M;A<V\1,D>YUSTX.8SP?45G76J>'K'S/M7A&Q3RBL;A8X682M&) N,?=VLN6Z
M D]AF@#K?^$I\/?]![2__ R/_&C_ (2GP]_T'M+_ / R/_&N8%SH\K!+?P99
M32+)Y4@"0!5?S&C&"1\PRO4=![C%27UQX?LK*SOF\+Z>UK/9R73_ +F(.FW9
MA0,8/+\G/&,T ='_ ,)3X>_Z#VE_^!D?^-'_  E/A[_H/:7_ .!D?^-<S?\
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MM3VK:#>:/]M@\+6#S?:OL@A\B(9;<!G<5'&#GIGVH W_ /A*?#W_ $'M+_\
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M[.=Z*)&P/]7\V#T^8ISR: .K_P"$I\/?]![2_P#P,C_QH_X2GP]_T'M+_P#
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MEH Z:BBB@ HHHH **** "BBB@#E_%_\ R$?"O_893_T1-745R_B__D(^%?\
ML,I_Z(FKJ* "BBB@ HHHH **** "BBB@ HHHH **** "N&\-:K?6J:O%!H%]
M>1C5[PB:&2 *?WK=GD!_2NYKF_!G_'EJW_88O?\ T<U $W]O:I_T*>J?]_K;
M_P".T?V]JG_0IZI_W^MO_CM<QJL/BZUUO6I]%@N94GV%);AQ^Y&^,,L*[RK
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MS@=.]RXO/%$6F.T-M=2WKB1-ICBVQR97:5Y&4QNY.3TH T_[>U3_ *%/5/\
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M444 %%%% !1110 4444 %%%% !7-^#/^/+5O^PQ>_P#HYJZ2N;\&?\>6K?\
M88O?_1S4 2'Q,L&H7T5U;R+!!-Y,;(A8G;&)'=NP4 _7\\4W_A,;# _T:_\
M,R-T0MR60'9M) ['S$Z>OL<:DEEIOVG;+%#YT[.^UCS(2H5CCO\ * #[4RWT
M'2[2,)#9HH'N2>JGJ3D_<7_OD4 5IO$42VMG-%:W#?:VD10R;3&R*Q.\$\<J
M1QFJ,'CG2V%O'.MQ%=2E0\)B.Y,JAW'_ &?WB>_/3@XW9=,LI8XTD@4K%(TB
M#)&&;.3^.YL_6H!H&EBX6X6T5)@01(C%6X55 )!Y&$48Z?** ,NX\6BU\3S:
M3):?N8@NZ;><DF-I!@$;?X2,;L]\8!I[>-]'CMOM#O*L>QG.4'59#&5'/)WC
M'&1T.<$&KUUH.C7E])-<VD,MS,GSAR3N 7;G;G' ;&<9&?>HG\,Z#'#^]LHA
M%&K?ZQSM7<26;D\,22=W7WH HZQXQ2PTJPO[2S>X6\:0*C[D*[$=SD!6/\!&
M>G.<XJ_+X@@V0B##22Y(#9VX#*IP1D'EQCL?6IIM'TK4[*".6);B",EHF\UF
MZ@J?FSDY!(//>E3P_I4=V]TEE&LSC!89Z9!X'0<JO3TH R8_%PGE@CBMCAHM
MTLK@B,.#'E5(R3CS/3M]:EE\:Z9!%ODBO%R1L4PX9U.?F4$\CY3[\<"KL&@Z
M*9VNH+2$N08RRL2."N1UP#F-<_[HS5?5?".FZJUN[>;;O NQ&@8*0,$#!(."
M,G!'(S0!-J?B73])N)(;HR*Z1I)POWMS;% R>26./0=R*+3Q+8WK 0+<,N(]
MSF(A49\;5.>A^8?G4]UH6FWUP;BZM1+-M"AF9OEP0<CGY3E1R,'@5%)H.CS3
M2*]NC3-$BR R-N*@_*QYSD%>&//'6@"K/XKMECEDMX9I5@&Z0E"H/#':I[M\
MAXZ>I'%6+#Q'9W]Q#;(D\=S(NXPNG*#8KY..,88#/KQ5BWT33+6W6W@LXDA7
M&$QQP"/Y$_G3+70-/LM0-[!%ME-JEF.<[8E)('KU;N>PH J1^+]*DB5U,^6&
M5C$)+L,L#\HYR-IR.HXR.:AF\::= OF217 B:.)XW4*PD,F["C!QD!&)[<5:
M7PKI*7D-REMM>)9@I#'),H4.Q;[V<(!G/2I5\-:.B(B62H$QM*LP((8L#D'.
M<LQSU^8^IH JR>+M/CF">1?,I4-Y@MFV@80G)]@ZY^I[@U>U/4)K.2TM[:!)
MKFZD*())-B+A2Q).">@Z =Z<NG:;<Q;UBBEC<'Y@VX," #SWSM7\J6ZT>PO;
M=(+FW$B1R&5/F(9'.<D,#D'D]#T)% %'_A)[5;B6T>"=KR)HU:&)0^2Q(X(/
M0$'DXZ9J+3?%46I3Z@\=O*ME;6T5Q%*R[3,KF3Y@"?N_)P3CK6A;Z%IEI.T\
M%FB2,02P)[$D?3DD_4FHX?#>CV\-W#%81+%=J$G09PZC.![ ;C@#IF@"JGC#
M3'M&NE6X,"(SRN(LB/#,F#@]2R,!C/3T(I)_&&FVMQ+;S17:S11>;(@@)*<;
ML''?'/I[U:'AG1A'Y?V"/9L:,J22&5B6.>?FY9CD]R32)I&CHLCHH4'$4C+<
M,,D' #'=RV3C)YYQ0!);Z[9W4ETD9;=:QK+)G'*LNX8YY&.XX]^#5?3?$UKJ
MM\EM;03X:%Y3(P&U2KE"IP>N1VR/>I;70=%MFFAM[2!2;<6[Q@YVQ'HN,_*I
MQVQG%2V^DZ9ISQRP0)"R!D5MQR=[9(.3SEO7O0!G6_C72+GRBAN )YA!"3"<
M2.PRH!]QD\]E.<5#;>.]*G@M7DCNH9)[871C,>XQH0Q7.W/78V,>G;(K57P]
MI2K&HLU*Q-NB#,Q$9R#\N3\O('3%1P:+HA+);P1?NT,+I'(<!3N^5@#T&YL
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MEH Z:BBB@ HHHH **** "BBB@#E_%_\ R$?"O_893_T1-745R_B__D(^%?\
ML,I_Z(FKJ* "BBB@ HHHH **** "BBB@ HHHH **** "N;\&?\>6K?\ 88O?
M_1S5TE<#X=C\3,-8.EW.D):_VO>;5N;>5WSYK9R5<#K[4 =V\,4@P\:,,[L,
MH//K2F-",%%/U%<MYWB[[;]C_M3PU]J\OS?)^SR[]F<;MOFYQGC-5K;5O$=W
M'));ZYX6D6.7R7(@E^5RVT*?WO4G@>O:@#L1#$KEQ&@8]6"C)I#;PLVXPQD[
M=F2H^[Z?2N:F?QA;F,3:EX;C\UQ''OMIAN8]%'[SD\'BI/*\;_\ /[X>_P#
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M3'!9L&QUQB/G%6/^$5\0?]#YJW_@):__ !J@#K:*Y+_A%?$'_0^:M_X"6O\
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M#OAVU\,:<VG6#R_8A(7AA<Y$(.,JI]-V6Y[L:UZ** "BBB@#E_%__(1\*_\
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MK\KBC^T_'/\ U+7Y7%0?\)-9_P#/AK7_ (*;C_XBC_A)K3_GPUK_ ,%-Q_\
M$4 3_P!I^.?^I:_*XH_M/QS_ -2U^5Q4'_"36?\ SX:U_P""FX_^(H_X2:T_
MY\-:_P#!3<?_ !% $_\ :?CG_J6ORN*/[3\<_P#4M?E<5!_PDUG_ ,^&M?\
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M0!/_ &GXY_ZEK\KBC^T_'/\ U+7Y7%0?\)-9_P#/AK7_ (*;C_XBC_A)K/\
MY\-:_P#!3<?_ !% $_\ :?CG_J6ORN*/[3\<_P#4M?E<5!_PDUG_ ,^&M?\
M@IN/_B*/^$FL_P#GPUK_ ,%-Q_\ $4 3-JOCA5+,WAE549)/G@ 57@\1^++I
MHUMKSPG.9%9T\IYGW!2 Q&/0D9^HJKJNMVU_HU_91V6L+)<6TD*EM)N, LI
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MG_J6ORN*@_X2:S_Y\-:_\%-Q_P#$4?\ "36?_/AK7_@IN/\ XB@"?^T_'/\
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M^&M?^"FX_P#B* )_[3\<_P#4M?E<4?VGXY_ZEK\KBH/^$FL_^?#6O_!3<?\
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M9=X\IA@ A2.3@<AEXSGD>HH Q/[<U^_N'"V\]O;+"RD"SD5I)# &P&/*X?<
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MY50H8 #*G  P#CCI5ZWT:*":^S*\EK=YWVS\J"Q8N?QW8^@%8=TOB%H;F6:
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MM_R4^+_L#/\ ^CEKIJYEO^2GQ?\ 8&?_ -'+0!TU%%% !1110 4444 %%%%
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M,>GX5TM% "/]QOI7*_#+_DFGA[_KS2NJ?[C?2N5^&7_)-/#W_7FE '5T444
M%%%% !1110 4444 <WX9_P"0WXJ_[":_^DT-=)7-^&?^0WXJ_P"PFO\ Z30U
MTE !1110 4444 %%%% !7,M_R4^+_L#/_P"CEKIJYEO^2GQ?]@9__1RT =-1
M110 4444 %%%% !1110!R_B__D(^%?\ L,I_Z(FKJ*Y?Q?\ \A'PK_V&4_\
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M^&7_ "33P]_UYI75/]QOI7*_#+_DFGA[_KS2@#JZ*** "BBB@ HHHH ****
M.;\,_P#(;\5?]A-?_2:&NDKF_#/_ "&_%7_837_TFAKI* "BBB@ HHHH ***
M* "N9;_DI\7_ &!G_P#1RUTU<RW_ "4^+_L#/_Z.6@#IJ*** "BBB@ HHHH
M**** .7\7_\ (1\*_P#893_T1-745R_B_P#Y"/A7_L,I_P"B)JZB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KF_!G_ !Y:M_V&+W_T<U=)7-^#/^/+5O\
ML,7O_HYJ .DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $?[C?2N5^&7_)-/#W_7
MFE=4_P!QOI7*_#+_ ))IX>_Z\TH ZNBBB@ HHHH **** "BBB@#F_#/_ "&_
M%7_837_TFAKI*YOPS_R&_%7_ &$U_P#2:&NDH **** "BBB@ HHHH *YEO\
MDI\7_8&?_P!'+735S+?\E/B_[ S_ /HY: .FHHHH **** "BBB@ HHHH Y?Q
M?_R$?"O_ &&4_P#1$U=17+^+_P#D(^%?^PRG_HB:NHH **** "BBB@ HHHH
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M>3R(\L!W.,^E7-*FUU[UHK[>T1M21*L0C429XX/))!]@,'CI0!'_ ,)?=_\
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M)!X^4,,_,* +G_"7W?\ T)_B+_OU!_\ ':/^$ON_^A/\1?\ ?J#_ ..UT]%
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M@ HHHH 1_N-]*Y7X9?\ )-/#W_7FE=4WW&^E<K\,_P#DFGA[_KS2@#JZ***
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M2< %N3B@#B5\.>%(((9-3T_5;)IU\R-/[5NI2(P%R[;9#M"E@"3P,]:>N@>
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MW=II5I8LK6\95E3RP2Q)V\>OT%5[GPYIEU;?9Y86\HJ$95D8;EW%L'!Z9.:
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M5MX9_P">.H_^#6Z_^.4?\*V\,_\ /'4?_!K=?_'*ZVB@#DO^%;>&?^>.H_\
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MC-E0&R>%] #V-5([+P5)J4-H='GC>4.!$[3"4,@5B-N[IL8-GW'?B@#TFBN
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M_0,'_?\ D_\ BJ/^$ \,?] P?]_Y/_BJ .EHKFO^$ \,?] P?]_Y/_BJ/^$
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M%M;:%=VUM?>+_%2R70(MPCQMYK[E&Q<1?>^8''H">QK=_M3Q9_T*]E_X-O\
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MX\-Z$^L6.I:I';W*ZO>,T9C<D RL1T&*]%KF_!G_ !Y:M_V&+W_T<U '*_\
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MQQ)XK\NW:0ES'-,-Z;U*A%"?N\*"IQUS^-22>.=,DTS1X&\6Q"ZAC,=Y,IE
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M;!;QP+ 2D<[W W.Q)D=65B>><AV_.ET_0=/TMU>VC<.J[ SRLYVX4 9)Z *
M/_KF@#D&L_#*7"I)-KT41DEB:5]1NP%:-U0Y^?[N6'S=*66T\*?V1J.I6U[J
M]S'I\9DD6/5KD$CG&"9,8.#STX-=9+X=TV>.>.6%V29G9E,C8RS*[8YXRR@_
M_KI(_#>EQZ7<Z8L#?8KA2CPESC:<\#T')H Y"WM_"TEJ99[G6X&3.Y?[4NG7
M&\Q@AU<J0S# YYI[0^#55&_M+6V5TWADO[UAC;N/(;LO)'8"NTN](LKU)%FB
M)WK&IVL5QL8LF,=,$YI@T2QVD&-FR""2YR<IL/\ X[Q0!R9TWPO#]I^TWVJQ
M&W#/*?[6NB%4.44D[\9)! %3V.B>&-2D:.TOM8E81^8P&IW7 R1@_/UR#Q[5
MN77A32+U]US;M( KA5,K87>=S$#/!SS^ JS;Z+9VUZEX@D:=(C$K/(6PI()X
MZ<D"@#D;2R\*7CVJ)>ZXDERJ%$EU&[4J7!*!COP"P!(!/./I44NG>$8[B07E
MSJ\4UK,\<>_4KO+'(4[#NP2=PSCINYKK+?PQI5K<PSQ0/OBV[0TK$?*"$)!.
M"5#$#/08]!23^%M*N;A[B6&1I6?S%)F8^6Q(8E!G"Y(&<=<4 <]-H_AN&.SF
M%UK#VMU"9(I$U6Z.[E H"A\DL7'%-BTWPK/$TEO>:[*B+EC'?WA"G.-I^;AO
M]D\UUESHUE>10QS(Y\A0L;B1@RX*D$$'KE5.?:JH\*Z4L+Q)%*D;A=Z+.^&9
M3N#D9Y;(Z]^] ')JO@YDFD_M#6Q#'Y6V4ZE=[9/,3>NP[^?ER3Z8-6H-)\.W
M>JI8VEQK4V8GD,PU6Z"?+LX#;\$_..AXKH%\(Z-'%''%;/&L8C\O9*WRE%**
M1SUVDKGN*M6^A6%K?M>PQR"9@XYE8J-VW<0N< G:N3[4 <O8Z1X;OIX[9+O6
M1<O&'*?VI=[<[58J'W8) 93QV-58+?PO-+"'GUZ"*:)9$DFU&[4#+,H#?/\
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MW&><'C@4[3["WTO3[>PM%9;>W01Q*SEBJCH,GGB@#$_X0?2?^?C6/_!M<_\
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M:CIUK,CO=)L625.=H)(#9)#8W'L,UU5% ')IX'MQ<+-)=>8Q#EP8L ,S,P*
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M0?\ GW\,_P#?^?\ ^(HW_$'_ )]_#/\ W_G_ /B*ZNB@#E-_Q!_Y]_#/_?\
MG_\ B*-_Q!_Y]_#/_?\ G_\ B*ZNB@#E-_Q!_P"??PS_ -_Y_P#XBC?\0?\
MGW\,_P#?^?\ ^(KJZ* .4W_$'_GW\,_]_P"?_P"(HW_$'_GW\,_]_P"?_P"(
MKJZ* .4W_$'_ )]_#/\ W_G_ /B*-_Q!_P"??PS_ -_Y_P#XBNKHH Y3?\0?
M^??PS_W_ )__ (BC?\0?^??PS_W_ )__ (BNKHH Y3?\0?\ GW\,_P#?^?\
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M[^&?^_\ /_\ $5U=% '*;_B#_P ^_AG_ +_S_P#Q%&_X@_\ /OX9_P"_\_\
M\175T4 <9)I7B_5=5TB351H<5I87@NF^RR2M(Q".N!N4#^/]*[.BB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
2444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>gqr1p20dfppl000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqr1p20dfppl000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,H G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7EVL(E6(0Q*"C,80Q5AG( .X[L>@SBJ [JBBB@84444 %%%% !1110 4444
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M85_[[9E)WGGCIR:U[+PO=P^&;KP]-J"FP^PQV-HR1C>BB/8SMZL3SCH,#UH
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M*C_YYI_WR*/9ASGU-_PG7A+_ *&?1_\ P-C_ ,:/^$Z\)?\ 0SZ/_P"!L?\
MC7RSY4?_ #S3_OD4>5'_ ,\T_P"^11[,.<^IO^$Z\)?]#/H__@;'_C1_PG7A
M+_H9]'_\#8_\:^6?*C_YYI_WR*/*C_YYI_WR*/9ASGU-_P )UX2_Z&?1_P#P
M-C_QH_X3KPE_T,^C_P#@;'_C7RSY4?\ SS3_ +Y%'E1_\\T_[Y%'LPYSZF_X
M3KPE_P!#/H__ (&Q_P"-'_"=>$O^AGT?_P #8_\ &OEGRH_^>:?]\BCRH_\
MGFG_ 'R*/9ASGU-_PG7A+_H9]'_\#8_\:/\ A.O"7_0SZ/\ ^!T?^-?+/E1_
M\\T_[Y%'E1_\\T_[Y%'LPYSZF_X3KPE_T,^C_P#@;'_C1_PG7A+_ *&?1_\
MP-C_ ,:^6?*C_P">:?\ ?(H\J/\ YYI_WR*/9ASGU-_PG7A+_H9]'_\  V/_
M !H_X3KPE_T,^C_^!L?^-?+/E1_\\T_[Y%'E1_\ /-/^^11[,.<^IO\ A.O"
M7_0SZ/\ ^!L?^-'_  G7A+_H9]'_ / Z/_&OEGRH_P#GFG_?(H\J/_GFG_?(
MH]F'.?4W_"=>$O\ H9]'_P# V/\ QH_X3KPE_P!#/H__ (&Q_P"-?+/E1_\
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MOX%_=CDCD\4<J[A<]K_X3KPE_P!#/H__ (&Q_P"-'_"=>$O^AGT?_P #8_\
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MFOJZOE'Q3_R.OB+_ +"=Q_Z&:TI[DRV,JBBBMC,**** "BBB@ HHHH ****
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M^?B'_OX*/M=M_P _$/\ W\%?2G]AZ/\ ] C3_P#P%C_PH_L/1_\ H$:?_P"
ML?\ A1[0.0^:_M5M_P _$/\ W\%'VJV_Y^(?^_@KZ4_L/1_^@1I__@+'_A1_
M8>C_ /0(T_\ \!8_\*/:!R'S7]KMO^?B'_OX*/M5M_S\0_\ ?P5]*?V'H_\
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MG_\ @+'_ (4_:"Y#YK^UVW_/Q#_W\%'VJV_Y^(?^_@KZ4_L/1_\ H$:?_P"
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M_OX*/M=M_P _$/\ W\%?2G]AZ/\ ] C3_P#P%C_PH_L/1_\ H$:?_P" L?\
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MF?8)[Y?&>J26MO@2RQSPN%SC&<1^X_.MBW\)V4%V+CSIW\N5I(48KB+=+YK
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M_P"-UTU% ',_\(>W_0R:W_W\A_\ C='_  A[?]#)K?\ W\A_^-UTU% ',_\
M"'M_T,FM_P#?R'_XW1_PA[?]#)K?_?R'_P"-UTU% ',_\(>W_0R:W_W\A_\
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M\C4 =A17'RP>.( AD\0Z N]PBYTN7ECT'^NI9;;QU!"\LGB#0%C12S,=+EX
MZG_74 =?17)):>.Y$5UU_0"K#(/]ER\C_O\ 4OV+Q[_T'M!_\%<O_P >H ZR
MBN/@@\<7,*RP^(= >-NC#2Y>?_(U2?8?'O\ T'M!_P#!7+_\>H ZRBN1>T\=
MQHSOX@\/JBC)9M+E  _[_4[[#X]_Z#V@_P#@KE_^/4 =917$Q/XPF<I%XG\.
M2,)F@(339#B11DJ<3<$#M3Y_^$SM2PG\3>'(BL3S'?IL@PBXW-_K^@R,GWH
M[.BN2%GX\(!&OZ 0?^H7+_\ 'JJW<GC&P>)+KQ+X>B:4,4#:5+\VT9/_ "V[
M"@#MZ*Y/[%X]_P"@]H/_ (*Y?_CU,EMO'4$+S2>(- 6.-2S,=+EX ZG_ %U
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M\>_]![0?_!7+_P#'J/L/CW_H/:#_ ."N7_X]0!UE%<G]A\>_]![0?_!7+_\
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M?BI[B_BM]0BCM?-MXV3;D_O&(4J3_#DD8!'(YSUP +K'A$:K-J5Q]MEBGN%
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M]!QGS&_'\: -8:QIC>7C4+4^8I9#YJ_,!U(Y[8/Y&EDU.UC2*4RKY$JLXFW
M(J@9)))Z5D/X2BFN%N+F[-Q,(/(9IK>)@0-VTXVX!&\_6K"^&H#IEK8S75Q,
M+='022$,S!O7CMT'M0!JQ7$-U:^=;RI+$P.UT8,#^(KFOAE_R33P]_UYI6_9
M6$>G6DT,;,RO-+.2WK([.1],L:P/AE_R33P]_P!>:4 =71110 4444 %%%%
M!1110!S?AG_D-^*O^PFO_I-#725S?AG_ )#?BK_L)K_Z30UTE !1110 4444
M %%%% !7,M_R4^+_ + S_P#HY:Z:N9;_ )*?%_V!G_\ 1RT =-1110 4444
M%%%% !1110!R_B__ )"/A7_L,I_Z(FKJ*Y?Q?_R$?"O_ &&4_P#1$U=10 44
M44 %%%% !1110 4444 %%%% !1110 5S?@S_ (\M6_[#%[_Z.:NDK@?#OA32
M-6&L7=Y#<-,VKW@)2\FC'$K <*P'Z4 6[I->MM3URXT^%I+EW3[$DL3>6PQ'
MU??M"Y#9 4$<G)Z46\.OB]&]9I+.Z?S)(Y$53$P,.#E3D9_>9&2./SS/[/\
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MQ?\ \A'PK_V&4_\ 1$U=10 4444 %%%% !1110 4444 %%%% !1110 5Y[H
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M-' \;[)"Q(?RW5W!.>22I_X#4=QX2OY;V]N/MPE\^Y$H261@CQA@PC8 =!C
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M8W4ES#+';-D,Q<R!1&Z"-<G&WY@<]?YT (DOCF2)I4NO"YC4L&;RY\ @X/\
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MS8ZNPEU%6 739V(_T>(<@+P>.A[8/>M__A++3_H':W_X*KC_ .(H WJ*P?\
MA++3_H':W_X*KC_XBC_A++3_ *!VM_\ @JN/_B* -ZBL'_A++3_H':W_ ."J
MX_\ B*/^$LM/^@=K?_@JN/\ XB@#>HK!_P"$LM/^@=K?_@JN/_B*/^$LM/\
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M;:'',7N$D6[3>S0O*53:,DHO)%7XO%6G2W36_P"^1A=FTWNF%+;68-G^Z=C
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M5XSBMR@!'^XWTKE?AE_R33P]_P!>:5U3_<;Z5ROPR_Y)IX>_Z\TH ZNBBB@
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MZ$]*O_\ "/:0-W_$O@.^,Q-E<Y4C!!_"I#HFF-/%,UC 98ON.4Y'?\>1GZT
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M* "BBB@ HHHH Y?Q?_R$?"O_ &&4_P#1$U=17+^+_P#D(^%?^PRG_HB:NHH
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M%6H6-M-+>V-J@1MH*3,<A9&1S@J"3\NX*.2#WQR 2?\ "QO"7_09B_[]O_\
M$T?\+&\)?]!F+_OV_P#\33M7\5OINMII\=O'+NA9R6<IM(1W!)(P%.S&>Q89
MQTITWB6Y&C6VI6UD+A&M);J5065L1@?*@QR23W].] $?_"QO"7_09B_[]O\
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M *#,7_?M_P#XFC_A8WA+_H,Q?]^W_P#B:B;Q;>17$<#V4+3/9M<%$=OE;9O
MR5Y';('7\JU-(U74+R\E@O;2"$*'VM#*S9*2%#G*CK@$?6@"@WQ%\)%2/[9B
MZ?\ /-__ (FN<^'_ (Y\-:?X T.TNM5CCGBM55T*.<'TX%>EM]QOI7*_#/\
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M,#%+10!$+:%1#B)!Y(Q'Q]SC''IQQ4F!Z=*6B@!,#THP/2EHH 3 ]*7 HHH
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M+0!TU%%% !1110 4444 %%%% '+^+_\ D(^%?^PRG_HB:NHKE_%__(1\*_\
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MK>,_^??P_P#]_9__ (FC^UO&?_/OX?\ ^_L__P 369_PFFE_\^NM?^">Y_\
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M^UO&?_/OX?\ ^_L__P 369_PFFE_\^NM?^">Y_\ B*/^$TTO_GUUK_P3W/\
M\10!I_VMXS_Y]_#_ /W]G_\ B:/[6\9_\^_A_P#[^S__ !-9G_"::7_SZZU_
MX)[G_P"(H_X332_^?76O_!/<_P#Q% &G_:WC/_GW\/\ _?V?_P")H_M;QG_S
M[^'_ /O[/_\ $UF?\)II?_/KK7_@GN?_ (BC_A--+_Y]=:_\$]S_ /$4 :?]
MK>,_^??P_P#]_9__ (FC^UO&?_/OX?\ ^_L__P 369_PFFE_\^NM?^">Y_\
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M ']G_P#B:/[6\9_\^_A__O[/_P#$UF?\)II?_/KK7_@GN?\ XBC_ (332_\
MGUUK_P $]S_\10!I_P!K>,_^??P__P!_9_\ XFC^UO&?_/OX?_[^S_\ Q-9G
M_"::7_SZZU_X)[G_ .(H_P"$TTO_ )]=:_\ !/<__$4 2:>WB_3[S4KA$T%V
MO[@7#@R3#:1&B8'R^B9_&K_]K>,_^??P_P#]_9__ (FLE/'6C2O(D<6KNT3;
M9 NDW!*' .#\G!P0?QI__"::7_SZZU_X)[G_ .(H T_[6\9_\^_A_P#[^S__
M !-']K>,_P#GW\/_ /?V?_XFLS_A--+_ .?76O\ P3W/_P 11_PFFE_\^NM?
M^">Y_P#B* -/^UO&?_/OX?\ ^_L__P 31_:WC/\ Y]_#_P#W]G_^)K,_X332
M_P#GUUK_ ,$]S_\ $4?\)II?_/KK7_@GN?\ XB@#3_M;QG_S[^'_ /O[/_\
M$T?VMXS_ .??P_\ ]_9__B:S/^$TTO\ Y]=:_P#!/<__ !%'_"::7_SZZU_X
M)[G_ .(H T_[6\9_\^_A_P#[^S__ !-9Y_X2\^(EUG9H/F+:&U\OS)L8+ALY
MV]>*9_PFFE_\^NM?^">Y_P#B*9_PG6B^?Y'E:OYQ7?Y?]DW&[;G&<;,XSWH
MUO[6\9_\^_A__O[/_P#$T?VMXS_Y]_#_ /W]G_\ B:S/^$TTO_GUUK_P3W/_
M ,11_P )II?_ #ZZU_X)[G_XB@#3_M;QG_S[^'_^_L__ ,31_:WC/_GW\/\
M_?V?_P")K,_X332_^?76O_!/<_\ Q%'_  FFE_\ /KK7_@GN?_B* -/^UO&?
M_/OX?_[^S_\ Q-']K>,_^??P_P#]_9__ (FLS_A--+_Y]=:_\$]S_P#$4?\
M"::7_P ^NM?^">Y_^(H T_[6\9_\^_A__O[/_P#$T?VMXS_Y]_#_ /W]G_\
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M;&.UCM4LX%MXV#I$(QM5@<@@>N><T <]%XS*PV\<^EWCWDB(XBA56+H5+%E
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MS=FS?Y8SMYX^G)_.@#+T[Q*=0U5[-;%XDCA=Y)'D7*.DC1LN >1E.H]:J_\
M"<6GV-KH6=P\<;N)2C(0B*$)?.?F&)4Z>]="MC:)*)5MH5D&[#A!GYCEN?<\
MGUJ-=)TY(6A6PMEB;.Y!$N#G&<C'? _(>E &$OBJ>:[U3RK8+;VEE)<1&0@F
M1D=U)X/ RAX/-11^,9[72OM6I:=-PID+Q)L!3*JAV.=P+,P&/8GI71QZ7I\4
MEQ)'8VZ/<@B=EB ,F>N[CGJ>OJ:EDM+::-HY;>)T9/+960$%?[OT]J ,.3Q2
MZ"$#1KYI9%&8SL0JQ+@ [F'7RV.?3'K4<WC&VL\R7,4GD$.ZN%"X"QJX3D_,
MY!Z#T/I6]%86<,:)%:PHJ8"@(,+C.,?F?S-1OI.G22+))86SLJE06B4X!&".
MGIQ]* *-GXA6ZO+6TFL;FTFN$<J)QM&5)RH]3@9^G/KANG>(HKJ1H)U,<B6W
MVG>5VB1>Y09)(' /H?J*T(-*T^VECE@L;>.2)2D;K& 54]0#VZFGPZ?96]PU
MQ#:01S,H0R)& Q7TSZ=* .5L_%E_J-L7MA8BX.H"U6W.YR48*X)(/#!"Q/4<
M8K6AU;4)].U1X[>!KVUN)(8(E8D2;0".N.<'GI6N+2V$XF%O%YH)8/L&02 "
M<^I  _"J7_"/:1YQE&G6X8[]V$ #%QAB1T)(XR: .9D\?>7-,GE@I;0GS6:!
MD#3_ +S]W]X[,>4<D[JTQXI^P:;<W&K(K-;79M6>U4E6.P.N 3GDD(.?O$>M
M;*Z/IJ-$RZ?:AH4,<9$*_(ISD#C@<G\SZT^/3;&&S%I'9VZVP8,(1&-F0<@X
MZ9R ?PH Y_\ X3FQD^S&W@ED%RQ2,[E!W $\C/3<&7/JI]*CM_&[,7:YTN2&
M)(;:1I!*K!?.!/S>BC'7W[5T2Z5IRR12+8VP>$DQL(ERA))...,DD_B:8=$T
MI@@.FVA$8 0&%?E )( X[$G\Z +RL&&5((]0:6F0PQ6\?EPQK&F2VU1@9)R3
M^))-/H **** "BBB@ HHHH **** $?[C?2N5^&7_ "33P]_UYI75/]QOI7*_
M#+_DFGA[_KS2@#JZ*** "L#7_"T/B"[M+F:\N(9++Y[4Q$#RI=RGS.1R<+MP
M>,,WK6_10 #IS1110 4444 <WX9_Y#?BK_L)K_Z30UTE<WX9_P"0WXJ_[":_
M^DT-=)0 4444 %%%% !1110 5S+?\E/B_P"P,_\ Z.6NFKF6_P"2GQ?]@9__
M $<M '34444 %%%% !1110 4444 <OXO_P"0CX5_[#*?^B)JZBN7\7_\A'PK
M_P!AE/\ T1-744 %%%% !1110 4444 %%%% !1110 4444 %<+X:T"#4$UBX
MDO=3B8ZO>#;;W\L2<2MT56 KNJX;P]K/]FG48#;/,)-3O7 C(W%C="-0 <#J
M_4GC% &U_P (G:?]!+6__!K/_P#%4?\ ")VG_02UO_P:S_\ Q554\;VUQ'";
M2RN)7E,.U'98RPD<(2N3SM)P2.,\9IG_  FD5TTZV,.6MV99/,((/R[E*E20
M0>: +O\ PB=I_P!!+6__  :S_P#Q5'_")VG_ $$M;_\ !K/_ /%5"?%T<ERU
MO;6<CLDS0NY==JXC9P_!^8':1@<TV+QG;,T<1M+F263Y(C&JXFD!0.JY;C!<
M<M@<'TH L?\ ")VG_02UO_P:S_\ Q5'_  B=I_T$M;_\&L__ ,52S^*K6#3+
M6^%K<R"X1Y/+4+N14!+DY..,=B<]JK6GB2[N=)?419;E?4&M8(4(W,@DV9R6
MQDD$\XQ_, L?\(G:?]!+6_\ P:S_ /Q5'_")VG_02UO_ ,&L_P#\535\8:?+
MI\=Y##<RK(&*QH@+DJ@<C&>N#C_ZW-0:UXOCL=/M9K&$74MS'',A#*8UC:1$
M+%@>>9!]W- %G_A$[3_H):W_ .#6?_XJC_A$[3_H):W_ .#6?_XJI#XFMFN8
M+:WMYYYYU5T1=HX._G)(''EM^E+!X@:;28KUM.N \UP;>.!&1F8ABN[.0 ."
M>: (O^$3M/\ H):W_P"#6?\ ^*H_X1.T_P"@EK?_ (-9_P#XJJI\:6]O;I]I
MMYFF94VB-0!(6) V@G...3TSQ5K_ (2JW(5Q9W8A:6*+SI%5%#.H8 [B"N P
M!R!R<#)H /\ A$[3_H):W_X-9_\ XJC_ (1.T_Z"6M_^#6?_ .*HOO%=K87E
MU:M;SRR6\/FGRMK9 *@]^,;U)SCC)HUCQ/'IMNC10M*\UN9X&!&R3 SM!S\S
M$<X';GI0 ?\ ")VG_02UO_P:S_\ Q5'_  B=I_T$M;_\&L__ ,54,GC2TBW!
MK*\W1';<*%4F$F0Q*#\WS9<8&W/K26_CC3;UWCLH;FXE0J#&BJ"=VP*>3C!,
MF,^JMZ4 3_\ ")VG_02UO_P:S_\ Q5'_  B=I_T$M;_\&L__ ,52W'BJU@TR
MUOA:W,BW$3S>6H7=&B#+DY(''H"<]J=:>*+.Z>Y'DW$4<,+SB211B2-6*LRX
M)/5>AP>10 S_ (1.T_Z"6M_^#6?_ .*H_P"$3M/^@EK?_@UG_P#BJIV'C(W-
MS>I-ITT20G>N60%8A%&^YSNP"3(  /QH;X@:1$D)N$N83*#@,@[>8#T/0-&5
MSZLH[T 7/^$3M/\ H):W_P"#6?\ ^*H_X1.T_P"@EK?_ (-9_P#XJHV\5Q6T
M@2ZM9]N_:\L:#;%EW5 W.2V4(. :=IOBVVU*:UC6TN(5NF98I)2FQ\*&X()R
M2#T'/!]* '?\(G:?]!+6_P#P:S__ !5'_")VG_02UO\ \&L__P 539O%UM!=
M1P&QO6:262--D8;<$<(S@ YV[B/?J<51LO',?D(+ZSG^U&#[3(EO'N6-&#L@
M)R<DJAYX&<=,T :'_")VG_02UO\ \&L__P 51_PB=I_T$M;_ /!K/_\ %5&?
M%]N+FXMSI]\98  X5%(#G9\F<XW?.O?'7GBD?QG:16L]S)9W2Q6P N"0N8W+
ME F-W)+#&1D>] $O_")VG_02UO\ \&L__P 51_PB=I_T$M;_ /!K/_\ %55_
MX3)+C4+"TM+.<--.D=P9UV>2&$A P3DD^6>@(Q]:N#Q(D=W';36\K;[@P^=&
MHV(3(R(&R<Y)0]!0 W_A$[3_ *"6M_\ @UG_ /BJ/^$3M/\ H):W_P"#6?\
M^*JO-XN2QN=:>]@=+#2Y%225(F;@JC;MW0XW\J,GC-21^)99+IK9[-X)&E B
M>0 HR[HPPX;.X>8/;KUQ0!)_PB=I_P!!+6__  :S_P#Q5'_")VG_ $$M;_\
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M %;W_"*ZG_T.>N?]\VW_ ,:H Z>BN8_X174_^ASUS_OFV_\ C5'_  BNI_\
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MM;\+37'B'4M00ZNJB&Z$6T'R9?F^1%.?Q[UZ!0 4444 %%%% !1110 4444
M%%%% !1110 5YQI%G>SZMYT",UK'JFHK+B/>-QN 1_$-IP#\V&^E>CUY[I'B
M&329YK**S-R]WK%\=BL=Y N0IV@ C@/N.2!@&@"VG_"5V[2Q@S+;11Q(D<<2
M,QCQ&&9&)_U@/F<'(.![9LQ6VOO/=1O/>?9Y)GDQ,(SF,Q#:@QT^?.<?AUS5
MS_A,M.$D*/#>)YL?FJ6AZ)\VUB,YPVQL?KC(IR>*8IRR)9W<$BNJD7,6T??1
M2!C.2!(I_'ZX ,F\D\40Z==1V5O=FZ5@L&WRA$B!#MQG+-DX#9_05=O6U.QT
MQ5B%TDUQJ#[OLR(\GEMN;Y=_RCH.M6%\9:8\UO$J71DG&0BQ[F0;BHW $D9(
M(QU'<"KR:U#/X>DUBW1FC6%Y0C$ _*#P<9P>/PH YQ)O&B&>1XF>:*+?Y&(Q
M%(0$(1&Z[F/F*2>!D=.*0/XU,<*SMY;";RVDAB1\@ $.5S]UB2".HVCIFM<>
M+;0,(WM;L2L (U6,$2ME050YYP7')P*G@\01'S1<1M&R3B, #. 7"#/OD\T
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MI0!U=%%% !1110 4444 %%%% '-^&?\ D-^*O^PFO_I-#725S?AG_D-^*O\
ML)K_ .DT-=)0 4444 %%8OBG7QX8T5M6DMS/;0R()U5L.J,P4LH_B()'R\9J
M_IEU+?:7:W<T:123Q+(423>J[AG 8=?K0!;HHHH *YEO^2GQ?]@9_P#T<M=-
M7,M_R4^+_L#/_P"CEH Z:BBB@ HHHH **** "BBB@#E_%_\ R$?"O_893_T1
M-745R_B__D(^%?\ L,I_Z(FKJ* "BBB@ HHHH **** "BBB@ HHHH **** "
MN7\&P1&+5)R@\U=6OD#XY"F<DC\P/RKJ*\]T72K^_NYIX+J2.UAU>^$J1S&,
M[C<9W?=(8;0RXXZ]: .S_L?3B\<@MDRD7DJ5) \OGY3CJ.3U]34K:;9/G=;1
MG)W'CJ<J<_FJ_D*YO0]#UC18[9!Y,ZP6<<$:M=R!49<ACC!R'X.3TQCL*ZZ@
M#+C\.Z3$5:.R1&7=\RDACN.3DYR>?6IH-'T^V@DAAM46.5"DB]=ZDDG.>N2S
M?G5ZB@"A-HFFW$8CELXF4=..G(/![<JI_"FOH.E22P2M8PEX&WQ''W3D'/Y@
M'\*T:* ,NV\.:/9[_L^G01[R"VU>N!@?D. .U0OX9LCKL>K1R30S)R4B8*K'
M+$YXS@EV)&<$XK:HH I7&DV%V&$]LC;I1,3R#O"[=P(Y!V\?2FW.BZ==IMGM
M(W )()'()().>N<JOY5?HH SWT/2Y(5B>Q@:-5*A2G !3RR/^^ %^E$VAZ;<
M2V\LUI'(]NH6(OD[0""![X(!Y[C-:%% &1'X8T6+=LTZ%=TBR,,'#,OW<COC
ML#P*:/">@B%H1I=OY;MO9=O4[=OY;>,=,<5LT4 9Z:'IL<PF2TC602^<&7(P
M_/(]/O'ZY--D\/Z5-)-)-8Q2-,RM(7&[)5@XZ]/F /'<5I44 9XT+2UMEMUL
M85A5MRHJX"G?OR,=/F)/U-$.AZ9;Q&**RB2,G[H''4' ]!E1Q[5H44 9@\/:
M6%55M$55E\U5!.U7SG(7..O/3&:L0:=;0:6FG!"]JL7D[9"6W+C!!)ZYJW10
M!2.D6#7$DYMD,DH D.3A\8QD=">!S["HSH.EM=&Y-E%YQW9;'7=NSGZ[V_[Z
M/K6C10!372[)+M;I;=%G5F82#@Y;&[ZYP/R%12Z#I<]I#:26,+6\))CCQ@+G
M.?SR?SK1HH H3Z-IUSDS6D;$_P 6,'[V_@CD?,2?K39M"TNXEAEFLHI)(3N1
MF&2#\OY\JIY_NBM&B@#);PSHK(4.G0E2^_&#UY_3D\=.3Q4MYH6EW_E?:[&&
M;RF+IN7H2P8_^/ 'Z@&M&B@#/M-&LK&\>ZMHS'(ZD-AB0<D9)SU/RJ,^@ IY
MTC3VMV@-I$8F6163;P1(=SC_ ($>35VB@"@FBZ<D"PK:1B-2& ]""6SGKG+,
M<^I-1_\ ".Z3]F^S_88A'D' SG(9FSGKG+,<]?F/K6G10!573;)8!"MM$L0Z
M(%P!\FSI_N\?2F-I%@\\<YMD$L9^1UR".G''4?*O'3@5=HH I?V58I<1W:VR
M">&(Q1-_<7&, =!T'2L'X9?\DT\/?]>:5U3_ '&^E<K\,O\ DFGA[_KS2@#J
MZ*** "BBB@ HHHH **** .;\,_\ (;\5?]A-?_2:&NDKF_#/_(;\5?\ 837_
M -)H:Z2@ HHHH KW5C:WOD_:H$F$,@EC#C.UQG#?49-+9V=MI]G#9VD*0V\*
MA(XT&%11T ]JGHH **** "N9;_DI\7_8&?\ ]'+735S+?\E/B_[ S_\ HY:
M.FHHHH **** "BBB@ HHHH Y?Q?_ ,A'PK_V&4_]$35U%<OXO_Y"/A7_ +#*
M?^B)JZB@ HHHH **** "BBB@ HHHH **** "BBB@ KS_ ,/Z+JE[_;$UKXFO
MK"(ZO> 00PPLH_>MSET)Y^M>@5QOA?5(+,WUHZRM-/JU^ZA%R JSD$D]N2*
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M^V=Y@3$JRJ2^.N.>>A_(U&FMZ6[E!J%MN$S6Y4R 'S!P5Y[T 8W_  C6N?\
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M8DU?Q(J>+M2C:/4%5V6WMR9#Y$1W',?!P0.,#@5N_P#"-:Y_T.NJ?^ UM_\
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M3Q)IJ6T$ZO)(MQ;-=1!(R2T:KN)QVZC@^M-7Q/II12YGC9H5G"- VXJQ4#
MY.748'K3QX?M)+:QBO6EO&LTVJ\KGYCM*EB!P3@G\Z2#PSI=O.)HX',@55W-
M*S<*4(ZGUC3_ +YH JR^+]/\RS2V$L_VB158K&P$8._[QQ][*,-O7BI?^$LT
MCR5E\V8@ALX@<E2'V8/'!+X4#J2>*&\(Z*Q3-JVU"2%$SA23OY(S@G]X_7IN
MJ9/#6EI9/:"W/DORW[QLYW[]V<Y!W<Y]: *=OXI%UIUC/#9.;F^N9H(;=VV'
M]VSABQ(XXC)QC/.*L6/B?3KVSMYRSQ/,QC$3*2P<!R5XR#_JW_+WJ9/#VG1V
M-O:1Q2)';R-+"RS.'1V+%B'SNR=S9YYR:J0>#=(A2-2D\JQ!@@DG8@ JZ],\
MD+(XR<GGK0 C>+M/<VR6HEGDFF2)E$;#RMTGEY<X^7D'&>N.*M/K]I$MP95E
M!BNOLBHB%VE?:&^4#D\$_D:CB\*:1#)"\=NX:)Q(")G^9@Y<%N?FPQ)&>F33
MYO#6FS7,UPRW EFD$K%+F10K@;=R@-A6QQD8R,T 5XO%VDW3 6<XF!"-YFUE
M3:652=V,9&]>/?ZTW4/$FGZ9H?\ :T=I-);23QJP6'86#D?O,,!D '=GT%1Z
M?X+L=/U&YGCD<VTV#]D PG!4KGUV[./J<YK431+!+**S\MWMX9%DC221GVE?
MNCD]!CITH S7\::5!=7D5RYABMY%C28\B8E69MN.<+M;)]C4B>,-'81F266$
MR3R01B2(C<4?86'^SN(&??ZU)'X2T6&WMH(+3REM558#'(P:, ,!@YST=L^N
M:G'A_3EN%G2)TD61Y 5E88+D,PZ]"P!(Z9SZT 5SXHT\(TS>=]GVJR,(7+/G
M><A=N=N(V.?8_C:L]>T[4-0DL;:8O-&F\_(0I''0XP?O+^=._L6P\M4\CY5B
M$0&X_< 90.OH[?G5+2/#,.C:M=7MO<R&.X!!A(X'3&3WP!@>Q.<T ;M%%% !
M1110 4444 -?[C?2N6^&7_)-/#W_ %YI75/]QOI7*_#+_DFGA[_KS2@#JZ**
M* "BBB@ HHHH **** .;\,_\AOQ5_P!A-?\ TFAKI*YOPS_R&_%7_837_P!)
MH:Z2@ HHHH **** "BBB@ KF6_Y*?%_V!G_]'+735S+?\E/B_P"P,_\ Z.6@
M#IJ*** "BBB@ HHHH **** .7\7_ /(1\*_]AE/_ $1-745R_B__ )"/A7_L
M,I_Z(FKJ* "BBB@ HHHH **** "BBB@ HHHH **** "N!\.W^OVXUB/3]#MK
MNW&KWA$KW_E$GS6S\NP_SKOJXKPYKFG:7%J4%[<B*634M2G12I.Y(Y27/ Z@
M'..IYQTH T?[5\6?]"O9_P#@V_\ M5']J^+/^A7L_P#P;?\ VJM5];TN/R]^
MH6R^9*L*@R#[Y!(4^A(!X/I5A[VUBV^9<PIN("[I ,YZ8^M &%_:OBS_ *%>
MS_\ !M_]JH_M7Q9_T*]G_P"#;_[56PFJV4LH2*XCD4Q-+YB,"FU2 3NZ<$U#
M;:[I]S;BX$QB@;;Y<MPC1+)NZ%2P&[/M0!F_VKXL_P"A7L__  ;?_:J/[5\6
M?]"O9_\ @V_^U5LSZG8VUO<SRW40CMO]<0VXH?0@<Y]NM10:WITP;-RL+I((
MFCN/W3AR 0,-@Y(((]<T 9?]J^+/^A7L_P#P;?\ VJC^U?%G_0KV?_@V_P#M
M5:D>N:9*C2I>0F!02TVX",$-M(+= <\8J<ZC8JSJUY;AD3S'!E7*K_>// Y'
M/O0!B?VKXL_Z%>S_ /!M_P#:J/[5\6?]"O9_^#;_ .U5IRZYI\,-S.\X\FW1
M)'D4;E(;[N,=<^U":]I;2RPO>PQ30JC2Q3-Y;1AON[@V,9H S/[5\6?]"O9_
M^#;_ .U4?VKXL_Z%>S_\&W_VJMMM0LD:96O+=6A&Z4&5<QCU;GC\:HZ=XETG
M4X]]O>1@%=X\Q@I*Y(W#/4<=: *7]J^+/^A7L_\ P;?_ &JC^U?%G_0KV?\
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M_P#P;?\ VJNDHH YO^U?%G_0KV?_ (-O_M5']J^+/^A7L_\ P;?_ &JNDHH
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M8BP *C/[SH.>P)/.,57N=?\ $6XQBVFMV.Q$/V(NSR>7*SA1GD;EC&>F"?J
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MDD:0$$Y*Y+'.#S3/AE_R33P]_P!>:5U3_<;Z5ROPR_Y)IX>_Z\TH ZNBBB@
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M.\MKNT>&"TCCD>XW[P1(S*F%7+$DJ1C'<5+)XFTJ'S_-GD1H"H=#!)N^8$C
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M@@C)ZYR!4$>@V,5Y-=(CAYI1,R[SMW@@[@.QX% $)\4Z,H0M>;5DM_M*,8W
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M_P#XJC^QO$__ $-B_P#@MC_^*KI** .;_L;Q/_T-B_\ @MC_ /BJ/[&\3_\
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M/_XJC^QO$_\ T-B_^"V/_P"*KI** .;_ +&\3_\ 0V+_ ."V/_XJC^QO$_\
MT-B_^"V/_P"*KI** .!UNPUBUUKPL^H:X+Z$ZNH$0LUBP?)EYR#]>/>N^KE_
M%_\ R$?"O_893_T1-744 %%%% !1110 4444 %%%% !1110 4444 %<#HGB*
M'1WN[22VFF:XU:_D)BP=B+.03COC.3[ UWU>8:7'+)?ZA./#.HW[6VKW>R>"
MXA1&Q<%P,,X/##TY]Q0!TP\:1#3XKR32[V.)P78L%&V+Y/G&2-P_>+P,]_2I
M;+Q:M_ LT&FW?ER2[(GDVHKKAB7R3C "-D?3UJE'>W,4!@C^'UVL)SF-7M O
M.">/,]A^0I\6I7D#.T/@&]C:1R[E9;4;F.02?WG7D_F: &Q^.!>2(EG:':5F
MWRNX8(4\G& "-P(F4\&IX?&D-R"+?3KF1WY@4,@\U,N-V2?EYC;@\]/?%=+R
MXC1$3X>W2JC%E"O:  D8)'[ST 'X4^+4;R!Y'B\ WJ/(_F.RR6@+-R,G]YR>
M3^9H G3Q8LC"\2)SIK"W16*@%7D7>2QS@ *R#ZM20>,5-O;R7&GRQ^9&DDNV
M1&$8=RB=\MDJ>G2JD5Q/% L*_#^],:RF95:6U(5SW&9./;T'%.^V7'FI)_PK
MZ[\R,L4;?:97=RV/WG&23GZT 3S^.+:U ^T64Z$VQN-@=&9>-P5@#P2"#UJS
M8>*5O[RVMETV]1I4#R,4R(MQ8*6QV.PD'W7UXRKZ6?4(9(Y_ -_\\8C+K-:A
MPHZ 'S,XXZ4ME/<V A,/@/43)#NV2O/:LXW$L?F\S.,L>.G- &HWBI1>16R:
M;>2-)+(JE%#?(CB-I, ]-Q[\XYJ*'QK9NDCRVTL*"$SH2Z'?'M=P>&X)"'@U
M7DU*]E>)I/ 5Z[1,7C+2VI*,3DD?O."3S57K),Q^'-TPG*M(C/:%68;L-CS,
M9^9N?>@#4E\5+;)*SVDLRH-VZ,  ;GV(I!8DDL>H&.]0)XO>YUO3[&.RDME>
M;R[LW.U6C/D/*% SG^%3NQC!IKZG?2QR1R> KYDD7:ZM+:D,/0_O.:A-S,75
MS\/+HLL9B5BUID(005SYG3!(Q[F@#LZ*YH>(M9  '@S5 !T'VBV_^.T?\)'K
M7_0FZI_X$6W_ ,=H Z6BN:_X2/6O^A-U3_P(MO\ X[1_PD>M?]";JG_@1;?_
M !V@#I:*YK_A(]:_Z$W5/_ BV_\ CM'_  D>M?\ 0FZI_P"!%M_\=H Z6BN:
M_P"$CUK_ *$W5/\ P(MO_CM'_"1ZU_T)NJ?^!%M_\=H Z6BN:_X2/6O^A-U3
M_P "+;_X[1_PD>M?]";JG_@1;?\ QV@#I:*YK_A(]:_Z$W5/_ BV_P#CM'_"
M1ZU_T)NJ?^!%M_\ ': .EHKFO^$CUK_H3=4_\"+;_P".T?\ "1ZU_P!";JG_
M ($6W_QV@#I:*YK_ (2/6O\ H3=4_P# BV_^.T?\)'K7_0FZI_X$6W_QV@#I
M:*YK_A(]:_Z$W5/_  (MO_CM'_"1ZU_T)NJ?^!%M_P#': .EHKFO^$CUK_H3
M=4_\"+;_ ..T?\)'K7_0FZI_X$6W_P =H Z6BN:_X2/6O^A-U3_P(MO_ ([1
M_P )'K7_ $)NJ?\ @1;?_': .D?[C?2N5^&7_)-/#W_7FE3-XBUG:?\ BC=4
MZ?\ /Q;?_':YOX?:YJMO\/\ 0X8?"NHW,:6BA9HY[<*X]0&D!_,4 >DT5S7_
M  D>M?\ 0FZI_P"!%M_\=H_X2/6O^A-U3_P(MO\ X[0!TM%<U_PD>M?]";JG
M_@1;?_':/^$CUK_H3=4_\"+;_P".T =+17-?\)'K7_0FZI_X$6W_ ,=H_P"$
MCUK_ *$W5/\ P(MO_CM '2T5S7_"1ZU_T)NJ?^!%M_\ ':/^$CUK_H3=4_\
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MZM_PL..;_A%-1\W^R77R?/M]V/-4[L^9C';KF@#T2BN:_P"$CUK_ *$W5/\
MP(MO_CM'_"1ZU_T)NJ?^!%M_\=H Z6BN:_X2/6O^A-U3_P "+;_X[1_PD>M?
M]";JG_@1;?\ QV@#I:*YK_A(]:_Z$W5/_ BV_P#CM'_"1ZU_T)NJ?^!%M_\
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M<PSK;H)([F3S)5;'.YOXCG//>@#3HHHH *YEO^2GQ?\ 8&?_ -'+735S+?\
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M ,&=S_\ '*/^$#T'_GGJ'_@SN?\ XY0!TM%<U_P@>@_\\]0_\&=S_P#'*/\
MA ]!_P">>H?^#.Y_^.4 =+17-?\ "!Z#_P \]0_\&=S_ /'*/^$#T'_GGJ'_
M (,[G_XY0!TM%<U_P@>@_P#//4/_  9W/_QRC_A ]!_YYZA_X,[G_P".4 =+
M17-?\('H/_//4/\ P9W/_P <H_X0/0?^>>H?^#.Y_P#CE '2T5S7_"!Z#_SS
MU#_P9W/_ ,<H_P"$#T'_ )YZA_X,[G_XY0!TM%<U_P ('H/_ #SU#_P9W/\
M\<H_X0/0?^>>H?\ @SN?_CE '2-]QOI7*_#/_DFGA[_KS2I6\!Z"$;]W?]/^
M@G<__'*YOX?>#M&OOA_H=U.EZ99;16;9J$Z#/LJN /P% 'I5%<U_P@>@_P#/
M/4/_  9W/_QRC_A ]!_YYZA_X,[G_P".4 =+17-?\('H/_//4/\ P9W/_P <
MH_X0/0?^>>H?^#.Y_P#CE '2T5S7_"!Z#_SSU#_P9W/_ ,<H_P"$#T'_ )YZ
MA_X,[G_XY0!TM%<U_P ('H/_ #SU#_P9W/\ \<H_X0/0?^>>H?\ @SN?_CE
M"^&@?[;\5<?\Q-?_ $FAKI*\\\/^#-%GU?Q)&Z7NV'4%1,:C<#CR(CR0_/)/
M)K>_X0/0?^>>H?\ @SN?_CE '2T5S7_"!Z#_ ,\]0_\ !G<__'*/^$#T'_GG
MJ'_@SN?_ (Y0!TM%<!XJT3P_X6T-]7EL]0GMH9$$X75KD,J,P4LHW_,02/EX
MSS5_3/!VBW^E6EW-;7L,D\2R&--7N) N1G&X/@_44 =A17-?\('H/_//4/\
MP9W/_P <H_X0/0?^>>H?^#.Y_P#CE '2US+?\E/B_P"P,_\ Z.6E_P"$#T'_
M )YZA_X,[G_XY7/MX-T7_A8<=ILO?*.DO)_R$+C=N\U1][?G'MG% 'HM%<U_
MP@>@_P#//4/_  9W/_QRC_A ]!_YYZA_X,[G_P".4 =+17-?\('H/_//4/\
MP9W/_P <H_X0/0?^>>H?^#.Y_P#CE '2T5S7_"!Z#_SSU#_P9W/_ ,<H_P"$
M#T'_ )YZA_X,[G_XY0!TM%<U_P ('H/_ #SU#_P9W/\ \<H_X0/0?^>>H?\
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M-@1*D:NUJ+?*NHC5VQ)N'SE]R!>WX9(!?\OQ[_S]>&O_  'G_P#BZ/+\>_\
M/UX:_P# >?\ ^+K-&K>-6@B#:?%$_FF-Y#$Q'"E@V!D[3E5/'56Z9%;=[/K5
MOHU[<QL9+GSV\B%+?)6,,0 .N20,[CQST H K>7X]_Y^O#7_ (#S_P#Q='E^
M/?\ GZ\-?^ \_P#\75>ZUS7%8Q_9;BV4?*TIM=_S-.JKM /S'RR3QGGUZ57A
MU+Q->[H)H)%8Q%)8T@VB,^2&#!\_?+%1L[;CZ9H T/+\>_\ /UX:_P# >?\
M^+H\OQ[_ ,_7AK_P'G_^+JJ+WQ/#>RP1VXCM4C9HWDBDE+L3)Z9/!"<9'!Z'
MBK%]J>OIIVC26=C<-<S%#<H\0.T;D#!L?=.TL1T^[^! '>7X]_Y^O#7_ (#S
M_P#Q='E^/?\ GZ\-?^ \_P#\75#4[GQ6EA-'B1_.B+![>TR\9*R8C W>JQ_-
MVW=L\2ZW)KX32[:SBN=H6V>3RX]Q=Q*N]7?/R *,GUR: +7E^/?^?KPU_P"
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M;FD.,D_/A>G3/U%M9/$IU!7>2,6Q<%HEMNB^8JD!MV>5+-G'8>] #?+\>_\
M/UX:_P# >?\ ^+H\OQ[_ ,_7AK_P'G_^+JBVH>*(+8006DI*K /,:)B(@1\_
M7)=LXY&X8/J*V]#N]5GO+N+4HB$18VCD6(HF2/F4;N2<C/I@CW% %$Q^/=IS
M=>&L8_Y]Y_\ XNN<\ )XR/@#0S87&@BU^RKY0G@F+@?[1#@9^E>F/]QOI7*_
M#+_DFGA[_KS2@!WE^/?^?KPU_P" \_\ \71Y?CW_ )^O#7_@//\ _%UU-% '
M+>7X]_Y^O#7_ (#S_P#Q='E^/?\ GZ\-?^ \_P#\774T4 <MY?CW_GZ\-?\
M@//_ /%T>7X]_P"?KPU_X#S_ /Q==310!RWE^/?^?KPU_P" \_\ \71Y?CW_
M )^O#7_@//\ _%UU-% 'G.@)XT_M;Q'Y%SX?$G]H+YV^"8@MY$7W?GZ8QU[Y
MK=\OQ[_S]>&O_ >?_P"+J7PS_P AOQ5_V$U_])H:Z2@#EO+\>_\ /UX:_P#
M>?\ ^+H\OQ[_ ,_7AK_P'G_^+KJ:* ..NM.\:7OD_:7\,2^3()8P]M.0KC.#
M]_J,FBQTWQIIME#963^&(;:%=D<:6T^$'H/GZ5U5Q>6UIY7VF>.'S9!%'YC!
M=SGHHSU)]*=;7,%Y;1W%M,DT$B[DDC;<K#U!'44 <WY?CW_GZ\-?^ \__P 7
M1Y?CW_GZ\-?^ \__ ,774T4 <MY?CW_GZ\-?^ \__P 76 R>-/\ A8,8^T:!
M]K_LI\'R)MFSS5[;\YSCO7I%<RW_ "4^+_L#/_Z.6@!GE^/?^?KPU_X#S_\
MQ='E^/?^?KPU_P" \_\ \774T4 <MY?CW_GZ\-?^ \__ ,71Y?CW_GZ\-?\
M@//_ /%UU-% '+>7X]_Y^O#7_@//_P#%T>7X]_Y^O#7_ (#S_P#Q==310!RW
ME^/?^?KPU_X#S_\ Q='E^/?^?KPU_P" \_\ \774T4 >?:POB<:WX7.M3:0]
MM_:Z[19Q2J^[R9<<LQ&.OZ5Z#7+^+_\ D(^%?^PRG_HB:NHH **** "BBB@
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M"[8';/%6XO'O@:&<31W\@D&<'[)<=U53_!Z(OY4 =Q17(_\ "SO"'_04D_\
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MWWO-4XQLST'6@#TVBN1_X6=X0_Z"DG_@'/\ _$4?\+.\(?\ 04D_\ Y__B*
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M1'DB*L!;.6#D2X<9. !LC.#G[_7I4]]K>K6FEZ8\$:W%U-;-+(AM),RNH3Y
M ?D)+'EN!3)O"7A>!=TCWH&]4)&J7)P6.!G]YQFA?!_A>2X=0+SS(R$).IW/
M\0! !\SG(QTH +[6O$%I<J%LXWC9I&4"VD)95E"!"P.%)7+[CQ[8R:KZ1XFU
MK4K W1BMB$5Y9$BMY&<*(U94"[OO$L<'/( X!-77\$^'(P=_VU>,G=JMR./7
M_6=*@7P%X1TRUD>.":TMUR[E-2GC4>YQ)B@!;/5O$]];0LMI;V[%RKM-;2'<
M/-*!@-W'R8?&?R'-='ID]S<Z9;S7D0BN70&1 " &[X!Y'XUS\7@_PS/G9]N)
MWE.=3NADCKC,G/U%17?A;PK96;W<S7WDJP7*:G=,2Q. H DR220,4 =A17+#
MP5X;+*O^F[F) ']JW.21U_Y:4J^"?#C-M7[:6YX&JW.>.O\ RTH ZBBN4@\'
M>&;F,O%]N8!BI_XFESP02#_RT]0:8/"GA9IWAS?AT!+;M2N@ !C/)DQ_$* .
MNHKC=/\ #7A+4[5+FT>_>%\;6;4KI=V1D8RXSUI]YX6\)Z?97-Y=2W<5O;*7
MF<ZI<D1@=<XDH Z^BN'N=$\%6<BQSW5VKM"LZJ-3NF)1G"*P ?G+,H'UI]OH
M'@Z[FABMY;Z5Y5+J$U"[. "5.?G^7!!'..10!VC9VG'7%<K\,\_\*T\/9_Y\
MTJ5O F@A2?+O^G_03N?_ (Y7.?#[P=HU]\/M#N9TO3++:*S;-0N$&?8*X _
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M_P#CE'_"!Z!_SSO_ /P9W/\ \<H Z6N:;/\ PLZ+T_L9_P#T<M'_  @>@?\
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MS';I+)YB*(?EB/RD%0"!D%<\\<G(K.U+6O$JZ=-"T"Q3/%N2:"TE8EBBD1J
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MHH 1_N-]*Y7X9?\ )-/#W_7FE=4_W&^E<K\,O^2:>'O^O-* .KHHHH ****
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MJZ* .4_XN!Z^&?RGH_XN!Z^&?RGKJZ* .4_XN!Z^&?RGH_XN!Z^&?RGKJZ*
M//=7_P"$H_MSPO\ VT='^S?VLNW[$)=^[R9<?>XQU_2O0JY?Q?\ \A'PK_V&
M4_\ 1$U=10 4444 %%%% !1110 4444 %%%% !1110 5S?@S_CRU;_L,7O\
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M[M+. P14X_>],(/UJY_9WBG_ *&+3_\ P5'_ ./4 =!17/\ ]G>*?^ABT_\
M\%1_^/4?V=XI_P"ABT__ ,%1_P#CU '045S_ /9WBG_H8M/_ /!4?_CU']G>
M*?\ H8M/_P#!4?\ X]0!T%%<_P#V=XI_Z&+3_P#P5'_X]1_9WBG_ *&+3_\
MP5'_ ./4 =!7,M_R4^+_ + S_P#HY:F_L[Q3_P!#%I__ (*C_P#'JI'PWXA.
MMKJW_"16?VE;8VP']F';L+!NGF]<B@#K:*Y_^SO%/_0Q:?\ ^"H__'J/[.\4
M_P#0Q:?_ ."H_P#QZ@#H**Y_^SO%/_0Q:?\ ^"H__'J/[.\4_P#0Q:?_ ."H
M_P#QZ@#H**Y_^SO%/_0Q:?\ ^"H__'J/[.\4_P#0Q:?_ ."H_P#QZ@#H**Y_
M^SO%/_0Q:?\ ^"H__'J/[.\4_P#0Q:?_ ."H_P#QZ@"OXO\ ^0CX5_[#*?\
MHB:NHKF)?#NLWVH:9/J6N6TT-A="Z6*&P,9=@C* 6,C8'SGM73T %%%% !11
M10 4444 %%%% !1110 4444 %<WX,_X\M6_[#%[_ .CFKI*YOP9_QY:M_P!A
MB]_]'-0!TE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5Y]X?TK7+O\ MB6Q\2/8P'5[P" 6
M44F#YK9.YN>:]!KF_!G_ !Y:M_V&+W_T<U $?]@^*/\ H=)/_!;#1_8/BC_H
M=)/_  6PUU%% '+_ -@^*/\ H=)/_!;#1_8/BC_H=)/_  6PUU%% '+_ -@^
M*/\ H=)/_!;#1_8/BC_H=)/_  6PUU%% '+_ -@^*/\ H=)/_!;#1_8/BC_H
M=)/_  6PUU%% '+_ -@^*/\ H=)/_!;#1_8/BC_H=)/_  6PUU%% '+_ -@^
M*/\ H=)/_!;#1_8/BC_H=)/_  6PUU%% '+_ -@^*/\ H=)/_!;#1_8/BC_H
M=)/_  6PUU%% '+_ -@^*/\ H=)/_!;#1_8/BC_H=)/_  6PUU%% '+_ -@^
M*/\ H=)/_!;#1_8/BC_H=)/_  6PUU%% '+_ -@^*/\ H=)/_!;#1_8/BC_H
M=)/_  6PUU%% '+_ -@^*/\ H=)/_!;#1_8/BC_H=)/_  6PUU%% '+_ -@^
M*/\ H=)/_!;#1_8/BC_H=)/_  6PUU%% '+_ -@^*/\ H=)/_!;#1_8/BC_H
M=)/_  6PUU%% '+_ -@^*/\ H=)/_!;#1_8/BC_H=)/_  6PUU%% '+_ -@^
M*/\ H=)/_!;#1_8/BC_H=)/_  6PUU%% '+_ -@^*/\ H=)/_!;#1_8/BC_H
M=)/_  6PUU%% '+_ -@^*/\ H=)/_!;#1_8/BC_H=)/_  6PUU%% '+_ -@^
M*/\ H=)/_!;#1_8/BC_H=)/_  6PUU%% '+_ -@^*/\ H=)/_!;#1_8/BC_H
M=)/_  6PUU%% '+_ -@^*/\ H=)/_!;#1_8/BC_H=)/_  6PUU%% '+_ -@^
M*/\ H=)/_!;#1_8/BC_H=)/_  6PUU%% '+_ -@^*/\ H=)/_!;#1_8/BC_H
M=)/_  6PUU%% '+_ -@^*/\ H=)/_!;#1_8/BC_H=)/_  6PUU%% '+_ -@^
M*/\ H=)/_!;#1_8/BC_H=)/_  6PUU%% '+_ -@^*/\ H=)/_!;#1_8/BC_H
M=)/_  6PUU%% '+_ -@^*/\ H=)/_!;#1_8/BC_H=)/_  6PUU%% '+_ -@^
M*/\ H=)/_!;#1_8/BC_H=)/_  6PUU%% '+_ -@^*/\ H=)/_!;#1_8/BC_H
M=)/_  6PUU%% '+_ -@^*/\ H=)/_!;#1_8/BC_H=)/_  6PUU%% '+_ -@^
M*/\ H=)/_!;#1_8/BC_H=)/_  6PUU%% '+_ -@^*/\ H=)/_!;#1_8/BC_H
M=)/_  6PUU%% &%INDZ[:WR37WB5[ZW (: V44>XXX^9>>*W:** "BBB@ HH
MHH **** "BBB@ HHHH **** "N;\&?\ 'EJW_88O?_1S5TE<P/!S0SW4EGXB
MUFTCN+B2X:&%XMBN[;FQNC)QD^M '3T5S7_"*WG_ $-VO_\ ?<'_ ,:H_P"$
M5O/^ANU__ON#_P"-4 =+17-?\(K>?]#=K_\ WW!_\:H_X16\_P"ANU__ +[@
M_P#C5 '2T5S7_"*WG_0W:_\ ]]P?_&J/^$5O/^ANU_\ [[@_^-4 =+17-?\
M"*WG_0W:_P#]]P?_ !JC_A%;S_H;M?\ ^^X/_C5 '2T5S7_"*WG_ $-VO_\
M?<'_ ,:H_P"$5O/^ANU__ON#_P"-4 =+17-?\(K>?]#=K_\ WW!_\:H_X16\
M_P"ANU__ +[@_P#C5 '2T5S7_"*WG_0W:_\ ]]P?_&J/^$5O/^ANU_\ [[@_
M^-4 =+17-?\ "*WG_0W:_P#]]P?_ !JC_A%;S_H;M?\ ^^X/_C5 '2T5S7_"
M*WG_ $-VO_\ ?<'_ ,:H_P"$5O/^ANU__ON#_P"-4 =+17-?\(K>?]#=K_\
MWW!_\:H_X16\_P"ANU__ +[@_P#C5 '2T5S7_"*WG_0W:_\ ]]P?_&J/^$5O
M/^ANU_\ [[@_^-4 =+17-?\ "*WG_0W:_P#]]P?_ !JC_A%;S_H;M?\ ^^X/
M_C5 '2T5S7_"*WG_ $-VO_\ ?<'_ ,:H_P"$5O/^ANU__ON#_P"-4 =+17-?
M\(K>?]#=K_\ WW!_\:H_X16\_P"ANU__ +[@_P#C5 '2T5S7_"*WG_0W:_\
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M_P#C5 '2T5S7_"*WG_0W:_\ ]]P?_&J/^$5O/^ANU_\ [[@_^-4 =+17-?\
M"*WG_0W:_P#]]P?_ !JC_A%;S_H;M?\ ^^X/_C5 '2T5S7_"*WG_ $-VO_\
M?<'_ ,:H_P"$5O/^ANU__ON#_P"-4 =+17-?\(K>?]#=K_\ WW!_\:H_X16\
M_P"ANU__ +[@_P#C5 '2T5S7_"*WG_0W:_\ ]]P?_&J/^$5O/^ANU_\ [[@_
M^-4 =+17-?\ "*WG_0W:_P#]]P?_ !JC_A%;S_H;M?\ ^^X/_C5 '2T5S7_"
M*WG_ $-VO_\ ?<'_ ,:H_P"$5O/^ANU__ON#_P"-4 =+17-?\(K>?]#=K_\
MWW!_\:H_X16\_P"ANU__ +[@_P#C5 '2T5S7_"*WG_0W:_\ ]]P?_&J/^$5O
M/^ANU_\ [[@_^-4 =+16+IV@7-A>K<2>(=6O%4$&&Y:(H<COMC!X^M;5 !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-RWF9C0,QSW+!C0!T5%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g5lvsimk4gaq000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5lvsimk4gaq000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $@ E,# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<,9P[+]YCZ#TI-V&D62P#*OK67<8-XY/J,_@:8\B0WJ_9RS1I_K/FR,^WO\
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MRAMY_P!9@ _IQ0!#8:NMYI<<EJD,4TZ&2"%P>5Z?-CO[57@UF_G6TF2R@+3
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MZ>U=$*?+JS*4KZ'145BR>(4AN7A>UE^64Q @CYB"!QGZUM5H0%%%% !1110
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M:H6P205Q]SKSCK6]-6@C*;O)FVVJ6"/L:\AW;"X&\<@=3^%2K=VS1F03Q;0
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M_712O\Z '7,!E"NC;9D.4;^A]C3!>A !/&\3=_E)'YCBITECD&4=6'J#FGT
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M.'7(X]1Z5*70;9!;YB/E-]W^'V]OI5FF.@;GO3ATYJA"T444 %%%% !1110
M4444 %%%% !1110 444ASVYH 6FM1O'?CZTUG0#EA^=)@1O4)J5G4]"#]*B)
MST!/T%8R1JF1R()$VG@]0?0T@;SHVC<88C##U]Z<Y$:AI&6)2>KG&?PJ'[1"
MQQ&DTT@/ V[?_KTE3D-R1B7<9BO)%(QNPX]\_P#UZBK:U&%YTC^TPB!E^Y*A
MW8]C[5G?8N#F[C+#IL1F3_OK%<]2A/FT1M"K&VID7<>Z[C<C.$('US3,'&:V
MX]-$LBB8QS\_+'"QY/N>PJQ?:''Y:MMCMF[2Q#A?9AW'O7H86K*%-1DCRL7A
M55J.<9;G.45??1+^-PKM91J>DC3''Y8J:7PS>"#S;34X;AQUC= %/T(YKJ]O
M X5@JK,JBF2"[MW\NXT^=)/12I!^AS31#?S_ "A%MD/5V(9OP XHEB:45=R)
MC@Z\G91*EO"LNNDD9CB.3Z;B.!786 N5M#,5+VH.%/5EQU_"LFVLX;:#RD&0
M>6)ZL?4UN^'[LQ.UA*>N7B)[^HKR)U%7K7>BZ'OT:3H4;;OJ6(Y,#*D,K?D:
MD\L/S$<_[)ZT75DRNSV87=GYHB<!OIZ&JD5RCOL(:.4=8Y!AA2E%PTEL:1DI
M:HE>+)R058=".#3/WJ_W&]^AJP9G,>PG(]ZCK-VZ%J_49F4]%4?4T"/)R[;B
M.@["GTQI%4A<Y8]%49)_"D ^I;* W,HG8?N4.4S_ !'U^E+!8/,0UR-D?:+/
M)^O^%:8  P!@#M732HN_-(QJ5.B%HHHKJ, HHHH **** "BBB@#'L5-MKU[;
M#B-U$Z_CP?U'ZUL5F3_N_$-FW_/6&1#[XP?Z5IT %4RBKJRN5'SQ8!QW!Y_2
MKE5I/FU&$?W$9OSXH &GDD=H[=!\IPTC= ?;U-2P0B"(("6/4L>I/K45EQ;!
M3]Y6(;ZYJS0 44C,JC+, /<TN<C(H **** "BBB@ JI;'=>WC=@RJ#]%&:MU
M5L?N3G_IN_\ .@"9M[@A"5(/4CK1(S<(I^9N_H/6GXY!]*:GS.S_ ("@!OD)
MG)+D^NXTGD ?<D=?^!9_G4U% $/DR=KB3'T'^%<]XI&LVT-FVAB4RM./M#*H
M8E.,]0?R&*Z>B@#CCK_B159CI!?YRG$3 J<':.O(SC+=.:CO-8\5)9S 6(1V
M)\MXK=G*?? &,\GY5YZ#=TKM:* .8OM0\06U[9Q6FEI<1RQ)YMPW!B)X;/K@
MX/YUG6^L^+(8(_.T[>NS#.86+I@+EB ?F^\>!CI79?:[?[5]E^T1?:-N_P K
M>-^WUQUQ4C2(A4.ZJ7.%!.,GT% '%V6L^*EMT233C+*L.\^9$5+]\YS@'J-O
M6M6SU#5;K1II-1LUM+B23R8HASU[Y]\_I70,RHC.[!549))P *I2%;G4;8++
M&41#,%# EL\ X]/>@"W%$L,*1(/D10HSZ"D"[&R.AI[,%4LQ 4#))/2F>=%M
M1O,3;)C8=PPV>F/6@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I" :
M6B@")DE_@?\ .H2EY_"T(_X!_P#7JT:122Q_NT 4S%J#'F>-1_LCG^1I#97+
M#Y[UR/3&/Y8J\<X.,9[9IK%0@WG'X]Z *L.F01MO?=*_K(<_SJWE$0D8"J.U
M1/-&?D+8)_O @&G+'\P;8J8_NGK0!)@.O(!![$4U1&N40*,=5 H,A$H0*>>]
M SYC'"[2.HZF@!H"QRX6( $9+ 5)PR\C@^M-<QQYE<A0!RS'I4 N)IS_ */%
MA/\ GI)D9^@Z_P J %EM+)8V:6W@V*,DL@Q6?'8H\\,L-@(06R22,%?0KZ]*
MOFVEF8?:959 <^6BX!^OK5J@#&\F2[C9X4B$)8@1R$L&QW]OH*SI['@M"C*P
M&6A)SQZJ>];LUO) SW%KDY.Z2$]']2/0T,B7%JCQ. <9A(&"#43IQFM2HS<7
MH<RHSS4ODE]I4E74[D8=0:LS1*Q6YC7:DC;9%_N/W_.IHHO:N+V3B[,Z>=-7
M+*7C/!Y[?*00LZC^$_WA[?TJ:[ACF$,DJ!A'( 2P_A/''Z5"(&!WHH+8PRGH
MZ]P:(+A((Q;RL/+?Y87<X!_V&/9A7;!W5F<TE9W1.VE1_P#+*:6/VSN'Z\TS
M^S)O^?H8_P"N?_UZN0L0S1,<E,8/J*FI.E!]!^TEW*"Z6O\ RUGE?U (4?IS
M5J&VAMQB*-5SU/<_4U+151A&.R$Y-[A1115$A1110 4444 %%%% !1110!F:
MM^Z>QN?^>5PH)]F^7^M:=5=1MOM>GSP#[S*=I]#V_6ET^Y^V6$,_1F7YAZ-W
M'YT 6:J7+""ZBN&XC(,;M_=]/UJW2,H92K %3P0: *Y#V\S2(A>*3E@O4'UI
M?M8<8BBD=O==H'YTS[)+#Q;3E$_YYN-P'T[BC[-<R<37;!3U6-0OZ]: *L]U
M#;O^\B:ZN"V&$8SM]N?Y5:CV+<1&'B.5"Q Z<8P?UJ&1(X;F"&- J1H\O'J.
M/ZFI;=-OV4?W(B/Y4 7**** "BBB@ JM9_*UPG<2L3^//]:LU @VWDH_OJ&_
MI_2@">FQ\+CT-.I ,9]Z %HHHH **** "BBB@#FM1\,W-UKL^IV]ZL+/%$J@
MAN"C[N<, 0>G3-4#X'NG_P!9JS$@(4?:=P8(5)SGOGH/2NTHH X^'PA>QIM?
M4(G5DD3:4?;'NSRGS=>>^>E1GP/<I"([?4\(L>Q8W5BO;KAL]LBNTHH YC3?
M"<MDMP)]0>X,]NT,F[/.0H!Z]MI_[ZJC_P (3>"&.'^TTDB@V^5')&Q' &<X
M;VXQCK7:T4 <UHGAF\TO5?M<^K2W:>2(]K@Y)  Y.>G&?QKI:** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ I",D')&*6@<T (S;5)()QZ5%(K>>DF
MTLH!&!V/K3Y'V!<=6.!43NVXKYA![;0#0 R57E22-8F!DX+MC %6AD'';%)'
MN\M=_P!['-.H *BDDCMHMQX4<  <D^@I45O,9FQCH,&H8A]HN#.>40[8Q_,T
M $<#3/YURO/\$?4)_P#7JU110 4444 %5$C,4TD:@8)\Q 1^8JW3)(]X&#M8
M<JP[4 9<L?EWC[P##<1[I%'8C@D?Y[4Z",AFC8Y9._J.QJZEN?.\V0J2%*J%
M& ,]:KNC02K@$[1E/]I>Z_4=142C?4J+MH6DCQ5>\M$=')3?&_\ K$]?<>XJ
MVA5T#*<J1D&GT["N4; I$/(VH&QE748$@]?KZU>JG- %;(.U2V5(_@;_  -6
M(I"Z_,,.O#"FA$E%%%, HHHH **** "BBB@ HHHH **** "LN(_V=JCPMQ;W
M;%XCV63^)?QZC\:U*AN;:*[@:&9<HWY@]B/>@":BLM;JXT[]W?!I81PMRHSQ
M_MCL?>M"*XAG7=%*CC_9;- $E!.!DU%+<PP F65%QZGFJQ\S4/E"M':]R>&D
M]O84 -CS<)=77\+J4C_W1GG\3G]*M(,/&?\ 8Q4NT!-H "XP *C0<1GT6@"6
MBBB@ HHHH *85_?*X]"#3Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DSZ4M% ",JNNUAD
M'UIJ(J<*@4>HI]% "'&WK@>M ^Z.<\=:1DRH .,=.*0LD$66;"J.IH AN/DC
M\J,_/*V.O3U-3HBQHJ*,*HP*AA5I)#/(,$C"*?X1_B:L4 %%%% !1110 444
M4 %1RQB5-N<$<J1V-244 4X',3E&&%8X(_NMZ?0]15RH)X@WS@9XPP]1_B*=
M"Y(VL<D=#ZCUI;#)" 1@\@U&$*L".H_45+13$':BDI: "BBB@ HHHH ****
M"BBB@ HHHH **** "JDFF64K;FMD#'J5&W/Y5;HH KPV%K VZ.! PZ$C)_,U
M8HHH *:!@?0TZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HQ110 A7
MT)%-(DZ!A]<4^B@"(B?H&3ZXH6 ;P\C&1ATST'T%2T4 %%%% !1110 4444
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A** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>gqr1p20dfppl000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqr1p20dfppl000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0@!F # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\
MTX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^
M?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?
MG_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O
M6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1
M_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\
M:O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]
M_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX
M7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G
M_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_
M .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44
M9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_
M].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_V
MK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7
MW_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W
M_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KU
MH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]
M']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10
M!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_
M $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\
MTX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^
M?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?
MG_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O
M6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1
M_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\
M:O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]
M_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX
M7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G
M_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_
M .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44
M9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_
M].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_V
MK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7
MW_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W
M_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KU
MH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]
M']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10
M!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_
M $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\
MTX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^
M?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?
MG_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O
M6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1
M_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\
M:O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]
M_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX
M7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G
M_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_
M .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44
M9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_
M].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_V
MK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7
MW_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W
M_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KU
MH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]
M']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10
M!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_
M $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\
MTX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^
M?_KUH44 9_\ :O\ TX7W_?G_ .O4]A?0ZC9)=0!Q&Y8 .N"""0<CZ@U9K'\,
M?\@&+_KK-_Z->@#8HHHH **** ,_6?\ CQC_ .ONV_\ 1R5H5GZS_P >,?\
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MB,Z#]IMX'C,*Y7S8UYWXSPS9Z]J:5Y**Z@W9-OH>V44V21(HGDD8*B*68GH
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M&!YG  Z#(R0""H/S U26O+U)OI<]<HKR7X@>)?&D?Q+TKPMX4OK6V:\L3/\
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M"#[JU=O\,/\ DF/AW_KR2O+?C)I=WX.UJ[\2Z7'G3]?LY=/U&(<*)&0[6_'
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MVZZ>?LYMQ;@"/89%(VXXQS6K\0/$O@VX\!:F-0U+3+R&:V?R(TF21I)"IV%
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M[7"X"M^ V?K4GC+1!X<\%?#?2=H5[?5;82@?\]""S_\ CQ-&ZC)_W5_Y,O\
MY%?>%3127>[_  _S?X$GQ3UB;0/B]X2U2WTZ?498+64K:P9WR9W#C /3.>G:
MKW_"Z-9_Z)MKW_?+_P#QNE\=7MIIWQT\%7=]=0VMM';3[YIY B+E7 RQX')
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M[>U\1V=Q)%,ER4A\P G&T< D<@@<\9[UC2NX0M_*:3=ISOMS?H2>$?B-X/\
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M.DZZ]W9.GW\J[EE'N0 1[JM=-X#T^/X<?&/4O""33/I^J6B7%F\[ N[*">2
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M_P"3MQ_\<KK[;0=+M=!30X[*,Z6D7D"VES(I3^Z=V2?QK1HHZ6#K<\X;X%^
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M<ZW@3PVWA)?"QTW_ (DJMN%MY\G7?O\ O;MWWN>M;\,,=O!'!$NV.-0B#.<
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M** ,_6?^/&/_ *^[;_T<E:%9^L_\>,?_ %]VW_HY*T* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *Q_#'_(!B_P"NLW_HUZV*Q_#'_(!B_P"N
MLW_HUZ -BBBB@ HHHH S]9_X\8_^ONV_]')6A6?K/_'C'_U]VW_HY*T* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_#'_(!B_ZZS?\ HUZV
M*Q_#'_(!B_ZZS?\ HUZ -BBBB@ HHHH S]9_X\8_^ONV_P#1R5H5GZS_ ,>,
M?_7W;?\ HY*T* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_
M#'_(!B_ZZS?^C7K8K'\,?\@&+_KK-_Z->@#8HHHH **** ,_6?\ CQC_ .ON
MV_\ 1R5H5GZS_P >,?\ U]VW_HY*T* "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *Q_#'_ " 8O^NLW_HUZV*Q_#'_ " 8O^NLW_HUZ -BBBB@
M HHHH S]9_X\8_\ K[MO_1R5H5GZS_QXQ_\ 7W;?^CDK0H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K'\,?\@&+_ *ZS?^C7K8K'\,?\@&+_
M *ZS?^C7H V**** "BBB@#/UG_CQC_Z^[;_T<E:%9^L_\>,?_7W;?^CDK0H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\,?\@&+_KK-_P"C
M7K8K'\,?\@&+_KK-_P"C7H V**** "BBB@#/UG_CQC_Z^[;_ -')6A6?K/\
MQXQ_]?=M_P"CDK0H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK'\,?\@&+_KK-_Z->MBL?PQ_R 8O^NLW_HUZ -BBBB@ HHHH S]9_P"/&/\
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M-%<MY&L_\_7B7\M._P#B:/(UG_GZ\2_EIW_Q- '4T5RWD:S_ ,_7B7\M._\
MB:/(UG_GZ\2_EIW_ ,30!U-%<MY&L_\ /UXE_+3O_B:/(UG_ )^O$OY:=_\
M$T =317+>1K/_/UXE_+3O_B:/(UG_GZ\2_EIW_Q- '4T5RWD:S_S]>)?RT[_
M .)H\C6?^?KQ+^6G?_$T =317+>1K/\ S]>)?RT[_P")H\C6?^?KQ+^6G?\
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MB@ HHHH **** "L?PQ_R 8O^NLW_ *->MBL?PQ_R 8O^NLW_ *->@#8HHHH
M**** ,_6?^/&/_K[MO\ T<E:%9^L_P#'C'_U]VW_ *.2M"@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *YSQ5_Q[W?_ &![[^4=='7.>*O^/>[_ .P/??RCH Z.BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** ,36_^/ZT_Z][G_P! %:=C_P @^V_ZY+_(5F:W_P ?UI_U
M[W/_ * *T['_ )!]M_UR7^0H L4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !6/X8_Y ,7_76;_T:];%8_AC_D Q?]=9O_1KT ;%%%% !111
M0!GZS_QXQ_\ 7W;?^CDK0K/UG_CQC_Z^[;_T<E:% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5SGBK_CWN_P#L#WW\HZZ.N<\5?\>]W_V![[^4= '1T444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!B:W_ ,?UI_U[W/\ Z *T['_D'VW_ %R7^0K,UO\ X_K3_KWN?_0!
M6G8_\@^V_P"N2_R% %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *Q_#'_(!B_ZZS?^C7K8K'\,?\@&+_KK-_Z->@#8HHHH **** ,_6?\
MCQC_ .ONV_\ 1R5H5GZS_P >,?\ U]VW_HY*T* "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KG/%7_'O=_]@>^_E'71USGBK_CWN_\ L#WW\HZ .CHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#$UO_C^M/\ KWN?_0!6G8_\@^V_ZY+_ "%9FM_\?UI_U[W/_H K3L?^
M0?;?]<E_D* +%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MC^&/^0#%_P!=9O\ T:];%8_AC_D Q?\ 76;_ -&O0!L4444 %%%% &?K/_'C
M'_U]VW_HY*T*S]9_X\8_^ONV_P#1R5H4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M.>*O^/>[_P"P/??RCKHZYSQ5_P >]W_V![[^4= '1T444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!B:W_P ?UI_U[W/_ * *T['_ )!]M_UR7^0K,UO_ (_K3_KWN?\ T 5IV/\
MR#[;_KDO\A0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
ML?PQ_P @&+_KK-_Z->MBL?PQ_P @&+_KK-_Z->@#8HHHH **** ,_6?^/&/_
M *^[;_T<E:%9^L_\>,?_ %]VW_HY*T* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG
M/%7_ ![W?_8'OOY1UT=<YXJ_X][O_L#WW\HZ .CHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#$
MUO\ X_K3_KWN?_0!6G8_\@^V_P"N2_R%9FM_\?UI_P!>]S_Z *T['_D'VW_7
M)?Y"@"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8_AC_D
M Q?]=9O_ $:];%8_AC_D Q?]=9O_ $:] &Q1110 4444 9^L_P#'C'_U]VW_
M *.2M"L_6?\ CQC_ .ONV_\ 1R5H4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.>*
MO^/>[_[ ]]_*.NCKG/%7_'O=_P#8'OOY1T ='1110 4444 %%%% !1110 44
M44 %%%8=Q:W!UF28V#30EE.X&/D;<'@D9R<=>F..M &Y16-I%K<0SEIK4P_(
M022IW'Y>>"?0G'09XK9H **** "BBB@ HHHH **** "BBB@ HHK%U2UN)=06
M2*T:9/+5<@IP=Q.?F/.!VZ'/M0!M45A6MI<C58Y?L301+(S%B4Y&U@!@$XQD
M#CKC-;M !1110 4444 %%%% !1110 45EZ[XATOPU8QWFK7+0022K"A6)Y"S
MMG"A4!/.#VKR?4_&OA>?XD6FH"65CYULT;MITXDV)'<B3:"F[ +1YP.>/3@
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M=90PU X(SS!(#_Z#0!T-%<__ ,)MX=_Z"'_D&3_XFC_A-O#O_00_\@R?_$T
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MH_XF?_3G_P"/5=HH I?\3/\ Z<__ !ZC_B9_].?_ (]5VB@"E_Q,_P#IS_\
M'J/^)G_TY_\ CU7:* *7_$S_ .G/_P >H_XF?_3G_P"/5=HH I?\3/\ Z<__
M !ZC_B9_].?_ (]5VB@"E_Q,_P#IS_\ 'J/^)G_TY_\ CU7:* *7_$S_ .G/
M_P >H_XF?_3G_P"/5=HH I?\3/\ Z<__ !ZC_B9_].?_ (]5VB@"E_Q,_P#I
MS_\ 'J/^)G_TY_\ CU7:* *7_$S_ .G/_P >H_XF?_3G_P"/5=HH I?\3/\
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M0 S_ $G_ *"6I_\ @8?\*/\ 2?\ H):G_P"!A_PI]% #/])_Z"6I_P#@8?\
M"C_2?^@EJ?\ X&'_  I]% #/])_Z"6I_^!A_PK'\.>(I+NXLA/K\DEU+<P[4
M&H1LKJSK\NT'T)XZ_C6W2M_Q[C_K\LO_ $KAH XWPSXHB'AV::70M(\U;F[D
M:*_$OV@DS.VTXA89&=H^;MVKU+^PH_\ H%:+_P" X_PJK\/_ /D4Q_V$+_\
M]*YJZ>@#"_L*/_H%:+_X#C_"C^PH_P#H%:+_ . X_P *W:* ,+^PH_\ H%:+
M_P" X_PH_L*/_H%:+_X#C_"MVB@#"_L*/_H%:+_X#C_"C^PH_P#H%:+_ . X
M_P *W:* ,+^PH_\ H%:+_P" X_PH_L*/_H%:+_X#C_"MVB@#"_L*/_H%:+_X
M#C_"C^PH_P#H%:+_ . X_P *W:* ,+^PH_\ H%:+_P" X_PH_L*/_H%:+_X#
MC_"MVB@#"_L*/_H%:+_X#C_"L+X<?;?^$2_T?[/Y?VNX_P!9G/\ K&]*[JN-
M^&/_ ")P_P"ORX_]&M0!TO\ Q,_^G/\ \>H_XF?_ $Y_^/5=HH I?\3/_IS_
M /'J/^)G_P!.?_CU7:* .>U-;O[9;M<>3@07 'EY_N>_TK9L?^0?;?\ 7)?Y
M"L_6O]?;_P#7*?\ ] K0L?\ D'VW_7)?Y"@"Q1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %8_AC_D Q?]=9O_1KUL5C^&/^0#%_UUF_]&O0
M!L4444 %%%% &?K/_'C'_P!?=M_Z.2M"L_6?^/&/_K[MO_1R5H4 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7.>*O^/>[_ .P/??RCKHZYSQ5_Q[W?_8'OOY1T ='1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% '%_$7[GA;_ +&.R_\ 0FKF])EU
M#4[!KJ74G1GGF4I'9VNT 2LHZQ$]!W-=)\1?N>%O^QCLO_0FKG?"_P#R U_Z
M^+C_ -'/0!>>"^DD:235[AY&ZLUI:$GC'7R?2D^S7O\ T%I__ 2T_P#C-6Z*
M *GV:]_Z"T__ ("6G_QFC[->_P#06G_\!+3_ .,U;HH J?9KW_H+3_\ @):?
M_&:/LU[_ -!:?_P$M/\ XS5NB@"I]FO?^@M/_P" EI_\9H^S7O\ T%I__ 2T
M_P#C-6Z* *;6]ZJD_P!K3' SS:6G_P 9J+Q#I >?PG<S/.[3:DJ%);>U*-O@
MER  G7TW<?CBM&LK5M':_%B;:>.V>UN1/S#O5P%9=I *\?-GKVH U-?\)6%Q
M9P6(MYDENKF)4V6]HC85@[D$)QA$8^A.!WIVJV=S;7L=O%>7,2M&7)>UM"2<
MX[1D8JA:Z8D,C3SO]HN&&"Q4!5'HJ] /S/J3@5<6-$.515)[@8H K?9KW_H+
M3_\ @):?_&:/LU[_ -!:?_P$M/\ XS5NB@"I]FO?^@M/_P" EI_\9H^S7O\
MT%I__ 2T_P#C-6Z* *GV:]_Z"T__ ("6G_QFC[->_P#06G_\!+3_ .,U;HH
MJ?9KW_H+3_\ @):?_&:/LU[_ -!:?_P$M/\ XS5NB@"I]FO?^@M/_P" EI_\
M9H^S7O\ T%I__ 2T_P#C-6Z* *GV:]_Z"T__ ("6G_QF@6]\N_;J\XWH4?%I
M:?,IZ@_N>0?2K=% &7J!NH=(UN&2]>XCET'4&*O! F"JQ@$&.-3_ !GC..GI
M7=>$O^1,T/\ [!]O_P"BUKB-9_Y!VJ_]B_J?\H:[?PE_R)FA_P#8/M__ $6M
M &Q1110 4444 %%%% !1110 4444 >5>$/\ D5M-_P"P'IO\[FM>LCPA_P B
MMIO_ & ]-_G<UKT %%%% !1110 4444 %%%% !1163_;N;>6YCTK4Y+6*62%
MKA+?,>4<HQSGH&4\T :U%5+&_6]:ZC^SW%O+:R^3+%<)M96**XX_W76K= !1
M110 4444 %%%% !1110 4444 %*W_'N/^ORR_P#2N&DI6_X]Q_U^67_I7#0!
MK?#_ /Y%,?\ 80O_ /TKFKIZYCX?_P#(IC_L(7__ *5S5T] !1110 4444 %
M%%% !1110 4444 %%%% !7&_#'_D3A_U^7'_ *-:NRKC?AC_ ,B</^ORX_\
M1K4 =E1110 4444 8^M?Z^W_ .N4_P#Z!6A8_P#(/MO^N2_R%9^M?Z^W_P"N
M4_\ Z!6A8_\ (/MO^N2_R% %BBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *Q_#'_(!B_P"NLW_HUZV*Q_#'_(!B_P"NLW_HUZ -BBBB@ HH
MHH S]9_X\8_^ONV_]')6A6?K/_'C'_U]VW_HY*T* "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KG/%7_'O=_P#8'OOY1UT=<YXJ_P"/>[_[ ]]_*.@#HZ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH XOXB_<\+?\ 8QV7_H35SOA?_D!K_P!?%Q_Z
M.>NB^(OW/"W_ &,=E_Z$U<[X7_Y :_\ 7Q<?^CGH V**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH SM9_Y!VJ_]B_J?
M\H:[?PE_R)FA_P#8/M__ $6M<1K/_(.U7_L7]3_E#7;^$O\ D3-#_P"P?;_^
MBUH V**** "BBB@ HHHH **** "BBB@#RKPA_P BMIO_ & ]-_G<UKUD>$/^
M16TW_L!Z;_.YK7H **** "BBB@ HHHH 4#<0H').!1VZ?C11^%  >"01R*=X
M%O)[/1&CO4C;3I]0OEAG _U;&[E&R3V)Z-TYVG!QN;QZ4>"+YK?0VM-2AB.G
MW>HWT<$VW*[C=R@Q2 \98YVGH<[>#C< 4+:VBLO$?B:WA4B)-0CVJ6)VC[);
MG ]AT [  5>[9K/L[5;+Q%XFMUDED1-13:97W, ;6W(&3R0,X&>< =:T* "B
MBB@ HHHH **** "BBB@ HHHH *5O^/<?]?EE_P"E<-)2M_Q[C_K\LO\ TKAH
M UOA_P#\BF/^PA?_ /I7-73US'P__P"13'_80O\ _P!*YJZ>@ HHHH ****
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M3C)).36CVS67H]KJ,$NH7&J30SW%W<++NCS]U88XQG..?W>3]?PK3H ****
M"BBB@ HHHH **** "BBB@ I6_P"/<?\ 7Y9?^E<-)2M_Q[C_ *_++_TKAH U
MOA__ ,BF/^PA?_\ I7-73US'P_\ ^13'_80O_P#TKFKIZ "BBB@ HHHH ***
M* "BBB@ HHHH **** "N-^&/_(G#_K\N/_1K5V5<;\,?^1.'_7Y<?^C6H [*
MBBB@ HHHH Q]:_U]O_URG_\ 0*T+'_D'VW_7)?Y"L_6O]?;_ /7*?_T"M"Q_
MY!]M_P!<E_D* +%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5C^&/\ D Q?]=9O_1KUL5C^&/\ D Q?]=9O_1KT ;%%%% !1110!GZS_P >
M,?\ U]VW_HY*T*S]9_X\8_\ K[MO_1R5H4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7.>*O\ CWN_^P/??RCKHZYSQ5_Q[W?_ &![[^4= '1T444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!Q?Q%^YX6_[&.R_P#0FKG?"_\ R U_Z^+C_P!'/71?
M$7[GA;_L8[+_ -":N=\+_P#(#7_KXN/_ $<] &Q1110 4444 %%%% !1110
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M]<E_D*S]:_U]O_URG_\ 0*T+'_D'VW_7)?Y"@"Q1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %8_AC_D Q?]=9O_ $:];%8_AC_D Q?]=9O_
M $:] &Q1110 4444 9^L_P#'C'_U]VW_ *.2M"L_6?\ CQC_ .ONV_\ 1R5H
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7.>*O^/>[_[ ]]_*.NCKG/%7_'O=_P#8
M'OOY1T ='1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%_$7[GA;_L8[+_T
M)JYWPO\ \@-?^OBX_P#1SUT7Q%^YX6_[&.R_]":N=\+_ /(#7_KXN/\ T<]
M&Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'ITS5
M>RN);JRBGFM9+61URT,A!9/8XR*L44 %%%% &=K/_(.U7_L7]3_E#7;^$O\
MD3-#_P"P?;_^BUKB-9_Y!VJ_]B_J?\H:[?PE_P B9H?_ &#[?_T6M &Q5 6D
M,]S=.\:,XD !=0W&Q>.:OU7M_P#7W?\ UU'_ * M $8MK0';):0*3T/EC!_'
M%2?8;3_GU@_[]BI'=?N8WL1]T?UJ+R),9)#+_P \L\?GW_'B@!GV6U?B*T@/
M^T8QC_Z])%;16U_'Y:*I:)]Q50,\KV%6DD5N!PPZJ>HJCJ*J\\"L 588(/<>
M9'0!HT50:VM+?[]M"RG[I\M<_0_X_G2&UBBNK658HT8R$810,#8WYT :%%%%
M 'E7A#_D5M-_[ >F_P [FM>LCPA_R*VF_P#8#TW^=S6O0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5#>2O!93RQ[=Z1LR[AD9 SS4U5
MM1_Y!EW_ -<7_P#030!6DN;Q+B>)8;J813/%YB6<05BK%21FY!QD=P*3[7??
M\^E[_P" D'_R56@G^OO/^OVY_P#1ST^@#,^UWW_/I>_^ D'_ ,E5'=/>WFGR
MVKVMXL<TL"DFVA'S><FP9%R< OM!.#@'-:]*W_'N/^ORR_\ 2N&@#1^'4*)X
M5\W8HF:]O$=\?,P6ZE503W ' ]!765S'@#_D5!_V$+__ -*YJZ>@ HHHH **
M** "BBB@ HHHH **** "BBB@ KC?AC_R)P_Z_+C_ -&M795QOPQ_Y$X?]?EQ
M_P"C6H [*BBB@ HHHH Q]:_U]O\ ]<I__0*T+'_D'VW_ %R7^0K/UK_7V_\
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MQ)'UKL_+U;_GMX@_*P_PH Z.BN<\O5O^>WB#\K#_  H\O5O^>WB#\K#_  H
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M*H SO^$AT7_H,:?_ .!*?XT?\)#HO_08T_\ \"4_QK1_??\ /[?_ /@;+_\
M%4?OO^?V_P#_  -E_P#BJ ,[_A(=%_Z#&G_^!*?XT?\ "0Z+_P!!C3__  )3
M_&M']]_S^W__ (&R_P#Q5'[[_G]O_P#P-E_^*H SO^$AT7_H,:?_ .!*?XT?
M\)#HO_08T_\ \"4_QK1_??\ /[?_ /@;+_\ %4?OO^?V_P#_  -E_P#BJ ,[
M_A(=%_Z#&G_^!*?XT?\ "0Z+_P!!C3__  )3_&M']]_S^W__ (&R_P#Q5'[[
M_G]O_P#P-E_^*H SO^$AT7_H,:?_ .!*?XT?\)#H@&3K&G_^!*?XUH_OO^?V
M_P#_  -E_P#BJBN+<W=M+;3W5])#,ACD1KR7#*1@@_-Z4 2JRNH92&4C((.0
M12UE:-<);^$].N+B3")91,[L<_P#GWHT.YN);:2&]W+>(YD=&ZA7)9,>P!V_
M5".U %B?6=+M9V@N-2LX9DQNCDG56&1GD$^AJE?Z]HSZ=<JNK6#,T3  7*$D
MX/O1H"OYFL2+<W:-)J,A;R[F1 2%51P& ^ZJC\*U+BW-W;2VT]U?20S(8Y$:
M\EPRD8(/S>E %.36])M;N_CN-4LHI$O;G>LEPBE?WS]03Q6E5:^M&O\ 3[FS
MFN[YHKB)HG5KR4@A@00?F]Z;IMR;NPBD;B4#9*IZHXX8'\?\: (?^$@T4$@Z
MO89!P?\ 24X/YU)'K>DW B@@U.REFDO;()&EPC,V+J(\ ')X!-86@#4(/"/A
MV/3;F=6N+='E\V_F1 6C,C-QGDMGC');M6W/;^,--,4@N[7>;F&(-)?W$RKN
MGC0DIA=P^?&"1P3Z"@#H? MS#!X;,,CA95OKTLO4@-=2L/S!!_&NE^VV_P#S
MT_\ '36+X9TORO#\<-V4DN8KBY#31 IR9W)V\Y SVS6MMNX/NL+E/1\*X_'H
M?Q ^M $GVVW_ .>G_CIH^VV__/3_ ,=-$5W%(_EDF.7_ )YR#:WX>OU&14]
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M% !1110 5%);P3$&6&.0@8!90:EHH 155%"JH50,  8 I:** "BBB@ HHHH
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M-5\7QW,,;+HVK!4O;:1B(HW('VJ$_=1RQ^[C !Y(]\ '=Z/_ ,>4G_7U<_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5?[T7_?[_P"UT;-5_O1?]_O_ +76E10!F[-5_O1?]_O_ +71LU7^]%_W^_\
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MW_7)?Y"L?5[:."^M6C3&8;@,Q))/R=R:V+'_ )!]M_UR7^0H L4444 %%%%
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M Q_U;>E1:3_R!K'_ *]X_P#T$4 7**** "BBB@ HHHH **** "BBB@ HHHH
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M *^[;_T<E:% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !6/X8_Y ,7_ %UF_P#1KUL5
MC^&/^0#%_P!=9O\ T:] &Q1110 4444 9^L_\>,?_7W;?^CDK0K/UG_CQC_Z
M^[;_ -')6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGXFI(+5(&+Y:29AAI7Y8^WL/8<4 1&WEN^;KY8NUNIZ_[Y[_ $Z?6K8
M Z 4M% !1110 4444 %%%% !7&_#'_D3A_U^7'_HUJ[*N-^&/_(G#_K\N/\
MT:U '94V2-)8VCD171A@JPR#3J* *>)[/[N^XM_[I.9$'M_>'UY^O2K,4L<\
M8DB<,I[BGU6EM29#/;OY4YZG&5?_ 'AW^O6@"AK7^OM_^N4__H%:%C_R#[;_
M *Y+_(5CZO,\TD<+JT$X@GYZC[G53W_GZBL_3["5=+M?MJE9#"F\S:S. YVC
M)V#Y<=>* .O9@JEF("@9))X%4IM6LDL[BXBN8)A #N5)E^\!G;G. >.]8<>E
M6)?<UMH;2]08K SM_P!]9R3U[5"F@/'K<^HP.DLEQ%'&WF:6H*;"W*,2H&0V
M#D'H/I0!IZ?K=]>WNGHUC:+:WMJ]TLT=VSL%&S'R^6 2?,7OZUNUQF@6JZ3<
M6-@AE(L[J73U\P#*H\*SXXX ^48&>.!VKLZ "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "L?PQ_R 8O\ KK-_Z->MBL?PQ_R 8O\ KK-_Z->@#8HHHH *
M*** ,_6?^/&/_K[MO_1R5H5GZS_QXQ_]?=M_Z.2M"@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .+^(OW/"W_8
MQV7_ *$U<[X7_P"0&O\ U\7'_HYZZ+XB_<\+?]C'9?\ H35SOA?_ ) :_P#7
MQ<?^CGH V**** "LOQ#)Y.E"78[[+FV;:BY8XF3H.YK4K+\0RK!I0F<,52YM
MF.U2QP)DZ <G\* .T="I&N:&5N([@![BW1AMN5QC<N>!( ,<XW8VMC *C+]I
MVZ[H3+)+(,30'Y%N0O&UL_<D7! )QC&UN/NCHUB_]KZ0/M-E<_O;BVA.X2 \
M^;%C^+N0/O=1\WWAT*D:YH96XCN 'N+=&&VY7&-RYX$@ QSC=C:V, J 8'C5
M+35/"SZQ92O%,)K>*==N"X$Z9CD4]&4G([@Y[$@I2^-8;:^\,2:UIEQL6::V
M6X4+Q,!.@PRGE74C&>HP5(Z82@ I1U_"DI1U_"@!*YSQ9)Y0TV4J6$=W&Y (
MR0'4\9[UT=96M:3/JALC!=I;M;7"3'?#Y@<*0=OWACD#F@"+PK=S,NIW"6ZQ
MK)>/M%S &)'!!'_?1'&>E;5R\UUY0D\A1&^_]W"%)X(Z_C6?'>W$%Q';W\*)
MYAVQSQ-E&;T(/*D]AR/?/%:% !2V\LMJKK&+<JSE_P!Y &//O244 2V<\DWB
MO1_,6$8,V/*B"?\ +,]<=:SM)_Y UC_U[Q_^@BKMA_R->D?[TW_HLU2TG_D#
M6/\ U[Q_^@B@"Y1110 4444 %%%% !1110 4444 %%%% !1110 4450BUK3I
MGV+<A6+M&OF*4#,K%2%+ ;B""./2@"_15:YO8;:/<2TC$[5CB&YF/H /_P!0
M[U7L-1GN;VZM;JQ>TDAVE$=P692,Y(' YXZGIUH T:**RKK4KR/6H]/MK*&4
M-;F<R23E.C!2  AYY'<=: -6BLXZQ"EO.TL4L<\&W?;$#>2QPH7G!W'@$'&>
M."#BE<SZE:7>ESW-T%6XNO)EMHD4QJ&C<@;B-Q(8+SD ^E #-8_Y''PW];G_
M -%BNB' )_"N=UC_ )''PW];G_T6*Z'- !12,RHI9B%4=2353^U=.+;!?6[/
MG&U906_(<T &KD?V'J&>GV:3_P!!-0Z#_P @B/\ ZZ2_^C&IVHM-=:3>106&
MHRO) ZH!8RX8E3C!*X_6J.E7_P!DT^."XCB@E+.VV>]MHR-SDC(,FX=1V[T
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M1110 4444 %%%% !45_N'A_5)4W;[:%;L%6P1Y4BR9S_ ,!J6FWJE_#7B)%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#B_B+]SPM_V,=E_P"A-7/>%\?V$O!_X^+CO_TV>NA^(OW/"W_8
MQV7_ *$U<[X7_P"0&O\ U\7'_HYZ -GCT/YT<>A_.DHH *I:K9R7]@T$,L<4
MGF1R*\D9D4%'5N5!&0=N.HZU=HH IZ?<^*],MS;P:KHY@#$Q1OIDI$*_W%_T
MC.T=@<XS@8  "6%QXJTU98[;5-&6!WWI =+EV1>H3_2,@9YQG [8'%7:* ,:
M>SU^ZM[FSEU33$L;F:.:2"#3I%"LKAR4)G.TL0,\$9R<9))VN/0_G244 +QZ
M'\Z,CT/YTE% !1110 4444 %%%% !1110 4444 %%%% !1110!%]DM[O6=#6
M>*.0F^=!YBA@ ;:<G ((SE%//I5OPM;7GBGP9I.IS^*M68W=HCRK;""%5DVX
M=05B###9'7M524M'/87"G!@O[8\,0?GD$)Z>TI]L9K8^'%F--\%0V"[MMK>7
ML"[CD@)=2J.?H* )I/!=A+I#V5Q=:G?,49=]WJ$S[B<XR P7VZ=/QJG#X+\.
MVLIMH-(M,&4QCS(P_!BSGYL_Q#K78UGP:=*A4RW*OL50I6,J<J" 3DG/!H S
M[&SL[<P"WM(8%=D?$<87"O$1C@?WA4UL2GV=^!_J)6^KJ8_\*NPZ;'$,-++(
MH1$ ; P%)*] #QFI(M/MH22B,<@ AW9A@'(X)[&@#%>:6WCM_*A+,(X 7X*H
M0S(21G)Z]OS%4[6\L$D7,S37"+$@)C)90DG.T <#&.E=3%:6T#%HK>*-B,$H
M@!(J8# P.E %73FW62D*P7<^T.I4[=QQP0#TQ5JBB@ HHHH \\BTQ+'6YH@X
MD>3Q%<R;MG*B73VD*^PSCGOBI:@O_M0\7ZP9$VPP:II4\)92-XE'D,0>XY(]
M.#5@C:Q!['% "4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !5[2_];*W9$$A^BNK'^54:SM.O]<O/MHM;;3H55)HV\VY=F9%
M;:3@1\'&"!SG/:@"YI=Y%:>--"CD1S)=OKT"D8."+Q)!N/IM1L?45Z'7F.@^
M']1D^($<^IWML6TR[N[B-+> C<\L,6\;B1QB93]WJO6O3J ,Z_1&N$_=-*^P
M_*(E? S[TS5X!/"R&/AHBOF&-2$]R2> *AUV,2^7$FTRRCR\&+>=I/)'(P<9
M_+M69J=W>-I<GG1P22@/$^ZU(*X4G(.[CL>G\0H ZVBBB@ HHHH **** "BB
MB@ HHHH *XWX8_\ (G#_ *_+C_T:U=E7&_#'_D3A_P!?EQ_Z-:@#LJ*** "B
MBB@ HHHH **** ,?Q3E?#EU.!DVICNNG_/)UD_\ 9*ET;]V=0MA_RPO9/_'\
M2_\ M2IM9M#?Z'J%FO6XMI(A_P "4C^M9WAV[%W+<3C_ )?(+:_Q_P!=(]O_
M +2H WJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_#'_ " 8O^NLW_HU
MZV*Q_#'_ " 8O^NLW_HUZ -BBBB@ HHHH S]9_X\8_\ K[MO_1R5H5GZS_QX
MQ_\ 7W;?^CDK0H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#B_B+]SPM_V,=E_Z$U<[X7_ .0&O_7Q<?\ HYZZ
M+XB_<\+?]C'9?^A-7.^%_P#D!K_U\7'_ *.>@#8HHHH **** "BBB@ HHHH
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M;_T<E:%9^L_\>,?_ %]VW_HY*T* "BBB@ HHHH **** "BBB@ HHHH ****
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MG#=E0L._7/:LKPO_ ,@-?^OBX_\ 1ST ;%%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BO.KSQ%X\L]3A2WT_2M5AE:Y806\9@<1PRK&=TDDVU<[@<A6Z=.XMZ=
MXQU6_N+F&Z@M].N+<IOMK>VFU/AAGF2+: >&&,'D=3TH [JBN4%[J4[9A;7Y
MCW,-G!;IV[3@-V/?O0+/5+ALKIU_G'WKW6G@/_?,&Y>U '5U1GUO2K9]EQJ=
ME$X_ADN%4_J:PAX=O)SF73]!A/\ >GBDOF[?Q-L-7H-$U*-0O]L):QC^#3K&
M.(?^/^9_DT 6CX@T_K&UQ.O]ZWM)9E_-%(H_M>5QF#2-1F7UV)'Z]I'4]O3N
M*B_L#S&S=ZMJMSC_ *>?)_\ 1(2C_A%M&9LSV9NS_P!/LKW'_HPM0!!>^()[
M(YGATZS7L-0U)86/7'"JP]._?VJF?$S3-BWU33&;LEG;37Y[]XR/;M6]::1I
MFGG-EIUI;'UA@5/Y"KM '*'4-0N&/E2ZW*W]VVTU+9>__/R/ZT-;ZK<G']G:
MH[?W[S55MAW[6Y;V[5U=% '*?V!?3G$NG:,G_32ZDEU!OK\X0^G>K=OH6HP8
M6/4K.SC'&-.TY(CC_@;./TKH** ,<Z%)*1]JUO59U'\(E2']8E0_K1_PB^DN
M1Y\,]T!T6[NI9U_*1B*V** //?'&C:7II\+R6&FV=K(WB*R5F@@5"1N/!('L
M/RK+\+_\@-?^OBX_]'/71?$7[GA;_L8[+_T)JYWPO_R U_Z^+C_T<] &Q111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!699PS#QCX8EW;5MM6U.V9=I&X7$!N@>OT^O'I6G61=7T]CJ=A/#%O9?%%GO
M+(2!'-9"VW=?4D9]<=: /5:;)&DJ%)$5T/56&0:=10 R.&*$8BC1 >RJ!3Z*
M* "BBB@ HHHH **** ,+Q?-%:Z +N8)LM[RUE)<X"XGCYSVXSS7/1<6LR$$/
M'J-\K9 '6X>08_!Q6[XZL$U+P-K-O(Y11;-+D>J?./U6L>5$^VZV\84)_:8(
MVK@'=:VY)]\G)S0!%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% #[NV%Y/X;C8!DDFN[1PWW2KV\C$$=QE16WX%_P"2
M>^&O^P5:_P#HI:Q)9S NB3@ B#68P<@G'FQ20_AS)5OX6QS0?#K3+6X.9K5I
M[9OFW?ZN>1.#Z?+Q0!V%%%% !1110 4444 %%%% !1110 4444 %<;\,?^1.
M'_7Y<?\ HUJ[*N-^&/\ R)P_Z_+C_P!&M0!V5%%% !1110 4444 %%%% !7.
M>)+=I[^UB!(^V6=Y8K@_Q.BN._I$:Z.L37YXX+O196E0-'J"?(6Y/F(\0XSZ
MR"@#4L;E;W3[:[3[L\2R#Z, ?ZU/69X>.- LX>]NGV<_6,E#^JUIT %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5C^&/\ D Q?]=9O_1KUL5C^&/\ D Q?]=9O
M_1KT ;%%%% !1110!GZS_P >,?\ U]VW_HY*T*S]9_X\8_\ K[MO_1R5H4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 <I#8VE[JE@MW:P7 2342HEC#X/GCIFNI2-(D"
M1HJ*.BJ, 5SUA_R%K+_?U#_T>*Z.@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH XOXB_<\+?]C'9?^A-7.^%_P#D!K_U\7'_ *.>NB^(OW/"W_8QV7_H
M35SOA?\ Y :_]?%Q_P"CGH V**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *QM<N;?3[74=0FB)CLSHUS)Y:_,=M_)D
M]>3M&.?:MFL+Q391W.B:VKJK"70+UVW*#@P-$Z>_5S],4 >MT4BLKJ&4AE(R
M"#P12T %%%% !1110 4444 %%%% &;XA@FNO#6JV]NK//+9S)&J]2Q0@ ?C7
M$Z499+<RRD-)<Z;IMY(P3'SO'(A]C_JA^=>D5Y=X<O?M>G6DN&VSZ-"@+@YS
M;3R1GV_Y:CWZ4 :=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 .E?&FE/6_T]NN.EW%_C6GX#N89M(U*VA!4V>LZA"X
M(P 3<R.,>VUUK!U3'_"/:NQV_NK-YQN7<,QXD''_  "MWP;:+8ZCXNA0$*=<
M>7&<\R6\$A_,L3^- '54444 %%%% !1110 4455DU.PB;;)?6R-Z-*H/\Z +
M5%4AJUFV?+:64#^**!W'YJ"*0:B[Y\K3KQU'<JJ?HS T 7J*SI;Z[B1I'M;>
M",?Q7-T$]?16'ZUG_P#"0PNS!=9T<-GB.%C<-W[*P/;T]: .AKC?AC_R)P_Z
M_+C_ -&M1=>,M)MI"MWXADADZB,6H@'?O*N/UJI\-+2*Z\)&1Y;C'VRX \NY
M95_UC<C8V#GUH [VJTNH65NVV:[MXV]'D /ZFHAH^GY)>U24GO-F0_FV:LPV
MUO;C$$$40_V$"_RH KC5[)CB*5IL=X(FD'YJ#2#42[8AL;R0>IC$?_H96KU%
M %+[3?N?W>GJB_\ 3><*?_'0U _M20\FS@'IAI?_ (GWJ[10!1^RWSMF742H
M]((57_T+=2_V;N;,U[>2_P#;7R__ $#;5VB@"C_9%B6W20><?^F[M+_Z$36=
MXBM+2RT&6Y@M88OLTL-RQCC"_+'*CGI[*:WZS]>MGO/#NIVJ??FM)8U^I0C^
MM #-%_=Q7MN?O0WLV?\ @;>:/TD%:=8F@W*W-S?3*/ENQ!>I_NO$JC]8S6W0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !6/X8_P"0#%_UUF_]&O6Q6/X8_P"0
M#%_UUF_]&O0!L4444 %%%% &?K/_ !XQ_P#7W;?^CDK0K/UG_CQC_P"ONV_]
M')6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!SEA_R%K+_?U#_T>*Z.N<L/^0M9?[^H
M?^CQ71T %%%% !1110 4444 %%%% !1110 4444 %%%% '%_$7[GA;_L8[+_
M -":N=\+_P#(#7_KXN/_ $<]=%\1?N>%O^QCLO\ T)JYWPO_ ,@-?^OBX_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 <Y8?\A:R_W]0_]'BNCKG+#_D+67^_J'_H\5T= !1110 4
M444 %%%% !1110 4444 %%%% !1110!Q?Q%^YX6_[&.R_P#0FKG?"_\ R U_
MZ^+C_P!'/71?$7[GA;_L8[+_ -":N=\+_P#(#7_KXN/_ $<] &Q1110 4444
M %%%% !115"XUO2;20QW.J64,@ZK)<(I'X$^Q_*@"_16?%K-I<;OLBW=XJ]7
ML[.:=1U_B12.QJ9)]1F5WM_#^JO&@)+R1I;C'KB9T/Z4 6JQ?%=Y=V'ARYN;
M&7RKB,HP? .%# OU!'W0W:K O+]V?$.E6RIG(O-517_[YB63GVS5;5=-UC5-
M U%-\0#V\@BBL[.YF:1]IP%E*JH.>^TT :<UAK.E'S;K;)9_QM,R+)&/7Y.&
M ], @<Y/2I(9/.A63 &>P.?UJVEMXF*@)9)Y;+M;'D6Y;C&2-LG7Z_Q52TKP
M1J2V$?\ :8>:ZVX8#5I8D5O4+$@XXS@L>I_  FJI=:KIUB^R[U"UMV])9E0_
MJ:UH? -J 7FMM+FD((S=V\MX5],-+*>>!VK2L/"5MIJ'['.+1F!#&SM+>$8]
ML1Y';OVH Y&/7=/N'V6<LEZW7_0H'N,?]^U:IDN;Z=]MIH.KSX&2S6WV<?G,
M4KMAH=OLQ+<W\I/4M>RC/X*P'Z4J>'M&0?\ (,M7.<[I(@[?FV30!P7VV^DE
M*+;:?;8Z_;]4A3](_,-20PZQ>-E;BQ@B_OP6=U>@_B$C'<=Z](BABMXQ'#$D
M:#HJ* /R%/H \[@T+6;IMTUUJ0BZ?Z'8P6YZ?]-I'/<=NU68?!UW,WF77VZ9
M>@CGU7R#_P"2\0]?7L*[NB@#BH? -NS^;=6NFRMV2\$]Z!U_YZRX[GM6EI_A
M"WTZ4S6TD%I*?XK&PMX<=?\ 88]SW[UNR7=M"VV6XB0^C.!3/M]N?N,T@]8H
MV<?H#0!E:GHKC1[]H[_49+LP2&)S=NFU]IQPA4=:H+H^G>(K?7EEM8)VN&V0
MR3J&*J]NA&#S@9=NE:]]XCTW3O\ C\GCMP>AN)4A_P#0V6N=\.ZNEO!;O C7
M$$NFVN'A5Y0SH9(WP8U?/W5[^E %+PSK.EZ7JEWJ6J:G!;2:OIFG78%Q, S_
M +MU)&>3]WFNZTS4[/6+!+[3YUGMI&95D4$ E6*MU]""/PKR&WTV0^)] 6^U
M"]T)6\,I"SQS-"\K02A=K A7R0X/8_E796VNZ!X:T^.PDUNYB1&9@TT$FZ1F
M8NQ+R@Y)9B<Y[T =O17$1_$32A(4MDU#4G;A3;B*8?E$Q('([=ZF;QAK$K[;
M+PK>SYZ%Q)#CW(EC0>G&?7TY .QHKC7U'QW<28MM&M+=#WO"B[?Q25\GI_#V
M]^,^6;QM<3NBW]M:*I8,49)EXW9 S&A'0]\\ ^M 'H5(2 "2< =37!6OAW6M
M5N)5N_$]W 8P"PM5EB)SNP"KR,!QVV]Q^%U_AOI=PX:\OM0NB/[QBC)Z_P 4
M<:MW]: .ADU[1X9#')JUBCCJK7" _EFJ5YXRT'3UW75ZT2'H[02;3_P+;C]:
MC'@?P_@+)9RW"#^"YNYIE[_PNY'>KMOX:T&SD\RUT338)!_%%:(I_,"@#GY_
MB-X>F 2.*:_4G(6W\J8_]\!]WKV[?2N;UG5TO?$3W<WASQ%)!=Z/+I^VRT^0
MR)F1"& D15!&6(.2/E'X^L=*K3?+>VS\\[X_S&?_ &6@#SN:#Q T$;VF@^*+
M@MA@D]YIUB.<?>:#YQQVZ_2IKCPWXEOK2(KH>DK(0K&/5?$%[?*AXR#&4"D]
MN#CW(KT>B@#R;7O"]WHFFZ=K=]_PCMJEC?VTEQ#I.DM;LP>01,!-YN<!9&/0
M=!76>*O#NGS^'+FS8W4DEULMHO-NY9"&=E4$;V.,=2<<8)K3\7:(_B/PEJ>D
M1.D<US 5B=\[5D'*DXYQN Z5/;Z9.]['?:E<K<3Q9\F.--D4.1@D DDM@D;B
M>A. N3D QY_AUH%[9I;:BVK:@BJ WVO5[I]Y&.2OF;<DC/  ]JL6_P /_!UK
M#'%%X7T?$8PK/9QNWXLP))]R:Z.B@".""&U@2"WACAAC&U(XU"JH] !P*DHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YCQ1"T
MM[$BCYKG3;ZT0X_C98V'Z1M716TZW-K#<)]R5 Z_0C-9FN$1W>B3L/ECU !C
M_OQ21C_QYQ4OA[CP[I\9^]# L+?[R#:?U4T :=%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5C^&/^0#%_UUF_\ 1KUL5C^&/^0#%_UUF_\ 1KT ;%%%% !1110!
MGZS_ ,>,?_7W;?\ HY*T*S]9_P"/&/\ Z^[;_P!')6A0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!SEA_P A:R_W]0_]'BNCKG+#_D+67^_J'_H\5T= !1110 4444 %
M%%% !1110 4444 %%%% !1110!Q?Q%^YX6_[&.R_]":N.\/ZYI%KI'DW&J64
M4JW%QF-[A58?OGQP3FNQ^(OW/"W_ &,=E_Z$U9/@S4K_ %RW:*YO)(8EU2[M
MB+1$AW'8DB9*KV!?T)ZG- #(=7@N4#VUOJ-Q&>DD&GSR(>G\2H1W%2>?J1A\
M_P#X1_44A!QYDS00^G:213W].QKMGT&PE&V;[5*O7;+>3.OY%L5(FAZ3&P9-
M+LE8="(%S^>* //DN]0DC\P+HL?.!%)JNZ3M_#'&X[GH>U3QV6M2Q!VNX8W.
M,1Q:-<R@^^]FC'Z5Z0 %    '  I: //HO#>K21[I;O6C(V,"*.SA0?4-YC"
MIXO!4S19GCGEE;!WRZU.I7U^6)47UZ5W5(2 ,D@ =S0!QT?@"R$6)+/1I';[
MSSV#7#CUPTLC>I[=ZUK/PTEC 8;:^FME8#<MK!!"#_WS'D=3W[UJ-?V:D@W4
M(8=O,&?RI/MT/\*SM[K Y!_'&.U %7^PK0Q[)9KZ7(^;?>R_-]1NQ^E.70-'
M0#&EV9(_B:%6/YD9JE<^,-$M)3%/J%I%)_=EO(4/Y,X/IV[U63QK8SD_95DN
ME'\=M;W$Z_G'$P[CO0!TL<:1($C140=%48 J.[#M9SK&2KF-@I!P0<<5SP\1
M:E.&:VT34GC')9K5(<#_ +;2H?TK%G\=/#</%/>Z-8.GWHK_ %RWA<=/X423
MG\: -NP>5]3@D_>21AR=WW^HP,,,G'/<]AWS735Y;;>.5U.]E@M-;M)9HQN,
M>GV-_J/''\46Q<<CG'>FPZEJ=[<S@V/B>18D+F6#1+:TCP,9P;QBQ^G7CVH
M]-:]M$;:]U"K>AD IOV^ _=\UQZI"[#\P*\M@N/$%Q=2A]!U<6Z\":^\0_8Q
MNQTV6J8!Z_EVJ[8>$=>U&Y:XN[#PHELV0#>+<ZK*&!P1F1T'7/(_6@#M+SQ5
MI&GR;+N\@MV])[B*(_D[ U3_ .$VTV5RMHPO,=?LB2W./^_,;C]:S-.\#ZU8
MWIE3Q/;V5N1@P:3HEM;?^/.)#5Q/ @:^%U>^*?%%X ,&%M2,$9X](!'_ #[4
M 3_\))?W$A6ST74I@._V(Q#\YWB_E61?>-9[6Y\BYFT[3GQG;J6KVUL>_P#"
MHE/:M%?AIX0^W"]N-'%[< 8#7]Q+=#'/:5F'<]JUK#POX?TNY6YT_0M,LYUZ
M2V]I'&PX(ZJ >A(_&@#@QX]COM26RAUW36G8$JFGI>:FQX)_Y8+&.@/^12-J
MNIWFI);BT\27(?\ CM/#RVZ=^KWK''_UZ]3HH \R%KXJEOXXD\/ZW);GAI;S
M7;>R5>>ZVBDGU_$T^3P=XDNM1C>73O#0M\X=M0O+S5' ]A(4'3%>E44 <%!X
M#UFWOXY[;7]+TR('YX]*\/P0LPSV:1I,'\*OW'@::\N4EN_&/BF0*<F..\CM
MU;V/DQH?UKKJ* .97X?^&?MPO)["6]G"E U_>370 )!/$KL.JCM6M9Z#H^G/
MOLM)L+9O6"V1#^@]A^5:%% !1110 5G_ -DQ_:6F6>92Q)VC;M!.<\$'GD\^
M]:%% %:UL+>S+&%2"P //''MT'6K-%% !1110 4A )!(!P<CVI:* "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#'\3X71?.;[L%S;3L?14G1F_0&I=#^6UNH2?GCO;C=[;I6<=_1Q1XC
MA:X\+ZM"@R\EG,JCW*'%1:)<I<7>I2(<K/)%<IS_  -#&!W]4;TH V**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ K'\,?\ (!B_ZZS?^C7K8K'\,?\ (!B_ZZS?
M^C7H V**** "BBB@#/UG_CQC_P"ONV_]')6A6?K/_'C'_P!?=M_Z.2M"@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 A (P1D'J*Y7P@P6.S0GYO[(MH<9_BA:17[^K"NKKE-$;R]6AC/_+.?
M4H2,]&:=95'7^Y_D4 =71110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8_AC_ ) ,
M7_76;_T:];%8_AC_ ) ,7_76;_T:] &Q1110 4444 9^L_\ 'C'_ -?=M_Z.
M2M"L_6?^/&/_ *^[;_T<E:% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y
MBQ_Y#^G_ /<2_P#2A*Z>N8L?^0_I_P#W$O\ TH2NGH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#AI->8?W9[FU@7_OJ$%N_P"E!\.7-Q\L]I"5_P"GC5KJ[7O_  -M'?UKJZ*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .8L?\
MD/Z?_P!Q+_TH2NGKF+'_ )#^G_\ <2_]*$KIZ "BBB@ HHHH **** "BBB@
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MG8 #\30 ^BLB3Q5X?C)4ZU8,XXV1W"NW_?()-(?$ED1F*VU.8GILTZ?!^C%
MOZT ;%%8LFN7@C+KX?U *.CS2V\:]^N9,C\N]9[^*;EMRQOX?1^@5M6+N#_N
M+'R>G />@#JJ*Y0ZKJ\JG;?(-W00Z%<M^3LX4]N<8ZT&+6IEP9_$!W?W191+
MW]BX_G0!U=(S*BEF8*HZDFN5.A7\JX>WD?/4S:[<_JBJ%_ 4H\'QD[C9Z"I]
M6TOS7'7^-GY/3J.U &K)XFT&%BDFM:<KC^'[2F[\LYI@\3:<XS"E_,.S1:?.
MZGI_$$QW]:6+1;B*,(FL7<2?\\X(8$0#GH/+)'4=^PJ0Z%:MDR3W\A/7-],
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M7+'HMIF<_DF3W%!\0Q.0MMINJW#'M]B>+]90H_6@#8HK!N=?O8%!;1GME/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***S?$3O'X9U9XY'C=;.8J\;%64[#@@CD'W% &E
M17F_V(_]!#5__!I<_P#QRC[$?^@AJ_\ X-+G_P".4 >D45YO]B/_ $$-7_\
M!I<__'*Z[PHSMX=A\R665EEG7?-(TC$"5P,LQ)/  Y- &U1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5C^&/^0#%_P!=9O\ T:];
M%8_AC_D Q?\ 76;_ -&O0!L4444 %%%% &?K/_'C'_U]VW_HY*T*S]9_X\8_
M^ONV_P#1R5H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=0>]L]D-M*(0R&)S$N3O.  6!&3VS7K^F:-;Z5IDEA \K1/+-*2Y!;,KL[=
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^[;_ -')6A6?K/\ QXQ_]?=M_P"CDK0H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_#'_(!B_P"N
MLW_HUZV*Q_#'_(!B_P"NLW_HUZ -BBBB@ HHHH S]9_X\8_^ONV_]')6A6?K
M/_'C'_U]VW_HY*T* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*Q_#'_(!B_ZZS?\ HUZV*Q_#'_(!B_ZZS?\ HUZ -BBBB@ HHHH S]9_X\8_
M^ONV_P#1R5H5GZS_ ,>,?_7W;?\ HY*T* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *Q_#'_(!B_ZZS?^C7K8K'\,?\@&+_KK-_Z->@#8HHHH
M **** ,_6?\ CQC_ .ONV_\ 1R5H5GZS_P >,?\ U]VW_HY*T* "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *Q_#'_ " 8O^NLW_HUZV*Q_#'_
M " 8O^NLW_HUZ -BBBB@ HHHH S]9_X\8_\ K[MO_1R5H5GZS_QXQ_\ 7W;?
M^CDK0H **** "BBCI0 45REUX_TP74EII%K?Z[=1ML==,@\R-&]&E)$8]_FR
M/2O'KCX\^(M.\?WD-]81)I=O/)!)IYV>8FS(/[S."V1ZD'H.QH ^C**\U\,?
M&WPQXA,BW N=+9'"EKI,Q#/3=(N57//WL=.M>DHZR(KHP96&58'((]: %HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *Q_#'_ " 8O^NLW_HUZV*Q_#'_ " 8O^NLW_HUZ -B
MBBB@ HHHH S]9_X\8_\ K[MO_1R5H5GZS_QXQ_\ 7W;?^CDK0H **** $9@J
MEF("@9))X%<5''+\09&GFDDB\*(^V&%"5;4\=7<]1#GHH^]C)XP#9\=S27-K
MIOARWE:.77+L6TC(<,MNJEYB#V^12N?]NNI@@BMK>.""-8X8D"(BC 50, #V
MQ0 VUM+:QM8[6TMXK>WB&U(HD"JH] !P*^/-4O8M-^,FN7TT22I;:K>S".10
MRLRM(5!!XZ@5]DU\::OI?]M_&G4=*R0+SQ!- Q'8-.03^1- 'NOP^^&L5AI_
MAG71<M#<MI[IJ5N\6];Q)LN%?)X*EO0YV@=JZ&ZTV;P(7U/1$=]!!W7NE*"1
M O\ %- .V.K1C@C.,'KVB(L:*B*%51@ = *7K0!%;7,%Y:PW5M*DL$R"2.1#
ME74C((/H14M<?X0/]CZ[KGA0G%O:.EY8*>UO-N)0>R2!P/8@5V% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !6/X8_Y ,7_ %UF_P#1KUL5C^&/^0#%_P!=9O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV/\ X&/_ /&J/.UC_GQL?_ Q_P#XU0!H45G^=K'_ #XV/_@8_P#\:H\[6/\
MGQL?_ Q__C5 &A16?YVL?\^-C_X&/_\ &J/.UC_GQL?_  ,?_P"-4 :%%9_G
M:Q_SXV/_ (&/_P#&J/.UC_GQL?\ P,?_ .-4 :%%9_G:Q_SXV/\ X&/_ /&J
M/.UC_GQL?_ Q_P#XU0!H45G^=K'_ #XV/_@8_P#\:H\[6/\ GQL?_ Q__C5
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MV/\ X&/_ /&J/.UC_GQL?_ Q_P#XU0!H45G^=K'_ #XV/_@8_P#\:H\[6/\
MGQL?_ Q__C5 &A16?YVL?\^-C_X&/_\ &J/.UC_GQL?_  ,?_P"-4 :%%9_G
M:Q_SXV/_ (&/_P#&J/.UC_GQL?\ P,?_ .-4 :%%9_G:Q_SXV/\ X&/_ /&J
M/.UC_GQL?_ Q_P#XU0!H45G^=K'_ #XV/_@8_P#\:H\[6/\ GQL?_ Q__C5
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MV/\ X&/_ /&J/.UC_GQL?_ Q_P#XU0!H45G^=K'_ #XV/_@8_P#\:H\[6/\
MGQL?_ Q__C5 &A16?YVL?\^-C_X&/_\ &J/.UC_GQL?_  ,?_P"-4 :%%9_G
M:Q_SXV/_ (&/_P#&J/.UC_GQL?\ P,?_ .-4 :%%9_G:Q_SXV/\ X&/_ /&J
M/.UC_GQL?_ Q_P#XU0!H45G^=K'_ #XV/_@8_P#\:H\[6/\ GQL?_ Q__C5
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MV/\ X&/_ /&J/.UC_GQL?_ Q_P#XU0!H45G^=K'_ #XV/_@8_P#\:H\[6/\
MGQL?_ Q__C5 &A16?YVL?\^-C_X&/_\ &J/.UC_GQL?_  ,?_P"-4 :%%9_G
M:Q_SXV/_ (&/_P#&J/.UC_GQL?\ P,?_ .-4 :%%9_G:Q_SXV/\ X&/_ /&J
M/.UC_GQL?_ Q_P#XU0!H45G^=K'_ #XV/_@8_P#\:H\[6/\ GQL?_ Q__C5
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MV/\ X&/_ /&J/.UC_GQL?_ Q_P#XU0!H45G^=K'_ #XV/_@8_P#\:H\[6/\
MGQL?_ Q__C5 &A16?YVL?\^-C_X&/_\ &J/.UC_GQL?_  ,?_P"-4 :%%9_G
M:Q_SXV/_ (&/_P#&J/.UC_GQL?\ P,?_ .-4 :%%9_G:Q_SXV/\ X&/_ /&J
M/.UC_GQL?_ Q_P#XU0!H45G^=K'_ #XV/_@8_P#\:H\[6/\ GQL?_ Q__C5
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M,5O<>7YH9V;RV)4;G9N"0,]?2@#0HHHH **** "BBB@ HHHH **** "BBB@
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M<>6J[RPY&.N: 'T5C?\ "5Z)_P _P_[]O_A5ZPU.SU-'>SF$JH<,0I&#^(H
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M^_;_ .%; ((!'0T +15:]O[;3H//NY1''NV[B">?PK/_ .$KT3_G^'_?M_\
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M;&,BFWE[;V%N;BZD$<0(!;!/7Z4 3T5D)XHT5V"B_0$_WE8#\R*T_M$/V<W
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MF=@!+$L[9SN' QC!Y.>.YH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M040$'_?-/5V#;F%M]0^V?#^ZA9LR6P6,_P"[N&W_  _"MCP7_P B['_UT?\
MG7&WJOHM[J>G<^5*NT?3(93^7'XUU7AJ]CT_P>;N569(G8D+U/.*=[IL36R\
M_P!#J:\[U.UCOO'KVTV?+DD4-M.#]P5T=AXPL=0OHK2*"X5Y3@%@N!^M<OK9
MNE\;3&QS]I#KY> #SL'KQ27Q('LQ?$>DQ^'KZTFL99!ORR[CDJRD=_QJWXY?
MS6TV3&-\1;'UQ1'X?UW6K^.75V*1+@%F*YQZ +TIWCX!;BQ & $8 ?B*3Z7[
MC6YI1^!M+*HYGN\X!^^O_P 353Q__J[#ZO\ ^RU)H>E:_;ZI;S7ES(UJ =RF
MX+ _*<<?7%1_$#_5V'U?_P!EIL($7AG4/,\.ZG8.WS10NZ#_ &2#G]?YU)X-
MM4O=$U&VE+!)7VL5/.,5D:@C:%K+.@/DW5N3@=PZX/Y-S^ K>\ _\>%W_P!=
M1_*GO<F^B]?T,+Q1H=KHLELML\S"4,6\P@],=, >M=;HWAFRTR>.]ADG:0QX
MP[ CD>PK%^('^NL/]U__ &6NTM_^/:+_ '!_*E%^Z$M['#>$_P#D;+[_ ')/
M_0Q3?''_ "'+7_KB/_0C67:6FH7FN7<>G2-',&<DK)L^7=Z_E4>JVFHV=_#'
MJ4K22E05+2%_ESZ_G13^R6]Y'1>/KAP+*V!(0[G8>IX _K5;7/"UKINA+=Q2
M2&9-N_<1AL\=.W-/\??\?=E_US;^8K<\7?\ (K3?5/\ T(5*?N_/]1/=(I6]
MP]S\/)&D)++"R9/H#@?IBG^ _P#D#3_]?!_]!6JVG_\ ).KC_=D_]"JSX#_Y
M T__ %\'_P!!6J^T_D+[*]69.E_\E#F_Z[3?R:HM8$5YXW,%_*4MPZH23C"[
M0<>V2?UJ72_^2AS?]=IOY-6]XB\,1ZP?M$#B*[5<9/W7'H?\:-E%E2W:,^7P
MC<6NMP7.DR+'"A#GS'/RG/(]2"/ZU%\0.NG_ /;3_P!EJKHVMW^A:@NFZD&\
MC<%P_)CST(/]W_(JU\0.NG_]M/\ V6A]"5N6;;P1IDUK#*TUWN= QPZXY'^[
M76* JA1T Q7%Z'I6OQ7UG//<R&T&&*FX)&W''&:[6G(2.:\<?\@!?^NZ_P C
M69H?A*PU+1X+N:6Y623=D(R@<,1W'M6GXX_Y "_]=U_D:YW2=*U^XLX)K.YD
M2U)^51<%0!GGCZYI1ZE2V1T'B1!I'A(6=NS["5A#,><<D_RK'T[PO:W?AAK]
MY)!<,CNN"-HVYP,?A6SXY_Y *?\ 7=?Y&F:5>VUMX/M89I522>*58P?XB"W&
M?QI?9;&EK%%?P+<N]A>VS$E(R&7VW Y_E57P#_Q^WG_7-?YT_P !?<U+_=3_
M -FIG@'_ (_;S_KFO\ZK[3]#.6WS&Z__ ,CU9_[\/_H53?$#[^G_ $D_]EJ'
M7_\ D>K/_?A_]"J;X@??T_Z2?^RU"V7JRWO\D3^,?^1:L/\ KHG_ * :I?\
M",V<GA0:BKRK<" RGYLJ<=L5=\8_\BU8?]=$_P#0#61;VWB;4-*BM8E<V+*
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MIP?YU'KT\5QXWMXYI$2&W,8=G.!@?,?YXIMO<P0?$#S;>9'@GDQN1L@EE_\
MBJ(?G?\ X Y;>A)X^_X_+/\ ZYM_.GZ7J'VKP/J%LYS);1E1_NGD?U'X4GCG
M_D):?_NG^8K)OU;0M7U&T (@GB95'^RW*_D>/SJ5\#7>Y3^)/M8V_#__ "(V
MI_27_P! %9GAOP];:W:7+S2RQR1L%0H1CD=P16GX?_Y$;4_I+_Z *D\ _P#'
MG>?]=%_E6CW?HB+[>I4\%336NL7>G.WR;6)7L&4XX_SZ5W=<%X;_ .1UO?K+
M_P"A5WM1>Z3'U9Y]KR-JOC5+&1RL8*1C'8$ G'OR:-;\.3:5?6TVDQ74H^]\
MJ%RC CN!W_QJ2X_Y*0O_ %U3_P! %2WWC/4K2]FA^R0!$D95+*W(!QZTUHE8
M'NT2>/&+VFG,05)+$@]N!4EAX+TVZT^VN'FN@\L2NP5UQDC/]VH?',AEL=,D
M(P7W,0/<+4>B:5KXGL+AKF3['E'V?:#C9Z8^G:FENO,&_=3\B]XWC6'0;2)<
M[4F51GT"FJ7@;4,?:M/<]1YL?UZ'^GZU?\>?\@>W_P"O@?\ H+5STZ-HE]I.
MI1K^[F@C<X[G: X_+G\:E/?S"VFAJ> /OZA](_\ V:LC0-(M]9U>XM[AY%14
M9P8R <[@.X/K6OX ^_J'TC_]FKG],M-0O-2GCTV5HY@&+%9-GRY'?\JKJ-;/
MU/0-(\.V>BS22VTD[-(NT^8P/'X 5QNDZ9;ZMXGO;>YW^6#(WRG!R&_^O7:>
M'K6_L]-,>HR-)/YA(+2%^..]<% ^I1Z[?/I>[SU:0MM )V[N>OX5+^+Y"6Q=
M6W_L#QK!;VTC&,R(OS'DJV,@_G_*NI\77/V?P[. <-*5C'XGG] :YGPI:-J^
MMR:A=W&^2 AR&^\Q['Z#'\JO^/KC$5G:@]6:1A].!_,TWLD-?%=&)X<:33_$
M5B9?E6<8'N&! _7%=SJ_A^TUIXGN9)E,0('EL!U^H-<;X@EM8+G2I[&YBF:W
MB5#Y; X*$$9_.O14<21JZG*L 0:;U5R>IYGI.BVU_P"(KC3Y7E$,9?!4C=\I
MP.U;WB*U30O"BV5H\ACEG"L7(R0<D],>@JEX<_Y':]^LW_H5:GCS_D#6_P#U
M\#_T%JB_NH:^)F5;^%[67PHVH-))]I\II1@C;QGC'T%6?"]R\GA?5(&)*Q*Y
M7/8%3Q^8/YUJ6G_(A_\ ;F_\C6)X3_Y 6M?]<_\ V5JM_:"&O*RIX5T.TUE;
MO[49 8]NTHV,9S_A5CPJ7T_Q5<6"N6C)>,^^T\']/UK&TRYU6TM+N?3W9(5V
M^>RA>,Y Z\^O2NE\$:<KF;59)M\A)C"]P>"2?<T^OR!['9US7C>Y\K0UA!YF
ME"D>PY_F!72UPOCF83:G8V98*%7<6)X&XXY_*HW:0UW*GA(O8>)4MY1@S0XQ
M]5#BM/Q__J+'_>?^0K.UBZM(/%EE>6<\<D0$9<QL"!@X(_("M#Q__J+'_>?^
M0IO5)A'XOZ[%+4?#=G!X6BU.%Y%F\J-V!;*MNQG^=:&GW,ES\/[KS"28HWC!
M/H.G\\?A7,WMSJQMK2RO9F2V=$:)6P%V= 3C^M=M<:<FE>#+FT1M^V!BSX^\
M3R31/X9 MT<YX9\-V>LV,L]S).K))L C8 8P#W!]:[32=)M]'M&M[=I&1G+D
MR$$YP!V ]*\^T;3=:O+:1]-G>.(/A@LQ3G [?E7HUH)+;2X1=-F2*$>:Q;/(
M')S0W9"1YWXD:34/$5\8_F6!<'V"@ _KFNQ\(7'VCP[ "<M$6C/YY'Z$5ROA
M^6UN+C5IKVYBA:XB9!YC 9+DDXS]*U/ -QF*\M2?NLLBCZ\'^0H6U@EO<[.B
MBBD 4444 %%%% !7C7Q5M]7NOBCX*@T*]CLM3>.X$%Q(@=4..2000>,CIWKV
M6LN]\.:5J.N:?K-U:^9J&GAA:S>8P\O<,-P#@Y'J#0!R'@GX?:KH_B>]\4^)
MM;75=:N8?(5HX]B1IQ[#GY0,  #GKFH?CM_R2G4/^NT'_HP5Z36;KV@:9XFT
MF32]7MOM-G(RL\?F,F2#D<J0>H]: //O!W@_Q+:#1M1N?B+<7-DD<4C:>UN
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M] HS^G\JZ66SM9H4AEMH9(DQM1XP57' P.U2+%&L0B5%$87:$ X ],>E)];
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MD+GK@8XHZ#3UN<EXAL?/\(Z9>*/FMXHPW^ZR@?SQ5V"__M#P%.[',D<#1/\
M4#_#!KI3;PM!Y#0QF';M\LJ-N/3'3%1QV-G%"\,=I D4GWT6,!6^H[T2U37<
M2Z>1Y_X>\31Z)9RP/;/*7DWY5@,< ?TKH+CQ"FH^%-0NDA:+'[G!;.2V!_6M
MO^QM+_Z!MG_WX7_"I!IUB(# +*W$+'<8Q$NTGUQCK0]06C.&T'PG%JVF"[FN
M)(MSD*% Y [_ )YI_AZ/^R/&<M@6)#!HP3W'W@?R%=Y##%;Q"*&-(XUZ(B@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% $%Y=QV-I)<R[MB#.%&23T 'N35
M1-3F2:)+RQ>V69ML;^8KC=V!QT-6=0@M[FRD@N7V1R87=NVD'/&#ZYQBJ+3W
M^EM%]KDCN[5W6/S@NR1"QP"1T(SCIBA!T->BL2ULH]5BN+FY>4S--(B,LA4Q
M!6*C;@\'C/XTMZL4ES%:R)<W\\<0)B5@B#_;8Y R<>_L* -*[NUM(XW92V^5
M(ACL6.,U8KF4>1M'A27(,6I+&%+E]H$O R>N.E*/,U">\DEL;NX*SO%&\4ZH
M(PO V@N,'OG'>C^OR_S#^OS.EHJA9_VE]GL?/6(,%(NMYRV<<;<<=>M7Z& 5
M1U#46L#&?LLDB,ZJT@90J[FQZY_2KU9FO?\ (.3_ *^(?_1BT ]C1D=8HVD<
MX506)/8"LU-4N9XXS;Z;,[-&KMN8(JY&0 3U/TI^LDR6L=FI^:[D$1Q_=ZM_
MXZ#5BZBNI(U6SN8X"."6BW_3'(Q0!776(#8FY,<@<2^28<#?YF<;>N/UI8=1
ME^UQV]W9O;-*#Y3;PZL0,D9'0XJII3PVMA<B\VK);3L9Y6.0SD [QQW!''X5
M8A2XU"]AO)HS!;PY,$3#YV)&-S>G!.![\^E,"6QU)+Z:6-8V4QC))/7YW7_V
M0_G5ZHX[>&%BT42(6ZE5 SR3_,D_B:JZE=26PC,=W96^[.?M1Z_3D4@+U(QP
MI."<#H.IK'MM1GEN8T;4M)D#-@I$3N/T^;K6S0!1L=1:\N+J%[9X'@*@J[ D
MY&1T)'ZU/;W*W#W"A2/)D\LY[G /]:HZ?_R'=8_WHO\ T"KL[K9QM)':R2L[
MY985&XG'4Y(]!38#;V]%IY:+&TT\K;8XD(!; R>3T ]:BM]1+RR07%NUO<(G
MF;"P8,OJ"*K"8SZ_92/#)"&MI0J2@!@=RYZ$]J?>#=XATT 9_=3;Q_LX7^N*
M6X%G3M03486D1&0+MX)]45O_ &:KE1Q010*5AB2,'&0JXZ  ?H /PJ2A@%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BN;:
M*\MGMYUW1N,$5372<O%]HOKFYCB8,D<A7&1T)( )Q[FM&B@#/?2AYLK07=Q;
MI,=TD<17#'N1D$@GV(I#I")+OM;F>US&L;"+:0RKG'W@>>>M:-% &?'H]O%:
MK;B28H)Q<99LG<&W=<<C/XT2:7F>:6WO+BV\XYE6+;ACC&?F!P?<5H44 55L
M4C-J(I9HTMP0(U?Y7R,?-Z^OUJU110 52U#3AJ 57NIXD4AML>W!(.0>5)ZU
M=HH J+8@7$$\DTDKPHRJ7QSNQDG '/&*B?2\7$L]M=SVK2G,BQ[2K'UPP.#]
M*T** ,QM$@-LD*SSHRS>>905+._JV00?R["K$-G-%*KMJ%U*HZHXCP?R4']:
MMT4 %,>*.7'F1J^.FX9I]% $2V\"L&6&,$="%%2'D$9Q[BEHH S[72OLMY)<
MB^NI'E(,BOLP^!@9PH_2M"BB@"M>64=XL99WCDB;='+&<,A]OP[&F6M@MO.]
MQ)-+<7#J%,DN,A?0   "KE% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
-44 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>gqr1p20dfppl000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqr1p20dfppl000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (? K\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *;)(L4;2.=J*,D^@JOJ5]%IFF75_,"8[>)I6
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(2%!)(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH YGXB?\DW\2?]@Z?_ - -;]G_ ,>-
MO_US7^58'Q$_Y)OXD_[!T_\ Z :W[/\ X\;?_KFO\J ,SP]_QZZE_P!A"Y_]
M#-2^&?\ D5=(_P"O*'_T 5%X>_X]=2_["%S_ .AFD\-Q3'POI)%RP'V.' V+
MQ\@]J -NBH+<OF57?>4? .,<8!_K4] !7):W_P E,\)_]>NH?RAKK:Y+6_\
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M[+9#[1#[WU<L:Z)$6-%1%"JHPJJ, "EH :B)&BI&JJBC"JHP *=110 4444
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MF4@ DI@<UTUMX/TC[+#OCO0VQ<C[?<#!Q_OUD_\ "V?"W_/2^_\  -_\*/\
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M?_A;/A;_ )Z7W_@&_P#A7#>-_$FCZA\!;BVM[^$W1:-/L[-B3<LXR-O7H":
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M?REH [.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KP7XC?\ )(M8_P"Q@G_]'M7O5>"_$;_DD6L?]C!/
M_P"CVH M_L]7EMI_@'7+R\G2"WAO2\DCG"J!&G)KT&SL[GQ=>0ZKJL+P:1"P
MDL-/E&&E(Z33#U[JAZ=3ST\0^#NK^&-/TN=?$^N10017OGP:?(AVO(%4"5\
M[@,< \ @GTKVG_A;7@/_ *&2T_[Y?_XF@#K;R\MM/LYKR\G2"WA4O)(YP% [
MFN8L[.Y\6WD.K:M"\&DPL)+#3I1AI".DTP]>ZH>G4\].0C^(W@_Q)JBW^M:]
M;0:;:R;K+3G#9=P>)IAC&>ZKT'4\].I_X6UX#_Z&2T_[Y?\ ^)H ZV\O;;3K
M*:\O)T@MX5+R2.<!0.]?-?@2[2^_:4N+N..6-)KJ\D594*N 4<C(/0^U=]%\
M1O!_B/5$U#6M>MH--M9-UEISALNP/$TPQ@G^ZO0=3STX'P)>VVI?M)W%]9S+
M-;7%U>212+T92CD&@#Z;HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *Y^X(/Q L #R--N,_\ ?R*N@KGYR#\0
M+ #MIMQV_P"FD5 %^V_Y#U__ -<8?_9ZYW1/^2K^+?\ KSL/Y2UT5M_R'K__
M *XP_P#L]<[HG_)5_%O_ %YV'\I: .SHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\HNO#$?C'PI=Z%+
M=-:I<Z_=DRJFXKMD=NF1Z5ZO7#^%N@_[#U__ #DH X'_ (9IL/\ H9KG_P !
M5_\ BJ/^&:;#_H9KG_P%7_XJO=J* /"?^&:;#_H9KG_P%7_XJC_AFFP_Z&:Y
M_P# 5?\ XJO=J* /"?\ AFFP_P"AFN?_  %7_P"*KH/!7P1M?!GBFUUR+7)[
MI[=7 B:W"AMRE>N3ZYKU:B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *Y^X(/Q T_!'&FW'_HR*N@KGIRI
M^(%AMQG^S;C./^ND5 &A;?\ (>O_ /KC#_[/7.Z)_P E7\6_]>=A_*6NBMO^
M0]?_ /7&'_V>N=T3_DJ_BW_KSL/Y2T =G1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P_A;H/^P]?_SD
MKN*X?PMT'_8>O_YR4 =Q1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@7'_(_Z?\ ]@VX
M_P#1D5;]<],$_P"%@6&W'_(-N,X_ZZ14 :%M_P AZ_\ ^N,/_L]<[HG_ "5?
MQ;_UYV'\I:Z*V_Y#U_\ ]<8?_9ZYW1/^2K^+?^O.P_E+0!V=%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7#^%N@_[#U__.2NXKA_"W0?]AZ__G)0!W%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M6%.JCQU8$  _V?<<X_Z:15NU@S*J^.;#:H&=/N,X_P"ND5 %VV_Y#U__ -<8
M?_9ZYW1/^2K^+?\ KSL/Y2UT5M_R'K__ *XP_P#L]<[HG_)5_%O_ %YV'\I:
M .SHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *X?PMT'_ &'K_P#G)7<5P_A;H/\ L/7_ /.2@#N****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "L&957QS8;5 SI]QT'^W%6]6#,@7QS88S_R#[COG
M^.*@"[;?\AZ__P"N,/\ [/7-Z*RK\5_%A9@/]#L.I]I:Z2V_Y#U__P!<8?\
MV>J=_P"#?#FJ:M_:M_I%M<7NT(99 3D 8 (Z?I0!M>=%_P ]$_[Z%'G1?\]$
M_P"^A6)_PA/A?_H Z?\ ]^%H_P"$)\+_ /0!T_\ [\+0!M^=%_ST3_OH4>=%
M_P ]$_[Z%8G_  A/A?\ Z .G_P#?A:/^$)\+_P#0!T__ +\+0!M^=%_ST3_O
MH4>=%_ST3_OH5B?\(3X7_P"@#I__ 'X6C_A"?"__ $ =/_[\+0!M^=%_ST3_
M +Z%'G1?\]$_[Z%8G_"$^%_^@#I__?A:/^$)\+_] '3_ /OPM &WYT7_ #T3
M_OH4>=%_ST3_ +Z%8G_"$^%_^@#I_P#WX6H+SP7X92QN&70K ,(F((@''!H
MZ7J.**P_!I)\$:$223]@@Y/^X*W* "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KA_"W0?\ 8>O_ .<E=Q7#^%N@_P"P]?\ \Y* .XHHHH ****
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M78W_ !*+'H?^7=?4^U:7_+2/Z4?P/]#_ #- $,5A9V\"Q06D$42YVHD8"CZ
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M.K?CU_"D_P"6GX?UI1P6[=?;TH :.W]/I3O^6GY=/QIO8?Y_AIW_ "T_+^M
M#3]W\?ZTX]OH::?N_P# OZFG'J/H: $/WS]>WTH[+TZCK]*#RY^O]*!T7ZC^
M5 "?QQ_3O1_ _P!#_,TO_+2/Z4G\#_0_S- #C_4UDWI?_A%=3'V'<ODW/[W<
MO^WSZUK'^IK&OEC_ .$>U*(M>B<Q7 $:K)M).XCMC!XH T/!O_(D:%_UX0?^
M@"MRL/P;_P B1H7_ %X0?^@"MR@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** .!^+T6?!L5UN*BUO892PZCJO\ -A7=02K/;Q3(<K(@=3Z@
MC-<S\2+<W'P]U@!-S1Q"91CNC!OZ5I>%+@W7A+29F&&:UC##W"@'^5 &Q111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P! % %VBBB@ HHHH **** .2^'_ /QX:Y_V';__ -'-76UR7P__ ./#7/\
ML.W_ /Z.:NMH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#M__ .CFKK: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M <E\/_\ CPUS_L.W_P#Z.:NMKDOA_P#\>&N?]AV__P#1S5UM !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%->1(E+2.J*.I8X%9%UXM\.60)N==TV/'4&Y3/Y9H V:*YC_A8'AQ_^
M/:[GO">GV2SFF!_%5(_6C_A,)ILBS\+:_,W8O;+"I_&1A0!T]%<Q_;'BR?\
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MM%D4>)?$^X_\O</;_IWCIOAD@ZWXI(Z?VDO_ *3Q4 =+5&T_Y"6H_P"^G_H
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M!_.@67C.YYFUS2K/U%MI[2?J\G]*Z7_/2B@#F?\ A&-5G_X_/&&KN#_#;I#
M/S"9_6C_ (072I<?;;K5[XC_ )^=3F/Z*P'Z5TOY4M '/P>!_"ULV]- T]G_
M +TD(D/YMFMBVL;2R7;:6D$"^D42J/T%6** #)_R:/RHH_.@ _STHH_SUHH
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M^<D?E6M;6%G9+MM;2"!?2*,*/TJQ10 4UT61"CJ&4C!![TZB@!%544*H 4#
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M\D*@_F!5P  8 Q110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYL<V26D")!$VUXX9-^6ST8\8'0<]:VO$FA7VJW5K/874%N\5O<0,98]^!*H
M8#H2"HX/!KHJ*EJ^X=;GGVF> =0M]6CO[N]@<K=6LY0M)*?W,<J??<YR3(".
M !C%)8_#JZL-5M=5BOX?MEHW[D%#Y91II7D4KGJ5EP".01Z'%>A453=PZ6"B
MBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M % P !P!2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
D !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>47
<FILENAME>freq-20191231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Instance Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-03-26T03:10:11.1875681+00:00 -->
<!-- Version            : 5.0.1.369 -->
<!-- Package ID         : da71a932536d471fac83859dace20368 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:freq="http://www.frequencytx.com/20191231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="freq-20191231.xsd" />
  <xbrli:unit id="U_iso4217USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlishares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD_xbrlishares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlipure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_utrsqft">
    <xbrli:measure>utr:sqft</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_freqTerm">
    <xbrli:measure>freq:Term</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="C_0001703647_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20190630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20200320">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20190919_20190920">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-09-19</xbrli:startDate>
      <xbrli:endDate>2019-09-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20190920">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-09-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191001_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-01</xbrli:startDate>
      <xbrli:endDate>2019-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_freqLabEquipmentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">freq:LabEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_freqFurnitureAndOfficeEquipmentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">freq:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqUnvestedRestrictedCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:UnvestedRestrictedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqUnvestedRestrictedCommonStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:UnvestedRestrictedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqUnvestedRestrictedCommonStockMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:UnvestedRestrictedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqSeriesCPreferredAsConvertedToCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:SeriesCPreferredAsConvertedToCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqSeriesBPreferredAsConvertedToCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:SeriesBPreferredAsConvertedToCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqSeriesBPreferredAsConvertedToCommonStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:SeriesBPreferredAsConvertedToCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqSeriesAPreferredAsConvertedCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:SeriesAPreferredAsConvertedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqSeriesAPreferredAsConvertedCommonStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:SeriesAPreferredAsConvertedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqSeriesAPreferredAsConvertedCommonStockMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:SeriesAPreferredAsConvertedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqConversionOfFrequencyJapanPreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:ConversionOfFrequencyJapanPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqConversionOfFrequencyJapanPreferredStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:ConversionOfFrequencyJapanPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqOutstandingStockOptionsAsConvertedToCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:OutstandingStockOptionsAsConvertedToCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqOutstandingStockOptionsAsConvertedToCommonStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:OutstandingStockOptionsAsConvertedToCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqOutstandingStockOptionsAsConvertedToCommonStockMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">freq:OutstandingStockOptionsAsConvertedToCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtRangeAxis_srtMinimumMember_srtStatementGeographicalAxis_freqWoburnMassachusettsFacilityMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">freq:WoburnMassachusettsFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_freqWoburnMassachusettsFacilityMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">freq:WoburnMassachusettsFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesBFinancingMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:SeriesBNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">freq:QualifiedSeriesBFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesBFinancingMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:SeriesBNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">freq:QualifiedSeriesBFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesBFinancingMember_20181017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">freq:QualifiedSeriesBFinancingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:SeriesBNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesBFinancingMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">freq:QualifiedSeriesBFinancingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:SeriesBNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesBFinancingMember_20181017_20181017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">freq:QualifiedSeriesBFinancingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:SeriesBNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-17</xbrli:startDate>
      <xbrli:endDate>2018-10-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20151231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:SeriesANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">freq:QualifiedSeriesAFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:SeriesANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">freq:QualifiedSeriesAFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20150101_20151231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:SeriesANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">freq:QualifiedSeriesAFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20160101_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:SeriesANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">freq:QualifiedSeriesAFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqPriorToQualifiedSeriesAFinancingMember_20150101_20151231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:SeriesANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">freq:PriorToQualifiedSeriesAFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqPriorToQualifiedSeriesAFinancingMember_20160101_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:SeriesANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">freq:PriorToQualifiedSeriesAFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20170330">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:SeriesANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">freq:QualifiedSeriesAFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:SeriesANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">freq:QualifiedSeriesAFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20170330_20170330">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:SeriesANotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">freq:QualifiedSeriesAFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-30</xbrli:startDate>
      <xbrli:endDate>2017-03-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20170330">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:SeriesANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20170330_20170330">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:SeriesANotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-30</xbrli:startDate>
      <xbrli:endDate>2017-03-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20170330">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:SeriesBNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181017_20181017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">freq:SeriesBNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-17</xbrli:startDate>
      <xbrli:endDate>2018-10-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20190131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20190228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20181017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20181017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190717">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-07-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqDelawareLimitedLiabilityCompanyMember_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:DelawareLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqDelawareLimitedLiabilityCompanyMember_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:DelawareLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqDelawareLimitedLiabilityCompanyMember_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:DelawareLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqDelawareLimitedLiabilityCompanyMember_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:SeriesB1ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:DelawareLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapStatementClassOfStockAxis_freqConversionOfFrequencyJapanPreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">freq:ConversionOfFrequencyJapanPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20141113">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndFourteenStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-11-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndFourteenStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20190917">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-09-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtRangeAxis_srtMaximumMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndFourteenStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndFourteenStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndFourteenStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndFourteenStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">freq:TwoThousandAndNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtRangeAxis_srtMinimumMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtRangeAxis_srtMaximumMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20190919_20190920">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-09-19</xbrli:startDate>
      <xbrli:endDate>2019-09-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20190920">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-09-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191230_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-12-30</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtStatementGeographicalAxis_stprMA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtStatementGeographicalAxis_stprMA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtStatementGeographicalAxis_stprMA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtRangeAxis_srtMinimumMember_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20170228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20170331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20171222_20171222">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-12-22</xbrli:startDate>
      <xbrli:endDate>2017-12-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20180101_20180101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-01-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqPatentLicenseAgreementMember_20161201_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">freq:PatentLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-12-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_20161201_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-12-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_srtRangeAxis_srtMaximumMember_20161201_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-12-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtProductOrServiceAxis_us-gaapRoyaltyMember_20161201_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-12-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqPatentLicenseAgreementMember_20180901_20180930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CaliforniaInstituteForBiomedicalResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">freq:PatentLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-09-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_20180930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CaliforniaInstituteForBiomedicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_srtRangeAxis_srtMaximumMember_20180901_20180930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CaliforniaInstituteForBiomedicalResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-09-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_20180901_20180930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CaliforniaInstituteForBiomedicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-09-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CaliforniaInstituteForBiomedicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarInfirmaryMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqNonExclusivePatentLicenseAgreementMember_20190201_20190228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">freq:NonExclusivePatentLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsEyeAndEarInfirmaryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarInfirmaryMember_20190228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsEyeAndEarInfirmaryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarInfirmaryMember_srtRangeAxis_srtMaximumMember_20190201_20190228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsEyeAndEarInfirmaryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarInfirmaryMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsEyeAndEarInfirmaryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarInfirmaryMember_20190201_20190228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:MassachusettsEyeAndEarInfirmaryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqPatentLicenseAgreementMember_20191201_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CambridgeEnterpriseLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">freq:PatentLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-12-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CambridgeEnterpriseLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_20191201_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CambridgeEnterpriseLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-12-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_srtRangeAxis_srtMaximumMember_20191201_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CambridgeEnterpriseLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-12-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">freq:CambridgeEnterpriseLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtProductOrServiceAxis_us-gaapGrantMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqResearchAndDevelopmentMember_20180601_20180630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">freq:ResearchAndDevelopmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-06-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtProductOrServiceAxis_us-gaapGrantMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtProductOrServiceAxis_us-gaapGrantMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_freqPhase2bClinicalTrialMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">freq:Phase2bClinicalTrialMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtStatementGeographicalAxis_srtAsiaMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_freqPhase2bClinicalTrialMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">freq:Phase2bClinicalTrialMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_freqPhase3ClinicalTrailMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">freq:Phase3ClinicalTrailMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtStatementGeographicalAxis_srtAsiaMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_freqPhase3ClinicalTrailMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">freq:Phase3ClinicalTrailMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtProductOrServiceAxis_us-gaapRoyaltyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">freq:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:AstellasPharmaLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtStatementGeographicalAxis_stprMA_20160101_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtStatementGeographicalAxis_stprMA_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200201_20200229">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtStatementGeographicalAxis_stprCT_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqHaydenLLCMember_us-gaapLeaseArrangementTypeAxis_freqLexingtonLeaseMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200107">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:HaydenLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">freq:LexingtonLeaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtCounterpartyNameAxis_freqHaydenLLCMember_us-gaapLeaseArrangementTypeAxis_freqLexingtonLeaseMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200107_20200107">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">freq:HaydenLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">freq:LexingtonLeaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-07</xbrli:startDate>
      <xbrli:endDate>2020-01-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_srtRangeAxis_srtMinimumMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20190701_20190930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20191001_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20190101_20190331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20190401_20190630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20180101_20180331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20180401_20180630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20180701_20180930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-07-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001703647_20181001_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001703647</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <dei:DocumentType id="F_000000" contextRef="C_0001703647_20190101_20191231">10-K</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001703647_20190101_20191231">false</dei:AmendmentFlag>
  <dei:DocumentAnnualReport id="F_000002" contextRef="C_0001703647_20190101_20191231">true</dei:DocumentAnnualReport>
  <dei:DocumentPeriodEndDate id="F_000003" contextRef="C_0001703647_20190101_20191231">2019-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentTransitionReport id="F_000004" contextRef="C_0001703647_20190101_20191231">false</dei:DocumentTransitionReport>
  <dei:DocumentFiscalYearFocus id="F_000005" contextRef="C_0001703647_20190101_20191231">2019</dei:DocumentFiscalYearFocus>
  <dei:CurrentFiscalYearEndDate id="F_000006" contextRef="C_0001703647_20190101_20191231">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus id="F_000007" contextRef="C_0001703647_20190101_20191231">FY</dei:DocumentFiscalPeriodFocus>
  <dei:EntityCentralIndexKey id="F_000008" contextRef="C_0001703647_20190101_20191231">0001703647</dei:EntityCentralIndexKey>
  <dei:EntityFileNumber id="F_000009" contextRef="C_0001703647_20190101_20191231">001-39062</dei:EntityFileNumber>
  <dei:EntityRegistrantName id="F_000010" contextRef="C_0001703647_20190101_20191231">Frequency Therapeutics, Inc.</dei:EntityRegistrantName>
  <dei:EntityIncorporationStateCountryCode id="F_000011" contextRef="C_0001703647_20190101_20191231">DE</dei:EntityIncorporationStateCountryCode>
  <dei:EntityTaxIdentificationNumber id="F_000012" contextRef="C_0001703647_20190101_20191231">47-2324450</dei:EntityTaxIdentificationNumber>
  <dei:EntityAddressAddressLine1 id="F_000013" contextRef="C_0001703647_20190101_20191231">19 Presidential Way</dei:EntityAddressAddressLine1>
  <dei:EntityAddressAddressLine2 id="F_000014" contextRef="C_0001703647_20190101_20191231">2nd Floor</dei:EntityAddressAddressLine2>
  <dei:EntityAddressCityOrTown id="F_000015" contextRef="C_0001703647_20190101_20191231">Woburn</dei:EntityAddressCityOrTown>
  <dei:EntityAddressStateOrProvince id="F_000016" contextRef="C_0001703647_20190101_20191231">MA</dei:EntityAddressStateOrProvince>
  <dei:EntityAddressPostalZipCode id="F_000017" contextRef="C_0001703647_20190101_20191231">01801</dei:EntityAddressPostalZipCode>
  <dei:CityAreaCode id="F_000018" contextRef="C_0001703647_20190101_20191231">866</dei:CityAreaCode>
  <dei:LocalPhoneNumber id="F_000019" contextRef="C_0001703647_20190101_20191231">389-1970</dei:LocalPhoneNumber>
  <dei:Security12bTitle id="F_000020" contextRef="C_0001703647_20190101_20191231">Common Stock, $0.001 par value per share</dei:Security12bTitle>
  <dei:TradingSymbol id="F_000021" contextRef="C_0001703647_20190101_20191231">FREQ</dei:TradingSymbol>
  <dei:SecurityExchangeName id="F_000022" contextRef="C_0001703647_20190101_20191231">NASDAQ</dei:SecurityExchangeName>
  <dei:EntityWellKnownSeasonedIssuer id="F_000023" contextRef="C_0001703647_20190101_20191231">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityVoluntaryFilers id="F_000024" contextRef="C_0001703647_20190101_20191231">No</dei:EntityVoluntaryFilers>
  <dei:EntityCurrentReportingStatus id="F_000025" contextRef="C_0001703647_20190101_20191231">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityInteractiveDataCurrent id="F_000026" contextRef="C_0001703647_20190101_20191231">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityFilerCategory id="F_000027" contextRef="C_0001703647_20190101_20191231">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntitySmallBusiness id="F_000028" contextRef="C_0001703647_20190101_20191231">true</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany id="F_000029" contextRef="C_0001703647_20190101_20191231">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod id="F_000030" contextRef="C_0001703647_20190101_20191231">false</dei:EntityExTransitionPeriod>
  <dei:EntityShellCompany id="F_000031" contextRef="C_0001703647_20190101_20191231">false</dei:EntityShellCompany>
  <dei:EntityPublicFloat id="F_000032" contextRef="C_0001703647_20190630" decimals="0" unitRef="U_iso4217USD">0</dei:EntityPublicFloat>
  <dei:EntityCommonStockSharesOutstanding id="F_000033" contextRef="C_0001703647_20200320" decimals="INF" unitRef="U_xbrlishares">30946354</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000034" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">200158000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000035" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">42189000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000036" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">17197000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000037" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">4000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000038" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">748000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000039" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">221355000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000040" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">42937000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000041" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">1762000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000042" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">1511000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OtherAssetsNoncurrent id="F_000043" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">101000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000044" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">100000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="F_000045" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">223218000</us-gaap:Assets>
  <us-gaap:Assets id="F_000046" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">44548000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000047" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">1219000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000048" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">1863000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000049" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">3239000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000050" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">1749000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:ContractWithCustomerLiabilityCurrent id="F_000051" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">48152000</us-gaap:ContractWithCustomerLiabilityCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000052" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">170000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000053" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">161000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000054" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">52780000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000055" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">3773000</us-gaap:LiabilitiesCurrent>
  <us-gaap:ContractWithCustomerLiabilityNoncurrent id="F_000056" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">2900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="F_000057" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">180000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="F_000058" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">349000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:Liabilities id="F_000059" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">55860000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000060" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">4122000</us-gaap:Liabilities>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000061" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">38224000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000062" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">9000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000063" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">46694000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000064" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount id="F_000065" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">3773000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
  <us-gaap:CommonStockValue id="F_000066" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">31000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000067" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000068" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">236161000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000069" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">804000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000070" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">54000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000071" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">-68888000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000072" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">-49088000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000073" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">167358000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000074" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">-48282000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000075" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">223218000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000076" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">44548000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000077" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000078" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000079" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000080" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">49296987</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="F_000081" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000082" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">41857005</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000083" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000084" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">41857005</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000085" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000086" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000087" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000088" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">10000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="F_000089" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000090" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">10000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000091" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000092" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">10000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000093" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000094" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000095" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000096" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">64891735</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="F_000097" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000098" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">62528507</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000099" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000100" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">62528507</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000101" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000102" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000103" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000104" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">10000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="F_000105" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000106" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">10000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000107" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000108" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">10000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000109" contextRef="C_0001703647_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000110" contextRef="C_0001703647_20181231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000111" contextRef="C_0001703647_20191231" decimals="INF" unitRef="U_xbrlishares">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000112" contextRef="C_0001703647_20181231" decimals="INF" unitRef="U_xbrlishares">165000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000113" contextRef="C_0001703647_20191231" decimals="INF" unitRef="U_xbrlishares">30844507</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000114" contextRef="C_0001703647_20181231" decimals="INF" unitRef="U_xbrlishares">2084710</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000115" contextRef="C_0001703647_20191231" decimals="INF" unitRef="U_xbrlishares">30844507</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000116" contextRef="C_0001703647_20181231" decimals="INF" unitRef="U_xbrlishares">2084710</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000117" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">28947000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RoyaltyExpense id="F_000118" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">16000000</us-gaap:RoyaltyExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000119" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">18784000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000120" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">11880000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000121" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">11966000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000122" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">14838000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000123" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">7064000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000124" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">4340000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000125" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">49622000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000126" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">18944000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000127" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">16306000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000128" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-20675000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000129" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-18944000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000130" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-16306000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestIncomeExpenseNet id="F_000131" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1784000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestIncomeExpenseNet id="F_000132" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-106000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestIncomeExpenseNet id="F_000133" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-174000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="F_000134" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-269000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="F_000135" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-3749000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:RealizedInvestmentGainsLosses id="F_000136" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">138000</us-gaap:RealizedInvestmentGainsLosses>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="F_000137" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="F_000138" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">151000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="F_000139" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-8000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:NetIncomeLoss id="F_000140" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-18746000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000141" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-19168000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000142" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-20237000</us-gaap:NetIncomeLoss>
  <us-gaap:TemporaryEquityDividendsAdjustment id="F_000143" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1054000</us-gaap:TemporaryEquityDividendsAdjustment>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000144" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-19800000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000145" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-19168000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000146" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-20237000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000147" contextRef="C_0001703647_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-2.29</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000148" contextRef="C_0001703647_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-12.53</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000149" contextRef="C_0001703647_20170101_20171231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-28.79</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000150" contextRef="C_0001703647_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">8649245</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000151" contextRef="C_0001703647_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">1530218</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000152" contextRef="C_0001703647_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">702918</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000153" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">54000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="F_000154" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">54000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000155" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-18692000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000156" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-19168000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000157" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-20237000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:CommonStockSharesOutstanding id="F_000158" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231" decimals="INF" unitRef="U_xbrlishares">1658459</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000159" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000160" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20161231" decimals="-3" unitRef="U_iso4217USD">18000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000161" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20161231" decimals="-3" unitRef="U_iso4217USD">-9683000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000162" contextRef="C_0001703647_20161231" decimals="-3" unitRef="U_iso4217USD">-9663000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross id="F_000163" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">230974</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000164" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">91000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000165" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">91000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <freq:StockIssuedDuringPeriodSharesIssuedForPatentLicense id="F_000166" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">64802</freq:StockIssuedDuringPeriodSharesIssuedForPatentLicense>
  <freq:StockIssuedDuringPeriodValueIssuedForPatentLicense id="F_000167" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">140000</freq:StockIssuedDuringPeriodValueIssuedForPatentLicense>
  <freq:StockIssuedDuringPeriodValueIssuedForPatentLicense id="F_000168" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">140000</freq:StockIssuedDuringPeriodValueIssuedForPatentLicense>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000169" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000170" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <freq:TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue id="F_000171" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">37538421</freq:TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue>
  <freq:TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue id="F_000172" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">27951000</freq:TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000173" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20170101_20171231" decimals="INF" unitRef="U_xbrlishares">24990086</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000174" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">18743000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:NetIncomeLoss id="F_000175" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-20237000</us-gaap:NetIncomeLoss>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000176" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20171231" decimals="INF" unitRef="U_xbrlishares">62528507</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests id="F_000177" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20171231" decimals="-3" unitRef="U_iso4217USD">46694000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
  <us-gaap:CommonStockSharesOutstanding id="F_000178" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="INF" unitRef="U_xbrlishares">1954235</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000179" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000180" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231" decimals="-3" unitRef="U_iso4217USD">276000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000181" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231" decimals="-3" unitRef="U_iso4217USD">-29920000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000182" contextRef="C_0001703647_20171231" decimals="-3" unitRef="U_iso4217USD">-29642000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000183" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">455000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000184" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">455000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000185" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">126253</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000186" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">73000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000187" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">73000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross id="F_000188" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">7423</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
  <freq:StockRepurchaseDuringPeriodSharesRestrictedStock id="F_000189" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">3201</freq:StockRepurchaseDuringPeriodSharesRestrictedStock>
  <freq:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="F_000190" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">10000</freq:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="F_000191" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <freq:TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue id="F_000192" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">36017542</freq:TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue>
  <freq:TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue id="F_000193" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">32849000</freq:TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000194" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">5839463</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000195" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">5375000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <freq:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="F_000196" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">10000</freq:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="F_000197" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">9000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance id="F_000198" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">3773000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
  <us-gaap:NetIncomeLoss id="F_000199" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-19168000</us-gaap:NetIncomeLoss>
  <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests id="F_000200" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">38224000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
  <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests id="F_000201" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">9000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
  <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests id="F_000202" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">46694000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
  <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests id="F_000203" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
  <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests id="F_000204" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20181231" decimals="-3" unitRef="U_iso4217USD">3773000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
  <us-gaap:CommonStockSharesOutstanding id="F_000205" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">2084710</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000206" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000207" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" unitRef="U_iso4217USD">804000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000208" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" unitRef="U_iso4217USD">-49088000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000209" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3609000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000210" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3609000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000211" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">357170</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000212" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000213" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">365000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000214" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">366000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <freq:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="F_000215" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">288991</freq:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="F_000216" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">266000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <freq:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="F_000217" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">39492960</freq:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="F_000218" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">61687000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <freq:ConvertiblePreferredStockAccretionOfDividend id="F_000219" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1054000</freq:ConvertiblePreferredStockAccretionOfDividend>
  <freq:ConvertiblePreferredStockAccretionOfDividend id="F_000220" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1054000</freq:ConvertiblePreferredStockAccretionOfDividend>
  <us-gaap:TemporaryEquityAccretionOfDividends id="F_000221" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1054000</us-gaap:TemporaryEquityAccretionOfDividends>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000222" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">6325000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000223" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000224" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">79690000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000225" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">79696000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <freq:TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000226" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-39492960</freq:TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000227" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-62741000</freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000228" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-42145996</freq:TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000229" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-38490000</freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000230" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-10000</freq:TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000231" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-9000</freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000232" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-62528507</freq:TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000233" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-46694000</freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000234" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-10000</freq:TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000235" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-8000</freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000236" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-3773000</freq:TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000237" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">22077627</freq:StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000238" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">22000</freq:StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000239" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">151693000</freq:StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <freq:StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering id="F_000240" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">151715000</freq:StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax id="F_000241" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">54000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax id="F_000242" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">54000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:NetIncomeLoss id="F_000243" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-18746000</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockSharesOutstanding id="F_000244" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">30844507</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000245" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">31000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000246" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" unitRef="U_iso4217USD">236161000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000247" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" unitRef="U_iso4217USD">54000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000248" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" unitRef="U_iso4217USD">-68888000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000249" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">203000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000250" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">302000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProfitLoss id="F_000251" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-18746000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000252" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-19168000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000253" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-20237000</us-gaap:ProfitLoss>
  <us-gaap:ShareBasedCompensation id="F_000254" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3609000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000255" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">455000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000256" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">91000</us-gaap:ShareBasedCompensation>
  <us-gaap:Depreciation id="F_000257" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">813000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="F_000258" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">654000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="F_000259" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">531000</us-gaap:Depreciation>
  <us-gaap:PaidInKindInterest id="F_000260" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">106000</us-gaap:PaidInKindInterest>
  <us-gaap:PaidInKindInterest id="F_000261" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">174000</us-gaap:PaidInKindInterest>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="F_000262" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">54000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="F_000263" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">140000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <freq:DeferredLeaseIncentives id="F_000264" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">160000</freq:DeferredLeaseIncentives>
  <freq:DeferredLeaseIncentives id="F_000265" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">159000</freq:DeferredLeaseIncentives>
  <freq:DeferredLeaseIncentives id="F_000266" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-662000</freq:DeferredLeaseIncentives>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000267" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3253000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000268" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">727000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000269" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-142000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000270" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-644000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000271" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">869000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000272" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-231000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="F_000273" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">51052000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="F_000274" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1490000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="F_000275" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">677000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="F_000276" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">365000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000277" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">34215000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000278" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-17024000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000279" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-14614000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000280" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1064000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000281" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">436000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000282" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">1863000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <freq:PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt id="F_000283" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">282618000</freq:PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt id="F_000284" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">265421000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000285" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-18261000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000286" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-436000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000287" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-1863000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromMinorityShareholders id="F_000288" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">3773000</us-gaap:ProceedsFromMinorityShareholders>
  <us-gaap:ProceedsFromConvertibleDebt id="F_000289" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">5000000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000290" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">27951000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000291" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000292" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">266000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000293" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">32849000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000294" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">9000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000295" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">61687000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000296" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">80062000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000297" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">73000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000298" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000299" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">142015000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000300" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">41712000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000301" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">27978000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000302" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">157969000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000303" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">24252000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000304" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">11501000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000305" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">42189000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000306" contextRef="C_0001703647_20171231" decimals="-3" unitRef="U_iso4217USD">17937000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000307" contextRef="C_0001703647_20161231" decimals="-3" unitRef="U_iso4217USD">6436000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations id="F_000308" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">200158000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
  <us-gaap:IncomeTaxesPaidNet id="F_000309" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">94000</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 id="F_000310" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">5375000</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 id="F_000311" contextRef="C_0001703647_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">18743000</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <freq:NonCashDividendOnCumulativeConvertiblePreferredStock id="F_000312" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1054000</freq:NonCashDividendOnCumulativeConvertiblePreferredStock>
  <us-gaap:ConversionOfStockAmountIssued1 id="F_000313" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">151715000</us-gaap:ConversionOfStockAmountIssued1>
  <dei:DocumentsIncorporatedByReferenceTextBlock id="F_000314" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:3pt;margin-top:3pt;text-indent:4.86%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Portions of the Proxy Statement for the registrant&amp;#8217;s&amp;#160;2020&amp;#160;Annual Meeting of Stockholders are incorporated by reference into Part&amp;#160;III of this Annual Report on Form 10-K.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="F_000315" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. Organization and basis of presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Frequency Therapeutics, Inc., together with its wholly owned subsidiaries, Frequency Therapeutics, PTY, LTD, Frequency Therapeutics Securities Corporation and Frequency Therapeutics Japan KK (Frequency Japan) (the Company), headquartered in Woburn, Massachusetts, was incorporated in November 2014 as a Delaware corporation. The Company is a clinical-stage biotechnology company focused on harnessing the body&amp;#8217;s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 20, 2019, the Company effected a 1-for-6.7355 reverse stock split of its common stock. The par value of the common stock was not adjusted as a result of the reverse stock split and the authorized capital was amended to 100,000,000 shares of common stock and 148,724,922 shares of $0.001 par value preferred stock (the Preferred Stock). The reverse stock split resulted in an adjustment to the Series A Convertible  Preferred Stock (Series A Preferred), Series B Convertible Preferred Stock (Series B Preferred) and Series C Convertible Preferred Stock (Series C Preferred) conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. Shares of common stock underlying outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2019, the Company completed the initial public offering of its common stock (the &amp;#8220;IPO&amp;#8221;). In the IPO, the Company issued and sold 6,325,000 shares of its common stock at a price to the public of $14.00 per share, inclusive of the underwriters&amp;#8217; exercise in part of their over-allotment option. The Company received approximately $79.7 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. In connection with the IPO, on October 7, 2019 all Preferred Stock and the preferred stock of Frequency Japan converted into 22,077,627 shares of common stock and all outstanding shares of Series A-1 Preferred Stock and B-1 Preferred Stock were forfeited.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Uncertainties &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&amp;#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Liquidity and capital resources &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has funded its operations primarily with proceeds from the sale of its capital stock, convertible notes and amounts received under a collaboration agreement. The Company has incurred recurring losses since its inception. In addition, as of December&amp;#160;31, 2019, the Company had an accumulated deficit of ($68,888). The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&amp;#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. The Company believes that existing resources will be sufficient to fund planned operations for at least 12 months from the date the financial statements were available to be issued.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock id="F_000316" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. Summary of significant accounting policies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB &lt;font style="font-style:italic;"&gt;Accounting Standards&lt;/font&gt; Codification (ASC). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Principles of consolidation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics PTY, LTD and Frequency Japan (majority owned at December 31, 2018). All intercompany transactions and balances have been eliminated. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the Company&amp;#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&amp;#8217;s management evaluates its estimates, which include but are not limited to management&amp;#8217;s judgments of accrued expenses, revenue, fair value of common stock, valuation of share-based awards and income taxes. Actual results could differ from those estimates. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company utilizes significant estimates and assumptions in determining the fair value of its common stock in periods prior to the IPO. The Company had utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation (the Practice Aid), to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&amp;#8217;s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&amp;#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Comprehensive income (loss) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive loss includes net loss as well as other changes in stockholders&amp;#8217; equity that result from transactions and economic events other than those with stockholders which for the year ended December 31, 2019 consists of unrealized gain on marketable securities.&amp;nbsp;&amp;nbsp;There were no elements of comprehensive loss for the years ended December 31, 2018 and 2017.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segment information &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&amp;#8217;s chief operating decision-maker, the Company&amp;#8217;s chief executive officer, views the Company&amp;#8217;s operations and manages its business as a single operating segment, which is in the business of discovering and developing small molecule drugs that activate progenitor cells within the body to create healthy tissue. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Foreign currency &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All periods presented are reported in US dollars. The functional currency for entities outside the United States is the US dollar. Realized and unrealized gains and losses from foreign currency transactions are reflected in the consolidated statements of operations as other expense. During the years ended December&amp;#160;31, 2019, 2018 and 2017 the Company recorded $7, $151 and ($8) of foreign currency exchange gains (losses), respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with an original maturity of six months or less at acquisition to be cash equivalents which are stated at fair market value. Cash and cash equivalents at December&amp;#160;31, 2019 and 2018 consists entirely of cash held in banks and money market funds. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;"&gt;Short-term marketable debt securities&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company&amp;#8217;s investment policy. Short-term marketable investment mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders&amp;#8217; equity (deficit) until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, together with interest on securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investment are reflected as a component of other income (expense).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term marketable securities at December 31, 2019 consist of investment in U.S. Treasury Securities.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;"&gt;Concentration of credit risk and off-balance sheet risk&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instrument that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of U.S. Treasury securities with maturities of less than twelve months. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has no significant off-balance sheet such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Significant suppliers &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a single manufacturer of its product candidates for use in clinical trials. The Company would be adversely affected by a significant interruption in the supply of product for use in clinical programs. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair value measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic&amp;#160;820, &lt;font style="font-style:italic;"&gt;Fair Value Measurement&lt;/font&gt; (ASC&amp;#160;820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.86%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.86%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.86%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:9.38%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Inputs other than quoted prices included within Level&amp;#160;1 that are either directly or indirectly observable, &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;such as quoted market prices, interest rates and yield curves.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.86%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:9.38%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&amp;#160;3. A financial instrument&amp;#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying values of other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of lab equipment, computer equipment, furniture and office equipment and leasehold improvements recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of the estimated useful&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;life or lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statements of operations.&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Impairment of long-lived assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December&amp;#160;31, 2019, 2018 and 2017.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and development costs and accruals &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with research institutions, contract research organizations, contract manufacturers and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, pre-clinical and clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Collaborative arrangements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company analyzes its collaborative arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements (&amp;#8220;ASC 808&amp;#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship (e.g., a licensing arrangement) where the contracted party has obtained goods or services that are an output of the Company&amp;#8217;s ordinary activities in exchange for a consideration and therefore within the scope of Topic 606. For those elements of the arrangement that are accounted for pursuant to Topic 606, including those to which Topic 606 is applied by analogy, the Company applies the five-step model described in the Company&amp;#8217;s revenue recognition policy. For elements of collaborative arrangements that are accounted for pursuant to ASC 808, an appropriate and rational recognition method is determined and applied consistently. Reimbursements from the counterparty that are the result of a collaborative relationship with the counterparty, instead of a customer relationship, such as co-development or clinical activities, are recorded as a reduction to research and development expense as the services are performed. Similarly, amounts that are owed to a collaboration partner related to the co-development clinical activities are recognized as research and development expense. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into out-licensing agreements that are within the scope of Topic 606. The terms of such out-license agreements include licenses to functional intellectual property (IP), given the functionality of the intellectual property is not expected to change substantially as a result of the licensor&amp;#8217;s ongoing activities. Such arrangements typically include payment of one or more of the following: non-refundable up-front license fees; reimbursement of certain costs; development and regulatory milestone payments and milestone payments based on the level of sales; and royalties on net sales of licensed products. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers the economic and regulatory characteristics of the licensed IP, research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace to determine if it has standalone value at the inception of the licensing arrangement, which would make the license distinct. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of any additional good or services promised in the contract, whether the value of the license is dependent on the remaining goods and services, whether there are other vendors that could provide the remaining promise, and whether the license is separately identifiable from the remaining good and services. For licenses that are combined with other goods and services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue is allocated to the licensed IP on a relative standalone selling price basis and, for functional IP, is recognized at a point when the licensed IP is made available for the customer&amp;#8217;s use and benefit, which generally occurs at the inception of the arrangement. However, in cases, where the functionality of the IP is expected to substantively change as a result of activities of the Company that do not transfer additional promised goods or services, or in cases, where there is an expectation that the Company will undertake activities to change the standalone functionality of the IP and the customer is contractually or practically required to use the latest version of the IP, revenue for the license to functional IP is recognized over time. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into a collaboration arrangement with Astellas Pharma Inc. (&amp;#8220;Astellas&amp;#8221;), as further described in Note 15 of notes to unaudited consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Revenue recognition &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for contracts with customers in accordance with Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;), Topic 606, Revenue from Contracts with Customers (&amp;#8220;Topic 606&amp;#8221;), including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. The Company&amp;#8217;s disclosure within the below sections or elsewhere within these consolidated financial statements reflects the Company&amp;#8217;s accounting policies in compliance with this new standard.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under Topic 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i)&amp;#160;identify the contract(s) with a customer; (ii)&amp;#160;identify the performance obligations in the contract; (iii)&amp;#160;determine the transaction price, including variable consideration, if any; (iv)&amp;#160;allocate the transaction price to the performance obligations in the contract; and (v)&amp;#160;recognize revenue when (or as) the entity satisfies its performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a) a good or service (or bundle of goods and services) that is distinct, or (b) a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&amp;#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&amp;#160;the entity&amp;#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the &amp;#8220;customer&amp;#8221; in this type of arrangement) and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, the Company identifies all performance obligations, which may include, for example, a license to IP and know-how, research and development activities, and/or manufacturing services. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the estimated variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestone payments at the later of (i)&amp;#160;when the related sales occur, or (ii)&amp;#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company&amp;#8217;s customer with a significant benefit of financing the transfer of goods and services. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time.&amp;nbsp;&amp;nbsp;For performance obligations satisfied over time, the Company measures progress toward completion of its performance obligations using an input method based on the Company&amp;#8217;s efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Patent costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-based compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic&amp;#160;718, &lt;font style="font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation&lt;/font&gt; (ASC&amp;#160;718). ASC&amp;#160;718 requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company adopted FASB Accounting Standards Update (ASU) 2016-09 which identifies areas for simplification of several areas of share-based payment transactions. The Company retroactively applied the mark to market approach on vesting to non-employee grants and the impact on the consolidated financial statements was not material and as such, the Company will treat non-employee grants the same as employee grants. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a)&amp;#160;the expected stock price volatility, (b)&amp;#160;the expected term of the award, (c)&amp;#160;the risk-free interest rate and (d)&amp;#160;expected dividends. Due to the lack of sufficient company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&amp;#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There are significant judgments and estimates inherent in the determination of the fair value of the Company&amp;#8217;s common stock prior to the IPO. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expenses the fair value of its share-based compensation awards to employees and non-employees on a straight-line basis over the requisite service period, which is generally the vesting period. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Non-controlling interest &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2018, the Company accounted for shares of preferred stock issued in Frequency Japan as a non-controlling interest in the mezzanine section of the consolidated balance sheets. The value ascribed to the non-controlling interest was the liquidation preference of the preferred stock in Frequency Japan as the holders of such shares do not share in any profits or losses of the subsidiary. &lt;font style="color:#000000;"&gt;In connection with the IPO, all preferred stock of Frequency Japan converted into shares of the Company&amp;#8217;s common stock, see Note 1.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, &lt;font style="font-style:italic;"&gt;Income Taxes&lt;/font&gt; (ASC 740) which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&amp;#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December&amp;#160;31, 2019 and 2018, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 13). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net loss per share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&amp;#160;31, 2019, 2018 and 2017 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses are not allocated to such participating securities. In periods where the Company reported a net loss attributable to common stockholders, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December&amp;#160;31, 2019, 2018 and 2017.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.92%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except share and per share amounts)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,168&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,237&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average shares of common stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; outstanding-basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,649,245&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,530,218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;702,918&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributed to common&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; stockholders-basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12.53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28.79&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.82%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted Common Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,366&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;345,608&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;637,746&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series C Preferred (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,172,676&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B Preferred (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,759,079&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,214,387&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A Preferred (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,070,574&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,283,425&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,283,425&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion of Frequency Japan preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;513,047&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;673,605&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding stock options (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,968,672&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,089,334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;985,521&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,554,414&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,606,359&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,906,692&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently adopted accounting pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2014, the FASB issued ASU 2014-09, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;. The standard will apply one comprehensive revenue recognition model across all contracts, entities, and sectors. The core principle of the new standard is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Once effective, ASU 2014-09 will replace most of the existing revenue recognition requirements in U.S. GAAP. The FASB also issued ASU 2015-14, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&lt;/font&gt;, which deferred the effective date of the standard one year. As a result, the new standard is effective for annual reporting periods beginning after December&amp;#160;15, 2018, including interim periods within the reporting period. Early adoption is permitted. The Company early adopted ASU 2014-09 effective January&amp;#160;1, 2018, and its adoption had no impact on the Company&amp;#8217;s consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2016, the FASB issued ASU No.&amp;#160;2016-15, &lt;font style="font-style:italic;"&gt;Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt; (ASU No.&amp;#160;2016-15). This guidance addresses the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. The standard is effective for annual periods beginning after December&amp;#160;15, 2017 and for interim periods within those fiscal years. Early adoption is permitted. The Company adopted this standard effective January&amp;#160;1, 2018. The adoption of ASU No.&amp;#160;2016-15 did not have a material impact on the Company&amp;#8217;s consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2017, the FASB issued ASU No.&amp;#160;2017-09, &lt;font style="font-style:italic;"&gt;Compensation-Stock Compensation (Topic&amp;#160;718): Scope of Modification Accounting&lt;/font&gt; (ASU No.&amp;#160;2017-09). This update clarifies the changes to terms or conditions of a share-based payment award that require an entity to apply modification accounting. ASU No.&amp;#160;2017-09 is effective for annual reporting periods, and interim periods therein, beginning after December&amp;#160;15, 2017. Early application is permitted, and prospective application is required. The Company adopted this standard effective January&amp;#160;1, 2018. The adoption of this guidance did not have a material impact on the Company&amp;#8217;s consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently issued accounting pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &amp;#8220;emerging growth company&amp;#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued &lt;font style="font-style:italic;"&gt;ASU No. 2016-02, Leases&lt;/font&gt;, which is intended to increase transparency and comparability among companies that enter into leasing arrangements. The new standard establishes a right-of-use model that requires a lessee to record a right-of-use asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either financing or operating, with classification affecting the pattern of expense recognition. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. In July 2018, the FASB &lt;font style="font-style:italic;"&gt;issued ASU No. 2018-11,&lt;/font&gt; with targeted improvements to the guidance including an additional transition method, which allows companies to apply the provisions of the new leasing standard as of January 1, 2020, without adjusting the comparative periods presented by recognizing a cumulative-effect adjustment to the opening balance of retained earnings.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company plans to elect early adoption of this standard effective January 1, 2020 and elect the new transition method approved by the FASB. The Company also plans to elect the package of practical expedients intended to ease transition whereby the Company need not assess (1) whether any expired or existing contracts are or contain leases, (2) the lease classification for any expired or existing leases and (3) initial direct costs for any existing leases. Furthermore, the Company will elect the practical expedient to combine non-lease components and lease components. As the Company finalizes its adoption processes, it estimates the adoption of the ASU in the first quarter of 2020 will result in the recognition of a right-of-use asset and related lease liability related to the lease for our Woburn Massachusetts facility in the range of approximately $1,000 to $2,000 with an estimated immaterial effect to the retained earnings and the consolidated statement of operations. As disclosed in Note 16, the Company has entered into a lease for a facility in Lexington Massachusetts which has an estimated commencement date of December 1, 2020. In accordance with ASU No. 2016-02, the Company will recognize a right-of-use asset and related lease liability at such time.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000317" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. Fair value measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s financial assets measures at fair value on a recurring basis by level within the fair value hierarchy at December 31, 2019 are summarized as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Market&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Hierarchy&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gain&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,131&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,119&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Government treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,131&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,197&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,262&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,316&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had no financial assets subject to fair value reporting requirements at December 31, 2018.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts reflected in the consolidated balance sheet for prepaid expenses and other current assets, accounts payable and accrued expenses and other liabilities are shown at their historical values which approximate their fair values.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <freq:PrepaidExpensesAndOtherCurrentAssetsTextBlock id="F_000318" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. Prepaid expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rent and deposits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;801&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;428&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant receivable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;805&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;161&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Insurance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,132&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;199&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;159&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</freq:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="F_000319" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. Property and equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment include the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,846&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,109&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;245&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,419&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,406&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;306&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,828&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,764&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,066&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,253&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,762&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,511&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized $813 and $654 of depreciation expense for the years ended December&amp;#160;31, 2019 and 2018, respectively. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock id="F_000320" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. Accrued expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll and employee related expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,686&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,034&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;435&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;322&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Third-party research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;118&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;393&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,239&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,749&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <us-gaap:DebtDisclosureTextBlock id="F_000321" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. Convertible notes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2018, the Company entered into $5,000 of convertible notes with existing shareholders and investors (Series B Notes) with a maturity date of May&amp;#160;31, 2019. The Series B Notes bore interest at a rate of 5% per annum and were automatically convertible into the security issued in the next financing of at least $5,000, excluding the proceeds of the Series B Notes (Qualified Series B Financing) at a conversion price equal to 95% of the per share price paid by investors in such financing. In the event of a sale of the Company, prior to the conversion or repayment of the Series B Notes at maturity, the Series B Notes would have been repaid at an amount equal to one and one-half times the outstanding principal and interest. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October&amp;#160;17, 2018, the Company closed a Qualified Series B Financing and the Series B Notes converted pursuant to their contractual terms. The $5,000 of principal plus $106 of accrued interest were converted into Series B Preferred shares at a 5% discount to the offering price of $0.92 per share resulting in the issuance of 5,839,463 Series B shares and the recognition of a loss on conversion of $269 (see Note 8). For the year ended December&amp;#160;31, 2018, the Company recorded $106 in interest expense on the Series B Notes. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2015 and 2016, the Company entered into $14,285 of convertible notes with investors (Series A Notes) with a maturity date of January&amp;#160;21, 2017, which was extended to April&amp;#160;30, 2017. The Series A Notes bore interest at a rate of 5% per annum and were automatically convertible into the security issued in the next financing in excess of $4,000 (Qualified Series A Financing) at a conversion price equal to 80% of the per share price paid by investors in such financing. If, prior to the Company completing a Qualified Series A Financing, the Company received funds in excess of $15,000 pursuant to a non-equity financing, grant or other similar event, then the Company would have obtained an outside valuation and thereafter the Series A Notes would have automatically converted into shares of common stock of the Company, at a 20% discount to such valuation. In the event of a sale of the Company, prior to conversion or repayment of the Series A Notes at maturity, the Series A Notes would have been repaid at an amount equal to three times the outstanding principal and interest. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March&amp;#160;30, 2017, the Company closed a Qualified Series A Financing and the Series A Notes converted pursuant to their contractual terms. The $14,285 of principal plus $709 of accrued interest were converted into Series A Preferred shares at a 20% discount to the offering price of $0.75 per share resulting in the issuance of 24,990,086 Series A Preferred shares and the recognition of a loss on conversion of $3,749 (see Note 8). For the year ended December&amp;#160;31, 2017, the Company recorded $174 in interest expense on the Series A Notes. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Series A Notes and Series B Notes did not contain an optional conversion feature. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluated all the settlement features included within the Series A Notes and Series B Notes, noting that none of the features was considered to be predominant or met the definition of a derivative under FASB ASC Topic 815, &lt;font style="font-style:italic;"&gt;Derivatives and Hedging&lt;/font&gt; with the exception of the repayment premium in the event of a Company sale. In such event the noteholders were entitled to receive an amount equal to three times the outstanding principal, in the case of Series A Notes, and one and one half and three times the outstanding principal, in the case of the Series B Notes, plus all accrued and unpaid interest. Based on the qualitative and quantitative considerations, management determined that the fair value of the derivative was de minimis as of December&amp;#160;31, 2017. &lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
  <freq:TemporaryEquityTextBlock id="F_000322" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. Convertible preferred stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2018, the Company had authorized 114,208,722 shares of Preferred Stock and had designated 64,891,735 shares as Series A Preferred, 10,000 shares as Series A-1 Preferred Stock, 49,296,987 shares as Series B Preferred and 10,000 shares as Series B-1 Preferred Stock. Since the Preferred Stock was redeemable upon a liquidation event, which is not considered to be within the Company&amp;#8217;s control, it has been classified in temporary equity on the accompanying consolidated balance sheet as of December 31, 2018. The carrying value of the Preferred Stock was the proceeds received less issuance costs. In October 2019, in connection with the IPO, all shares of Preferred Stock were automatically converted into common stock.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Issuances of preferred stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March&amp;#160;30, 2017, the Company converted $14,285 of Series A Notes plus accrued interest of $709 into 24,990,086 shares of Series A Preferred at a 20% discount to the offering price of $0.75 per share. The Company also issued 9,783,522 shares of Series A Preferred for proceeds of $7,338 on the same date. Additional issuances of Series A Preferred took place in April, May, August and December of 2017 for an additional aggregate issuance of 27,754,899 shares of Series A Preferred shares for proceeds of $20,816. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company incurred $203 of share issuance costs in connection with the issuance of the Series A Preferred described above which was recorded as a reduction in the proceeds received and the carrying value. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October&amp;#160;17, 2018, the Company converted $5,000 of Series B Notes plus accrued interest of $106 into 5,839,463 shares of Series B Preferred at a 5% discount to the offering price of $0.92 per share. The Company also issued 7,544,029 shares of Series B Preferred for proceeds of $6,944 on the same date. Additional issuances of Series B Preferred took place in November and December of 2018 for an additional aggregate issuance of 28,473,513 shares of Series B Preferred shares for proceeds of $26,208. The Company also issued 288,991 shares of Series B Preferred in January and February 2019 for proceeds of $266. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company incurred $302 of share issuance costs in connection with Series B Preferred described above which was recorded as a reduction in the proceeds received and the carrying value. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October&amp;#160;17, 2018, the Company issued 10,000 shares of Series A-1 Preferred Stock (Series A-1 Preferred) at a price of $0.75 per share for proceeds of $8. The Company also issued 10,000 shares of Series B-1 Preferred Stock (Series B-1 Preferred) at a price of $0.92 per share for proceeds of $9 on the same date. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has evaluated the tranched nature of the issuance of Series A Preferred and Series B Preferred as well as the rights, preferences, and privileges of such shares and has concluded that there were no freestanding derivative instruments or any embedded derivatives requiring bifurcation. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July&amp;#160;17, 2019, the Company authorized and issued 39,492,960 shares of Series&amp;#160;C Preferred for net proceeds of $61,687. The Company has evaluated the rights, preferences and privileges of the Series C Preferred and has concluded that there were no freestanding derivative investments or any embedded derivatives requiring bifurcation. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;</freq:TemporaryEquityTextBlock>
  <us-gaap:MinorityInterestDisclosureTextBlock id="F_000323" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9. Non-controlling Interest&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2018, the Company issued shares of preferred stock in its subsidiary, Frequency Japan, to a Japanese investor. The Company has consolidated Frequency Japan in the consolidated financial statements and has recorded the proceeds received for the sale of the preferred stock in Frequency Japan as a non-controlling interest in the temporary equity section of the consolidated balance sheets as of December 31, 2018. The liquidation preference of the shares of preferred stock equaled the purchase price of such shares. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Frequency Japan preferred stock held by such investor was convertible, at the option of the holder, into 673,605 shares of Company common stock, adjustable for certain dilutive events, upon an initial public offering of Company common stock, a Company liquidation or upon a 70% vote of the holders of the Preferred Stock. The preferred shares also had a liquidation preference equal to the amount paid for the shares. The Company had the option to acquire the preferred shares of Frequency Japan under certain circumstances and the holder of such preferred shares had the right to require the Company to purchase such shares under certain circumstances, primarily a merger or liquidation. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with this sale of the preferred stock in Frequency Japan, FT-FJ Investment, LLC (FT-FJ), a Delaware limited liability company controlled by the Company, purchased 10,000 shares of the Company&amp;#8217;s Series A-1 Preferred Stock and 10,000 shares of the Company&amp;#8217;s Series B-1 Preferred Stock. FT-FJ also granted to the Japanese investor an irrevocable proxy to vote the shares of Series A-1 and Series B-1 Preferred Stock held by FT-FJ. Each share of Series A-1 Preferred had 236 times the voting power of one share of common stock and each share of Series B-1 Preferred Stock has 217 times the voting power of one share of common stock. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 20, 2019, the Company, Frequency Japan, the Japanese investor, and FT-FJ entered into an agreement pursuant to which, contingent upon the closing of an initial public offering of the Company&amp;#8217;s common stock: (i) the Japanese investor agreed to convert its shares of preferred stock held in Frequency Japan and to terminate its proxy over the shares of Series A-1 and B-1 Preferred Stock held by FT-FJ and (ii) FT-FJ agreed to forfeit its shares of Series A-1 and Series B-1 Preferred Stock. The shares were converted into common stock and the Series A-1 and B-1 preferred shares were forfeited in conjunction with the IPO.&lt;/p&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="F_000324" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;10. Stockholders&amp;#8217; deficit &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Common stock &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has authorized 100,000,000 shares of $0.001 par value common stock of which 30,844,507 were issued and outstanding as of December 31, 2019. Common shares are voting, and dividends may be paid when, as and if declared by the Board of Directors.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 20, 2019, the Company effected a 1-for-6.7355 reverse stock split of its common stock. The par value of the common stock was not adjusted as a result of the reverse stock split and the authorized capital was amended to 100,000,000 shares of common stock and 148,724,922 shares of $0.001 par value preferred stock. The reverse stock split resulted in an adjustment to the Series A Preferred, Series B Preferred and Series C Preferred conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has reserved the following shares of common stock for future issuance as of December 31, 2019, 2018 and 2017:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A Preferred conversion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,283,425&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,283,425&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion of Frequency Japan preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;673,605&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B Preferred conversion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,214,387&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,968,672&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,089,334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;985,521&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for future grant under stock option plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,859,654&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,028,096&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;646,871&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,828,326&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,288,847&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,915,817&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000325" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;11. Stock-based compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On November&amp;#160;13, 2014, the Company adopted the 2014 Stock Incentive Plan (2014 Plan). All of the Company&amp;#8217;s employees, officers, directors, and consultants are eligible to be granted options to purchase common shares and restricted stock under the terms of the 2014 Plan. The Company reserved an aggregate of 8,550,415 shares of common stock for issuance under the 2014 Plan. As of December&amp;#160;31, 2019, there were no shares of common stock available for future grants under the 2014 Plan.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 17, 2019, the Company&amp;#8217;s board of directors and on September 19, 2019, its stockholders approved and adopted the 2019 Incentive Award Plan (&amp;#8220;the &amp;#8220;2019 Plan&amp;#8221;) which became effective on the day prior to the IPO.&amp;nbsp;&amp;nbsp;Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock and cash-based awards to individuals who are then employees, officers, directors or consultants of the Company, and employees and consultants of the Company&amp;#8217;s subsidiaries.&amp;nbsp;&amp;nbsp;A total of 3,100,000 shares of common stock were approved to be initially reserved for issuance under the 2019 plan.&amp;nbsp;&amp;nbsp;The number of shares under the 2014 Plan subject to outstanding awards as of the effective date of the 2019 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2019 Plan.&amp;nbsp;&amp;nbsp;In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company&amp;#8217;s common stock on December 31, of the preceding calendar year or such lesser amount as determined by the Company&amp;#8217;s board of directors.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All stock option grants are non-statutory stock options except option grants to employees (including officers and directors) intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Incentive stock options may not be granted at less than the fair market value of the Company&amp;#8217;s common stock on the date of grant, as determined in good faith by the Board of Directors at its sole discretion. Nonqualified stock options may be granted at an exercise price established by the Board of Directors at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Vesting periods are generally four years and are determined by the Board of Directors. Stock options become exercisable as they vest. Options granted under the 2014 Plan and the 2019 Plan expire no more than ten years from the date of grant. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock options &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;exercise&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;exercise&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019 Plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014 Plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;985,520&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.54&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,436,734&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.67&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(126,253&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.54&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(206,667&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.54&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,089,334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.61&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,247,338&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,015,381&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(357,170&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.02&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,211&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,247,338&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,287&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,721,334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.85&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,051&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,433&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;174&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,866,700&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.71&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,034&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options unvested as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,197,905&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,113&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,854,634&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock option valuation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions that the Company used to determine the grant-date fair value of stock options granted to&lt;font style="font-weight:bold;font-style:italic;"&gt; &lt;/font&gt;employees and directors were as follows, presented on a weighted average basis: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.1%-2.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;% &lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.0-7.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.14%;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Risk-Fee Interest Rate&lt;font style="font-style:normal;"&gt;: The Company based the risk-free interest rate over the expected term of the options based on the constant maturity of U.S. Treasury securities with similar maturities as of the date of the grant.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected Term&lt;font style="font-style:normal;"&gt;:&amp;nbsp;&amp;nbsp;The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected Volatility&lt;font style="font-style:normal;"&gt;: The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock.&amp;nbsp;&amp;nbsp;The Company will continue to apply this process until a sufficient amount of historical information regarding volatility of its own stock price options becomes available.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected Dividend Yield&lt;font style="font-style:normal;"&gt;: The Company has not paid and does not anticipate paying any dividends in the near future.&amp;nbsp;&amp;nbsp;Therefore, the expected dividend yield was zero.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&amp;#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&amp;#8217;s common stock. During the years ended December&amp;#160;31, 2019 and 2018, 357,170 and 126,253 shares were exercised, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2019 and 2018 was $5,896 and $149 respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average grant date fair value of options granted to employees during the years ended December&amp;#160;31, 2019, 2018 and 2017 was $4.05, $0.47 and $.041, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The total grant date fair value of options vested during the years ended December&amp;#160;31, 2019 and 2018 was $2,990 and $244, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted common stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company issued common stock to founders, employees and advisors which was subject to vesting over four years. If any of these individuals ceased to be employed or to provide services to the Company prior to vesting, the Company had the right to repurchase any unvested Common Stock at the price paid by the holder. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the status of restricted common stock as of December&amp;#160;31, 2019 and 2018 is presented below: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,658,459&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,423&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,336&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Repurchased&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,201&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,657,345&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Repurchased&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,657,345&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested during period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;275,243&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,366&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.36&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company repurchased 3,201 shares of restricted stock forfeited by a former employee in 2018. The total value of restricted stock awards that vested during the years ended December&amp;#160;31, 2019 and 2018, based on estimated fair values of the stock underlying the restricted stock awards on the day of vesting was $73 and $81, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-based compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense of $3,609 and $455 for the years ended December&amp;#160;31, 2019 and 2018 respectively, is included in research and development and general and administrative expenses in the Company&amp;#8217;s consolidated statements of operations and comprehensive loss. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019 and 2018, total unrecognized stock-based compensation expense relating to unvested stock options was $13,820 and $717, respectively. This amount is expected to be recognized over a weighted-average period of 2.76 years and 2.76 years, respectively. &lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <freq:EmployeeStockPurchasePlanDisclosureTextBlock id="F_000326" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12. Employee stock purchase plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 20, 2019, the Company&amp;#8217;s board of directors and stockholders approved and adopted the 2019 Employee stock Purchase Plan (the &amp;#8220;ESPP&amp;#8221;) which became effective on the date of the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. A total of 315,000 shares of common stock were approved to be initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first ten-years of the term of the ESPP, beginning with January 1, 2020 and ending with January 1, 2029, by an amount equal to 1% of the outstanding number of shares of the Company&amp;#8217;s common stock on December 31 of the preceding calendar year or such lesser amount as determined by the Company&amp;#8217;s board of directors. No shares were issued under the ESPP at December 31, 2019.&lt;/p&gt;</freq:EmployeeStockPurchasePlanDisclosureTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000327" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;13. Income taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since inception in 2014, the Company has generated cumulative federal and state net operating loss and research and development credit carryforwards for which we have not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within the respective carryforward periods. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019, the Company had federal net operating loss carryforwards of approximately $50,199 and Massachusetts state operating loss carryforwards of approximately $41,242&amp;#160;which may be available to offset future taxable income. The U.S. federal net operating loss carryforwards include $22,400 available to reduce future taxable income through 2037 and approximately $27,779 which do not expire and are available to reduce future taxable income indefinitely. The state net operating loss carryforwards are available to offset future taxable income through 2039. As of December&amp;#160;31, 2019, the Company also had federal and Massachusetts research and development tax credit carryforwards of $701 and $533, respectively, which are available to offset federal and state tax liabilities through 2039 and 2034, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Realization of future tax benefits is dependent on many factors, including the Company&amp;#8217;s ability to generate taxable income within the net operating loss carryforward period. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as provided under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, respectively, as well as similar state provisions. These ownership changes may limit the number of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section&amp;#160;382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has completed several financings and has conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception and has determined that an ownership change did occur in March 2017. Accordingly, utilization of $12,400 of the U.S. net operating loss carryforwards which were incurred prior to March 2017 (pre-ownership change) is limited under Section 382. After the Section 382 limitations, the Company may utilize approximately $10,800 of its pre-ownership change net operating loss carryforwards based upon an annual usage of approximately $1,600 for each of the next five years after the ownership change and approximately $180 for each of the 15 years thereafter. The remaining pre-ownership change net operating losses of approximately $1,600 were written off due to expiration under limitation. The limitation has been determined by first multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate. These carryforwards may be subject to further annual limitations under Section&amp;#160;382 in the event of future changes in ownership.  Additionally, the Company has determined an ownership changed occurred in October of 2019 as a result of the IPO.&amp;nbsp;&amp;nbsp;Accordingly, utilization of approximately $46,123 of the U.S. net operating loss carryforwards incurred prior to October 2019 is also limited under Section 382.&amp;nbsp;&amp;nbsp;The Company has determined it will be able to utilize the entire $46,123 of its pre-ownership change net operating loss carryforwards based upon the limitations calculated from the October 2019 ownership change. These carryforwards may be subject to further annual limitations under Section 382 in the event of future changes in ownership.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December&amp;#160;31, 2019 and 2018 because the Company&amp;#8217;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its cumulative loss position and, as a result, a valuation allowance of approximately $16,204 and $12,229 as of December&amp;#160;31, 2019 and 2018 has been established. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has no unrecognized tax benefits. The Company has not, as yet, conducted a study of its research and development credit carryforwards. Such a study may result in an adjustment to the Company&amp;#8217;s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&amp;#8217;s research and development credits and, if an adjustment were required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheet or consolidated statements of operations if an adjustment were required. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which no interest or penalties were recorded for the years ended December&amp;#160;31, 2019 and 2018. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company files income tax returns in the U.S. and Massachusetts. The statute of limitations for assessment by the Internal Revenue Service and Massachusetts tax authorities remains open for all years since 2014. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state authorities to the extent utilized in a future period. No federal or state tax audits are currently in process. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&amp;#8217;s effective income tax rate for the years ended December&amp;#160;31, 2019, 2018 and 2017 is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impact of federal rate change&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other items&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in deferred tax asset valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s deferred tax assets at December&amp;#160;31, 2019 and 2018 consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,253&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,710&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,138&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangibles&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;358&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;256&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;686&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;496&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;189&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;210&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,229&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,229&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December&amp;#160;22, 2017, the Tax Cuts and Jobs Act was signed into United States law. The Tax Cuts and Jobs Act includes a number of changes to existing tax law, including, among other things, a permanent reduction in the federal corporate income tax rate from a top marginal tax rate of 35% to a flat rate of 21%, effective as of January&amp;#160;1, 2018, as well as a limitation of the deduction for net operating losses to 80% of annual taxable income and elimination of net operating loss carrybacks, in each case, for losses arising in taxable years beginning after December&amp;#160;31, 2017 (though any such net operating losses may be carried forward indefinitely). The federal tax rate change resulted in a reduction in the gross amount of our deferred tax assets and liabilities recorded as of December&amp;#160;31, 2017, and a corresponding reduction in our valuation allowance. As a result, no income tax expense or benefit was recognized as of the enactment date of the Tax Cuts and Jobs Act. &lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <freq:ResearchAndLicenseAgreementsDisclosureTextBlock id="F_000328" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;14. Research and license agreements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Massachusetts Institute of Technology &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2016, the Company entered into an exclusive patent license agreement (MIT License Agreement), with the Massachusetts Institute of Technology, (MIT), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products (Licensed Products) and to develop and perform processes (Licensed Processes) which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. The Company also has the right to grant sublicenses of its rights under the MIT License Agreement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is required to use diligent efforts to develop and commercialize the Licensed Products or Processes, and to make such products or processes reasonably available to the public and to spend certain minimum amounts on research and development of Licensed Products and/or Processes each year until the first commercial sale of a Licensed Product and/or a first commercial performance of a Licensed Process. The Company is also subject to certain development obligations with regards to a first Licensed Product. The Company has satisfied certain obligations related to preclinical studies and the filing of an IND for a first Licensed Product with its development activities related to FX-322. The Company&amp;#8217;s future development obligations are: (i) to commence a Phase II clinical trial for such Product, (ii) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product within two years of the IND filing for such product, (iii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such product, and (iv) to make a first commercial sale of such Product within 11 years of the IND filing for such product. The Company also has certain development obligations for as second Licensed Product. In the event that the Company has failed to fulfill the development timeline obligation with respect to a second Licensed Product and fail to cure such breach within ninety (90)&amp;#160;days of written notice by MIT, MIT may restrict the licensed field to the prevention and remediation of hearing loss in humans and animals. The Company does not have the right to control prosecution of the in-licensed patent applications, and its rights to enforce the in-licensed patents are subject to certain limitations. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon entering into the MIT License Agreement, the Company paid a $50 license fee payment and issued to MIT shares of our common stock equal to 5% of total then-outstanding capital stock. The Company is required to pay certain annual license maintenance fees which may be credited to running royalties during the same calendar year, if any, and to make potential milestone payments up to $2,900 on each Licensed Product or Licensed Process. In addition, The Company is required to pay a low single-digit royalty on Licensed Products and Licensed Processes and a low-twenties royalty on sublicense revenues. In the year ended December 31, 2019 the Company paid MIT a royalty of $16,000 related to the upfront payment received from Astellas, see Note 15.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The MIT License Agreement will remain effect until the expiration or abandonment of all issued patents and filed patent applications licensed thereunder remain in effect, unless terminated earlier. The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company&amp;#8217;s material breach uncured within ninety (90)&amp;#160;days (or thirty (30)&amp;#160;days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30)&amp;#160;days after MIT&amp;#8217;s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2019, the Company entered into an amendment with MIT, updating the diligence milestones for a second Licensed Product. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;California Institute for Biomedical Research &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2018, the Company entered into a license agreement, (CALIBR License Agreement), with the California Institute for Biomedical Research, (CALIBR), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products (CALIBR Licensed Products) which incorporate the licensed technology for the treatment of multiple sclerosis. The Company also have the right to grant sublicenses of our rights under the CALIBR License Agreement. CALIBR reserves the right to use for itself and the right to grant non-exclusive licenses to other nonprofit or academic institutions, for any internal research and educational purposes. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is required to use commercially reasonable efforts to develop, manufacture, and sell at least one Licensed Product and does not have the right to control prosecution of the in-licensed patent applications, and to enforce the in-licensed patents are subject to certain limitations. The Company is also subject to certain milestone timeline obligations to: (i) submit an IND (or equivalent) for a CALIBR Licensed Product by the 30th month after the effective date of the CALIBR License Agreement, (ii) initiate a Phase II clinical trial (or equivalent) for a CALIBR Licensed Product by the fourth anniversary of the effective date of the CALIBR License Agreement, and (iii) initiate a Phase III clinical trial (or equivalent) for a CALIBR Licensed Product by the sixth anniversary of the effective date of the CALIBR License Agreement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon entering into the CALIBR License Agreement, the Company made a $1,000 license fee payment and are required to make milestone payments up to $26,000 for each Category of CALIBR Licensed Products (Category 1 means any CALIBR Licensed Products containing a compound that modulates any muscarinic receptor and Category 2 means any CALIBR Licensed Products not included in Category 1 that could differentiate oligodendrocyte precursors) . The Company is also required to pay a middle single-digit royalty on CALIBR Licensed Products and a royalty on sublicense revenues ranging from low-teen percentage to 50%. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The CALIBR License Agreement shall continue in effect until expiration of all Company obligations to pay royalties. Royalties shall be payable on a country-by-country and CALIBR Licensed Product-by-CALIBR Licensed Product basis upon the later of (1)&amp;#160;the expiration or abandonment of all valid claims of the licensed patent rights in such country and (2)&amp;#160;ten years from the first commercial sale of each CALIBR Licensed Product. The Company may terminate the CALIBR License Agreement at will upon a 30-day prior written notice. The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90)&amp;#160;days&amp;#8217; prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30)&amp;#160;days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Massachusetts Eye and Ear Infirmary &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2019, the Company entered into an Non-Exclusive Patent License Agreement (MEEI License Agreement) with the Massachusetts Eye and Ear Infirmary (MEEI) under which it received a non-exclusive, non-sublicensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products and to develop and perform processes which incorporate the licensed technology for the treatment or prevention of hearing loss. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is required to use diligent efforts to develop and commercialize the licensed products and MEEI has control over the filing, prosecution, enforcement and defense of any licensed patent rights. The Company is also subject to milestone timeline obligations to dose a first patient in a Phase II trial by December&amp;#160;31, 2020 and to dose a first patient in a Phase III trial by December&amp;#160;31, 2024. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon entering into the MEEI License Agreement, the Company made a $20 license fee payment and is required to pay certain annual license maintenance fees until the first commercial sale and a minimum annual royalty payment after the first commercial sale. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is also required to make milestone payments up to $350 on each product or process which incorporates the licensed patent rights and pay a low single-digit royalty on products and processes that incorporate the licensed patent rights. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The MEEI License Agreement shall remain in effect until all issued patents and filed patent applications within the licensed patent rights have expired or been abandoned, unless terminated earlier. The Company has the right to terminate the MEEI License Agreement at will by giving thirty (30)&amp;#160;business days advance written notice to MEEI. MEEI has the right to terminate the MEEI License Agreement if the Company fails to make any payment due within thirty (30)&amp;#160;business days after MEEI notifies the Company of such failure. MEEI shall have the right to terminate if the Company fails to maintain the required insurance. MEEI shall also have the right to terminate the MEEI License Agreement upon forty-five (45)&amp;#160;business days written notice if the Company becomes insolvent. MEEI has the right to terminate for any other default not cured within sixty (60)&amp;#160;business days written notice. MEEI also has the right to terminate if the Company or its affiliates challenge the validity of the licensed patent rights. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cambridge Enterprise Limited&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.14%;"&gt;In December 2019, we entered into an Exclusive Patent License Agreement ( the &amp;#8220;Cambridge License&amp;#8221;) with Cambridge Enterprise Limited (the technology transfer arm of the University of Cambridge)&lt;font style="font-size:12pt;"&gt; &lt;/font&gt;(&amp;#8220;Cambridge&amp;#8221;) under which we received an executive worldwide royalty-bearing license to certain patent rights to make, have made, sell, offer to sell and import products, or the (the &amp;#8220;Cambridge License Product&amp;#8221;) which incorporate licensed technology for the treatment of demyelinating diseases.&amp;nbsp;&amp;nbsp;We also have the right to grant nonexclusive licenses to other academic institutions for any academic publication, research and teaching and clinical patient care.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.14%;"&gt;We have agreed to use diligent and good faith efforts to develop and commercially exploit at least one Cambridge Licensed Product.&amp;nbsp;&amp;nbsp;Upon entering into the Cambridge License, we made a $50 license fee payment.&amp;nbsp;&amp;nbsp;We are obligated to pay an annual license fee of $50. We are also obligated to make milestone payments up to $10.5 million on each Cambridge License Product.&amp;nbsp;&amp;nbsp;In addition, we have agreed to pay a low single-digit royalty on products that incorporate the licensed patent rights, subject to offset in certain circumstances. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.14%;"&gt;The Cambridge License continues in effect on a country-by-country basis until the expiration or revocation, without right of further appeal, of all licensed issued patents and filed patent applications, unless terminated earlier.&amp;nbsp;&amp;nbsp;We have the right to terminate for any reason upon 90 days&amp;#8217; prior to written notice.&amp;nbsp;&amp;nbsp;Each party has the right to terminate immediately if the other party ceases to carry on its business.&amp;nbsp;&amp;nbsp;Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days.&amp;nbsp;&amp;nbsp;Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge Licensed Product or we or our affiliates or sub-licenses commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Department of Defense &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2018, the Company received a grant (the Grant) from the Department of Defense (DoD) under which the Company is receiving funding to further the Company&amp;#8217;s research and development of a therapeutic drug to treat hearing loss. The Company is receiving funding of $1,596 over two years from the date of the Grant. The Company has determined that the DoD is not considered a customer under ASC Topic 606, therefore funding received from the DoD under the Grant is recorded as a reduction of research and development expenses. The Company has recorded $845 and $428 as a reduction in research and development expenses for the years ended December&amp;#160;31, 2019 and 2018, respectively. &lt;/p&gt;</freq:ResearchAndLicenseAgreementsDisclosureTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock id="F_000329" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;15. Collaboration agreement &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2019, the Company entered into a License and Collaboration Agreement with Astellas (the Astellas Agreement), under which the Company granted Astellas an exclusive, royalty-bearing, sub-licensable, nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a GSK-3 inhibitor and an HDAC inhibitor, (the Astellas Licensed Products), including the product candidate FX-322, outside of the United States. The Company also granted Astellas a right of first negotiation and a right of last refusal if it entered into any negotiation or agreement of any kind (other than an acquisition of all of the stock or assets of the Company) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas Licensed Products in the United States. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has agreed to conduct Phase 2a clinical studies in the United States. Upon the completion thereof, the Company and Astellas have agreed to jointly develop the Astellas Licensed Products, including carrying out joint studies. Each party has agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in sensorineural hearing loss and in age-related hearing loss, in each case, in one major Asian country and one major European country. The Company has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in the United States. Astellas has the sole right to commercialize the Astellas Licensed Products outside of the United States, and the Company has the sole right to commercialize the Astellas Licensed Products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas Licensed Products in a major Asian country and a major European country following receipt of regulatory approval in such countries. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The collaboration is governed by a joint steering committee (&amp;#8220;JSC&amp;#8221;) established under the Astellas Agreement and shall be comprised of three representatives each from the Company and Astellas. The JSC shall oversee and coordinate the overall conduct of the development, manufacture and commercialization of the Astellas Licensed Products. All decisions of JSC shall be taken through a unanimous vote with each party&amp;#8217;s representatives collectively having one vote. Both the parties shall be responsible for carrying out the development and manufacturing activities in their defined territory in accordance with the plan as reviewed and approved in the JSC. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As consideration for the licensed rights under the Astellas Agreement, Astellas paid the Company an upfront payment of $80.0&amp;#160;million in July 2019 and has agreed to pay potential development milestone payments up to $230.0&amp;#160;million and commercialization milestones of up to $315.0 million. Specifically, the Company would receive development milestone payments of $65.0. million and $25.0 million upon the first dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively and $100.0 million and $40.0 million upon the first dosing of a patient in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively.  If the Astellas Licensed Products are successfully commercialized, the Company would be eligible for up to $315.0&amp;#160;million in potential commercial milestone payments and also tiered royalties at rates ranging from low- to mid-teen percentages. The parties shall share equally, on a 50/50 basis, all out-of-pocket costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Astellas Agreement remains in effect until the expiration of all royalty obligations. Royalties are paid on a licensed product-by-licensed product and country-by-country basis until the latest of (i)&amp;#160;the expiration of the last valid claim in the licensed patent rights with respect to such Astellas Licensed Product in such country or (ii) a set number of years from the first commercial sale of such Astellas Licensed Product in such country. Astellas may terminate the Astellas Agreement at will upon 60 days&amp;#8217; written notice. Each party has the right to terminate the Astellas Agreement due to the other party&amp;#8217;s material breach if such breach remains uncured for 90 days (or 45 days in the case of nonpayment) or if the other party becomes bankrupt. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Astellas Agreement is a collaborative agreement that is within the scope of ASC 808. The Company analyzed the joint research and development activities to assess whether they fall within the scope of ASC 808, and will reassess this throughout the life of the arrangement based on changes in the roles and responsibilities of the parties. Based on the terms of the arrangement as outlined above, both parties are deemed to be active participants in the collaboration. Both parties are performing research and development activities in their defined territory and will be performing joint clinical studies in accordance with the development plan and the study protocol approved by the JSC. Additionally, Astellas and the Company are exposed to significant risks and rewards dependent on the commercial success of any product candidates that may result from the collaboration. As such, the collaboration arrangement is deemed to be within the scope of ASC 808. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The arrangement consists of two components; the license of IP and the research and development activities, including committee participation, to support the co-development and research plan. Under the provisions of ASC 808, the Company has determined that it will apply the guidance in ASC 606 to recognize the revenue related to the license since that component of the arrangement is more reflective of a vendor-customer relationship. The Company determined that the license and the related research and development services associated with the Phase 2a clinical study were not distinct from one another, as the license has limited value to Astellas without the performance of the research and development activities and the Phase 2a study is essential to the use of the license. As such, the Company determined that these activities should be accounted for as a single combined performance obligation. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue associated with this single performance obligation is being recognized as the research and development work is performed, using an input method on the basis of research and development costs incurred to date relative to total research and development costs expected to be incurred. The transfer of control occurs over this time period and, in management&amp;#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. The Company has determined that the period of performance of the research and development services began upon the signing of the Astellas Agreement and will continue until the completion of the Phase 2a clinical trial of FX-322. The transaction price of $80.0 million has been allocated to the single combined performance obligation and will be recognized over such period. Management has analyzed the progress of the Phase 2a clinical trial and has estimated the completion date of such trial and the total costs it expects to incur in performing the trial and is recognizing the $80.0 million upfront fee as revenue over the period from July 2019 until the estimated completion date using the input method. The Company regularly assesses its estimates and to the extent that facts and circumstances dictate, the Company revises its estimates of total cost or completion date and accounts for such change on a prospective basis. The estimated completion date of the Phase 2a clinical trial as of December 31, 2019 has changed from the date used for accounting purposes as of September 30, 2019.&amp;nbsp;&amp;nbsp;The Company was required to pay MIT a royalty of $16.0 million on the $80.0 million of sublicense revenues. The $16.0 million royalty was expensed in the third quarter of 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The $80.0&amp;#160;million upfront payment received from Astellas in July 2019 was initially recorded as deferred revenue and is being recognized as revenue according to the policy described above. In the year ended December 31, 2019, the Company recorded $28.9 million of revenue under the Astellas Agreement which included $16.0 million related to the royalty payment to MI0T and $12.9 million based upon the application of the input method to the remaining $64.0 million to be recognized over the estimated period to completion of the Phase 2a clinical trial for FX-322. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The potential development and regulatory milestone payments are fully constrained until the Company can conclude that achievement of the milestone is probable and that it is probable that recognition of revenue related to the milestone will not result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is ultimately resolved and as such these have been excluded from the transaction price. As part of its evaluation of the constraint, the Company considers numerous factors, including the fact that achievement of the milestones is outside the control of the Company and contingent upon the future success of clinical trials, the licensee&amp;#8217;s efforts, and the receipt of regulatory approval. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to Astellas and therefore are recognized at the later of when the performance obligation is satisfied, or the related sales of licensed products occur. The Company re-evaluates the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, at each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Astellas Agreement contains joint research and development activities that are not within the scope of ASC 606. The Company will recognize research and development expense related to the joint study costs for all the joint activities in future periods and reimbursements received from Astellas will be recognized as an offset to research and development expense on the consolidated statement of operations during the development period. In the year ended December 31, 2019, the Company received $186 from Astellas for joint costs.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="F_000330" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;16. Commitments and contingencies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Operating leases &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2016, the Company and a related third party (see Note 18) entered into a five-year operating lease for the Company&amp;#8217;s primary office and laboratory space in Woburn, Massachusetts. In February 2020, the Company entered into a new lease for its office and laboratory space with the same landlord in Woburn, Massachusetts.&amp;nbsp;&amp;nbsp;The new lease includes additional office space and is for a five-year period.&amp;nbsp;&amp;nbsp;The Company intends to sublease this facility at the time it moves into its new facility discussed below. The Company also leases a laboratory facility in Connecticut under an operating lease which expires in 2019. Rent expense was $269 and $271 for the years ended December&amp;#160;31, 2019 and 2018, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 7, 2020 the Company entered into an indenture of lease (the &amp;#8220;Lexington Lease&amp;#8221;) with HCP/KING 75Hayden LLC,(the &amp;#8220;Landlord&amp;#8221;), for the lease of approximately 61,307 square feet of rentable area in Lexington, Massachusetts or (the &amp;#8220;Lexington Premises&amp;#8221;).&amp;nbsp;&amp;nbsp;The commencement date of the Lexington Lease is expected to be on or about December 1, 2020, (the &amp;#8220;Commencement Date&amp;#8221;).&amp;nbsp;&amp;nbsp;The Company expects to use the Lexington Premises as its new principal executive offices and as a laboratory for research and development, and other related uses.&amp;nbsp;&amp;nbsp;The term of the Lexington Lease, (the &amp;#8220; Initial Term&amp;#8221;), is ten years from the rent commencement date (which is five months following the Commitment Date) and the Initial Term is expected to end on April 30, 2031 (assuming a December 1, 2020 Commencement Date).&amp;nbsp;&amp;nbsp;We also have the option to extend the Initial Term for two additional terms of five years each.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The minimum aggregate future operating lease commitments for the leases noted above are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Minimum&amp;#160;lease&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;commitments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;504&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,613&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,741&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,883&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,034&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,596&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,371&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Contract commitments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has contracted with a research institution to provide research for a therapeutic drug to treat multiple sclerosis. As of December&amp;#160;31, 2019, the Company has committed to total payments of $705 over twelve months beginning in October 2019.&amp;nbsp;&amp;nbsp;We also enter into contracts in the normal course of business with CROs, CMOs, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by us upon prior written notice although, purchase orders for clinical materials are generally non-cancelable. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation or upon the completion of a manufacturing run. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Guarantees &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, &lt;font style="font-style:italic;"&gt;Guarantees&lt;/font&gt;. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&amp;#8217;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&amp;#8217; and officers&amp;#8217; insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases office space under a five-year noncancelable operating lease. The Company has standard indemnification arrangements under this lease that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019, 2018 and 2017, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock id="F_000331" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;17. Employee benefit plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employees of the Company are eligible to participate in the Company&amp;#8217;s 401(k) retirement plan (the &amp;#8220;401(k) Plan&amp;#8221;). Participants may contribute up to 90% of their annual compensation to the 401(k) Plan, subject to statutory limitations. The 401(k) Plan has a Safe Harbor Match of 100% of the first 5% and vests 100% at time of match. &lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="F_000332" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;18. Related party transactions &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company&amp;#8217;s lease for its Woburn, Massachusetts facility, see Note 16, is with an entity affiliated with one of the Company&amp;#8217;s directors and shareholders. &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:SubsequentEventsTextBlock id="F_000333" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;19. Subsequent events &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has evaluated subsequent events for recognition, remeasurement and disclosure purposes through March 26, 2020, the date which the consolidated financial statements were available to be issued. The identified subsequent event is as follows; &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 30, 2020, the World Health Organization declared the coronavirus outbreak a "Public Health Emergency of International Concern" and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The coronavirus and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in&lt;font style="color:#000000;"&gt;&lt;br /&gt;&lt;/font&gt;which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will be to the Company, it is reasonably possible that estimates made in the consolidated financial statements, including the estimated time and costs necessary to complete our performance obligations under the Astellas Agreement, will be materially and adversely impacted in the near term as a result of these&lt;font style="color:#000000;"&gt;&lt;br /&gt;&lt;/font&gt;conditions.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:QuarterlyFinancialInformationTextBlock id="F_000334" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;20. Selected Quarterly Data (Unaudited) &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table contains quarterly financial information for 2019 and 2018.&amp;nbsp;&amp;nbsp;The Company believes that the following information reflects all normal recurring adjustments necessary for the fair statement of the information for the periods presented.&amp;nbsp;&amp;nbsp;The operating results for any quarter are not necessarily indicative of results for any future period.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except per share amounts)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,238&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,709&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,947&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,826&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,852&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,813&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,202&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,693&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,826&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,852&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(575&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,493&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,746&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative series C convertible preferred stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; dividends&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(40&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,054&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,826&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,852&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,533&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common shareholders -&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.24&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.42&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.73&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.19&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except per share amounts)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,149&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,436&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,136&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,447&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,168&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,149&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,436&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,136&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,447&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,168&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative series C convertible preferred stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; dividends&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,149&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,436&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,136&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,447&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,168&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common shareholders -&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.03&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12.53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="F_000335" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB &lt;font style="font-style:italic;"&gt;Accounting Standards&lt;/font&gt; Codification (ASC). &lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock id="F_000336" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Principles of consolidation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics PTY, LTD and Frequency Japan (majority owned at December 31, 2018). All intercompany transactions and balances have been eliminated. &lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:UseOfEstimates id="F_000337" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the Company&amp;#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&amp;#8217;s management evaluates its estimates, which include but are not limited to management&amp;#8217;s judgments of accrued expenses, revenue, fair value of common stock, valuation of share-based awards and income taxes. Actual results could differ from those estimates. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company utilizes significant estimates and assumptions in determining the fair value of its common stock in periods prior to the IPO. The Company had utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation (the Practice Aid), to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&amp;#8217;s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&amp;#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date. &lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock id="F_000338" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Comprehensive income (loss) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive loss includes net loss as well as other changes in stockholders&amp;#8217; equity that result from transactions and economic events other than those with stockholders which for the year ended December 31, 2019 consists of unrealized gain on marketable securities.&amp;nbsp;&amp;nbsp;There were no elements of comprehensive loss for the years ended December 31, 2018 and 2017.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock id="F_000339" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segment information &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&amp;#8217;s chief operating decision-maker, the Company&amp;#8217;s chief executive officer, views the Company&amp;#8217;s operations and manages its business as a single operating segment, which is in the business of discovering and developing small molecule drugs that activate progenitor cells within the body to create healthy tissue. &lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock id="F_000340" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Foreign currency &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All periods presented are reported in US dollars. The functional currency for entities outside the United States is the US dollar. Realized and unrealized gains and losses from foreign currency transactions are reflected in the consolidated statements of operations as other expense. During the years ended December&amp;#160;31, 2019, 2018 and 2017 the Company recorded $7, $151 and ($8) of foreign currency exchange gains (losses), respectively. &lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="F_000341" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with an original maturity of six months or less at acquisition to be cash equivalents which are stated at fair market value. Cash and cash equivalents at December&amp;#160;31, 2019 and 2018 consists entirely of cash held in banks and money market funds. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:MarketableSecuritiesPolicy id="F_000342" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;"&gt;Short-term marketable debt securities&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company&amp;#8217;s investment policy. Short-term marketable investment mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders&amp;#8217; equity (deficit) until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, together with interest on securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investment are reflected as a component of other income (expense).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term marketable securities at December 31, 2019 consist of investment in U.S. Treasury Securities.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
  <us-gaap:ConcentrationRiskCreditRisk id="F_000343" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;"&gt;Concentration of credit risk and off-balance sheet risk&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instrument that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of U.S. Treasury securities with maturities of less than twelve months. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has no significant off-balance sheet such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <freq:SignificantSuppliersPolicyTextBlock id="F_000344" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Significant suppliers &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a single manufacturer of its product candidates for use in clinical trials. The Company would be adversely affected by a significant interruption in the supply of product for use in clinical programs. &lt;/p&gt;</freq:SignificantSuppliersPolicyTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="F_000345" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair value measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic&amp;#160;820, &lt;font style="font-style:italic;"&gt;Fair Value Measurement&lt;/font&gt; (ASC&amp;#160;820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.86%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.86%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.86%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:9.38%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Inputs other than quoted prices included within Level&amp;#160;1 that are either directly or indirectly observable, &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;such as quoted market prices, interest rates and yield curves.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.86%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:9.38%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&amp;#160;3. A financial instrument&amp;#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying values of other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. &lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="F_000346" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of lab equipment, computer equipment, furniture and office equipment and leasehold improvements recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of the estimated useful&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;life or lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statements of operations.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock id="F_000347" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Impairment of long-lived assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December&amp;#160;31, 2019, 2018 and 2017.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="F_000348" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and development costs and accruals &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with research institutions, contract research organizations, contract manufacturers and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, pre-clinical and clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:CollaborativeArrangementAccountingPolicy id="F_000349" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Collaborative arrangements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company analyzes its collaborative arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements (&amp;#8220;ASC 808&amp;#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship (e.g., a licensing arrangement) where the contracted party has obtained goods or services that are an output of the Company&amp;#8217;s ordinary activities in exchange for a consideration and therefore within the scope of Topic 606. For those elements of the arrangement that are accounted for pursuant to Topic 606, including those to which Topic 606 is applied by analogy, the Company applies the five-step model described in the Company&amp;#8217;s revenue recognition policy. For elements of collaborative arrangements that are accounted for pursuant to ASC 808, an appropriate and rational recognition method is determined and applied consistently. Reimbursements from the counterparty that are the result of a collaborative relationship with the counterparty, instead of a customer relationship, such as co-development or clinical activities, are recorded as a reduction to research and development expense as the services are performed. Similarly, amounts that are owed to a collaboration partner related to the co-development clinical activities are recognized as research and development expense. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into out-licensing agreements that are within the scope of Topic 606. The terms of such out-license agreements include licenses to functional intellectual property (IP), given the functionality of the intellectual property is not expected to change substantially as a result of the licensor&amp;#8217;s ongoing activities. Such arrangements typically include payment of one or more of the following: non-refundable up-front license fees; reimbursement of certain costs; development and regulatory milestone payments and milestone payments based on the level of sales; and royalties on net sales of licensed products. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers the economic and regulatory characteristics of the licensed IP, research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace to determine if it has standalone value at the inception of the licensing arrangement, which would make the license distinct. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of any additional good or services promised in the contract, whether the value of the license is dependent on the remaining goods and services, whether there are other vendors that could provide the remaining promise, and whether the license is separately identifiable from the remaining good and services. For licenses that are combined with other goods and services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue is allocated to the licensed IP on a relative standalone selling price basis and, for functional IP, is recognized at a point when the licensed IP is made available for the customer&amp;#8217;s use and benefit, which generally occurs at the inception of the arrangement. However, in cases, where the functionality of the IP is expected to substantively change as a result of activities of the Company that do not transfer additional promised goods or services, or in cases, where there is an expectation that the Company will undertake activities to change the standalone functionality of the IP and the customer is contractually or practically required to use the latest version of the IP, revenue for the license to functional IP is recognized over time. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into a collaboration arrangement with Astellas Pharma Inc. (&amp;#8220;Astellas&amp;#8221;), as further described in Note 15 of notes to unaudited consolidated financial statements. &lt;/p&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="F_000350" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Revenue recognition &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for contracts with customers in accordance with Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;), Topic 606, Revenue from Contracts with Customers (&amp;#8220;Topic 606&amp;#8221;), including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. The Company&amp;#8217;s disclosure within the below sections or elsewhere within these consolidated financial statements reflects the Company&amp;#8217;s accounting policies in compliance with this new standard.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under Topic 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i)&amp;#160;identify the contract(s) with a customer; (ii)&amp;#160;identify the performance obligations in the contract; (iii)&amp;#160;determine the transaction price, including variable consideration, if any; (iv)&amp;#160;allocate the transaction price to the performance obligations in the contract; and (v)&amp;#160;recognize revenue when (or as) the entity satisfies its performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a) a good or service (or bundle of goods and services) that is distinct, or (b) a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&amp;#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&amp;#160;the entity&amp;#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the &amp;#8220;customer&amp;#8221; in this type of arrangement) and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, the Company identifies all performance obligations, which may include, for example, a license to IP and know-how, research and development activities, and/or manufacturing services. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the estimated variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestone payments at the later of (i)&amp;#160;when the related sales occur, or (ii)&amp;#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company&amp;#8217;s customer with a significant benefit of financing the transfer of goods and services. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time.&amp;nbsp;&amp;nbsp;For performance obligations satisfied over time, the Company measures progress toward completion of its performance obligations using an input method based on the Company&amp;#8217;s efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <freq:PatentCostsPolicyTextBlock id="F_000351" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Patent costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations. &lt;/p&gt;</freq:PatentCostsPolicyTextBlock>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="F_000352" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-based compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic&amp;#160;718, &lt;font style="font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation&lt;/font&gt; (ASC&amp;#160;718). ASC&amp;#160;718 requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company adopted FASB Accounting Standards Update (ASU) 2016-09 which identifies areas for simplification of several areas of share-based payment transactions. The Company retroactively applied the mark to market approach on vesting to non-employee grants and the impact on the consolidated financial statements was not material and as such, the Company will treat non-employee grants the same as employee grants. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a)&amp;#160;the expected stock price volatility, (b)&amp;#160;the expected term of the award, (c)&amp;#160;the risk-free interest rate and (d)&amp;#160;expected dividends. Due to the lack of sufficient company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&amp;#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There are significant judgments and estimates inherent in the determination of the fair value of the Company&amp;#8217;s common stock prior to the IPO. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expenses the fair value of its share-based compensation awards to employees and non-employees on a straight-line basis over the requisite service period, which is generally the vesting period. &lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <freq:NonControllingInterestPolicyTextBlock id="F_000353" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Non-controlling interest &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2018, the Company accounted for shares of preferred stock issued in Frequency Japan as a non-controlling interest in the mezzanine section of the consolidated balance sheets. The value ascribed to the non-controlling interest was the liquidation preference of the preferred stock in Frequency Japan as the holders of such shares do not share in any profits or losses of the subsidiary. &lt;font style="color:#000000;"&gt;In connection with the IPO, all preferred stock of Frequency Japan converted into shares of the Company&amp;#8217;s common stock, see Note 1.&lt;/font&gt;&lt;/p&gt;</freq:NonControllingInterestPolicyTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock id="F_000354" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, &lt;font style="font-style:italic;"&gt;Income Taxes&lt;/font&gt; (ASC 740) which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&amp;#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December&amp;#160;31, 2019 and 2018, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 13). &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock id="F_000355" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net loss per share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&amp;#160;31, 2019, 2018 and 2017 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses are not allocated to such participating securities. In periods where the Company reported a net loss attributable to common stockholders, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December&amp;#160;31, 2019, 2018 and 2017.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.92%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except share and per share amounts)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,168&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,237&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average shares of common stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; outstanding-basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,649,245&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,530,218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;702,918&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributed to common&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; stockholders-basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12.53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28.79&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.82%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted Common Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,366&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;345,608&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;637,746&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series C Preferred (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,172,676&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B Preferred (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,759,079&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,214,387&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A Preferred (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,070,574&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,283,425&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,283,425&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion of Frequency Japan preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;513,047&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;673,605&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding stock options (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,968,672&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,089,334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;985,521&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,554,414&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,606,359&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,906,692&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000356" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently adopted accounting pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2014, the FASB issued ASU 2014-09, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;. The standard will apply one comprehensive revenue recognition model across all contracts, entities, and sectors. The core principle of the new standard is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Once effective, ASU 2014-09 will replace most of the existing revenue recognition requirements in U.S. GAAP. The FASB also issued ASU 2015-14, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&lt;/font&gt;, which deferred the effective date of the standard one year. As a result, the new standard is effective for annual reporting periods beginning after December&amp;#160;15, 2018, including interim periods within the reporting period. Early adoption is permitted. The Company early adopted ASU 2014-09 effective January&amp;#160;1, 2018, and its adoption had no impact on the Company&amp;#8217;s consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2016, the FASB issued ASU No.&amp;#160;2016-15, &lt;font style="font-style:italic;"&gt;Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt; (ASU No.&amp;#160;2016-15). This guidance addresses the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. The standard is effective for annual periods beginning after December&amp;#160;15, 2017 and for interim periods within those fiscal years. Early adoption is permitted. The Company adopted this standard effective January&amp;#160;1, 2018. The adoption of ASU No.&amp;#160;2016-15 did not have a material impact on the Company&amp;#8217;s consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2017, the FASB issued ASU No.&amp;#160;2017-09, &lt;font style="font-style:italic;"&gt;Compensation-Stock Compensation (Topic&amp;#160;718): Scope of Modification Accounting&lt;/font&gt; (ASU No.&amp;#160;2017-09). This update clarifies the changes to terms or conditions of a share-based payment award that require an entity to apply modification accounting. ASU No.&amp;#160;2017-09 is effective for annual reporting periods, and interim periods therein, beginning after December&amp;#160;15, 2017. Early application is permitted, and prospective application is required. The Company adopted this standard effective January&amp;#160;1, 2018. The adoption of this guidance did not have a material impact on the Company&amp;#8217;s consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently issued accounting pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &amp;#8220;emerging growth company&amp;#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued &lt;font style="font-style:italic;"&gt;ASU No. 2016-02, Leases&lt;/font&gt;, which is intended to increase transparency and comparability among companies that enter into leasing arrangements. The new standard establishes a right-of-use model that requires a lessee to record a right-of-use asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either financing or operating, with classification affecting the pattern of expense recognition. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. In July 2018, the FASB &lt;font style="font-style:italic;"&gt;issued ASU No. 2018-11,&lt;/font&gt; with targeted improvements to the guidance including an additional transition method, which allows companies to apply the provisions of the new leasing standard as of January 1, 2020, without adjusting the comparative periods presented by recognizing a cumulative-effect adjustment to the opening balance of retained earnings.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company plans to elect early adoption of this standard effective January 1, 2020 and elect the new transition method approved by the FASB. The Company also plans to elect the package of practical expedients intended to ease transition whereby the Company need not assess (1) whether any expired or existing contracts are or contain leases, (2) the lease classification for any expired or existing leases and (3) initial direct costs for any existing leases. Furthermore, the Company will elect the practical expedient to combine non-lease components and lease components. As the Company finalizes its adoption processes, it estimates the adoption of the ASU in the first quarter of 2020 will result in the recognition of a right-of-use asset and related lease liability related to the lease for our Woburn Massachusetts facility in the range of approximately $1,000 to $2,000 with an estimated immaterial effect to the retained earnings and the consolidated statement of operations. As disclosed in Note 16, the Company has entered into a lease for a facility in Lexington Massachusetts which has an estimated commencement date of December 1, 2020. In accordance with ASU No. 2016-02, the Company will recognize a right-of-use asset and related lease liability at such time.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <freq:PropertyAndEquipmentTableTextBlock id="F_000357" contextRef="C_0001703647_20190101_20191231">These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of the estimated useful&lt;/p&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;life or lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</freq:PropertyAndEquipmentTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="F_000358" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.92%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except share and per share amounts)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,168&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,237&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average shares of common stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; outstanding-basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,649,245&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,530,218&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;702,918&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributed to common&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; stockholders-basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12.53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28.79&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000359" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.82%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted Common Stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,366&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;345,608&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;637,746&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series C Preferred (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,172,676&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B Preferred (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,759,079&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,214,387&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A Preferred (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,070,574&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,283,425&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,283,425&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion of Frequency Japan preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;513,047&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;673,605&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding stock options (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,968,672&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,089,334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;985,521&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,554,414&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,606,359&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,906,692&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock id="F_000360" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s financial assets measures at fair value on a recurring basis by level within the fair value hierarchy at December 31, 2019 are summarized as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Market&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Hierarchy&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gain&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,131&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,119&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Government treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,131&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,197&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,262&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,316&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
  <freq:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock id="F_000361" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rent and deposits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;801&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;428&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant receivable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;805&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;161&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Insurance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,132&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;199&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;159&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</freq:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000362" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment include the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,846&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,109&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;245&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,419&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,406&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;306&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,828&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,764&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,066&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,253&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,762&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,511&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="F_000363" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll and employee related expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,686&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,034&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;435&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;322&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Third-party research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;118&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;393&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,239&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,749&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <freq:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock id="F_000364" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has reserved the following shares of common stock for future issuance as of December 31, 2019, 2018 and 2017:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A Preferred conversion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,283,425&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,283,425&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion of Frequency Japan preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;673,605&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B Preferred conversion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,214,387&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,968,672&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,089,334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;985,521&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for future grant under stock option plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,859,654&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,028,096&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;646,871&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,828,326&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,288,847&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,915,817&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</freq:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000365" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;exercise&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;exercise&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019 Plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014 Plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;985,520&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.54&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,436,734&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.67&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(126,253&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.54&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(206,667&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.54&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,089,334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.61&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,247,338&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,015,381&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(357,170&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.02&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,211&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,247,338&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,287&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,721,334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.85&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,051&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,433&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;174&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,866,700&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.71&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,034&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options unvested as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,197,905&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,113&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,854,634&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000366" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions that the Company used to determine the grant-date fair value of stock options granted to&lt;font style="font-weight:bold;font-style:italic;"&gt; &lt;/font&gt;employees and directors were as follows, presented on a weighted average basis: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.1%-2.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;% &lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.0-7.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock id="F_000367" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the status of restricted common stock as of December&amp;#160;31, 2019 and 2018 is presented below: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,658,459&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,423&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,336&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Repurchased&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,201&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,657,345&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Repurchased&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,657,345&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested during period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;275,243&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,366&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.36&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="F_000368" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&amp;#8217;s effective income tax rate for the years ended December&amp;#160;31, 2019, 2018 and 2017 is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impact of federal rate change&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other items&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in deferred tax asset valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="F_000369" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s deferred tax assets at December&amp;#160;31, 2019 and 2018 consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,253&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,710&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,138&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangibles&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;358&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;256&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;686&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;496&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;189&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;210&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,229&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,229&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock id="F_000370" contextRef="C_0001703647_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The minimum aggregate future operating lease commitments for the leases noted above are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Minimum&amp;#160;lease&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;commitments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;504&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,613&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,741&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,883&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,034&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,596&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,371&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock id="F_000371" contextRef="C_0001703647_20190101_20191231">
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table contains quarterly financial information for 2019 and 2018.&amp;nbsp;&amp;nbsp;The Company believes that the following information reflects all normal recurring adjustments necessary for the fair statement of the information for the periods presented.&amp;nbsp;&amp;nbsp;The operating results for any quarter are not necessarily indicative of results for any future period.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except per share amounts)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,238&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,709&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,947&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,826&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,852&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,813&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,202&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,693&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,826&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,852&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(575&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,493&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,746&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative series C convertible preferred stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; dividends&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(40&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,054&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,826&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,852&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,533&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common shareholders -&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.24&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.42&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.73&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.19&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except per share amounts)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,149&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,436&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,136&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,447&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,168&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,149&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,436&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,136&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,447&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,168&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative series C convertible preferred stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; dividends&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,149&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,436&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,136&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,447&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,168&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common shareholders -&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.03&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12.53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <dei:EntityIncorporationDateOfIncorporation id="F_000372" contextRef="C_0001703647_20190101_20191231">2014-11-30</dei:EntityIncorporationDateOfIncorporation>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="F_000373" contextRef="C_0001703647_20190919_20190920" decimals="6" unitRef="U_xbrlipure">0.148467</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:StockholdersEquityReverseStockSplit id="F_000374" contextRef="C_0001703647_20190101_20191231">1-for-6.7355</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:CommonStockSharesAuthorized id="F_000375" contextRef="C_0001703647_20190920" decimals="INF" unitRef="U_xbrlishares">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000376" contextRef="C_0001703647_20190920" decimals="INF" unitRef="U_xbrlishares">148724922</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000377" contextRef="C_0001703647_20190920" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000378" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191001_20191031" decimals="INF" unitRef="U_xbrlishares">6325000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000379" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191031" decimals="INF" unitRef="U_iso4217USD_xbrlishares">14.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="F_000380" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191001_20191031" decimals="-5" unitRef="U_iso4217USD">79700000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000381" contextRef="C_0001703647_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20191001_20191031" decimals="INF" unitRef="U_xbrlishares">22077627</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000382" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_freqLabEquipmentMember_20190101_20191231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000383" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20190101_20191231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000384" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_freqFurnitureAndOfficeEquipmentMember_20190101_20191231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives id="F_000385" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20190101_20191231">Shorter of the estimated useful
life or lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="F_000386" contextRef="C_0001703647_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="F_000387" contextRef="C_0001703647_20180101_20181231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="F_000388" contextRef="C_0001703647_20170101_20171231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000389" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqUnvestedRestrictedCommonStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">70366</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000390" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqUnvestedRestrictedCommonStockMember_20180101_20181231" decimals="0" unitRef="U_xbrlishares">345608</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000391" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqUnvestedRestrictedCommonStockMember_20170101_20171231" decimals="0" unitRef="U_xbrlishares">637746</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000392" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqSeriesCPreferredAsConvertedToCommonStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">1172676</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000393" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqSeriesBPreferredAsConvertedToCommonStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">4759079</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000394" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqSeriesBPreferredAsConvertedToCommonStockMember_20180101_20181231" decimals="0" unitRef="U_xbrlishares">6214387</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000395" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqSeriesAPreferredAsConvertedCommonStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">7070574</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000396" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqSeriesAPreferredAsConvertedCommonStockMember_20180101_20181231" decimals="0" unitRef="U_xbrlishares">9283425</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000397" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqSeriesAPreferredAsConvertedCommonStockMember_20170101_20171231" decimals="0" unitRef="U_xbrlishares">9283425</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000398" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqConversionOfFrequencyJapanPreferredStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">513047</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000399" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqConversionOfFrequencyJapanPreferredStockMember_20180101_20181231" decimals="0" unitRef="U_xbrlishares">673605</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000400" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqOutstandingStockOptionsAsConvertedToCommonStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">5968672</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000401" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqOutstandingStockOptionsAsConvertedToCommonStockMember_20180101_20181231" decimals="0" unitRef="U_xbrlishares">2089334</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000402" contextRef="C_0001703647_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_freqOutstandingStockOptionsAsConvertedToCommonStockMember_20170101_20171231" decimals="0" unitRef="U_xbrlishares">985521</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000403" contextRef="C_0001703647_20190101_20191231" decimals="0" unitRef="U_xbrlishares">19554414</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000404" contextRef="C_0001703647_20180101_20181231" decimals="0" unitRef="U_xbrlishares">18606359</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000405" contextRef="C_0001703647_20170101_20171231" decimals="0" unitRef="U_xbrlishares">10906692</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000406" contextRef="C_0001703647_srtRangeAxis_srtMinimumMember_srtStatementGeographicalAxis_freqWoburnMassachusettsFacilityMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200331" decimals="INF" unitRef="U_iso4217USD">1000000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000407" contextRef="C_0001703647_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_freqWoburnMassachusettsFacilityMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200331" decimals="INF" unitRef="U_iso4217USD">2000000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseLiability id="F_000408" contextRef="C_0001703647_srtRangeAxis_srtMinimumMember_srtStatementGeographicalAxis_freqWoburnMassachusettsFacilityMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200331" decimals="INF" unitRef="U_iso4217USD">1000000</us-gaap:OperatingLeaseLiability>
  <us-gaap:OperatingLeaseLiability id="F_000409" contextRef="C_0001703647_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_freqWoburnMassachusettsFacilityMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200331" decimals="INF" unitRef="U_iso4217USD">2000000</us-gaap:OperatingLeaseLiability>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000410" contextRef="C_0001703647_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" unitRef="U_iso4217USD">200131000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax id="F_000411" contextRef="C_0001703647_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" unitRef="U_iso4217USD">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000412" contextRef="C_0001703647_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" unitRef="U_iso4217USD">200119000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000413" contextRef="C_0001703647_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">17131000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000414" contextRef="C_0001703647_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">217262000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000415" contextRef="C_0001703647_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">66000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000416" contextRef="C_0001703647_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">54000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000417" contextRef="C_0001703647_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">17197000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000418" contextRef="C_0001703647_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">217316000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AssetsFairValueDisclosure id="F_000419" contextRef="C_0001703647_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <freq:PrepaidRentAndDepositsCurrent id="F_000420" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">63000</freq:PrepaidRentAndDepositsCurrent>
  <freq:PrepaidResearchAndDevelopmentExpenseCurrent id="F_000421" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">801000</freq:PrepaidResearchAndDevelopmentExpenseCurrent>
  <freq:PrepaidResearchAndDevelopmentExpenseCurrent id="F_000422" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">428000</freq:PrepaidResearchAndDevelopmentExpenseCurrent>
  <us-gaap:GrantsReceivableCurrent id="F_000423" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">805000</us-gaap:GrantsReceivableCurrent>
  <us-gaap:GrantsReceivableCurrent id="F_000424" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">161000</us-gaap:GrantsReceivableCurrent>
  <us-gaap:PrepaidInsurance id="F_000425" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">2132000</us-gaap:PrepaidInsurance>
  <us-gaap:OtherAssetsCurrent id="F_000426" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">199000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent id="F_000427" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">159000</us-gaap:OtherAssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000428" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">1846000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000429" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20181231" decimals="-3" unitRef="U_iso4217USD">1109000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000430" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">12000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000431" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20181231" decimals="-3" unitRef="U_iso4217USD">12000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000432" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231" decimals="-3" unitRef="U_iso4217USD">245000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000433" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20181231" decimals="-3" unitRef="U_iso4217USD">204000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000434" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231" decimals="-3" unitRef="U_iso4217USD">1419000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000435" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20181231" decimals="-3" unitRef="U_iso4217USD">1406000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000436" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231" decimals="-3" unitRef="U_iso4217USD">306000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000437" contextRef="C_0001703647_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20181231" decimals="-3" unitRef="U_iso4217USD">33000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000438" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">3828000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000439" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">2764000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000440" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">2066000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000441" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">1253000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000442" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">2686000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000443" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">1034000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000444" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">435000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000445" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">322000</us-gaap:AccruedProfessionalFeesCurrent>
  <freq:AccruedThirdPartyResearchAndDevelopmentExpensesCurrent id="F_000446" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">118000</freq:AccruedThirdPartyResearchAndDevelopmentExpensesCurrent>
  <freq:AccruedThirdPartyResearchAndDevelopmentExpensesCurrent id="F_000447" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">393000</freq:AccruedThirdPartyResearchAndDevelopmentExpensesCurrent>
  <us-gaap:DebtInstrumentCarryingAmount id="F_000448" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesBFinancingMember_20181231" decimals="-3" unitRef="U_iso4217USD">5000000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DebtInstrumentMaturityDate id="F_000449" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesBFinancingMember_20180101_20181231">2019-05-31</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="F_000450" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesBFinancingMember_20181231" decimals="2" unitRef="U_xbrlipure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000451" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesBFinancingMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">5000000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 id="F_000452" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesBFinancingMember_20180101_20181231" decimals="2" unitRef="U_xbrlipure">0.95</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:DebtInstrumentFaceAmount id="F_000453" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesBFinancingMember_20181017" decimals="-3" unitRef="U_iso4217USD">5000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:InterestPayableCurrent id="F_000454" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesBFinancingMember_20181017" decimals="-3" unitRef="U_iso4217USD">106000</us-gaap:InterestPayableCurrent>
  <us-gaap:InterestExpenseDebtExcludingAmortization id="F_000455" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesBFinancingMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">106000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="F_000456" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesBFinancingMember_20181017" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.92</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <freq:DebtInstrumentDiscountRate id="F_000457" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesBFinancingMember_20181017_20181017" decimals="2" unitRef="U_xbrlipure">0.05</freq:DebtInstrumentDiscountRate>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="F_000458" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesBFinancingMember_20181017_20181017" decimals="INF" unitRef="U_xbrlishares">5839463</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <freq:DebtInstrumentLossOnConversion id="F_000459" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesBFinancingMember_20181017_20181017" decimals="-3" unitRef="U_iso4217USD">269000</freq:DebtInstrumentLossOnConversion>
  <us-gaap:DebtInstrumentCarryingAmount id="F_000460" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20151231" decimals="-3" unitRef="U_iso4217USD">14285000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DebtInstrumentCarryingAmount id="F_000461" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20161231" decimals="-3" unitRef="U_iso4217USD">14285000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DebtInstrumentMaturityDate id="F_000462" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20150101_20151231">2017-01-21</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentMaturityDate id="F_000463" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20160101_20161231">2017-01-21</us-gaap:DebtInstrumentMaturityDate>
  <freq:DebtInstrumentExtendedMaturityDate id="F_000464" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20150101_20151231">2017-04-30</freq:DebtInstrumentExtendedMaturityDate>
  <freq:DebtInstrumentExtendedMaturityDate id="F_000465" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20160101_20161231">2017-04-30</freq:DebtInstrumentExtendedMaturityDate>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="F_000466" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20151231" decimals="2" unitRef="U_xbrlipure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="F_000467" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20161231" decimals="2" unitRef="U_xbrlipure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <freq:DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion id="F_000468" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">4000000</freq:DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion>
  <freq:DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion id="F_000469" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">4000000</freq:DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 id="F_000470" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20150101_20151231" decimals="2" unitRef="U_xbrlipure">0.80</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 id="F_000471" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20160101_20161231" decimals="2" unitRef="U_xbrlipure">0.80</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <freq:DebtInstrumentExcessFinancingFundReceived id="F_000472" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqPriorToQualifiedSeriesAFinancingMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">15000000</freq:DebtInstrumentExcessFinancingFundReceived>
  <freq:DebtInstrumentExcessFinancingFundReceived id="F_000473" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqPriorToQualifiedSeriesAFinancingMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">15000000</freq:DebtInstrumentExcessFinancingFundReceived>
  <freq:DebtInstrumentDiscountRate id="F_000474" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqPriorToQualifiedSeriesAFinancingMember_20150101_20151231" decimals="2" unitRef="U_xbrlipure">0.20</freq:DebtInstrumentDiscountRate>
  <freq:DebtInstrumentDiscountRate id="F_000475" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapSubsidiarySaleOfStockAxis_freqPriorToQualifiedSeriesAFinancingMember_20160101_20161231" decimals="2" unitRef="U_xbrlipure">0.20</freq:DebtInstrumentDiscountRate>
  <us-gaap:DebtInstrumentFaceAmount id="F_000476" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20170330" decimals="-3" unitRef="U_iso4217USD">14285000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:InterestPayableCurrent id="F_000477" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20170330" decimals="-3" unitRef="U_iso4217USD">709000</us-gaap:InterestPayableCurrent>
  <us-gaap:InterestExpenseDebtExcludingAmortization id="F_000478" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">174000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="F_000479" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20170330" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.75</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <freq:DebtInstrumentDiscountRate id="F_000480" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20170330_20170330" decimals="2" unitRef="U_xbrlipure">0.20</freq:DebtInstrumentDiscountRate>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="F_000481" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20170330_20170330" decimals="INF" unitRef="U_xbrlishares">24990086</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <freq:DebtInstrumentLossOnConversion id="F_000482" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_freqQualifiedSeriesAFinancingMember_20170330_20170330" decimals="-3" unitRef="U_iso4217USD">3749000</freq:DebtInstrumentLossOnConversion>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000483" contextRef="C_0001703647_20181231" decimals="INF" unitRef="U_xbrlishares">114208722</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000484" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">64891735</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:DebtInstrumentFaceAmount id="F_000485" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20170330" decimals="-3" unitRef="U_iso4217USD">14285000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:InterestPayableCurrent id="F_000486" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20170330" decimals="-3" unitRef="U_iso4217USD">709000</us-gaap:InterestPayableCurrent>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="F_000487" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20170330_20170330" decimals="INF" unitRef="U_xbrlishares">24990086</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <freq:DebtInstrumentConvertibleDiscountOnConversionPrice id="F_000488" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20170330" decimals="2" unitRef="U_xbrlipure">0.20</freq:DebtInstrumentConvertibleDiscountOnConversionPrice>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="F_000489" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesANotesMember_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20170330" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.75</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:TemporaryEquitySharesIssued id="F_000490" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20170330" decimals="INF" unitRef="U_xbrlishares">9783522</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000491" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20170330" decimals="-3" unitRef="U_iso4217USD">7338000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquitySharesIssued id="F_000492" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20171231" decimals="INF" unitRef="U_xbrlishares">27754899</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000493" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20171231" decimals="-3" unitRef="U_iso4217USD">20816000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:DebtInstrumentFaceAmount id="F_000494" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181017" decimals="-3" unitRef="U_iso4217USD">5000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:InterestPayableCurrent id="F_000495" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181017" decimals="-3" unitRef="U_iso4217USD">106000</us-gaap:InterestPayableCurrent>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="F_000496" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181017_20181017" decimals="INF" unitRef="U_xbrlishares">5839463</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <freq:DebtInstrumentConvertibleDiscountOnConversionPrice id="F_000497" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181017" decimals="2" unitRef="U_xbrlipure">0.05</freq:DebtInstrumentConvertibleDiscountOnConversionPrice>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="F_000498" contextRef="C_0001703647_us-gaapDebtInstrumentAxis_freqSeriesBNotesMember_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181017" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.92</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:TemporaryEquitySharesIssued id="F_000499" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181017" decimals="INF" unitRef="U_xbrlishares">7544029</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000500" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181017" decimals="-3" unitRef="U_iso4217USD">6944000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <freq:TemporaryEquityAdditionalSharesIssued id="F_000501" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">28473513</freq:TemporaryEquityAdditionalSharesIssued>
  <freq:TemporaryEquityAdditionalSharesIssuedCarryingAmountAttributableToParent id="F_000502" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">26208000</freq:TemporaryEquityAdditionalSharesIssuedCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquitySharesIssued id="F_000503" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20190131" decimals="INF" unitRef="U_xbrlishares">288991</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000504" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20190228" decimals="INF" unitRef="U_xbrlishares">288991</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000505" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20190131" decimals="-3" unitRef="U_iso4217USD">266000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000506" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20190228" decimals="-3" unitRef="U_iso4217USD">266000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquitySharesIssued id="F_000507" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20181017" decimals="INF" unitRef="U_xbrlishares">10000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:SharesIssuedPricePerShare id="F_000508" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20181017" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.75</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000509" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20181017" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquitySharesIssued id="F_000510" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20181017" decimals="INF" unitRef="U_xbrlishares">10000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:SharesIssuedPricePerShare id="F_000511" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20181017" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.92</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000512" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20181017" decimals="-3" unitRef="U_iso4217USD">9000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000513" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190717" decimals="INF" unitRef="U_xbrlishares">39492960</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="F_000514" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190717" decimals="INF" unitRef="U_xbrlishares">39492960</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000515" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesCConvertiblePreferredStockMember_20190717" decimals="-3" unitRef="U_iso4217USD">61687000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000516" contextRef="C_0001703647_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_20181231" decimals="INF" unitRef="U_xbrlishares">673605</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <freq:PercentageOfVoteOfHoldersOfPreferredStock id="F_000517" contextRef="C_0001703647_srtConsolidatedEntitiesAxis_srtSubsidiariesMember_20180101_20181231" decimals="INF" unitRef="U_xbrlipure">0.70</freq:PercentageOfVoteOfHoldersOfPreferredStock>
  <freq:PreferredStockSharesPurchased id="F_000518" contextRef="C_0001703647_deiLegalEntityAxis_freqDelawareLimitedLiabilityCompanyMember_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">10000</freq:PreferredStockSharesPurchased>
  <freq:PreferredStockSharesPurchased id="F_000519" contextRef="C_0001703647_deiLegalEntityAxis_freqDelawareLimitedLiabilityCompanyMember_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">10000</freq:PreferredStockSharesPurchased>
  <us-gaap:PreferredStockVotingRights id="F_000520" contextRef="C_0001703647_deiLegalEntityAxis_freqDelawareLimitedLiabilityCompanyMember_us-gaapStatementClassOfStockAxis_freqSeriesA1ConvertiblePreferredStockMember_20190101_20191231">Each share of Series A-1 Preferred had 236 times the voting power of one share of common stock</us-gaap:PreferredStockVotingRights>
  <us-gaap:PreferredStockVotingRights id="F_000521" contextRef="C_0001703647_deiLegalEntityAxis_freqDelawareLimitedLiabilityCompanyMember_us-gaapStatementClassOfStockAxis_freqSeriesB1ConvertiblePreferredStockMember_20190101_20191231">Each share of Series B-1 Preferred Stock has 217 times the voting power of one share of common stock</us-gaap:PreferredStockVotingRights>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000522" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">9283425</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000523" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesAConvertiblePreferredStockMember_20171231" decimals="INF" unitRef="U_xbrlishares">9283425</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000524" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqConversionOfFrequencyJapanPreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">673605</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000525" contextRef="C_0001703647_us-gaapStatementClassOfStockAxis_freqSeriesBConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">6214387</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000526" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231" decimals="INF" unitRef="U_xbrlishares">5968672</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000527" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181231" decimals="INF" unitRef="U_xbrlishares">2089334</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000528" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20171231" decimals="INF" unitRef="U_xbrlishares">985521</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000529" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">1859654</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000530" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20181231" decimals="INF" unitRef="U_xbrlishares">1028096</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000531" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20171231" decimals="INF" unitRef="U_xbrlishares">646871</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000532" contextRef="C_0001703647_20191231" decimals="INF" unitRef="U_xbrlishares">7828326</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000533" contextRef="C_0001703647_20181231" decimals="INF" unitRef="U_xbrlishares">19288847</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000534" contextRef="C_0001703647_20171231" decimals="INF" unitRef="U_xbrlishares">10915817</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000535" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20141113" decimals="INF" unitRef="U_xbrlishares">8550415</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000536" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000537" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20190917" decimals="INF" unitRef="U_xbrlishares">3100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <freq:PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance id="F_000538" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20190101_20191231">P10Y</freq:PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum id="F_000539" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription id="F_000540" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20190101_20191231">In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company&#8217;s common stock on December 31, of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000541" contextRef="C_0001703647_20190101_20191231">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="F_000542" contextRef="C_0001703647_srtRangeAxis_srtMaximumMember_20190101_20191231">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000543" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20171231" decimals="INF" unitRef="U_xbrlishares">985520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000544" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">1436734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000545" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">126253</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000546" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">206667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000547" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20181231" decimals="INF" unitRef="U_xbrlishares">2089334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000548" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">1247338</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000549" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">3015381</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000550" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">357170</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000551" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">26211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000552" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">1247338</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000553" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">4721334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000554" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">49433</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000555" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">1866700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_000556" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">1197905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_000557" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">2854634</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000558" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20171231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000559" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000560" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000561" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000562" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000563" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">14.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000564" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">4.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000565" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000566" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000567" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">14.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000568" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000569" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">14.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000570" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000571" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20190101_20191231">P9Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000572" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20190101_20191231">P8Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000573" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20190101_20191231">P9Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000574" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20190101_20191231">P8Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000575" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20191231" decimals="-3" unitRef="U_iso4217USD">4287000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000576" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20191231" decimals="-3" unitRef="U_iso4217USD">65051000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="F_000577" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20191231" decimals="-3" unitRef="U_iso4217USD">174000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="F_000578" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20191231" decimals="-3" unitRef="U_iso4217USD">26034000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="F_000579" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndNineteenIncentiveAwardPlanMember_20191231" decimals="-3" unitRef="U_iso4217USD">4113000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="F_000580" contextRef="C_0001703647_us-gaapPlanNameAxis_freqTwoThousandAndFourteenStockIncentivePlanMember_20191231" decimals="-3" unitRef="U_iso4217USD">39017000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000581" contextRef="C_0001703647_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000582" contextRef="C_0001703647_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000583" contextRef="C_0001703647_srtRangeAxis_srtMinimumMember_20170101_20171231" decimals="INF" unitRef="U_xbrlipure">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000584" contextRef="C_0001703647_srtRangeAxis_srtMaximumMember_20170101_20171231" decimals="INF" unitRef="U_xbrlipure">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000585" contextRef="C_0001703647_20190101_20191231">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000586" contextRef="C_0001703647_20180101_20181231">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000587" contextRef="C_0001703647_srtRangeAxis_srtMinimumMember_20170101_20171231">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000588" contextRef="C_0001703647_srtRangeAxis_srtMaximumMember_20170101_20171231">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000589" contextRef="C_0001703647_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000590" contextRef="C_0001703647_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.811</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000591" contextRef="C_0001703647_20170101_20171231" decimals="3" unitRef="U_xbrlipure">0.790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000592" contextRef="C_0001703647_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000593" contextRef="C_0001703647_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000594" contextRef="C_0001703647_20170101_20171231" decimals="3" unitRef="U_xbrlipure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000595" contextRef="C_0001703647_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">357170</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000596" contextRef="C_0001703647_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">126253</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000597" contextRef="C_0001703647_20190101_20191231" decimals="0" unitRef="U_iso4217USD_xbrlishares">5896</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000598" contextRef="C_0001703647_20180101_20181231" decimals="0" unitRef="U_iso4217USD_xbrlishares">149</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000599" contextRef="C_0001703647_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">4.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000600" contextRef="C_0001703647_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000601" contextRef="C_0001703647_20170101_20171231" decimals="3" unitRef="U_iso4217USD_xbrlishares">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue id="F_000602" contextRef="C_0001703647_20190101_20191231" decimals="0" unitRef="U_iso4217USD_xbrlishares">2990</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue id="F_000603" contextRef="C_0001703647_20180101_20181231" decimals="0" unitRef="U_iso4217USD_xbrlishares">244</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000604" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20190101_20191231">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber id="F_000605" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20171231" decimals="INF" unitRef="U_xbrlishares">1658459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted id="F_000606" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">7423</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
  <freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriod id="F_000607" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">-5336</freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriod>
  <freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod id="F_000608" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">3201</freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber id="F_000609" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">1657345</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber id="F_000610" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">1657345</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="F_000611" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">275243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000612" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">70366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue id="F_000613" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20171231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.27</freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue>
  <freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000614" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.75</freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageFairValue id="F_000615" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.07</freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageFairValue>
  <freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriodWeightedAverageFairValue id="F_000616" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.07</freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriodWeightedAverageFairValue>
  <freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue id="F_000617" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.28</freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue>
  <freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue id="F_000618" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.28</freq:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue id="F_000619" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_000620" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue id="F_000621" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">81000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue id="F_000622" contextRef="C_0001703647_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">73000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000623" contextRef="C_0001703647_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3609000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000624" contextRef="C_0001703647_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">455000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_000625" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">13820000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_000626" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">717000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000627" contextRef="C_0001703647_20190101_20191231">P2Y9M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000628" contextRef="C_0001703647_20180101_20181231">P2Y9M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <freq:PercentageOfEligibleEmployeeCompensation id="F_000629" contextRef="C_0001703647_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20190919_20190920" decimals="2" unitRef="U_xbrlipure">0.20</freq:PercentageOfEligibleEmployeeCompensation>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000630" contextRef="C_0001703647_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20190920" decimals="INF" unitRef="U_xbrlishares">315000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <freq:PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance id="F_000631" contextRef="C_0001703647_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20190919_20190920">P10Y</freq:PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum id="F_000632" contextRef="C_0001703647_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20190919_20190920" decimals="INF" unitRef="U_xbrlipure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod id="F_000633" contextRef="C_0001703647_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191230_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000634" contextRef="C_0001703647_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:OperatingLossCarryforwards id="F_000635" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231" decimals="-3" unitRef="U_iso4217USD">50199000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="F_000636" contextRef="C_0001703647_srtStatementGeographicalAxis_stprMA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20191231" decimals="-3" unitRef="U_iso4217USD">41242000</us-gaap:OperatingLossCarryforwards>
  <freq:NetOperatingLossCarryforwardsExpirationWithLimitation id="F_000637" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231" decimals="-3" unitRef="U_iso4217USD">22400000</freq:NetOperatingLossCarryforwardsExpirationWithLimitation>
  <freq:OperatingLossCarryforwardsExpirationYear id="F_000638" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231">2037</freq:OperatingLossCarryforwardsExpirationYear>
  <freq:NetOperatingLossCarryforwardsExpirationWithoutLimitation id="F_000639" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231" decimals="-3" unitRef="U_iso4217USD">27779000</freq:NetOperatingLossCarryforwardsExpirationWithoutLimitation>
  <freq:OperatingLossCarryforwardsExpirationYear id="F_000640" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20190101_20191231">2039</freq:OperatingLossCarryforwardsExpirationYear>
  <freq:TaxCreditCarryforwardExpirationYear id="F_000641" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231">2039</freq:TaxCreditCarryforwardExpirationYear>
  <freq:TaxCreditCarryforwardExpirationYear id="F_000642" contextRef="C_0001703647_srtStatementGeographicalAxis_stprMA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20190101_20191231">2034</freq:TaxCreditCarryforwardExpirationYear>
  <us-gaap:TaxCreditCarryforwardAmount id="F_000643" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20191231" decimals="-3" unitRef="U_iso4217USD">701000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardAmount id="F_000644" contextRef="C_0001703647_srtStatementGeographicalAxis_stprMA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20191231" decimals="-3" unitRef="U_iso4217USD">533000</us-gaap:TaxCreditCarryforwardAmount>
  <freq:CumulativeChangeInOwnershipPercentage id="F_000645" contextRef="C_0001703647_srtRangeAxis_srtMinimumMember_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.50</freq:CumulativeChangeInOwnershipPercentage>
  <freq:PeriodOfCumulativeChangeInOwnership id="F_000646" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20190101_20191231">P3Y</freq:PeriodOfCumulativeChangeInOwnership>
  <us-gaap:OperatingLossCarryforwards id="F_000647" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20170228" decimals="-3" unitRef="U_iso4217USD">12400000</us-gaap:OperatingLossCarryforwards>
  <freq:OperatingLossCarryforwardsUsageAfterOwnershipChange id="F_000648" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20170331" decimals="-3" unitRef="U_iso4217USD">10800000</freq:OperatingLossCarryforwardsUsageAfterOwnershipChange>
  <freq:OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange id="F_000649" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20170331" decimals="-3" unitRef="U_iso4217USD">1600000</freq:OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange>
  <freq:OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange id="F_000650" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20170331" decimals="-3" unitRef="U_iso4217USD">180000</freq:OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange>
  <freq:RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration id="F_000651" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20170331" decimals="-3" unitRef="U_iso4217USD">1600000</freq:RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration>
  <us-gaap:OperatingLossCarryforwards id="F_000652" contextRef="C_0001703647_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapIncomeTaxAuthorityNameAxis_us-gaapInternalRevenueServiceIRSMember_20191031" decimals="-3" unitRef="U_iso4217USD">46123000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit id="F_000653" contextRef="C_0001703647_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
  <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit id="F_000654" contextRef="C_0001703647_20180101_20181231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000655" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">16204000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000656" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">12229000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:UnrecognizedTaxBenefits id="F_000657" contextRef="C_0001703647_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits id="F_000658" contextRef="C_0001703647_20181231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense id="F_000659" contextRef="C_0001703647_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense id="F_000660" contextRef="C_0001703647_20180101_20181231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000661" contextRef="C_0001703647_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000662" contextRef="C_0001703647_20180101_20181231" decimals="INF" unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000663" contextRef="C_0001703647_20170101_20171231" decimals="INF" unitRef="U_xbrlipure">0.340</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate id="F_000664" contextRef="C_0001703647_20170101_20171231" decimals="3" unitRef="U_xbrlipure">-0.130</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential id="F_000665" contextRef="C_0001703647_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.028</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential id="F_000666" contextRef="C_0001703647_20180101_20181231" decimals="3" unitRef="U_xbrlipure">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential id="F_000667" contextRef="C_0001703647_20170101_20171231" decimals="3" unitRef="U_xbrlipure">-0.050</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000668" contextRef="C_0001703647_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.040</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000669" contextRef="C_0001703647_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.048</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000670" contextRef="C_0001703647_20170101_20171231" decimals="3" unitRef="U_xbrlipure">0.063</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="F_000671" contextRef="C_0001703647_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="F_000672" contextRef="C_0001703647_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="F_000673" contextRef="C_0001703647_20170101_20171231" decimals="3" unitRef="U_xbrlipure">0.036</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent id="F_000674" contextRef="C_0001703647_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent id="F_000675" contextRef="C_0001703647_20180101_20181231" decimals="3" unitRef="U_xbrlipure">-0.020</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000676" contextRef="C_0001703647_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.230</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000677" contextRef="C_0001703647_20180101_20181231" decimals="3" unitRef="U_xbrlipure">-0.263</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000678" contextRef="C_0001703647_20170101_20171231" decimals="3" unitRef="U_xbrlipure">-0.259</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000679" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">13253000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000680" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">10710000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000681" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">1138000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000682" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">1014000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets id="F_000683" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">358000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets id="F_000684" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">256000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000685" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">686000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000686" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">68000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities id="F_000687" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">48000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities id="F_000688" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">22000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
  <us-gaap:DeferredTaxAssetsDeferredIncome id="F_000689" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">496000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsOther id="F_000690" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">189000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther id="F_000691" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">210000</us-gaap:DeferredTaxAssetsOther>
  <freq:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment id="F_000692" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">36000</freq:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment>
  <freq:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment id="F_000693" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">-51000</freq:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsGross id="F_000694" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">16204000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross id="F_000695" contextRef="C_0001703647_20181231" decimals="-3" unitRef="U_iso4217USD">12229000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000696" contextRef="C_0001703647_20171222_20171222" decimals="INF" unitRef="U_xbrlipure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000697" contextRef="C_0001703647_20180101_20180101" decimals="INF" unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit id="F_000698" contextRef="C_0001703647_20171222_20171222" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit>
  <freq:OperatingLossDeductionLimitationAsPercentageOfTaxableIncome id="F_000699" contextRef="C_0001703647_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.80</freq:OperatingLossDeductionLimitationAsPercentageOfTaxableIncome>
  <freq:LicenseAgreementEnteredDate id="F_000700" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqPatentLicenseAgreementMember_20161201_20161231">2016-12</freq:LicenseAgreementEnteredDate>
  <freq:DescriptionOfFutureDevelopmentObligations id="F_000701" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_20190101_20191231">The Company&#8217;s future development obligations are: (i) to commence a Phase II clinical trial for such Product, (ii) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product within two years of the IND filing for such product, (iii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such product, and (iv) to make a first commercial sale of such Product within 11 years of the IND filing for such product.</freq:DescriptionOfFutureDevelopmentObligations>
  <freq:LicenseFeePayment id="F_000702" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_20161231" decimals="-3" unitRef="U_iso4217USD">50000</freq:LicenseFeePayment>
  <freq:PercentageOfSharesOfCommonStockIssued id="F_000703" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_20161201_20161231" decimals="INF" unitRef="U_xbrlipure">0.05</freq:PercentageOfSharesOfCommonStockIssued>
  <freq:MilestonePayments id="F_000704" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_srtRangeAxis_srtMaximumMember_20161201_20161231" decimals="-3" unitRef="U_iso4217USD">2900000</freq:MilestonePayments>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000705" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtProductOrServiceAxis_us-gaapRoyaltyMember_20161201_20161231" decimals="-3" unitRef="U_iso4217USD">16000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <freq:DescriptionOfConditionsToTerminateLicenseAgreement id="F_000706" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_20190101_20191231">The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company&#8217;s material breach uncured within ninety (90) days (or thirty (30) days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30) days after MIT&#8217;s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge.</freq:DescriptionOfConditionsToTerminateLicenseAgreement>
  <freq:RightToTerminateAgreementUponPriorWrittenNotice id="F_000707" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_20161201_20161231">P3M</freq:RightToTerminateAgreementUponPriorWrittenNotice>
  <freq:RightToTerminateAgreementIfBreachRemainsUncured id="F_000708" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_20161201_20161231">P90D</freq:RightToTerminateAgreementIfBreachRemainsUncured>
  <freq:RightToTerminateAgreementIncaseOfNonpayment id="F_000709" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsInstituteOfTechnologyMember_20161201_20161231">P30D</freq:RightToTerminateAgreementIncaseOfNonpayment>
  <freq:LicenseAgreementEnteredDate id="F_000710" contextRef="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqPatentLicenseAgreementMember_20180901_20180930">2018-09</freq:LicenseAgreementEnteredDate>
  <freq:LicenseFeePayment id="F_000711" contextRef="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_20180930" decimals="-3" unitRef="U_iso4217USD">1000000</freq:LicenseFeePayment>
  <freq:MilestonePayments id="F_000712" contextRef="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_srtRangeAxis_srtMaximumMember_20180901_20180930" decimals="-3" unitRef="U_iso4217USD">26000000</freq:MilestonePayments>
  <freq:PercentageOfSharesOfCommonStockIssued id="F_000713" contextRef="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_20180901_20180930" decimals="INF" unitRef="U_xbrlipure">0.50</freq:PercentageOfSharesOfCommonStockIssued>
  <freq:DescriptionOfConditionsToTerminateLicenseAgreement id="F_000714" contextRef="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_20190101_20191231">The Company may terminate the CALIBR License Agreement at will upon a 30-day prior written notice. The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90) days&#8217; prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30) days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products.</freq:DescriptionOfConditionsToTerminateLicenseAgreement>
  <freq:RightToTerminateAgreementUponPriorWrittenNotice id="F_000715" contextRef="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_20180901_20180930">P30D</freq:RightToTerminateAgreementUponPriorWrittenNotice>
  <freq:RightToTerminateLicensedPatentsUponPriorWrittenNotice id="F_000716" contextRef="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_20180901_20180930">P90D</freq:RightToTerminateLicensedPatentsUponPriorWrittenNotice>
  <freq:RightToTerminateAgreementIfBreachRemainsUncured id="F_000717" contextRef="C_0001703647_deiLegalEntityAxis_freqCaliforniaInstituteForBiomedicalResearchMember_20180901_20180930">P30D</freq:RightToTerminateAgreementIfBreachRemainsUncured>
  <freq:LicenseAgreementEnteredDate id="F_000718" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarInfirmaryMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqNonExclusivePatentLicenseAgreementMember_20190201_20190228">2019-02</freq:LicenseAgreementEnteredDate>
  <freq:LicenseFeePayment id="F_000719" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarInfirmaryMember_20190228" decimals="-3" unitRef="U_iso4217USD">20000</freq:LicenseFeePayment>
  <freq:MilestonePayments id="F_000720" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarInfirmaryMember_srtRangeAxis_srtMaximumMember_20190201_20190228" decimals="-3" unitRef="U_iso4217USD">350000</freq:MilestonePayments>
  <freq:DescriptionOfConditionsToTerminateLicenseAgreement id="F_000721" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarInfirmaryMember_20190101_20191231">The Company has the right to terminate the MEEI License Agreement at will by giving thirty (30) business days advance written notice to MEEI. MEEI has the right to terminate the MEEI License Agreement if the Company fails to make any payment due within thirty (30) business days after MEEI notifies the Company of such failure. MEEI shall have the right to terminate if the Company fails to maintain the required insurance. MEEI shall also have the right to terminate the MEEI License Agreement upon forty-five (45) business days written notice if the Company becomes insolvent. MEEI has the right to terminate for any other default not cured within sixty (60) business days written notice. MEEI also has the right to terminate if the Company or its affiliates challenge the validity of the licensed patent rights.</freq:DescriptionOfConditionsToTerminateLicenseAgreement>
  <freq:RightToTerminateAgreementUponPriorWrittenNotice id="F_000722" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarInfirmaryMember_20190201_20190228">P30D</freq:RightToTerminateAgreementUponPriorWrittenNotice>
  <freq:RightToTerminateAgreementIncaseOfNonpayment id="F_000723" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarInfirmaryMember_20190201_20190228">P30D</freq:RightToTerminateAgreementIncaseOfNonpayment>
  <freq:RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent id="F_000724" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarInfirmaryMember_20190201_20190228">P45D</freq:RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent>
  <freq:RightToTerminateAgreementIfBreachRemainsUncured id="F_000725" contextRef="C_0001703647_deiLegalEntityAxis_freqMassachusettsEyeAndEarInfirmaryMember_20190201_20190228">P60D</freq:RightToTerminateAgreementIfBreachRemainsUncured>
  <freq:LicenseAgreementEnteredDate id="F_000726" contextRef="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqPatentLicenseAgreementMember_20191201_20191231">2019-12</freq:LicenseAgreementEnteredDate>
  <freq:LicenseFeePayment id="F_000727" contextRef="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_20191231" decimals="-3" unitRef="U_iso4217USD">50000</freq:LicenseFeePayment>
  <freq:AnnualLicenseFee id="F_000728" contextRef="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_20191201_20191231" decimals="-3" unitRef="U_iso4217USD">50000</freq:AnnualLicenseFee>
  <freq:MilestonePayments id="F_000729" contextRef="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_srtRangeAxis_srtMaximumMember_20191201_20191231" decimals="-2" unitRef="U_iso4217USD">10500</freq:MilestonePayments>
  <freq:DescriptionOfConditionsToTerminateLicenseAgreement id="F_000730" contextRef="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_20190101_20191231">We have the right to terminate for any reason upon 90 days&#8217; prior to written notice.  Each party has the right to terminate immediately if the other party ceases to carry on its business.  Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days.  Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge Licensed Product or we or our affiliates or sub-licenses commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed.</freq:DescriptionOfConditionsToTerminateLicenseAgreement>
  <freq:RightToTerminateAgreementUponPriorWrittenNotice id="F_000731" contextRef="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_20191201_20191231">P90D</freq:RightToTerminateAgreementUponPriorWrittenNotice>
  <freq:RightToTerminateAgreementIfBreachRemainsUncured id="F_000732" contextRef="C_0001703647_deiLegalEntityAxis_freqCambridgeEnterpriseLimitedMember_20191201_20191231">P30D</freq:RightToTerminateAgreementIfBreachRemainsUncured>
  <freq:AmountOfFundingReceivedAsGrant id="F_000733" contextRef="C_0001703647_srtProductOrServiceAxis_us-gaapGrantMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqResearchAndDevelopmentMember_20180601_20180630" decimals="-3" unitRef="U_iso4217USD">1596000</freq:AmountOfFundingReceivedAsGrant>
  <freq:GrantTermPeriod id="F_000734" contextRef="C_0001703647_srtProductOrServiceAxis_us-gaapGrantMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_freqResearchAndDevelopmentMember_20180601_20180630">P2Y</freq:GrantTermPeriod>
  <freq:IncreaseDecreaseInResearchAndDevelopmentExpense id="F_000735" contextRef="C_0001703647_srtProductOrServiceAxis_us-gaapGrantMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">845000</freq:IncreaseDecreaseInResearchAndDevelopmentExpense>
  <freq:IncreaseDecreaseInResearchAndDevelopmentExpense id="F_000736" contextRef="C_0001703647_srtProductOrServiceAxis_us-gaapGrantMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">428000</freq:IncreaseDecreaseInResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromCollaborators id="F_000737" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731" decimals="-5" unitRef="U_iso4217USD">80000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000738" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731" decimals="-5" unitRef="U_iso4217USD">230000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <freq:ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones id="F_000739" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731" decimals="-5" unitRef="U_iso4217USD">315000000</freq:ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000740" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_freqPhase2bClinicalTrialMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731" decimals="-5" unitRef="U_iso4217USD">65000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000741" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtStatementGeographicalAxis_srtAsiaMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_freqPhase2bClinicalTrialMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731" decimals="-5" unitRef="U_iso4217USD">25000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000742" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_freqPhase3ClinicalTrailMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731" decimals="-5" unitRef="U_iso4217USD">100000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000743" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtStatementGeographicalAxis_srtAsiaMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_freqPhase3ClinicalTrailMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731" decimals="-5" unitRef="U_iso4217USD">40000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <freq:RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization id="F_000744" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731" decimals="-5" unitRef="U_iso4217USD">315000000</freq:RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization>
  <freq:AgreementTerminationNoticePeriod id="F_000745" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731">P60D</freq:AgreementTerminationNoticePeriod>
  <freq:RightToTerminateAgreementIfBreachRemainsUncured id="F_000746" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731">P90D</freq:RightToTerminateAgreementIfBreachRemainsUncured>
  <freq:RightToTerminateAgreementIncaseOfNonpayment id="F_000747" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190731">P45D</freq:RightToTerminateAgreementIncaseOfNonpayment>
  <freq:RevenueRecognitionTransactionPrice id="F_000748" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">80000000</freq:RevenueRecognitionTransactionPrice>
  <us-gaap:AccruedRoyaltiesCurrent id="F_000749" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20191231" decimals="-5" unitRef="U_iso4217USD">16000000</us-gaap:AccruedRoyaltiesCurrent>
  <us-gaap:RoyaltyExpense id="F_000750" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20190930" decimals="-5" unitRef="U_iso4217USD">16000000</us-gaap:RoyaltyExpense>
  <freq:UpfrontFeeRecognizedAsRevenue id="F_000751" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190701_20191231" decimals="-5" unitRef="U_iso4217USD">80000000</freq:UpfrontFeeRecognizedAsRevenue>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000752" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">28900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000753" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_srtProductOrServiceAxis_us-gaapRoyaltyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">16000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <freq:RevenueFromContractWithCustomerApplicationInputMethod id="F_000754" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">12900000</freq:RevenueFromContractWithCustomerApplicationInputMethod>
  <us-gaap:RevenueRemainingPerformanceObligation id="F_000755" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20191231" decimals="-5" unitRef="U_iso4217USD">64000000</us-gaap:RevenueRemainingPerformanceObligation>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000756" contextRef="C_0001703647_srtCounterpartyNameAxis_freqAstellasPharmaLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_freqLicenseAndCollaborationAgreementMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">186000</us-gaap:ResearchAndDevelopmentExpense>
  <freq:OperatingLeasesTermOfContract id="F_000757" contextRef="C_0001703647_srtStatementGeographicalAxis_stprMA_20160101_20161231">P5Y</freq:OperatingLeasesTermOfContract>
  <freq:OperatingLeasesTermOfContract id="F_000758" contextRef="C_0001703647_srtStatementGeographicalAxis_stprMA_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200201_20200229">P5Y</freq:OperatingLeasesTermOfContract>
  <freq:LeaseExpirationYear id="F_000759" contextRef="C_0001703647_srtStatementGeographicalAxis_stprCT_20190101_20191231">2019</freq:LeaseExpirationYear>
  <us-gaap:OperatingLeasesRentExpenseNet id="F_000760" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">269000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet id="F_000761" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">271000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:NetRentableArea id="F_000762" contextRef="C_0001703647_srtCounterpartyNameAxis_freqHaydenLLCMember_us-gaapLeaseArrangementTypeAxis_freqLexingtonLeaseMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200107" decimals="INF" unitRef="U_utrsqft">61307</us-gaap:NetRentableArea>
  <freq:OperatingLeaseCommencementDate id="F_000763" contextRef="C_0001703647_srtCounterpartyNameAxis_freqHaydenLLCMember_us-gaapLeaseArrangementTypeAxis_freqLexingtonLeaseMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200107_20200107">2020-12-01</freq:OperatingLeaseCommencementDate>
  <freq:OperatingLeasesTermOfContract id="F_000764" contextRef="C_0001703647_srtCounterpartyNameAxis_freqHaydenLLCMember_us-gaapLeaseArrangementTypeAxis_freqLexingtonLeaseMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200107_20200107">P10Y</freq:OperatingLeasesTermOfContract>
  <us-gaap:LeaseExpirationDate1 id="F_000765" contextRef="C_0001703647_srtCounterpartyNameAxis_freqHaydenLLCMember_us-gaapLeaseArrangementTypeAxis_freqLexingtonLeaseMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200107_20200107">2031-04-30</us-gaap:LeaseExpirationDate1>
  <freq:OperatingLeaseNumberOfAdditionalExtensionTerms id="F_000766" contextRef="C_0001703647_srtCounterpartyNameAxis_freqHaydenLLCMember_us-gaapLeaseArrangementTypeAxis_freqLexingtonLeaseMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200107" decimals="INF" unitRef="U_freqTerm">2</freq:OperatingLeaseNumberOfAdditionalExtensionTerms>
  <freq:OperatingLeasesAdditionalExtensionTerm id="F_000767" contextRef="C_0001703647_srtCounterpartyNameAxis_freqHaydenLLCMember_us-gaapLeaseArrangementTypeAxis_freqLexingtonLeaseMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200107_20200107">P5Y</freq:OperatingLeasesAdditionalExtensionTerm>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="F_000768" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">504000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears id="F_000769" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">3613000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears id="F_000770" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">4741000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears id="F_000771" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">4883000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears id="F_000772" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">5034000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter id="F_000773" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">35596000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue id="F_000774" contextRef="C_0001703647_20191231" decimals="-3" unitRef="U_iso4217USD">54371000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:LongTermPurchaseCommitmentAmount id="F_000775" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">705000</us-gaap:LongTermPurchaseCommitmentAmount>
  <us-gaap:LongtermPurchaseCommitmentPeriod id="F_000776" contextRef="C_0001703647_srtRangeAxis_srtMinimumMember_20190101_20191231">P12M</us-gaap:LongtermPurchaseCommitmentPeriod>
  <freq:OperatingLeasesTermOfContract id="F_000777" contextRef="C_0001703647_20190101_20191231">P5Y</freq:OperatingLeasesTermOfContract>
  <us-gaap:LossContingencyLossInPeriod id="F_000778" contextRef="C_0001703647_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:LossContingencyLossInPeriod>
  <us-gaap:LossContingencyLossInPeriod id="F_000779" contextRef="C_0001703647_20180101_20181231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:LossContingencyLossInPeriod>
  <us-gaap:LossContingencyLossInPeriod id="F_000780" contextRef="C_0001703647_20170101_20171231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:LossContingencyLossInPeriod>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent id="F_000781" contextRef="C_0001703647_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.90</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch id="F_000782" contextRef="C_0001703647_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">1.00</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent id="F_000783" contextRef="C_0001703647_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
  <us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage id="F_000784" contextRef="C_0001703647_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">1.00</us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000785" contextRef="C_0001703647_20190701_20190930" decimals="-3" unitRef="U_iso4217USD">24238000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000786" contextRef="C_0001703647_20191001_20191231" decimals="-3" unitRef="U_iso4217USD">4709000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <freq:OperatingAndNonOperatingExpensesNet id="F_000787" contextRef="C_0001703647_20190101_20190331" decimals="-3" unitRef="U_iso4217USD">5826000</freq:OperatingAndNonOperatingExpensesNet>
  <freq:OperatingAndNonOperatingExpensesNet id="F_000788" contextRef="C_0001703647_20190401_20190630" decimals="-3" unitRef="U_iso4217USD">6852000</freq:OperatingAndNonOperatingExpensesNet>
  <freq:OperatingAndNonOperatingExpensesNet id="F_000789" contextRef="C_0001703647_20190701_20190930" decimals="-3" unitRef="U_iso4217USD">24813000</freq:OperatingAndNonOperatingExpensesNet>
  <freq:OperatingAndNonOperatingExpensesNet id="F_000790" contextRef="C_0001703647_20191001_20191231" decimals="-3" unitRef="U_iso4217USD">10202000</freq:OperatingAndNonOperatingExpensesNet>
  <freq:OperatingAndNonOperatingExpensesNet id="F_000791" contextRef="C_0001703647_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">47693000</freq:OperatingAndNonOperatingExpensesNet>
  <us-gaap:NetIncomeLoss id="F_000792" contextRef="C_0001703647_20190101_20190331" decimals="-3" unitRef="U_iso4217USD">-5826000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000793" contextRef="C_0001703647_20190401_20190630" decimals="-3" unitRef="U_iso4217USD">-6852000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000794" contextRef="C_0001703647_20190701_20190930" decimals="-3" unitRef="U_iso4217USD">-575000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000795" contextRef="C_0001703647_20191001_20191231" decimals="-3" unitRef="U_iso4217USD">-5493000</us-gaap:NetIncomeLoss>
  <us-gaap:TemporaryEquityDividendsAdjustment id="F_000796" contextRef="C_0001703647_20190701_20190930" decimals="-3" unitRef="U_iso4217USD">1014000</us-gaap:TemporaryEquityDividendsAdjustment>
  <us-gaap:TemporaryEquityDividendsAdjustment id="F_000797" contextRef="C_0001703647_20191001_20191231" decimals="-3" unitRef="U_iso4217USD">40000</us-gaap:TemporaryEquityDividendsAdjustment>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000798" contextRef="C_0001703647_20190101_20190331" decimals="-3" unitRef="U_iso4217USD">-5826000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000799" contextRef="C_0001703647_20190401_20190630" decimals="-3" unitRef="U_iso4217USD">-6852000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000800" contextRef="C_0001703647_20190701_20190930" decimals="-3" unitRef="U_iso4217USD">-1589000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000801" contextRef="C_0001703647_20191001_20191231" decimals="-3" unitRef="U_iso4217USD">-5533000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000802" contextRef="C_0001703647_20190101_20190331" decimals="2" unitRef="U_iso4217USD_xbrlishares">-3.24</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000803" contextRef="C_0001703647_20190401_20190630" decimals="2" unitRef="U_iso4217USD_xbrlishares">-3.42</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000804" contextRef="C_0001703647_20190701_20190930" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.73</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000805" contextRef="C_0001703647_20191001_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.19</us-gaap:EarningsPerShareBasicAndDiluted>
  <freq:OperatingAndNonOperatingExpensesNet id="F_000806" contextRef="C_0001703647_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">4149000</freq:OperatingAndNonOperatingExpensesNet>
  <freq:OperatingAndNonOperatingExpensesNet id="F_000807" contextRef="C_0001703647_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">4436000</freq:OperatingAndNonOperatingExpensesNet>
  <freq:OperatingAndNonOperatingExpensesNet id="F_000808" contextRef="C_0001703647_20180701_20180930" decimals="-3" unitRef="U_iso4217USD">5136000</freq:OperatingAndNonOperatingExpensesNet>
  <freq:OperatingAndNonOperatingExpensesNet id="F_000809" contextRef="C_0001703647_20181001_20181231" decimals="-3" unitRef="U_iso4217USD">5447000</freq:OperatingAndNonOperatingExpensesNet>
  <freq:OperatingAndNonOperatingExpensesNet id="F_000810" contextRef="C_0001703647_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">19168000</freq:OperatingAndNonOperatingExpensesNet>
  <us-gaap:NetIncomeLoss id="F_000811" contextRef="C_0001703647_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-4149000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000812" contextRef="C_0001703647_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">-4436000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000813" contextRef="C_0001703647_20180701_20180930" decimals="-3" unitRef="U_iso4217USD">-5136000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000814" contextRef="C_0001703647_20181001_20181231" decimals="-3" unitRef="U_iso4217USD">-5447000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000815" contextRef="C_0001703647_20180101_20180331" decimals="-3" unitRef="U_iso4217USD">-4149000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000816" contextRef="C_0001703647_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">-4436000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000817" contextRef="C_0001703647_20180701_20180930" decimals="-3" unitRef="U_iso4217USD">-5136000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000818" contextRef="C_0001703647_20181001_20181231" decimals="-3" unitRef="U_iso4217USD">-5447000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000819" contextRef="C_0001703647_20180101_20180331" decimals="2" unitRef="U_iso4217USD_xbrlishares">-3.03</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000820" contextRef="C_0001703647_20180401_20180630" decimals="2" unitRef="U_iso4217USD_xbrlishares">-3.01</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000821" contextRef="C_0001703647_20180701_20180930" decimals="2" unitRef="U_iso4217USD_xbrlishares">-3.26</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000822" contextRef="C_0001703647_20181001_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-3.23</us-gaap:EarningsPerShareBasicAndDiluted>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>48
<FILENAME>freq-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-03-26T03:10:11.1885690+00:00 -->
<!-- Version            : 5.0.1.369 -->
<!-- Package ID         : da71a932536d471fac83859dace20368 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:freq="http://www.frequencytx.com/20191231" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.frequencytx.com/20191231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" namespace="http://fasb.org/srt/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd" namespace="http://fasb.org/srt-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" namespace="http://fasb.org/srt-types/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" namespace="http://fasb.org/us-gaap/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" namespace="http://fasb.org/us-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" namespace="http://fasb.org/us-types/2019-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.frequencytx.com/20191231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="freq-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="freq-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="freq-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="freq-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficit" id="Role_StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficit">
        <link:definition>100050 - Statement - Consolidated Statement of Convertible Preferred Stock, Non-controlling Interest and Stockholder&apos;s Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficitParenthetical" id="Role_StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficitParenthetical">
        <link:definition>100060 - Statement - Consolidated Statement of Convertible Preferred Stock, Non-controlling Interest and Stockholder&apos;s Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation" id="Role_DisclosureOrganizationAndBasisOfPresentation">
        <link:definition>100080 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100090 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePrepaidExpenses" id="Role_DisclosurePrepaidExpenses">
        <link:definition>100110 - Disclosure - Prepaid Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100120 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100130 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureConvertibleNotes" id="Role_DisclosureConvertibleNotes">
        <link:definition>100140 - Disclosure - Convertible Notes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureConvertiblePreferredStock" id="Role_DisclosureConvertiblePreferredStock">
        <link:definition>100150 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureNonControllingInterest" id="Role_DisclosureNonControllingInterest">
        <link:definition>100160 - Disclosure - Non-controlling Interest</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockholdersDeficit" id="Role_DisclosureStockholdersDeficit">
        <link:definition>100170 - Disclosure - Stockholders&apos; Deficit</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100180 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureEmployeeStockPurchasePlan" id="Role_DisclosureEmployeeStockPurchasePlan">
        <link:definition>100190 - Disclosure - Employee Stock Purchase Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTax" id="Role_DisclosureIncomeTax">
        <link:definition>100200 - Disclosure - Income Tax</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureResearchAndLicenseAgreements" id="Role_DisclosureResearchAndLicenseAgreements">
        <link:definition>100210 - Disclosure - Research and License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCollaborationAgreement" id="Role_DisclosureCollaborationAgreement">
        <link:definition>100220 - Disclosure - Collaboration Agreement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100230 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureEmployeeBenefitPlan" id="Role_DisclosureEmployeeBenefitPlan">
        <link:definition>100240 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100250 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100260 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSelectedQuarterlyDataUnaudited" id="Role_DisclosureSelectedQuarterlyDataUnaudited">
        <link:definition>100270 - Disclosure - Selected Quarterly Data (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100280 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100290 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100300 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePrepaidExpensesTables" id="Role_DisclosurePrepaidExpensesTables">
        <link:definition>100310 - Disclosure - Prepaid Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100320 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100330 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockholdersDeficitTables" id="Role_DisclosureStockholdersDeficitTables">
        <link:definition>100340 - Disclosure - Stockholders&apos; Deficit (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100350 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100360 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100370 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedTables" id="Role_DisclosureSelectedQuarterlyDataUnauditedTables">
        <link:definition>100380 - Disclosure - Selected Quarterly Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails">
        <link:definition>100410 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100420 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100430 - Disclosure - Summary of Significant Accounting Policies - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails">
        <link:definition>100440 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePrepaidExpensesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="Role_DisclosurePrepaidExpensesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>100460 - Disclosure - Prepaid Expenses - Summary of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>100470 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" id="Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
        <link:definition>100490 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails" id="Role_DisclosureConvertibleNotesAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Convertible Notes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100510 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureNonControllingInterestAdditionalInformationDetails" id="Role_DisclosureNonControllingInterestAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Non-controlling Interest - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails" id="Role_DisclosureStockholdersDeficitAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Stockholders&apos; Deficit - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockholdersDeficitScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" id="Role_DisclosureStockholdersDeficitScheduleOfCommonStockSharesReservedForFutureIssuanceDetails">
        <link:definition>100540 - Disclosure - Stockholders&apos; Deficit - Schedule of Common Stock Shares Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnder2014PlanAnd2019PlanDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnder2014PlanAnd2019PlanDetails">
        <link:definition>100560 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity under 2014 Plan and 2019 Plan (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails" id="Role_DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails">
        <link:definition>100570 - Disclosure - Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockDetails">
        <link:definition>100580 - Disclosure - Stock-based Compensation - Summary of Status of Restricted Common Stock (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails" id="Role_DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails">
        <link:definition>100590 - Disclosure - Employee Stock Purchase Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails">
        <link:definition>100610 - Disclosure - Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails">
        <link:definition>100620 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureResearchAndLicenseAgreementsAdditionalInformationDetails" id="Role_DisclosureResearchAndLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100630 - Disclosure - Research and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails" id="Role_DisclosureCollaborationAgreementAdditionalInformationDetails">
        <link:definition>100640 - Disclosure - Collaboration Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100650 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetails">
        <link:definition>100660 - Disclosure - Commitments and Contingencies - Schedule of Minimum Aggregate Future Operating Lease Commitments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" id="Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails">
        <link:definition>100670 - Disclosure - Employee Benefit Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedScheduleOfQuarterlyFinancialInformationDetails" id="Role_DisclosureSelectedQuarterlyDataUnauditedScheduleOfQuarterlyFinancialInformationDetails">
        <link:definition>100680 - Disclosure - Selected Quarterly Data (Unaudited) - Schedule of Quarterly Financial Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="freq_OperatingAndNonOperatingExpensesNet" name="OperatingAndNonOperatingExpensesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_SeriesB1ConvertiblePreferredStockMember" name="SeriesB1ConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_SeriesA1ConvertiblePreferredStockMember" name="SeriesA1ConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_StockIssuedDuringPeriodValueIssuedForPatentLicense" name="StockIssuedDuringPeriodValueIssuedForPatentLicense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_StockIssuedDuringPeriodSharesIssuedForPatentLicense" name="StockIssuedDuringPeriodSharesIssuedForPatentLicense" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue" name="TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue" name="TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_StockRepurchaseDuringPeriodValueRestrictedStock" name="StockRepurchaseDuringPeriodValueRestrictedStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_StockRepurchaseDuringPeriodSharesRestrictedStock" name="StockRepurchaseDuringPeriodSharesRestrictedStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_ConvertiblePreferredStockAccretionOfDividend" name="ConvertiblePreferredStockAccretionOfDividend" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" name="TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" name="TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" name="StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" name="StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_SeriesCConvertiblePreferredStockMember" name="SeriesCConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_DeferredLeaseIncentives" name="DeferredLeaseIncentives" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt" name="PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_NonCashDividendOnCumulativeConvertiblePreferredStock" name="NonCashDividendOnCumulativeConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_CashPaidDuringPeriodForAbstract" name="CashPaidDuringPeriodForAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_TemporaryEquityTextBlock" name="TemporaryEquityTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_EmployeeStockPurchasePlanDisclosureTextBlock" name="EmployeeStockPurchasePlanDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_ResearchAndLicenseAgreementsDisclosureTextBlock" name="ResearchAndLicenseAgreementsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_SignificantSuppliersPolicyTextBlock" name="SignificantSuppliersPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_NonControllingInterestPolicyTextBlock" name="NonControllingInterestPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_PropertyAndEquipmentTableTextBlock" name="PropertyAndEquipmentTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_WoburnMassachusettsFacilityMember" name="WoburnMassachusettsFacilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_LabEquipmentMember" name="LabEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_FurnitureAndOfficeEquipmentMember" name="FurnitureAndOfficeEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_UnvestedRestrictedCommonStockMember" name="UnvestedRestrictedCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_SeriesCPreferredAsConvertedToCommonStockMember" name="SeriesCPreferredAsConvertedToCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_SeriesBPreferredAsConvertedToCommonStockMember" name="SeriesBPreferredAsConvertedToCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_SeriesAPreferredAsConvertedCommonStockMember" name="SeriesAPreferredAsConvertedCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_ConversionOfFrequencyJapanPreferredStockMember" name="ConversionOfFrequencyJapanPreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_OutstandingStockOptionsAsConvertedToCommonStockMember" name="OutstandingStockOptionsAsConvertedToCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_PrepaidRentAndDepositsCurrent" name="PrepaidRentAndDepositsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_PrepaidResearchAndDevelopmentExpenseCurrent" name="PrepaidResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" name="AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_QualifiedSeriesBFinancingMember" name="QualifiedSeriesBFinancingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_SeriesBNotesMember" name="SeriesBNotesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_QualifiedSeriesAFinancingMember" name="QualifiedSeriesAFinancingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_PriorToQualifiedSeriesAFinancingMember" name="PriorToQualifiedSeriesAFinancingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_SeriesANotesMember" name="SeriesANotesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_DebtInstrumentDiscountRate" name="DebtInstrumentDiscountRate" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_DebtInstrumentLossOnConversion" name="DebtInstrumentLossOnConversion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion" name="DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_DebtInstrumentExcessFinancingFundReceived" name="DebtInstrumentExcessFinancingFundReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_DebtInstrumentExtendedMaturityDate" name="DebtInstrumentExtendedMaturityDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_DebtInstrumentConvertibleDiscountOnConversionPrice" name="DebtInstrumentConvertibleDiscountOnConversionPrice" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="freq_TemporaryEquityAdditionalSharesIssued" name="TemporaryEquityAdditionalSharesIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="freq_TemporaryEquityAdditionalSharesIssuedCarryingAmountAttributableToParent" name="TemporaryEquityAdditionalSharesIssuedCarryingAmountAttributableToParent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_PercentageOfVoteOfHoldersOfPreferredStock" name="PercentageOfVoteOfHoldersOfPreferredStock" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_DelawareLimitedLiabilityCompanyMember" name="DelawareLimitedLiabilityCompanyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_PreferredStockSharesPurchased" name="PreferredStockSharesPurchased" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_TwoThousandAndFourteenStockIncentivePlanMember" name="TwoThousandAndFourteenStockIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" name="TwoThousandAndNineteenIncentiveAwardPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" name="PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageFairValue" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriodWeightedAverageFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriodWeightedAverageFairValue" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="freq_PercentageOfEligibleEmployeeCompensation" name="PercentageOfEligibleEmployeeCompensation" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_IncomeTaxesDisclosureLineItems" name="IncomeTaxesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_IncomeTaxesDisclosureTable" name="IncomeTaxesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_NetOperatingLossCarryforwardsExpirationWithLimitation" name="NetOperatingLossCarryforwardsExpirationWithLimitation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" name="NetOperatingLossCarryforwardsExpirationWithoutLimitation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" name="OperatingLossCarryforwardsUsageAfterOwnershipChange" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" name="OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" name="OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" name="RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_CumulativeChangeInOwnershipPercentage" name="CumulativeChangeInOwnershipPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_PeriodOfCumulativeChangeInOwnership" name="PeriodOfCumulativeChangeInOwnership" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" name="DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_OperatingLossDeductionLimitationAsPercentageOfTaxableIncome" name="OperatingLossDeductionLimitationAsPercentageOfTaxableIncome" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_LicenseAgreementEnteredDate" name="LicenseAgreementEnteredDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_MassachusettsInstituteOfTechnologyMember" name="MassachusettsInstituteOfTechnologyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_PatentLicenseAgreementMember" name="PatentLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_AstellasPharmaLimitedLiabilityCompanyMember" name="AstellasPharmaLimitedLiabilityCompanyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_CaliforniaInstituteForBiomedicalResearchMember" name="CaliforniaInstituteForBiomedicalResearchMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_NonExclusivePatentLicenseAgreementMember" name="NonExclusivePatentLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_MassachusettsEyeAndEarInfirmaryMember" name="MassachusettsEyeAndEarInfirmaryMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_CambridgeEnterpriseLimitedMember" name="CambridgeEnterpriseLimitedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_ResearchAndDevelopmentMember" name="ResearchAndDevelopmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_DescriptionOfFutureDevelopmentObligations" name="DescriptionOfFutureDevelopmentObligations" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_LicenseFeePayment" name="LicenseFeePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_PercentageOfSharesOfCommonStockIssued" name="PercentageOfSharesOfCommonStockIssued" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_RightToTerminateAgreementUponPriorWrittenNotice" name="RightToTerminateAgreementUponPriorWrittenNotice" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_RightToTerminateAgreementIfBreachRemainsUncured" name="RightToTerminateAgreementIfBreachRemainsUncured" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_RightToTerminateAgreementIncaseOfNonpayment" name="RightToTerminateAgreementIncaseOfNonpayment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_DescriptionOfConditionsToTerminateLicenseAgreement" name="DescriptionOfConditionsToTerminateLicenseAgreement" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" name="RightToTerminateLicensedPatentsUponPriorWrittenNotice" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" name="RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_AnnualLicenseFee" name="AnnualLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_IncreaseDecreaseInResearchAndDevelopmentExpense" name="IncreaseDecreaseInResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="freq_AmountOfFundingReceivedAsGrant" name="AmountOfFundingReceivedAsGrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_GrantTermPeriod" name="GrantTermPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" name="ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" name="RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_LicenseAndCollaborationAgreementMember" name="LicenseAndCollaborationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_Phase2bClinicalTrialMember" name="Phase2bClinicalTrialMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_Phase3ClinicalTrailMember" name="Phase3ClinicalTrailMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_AgreementTerminationNoticePeriod" name="AgreementTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_RevenueRecognitionTransactionPrice" name="RevenueRecognitionTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_UpfrontFeeRecognizedAsRevenue" name="UpfrontFeeRecognizedAsRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_RevenueFromContractWithCustomerApplicationInputMethod" name="RevenueFromContractWithCustomerApplicationInputMethod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="freq_OperatingLeasesTermOfContract" name="OperatingLeasesTermOfContract" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_LeaseExpirationYear" name="LeaseExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_HaydenLLCMember" name="HaydenLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_LexingtonLeaseMember" name="LexingtonLeaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="freq_OperatingLeaseCommencementDate" name="OperatingLeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="freq_OperatingLeaseNumberOfAdditionalExtensionTerms" name="OperatingLeaseNumberOfAdditionalExtensionTerms" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="freq_OperatingLeasesAdditionalExtensionTerm" name="OperatingLeasesAdditionalExtensionTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>49
<FILENAME>freq-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-03-26T03:10:11.1885690+00:00 -->
<!-- Version            : 5.0.1.369 -->
<!-- Package ID         : da71a932536d471fac83859dace20368 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="freq-20191231.xsd#TemplateLink" roleURI="http://www.frequencytx.com/20191231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="freq-20191231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="locator" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_CommonStockValue" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="freq-20191231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNet" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RoyaltyExpense" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10120.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="freq-20191231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="freq-20191231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DeferredLeaseIncentives" xlink:type="locator" xlink:label="freq_DeferredLeaseIncentives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="freq_PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMinorityShareholders" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromMinorityShareholders" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="freq_PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="10140.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_PaidInKindInterest" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="freq_DeferredLeaseIncentives" order="10210.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10220.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10250.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:href="freq-20191231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePrepaidExpensesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="freq-20191231.xsd#Role_DisclosurePrepaidExpensesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePrepaidExpensesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_GrantsReceivableCurrent" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="freq_PrepaidResearchAndDevelopmentExpenseCurrent" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PrepaidRentAndDepositsCurrent" xlink:type="locator" xlink:label="freq_PrepaidRentAndDepositsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="freq_PrepaidRentAndDepositsCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="freq_PrepaidResearchAndDevelopmentExpenseCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_GrantsReceivableCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="freq-20191231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="freq-20191231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
    <link:loc xlink:href="freq-20191231.xsd#freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" xlink:href="freq-20191231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" xlink:href="freq-20191231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails">
    <link:loc xlink:href="freq-20191231.xsd#freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" order="10100.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetails" xlink:href="freq-20191231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedScheduleOfQuarterlyFinancialInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureSelectedQuarterlyDataUnauditedScheduleOfQuarterlyFinancialInformationDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedScheduleOfQuarterlyFinancialInformationDetails">
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingAndNonOperatingExpensesNet" xlink:type="locator" xlink:label="freq_OperatingAndNonOperatingExpensesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="freq_OperatingAndNonOperatingExpensesNet" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>50
<FILENAME>freq-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-03-26T03:10:11.1885690+00:00 -->
<!-- Version            : 5.0.1.369 -->
<!-- Package ID         : da71a932536d471fac83859dace20368 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="freq-20191231.xsd#TemplateLink" roleURI="http://www.frequencytx.com/20191231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="freq-20191231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="locator" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10250.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesB1ConvertiblePreferredStockMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesAConvertiblePreferredStockMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesA1ConvertiblePreferredStockMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11820.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="freq-20191231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesB1ConvertiblePreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesAConvertiblePreferredStockMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesA1ConvertiblePreferredStockMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficit" xlink:href="freq-20191231.xsd#Role_StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficit" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="freq-20191231.xsd#freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:loc xlink:href="freq-20191231.xsd#freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ConvertiblePreferredStockAccretionOfDividend" xlink:type="locator" xlink:label="freq_ConvertiblePreferredStockAccretionOfDividend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue" xlink:type="locator" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue" xlink:type="locator" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="freq-20191231.xsd#freq_StockRepurchaseDuringPeriodSharesRestrictedStock" xlink:type="locator" xlink:label="freq_StockRepurchaseDuringPeriodSharesRestrictedStock" />
    <link:loc xlink:href="freq-20191231.xsd#freq_StockRepurchaseDuringPeriodValueRestrictedStock" xlink:type="locator" xlink:label="freq_StockRepurchaseDuringPeriodValueRestrictedStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="freq-20191231.xsd#freq_StockIssuedDuringPeriodSharesIssuedForPatentLicense" xlink:type="locator" xlink:label="freq_StockIssuedDuringPeriodSharesIssuedForPatentLicense" />
    <link:loc xlink:href="freq-20191231.xsd#freq_StockIssuedDuringPeriodValueIssuedForPatentLicense" xlink:type="locator" xlink:label="freq_StockIssuedDuringPeriodValueIssuedForPatentLicense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesCConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesB1ConvertiblePreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesAConvertiblePreferredStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesA1ConvertiblePreferredStockMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_StockIssuedDuringPeriodValueIssuedForPatentLicense" order="11900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_StockIssuedDuringPeriodSharesIssuedForPatentLicense" order="12140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="12620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="12860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_StockRepurchaseDuringPeriodValueRestrictedStock" order="12980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_StockRepurchaseDuringPeriodSharesRestrictedStock" order="13220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="13340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="13520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue" order="13700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue" order="13840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="14060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="14200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" order="14420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_ConvertiblePreferredStockAccretionOfDividend" order="14780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionOfDividends" order="15140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="15500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="15740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" order="15860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" order="15880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" order="15900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" order="16100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="16220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="16580.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficitParenthetical" xlink:href="freq-20191231.xsd#Role_StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficitParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficitParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesAConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="freq-20191231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" />
    <link:loc xlink:href="freq-20191231.xsd#freq_NonCashDividendOnCumulativeConvertiblePreferredStock" xlink:type="locator" xlink:label="freq_NonCashDividendOnCumulativeConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:loc xlink:href="freq-20191231.xsd#freq_CashPaidDuringPeriodForAbstract" xlink:type="locator" xlink:label="freq_CashPaidDuringPeriodForAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMinorityShareholders" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="freq_PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DeferredLeaseIncentives" xlink:type="locator" xlink:label="freq_DeferredLeaseIncentives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10260.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesAConvertiblePreferredStockMember" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesA1ConvertiblePreferredStockMember" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesB1ConvertiblePreferredStockMember" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesCConvertiblePreferredStockMember" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="freq_DeferredLeaseIncentives" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="freq_PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="11770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMinorityShareholders" order="12010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="12130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="12550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="12610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_CashPaidDuringPeriodForAbstract" order="12730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_CashPaidDuringPeriodForAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="12850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="12910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="13030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="freq_NonCashDividendOnCumulativeConvertiblePreferredStock" order="13090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="13150.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10590.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="freq-20191231.xsd#freq_WoburnMassachusettsFacilityMember" xlink:type="locator" xlink:label="freq_WoburnMassachusettsFacilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="freq_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="freq_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="freq_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="freq_WoburnMassachusettsFacilityMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10520.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails" xlink:href="freq-20191231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_FurnitureAndOfficeEquipmentMember" xlink:type="locator" xlink:label="freq_FurnitureAndOfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_LabEquipmentMember" xlink:type="locator" xlink:label="freq_LabEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="freq_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="freq_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="freq_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="freq_LabEquipmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="freq_FurnitureAndOfficeEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="freq-20191231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OutstandingStockOptionsAsConvertedToCommonStockMember" xlink:type="locator" xlink:label="freq_OutstandingStockOptionsAsConvertedToCommonStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ConversionOfFrequencyJapanPreferredStockMember" xlink:type="locator" xlink:label="freq_ConversionOfFrequencyJapanPreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesAPreferredAsConvertedCommonStockMember" xlink:type="locator" xlink:label="freq_SeriesAPreferredAsConvertedCommonStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBPreferredAsConvertedToCommonStockMember" xlink:type="locator" xlink:label="freq_SeriesBPreferredAsConvertedToCommonStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesCPreferredAsConvertedToCommonStockMember" xlink:type="locator" xlink:label="freq_SeriesCPreferredAsConvertedToCommonStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_UnvestedRestrictedCommonStockMember" xlink:type="locator" xlink:label="freq_UnvestedRestrictedCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_UnvestedRestrictedCommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_SeriesCPreferredAsConvertedToCommonStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_SeriesBPreferredAsConvertedToCommonStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_SeriesAPreferredAsConvertedCommonStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_ConversionOfFrequencyJapanPreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_OutstandingStockOptionsAsConvertedToCommonStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:href="freq-20191231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10910.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="freq-20191231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureConvertibleNotesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails">
    <link:loc xlink:href="freq-20191231.xsd#freq_DebtInstrumentExcessFinancingFundReceived" xlink:type="locator" xlink:label="freq_DebtInstrumentExcessFinancingFundReceived" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion" xlink:type="locator" xlink:label="freq_DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DebtInstrumentExtendedMaturityDate" xlink:type="locator" xlink:label="freq_DebtInstrumentExtendedMaturityDate" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DebtInstrumentLossOnConversion" xlink:type="locator" xlink:label="freq_DebtInstrumentLossOnConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DebtInstrumentDiscountRate" xlink:type="locator" xlink:label="freq_DebtInstrumentDiscountRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesANotesMember" xlink:type="locator" xlink:label="freq_SeriesANotesMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PriorToQualifiedSeriesAFinancingMember" xlink:type="locator" xlink:label="freq_PriorToQualifiedSeriesAFinancingMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_QualifiedSeriesAFinancingMember" xlink:type="locator" xlink:label="freq_QualifiedSeriesAFinancingMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBNotesMember" xlink:type="locator" xlink:label="freq_SeriesBNotesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_QualifiedSeriesBFinancingMember" xlink:type="locator" xlink:label="freq_QualifiedSeriesBFinancingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="freq_QualifiedSeriesBFinancingMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="freq_SeriesBNotesMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="freq_QualifiedSeriesAFinancingMember" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="freq_PriorToQualifiedSeriesAFinancingMember" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="freq_SeriesANotesMember" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesAConvertiblePreferredStockMember" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" order="11900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="11950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="11970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="11990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="12010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="freq_DebtInstrumentDiscountRate" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="12050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="freq_DebtInstrumentLossOnConversion" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="freq_DebtInstrumentExtendedMaturityDate" order="12200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="freq_DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion" order="12280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="freq_DebtInstrumentExcessFinancingFundReceived" order="12360.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityAdditionalSharesIssuedCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="freq_TemporaryEquityAdditionalSharesIssuedCarryingAmountAttributableToParent" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityAdditionalSharesIssued" xlink:type="locator" xlink:label="freq_TemporaryEquityAdditionalSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DebtInstrumentConvertibleDiscountOnConversionPrice" xlink:type="locator" xlink:label="freq_DebtInstrumentConvertibleDiscountOnConversionPrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBNotesMember" xlink:type="locator" xlink:label="freq_SeriesBNotesMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesANotesMember" xlink:type="locator" xlink:label="freq_SeriesANotesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesA1ConvertiblePreferredStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesB1ConvertiblePreferredStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="freq_SeriesANotesMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesAConvertiblePreferredStockMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="freq_SeriesBNotesMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesCConvertiblePreferredStockMember" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="freq_DebtInstrumentConvertibleDiscountOnConversionPrice" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="freq_TemporaryEquityAdditionalSharesIssued" order="11850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="freq_TemporaryEquityAdditionalSharesIssuedCarryingAmountAttributableToParent" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="12070.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureNonControllingInterestAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureNonControllingInterestAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureNonControllingInterestAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:type="locator" xlink:label="us-gaap_PreferredStockVotingRights" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PreferredStockSharesPurchased" xlink:type="locator" xlink:label="freq_PreferredStockSharesPurchased" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PercentageOfVoteOfHoldersOfPreferredStock" xlink:type="locator" xlink:label="freq_PercentageOfVoteOfHoldersOfPreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DelawareLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="freq_DelawareLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SubsidiariesMember" xlink:type="locator" xlink:label="srt_SubsidiariesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_SubsidiariesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesA1ConvertiblePreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesB1ConvertiblePreferredStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="freq_DelawareLimitedLiabilityCompanyMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="freq_PercentageOfVoteOfHoldersOfPreferredStock" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="freq_PreferredStockSharesPurchased" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockVotingRights" order="10430.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockholdersDeficitScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:href="freq-20191231.xsd#Role_DisclosureStockholdersDeficitScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockholdersDeficitScheduleOfCommonStockSharesReservedForFutureIssuanceDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ConversionOfFrequencyJapanPreferredStockMember" xlink:type="locator" xlink:label="freq_ConversionOfFrequencyJapanPreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesAConvertiblePreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_ConversionOfFrequencyJapanPreferredStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xlink:type="locator" xlink:label="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TwoThousandAndNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TwoThousandAndFourteenStockIncentivePlanMember" xlink:type="locator" xlink:label="freq_TwoThousandAndFourteenStockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="freq_TwoThousandAndFourteenStockIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnder2014PlanAnd2019PlanDetails" xlink:href="freq-20191231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnder2014PlanAnd2019PlanDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnder2014PlanAnd2019PlanDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TwoThousandAndFourteenStockIncentivePlanMember" xlink:type="locator" xlink:label="freq_TwoThousandAndFourteenStockIncentivePlanMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TwoThousandAndNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="freq_TwoThousandAndFourteenStockIncentivePlanMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="12180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="12390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="12570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="12930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="14010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="14190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="14790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="14970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="15150.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails" xlink:href="freq-20191231.xsd#Role_DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockDetails" xlink:href="freq-20191231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriodWeightedAverageFairValue" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriodWeightedAverageFairValue" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageFairValue" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageFairValue" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriod" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriod" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageFairValue" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriodWeightedAverageFairValue" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="11470.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xlink:type="locator" xlink:label="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PercentageOfEligibleEmployeeCompensation" xlink:type="locator" xlink:label="freq_PercentageOfEligibleEmployeeCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_PercentageOfEligibleEmployeeCompensation" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="10280.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLossDeductionLimitationAsPercentageOfTaxableIncome" xlink:type="locator" xlink:label="freq_OperatingLossDeductionLimitationAsPercentageOfTaxableIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" xlink:type="locator" xlink:label="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PeriodOfCumulativeChangeInOwnership" xlink:type="locator" xlink:label="freq_PeriodOfCumulativeChangeInOwnership" />
    <link:loc xlink:href="freq-20191231.xsd#freq_CumulativeChangeInOwnershipPercentage" xlink:type="locator" xlink:label="freq_CumulativeChangeInOwnershipPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="freq_TaxCreditCarryforwardExpirationYear" />
    <link:loc xlink:href="freq-20191231.xsd#freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" xlink:type="locator" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="freq-20191231.xsd#freq_NetOperatingLossCarryforwardsExpirationWithLimitation" xlink:type="locator" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithLimitation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA" xlink:type="locator" xlink:label="stpr_MA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_IncomeTaxesDisclosureTable" xlink:type="locator" xlink:label="freq_IncomeTaxesDisclosureTable" />
    <link:loc xlink:href="freq-20191231.xsd#freq_IncomeTaxesDisclosureLineItems" xlink:type="locator" xlink:label="freq_IncomeTaxesDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_IncomeTaxesDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="srt_StatementGeographicalAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_2" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="srt_RangeAxis" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_NetOperatingLossCarryforwardsExpirationWithLimitation" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_OperatingLossCarryforwardsExpirationYear" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_TaxCreditCarryforwardExpirationYear" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_CumulativeChangeInOwnershipPercentage" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_PeriodOfCumulativeChangeInOwnership" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_OperatingLossDeductionLimitationAsPercentageOfTaxableIncome" order="11650.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureResearchAndLicenseAgreementsAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureResearchAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureResearchAndLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="freq-20191231.xsd#freq_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="freq_IncreaseDecreaseInResearchAndDevelopmentExpense" />
    <link:loc xlink:href="freq-20191231.xsd#freq_GrantTermPeriod" xlink:type="locator" xlink:label="freq_GrantTermPeriod" />
    <link:loc xlink:href="freq-20191231.xsd#freq_AmountOfFundingReceivedAsGrant" xlink:type="locator" xlink:label="freq_AmountOfFundingReceivedAsGrant" />
    <link:loc xlink:href="freq-20191231.xsd#freq_AnnualLicenseFee" xlink:type="locator" xlink:label="freq_AnnualLicenseFee" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" xlink:type="locator" xlink:label="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RightToTerminateAgreementIncaseOfNonpayment" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementIncaseOfNonpayment" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RightToTerminateAgreementIfBreachRemainsUncured" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementIfBreachRemainsUncured" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RightToTerminateAgreementUponPriorWrittenNotice" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNotice" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DescriptionOfConditionsToTerminateLicenseAgreement" xlink:type="locator" xlink:label="freq_DescriptionOfConditionsToTerminateLicenseAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="freq-20191231.xsd#freq_MilestonePayments" xlink:type="locator" xlink:label="freq_MilestonePayments" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PercentageOfSharesOfCommonStockIssued" xlink:type="locator" xlink:label="freq_PercentageOfSharesOfCommonStockIssued" />
    <link:loc xlink:href="freq-20191231.xsd#freq_LicenseFeePayment" xlink:type="locator" xlink:label="freq_LicenseFeePayment" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DescriptionOfFutureDevelopmentObligations" xlink:type="locator" xlink:label="freq_DescriptionOfFutureDevelopmentObligations" />
    <link:loc xlink:href="freq-20191231.xsd#freq_LicenseAgreementEnteredDate" xlink:type="locator" xlink:label="freq_LicenseAgreementEnteredDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantMember" xlink:type="locator" xlink:label="us-gaap_GrantMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ResearchAndDevelopmentMember" xlink:type="locator" xlink:label="freq_ResearchAndDevelopmentMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_CambridgeEnterpriseLimitedMember" xlink:type="locator" xlink:label="freq_CambridgeEnterpriseLimitedMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_MassachusettsEyeAndEarInfirmaryMember" xlink:type="locator" xlink:label="freq_MassachusettsEyeAndEarInfirmaryMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_NonExclusivePatentLicenseAgreementMember" xlink:type="locator" xlink:label="freq_NonExclusivePatentLicenseAgreementMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_CaliforniaInstituteForBiomedicalResearchMember" xlink:type="locator" xlink:label="freq_CaliforniaInstituteForBiomedicalResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_AstellasPharmaLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="freq_AstellasPharmaLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PatentLicenseAgreementMember" xlink:type="locator" xlink:label="freq_PatentLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_MassachusettsInstituteOfTechnologyMember" xlink:type="locator" xlink:label="freq_MassachusettsInstituteOfTechnologyMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="dei_LegalEntityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="freq_MassachusettsInstituteOfTechnologyMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="freq_PatentLicenseAgreementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="freq_AstellasPharmaLimitedLiabilityCompanyMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_ProductOrServiceAxis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="freq_CaliforniaInstituteForBiomedicalResearchMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="freq_NonExclusivePatentLicenseAgreementMember" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="freq_MassachusettsEyeAndEarInfirmaryMember" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="freq_CambridgeEnterpriseLimitedMember" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="freq_ResearchAndDevelopmentMember" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" order="11810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_LicenseAgreementEnteredDate" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_DescriptionOfFutureDevelopmentObligations" order="11930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_LicenseFeePayment" order="11980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_PercentageOfSharesOfCommonStockIssued" order="12000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_MilestonePayments" order="12020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_DescriptionOfConditionsToTerminateLicenseAgreement" order="12090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_RightToTerminateAgreementUponPriorWrittenNotice" order="12110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_RightToTerminateAgreementIfBreachRemainsUncured" order="12130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_RightToTerminateAgreementIncaseOfNonpayment" order="12150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" order="12380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" order="12660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_AnnualLicenseFee" order="12800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_AmountOfFundingReceivedAsGrant" order="12960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_GrantTermPeriod" order="13020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_IncreaseDecreaseInResearchAndDevelopmentExpense" order="13080.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureCollaborationAgreementAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RevenueFromContractWithCustomerApplicationInputMethod" xlink:type="locator" xlink:label="freq_RevenueFromContractWithCustomerApplicationInputMethod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="freq-20191231.xsd#freq_UpfrontFeeRecognizedAsRevenue" xlink:type="locator" xlink:label="freq_UpfrontFeeRecognizedAsRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RevenueRecognitionTransactionPrice" xlink:type="locator" xlink:label="freq_RevenueRecognitionTransactionPrice" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RightToTerminateAgreementIncaseOfNonpayment" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementIncaseOfNonpayment" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RightToTerminateAgreementIfBreachRemainsUncured" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementIfBreachRemainsUncured" />
    <link:loc xlink:href="freq-20191231.xsd#freq_AgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="freq_AgreementTerminationNoticePeriod" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" xlink:type="locator" xlink:label="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" xlink:type="locator" xlink:label="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_AsiaMember" xlink:type="locator" xlink:label="srt_AsiaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_Phase3ClinicalTrailMember" xlink:type="locator" xlink:label="freq_Phase3ClinicalTrailMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_Phase2bClinicalTrialMember" xlink:type="locator" xlink:label="freq_Phase2bClinicalTrialMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_AstellasPharmaLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="freq_AstellasPharmaLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="freq_LicenseAndCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="freq_LicenseAndCollaborationAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="freq_AstellasPharmaLimitedLiabilityCompanyMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="freq_Phase2bClinicalTrialMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="freq_Phase3ClinicalTrailMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_AsiaMember" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="11700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_AgreementTerminationNoticePeriod" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_RightToTerminateAgreementIfBreachRemainsUncured" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_RightToTerminateAgreementIncaseOfNonpayment" order="11910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_RevenueRecognitionTransactionPrice" order="11960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="11980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="12000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_UpfrontFeeRecognizedAsRevenue" order="12020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_RevenueFromContractWithCustomerApplicationInputMethod" order="12110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="12130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyLossInPeriod" xlink:type="locator" xlink:label="us-gaap_LossContingencyLossInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="locator" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLeasesAdditionalExtensionTerm" xlink:type="locator" xlink:label="freq_OperatingLeasesAdditionalExtensionTerm" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLeaseNumberOfAdditionalExtensionTerms" xlink:type="locator" xlink:label="freq_OperatingLeaseNumberOfAdditionalExtensionTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLeaseCommencementDate" xlink:type="locator" xlink:label="freq_OperatingLeaseCommencementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetRentableArea" xlink:type="locator" xlink:label="us-gaap_NetRentableArea" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:loc xlink:href="freq-20191231.xsd#freq_LeaseExpirationYear" xlink:type="locator" xlink:label="freq_LeaseExpirationYear" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLeasesTermOfContract" xlink:type="locator" xlink:label="freq_OperatingLeasesTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_LexingtonLeaseMember" xlink:type="locator" xlink:label="freq_LexingtonLeaseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_HaydenLLCMember" xlink:type="locator" xlink:label="freq_HaydenLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CT" xlink:type="locator" xlink:label="stpr_CT" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA" xlink:type="locator" xlink:label="stpr_MA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CT" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="freq_HaydenLLCMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain_2" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="freq_LexingtonLeaseMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeasesTermOfContract" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_LeaseExpirationYear" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_NetRentableArea" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeaseCommencementDate" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeaseNumberOfAdditionalExtensionTerms" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeasesAdditionalExtensionTerm" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LossContingencyLossInPeriod" order="11320.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>51
<FILENAME>freq-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-03-26T03:10:11.1885690+00:00 -->
<!-- Version            : 5.0.1.369 -->
<!-- Package ID         : da71a932536d471fac83859dace20368 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingAndNonOperatingExpensesNet" xlink:type="locator" xlink:label="freq_OperatingAndNonOperatingExpensesNet" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingAndNonOperatingExpensesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating and non-operating expenses net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingAndNonOperatingExpensesNet" xlink:to="freq_OperatingAndNonOperatingExpensesNet_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Address Line</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address City Or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address State Or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SeriesBConvertiblePreferredStockMember" xlink:to="freq_SeriesBConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B-1 convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SeriesB1ConvertiblePreferredStockMember" xlink:to="freq_SeriesB1ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B-1 Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B1 Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SeriesAConvertiblePreferredStockMember" xlink:to="freq_SeriesAConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-1 convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SeriesA1ConvertiblePreferredStockMember" xlink:to="freq_SeriesA1ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1 Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A1 Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Convertible Preferred Stock, Non-Controlling Interest and Stockholders&#8217; Equity (Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="locator" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-controlling interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Noncontrolling Interest Equity Carrying Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity (deficit):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 100,000,000 and 165,000,000 shares authorized at December 31, 2019 and December 31, 2018, respectively; 30,844,507 and 2,084,710 shares issued and outstanding at December 31, 2019 and 2018, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Including Portion Attributable To Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, convertible preferred stock, non-controlling interest and stockholders&#8217; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock , par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, authorized shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, issued shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, outstanding shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, authorized shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, issued shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, outstanding shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income Expense Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on extinguishment of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gains Losses On Extinguishment Of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gain on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Realized Investment Gains Losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange gain (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transaction Gain Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cumulative Series C preferred stock dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDividendsAdjustment" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Dividends Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common shareholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders-basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares of common stock outstanding-basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive gain:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total comprehensive gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_StockIssuedDuringPeriodValueIssuedForPatentLicense" xlink:type="locator" xlink:label="freq_StockIssuedDuringPeriodValueIssuedForPatentLicense" />
    <link:label xml:lang="en-US" xlink:label="freq_StockIssuedDuringPeriodValueIssuedForPatentLicense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value issued for patent license.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_StockIssuedDuringPeriodValueIssuedForPatentLicense" xlink:to="freq_StockIssuedDuringPeriodValueIssuedForPatentLicense_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_StockIssuedDuringPeriodSharesIssuedForPatentLicense" xlink:type="locator" xlink:label="freq_StockIssuedDuringPeriodSharesIssuedForPatentLicense" />
    <link:label xml:lang="en-US" xlink:label="freq_StockIssuedDuringPeriodSharesIssuedForPatentLicense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares issued for patent license.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_StockIssuedDuringPeriodSharesIssuedForPatentLicense" xlink:to="freq_StockIssuedDuringPeriodSharesIssuedForPatentLicense_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue" xlink:type="locator" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue" />
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period value net of issuance cost new issue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue" xlink:to="freq_TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue" xlink:type="locator" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue" />
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares net of issuance cost new issue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue" xlink:to="freq_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_StockRepurchaseDuringPeriodValueRestrictedStock" xlink:type="locator" xlink:label="freq_StockRepurchaseDuringPeriodValueRestrictedStock" />
    <link:label xml:lang="en-US" xlink:label="freq_StockRepurchaseDuringPeriodValueRestrictedStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock repurchase during period value restricted stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_StockRepurchaseDuringPeriodValueRestrictedStock" xlink:to="freq_StockRepurchaseDuringPeriodValueRestrictedStock_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_StockRepurchaseDuringPeriodSharesRestrictedStock" xlink:type="locator" xlink:label="freq_StockRepurchaseDuringPeriodSharesRestrictedStock" />
    <link:label xml:lang="en-US" xlink:label="freq_StockRepurchaseDuringPeriodSharesRestrictedStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock repurchase during period shares restricted stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_StockRepurchaseDuringPeriodSharesRestrictedStock" xlink:to="freq_StockRepurchaseDuringPeriodSharesRestrictedStock_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, stock issued during period, shares, new issues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ConvertiblePreferredStockAccretionOfDividend" xlink:type="locator" xlink:label="freq_ConvertiblePreferredStockAccretionOfDividend" />
    <link:label xml:lang="en-US" xlink:label="freq_ConvertiblePreferredStockAccretionOfDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock accretion of dividend.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_ConvertiblePreferredStockAccretionOfDividend" xlink:to="freq_ConvertiblePreferredStockAccretionOfDividend_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock shares conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:to="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock value conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:to="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:to="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:to="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesCConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SeriesCConvertiblePreferredStockMember" xlink:to="freq_SeriesCConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-controlling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional-paid in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Share Based Compensation Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_StockIssuedDuringPeriodValueIssuedForPatentLicense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for exclusive patent license</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_StockIssuedDuringPeriodValueIssuedForPatentLicense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Issued For Patent License</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_StockIssuedDuringPeriodSharesIssuedForPatentLicense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for exclusive patent license (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_StockIssuedDuringPeriodSharesIssuedForPatentLicense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issued For Patent License</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Restricted Stock Award Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_StockRepurchaseDuringPeriodValueRestrictedStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of restricted stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_StockRepurchaseDuringPeriodValueRestrictedStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase During Period Value Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_StockRepurchaseDuringPeriodSharesRestrictedStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of restricted stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_StockRepurchaseDuringPeriodSharesRestrictedStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase During Period Shares Restricted Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value Net Of Issuance Cost New Issue</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, net of issuance costs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares Net Of Issuance Cost New Issue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock related to the conversion of convertible notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock related to the conversion of convertible notes payable (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-controlling interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest Increase From Subsidiary Equity Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ConvertiblePreferredStockAccretionOfDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of Series C preferred dividend</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ConvertiblePreferredStockAccretionOfDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Accretion Of Dividend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of Series C preferred dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionOfDividends" xlink:to="us-gaap_TemporaryEquityAccretionOfDividends_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Accretion Of Dividends</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering of common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Preferred Stock And Non Controlling Interest Into Common Stock In Connection With Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Shares Conversion Of Preferred Stock And Non Controlling Interest Into Common Stock In Connection With Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Value Conversion Of Preferred Stock And Non Controlling Interest Into Common Stock In Connection With Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Preferred Stock And Non Controlling Interest Into Common Stock In Connection With Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_DeferredLeaseIncentives" xlink:type="locator" xlink:label="freq_DeferredLeaseIncentives" />
    <link:label xml:lang="en-US" xlink:label="freq_DeferredLeaseIncentives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred lease incentives.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DeferredLeaseIncentives" xlink:to="freq_DeferredLeaseIncentives_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="freq_PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <link:label xml:lang="en-US" xlink:label="freq_PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for (proceeds from) sale of available for sale securities debt.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="freq_PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_NonCashDividendOnCumulativeConvertiblePreferredStock" xlink:type="locator" xlink:label="freq_NonCashDividendOnCumulativeConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="freq_NonCashDividendOnCumulativeConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash dividend on cumulative convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_NonCashDividendOnCumulativeConvertiblePreferredStock" xlink:to="freq_NonCashDividendOnCumulativeConvertiblePreferredStock_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_CashPaidDuringPeriodForAbstract" xlink:type="locator" xlink:label="freq_CashPaidDuringPeriodForAbstract" />
    <link:label xml:lang="en-US" xlink:label="freq_CashPaidDuringPeriodForAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid during the year for.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_CashPaidDuringPeriodForAbstract" xlink:to="freq_CashPaidDuringPeriodForAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Paid In Kind Interest</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on extinguishment of convertible notes payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for license agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Stock And Warrants For Services Or Claims</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DeferredLeaseIncentives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred lease incentives</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DeferredLeaseIncentives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Lease Incentives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Redemption of available for sale securities</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment For Proceeds From Sale Of Available For Sale Securities Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of available for sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Available For Sale Securities Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMinorityShareholders" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromMinorityShareholders_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of non-controlling interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMinorityShareholders" xlink:to="us-gaap_ProceedsFromMinorityShareholders_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromMinorityShareholders_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Minority Shareholders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible preferred stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash at end of year</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_CashPaidDuringPeriodForAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid during the year for:</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_CashPaidDuringPeriodForAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid During Period For [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible notes payable and accrued interest into convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion Converted Instrument Amount1</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_NonCashDividendOnCumulativeConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Series C convertible preferred stock dividends</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_NonCashDividendOnCumulativeConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Dividend On Cumulative Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock and non-controlling interest into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Amount Issued1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="locator" xlink:label="freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses and other current assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityTextBlock" xlink:type="locator" xlink:label="freq_TemporaryEquityTextBlock" />
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_TemporaryEquityTextBlock" xlink:to="freq_TemporaryEquityTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_NoncontrollingInterestAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-controlling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_EmployeeStockPurchasePlanDisclosureTextBlock" xlink:type="locator" xlink:label="freq_EmployeeStockPurchasePlanDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="freq_EmployeeStockPurchasePlanDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_EmployeeStockPurchasePlanDisclosureTextBlock" xlink:to="freq_EmployeeStockPurchasePlanDisclosureTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_EmployeeStockPurchasePlanDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_EmployeeStockPurchasePlanDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_ResearchAndLicenseAgreementsDisclosureTextBlock" xlink:type="locator" xlink:label="freq_ResearchAndLicenseAgreementsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="freq_ResearchAndLicenseAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and license agreements disclosure text block.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_ResearchAndLicenseAgreementsDisclosureTextBlock" xlink:to="freq_ResearchAndLicenseAgreementsDisclosureTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_ResearchAndLicenseAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ResearchAndLicenseAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And License Agreements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pension And Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selected Quarterly Data (Unaudited)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions And Translations Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Marketable Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Off-balance Sheet Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_SignificantSuppliersPolicyTextBlock" xlink:type="locator" xlink:label="freq_SignificantSuppliersPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="freq_SignificantSuppliersPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant suppliers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SignificantSuppliersPolicyTextBlock" xlink:to="freq_SignificantSuppliersPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SignificantSuppliersPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Suppliers</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SignificantSuppliersPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Suppliers Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs and Accruals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Accounting Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_PatentCostsPolicyTextBlock" xlink:type="locator" xlink:label="freq_PatentCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="freq_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PatentCostsPolicyTextBlock" xlink:to="freq_PatentCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Patent Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_NonControllingInterestPolicyTextBlock" xlink:type="locator" xlink:label="freq_NonControllingInterestPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="freq_NonControllingInterestPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-controlling interest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_NonControllingInterestPolicyTextBlock" xlink:to="freq_NonControllingInterestPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_NonControllingInterestPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Controlling Interest</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_NonControllingInterestPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Controlling Interest Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_PropertyAndEquipmentTableTextBlock" xlink:type="locator" xlink:label="freq_PropertyAndEquipmentTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="freq_PropertyAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PropertyAndEquipmentTableTextBlock" xlink:to="freq_PropertyAndEquipmentTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_PropertyAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PropertyAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property And Equipment Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="locator" xlink:label="freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of prepaid expenses and other current assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Prepaid Expenses And Other Current Assets Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:type="locator" xlink:label="freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock shares reserved for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:to="freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Shares Reserved For Future Issuance Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity under 2014 Plan and 2019 Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Status of Restricted Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Sharebased Compensation Restricted Stock And Restricted Stock Units Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Minimum Aggregate Future Operating Lease Commitments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Quarterly Financial Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Quarterly Financial Information Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Sale Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of incorporation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation Date Of Incorporation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Reverse Stock Split</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, value per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares issued and sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common stock issued upon conversion of preferred stock</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="freq_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="freq_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="freq_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="freq_SummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="freq_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="freq_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_WoburnMassachusettsFacilityMember" xlink:type="locator" xlink:label="freq_WoburnMassachusettsFacilityMember" />
    <link:label xml:lang="en-US" xlink:label="freq_WoburnMassachusettsFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Woburn Massachusetts facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_WoburnMassachusettsFacilityMember" xlink:to="freq_WoburnMassachusettsFacilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_WoburnMassachusettsFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Woburn Massachusetts Facility</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_WoburnMassachusettsFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Woburn Massachusetts Facility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Foreign currency exchange gains (losses)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_LabEquipmentMember" xlink:type="locator" xlink:label="freq_LabEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="freq_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_LabEquipmentMember" xlink:to="freq_LabEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_FurnitureAndOfficeEquipmentMember" xlink:type="locator" xlink:label="freq_FurnitureAndOfficeEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="freq_FurnitureAndOfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Furniture and office equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_FurnitureAndOfficeEquipmentMember" xlink:to="freq_FurnitureAndOfficeEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_FurnitureAndOfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Office Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_FurnitureAndOfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Office Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful lives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements, estimated useful lives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets Held For Use</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss attributable to common stockholders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted Other Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares of common stock outstanding-basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share attributed to common stockholders-basic and diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_UnvestedRestrictedCommonStockMember" xlink:type="locator" xlink:label="freq_UnvestedRestrictedCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_UnvestedRestrictedCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested Restricted Common Stock [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_UnvestedRestrictedCommonStockMember" xlink:to="freq_UnvestedRestrictedCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_UnvestedRestrictedCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_UnvestedRestrictedCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Common Stock [Member]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesCPreferredAsConvertedToCommonStockMember" xlink:type="locator" xlink:label="freq_SeriesCPreferredAsConvertedToCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesCPreferredAsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C Preferred As Converted To Common Stock [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SeriesCPreferredAsConvertedToCommonStockMember" xlink:to="freq_SeriesCPreferredAsConvertedToCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesCPreferredAsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Preferred (as converted to common stock)</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesCPreferredAsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred As Converted To Common Stock [Member]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBPreferredAsConvertedToCommonStockMember" xlink:type="locator" xlink:label="freq_SeriesBPreferredAsConvertedToCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesBPreferredAsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B Preferred as converted to common stock member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SeriesBPreferredAsConvertedToCommonStockMember" xlink:to="freq_SeriesBPreferredAsConvertedToCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesBPreferredAsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred (as converted to common stock)</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesBPreferredAsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred As Converted To Common Stock [Member]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesAPreferredAsConvertedCommonStockMember" xlink:type="locator" xlink:label="freq_SeriesAPreferredAsConvertedCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesAPreferredAsConvertedCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A Preferred as converted to common stock member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SeriesAPreferredAsConvertedCommonStockMember" xlink:to="freq_SeriesAPreferredAsConvertedCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesAPreferredAsConvertedCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred (as converted to common stock)</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesAPreferredAsConvertedCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred As Converted Common Stock [Member]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_ConversionOfFrequencyJapanPreferredStockMember" xlink:type="locator" xlink:label="freq_ConversionOfFrequencyJapanPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_ConversionOfFrequencyJapanPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of Frequency Japan preferred stock member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_ConversionOfFrequencyJapanPreferredStockMember" xlink:to="freq_ConversionOfFrequencyJapanPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_ConversionOfFrequencyJapanPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Frequency Japan Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ConversionOfFrequencyJapanPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Frequency Japan Preferred Stock [Member]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_OutstandingStockOptionsAsConvertedToCommonStockMember" xlink:type="locator" xlink:label="freq_OutstandingStockOptionsAsConvertedToCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="freq_OutstandingStockOptionsAsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Outstanding stock options as converted to common stock member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OutstandingStockOptionsAsConvertedToCommonStockMember" xlink:to="freq_OutstandingStockOptionsAsConvertedToCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_OutstandingStockOptionsAsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Stock Options (as converted to common stock)</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OutstandingStockOptionsAsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding Stock Options As Converted To Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Treasury Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Market Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets, Fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_PrepaidRentAndDepositsCurrent" xlink:type="locator" xlink:label="freq_PrepaidRentAndDepositsCurrent" />
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidRentAndDepositsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Rent and deposits.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PrepaidRentAndDepositsCurrent" xlink:to="freq_PrepaidRentAndDepositsCurrent_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="freq_PrepaidResearchAndDevelopmentExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid research and development expense current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:to="freq_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidRentAndDepositsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent and deposits</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidRentAndDepositsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Rent And Deposits Current</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research And Development Expense Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_GrantsReceivableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grants Receivable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Office Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" />
    <link:label xml:lang="en-US" xlink:label="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued third-party research and development expenses current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:to="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and employee related expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third-party research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Third Party Research And Development Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_QualifiedSeriesBFinancingMember" xlink:type="locator" xlink:label="freq_QualifiedSeriesBFinancingMember" />
    <link:label xml:lang="en-US" xlink:label="freq_QualifiedSeriesBFinancingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Qualified Series B financing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_QualifiedSeriesBFinancingMember" xlink:to="freq_QualifiedSeriesBFinancingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_QualifiedSeriesBFinancingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Qualified Series B Financing</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_QualifiedSeriesBFinancingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Qualified Series B Financing [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBNotesMember" xlink:type="locator" xlink:label="freq_SeriesBNotesMember" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesBNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B notes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SeriesBNotesMember" xlink:to="freq_SeriesBNotesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesBNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Notes</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesBNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Notes [Member]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_QualifiedSeriesAFinancingMember" xlink:type="locator" xlink:label="freq_QualifiedSeriesAFinancingMember" />
    <link:label xml:lang="en-US" xlink:label="freq_QualifiedSeriesAFinancingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Qualified Series A financing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_QualifiedSeriesAFinancingMember" xlink:to="freq_QualifiedSeriesAFinancingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_QualifiedSeriesAFinancingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Qualified Series A Financing</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_QualifiedSeriesAFinancingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Qualified Series A Financing [Member]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_PriorToQualifiedSeriesAFinancingMember" xlink:type="locator" xlink:label="freq_PriorToQualifiedSeriesAFinancingMember" />
    <link:label xml:lang="en-US" xlink:label="freq_PriorToQualifiedSeriesAFinancingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prior to qualified Series A financing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PriorToQualifiedSeriesAFinancingMember" xlink:to="freq_PriorToQualifiedSeriesAFinancingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_PriorToQualifiedSeriesAFinancingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior to Qualified Series A Financing</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PriorToQualifiedSeriesAFinancingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prior To Qualified Series A Financing [Member]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesANotesMember" xlink:type="locator" xlink:label="freq_SeriesANotesMember" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesANotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A notes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_SeriesANotesMember" xlink:to="freq_SeriesANotesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_SeriesANotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Notes</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesANotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Notes [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument carrying amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Carrying Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issued conversion of convertible securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument convertible conversion percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Convertible Conversion Ratio1</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_DebtInstrumentDiscountRate" xlink:type="locator" xlink:label="freq_DebtInstrumentDiscountRate" />
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentDiscountRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument discount rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DebtInstrumentDiscountRate" xlink:to="freq_DebtInstrumentDiscountRate_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DebtInstrumentLossOnConversion" xlink:type="locator" xlink:label="freq_DebtInstrumentLossOnConversion" />
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentLossOnConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument loss on conversion.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DebtInstrumentLossOnConversion" xlink:to="freq_DebtInstrumentLossOnConversion_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense Debt Excluding Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Convertible Conversion Price1</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentDiscountRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount rate</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentDiscountRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Discount Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued upon conversion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion Converted Instrument Shares Issued1</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentLossOnConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on conversion</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentLossOnConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Loss On Conversion</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion" xlink:type="locator" xlink:label="freq_DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion" />
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Instrument, convertible, threshold value of financing receivable for conversion.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion" xlink:to="freq_DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DebtInstrumentExcessFinancingFundReceived" xlink:type="locator" xlink:label="freq_DebtInstrumentExcessFinancingFundReceived" />
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentExcessFinancingFundReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument excess financing fund received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DebtInstrumentExcessFinancingFundReceived" xlink:to="freq_DebtInstrumentExcessFinancingFundReceived_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DebtInstrumentExtendedMaturityDate" xlink:type="locator" xlink:label="freq_DebtInstrumentExtendedMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentExtendedMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument extended maturity date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DebtInstrumentExtendedMaturityDate" xlink:to="freq_DebtInstrumentExtendedMaturityDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentExtendedMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument extended maturity date</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentExtendedMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Extended Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Threshold value of financing receivable for conversion</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Convertible Threshold Value Of Financing Receivable For Conversion</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentExcessFinancingFundReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Excess of financing funds received</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentExcessFinancingFundReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Excess Financing Fund Received</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A-1 Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series B-1 Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_DebtInstrumentConvertibleDiscountOnConversionPrice" xlink:type="locator" xlink:label="freq_DebtInstrumentConvertibleDiscountOnConversionPrice" />
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentConvertibleDiscountOnConversionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument convertible discount on conversion price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DebtInstrumentConvertibleDiscountOnConversionPrice" xlink:to="freq_DebtInstrumentConvertibleDiscountOnConversionPrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentConvertibleDiscountOnConversionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount rate on offering price</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DebtInstrumentConvertibleDiscountOnConversionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Convertible Discount On Conversion Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, net proceeds from shares issued</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityAdditionalSharesIssued" xlink:type="locator" xlink:label="freq_TemporaryEquityAdditionalSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityAdditionalSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity additional shares issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_TemporaryEquityAdditionalSharesIssued" xlink:to="freq_TemporaryEquityAdditionalSharesIssued_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityAdditionalSharesIssuedCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="freq_TemporaryEquityAdditionalSharesIssuedCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityAdditionalSharesIssuedCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity additional shares issued carrying amount attributable to parent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_TemporaryEquityAdditionalSharesIssuedCarryingAmountAttributableToParent" xlink:to="freq_TemporaryEquityAdditionalSharesIssuedCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityAdditionalSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, additional shares issued</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityAdditionalSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Additional Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityAdditionalSharesIssuedCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, net proceeds from additional shares issued</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TemporaryEquityAdditionalSharesIssuedCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Additional Shares Issued Carrying Amount Attributable To Parent</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock issued price per share</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_PercentageOfVoteOfHoldersOfPreferredStock" xlink:type="locator" xlink:label="freq_PercentageOfVoteOfHoldersOfPreferredStock" />
    <link:label xml:lang="en-US" xlink:label="freq_PercentageOfVoteOfHoldersOfPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of vote of the holders of preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PercentageOfVoteOfHoldersOfPreferredStock" xlink:to="freq_PercentageOfVoteOfHoldersOfPreferredStock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SubsidiariesMember" xlink:type="locator" xlink:label="srt_SubsidiariesMember" />
    <link:label xml:lang="en-US" xlink:label="srt_SubsidiariesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Frequency Japan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SubsidiariesMember" xlink:to="srt_SubsidiariesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SubsidiariesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiaries [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_DelawareLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="freq_DelawareLimitedLiabilityCompanyMember" />
    <link:label xml:lang="en-US" xlink:label="freq_DelawareLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Delaware Limited Liability Company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DelawareLimitedLiabilityCompanyMember" xlink:to="freq_DelawareLimitedLiabilityCompanyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_DelawareLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LLC(FT-FJ)</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DelawareLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Delaware Limited Liability Company [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred Stock, shares issued upon conversion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PercentageOfVoteOfHoldersOfPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Voting percentage of preferred stock holder</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PercentageOfVoteOfHoldersOfPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Vote Of Holders Of Preferred Stock</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_PreferredStockSharesPurchased" xlink:type="locator" xlink:label="freq_PreferredStockSharesPurchased" />
    <link:label xml:lang="en-US" xlink:label="freq_PreferredStockSharesPurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock, shares purchased.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PreferredStockSharesPurchased" xlink:to="freq_PreferredStockSharesPurchased_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_PreferredStockSharesPurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares purchased</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PreferredStockSharesPurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Purchased</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:type="locator" xlink:label="us-gaap_PreferredStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, voting rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockVotingRights" xlink:to="us-gaap_PreferredStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Voting Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Future Grant Under Stock Option Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Compensation Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock reserved for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_TwoThousandAndFourteenStockIncentivePlanMember" xlink:type="locator" xlink:label="freq_TwoThousandAndFourteenStockIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="freq_TwoThousandAndFourteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and fourteen stock incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_TwoThousandAndFourteenStockIncentivePlanMember" xlink:to="freq_TwoThousandAndFourteenStockIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_TwoThousandAndFourteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TwoThousandAndFourteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Fourteen Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_TwoThousandAndNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" />
    <link:label xml:lang="en-US" xlink:label="freq_TwoThousandAndNineteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and nineteen incentive award plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" xlink:to="freq_TwoThousandAndNineteenIncentiveAwardPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_TwoThousandAndNineteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TwoThousandAndNineteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Nineteen Incentive Award Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares reserved for issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares available for future grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xlink:type="locator" xlink:label="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period for automatic increase in common stock available for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xlink:to="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of authorized shares reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period for automatic increase in common stock available for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period For Automatic Increase In Common Stock Available For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of shares issued from outstanding number of shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock future issuance, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Options exercisable as of December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Options unvested as of December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Options exercisable as of December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Options unvested as of December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term (in years), Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term (in years), Options exercisable as of December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Outstanding as of December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Options exercisable as of December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Options unvested as of December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate intrinsic value of stock options exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value of stock options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total grant date fair value of stock options vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriod" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award non-option equity instruments issued in period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriod" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriod_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award non-option equity instruments repurchased in period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Repurchased</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Repurchased In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Vested during period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Unvested as of December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award non-option equity instruments grants in period weighted average grant date fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageFairValue" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageFairValue" />
    <link:label xml:lang="en-US" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award non-option equity instruments issued in progress weighted average fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageFairValue" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageFairValue_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriodWeightedAverageFairValue" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriodWeightedAverageFairValue" />
    <link:label xml:lang="en-US" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriodWeightedAverageFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award non-option equity instruments repurchased in period weighted average fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriodWeightedAverageFairValue" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriodWeightedAverageFairValue_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award non-option equity instruments weighted average grant date fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average fair value, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average fair value, Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average fair value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued In Period Weighted Average Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriodWeightedAverageFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average fair value, Repurchased</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriodWeightedAverageFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Repurchased In Period Weighted Average Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average fair value, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average fair value, Vested during period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average fair value, Unvested as of December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Repurchased</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total value of restricted stock awards, vested based on estimated fair value of stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized stock-based compensation expense relating to unvested stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized unvested stock options, weighted-average period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_PercentageOfEligibleEmployeeCompensation" xlink:type="locator" xlink:label="freq_PercentageOfEligibleEmployeeCompensation" />
    <link:label xml:lang="en-US" xlink:label="freq_PercentageOfEligibleEmployeeCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of eligible employee compensation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PercentageOfEligibleEmployeeCompensation" xlink:to="freq_PercentageOfEligibleEmployeeCompensation_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Employee Stock Purchase Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PercentageOfEligibleEmployeeCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of eligible employee compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PercentageOfEligibleEmployeeCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Eligible Employee Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Period for automatic increase in common available for future issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_IncomeTaxesDisclosureLineItems" xlink:type="locator" xlink:label="freq_IncomeTaxesDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="freq_IncomeTaxesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_IncomeTaxesDisclosureLineItems_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_IncomeTaxesDisclosureTable" xlink:type="locator" xlink:label="freq_IncomeTaxesDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="freq_IncomeTaxesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="freq_IncomeTaxesDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_IncomeTaxesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_IncomeTaxesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA" xlink:type="locator" xlink:label="stpr_MA" />
    <link:label xml:lang="en-US" xlink:label="stpr_MA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Massachusetts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MA" xlink:to="stpr_MA_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_MA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">MASSACHUSETTS</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Internal Revenue Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Internal Revenue Service I R S [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_IncomeTaxesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_IncomeTaxesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="freq_TaxCreditCarryforwardExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="freq_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_TaxCreditCarryforwardExpirationYear" xlink:to="freq_TaxCreditCarryforwardExpirationYear_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_NetOperatingLossCarryforwardsExpirationWithLimitation" xlink:type="locator" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithLimitation" />
    <link:label xml:lang="en-US" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithLimitation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss carryforwards expiration with limitation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_NetOperatingLossCarryforwardsExpirationWithLimitation" xlink:to="freq_NetOperatingLossCarryforwardsExpirationWithLimitation_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingLossCarryforwardsExpirationYear" xlink:to="freq_OperatingLossCarryforwardsExpirationYear_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" xlink:type="locator" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" />
    <link:label xml:lang="en-US" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss carryforwards expiration without limitation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" xlink:to="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithLimitation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards expire through 2037</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithLimitation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforwards Expiration With Limitation</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards without expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforwards Expiration Without Limitation</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Loss Carryforwards Usage After Ownership Change.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" xlink:to="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards annual usage for next each five years after ownership change.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" xlink:to="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards annual usage for next each after five years and thereafter after ownership change.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" xlink:to="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" xlink:type="locator" xlink:label="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" />
    <link:label xml:lang="en-US" xlink:label="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining pre ownership change in operating loss carryforwards written off due to expiration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" xlink:to="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_CumulativeChangeInOwnershipPercentage" xlink:type="locator" xlink:label="freq_CumulativeChangeInOwnershipPercentage" />
    <link:label xml:lang="en-US" xlink:label="freq_CumulativeChangeInOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative change in ownership percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_CumulativeChangeInOwnershipPercentage" xlink:to="freq_CumulativeChangeInOwnershipPercentage_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PeriodOfCumulativeChangeInOwnership" xlink:type="locator" xlink:label="freq_PeriodOfCumulativeChangeInOwnership" />
    <link:label xml:lang="en-US" xlink:label="freq_PeriodOfCumulativeChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of cumulative change in ownership.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PeriodOfCumulativeChangeInOwnership" xlink:to="freq_PeriodOfCumulativeChangeInOwnership_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_CumulativeChangeInOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative change in ownership percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_CumulativeChangeInOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Change In Ownership Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PeriodOfCumulativeChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of cumulative change in ownership</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PeriodOfCumulativeChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period Of Cumulative Change In Ownership</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, utilization after ownership change</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Usage After Ownership Change</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating loss carryforwards, utilization after five years after ownership change</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Annual Usage For Next Each Five Years After Ownership Change</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, utilization after 15 years thereafter after ownership change</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Annual Usage For Next Each After Five Years And Thereafter After Ownership Change</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining pre ownership change in operating loss carryforwards written off due to expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Pre Ownership Change In Operating Loss Carryforwards Written Off Due To Expiration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state deferred tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal State And Local Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and penalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S federal statutory income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact of federal rate change</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Reconciling Items Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in deferred tax asset valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets liabilities property plant and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:to="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangibles</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Goodwill And Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLossDeductionLimitationAsPercentageOfTaxableIncome" xlink:type="locator" xlink:label="freq_OperatingLossDeductionLimitationAsPercentageOfTaxableIncome" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossDeductionLimitationAsPercentageOfTaxableIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss deduction limitation as percentage of taxable income.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingLossDeductionLimitationAsPercentageOfTaxableIncome" xlink:to="freq_OperatingLossDeductionLimitationAsPercentageOfTaxableIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Federal corporate statutory income tax rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense or benefit in connection with enactment of Tax Cuts and Jobs Act</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" xlink:to="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossDeductionLimitationAsPercentageOfTaxableIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss deduction limitation as percentage of taxable income</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLossDeductionLimitationAsPercentageOfTaxableIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Deduction Limitation As Percentage Of Taxable Income</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_LicenseAgreementEnteredDate" xlink:type="locator" xlink:label="freq_LicenseAgreementEnteredDate" />
    <link:label xml:lang="en-US" xlink:label="freq_LicenseAgreementEnteredDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement entered date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_LicenseAgreementEnteredDate" xlink:to="freq_LicenseAgreementEnteredDate_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_MassachusettsInstituteOfTechnologyMember" xlink:type="locator" xlink:label="freq_MassachusettsInstituteOfTechnologyMember" />
    <link:label xml:lang="en-US" xlink:label="freq_MassachusettsInstituteOfTechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Massachusetts Institute of Technology.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_MassachusettsInstituteOfTechnologyMember" xlink:to="freq_MassachusettsInstituteOfTechnologyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_MassachusettsInstituteOfTechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MIT</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_MassachusettsInstituteOfTechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Massachusetts Institute Of Technology [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_PatentLicenseAgreementMember" xlink:type="locator" xlink:label="freq_PatentLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="freq_PatentLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PatentLicenseAgreementMember" xlink:to="freq_PatentLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_PatentLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PatentLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Patent License Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_AstellasPharmaLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="freq_AstellasPharmaLimitedLiabilityCompanyMember" />
    <link:label xml:lang="en-US" xlink:label="freq_AstellasPharmaLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Astellas pharma limited liability company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_AstellasPharmaLimitedLiabilityCompanyMember" xlink:to="freq_AstellasPharmaLimitedLiabilityCompanyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_AstellasPharmaLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Astellas Pharma LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_AstellasPharmaLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Astellas Pharma Limited Liability Company [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty [Member]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_CaliforniaInstituteForBiomedicalResearchMember" xlink:type="locator" xlink:label="freq_CaliforniaInstituteForBiomedicalResearchMember" />
    <link:label xml:lang="en-US" xlink:label="freq_CaliforniaInstituteForBiomedicalResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">California Institute for Biomedical Research.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_CaliforniaInstituteForBiomedicalResearchMember" xlink:to="freq_CaliforniaInstituteForBiomedicalResearchMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_CaliforniaInstituteForBiomedicalResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CALIBR</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_CaliforniaInstituteForBiomedicalResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">California Institute For Biomedical Research [Member]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_NonExclusivePatentLicenseAgreementMember" xlink:type="locator" xlink:label="freq_NonExclusivePatentLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="freq_NonExclusivePatentLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-exclusive patent license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_NonExclusivePatentLicenseAgreementMember" xlink:to="freq_NonExclusivePatentLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_NonExclusivePatentLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Exclusive Patent License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_NonExclusivePatentLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Exclusive Patent License Agreement [Member]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_MassachusettsEyeAndEarInfirmaryMember" xlink:type="locator" xlink:label="freq_MassachusettsEyeAndEarInfirmaryMember" />
    <link:label xml:lang="en-US" xlink:label="freq_MassachusettsEyeAndEarInfirmaryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Massachusetts Eye And Ear Infirmary.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_MassachusettsEyeAndEarInfirmaryMember" xlink:to="freq_MassachusettsEyeAndEarInfirmaryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_MassachusettsEyeAndEarInfirmaryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MEEI</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_MassachusettsEyeAndEarInfirmaryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Massachusetts Eye And Ear Infirmary [Member]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_CambridgeEnterpriseLimitedMember" xlink:type="locator" xlink:label="freq_CambridgeEnterpriseLimitedMember" />
    <link:label xml:lang="en-US" xlink:label="freq_CambridgeEnterpriseLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cambridge Enterprise Limited.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_CambridgeEnterpriseLimitedMember" xlink:to="freq_CambridgeEnterpriseLimitedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_CambridgeEnterpriseLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cambridge</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_CambridgeEnterpriseLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cambridge Enterprise Limited [Member]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_ResearchAndDevelopmentMember" xlink:type="locator" xlink:label="freq_ResearchAndDevelopmentMember" />
    <link:label xml:lang="en-US" xlink:label="freq_ResearchAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and Development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_ResearchAndDevelopmentMember" xlink:to="freq_ResearchAndDevelopmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_ResearchAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ResearchAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantMember" xlink:type="locator" xlink:label="us-gaap_GrantMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_LicenseAgreementEnteredDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement entered date</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_LicenseAgreementEnteredDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Entered Date</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_DescriptionOfFutureDevelopmentObligations" xlink:type="locator" xlink:label="freq_DescriptionOfFutureDevelopmentObligations" />
    <link:label xml:lang="en-US" xlink:label="freq_DescriptionOfFutureDevelopmentObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of future development obligations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DescriptionOfFutureDevelopmentObligations" xlink:to="freq_DescriptionOfFutureDevelopmentObligations_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_DescriptionOfFutureDevelopmentObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of future development obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DescriptionOfFutureDevelopmentObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Future Development Obligations</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_LicenseFeePayment" xlink:type="locator" xlink:label="freq_LicenseFeePayment" />
    <link:label xml:lang="en-US" xlink:label="freq_LicenseFeePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License fee payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_LicenseFeePayment" xlink:to="freq_LicenseFeePayment_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PercentageOfSharesOfCommonStockIssued" xlink:type="locator" xlink:label="freq_PercentageOfSharesOfCommonStockIssued" />
    <link:label xml:lang="en-US" xlink:label="freq_PercentageOfSharesOfCommonStockIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of shares of common stock issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_PercentageOfSharesOfCommonStockIssued" xlink:to="freq_PercentageOfSharesOfCommonStockIssued_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_MilestonePayments" xlink:type="locator" xlink:label="freq_MilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="freq_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_MilestonePayments" xlink:to="freq_MilestonePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_LicenseFeePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fee payment</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_LicenseFeePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Fee Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PercentageOfSharesOfCommonStockIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of shares of common stock issued</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_PercentageOfSharesOfCommonStockIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Shares Of Common Stock Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_RightToTerminateAgreementUponPriorWrittenNotice" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNotice" />
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNotice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Right to terminate agreement upon prior written notice.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_RightToTerminateAgreementUponPriorWrittenNotice" xlink:to="freq_RightToTerminateAgreementUponPriorWrittenNotice_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RightToTerminateAgreementIfBreachRemainsUncured" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementIfBreachRemainsUncured" />
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementIfBreachRemainsUncured_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Right to terminate agreement if breach remains uncured.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_RightToTerminateAgreementIfBreachRemainsUncured" xlink:to="freq_RightToTerminateAgreementIfBreachRemainsUncured_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RightToTerminateAgreementIncaseOfNonpayment" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementIncaseOfNonpayment" />
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementIncaseOfNonpayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Right to terminate agreement incase of nonpayment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_RightToTerminateAgreementIncaseOfNonpayment" xlink:to="freq_RightToTerminateAgreementIncaseOfNonpayment_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DescriptionOfConditionsToTerminateLicenseAgreement" xlink:type="locator" xlink:label="freq_DescriptionOfConditionsToTerminateLicenseAgreement" />
    <link:label xml:lang="en-US" xlink:label="freq_DescriptionOfConditionsToTerminateLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of conditions to terminate license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_DescriptionOfConditionsToTerminateLicenseAgreement" xlink:to="freq_DescriptionOfConditionsToTerminateLicenseAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_DescriptionOfConditionsToTerminateLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of conditions to terminate license agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_DescriptionOfConditionsToTerminateLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Conditions To Terminate License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNotice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right to terminate agreement upon prior written notice</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNotice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right To Terminate Agreement Upon Prior Written Notice</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementIfBreachRemainsUncured_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right to terminate agreement if breach remains uncured</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementIfBreachRemainsUncured_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right To Terminate Agreement If Breach Remains Uncured</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementIncaseOfNonpayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right to terminate agreement incase of nonpayment</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementIncaseOfNonpayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right To Terminate Agreement Incase Of Nonpayment</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" xlink:type="locator" xlink:label="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" />
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Right to terminate licensed patents upon prior written notice.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" xlink:to="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right to terminate licensed patents upon prior written notice</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right To Terminate Licensed Patents Upon Prior Written Notice</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" />
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Right to terminate agreement upon prior written notice if insolvent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" xlink:to="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right to terminate agreement upon prior written notice if insolvent</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right To Terminate Agreement Upon Prior Written Notice If Insolvent</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_AnnualLicenseFee" xlink:type="locator" xlink:label="freq_AnnualLicenseFee" />
    <link:label xml:lang="en-US" xlink:label="freq_AnnualLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual license fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_AnnualLicenseFee" xlink:to="freq_AnnualLicenseFee_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_AnnualLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license fee</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_AnnualLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual License Fee</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="freq_IncreaseDecreaseInResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="freq_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in research and development expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:to="freq_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_AmountOfFundingReceivedAsGrant" xlink:type="locator" xlink:label="freq_AmountOfFundingReceivedAsGrant" />
    <link:label xml:lang="en-US" xlink:label="freq_AmountOfFundingReceivedAsGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of funding received as grant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_AmountOfFundingReceivedAsGrant" xlink:to="freq_AmountOfFundingReceivedAsGrant_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_GrantTermPeriod" xlink:type="locator" xlink:label="freq_GrantTermPeriod" />
    <link:label xml:lang="en-US" xlink:label="freq_GrantTermPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant term period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_GrantTermPeriod" xlink:to="freq_GrantTermPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_AmountOfFundingReceivedAsGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of funding received as grant</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_AmountOfFundingReceivedAsGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amount Of Funding Received As Grant</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_GrantTermPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant term period</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_GrantTermPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grant Term Period</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Research And Development Expense</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" xlink:type="locator" xlink:label="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" />
    <link:label xml:lang="en-US" xlink:label="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability revenue recognized from commercialization milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" xlink:to="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" xlink:type="locator" xlink:label="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" />
    <link:label xml:lang="en-US" xlink:label="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognition potential commercial milestone payments eligible upon successful commercialization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" xlink:to="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="freq_LicenseAndCollaborationAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="freq_LicenseAndCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License and collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_LicenseAndCollaborationAgreementMember" xlink:to="freq_LicenseAndCollaborationAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_LicenseAndCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License And Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_LicenseAndCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_Phase2bClinicalTrialMember" xlink:type="locator" xlink:label="freq_Phase2bClinicalTrialMember" />
    <link:label xml:lang="en-US" xlink:label="freq_Phase2bClinicalTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Phase 2b clinical trial.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_Phase2bClinicalTrialMember" xlink:to="freq_Phase2bClinicalTrialMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_Phase2bClinicalTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Phase 2b Clinical Trial</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_Phase2bClinicalTrialMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Phase2b Clinical Trial [Member]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_Phase3ClinicalTrailMember" xlink:type="locator" xlink:label="freq_Phase3ClinicalTrailMember" />
    <link:label xml:lang="en-US" xlink:label="freq_Phase3ClinicalTrailMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Phase 3 clinical trail.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_Phase3ClinicalTrailMember" xlink:to="freq_Phase3ClinicalTrailMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_Phase3ClinicalTrailMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Phase 3 Clinical Trial</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_Phase3ClinicalTrailMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Phase3 Clinical Trail [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_EuropeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Europe</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_EuropeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Europe [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_AsiaMember" xlink:type="locator" xlink:label="srt_AsiaMember" />
    <link:label xml:lang="en-US" xlink:label="srt_AsiaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asia</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaMember" xlink:to="srt_AsiaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_AsiaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asia [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments received under collaboration agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Collaborators</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized potential development milestone payments to receive</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized commercialization milestone payments to receive</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized From Commercialization Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential commercial milestone payments eligible to receive upon successful commercialization</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Potential Commercial Milestone Payments Eligible Upon Successful Commercialization</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_AgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="freq_AgreementTerminationNoticePeriod" />
    <link:label xml:lang="en-US" xlink:label="freq_AgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement termination notice period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_AgreementTerminationNoticePeriod" xlink:to="freq_AgreementTerminationNoticePeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_AgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement termination notice period</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_AgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Termination Notice Period</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_RevenueRecognitionTransactionPrice" xlink:type="locator" xlink:label="freq_RevenueRecognitionTransactionPrice" />
    <link:label xml:lang="en-US" xlink:label="freq_RevenueRecognitionTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognition transaction price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_RevenueRecognitionTransactionPrice" xlink:to="freq_RevenueRecognitionTransactionPrice_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_UpfrontFeeRecognizedAsRevenue" xlink:type="locator" xlink:label="freq_UpfrontFeeRecognizedAsRevenue" />
    <link:label xml:lang="en-US" xlink:label="freq_UpfrontFeeRecognizedAsRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee recognized as revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_UpfrontFeeRecognizedAsRevenue" xlink:to="freq_UpfrontFeeRecognizedAsRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_RevenueRecognitionTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price allocated to single combined performance obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RevenueRecognitionTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Transaction Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued upfront payment related to sub License revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Royalties Current</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_UpfrontFeeRecognizedAsRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee recognized as revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_UpfrontFeeRecognizedAsRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee Recognized As Revenue</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_RevenueFromContractWithCustomerApplicationInputMethod" xlink:type="locator" xlink:label="freq_RevenueFromContractWithCustomerApplicationInputMethod" />
    <link:label xml:lang="en-US" xlink:label="freq_RevenueFromContractWithCustomerApplicationInputMethod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue from contract with customer application input method.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_RevenueFromContractWithCustomerApplicationInputMethod" xlink:to="freq_RevenueFromContractWithCustomerApplicationInputMethod_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_RevenueFromContractWithCustomerApplicationInputMethod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from contract with customer application input method</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_RevenueFromContractWithCustomerApplicationInputMethod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Application Input Method</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue remaining performance obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLeasesTermOfContract" xlink:type="locator" xlink:label="freq_OperatingLeasesTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeasesTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases term of contract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingLeasesTermOfContract" xlink:to="freq_OperatingLeasesTermOfContract_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_LeaseExpirationYear" xlink:type="locator" xlink:label="freq_LeaseExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="freq_LeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_LeaseExpirationYear" xlink:to="freq_LeaseExpirationYear_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CT" xlink:type="locator" xlink:label="stpr_CT" />
    <link:label xml:lang="en-US" xlink:label="stpr_CT_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Connecticut</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CT" xlink:to="stpr_CT_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_CT_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CONNECTICUT</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_HaydenLLCMember" xlink:type="locator" xlink:label="freq_HaydenLLCMember" />
    <link:label xml:lang="en-US" xlink:label="freq_HaydenLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Hayden LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_HaydenLLCMember" xlink:to="freq_HaydenLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_HaydenLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hayden LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_HaydenLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Hayden L L C [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseArrangementTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Arrangement, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseArrangementTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Arrangement Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Arrangement, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="us-gaap_LeaseArrangementTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Arrangement Type [Domain]</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_LexingtonLeaseMember" xlink:type="locator" xlink:label="freq_LexingtonLeaseMember" />
    <link:label xml:lang="en-US" xlink:label="freq_LexingtonLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lexington lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_LexingtonLeaseMember" xlink:to="freq_LexingtonLeaseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="freq_LexingtonLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lexington Lease</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_LexingtonLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lexington Lease [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeasesTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeasesTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Term Of Contract</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_LeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_LeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Rent Expense Net</link:label>
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLeaseCommencementDate" xlink:type="locator" xlink:label="freq_OperatingLeaseCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingLeaseCommencementDate" xlink:to="freq_OperatingLeaseCommencementDate_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLeaseNumberOfAdditionalExtensionTerms" xlink:type="locator" xlink:label="freq_OperatingLeaseNumberOfAdditionalExtensionTerms" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseNumberOfAdditionalExtensionTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease number of additional extension terms.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingLeaseNumberOfAdditionalExtensionTerms" xlink:to="freq_OperatingLeaseNumberOfAdditionalExtensionTerms_lbl" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLeasesAdditionalExtensionTerm" xlink:type="locator" xlink:label="freq_OperatingLeasesAdditionalExtensionTerm" />
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeasesAdditionalExtensionTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases additional extension term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="freq_OperatingLeasesAdditionalExtensionTerm" xlink:to="freq_OperatingLeasesAdditionalExtensionTerm_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetRentableArea" xlink:type="locator" xlink:label="us-gaap_NetRentableArea" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetRentableArea_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rentable area of office space</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetRentableArea_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Rentable Area</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Commencement Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseNumberOfAdditionalExtensionTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional lease extension terms</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeaseNumberOfAdditionalExtensionTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Number Of Additional Extension Terms</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeasesAdditionalExtensionTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease extension term</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingLeasesAdditionalExtensionTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Additional Extension Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum lease commitments, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum lease commitments, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum lease commitments, 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum lease commitments, 2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum lease commitments, 2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum lease commitments, thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Minimum lease commitments, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment payments related to research</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Purchase Commitment Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="locator" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment payment period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Purchase Commitment Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyLossInPeriod" xlink:type="locator" xlink:label="us-gaap_LossContingencyLossInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyLossInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Losses related to indemnification obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyLossInPeriod" xlink:to="us-gaap_LossContingencyLossInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyLossInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Loss In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of employee contribution to retirement plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Maximum Annual Contributions Per Employee Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of employer matching contribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent Of Match</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of employee annual compensation matched by the employer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employers matching contribution vesting percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingAndNonOperatingExpensesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="freq_OperatingAndNonOperatingExpensesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating And Non Operating Expenses Net</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>52
<FILENAME>freq-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-03-26T03:10:11.1895688+00:00 -->
<!-- Version            : 5.0.1.369 -->
<!-- Package ID         : da71a932536d471fac83859dace20368 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/role/TemplateLink" xlink:href="freq-20191231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="freq-20191231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="freq-20191231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="locator" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesB1ConvertiblePreferredStockMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesAConvertiblePreferredStockMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesA1ConvertiblePreferredStockMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="freq-20191231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesB1ConvertiblePreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesAConvertiblePreferredStockMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesA1ConvertiblePreferredStockMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="freq-20191231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RoyaltyExpense" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="freq-20191231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficit" xlink:href="freq-20191231.xsd#Role_StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficit" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="freq-20191231.xsd#freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:loc xlink:href="freq-20191231.xsd#freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" xlink:type="locator" xlink:label="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ConvertiblePreferredStockAccretionOfDividend" xlink:type="locator" xlink:label="freq_ConvertiblePreferredStockAccretionOfDividend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue" xlink:type="locator" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue" xlink:type="locator" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="freq-20191231.xsd#freq_StockRepurchaseDuringPeriodSharesRestrictedStock" xlink:type="locator" xlink:label="freq_StockRepurchaseDuringPeriodSharesRestrictedStock" />
    <link:loc xlink:href="freq-20191231.xsd#freq_StockRepurchaseDuringPeriodValueRestrictedStock" xlink:type="locator" xlink:label="freq_StockRepurchaseDuringPeriodValueRestrictedStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="freq-20191231.xsd#freq_StockIssuedDuringPeriodSharesIssuedForPatentLicense" xlink:type="locator" xlink:label="freq_StockIssuedDuringPeriodSharesIssuedForPatentLicense" />
    <link:loc xlink:href="freq-20191231.xsd#freq_StockIssuedDuringPeriodValueIssuedForPatentLicense" xlink:type="locator" xlink:label="freq_StockIssuedDuringPeriodValueIssuedForPatentLicense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesCConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesB1ConvertiblePreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesAConvertiblePreferredStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesA1ConvertiblePreferredStockMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_StockIssuedDuringPeriodValueIssuedForPatentLicense" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_StockIssuedDuringPeriodSharesIssuedForPatentLicense" order="12130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="12610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="12850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_StockRepurchaseDuringPeriodValueRestrictedStock" order="12970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_StockRepurchaseDuringPeriodSharesRestrictedStock" order="13210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="13330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="13510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue" order="13690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue" order="13830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="14050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="14190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" order="14410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_ConvertiblePreferredStockAccretionOfDividend" order="14770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionOfDividends" order="15130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="15490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="15730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" order="15850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" order="15870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" order="15890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering" order="16090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="16210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="16570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_li0l2" order="16930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_li0l2" order="17290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_li0l2" order="17650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_li0l2" order="17890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficitParenthetical" xlink:href="freq-20191231.xsd#Role_StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficitParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficitParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesAConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="freq-20191231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" />
    <link:loc xlink:href="freq-20191231.xsd#freq_NonCashDividendOnCumulativeConvertiblePreferredStock" xlink:type="locator" xlink:label="freq_NonCashDividendOnCumulativeConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:loc xlink:href="freq-20191231.xsd#freq_CashPaidDuringPeriodForAbstract" xlink:type="locator" xlink:label="freq_CashPaidDuringPeriodForAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMinorityShareholders" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="freq_PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DeferredLeaseIncentives" xlink:type="locator" xlink:label="freq_DeferredLeaseIncentives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesAConvertiblePreferredStockMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesA1ConvertiblePreferredStockMember" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesB1ConvertiblePreferredStockMember" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesCConvertiblePreferredStockMember" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="freq_DeferredLeaseIncentives" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="freq_PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMinorityShareholders" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="12540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="12600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="12660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="freq_CashPaidDuringPeriodForAbstract" order="12720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_CashPaidDuringPeriodForAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="12840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="12900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="13020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="freq_NonCashDividendOnCumulativeConvertiblePreferredStock" order="13080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="13140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation" xlink:href="freq-20191231.xsd#Role_DisclosureOrganizationAndBasisOfPresentation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="freq-20191231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="freq-20191231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePrepaidExpenses" xlink:href="freq-20191231.xsd#Role_DisclosurePrepaidExpenses" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePrepaidExpenses">
    <link:loc xlink:href="freq-20191231.xsd#freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="locator" xlink:label="freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="freq-20191231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipment">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureAccruedExpenses" xlink:href="freq-20191231.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureAccruedExpenses">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureConvertibleNotes" xlink:href="freq-20191231.xsd#Role_DisclosureConvertibleNotes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureConvertibleNotes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureConvertiblePreferredStock" xlink:href="freq-20191231.xsd#Role_DisclosureConvertiblePreferredStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureConvertiblePreferredStock">
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityTextBlock" xlink:type="locator" xlink:label="freq_TemporaryEquityTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="freq_TemporaryEquityTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureNonControllingInterest" xlink:href="freq-20191231.xsd#Role_DisclosureNonControllingInterest" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureNonControllingInterest">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockholdersDeficit" xlink:href="freq-20191231.xsd#Role_DisclosureStockholdersDeficit" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockholdersDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="freq-20191231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureEmployeeStockPurchasePlan" xlink:href="freq-20191231.xsd#Role_DisclosureEmployeeStockPurchasePlan" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureEmployeeStockPurchasePlan">
    <link:loc xlink:href="freq-20191231.xsd#freq_EmployeeStockPurchasePlanDisclosureTextBlock" xlink:type="locator" xlink:label="freq_EmployeeStockPurchasePlanDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="freq_EmployeeStockPurchasePlanDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTax" xlink:href="freq-20191231.xsd#Role_DisclosureIncomeTax" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTax">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureResearchAndLicenseAgreements" xlink:href="freq-20191231.xsd#Role_DisclosureResearchAndLicenseAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureResearchAndLicenseAgreements">
    <link:loc xlink:href="freq-20191231.xsd#freq_ResearchAndLicenseAgreementsDisclosureTextBlock" xlink:type="locator" xlink:label="freq_ResearchAndLicenseAgreementsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="freq_ResearchAndLicenseAgreementsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCollaborationAgreement" xlink:href="freq-20191231.xsd#Role_DisclosureCollaborationAgreement" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCollaborationAgreement">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="freq-20191231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureEmployeeBenefitPlan" xlink:href="freq-20191231.xsd#Role_DisclosureEmployeeBenefitPlan" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureEmployeeBenefitPlan">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="freq-20191231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureRelatedPartyTransactions">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="freq-20191231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSelectedQuarterlyDataUnaudited" xlink:href="freq-20191231.xsd#Role_DisclosureSelectedQuarterlyDataUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSelectedQuarterlyDataUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="freq-20191231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="freq-20191231.xsd#freq_NonControllingInterestPolicyTextBlock" xlink:type="locator" xlink:label="freq_NonControllingInterestPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PatentCostsPolicyTextBlock" xlink:type="locator" xlink:label="freq_PatentCostsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SignificantSuppliersPolicyTextBlock" xlink:type="locator" xlink:label="freq_SignificantSuppliersPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="freq_SignificantSuppliersPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="freq_PatentCostsPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="freq_NonControllingInterestPolicyTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="freq-20191231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PropertyAndEquipmentTableTextBlock" xlink:type="locator" xlink:label="freq_PropertyAndEquipmentTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="freq_PropertyAndEquipmentTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="freq-20191231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePrepaidExpensesTables" xlink:href="freq-20191231.xsd#Role_DisclosurePrepaidExpensesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePrepaidExpensesTables">
    <link:loc xlink:href="freq-20191231.xsd#freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="locator" xlink:label="freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="freq-20191231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureAccruedExpensesTables" xlink:href="freq-20191231.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureAccruedExpensesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockholdersDeficitTables" xlink:href="freq-20191231.xsd#Role_DisclosureStockholdersDeficitTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockholdersDeficitTables">
    <link:loc xlink:href="freq-20191231.xsd#freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:type="locator" xlink:label="freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="freq-20191231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="freq-20191231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="freq-20191231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedTables" xlink:href="freq-20191231.xsd#Role_DisclosureSelectedQuarterlyDataUnauditedTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="freq_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="freq-20191231.xsd#freq_WoburnMassachusettsFacilityMember" xlink:type="locator" xlink:label="freq_WoburnMassachusettsFacilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="freq_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="freq_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="freq_WoburnMassachusettsFacilityMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="freq_SummaryOfSignificantAccountingPoliciesLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails" xlink:href="freq-20191231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="freq_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_FurnitureAndOfficeEquipmentMember" xlink:type="locator" xlink:label="freq_FurnitureAndOfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_LabEquipmentMember" xlink:type="locator" xlink:label="freq_LabEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="freq_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="freq_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="freq_LabEquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="freq_FurnitureAndOfficeEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesTable" xlink:to="freq_SummaryOfSignificantAccountingPoliciesLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="freq-20191231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="freq-20191231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OutstandingStockOptionsAsConvertedToCommonStockMember" xlink:type="locator" xlink:label="freq_OutstandingStockOptionsAsConvertedToCommonStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ConversionOfFrequencyJapanPreferredStockMember" xlink:type="locator" xlink:label="freq_ConversionOfFrequencyJapanPreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesAPreferredAsConvertedCommonStockMember" xlink:type="locator" xlink:label="freq_SeriesAPreferredAsConvertedCommonStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBPreferredAsConvertedToCommonStockMember" xlink:type="locator" xlink:label="freq_SeriesBPreferredAsConvertedToCommonStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesCPreferredAsConvertedToCommonStockMember" xlink:type="locator" xlink:label="freq_SeriesCPreferredAsConvertedToCommonStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_UnvestedRestrictedCommonStockMember" xlink:type="locator" xlink:label="freq_UnvestedRestrictedCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_UnvestedRestrictedCommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_SeriesCPreferredAsConvertedToCommonStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_SeriesBPreferredAsConvertedToCommonStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_SeriesAPreferredAsConvertedCommonStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_ConversionOfFrequencyJapanPreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="freq_OutstandingStockOptionsAsConvertedToCommonStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:href="freq-20191231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10060.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10060.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePrepaidExpensesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="freq-20191231.xsd#Role_DisclosurePrepaidExpensesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePrepaidExpensesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_GrantsReceivableCurrent" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="freq_PrepaidResearchAndDevelopmentExpenseCurrent" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PrepaidRentAndDepositsCurrent" xlink:type="locator" xlink:label="freq_PrepaidRentAndDepositsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="freq_PrepaidRentAndDepositsCurrent" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="freq_PrepaidResearchAndDevelopmentExpenseCurrent" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_GrantsReceivableCurrent" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="freq-20191231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="freq-20191231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="freq-20191231.xsd#freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureConvertibleNotesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails">
    <link:loc xlink:href="freq-20191231.xsd#freq_DebtInstrumentExcessFinancingFundReceived" xlink:type="locator" xlink:label="freq_DebtInstrumentExcessFinancingFundReceived" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion" xlink:type="locator" xlink:label="freq_DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DebtInstrumentExtendedMaturityDate" xlink:type="locator" xlink:label="freq_DebtInstrumentExtendedMaturityDate" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DebtInstrumentLossOnConversion" xlink:type="locator" xlink:label="freq_DebtInstrumentLossOnConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DebtInstrumentDiscountRate" xlink:type="locator" xlink:label="freq_DebtInstrumentDiscountRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesANotesMember" xlink:type="locator" xlink:label="freq_SeriesANotesMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PriorToQualifiedSeriesAFinancingMember" xlink:type="locator" xlink:label="freq_PriorToQualifiedSeriesAFinancingMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_QualifiedSeriesAFinancingMember" xlink:type="locator" xlink:label="freq_QualifiedSeriesAFinancingMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBNotesMember" xlink:type="locator" xlink:label="freq_SeriesBNotesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_QualifiedSeriesBFinancingMember" xlink:type="locator" xlink:label="freq_QualifiedSeriesBFinancingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="freq_QualifiedSeriesBFinancingMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="freq_SeriesBNotesMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="freq_QualifiedSeriesAFinancingMember" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="freq_PriorToQualifiedSeriesAFinancingMember" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="freq_SeriesANotesMember" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesAConvertiblePreferredStockMember" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="freq_DebtInstrumentDiscountRate" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="freq_DebtInstrumentLossOnConversion" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="freq_DebtInstrumentExtendedMaturityDate" order="12190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="freq_DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="freq_DebtInstrumentExcessFinancingFundReceived" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityAdditionalSharesIssuedCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="freq_TemporaryEquityAdditionalSharesIssuedCarryingAmountAttributableToParent" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TemporaryEquityAdditionalSharesIssued" xlink:type="locator" xlink:label="freq_TemporaryEquityAdditionalSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DebtInstrumentConvertibleDiscountOnConversionPrice" xlink:type="locator" xlink:label="freq_DebtInstrumentConvertibleDiscountOnConversionPrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBNotesMember" xlink:type="locator" xlink:label="freq_SeriesBNotesMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesANotesMember" xlink:type="locator" xlink:label="freq_SeriesANotesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesA1ConvertiblePreferredStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesB1ConvertiblePreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="freq_SeriesANotesMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesAConvertiblePreferredStockMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="freq_SeriesBNotesMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesCConvertiblePreferredStockMember" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="freq_DebtInstrumentConvertibleDiscountOnConversionPrice" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="freq_TemporaryEquityAdditionalSharesIssued" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="freq_TemporaryEquityAdditionalSharesIssuedCarryingAmountAttributableToParent" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureNonControllingInterestAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureNonControllingInterestAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureNonControllingInterestAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:type="locator" xlink:label="us-gaap_PreferredStockVotingRights" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PreferredStockSharesPurchased" xlink:type="locator" xlink:label="freq_PreferredStockSharesPurchased" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PercentageOfVoteOfHoldersOfPreferredStock" xlink:type="locator" xlink:label="freq_PercentageOfVoteOfHoldersOfPreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DelawareLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="freq_DelawareLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesB1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesB1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesA1ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SubsidiariesMember" xlink:type="locator" xlink:label="srt_SubsidiariesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_SubsidiariesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesA1ConvertiblePreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesB1ConvertiblePreferredStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="freq_DelawareLimitedLiabilityCompanyMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="freq_PercentageOfVoteOfHoldersOfPreferredStock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="freq_PreferredStockSharesPurchased" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockVotingRights" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureStockholdersDeficitAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockholdersDeficitScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:href="freq-20191231.xsd#Role_DisclosureStockholdersDeficitScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockholdersDeficitScheduleOfCommonStockSharesReservedForFutureIssuanceDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ConversionOfFrequencyJapanPreferredStockMember" xlink:type="locator" xlink:label="freq_ConversionOfFrequencyJapanPreferredStockMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="freq_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesAConvertiblePreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_ConversionOfFrequencyJapanPreferredStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="freq_SeriesBConvertiblePreferredStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xlink:type="locator" xlink:label="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TwoThousandAndNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TwoThousandAndFourteenStockIncentivePlanMember" xlink:type="locator" xlink:label="freq_TwoThousandAndFourteenStockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="freq_TwoThousandAndFourteenStockIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnder2014PlanAnd2019PlanDetails" xlink:href="freq-20191231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnder2014PlanAnd2019PlanDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnder2014PlanAnd2019PlanDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TwoThousandAndFourteenStockIncentivePlanMember" xlink:type="locator" xlink:label="freq_TwoThousandAndFourteenStockIncentivePlanMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TwoThousandAndNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="freq_TwoThousandAndNineteenIncentiveAwardPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="freq_TwoThousandAndFourteenStockIncentivePlanMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="12560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="12920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="13100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="14000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="14180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="14780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="14960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="15140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails" xlink:href="freq-20191231.xsd#Role_DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockDetails" xlink:href="freq-20191231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriodWeightedAverageFairValue" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriodWeightedAverageFairValue" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageFairValue" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageFairValue" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_li0l2" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriod" xlink:type="locator" xlink:label="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriod" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageFairValue" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriodWeightedAverageFairValue" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue_li0l2" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" xlink:type="locator" xlink:label="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PercentageOfEligibleEmployeeCompensation" xlink:type="locator" xlink:label="freq_PercentageOfEligibleEmployeeCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_PercentageOfEligibleEmployeeCompensation" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLossDeductionLimitationAsPercentageOfTaxableIncome" xlink:type="locator" xlink:label="freq_OperatingLossDeductionLimitationAsPercentageOfTaxableIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" xlink:type="locator" xlink:label="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PeriodOfCumulativeChangeInOwnership" xlink:type="locator" xlink:label="freq_PeriodOfCumulativeChangeInOwnership" />
    <link:loc xlink:href="freq-20191231.xsd#freq_CumulativeChangeInOwnershipPercentage" xlink:type="locator" xlink:label="freq_CumulativeChangeInOwnershipPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="freq-20191231.xsd#freq_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="freq_TaxCreditCarryforwardExpirationYear" />
    <link:loc xlink:href="freq-20191231.xsd#freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" xlink:type="locator" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="freq_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="freq-20191231.xsd#freq_NetOperatingLossCarryforwardsExpirationWithLimitation" xlink:type="locator" xlink:label="freq_NetOperatingLossCarryforwardsExpirationWithLimitation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="freq-20191231.xsd#freq_IncomeTaxesDisclosureLineItems" xlink:type="locator" xlink:label="freq_IncomeTaxesDisclosureLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA" xlink:type="locator" xlink:label="stpr_MA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_IncomeTaxesDisclosureTable" xlink:type="locator" xlink:label="freq_IncomeTaxesDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="freq_IncomeTaxesDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="srt_StatementGeographicalAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="srt_RangeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureTable" xlink:to="freq_IncomeTaxesDisclosureLineItems" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_NetOperatingLossCarryforwardsExpirationWithLimitation" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_OperatingLossCarryforwardsExpirationYear" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_TaxCreditCarryforwardExpirationYear" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_CumulativeChangeInOwnershipPercentage" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_PeriodOfCumulativeChangeInOwnership" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_OperatingLossCarryforwardsUsageAfterOwnershipChange" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="freq_IncomeTaxesDisclosureLineItems" xlink:to="freq_OperatingLossDeductionLimitationAsPercentageOfTaxableIncome" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" xlink:href="freq-20191231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" xlink:href="freq-20191231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureResearchAndLicenseAgreementsAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureResearchAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureResearchAndLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="freq-20191231.xsd#freq_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="freq_IncreaseDecreaseInResearchAndDevelopmentExpense" />
    <link:loc xlink:href="freq-20191231.xsd#freq_GrantTermPeriod" xlink:type="locator" xlink:label="freq_GrantTermPeriod" />
    <link:loc xlink:href="freq-20191231.xsd#freq_AmountOfFundingReceivedAsGrant" xlink:type="locator" xlink:label="freq_AmountOfFundingReceivedAsGrant" />
    <link:loc xlink:href="freq-20191231.xsd#freq_AnnualLicenseFee" xlink:type="locator" xlink:label="freq_AnnualLicenseFee" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" xlink:type="locator" xlink:label="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RightToTerminateAgreementIncaseOfNonpayment" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementIncaseOfNonpayment" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RightToTerminateAgreementIfBreachRemainsUncured" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementIfBreachRemainsUncured" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RightToTerminateAgreementUponPriorWrittenNotice" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementUponPriorWrittenNotice" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DescriptionOfConditionsToTerminateLicenseAgreement" xlink:type="locator" xlink:label="freq_DescriptionOfConditionsToTerminateLicenseAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="freq-20191231.xsd#freq_MilestonePayments" xlink:type="locator" xlink:label="freq_MilestonePayments" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PercentageOfSharesOfCommonStockIssued" xlink:type="locator" xlink:label="freq_PercentageOfSharesOfCommonStockIssued" />
    <link:loc xlink:href="freq-20191231.xsd#freq_LicenseFeePayment" xlink:type="locator" xlink:label="freq_LicenseFeePayment" />
    <link:loc xlink:href="freq-20191231.xsd#freq_DescriptionOfFutureDevelopmentObligations" xlink:type="locator" xlink:label="freq_DescriptionOfFutureDevelopmentObligations" />
    <link:loc xlink:href="freq-20191231.xsd#freq_LicenseAgreementEnteredDate" xlink:type="locator" xlink:label="freq_LicenseAgreementEnteredDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantMember" xlink:type="locator" xlink:label="us-gaap_GrantMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ResearchAndDevelopmentMember" xlink:type="locator" xlink:label="freq_ResearchAndDevelopmentMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_CambridgeEnterpriseLimitedMember" xlink:type="locator" xlink:label="freq_CambridgeEnterpriseLimitedMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_MassachusettsEyeAndEarInfirmaryMember" xlink:type="locator" xlink:label="freq_MassachusettsEyeAndEarInfirmaryMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_NonExclusivePatentLicenseAgreementMember" xlink:type="locator" xlink:label="freq_NonExclusivePatentLicenseAgreementMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_CaliforniaInstituteForBiomedicalResearchMember" xlink:type="locator" xlink:label="freq_CaliforniaInstituteForBiomedicalResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_AstellasPharmaLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="freq_AstellasPharmaLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_PatentLicenseAgreementMember" xlink:type="locator" xlink:label="freq_PatentLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_MassachusettsInstituteOfTechnologyMember" xlink:type="locator" xlink:label="freq_MassachusettsInstituteOfTechnologyMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="dei_LegalEntityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="freq_MassachusettsInstituteOfTechnologyMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="freq_PatentLicenseAgreementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="freq_AstellasPharmaLimitedLiabilityCompanyMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_ProductOrServiceAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="freq_CaliforniaInstituteForBiomedicalResearchMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="freq_NonExclusivePatentLicenseAgreementMember" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="freq_MassachusettsEyeAndEarInfirmaryMember" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="freq_CambridgeEnterpriseLimitedMember" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="freq_ResearchAndDevelopmentMember" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_LicenseAgreementEnteredDate" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_DescriptionOfFutureDevelopmentObligations" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_LicenseFeePayment" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_PercentageOfSharesOfCommonStockIssued" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_MilestonePayments" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_DescriptionOfConditionsToTerminateLicenseAgreement" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_RightToTerminateAgreementUponPriorWrittenNotice" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_RightToTerminateAgreementIfBreachRemainsUncured" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_RightToTerminateAgreementIncaseOfNonpayment" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice" order="12370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent" order="12650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_AnnualLicenseFee" order="12790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_AmountOfFundingReceivedAsGrant" order="12950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_GrantTermPeriod" order="13010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="freq_IncreaseDecreaseInResearchAndDevelopmentExpense" order="13070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureCollaborationAgreementAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RevenueFromContractWithCustomerApplicationInputMethod" xlink:type="locator" xlink:label="freq_RevenueFromContractWithCustomerApplicationInputMethod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="freq-20191231.xsd#freq_UpfrontFeeRecognizedAsRevenue" xlink:type="locator" xlink:label="freq_UpfrontFeeRecognizedAsRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RevenueRecognitionTransactionPrice" xlink:type="locator" xlink:label="freq_RevenueRecognitionTransactionPrice" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RightToTerminateAgreementIncaseOfNonpayment" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementIncaseOfNonpayment" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RightToTerminateAgreementIfBreachRemainsUncured" xlink:type="locator" xlink:label="freq_RightToTerminateAgreementIfBreachRemainsUncured" />
    <link:loc xlink:href="freq-20191231.xsd#freq_AgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="freq_AgreementTerminationNoticePeriod" />
    <link:loc xlink:href="freq-20191231.xsd#freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" xlink:type="locator" xlink:label="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" />
    <link:loc xlink:href="freq-20191231.xsd#freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" xlink:type="locator" xlink:label="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_AsiaMember" xlink:type="locator" xlink:label="srt_AsiaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_Phase3ClinicalTrailMember" xlink:type="locator" xlink:label="freq_Phase3ClinicalTrailMember" />
    <link:loc xlink:href="freq-20191231.xsd#freq_Phase2bClinicalTrialMember" xlink:type="locator" xlink:label="freq_Phase2bClinicalTrialMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_AstellasPharmaLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="freq_AstellasPharmaLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="freq_LicenseAndCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="freq_LicenseAndCollaborationAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="freq_AstellasPharmaLimitedLiabilityCompanyMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="freq_Phase2bClinicalTrialMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="freq_Phase3ClinicalTrailMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_AsiaMember" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_AgreementTerminationNoticePeriod" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_RightToTerminateAgreementIfBreachRemainsUncured" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_RightToTerminateAgreementIncaseOfNonpayment" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_RevenueRecognitionTransactionPrice" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_UpfrontFeeRecognizedAsRevenue" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="freq_RevenueFromContractWithCustomerApplicationInputMethod" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyLossInPeriod" xlink:type="locator" xlink:label="us-gaap_LossContingencyLossInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="locator" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLeasesAdditionalExtensionTerm" xlink:type="locator" xlink:label="freq_OperatingLeasesAdditionalExtensionTerm" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLeaseNumberOfAdditionalExtensionTerms" xlink:type="locator" xlink:label="freq_OperatingLeaseNumberOfAdditionalExtensionTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLeaseCommencementDate" xlink:type="locator" xlink:label="freq_OperatingLeaseCommencementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetRentableArea" xlink:type="locator" xlink:label="us-gaap_NetRentableArea" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:loc xlink:href="freq-20191231.xsd#freq_LeaseExpirationYear" xlink:type="locator" xlink:label="freq_LeaseExpirationYear" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingLeasesTermOfContract" xlink:type="locator" xlink:label="freq_OperatingLeasesTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_LexingtonLeaseMember" xlink:type="locator" xlink:label="freq_LexingtonLeaseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <link:loc xlink:href="freq-20191231.xsd#freq_HaydenLLCMember" xlink:type="locator" xlink:label="freq_HaydenLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CT" xlink:type="locator" xlink:label="stpr_CT" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA" xlink:type="locator" xlink:label="stpr_MA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CT" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="freq_HaydenLLCMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="freq_LexingtonLeaseMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeasesTermOfContract" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_LeaseExpirationYear" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_NetRentableArea" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeaseCommencementDate" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeaseNumberOfAdditionalExtensionTerms" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="freq_OperatingLeasesAdditionalExtensionTerm" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LossContingencyLossInPeriod" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetails" xlink:href="freq-20191231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedScheduleOfQuarterlyFinancialInformationDetails" xlink:href="freq-20191231.xsd#Role_DisclosureSelectedQuarterlyDataUnauditedScheduleOfQuarterlyFinancialInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedScheduleOfQuarterlyFinancialInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="freq-20191231.xsd#freq_OperatingAndNonOperatingExpensesNet" xlink:type="locator" xlink:label="freq_OperatingAndNonOperatingExpensesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="freq_OperatingAndNonOperatingExpensesNet" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6782584208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">79.40%<span></span>
</td>
<td class="nump">81.10%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791406864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee related expenses</a></td>
<td class="nump">$ 2,686<span></span>
</td>
<td class="nump">$ 1,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent', window );">Third-party research and development expenses</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 3,239<span></span>
</td>
<td class="nump">$ 1,749<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued third-party research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_AccruedThirdPartyResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795595440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 20, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">165,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,844,507<span></span>
</td>
<td class="nump">2,084,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,844,507<span></span>
</td>
<td class="nump">2,084,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.148467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-6.7355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">148,724,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, value per share | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797016576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Convertible Preferred Stock, Non-controlling Interest and Stockholder's Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Non-controlling Interest</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional-paid in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Series C Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Convertible Preferred Stock</div></th>
<th class="th"><div>Series B-1 Convertible Preferred Stock</div></th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
<th class="th"><div>Series A-1 Convertible Preferred Stock</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2016</a></td>
<td class="num">$ (9,663)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,658,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock-based compensation expense (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_StockIssuedDuringPeriodValueIssuedForPatentLicense', window );">Issuance of common stock for exclusive patent license</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_StockIssuedDuringPeriodSharesIssuedForPatentLicense', window );">Issuance of common stock for exclusive patent license (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue', window );">Issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue', window );">Issuance of convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,538,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of convertible preferred stock related to the conversion of convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of convertible preferred stock related to the conversion of convertible notes payable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,990,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending Balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,528,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2017</a></td>
<td class="num">(29,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,954,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">126,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_StockRepurchaseDuringPeriodSharesRestrictedStock', window );">Repurchase of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue', window );">Issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue', window );">Issuance of convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,017,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of convertible preferred stock related to the conversion of convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of convertible preferred stock related to the conversion of convertible notes payable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,839,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,224<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 46,694<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,857,005<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">62,528,507<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="num">$ (48,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">2,084,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,084,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">357,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,687<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,492,960<span></span>
</td>
<td class="nump">288,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_ConvertiblePreferredStockAccretionOfDividend', window );">Accretion of Series C preferred dividend</a></td>
<td class="num">$ (1,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionOfDividends', window );">Accretion of Series C preferred dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Initial public offering of common stock</a></td>
<td class="nump">79,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">79,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering', window );">Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO</a></td>
<td class="nump">151,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">151,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering', window );">Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,492,960)<span></span>
</td>
<td class="num">(42,145,996)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="num">(62,528,507)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering', window );">Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,773)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (62,741)<span></span>
</td>
<td class="num">$ (38,490)<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
<td class="num">$ (46,694)<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering', window );">Conversion of preferred stock and non-controlling interest into common stock in connection with the IPO (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,077,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 167,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 236,161<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="num">$ (68,888)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">30,844,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,844,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ConvertiblePreferredStockAccretionOfDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock accretion of dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ConvertiblePreferredStockAccretionOfDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_StockIssuedDuringPeriodSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_StockIssuedDuringPeriodSharesIssuedForPatentLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issued for patent license.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_StockIssuedDuringPeriodSharesIssuedForPatentLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_StockIssuedDuringPeriodValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_StockIssuedDuringPeriodValueIssuedForPatentLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issued for patent license.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_StockIssuedDuringPeriodValueIssuedForPatentLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_StockRepurchaseDuringPeriodSharesRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock repurchase during period shares restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_StockRepurchaseDuringPeriodSharesRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares net of issuance cost new issue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_TemporaryEquityStockIssuedDuringPeriodSharesNetOfIssuanceCostNewIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, stock issued during period, shares, new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period value net of issuance cost new issue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_TemporaryEquityStockIssuedDuringPeriodValueNetOfIssuanceCostNewIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock shares conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_TemporaryEquityStockSharesConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock value conversion of preferred stock and non-controlling interest into common stock in connection with initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_TemporaryEquityStockValueConversionOfPreferredStockAndNonControllingInterestIntoCommonStockInConnectionWithInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity during the period due to unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794142368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 200,158<span></span>
</td>
<td class="nump">$ 42,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="nump">17,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">221,355<span></span>
</td>
<td class="nump">42,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,762<span></span>
</td>
<td class="nump">1,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">223,218<span></span>
</td>
<td class="nump">44,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,219<span></span>
</td>
<td class="nump">1,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,239<span></span>
</td>
<td class="nump">1,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">48,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">52,780<span></span>
</td>
<td class="nump">3,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term liabilities</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">55,860<span></span>
</td>
<td class="nump">4,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 and 165,000,000 shares authorized at December 31, 2019 and December 31, 2018, respectively; 30,844,507 and 2,084,710 shares issued and outstanding at December 31, 2019 and 2018, respectively</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">236,161<span></span>
</td>
<td class="nump">804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(68,888)<span></span>
</td>
<td class="num">(49,088)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">167,358<span></span>
</td>
<td class="num">(48,282)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock, non-controlling interest and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 223,218<span></span>
</td>
<td class="nump">44,548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6720085312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. Prepaid expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent and deposits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">801</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">428</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant receivable</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">805</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,132</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">748</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6654093344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_TemporaryEquityTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Convertible preferred stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2018, the Company had authorized 114,208,722 shares of Preferred Stock and had designated 64,891,735 shares as Series A Preferred, 10,000 shares as Series A-1 Preferred Stock, 49,296,987 shares as Series B Preferred and 10,000 shares as Series B-1 Preferred Stock. Since the Preferred Stock was redeemable upon a liquidation event, which is not considered to be within the Company&#8217;s control, it has been classified in temporary equity on the accompanying consolidated balance sheet as of December 31, 2018. The carrying value of the Preferred Stock was the proceeds received less issuance costs. In October 2019, in connection with the IPO, all shares of Preferred Stock were automatically converted into common stock.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Issuances of preferred stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;30, 2017, the Company converted $14,285 of Series A Notes plus accrued interest of $709 into 24,990,086 shares of Series A Preferred at a 20% discount to the offering price of $0.75 per share. The Company also issued 9,783,522 shares of Series A Preferred for proceeds of $7,338 on the same date. Additional issuances of Series A Preferred took place in April, May, August and December of 2017 for an additional aggregate issuance of 27,754,899 shares of Series A Preferred shares for proceeds of $20,816. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurred $203 of share issuance costs in connection with the issuance of the Series A Preferred described above which was recorded as a reduction in the proceeds received and the carrying value. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;17, 2018, the Company converted $5,000 of Series B Notes plus accrued interest of $106 into 5,839,463 shares of Series B Preferred at a 5% discount to the offering price of $0.92 per share. The Company also issued 7,544,029 shares of Series B Preferred for proceeds of $6,944 on the same date. Additional issuances of Series B Preferred took place in November and December of 2018 for an additional aggregate issuance of 28,473,513 shares of Series B Preferred shares for proceeds of $26,208. The Company also issued 288,991 shares of Series B Preferred in January and February 2019 for proceeds of $266. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurred $302 of share issuance costs in connection with Series B Preferred described above which was recorded as a reduction in the proceeds received and the carrying value. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;17, 2018, the Company issued 10,000 shares of Series A-1 Preferred Stock (Series A-1 Preferred) at a price of $0.75 per share for proceeds of $8. The Company also issued 10,000 shares of Series B-1 Preferred Stock (Series B-1 Preferred) at a price of $0.92 per share for proceeds of $9 on the same date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated the tranched nature of the issuance of Series A Preferred and Series B Preferred as well as the rights, preferences, and privileges of such shares and has concluded that there were no freestanding derivative instruments or any embedded derivatives requiring bifurcation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;17, 2019, the Company authorized and issued 39,492,960 shares of Series&#160;C Preferred for net proceeds of $61,687. The Company has evaluated the rights, preferences and privileges of the Series C Preferred and has concluded that there were no freestanding derivative investments or any embedded derivatives requiring bifurcation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:12pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_TemporaryEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_TemporaryEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6652644128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Shares Reserved for Future Issuance</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reserved the following shares of common stock for future issuance as of December 31, 2019, 2018 and 2017:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred conversion</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,283,425</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,283,425</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Frequency Japan preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">673,605</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred conversion</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,214,387</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,968,672</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,089,334</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">985,521</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future grant under stock option plan</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,859,654</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,028,096</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">646,871</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,828,326</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,288,847</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,915,817</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6614272752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial assets measures at fair value on a recurring basis by level within the fair value hierarchy at December 31, 2019 are summarized as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Market</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,131</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,119</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Government treasury securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,131</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,197</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,262</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,316</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6659998592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Quarterly Financial Information</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table contains quarterly financial information for 2019 and 2018.&nbsp;&nbsp;The Company believes that the following information reflects all normal recurring adjustments necessary for the fair statement of the information for the periods presented.&nbsp;&nbsp;The operating results for any quarter are not necessarily indicative of results for any future period.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,238</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,709</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">28,947</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,826</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,852</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,813</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,202</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">47,693</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,826</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,852</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(575</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,493</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative series C convertible preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; dividends</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1,054</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,826</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,852</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,589</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,533</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders -</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.24</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.42</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.73</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.19</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2.29</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,149</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,436</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,136</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,447</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">19,168</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,149</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,436</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,136</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,447</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative series C convertible preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; dividends</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,149</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,436</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,136</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,447</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders -</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.03</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.01</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.26</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.23</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(12.53</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118952077&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6614746736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Data (Unaudited)</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">20. Selected Quarterly Data (Unaudited) </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table contains quarterly financial information for 2019 and 2018.&nbsp;&nbsp;The Company believes that the following information reflects all normal recurring adjustments necessary for the fair statement of the information for the periods presented.&nbsp;&nbsp;The operating results for any quarter are not necessarily indicative of results for any future period.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,238</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,709</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">28,947</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,826</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,852</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,813</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,202</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">47,693</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,826</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,852</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(575</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,493</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(18,746</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative series C convertible preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; dividends</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1,054</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,826</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,852</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,589</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,533</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders -</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.24</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.42</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.73</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.19</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2.29</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,149</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,436</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,136</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,447</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">19,168</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,149</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,436</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,136</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,447</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative series C convertible preferred stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; dividends</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,149</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,436</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,136</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,447</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders -</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.03</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.01</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.26</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.23</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(12.53</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6784932928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Stock Purchase Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_EmployeeStockPurchasePlanDisclosureTextBlock', window );">Employee Stock Purchase Plan</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. Employee stock purchase plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 20, 2019, the Company&#8217;s board of directors and stockholders approved and adopted the 2019 Employee stock Purchase Plan (the &#8220;ESPP&#8221;) which became effective on the date of the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. A total of 315,000 shares of common stock were approved to be initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first ten-years of the term of the ESPP, beginning with January 1, 2020 and ending with January 1, 2029, by an amount equal to 1% of the outstanding number of shares of the Company&#8217;s common stock on December 31 of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors. No shares were issued under the ESPP at December 31, 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_EmployeeStockPurchasePlanDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_EmployeeStockPurchasePlanDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6961136160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16. Commitments and contingencies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating leases </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2016, the Company and a related third party (see Note 18) entered into a five-year operating lease for the Company&#8217;s primary office and laboratory space in Woburn, Massachusetts. In February 2020, the Company entered into a new lease for its office and laboratory space with the same landlord in Woburn, Massachusetts.&nbsp;&nbsp;The new lease includes additional office space and is for a five-year period.&nbsp;&nbsp;The Company intends to sublease this facility at the time it moves into its new facility discussed below. The Company also leases a laboratory facility in Connecticut under an operating lease which expires in 2019. Rent expense was $269 and $271 for the years ended December&#160;31, 2019 and 2018, respectively. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 7, 2020 the Company entered into an indenture of lease (the &#8220;Lexington Lease&#8221;) with HCP/KING 75Hayden LLC,(the &#8220;Landlord&#8221;), for the lease of approximately 61,307 square feet of rentable area in Lexington, Massachusetts or (the &#8220;Lexington Premises&#8221;).&nbsp;&nbsp;The commencement date of the Lexington Lease is expected to be on or about December 1, 2020, (the &#8220;Commencement Date&#8221;).&nbsp;&nbsp;The Company expects to use the Lexington Premises as its new principal executive offices and as a laboratory for research and development, and other related uses.&nbsp;&nbsp;The term of the Lexington Lease, (the &#8220; Initial Term&#8221;), is ten years from the rent commencement date (which is five months following the Commitment Date) and the Initial Term is expected to end on April 30, 2031 (assuming a December 1, 2020 Commencement Date).&nbsp;&nbsp;We also have the option to extend the Initial Term for two additional terms of five years each.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The minimum aggregate future operating lease commitments for the leases noted above are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum&#160;lease</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">commitments</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">504</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,613</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,741</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,883</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,034</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,596</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,371</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contract commitments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has contracted with a research institution to provide research for a therapeutic drug to treat multiple sclerosis. As of December&#160;31, 2019, the Company has committed to total payments of $705 over twelve months beginning in October 2019.&nbsp;&nbsp;We also enter into contracts in the normal course of business with CROs, CMOs, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancelable by us upon prior written notice although, purchase orders for clinical materials are generally non-cancelable. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation or upon the completion of a manufacturing run. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Guarantees </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, <font style="font-style:italic;">Guarantees</font>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#8217;s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#8217; and officers&#8217; insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office space under a five-year noncancelable operating lease. The Company has standard indemnification arrangements under this lease that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the lease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, 2018 and 2017, the Company had not experienced any losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves have been established. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781101136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details) - Recurring Basis<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortization Cost</a></td>
<td class="nump">$ 217,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">217,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortization Cost</a></td>
<td class="nump">200,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">200,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Government Treasury Securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortization Cost</a></td>
<td class="nump">17,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">$ 17,197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6778679344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency exchange gains (losses)</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 151,000<span></span>
</td>
<td class="num">$ (8,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Minimum | Woburn Massachusetts Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Maximum | Woburn Massachusetts Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 220<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873921&amp;loc=SL114875236-224282<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=freq_WoburnMassachusettsFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=freq_WoburnMassachusettsFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6937361136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 813<span></span>
</td>
<td class="nump">$ 654<span></span>
</td>
<td class="nump">$ 531<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6962546048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Dec. 22, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Impact of federal rate change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Permanent differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.80%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in deferred tax asset valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.00%)<span></span>
</td>
<td class="num">(26.30%)<span></span>
</td>
<td class="num">(25.90%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796513072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 07, 2020 </div>
<div>ft&#178; </div>
<div>Term</div>
</th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLeasesTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 269,000<span></span>
</td>
<td class="nump">$ 271,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Commitment payments related to research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">705,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyLossInPeriod', window );">Losses related to indemnification obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Commitment payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Hayden LLC | Lexington Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLeasesTermOfContract', window );">Operating lease term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable area of office space | ft&#178;</a></td>
<td class="nump">61,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">Dec.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Apr. 30,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLeaseNumberOfAdditionalExtensionTerms', window );">Number of additional lease extension terms | Term</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLeasesAdditionalExtensionTerm', window );">Lease extension term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLeasesTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Massachusetts | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLeasesTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CT', window );">Connecticut</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_LeaseExpirationYear', window );">Lease, expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_LeaseExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_LeaseExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLeaseNumberOfAdditionalExtensionTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease number of additional extension terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLeaseNumberOfAdditionalExtensionTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLeasesAdditionalExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases additional extension term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLeasesAdditionalExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases term of contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyLossInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyLossInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=freq_HaydenLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=freq_HaydenLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=freq_LexingtonLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=freq_LexingtonLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6961226048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income tax</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13. Income taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception in 2014, the Company has generated cumulative federal and state net operating loss and research and development credit carryforwards for which we have not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within the respective carryforward periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, the Company had federal net operating loss carryforwards of approximately $50,199 and Massachusetts state operating loss carryforwards of approximately $41,242&#160;which may be available to offset future taxable income. The U.S. federal net operating loss carryforwards include $22,400 available to reduce future taxable income through 2037 and approximately $27,779 which do not expire and are available to reduce future taxable income indefinitely. The state net operating loss carryforwards are available to offset future taxable income through 2039. As of December&#160;31, 2019, the Company also had federal and Massachusetts research and development tax credit carryforwards of $701 and $533, respectively, which are available to offset federal and state tax liabilities through 2039 and 2034, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realization of future tax benefits is dependent on many factors, including the Company&#8217;s ability to generate taxable income within the net operating loss carryforward period. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as provided under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, respectively, as well as similar state provisions. These ownership changes may limit the number of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has completed several financings and has conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception and has determined that an ownership change did occur in March 2017. Accordingly, utilization of $12,400 of the U.S. net operating loss carryforwards which were incurred prior to March 2017 (pre-ownership change) is limited under Section 382. After the Section 382 limitations, the Company may utilize approximately $10,800 of its pre-ownership change net operating loss carryforwards based upon an annual usage of approximately $1,600 for each of the next five years after the ownership change and approximately $180 for each of the 15 years thereafter. The remaining pre-ownership change net operating losses of approximately $1,600 were written off due to expiration under limitation. The limitation has been determined by first multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate. These carryforwards may be subject to further annual limitations under Section&#160;382 in the event of future changes in ownership.  Additionally, the Company has determined an ownership changed occurred in October of 2019 as a result of the IPO.&nbsp;&nbsp;Accordingly, utilization of approximately $46,123 of the U.S. net operating loss carryforwards incurred prior to October 2019 is also limited under Section 382.&nbsp;&nbsp;The Company has determined it will be able to utilize the entire $46,123 of its pre-ownership change net operating loss carryforwards based upon the limitations calculated from the October 2019 ownership change. These carryforwards may be subject to further annual limitations under Section 382 in the event of future changes in ownership.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December&#160;31, 2019 and 2018 because the Company&#8217;s management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets primarily due to its cumulative loss position and, as a result, a valuation allowance of approximately $16,204 and $12,229 as of December&#160;31, 2019 and 2018 has been established. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no unrecognized tax benefits. The Company has not, as yet, conducted a study of its research and development credit carryforwards. Such a study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment were required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheet or consolidated statements of operations if an adjustment were required. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which no interest or penalties were recorded for the years ended December&#160;31, 2019 and 2018. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the U.S. and Massachusetts. The statute of limitations for assessment by the Internal Revenue Service and Massachusetts tax authorities remains open for all years since 2014. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state authorities to the extent utilized in a future period. No federal or state tax audits are currently in process. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2019, 2018 and 2017 is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S federal statutory income tax rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of federal rate change</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other items</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in deferred tax asset valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26.3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25.9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s deferred tax assets at December&#160;31, 2019 and 2018 consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,253</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,710</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,138</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangibles</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">358</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">496</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax asset</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,204</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,229</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,204</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,229</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December&#160;22, 2017, the Tax Cuts and Jobs Act was signed into United States law. The Tax Cuts and Jobs Act includes a number of changes to existing tax law, including, among other things, a permanent reduction in the federal corporate income tax rate from a top marginal tax rate of 35% to a flat rate of 21%, effective as of January&#160;1, 2018, as well as a limitation of the deduction for net operating losses to 80% of annual taxable income and elimination of net operating loss carrybacks, in each case, for losses arising in taxable years beginning after December&#160;31, 2017 (though any such net operating losses may be carried forward indefinitely). The federal tax rate change resulted in a reduction in the gross amount of our deferred tax assets and liabilities recorded as of December&#160;31, 2017, and a corresponding reduction in our valuation allowance. As a result, no income tax expense or benefit was recognized as of the enactment date of the Tax Cuts and Jobs Act. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6961226048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17. Employee benefit plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employees of the Company are eligible to participate in the Company&#8217;s 401(k) retirement plan (the &#8220;401(k) Plan&#8221;). Participants may contribute up to 90% of their annual compensation to the 401(k) Plan, subject to statutory limitations. The 401(k) Plan has a Safe Harbor Match of 100% of the first 5% and vests 100% at time of match. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6778741280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB <font style="font-style:italic;">Accounting Standards</font> Codification (ASC). </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of consolidation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics PTY, LTD and Frequency Japan (majority owned at December 31, 2018). All intercompany transactions and balances have been eliminated. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include but are not limited to management&#8217;s judgments of accrued expenses, revenue, fair value of common stock, valuation of share-based awards and income taxes. Actual results could differ from those estimates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes significant estimates and assumptions in determining the fair value of its common stock in periods prior to the IPO. The Company had utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation (the Practice Aid), to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (loss)</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive income (loss) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders which for the year ended December 31, 2019 consists of unrealized gain on marketable securities.&nbsp;&nbsp;There were no elements of comprehensive loss for the years ended December 31, 2018 and 2017.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s chief executive officer, views the Company&#8217;s operations and manages its business as a single operating segment, which is in the business of discovering and developing small molecule drugs that activate progenitor cells within the body to create healthy tissue. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign currency </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All periods presented are reported in US dollars. The functional currency for entities outside the United States is the US dollar. Realized and unrealized gains and losses from foreign currency transactions are reflected in the consolidated statements of operations as other expense. During the years ended December&#160;31, 2019, 2018 and 2017 the Company recorded $7, $151 and ($8) of foreign currency exchange gains (losses), respectively. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and cash equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with an original maturity of six months or less at acquisition to be cash equivalents which are stated at fair market value. Cash and cash equivalents at December&#160;31, 2019 and 2018 consists entirely of cash held in banks and money market funds. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Short-term Marketable Debt Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;">Short-term marketable debt securities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company&#8217;s investment policy. Short-term marketable investment mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders&#8217; equity (deficit) until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, together with interest on securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investment are reflected as a component of other income (expense).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities at December 31, 2019 consist of investment in U.S. Treasury Securities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Off-balance Sheet Risk</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;">Concentration of credit risk and off-balance sheet risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instrument that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of U.S. Treasury securities with maturities of less than twelve months. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_SignificantSuppliersPolicyTextBlock', window );">Significant Suppliers</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Significant suppliers </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a single manufacturer of its product candidates for use in clinical trials. The Company would be adversely affected by a significant interruption in the supply of product for use in clinical programs. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair value measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic&#160;820, <font style="font-style:italic;">Fair Value Measurement</font> (ASC&#160;820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quoted prices in active markets for identical assets or liabilities.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable, &nbsp;&nbsp;&nbsp;&nbsp;such as quoted market prices, interest rates and yield curves.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of lab equipment, computer equipment, furniture and office equipment and leasehold improvements recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</p></td>
</tr>
<tr>
<td valign="top" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of the estimated useful</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">life or lease term</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of long-lived assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December&#160;31, 2019, 2018 and 2017.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs and Accruals</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development costs and accruals </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with research institutions, contract research organizations, contract manufacturers and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, pre-clinical and clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Collaborative arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company analyzes its collaborative arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements (&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship (e.g., a licensing arrangement) where the contracted party has obtained goods or services that are an output of the Company&#8217;s ordinary activities in exchange for a consideration and therefore within the scope of Topic 606. For those elements of the arrangement that are accounted for pursuant to Topic 606, including those to which Topic 606 is applied by analogy, the Company applies the five-step model described in the Company&#8217;s revenue recognition policy. For elements of collaborative arrangements that are accounted for pursuant to ASC 808, an appropriate and rational recognition method is determined and applied consistently. Reimbursements from the counterparty that are the result of a collaborative relationship with the counterparty, instead of a customer relationship, such as co-development or clinical activities, are recorded as a reduction to research and development expense as the services are performed. Similarly, amounts that are owed to a collaboration partner related to the co-development clinical activities are recognized as research and development expense. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into out-licensing agreements that are within the scope of Topic 606. The terms of such out-license agreements include licenses to functional intellectual property (IP), given the functionality of the intellectual property is not expected to change substantially as a result of the licensor&#8217;s ongoing activities. Such arrangements typically include payment of one or more of the following: non-refundable up-front license fees; reimbursement of certain costs; development and regulatory milestone payments and milestone payments based on the level of sales; and royalties on net sales of licensed products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers the economic and regulatory characteristics of the licensed IP, research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace to determine if it has standalone value at the inception of the licensing arrangement, which would make the license distinct. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of any additional good or services promised in the contract, whether the value of the license is dependent on the remaining goods and services, whether there are other vendors that could provide the remaining promise, and whether the license is separately identifiable from the remaining good and services. For licenses that are combined with other goods and services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue is allocated to the licensed IP on a relative standalone selling price basis and, for functional IP, is recognized at a point when the licensed IP is made available for the customer&#8217;s use and benefit, which generally occurs at the inception of the arrangement. However, in cases, where the functionality of the IP is expected to substantively change as a result of activities of the Company that do not transfer additional promised goods or services, or in cases, where there is an expectation that the Company will undertake activities to change the standalone functionality of the IP and the customer is contractually or practically required to use the latest version of the IP, revenue for the license to functional IP is recognized over time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into a collaboration arrangement with Astellas Pharma Inc. (&#8220;Astellas&#8221;), as further described in Note 15 of notes to unaudited consolidated financial statements. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for contracts with customers in accordance with Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;), including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. The Company&#8217;s disclosure within the below sections or elsewhere within these consolidated financial statements reflects the Company&#8217;s accounting policies in compliance with this new standard.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Topic 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies its performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a) a good or service (or bundle of goods and services) that is distinct, or (b) a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&#160;the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the &#8220;customer&#8221; in this type of arrangement) and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, the Company identifies all performance obligations, which may include, for example, a license to IP and know-how, research and development activities, and/or manufacturing services. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the estimated variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestone payments at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company&#8217;s customer with a significant benefit of financing the transfer of goods and services. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time.&nbsp;&nbsp;For performance obligations satisfied over time, the Company measures progress toward completion of its performance obligations using an input method based on the Company&#8217;s efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for its stock-based compensation in accordance with ASC Topic&#160;718, <font style="font-style:italic;">Compensation&#8212;Stock Compensation</font> (ASC&#160;718). ASC&#160;718 requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company adopted FASB Accounting Standards Update (ASU) 2016-09 which identifies areas for simplification of several areas of share-based payment transactions. The Company retroactively applied the mark to market approach on vesting to non-employee grants and the impact on the consolidated financial statements was not material and as such, the Company will treat non-employee grants the same as employee grants. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a)&#160;the expected stock price volatility, (b)&#160;the expected term of the award, (c)&#160;the risk-free interest rate and (d)&#160;expected dividends. Due to the lack of sufficient company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s common stock prior to the IPO. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses the fair value of its share-based compensation awards to employees and non-employees on a straight-line basis over the requisite service period, which is generally the vesting period. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_NonControllingInterestPolicyTextBlock', window );">Non-Controlling Interest</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Non-controlling interest </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2018, the Company accounted for shares of preferred stock issued in Frequency Japan as a non-controlling interest in the mezzanine section of the consolidated balance sheets. The value ascribed to the non-controlling interest was the liquidation preference of the preferred stock in Frequency Japan as the holders of such shares do not share in any profits or losses of the subsidiary. <font style="color:#000000;">In connection with the IPO, all preferred stock of Frequency Japan converted into shares of the Company&#8217;s common stock, see Note 1.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, <font style="font-style:italic;">Income Taxes</font> (ASC 740) which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December&#160;31, 2019 and 2018, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 13). </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net loss per share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&#160;31, 2019, 2018 and 2017 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses are not allocated to such participating securities. In periods where the Company reported a net loss attributable to common stockholders, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,237</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> outstanding-basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,649,245</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,530,218</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">702,918</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributed to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> stockholders-basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.29</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12.53</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28.79</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted Common Stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,366</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345,608</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">637,746</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C Preferred (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,172,676</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,759,079</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,214,387</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,070,574</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,283,425</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,283,425</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Frequency Japan preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,047</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">673,605</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,968,672</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,089,334</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">985,521</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,554,414</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,606,359</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,906,692</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently adopted accounting pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU 2014-09, <font style="font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font>. The standard will apply one comprehensive revenue recognition model across all contracts, entities, and sectors. The core principle of the new standard is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Once effective, ASU 2014-09 will replace most of the existing revenue recognition requirements in U.S. GAAP. The FASB also issued ASU 2015-14, <font style="font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font>, which deferred the effective date of the standard one year. As a result, the new standard is effective for annual reporting periods beginning after December&#160;15, 2018, including interim periods within the reporting period. Early adoption is permitted. The Company early adopted ASU 2014-09 effective January&#160;1, 2018, and its adoption had no impact on the Company&#8217;s consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2016, the FASB issued ASU No.&#160;2016-15, <font style="font-style:italic;">Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments</font> (ASU No.&#160;2016-15). This guidance addresses the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. The standard is effective for annual periods beginning after December&#160;15, 2017 and for interim periods within those fiscal years. Early adoption is permitted. The Company adopted this standard effective January&#160;1, 2018. The adoption of ASU No.&#160;2016-15 did not have a material impact on the Company&#8217;s consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, the FASB issued ASU No.&#160;2017-09, <font style="font-style:italic;">Compensation-Stock Compensation (Topic&#160;718): Scope of Modification Accounting</font> (ASU No.&#160;2017-09). This update clarifies the changes to terms or conditions of a share-based payment award that require an entity to apply modification accounting. ASU No.&#160;2017-09 is effective for annual reporting periods, and interim periods therein, beginning after December&#160;15, 2017. Early application is permitted, and prospective application is required. The Company adopted this standard effective January&#160;1, 2018. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently issued accounting pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued <font style="font-style:italic;">ASU No. 2016-02, Leases</font>, which is intended to increase transparency and comparability among companies that enter into leasing arrangements. The new standard establishes a right-of-use model that requires a lessee to record a right-of-use asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either financing or operating, with classification affecting the pattern of expense recognition. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. In July 2018, the FASB <font style="font-style:italic;">issued ASU No. 2018-11,</font> with targeted improvements to the guidance including an additional transition method, which allows companies to apply the provisions of the new leasing standard as of January 1, 2020, without adjusting the comparative periods presented by recognizing a cumulative-effect adjustment to the opening balance of retained earnings.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company plans to elect early adoption of this standard effective January 1, 2020 and elect the new transition method approved by the FASB. The Company also plans to elect the package of practical expedients intended to ease transition whereby the Company need not assess (1) whether any expired or existing contracts are or contain leases, (2) the lease classification for any expired or existing leases and (3) initial direct costs for any existing leases. Furthermore, the Company will elect the practical expedient to combine non-lease components and lease components. As the Company finalizes its adoption processes, it estimates the adoption of the ASU in the first quarter of 2020 will result in the recognition of a right-of-use asset and related lease liability related to the lease for our Woburn Massachusetts facility in the range of approximately $1,000 to $2,000 with an estimated immaterial effect to the retained earnings and the consolidated statement of operations. As disclosed in Note 16, the Company has entered into a lease for a facility in Lexington Massachusetts which has an estimated commencement date of December 1, 2020. In accordance with ASU No. 2016-02, the Company will recognize a right-of-use asset and related lease liability at such time.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_NonControllingInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_NonControllingInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_SignificantSuppliersPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant suppliers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_SignificantSuppliersPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6778585600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 3,828<span></span>
</td>
<td class="nump">$ 2,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(2,066)<span></span>
</td>
<td class="num">(1,253)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,762<span></span>
</td>
<td class="nump">1,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">1,846<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">1,419<span></span>
</td>
<td class="nump">1,406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794659472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">19,554,414<span></span>
</td>
<td class="nump">18,606,359<span></span>
</td>
<td class="nump">10,906,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_UnvestedRestrictedCommonStockMember', window );">Unvested Restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">70,366<span></span>
</td>
<td class="nump">345,608<span></span>
</td>
<td class="nump">637,746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesCPreferredAsConvertedToCommonStockMember', window );">Series C Preferred (as converted to common stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">1,172,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesBPreferredAsConvertedToCommonStockMember', window );">Series B Preferred (as converted to common stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">4,759,079<span></span>
</td>
<td class="nump">6,214,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesAPreferredAsConvertedCommonStockMember', window );">Series A Preferred (as converted to common stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">7,070,574<span></span>
</td>
<td class="nump">9,283,425<span></span>
</td>
<td class="nump">9,283,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_ConversionOfFrequencyJapanPreferredStockMember', window );">Conversion of Frequency Japan Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">513,047<span></span>
</td>
<td class="nump">673,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_OutstandingStockOptionsAsConvertedToCommonStockMember', window );">Outstanding Stock Options (as converted to common stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">5,968,672<span></span>
</td>
<td class="nump">2,089,334<span></span>
</td>
<td class="nump">985,521<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_UnvestedRestrictedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_UnvestedRestrictedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesCPreferredAsConvertedToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesCPreferredAsConvertedToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesBPreferredAsConvertedToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesBPreferredAsConvertedToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesAPreferredAsConvertedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_SeriesAPreferredAsConvertedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_ConversionOfFrequencyJapanPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_ConversionOfFrequencyJapanPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_OutstandingStockOptionsAsConvertedToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=freq_OutstandingStockOptionsAsConvertedToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780587968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 20, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 30,  2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.148467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-6.7355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">165,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">148,724,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, value per share | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (68,888)<span></span>
</td>
<td class="num">$ (49,088)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of common stock issued upon conversion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,077,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001564590-20-012977-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-20-012977-xbrl.zip
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MHB,@JD*I=0(4U01AM>>#A]6#"R= %TU($C6-&(J#F2= &(V(83:82%98*B=
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M)7Y[=K_-W-#7'1-O^71#+V#,(?C<.@9NYXDEZ>&BU^L-#I4>U/T+Q[ :!/9
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M2O MS:9S'@7RD/0<K5'[H7<!\@^)F(_00=JP0VS7(]%/9/L,2 <64#1S3'E
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M9+8(4B!:&2+DOIV<R5=CS[E1^ZCS0+)()V&(8?6>[?IA<MH'T$_/V#-?W"N
MB0*?<>,D?LPO4U\A4D[YMP_J,=XI,R'2.U1Z8JF7[& $$JA8PB#S'M'CD>&_
MH56G4C6_]-(*DDI7D#KI1>JHQ-/;THCC23AAR;FV\!]S;5&+:H*$IR4NEU70
ME\RQ1=:H6);2GES4N"REZ7@N;&EB($]7J:54;<6,-%0$!R6#6AA9[Z@K%<:#
MGPP94X9-PPR;_PY-DKA 4\1K7A*1J-?^&W%Q4@3N'\E(R7DOVV+QTP$N&D,=
M) ZO4&U+?.4@]^)4*95G&5H4;\.1GY2!HXM+,\>51F/I9=.=@NKXRP@E*GU-
M9/I&Q8<TPCCQYLR8-#Q=QUZ='A5-\H7\Q8FS3%YE$63FHC3%B$@JIV';<3PL
MP0)N="4'?_]!#&=SVR=%_!FDCV]*CS$JM);T=*Y]02#H<55C,EN:7PB0HOM(
M.5.83T!L>2V1:!!#4HPKFAL1+".73-P(FV.&TXLR-*PV=$]M4+:^?*V_@<%2
M06"BE ?P;GFC^.6XYAM-=L22H6WN*#R\H2O'/.&HRQ\S1HAU;A+A!$N=!QYY
M6(J<A>AKI10Q;VM'>OE*1$$RUJNBVEQ"H8*;B =D9@#;U L!*8\@E!0V&95#
MO#3*ER%-E.2)3G,RSBH;S,413KI_[?>XW9PO+I3F<:>H2C5?;2:"_J)JBXEP
M?R+ SVTXW>=J,A8H,L:2J"XXU^Z2,R;H-G5*(H*Q2$^81-@I+99@O*54CI0(
M*O8$=V*T'A?\3"9&\@8ZOJ?XZNN(H3RFFWCE5!P03//^:\&]G<RY,?R$V3C.
M_ ^,[L$6VWS#E8V5WAV7Y GK,E,(94R77EQ1PH;O6XR^1*"IO95=A,HMBE3'
M48%ATQ3SAB?RB D0.I($]5+LF)?XPQ0IYKRD?Z&&]]=/HF97G;S&GQ0W+!TJ
M!B^,0];RH^A7H@2MQI1LZG9VVW=3*>DHLRG9)H4.,IXK(F,#$J.#4ZM'QYA=
MC.[8;J80:QR\%9DZSKKI810F7R$!^76<:& I]L&2[EXJ 53(492CZ<D"$.F#
M8 3>YZ7Q9$FF4IKJK/Q2\2PMHIXM$-4D//'!ONMXS"$N=21.%3'QWQWW^6SF
M/L=U!2O*\BDG]Q9K4A)\$OLYQV,4*#4$%._ S/*"5]B(NI>.K,=/VLQJ9E^U
M;#E&D&XB-X8[HDE<QXG*9%)P$\-<R.3H).0*2N<!U,@^5V6&XHXFEY;MEF&B
M-6[H&.6B9!-7GLWF>F*.9Y]MZW>Z>HL/RQ](+B "(0T8G=;/F=Y2;@[*<OQ$
MMJ!"H@"QP ]=\R++1,3S#W(KDIF$*^F 4=Z>F!_M<)!-C,9-)M?3]Z*=)9/T
M)38L&O+G[CR^^#8ZDT:--IV )]NS$_MH&\G)I5*@0[>VO3P';!HFX,J5WL\X
M2D;I6P62X*0;L[-P(1*V5I0!L7C!0SS040D8?E65H@PB^JY4E)<2'Q'-J,4J
M:FXJ:5E'A!\9H?($$9V0R!)&XLAR(;7%S+^:OWDJ.*)E7$Q4NB/\'C/=Y5IN
MKASW<C:5Z3ZJQ5"X]':ZUC )7N^D3;(83U$O[D*(G6N_+M=61@X'SI4RFD7$
M4\6_&[4SB:K:I*6K4!$5%L'"1-%V7): DZRD#J -O"76%"81#WA&PTD^IP.
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MJONQ#=&Z.6Y5J 1XR>NFNA,'7&/$8]3#)4D5,?4EA4@H2R"E^L! (?>*>3M
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MCCS"C*+R5A3V3D, :PX,H]K0*-F6!8?7L4H=O#D6"YKQ>YW0+Q"6T-&HT_=
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M-QGM;A7DY@JRVYF @AQ.UJUE.DD%R5$B,;(*>?L-B+\-] >;14^9UM,:$$H
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M#(F@)-?<2[ A]5[K_DR[L=UG_YUV;>N^;TTM@\L9_)5Y@0YT0T^AHK06B$!
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M)ZN4R&WJE;N8K%5,C9*+ZZ0Q_G_VWK7';21)%_Z^P/X'PFL#-L!2ZRZ5/3U
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M+D10X%> [L9/TBCV70"74,QOB7>6RSCZ3C?$JR=+I!,-OO+:[:V79<M[M>?
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M 9/ ;,&JW6[UMUE[FHE>?^?+']A/P=GV[.GHTAZ/#@V)'UE;&EA;W22TC!%
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M'D?'DRL*&(L,7Z%F*C(L,X8BPU>HL?%I"S1&"Q*'2J8 P2)B*#)\A1K;FK9
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M&MI/+SPG%=;<\6.BC, SDXE&KT0^1N\CE7 4.:%VP)3&)RF-/^(GL5@&T4H
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MJC$%"59EIB+#N;,2KLEEY]B%Y5F$VK-1@*V+(4B<J6BT !G.F95P37N=GK%
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M7O !)+A %33( EJ1@TIOXBB[OH&G5W$4!*#_O<R5&@-:SY;X9K_[2G4%WHR
M4,4'M[>BB#K6E=);\-R@-[)!7#0OKM+CG8A%23BI6L"LI+X3!"LR1C'^@*;.
M3Y+,"5TAW26:*TZQ8WT*+8QQL&L)8)@1JM!70Z_.K>,'Z*YO:]BZ\X$$,!XG
M YZ&F;DT)C"6L<B=.WQV[L=)FGMEP@&8X$&PQDY,.D[W(N6CJ0@OI#)4D*4
M4OXW]@S>HP#9"<F]\],;ZQ].F#GQRB+[H%2VD*<W:WX'-D9W.,R5M_@S RR
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MP!('A,YF&**;&?@0;SBY=<21 #?BA,$%E\9&-XG@9H779=(HNH-Y)3?^$KX
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MEE09MJ(2-VR=TKZ:?2O&WK&L*Y6N0I6]&3QJ]*H1=:_4,]#J9W ?E)F0*P?
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M[G>',A@'IZS?OUP[6K*-N(6AA7@)5)^?W""WG(Y<KRO],*HNB.M1]J;;#ZQ
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MG05:_<ZAEY:Q )VM +&%,0(&%A!CD>%$9PG7H#,V%B>6(-[7:2) G],;$5O
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M"VPY+%K>;,=RG3A>S1SWCP3):@G'O8'O$F%3QZHKX)4$WT 2JDY6PHD3:R:
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MFAKU8_QUL/&K2N1BDIIRVE&H1.A-.71RE789_QH!H6/4[LX<'3):NRB=9_3
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M.??"4]^#.*BE[TG*-69WBOZVY#DI 0;P5:(=N1!8&Q.L9]]P13#9?U,'.,'
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MGIL0\"I+J64EKOE"A;^897&BKN%N<(5K])P\&*).AVM'.!I'7RR 8#D<6N
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M735C!\ 4)%AYF8H,.P#:#@"[.S!7F[$,F9<!>*R]_B>&&94:<>:IB,W8<VO
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MUV;5,O_JVC;]WIF%\P=5&\Q"=5'=.^LFNL.;$6KN$LSIH5_02Q9*44W_'CR
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M8J%79XI:";\%(\J#6'6\<T=8PZL ^*7RN3ZKFP8P9:[]6_Q;M5BLPB-[3NM
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M"8""M&01F%A?BHI'6RNS92B:Y@L-? :RYYBPC5B@8\4V-O1J4\H$SCK>CW4
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M*8I&9*T1!T>B$7]W?#3K@9HH'GIP.9V,JP[=X>:V<[2KOM#D2INPF,W^-7O
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MQCI@E%- PH]V..@F1?=M;OPOMS@\:280;/'"IH?%QC>O.WM7I_FH]FM2Z$2
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M4*:OT[.7!@]/61X\?!^T4F'+*=2P;L/4P"5@$>J2")U&-'$EGKZ5?EGJ_Y3
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M71_L.<(YYZ*Z>IW^2'37)MTUYB$WV]L%HN-V"T+ B[OXO7O_OOO^W5X"WX^
MS1HH]A;S_K6<X[ES&,^.HO3D4#QAS)L3$ ^V!9X>B%K-X12O):%GTV\"W;V@
MZ[L>T /1<ZP*.N_U&$:%P,EU-T.0N1]9891(D&" A+!5:Z$3MCHH.(6MN"+S
MA $_04+8ZCB@ZS9"M$)7;<=3Z.KQ K6M3A7K#3IC]K#]>H^C"SQV2_:?*L8)
M/S9[P-O8)K?M/QZETOR&+6C];7->Q"ZAO-O>F3_I=GEH2(;[R9RPXI+RO/^$
M0$ZH")&U&3TAL@,!$HFL-V*3U"E$U@(BZ^[]_!4G5(3(VHP>7R+K;IW**TQ&
M3-;O^OV!I/BV :M;F$R2>_>&RH\JH<[(DMZ[=RA:L>\E6] MA4X2I@X*3MF!
MYHJ,I/=R04+8JK70"5L=%)S"5ER1D?1>+D@(6[46.DGO/2P\A:XDO;<]Z;W_
M6NZ-L+X\>HWIH4^(VV'BY&*Y!#F/S2+)<);]=$%/,L1X(CKQ1\,SOS\\Y:$L
M96>]'?(G6<^LX1%R.TSTA-SNA6C//QUT_3Z?JK9";FV0/\F$9@V/D-MAHB<I
MT?>#=-SM^V?";:W BG7A8PFX;X)M3==J6UE#=QW58?<C"KB[%40>+>+^N M9
M(N[MVX6]<T==#+M'/N+&);-/[+WMC\!U^KNV('MD#2O6WI,<Y7YL'I3HO!#A
MT0B=$.'1$"'.Z("'CA4F; 432BA?F/!HA(XO$VZ9/B]4N+U/..F,Q2EL U1;
M5D7YEFHV5U=-H^L=9J8Q$7]=?KF-''"/I_27GC+L3$8K#[ISPA]WAC]=*>]=
M.E\$R8VGOH9Q.<4@/7PX2^,X_0*KUEND!8PV"N(-J?/>+$OG]!WX=%$601'!
MG^ B$^#VDLT[ K?4VO8N5!B4N?*B!(>%(X%GS+TO:1E/O:O@6L%_IEZ0P/^+
MZ(0>%L&':C938='Q=MY@>,A"<)>>?CDMWC^\Z+[P0A5C3]P07J7ZW:@&^MTH
M'=UIME(Q1C^ 6,;!(E>O[0_?>5J'C+ON$<7UFV![V)H^'77&ZX_Z._SR>$UU
MVVX=/GVJ0&?P9)47W EEWRO7[4W=Z^ZU.?6PVYGTGT]&V,#T?RK(/)4@U?RH
M0C6_ %X8]-A*SC,>>&0#T>,D7SQU"HTAF0=$*0Y;T-C0DLM!^XTIM0V;BJOZ
M>Z6J7G_K3,.CD[)^M[=K..'1,PJ%J?:-@>@XT7$'J>/89$V+CMLW!IW>D]7%
M:MN<<]%=O<ZX+[IKD^Z2(OCL46)]W&.',/>!;<7]GERK''=S,O@GBT+\\9W>
MM3EO%E!BMG_^A'%O3O@<1G[*4>YRMP"ZGM1PO,\A4W\P&K'%4NHW<D5&J(H+
M$D)5K85.J.H>> Z&I_ZHNVMD3[CJ>,7L"4. @H1PU7% UVT$;86K;L5S-!C[
MXZ'X5<Q@85T77^*VYRJ+X)'OO(^9FJDL4U/O99![89I<JZQ1D4=GW^^[I;IX
MQUSV>D73M0\9[?R*O8!OV_-[X[X_&N]J,8@<':\<"==P04)DA"LRPC5+</UE
MTN_U^>(EDL05&8FE<D%"9(0K,CI4*FPC;,,?&LEBY0J/B8:^?>IHJ.0*<6$F
MV?<Y7F3$0ZWA&OKCTS._N_?"9R)'[9,CX1HN2(B,<$5&N,;)U/'[O:$_F.QZ
MZE+DZ'CE2&*A7) 0&>&*C,1"'S,6*I+4IEBH9(8^<BSTC62&M@2P%NS2B:;C
MBHSXI\X!?;\[[OJGXR%;M$2.N"(C7,,%"9$1KL@(U]1PG?G]R< ?]D_9HB5R
MQ!49B85R04)DA"LR$@L5KF$/C&2%LH;G'84\<].V[GVF_BA5$MYX_P@60>(M
MJO!H+H5.]P]6"_;G1,MQ148\TQJNT][ [PXE1X<9+"V0(F$:+DB(C'!%1IC&
MR0<=#_Q1=U>O5*3H>*5((J!<D! 9X8J,1$ E&[0MT'#-!GVL=M('AMF'LLB+
M(,'9TL%/+UT449KDO#-%^71BY01F"S;SMFM@*.J3)WJ]K=OGBK%" 5C_;#3Q
M1^,^#W7)L#DE)[38"*"P&VMXA-T.$SUAM_M!VO>[DS-_,-CW(0MAMU8)H!OX
M%79C!X^PVV&BUVUTHA)VNS/5=G+JG_9[/)2E<%M[LV\E\KP6LT]I$<1[WL(1
M1[NE.Z);M%046Z6]\&[9X5F,F:T[99WYIZ=#?]C;U5=_9(TK]DP[1%0(DC4\
M0I!'"J\0Y&,3Y,0?=4?^X'3?U=.%(%LEHA+,9@V/$.21PMN,=@M!/IP@N_X9
M$.3H;-=<IJ,D2 V)1>0V\/8;$/^V""YB55TUC:YWF*'&A/QU>4UN'-?WWY;Y
MR640+%[_%&0)H)U_5-GY%8#W$2 -;S[!;=_&:?CY;W_^D^=];R^&^7L3AFF9
M%/"5CUF:P(^AFL/#<_V]I6][T?2'%^__#= ,3D<O,+49Q_N;FOWPXAU^VAMW
M!Z/A^-_];N^LV^OVZ(=>?]![\;=[S,-DPSP8>"_2>.J"&Q4@+^%:\=VP6.ZW
M#GY3(8PBOO&":;K /.Z@FC)OT9@SKP;D'J\[6GK=86<R6D'^F=?^SXGWS^#&
M _B&OE=<*>_]F_.W7I3G);S_F_/?Z2\GW3.?7AGO8U]U%1@SB=<J*94WR]*Y
M]PZNR8(0)NQ+5%QY[\H<ID5EN?<2=%04>N!%Z.1XO!E^N^-]@C%0DGV03>%;
M<>P%BP5@ J^!2?6+3%VI)(^NE9>9)V4J3"^3"!/QO7DZ5?"-,$OSW O@RZ$=
M@>_!E,-%"GZ"NWNY"HLTR_4#PS13 '&4A-$B5ECU!*<B@8FOAA+E\%E05$_-
MK](RGGH7U?/_JQ/_IPI>K*#O:Q!4AO>#]3./<KCD,DVGN9=F,(#L.@H!7SPM
M4$U,E,#HO&".Z\X^<!8KG,*"!@KO#GH\H+>%;X*^#J_H3_1Z-Y[ZNM!7IS@V
M^C"&Q\)]U=?P*D@N 1IX>G&5YFIU,!WO ZQQ3\UF<!.89-]= QJ.3"UB8 >8
MZKRP,Z6^1CF)R3I,L'Y,E!G!@7'\WCGO>']_\^:CGGM:<$&<ITNK[O0$E^13
MK;K7WH]4QB:([3O\9-_9^S$H5&-5^F::I[;R#;US=?T4KK=WJ=8+KM<;%60=
M[PVL1)B$O(P+?^VZJN^$R 1)4@8TS6FF58_*(H3I0H$B097O!;,"5M6/H*[F
M%RK3A[QZH^YWO5,?9V[BPS2'<4GG5"+0W%DTK^Z"4P(@X#B6']'Q@%.L^D/D
M8&SPEWE4@#+48+T#"0P26&7UA4T]X;S,/P)XD>S&&9X='<I?!/!4#[H*IJ"5
MO AN#K*3ZN&99U5GV,;?T1D;,ET"?.PL2@*06)@LF,U"+[#.;JJYU^>IF]^4
ME[!Z<=I&Z]7SKVFGGF"\[ 07P992<VZG#5?ONR"_\M['Z9?\M?<N#O(\FD6A
MUC/X5Y45 :P;N@J),EH@@  D??(QN*'I;XB-]W+3"%_A:H+5=5D"E*APP'(%
M"<F5UG*@Y'.XFWXX/B-<&4]HQA/BTS-W//3)PHS',TL]=]^4KICAFR[1S299
MO+<$CFDD>(>-XH?J=Q;E(=P>U41^#^&S8E?@%%:#OUOP]%VJ!\!,;,+'FT8H
MD 4()MPO\.8!O@4,521T@_4TWDX\Q_<QI7!ZP=:A-7]R3N<-W8\,G=7W'_<F
MP&OG8;H@.OIG.JU%IK;^MQ!1'*45T7)!] 82F,'=C(!J0X*,#%@8<S(A /AI
MI$]#PL,#,)# *3FY"-#H,>+H!5]PI1JSAJP"M':,Y0(WTZ;>W!UX;8-W-L[H
M]B1JN&=)*.&5,A4E_CT$O!)7&+$=JBNQ^D%@]>4+,ZRE*\W[/YEH%PW]RE">
MN3I_1GJ/P/=[C\9R <\A.89_?3)--[\Y"+2=GHN;6M^!O*4H0O6"S55!W[\
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M41&I_*>O85Q.U?1]EL[?I?-%601%E":KSZSN[T73'UZ\_S=,\^#T[(47PC3
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M,L(5&?%G:KAZHUVC9B)!;?)G9,/FL>#Y.<E+N#;<U9&1F"87II&(S/$B(S:
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M<LH"/!&Q=FE$X2O.Z(@PM0DN.5!X?P@GG8DD?+0!*&:R)L3%&AT1IE8X6G*
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MI@+U2Q,T8(D&%,TX;WUK&U19QQB 'I-?CPUJ0NTGK,B@_;OT*$F=H%,J=EF
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M[>'R)2&YF:M3]2@^5P)4R-Y\0@&:>(FT>P*P\)0%B1/5;3U !L*:*[C$CW*
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M5;1M6MM\OK ,8Y!W6]@[ _;+[ <T6[3<W<9QT<9L;7/<T,EYH0,RH5O%+=H
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MI7%:975+TE39(*]%F"JZ<T5)=LJGB-IV9<R@N"#Y,<0F&OOXTYLPHD?(L2M
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MV8T!K3UY^\%C\S&@"R3OE.@Z!WCJPV(&=6&B=H(]2(S=+0B1(H-C V(3B@>
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MZ>S"!W_BE3=*1'RJ$A8M9/9H9;IHUZKP&[+U7%\^(VZ@;[%)0YVQR$YB53M
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MRRJ$K_!\E=2OZP)_W -5A;,@2_S3_P-02P,$%     @ W#AZ4,;^TJ@[#P
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M+GR$MD^1AR ;P6<O_DD!H[1H'7@O 9MRNL5?5U]]M.!Z88\-O4M Z8JO6;\
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MRIVP"SXQ'>'!<9LAK7.6!$V%VL;(D]TS)9_2,X97@9/T1(;V5Q]1F)^J*C?
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M0TWRU&C6RKGM"X;'F>! #\@4\FEO@##;8DOD&CFQ?>'4IV?X<$=R;5@?SQ&
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M?/U&.^ 1L8E)D=4PBA"L@$)T!#W2YV9B#9P@8F\A5(7\@DQS=^MC.-FGO%?
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MA(.<"KD2<T1KN,GV%>+7Q/V+X'F>6C)"T>X;XG1Y,5D<]"Z6"5D3*-<1L,Z
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MD\,P=()I,D6BBQ7[SKI"=4C./N/DGV<BX3 84\V+0=MT,WZO.;'Q5=UNS#@
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MC$0UE;?/M)TKA]=L(VE)XRH+95MG3JE=+I'.VI8:F(!V]<)4MV4(>5DV];6
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MKPU[*!! K$,N+-6B'@PM$#\J-,MB&>GMM-PU!0T$C)@5E0F_-.M'I!L&8W&
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M[W3X#&Q!+P'L.#WDP:%!'NS$A.R#-0":[^I@'.OHUEUPQP<YT!B:;)"Z#!I
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MDE5-BB!9%0+0'P=DR'_CW8K0-&&7G42RT6\2LNW59LZ6#&KI7:]U;!+\&S>
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M C/_+IS:?*!5=U Q:?<&#3B<N\0-2;,@^O_"G?YN4CL%!ZJO4?3N#((;HNQ
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M37,]URFYMVU!'X8M=^B;]&L#EFXC6:U*I_X>33>_;V9NP4<$;)7=(.COK<.
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M$:P@>,ZR.LRV=I\:+<?@2+1'=B3YN!^\-[7!.>121ZJ%#MV <TG\IBO;<;$
M4R+GI"QCS(677.\#;*&E@U][O8RO!=9H6+55U4!:6$F*L%E4]9)Q M,8BRG9
ME8"NGE3P:G<EUZLF[]BTN<[4JZ6C0>NOE#I).(3"WPI)=A& 2Z(A?/I<P\U2
MR"L6/2XQR1+H:+"&RY]^.@[!\+SLD;T#ZCI'";,^/W&XOO&/3X_'3+>N*=_-
M76Y$/1E[J.ZXR,WL2H\F:0>/"ZNQ\O3R\')3U.3QI_?:BO54KIV,6RYB!G_;
M4]$ZNG\W@FG?BO8QEW3 ;2U0+E[R$@W6:Y[^_UJSR-B(O$U=G#8[]]/*+:1V
MAS;X$@>*G2&640U&Q 1 ':UZ2B%0(<4$U<7+'4Z"C J1O\EF]+9Z#Q&+/GU=
M1#WT3"Q8E0UZ@5PC'4:'*"L,+!)1$X2"S7172&_)(8BR0RZ(UIS5^*9%"*M1
M\C#3"/HP#+U#X:1?';"4&]7T6ECQZ+=%4DSUSE[#/J=S4$3X"VLFAMQ/R&9J
M[B'L(Z$2['B5Z+IB",3NE> B6MH##4W40&7![Y>7O";RFA]Q3">?B JS6&_#
M.&2S#KMX;N W@Z3,X1D@[=YW<H;<=8(:2QC>HPH;T=0A<(BB.CK,A>K<)O*B
MHSS1:@WA-&/U=7N!'*T<8'A&-Q1]"P;G"P7/"X2I[+NZEFQDX?+7'2B[(N?>
MROG59V9:A:63&)J%MX#19N--+0%4_)&=2_?/1S;UXK*<D"#W-\WGQ+MIF.N^
MBZ;[W*=L 2?:.Z!O\P /Y!;9($!$56E0P8@:..3.D+.9X,WP'X,P3IDOXG09
M7[PP#]V'Z9,XF&$-I[66"</$+++0(>(^&I_3B8+$- V2N;$W!=:4'PR?40>0
M:.L2/%C%HH%Q0X(=6L:HSI =L)[WXN5ITRJ(6'W75?Q,/9T)(BE%;].JEY#-
MSD@/81^;5H(=>J1<F%N%)5\@Z9<:9$1+@Z#AB1K(5*R0[%,C>\XE27#X&(M7
M=U:'^R2(TV#%TG0F%!/I%&_H[VB>O&N1-8=-@XU['\N9TQEK]40EQ<+7OHTH
M5R YG@FXQ$*[,P(RJF-8,$829^Z6HG>78#[!Z3I-4LWV"AI?-$>F1LC]_@#K
MBA;U+D_'=)AV=9->;8!2;51I=;JU?^,>VGGX'*YQO$X7Z_^S%S.>CB6K4'-V
M9ZZ%NB4P/PA@8OS([N_D5G\FVI>QG?8[G/!G[XX:8:P+46"XA@:HW5<>.]4+
M&,"!:X\E0U1QG'*26#P'820::TGUTGEWG-,@#5?&TX@*:4?1<)B5OZD(!7(?
ML(RP;JV\4I\5@N<BP/!)4^"[)C15K<\,Y/9)$97L6:\WN>2_:"7%11C9EXL>
ME\6]4BX#*Z<(HWVF=W5LD)0YC .D/3RB4_CF#B?"$3N]5$+PY('))0IWA&0P
M_%859**I<>" YGY8MG$M;S$+3Q.E/$,X>?&ZO])%X!-ENWC&2?"(/^_9DQ++
M#1=.NOACX8RF',PA->/HWG4+.4X"(4CQI@=[+5AR6?D&'%2_M303X@:<>9I$
M5+<&E,N A!#LW$"$ DD.G; P\8Y&RU0U_N7:YGVNHN6]R8T,)7)65SF'R'NX
MI='R]@+;LP5R5T,'06*@RAF@E0>)UGN9U?L)TUWKZ'I@XJ<XR8]U_D(S3QJZ
MBEWK97R'5_M$-,9-PI3^TSG]:_Q(<Y^0K$U>3O$G@T5%DR>9W,> 2J+R:'0;
M)+]BL8Q(2Z%@A 3O]D;&PO"UVE8D3RVM<4NRN%Q0Z6!I&:-*6)1+BX2X2,@[
MW<,Q*L_IM';TUW_EVYJ5>_M29.T^1(G"\.,T!79(TC4*A<BCA<#,#6 XCC0>
MD>I\M6*2I\-[,D1'JPY/^:O[8X0Z>'#.ME4@4EM6>%Q.C+F,4':138)_XX;_
MX6-N]NP3\<Z-:*0EYQ>\0Z/X^)(D-T%&O?$Z7*E> S0FK8^'(2LW&*W):L_.
M2OF5D/R%GJ)'W%KD/SN1__ 6I<4_;4B"=EP:% EQWD[K7K:F0"QQZ&_3HV>Z
M<@LZU[;;3]NM\?;Q&MMZZR]8S\I\E<QAP'Z'H3 RX&:KZQ[GX5,+^[> *N&,
MI-EG_(7_JK)%NV%F:.(NF'NQ^:H2)G\F*QT*X3'F]SG"7$*ZQ$DS^N$7\1T(
MCN#4K(AS!#VZBO#3L7QED)M79QG@/KFWY%/&:W$75=/2\Q<E$,V3HUN\HX@_
M!2D^<M);G-(5]RK#Z_K[]$J)D0Y=FZ1(G8_'A"@IA6B=#Y)2$.$-$$S:%'QB
MHWS79BI\PX.==A!V;ZBMC*:PU#P6S\Q4^PU P59[]#]"$B)"N-)]%QOJHR09
M.;=1DHHW/5G%F]R4WU0I1 K!BNTLPRQGJ&%B9,_2FU4WQ;T-SG2Q6B68H;/<
M%#<#E,U8CZBA]>HP\6*T?8^_!H4,_-Y_+@4$*S7"FQBKW%F,%18O!$@YHX8$
M\?HSB<^.GU^G?\I%^5?L=V+,[T6R)L17<9B%072S?XC"U7)#*2J^X0!%4H>Q
M?U3)QUR<YKG/JAP9\\HCEXW7W0^KTQ_JA?GT$T8O'R7ZPOI9AV*<:,<'2GF(
MD4)P^\GA5IKH)C! 9P&*+XKF$)_&%=1A>!I3\#&CD]A#^$=PFMZ=^F+3^-;G
M_D 46GB"(:R/(]LYAZGA,^"O.%9!0%WOR'JV,0MD1@5"5@\54J\T8'WUN14
MS+4JQ !%*^>/'G+Q\AO](K.T?.JPCZ"3!PZ[&?A[UE#F6?2F ?R4H0*H[0\8
M#NG6;"KE39C..C=J/V%V25E]ME,D9SHA*9'W,V<4W:I6W;OX(.*W'J#$0+,S
M $^^550B)Y^_E*Q%^+"Z7C_ZZ"+U@:%?!..Q[PN7<4M$*G8A@<2L!^_B)=1J
MYSA R,&LU4;8O14N5BO1^HXBTWW7"=ALU0M>VRS5K4O00!VE%7D:4?&B&07E
M-K87-49\3K9!&.MX3P<!BW9);03=>TM3_S#\HA\.HJ0ED*J/VK6.?A%,QC9[
MNFQ;'2_;U%-1-3H6O?QZZ'IHJ]/8:BCXP? )):R(CNX@XQ*5D+0A,E6R)6UF
MZ#M)RY>M+KC6B;EW![E?)0P7Z%8_&=0,.%5'QUJ>RJP7ZW7(%M]!=!.$ZZOX
M+-B%61#IF_@ (7,,>@E[6$.4[$YVE!_;6<XYPG $-<"(EOY @Q,U<4&,%9T/
M"EPF<YUJM=G5Y,/ C=2)6J"FRN3K7J+K TR,=3P;,",='*=RS5N<T2457A?-
M@/7]L(N"S2-0;13]>M@YWH2K$,@J9@ 4HJ8JF #D7E&P0&47ZHD<H%$L=Q8D
MR8'*L]B2?<SZTT9[UBJNM>]4^P)/:S_9!W=G;W@XD,:-S8AJB+LL2++<=4_Q
M8Q@SNT&G0<3N',-P7(_&U/V8BS.87I_AY,'FZ+&80D D)$2EB)W=W#KV6 9Z
MBIFI3Q2^20VX1_,B]&V8OZ\R]'2>\FE)LTK Q!J 1!']K1#H2'K:*"G>7TKO
M2<>REROF(4CQFB7#-!/F=0VW[&)!&F;X#B?/X0J+PJI;O"*/,:?":ZST]EI\
MRV*S(^!7-@^U"\RF3[@XO"]J(0_*GU2',0F/9G]D;"Q?NZV5&UBEL&SJ[=G/
MJD1&LLRH%!KE4A<]G"6Y$1=\]$*4GE+WXL6?.@ _)II/CIKSL*F*,.,Y?HQ2
M3W'&JV^QM GB"H>YXA])T",A1:-WNQ"D>N6J&3"X, [*[GI*PWVVP90=H.C"
M=?2P$^MYB5]H]LVW'>O=+^<[]&'LN0C%/U$AD) "77L>NO_NI]:P.UOO3:L'
M9?\W,((QTP!NJ?S?ECL6EM*+%YRLPE3OB3L#XLX#?S>S$2U_O^/3OF#,_E5\
M3(1$H"=_!4L8GO6'0)@=ZJJQ7OQ"+@,JA8#AY'E.Y,G+>ZG[RN^@^7GNX7-+
M]2W=?1",^<&OGMA#]OBVAJ.++T&R=K6T'V+@)]!W,O3K^DFC!2AHSU:$7G$N
M']#X+&%6G=,K,7)GYX(,+=S'G]A]^OD@!T\1'HBGSVP^=^'V2OJ?)^K*<[N9
MYVMM6HS6I?T',?88/[*JL^NB%JIL>JT]O\$;8AN\T@A58KO7(?MH:6X JX>M
MM]%;N*MAW.'&T];Y]64\6HW/[>@[*[E2XN=[3=[9B@+&;&UE MWU=QJJGR/<
M735T@QD[E4/\LX-9>L)>_P;F[C:V3SAV ^SS:#\^^&,\O69@"V]:WX]Z55JQ
MB!"\95:I229:93EC>\Y,+&?*X +-C,I@8V9'HV\"R^T!I39)=WA%?S,+]3).
M2T9^=@L'&4\W*2=87/7*",J>FETUY2_&)*-&M0L.K"8=1NKJQJ@4MYD5,9RU
M :EN.U?BL @CMS:K)((18([;)?N*,,J</&U,OKH8,[.-;9<!1PO1>=N3\H8W
MP)C3?B_K*EXE.$CQ);6=N_U#&J[#,I,L/$8GWMAP<=VG286K_^Y:X0RZ:VE9
MP6#O+76]SQ?QJ 2[M6]7(0ABDJ!*E&)!5 ACO_KK[ _K_A'"UB.2A?S.8-E
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MS[M,YW1JX/:ZH()F9P9DGWL6[,4]_4( 5$HPN;NRMI][FKA5"RSKR>^(GN,
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M!NN]ZH!XG#:B"JT&V[4Z%_2B >".+RJ,/O$]XWB/;_&*/,:AY<T$!6(V07.
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M58[E<&:%3N7RG(@%V9Z_"UL)5$OM048U/_;7'>,\X/F:;:TK_CT<YW"2U8E
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M5)<#$0E6M4Y]U[$A/(CPI"HAG*BD)O$L@Y%4T9>01RIP>AR.7GT,TO29T>H
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MF0S(;XZ0-UHXQ3'>A)E1>M DX6#^J9/TT.0+9ZS.#3T(!E#"63\F;4E FZ*
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M.# ]OE9^)OA-[3R\"L9N]UQ0<+FWRBAZJ@4#ZA9U&'KWN"OEP%1YW\[U, +
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MH9#MF<!,Q%+7O_WHY5$*XW&L9H+7IA8FN8F3??'=:9<5*'VQLJVC .%GMUR
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M!VNB6GL")KA7T)Y:.G&/C0(3RI[VI)=J0;;WZ(NC- (HIPTS5 PGATFJ3M*
M!A&D%))U-69OOU+4$.9Z-94A=2$:[:Q1<C>OEX3=+/H%1AI=/F3?-6T+,:3E
MIG\'[34,&R#PAI%",(<I1: Y(?EH^;B'10'AGC6,;AX6UN[=.$G&/+1/D'70
M2X2"@3UO8-V^LAQ41T05A2$-"0:LG'2I7B0>4]0N4\#XKT_HY6]%><F)N_Q(
M?R)N\J-8#((_^_7ZH.(*S9\:%"^PK[JXH)YE,"Z3N%KY3FE?CJ@WZ)5E5E\'
MNK^[N[D^[*Z_'Y:F;O^.WHXPV^^O-4M1!]\SG'E[=)S,N@P#8) 0IMHQB:,I
MB80D7=%Q6]$NW\%PPFS:Y1/_[WJM&BDZ,8AU&08]IL9I+)D?Y31=9"YD:NPT
M6PFGF<JL>I"JR$)513JBA15;(\D&K-_O:(J*766XZDRT.<\8[QTT)[9P%3+C
M'Y9Z]NSA:Y(]E2BC.+JM3:5?-M[U&!)SM.W!@=B.6 A9V*06T*R @I-X-YC4
MXJ8P%AJ+.F,[E7*\7H8FVRG8FQ2FSY*RO9^Q=U<^/KZQL0^M'%Q5@[,[3WM;
M1=M>M#6[ Z6LJ$".5$3SZYVGT..430PB[?//H-BSD?1%$H9F(T [.K\8Y*@?
M^J<7 3/?R>=: /#+)-M.9I:>M7V#S;N6=U#K/N@,(?,X-4G8Q<4"E8<U?4X=
M:BI"6A(+6AUCX4E4#<!H=F\'T#(_K RR//@2E>KU$W-DK-P/Z)/U<4& U9)R
M4'#$J"$LD!2U)K\A(!>CT16!+N&[BJP+[D]7QR.]XA^E-Z\E-E1RH(=G5?5G
M<77)6K&N.1@OUI91)LA]E*AA T_JG ^:707Q;JVAXN4&J29Y"P9:C" 8&N8X
M.3O7H4;(^[D7-6I_X9G?K%I';DI-RM?'O1D\?Y/YG%Q N,IAI)-J#KYJGLWT
M2+E))PEU$&'R)+:ATXE4OA67:*KJRV=^.:8)-".FP*3.LT9,&S1")]1MK\C=
M9&+#,Y=!\K6-@<B3=R""@2^3HW%WGM<NM0D'?]<^R1M\?^&148^>*TL2-D;F
M[<CKV=V80OJG=E)!A2C\L9T="F';@?UD[:(]W<E2])0;62=1W^981X(7'S9Y
M0[8==H-/MTVM#]AM!BP+$J+^MC6:L0VC46VMN\EZ6Y55#K\F67*NSG7_J2\5
M-*C"UZ5L;=]O!LF^E7(H86<J*2GH!_#QAX\_A#&I&2IZ?.]62<S;4NJ8LS)P
M4.NYZ<N&\>>+_]=TVUUV^ V1HQNM<W@#XL[UW(+Y]M^9W"@P_Y5H7-^%^\+>
MG'9-''F'Y]_?$#WH]-T76EU*&!4Z]&>!O ^=-W"^??KCUGQZJ'<CK^X)?(,Z
M-O5LPD;8OGV+9>'.M07J'K3>H/EV[$\;<^RATDW\NB?N[2G8T*L)%X$[=?+B
M<+X6J/O0>8WFVZG_L36G'BC=R*F[XMZ>@DV=FK2.#]BI#\\PA]&I5*M 64#<
MN<9;,*\>73:PF_)KB=[UW;HO\LWIV,2I#PH*7].C'?BQ!\U:\EE41NF\SQ[(
MGVW*71<XJ2?77,TA?=]O0-D3.=EZP$-[YI<[F&%=G5&E=Z@T3VO!T?L,;1<M
M7&J$]B$=H=$S)H_3H/@Y#+]35B/2%6GH*JMO3F P5H=4PP%!@0QP!=<JI>-7
M?ZY'G=8R/4W1]N%:2@_ ^'0F)<4A72&&KB3!F<HQ7])\V,:6+Q4%J2[$<RC,
MXC?RZRXS<:,),DN4,TK6P;4;3!UVIJ(D.\)SEISJ/L1M%]N9VT7^'&I>>TA#
MG %K*FV5! 0@0#_89>MXSQ=X(B^CT/+<Y+&B[Y5@67V-7DGZ>95E%7F1K_W'
M G-Y<[ZDZ V2=[-BS<M%5N#,=6P!WL&6"T,G\QP!B)X@N0T).2SKI,OY8=EE
MF>3LTO,%\QZ&&]LT(^1 7^_ 9'CXX/P $1,0CD!M1XRGSA\4)+B FBW ^0HC
MU'"N\J]1&3_CF-CY=\;H_8G^HX5 HP-FW6;4P1V\!RL++CDX<U8Z42;HD&)@
M+O,!15<SFS>-V6!2,P1JCGI_PW@B]]?I'VPFE/B)(>M8B*>H 4'$9I@8G4GC
M!+:RH)$$F]+C&SDH:B+,UF.)W2"R7O0(*FR$%2T*F=A8$O4?6)3L]1+N!A;#
MAQZL,YO18<-^@&FXD&<BX(6Q(*R--A%0C$Q*/<+HZ^P=F8]R#"I&@A!?'W'V
MP(.B:>F]?#3V-MG-:YQ61XQ[1;;J"G@\1*]VY/("\T?4/HQ+#G[MO0?9'%->
M9<<[E#6_\M9)A9.^66P,D$-L:!"#LUT,"# B:#^I,:5-I\0/]O@G_&']$?[/
M8U3 ?_X/4$L#!!0    ( -PX>E! G% L7E8  ,;L!@ 5    9G)E<2TR,#$Y
M,3(S,5]P<F4N>&UL[7U;<^.XDN;[1NQ_\-:\[,1N5?E2UX[IF9!O=7S&97EL
M5_?,OG30)"1CFB)T>%%9_>L7($6"DGA!@B!(@=R8/5WE,A.)#T!F(I&7?_FW
MUX5[M$)^@(GWZYN3=\=OCI!G$P=[\U_?1,%;*[ Q?G,4A);G6"[QT*]OUBAX
M\V__^C__Q[_\K[=OCRZO;^Z.)G:(5^@2![9+@LA'__OQ^S\?_>?YP^W1+?;^
M?+8"='1)[&B!O/#H[=%+&"Y_>?_^Y\^?[YP9]@+B1B$=/7AGD\7[H[=O4](7
M/K+8/QQ=6B$ZBO_?+T>GQZ?';X_/WIY^>CH^^^7D^)>3DW<G7[Y^_/3ER_\Y
M/O[E^#A'X+=D6D>Y__?+T<=WQ^].WIU]^IK[Q7O+_M.:HZ.;R]PO.M;G$^OK
MV>G'LT_.A\\G,\O^<O;EXU?'LM'I\=FG+WE.R7+MX_E+>/2_[7^.6:3S]3SD
MNFA]=(T]R[.QY1X]IC/]OT<WGOWN:.*Z1P_LL^#H 07(7R'GW8:J2W'[Q4W!
MHVOD!?%??WV30^_UV7??$7_^_O3X^.Q]^MMO-K_^NO?[/\_BWS[Y^O7K^_A?
MLU\-<-$O4K(G[__S^^VC_8(6UENZ5'07V&R  /\2Q#^\)7:\1@)\'97^!OO;
MV_37WK(?O3TY?7MV\NXU<-Y0-(Z.$CQ\XJ('-#MB__WQ<+,UYLQ'_XCHSEV'
MK_$^.CT^^7IR>G;RGOWR^R>T6+IT%]TFDXZIO?AH]NL;]MW;])?9@/]4]+OA
M>DDW?H#IO]#IOV_*4VB]$H\LU@ESZ=%(_SOQG"LOQ.'ZQIL1?Q'C6\?T R7T
M!X10^8R6/MV+7AC_-L-@ZP/T&B+/04Y*ADV@M3G'3*5LN<3>PH"-&=!!XZT4
M(/O=G*S>.PC'([(_Q "]/3[9;*1_HC_*$ KH^2/^DOATG9WS-5U Y%.FT1.=
MWSD=:6?A7;;+B9_^T+6>D?OK&R#!]^JGDT!V018+XCV&=)3'%XNNWC0*8WE-
M9;CH/$0HM3:!^^C9Q?:U2ZP0QN_6AZVQ]_A"!3F%9FEY:QA_VU^VQN#5ZY-O
M>0%FA^8>^9@X,#:+OF^/V07RYW0_??/)S_!%"M82$NUM@(7ENN=1@#T4!, =
ML/UI:RQ>8Q?Y%U3XS(D/1'/GT]98O/%"Y%N)I6B%UD7D4PD)//!E--J3K<D(
M#XB*]I!NN4>J%R/@'BBCT1K3OU$[DRIP/UE:(+=['[?&YN]4./Z[1WYZC\@*
MZ,W"N0F""/DP=DN)M,#V([(C/Y:7]HOES=&=M4"BW!9_VP*35)0S=?VX7CP3
M5Y2[G8]:Q.[D]/D)ARX8-_Y="\RQ6XQ[_T*WSUVT>!;?@OO?M<#<!9W]A%Z%
M+X@CC-KV-ZV=X(GC4",QN"?42'3_'UY"6*RBT#;#3 *CJ7_ODQ5.+K1PEO=H
MM,TT6].I_T1%G12_^<_;9G7S'WI[1*=2S&X3T,CN25-V3UID]\EZO7&H)8%G
M./&ZP*15#9$6#;_T:HS9Y9(>FPM"30Q_#1<7-:1:F\(#FN,@I)>D$*+SB[]M
M]0X@LR/RW[5G2-,MYUONC>>@UW]'P"O*WL<ML)EZ<JYQP)1Z? V^IC\3-I\K
M"+1A%227BF2P_T*6?^4YS$\N;"&4?M\ZMFRT!LCF/F^15>X12>YM4%[WOV^1
MV62S 7= R<<MLCGQO,ARY?#<_K8%)B=T%"?>9:XE[#;=^:C-_4@Y >_!^)LV
MA ]9(7_RS+2:+;R2.Q]MLY5_=)CX]A9)R[=3<O2/>R\.VV])F]]XO[28>'MK
MOV W\X;.?+(HY&4S&BF"C_@.\G]]<W)\?'+\[OCXS=&2'A=V(_WU#35-HX R
M0Y:,;<ME_\8<_SYR;I-YE[(9\Q@B/T#Q;_89CIT]SO$X4XT'9>*9'  BQ3*)
M _-QF!NE1*%P7#X/&Y=]DX!#\W78T.Q9=ADR)P.5NN7V.8=&N0 ^#&@J+EH<
MFX'*X)+[,L=EH#)XW]/!(1FH["WV3F6PG Y4\ HY&CE* Y7!-;YDCL^@Y7#A
M\P#'9M"RN/"EAV,S:*%<\&27(7,V:+E<]OC*X1FT0"Y^3N?@#%0:;X=#<#@&
M*H#WPU8X) .5N_MA1ADD'P8J<'=BPC@> Y6PQ1%\'):!RM::,$R.ST"%;4E4
M+<=EH!*W.C8Z@^?C0*5O=;P[AV>@PIC[\W*I"QR50<OBG9P3CLJ@)7!)TA!'
M9]!RN"@%+(/FTZ!E\'82'P=ET))W*_.28S)HN5N=/<M!4BZ&#RUN1B!9FJ.E
M02S_R_L]J&[I#]1F^<<N2S;["\)*7F GGKSELHH*5,2@, N'K<SQ%R?3<8:_
M *.U@8EI7.+,"I[C58R"MW/+6B;!B<@-@_0GNU&*FQ__<8NM9^Q2M8:"B>?$
M9_.%N'1O!5?_B.AV$@E>%*=5'VK9?$;[X]+3Y$9,R-RS.Q0]YF'HX^<HM)Y=
M]$3N"#UL7DC7A+(RCR\4*! *VE0]H@YT'E!H4;O7N;)\CPX>3&PJ<B)6SL.Y
M1#-L8]#,1:CIF%5NW&GX0J\\U!KQT0NB!ML*,6&Z0+<D".Y0.)T]6:^0*8))
M:YFOX^!$N-];V+GQ+JPE#BTWIV!!4Q2@IF-6N0%_L]Q(*)R[_-MN9 TDZ%N$
MBAZ9X""T8+*I6#(E/%U8OK^F/YTL6* '3$K(T-<Q<U;*B%I9_KJ(A6VA?6^)
M5F-H0%S'G'-:6E*Y:^*3>/,GY"\NT7/(]HUX.8PZ"GIDF1>?X-]Q^'(1!2%5
M$WX*X5IN.L(D->\B0*&2JJ]U<!UK\&:LEY+H?%=)3$:,GB8+SH_H!;71VE00
MT30')MJ#>VO-Q+K<! HI='.B96R9*BJ:9U%X!VTXIQJ:6G99$.PY,6IVU>8+
M;1(V&5!.RY40T,'[O4^6R _7]ZZ5%%RDJ[MD'AIZN8-,H9J.OCTB(X"V/]2#
M.EK2:^?5ZY+>J1&%*[<#)&8@1$[+&JPL[#(I?DW\1\M%F_ 8*D28/<K_)K-*
M4-):;!,K>*%PL_^P#;^B?%%--@G3>P_\2B]&4/MYDE$A)03T\2[/M%YN,Z_X
M+?;0#?TC2-,5?5W-]?XK OO)'X_(9]K^A!K(*RK*,3UK]^DC2FP ?$>B=61@
M])IPJYC9-GD]5XRL +TFW"IFMB&OBN2U:P7!=!:/>TD6%A8JFU;UM5;YD&=@
M\HKEQ,0^$:US>&(Z7(KQS9=:N9W.LDK]]R2)A)'S=HO0Z^R17FK:I'R)>,;6
M)R-C/VHV=1$R^Z?.])0_<>E%JD4LST,Y-AJH"N5$@+J40W8Z0B9H*W',/HR8
MB1G#'#*SY;PX9)!M]L5HS "Z,7=QY1DP9LOZBBL_*7=&F)Y^6..^V4-FS[=D
M>@*5F&^.@/V)IJ>#@'$#>YM-SXL (RCT)F%ZD@!\WY7AHUZ>D=!R^X5/]7:J
M>E_,</IL9@*..$XE3\D<H"$(^/H3ED/DBWJ!W:>C)69IBH=[<-S,%MG@H)IB
M-,M-U*]FBRJ!T*K\J2P) DO1.C&TT+8T6F4Q?QRPP1Q/D6N04,PGQ\[LVR,,
MN]+@WPPN0VL.R\%5C91ZZZM/MD83G2D<Z9^!:6@Q6B4&2$D6",=N,-JAB?&6
M!\SL"W@3P"1ROC)8#:W,J0)6N0S"#%G#/>!-D!6YWIX86D1+!(,BY;R;:9SA
M9+B_&X:32%8Y1\YL'0Q$#EIR@,-HMJ"#*HWZXA09<H8[RYLJ!;F")AS=\:XG
M8&*7%,W)4-3AG>])J:?$.'Y!(;;9K!+8&M9]*J39^R)0VUSKK<)24*4M#X)P
M198".IKKR20<Q#67G4:32$ETPO\D"E_HR?^KX1SR9#3/@^[FJ1]O>B<VGN^1
M'_,D.9]R<AU4CVET6NII=38C^*FI)-/9/.1.3RVI#N:CXA0)DQRS/L>LSS'K
M<\SZ'+,^QZS/,>L3FO5Y;';2F9JLSV/3G6^JLCZ/Q]PR:-;GL=FI9:UD?9Z,
MVPR:]7DZ)LK"LSY'W3AF?5;'X@M[*8:2#BH%V[[3RO2NC K@2OV50\FC;0!5
M<1\?XZ.&1/ 2>JP82J("&+)RP65Z7H(D5+M"R_1\!$F8"@56&QD)/6JEE?V0
MVO'3)?+CL1OTU*JFU\>XBA*.-7A3?T=X_D(YF-";D37?=)6GURFV&7-[\=P*
ML#WQG$OL1B'LF5)V!!V^Y#0 +U5X#:992TK'?.Y0R*,PL^H83R0G9C8A7#%[
MD/F!27?P^GR)5]BAIS28./\=!>$"-6J+4TA-^RI*KY$>7J^)3\^WER31V>NX
M%2WK>DV\;Q;V&!_G:$9_!]C;#$163R<JRV5VWHVW0LE>8(P$C!-8MZ(:0CKF
MDAMPZEV]LN;M$0Y>DL<EEHP&F8\ ,1US2D-[D_V_J6<#[(Y03D-+?XI$[[,H
M99FS7_BY5KXW@,EQS3_6<@*01\=UJ7J>. OL8?9\&N)5NN:@_5]'2H]T"A"]
MFK B8I=HA5P2%]V1F$T-(2US(6O+96W-X<SO?-G)[I<)0:@@HF?WK) 7H6MZ
M?RW*[[YZW618L*(\]/\<H"Z7(J\YDB01FJP&WWY&4\.@$C'2_?%7 ,$@#1>:
M/^T.Q!\DCV^%F. HFNU\K!>WI%P?\.==LU_B8"!5:WR.F=DEZ4"8U=I\_&7.
M;*$&0JW UF_S!;-/:9@JA7_^?L=?--4_SQF&7_GE?BA%@16 *.#LX6B:K3"4
MV,N5KL"AE,M5@"3(7<QQ-=M65H#KSH-"FU5E#5,W(F])O,BL.L7S-8'30W/V
MKFP0H.#W1XZNV24^%&!;^W;-8YM&552#I6RX@];PL7[$^FPAFW_O:A;R4TJV
M[Y$_^XSK*8&QN[UY^2YQAW<E&2T/,0+UR I+1*75+@'/-4V'ZA*/'YZ_N7;\
MC:I+*HE2"WGJ\88Y$Q\'])\NZ5^].=4*F#@RFZ(]'C05ARG;TC)/0D+DQO"B
M\8FNBPO=:-?5(2=T?#F>9KL6(*)QMTE!*_J 9[N:[<-5#+RPQ3*X-MBM"(K\
M<ZIZ@=NCBIDY&$N3KN^(=[%?FG6[TNCCQGN6%L5M?#ULA9]>WRO5SMB0*I]_
MN/C8/=5EPJHI60RQ;%6,J!,CG?4J.YS7=AL(F44!W=?4CZX3NT.ZIHH5PU?K
M89*M(,B$0Y*,FS>EDV.2J(J ;H?I;%M74*U0K"[H?_-O,#?L=SP4O[VRX,\;
MCQKOEGL?/;O8GLXH1<'CW"-FI7#>%4-95XZ^8=P]H\KP[><F[@&G*B5%+S=Q
M+WC59DV62<0[]#/^)V#Q43&*'<XN7D:5D]LEV($MR+K#HC#>E%EP2 /CKIB<
MU+DOO2\6C"%\0&%$M=B7A28NM;-\9 5Q$LMC]!Q@!V<8L]W"VE^ C-$&HW0N
M3_*2,[> W">K3,X(C-2U_-$!ANA RBRF<KG//*";G7A!@C 5EHVL'HG16ISI
M1@GHF6C=8!I6%* ^FU#OPE^DVFR0HR]O93^@9>3;+U0C[$/[0/6%C^UPHR]A
M)C&(L&K^8WQ:8+^8;N?:<H>CR4_+=[[Y0.>5[ A=:\<V)U\W0.<K'__C-'ZW
M"ZY>D6_C %8\2H9ZURO>UJ2KB*OW>"8_OR;^O17&Q?ILT:H3\K25>V/:F40E
MZ>[/W"90'<7O\Y2I^)%5K;RM'$,' CQ;)'@B)6V+8R:?=YE\0-1R"7!(KPW^
MBBY:,JT'9).Y%U/9=(@61ZI]7CKI7'BP/20/]5W9O!?E\2U9;G03^_>IJLBT
MW2!<O*U;'04M6JN^2SQ\0@"B>C1SH0*4F%<U(<TZ$<Y_P<?=>>_A[%?3T5*#
M.!&H=#L3CTH:>.O#$@):I>L.#X%T!\1B0F//U+%GJED]4RMYO5#+:SVYL;_K
MV-^UDO%N^KON7S@;)OI5$>Q3[HG Q,<6KV.+U['%:Q>-).O5Z=CB5;XK[HG9
M,FOLBMLB9I"NN&;W,&VE*Z[AG80!YD2QEV+;I#@U'ZA*KP^I]5#Q9&BS#V.U
MAX^(.B.'TIU:&*X"US/'R&Q9)8Q1S?,"Q\ML2U4<+_%GIJ'T0Q?&KNS-D0-E
MMN "&!"W_#V9HV.VR)+JXJTDSJ#%EO++)%HLM/SPH'&NZI;^17E)I8-%354$
M5(N-G0\6V^J(N@RQ#^-NU!>1F:'^<2!.\OK3+Q4KG.'X>2#ETPIQE XVS^#[
M8G9917GXJA,.4OQ.A])C3^885^6=9 ">JF]\80R E=E*&8(M=/HR!L&Z1+<,
MQ*%TJI+?AB(HMM#%YG!0E$NRS;!3V%2EYRUKI- KR;!.X3M36*;X$.$K\T*(
MY=EG*+901/? #K!DC88,P8]#5B0*RW=D@'X:LGFCLO!+ANB7(1]R$8-1H%Y0
M"N:'XR&;/$*&(P1-PYNMBZ'9I,)9AJ1ZK^X!(2E1("\#3J%#T2!#LK@:8@K:
MQ]$-)EX:,P-M=-P BJ5FJ VE=[.<PU];:=YL/4:?3P_*4?/5&/QS6/?5U_EB
M#%G ]ZC=0+H@GPQO(B>F<<5:8628&=[_3?!*5MSE\=/'(8O;]B(,TZXX&<Y?
ME1M]28S2E7?8U[+27DPI<I]/E8N\ T5.3:3A'KZ?6HJ /3A\1;K#9:BIMXR*
M43.M86/2/?0%A=AF$"6KT)?NC87,#:>5X_;T-=3UN+?6<:CJ)BLU_^H#*J92
M3<?$FH+&U#7J676KL:X1&NL:C76-M!ED8UTCY7F$8UVCL:Y1#5!M5$\9ZQK!
MZQJ9G23>,/?9\*I/8CZ)ZIL-QTJ#8.^!)X+"<&$%+]<N^9FAU<!W4$2NU[?]
M+8:U5 'G[UN),DT\XO%SV GH3E-#2>H&R3P<%(XTG&?J721U.O *E0IAX?ND
M''$=MX9+]!QR/#?,(.?&HV9SQ+9)@BUH?<1IZJKD3K&_H5P$(7N(\9QK[%'!
MQQQ93%3*W(T 1'7,,7F->[)>4<"RL^\0:#)%7\MU]J60, KYQ^UKXD, %J.C
MQ>]"F6#_G]TC5Y;+)";/MV'_0-=\^P>YW\P>4RYQL"2!Y7[S2;2D7]"_LW<4
M[%%1-5TB/]8 (*>(3K[2EXH1;UU\]1[IY#2FX=>7*/EO-L^K5_O%\N;H@5H9
M5[,9@HE5W9QIT3\HC.693YCR=\[7/P*F"S-U,;&I&0!N\ RAJF.6E!$;(2=@
M\?CIQ8*])V6OH* GF'IB7<ZI@34H35KW?'.L,'-.=FY[9'3/XSOVXDML_ B_
M\0S+3J:85K]DB)0Q*T&]PUESHUNEY"RDJF6W;KPR3V1B4V7FH\G*PB[S<E&3
M]]'*IX:!3R*4M)35OQF%E87)'19&?CIK/I?&0W2RAI1-:M2%ZWO7\EB8!#-3
MENQ7&BU?!=5^G4>%4JB2>H>SWACMBJ50(55-'H0=LYGEN-'+R2VVGK$+GI\8
MO6YF%D<RT?W#8N0OHB D"^2G;*V;3;*&=&<KR?QM 94GT$ & 6+=S(G:QTOF
M(=I8R5>OK"0>HC(QCN>?! &"17W)CM#-[#,QL:G"*"-O(52E[((4N=O--9SJ
M*;P2DR+5WVO!/+N4I2DXOUN^3]5NP,R,I*IE,/4O7 O#PO. A'7,]9N%O8"E
M<M"!O:M7M@,B'+PD(350FU. F!Z+C!4I_7?L.3*=R(N^UO,:L_21C6-G(.S%
M)?^=EFBSPG*DH/"R$@IZNBOG*MNRLK3TGNNBK;2F)R)HG\G(WG;&U^1;F>$P
MR?L">5&RK_IELRN\J72^-KV*&^]9C]FQTW ILZU&Y(_=L<?\@3%_X,#R![*X
ML(9I P5T^A,J635-D22!TX$DNS=*$C@U.Y!;79+ F=EU)=I($C"\.F\K+5;/
MS"Y/U49BQ9G9<KZ5AM%G9E<6:J.5^U JE$KV+C1;U@N770+[G8;2_;&!QX\4
M^RDSY#Z:G;^I!KEV/-K9&GPR.W^OU?<(4O_FDN'\V6PIH0OG[?<XWNG4[!Q=
M7>@6O<YRC,V6UKHP%GC&SR#_JDXX][-&O"[0@;$A? ',]K*U#7]UM%'6'/18
MG6[LYS978PE"XLIXGVJS-:-$!%\EHF*QB1FZIZ8+:-7X[@6Y<BC-%K6J@:R)
MA\Y@/3/[WM'"_MR+I><=[,V6I6JT%"3_@B.K_FY!Z-KW!=E&7LC*/)T,P8]F
M^W$:9$@5U&D2R?O*D/TT4.M4$-O&:809T)_5B==MH)\&L)/%43;;C:,&7D@J
M<X;L%_4BV!@E5IGRSA$T^P[0H-C ]E-:3>&$K-?[\2 -U@9X[E75X% .4FPV
M@%*H^$H&K^%E1-N%-U>])P/TPPBHM)HOK/7$D56OI Y/S>NN)Y:A_U&]/VM@
MZ(,KYV78?U)N3B3=E.BD_7!<@;I:D7P=E-LB!]8+3*R6:8;79S-U(:@R[+;7
M>Z\J;8;5%[/?"P0OL>)%B#/@OAI^UP(7>]Z*VA*M6YW">69XIQ@I.!M4/.>X
M&NYB:;)-Z\K?9R">:!"26AHY,(/#)4'DHZD_MSS\5[)6GG-N!3B(VV5GHZ>(
M5;9RD"'8<3,'$,L:TH7S7/#^$@E+>5ZFL\W.MES>>H)/YHGB<^X"J^>J'UM'
M@G4CKF4RL14-V+FT5 L<:7,?\0Y6&M*Y-,O>QVBQL/PU53IX[N$9MMEC=!(H
M%7>-=K&=*Q(I*']A1'LC@P79UB!5"L0_:\M;Q9:4S&TVCI:B7GL,2)7FJJ#2
MN204F")1M60FB[)K"_N_66Z$OB.+_3T6Z$#)54FC-X*JF$L-IS$;F/,B)WAJ
M".F0+$4LR,B6:CJ=2Q>A:1+AE3%9@&P"\#>!]U#14?)U;X3&+G]270&V::2Y
M"1>1S[9ADJ( D@<R5/54Q,RSM)V#D?(E(2M 9#L7'3(@$+DU-5NL)(&^11TC
MA&5+.8D>"9@")O54KRT.I&[HD(+1U52GMY@C.5E42ZP'$DATPD1VW4R6/)N,
M(DF#IN3KWLB;7?[T>2/2%,+]C*U4S^5^Q!G>*#\I8:1Z9$T-E!BOC+687\N5
MNF!5DNE>1 E,DK2WCB:+K]R;\AT)P?*K[//>"+ ]!C6U!F]H%Y62T-7:/*<"
M),1)&87.)4G-U(C "@Q$&NQ&F,B*A6(Z?90/.YS*^&Z>T&))?,M?,WLX7,/=
M-.4$=!S\G=&;R0 !8IV+ _$)D]H%,EDNW)&D( 5Q719HM=,82E H5!/IC40H
M85/#\4NS_=(Q&]H00N2T-!4BGKV/J%0#H1I*G0L4P:D2X"J9+%MB;;O);;U$
M,VQCJ&"IH- ;J5+$HY;>)'S81&.Q6U!#P0(@JD.\)"S(B)/=+SL7'R53(5+8
M&R\T2KLH0N1&32O&OHB.?39U. )XZ/0L/_8#<EG=E0L2A &OC)S5+)%R>#0=
M2HMC1)3)YSR34@Z4AB-U+LD40444[A"3Y>$5E5)DC1)9<1_Y]@L%@3W. 45B
M+9W>2,5R3F4<-Z74)$TE":):6AKFSDV<P1SB)+*QF:L'1+9ST20# I%:4I,E
M3I9E#)0P>]_U1J)PSC2<Q&RPAG>Q:CHZ9$H!!S(RI)),YS)#9))%*?B#$PL/
M=!@**ZN/<8OM.*9Q[B.I/ $14KT1'I7,RE@D502;&"5@NCID2(ZI2[1"+I&.
MN*NCU+DD$9PJD5TNDX7+!7'I<I.D;DZ& _AMNHI(;P1*"9M:+@G9R"LT86U4
MYDA!J"^([)A6/L2T<M 6,5O0+18X:=Q#,;V(:X;-*0%XFK@ I1Z)O')>]3A'
MRH9O+/I@E#6Y@NIYDG0&00AW+LWD@"#RJVNRX$K]8^?(0S,<-O! %U#HC: J
MXE%'K#\U_Q,M&T>OWQ.Z)S/GY8:7IJ)*?HS1?]UO_W7S%399<&U>$>\M/UP_
M4<,SH.CAN#PNT&=53:8W(JR442W>GN*Q&XHN$%D]7JUBAN3\6G6T.I=+PM,E
MDFMFLOQYC)Z#^)/P:B7A*R_[O#?R9H]!'<&/.V/*!3N6$]$A0W:'EY$=Y30Z
MEQFUTR-"*V&T9$ N8D7F_R.B0A+Y[OK2"JT?GA4Y..0G5%1."!'KC]2H9E?#
M^<M&SER9-]Z,^(L8 2F!(DI1AW2IY*79G0I,NG-9) L&@:^MT?)*J,)GJU5/
M#[SZJ<XJJ'?H9XX!GW(=>7;R4A.SL4[^5TK2P6EK21>Q?(_RP[H4Q>'"#298
M2TIK_%6#B933J)Y!2>Q*<0JE!'\0:EJL\2R^/.^$FRXWKC@*(]W<>!5'A&[V
M.,A0ER$OM4+W]-;MA7',O.RR5)'0XUVAMX"(ZBV;4%G*(&IP  2(Z?%O%S^
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MF+_=3\<^,;P_;-T+9RE6N\^Q'#"S,["E =M^A^=PF>W)D8:K.AB#PV=V52<
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M &9R97$M,C Q.3$R,S$N>'-D4$L! A0#%     @ W#AZ4,;^TJ@[#P  5-T
M !4              ( !';P! &9R97$M,C Q.3$R,S%?8V%L+GAM;%!+ 0(4
M Q0    ( -PX>E#+ULRWMSL  -F !  5              "  8O+ 0!F<F5Q
M+3(P,3DQ,C,Q7V1E9BYX;6Q02P$"% ,4    " #<.'I02;UWFA:)   _B@@
M%0              @ %U!P( 9G)E<2TR,#$Y,3(S,5]L86(N>&UL4$L! A0#
M%     @ W#AZ4$"<4"Q>5@  QNP& !4              ( !OI " &9R97$M
F,C Q.3$R,S%?<')E+GAM;%!+!08     !@ & (H!  !/YP(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780528240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 13,253<span></span>
</td>
<td class="nump">$ 10,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">1,138<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">686<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">36<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax asset</a></td>
<td class="nump">16,204<span></span>
</td>
<td class="nump">12,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (16,204)<span></span>
</td>
<td class="num">$ (12,229)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets liabilities property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6606219600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Minimum Aggregate Future Operating Lease Commitments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Minimum lease commitments, 2020</a></td>
<td class="nump">$ 504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Minimum lease commitments, 2021</a></td>
<td class="nump">3,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Minimum lease commitments, 2022</a></td>
<td class="nump">4,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">Minimum lease commitments, 2023</a></td>
<td class="nump">4,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">Minimum lease commitments, 2024</a></td>
<td class="nump">5,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Minimum lease commitments, thereafter</a></td>
<td class="nump">35,596<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Minimum lease commitments, Total</a></td>
<td class="nump">$ 54,371<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795018352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 17, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 30, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issued conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issued conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=freq_SeriesBNotesMember', window );">Series B Notes | Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">$ 106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Offering price per share | $ / shares</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares issued upon conversion | shares</a></td>
<td class="nump">5,839,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=freq_SeriesANotesMember', window );">Series A Notes | Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares issued upon conversion | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,990,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=freq_QualifiedSeriesBFinancingMember', window );">Qualified Series B Financing | Series B Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt instrument carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issued conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument convertible conversion percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=freq_QualifiedSeriesBFinancingMember', window );">Qualified Series B Financing | Series B Notes | Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">$ 106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Offering price per share | $ / shares</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DebtInstrumentDiscountRate', window );">Discount rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares issued upon conversion | shares</a></td>
<td class="nump">5,839,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DebtInstrumentLossOnConversion', window );">Loss on conversion</a></td>
<td class="nump">$ 269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=freq_QualifiedSeriesAFinancingMember', window );">Qualified Series A Financing | Series A Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt instrument carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,285<span></span>
</td>
<td class="nump">$ 14,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 21,  2017<span></span>
</td>
<td class="text">Jan. 21,  2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument convertible conversion percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80<span></span>
</td>
<td class="nump">0.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DebtInstrumentExtendedMaturityDate', window );">Debt instrument extended maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2017<span></span>
</td>
<td class="text">Apr. 30,  2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion', window );">Threshold value of financing receivable for conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=freq_QualifiedSeriesAFinancingMember', window );">Qualified Series A Financing | Series A Notes | Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DebtInstrumentDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares issued upon conversion | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,990,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DebtInstrumentLossOnConversion', window );">Loss on conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=freq_PriorToQualifiedSeriesAFinancingMember', window );">Prior to Qualified Series A Financing | Series A Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DebtInstrumentDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DebtInstrumentExcessFinancingFundReceived', window );">Excess of financing funds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, convertible, threshold value of financing receivable for conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DebtInstrumentConvertibleThresholdValueOfFinancingReceivableForConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DebtInstrumentDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DebtInstrumentDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DebtInstrumentExcessFinancingFundReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument excess financing fund received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DebtInstrumentExcessFinancingFundReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DebtInstrumentExtendedMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument extended maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DebtInstrumentExtendedMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DebtInstrumentLossOnConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument loss on conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DebtInstrumentLossOnConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=freq_SeriesBNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=freq_SeriesBNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=freq_SeriesANotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=freq_SeriesANotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=freq_QualifiedSeriesBFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=freq_QualifiedSeriesBFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=freq_QualifiedSeriesAFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=freq_QualifiedSeriesAFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=freq_PriorToQualifiedSeriesAFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=freq_PriorToQualifiedSeriesAFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791427744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Deficit - Schedule of Common Stock Shares Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">7,828,326<span></span>
</td>
<td class="nump">19,288,847<span></span>
</td>
<td class="nump">10,915,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,283,425<span></span>
</td>
<td class="nump">9,283,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_ConversionOfFrequencyJapanPreferredStockMember', window );">Conversion of Frequency Japan Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">673,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,214,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">5,968,672<span></span>
</td>
<td class="nump">2,089,334<span></span>
</td>
<td class="nump">985,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Shares Available for Future Grant Under Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">1,859,654<span></span>
</td>
<td class="nump">1,028,096<span></span>
</td>
<td class="nump">646,871<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_ConversionOfFrequencyJapanPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_ConversionOfFrequencyJapanPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_>%W$_;!NH/[Q\970=7 K[M07U!+ P04    " #;.'I0F5R<(Q &  "<)P
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M_0Y$?V'T>=A=B<8MGO4_4$L#!!0    ( -LX>E! 'X-8Y@,  -P2   8
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MOPVG/+#\R!+Y$;O\@(B%9^9W(B"_N1^:L/S($OF19?*SQJ9 L/S($OD1N_R
MR(-7G,#R(TOD1^SR R*/8&#YD27R(W;Y 1$(QAOMF)HM[ ]6G=.B=O9"JLU7
MNT4Z"2&Y:A(]J?%=U*YYN,CX23:GD3JONJUC=R%%V6^+O6%OOOD/4$L#!!0
M   ( -LX>E#1$-V.80,  ,,-   8    >&PO=V]R:W-H965T<R]S:&5E=#0N
M>&UL?5=M;]HP$/XK4;Z7^!S'22I *J!IDS:IZK3M<PH&HB8Q2PQT_W[.2RF<
M+WPAL?/<W7,/]IT]/>OZK=DK9;SWLJB:F;\WYO 8!,UZK\JLF>B#JNR7K:[+
MS-AAO0N:0ZVR36=4%@%G3 9EEE?^?-K-/=?SJ3Z:(J_4<^TUQ[+,ZG\+5>CS
MS ?_8^(EW^U-.Q',IX=LIWXJ\^OP7-M1</&RR4M5-;FNO%IM9_X3/*X@;0TZ
MQ.]<G9NK=Z]-Y57KMW;P;3/S6<M(%6IM6A>9?9S44A5%Z\GR^#LX]2\Q6\/K
M]P_O7[KD;3*O6:.6NOB3;\Q^YB>^MU';[%B8%WW^JH:$(M\;LO^N3JJP\):)
MC;'61=/]>NMC8W0Y>+%4RNR]?^95]SSW7^)P,*,-^&# +P8@[QJ$@T'X:2#N
M&HC!0""#H$^ETV:5F6P^K?79J_N_]Y"UJP@>A55_W4YV8G??K#R-G3W-@273
MX-0Z&C"+'L.O,1=$8+U?0G JQ(([YOPVP-)%2,1AY4* I32+D$PT[!R$UPZ
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M$/T5Y ]8<PN[B0!I256U4BM%6W7[[,!PT?I";1.V?U_;$!8EJ'W!GN&<,V?
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M\0K/=ARST?"FFWX0F[]Q_A=02P,$%     @ VSAZ4$E.0,*U 0  T@,  !D
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M[GA*0WP,>)0PVM69A$HNB$_!^%+E- F"0$'I H/PVQ7N0:E Y&7\FCGIDC(
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MKN<-)7/QG^ *"L.C$LQ16>732JK!!ZMG%I2BQ<NT2Y/V<;JYY3-L&\!G %\
M=RD/FQ(EY>]$$&7N[$C<U/M>Q"?>'3GVIHK.U(ITA^(]>J\EWV<YNT:B.>8T
MQ?!5S&Z)8,B^I.!;*4[\+SC?AN\W%>X3?/^;PG_D/VP2'!+!X;\E;L7\J9*M
M>JK!M6F:/*GL8-(DK[S+P-ZG1V2_PJ=I_RQ<*XTG%QOP95/_&VL#H)3L!D>H
MPP^V& J:$(^W>';3F$U&L/W\@]CRC<N?4$L#!!0    ( -LX>E H$F'TM $
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M4+MP?._/9AJSR7#8SS^(+=^X^ U02P,$%     @ VSAZ4 $V<-"W 0  T@,
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MF3CIG#( E^<W]N^Q=JSE+!S<&?4D2]]D=$])"97HE7\PPSU,]7RA9"K^)UQ
M87A0@CD*HUQ<2=$[;_3$@E*T>!UWV<9]&&^29(*M _@$X#-@'_.P,5%4_DUX
MD:?6#,2.O>]$>.+M@6-OBN",K8AW*-ZA]Y+SY#IEET TQ1S'&+Z(V<X1#-GG
M%'PMQ9'_!^?K\&1581+AR0>%-^L$NU6"7238?2#8?RIQ+>;KIR1LT5,-MH[3
MY$AA^C9.\L([#^PMCV_R'CY.^R]A:]DZ<C8>7S;VOS+& TK97.$(-?C!9D-!
MY</Q!L]V'+/1\*:;?A";OW'^#U!+ P04    " #;.'I0IY]B\;,!  #2 P
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M(GVWI.^2=8%D52") LE_2US#?/XK"%OT5(.IXS194F#?QDE>>.>!O>?Q3?[
MQVE_%J:6K25G=/YE8_\K1 <^E<V-'Z'&?[#94%"Y</SDSV8<L]%PV$T_B,W?
M./\-4$L#!!0    ( -LX>E#UF248M $  -(#   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(V+GAM;'U3VV[<(!#]%<0'!"^[25<KVU(V595*K;1*U>:9M<<7
M!1@7\#K]^P)V'"=U\P+,,.?,F6%(!S1/M@%PY%E);3/:.-<=&+-% TK8*^Q
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MYU\V]K]"=."E;&[\"#7^@\V&@LJ%XYT_FW',1L-A-_T@-G_C_!U02P,$%
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M:'PXWN+93F,V&=[T\P]BRS<NWP!02P,$%     @ VSAZ4"I$J7VV 0  T@,
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MX]E.8S89WO3S#V++-R[_ %!+ P04    " #;.'I0F@>C&[<!  #2 P  &0
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M?S;3F$V&T_W\@\CRC<N_4$L#!!0    ( -LX>E 5>G\%M@$  -(#   9
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M@=M,C,9&%:W[#3;'5JNR9S&IE.*E>^>5>Y][_M<P.(#T 60(B-\.B/N ^']
M\F8 [0/H$$#>#F!] /,"HLZ[F\Q;H<5JT:AST'3[H19VV^%K9I9K8P?=ZKC_
MS'RV9O2TBBE91"=+U&/6'8:,,/$8<P-AZ!AS"V'8&','8?B B8R7P1 !#1%'
M$(\($I@@!@EB1T!'!*GG!,)DL @%1>B4@"%OVCM,YC"5PZ K3%/*9^PP4(D!
M2MBS V$(+,)!$3XAP,C?11V&7]C!J'^\=-Z-O .0G'G(4?H)F'X"^/<V^#J9
M2M$T(30C,S.5@E(I(.6=DW6'248+CQ"&93)0)@-DO*-VVV'8A<PGGIK'FV,
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MWH;P3"'6WHCN]0-LQH@H[D.V8PAPYWW,;HSQ(\_LU#<6PU<"?D_ -PL$1H%
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MJEH'>VEL;_,=Z"BE 5M+]&!_IM+>,<."P]&XZ<+.5==HNX6137^)D.$FR_\
M4$L#!!0    ( -LX>E -S[!S#@,  -X+   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;(V6VW+:,!"&7\7C^V)+/L( ,P%RX-"93#IMKQT0X(EM45M
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M$TW!X<=0^J?<A3.(^2>L@5.(Q1QK!! CB;@<OH, 8$1"R@@?1&D&L-\]_ K
MT#M@ZF>  XG#3W@(1Q)'<SR,1HHYIHC)H85CG)!4H EC")QQ F4\G*" HTOP
M?&,('%U"9AC3@GK&1"(4<O27/@82%$:4#I["+0",0L[)L/G@9J+)5'ETTV+E
M[?0Y-_5@<+/;3:0/;B =[*_MI-K,E>\TS9C[(RZ/25YYS]K8><M-10>MC;)M
MHCN;WI.=K+M%J@ZFOI7VOFS&RV9A=-&.SD$WOZ_^ U!+ P04    " #;.'I0
M,0\BNSH"  "E!P  &0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6R5E=V.
MFS 0A5\%<=\%F[\0$:3-KJI6:J5HJ[;73N($M 93VPG;MZ]M"")DD.A-L,V9
M\\W8&9RU7+S+@E+E?%2LEANW4*I9>YX\%+0B\HDWM-9O3EQ41.FI.'NR$90<
M;5#%/.S[L5>1LG;SS*[M1)[QBV)E37?"D9>J(N+OEC+>;ESDWA;>RG.AS(*7
M9PTYTQ]4_6QV0L^\P>585K26):\=04\;]QFMMR@R 5;QJZ2M'(T=4\J>\W<S
M^7K<N+[)B#)Z4,:"Z,>5OE#&C)/.XT]OZ@Y,$S@>W]P_V^)U,7LBZ0MGO\NC
M*C;NRG6.]$0N3+WQ]@OM"XI<IZ_^&[U2IN4F$\TX<";MKW.X2,6KWD6G4I&/
M[EG6]MGV_K<P. #W 7@(P%TM'<AF_DH4R3/!6T=TF]\0<\9HC?7>',RBW0K[
M3B<O]>HU#](T\Z[&J-=L.PT>:4+?'S2>]A\@&(1@:Q#<&2#8(  - FL0WAG@
M29:=)K*:VFHP2G",84X(<D* $TPXG28><:(09D0@(P(8X801/3!T+0&*84X,
M<F* $\$&"6B0+#^U%6BP6G!JJ\=*?1\%,YP4Y*0 )YYPT@?.)S3SUT ^W"G^
M@H/K1=-Z4#J#FFE*!*"2&0NXY=!_]!R"FPXMZ;I>-"X8);/GA^"V0TOZ#CTV
M7CS3$ CN/+2D]7I1=%]0.MU];_2!-1?8=R+.92V=/5?Z6VV_J"?.%=66_I,V
M*_2=.4P8/2DS3/18=!='-U&\Z2]%;[B9\W]02P,$%     @ VSAZ4(:[@R2A
M 0  F0,  !D   !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL;9/M3JPP$(9O
MI>D%6&#QJ!L@<3TYT423C4;]W85A:>P'I^TN>O=."TM6PQ_:F;[SS$=I,1C[
MX3H 3SZ5U*ZDG??]FC%7=Z"XNS ]:#QIC57<HVGWS/46>!.#E&19DOQAB@M-
MJR+ZMK8JS,%+H6%KB3LHQ>W7!J092IK2D^-9[#L?'*PJ>KZ'%_"O_=:BQ69*
M(Q1H)XPF%MJ2WJ;K31[T4? F8'!G>Q(ZV1GS$8R'IJ1)* @DU#X0."Y'N ,I
M PC+^#\QZ9PR!)[O3_1_L7?L9<<=W!GY+AK?E?2:D@9:?I#^V0SW,/5S2<G4
M_",<0:(\5((Y:B-=_)+ZX+Q1$P5+4?QS7(6.ZS#Q3V'+ =D4D,T!V=C+F"A6
M_I=[7A76#,2.L^]YN.)TG>%LZN",HXAG6+Q#[['*D^N"'0-HTFQ&3?9#<S-K
M&/+G)-EBDBP"\G- FBP#5HN 502L?E20+@/R14"^4$'ZJ\U1<QDU.FI^U\C.
MIAI^VB=N]T([LC,>+RB.L37& ]*2"P1U^$YF0T+KP_8*]W;\6T;#FWYZ"&Q^
MC=4W4$L#!!0    ( -LX>E 2*)ID$@(  #8&   9    >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;'U5V8Z;,!3]%<0'C#%[(H+4H:I:J96BJ=H^.\DEH#&8
MVDZ8_GUM0Q UGK[$"^>>Q9B;8F3\530 TGOK:"\.?B/EL$=(G!OHB'AB _3J
M2<UX1Z1:\BL2 P=R,44=16$0I*@C;>^7A=D[\K)@-TG;'H[<$[>N(_S/,U V
M'GSL/S9>VFLC]08JBX%<X3O('\.1JQ5:6"YM![UH6>]QJ _^![RO<HTW@)\M
MC&(U]W22$V.O>O'E<O #;0@HG*5F(&JX0P64:B)EX_?,Z2^2NG ]?[!_,ME5
MEA,14#'ZJ[W(YN#GOG>!FMRH?&'C9YCS)+XWA_\*=Z *KITHC3.CPOQZYYN0
MK)M9E)6.O$UCVYMQG/D?9>Z"<"X(EP(<_[<@F@LBJP!-SDS4CT22LN!L]/CT
ML@:B[P3>1^HPSWK3G)UYIM(*M7LO8QP6Z*Z)9LSSA E7& M1;1%IOD"0,K"X
M")TN0E,?K14P=A-$3H+($,3_Q(BL&!,F,9A^,AFY-6*G1NS0B"V-"9.N-/(
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M$)H;3G!GEN5H3E;#H.)[;6]S<R^[XT4WT*+MCT[)<'Y;_0-02P,$%     @
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M<R]S:&5E=#4X+GAM;)56VXZ;,!#]%<0'+-C<DA5!2H*J5FJE:*MNGQWB!+2
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MV#D8[!PP<*JV@ACW-(&83UJ<@X'D@(';8HAQVK>&&/<)A1CW6$)7I[I^\?_
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MZN_%X03U\*/*=]WI<' \HI[\#U!+ P04    " #;.'I0M'A$3A8$  !2%
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MYKYLCY[M@U;[[E3MG8_VX[]02P,$%     @ VSAZ4"(C(G#<L0  PLH" !0
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M^O")PM=[/DP1C06D'%=#JXA-;2 '^H,S46[HHHDHK;YO6T\DF@UOD5VPBT[
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M>OL=I$-6KZ% -9F!HMJ,6=_S&/A>$N1T"^,B]>E  /%-]D1R.8L7B*%( =#
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M/-/8[\K^23X%X<VLDTN(M]TNQJP3A2[SB_MLS:%M[/#0KD)8;HG>&(DH%+S
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M0@:7BL[[@R'!E>1YP\HI(Z6AT@8JWU<2;$\OX&D9 5]P&CT-3@B4%&K-!C,
MUG4JL$DF%I!JG5/40IVSF?5=5?[#ALBV-^9OBHHN2'E;"1HG$W[1W!_2GCLF
M3\Z8 =Z+4DL180YN$9A%X.%Z_?EE*GGY#U0"\:_!+YG73F=5[6M)M"/^7N>1
M&Q S"?AR/;!QK#$H\.$47[(R/M'*0%X)ZOC&J+_9BR-TG"B/<M.F(A:*& 5P
MX@7;4DD>3,*E74L&N6V!Z-U3Z5+W=.*"J-R2RD)_%Y J6\LJ,;6L#,JT?ZGS
M3<9=4L*PZMZUBRJ!7XJR*1;_SJGL?GN$YU1+C$!^WB-<[%D0=3WP_JCURFF(
M+UHUG%@+Q*SA_B4H<N'//S(.M;XW_P[2\6B:SD"=[%].9ZV?7PN8N@<X&V
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M[?P0-.L<(<YF)$M=9-=$*?HYZ_@-6_0O8QHQ"!@D6-0=$.\07=UI%LJ%"G
M*G&*<NQ0ZB2-<9!.)_-T/+DBS7 XL[K.+!T/1Z!,@&C^EO"A=P8JSFA*ZA<(
MYA^=B1?4EQ0&,[^<HHCAM*!KC"<XZ;Q3_929PZ_UW-^FZ7BS_]6[;RS ]8:S
M">A#(WQBZJHP=XTH59@1AJ-I4*K)F<()3,H"VW**."/Z+48R(M?'XE:F>%%1
MJCA?)B:6>+3&,JX3Y#K?2E%2)V^[_NVJ )S/-XD\<(54CA&(KTBYH^!U0Q^(
M=LVDE-6\13X[';2=/]B<;LH?G_9Y5R_&D\DSJV%Y*TG#IMZ=E:#P[V>T2(RD
MMQ[ODB@.JPW0B7L8#<?%#/I.UZDZ6$:??:E*B37'0,F=/_%X*T<H?8Y/QSC
M<FC"@V;H20U9(98.9D&7JLMV]=LDGI&U>;SKA#>\G$V5K=7]>:R$V6MSIYC
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MI=GMEP1(Z?9@.ST(B%CJI4Q'>K=:2/D+8NK\[(Y">5U=OPU6EMNN'<*K,9I
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MJJD"UVHJ:!^_IL+<CH ^MX#*F.**W=1KF=H6H&L"&?$M:#:%D3X_NVR/MYI
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M'!&B@"FKZIYSAX1>Q:H$:O[D>^X)A.Q E)$:=*M;I,.@U TVDA.S1G4@I!5
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MC@6>AISBF:XLK+2J.Y08FV2QN06-6$IY=XA<$>K @9V2**%",#M7;VV=L49
M5%S(]0%2E1$]ZZUH;]\B??&V7@SFTV!O"#0Q*",06UW<;\C\Z%R;-X;@+P"J
MAQZ^#A\^J==[1QGV*4;_^@M9>&._=Y7Z.2OB;1DILRY!F :15"SCF:MK.#\/
MXX8Q/XX;S%;^-)V%\[B%&BH:*T/ Q "-'(SVAQCYMPJ0KTS#'D9^"O^P?S"H
MN<P?U6*XV5OWI%:XH9*;:WAF75$#@ZZUX(UU4[C.%]8Q8*;C\47+,,6='PXT
MYJ4$9:Y%C6H6C4\V*9!2N,NU;@-:8-68![K(.^Y(AZNRCRX!M_8-<J];N"^/
MD7!=P8M,P\2^CO5BJK)$S7>Q5Z&0X7DSY>7\6J(IK,Q]U#<==;(7P^F51&[,
M!K\R8OY]:;MRS"19O1L=2NI%4>[$+,>KIA!IB1+[*?\*V]EAJ5+\S4\A_-/-
MA^_^\O;=C\EL\J?L"<9)?OKI)O5>%XPQ[Z4N#B@W5?V\+G_303KJSY(&%6#*
MIQ-QCM->D&MD"$>[K  !R<L=7?X'4,30"&)68H+H.'^'7<.*(0?[)C.W;STU
MQ6/0K&Y/1\H#I-XB;O0DKV 2?PWV9)Q9R[2 ;"\?.8G!9J :)?IWL"0/E5,@
M%\>*O0VE9()H]*7DHSCC49'WEN#M;6H(=<F-0\;?*M BLBXDG^$-=^AH!6[7
MPZE9?@A/X$S4]X9KG5.!LD:%2PHV"W4G@)Y;'4#/'QY:3N&YR37 ;2VVH-$@
M.0/\V6^X[%1XCDGKZ,XYL=-+I*ZX"3?.@!:ZR$((Z1\K30:M[UD5=$?!E %N
M"RO<W6$-_IW5DD(*LU!LSKM:E'MD3#"<B:HZD/TLX[<&Z>&V>R]ZD_X8/PYZ
MHW0Z&.''86^<SL8#_#B"C_,Y?3ON3=+^:-S;V1;3O=$$$ZJXNQ..-$Y'LT'O
MAA)5%CMOQ:$Y?R$/&;4Z<_BJBA22D8Z[0[K?F87L.A/#8H4=K^/FQK9GTSA5
ME\[5XH7@S?H3DT"6KQW.NC9"JA,SLP"#1$2.F1B;S5LYO$3=#-48E#AQ'IO=
MS@G<']^#<'_S\WM*2Y5<[,($6-N.42*S%)**I9LN6.!)3$ ::MY\K7+N3M6.
M)34^$]O)V.Z ^PNB]6A9F20XK\G&=@_SA@AL*M,M4)7BOAVW3T"&V%80+0D%
M&CDU8DK=B*@4U;Q9NQT3UL.:DUL=E@QRLUTF'U3!6IZ5?V47L>O?5J[)*FR1
M@*SCQH-D.Y=BN3R3!F><;5K?A=G55G5]&JD>*D.:$=%"P_&&UOZ-UA*]0HI(
M;.>HD.?;/[QZ7UXF/P*;16M"WKZ+V!N9ZE<LQ75OGW3V71*>R'S,LCKGI$4B
M2U"C&T^!Y*H)K\E%*O>*1:A7 (I'/"'J@K;SI+]EOBFYG(836FO&F26(5V3
MXD/W]7=4V;DA.NGGP%S60K9Y"'S #)"@NHQ(QJ7+:PK*]KLQJ'CN?^S1JVD#
MWS*0:$$X% *>?64\M^979V\TBJ5!'M\X)_[N5AD<"B\4#[]JX!N2*@L+$SU'
MQ$"@9;ZSY4%@/K0\W(G15=SM- O;*3!*Q\32YYPB4>Q,S 92O,QUZ>8@'-F=
ML71A>&6[T(^H4:R1V%!$U27+$U.%'G(R0/T4HX@2#R*E4)ZV=.M5W K];LHP
M>$"C\1FY.$C%A>5)J!M;7]S:[ 5S>$7WT,,[:>EL\=9X"OQ^,D#<*#!7A;.V
M,H]%N'.&7?$\D#SLE;?+C.G&MG0('H]WNI5()2MJM'%7SM1TD+/%3@P,^?8V
ML0VK,RB4=<U'"9%8/-50E"JE%0;DTI>$(GV(L'6%:;>GEZ2BA%S^ 2S.Z)3D
M?:#;)[CNXX?5@DVB/]L:&[0N&G(/>@[B)>;K%COBJUA*,I72Z?!!->.37GM2
M&I'O[]H$K-FX;RJA0T&H:?)05&N)ZN+B\6$[*"(D#UC/R[237A8:@P1BG?*/
MU[TVI#%+8NBXT[I W.<FX=+QT+>ZD0F@\P+PQLO*!=U*Q4T_TADE2ZR)@3%1
MJB-)1]\7%O@]SX^,^IREL?T6V3U2>;3"I];+I4)-5EE12[050[;QV3A6 ,CO
M)%W ;E?'C%&E;^7YT6WJ0W/9:V#GU5.>)R^E=^('0,73#&*SR\2^;3HO4G2G
M^39,\.4839/H0%YQ$TV8&WH<<L1Q?W#VY1RVM2OJW 60:OU0'L&%.R7X@XZ:
MQ5A-DB.Y636+.U?<$'1'@:]2<V>A.M4:4J>&]RK4N*[*+;*G7N'@EN13MLJ3
M/V4UZ,W)SVA*QZD'?;L$"9&?_)[.$\X/5DT_9]R$"1_;X'NQMI1\\A^(^WUV
MQOY(1\JN)Y]M#)VCP8E'$ZZK1_L<.4C?/ABU]%E;F&[Q,DU-\#F5,0#>@58Y
M4SU%=#HJ&KN*(I"3XR3/L,[OJS7*O6U0?MK?RMU,7A/#/?K LP%WA3S<#B+B
M9,AEC'MKB?@6/,L&%^O'1DN=Q,"Y:I?.R&W#5DQJX<^DFPVGJ;+JDE#@RDAX
M_H$5.@PY+MIX"AHFFUX?1(S\HYI'? &4G!_NP.];_H,V+;+YQ*SJ;UAF-?E3
MCMI8\KZ^RTJ3"R=U;TRT5UV5V4-1[\EAC.SL"URXWWW@KHSR_NM-7G-_. R$
MYBX$8C2YJ5!^*'\GF=8"H8%=BYV-^3:&C0+.E]3FX!([Q;(L2 F<62T%QG.N
M$HLOW.?K+:BH.R<E-H /TK(DV(#8MA/3XHSUMA)OUT,N?2O^P=I.48JGT!3?
MQ.P'?H)*^&#^#^& K\" &,MT6;I6 C4UICTC][ID8+<P+4U(KFKE-E5(AP3D
MXT;?UD8R&\2X$PL7I@ L*2D7BW1D"QN'CTU1JHT)#7;(M\GJ+U(Q8B,J#><M
MA^$%=WEU5V?;>Y+5C66W=8VI##6L[3\Y) HDHU?9+DO.?BFS/;4+.P]?<4^^
ML8MZ6Y* 1#CY[8ZE81](PO$%<4=G9[ T7FQVE/[#ON=@5JCE(0IX%GY?T@&=
M&T,Q&B6%V)GT,!+WWI!X*J8DJE?/:<#*F6Q]U-:"2'*-YV[<47B3OTCG*T:;
M!^4V&Z+BA',68QM;_LQ$MAG_KYF\("5H2;(8A^J';WK^V,L>@JC'!  $UQY5
MM0*JU//"_7I:N!63Y!F)+]6^84D\_XH]!'!8R944S=7TIS?=[6-MY%_TAN-T
M.)K#AW$ZZU_A%_/T:CR3=XTZT)ND\^&T-TWGDR&^,A^,>D"U@&CUQK-T>C6B
MYO4H0O?.^-'SWAD_#1\FLPG]DX[A0>QX/T]G8WSDQOG\&Q3&F^0&T0PNZX[$
M-C@4B>KC:B[+ JU(L&N[ ?/OV2#M#\8X^+A/4Z3]"?YIE@6R#4MDAHDL5 =!
MX=&QI0_2R?R*%S\9\>*OTGF_KX=6D.^81 D"R05%-2R$>:Y!1EP"U,]&ET-<
M+WT:#_E3_W(V,I\&5_QI>#G$3WBM_ON1Y]"G ('&Z6!\!?\=CZ: 3 /Z[QCP
M#, YF,X5^O"#>)#T+(%^8#[@&WP&^-)OB4!=_SX/@9ZU^-\:@?HC@T#]@?E$
MZ,R?Y-?!\'("'R/RZ$9<^,DGI7M>N[#D#Q@=BS ^,Y]:G.NE207Y8$M%5*&&
MYQ[:JH?8A+-8,)/@1+!CHJ%3.V&D+<M-;=.M"JPV%I6&4H@E\<_Q6+773_;)
MEQ6:8,[>7']Z*?Y._)A032EGAX=)\.8MO3!N=F]BN-G9C]?7'\Z35F=<D4S9
MN4<,'146MUEK^$@M-_%"9U@&6V3-?;*B@<C[P$9^TOHE3 S9VL><.L$LV":(
M"S*E0PT@<%^L&C?$V_C)T\3T_Z^]+_UM)#GV_/SX5Q#8]CX)H/AXB(=L8 'U
M96O0,]UN:6P\+/9#B2RI:X<B91:I'AGSQV]<F1EY%8OJMG>QS\!,2R*K\HR,
MC/,7V+$\3.VDUC(DA$]N@1" U_81TTQ:FO'?7^CW1:@\-.K*QOV6+E, ,UG(
M.(XB_(USR,%J7ZU!#*>8#]1,X$2B&^7K6E2/:ED5Q(32KW<_W?QGK_OAYBVU
MX)[YH7A$*P/![)!MDAHL=I%A:W[*T"Y4V6QAS+]:&2;1NEAQ))^RRJ#5@-!>
M8SWT9S9$OS-I%:U67EYRN1BXW'P(O1#>4$%NLR/X$*7"8((!'F B53%HUBI;
MRWH6_&03<H<_[IS57$(&V6//I\%:]]'82/AP@453[CUG$)7P.39#**57DLTD
M)EBPYB@4R35G/# Z/J/%B:(.X_':$:FPN3 8E*)H,)YG?;\AB$$.I$QMB5I/
M%^GJ)=KT_'P$T-U<]*/)V*2MR*;1\3HO%EOD-L[$;!?9-T/JF[77]<+"Z2*4
M(.>"$^\8_0S!!T!/^950LQ:[/3N'B6'J0EC&.8%5+^S\?/4$CBIBI]2>!39/
M896+@'91YWHVU:[V9B3)7J)T"%XR!5Q\^ACZ )9F-!Q,3!!-=CDX30/AS1NR
MX>^VQ4-)"9TF_^\!^L:<!U=<$WDO"DQD0A%3AK!OLFC>((PZZ;B?4--$#\<E
MXOG^1>\,\.(GCH#Z$]9&-W-X!Z<6SO$UZFU\%J[XSBEJ>L8:0,G(JML_I8QO
M&V=\>&$%5R.U0,\ND.\ KS!^D]1),=1LH@6:B$(,[=HYN"%K+N%=K)?&N(M_
M)I(7, Z':E>R+<+) 7*(*;2:^$J,R$J0I*Y<>B "\_OUGDAPZ]4.V3H! 8^:
MVS(0TA2=QCQ=$;<.841(21/6M*I^@4OHRX;"LGN2CL$Q2ZL*EIPJ$)#-KB?N
MRIJ#^S@(20Q(!,1*R:Q;*<"B1543TB[C_*5\]C9EKY+4+)$8]D!W)7,,?LH6
MSE-45X?<R0;C.Z)#AIY"_7V Y?T"U(X;?L7LZ@2%_TB$]A^M]*.T] RX(".)
MGX25,:"/-DJCW$7?<OR]7"Z5P;-*W\?.3()_68)[#M(TX,XAQW/3L!A_@G$_
M) U=TC'1?\R\0JZUPDM<C:0<=G*;%(<HC91>PN 8%*: 6#;[+<7Y_.360M;4
M-98<N'E*K]>ZM)BTUB=7_&K\WQ@3L-W2.=\UM4DAWNI+7A_#I]96[T03^(I3
M2W=!YH96/DUHA*RB<#.%&1*NH)@_%S;.9&>!=?F"I$M$=R%[K\-[L]&]&BMD
MO]Z6#$C618\SVE^9K[%/WS(:8JRPT((>@07\'M+$3BO3)LS8>8&C2/_K\E[@
MM*U5L)7L:][3UD07CE^7]TXA4J2^\(YN(<4]N&@)Q^ *ZC#+T"7)F-MRYULM
MT9]A72%4S=1Q'M'BD+/>*?NEP8$\0U%YR_+*HB+&\&7SE:A5TN\I2XC.B;G0
MRKK6.58A]-(R?1\T#B MA/([813P%B,%RJ]U\A65/R*!?<6]2*XVJ$:C;&S"
M+;)BK65R]CW8(5Q^C \R@8,2:DSO/Z!%^F&S@M%"PQBF:30-O- Y_VT#^@#!
M>&-HFP=H=;M94M .EIF'1[^0TP@^(64\OCK>;[8E7'+=-QRI\]R*1LU+$M[S
M3&IC9.J.;H&?K[M+A [:BDQ\MU\OQ'-E6R*J0\\HH5.IK$D/N];@9M@6T?X@
M/ "7,V )HC)Q" :QJ[MP!C[_<K@X[OY*YQH%%A/'1T4/Z7??.CVJ,6,A8"AA
MRI$D?,]ZW5?#R9 >.WDU/Z6 N7 RY:]R[?'D3WCFIP>+!Z"AA[*2\)=WML!S
M.Z7=ODWV(E<>VO<)N^Q:JN@%\N'J660T6&B,%A"_K'C)-R!"5BRJ8F FQU;5
MU:\FAAAO?CJ+.P^LG;V;T4CX2!*LY8[VL1 !3 1ADL/ZW?Q4$F83YXARMQ)2
M\+;D(%AJXPMJ+=6:\.N$HP"[?C;]8CF+E!/_"YR=,\HN^-'=:&_+VYU2>1I>
M4M?@$E]20G?Z*?6 Q>/MXO5,^8]XLYCKX0R([HRP#QLZR6B-(:]U^RX0"?W,
M\-2#1 X68 S6DF/@;'2@F*E 4\$<&1:;KQ1]51DAP4\=+;1\WG.@_DW\Q7(\
M&1NL +L1RD9)D"\3<SU[T%T-<M@)R@"+:G<JT -V6!CHS%41K0'!WO%4T(MO
ME#4/Z0SE,EANK#*!5OHE!<&7;I5$+\:(#HGJ%$]F\8"6H;\3E@D#>D9$4(LW
MU2"1\!M6M7_$U!T0K0V>RM:&9-,E278ILO_P^9? 4:\5[TU4[.\9=9'VB\R9
M!#:Z]K1.U&,K#R+)XB=R9 ,C$-L D(56^[E++E>EZ4 4D;*VS0@\J")=_W8I
M:E//W6PW$XD1YN4>.<V="4VZ*>9D8_*],>!MW+^&+=Q2P(TVH21R5M>(H.M,
MKV]@]ZM=]W-5<[V3CW=W9^:\7=-YPZ\.-K/@9K:FF8UJAH\M??5>10'4N^W>
M(7G: %RN8+6IH\CEA>ZS#CLU2\/II95BUVG>3W)@3K%0A6<KB60@$U+355*7
ME-?.M$NQ$5[,@\WHX2(+QDA+<T?/*CY>+L5%1#'KI02G4W'K%(DH:O#W7SU#
MIT:.FV"$KB2&?.UG\'C05W'@A8IHE]#3%*2EWA&%/NL6 M[RHG.7)7W"..QN
MC9SU -?=NUZM[P6/GMF?<AG'1*_]H<44:8Q'1N2RDI;-[>F9?#?]B8%%,*]]
M*9<$6:U#K6,-4HWD>H]1ZL#_V^F0ZLW:O!DF&03 H=5V>69*V]D: =O:X&*N
MGAV015.BI 8)$"LJ0: 5#Y[12*=9T>FPB56<3459VQQ3B_A?80+^RH15J:10
M'9G%LM?:J6=Z3FI<(1PJ(993Z'.8ZA6 +5C810[]6CV+&ZB4\A*:BN@"0M!B
MAN<P%M)'R9&24:2Z-BL72889M<P9L%4<9=U5G\<&,L8$H3/[U277",(!I7*8
M*XQJ&Z!G&]/DJ-[ 1A4^5=D/MR5PB=**#A[J;['38R/!#'TJML[;'.,4:<!_
MH0'_Z![N?$ RZPX[?]Y3ZJ98J4G$(K7>1-919"[=VD1>4J!IJWUF?6ELU+E"
M4"K///6WH'DQMHLX)X/H6I2.DLM"VL0$['SM_KK%S>'$+\,\I .S/-1/S\DI
M6VOT?ZY0;0#&_.1&/.[\O':-,J96;4X@9263A=_!V&T],[5[4 PZ0M+&7"&"
MB=CH>)*)C11:$8+%*1@=UY*(I0<X.C% GV<F)R0U(WP];);EJN9EI+G9E:9;
M2,V=9%QO+:A9'JW$ WNR+^K*[BPXGR^" CGWRZ7!;3.E)Y8EIA'AV^8AM"5M
M%U3;Q5_&T&%WYQV]>[+)U'S8G32#4L*NO =5]^]L;I"=AJ$$\@ _KP+1\3EE
M_%'=?0&>CPSZV5M<<I9LON(8^&4Q-#,TF\%'U]S+7,=)WB+1M:;$BG-CB*)#
M!HF=]8';>_BQ>"YLRD?HN=60!Y+3H)TD2D:HG42\+@Q( \>7I%WEL8K]"4MD
MX*U'MPD0!-]BF8^5^ 1:L/N":OK!"J+=QWUVM]^N*UMJ1[*W7&,T-DPE^$*J
MR ,!AEOD'*N HEYE?()&!&3K+UZBE4 1F.-'B$[W7W9GI+\9)-T8.P].[MT>
MR_P^N=P6LV8J$?Y=_,)=V?F@Y]X9LUVK\R9: OO5^\:5L(]]2*Y&AQ0?OK<S
MD[AC%Q GJ"$Y4"$ZE6ECBRNR):_>!7,&59.%4SH//G:U5N#MHG.B7*EB7W*V
M!QW9$2J)+S<T1M+B%?"?:FOBD3]LUO=G'^@.OZ09-C^^PL=77-Z6%R2PV:%D
MQ7J6#>*(WZ'\>9L46;D>"%'-Y1MGP<$DP%E@\CRN$NP7ID&A3B$P4D]<WA.M
MP/*' -'4AEL1HZ:@)FN-O=UL?E$L2[5N 64E[E]"J]%IAG5G:P.UK2+C[*5F
M#E&0-\"Q?&2%NC."@'U0E<"5!!1:.U-A1ZUD!(L9S'#WQ2(WPE_.>Y^?JRB2
M(9\-T@>KI8!'&GPQNC3<N(QMO0TTSR'/V6>M6KQ5JL4;6WCG$J\,D,I;B<6?
M<ZJ**^132'O=[+,:J(#"E("=<#0>!<5QSF#=TT@*%(9!RA=\GE=X*+/312V1
ML4]BD+P</GFDY_,@C-C2MY"@B#A8?>M_-LZ4?%5C+ZG<1 3E%#U;#-*A6IB\
MU B1I%8CL]]O5!Z4?L!7/WW_.;S@X#14RKF/6N&RH'L>]_7 6S6Z[^$JS85#
MJ.@+':J4]ES9"2/P>\@21 MG[8@A0*JT8APZ>"- 4P4:'V!;6%OFKJA_J16,
MAYQ7OZ@ =NH)C%X=&.313]5R3SE)SGIA] =DS'XP'"(Y[##>B/WL&JJ_9U.L
MFB_!= !CS2&A%1F[C1#9#/'?[_ZT66.=X/62\0&63W13>T E]QMT8VK$$LMU
M62LVPC;?"DIQ;U4G@AWW'#/%AL'':L=&9"-.VP\\@<]"8=L*"R)4T'BY7;R/
MMVS^)VG0L@%72<=1L*V8@!Z46U,O>H?Q>!S6)ABF<DE]*;;WY;(5/",:M1<"
MT%&MSX R";LV^YY4?(J[7HI9#OE&L<#ZF_89.C!W</=5<MECHV+$*U:2%OED
MMVE?)P.G=*&H2T7/[5R>?ITIC9O@AS)000 Q".??R92-*K:-A71ZW?PL;#53
M>=;BTU%5:7%\V-Z87>G7J_43 KL*I*6+<5#T;*D*!0Z+"F)4=BX^GJ_^%!10
M^=Y5CWA&M@\\7Y2SBXO\(!F\;@+?6F8K45P+G=QF4<R475/][GN"G\B44VHL
M5-;U(%TL?)<):O(MIE)+TNRX<83K""A>1'\D016OIM&PTN1L1FAH/[:\4/>D
M[-_W>[;48& A/T5"W2H,;49"<Y7NF(=9CNAQ<#,H]'CN=VCLR.006!0='^W6
M&OH92,;'7"X\>.G4,K%QDT![WQ-OIA#Q8/DUD;D!>X5]=.%(VZ:?.$Q[L)$=
MML^0&Y:$4;90 TL"-AO@N;*P*NZ7I_*LWI6/;(]3H%89=(L &I[!;<2;CU/V
MH^WR//#PO%6U/#85/6XK4X]C:U+A]3#$"N([>TGRD 71*4VH0WHHQJHDVIZ"
MZA@DPHQ33CX&0A*!^W/SR-L&0.B6>B0H2Q(]XE0G#H:3)(.R9!K#30N>H8"+
M0('H99#0F#;W=Y/X<%T]5%25I><[)?&QS5?F%T7 37"R:X6>:5._O DE9A/!
MM1^6UP/@4%QK0;K%2JZ*N3@-PH[_P.F]T?(P[8IKTE-)C)YH92CH706\H;6?
M"ESOV<_#UL:3JT^GO>X]4(X1,<T+"E4J_6JE\7UX?85C8>X8IEJPHURHP1 L
M7W0XQ,W6\4#)Z]$WYW4D' B,V,JF/^A*TP1CLN4[P.#"F#S\WU/HM!+#]X]G
M7*S%K.-=6=9_\.'$M;Y%LOP?CJW8L5ZF/O9-X\8F3C#^# [G*@[#0V@"RD/\
M]S.A;F1,,O'0P4A1K,:+;(NE[!:UOR?0]M6GGJ7W7JZ8NPDC743%MA%V+ZSV
M:4I%6$NG1'5YV&6JA =A6>VJVGI81-463POA;O@2977'0!H&96Q%E=O)CB=F
M,JQ2^.AA;J6N?!^<G[+QU 1L^3_R%AOPV%PU#R53NQ7 5"4#^,0X8KB9""5L
M\7T86+M<&@ :KUB@JJE!-Z@#L+VG9!0?]O*A4DDB1H3I>2/SC)UFGK&W7A?.
M$?T/S4W2E]>D%+Q@(PJ+7Q8/$%?50,7ZC<IHI21MO'3D)I)H->0 $B3%D>,.
MP5B/T1LB"P6..1KVNS!%V1@,B;I-35#OL<VIL^XYITGA<YYOR/60*>^15(W:
MO*CK@HC+I>+<%'*B/I(.A9N/GQ92 ,,^QU/2\HQQWMR)A5>VA6T\(A0Q(A*A
M@;@B;B**!;>@5V<D56LP6_<C5ZDCUY"VN27$0D$ C5_L.4$:=4F))Z<5,LYI
M;LR5O71R04^JU5M0,^<"OWW6::@<QO5L"[4]V>TUJ)DBTF5,.>11C"0(<T%V
M;3R0S?LJ'("?CQ#D($_-Q#15L_R6*+7A*G96=5S<4%T<' %CRV J5ER# "$8
M @M389,V&LE*22EX^:@*@>R0-*1LZ^3H+DUXJ9]'0NLKDJV5,O92)U;XK^'U
MSHXKY35S-X:G2/_) +ZB>%#4P@-%/D^*43Q8+2]900G#X\U&!O*2']ZD]XM8
MF, YN[ 8=R%8_A]IIST.=HC&O>4=7LL@A3V%T75<%QYA.A'-*BA#+I-@S[#=
M_MQZ&'G *B&5PQQG]Q\A9%,6K93(<RB\!I1_Q2$.A+?M-HO%&"9;"\0N5XDO
M&?.^1)7?@$7V/6]05N)#X;&G0OT+0@K#@:1+)D5F=E7#+U%:,E6-+5-*S19=
M2Y9^DOYJ6V-/UQ;,U-L*:U6=5*>-I;6(M$XJ_53^VG/N0C.B1 U5^Y&]ZPXX
MDD)%4%LY&/S:%,_Y!*+P0\$H&-9P*5^Z8@D8GK#?TJWL&2488W&"JV+!1?8&
M<^RP/R&%1LG;\=E=7;E'M+7!L_SJ\J"!H\P<LF2:1!(KYLUFZ>+0E677K8TR
M"9FAD3#VQN_ZC>W:M&)?5$4IK$T)C9@%+-+2XG$CXJP84RV,L+4>;4QUL>1L
M+2B4OR2-^C>+@19>1YM#LH8D&UWC:V4*3-.";.CL.4)LKTN#5XAVJ[IDCNP>
MJ]OXIRS 7,I:IG%\#.X1*;8/L(@Z6Z;B6B9F[J;LO-IH!R6J68KL/IUZ+@A.
MS@?#V-E4*MR=:Q$VW4\5N1Q%7I'<7S4[WQIJ;R@9EHK1%1=:9%!EJV74,44.
MZIIF[OY(& WM.B@[]T&+3D^/5%AC[9LKN 0)VD+KWQ/#%67GV5/C3NI34Y3#
MK/(?F/-ZCZ>Y;QTJA?0JO.LT$?*/-54'S%UN%:FFV.#3J4O&339G"]6V'21E
M(3Z=)O:(".^$*.]4+[&Y-9@>,QWY-PI5DVBR37O%0:CCU!VM!B'ER,F(%IK'
M5BNG*'I4O;'9!;:"'36WXNLGH.<$-1/JJ@B&#OI*: 4A=;!>AXN#\,W5>0],
M0,KVZC'ULM-CL:==FB3ES_9-J#<&^%82G3-R [UH;"8Z(CR8H(F3/BF "D/K
M"%'*+0BQ'&D>*_P";E;5UN;#DLWM*67-;44>-U\F6G WC+_AM)8%:^0*T\I^
MK((7<E,+$M?-PAO;@5ZA931S-26'&BJ6)DQ4$.9A@M9:'LV$IY-=N;6&AO&B
MHXW>G@?"<GA+#"G 6ID-!\E?()X12;S,I9B//(,17_1%S1>&.X=& _&\(GV,
MTM4]>ML=Q-79-;;59Y >F)][9!I9!,WYT9LFM(Q&'QSG5[IC_;1#4RO,8!Y8
M\D/ 9,PU\T"GO2&<"*WWDGVC3H9&73XJ7(#<S([Q1NC6<>Q.E5%,G-)$#^%X
M#IGZI"((MQZ18C"=MH/0YT*Q/6P5M+&0-D[9!$SDC@MBB*UH=?!R)F.!3K+B
MIC8,O=S\GO:+Z3( VE0"PCBO:%5;/=9SBG]'(WZBSJ/OQ+"V<'-"@FT@0?'(
M3?@&TJ)@VN;64?MVV^QDQ*KVC!=BV^53&C:CSG,#C^-T:Y0\U,4976I14((B
M0W&4%[ZCS<C;##='469<G#BH *5Z932.U#VAP_3$:\=&O_+7 B,&7? %G5"Q
M"?VRWGP]^[+YZCQ1#1%N9,7]#_3]98JA*5\-*8MHP7]D_Y]XY7HF(,P7P;0'
M10M*MHJJDX%950DJO5J#L&]\_18Y3SB8C2EOH \VA21%!J6P^$/+U/BFJF^F
M2VO!--DY[#5@KOJ J0Z$CO9LFN4'PN*QLH34X.$2X\WJ@UC+CC"4X2XXK.7
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MV!]?S^G!DQ]DM1!@#I<:K303N@[)*$\%W7<*@]2G 4=90;4.XT"M:7>(,QH
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M7* B#X#AP(\)/4JQ55X>!NG(ND?!.>G@B,ZAB6E_G#>WX'06H&"@B68(#X^
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M)=!_W-X7:P/5CFV_YHQ]<HL*) Y\<]:]=&7<U+72/7F+(86K^K3[JOL?QLL
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M%SLL[?AK/ED\ U=RTTQ\N6&,2K5H7,O7-N5J007[P1HXK(7"8 6A>,F[$1T
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M$<'!_H)34K-+6W!X6\<_ 5!+ P04    " #;.'I08[>:!%0%  #5+0  #P
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M*3C6/PO<^K)8/E<%$7N'9?90P@Y[60P].!WD&?PV2A9P]X*=<L5U+E@3<A<
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M+LF#<YOW^6SZK^+5?U!+ 0(4 Q0    ( -LX>E ?(\\#P    !,"   +
M          "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( -LX>E GZ(<.
M@@   +$    0              "  >D   !D;V-0<F]P<R]A<' N>&UL4$L!
M A0#%     @ VSAZ4"<KE.ON    *P(  !$              ( !F0$  &1O
M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ VSAZ4)E<G",0!@  G"<  !,
M             ( !M@(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" #;.'I07F6"58H#  #N$0  &               @ 'W"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ VSAZ4$ ?@UCF P  W!(  !@
M             ( !MPP  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( -LX>E#%6C3Z* ,  *</   8              "  =,0  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #;.'I0T1#=CF$#  ##
M#0  &               @ $Q%   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ VSAZ4(:]#>@U @  HP8  !@              ( !R!<
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( -LX>E "$]7J
ME 8  ,0C   8              "  3,:  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    " #;.'I0U1)/#>H!  #D!   &
M@ '](   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ VSAZ
M4'7#BF(Q!0  GAH  !@              ( !'2,  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( -LX>E#,5TB[M $  -(#   8
M      "  80H  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -LX>E >'V<QM0$  -(#   9              "
M 1LR  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ VSAZ
M4.9!8B>T 0  T@,  !D              ( !!S0  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    " #;.'I0IZDE+[0!  #2 P  &0
M        @ 'R-0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( -LX>E">.2C;M0$  -(#   9              "  =TW  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ VSAZ4,YOZ-ZT 0  T@,
M !D              ( !R3D  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    " #;.'I091F_6;,!  #2 P  &0              @ &T.P
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( -LX>E H$F'T
MM $  -(#   9              "  9X]  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ VSAZ4 $V<-"W 0  T@,  !D
M ( !B3\  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #;
M.'I0IY]B\;,!  #2 P  &0              @ %W00  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( -LX>E#\VUF\M $  -(#   9
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M970R-RYX;6Q02P$"% ,4    " #;.'I0.QBC$;4!  #2 P  &0
M    @ 'Z3   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M -LX>E"KV=J%S0(  $P,   9              "  >9.  !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ VSAZ4!J=^FS- 0  G 0  !D
M             ( !ZE$  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    " #;.'I0R/S0K[<!  #2 P  &0              @ 'N4P  >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( -LX>E J1*E]M@$
M -(#   9              "  =Q5  !X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ VSAZ4%L/;:&V 0  T@,  !D              ( !
MR5<  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #;.'I0
MF@>C&[<!  #2 P  &0              @ &V60  >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( -LX>E 5>G\%M@$  -(#   9
M      "  :1;  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ VSAZ4)COUDK/ 0  G 0  !D              ( !D5T  'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #;.'I0U(R/IL,!   W!
M&0              @ &77P  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( -LX>E!][Q+%MP$  -(#   9              "  9%A  !X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ VSAZ4 0V$[2W
M 0  T@,  !D              ( !?V,  'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6Q02P$"% ,4    " #;.'I0T:O)WKT"  !K"@  &0
M@ %M90  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( -LX
M>E!-W^TD<@(  ) (   9              "  6%H  !X;"]W;W)K<VAE971S
M+W-H965T-#$N>&UL4$L! A0#%     @ VSAZ4/+V2(X5 @  U08  !D
M         ( !"FL  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
M    " #;.'I0#<^P<PX#  #>"P  &0              @ %6;0  >&PO=V]R
M:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( -LX>E '018!]P(  ,L+
M   9              "  9MP  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL
M4$L! A0#%     @ VSAZ4#$/(KLZ @  I0<  !D              ( !R7,
M 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " #;.'I0AKN#
M)*$!  "9 P  &0              @ $Z=@  >&PO=V]R:W-H965T<R]S:&5E
M=#0V+GAM;%!+ 0(4 Q0    ( -LX>E 2*)ID$@(  #8&   9
M  "  1)X  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @
MVSAZ4)))I &: @  0 H  !D              ( !6WH  'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6Q02P$"% ,4    " #;.'I0N@F!I>\!  #;!   &0
M            @ $L?0  >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4
M Q0    ( -LX>E"ONXE,^P$  &\%   9              "  5)_  !X;"]W
M;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ VSAZ4!Z8$52-!
M8!D  !D              ( !A($  'AL+W=O<FMS:&5E=',O<VAE970U,2YX
M;6Q02P$"% ,4    " #;.'I0HLIZY^8$  !)&@  &0              @ %(
MA@  >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( -LX>E!_
M89XG20(  )$'   9              "  66+  !X;"]W;W)K<VAE971S+W-H
M965T-3,N>&UL4$L! A0#%     @ VSAZ4,:K9+55 @  M <  !D
M     ( !Y8T  'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -LX>E#\>I8PS@(  % *   9              "
M :.>  !X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ VSAZ
M4'\EF9!! @  + <  !D              ( !J*$  'AL+W=O<FMS:&5E=',O
M<VAE970V,"YX;6Q02P$"% ,4    " #;.'I0 E][IO<#  #\%   &0
M        @ $@I   >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0
M   ( -LX>E"TG=*560(  -T(   9              "  4ZH  !X;"]W;W)K
M<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ VSAZ4&92VRUU @  E @
M !D              ( !WJH  'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q0
M2P$"% ,4    " #;.'I0J%BYOD0%  "N'@  &0              @ &*K0
M>&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( -LX>E"T>$1.
M%@0  %(4   9              "  06S  !X;"]W;W)K<VAE971S+W-H965T
M-C4N>&UL4$L! A0#%     @ VSAZ4)?VC8W[ @  2 T  !D
M ( !4K<  'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " #;
M.'I0(L?8^0$"  # !0  &0              @ &$N@  >&PO=V]R:W-H965T
M<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( -LX>E"%JKLBX0$   $%   9
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M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( -LX>E!CMYH$5 4  -4M   /
M      "  2YW 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #;.'I04?TP
MDT0"  "$*0  &@              @ &O? $ >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " #<.'I0!0U48P$"  "S*   $P
M    @ $K?P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     3@!. %05  !=
%@0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781735840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Status of Restricted Common Stock (Details) - Restricted Common Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of shares, Beginning Balance</a></td>
<td class="nump">1,657,345<span></span>
</td>
<td class="nump">1,658,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriod', window );">Number of shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,336)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod', window );">Number of shares, Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,201)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of shares, Ending Balance</a></td>
<td class="nump">1,657,345<span></span>
</td>
<td class="nump">1,657,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, Vested during period</a></td>
<td class="nump">275,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Unvested as of December 31, 2019</a></td>
<td class="nump">70,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Beginning balance</a></td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageFairValue', window );">Weighted average fair value, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriodWeightedAverageFairValue', window );">Weighted average fair value, Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Ending Balance</a></td>
<td class="nump">0.28<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Vested during period</a></td>
<td class="nump">0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Unvested as of December 31, 2019</a></td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non-option equity instruments grants in period weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non-option equity instruments issued in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non-option equity instruments issued in progress weighted average fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non-option equity instruments repurchased in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriodWeightedAverageFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non-option equity instruments repurchased in period weighted average fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriodWeightedAverageFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non-option equity instruments weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780808992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Convertible Preferred Stock, Non-controlling Interest and Stockholder's Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance of convertible preferred stock, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance of convertible preferred stock, issuance costs</a></td>
<td class="nump">$ 302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795277296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,208,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">165,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="nump">30,844,507<span></span>
</td>
<td class="nump">2,084,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="nump">30,844,507<span></span>
</td>
<td class="nump">2,084,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock , par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">49,296,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">41,857,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">41,857,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock , par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock , par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">64,891,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">62,528,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">62,528,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock , par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6784184992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5. Property and equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment include the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,846</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,109</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,419</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,406</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">306</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,828</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,764</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,066</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,253</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,762</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,511</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized $813 and $654 of depreciation expense for the years ended December&#160;31, 2019 and 2018, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6659951072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling Interest<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">Non-controlling Interest</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Non-controlling Interest</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, the Company issued shares of preferred stock in its subsidiary, Frequency Japan, to a Japanese investor. The Company has consolidated Frequency Japan in the consolidated financial statements and has recorded the proceeds received for the sale of the preferred stock in Frequency Japan as a non-controlling interest in the temporary equity section of the consolidated balance sheets as of December 31, 2018. The liquidation preference of the shares of preferred stock equaled the purchase price of such shares. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Frequency Japan preferred stock held by such investor was convertible, at the option of the holder, into 673,605 shares of Company common stock, adjustable for certain dilutive events, upon an initial public offering of Company common stock, a Company liquidation or upon a 70% vote of the holders of the Preferred Stock. The preferred shares also had a liquidation preference equal to the amount paid for the shares. The Company had the option to acquire the preferred shares of Frequency Japan under certain circumstances and the holder of such preferred shares had the right to require the Company to purchase such shares under certain circumstances, primarily a merger or liquidation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with this sale of the preferred stock in Frequency Japan, FT-FJ Investment, LLC (FT-FJ), a Delaware limited liability company controlled by the Company, purchased 10,000 shares of the Company&#8217;s Series A-1 Preferred Stock and 10,000 shares of the Company&#8217;s Series B-1 Preferred Stock. FT-FJ also granted to the Japanese investor an irrevocable proxy to vote the shares of Series A-1 and Series B-1 Preferred Stock held by FT-FJ. Each share of Series A-1 Preferred had 236 times the voting power of one share of common stock and each share of Series B-1 Preferred Stock has 217 times the voting power of one share of common stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 20, 2019, the Company, Frequency Japan, the Japanese investor, and FT-FJ entered into an agreement pursuant to which, contingent upon the closing of an initial public offering of the Company&#8217;s common stock: (i) the Japanese investor agreed to convert its shares of preferred stock held in Frequency Japan and to terminate its proxy over the shares of Series A-1 and B-1 Preferred Stock held by FT-FJ and (ii) FT-FJ agreed to forfeit its shares of Series A-1 and Series B-1 Preferred Stock. The shares were converted into common stock and the Series A-1 and B-1 preferred shares were forfeited in conjunction with the IPO.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6607795168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Minimum Aggregate Future Operating Lease Commitments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The minimum aggregate future operating lease commitments for the leases noted above are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum&#160;lease</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">commitments</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">504</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,613</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,741</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,883</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,034</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,596</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,371</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6961114912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and employee related expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,686</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,034</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">435</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">322</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party research and development expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">393</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,239</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,749</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6959686352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PropertyAndEquipmentTableTextBlock', window );">Property And Equipment</a></td>
<td class="text">These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</p></td>
</tr>
<tr>
<td valign="top" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of the estimated useful</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">life or lease term</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,237</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> outstanding-basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,649,245</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,530,218</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">702,918</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributed to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> stockholders-basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.29</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12.53</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28.79</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Computation of Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted Common Stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,366</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345,608</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">637,746</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C Preferred (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,172,676</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,759,079</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,214,387</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,070,574</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,283,425</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,283,425</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Frequency Japan preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,047</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">673,605</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,968,672</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,089,334</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">985,521</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,554,414</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,606,359</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,906,692</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6961226048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreement</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15. Collaboration agreement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, the Company entered into a License and Collaboration Agreement with Astellas (the Astellas Agreement), under which the Company granted Astellas an exclusive, royalty-bearing, sub-licensable, nontransferable license to certain patent rights to research, develop, manufacture, have manufactured, use, seek and secure regulatory approval for, commercialize, offer for sale, sell, have sold and import, and otherwise exploit licensed products containing both a GSK-3 inhibitor and an HDAC inhibitor, (the Astellas Licensed Products), including the product candidate FX-322, outside of the United States. The Company also granted Astellas a right of first negotiation and a right of last refusal if it entered into any negotiation or agreement of any kind (other than an acquisition of all of the stock or assets of the Company) with any third party under which such third party would obtain the right to develop, manufacture, or commercialize Astellas Licensed Products in the United States. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has agreed to conduct Phase 2a clinical studies in the United States. Upon the completion thereof, the Company and Astellas have agreed to jointly develop the Astellas Licensed Products, including carrying out joint studies. Each party has agreed to use commercially reasonable efforts to carry out development activities assigned to it under an agreed-upon development plan. Astellas has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in sensorineural hearing loss and in age-related hearing loss, in each case, in one major Asian country and one major European country. The Company has agreed to use commercially reasonable efforts to obtain regulatory approval for at least one Astellas Licensed Product in the United States. Astellas has the sole right to commercialize the Astellas Licensed Products outside of the United States, and the Company has the sole right to commercialize the Astellas Licensed Products in the United States. Astellas has agreed to use commercially reasonable efforts to commercialize Astellas Licensed Products in a major Asian country and a major European country following receipt of regulatory approval in such countries. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collaboration is governed by a joint steering committee (&#8220;JSC&#8221;) established under the Astellas Agreement and shall be comprised of three representatives each from the Company and Astellas. The JSC shall oversee and coordinate the overall conduct of the development, manufacture and commercialization of the Astellas Licensed Products. All decisions of JSC shall be taken through a unanimous vote with each party&#8217;s representatives collectively having one vote. Both the parties shall be responsible for carrying out the development and manufacturing activities in their defined territory in accordance with the plan as reviewed and approved in the JSC. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the licensed rights under the Astellas Agreement, Astellas paid the Company an upfront payment of $80.0&#160;million in July 2019 and has agreed to pay potential development milestone payments up to $230.0&#160;million and commercialization milestones of up to $315.0 million. Specifically, the Company would receive development milestone payments of $65.0. million and $25.0 million upon the first dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively and $100.0 million and $40.0 million upon the first dosing of a patient in a Phase 3 clinical trial for SNHL in Europe and Asia, respectively.  If the Astellas Licensed Products are successfully commercialized, the Company would be eligible for up to $315.0&#160;million in potential commercial milestone payments and also tiered royalties at rates ranging from low- to mid-teen percentages. The parties shall share equally, on a 50/50 basis, all out-of-pocket costs and joint study costs for all the joint activities conducted pursuant to the development plans or the joint manufacturing plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Astellas Agreement remains in effect until the expiration of all royalty obligations. Royalties are paid on a licensed product-by-licensed product and country-by-country basis until the latest of (i)&#160;the expiration of the last valid claim in the licensed patent rights with respect to such Astellas Licensed Product in such country or (ii) a set number of years from the first commercial sale of such Astellas Licensed Product in such country. Astellas may terminate the Astellas Agreement at will upon 60 days&#8217; written notice. Each party has the right to terminate the Astellas Agreement due to the other party&#8217;s material breach if such breach remains uncured for 90 days (or 45 days in the case of nonpayment) or if the other party becomes bankrupt. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Astellas Agreement is a collaborative agreement that is within the scope of ASC 808. The Company analyzed the joint research and development activities to assess whether they fall within the scope of ASC 808, and will reassess this throughout the life of the arrangement based on changes in the roles and responsibilities of the parties. Based on the terms of the arrangement as outlined above, both parties are deemed to be active participants in the collaboration. Both parties are performing research and development activities in their defined territory and will be performing joint clinical studies in accordance with the development plan and the study protocol approved by the JSC. Additionally, Astellas and the Company are exposed to significant risks and rewards dependent on the commercial success of any product candidates that may result from the collaboration. As such, the collaboration arrangement is deemed to be within the scope of ASC 808. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The arrangement consists of two components; the license of IP and the research and development activities, including committee participation, to support the co-development and research plan. Under the provisions of ASC 808, the Company has determined that it will apply the guidance in ASC 606 to recognize the revenue related to the license since that component of the arrangement is more reflective of a vendor-customer relationship. The Company determined that the license and the related research and development services associated with the Phase 2a clinical study were not distinct from one another, as the license has limited value to Astellas without the performance of the research and development activities and the Phase 2a study is essential to the use of the license. As such, the Company determined that these activities should be accounted for as a single combined performance obligation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue associated with this single performance obligation is being recognized as the research and development work is performed, using an input method on the basis of research and development costs incurred to date relative to total research and development costs expected to be incurred. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. The Company has determined that the period of performance of the research and development services began upon the signing of the Astellas Agreement and will continue until the completion of the Phase 2a clinical trial of FX-322. The transaction price of $80.0 million has been allocated to the single combined performance obligation and will be recognized over such period. Management has analyzed the progress of the Phase 2a clinical trial and has estimated the completion date of such trial and the total costs it expects to incur in performing the trial and is recognizing the $80.0 million upfront fee as revenue over the period from July 2019 until the estimated completion date using the input method. The Company regularly assesses its estimates and to the extent that facts and circumstances dictate, the Company revises its estimates of total cost or completion date and accounts for such change on a prospective basis. The estimated completion date of the Phase 2a clinical trial as of December 31, 2019 has changed from the date used for accounting purposes as of September 30, 2019.&nbsp;&nbsp;The Company was required to pay MIT a royalty of $16.0 million on the $80.0 million of sublicense revenues. The $16.0 million royalty was expensed in the third quarter of 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $80.0&#160;million upfront payment received from Astellas in July 2019 was initially recorded as deferred revenue and is being recognized as revenue according to the policy described above. In the year ended December 31, 2019, the Company recorded $28.9 million of revenue under the Astellas Agreement which included $16.0 million related to the royalty payment to MI0T and $12.9 million based upon the application of the input method to the remaining $64.0 million to be recognized over the estimated period to completion of the Phase 2a clinical trial for FX-322. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The potential development and regulatory milestone payments are fully constrained until the Company can conclude that achievement of the milestone is probable and that it is probable that recognition of revenue related to the milestone will not result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is ultimately resolved and as such these have been excluded from the transaction price. As part of its evaluation of the constraint, the Company considers numerous factors, including the fact that achievement of the milestones is outside the control of the Company and contingent upon the future success of clinical trials, the licensee&#8217;s efforts, and the receipt of regulatory approval. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license granted to Astellas and therefore are recognized at the later of when the performance obligation is satisfied, or the related sales of licensed products occur. The Company re-evaluates the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, at each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Astellas Agreement contains joint research and development activities that are not within the scope of ASC 606. The Company will recognize research and development expense related to the joint study costs for all the joint activities in future periods and reimbursements received from Astellas will be recognized as an offset to research and development expense on the consolidated statement of operations during the development period. In the year ended December 31, 2019, the Company received $186 from Astellas for joint costs.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>215</ContextCount>
  <ElementCount>435</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statement of Convertible Preferred Stock, Non-controlling Interest and Stockholder's Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficit</Role>
      <ShortName>Consolidated Statement of Convertible Preferred Stock, Non-controlling Interest and Stockholder's Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statement of Convertible Preferred Stock, Non-controlling Interest and Stockholder's Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementOfConvertiblePreferredStockNonControllingInterestAndStockholderSEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statement of Convertible Preferred Stock, Non-controlling Interest and Stockholder's Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Prepaid Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePrepaidExpenses</Role>
      <ShortName>Prepaid Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Convertible Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureConvertibleNotes</Role>
      <ShortName>Convertible Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Non-controlling Interest</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureNonControllingInterest</Role>
      <ShortName>Non-controlling Interest</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockholdersDeficit</Role>
      <ShortName>Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Employee Stock Purchase Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureEmployeeStockPurchasePlan</Role>
      <ShortName>Employee Stock Purchase Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Income Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTax</Role>
      <ShortName>Income Tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Research and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureResearchAndLicenseAgreements</Role>
      <ShortName>Research and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Collaboration Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCollaborationAgreement</Role>
      <ShortName>Collaboration Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureEmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Selected Quarterly Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSelectedQuarterlyDataUnaudited</Role>
      <ShortName>Selected Quarterly Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Prepaid Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePrepaidExpensesTables</Role>
      <ShortName>Prepaid Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePrepaidExpenses</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureAccruedExpenses</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Stockholders' Deficit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockholdersDeficitTables</Role>
      <ShortName>Stockholders' Deficit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockholdersDeficit</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTax</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Selected Quarterly Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedTables</Role>
      <ShortName>Selected Quarterly Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSelectedQuarterlyDataUnaudited</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Organization and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Summary of Significant Accounting Policies - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Financial Assets Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Prepaid Expenses - Summary of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePrepaidExpensesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses - Summary of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Convertible Notes - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureConvertibleNotesAdditionalInformationDetails</Role>
      <ShortName>Convertible Notes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Non-controlling Interest - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureNonControllingInterestAdditionalInformationDetails</Role>
      <ShortName>Non-controlling Interest - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Stockholders' Deficit - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Deficit - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Stockholders' Deficit - Schedule of Common Stock Shares Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockholdersDeficitScheduleOfCommonStockSharesReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Deficit - Schedule of Common Stock Shares Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity under 2014 Plan and 2019 Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnder2014PlanAnd2019PlanDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Stock Option Activity under 2014 Plan and 2019 Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfGrantDateFairValueOfStockOptionsGrantedOnWeightedAverageBasisDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Stock-based Compensation - Summary of Status of Restricted Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStatusOfRestrictedCommonStockDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Status of Restricted Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Employee Stock Purchase Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureEmployeeStockPurchasePlanAdditionalInformationDetails</Role>
      <ShortName>Employee Stock Purchase Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Research and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureResearchAndLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Research and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Collaboration Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails</Role>
      <ShortName>Collaboration Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Commitments and Contingencies - Schedule of Minimum Aggregate Future Operating Lease Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Minimum Aggregate Future Operating Lease Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Employee Benefit Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="freq-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Selected Quarterly Data (Unaudited) - Schedule of Quarterly Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedScheduleOfQuarterlyFinancialInformationDetails</Role>
      <ShortName>Selected Quarterly Data (Unaudited) - Schedule of Quarterly Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.frequencytx.com/20191231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>freq-20191231.xml</File>
    <File>freq-20191231.xsd</File>
    <File>freq-20191231_cal.xml</File>
    <File>freq-20191231_def.xml</File>
    <File>freq-20191231_lab.xml</File>
    <File>freq-20191231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6962747456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">19. Subsequent events </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated subsequent events for recognition, remeasurement and disclosure purposes through March 26, 2020, the date which the consolidated financial statements were available to be issued. The identified subsequent event is as follows; </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 30, 2020, the World Health Organization declared the coronavirus outbreak a "Public Health Emergency of International Concern" and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The coronavirus and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in<font style="color:#000000;"><br /></font>which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will be to the Company, it is reasonably possible that estimates made in the consolidated financial statements, including the estimated time and costs necessary to complete our performance obligations under the Astellas Agreement, will be materially and adversely impacted in the near term as a result of these<font style="color:#000000;"><br /></font>conditions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6783180864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Data (Unaudited) - Schedule of Quarterly Financial Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 4,709<span></span>
</td>
<td class="nump">$ 24,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingAndNonOperatingExpensesNet', window );">Total expenses</a></td>
<td class="nump">10,202<span></span>
</td>
<td class="nump">24,813<span></span>
</td>
<td class="nump">$ 6,852<span></span>
</td>
<td class="nump">$ 5,826<span></span>
</td>
<td class="nump">$ 5,447<span></span>
</td>
<td class="nump">$ 5,136<span></span>
</td>
<td class="nump">$ 4,436<span></span>
</td>
<td class="nump">$ 4,149<span></span>
</td>
<td class="nump">47,693<span></span>
</td>
<td class="nump">$ 19,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,493)<span></span>
</td>
<td class="num">(575)<span></span>
</td>
<td class="num">(6,852)<span></span>
</td>
<td class="num">(5,826)<span></span>
</td>
<td class="num">(5,447)<span></span>
</td>
<td class="num">(5,136)<span></span>
</td>
<td class="num">(4,436)<span></span>
</td>
<td class="num">(4,149)<span></span>
</td>
<td class="num">(18,746)<span></span>
</td>
<td class="num">(19,168)<span></span>
</td>
<td class="num">$ (20,237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Cumulative Series C preferred stock dividends</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(1,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders</a></td>
<td class="num">$ (5,533)<span></span>
</td>
<td class="num">$ (1,589)<span></span>
</td>
<td class="num">$ (6,852)<span></span>
</td>
<td class="num">$ (5,826)<span></span>
</td>
<td class="num">$ (5,447)<span></span>
</td>
<td class="num">$ (5,136)<span></span>
</td>
<td class="num">$ (4,436)<span></span>
</td>
<td class="num">$ (4,149)<span></span>
</td>
<td class="num">$ (19,800)<span></span>
</td>
<td class="num">$ (19,168)<span></span>
</td>
<td class="num">$ (20,237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders-basic and diluted</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (3.42)<span></span>
</td>
<td class="num">$ (3.24)<span></span>
</td>
<td class="num">$ (3.23)<span></span>
</td>
<td class="num">$ (3.26)<span></span>
</td>
<td class="num">$ (3.01)<span></span>
</td>
<td class="num">$ (3.03)<span></span>
</td>
<td class="num">$ (2.29)<span></span>
</td>
<td class="num">$ (12.53)<span></span>
</td>
<td class="num">$ (28.79)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingAndNonOperatingExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and non-operating expenses net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingAndNonOperatingExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDividendsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDividendsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795357136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Dec. 22, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Net tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Federal and state deferred tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,204,000<span></span>
</td>
<td class="nump">12,229,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal corporate statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit', window );">Income tax expense or benefit in connection with enactment of Tax Cuts and Jobs Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLossDeductionLimitationAsPercentageOfTaxableIncome', window );">Operating loss deduction limitation as percentage of taxable income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PeriodOfCumulativeChangeInOwnership', window );">Period of cumulative change in ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLossCarryforwardsUsageAfterOwnershipChange', window );">Operating loss carryforwards, utilization after ownership change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange', window );">Operating loss carryforwards, utilization after five years after ownership change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange', window );">Operating loss carryforwards, utilization after 15 years thereafter after ownership change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration', window );">Remaining pre ownership change in operating loss carryforwards written off due to expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_CumulativeChangeInOwnershipPercentage', window );">Cumulative change in ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,199,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_NetOperatingLossCarryforwardsExpirationWithLimitation', window );">Net operating loss carryforwards expire through 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation', window );">Net operating loss carryforwards without expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,779,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Internal Revenue Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,123,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,242,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and Development | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 701,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and Development | State | Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 533,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_CumulativeChangeInOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative change in ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_CumulativeChangeInOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_IncomeTaxesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_IncomeTaxesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_NetOperatingLossCarryforwardsExpirationWithLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards expiration with limitation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_NetOperatingLossCarryforwardsExpirationWithLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards expiration without limitation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_NetOperatingLossCarryforwardsExpirationWithoutLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards annual usage for next each after five years and thereafter after ownership change.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLossCarryforwardsAnnualUsageForNextEachAfterFiveYearsAndThereafterAfterOwnershipChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards annual usage for next each five years after ownership change.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLossCarryforwardsAnnualUsageForNextEachFiveYearsAfterOwnershipChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLossCarryforwardsUsageAfterOwnershipChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards Usage After Ownership Change.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLossCarryforwardsUsageAfterOwnershipChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_OperatingLossDeductionLimitationAsPercentageOfTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss deduction limitation as percentage of taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_OperatingLossDeductionLimitationAsPercentageOfTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PeriodOfCumulativeChangeInOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of cumulative change in ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PeriodOfCumulativeChangeInOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining pre ownership change in operating loss carryforwards written off due to expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RemainingPreOwnershipChangeInOperatingLossCarryforwardsWrittenOffDueToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) for remeasurement of deferred tax from change in tax rate pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6798019216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,709<span></span>
</td>
<td class="nump">$ 24,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,784<span></span>
</td>
<td class="nump">$ 11,880<span></span>
</td>
<td class="nump">$ 11,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember', window );">License And Collaboration Agreement | Astellas Pharma LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received under collaboration agreement</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_AgreementTerminationNoticePeriod', window );">Agreement termination notice period</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementIfBreachRemainsUncured', window );">Right to terminate agreement if breach remains uncured</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementIncaseOfNonpayment', window );">Right to terminate agreement incase of nonpayment</a></td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RevenueRecognitionTransactionPrice', window );">Transaction price allocated to single combined performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued upfront payment related to sub License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_UpfrontFeeRecognizedAsRevenue', window );">Upfront fee recognized as revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RevenueFromContractWithCustomerApplicationInputMethod', window );">Revenue from contract with customer application input method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember', window );">License And Collaboration Agreement | Astellas Pharma LLC | Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember', window );">License And Collaboration Agreement | Astellas Pharma LLC | Phase 2b Clinical Trial | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized potential development milestone payments to receive</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember', window );">License And Collaboration Agreement | Astellas Pharma LLC | Phase 2b Clinical Trial | Asia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized potential development milestone payments to receive</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember', window );">License And Collaboration Agreement | Astellas Pharma LLC | Phase 3 Clinical Trial | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized potential development milestone payments to receive</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember', window );">License And Collaboration Agreement | Astellas Pharma LLC | Phase 3 Clinical Trial | Asia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized potential development milestone payments to receive</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember', window );">License And Collaboration Agreement | Maximum | Astellas Pharma LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized potential development milestone payments to receive</a></td>
<td class="nump">230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones', window );">Revenue recognized commercialization milestone payments to receive</a></td>
<td class="nump">315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization', window );">Potential commercial milestone payments eligible to receive upon successful commercialization</a></td>
<td class="nump">$ 315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_AgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_AgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability revenue recognized from commercialization milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RevenueFromContractWithCustomerApplicationInputMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from contract with customer application input method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RevenueFromContractWithCustomerApplicationInputMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition potential commercial milestone payments eligible upon successful commercialization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RevenueRecognitionPotentialCommercialMilestonePaymentsEligibleUponSuccessfulCommercialization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RevenueRecognitionTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RevenueRecognitionTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateAgreementIfBreachRemainsUncured">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right to terminate agreement if breach remains uncured.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateAgreementIfBreachRemainsUncured</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateAgreementIncaseOfNonpayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right to terminate agreement incase of nonpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateAgreementIncaseOfNonpayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_UpfrontFeeRecognizedAsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront fee recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_UpfrontFeeRecognizedAsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=freq_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=freq_AstellasPharmaLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=freq_AstellasPharmaLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=freq_Phase2bClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=freq_Phase2bClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=freq_Phase3ClinicalTrailMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=freq_Phase3ClinicalTrailMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6961167840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, Fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781409648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=freq_LabEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=freq_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Leasehold improvements, estimated useful lives</a></td>
<td class="text">Shorter of the estimated useful
life or lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=freq_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=freq_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=freq_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=freq_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780522432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,746)<span></span>
</td>
<td class="num">$ (19,168)<span></span>
</td>
<td class="num">$ (20,237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive gain:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total comprehensive gain</a></td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (18,692)<span></span>
</td>
<td class="num">$ (19,168)<span></span>
</td>
<td class="num">$ (20,237)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794255616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 20, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001703647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Frequency Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2324450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line</a></td>
<td class="text">19 Presidential Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Woburn<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">01801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">389-1970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FREQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,946,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="margin-bottom:3pt;margin-top:3pt;text-indent:4.86%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the Proxy Statement for the registrant&#8217;s&#160;2020&#160;Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form 10-K.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6784932928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Organization and basis of presentation </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frequency Therapeutics, Inc., together with its wholly owned subsidiaries, Frequency Therapeutics, PTY, LTD, Frequency Therapeutics Securities Corporation and Frequency Therapeutics Japan KK (Frequency Japan) (the Company), headquartered in Woburn, Massachusetts, was incorporated in November 2014 as a Delaware corporation. The Company is a clinical-stage biotechnology company focused on harnessing the body&#8217;s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 20, 2019, the Company effected a 1-for-6.7355 reverse stock split of its common stock. The par value of the common stock was not adjusted as a result of the reverse stock split and the authorized capital was amended to 100,000,000 shares of common stock and 148,724,922 shares of $0.001 par value preferred stock (the Preferred Stock). The reverse stock split resulted in an adjustment to the Series A Convertible  Preferred Stock (Series A Preferred), Series B Convertible Preferred Stock (Series B Preferred) and Series C Convertible Preferred Stock (Series C Preferred) conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. Shares of common stock underlying outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, the Company completed the initial public offering of its common stock (the &#8220;IPO&#8221;). In the IPO, the Company issued and sold 6,325,000 shares of its common stock at a price to the public of $14.00 per share, inclusive of the underwriters&#8217; exercise in part of their over-allotment option. The Company received approximately $79.7 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. In connection with the IPO, on October 7, 2019 all Preferred Stock and the preferred stock of Frequency Japan converted into 22,077,627 shares of common stock and all outstanding shares of Series A-1 Preferred Stock and B-1 Preferred Stock were forfeited.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Uncertainties </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and capital resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has funded its operations primarily with proceeds from the sale of its capital stock, convertible notes and amounts received under a collaboration agreement. The Company has incurred recurring losses since its inception. In addition, as of December&#160;31, 2019, the Company had an accumulated deficit of ($68,888). The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. The Company believes that existing resources will be sufficient to fund planned operations for at least 12 months from the date the financial statements were available to be issued.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795065632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling Interest - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 Preferred Stock | LLC(FT-FJ)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PreferredStockSharesPurchased', window );">Preferred stock, shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock, voting rights</a></td>
<td class="text">Each share of Series A-1 Preferred had 236 times the voting power of one share of common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 Preferred Stock | LLC(FT-FJ)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PreferredStockSharesPurchased', window );">Preferred stock, shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock, voting rights</a></td>
<td class="text">Each share of Series B-1 Preferred Stock has 217 times the voting power of one share of common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Frequency Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred Stock, shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">673,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PercentageOfVoteOfHoldersOfPreferredStock', window );">Voting percentage of preferred stock holder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PercentageOfVoteOfHoldersOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vote of the holders of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PercentageOfVoteOfHoldersOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PreferredStockSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock, shares purchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PreferredStockSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=freq_DelawareLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=freq_DelawareLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781715520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Stock Option Activity under 2014 Plan and 2019 Plan (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Exercised</a></td>
<td class="num">(357,170)<span></span>
</td>
<td class="num">(126,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">$ 5,896<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=freq_TwoThousandAndNineteenIncentiveAwardPlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="nump">1,247,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Ending balance</a></td>
<td class="nump">1,247,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Options exercisable as of December 31, 2019</a></td>
<td class="nump">49,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares, Options unvested as of December 31, 2019</a></td>
<td class="nump">1,197,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">$ 14.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending balance</a></td>
<td class="nump">14.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable as of December 31, 2019</a></td>
<td class="nump">$ 14.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (in years), Outstanding</a></td>
<td class="text">9 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (in years), Options exercisable as of December 31, 2019</a></td>
<td class="text">9 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding as of December 31, 2019</a></td>
<td class="nump">$ 4,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Options exercisable as of December 31, 2019</a></td>
<td class="nump">174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, Options unvested as of December 31, 2019</a></td>
<td class="nump">$ 4,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=freq_TwoThousandAndFourteenStockIncentivePlanMember', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Beginning balance</a></td>
<td class="nump">2,089,334<span></span>
</td>
<td class="nump">985,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="nump">3,015,381<span></span>
</td>
<td class="nump">1,436,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Exercised</a></td>
<td class="num">(357,170)<span></span>
</td>
<td class="num">(126,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, Forfeited</a></td>
<td class="num">(26,211)<span></span>
</td>
<td class="num">(206,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Ending balance</a></td>
<td class="nump">4,721,334<span></span>
</td>
<td class="nump">2,089,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Options exercisable as of December 31, 2019</a></td>
<td class="nump">1,866,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares, Options unvested as of December 31, 2019</a></td>
<td class="nump">2,854,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Beginning balance</a></td>
<td class="nump">$ 0.61<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">4.17<span></span>
</td>
<td class="nump">0.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">1.02<span></span>
</td>
<td class="nump">0.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">1.09<span></span>
</td>
<td class="nump">0.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending balance</a></td>
<td class="nump">2.85<span></span>
</td>
<td class="nump">$ 0.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable as of December 31, 2019</a></td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (in years), Outstanding</a></td>
<td class="text">8 years 10 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (in years), Options exercisable as of December 31, 2019</a></td>
<td class="text">8 years 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding as of December 31, 2019</a></td>
<td class="nump">$ 65,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Options exercisable as of December 31, 2019</a></td>
<td class="nump">26,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, Options unvested as of December 31, 2019</a></td>
<td class="nump">$ 39,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=freq_TwoThousandAndNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=freq_TwoThousandAndNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=freq_TwoThousandAndFourteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=freq_TwoThousandAndFourteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6660111952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity under 2014 Plan and 2019 Plan</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019 Plan</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014 Plan</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">985,520</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.54</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,436,734</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.67</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(126,253</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.54</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(206,667</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.54</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,089,334</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.61</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,247,338</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.09</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,015,381</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(357,170</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.02</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,211</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.09</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,247,338</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.09</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.76</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,287</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,721,334</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.85</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.89</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,051</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,433</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.01</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.75</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,866,700</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.71</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,034</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options unvested as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,197,905</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,113</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,854,634</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Grant-date Fair Value of Stock Options Granted on Weighted Average Basis</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions that the Company used to determine the grant-date fair value of stock options granted to<font style="font-weight:bold;font-style:italic;"> </font>employees and directors were as follows, presented on a weighted average basis: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1%-2.2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% </p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0-7.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Status of Restricted Common Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the status of restricted common stock as of December&#160;31, 2019 and 2018 is presented below: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,658,459</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.27</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,423</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.75</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,336</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.07</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchased</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,201</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,657,345</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.28</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchased</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,657,345</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.28</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested during period</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">275,243</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.26</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,366</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.36</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6784003888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Summary of Prepaid Expenses and Other Current Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent and deposits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">801</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">428</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant receivable</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">805</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,132</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">748</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6622213088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. Stock-based compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November&#160;13, 2014, the Company adopted the 2014 Stock Incentive Plan (2014 Plan). All of the Company&#8217;s employees, officers, directors, and consultants are eligible to be granted options to purchase common shares and restricted stock under the terms of the 2014 Plan. The Company reserved an aggregate of 8,550,415 shares of common stock for issuance under the 2014 Plan. As of December&#160;31, 2019, there were no shares of common stock available for future grants under the 2014 Plan.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 17, 2019, the Company&#8217;s board of directors and on September 19, 2019, its stockholders approved and adopted the 2019 Incentive Award Plan (&#8220;the &#8220;2019 Plan&#8221;) which became effective on the day prior to the IPO.&nbsp;&nbsp;Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock and cash-based awards to individuals who are then employees, officers, directors or consultants of the Company, and employees and consultants of the Company&#8217;s subsidiaries.&nbsp;&nbsp;A total of 3,100,000 shares of common stock were approved to be initially reserved for issuance under the 2019 plan.&nbsp;&nbsp;The number of shares under the 2014 Plan subject to outstanding awards as of the effective date of the 2019 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2019 Plan.&nbsp;&nbsp;In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company&#8217;s common stock on December 31, of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All stock option grants are non-statutory stock options except option grants to employees (including officers and directors) intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Incentive stock options may not be granted at less than the fair market value of the Company&#8217;s common stock on the date of grant, as determined in good faith by the Board of Directors at its sole discretion. Nonqualified stock options may be granted at an exercise price established by the Board of Directors at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Vesting periods are generally four years and are determined by the Board of Directors. Stock options become exercisable as they vest. Options granted under the 2014 Plan and the 2019 Plan expire no more than ten years from the date of grant. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock options </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019 Plan</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014 Plan</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">985,520</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.54</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,436,734</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.67</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(126,253</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.54</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(206,667</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.54</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,089,334</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.61</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,247,338</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.09</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,015,381</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(357,170</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.02</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,211</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.09</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,247,338</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.09</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.76</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,287</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,721,334</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.85</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.89</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,051</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,433</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.01</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.75</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,866,700</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.71</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,034</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options unvested as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,197,905</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,113</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,854,634</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock option valuation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions that the Company used to determine the grant-date fair value of stock options granted to<font style="font-weight:bold;font-style:italic;"> </font>employees and directors were as follows, presented on a weighted average basis: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1%-2.2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% </p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0-7.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.14%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Risk-Fee Interest Rate<font style="font-style:normal;">: The Company based the risk-free interest rate over the expected term of the options based on the constant maturity of U.S. Treasury securities with similar maturities as of the date of the grant.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Term<font style="font-style:normal;">:&nbsp;&nbsp;The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Volatility<font style="font-style:normal;">: The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock.&nbsp;&nbsp;The Company will continue to apply this process until a sufficient amount of historical information regarding volatility of its own stock price options becomes available.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected Dividend Yield<font style="font-style:normal;">: The Company has not paid and does not anticipate paying any dividends in the near future.&nbsp;&nbsp;Therefore, the expected dividend yield was zero.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. During the years ended December&#160;31, 2019 and 2018, 357,170 and 126,253 shares were exercised, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2019 and 2018 was $5,896 and $149 respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value of options granted to employees during the years ended December&#160;31, 2019, 2018 and 2017 was $4.05, $0.47 and $.041, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total grant date fair value of options vested during the years ended December&#160;31, 2019 and 2018 was $2,990 and $244, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted common stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issued common stock to founders, employees and advisors which was subject to vesting over four years. If any of these individuals ceased to be employed or to provide services to the Company prior to vesting, the Company had the right to repurchase any unvested Common Stock at the price paid by the holder. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the status of restricted common stock as of December&#160;31, 2019 and 2018 is presented below: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,658,459</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.27</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,423</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.75</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,336</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.07</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchased</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,201</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,657,345</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.28</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchased</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,657,345</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.28</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested during period</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">275,243</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.26</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested as of December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,366</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.36</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company repurchased 3,201 shares of restricted stock forfeited by a former employee in 2018. The total value of restricted stock awards that vested during the years ended December&#160;31, 2019 and 2018, based on estimated fair values of the stock underlying the restricted stock awards on the day of vesting was $73 and $81, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense of $3,609 and $455 for the years ended December&#160;31, 2019 and 2018 respectively, is included in research and development and general and administrative expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and 2018, total unrecognized stock-based compensation expense relating to unvested stock options was $13,820 and $717, respectively. This amount is expected to be recognized over a weighted-average period of 2.76 years and 2.76 years, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6784223344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Fair value measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial assets measures at fair value on a recurring basis by level within the fair value hierarchy at December 31, 2019 are summarized as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Market</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,131</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,119</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Government treasury securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,131</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,197</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,262</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,316</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had no financial assets subject to fair value reporting requirements at December 31, 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts reflected in the consolidated balance sheet for prepaid expenses and other current assets, accounts payable and accrued expenses and other liabilities are shown at their historical values which approximate their fair values.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6659951072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. Convertible notes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, the Company entered into $5,000 of convertible notes with existing shareholders and investors (Series B Notes) with a maturity date of May&#160;31, 2019. The Series B Notes bore interest at a rate of 5% per annum and were automatically convertible into the security issued in the next financing of at least $5,000, excluding the proceeds of the Series B Notes (Qualified Series B Financing) at a conversion price equal to 95% of the per share price paid by investors in such financing. In the event of a sale of the Company, prior to the conversion or repayment of the Series B Notes at maturity, the Series B Notes would have been repaid at an amount equal to one and one-half times the outstanding principal and interest. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;17, 2018, the Company closed a Qualified Series B Financing and the Series B Notes converted pursuant to their contractual terms. The $5,000 of principal plus $106 of accrued interest were converted into Series B Preferred shares at a 5% discount to the offering price of $0.92 per share resulting in the issuance of 5,839,463 Series B shares and the recognition of a loss on conversion of $269 (see Note 8). For the year ended December&#160;31, 2018, the Company recorded $106 in interest expense on the Series B Notes. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2015 and 2016, the Company entered into $14,285 of convertible notes with investors (Series A Notes) with a maturity date of January&#160;21, 2017, which was extended to April&#160;30, 2017. The Series A Notes bore interest at a rate of 5% per annum and were automatically convertible into the security issued in the next financing in excess of $4,000 (Qualified Series A Financing) at a conversion price equal to 80% of the per share price paid by investors in such financing. If, prior to the Company completing a Qualified Series A Financing, the Company received funds in excess of $15,000 pursuant to a non-equity financing, grant or other similar event, then the Company would have obtained an outside valuation and thereafter the Series A Notes would have automatically converted into shares of common stock of the Company, at a 20% discount to such valuation. In the event of a sale of the Company, prior to conversion or repayment of the Series A Notes at maturity, the Series A Notes would have been repaid at an amount equal to three times the outstanding principal and interest. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;30, 2017, the Company closed a Qualified Series A Financing and the Series A Notes converted pursuant to their contractual terms. The $14,285 of principal plus $709 of accrued interest were converted into Series A Preferred shares at a 20% discount to the offering price of $0.75 per share resulting in the issuance of 24,990,086 Series A Preferred shares and the recognition of a loss on conversion of $3,749 (see Note 8). For the year ended December&#160;31, 2017, the Company recorded $174 in interest expense on the Series A Notes. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Series A Notes and Series B Notes did not contain an optional conversion feature. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluated all the settlement features included within the Series A Notes and Series B Notes, noting that none of the features was considered to be predominant or met the definition of a derivative under FASB ASC Topic 815, <font style="font-style:italic;">Derivatives and Hedging</font> with the exception of the repayment premium in the event of a Company sale. In such event the noteholders were entitled to receive an amount equal to three times the outstanding principal, in the case of Series A Notes, and one and one half and three times the outstanding principal, in the case of the Series B Notes, plus all accrued and unpaid interest. Based on the qualitative and quantitative considerations, management determined that the fair value of the derivative was de minimis as of December&#160;31, 2017. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794671504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (18,746)<span></span>
</td>
<td class="num">$ (19,168)<span></span>
</td>
<td class="num">$ (20,237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">3,609<span></span>
</td>
<td class="nump">455<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">813<span></span>
</td>
<td class="nump">654<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">3,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of common stock for license agreement</a></td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DeferredLeaseIncentives', window );">Deferred lease incentives</a></td>
<td class="num">(160)<span></span>
</td>
<td class="num">(159)<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,253)<span></span>
</td>
<td class="num">(727)<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(644)<span></span>
</td>
<td class="nump">869<span></span>
</td>
<td class="num">(231)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">51,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,490<span></span>
</td>
<td class="nump">677<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">34,215<span></span>
</td>
<td class="num">(17,024)<span></span>
</td>
<td class="num">(14,614)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,064)<span></span>
</td>
<td class="num">(436)<span></span>
</td>
<td class="num">(1,863)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Redemption of available for sale securities</a></td>
<td class="num">(282,618)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of available for sale securities</a></td>
<td class="nump">265,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(18,261)<span></span>
</td>
<td class="num">(436)<span></span>
</td>
<td class="num">(1,863)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Proceeds from sale of non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">80,062<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">142,015<span></span>
</td>
<td class="nump">41,712<span></span>
</td>
<td class="nump">27,978<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">157,969<span></span>
</td>
<td class="nump">24,252<span></span>
</td>
<td class="nump">11,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash at beginning of year</a></td>
<td class="nump">42,189<span></span>
</td>
<td class="nump">17,937<span></span>
</td>
<td class="nump">6,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash at end of year</a></td>
<td class="nump">200,158<span></span>
</td>
<td class="nump">42,189<span></span>
</td>
<td class="nump">17,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_CashPaidDuringPeriodForAbstract', window );"><strong>Cash paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Taxes</a></td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible notes payable and accrued interest into convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,375<span></span>
</td>
<td class="nump">18,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_NonCashDividendOnCumulativeConvertiblePreferredStock', window );">Cumulative Series C convertible preferred stock dividends</a></td>
<td class="nump">1,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of preferred stock and non-controlling interest into common stock</a></td>
<td class="nump">151,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,951<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">32,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="nump">$ 61,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_CashPaidDuringPeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid during the year for.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_CashPaidDuringPeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DeferredLeaseIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred lease incentives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DeferredLeaseIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_NonCashDividendOnCumulativeConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash dividend on cumulative convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_NonCashDividendOnCumulativeConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for (proceeds from) sale of available for sale securities debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PaymentForProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791647600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 28,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">18,784<span></span>
</td>
<td class="nump">$ 11,880<span></span>
</td>
<td class="nump">$ 11,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">14,838<span></span>
</td>
<td class="nump">7,064<span></span>
</td>
<td class="nump">4,340<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">49,622<span></span>
</td>
<td class="nump">18,944<span></span>
</td>
<td class="nump">16,306<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(20,675)<span></span>
</td>
<td class="num">(18,944)<span></span>
</td>
<td class="num">(16,306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense)</a></td>
<td class="nump">1,784<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="num">(174)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(269)<span></span>
</td>
<td class="num">(3,749)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized gain on investments</a></td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain (loss)</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,746)<span></span>
</td>
<td class="num">(19,168)<span></span>
</td>
<td class="num">(20,237)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Cumulative Series C preferred stock dividends</a></td>
<td class="num">(1,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders</a></td>
<td class="num">$ (19,800)<span></span>
</td>
<td class="num">$ (19,168)<span></span>
</td>
<td class="num">$ (20,237)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders-basic and diluted</a></td>
<td class="num">$ (2.29)<span></span>
</td>
<td class="num">$ (12.53)<span></span>
</td>
<td class="num">$ (28.79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares of common stock outstanding-basic and diluted</a></td>
<td class="nump">8,649,245<span></span>
</td>
<td class="nump">1,530,218<span></span>
</td>
<td class="nump">702,918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDividendsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDividendsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795567872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 17, 2018</div></th>
<th class="th"><div>Mar. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jul. 17, 2019</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,208,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,891,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued shares</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred stock, net proceeds from shares issued</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Preferred stock issued price per share</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,296,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued shares</a></td>
<td class="nump">7,544,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,857,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,991<span></span>
</td>
<td class="nump">288,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred stock, net proceeds from shares issued</a></td>
<td class="nump">$ 6,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance of convertible preferred stock, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_TemporaryEquityAdditionalSharesIssued', window );">Preferred stock, additional shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,473,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_TemporaryEquityAdditionalSharesIssuedCarryingAmountAttributableToParent', window );">Preferred stock, net proceeds from additional shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock | Series B Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">$ 106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares issued upon conversion</a></td>
<td class="nump">5,839,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DebtInstrumentConvertibleDiscountOnConversionPrice', window );">Discount rate on offering price</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Offering price per share</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember', window );">Series B-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued shares</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred stock, net proceeds from shares issued</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Preferred stock issued price per share</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,891,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,783,522<span></span>
</td>
<td class="nump">62,528,507<span></span>
</td>
<td class="nump">27,754,899<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred stock, net proceeds from shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,338<span></span>
</td>
<td class="nump">$ 46,694<span></span>
</td>
<td class="nump">$ 20,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance of convertible preferred stock, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Series A Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,990,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DebtInstrumentConvertibleDiscountOnConversionPrice', window );">Discount rate on offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=freq_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,492,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,492,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred stock, net proceeds from shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DebtInstrumentConvertibleDiscountOnConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument convertible discount on conversion price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DebtInstrumentConvertibleDiscountOnConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_TemporaryEquityAdditionalSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity additional shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_TemporaryEquityAdditionalSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_TemporaryEquityAdditionalSharesIssuedCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity additional shares issued carrying amount attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_TemporaryEquityAdditionalSharesIssuedCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=freq_SeriesBNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=freq_SeriesBNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesB1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=freq_SeriesANotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=freq_SeriesANotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=freq_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=freq_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796606608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 17, 2019</div></th>
<th class="th"><div>Nov. 13, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="nump">7,828,326<span></span>
</td>
<td class="nump">19,288,847<span></span>
</td>
<td class="nump">10,915,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">357,170<span></span>
</td>
<td class="nump">126,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="nump">$ 5,896<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of stock options granted</a></td>
<td class="nump">4.05<span></span>
</td>
<td class="nump">0.47<span></span>
</td>
<td class="nump">$ 0.041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Total grant date fair value of stock options vested</a></td>
<td class="nump">$ 2,990<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized stock-based compensation expense relating to unvested stock options</a></td>
<td class="nump">$ 13,820<span></span>
</td>
<td class="nump">$ 717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized unvested stock options, weighted-average period</a></td>
<td class="text">2 years 9 months 3 days<span></span>
</td>
<td class="text">2 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod', window );">Number of shares, Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total value of restricted stock awards, vested based on estimated fair value of stock</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=freq_TwoThousandAndFourteenStockIncentivePlanMember', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,550,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares available for future grants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">357,170<span></span>
</td>
<td class="nump">126,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=freq_TwoThousandAndNineteenIncentiveAwardPlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of authorized shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance', window );">Period for automatic increase in common stock available for future issuance</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of shares issued from outstanding number of shares</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Common stock future issuance, description</a></td>
<td class="text">In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company&#8217;s common stock on December 31, of the preceding calendar year or such lesser amount as determined by the Company&#8217;s board of directors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for automatic increase in common stock available for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non-option equity instruments repurchased in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsRepurchasedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=freq_TwoThousandAndFourteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=freq_TwoThousandAndFourteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=freq_TwoThousandAndNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=freq_TwoThousandAndNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6784077456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2019, 2018 and 2017 is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S federal statutory income tax rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of federal rate change</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other items</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in deferred tax asset valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26.3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25.9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s deferred tax assets at December&#160;31, 2019 and 2018 consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,253</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,710</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,138</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,014</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangibles</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">358</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">686</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">496</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax asset</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,204</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,229</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,204</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,229</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6622296928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment include the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,846</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,109</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,419</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,406</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">306</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,828</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,764</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,066</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,253</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,762</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,511</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6961225760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of significant accounting policies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB <font style="font-style:italic;">Accounting Standards</font> Codification (ASC). </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of consolidation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of Frequency Therapeutics, Inc. and its wholly owned subsidiaries Frequency Therapeutics PTY, LTD and Frequency Japan (majority owned at December 31, 2018). All intercompany transactions and balances have been eliminated. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company&#8217;s management evaluates its estimates, which include but are not limited to management&#8217;s judgments of accrued expenses, revenue, fair value of common stock, valuation of share-based awards and income taxes. Actual results could differ from those estimates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes significant estimates and assumptions in determining the fair value of its common stock in periods prior to the IPO. The Company had utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation (the Practice Aid), to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive income (loss) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Other comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders which for the year ended December 31, 2019 consists of unrealized gain on marketable securities.&nbsp;&nbsp;There were no elements of comprehensive loss for the years ended December 31, 2018 and 2017.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company&#8217;s chief operating decision-maker, the Company&#8217;s chief executive officer, views the Company&#8217;s operations and manages its business as a single operating segment, which is in the business of discovering and developing small molecule drugs that activate progenitor cells within the body to create healthy tissue. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign currency </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All periods presented are reported in US dollars. The functional currency for entities outside the United States is the US dollar. Realized and unrealized gains and losses from foreign currency transactions are reflected in the consolidated statements of operations as other expense. During the years ended December&#160;31, 2019, 2018 and 2017 the Company recorded $7, $151 and ($8) of foreign currency exchange gains (losses), respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and cash equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with an original maturity of six months or less at acquisition to be cash equivalents which are stated at fair market value. Cash and cash equivalents at December&#160;31, 2019 and 2018 consists entirely of cash held in banks and money market funds. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;">Short-term marketable debt securities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company&#8217;s investment policy. Short-term marketable investment mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders&#8217; equity (deficit) until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, together with interest on securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investment are reflected as a component of other income (expense).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities at December 31, 2019 consist of investment in U.S. Treasury Securities.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;">Concentration of credit risk and off-balance sheet risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instrument that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents at several accredited financial institutions, in amounts that exceed federally insured limits. Marketable securities consist of U.S. Treasury securities with maturities of less than twelve months. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which its money market accounts are maintained.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Significant suppliers </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a single manufacturer of its product candidates for use in clinical trials. The Company would be adversely affected by a significant interruption in the supply of product for use in clinical programs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair value measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic&#160;820, <font style="font-style:italic;">Fair Value Measurement</font> (ASC&#160;820), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quoted prices in active markets for identical assets or liabilities.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable, &nbsp;&nbsp;&nbsp;&nbsp;such as quoted market prices, interest rates and yield curves.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of lab equipment, computer equipment, furniture and office equipment and leasehold improvements recorded at cost. These amounts are depreciated using the straight-line method over the estimated useful lives of the assets as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.38%;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</p></td>
</tr>
<tr>
<td valign="top" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" style="width:72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:27%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of the estimated useful</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">life or lease term</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the consolidated statements of operations.</p></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of long-lived assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development costs and accruals </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses include salaries and benefits, materials and supplies, preclinical and clinical trial expenses, stock-based compensation expense, depreciation of equipment, contract services and other outside expenses. The Company has entered into various research and development-related contracts with research institutions, contract research organizations, contract manufacturers and other companies. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. Costs of certain development activities, such as manufacturing, pre-clinical and clinical trial expenses, are recognized based on an evaluation of the progress to completion of specific tasks. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Collaborative arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company analyzes its collaborative arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements (&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship (e.g., a licensing arrangement) where the contracted party has obtained goods or services that are an output of the Company&#8217;s ordinary activities in exchange for a consideration and therefore within the scope of Topic 606. For those elements of the arrangement that are accounted for pursuant to Topic 606, including those to which Topic 606 is applied by analogy, the Company applies the five-step model described in the Company&#8217;s revenue recognition policy. For elements of collaborative arrangements that are accounted for pursuant to ASC 808, an appropriate and rational recognition method is determined and applied consistently. Reimbursements from the counterparty that are the result of a collaborative relationship with the counterparty, instead of a customer relationship, such as co-development or clinical activities, are recorded as a reduction to research and development expense as the services are performed. Similarly, amounts that are owed to a collaboration partner related to the co-development clinical activities are recognized as research and development expense. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into out-licensing agreements that are within the scope of Topic 606. The terms of such out-license agreements include licenses to functional intellectual property (IP), given the functionality of the intellectual property is not expected to change substantially as a result of the licensor&#8217;s ongoing activities. Such arrangements typically include payment of one or more of the following: non-refundable up-front license fees; reimbursement of certain costs; development and regulatory milestone payments and milestone payments based on the level of sales; and royalties on net sales of licensed products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers the economic and regulatory characteristics of the licensed IP, research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace to determine if it has standalone value at the inception of the licensing arrangement, which would make the license distinct. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of any additional good or services promised in the contract, whether the value of the license is dependent on the remaining goods and services, whether there are other vendors that could provide the remaining promise, and whether the license is separately identifiable from the remaining good and services. For licenses that are combined with other goods and services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue is allocated to the licensed IP on a relative standalone selling price basis and, for functional IP, is recognized at a point when the licensed IP is made available for the customer&#8217;s use and benefit, which generally occurs at the inception of the arrangement. However, in cases, where the functionality of the IP is expected to substantively change as a result of activities of the Company that do not transfer additional promised goods or services, or in cases, where there is an expectation that the Company will undertake activities to change the standalone functionality of the IP and the customer is contractually or practically required to use the latest version of the IP, revenue for the license to functional IP is recognized over time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development and regulatory milestone fees, which are a type of variable consideration, are recognized as revenue to the extent that it is probable that a significant reversal will not occur. The Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into a collaboration arrangement with Astellas Pharma Inc. (&#8220;Astellas&#8221;), as further described in Note 15 of notes to unaudited consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for contracts with customers in accordance with Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;), including all amendments thereto. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as collaborative arrangements and leases. The Company&#8217;s disclosure within the below sections or elsewhere within these consolidated financial statements reflects the Company&#8217;s accounting policies in compliance with this new standard.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Topic 606, an entity recognizes revenue when or as its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To recognize revenue for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies its performance obligations. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and identifies as a performance obligation each promise to transfer to the customer either (a) a good or service (or bundle of goods and services) that is distinct, or (b) a series of distinct goods and services that are substantially the same and have been the same pattern of transfer to the customer.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&#160;the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, manufacturing and commercialization capabilities of the collaboration partner (the &#8220;customer&#8221; in this type of arrangement) and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct. For each arrangement that results in revenues, the Company identifies all performance obligations, which may include, for example, a license to IP and know-how, research and development activities, and/or manufacturing services. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to any upfront payment, if the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the estimated variable consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or of the licensee such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For contracts that include sales-based royalties (including milestone payments based on the level of sales) promised in the exchange for licenses of intellectual property, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestone payments at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money if the timing of payments provides the Company or the Company&#8217;s customer with a significant benefit of financing the transfer of goods and services. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less. The Company assesses each of its revenue generating arrangements in order to determine whether a significant financing component exists. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time.&nbsp;&nbsp;For performance obligations satisfied over time, the Company measures progress toward completion of its performance obligations using an input method based on the Company&#8217;s efforts and inputs to satisfy its performance obligations relative to total expected inputs to the satisfaction of that performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received from a customer prior to revenue recognition are recorded as deferred revenue. Amounts received from a customer that are expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability in the accompanying consolidated balance sheets.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for its stock-based compensation in accordance with ASC Topic&#160;718, <font style="font-style:italic;">Compensation&#8212;Stock Compensation</font> (ASC&#160;718). ASC&#160;718 requires all share-based payments to employees and directors to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company adopted FASB Accounting Standards Update (ASU) 2016-09 which identifies areas for simplification of several areas of share-based payment transactions. The Company retroactively applied the mark to market approach on vesting to non-employee grants and the impact on the consolidated financial statements was not material and as such, the Company will treat non-employee grants the same as employee grants. The Company estimates the fair value of options granted using the Black-Scholes option pricing model for stock option grants to both employees and non-employees. The Company believes the fair value of the stock options granted to non-employees is more reliably determinable than the fair value of the services provided. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a)&#160;the expected stock price volatility, (b)&#160;the expected term of the award, (c)&#160;the risk-free interest rate and (d)&#160;expected dividends. Due to the lack of sufficient company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the contractual term of the share-based payment as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s common stock prior to the IPO. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses the fair value of its share-based compensation awards to employees and non-employees on a straight-line basis over the requisite service period, which is generally the vesting period. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Non-controlling interest </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2018, the Company accounted for shares of preferred stock issued in Frequency Japan as a non-controlling interest in the mezzanine section of the consolidated balance sheets. The value ascribed to the non-controlling interest was the liquidation preference of the preferred stock in Frequency Japan as the holders of such shares do not share in any profits or losses of the subsidiary. <font style="color:#000000;">In connection with the IPO, all preferred stock of Frequency Japan converted into shares of the Company&#8217;s common stock, see Note 1.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, <font style="font-style:italic;">Income Taxes</font> (ASC 740) which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December&#160;31, 2019 and 2018, the Company has concluded that a full valuation allowance is necessary for its deferred tax assets (see Note 13). </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net loss per share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&#160;31, 2019, 2018 and 2017 since all potential shares of common stock instruments are anti-dilutive as a result of the loss for such periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses are not allocated to such participating securities. In periods where the Company reported a net loss attributable to common stockholders, diluted net loss per share is the same as basic net loss per share, since dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December&#160;31, 2019, 2018 and 2017.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,168</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,237</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> outstanding-basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,649,245</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,530,218</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">702,918</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributed to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> stockholders-basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.29</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12.53</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28.79</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted Common Stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,366</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345,608</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">637,746</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C Preferred (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,172,676</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,759,079</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,214,387</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,070,574</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,283,425</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,283,425</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Frequency Japan preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,047</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">673,605</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,968,672</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,089,334</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">985,521</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,554,414</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,606,359</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,906,692</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently adopted accounting pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU 2014-09, <font style="font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font>. The standard will apply one comprehensive revenue recognition model across all contracts, entities, and sectors. The core principle of the new standard is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Once effective, ASU 2014-09 will replace most of the existing revenue recognition requirements in U.S. GAAP. The FASB also issued ASU 2015-14, <font style="font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font>, which deferred the effective date of the standard one year. As a result, the new standard is effective for annual reporting periods beginning after December&#160;15, 2018, including interim periods within the reporting period. Early adoption is permitted. The Company early adopted ASU 2014-09 effective January&#160;1, 2018, and its adoption had no impact on the Company&#8217;s consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2016, the FASB issued ASU No.&#160;2016-15, <font style="font-style:italic;">Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments</font> (ASU No.&#160;2016-15). This guidance addresses the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. The standard is effective for annual periods beginning after December&#160;15, 2017 and for interim periods within those fiscal years. Early adoption is permitted. The Company adopted this standard effective January&#160;1, 2018. The adoption of ASU No.&#160;2016-15 did not have a material impact on the Company&#8217;s consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, the FASB issued ASU No.&#160;2017-09, <font style="font-style:italic;">Compensation-Stock Compensation (Topic&#160;718): Scope of Modification Accounting</font> (ASU No.&#160;2017-09). This update clarifies the changes to terms or conditions of a share-based payment award that require an entity to apply modification accounting. ASU No.&#160;2017-09 is effective for annual reporting periods, and interim periods therein, beginning after December&#160;15, 2017. Early application is permitted, and prospective application is required. The Company adopted this standard effective January&#160;1, 2018. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently issued accounting pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued <font style="font-style:italic;">ASU No. 2016-02, Leases</font>, which is intended to increase transparency and comparability among companies that enter into leasing arrangements. The new standard establishes a right-of-use model that requires a lessee to record a right-of-use asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either financing or operating, with classification affecting the pattern of expense recognition. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. In July 2018, the FASB <font style="font-style:italic;">issued ASU No. 2018-11,</font> with targeted improvements to the guidance including an additional transition method, which allows companies to apply the provisions of the new leasing standard as of January 1, 2020, without adjusting the comparative periods presented by recognizing a cumulative-effect adjustment to the opening balance of retained earnings.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company plans to elect early adoption of this standard effective January 1, 2020 and elect the new transition method approved by the FASB. The Company also plans to elect the package of practical expedients intended to ease transition whereby the Company need not assess (1) whether any expired or existing contracts are or contain leases, (2) the lease classification for any expired or existing leases and (3) initial direct costs for any existing leases. Furthermore, the Company will elect the practical expedient to combine non-lease components and lease components. As the Company finalizes its adoption processes, it estimates the adoption of the ASU in the first quarter of 2020 will result in the recognition of a right-of-use asset and related lease liability related to the lease for our Woburn Massachusetts facility in the range of approximately $1,000 to $2,000 with an estimated immaterial effect to the retained earnings and the consolidated statement of operations. As disclosed in Note 16, the Company has entered into a lease for a facility in Lexington Massachusetts which has an estimated commencement date of December 1, 2020. In accordance with ASU No. 2016-02, the Company will recognize a right-of-use asset and related lease liability at such time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6720085312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. Accrued expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and employee related expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,686</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,034</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">435</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">322</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party research and development expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">393</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,239</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,749</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6961291952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Deficit</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Stockholders&#8217; deficit </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common stock </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has authorized 100,000,000 shares of $0.001 par value common stock of which 30,844,507 were issued and outstanding as of December 31, 2019. Common shares are voting, and dividends may be paid when, as and if declared by the Board of Directors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 20, 2019, the Company effected a 1-for-6.7355 reverse stock split of its common stock. The par value of the common stock was not adjusted as a result of the reverse stock split and the authorized capital was amended to 100,000,000 shares of common stock and 148,724,922 shares of $0.001 par value preferred stock. The reverse stock split resulted in an adjustment to the Series A Preferred, Series B Preferred and Series C Preferred conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reserved the following shares of common stock for future issuance as of December 31, 2019, 2018 and 2017:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A Preferred conversion</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,283,425</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,283,425</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Frequency Japan preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">673,605</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred conversion</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,214,387</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,968,672</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,089,334</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">985,521</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future grant under stock option plan</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,859,654</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,028,096</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">646,871</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,828,326</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,288,847</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,915,817</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6784187312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research And Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_ResearchAndLicenseAgreementsDisclosureTextBlock', window );">Research and License Agreements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14. Research and license agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Massachusetts Institute of Technology </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, the Company entered into an exclusive patent license agreement (MIT License Agreement), with the Massachusetts Institute of Technology, (MIT), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products (Licensed Products) and to develop and perform processes (Licensed Processes) which incorporate the licensed technology for the treatment of disease, including but not limited to the prevention and remediation of hearing loss. The Company also has the right to grant sublicenses of its rights under the MIT License Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to use diligent efforts to develop and commercialize the Licensed Products or Processes, and to make such products or processes reasonably available to the public and to spend certain minimum amounts on research and development of Licensed Products and/or Processes each year until the first commercial sale of a Licensed Product and/or a first commercial performance of a Licensed Process. The Company is also subject to certain development obligations with regards to a first Licensed Product. The Company has satisfied certain obligations related to preclinical studies and the filing of an IND for a first Licensed Product with its development activities related to FX-322. The Company&#8217;s future development obligations are: (i) to commence a Phase II clinical trial for such Product, (ii) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product within two years of the IND filing for such product, (iii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such product, and (iv) to make a first commercial sale of such Product within 11 years of the IND filing for such product. The Company also has certain development obligations for as second Licensed Product. In the event that the Company has failed to fulfill the development timeline obligation with respect to a second Licensed Product and fail to cure such breach within ninety (90)&#160;days of written notice by MIT, MIT may restrict the licensed field to the prevention and remediation of hearing loss in humans and animals. The Company does not have the right to control prosecution of the in-licensed patent applications, and its rights to enforce the in-licensed patents are subject to certain limitations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering into the MIT License Agreement, the Company paid a $50 license fee payment and issued to MIT shares of our common stock equal to 5% of total then-outstanding capital stock. The Company is required to pay certain annual license maintenance fees which may be credited to running royalties during the same calendar year, if any, and to make potential milestone payments up to $2,900 on each Licensed Product or Licensed Process. In addition, The Company is required to pay a low single-digit royalty on Licensed Products and Licensed Processes and a low-twenties royalty on sublicense revenues. In the year ended December 31, 2019 the Company paid MIT a royalty of $16,000 related to the upfront payment received from Astellas, see Note 15.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The MIT License Agreement will remain effect until the expiration or abandonment of all issued patents and filed patent applications licensed thereunder remain in effect, unless terminated earlier. The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company&#8217;s material breach uncured within ninety (90)&#160;days (or thirty (30)&#160;days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30)&#160;days after MIT&#8217;s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, the Company entered into an amendment with MIT, updating the diligence milestones for a second Licensed Product. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">California Institute for Biomedical Research </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, the Company entered into a license agreement, (CALIBR License Agreement), with the California Institute for Biomedical Research, (CALIBR), under which the Company received an exclusive, worldwide, royalty-bearing license to certain patent rights to make, have made, use, sell, offer to sell, and import products (CALIBR Licensed Products) which incorporate the licensed technology for the treatment of multiple sclerosis. The Company also have the right to grant sublicenses of our rights under the CALIBR License Agreement. CALIBR reserves the right to use for itself and the right to grant non-exclusive licenses to other nonprofit or academic institutions, for any internal research and educational purposes. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to use commercially reasonable efforts to develop, manufacture, and sell at least one Licensed Product and does not have the right to control prosecution of the in-licensed patent applications, and to enforce the in-licensed patents are subject to certain limitations. The Company is also subject to certain milestone timeline obligations to: (i) submit an IND (or equivalent) for a CALIBR Licensed Product by the 30th month after the effective date of the CALIBR License Agreement, (ii) initiate a Phase II clinical trial (or equivalent) for a CALIBR Licensed Product by the fourth anniversary of the effective date of the CALIBR License Agreement, and (iii) initiate a Phase III clinical trial (or equivalent) for a CALIBR Licensed Product by the sixth anniversary of the effective date of the CALIBR License Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering into the CALIBR License Agreement, the Company made a $1,000 license fee payment and are required to make milestone payments up to $26,000 for each Category of CALIBR Licensed Products (Category 1 means any CALIBR Licensed Products containing a compound that modulates any muscarinic receptor and Category 2 means any CALIBR Licensed Products not included in Category 1 that could differentiate oligodendrocyte precursors) . The Company is also required to pay a middle single-digit royalty on CALIBR Licensed Products and a royalty on sublicense revenues ranging from low-teen percentage to 50%. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CALIBR License Agreement shall continue in effect until expiration of all Company obligations to pay royalties. Royalties shall be payable on a country-by-country and CALIBR Licensed Product-by-CALIBR Licensed Product basis upon the later of (1)&#160;the expiration or abandonment of all valid claims of the licensed patent rights in such country and (2)&#160;ten years from the first commercial sale of each CALIBR Licensed Product. The Company may terminate the CALIBR License Agreement at will upon a 30-day prior written notice. The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90)&#160;days&#8217; prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30)&#160;days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Massachusetts Eye and Ear Infirmary </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, the Company entered into an Non-Exclusive Patent License Agreement (MEEI License Agreement) with the Massachusetts Eye and Ear Infirmary (MEEI) under which it received a non-exclusive, non-sublicensable, worldwide, royalty-bearing license to certain patent rights to develop, make, have made, use, sell, offer to sell, lease and import products and to develop and perform processes which incorporate the licensed technology for the treatment or prevention of hearing loss. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to use diligent efforts to develop and commercialize the licensed products and MEEI has control over the filing, prosecution, enforcement and defense of any licensed patent rights. The Company is also subject to milestone timeline obligations to dose a first patient in a Phase II trial by December&#160;31, 2020 and to dose a first patient in a Phase III trial by December&#160;31, 2024. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering into the MEEI License Agreement, the Company made a $20 license fee payment and is required to pay certain annual license maintenance fees until the first commercial sale and a minimum annual royalty payment after the first commercial sale. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also required to make milestone payments up to $350 on each product or process which incorporates the licensed patent rights and pay a low single-digit royalty on products and processes that incorporate the licensed patent rights. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The MEEI License Agreement shall remain in effect until all issued patents and filed patent applications within the licensed patent rights have expired or been abandoned, unless terminated earlier. The Company has the right to terminate the MEEI License Agreement at will by giving thirty (30)&#160;business days advance written notice to MEEI. MEEI has the right to terminate the MEEI License Agreement if the Company fails to make any payment due within thirty (30)&#160;business days after MEEI notifies the Company of such failure. MEEI shall have the right to terminate if the Company fails to maintain the required insurance. MEEI shall also have the right to terminate the MEEI License Agreement upon forty-five (45)&#160;business days written notice if the Company becomes insolvent. MEEI has the right to terminate for any other default not cured within sixty (60)&#160;business days written notice. MEEI also has the right to terminate if the Company or its affiliates challenge the validity of the licensed patent rights. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cambridge Enterprise Limited</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.14%;">In December 2019, we entered into an Exclusive Patent License Agreement ( the &#8220;Cambridge License&#8221;) with Cambridge Enterprise Limited (the technology transfer arm of the University of Cambridge)<font style="font-size:12pt;"> </font>(&#8220;Cambridge&#8221;) under which we received an executive worldwide royalty-bearing license to certain patent rights to make, have made, sell, offer to sell and import products, or the (the &#8220;Cambridge License Product&#8221;) which incorporate licensed technology for the treatment of demyelinating diseases.&nbsp;&nbsp;We also have the right to grant nonexclusive licenses to other academic institutions for any academic publication, research and teaching and clinical patient care.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.14%;">We have agreed to use diligent and good faith efforts to develop and commercially exploit at least one Cambridge Licensed Product.&nbsp;&nbsp;Upon entering into the Cambridge License, we made a $50 license fee payment.&nbsp;&nbsp;We are obligated to pay an annual license fee of $50. We are also obligated to make milestone payments up to $10.5 million on each Cambridge License Product.&nbsp;&nbsp;In addition, we have agreed to pay a low single-digit royalty on products that incorporate the licensed patent rights, subject to offset in certain circumstances. </p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.14%;">The Cambridge License continues in effect on a country-by-country basis until the expiration or revocation, without right of further appeal, of all licensed issued patents and filed patent applications, unless terminated earlier.&nbsp;&nbsp;We have the right to terminate for any reason upon 90 days&#8217; prior to written notice.&nbsp;&nbsp;Each party has the right to terminate immediately if the other party ceases to carry on its business.&nbsp;&nbsp;Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days.&nbsp;&nbsp;Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge Licensed Product or we or our affiliates or sub-licenses commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Department of Defense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the Company received a grant (the Grant) from the Department of Defense (DoD) under which the Company is receiving funding to further the Company&#8217;s research and development of a therapeutic drug to treat hearing loss. The Company is receiving funding of $1,596 over two years from the date of the Grant. The Company has determined that the DoD is not considered a customer under ASC Topic 606, therefore funding received from the DoD under the Grant is recorded as a reduction of research and development expenses. The Company has recorded $845 and $428 as a reduction in research and development expenses for the years ended December&#160;31, 2019 and 2018, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_ResearchAndLicenseAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and license agreements disclosure text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_ResearchAndLicenseAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6961323536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18. Related party transactions </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#8217;s lease for its Woburn, Massachusetts facility, see Note 16, is with an entity affiliated with one of the Company&#8217;s directors and shareholders. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6962779344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee Stock Purchase Plan - Additional Information (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 20, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">7,828,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,288,847<span></span>
</td>
<td class="nump">10,915,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PercentageOfEligibleEmployeeCompensation', window );">Percentage of eligible employee compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance', window );">Period for automatic increase in common available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of shares issued from outstanding number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PercentageOfEligibleEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of eligible employee compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PercentageOfEligibleEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for automatic increase in common stock available for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PeriodForAutomaticIncreaseInCommonStockAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6798075088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and License Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,709,000<span></span>
</td>
<td class="nump">$ 24,238,000<span></span>
</td>
<td class="nump">$ 28,947,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_IncreaseDecreaseInResearchAndDevelopmentExpense', window );">Decrease in research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 845,000<span></span>
</td>
<td class="nump">$ 428,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_ResearchAndDevelopmentMember', window );">Research and Development | Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_AmountOfFundingReceivedAsGrant', window );">Amount of funding received as grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,596,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_GrantTermPeriod', window );">Grant term period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsInstituteOfTechnologyMember', window );">MIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DescriptionOfFutureDevelopmentObligations', window );">Description of future development obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company&#8217;s future development obligations are: (i) to commence a Phase II clinical trial for such Product, (ii) to commence a Phase III clinical trial for such Product within five years of the IND filing for such product within two years of the IND filing for such product, (iii) to file a New Drug Application or equivalent with the FDA or comparable European regulatory agency for such Product within nine years of the IND filing for such product, and (iv) to make a first commercial sale of such Product within 11 years of the IND filing for such product.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_LicenseFeePayment', window );">License fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PercentageOfSharesOfCommonStockIssued', window );">Percentage of shares of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DescriptionOfConditionsToTerminateLicenseAgreement', window );">Description of conditions to terminate license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company&#8217;s material breach uncured within ninety (90) days (or thirty (30) days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or our affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if our sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30) days after MIT&#8217;s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementUponPriorWrittenNotice', window );">Right to terminate agreement upon prior written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementIfBreachRemainsUncured', window );">Right to terminate agreement if breach remains uncured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementIncaseOfNonpayment', window );">Right to terminate agreement incase of nonpayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsInstituteOfTechnologyMember', window );">MIT | Astellas Pharma LLC | Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsInstituteOfTechnologyMember', window );">MIT | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsInstituteOfTechnologyMember', window );">MIT | Patent License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_LicenseAgreementEnteredDate', window );">License agreement entered date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2016-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_CaliforniaInstituteForBiomedicalResearchMember', window );">CALIBR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_LicenseFeePayment', window );">License fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PercentageOfSharesOfCommonStockIssued', window );">Percentage of shares of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DescriptionOfConditionsToTerminateLicenseAgreement', window );">Description of conditions to terminate license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may terminate the CALIBR License Agreement at will upon a 30-day prior written notice. The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90) days&#8217; prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30) days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementUponPriorWrittenNotice', window );">Right to terminate agreement upon prior written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementIfBreachRemainsUncured', window );">Right to terminate agreement if breach remains uncured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice', window );">Right to terminate licensed patents upon prior written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_CaliforniaInstituteForBiomedicalResearchMember', window );">CALIBR | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_CaliforniaInstituteForBiomedicalResearchMember', window );">CALIBR | Patent License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_LicenseAgreementEnteredDate', window );">License agreement entered date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsEyeAndEarInfirmaryMember', window );">MEEI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_LicenseFeePayment', window );">License fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DescriptionOfConditionsToTerminateLicenseAgreement', window );">Description of conditions to terminate license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has the right to terminate the MEEI License Agreement at will by giving thirty (30) business days advance written notice to MEEI. MEEI has the right to terminate the MEEI License Agreement if the Company fails to make any payment due within thirty (30) business days after MEEI notifies the Company of such failure. MEEI shall have the right to terminate if the Company fails to maintain the required insurance. MEEI shall also have the right to terminate the MEEI License Agreement upon forty-five (45) business days written notice if the Company becomes insolvent. MEEI has the right to terminate for any other default not cured within sixty (60) business days written notice. MEEI also has the right to terminate if the Company or its affiliates challenge the validity of the licensed patent rights.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementUponPriorWrittenNotice', window );">Right to terminate agreement upon prior written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementIfBreachRemainsUncured', window );">Right to terminate agreement if breach remains uncured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementIncaseOfNonpayment', window );">Right to terminate agreement incase of nonpayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent', window );">Right to terminate agreement upon prior written notice if insolvent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsEyeAndEarInfirmaryMember', window );">MEEI | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_MassachusettsEyeAndEarInfirmaryMember', window );">MEEI | Non-Exclusive Patent License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_LicenseAgreementEnteredDate', window );">License agreement entered date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2019-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_CambridgeEnterpriseLimitedMember', window );">Cambridge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_LicenseFeePayment', window );">License fee payment</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_DescriptionOfConditionsToTerminateLicenseAgreement', window );">Description of conditions to terminate license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">We have the right to terminate for any reason upon 90 days&#8217; prior to written notice.  Each party has the right to terminate immediately if the other party ceases to carry on its business.  Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days.  Cambridge may also terminate the Cambridge License if we fail to diligently develop and commercially exploit at least one Cambridge Licensed Product or we or our affiliates or sub-licenses commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementUponPriorWrittenNotice', window );">Right to terminate agreement upon prior written notice</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_RightToTerminateAgreementIfBreachRemainsUncured', window );">Right to terminate agreement if breach remains uncured</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_AnnualLicenseFee', window );">Annual license fee</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_CambridgeEnterpriseLimitedMember', window );">Cambridge | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_MilestonePayments', window );">Milestone payments</a></td>
<td class="nump">$ 10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=freq_CambridgeEnterpriseLimitedMember', window );">Cambridge | Patent License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_LicenseAgreementEnteredDate', window );">License agreement entered date</a></td>
<td class="text">2019-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_AmountOfFundingReceivedAsGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funding received as grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_AmountOfFundingReceivedAsGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_AnnualLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual license fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_AnnualLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DescriptionOfConditionsToTerminateLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of conditions to terminate license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DescriptionOfConditionsToTerminateLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_DescriptionOfFutureDevelopmentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of future development obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_DescriptionOfFutureDevelopmentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_GrantTermPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant term period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_GrantTermPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_IncreaseDecreaseInResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_IncreaseDecreaseInResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_LicenseAgreementEnteredDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement entered date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_LicenseAgreementEnteredDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_LicenseFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License fee payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_LicenseFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PercentageOfSharesOfCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares of common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PercentageOfSharesOfCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateAgreementIfBreachRemainsUncured">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right to terminate agreement if breach remains uncured.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateAgreementIfBreachRemainsUncured</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateAgreementIncaseOfNonpayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right to terminate agreement incase of nonpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateAgreementIncaseOfNonpayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateAgreementUponPriorWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right to terminate agreement upon prior written notice.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateAgreementUponPriorWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right to terminate agreement upon prior written notice if insolvent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateAgreementUponPriorWrittenNoticeIfInsolvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right to terminate licensed patents upon prior written notice.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_RightToTerminateLicensedPatentsUponPriorWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=freq_MassachusettsInstituteOfTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=freq_MassachusettsInstituteOfTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=freq_AstellasPharmaLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=freq_AstellasPharmaLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_PatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_PatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=freq_CaliforniaInstituteForBiomedicalResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=freq_CaliforniaInstituteForBiomedicalResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=freq_MassachusettsEyeAndEarInfirmaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=freq_MassachusettsEyeAndEarInfirmaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_NonExclusivePatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=freq_NonExclusivePatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=freq_CambridgeEnterpriseLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=freq_CambridgeEnterpriseLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6961253424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum percentage of employee contribution to retirement plan</a></td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage of employer matching contribution</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of employee annual compensation matched by the employer</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage', window );">Employers matching contribution vesting percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6962916032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PrepaidRentAndDepositsCurrent', window );">Rent and deposits</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_freq_PrepaidResearchAndDevelopmentExpenseCurrent', window );">Research and development expenses</a></td>
<td class="nump">801<span></span>
</td>
<td class="nump">$ 428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grant receivable</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">2,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PrepaidRentAndDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rent and deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PrepaidRentAndDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_freq_PrepaidResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">freq_PrepaidResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>freq_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6778679328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Basic And Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (5,533)<span></span>
</td>
<td class="num">$ (1,589)<span></span>
</td>
<td class="num">$ (6,852)<span></span>
</td>
<td class="num">$ (5,826)<span></span>
</td>
<td class="num">$ (5,447)<span></span>
</td>
<td class="num">$ (5,136)<span></span>
</td>
<td class="num">$ (4,436)<span></span>
</td>
<td class="num">$ (4,149)<span></span>
</td>
<td class="num">$ (19,800)<span></span>
</td>
<td class="num">$ (19,168)<span></span>
</td>
<td class="num">$ (20,237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares of common stock outstanding-basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,649,245<span></span>
</td>
<td class="nump">1,530,218<span></span>
</td>
<td class="nump">702,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributed to common stockholders-basic and diluted</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (3.42)<span></span>
</td>
<td class="num">$ (3.24)<span></span>
</td>
<td class="num">$ (3.23)<span></span>
</td>
<td class="num">$ (3.26)<span></span>
</td>
<td class="num">$ (3.01)<span></span>
</td>
<td class="num">$ (3.03)<span></span>
</td>
<td class="num">$ (2.29)<span></span>
</td>
<td class="num">$ (12.53)<span></span>
</td>
<td class="num">$ (28.79)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
